(lp0
(dp1
S'line'
p2
VPancreatitis was induced in C57Bl/6 wild-type (control), cathepsin B-knockout, and cathepsin L-knockout mice by partial pancreatic duct ligation with supramaximal caerulein injection, or by repetitive supramaximal caerulein injections alone.
p3
sS'labels'
p4
(dp5
(Vcathepsin L
p6
VPancreatitis
p7
tp8
I01
ssS'diseases'
p9
(lp10
(dp11
S'index'
p12
I0
sS'name'
p13
g7
sS'lengthInChars'
p14
I12
sS'cui'
p15
VC0030305
p16
sS'lengthInWords'
p17
I1
sasS'genes'
p18
(lp19
(dp20
g12
I57
sg13
Vcathepsin B
p21
sg14
I11
sS'uniprot'
p22
VP07858
p23
sg17
I2
sa(dp24
g12
I83
sg13
g6
sg14
I11
sg22
VP07711
p25
sg17
I2
sasa(dp26
g2
VTrypsinogen became activated in macrophages cultured with purified trypsinogen or co-cultured with pancreatic acini and in pancreata of mice with pancreatitis; trypsinogen activation required macrophage endocytosis and expression and activity of cathepsin B, and was sensitive to pH.
p27
sg4
(dp28
(VTrypsinogen
p29
Vpancreatitis
p30
tp31
I00
ssg9
(lp32
(dp33
g12
I146
sg13
g30
sg14
I12
sg15
VC0030305
p34
sg17
I1
sasg18
(lp35
(dp36
g12
I67
sg13
Vtrypsinogen
p37
sg14
I11
sg22
VP07478
p38
sg17
I1
sa(dp39
g12
I246
sg13
Vcathepsin B
p40
sg14
I11
sg22
VP07858
p41
sg17
I2
sa(dp42
g12
I67
sg13
Vtrypsinogen
p43
sg14
I11
sg22
VP07478
p44
sg17
I1
sa(dp45
g12
I0
sg13
g29
sg14
I11
sg22
VP07478
p46
sg17
I1
sasa(dp47
g2
VActivation of trypsinogen in macrophages resulted in translocation of NF-kB and production of inflammatory cytokines; mice without trypsinogen activation (cathepsin B-knockout mice) in macrophages developed less severe pancreatitis compared with control mice.
p48
sg4
(dp49
(Vcathepsin B
p50
Vpancreatitis
p51
tp52
I00
ssg9
(lp53
(dp54
g12
I53
sg13
Vtranslocation
p55
sg14
I13
sg15
VC0040715
p56
sg17
I1
sa(dp57
g12
I219
sg13
g51
sg14
I12
sg15
VC0030305
p58
sg17
I1
sasg18
(lp59
(dp60
g12
I131
sg13
Vtrypsinogen activation
p61
sg14
I22
sg22
VP07478
p62
sg17
I2
sa(dp63
g12
I14
sg13
Vtrypsinogen
p64
sg14
I11
sg22
VP07478
p65
sg17
I1
sa(dp66
g12
I155
sg13
g50
sg14
I11
sg22
VP07858
p67
sg17
I2
sasa(dp68
g2
VTransfer of macrophage from control mice to cathepsin B-knockout mice increased the severity of pancreatitis.
p69
sg4
(dp70
(Vcathepsin B
p71
Vpancreatitis
p72
tp73
I00
ssg9
(lp74
(dp75
g12
I96
sg13
g72
sg14
I12
sg15
VC0030305
p76
sg17
I1
sasg18
(lp77
(dp78
g12
I44
sg13
g71
sg14
I11
sg22
VP07858
p79
sg17
I2
sasa(dp80
g2
VExperimental studies in acute pancreatitis (AP) suggest a strong association of acinar cell injury with cathepsin B-dependent intracellular activation of trypsin.
p81
sg4
(dp82
(Vtrypsin
p83
Vacute pancreatitis
p84
tp85
I01
ssg9
(lp86
(dp87
g12
I44
sg13
VAP
p88
sg14
I2
sg15
VC0001339
p89
sg17
I1
sa(dp90
g12
I87
sg13
Vcell injury
p91
sg14
I11
sg15
VC0599732
p92
sg17
I2
sa(dp93
g12
I24
sg13
g84
sg14
I18
sg15
VC0001339
p94
sg17
I2
sasg18
(lp95
(dp96
g12
I154
sg13
g83
sg14
I7
sg22
VP35030
p97
sg17
I1
sasa(dp98
g2
VPancreas, lung, and serum was harvested up to 48 h after pancreatitis induction and used for histopathology, amylase, lipase, cathepsin B, trypsin, and elastase activity measurements, myeloperoxidase (MPO) content and cytokine concentrations.
p99
sg4
(dp100
(Vtrypsin
p101
Vpancreatitis
p102
tp103
I00
ssg9
(lp104
(dp105
g12
I57
sg13
g102
sg14
I12
sg15
VC0030305
p106
sg17
I1
sasg18
(lp107
(dp108
g12
I126
sg13
Vcathepsin B
p109
sg14
I11
sg22
VP07858
p110
sg17
I2
sa(dp111
g12
I152
sg13
Velastase
p112
sg14
I8
sg22
VP30740
p113
sg17
I1
sa(dp114
g12
I184
sg13
Vmyeloperoxidase
p115
sg14
I15
sg22
VP05164
p116
sg17
I1
sa(dp117
g12
I118
sg13
Vlipase
p118
sg14
I6
sg22
VP04118
p119
sg17
I1
sa(dp120
g12
I201
sg13
VMPO
p121
sg14
I3
sg22
VP05164
p122
sg17
I1
sa(dp123
g12
I109
sg13
Vamylase
p124
sg14
I7
sg22
VP04746
p125
sg17
I1
sa(dp126
g12
I139
sg13
g101
sg14
I7
sg22
VP35030
p127
sg17
I1
sasa(dp128
g2
VIn taurocholate-pancreatitis AZD8309 reduced cathepsin B activity and MPO.
p129
sg4
(dp130
(VMPO
p131
Vpancreatitis
p132
tp133
I01
ssg9
(lp134
(dp135
g12
I16
sg13
g132
sg14
I12
sg15
VC0030305
p136
sg17
I1
sasg18
(lp137
(dp138
g12
I45
sg13
Vcathepsin B
p139
sg14
I11
sg22
VP07858
p140
sg17
I2
sa(dp141
g12
I70
sg13
g131
sg14
I3
sg22
VP05164
p142
sg17
I1
sasa(dp143
g2
VThe lysosomal hydrolase cathepsin B (CTSB) is a known activator of trypsinogen, and its deletion reduces disease severity in experimental pancreatitis.
p144
sg4
(dp145
(Vtrypsinogen
p146
Vpancreatitis
p147
tp148
I00
ssg9
(lp149
(dp150
g12
I138
sg13
g147
sg14
I12
sg15
VC0030305
p151
sg17
I1
sasg18
(lp152
(dp153
g12
I4
sg13
Vlysosomal hydrolase cathepsin B
p154
sg14
I31
sg22
VP07858
p155
sg17
I4
sa(dp156
g12
I37
sg13
VCTSB
p157
sg14
I4
sg22
VP07858
p158
sg17
I1
sa(dp159
g12
I67
sg13
g146
sg14
I11
sg22
VP07478
p160
sg17
I1
sasa(dp161
g2
VIn summary, CTSB in pancreatitis undergoes activation in a secretory, vesicular, and acidic compartment where it activates trypsinogen.
p162
sg4
(dp163
(Vtrypsinogen
p164
Vpancreatitis
p165
tp166
I00
ssg9
(lp167
(dp168
g12
I20
sg13
g165
sg14
I12
sg15
VC0030305
p169
sg17
I1
sasg18
(lp170
(dp171
g12
I123
sg13
g164
sg14
I11
sg22
VP07478
p172
sg17
I1
sasa(dp173
g2
VThis study investigated the role of miR-221 in regulating SOCS3/JAK-STAT3 signaling pathway and bladder cancer cell proliferation and apoptosis.
p174
sg4
(dp175
(VSTAT3
p176
Vbladder cancer
p177
tp178
I00
ssg9
(lp179
(dp180
g12
I96
sg13
g177
sg14
I14
sg15
VC0699885
p181
sg17
I2
sa(dp182
g12
I116
sg13
Vproliferation
p183
sg14
I13
sg15
VC0334094
p184
sg17
I1
sasg18
(lp185
(dp186
g12
I68
sg13
g176
sg14
I5
sg22
VP40763
p187
sg17
I1
sa(dp188
g12
I58
sg13
VSOCS3
p189
sg14
I5
sg22
S''
p190
sg17
I1
sa(dp191
g12
I36
sg13
VmiR-221
p192
sg14
I7
sg22
g190
sg17
I1
sasa(dp193
g2
VAs miR-221 targets several regulators of the PI3K-AKT-mTOR pathway and a link between this pathway and CD44 has been previously shown in prostate cancer, we considered miR-221 regulation of CD44 may be through this pathway.
p194
sg4
(dp195
(VPI3K
p196
Vprostate cancer
p197
tp198
I00
ssg9
(lp199
(dp200
g12
I137
sg13
g197
sg14
I15
sg15
VC0600139
p201
sg17
I2
sasg18
(lp202
(dp203
g12
I54
sg13
VmTOR
p204
sg14
I4
sg22
VP42345
p205
sg17
I1
sa(dp206
g12
I50
sg13
VAKT
p207
sg14
I3
sg22
g190
sg17
I1
sa(dp208
g12
I45
sg13
g196
sg14
I4
sg22
VP42336
p209
sg17
I1
sasa(dp210
g2
VThe aim of our study was to evaluate the relationship of TMPRSS2-ERG fusion gene status, tumor tissue prostate-specific antigen (PSA), prostate cancer antigen 3 (PCA3), miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy.
p211
sg4
(dp212
(Vtumor tissue prostate-specific antigen
p213
VPSA
p214
tp215
I00
ssg9
(lp216
(dp217
g12
I280
sg13
VPCa
p218
sg14
I3
sg15
VC0268398
p219
sg17
I1
sa(dp220
g12
I89
sg13
Vtumor
p221
sg14
I5
sg15
VC0027651
p222
sg17
I1
sa(dp223
g12
I284
sg13
Vrecurrence
p224
sg14
I10
sg15
VC1458156
p225
sg17
I1
sa(dp226
g12
I135
sg13
Vprostate cancer
p227
sg14
I15
sg15
VC0600139
p228
sg17
I2
sa(dp229
g12
I129
sg13
VPSA
p230
sg14
I3
sg15
VC1519176
p231
sg17
I1
sa(dp232
g12
I102
sg13
Vprostate-specific antigen
p233
sg14
I25
sg15
VC1519176
p234
sg17
I2
sa(dp235
g12
I129
sg13
g214
sg14
I3
sg15
VC1519176
p236
sg17
I1
sasg18
(lp237
(dp238
g12
I249
sg13
Vserum PSA
p239
sg14
I9
sg22
VP55786
p240
sg17
I2
sa(dp241
g12
I190
sg13
VmiR-221
p242
sg14
I7
sg22
g190
sg17
I1
sa(dp243
g12
I65
sg13
VERG
p244
sg14
I3
sg22
VP11308
p245
sg17
I1
sa(dp246
g12
I162
sg13
VPCA3
p247
sg14
I4
sg22
VP78358
p248
sg17
I1
sa(dp249
g12
I129
sg13
VPSA
p250
sg14
I3
sg22
VP55786
p251
sg17
I1
sa(dp252
g12
I89
sg13
g213
sg14
I38
sg22
VP07288
p253
sg17
I4
sa(dp254
g12
I135
sg13
Vprostate cancer antigen 3
p255
sg14
I25
sg22
VP78358
p256
sg17
I4
sa(dp257
g12
I178
sg13
VmiR-26a
p258
sg14
I7
sg22
g190
sg17
I1
sa(dp259
g12
I57
sg13
VTMPRSS2
p260
sg14
I7
sg22
g190
sg17
I1
sa(dp261
g12
I169
sg13
VmiR-23b
p262
sg14
I7
sg22
g190
sg17
I1
sasa(dp263
g2
VThe signature's genes are: Interferon Stimulated Gene 15 (ISG15), Interleukin 16 (IL16), 2',5'-Oligoadenylate Synthetase Like (OASL), and Adhesion G Protein Coupled Receptor E5 (ADGRE5).
p264
sg4
(dp265
(VISG15
p266
VAdhesion
p267
tp268
I00
ssg9
(lp269
(dp270
g12
I138
sg13
g267
sg14
I8
sg15
VC0001511
p271
sg17
I1
sasg18
(lp272
(dp273
g12
I127
sg13
VOASL
p274
sg14
I4
sg22
g190
sg17
I1
sa(dp275
g12
I66
sg13
VInterleukin 16
p276
sg14
I14
sg22
g190
sg17
I2
sa(dp277
g12
I89
sg13
V2',5'-Oligoadenylate Synthetase Like
p278
sg14
I36
sg22
g190
sg17
I3
sa(dp279
g12
I82
sg13
VIL16
p280
sg14
I4
sg22
g190
sg17
I1
sa(dp281
g12
I27
sg13
VInterferon Stimulated Gene 15
p282
sg14
I29
sg22
g190
sg17
I4
sa(dp283
g12
I58
sg13
g266
sg14
I5
sg22
VP05161
p284
sg17
I1
sasa(dp285
g2
VPrevious work has identified that following viral infection, type I IFN signaling induces the production of the 2'-5'-oligoadenylate synthetase (OAS) family, which include OAS1, OAS2, OAS3, and OAS-like (OASL) protein.
p286
sg4
(dp287
(VOAS2
p288
Vviral infection
p289
tp290
I01
ssg9
(lp291
(dp292
g12
I145
sg13
VOAS
p293
sg14
I3
sg15
VC0599973
p294
sg17
I1
sa(dp295
g12
I112
sg13
V2'-5'-oligoadenylate synthetase
p296
sg14
I31
sg15
VC0599973
p297
sg17
I2
sa(dp298
g12
I145
sg13
VOAS
p299
sg14
I3
sg15
VC0599973
p300
sg17
I1
sa(dp301
g12
I44
sg13
g289
sg14
I15
sg15
VC0042769
p302
sg17
I2
sasg18
(lp303
(dp304
g12
I68
sg13
VIFN
p305
sg14
I3
sg22
VP01562
p306
sg17
I1
sa(dp307
g12
I194
sg13
VOAS-like
p308
sg14
I8
sg22
g190
sg17
I1
sa(dp309
g12
I112
sg13
V2'-5'-oligoadenylate synthetase
p310
sg14
I31
sg22
g190
sg17
I2
sa(dp311
g12
I204
sg13
VOASL
p312
sg14
I4
sg22
g190
sg17
I1
sa(dp313
g12
I184
sg13
VOAS3
p314
sg14
I4
sg22
g190
sg17
I1
sa(dp315
g12
I178
sg13
g288
sg14
I4
sg22
VP29728
p316
sg17
I1
sa(dp317
g12
I145
sg13
VOAS
p318
sg14
I3
sg22
g190
sg17
I1
sasa(dp319
g2
VThe 2'5'-oligoadenylate synthetase (OAS) is an interferon (IFN)-induced protein that plays an important role in the antiviral action of IFN, with OAS3 being one of the four OAS classes (OAS1, OAS2, OAS3, OASL).
p320
sg4
(dp321
(VOAS2
p322
VOAS
p323
tp324
I00
ssg9
(lp325
(dp326
g12
I36
sg13
VOAS
p327
sg14
I3
sg15
VC0599973
p328
sg17
I1
sa(dp329
g12
I4
sg13
V2'5'-oligoadenylate synthetase
p330
sg14
I30
sg15
VC0599973
p331
sg17
I2
sa(dp332
g12
I36
sg13
g323
sg14
I3
sg15
VC0599973
p333
sg17
I1
sasg18
(lp334
(dp335
g12
I146
sg13
VOAS3
p336
sg14
I4
sg22
g190
sg17
I1
sa(dp337
g12
I4
sg13
V2'5'-oligoadenylate synthetase
p338
sg14
I30
sg22
g190
sg17
I2
sa(dp339
g12
I47
sg13
Vinterferon
p340
sg14
I10
sg22
VP01563
p341
sg17
I1
sa(dp342
g12
I59
sg13
VIFN
p343
sg14
I3
sg22
VP01562
p344
sg17
I1
sa(dp345
g12
I146
sg13
VOAS3
p346
sg14
I4
sg22
g190
sg17
I1
sa(dp347
g12
I204
sg13
VOASL
p348
sg14
I4
sg22
g190
sg17
I1
sa(dp349
g12
I36
sg13
VOAS
p350
sg14
I3
sg22
g190
sg17
I1
sa(dp351
g12
I192
sg13
g322
sg14
I4
sg22
VP29728
p352
sg17
I1
sa(dp353
g12
I59
sg13
VIFN
p354
sg14
I3
sg22
VP01562
p355
sg17
I1
sa(dp356
g12
I36
sg13
VOAS
p357
sg14
I3
sg22
g190
sg17
I1
sasa(dp358
g2
VThe present study suggests that any one of the three tested mania rating scales (YMRS, BRMS, and CARS-M) can be combined with the 21-HAM-D to assess treatment response in patients with mixed bipolar disorder.
p359
sg4
(dp360
(VCARS-M
p361
Vmania
p362
tp363
I00
ssg9
(lp364
(dp365
g12
I133
sg13
VHAM
p366
sg14
I3
sg15
VC0030481
p367
sg17
I1
sa(dp368
g12
I60
sg13
g362
sg14
I5
sg15
VC0338831
p369
sg17
I1
sa(dp370
g12
I185
sg13
Vmixed bipolar disorder
p371
sg14
I22
sg15
VC2937260
p372
sg17
I3
sasg18
(lp373
(dp374
g12
I97
sg13
g361
sg14
I6
sg22
VP49589
p375
sg17
I1
sasa(dp376
g2
VClinically, decreased levels of cGAS are associated with poor prognosis for patients with breast cancer harbouring high levels of miR-25/93.
p377
sg4
(dp378
(VcGAS
p379
Vbreast cancer
p380
tp381
I00
ssg9
(lp382
(dp383
g12
I90
sg13
g380
sg14
I13
sg15
VC0678222
p384
sg17
I2
sasg18
(lp385
(dp386
g12
I130
sg13
VmiR-25
p387
sg14
I6
sg22
g190
sg17
I1
sa(dp388
g12
I32
sg13
g379
sg14
I4
sg22
VP10645
p389
sg17
I1
sasa(dp390
g2
VExpression of a panel of seven microRNAs (hsa-miR-34a, hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, hsa-miR-326, and hsa-miR-375) and seven target genes ( E2F3, PI3KCA, TOM34, WNT5A, PDCD4, DFFA, and EGFR) in 43 glioblastoma multiforme specimens were profiled compared to non-cancer tissues via quantitative reverse transcription-polymerase chain reaction.
p391
sg4
(dp392
(VWNT5A
p393
Vhsa
p394
tp395
I00
ssg9
(lp396
(dp397
g12
I42
sg13
Vhsa
p398
sg14
I3
sg15
VC0393754
p399
sg17
I1
sa(dp400
g12
I280
sg13
Vcancer
p401
sg14
I6
sg15
VC0006826
p402
sg17
I1
sa(dp403
g12
I42
sg13
Vhsa
p404
sg14
I3
sg15
VC0393754
p405
sg17
I1
sa(dp406
g12
I216
sg13
Vglioblastoma multiforme
p407
sg14
I23
sg15
VC1621958
p408
sg17
I2
sa(dp409
g12
I42
sg13
Vhsa
p410
sg14
I3
sg15
VC0393754
p411
sg17
I1
sa(dp412
g12
I42
sg13
Vhsa
p413
sg14
I3
sg15
VC0393754
p414
sg17
I1
sa(dp415
g12
I42
sg13
Vhsa
p416
sg14
I3
sg15
VC0393754
p417
sg17
I1
sa(dp418
g12
I42
sg13
Vhsa
p419
sg14
I3
sg15
VC0393754
p420
sg17
I1
sa(dp421
g12
I42
sg13
g394
sg14
I3
sg15
VC0393754
p422
sg17
I1
sasg18
(lp423
(dp424
g12
I67
sg13
Vhsa-miR-17
p425
sg14
I10
sg22
g190
sg17
I1
sa(dp426
g12
I42
sg13
Vhsa
p427
sg14
I3
sg22
g190
sg17
I1
sa(dp428
g12
I194
sg13
VDFFA, and EGFR
p429
sg14
I14
sg22
g190
sg17
I3
sa(dp430
g12
I46
sg13
VmiR
p431
sg14
I3
sg22
g190
sg17
I1
sa(dp432
g12
I91
sg13
Vhsa-miR-221
p433
sg14
I11
sg22
g190
sg17
I1
sa(dp434
g12
I187
sg13
VPDCD4
p435
sg14
I5
sg22
g190
sg17
I1
sa(dp436
g12
I180
sg13
g393
sg14
I5
sg22
VP41221
p437
sg17
I1
sa(dp438
g12
I55
sg13
Vhsa-miR-16
p439
sg14
I10
sg22
g190
sg17
I1
sa(dp440
g12
I42
sg13
Vhsa
p441
sg14
I3
sg22
g190
sg17
I1
sa(dp442
g12
I104
sg13
Vhsa-miR-326
p443
sg14
I11
sg22
g190
sg17
I1
sa(dp444
g12
I42
sg13
Vhsa
p445
sg14
I3
sg22
g190
sg17
I1
sa(dp446
g12
I173
sg13
VTOM34
p447
sg14
I5
sg22
g190
sg17
I1
sa(dp448
g12
I159
sg13
VE2F3
p449
sg14
I4
sg22
g190
sg17
I1
sasa(dp450
g2
VThe mRNA levels of seven TAAs, Wilms' tumor gene (WT1), kinetochore associated-2 (KNTC2), cell division cycle associated-1 (CDCA1), M phase phosphoprotein-1 (MPHOSPH1), DEP domain-containing 1 (DEPDC1), 34-kDa translocase of the outer mitochondrial membrane (TOMM34) and ring finger protein-43 (RNF43), were analyzed using quantitative real-time reverse transcription-polymerase chain reaction, and their relationships with clinicopathological factors and the cell cycle were analyzed.
p451
sg4
(dp452
(Vring finger protein-43
p453
VWT1
p454
tp455
I00
ssg9
(lp456
(dp457
g12
I31
sg13
VWilms' tumor
p458
sg14
I12
sg15
VC0027708
p459
sg17
I2
sa(dp460
g12
I50
sg13
g454
sg14
I3
sg15
VC0027708
p461
sg17
I1
sasg18
(lp462
(dp463
g12
I82
sg13
VKNTC2
p464
sg14
I5
sg22
g190
sg17
I1
sa(dp465
g12
I203
sg13
V34-kDa translocase of the outer mitochondrial membrane (TOMM34)
p466
sg14
I63
sg22
g190
sg17
I8
sa(dp467
g12
I132
sg13
VM phase phosphoprotein-1
p468
sg14
I24
sg22
g190
sg17
I3
sa(dp469
g12
I169
sg13
VDEP domain-containing 1
p470
sg14
I23
sg22
g190
sg17
I3
sa(dp471
g12
I271
sg13
g453
sg14
I22
sg22
VP62877
p472
sg17
I3
sa(dp473
g12
I194
sg13
VDEPDC1
p474
sg14
I6
sg22
g190
sg17
I1
sa(dp475
g12
I295
sg13
VRNF43
p476
sg14
I5
sg22
g190
sg17
I1
sa(dp477
g12
I158
sg13
VMPHOSPH1
p478
sg14
I8
sg22
g190
sg17
I1
sa(dp479
g12
I31
sg13
VWilms' tumor gene (WT1), kinetochore associated-2
p480
sg14
I49
sg22
g190
sg17
I6
sasa(dp481
g2
VTo evaluate the safety of combination vaccine treatment of multiple peptides, phase I clinical trial was conducted for patients with advanced colorectal cancer using five novel HLA-A*2402-restricted peptides, three peptides derived from oncoantigens, ring finger protein 43 (RNF43), 34 kDa-translocase of the outer mitochondrial membrane (TOMM34), and insulin-like growth factor-II mRNA binding protein 3 (KOC1), and the remaining two from angiogenesis factors, vascular endothelial growth factor receptor 1 (VEGFR1) and VEGFR2.
p482
sg4
(dp483
(VVEGFR2
p484
Vcolorectal cancer
p485
tp486
I00
ssg9
(lp487
(dp488
g12
I142
sg13
g485
sg14
I17
sg15
VC1527249
p489
sg17
I2
sasg18
(lp490
(dp491
g12
I406
sg13
VKOC1
p492
sg14
I4
sg22
g190
sg17
I1
sa(dp493
g12
I251
sg13
Vring finger protein 43
p494
sg14
I22
sg22
g190
sg17
I4
sa(dp495
g12
I352
sg13
Vinsulin-like growth factor-II mRNA binding protein 3
p496
sg14
I52
sg22
VP01308
p497
sg17
I7
sa(dp498
g12
I339
sg13
VTOMM34
p499
sg14
I6
sg22
g190
sg17
I1
sa(dp500
g12
I509
sg13
VVEGFR1
p501
sg14
I6
sg22
VP17948
p502
sg17
I1
sa(dp503
g12
I177
sg13
VHLA-A*2402
p504
sg14
I10
sg22
VP30447
p505
sg17
I1
sa(dp506
g12
I462
sg13
Vvascular endothelial growth factor receptor 1
p507
sg14
I45
sg22
VP17948
p508
sg17
I6
sa(dp509
g12
I275
sg13
VRNF43
p510
sg14
I5
sg22
g190
sg17
I1
sa(dp511
g12
I521
sg13
g484
sg14
I6
sg22
VP35968
p512
sg17
I1
sasa(dp513
g2
VWe conducted a clinical trial of colorectal cancer-specific peptide( RNF43, TOMM34) vaccines with uracil/tegafur( UFT)+Leucovorin( LV) for the treatment of advanced or recurrent colorectal cancer.
p514
sg4
(dp515
(Vcolorectal cancer-specific peptide
p516
Vcolorectal cancer
p517
tp518
I00
ssg9
(lp519
(dp520
g12
I168
sg13
Vrecurrent colorectal cancer
p521
sg14
I27
sg15
VC0854750
p522
sg17
I3
sa(dp523
g12
I33
sg13
g517
sg14
I17
sg15
VC1527249
p524
sg17
I2
sasg18
(lp525
(dp526
g12
I69
sg13
VRNF43
p527
sg14
I5
sg22
g190
sg17
I1
sa(dp528
g12
I33
sg13
g516
sg14
I34
sg22
VP31749
p529
sg17
I3
sa(dp530
g12
I76
sg13
VTOMM34
p531
sg14
I6
sg22
g190
sg17
I1
sasa(dp532
g2
VWe started a clinical trial of vaccines against multiple peptides (RNF43, TOMM34, forkhead box protein M1 [FOXM1], maternal embryonic leucine zipper kinase [MELK], holliday junction recognition protein[HJURP], vascular endothelial growth factor receptor 1[VEGFR1], and VEGFR2) for the treatment of advanced or recurrent colorectal cancer.
p533
sg4
(dp534
(Vmaternal embryonic leucine zipper kinase
p535
Vrecurrent colorectal cancer
p536
tp537
I00
ssg9
(lp538
(dp539
g12
I310
sg13
g536
sg14
I27
sg15
VC0854750
p540
sg17
I3
sasg18
(lp541
(dp542
g12
I164
sg13
Vholliday junction recognition protein
p543
sg14
I37
sg22
g190
sg17
I4
sa(dp544
g12
I82
sg13
Vforkhead box protein M1 [FOXM1]
p545
sg14
I31
sg22
g190
sg17
I5
sa(dp546
g12
I157
sg13
VMELK
p547
sg14
I4
sg22
g190
sg17
I1
sa(dp548
g12
I202
sg13
VHJURP
p549
sg14
I5
sg22
g190
sg17
I1
sa(dp550
g12
I210
sg13
Vvascular endothelial growth factor receptor 1[VEGFR1], and VEGFR2
p551
sg14
I65
sg22
VP17948
p552
sg17
I8
sa(dp553
g12
I67
sg13
VRNF43
p554
sg14
I5
sg22
g190
sg17
I1
sa(dp555
g12
I74
sg13
VTOMM34
p556
sg14
I6
sg22
g190
sg17
I1
sa(dp557
g12
I115
sg13
g535
sg14
I40
sg22
VP30740
p558
sg17
I5
sasa(dp559
g2
VRecently, analysis of tumor antigens using micro-arrays has revealed upregulation             of cancer-testis antigens RNF43 and TOMM34 and vascular endothelial growth factor             receptors VEGFR1 and VEGFR2 in colorectal cancer.
p560
sg4
(dp561
(Vvascular endothelial growth factor             receptors VEGFR1 and VEGFR2
p562
Vcolorectal cancer
p563
tp564
I00
ssg9
(lp565
(dp566
g12
I97
sg13
Vcancer
p567
sg14
I6
sg15
VC0006826
p568
sg17
I1
sa(dp569
g12
I22
sg13
Vtumor
p570
sg14
I5
sg15
VC0027651
p571
sg17
I1
sa(dp572
g12
I219
sg13
g563
sg14
I17
sg15
VC1527249
p573
sg17
I2
sasg18
(lp574
(dp575
g12
I130
sg13
VTOMM34
p576
sg14
I6
sg22
g190
sg17
I1
sa(dp577
g12
I120
sg13
VRNF43
p578
sg14
I5
sg22
g190
sg17
I1
sa(dp579
g12
I141
sg13
g562
sg14
I74
sg22
VP17948
p580
sg17
I20
sasa(dp581
g2
VFurthermore, Wnt-11 was positively associated with P-JNK1 expression and promoted cervical cancer cell proliferation and invasion.
p582
sg4
(dp583
(VJNK1
p584
Vcervical cancer
p585
tp586
I01
ssg9
(lp587
(dp588
g12
I103
sg13
Vproliferation
p589
sg14
I13
sg15
VC0334094
p590
sg17
I1
sa(dp591
g12
I121
sg13
Vinvasion
p592
sg14
I8
sg15
VC2699153
p593
sg17
I1
sa(dp594
g12
I82
sg13
g585
sg14
I15
sg15
VC0302592
p595
sg17
I2
sasg18
(lp596
(dp597
g12
I53
sg13
g584
sg14
I4
sg22
VP45983
p598
sg17
I1
sasa(dp599
g2
VThese observations suggest that the increased Wnt-11 expression observed in cervical cancer cells may lead to the phosphorylation and activation of JNK-1 and significantly promote tumor cell proliferation and cell migration/invasion through activation of the Wnt/JNK pathway.
p600
sg4
(dp601
(VJNK
p602
Vcervical cancer
p603
tp604
I00
ssg9
(lp605
(dp606
g12
I191
sg13
Vproliferation
p607
sg14
I13
sg15
VC0334094
p608
sg17
I1
sa(dp609
g12
I180
sg13
Vtumor
p610
sg14
I5
sg15
VC0027651
p611
sg17
I1
sa(dp612
g12
I76
sg13
g603
sg14
I15
sg15
VC0302592
p613
sg17
I2
sa(dp614
g12
I224
sg13
Vinvasion
p615
sg14
I8
sg15
VC2699153
p616
sg17
I1
sasg18
(lp617
(dp618
g12
I148
sg13
VJNK-1
p619
sg14
I5
sg22
VP53779
p620
sg17
I1
sa(dp621
g12
I148
sg13
g602
sg14
I3
sg22
VP53779
p622
sg17
I1
sasa(dp623
g2
VIn this study, we aimed to explore the association among gene variants of five cytokines, tumor necrosis factor alpha (TNF-Alfa), transforming growth factor beta-1 (TGF-Beta1), interferon gamma (IFN-Gamma), interleukin-6 (IL-6), and interleukin-10 (IL-10), and clinical parameters and prognosis in patients with multiple myeloma (MM) treated with novel therapeutic drugs in Turkish population for the first time except TNF-Alfa.
p624
sg4
(dp625
(Vinterleukin-10
p626
Vtumor necrosis
p627
tp628
I01
ssg9
(lp629
(dp630
g12
I312
sg13
Vmultiple myeloma
p631
sg14
I16
sg15
VC0026764
p632
sg17
I2
sa(dp633
g12
I90
sg13
g627
sg14
I14
sg15
VC0333516
p634
sg17
I2
sasg18
(lp635
(dp636
g12
I249
sg13
VIL-10
p637
sg14
I5
sg22
VP22301
p638
sg17
I1
sa(dp639
g12
I207
sg13
Vinterleukin-6
p640
sg14
I13
sg22
VP05231
p641
sg17
I1
sa(dp642
g12
I130
sg13
Vtransforming growth factor beta-1
p643
sg14
I33
sg22
VP01137
p644
sg17
I4
sa(dp645
g12
I119
sg13
VTNF-Alfa
p646
sg14
I8
sg22
VP01375
p647
sg17
I1
sa(dp648
g12
I90
sg13
Vtumor necrosis factor alpha
p649
sg14
I27
sg22
VP01375
p650
sg17
I4
sa(dp651
g12
I165
sg13
VTGF-Beta1
p652
sg14
I9
sg22
VP01137
p653
sg17
I1
sa(dp654
g12
I195
sg13
VIFN-Gamma
p655
sg14
I9
sg22
VP01579
p656
sg17
I1
sa(dp657
g12
I177
sg13
Vinterferon gamma
p658
sg14
I16
sg22
VP01579
p659
sg17
I2
sa(dp660
g12
I222
sg13
VIL-6
p661
sg14
I4
sg22
VP05231
p662
sg17
I1
sa(dp663
g12
I233
sg13
g626
sg14
I14
sg22
VP22301
p664
sg17
I1
sasa(dp665
g2
VUsing absolute value of log2 fold-change &gt; 2 or extremely small P value (10-20) as a criterion, we identified nine significant genes (HBA1, HBB, HIST1H2AC, GSTT1, MYL7, NPPA, NPPB, PDK4, PLA2G2A) in LVH, also found in published data set for ischemic and dilated cardiomyopathy in heart failure.
p666
sg4
(dp667
(VPLA2G2A
p668
Vheart failure
p669
tp670
I00
ssg9
(lp671
(dp672
g12
I257
sg13
Vdilated cardiomyopathy
p673
sg14
I22
sg15
VC0007193
p674
sg17
I2
sa(dp675
g12
I202
sg13
VLVH
p676
sg14
I3
sg15
VC0149721
p677
sg17
I1
sa(dp678
g12
I283
sg13
g669
sg14
I13
sg15
VC0018802
p679
sg17
I2
sasg18
(lp680
(dp681
g12
I166
sg13
VMYL7
p682
sg14
I4
sg22
g190
sg17
I1
sa(dp683
g12
I159
sg13
VGSTT1
p684
sg14
I5
sg22
VP30711
p685
sg17
I1
sa(dp686
g12
I137
sg13
VHBA1
p687
sg14
I4
sg22
VP69905
p688
sg17
I1
sa(dp689
g12
I143
sg13
VHBB
p690
sg14
I3
sg22
VP02042
p691
sg17
I1
sa(dp692
g12
I172
sg13
VNPPA
p693
sg14
I4
sg22
VP01160
p694
sg17
I1
sa(dp695
g12
I178
sg13
VNPPB
p696
sg14
I4
sg22
VP16860
p697
sg17
I1
sa(dp698
g12
I148
sg13
VHIST1H2AC
p699
sg14
I9
sg22
g190
sg17
I1
sa(dp700
g12
I184
sg13
VPDK4
p701
sg14
I4
sg22
g190
sg17
I1
sa(dp702
g12
I190
sg13
g668
sg14
I7
sg22
VP14555
p703
sg17
I1
sasa(dp704
g2
VTolerized cow's milk protein (CMP)-sensitive atopic dermatitis had, in particular, decreased kappa-casein-specific IgG(1) levels, compared with clinically reactive patients.
p705
sg4
(dp706
(Vkappa-casein-specific IgG(1)
p707
Vatopic dermatitis
p708
tp709
I00
ssg9
(lp710
(dp711
g12
I45
sg13
g708
sg14
I17
sg15
VC0011615
p712
sg17
I2
sasg18
(lp713
(dp714
g12
I93
sg13
g707
sg14
I28
sg22
VP07498
p715
sg17
I2
sasa(dp716
g2
VTolerised patients, particularly those with atopic dermatitis, had decreased responses to kappa-casein which were restored after Treg depletion.
p717
sg4
(dp718
(Vkappa-casein
p719
Vatopic dermatitis
p720
tp721
I00
ssg9
(lp722
(dp723
g12
I44
sg13
g720
sg14
I17
sg15
VC0011615
p724
sg17
I2
sasg18
(lp725
(dp726
g12
I90
sg13
g719
sg14
I12
sg22
VP07498
p727
sg17
I1
sasa(dp728
g2
VA markedly decreased proliferative response to kappa-casein in tolerised IgE-mediated CMA patients with atopic dermatitis, which was abrogated by Treg depletion, suggested a role for kappa-casein in tolerance induction.
p729
sg4
(dp730
(Vkappa-casein
p731
Vatopic dermatitis
p732
tp733
I00
ssg9
(lp734
(dp735
g12
I21
sg13
Vproliferative
p736
sg14
I13
sg15
VC0334094
p737
sg17
I1
sa(dp738
g12
I73
sg13
VIgE
p739
sg14
I3
sg15
VC0270850
p740
sg17
I1
sa(dp741
g12
I104
sg13
g732
sg14
I17
sg15
VC0011615
p742
sg17
I2
sa(dp743
g12
I199
sg13
Vtolerance
p744
sg14
I9
sg15
VC0020963
p745
sg17
I1
sasg18
(lp746
(dp747
g12
I47
sg13
Vkappa-casein
p748
sg14
I12
sg22
VP07498
p749
sg17
I1
sa(dp750
g12
I73
sg13
VIgE
p751
sg14
I3
sg22
VP01854
p752
sg17
I1
sa(dp753
g12
I47
sg13
g731
sg14
I12
sg22
VP07498
p754
sg17
I1
sasa(dp755
g2
VIn order to investigate the role of food antigen-specific T cells circulating in the blood of patients with food allergy, we compared T cell response to three casein components (alpha s-, beta- and, kappa-casein) with specificities of IgG and IgE binding to the casein components in four milk-allergic patients (P1-4) with atopic dermatitis.
p756
sg4
(dp757
(VIgE
p758
VIgE
p759
tp760
I01
ssg9
(lp761
(dp762
g12
I323
sg13
Vatopic dermatitis
p763
sg14
I17
sg15
VC0011615
p764
sg17
I2
sa(dp765
g12
I108
sg13
Vfood allergy
p766
sg14
I12
sg15
VC0016470
p767
sg17
I2
sa(dp768
g12
I243
sg13
g759
sg14
I3
sg15
VC0270850
p769
sg17
I1
sasg18
(lp770
(dp771
g12
I243
sg13
g758
sg14
I3
sg22
VP01854
p772
sg17
I1
sasa(dp773
g2
VStudies have identified that PKM2 is related to the development of glucose intolerance and insulin resistance in rodents and humans.
p774
sg4
(dp775
(Vinsulin
p776
Vglucose intolerance
p777
tp778
I00
ssg9
(lp779
(dp780
g12
I91
sg13
Vinsulin resistance
p781
sg14
I18
sg15
VC0021655
p782
sg17
I2
sa(dp783
g12
I67
sg13
g777
sg14
I19
sg15
VC0271650
p784
sg17
I2
sasg18
(lp785
(dp786
g12
I91
sg13
g776
sg14
I7
sg22
VP01308
p787
sg17
I1
sasa(dp788
g2
VConversely, we found that pharmacological activation of PKM2 by a small-molecule PKM2 activator, TEPP-46, reversed hyperglycemia-induced elevation in toxic glucose metabolites and mitochondrial dysfunction, partially by increasing glycolytic flux and PGC-1Alfa mRNA in cultured podocytes.
p789
sg4
(dp790
(Vsmall-molecule PKM2 activator
p791
Vhyperglycemia
p792
tp793
I00
ssg9
(lp794
(dp795
g12
I115
sg13
g792
sg14
I13
sg15
VC0020456
p796
sg17
I1
sasg18
(lp797
(dp798
g12
I251
sg13
VPGC-1Alfa mRNA
p799
sg14
I14
sg22
VP20142
p800
sg17
I2
sa(dp801
g12
I97
sg13
VTEPP-46
p802
sg14
I7
sg22
g190
sg17
I1
sa(dp803
g12
I66
sg13
g791
sg14
I29
sg22
VP05154
p804
sg17
I3
sasa(dp805
g2
VFurther research suggested that METTL13 negatively regulates cell proliferation in bladder cancer and reinstates G1/S checkpoint via the coordinated downregulation of CDK6, CDK4 and CCND1, decreased phosphorylation of Rb and subsequent delayed cell cycle progression.
p806
sg4
(dp807
(VCDK4
p808
Vbladder cancer
p809
tp810
I00
ssg9
(lp811
(dp812
g12
I66
sg13
Vproliferation
p813
sg14
I13
sg15
VC0334094
p814
sg17
I1
sa(dp815
g12
I83
sg13
g809
sg14
I14
sg15
VC0699885
p816
sg17
I2
sasg18
(lp817
(dp818
g12
I182
sg13
VCCND1
p819
sg14
I5
sg22
VP24385
p820
sg17
I1
sa(dp821
g12
I173
sg13
g808
sg14
I4
sg22
VP11802
p822
sg17
I1
sa(dp823
g12
I167
sg13
VCDK6
p824
sg14
I4
sg22
g190
sg17
I1
sasa(dp825
g2
Vp34cdc2, collapsin response mediator protein 4 (CRMP4), doublecortin (DCX), HuD, and NeuN expression was assessed in tuber (n = 16) and subependymal giant cell astrocytoma (SEGA; n = 6) specimens in tuberous sclerosis complex to define the developmental phenotype and lineage of giant cells (CGs) in these lesions.
p826
sg4
(dp827
(Vp34cdc2
p828
VSEGA
p829
tp830
I01
ssg9
(lp831
(dp832
g12
I199
sg13
Vtuberous sclerosis complex
p833
sg14
I26
sg15
VC0041341
p834
sg17
I3
sa(dp835
g12
I136
sg13
Vsubependymal giant cell astrocytoma
p836
sg14
I35
sg15
VC0205768
p837
sg17
I4
sa(dp838
g12
I149
sg13
Vgiant
p839
sg14
I5
sg15
VC0017547
p840
sg17
I1
sa(dp841
g12
I173
sg13
g829
sg14
I4
sg15
VC0205768
p842
sg17
I1
sasg18
(lp843
(dp844
g12
I85
sg13
VNeuN
p845
sg14
I4
sg22
g190
sg17
I1
sa(dp846
g12
I48
sg13
VCRMP4
p847
sg14
I5
sg22
g190
sg17
I1
sa(dp848
g12
I70
sg13
VDCX
p849
sg14
I3
sg22
g190
sg17
I1
sa(dp850
g12
I9
sg13
Vcollapsin response mediator protein 4
p851
sg14
I37
sg22
g190
sg17
I5
sa(dp852
g12
I76
sg13
VHuD
p853
sg14
I3
sg22
VP26378
p854
sg17
I1
sa(dp855
g12
I0
sg13
g828
sg14
I7
sg22
VP06493
p856
sg17
I1
sa(dp857
g12
I56
sg13
Vdoublecortin
p858
sg14
I12
sg22
g190
sg17
I1
sasa(dp859
g2
VFirst, logistic regression analysis in two human prostate gene expression datasets revealed that expression levels of five genes (CXCL14, ITGAX, LPCAT2, RNASEH2A, and ZNF322) were positively correlated with aggressive prostate cancer and two genes (CCL19 and HIST1H1A) were protective for aggressive prostate cancer.
p860
sg4
(dp861
(VITGAX
p862
Vaggressive
p863
tp864
I00
ssg9
(lp865
(dp866
g12
I218
sg13
Vprostate cancer
p867
sg14
I15
sg15
VC0600139
p868
sg17
I2
sa(dp869
g12
I207
sg13
Vaggressive
p870
sg14
I10
sg15
VC0001807
p871
sg17
I1
sa(dp872
g12
I218
sg13
Vprostate cancer
p873
sg14
I15
sg15
VC0600139
p874
sg17
I2
sa(dp875
g12
I207
sg13
g863
sg14
I10
sg15
VC0001807
p876
sg17
I1
sasg18
(lp877
(dp878
g12
I153
sg13
VRNASEH2A
p879
sg14
I8
sg22
g190
sg17
I1
sa(dp880
g12
I130
sg13
VCXCL14
p881
sg14
I6
sg22
g190
sg17
I1
sa(dp882
g12
I167
sg13
VZNF322
p883
sg14
I6
sg22
g190
sg17
I1
sa(dp884
g12
I138
sg13
g862
sg14
I5
sg22
VP20702
p885
sg17
I1
sa(dp886
g12
I145
sg13
VLPCAT2
p887
sg14
I6
sg22
g190
sg17
I1
sa(dp888
g12
I259
sg13
VHIST1H1A
p889
sg14
I8
sg22
g190
sg17
I1
sa(dp890
g12
I249
sg13
VCCL19
p891
sg14
I5
sg22
g190
sg17
I1
sasa(dp892
g2
VSecond generation H1 antihistamines (H1A) are currently recommended as first choice medications for allergic rhinitis and rhinoconjunctivitis.
p893
sg4
(dp894
(VH1 antihistamines
p895
Vallergic rhinitis
p896
tp897
I00
ssg9
(lp898
(dp899
g12
I122
sg13
Vrhinoconjunctivitis
p900
sg14
I19
sg15
VC0861155
p901
sg17
I1
sa(dp902
g12
I100
sg13
g896
sg14
I17
sg15
VC2607914
p903
sg17
I2
sasg18
(lp904
(dp905
g12
I18
sg13
g895
sg14
I17
sg22
VP08620
p906
sg17
I2
sa(dp907
g12
I37
sg13
VH1A
p908
sg14
I3
sg22
g190
sg17
I1
sasa(dp909
g2
VAntibody 3.1 potently neutralizes influenza viruses from the H1a clade (i.e., H1, H2, H5, H6) but has little neutralizing activity against the H1b clade.
p910
sg4
(dp911
(VH1b
p912
Vinfluenza
p913
tp914
I00
ssg9
(lp915
(dp916
g12
I34
sg13
g913
sg14
I9
sg15
VC0021400
p917
sg17
I1
sasg18
(lp918
(dp919
g12
I143
sg13
g912
sg14
I3
sg22
VP16401
p920
sg17
I1
sasa(dp921
g2
VWe have overexpressed OTX2 in retinal pigmented epithelial cells before their transplantation in the eye of a model of retinitis pigmentosa carrying a mutation in Mertk, a gene specifically expressed by retinal pigmented epithelial cells.
p922
sg4
(dp923
(VOTX2
p924
Vretinitis pigmentosa
p925
tp926
I01
ssg9
(lp927
(dp928
g12
I119
sg13
g925
sg14
I20
sg15
VC0035334
p929
sg17
I2
sasg18
(lp930
(dp931
g12
I22
sg13
g924
sg14
I4
sg22
VP32243
p932
sg17
I1
sa(dp933
g12
I163
sg13
VMertk
p934
sg14
I5
sg22
g190
sg17
I1
sasa(dp935
g2
VTransplantation of OTX2-genetically modified cells may be medically effective for other retinal diseases involving the retinal pigmented epithelium as age-related macular degeneration.
p936
sg4
(dp937
(VOTX2
p938
Vage-related macular degeneration
p939
tp940
I00
ssg9
(lp941
(dp942
g12
I88
sg13
Vretinal diseases
p943
sg14
I16
sg15
VC0035309
p944
sg17
I2
sa(dp945
g12
I151
sg13
g939
sg14
I32
sg15
VC0242383
p946
sg17
I3
sasg18
(lp947
(dp948
g12
I19
sg13
g938
sg14
I4
sg22
VP32243
p949
sg17
I1
sasa(dp950
g2
VTherapeutic restoration of OTX2 expression might help revive RPE and visual function in retinal diseases such as AMD.
p951
sg4
(dp952
(VOTX2
p953
VAMD
p954
tp955
I00
ssg9
(lp956
(dp957
g12
I88
sg13
Vretinal diseases
p958
sg14
I16
sg15
VC0035309
p959
sg17
I2
sa(dp960
g12
I113
sg13
g954
sg14
I3
sg15
VC0242383
p961
sg17
I1
sasg18
(lp962
(dp963
g12
I27
sg13
g953
sg14
I4
sg22
VP32243
p964
sg17
I1
sasa(dp965
g2
VThe retinal disease resembles conditional mice models that show slow photoreceptor degeneration secondary to loss of Otx2 function in the adult RPE.
p966
sg4
(dp967
(VOtx2
p968
Vphotoreceptor degeneration
p969
tp970
I00
ssg9
(lp971
(dp972
g12
I83
sg13
Vdegeneration secondary
p973
sg14
I22
sg15
VC0043020
p974
sg17
I2
sa(dp975
g12
I4
sg13
Vretinal disease
p976
sg14
I15
sg15
VC0035309
p977
sg17
I2
sa(dp978
g12
I69
sg13
g969
sg14
I26
sg15
VC1998028
p979
sg17
I2
sasg18
(lp980
(dp981
g12
I117
sg13
g968
sg14
I4
sg22
VP32243
p982
sg17
I1
sasa(dp983
g2
VWhen the beads were coated with amelogenin gene splice products (A+4 or A-4), the expression of osteo-chondrogenic markers (RP59, Sox9, or BSP) was also observed.
p984
sg4
(dp985
(VSox9
p986
VRP59
p987
tp988
I00
ssg9
(lp989
(dp990
g12
I124
sg13
g987
sg14
I4
sg15
VC3151227
p991
sg17
I1
sasg18
(lp992
(dp993
g12
I32
sg13
Vamelogenin gene splice products
p994
sg14
I31
sg22
g190
sg17
I4
sa(dp995
g12
I130
sg13
g986
sg14
I4
sg22
VP48436
p996
sg17
I1
sasa(dp997
g2
VAutosomal recessive HMG-CoA synthase deficiency (HMGCS2D) is characterized by hypoketotic hypoglycemia, vomiting, lethargy, and hepatomegaly after periods of prolonged fasting or illness.
p998
sg4
(dp999
(VHMG-CoA synthase
p1000
Vlethargy
p1001
tp1002
I00
ssg9
(lp1003
(dp1004
g12
I90
sg13
Vhypoglycemia
p1005
sg14
I12
sg15
VC0020615
p1006
sg17
I1
sa(dp1007
g12
I104
sg13
Vvomiting
p1008
sg14
I8
sg15
VC0042963
p1009
sg17
I1
sa(dp1010
g12
I128
sg13
Vhepatomegaly
p1011
sg14
I12
sg15
VC0019209
p1012
sg17
I1
sa(dp1013
g12
I24
sg13
VCoA
p1014
sg14
I3
sg15
VC2678439
p1015
sg17
I1
sa(dp1016
g12
I114
sg13
g1001
sg14
I8
sg15
VC0023380
p1017
sg17
I1
sasg18
(lp1018
(dp1019
g12
I20
sg13
g1000
sg14
I16
sg22
VP54868
p1020
sg17
I2
sasa(dp1021
g2
VIf left untreated this deficiency of functional FAH leads to a buildup of toxic metabolites that can cause liver disease, kidney dysfunction and high mortality.
p1022
sg4
(dp1023
(VFAH
p1024
Vkidney dysfunction
p1025
tp1026
I00
ssg9
(lp1027
(dp1028
g12
I113
sg13
Vdisease, kidney
p1029
sg14
I15
sg15
VC0022658
p1030
sg17
I2
sa(dp1031
g12
I122
sg13
g1025
sg14
I18
sg15
VC0151746
p1032
sg17
I2
sasg18
(lp1033
(dp1034
g12
I48
sg13
g1024
sg14
I3
sg22
VP16930
p1035
sg17
I1
sasa(dp1036
g2
VIn this study, we investigated whether fumarylacetoacetate hydrolase deficient (FAH-/-) pigs, a novel large-animal model of HT1, develop fibrosis and cirrhosis characteristic of the human disease.
p1037
sg4
(dp1038
(Vfumarylacetoacetate hydrolase
p1039
Vfibrosis
p1040
tp1041
I00
ssg9
(lp1042
(dp1043
g12
I150
sg13
Vcirrhosis
p1044
sg14
I9
sg15
VC0023890
p1045
sg17
I1
sa(dp1046
g12
I137
sg13
g1040
sg14
I8
sg15
VC0016059
p1047
sg17
I1
sasg18
(lp1048
(dp1049
g12
I39
sg13
g1039
sg14
I29
sg22
VP16930
p1050
sg17
I2
sasa(dp1051
g2
VFah-deficient mice and pigs are phenotypically analogous to human HT1, but do not recapitulate all the chronic features of the human disorder, especially liver fibrosis and cirrhosis.
p1052
sg4
(dp1053
(VFah
p1054
Vcirrhosis
p1055
tp1056
I00
ssg9
(lp1057
(dp1058
g12
I154
sg13
Vliver fibrosis
p1059
sg14
I14
sg15
VC0239946
p1060
sg17
I2
sa(dp1061
g12
I173
sg13
g1055
sg14
I9
sg15
VC0023890
p1062
sg17
I1
sasg18
(lp1063
(dp1064
g12
I0
sg13
g1054
sg14
I3
sg22
VP16930
p1065
sg17
I1
sasa(dp1066
g2
VMore importantly, the Fah(-/-) rats developed remarkable liver fibrosis and cirrhosis, which have not been observed in Fah mutant mice or pigs.
p1067
sg4
(dp1068
(VFah mutant
p1069
Vcirrhosis
p1070
tp1071
I00
ssg9
(lp1072
(dp1073
g12
I57
sg13
Vliver fibrosis
p1074
sg14
I14
sg15
VC0239946
p1075
sg17
I2
sa(dp1076
g12
I76
sg13
g1070
sg14
I9
sg15
VC0023890
p1077
sg17
I1
sa(dp1078
g12
I123
sg13
Vmutant
p1079
sg14
I6
sg15
VC0596988
p1080
sg17
I1
sasg18
(lp1081
(dp1082
g12
I22
sg13
VFah(-/-)
p1083
sg14
I8
sg22
VP16930
p1084
sg17
I1
sa(dp1085
g12
I119
sg13
g1069
sg14
I10
sg22
VP16930
p1086
sg17
I2
sasa(dp1087
g2
VMoreover, the highly efficient repopulation of hepatocytes in Fah(-/-) livers prevented the progression of liver fibrosis to cirrhosis and in turn restored liver architecture.
p1088
sg4
(dp1089
(VFah(-/-)
p1090
Vliver fibrosis
p1091
tp1092
I00
ssg9
(lp1093
(dp1094
g12
I125
sg13
Vcirrhosis
p1095
sg14
I9
sg15
VC0023890
p1096
sg17
I1
sa(dp1097
g12
I107
sg13
g1091
sg14
I14
sg15
VC0239946
p1098
sg17
I2
sasg18
(lp1099
(dp1100
g12
I62
sg13
g1090
sg14
I8
sg22
VP16930
p1101
sg17
I1
sasa(dp1102
g2
VThese results indicate that Fah(-/-) rats may be used as an animal model of HT1 with liver cirrhosis.
p1103
sg4
(dp1104
(VFah
p1105
Vliver cirrhosis
p1106
tp1107
I00
ssg9
(lp1108
(dp1109
g12
I85
sg13
g1106
sg14
I15
sg15
VC0023890
p1110
sg17
I2
sasg18
(lp1111
(dp1112
g12
I28
sg13
g1105
sg14
I3
sg22
VP16930
p1113
sg17
I1
sasa(dp1114
g2
VRecent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).
p1115
sg4
(dp1116
(VCHAT
p1117
Vglaucoma
p1118
tp1119
I00
ssg9
(lp1120
(dp1121
g12
I60
sg13
Vglaucoma
p1122
sg14
I8
sg15
VC0017601
p1123
sg17
I1
sa(dp1124
g12
I114
sg13
Vopen-angle glaucoma
p1125
sg14
I19
sg15
VC0017612
p1126
sg17
I2
sa(dp1127
g12
I323
sg13
VXFS
p1128
sg14
I3
sg15
VC0206368
p1129
sg17
I1
sa(dp1130
g12
I100
sg13
VPOAG
p1131
sg14
I4
sg15
VC0339573
p1132
sg17
I1
sa(dp1133
g12
I301
sg13
Vexfoliation syndrome
p1134
sg14
I20
sg15
VC0206368
p1135
sg17
I2
sa(dp1136
g12
I223
sg13
Vprimary angle-closure glaucoma
p1137
sg14
I30
sg15
VC0017606
p1138
sg17
I3
sa(dp1139
g12
I60
sg13
g1118
sg14
I8
sg15
VC0017601
p1140
sg17
I1
sasg18
(lp1141
(dp1142
g12
I178
sg13
VARHGEF12
p1143
sg14
I8
sg22
g190
sg17
I1
sa(dp1144
g12
I268
sg13
VGLIS3
p1145
sg14
I5
sg22
g190
sg17
I1
sa(dp1146
g12
I201
sg13
VATXN2
p1147
sg14
I5
sg22
g190
sg17
I1
sa(dp1148
g12
I150
sg13
VGMDS
p1149
sg14
I4
sg22
g190
sg17
I1
sa(dp1150
g12
I255
sg13
VEPDR1
p1151
sg14
I5
sg22
g190
sg17
I1
sa(dp1152
g12
I194
sg13
VFOXC1
p1153
sg14
I5
sg22
g190
sg17
I1
sa(dp1154
g12
I162
sg13
VTGFBR3
p1155
sg14
I6
sg22
g190
sg17
I1
sa(dp1156
g12
I283
sg13
VDPM2-FAM102
p1157
sg14
I11
sg22
g190
sg17
I1
sa(dp1158
g12
I275
sg13
VFERMT2
p1159
sg14
I6
sg22
g190
sg17
I1
sa(dp1160
g12
I156
sg13
VPMM2
p1161
sg14
I4
sg22
g190
sg17
I1
sa(dp1162
g12
I188
sg13
VGAS7
p1163
sg14
I4
sg22
g190
sg17
I1
sa(dp1164
g12
I262
sg13
g1117
sg14
I4
sg22
VP28329
p1165
sg17
I1
sa(dp1166
g12
I143
sg13
VAFAP1
p1167
sg14
I5
sg22
g190
sg17
I1
sasa(dp1168
g2
VRecently, a genome-wide association study identified genetic variations in ITGA4 and HLA-DRB1 that affect the LMR levels and were widely believed to be susceptibility genes for autoimmune diseases, including rheumatoid arthritis (RA).
p1169
sg4
(dp1170
(VITGA4
p1171
Vautoimmune diseases
p1172
tp1173
I00
ssg9
(lp1174
(dp1175
g12
I208
sg13
Vrheumatoid arthritis
p1176
sg14
I20
sg15
VC0003873
p1177
sg17
I2
sa(dp1178
g12
I230
sg13
VRA
p1179
sg14
I2
sg15
VC0003873
p1180
sg17
I1
sa(dp1181
g12
I177
sg13
g1172
sg14
I19
sg15
VC0004364
p1182
sg17
I2
sasg18
(lp1183
(dp1184
g12
I85
sg13
VHLA
p1185
sg14
I3
sg22
VP30486
p1186
sg17
I1
sa(dp1187
g12
I89
sg13
VDRB1
p1188
sg14
I4
sg22
g190
sg17
I1
sa(dp1189
g12
I75
sg13
g1171
sg14
I5
sg22
VP13612
p1190
sg17
I1
sasa(dp1191
g2
VTo evaluate serum levels of fractalkine (FKN), a mediator of leukocyte transmigration, C-reactive protein (CRP) and expression of integrins CD11a and CD49d on peripheral blood lymphocytes in systemic sclerosis (SSc) and to investigate whether they are modulated by intravenous prostaglandin E1 (PGE1).
p1192
sg4
(dp1193
(VC-reactive protein
p1194
Vsystemic sclerosis
p1195
tp1196
I00
ssg9
(lp1197
(dp1198
g12
I211
sg13
VSSc
p1199
sg14
I3
sg15
VC0036421
p1200
sg17
I1
sa(dp1201
g12
I191
sg13
g1195
sg14
I18
sg15
VC0036421
p1202
sg17
I2
sasg18
(lp1203
(dp1204
g12
I140
sg13
VCD11a
p1205
sg14
I5
sg22
VP20701
p1206
sg17
I1
sa(dp1207
g12
I150
sg13
VCD49d
p1208
sg14
I5
sg22
VP13612
p1209
sg17
I1
sa(dp1210
g12
I107
sg13
VCRP
p1211
sg14
I3
sg22
VP02741
p1212
sg17
I1
sa(dp1213
g12
I87
sg13
g1194
sg14
I18
sg22
VP02741
p1214
sg17
I2
sasa(dp1215
g2
VProstaglandin E1 down-regulates serum fractalkine level, as well as CD11a and CD49d expression on peripheral blood lymphocytes, which suggests additional mechanisms in which this vasodilatatory agent exerts its efficacy in systemic sclerosis.
p1216
sg4
(dp1217
(VCD11a
p1218
Vsystemic sclerosis
p1219
tp1220
I01
ssg9
(lp1221
(dp1222
g12
I223
sg13
g1219
sg14
I18
sg15
VC0036421
p1223
sg17
I2
sasg18
(lp1224
(dp1225
g12
I78
sg13
VCD49d
p1226
sg14
I5
sg22
VP13612
p1227
sg17
I1
sa(dp1228
g12
I68
sg13
g1218
sg14
I5
sg22
VP20701
p1229
sg17
I1
sasa(dp1230
g2
VMR-1S directly phosphorylates and activates the MEK-ERK-RSK pathway to accelerate cancer growth and facilitates metastasis by activating the MLC2-FAK-AKT pathway.
p1231
sg4
(dp1232
(VRSK
p1233
Vmetastasis
p1234
tp1235
I00
ssg9
(lp1236
(dp1237
g12
I112
sg13
g1234
sg14
I10
sg15
VC0027627
p1238
sg17
I1
sa(dp1239
g12
I82
sg13
Vcancer
p1240
sg14
I6
sg15
VC0006826
p1241
sg17
I1
sasg18
(lp1242
(dp1243
g12
I141
sg13
VMLC2
p1244
sg14
I4
sg22
VP24844
p1245
sg17
I1
sa(dp1246
g12
I150
sg13
VAKT
p1247
sg14
I3
sg22
g190
sg17
I1
sa(dp1248
g12
I48
sg13
VMEK
p1249
sg14
I3
sg22
VP45985
p1250
sg17
I1
sa(dp1251
g12
I52
sg13
VERK
p1252
sg14
I3
sg22
VP29323
p1253
sg17
I1
sa(dp1254
g12
I146
sg13
VFAK
p1255
sg14
I3
sg22
g190
sg17
I1
sa(dp1256
g12
I0
sg13
VMR-1S
p1257
sg14
I5
sg22
VP08235
p1258
sg17
I1
sa(dp1259
g12
I56
sg13
g1233
sg14
I3
sg22
VP51812
p1260
sg17
I1
sasa(dp1261
g2
VAfter overexpressing TMEM17, levels of p-ERK and its downstream molecules, p-P90RSK and Snail, were down-regulated, while levels of Occludin and Zo-1 were up-regulated, which result in the inhibition of invasion and migration ability of lung cancer cells.
p1262
sg4
(dp1263
(VERK
p1264
Vlung cancer
p1265
tp1266
I00
ssg9
(lp1267
(dp1268
g12
I203
sg13
Vinvasion
p1269
sg14
I8
sg15
VC2699153
p1270
sg17
I1
sa(dp1271
g12
I237
sg13
g1265
sg14
I11
sg15
VC0684249
p1272
sg17
I2
sasg18
(lp1273
(dp1274
g12
I132
sg13
VOccludin
p1275
sg14
I8
sg22
g190
sg17
I1
sa(dp1276
g12
I41
sg13
g1264
sg14
I3
sg22
VP29323
p1277
sg17
I1
sa(dp1278
g12
I145
sg13
VZo-1
p1279
sg14
I4
sg22
g190
sg17
I1
sa(dp1280
g12
I21
sg13
VTMEM17
p1281
sg14
I6
sg22
g190
sg17
I1
sasa(dp1282
g2
VHerein, to understand the underlying relationship between obesity and brain tumors, we investigated the effect of leptin, alone or in combination with sPLA2-IIA on astrocytoma cell functions.
p1283
sg4
(dp1284
(VsPLA2-IIA
p1285
Vobesity
p1286
tp1287
I00
ssg9
(lp1288
(dp1289
g12
I164
sg13
Vastrocytoma
p1290
sg14
I11
sg15
VC0004114
p1291
sg17
I1
sa(dp1292
g12
I70
sg13
Vbrain tumors
p1293
sg14
I12
sg15
VC0006118
p1294
sg17
I2
sa(dp1295
g12
I58
sg13
g1286
sg14
I7
sg15
VC0028754
p1296
sg17
I1
sasg18
(lp1297
(dp1298
g12
I114
sg13
Vleptin
p1299
sg14
I6
sg22
VP41159
p1300
sg17
I1
sa(dp1301
g12
I151
sg13
g1285
sg14
I9
sg22
VP14555
p1302
sg17
I1
sasa(dp1303
g2
VPLA2g2a was elevated with hypothyroidism and high fat diets which may contribute to the low grade inflammation associated with hypothyroidism and diet induced obesity.
p1304
sg4
(dp1305
(VPLA2g2a
p1306
Vobesity
p1307
tp1308
I00
ssg9
(lp1309
(dp1310
g12
I26
sg13
Vhypothyroidism
p1311
sg14
I14
sg15
VC0020676
p1312
sg17
I1
sa(dp1313
g12
I26
sg13
Vhypothyroidism
p1314
sg14
I14
sg15
VC0020676
p1315
sg17
I1
sa(dp1316
g12
I98
sg13
Vinflammation
p1317
sg14
I12
sg15
VC0021368
p1318
sg17
I1
sa(dp1319
g12
I159
sg13
g1307
sg14
I7
sg15
VC0028754
p1320
sg17
I1
sasg18
(lp1321
(dp1322
g12
I0
sg13
g1306
sg14
I7
sg22
VP14555
p1323
sg17
I1
sasa(dp1324
g2
VThere were significant correlations between age, visceral obesity, MPO, sPLA2, and SAA (r = 0.43; p = 0.00; r = 0.30; p = 0.00; r = 0.28; p = 0.00 and r = 0.53; p = 0.00).
p1325
sg4
(dp1326
(VsPLA2
p1327
Vvisceral obesity
p1328
tp1329
I00
ssg9
(lp1330
(dp1331
g12
I49
sg13
g1328
sg14
I16
sg15
VC2936179
p1332
sg17
I2
sasg18
(lp1333
(dp1334
g12
I67
sg13
VMPO
p1335
sg14
I3
sg22
VP05164
p1336
sg17
I1
sa(dp1337
g12
I72
sg13
g1327
sg14
I5
sg22
VP14555
p1338
sg17
I1
sasa(dp1339
g2
VWe suggest that pla2g2a may have a causal relationship with chronic adiposity and metabolic syndrome and that its inhibition in vivo may be a valuable new approach to treat obesity, type 2 diabetes, and metabolic dysfunction in humans.
p1340
sg4
(dp1341
(Vpla2g2a
p1342
Vmetabolic syndrome
p1343
tp1344
I00
ssg9
(lp1345
(dp1346
g12
I182
sg13
Vtype 2 diabetes
p1347
sg14
I15
sg15
VC0011860
p1348
sg17
I3
sa(dp1349
g12
I68
sg13
Vadiposity
p1350
sg14
I9
sg15
VC0028754
p1351
sg17
I1
sa(dp1352
g12
I173
sg13
Vobesity
p1353
sg14
I7
sg15
VC0028754
p1354
sg17
I1
sa(dp1355
g12
I82
sg13
g1343
sg14
I18
sg15
VC0524620
p1356
sg17
I2
sasg18
(lp1357
(dp1358
g12
I16
sg13
g1342
sg14
I7
sg22
VP14555
p1359
sg17
I1
sasa(dp1360
g2
VTrypanosoma brucei, protozoan parasites that cause human African trypanosomiasis (HAT), depend on ornithine uptake and metabolism by ornithine decarboxylase (ODC) for survival.
p1361
sg4
(dp1362
(VODC
p1363
VAfrican trypanosomiasis
p1364
tp1365
I00
ssg9
(lp1366
(dp1367
g12
I57
sg13
g1364
sg14
I23
sg15
VC0041228
p1368
sg17
I2
sasg18
(lp1369
(dp1370
g12
I133
sg13
Vornithine decarboxylase
p1371
sg14
I23
sg22
VP11926
p1372
sg17
I2
sa(dp1373
g12
I158
sg13
g1363
sg14
I3
sg22
VP11926
p1374
sg17
I1
sa(dp1375
g12
I82
sg13
VHAT
p1376
sg14
I3
sg22
g190
sg17
I1
sa(dp1377
g12
I51
sg13
Vhuman African trypanosomiasis
p1378
sg14
I29
sg22
g190
sg17
I3
sasa(dp1379
g2
Varginase (ARG), ornithine decarboxylase (ODC), S-adenosylmethionine decarboxylase (AdoMetDC), spermidine synthase (SpdS), trypanothione synthetase (TryS or TSA), trypanothione reductase (TryR or TR), tryparedoxin peroxidase (TXNPx), deoxyhypusine synthase (DHS) and deoxyhypusine hydroxylase (DOHH) are promising targets for the development of new drugs against leishmaniasis.
p1380
sg4
(dp1381
(Vdeoxyhypusine synthase
p1382
Vleishmaniasis
p1383
tp1384
I00
ssg9
(lp1385
(dp1386
g12
I257
sg13
VDHS
p1387
sg14
I3
sg15
VC0272051
p1388
sg17
I1
sa(dp1389
g12
I362
sg13
g1383
sg14
I13
sg15
VC0023281
p1390
sg17
I1
sasg18
(lp1391
(dp1392
g12
I0
sg13
Varginase (ARG), ornithine decarboxylase
p1393
sg14
I39
sg22
VP11926
p1394
sg17
I4
sa(dp1395
g12
I266
sg13
Vdeoxyhypusine hydroxylase
p1396
sg14
I25
sg22
g190
sg17
I2
sa(dp1397
g12
I115
sg13
VSpdS
p1398
sg14
I4
sg22
VP35453
p1399
sg17
I1
sa(dp1400
g12
I225
sg13
VTXNPx
p1401
sg14
I5
sg22
VP30041
p1402
sg17
I1
sa(dp1403
g12
I83
sg13
VAdoMetDC
p1404
sg14
I8
sg22
VP17707
p1405
sg17
I1
sa(dp1406
g12
I156
sg13
VTSA
p1407
sg14
I3
sg22
VP32119
p1408
sg17
I1
sa(dp1409
g12
I94
sg13
Vspermidine synthase
p1410
sg14
I19
sg22
VP19623
p1411
sg17
I2
sa(dp1412
g12
I257
sg13
VDHS
p1413
sg14
I3
sg22
VP49366
p1414
sg17
I1
sa(dp1415
g12
I41
sg13
VODC
p1416
sg14
I3
sg22
VP11926
p1417
sg17
I1
sa(dp1418
g12
I162
sg13
Vtrypanothione reductase
p1419
sg14
I23
sg22
g190
sg17
I2
sa(dp1420
g12
I200
sg13
Vtryparedoxin peroxidase
p1421
sg14
I23
sg22
VP30041
p1422
sg17
I2
sa(dp1423
g12
I293
sg13
VDOHH
p1424
sg14
I4
sg22
g190
sg17
I1
sa(dp1425
g12
I47
sg13
VS-adenosylmethionine decarboxylase
p1426
sg14
I34
sg22
VP17707
p1427
sg17
I2
sa(dp1428
g12
I233
sg13
g1382
sg14
I22
sg22
VP49366
p1429
sg17
I2
sasa(dp1430
g2
VThe plasma levels of arginase I, ornithine decarboxylase (ODC), transforming growth factor Beta (TGF-Beta), and prostaglandin E2 (PGE2) were higher in patients with DCL, compared with patients with localized cutaneous leishmaniasis (LCL) or with controls from an area of endemicity.
p1431
sg4
(dp1432
(VTGF-Beta
p1433
Vcutaneous leishmaniasis
p1434
tp1435
I00
ssg9
(lp1436
(dp1437
g12
I208
sg13
g1434
sg14
I23
sg15
VC0023283
p1438
sg17
I2
sasg18
(lp1439
(dp1440
g12
I33
sg13
Vornithine decarboxylase
p1441
sg14
I23
sg22
VP11926
p1442
sg17
I2
sa(dp1443
g12
I21
sg13
Varginase I
p1444
sg14
I10
sg22
VP05089
p1445
sg17
I2
sa(dp1446
g12
I64
sg13
Vtransforming growth factor Beta
p1447
sg14
I31
sg22
VP18075
p1448
sg17
I4
sa(dp1449
g12
I58
sg13
VODC
p1450
sg14
I3
sg22
VP11926
p1451
sg17
I1
sa(dp1452
g12
I97
sg13
g1433
sg14
I8
sg22
VP18075
p1453
sg17
I1
sasa(dp1454
g2
VThe active form of vitamin B6, pyridoxal 5-phosphate, is, besides its antioxidative properties, a cofactor for a variety of essential enzymes present in the malaria parasite which includes the ornithine decarboxylase (ODC, synthesis of polyamines), the aspartate aminotransferase (AspAT, involved in the protein biosynthesis), and the serine hydroxymethyltransferase (SHMT, a key enzyme within the folate metabolism).
p1455
sg4
(dp1456
(VSHMT
p1457
Vmalaria
p1458
tp1459
I00
ssg9
(lp1460
(dp1461
g12
I157
sg13
g1458
sg14
I7
sg15
VC0024530
p1462
sg17
I1
sasg18
(lp1463
(dp1464
g12
I335
sg13
Vserine hydroxymethyltransferase
p1465
sg14
I31
sg22
VP34896
p1466
sg17
I2
sa(dp1467
g12
I281
sg13
VAspAT
p1468
sg14
I5
sg22
VP17174
p1469
sg17
I1
sa(dp1470
g12
I218
sg13
VODC
p1471
sg14
I3
sg22
VP11926
p1472
sg17
I1
sa(dp1473
g12
I193
sg13
Vornithine decarboxylase
p1474
sg14
I23
sg22
VP11926
p1475
sg17
I2
sa(dp1476
g12
I253
sg13
Vaspartate aminotransferase
p1477
sg14
I26
sg22
VP17174
p1478
sg17
I2
sa(dp1479
g12
I368
sg13
g1457
sg14
I4
sg22
VP34896
p1480
sg17
I1
sasa(dp1481
g2
VAlfa-Difluoromethylornithine (DFMO), a potent drug used for the treatment of African sleeping sickness is an irreversible inhibitor of ornithine decarboxylase (ODC), the first rate limiting enzyme of polyamine biosynthesis.
p1482
sg4
(dp1483
(VODC
p1484
VAfrican sleeping sickness
p1485
tp1486
I00
ssg9
(lp1487
(dp1488
g12
I77
sg13
g1485
sg14
I25
sg15
VC0041228
p1489
sg17
I3
sasg18
(lp1490
(dp1491
g12
I135
sg13
Vornithine decarboxylase
p1492
sg14
I23
sg22
VP11926
p1493
sg17
I2
sa(dp1494
g12
I160
sg13
g1484
sg14
I3
sg22
VP11926
p1495
sg17
I1
sasa(dp1496
g2
VGNs are categorized into three different morphological subtypes, namely, polypoid GN, ganglioneuromatous polyposis, and diffuse ganglioneuromatosis.
p1497
sg4
(dp1498
(VGNs
p1499
Vganglioneuromatosis
p1500
tp1501
I00
ssg9
(lp1502
(dp1503
g12
I105
sg13
Vpolyposis
p1504
sg14
I9
sg15
VC0334108
p1505
sg17
I1
sa(dp1506
g12
I128
sg13
g1500
sg14
I19
sg15
VC0334595
p1507
sg17
I1
sasg18
(lp1508
(dp1509
g12
I0
sg13
g1499
sg14
I3
sg22
VP15586
p1510
sg17
I1
sasa(dp1511
g2
VGanglioneuromas (GNs) are rare benign tumors and their association with neurofibromatosis type 1 (NF-1) is especially uncommon.
p1512
sg4
(dp1513
(VNF-1
p1514
VGanglioneuromas
p1515
tp1516
I00
ssg9
(lp1517
(dp1518
g12
I72
sg13
Vneurofibromatosis type 1
p1519
sg14
I24
sg15
VC0027831
p1520
sg17
I3
sa(dp1521
g12
I17
sg13
VGNs
p1522
sg14
I3
sg15
VC0017075
p1523
sg17
I1
sa(dp1524
g12
I98
sg13
VNF-1
p1525
sg14
I4
sg15
VC0027831
p1526
sg17
I1
sa(dp1527
g12
I31
sg13
Vbenign tumors
p1528
sg14
I13
sg15
VC0086692
p1529
sg17
I2
sa(dp1530
g12
I0
sg13
g1515
sg14
I15
sg15
VC0017075
p1531
sg17
I1
sasg18
(lp1532
(dp1533
g12
I72
sg13
Vneurofibromatosis type 1
p1534
sg14
I24
sg22
VP21359
p1535
sg17
I3
sa(dp1536
g12
I98
sg13
g1514
sg14
I4
sg22
VP21359
p1537
sg17
I1
sasa(dp1538
g2
VFour of eight T1D-specific regions contained known type 2 diabetes (T2D) candidate genes (COBL, GLIS3, RNLS and BCAR1), suggesting a shared cellular etiology.
p1539
sg4
(dp1540
(VBCAR1
p1541
Vtype 2 diabetes
p1542
tp1543
I00
ssg9
(lp1544
(dp1545
g12
I68
sg13
VT2D
p1546
sg14
I3
sg15
VC0011860
p1547
sg17
I1
sa(dp1548
g12
I51
sg13
g1542
sg14
I15
sg15
VC0011860
p1549
sg17
I3
sasg18
(lp1550
(dp1551
g12
I103
sg13
VRNLS
p1552
sg14
I4
sg22
g190
sg17
I1
sa(dp1553
g12
I90
sg13
VCOBL
p1554
sg14
I4
sg22
g190
sg17
I1
sa(dp1555
g12
I96
sg13
VGLIS3
p1556
sg14
I5
sg22
g190
sg17
I1
sa(dp1557
g12
I112
sg13
g1541
sg14
I5
sg22
VP56945
p1558
sg17
I1
sasa(dp1559
g2
VAutoantibodies to insulin (IAA), GAD (GADA), insulinoma-associated antigen-2 (IA-2A) and zinc transporter 8 (ZnT8A) were measured in follow-up sera, and genotyping for type 1 diabetes susceptibility genes (HLA-DR/HLA-DQ, INS variable number of tandem repeats [VNTR] and single nucleotide polymorphisms at PTPN22, PTPN2, ERBB3, IL2, SH2B3, CTLA4, IFIH1, KIAA0350 [also known as CLEC16A], CD25, IL18RAP, IL10, COBL) was performed on the DNA samples of children born to a parent with type 1 diabetes and prospectively followed from birth for up to 22 years.
p1560
sg4
(dp1561
(Vinsulin
p1562
Vtype 1 diabetes
p1563
tp1564
I00
ssg9
(lp1565
(dp1566
g12
I33
sg13
VGAD
p1567
sg14
I3
sg15
VC0270549
p1568
sg17
I1
sa(dp1569
g12
I45
sg13
Vinsulinoma
p1570
sg14
I10
sg15
VC0021670
p1571
sg17
I1
sa(dp1572
g12
I221
sg13
VINS
p1573
sg14
I3
sg15
VC1533172
p1574
sg17
I1
sa(dp1575
g12
I168
sg13
Vtype 1 diabetes
p1576
sg14
I15
sg15
VC0011854
p1577
sg17
I3
sa(dp1578
g12
I168
sg13
g1563
sg14
I15
sg15
VC0011854
p1579
sg17
I3
sasg18
(lp1580
(dp1581
g12
I353
sg13
VKIAA0350
p1582
sg14
I8
sg22
g190
sg17
I1
sa(dp1583
g12
I206
sg13
VHLA-DR
p1584
sg14
I6
sg22
VP30486
p1585
sg17
I1
sa(dp1586
g12
I393
sg13
VIL18RAP
p1587
sg14
I7
sg22
g190
sg17
I1
sa(dp1588
g12
I320
sg13
VERBB3
p1589
sg14
I5
sg22
VP21860
p1590
sg17
I1
sa(dp1591
g12
I89
sg13
Vzinc transporter 8
p1592
sg14
I18
sg22
g190
sg17
I3
sa(dp1593
g12
I305
sg13
VPTPN2
p1594
sg14
I5
sg22
VP17706
p1595
sg17
I1
sa(dp1596
g12
I206
sg13
VHLA
p1597
sg14
I3
sg22
VP30486
p1598
sg17
I1
sa(dp1599
g12
I305
sg13
VPTPN22
p1600
sg14
I6
sg22
g190
sg17
I1
sa(dp1601
g12
I377
sg13
VCLEC16A
p1602
sg14
I7
sg22
g190
sg17
I1
sa(dp1603
g12
I339
sg13
VCTLA4
p1604
sg14
I5
sg22
VP16410
p1605
sg17
I1
sa(dp1606
g12
I402
sg13
VIL10
p1607
sg14
I4
sg22
VP22301
p1608
sg17
I1
sa(dp1609
g12
I408
sg13
VCOBL
p1610
sg14
I4
sg22
g190
sg17
I1
sa(dp1611
g12
I332
sg13
VSH2B3
p1612
sg14
I5
sg22
g190
sg17
I1
sa(dp1613
g12
I346
sg13
VIFIH1
p1614
sg14
I5
sg22
g190
sg17
I1
sa(dp1615
g12
I387
sg13
VCD25
p1616
sg14
I4
sg22
VP01589
p1617
sg17
I1
sa(dp1618
g12
I327
sg13
VIL2
p1619
sg14
I3
sg22
VP60568
p1620
sg17
I1
sa(dp1621
g12
I18
sg13
g1562
sg14
I7
sg22
VP01308
p1622
sg17
I1
sasa(dp1623
g2
VChildren of parents with type 1 diabetes and prospectively followed from birth for the development of islet autoantibodies and diabetes were genotyped for single-nucleotide polymorphisms at 12 type 1 diabetes susceptibility genes (ERBB3, PTPN2, IFIH1, PTPN22, KIAA0350, CD25, CTLA4, SH2B3, IL2, IL18RAP, IL10 and COBL).
p1624
sg4
(dp1625
(VIL10
p1626
Vdiabetes
p1627
tp1628
I00
ssg9
(lp1629
(dp1630
g12
I25
sg13
Vtype 1 diabetes
p1631
sg14
I15
sg15
VC0011854
p1632
sg17
I3
sa(dp1633
g12
I25
sg13
Vtype 1 diabetes
p1634
sg14
I15
sg15
VC0011854
p1635
sg17
I3
sa(dp1636
g12
I32
sg13
g1627
sg14
I8
sg15
VC0011849
p1637
sg17
I1
sasg18
(lp1638
(dp1639
g12
I290
sg13
VIL2
p1640
sg14
I3
sg22
VP60568
p1641
sg17
I1
sa(dp1642
g12
I260
sg13
VKIAA0350
p1643
sg14
I8
sg22
g190
sg17
I1
sa(dp1644
g12
I231
sg13
VERBB3
p1645
sg14
I5
sg22
VP21860
p1646
sg17
I1
sa(dp1647
g12
I313
sg13
VCOBL
p1648
sg14
I4
sg22
g190
sg17
I1
sa(dp1649
g12
I276
sg13
VCTLA4
p1650
sg14
I5
sg22
VP16410
p1651
sg17
I1
sa(dp1652
g12
I295
sg13
VIL18RAP
p1653
sg14
I7
sg22
g190
sg17
I1
sa(dp1654
g12
I252
sg13
VPTPN22
p1655
sg14
I6
sg22
g190
sg17
I1
sa(dp1656
g12
I245
sg13
VIFIH1
p1657
sg14
I5
sg22
g190
sg17
I1
sa(dp1658
g12
I283
sg13
VSH2B3
p1659
sg14
I5
sg22
g190
sg17
I1
sa(dp1660
g12
I238
sg13
VPTPN2
p1661
sg14
I5
sg22
VP17706
p1662
sg17
I1
sa(dp1663
g12
I270
sg13
VCD25
p1664
sg14
I4
sg22
VP01589
p1665
sg17
I1
sa(dp1666
g12
I304
sg13
g1626
sg14
I4
sg22
VP22301
p1667
sg17
I1
sasa(dp1668
g2
VThe greatest diabetes discrimination was obtained by the sum of risk alleles for eight genes (IFIH1, CTLA4, PTPN22, IL18RAP, SH2B3, KIAA0350, COBL and ERBB3) in the HLA-risk children.
p1669
sg4
(dp1670
(VERBB3
p1671
Vdiabetes
p1672
tp1673
I00
ssg9
(lp1674
(dp1675
g12
I13
sg13
g1672
sg14
I8
sg15
VC0011849
p1676
sg17
I1
sasg18
(lp1677
(dp1678
g12
I165
sg13
VHLA
p1679
sg14
I3
sg22
VP30486
p1680
sg17
I1
sa(dp1681
g12
I101
sg13
VCTLA4
p1682
sg14
I5
sg22
VP16410
p1683
sg17
I1
sa(dp1684
g12
I116
sg13
VIL18RAP
p1685
sg14
I7
sg22
g190
sg17
I1
sa(dp1686
g12
I108
sg13
VPTPN22
p1687
sg14
I6
sg22
g190
sg17
I1
sa(dp1688
g12
I142
sg13
VCOBL
p1689
sg14
I4
sg22
g190
sg17
I1
sa(dp1690
g12
I94
sg13
VIFIH1
p1691
sg14
I5
sg22
g190
sg17
I1
sa(dp1692
g12
I125
sg13
VSH2B3
p1693
sg14
I5
sg22
g190
sg17
I1
sa(dp1694
g12
I132
sg13
VKIAA0350
p1695
sg14
I8
sg22
g190
sg17
I1
sa(dp1696
g12
I151
sg13
g1671
sg14
I5
sg22
VP21860
p1697
sg17
I1
sasa(dp1698
g2
VHowever, all of the eosinophil-activating cytokines, such as IL-5, IL-3, and GM-CSF, are typically present in atopic diseases, including allergic asthma.
p1699
sg4
(dp1700
(VGM-CSF
p1701
Vatopic
p1702
tp1703
I01
ssg9
(lp1704
(dp1705
g12
I137
sg13
Vallergic asthma
p1706
sg14
I15
sg15
VC0155877
p1707
sg17
I2
sa(dp1708
g12
I110
sg13
g1702
sg14
I6
sg15
VC0392707
p1709
sg17
I1
sasg18
(lp1710
(dp1711
g12
I61
sg13
VIL-5
p1712
sg14
I4
sg22
VP05113
p1713
sg17
I1
sa(dp1714
g12
I67
sg13
VIL-3
p1715
sg14
I4
sg22
VP08700
p1716
sg17
I1
sa(dp1717
g12
I77
sg13
g1701
sg14
I6
sg22
VP04141
p1718
sg17
I1
sasa(dp1719
g2
VIn a murine model of allergic asthma, we found that Tyk-2((-/-)) asthmatic mice have induced peribronchial collagen deposition, mucosal type mast cells in the lung, IRF4 and hyperproliferative lung Th2 CD4(+) effector T cells over-expressing IL-3, IL-4, IL-5, IL-10 and IL-13.
p1720
sg4
(dp1721
(VIL-13
p1722
Vasthmatic
p1723
tp1724
I00
ssg9
(lp1725
(dp1726
g12
I21
sg13
Vallergic asthma
p1727
sg14
I15
sg15
VC0155877
p1728
sg17
I2
sa(dp1729
g12
I65
sg13
g1723
sg14
I9
sg15
VC0004096
p1730
sg17
I1
sasg18
(lp1731
(dp1732
g12
I254
sg13
VIL-5
p1733
sg14
I4
sg22
VP05113
p1734
sg17
I1
sa(dp1735
g12
I165
sg13
VIRF4
p1736
sg14
I4
sg22
g190
sg17
I1
sa(dp1737
g12
I242
sg13
VIL-3
p1738
sg14
I4
sg22
VP08700
p1739
sg17
I1
sa(dp1740
g12
I248
sg13
VIL-4
p1741
sg14
I4
sg22
VP05112
p1742
sg17
I1
sa(dp1743
g12
I174
sg13
Vhyperproliferative lung Th2 CD4
p1744
sg14
I31
sg22
VP01730
p1745
sg17
I4
sa(dp1746
g12
I270
sg13
g1722
sg14
I5
sg22
VP35225
p1747
sg17
I1
sasa(dp1748
g2
VA link between ACSVL3 and cancer stem cell phenotype was further established by the findings that ACSVL3 expression was regulated by receptor tyrosine kinase pathways that support GBM stem cell self-renewal and tumor initiation, including EGFR and HGF/c-Met pathways.
p1749
sg4
(dp1750
(VHGF
p1751
Vtumor initiation
p1752
tp1753
I00
ssg9
(lp1754
(dp1755
g12
I180
sg13
VGBM
p1756
sg14
I3
sg15
VC0017636
p1757
sg17
I1
sa(dp1758
g12
I26
sg13
Vcancer
p1759
sg14
I6
sg15
VC0006826
p1760
sg17
I1
sa(dp1761
g12
I248
sg13
VHGF
p1762
sg14
I3
sg15
VC0399440
p1763
sg17
I1
sa(dp1764
g12
I211
sg13
g1752
sg14
I16
sg15
VC0598935
p1765
sg17
I2
sasg18
(lp1766
(dp1767
g12
I133
sg13
Vreceptor tyrosine kinase
p1768
sg14
I24
sg22
VP29401
p1769
sg17
I3
sa(dp1770
g12
I252
sg13
Vc-Met
p1771
sg14
I5
sg22
VP08581
p1772
sg17
I1
sa(dp1773
g12
I248
sg13
g1751
sg14
I3
sg22
VP05231
p1774
sg17
I1
sasa(dp1775
g2
VIn addition, rLj-HMGB2 could induce the generation of proinflammatory mediators in the activated human acute monocytic leukemia cell line (THP1), which suggested that Lj-HMGB2 may participate in the immune response of the lampreys.
p1776
sg4
(dp1777
(VLj-HMGB2
p1778
Vacute monocytic leukemia
p1779
tp1780
I00
ssg9
(lp1781
(dp1782
g12
I103
sg13
g1779
sg14
I24
sg15
VC1318544
p1783
sg17
I3
sasg18
(lp1784
(dp1785
g12
I139
sg13
VTHP1
p1786
sg14
I4
sg22
VP10070
p1787
sg17
I1
sa(dp1788
g12
I13
sg13
VrLj-HMGB2
p1789
sg14
I9
sg22
VP26583
p1790
sg17
I1
sa(dp1791
g12
I14
sg13
g1778
sg14
I8
sg22
VP26583
p1792
sg17
I1
sasa(dp1793
g2
VUlcerative colitis patients display increased numbers of circulating pro-inflammatory monocyte human leukocyte antigen-DR [HLA-DRhi] monocytes expressing high levels of the gut-homing C-C chemokine receptor 9 [CCR9] and tumour necrosis factor [TNF]-Alfa.
p1794
sg4
(dp1795
(Vtumour necrosis factor [TNF]-Alfa
p1796
Vtumour necrosis
p1797
tp1798
I00
ssg9
(lp1799
(dp1800
g12
I0
sg13
VUlcerative colitis
p1801
sg14
I18
sg15
VC0009324
p1802
sg17
I2
sa(dp1803
g12
I220
sg13
g1797
sg14
I15
sg15
VC0333516
p1804
sg17
I2
sasg18
(lp1805
(dp1806
g12
I86
sg13
Vmonocyte human leukocyte antigen-DR
p1807
sg14
I35
sg22
VP05534
p1808
sg17
I4
sa(dp1809
g12
I123
sg13
VHLA
p1810
sg14
I3
sg22
VP30486
p1811
sg17
I1
sa(dp1812
g12
I220
sg13
g1796
sg14
I33
sg22
VP01375
p1813
sg17
I4
sa(dp1814
g12
I173
sg13
Vgut-homing C-C chemokine receptor 9 [CCR9]
p1815
sg14
I42
sg22
g190
sg17
I6
sasa(dp1816
g2
VThe aim of this first-in-human, double-blind, randomised, placebo-controlled trial was to evaluate selective removal of circulating CCR9-expressing monocytes by leukapheresis in patients with moderate to severe ulcerative colitis, with regards to safety, tolerability, and immunological response.
p1817
sg4
(dp1818
(VCCR9
p1819
Vblind
p1820
tp1821
I00
ssg9
(lp1822
(dp1823
g12
I211
sg13
Vulcerative colitis
p1824
sg14
I18
sg15
VC0009324
p1825
sg17
I2
sa(dp1826
g12
I39
sg13
g1820
sg14
I5
sg15
VC0456909
p1827
sg17
I1
sasg18
(lp1828
(dp1829
g12
I132
sg13
g1819
sg14
I4
sg22
VP51686
p1830
sg17
I1
sasa(dp1831
g2
VPatients with ulcerative colitis were treated every second day with leukapheresis during five sessions with a C-C chemokine ligand 25 [CCL25; CCR9 ligand] column or a placebo column.
p1832
sg4
(dp1833
(VCCR9
p1834
Vulcerative colitis
p1835
tp1836
I00
ssg9
(lp1837
(dp1838
g12
I14
sg13
g1835
sg14
I18
sg15
VC0009324
p1839
sg17
I2
sasg18
(lp1840
(dp1841
g12
I110
sg13
VC-C chemokine ligand 25
p1842
sg14
I23
sg22
VP55773
p1843
sg17
I4
sa(dp1844
g12
I142
sg13
g1834
sg14
I4
sg22
VP51686
p1845
sg17
I1
sa(dp1846
g12
I135
sg13
VCCL25
p1847
sg14
I5
sg22
g190
sg17
I1
sasa(dp1848
g2
VCC chemokine receptor type 9 (CCR9) activation by CCL25 plays a key role in leukocyte recruitment to the gut and represents a therapeutic target in inflammatory bowel disease.
p1849
sg4
(dp1850
(VCCR9
p1851
Vinflammatory bowel disease
p1852
tp1853
I00
ssg9
(lp1854
(dp1855
g12
I148
sg13
g1852
sg14
I26
sg15
VC0021390
p1856
sg17
I3
sa(dp1857
g12
I86
sg13
Vrecruitment
p1858
sg14
I11
sg15
VC0271510
p1859
sg17
I1
sasg18
(lp1860
(dp1861
g12
I0
sg13
VCC chemokine receptor type 9
p1862
sg14
I28
sg22
g190
sg17
I5
sa(dp1863
g12
I30
sg13
g1851
sg14
I4
sg22
VP51686
p1864
sg17
I1
sa(dp1865
g12
I50
sg13
VCCL25
p1866
sg14
I5
sg22
g190
sg17
I1
sasa(dp1867
g2
VThe selective CCR9 antagonist vercirnon progressed to phase 3 clinical trials in Crohn's disease but efficacy was limited, with the need for very high doses to block receptor activation.
p1868
sg4
(dp1869
(VCCR9
p1870
VCrohn's disease
p1871
tp1872
I01
ssg9
(lp1873
(dp1874
g12
I81
sg13
g1871
sg14
I15
sg15
VC0010346
p1875
sg17
I2
sasg18
(lp1876
(dp1877
g12
I14
sg13
g1870
sg14
I4
sg22
VP51686
p1878
sg17
I1
sasa(dp1879
g2
VTo investigate whether Imiquimod (IMQ) as TLR7 ligand protects mice from colonic inflammation and the mechanisms underlying in such immunoregulatory conditions.#\u3000METHODS: Murine colitis was induced to Balb/c mice by administration of trinitrobenzene sulfonic acid (TNBS) with or without daily intraperitoneal administration of IMQ.#\u3000Colitis was evaluated by body weight decreases and by histological score.#\u3000Also colonic mRNA expression was measured by RT-PCR.#\u3000To confirm the induction of Regulatory T cells (Tregs) by type-1 IFN from pDCs, we generated mouse bone marrow-derived pDCs and co-cultured these with CD4+ T cells isolated from mouse spleen with or without IMQ stimulation.#\u3000Cytokine production in the culture supernatant was measured by ELISA and the number of Tregs were analyzed by flow cytometry.#\u3000Spleen and mesenteric lymph nodes (MLN) from IMQ-treated mice were collected, and mRNA expressions of cytokine were measured by RT-PCR and cytokine productions were measured by ELISA.#\u3000Tregs and chemokine expressions were analyzed in colon of TNBS-induced colitis mouse by immunohistochemistry.#\u3000RESULTS: Administration of IMQ significantly suppressed colonic inflammation of TNBS-induced colitis.#\u3000In the colons of IMQ-treated mice, mRNA expression of TNF-Alfa was decreased, and strong expressions of IL-6, IFN-Beta and TGF-Beta were detected.#\u3000IL-10 and TGF-Beta productions were increased in the supernatant of co-cultured cells stimulated with IMQ, although we were unable to detect Treg differentiaton in IMQ-stimulated co-cultured cells.#\u3000In MLN of IMQ-treated mice, strong expressions of TLR7, IFN-Beta, TGF-Beta and Foxp3 mRNA were detected.#\u3000IL-10 production from MLN cells was also increased in the IMQ-treated group.#\u3000Finally, Tregs in the inflamed colon and CCR9 in MLN of IMQ-treated mice were detected.#\u3000CONCLUSION: These results suggest that IMQ protects mice from TNBS colitis through induction of CCR9, which regulates accumulation of Tregs in the inflamed colon.
p1880
sg4
(dp1881
(VIFN-Beta
p1882
Vinflammation
p1883
tp1884
I00
ssg9
(lp1885
(dp1886
g12
I178
sg13
Vcolitis
p1887
sg14
I7
sg15
VC0009319
p1888
sg17
I1
sa(dp1889
g12
I178
sg13
Vcolitis
p1890
sg14
I7
sg15
VC0009319
p1891
sg17
I1
sa(dp1892
g12
I81
sg13
Vinflammation
p1893
sg14
I12
sg15
VC0021368
p1894
sg17
I1
sa(dp1895
g12
I332
sg13
V\u3000Colitis
p1896
sg14
I8
sg15
VC0009319
p1897
sg17
I1
sa(dp1898
g12
I178
sg13
Vcolitis
p1899
sg14
I7
sg15
VC0009319
p1900
sg17
I1
sa(dp1901
g12
I178
sg13
Vcolitis
p1902
sg14
I7
sg15
VC0009319
p1903
sg17
I1
sa(dp1904
g12
I81
sg13
g1883
sg14
I12
sg15
VC0021368
p1905
sg17
I1
sasg18
(lp1906
(dp1907
g12
I613
sg13
VCD4+
p1908
sg14
I4
sg22
VP01730
p1909
sg17
I1
sa(dp1910
g12
I1267
sg13
VTNF-Alfa
p1911
sg14
I8
sg22
VP01375
p1912
sg17
I1
sa(dp1913
g12
I849
sg13
VMLN
p1914
sg14
I3
sg22
VP12872
p1915
sg17
I1
sa(dp1916
g12
I520
sg13
Vtype-1 IFN
p1917
sg14
I10
sg22
VP01562
p1918
sg17
I2
sa(dp1919
g12
I1336
sg13
VTGF-Beta
p1920
sg14
I8
sg22
VP18075
p1921
sg17
I1
sa(dp1922
g12
I1785
sg13
VCCR9
p1923
sg14
I4
sg22
VP51686
p1924
sg17
I1
sa(dp1925
g12
I1323
sg13
VIFN-Beta
p1926
sg14
I8
sg22
VP01574
p1927
sg17
I1
sa(dp1928
g12
I1639
sg13
VFoxp3 mRNA
p1929
sg14
I10
sg22
g190
sg17
I2
sa(dp1930
g12
I1317
sg13
VIL-6
p1931
sg14
I4
sg22
VP05231
p1932
sg17
I1
sa(dp1933
g12
I42
sg13
VTLR7 ligand
p1934
sg14
I11
sg22
g190
sg17
I2
sa(dp1935
g12
I825
sg13
Vmesenteric lymph nodes
p1936
sg14
I22
sg22
VP12872
p1937
sg17
I3
sa(dp1938
g12
I1336
sg13
VTGF-Beta
p1939
sg14
I8
sg22
VP18075
p1940
sg17
I1
sa(dp1941
g12
I1336
sg13
VTGF-Beta
p1942
sg14
I8
sg22
VP18075
p1943
sg17
I1
sa(dp1944
g12
I1785
sg13
VCCR9
p1945
sg14
I4
sg22
VP51686
p1946
sg17
I1
sa(dp1947
g12
I42
sg13
VTLR7
p1948
sg14
I4
sg22
g190
sg17
I1
sa(dp1949
g12
I1323
sg13
g1882
sg14
I8
sg22
VP01574
p1950
sg17
I1
sasa(dp1951
g2
VWe here showed that CCR9+ CD11b+ macrophages play an important role during the course of Concanavalin A-induced murine acute liver injury as well as human acute hepatitis via the production of inflammatory cytokines and the Th1 induction.
p1952
sg4
(dp1953
(VCCR9+ CD11b+
p1954
Vacute hepatitis
p1955
tp1956
I00
ssg9
(lp1957
(dp1958
g12
I155
sg13
g1955
sg14
I15
sg15
VC0267797
p1959
sg17
I2
sasg18
(lp1960
(dp1961
g12
I20
sg13
g1954
sg14
I12
sg22
VP51686
p1962
sg17
I2
sasa(dp1963
g2
VWe found 54 single-nucleotide polymorphisms (SNPs) in 5 genes associated with celiac disease (TAGAP, IL18R1, RGS21, PLEK, and CCR9) in time to celiac disease analyses (10-4&gt;P&gt;5.8x10-6).
p1964
sg4
(dp1965
(VPLEK
p1966
Vceliac disease
p1967
tp1968
I00
ssg9
(lp1969
(dp1970
g12
I78
sg13
Vceliac disease
p1971
sg14
I14
sg15
VC0007570
p1972
sg17
I2
sa(dp1973
g12
I78
sg13
g1967
sg14
I14
sg15
VC0007570
p1974
sg17
I2
sasg18
(lp1975
(dp1976
g12
I126
sg13
VCCR9
p1977
sg14
I4
sg22
VP51686
p1978
sg17
I1
sa(dp1979
g12
I109
sg13
VRGS21
p1980
sg14
I5
sg22
g190
sg17
I1
sa(dp1981
g12
I116
sg13
g1966
sg14
I4
sg22
VP08567
p1982
sg17
I1
sa(dp1983
g12
I101
sg13
VIL18R1
p1984
sg14
I6
sg22
g190
sg17
I1
sa(dp1985
g12
I94
sg13
VTAGAP
p1986
sg14
I5
sg22
g190
sg17
I1
sasa(dp1987
g2
VIncluding chemokines [C-C motif ligand (CCL) 19, CCL20, CCL21, C-X-C motif ligand (CXCL) 6, CXCL10, and CXCL11] and soluble cytokine and chemokine receptors [soluble (s) interleukin (IL) 6 receptor (R), soluble tumor necrosis factor receptor (sTNFR) 1, sTNFR2, and sIL-R2], ten inflammation-related markers, were nominally associated with diabetes (P&lt;0.05).
p1988
sg4
(dp1989
(VCCL20
p1990
Vtumor necrosis
p1991
tp1992
I00
ssg9
(lp1993
(dp1994
g12
I339
sg13
Vdiabetes
p1995
sg14
I8
sg15
VC0011849
p1996
sg17
I1
sa(dp1997
g12
I21
sg13
V[C-C motif ligand
p1998
sg14
I17
sg15
VC1852438
p1999
sg17
I3
sa(dp2000
g12
I40
sg13
VCCL
p2001
sg14
I3
sg15
VC1852438
p2002
sg17
I1
sa(dp2003
g12
I265
sg13
VsIL
p2004
sg14
I3
sg15
VC0333873
p2005
sg17
I1
sa(dp2006
g12
I278
sg13
Vinflammation
p2007
sg14
I12
sg15
VC0021368
p2008
sg17
I1
sa(dp2009
g12
I211
sg13
g1991
sg14
I14
sg15
VC0333516
p2010
sg17
I2
sasg18
(lp2011
(dp2012
g12
I56
sg13
VCCL21
p2013
sg14
I5
sg22
g190
sg17
I1
sa(dp2014
g12
I92
sg13
VCXCL10
p2015
sg14
I6
sg22
VP02778
p2016
sg17
I1
sa(dp2017
g12
I211
sg13
Vtumor necrosis factor receptor (sTNFR) 1
p2018
sg14
I40
sg22
VP01375
p2019
sg17
I6
sa(dp2020
g12
I265
sg13
VsIL-R2
p2021
sg14
I6
sg22
VP40967
p2022
sg17
I1
sa(dp2023
g12
I104
sg13
VCXCL11
p2024
sg14
I6
sg22
g190
sg17
I1
sa(dp2025
g12
I49
sg13
g1990
sg14
I5
sg22
VP78556
p2026
sg17
I1
sasa(dp2027
g2
VA new variant of this was recently identified: seven families were described with transient antenatal Bartter's syndrome, polyhydramnios and MAGED2 mutations.Multiple compounds have been identified experimentally that may stimulate urinary concentration independently of the vasopressin V2 receptor.
p2028
sg4
(dp2029
(Vvasopressin V2 receptor
p2030
VBartter's syndrome
p2031
tp2032
I00
ssg9
(lp2033
(dp2034
g12
I122
sg13
Vpolyhydramnios
p2035
sg14
I14
sg15
VC0020224
p2036
sg17
I1
sa(dp2037
g12
I102
sg13
g2031
sg14
I18
sg15
VC0004775
p2038
sg17
I2
sasg18
(lp2039
(dp2040
g12
I275
sg13
g2030
sg14
I23
sg22
VP30518
p2041
sg17
I3
sa(dp2042
g12
I141
sg13
VMAGED2
p2043
sg14
I6
sg22
g190
sg17
I1
sasa(dp2044
g2
VBlockade of CD69-Myl9/12 interaction ameliorates allergic airway inflammation in ovalbumin-induced and house dust mite-induced mouse models of asthma.
p2045
sg4
(dp2046
(VMyl9
p2047
Vinflammation
p2048
tp2049
I00
ssg9
(lp2050
(dp2051
g12
I143
sg13
Vasthma
p2052
sg14
I6
sg15
VC0004096
p2053
sg17
I1
sa(dp2054
g12
I65
sg13
g2048
sg14
I12
sg15
VC0021368
p2055
sg17
I1
sasg18
(lp2056
(dp2057
g12
I12
sg13
VCD69
p2058
sg14
I4
sg22
g190
sg17
I1
sa(dp2059
g12
I17
sg13
g2047
sg14
I4
sg22
VP24844
p2060
sg17
I1
sasa(dp2061
g2
VA greater activation of myosin, via increased phosphorylation of its regulatory light chain (LC20) by myosin light chain kinase, correlates with an increased Vmax in models of AH and in human asthmatic bronchial SM cells.
p2062
sg4
(dp2063
(Vmyosin
p2064
Vasthmatic
p2065
tp2066
I00
ssg9
(lp2067
(dp2068
g12
I192
sg13
g2065
sg14
I9
sg15
VC0004096
p2069
sg17
I1
sasg18
(lp2070
(dp2071
g12
I24
sg13
g2064
sg14
I6
sg22
VP13535
p2072
sg17
I1
sa(dp2073
g12
I102
sg13
Vmyosin light chain kinase
p2074
sg14
I25
sg22
g190
sg17
I4
sasa(dp2075
g2
VSome of the differentially expressed lncRNAs that were upregulated, such as AK124776, lincRNA-RAB12-1, KRT8P25, RP11-474J18.4, AC000110.1, KRT8P13, KRT8P10, BC072678, and downregulated, such as nc-HOXB9-206, RP11-160A10.2, nc-HOXA11-86, nc-HOXD10-7, nc-HOXB9-205, CES4, nc-HOXD12-3, systematic research on these lncRNAs will help clarify the mechanisms of urothelial carcinoma of the bladder and guide the early diagnosis and treatment of this cancer in the future.
p2076
sg4
(dp2077
(Vnc-HOXD12-3
p2078
VRP11
p2079
tp2080
I00
ssg9
(lp2081
(dp2082
g12
I112
sg13
VRP11
p2083
sg14
I4
sg15
VC1838601
p2084
sg17
I1
sa(dp2085
g12
I367
sg13
Vcarcinoma of the bladder
p2086
sg14
I24
sg15
VC0699885
p2087
sg17
I4
sa(dp2088
g12
I444
sg13
Vcancer
p2089
sg14
I6
sg15
VC0006826
p2090
sg17
I1
sa(dp2091
g12
I112
sg13
g2079
sg14
I4
sg15
VC1838601
p2092
sg17
I1
sasg18
(lp2093
(dp2094
g12
I223
sg13
Vnc-HOXA11-86
p2095
sg14
I12
sg22
VP31270
p2096
sg17
I1
sa(dp2097
g12
I112
sg13
VRP11-474J18.4, AC000110.1
p2098
sg14
I25
sg22
g190
sg17
I2
sa(dp2099
g12
I250
sg13
Vnc-HOXB9-205
p2100
sg14
I12
sg22
VP17482
p2101
sg17
I1
sa(dp2102
g12
I197
sg13
VHOXB9-206
p2103
sg14
I9
sg22
VP17482
p2104
sg17
I1
sa(dp2105
g12
I86
sg13
VlincRNA-RAB12-1
p2106
sg14
I15
sg22
g190
sg17
I1
sa(dp2107
g12
I208
sg13
VRP11-160A10.2
p2108
sg14
I13
sg22
g190
sg17
I1
sa(dp2109
g12
I237
sg13
Vnc-HOXD10-7
p2110
sg14
I11
sg22
VP28358
p2111
sg17
I1
sa(dp2112
g12
I270
sg13
g2078
sg14
I11
sg22
VP35452
p2113
sg17
I1
sa(dp2114
g12
I264
sg13
VCES4
p2115
sg14
I4
sg22
g190
sg17
I1
sasa(dp2116
g2
VProteins labeled with LCA were Rab-3, Rab-12, Rab-16, and M-Ras.
p2117
sg4
(dp2118
(VRab-3
p2119
VLCA
p2120
tp2121
I00
ssg9
(lp2122
(dp2123
g12
I22
sg13
g2120
sg14
I3
sg15
VC0339527
p2124
sg17
I1
sasg18
(lp2125
(dp2126
g12
I46
sg13
VRab-16
p2127
sg14
I6
sg22
VP52594
p2128
sg17
I1
sa(dp2129
g12
I38
sg13
VRab-12
p2130
sg14
I6
sg22
VP52594
p2131
sg17
I1
sa(dp2132
g12
I31
sg13
g2119
sg14
I5
sg22
VP52594
p2133
sg17
I1
sa(dp2134
g12
I58
sg13
VM-Ras
p2135
sg14
I5
sg22
g190
sg17
I1
sasa(dp2136
g2
VMoreover, the ANT2 precursors were observed to change in oncocytomas.
p2137
sg4
(dp2138
(VANT2 precursors
p2139
Voncocytomas
p2140
tp2141
I00
ssg9
(lp2142
(dp2143
g12
I57
sg13
g2140
sg14
I11
sg15
VC0949541
p2144
sg17
I1
sasg18
(lp2145
(dp2146
g12
I14
sg13
g2139
sg14
I15
sg22
VP05141
p2147
sg17
I2
sasa(dp2148
g2
VIn particular, a high transcript level for the adenine nucleotide translocator isoform 2(ANT2) gene, which is usually not expressed in differentiated cells, was observed in oncocytoma and malignant urothelial renal tumor.
p2149
sg4
(dp2150
(VANT2
p2151
Vrenal tumor
p2152
tp2153
I01
ssg9
(lp2154
(dp2155
g12
I173
sg13
Voncocytoma
p2156
sg14
I10
sg15
VC0949541
p2157
sg17
I1
sa(dp2158
g12
I209
sg13
g2152
sg14
I11
sg15
VC0022665
p2159
sg17
I2
sasg18
(lp2160
(dp2161
g12
I89
sg13
g2151
sg14
I4
sg22
VP05141
p2162
sg17
I1
sa(dp2163
g12
I47
sg13
Vadenine nucleotide translocator isoform 2
p2164
sg14
I41
sg22
g190
sg17
I5
sasa(dp2165
g2
VEpoxyeicosatrienoic acid (EET) production via cytochrome P450 (CYP) epoxygenases closely correlates with the progression of breast cancer.
p2166
sg4
(dp2167
(VCYP
p2168
Vbreast cancer
p2169
tp2170
I00
ssg9
(lp2171
(dp2172
g12
I124
sg13
g2169
sg14
I13
sg15
VC0678222
p2173
sg17
I2
sasg18
(lp2174
(dp2175
g12
I46
sg13
Vcytochrome P450
p2176
sg14
I15
sg22
VP20853
p2177
sg17
I2
sa(dp2178
g12
I63
sg13
g2168
sg14
I3
sg22
VP20853
p2179
sg17
I1
sasa(dp2180
g2
VHere, we found that CYP3A4 expression and its epoxy-product, 11,12-epoxyeicosatrienoic acid (11,12-EET) was enhanced in tamoxifen (TAM)-resistant MCF-7 (TAMR-MCF-7) breast cancer cells compared to control MCF-7 cells.
p2181
sg4
(dp2182
(VCYP3A4
p2183
Vtamoxifen
p2184
tp2185
I00
ssg9
(lp2186
(dp2187
g12
I165
sg13
Vbreast cancer
p2188
sg14
I13
sg15
VC0678222
p2189
sg17
I2
sa(dp2190
g12
I131
sg13
VTAM
p2191
sg14
I3
sg15
VC1834582
p2192
sg17
I1
sa(dp2193
g12
I120
sg13
g2184
sg14
I9
sg15
VC1834582
p2194
sg17
I1
sasg18
(lp2195
(dp2196
g12
I20
sg13
g2183
sg14
I6
sg22
VP08684
p2197
sg17
I1
sasa(dp2198
g2
VOur findings suggest that the CYP3A4-mediated EET pathway represents a potential therapeutic target for the treatment of tamoxifen-resistant breast cancer.
p2199
sg4
(dp2200
(VCYP3A4
p2201
Vbreast cancer
p2202
tp2203
I00
ssg9
(lp2204
(dp2205
g12
I141
sg13
g2202
sg14
I13
sg15
VC0678222
p2206
sg17
I2
sasg18
(lp2207
(dp2208
g12
I30
sg13
g2201
sg14
I6
sg22
VP08684
p2209
sg17
I1
sasa(dp2210
g2
VCYP3A4 was unexpectedly associated with breast cancer mitochondria and synthesized arachidonic acid (AA)-derived epoxyeicosatrienoic acids (EETs), which promoted the electron transport chain/respiration and inhibited AMPKAlfa.
p2211
sg4
(dp2212
(VCYP3A4
p2213
Vbreast cancer
p2214
tp2215
I00
ssg9
(lp2216
(dp2217
g12
I40
sg13
g2214
sg14
I13
sg15
VC0678222
p2218
sg17
I2
sasg18
(lp2219
(dp2220
g12
I0
sg13
g2213
sg14
I6
sg22
VP08684
p2221
sg17
I1
sasa(dp2222
g2
VCYP3A4 knockdown activated AMPKAlfa, promoted autophagy, and prevented mammary tumor formation.
p2223
sg4
(dp2224
(VCYP3A4
p2225
Vmammary tumor
p2226
tp2227
I00
ssg9
(lp2228
(dp2229
g12
I71
sg13
g2226
sg14
I13
sg15
VC1458155
p2230
sg17
I2
sasg18
(lp2231
(dp2232
g12
I0
sg13
g2225
sg14
I6
sg22
VP08684
p2233
sg17
I1
sasa(dp2234
g2
VIt has been recently reported that CD38 was highly expressed in adipose tissues from obese people and CD38-deficient mice were resistant to high-fat diet (HFD)-induced obesity.
p2235
sg4
(dp2236
(VCD38
p2237
Vobese
p2238
tp2239
I01
ssg9
(lp2240
(dp2241
g12
I168
sg13
Vobesity
p2242
sg14
I7
sg15
VC0028754
p2243
sg17
I1
sa(dp2244
g12
I85
sg13
g2238
sg14
I5
sg15
VC0028754
p2245
sg17
I1
sasg18
(lp2246
(dp2247
g12
I35
sg13
VCD38
p2248
sg14
I4
sg22
VP28907
p2249
sg17
I1
sa(dp2250
g12
I35
sg13
g2237
sg14
I4
sg22
VP28907
p2251
sg17
I1
sasa(dp2252
g2
VIn this study, to explore the roles of CD38 in adipogenesis and lipogenesis in vivo and in vitro, obesity models were generated with male CD38-/- and WT mice fed with HFD.
p2253
sg4
(dp2254
(VCD38
p2255
Vobesity
p2256
tp2257
I01
ssg9
(lp2258
(dp2259
g12
I98
sg13
g2256
sg14
I7
sg15
VC0028754
p2260
sg17
I1
sasg18
(lp2261
(dp2262
g12
I39
sg13
VCD38
p2263
sg14
I4
sg22
VP28907
p2264
sg17
I1
sa(dp2265
g12
I39
sg13
g2255
sg14
I4
sg22
VP28907
p2266
sg17
I1
sasa(dp2267
g2
VThe results showed that CD38-/- male mice were significantly resistant to HFD-induced obesity.
p2268
sg4
(dp2269
(VCD38
p2270
Vobesity
p2271
tp2272
I01
ssg9
(lp2273
(dp2274
g12
I86
sg13
g2271
sg14
I7
sg15
VC0028754
p2275
sg17
I1
sasg18
(lp2276
(dp2277
g12
I24
sg13
g2270
sg14
I4
sg22
VP28907
p2278
sg17
I1
sasa(dp2279
g2
VThese results suggest that CD38 deficiency impairs adipogenesis and lipogenesis through activating Sirt1/PPARGamma-FASN signalling pathway during the development of obesity.
p2280
sg4
(dp2281
(VCD38
p2282
Vobesity
p2283
tp2284
I01
ssg9
(lp2285
(dp2286
g12
I165
sg13
g2283
sg14
I7
sg15
VC0028754
p2287
sg17
I1
sasg18
(lp2288
(dp2289
g12
I27
sg13
g2282
sg14
I4
sg22
VP28907
p2290
sg17
I1
sa(dp2291
g12
I99
sg13
VSirt1
p2292
sg14
I5
sg22
g190
sg17
I1
sasa(dp2293
g2
VWe also found that obesity development was associated with an increase in the number of CD38+ adipose progenitors, this effect being more pronounced in intra-abdominal than in subcutaneous fat, suggesting a higher rate of adipocyte commitment in visceral depots.
p2294
sg4
(dp2295
(VCD38+
p2296
Vobesity
p2297
tp2298
I01
ssg9
(lp2299
(dp2300
g12
I19
sg13
g2297
sg14
I7
sg15
VC0028754
p2301
sg17
I1
sasg18
(lp2302
(dp2303
g12
I88
sg13
g2296
sg14
I5
sg22
VP28907
p2304
sg17
I1
sasa(dp2305
g2
VIn this study, we show that CD45RO+CD38+ Beta cell Ag-specific CD4+ T cells were present at higher frequencies in type 1 diabetes subjects compared with those in healthy subjects.
p2306
sg4
(dp2307
(VCD4+
p2308
Vtype 1 diabetes
p2309
tp2310
I00
ssg9
(lp2311
(dp2312
g12
I114
sg13
g2309
sg14
I15
sg15
VC0011854
p2313
sg17
I3
sasg18
(lp2314
(dp2315
g12
I28
sg13
VCD45RO+CD38+ Beta cell Ag
p2316
sg14
I25
sg22
VP28907
p2317
sg17
I4
sa(dp2318
g12
I63
sg13
g2308
sg14
I4
sg22
VP01730
p2319
sg17
I1
sasa(dp2320
g2
VRegulation of the SIRT/NAD system was associated with early (SIRT4, SIRT7, NAPRT1 and NMNAT2) and late phases (NMNAT3, NMRK2, ABCA1 and CD38) of glucose intolerance.
p2321
sg4
(dp2322
(VCD38
p2323
VNAD
p2324
tp2325
I00
ssg9
(lp2326
(dp2327
g12
I145
sg13
Vglucose intolerance
p2328
sg14
I19
sg15
VC0271650
p2329
sg17
I2
sa(dp2330
g12
I23
sg13
g2324
sg14
I3
sg15
VC1850380
p2331
sg17
I1
sasg18
(lp2332
(dp2333
g12
I86
sg13
VNMNAT2
p2334
sg14
I6
sg22
g190
sg17
I1
sa(dp2335
g12
I68
sg13
VSIRT7
p2336
sg14
I5
sg22
g190
sg17
I1
sa(dp2337
g12
I136
sg13
g2323
sg14
I4
sg22
VP28907
p2338
sg17
I1
sa(dp2339
g12
I61
sg13
VSIRT4
p2340
sg14
I5
sg22
g190
sg17
I1
sa(dp2341
g12
I111
sg13
VNMNAT3
p2342
sg14
I6
sg22
g190
sg17
I1
sa(dp2343
g12
I75
sg13
VNAPRT1
p2344
sg14
I6
sg22
g190
sg17
I1
sasa(dp2345
g2
VA total of eleven of genes were differently expressed in celiac patients compared with disease controls of which CD36, CD38, FOXP1, SELL, PPARA, PPARG, AGT previously associated with type 2 diabetes and AKAP6, NTNG1 with anorexia nervosa remained significant after correction for multiple testing.
p2346
sg4
(dp2347
(VSELL
p2348
Vanorexia nervosa
p2349
tp2350
I00
ssg9
(lp2351
(dp2352
g12
I183
sg13
Vtype 2 diabetes
p2353
sg14
I15
sg15
VC0011860
p2354
sg17
I3
sa(dp2355
g12
I221
sg13
g2349
sg14
I16
sg15
VC0003125
p2356
sg17
I2
sasg18
(lp2357
(dp2358
g12
I152
sg13
VAGT
p2359
sg14
I3
sg22
VP21549
p2360
sg17
I1
sa(dp2361
g12
I119
sg13
VCD38
p2362
sg14
I4
sg22
VP28907
p2363
sg17
I1
sa(dp2364
g12
I145
sg13
VPPARG
p2365
sg14
I5
sg22
g190
sg17
I1
sa(dp2366
g12
I132
sg13
g2348
sg14
I4
sg22
VP14151
p2367
sg17
I1
sa(dp2368
g12
I138
sg13
VPPARA
p2369
sg14
I5
sg22
g190
sg17
I1
sa(dp2370
g12
I210
sg13
VNTNG1
p2371
sg14
I5
sg22
g190
sg17
I1
sa(dp2372
g12
I125
sg13
VFOXP1
p2373
sg14
I5
sg22
g190
sg17
I1
sa(dp2374
g12
I203
sg13
VAKAP6
p2375
sg14
I5
sg22
g190
sg17
I1
sasa(dp2376
g2
VPF significantly increased the expression of nuclear factor-YA (NF-YA), which strongly upregulated the molecules involved in the proteolytic machinery [molecular chaperones, carboxyl terminus of Hsc70-interacting protein and transcription factor EB], which thus mitigated the behavioral and pathological impairments in an SBMA mouse model through the upregulation of pathogenic androgen receptor protein clearance in motor neurons and muscles.
p2377
sg4
(dp2378
(VNF-YA
p2379
VSBMA
p2380
tp2381
I00
ssg9
(lp2382
(dp2383
g12
I322
sg13
g2380
sg14
I4
sg15
VC1839259
p2384
sg17
I1
sasg18
(lp2385
(dp2386
g12
I195
sg13
VHsc70-interacting protein
p2387
sg14
I25
sg22
VP50502
p2388
sg17
I2
sa(dp2389
g12
I378
sg13
Vandrogen receptor protein
p2390
sg14
I25
sg22
VP10275
p2391
sg17
I3
sa(dp2392
g12
I45
sg13
Vnuclear factor-YA
p2393
sg14
I17
sg22
VP01160
p2394
sg17
I2
sa(dp2395
g12
I225
sg13
Vtranscription factor EB
p2396
sg14
I23
sg22
VP19484
p2397
sg17
I3
sa(dp2398
g12
I64
sg13
g2379
sg14
I5
sg22
VP23511
p2399
sg17
I1
sasa(dp2400
g2
VOn univariate analysis, diabetes mellitus, hypertension (HTN), cerebrovascular accident (CVA), left ventricular dysfunction (LVD), peripheral vascular disease (PVD), smoking, hepatitis C, inadequate dialysis, intradialytic hypotension (IDH), interdialytic weight gain, low serum creatinine &lt;4 mg/dL, and anemia (Hb &lt;10 g/dL) were found to be statistically significantly different between frail and nonfrail groups On multivariate regression analysis, only HTN, PVD, CVA, anemia, smoking, and IDH were found to be significant.
p2401
sg4
(dp2402
(VIDH
p2403
VCVA
p2404
tp2405
I00
ssg9
(lp2406
(dp2407
g12
I160
sg13
VPVD
p2408
sg14
I3
sg15
VC0085096
p2409
sg17
I1
sa(dp2410
g12
I43
sg13
Vhypertension
p2411
sg14
I12
sg15
VC0020538
p2412
sg17
I1
sa(dp2413
g12
I89
sg13
VCVA
p2414
sg14
I3
sg15
VC0038454
p2415
sg17
I1
sa(dp2416
g12
I57
sg13
VHTN
p2417
sg14
I3
sg15
VC0020538
p2418
sg17
I1
sa(dp2419
g12
I125
sg13
VLVD
p2420
sg14
I3
sg15
VC0242698
p2421
sg17
I1
sa(dp2422
g12
I95
sg13
Vleft ventricular dysfunction
p2423
sg14
I28
sg15
VC0242698
p2424
sg17
I3
sa(dp2425
g12
I160
sg13
VPVD
p2426
sg14
I3
sg15
VC0085096
p2427
sg17
I1
sa(dp2428
g12
I307
sg13
Vanemia
p2429
sg14
I6
sg15
VC0002871
p2430
sg17
I1
sa(dp2431
g12
I63
sg13
Vcerebrovascular accident
p2432
sg14
I24
sg15
VC0038454
p2433
sg17
I2
sa(dp2434
g12
I307
sg13
Vanemia
p2435
sg14
I6
sg15
VC0002871
p2436
sg17
I1
sa(dp2437
g12
I57
sg13
VHTN
p2438
sg14
I3
sg15
VC0020538
p2439
sg17
I1
sa(dp2440
g12
I24
sg13
Vdiabetes mellitus
p2441
sg14
I17
sg15
VC0011849
p2442
sg17
I2
sa(dp2443
g12
I131
sg13
Vperipheral vascular disease
p2444
sg14
I27
sg15
VC0085096
p2445
sg17
I3
sa(dp2446
g12
I175
sg13
Vhepatitis C
p2447
sg14
I11
sg15
VC0019196
p2448
sg17
I2
sa(dp2449
g12
I89
sg13
g2404
sg14
I3
sg15
VC0038454
p2450
sg17
I1
sasg18
(lp2451
(dp2452
g12
I57
sg13
VHTN
p2453
sg14
I3
sg22
VP24821
p2454
sg17
I1
sa(dp2455
g12
I209
sg13
Vintradialytic hypotension
p2456
sg14
I25
sg22
VP48735
p2457
sg17
I2
sa(dp2458
g12
I43
sg13
Vhypertension
p2459
sg14
I12
sg22
VP24821
p2460
sg17
I1
sa(dp2461
g12
I236
sg13
g2403
sg14
I3
sg22
VP48735
p2462
sg17
I1
sasa(dp2463
g2
VFactors predicting frailty include HTN, smoking, LVD, PVD, CVA, smoking, anemia, and IDH.
p2464
sg4
(dp2465
(VIDH
p2466
VPVD
p2467
tp2468
I00
ssg9
(lp2469
(dp2470
g12
I59
sg13
VCVA
p2471
sg14
I3
sg15
VC0038454
p2472
sg17
I1
sa(dp2473
g12
I73
sg13
Vanemia
p2474
sg14
I6
sg15
VC0002871
p2475
sg17
I1
sa(dp2476
g12
I35
sg13
VHTN
p2477
sg14
I3
sg15
VC0020538
p2478
sg17
I1
sa(dp2479
g12
I54
sg13
g2467
sg14
I3
sg15
VC0085096
p2480
sg17
I1
sasg18
(lp2481
(dp2482
g12
I85
sg13
g2466
sg14
I3
sg22
VP48735
p2483
sg17
I1
sasa(dp2484
g2
VImmunohistochemical analysis with the anti-SOX6 antibody showed that all the glioma tissues analyzed (14 glioblastomas, 14 anaplastic astrocytomas, 3 anaplastic oligoastrocytomas, 5 diffuse astrocytomas, 1 oligodendroglioma, and 1 pilocytic astrocytoma) expressed SOX6 in tumor cells, but only a few SOX6-positive cells were detected in nonneoplastic tissues from the cerebral cortex.
p2485
sg4
(dp2486
(VSOX6
p2487
Vanaplastic astrocytomas
p2488
tp2489
I00
ssg9
(lp2490
(dp2491
g12
I134
sg13
Vastrocytomas
p2492
sg14
I12
sg15
VC0004114
p2493
sg17
I1
sa(dp2494
g12
I77
sg13
Vglioma
p2495
sg14
I6
sg15
VC0017638
p2496
sg17
I1
sa(dp2497
g12
I272
sg13
Vtumor
p2498
sg14
I5
sg15
VC0027651
p2499
sg17
I1
sa(dp2500
g12
I105
sg13
Vglioblastomas
p2501
sg14
I13
sg15
VC0017636
p2502
sg17
I1
sa(dp2503
g12
I231
sg13
Vpilocytic astrocytoma
p2504
sg14
I21
sg15
VC0334583
p2505
sg17
I2
sa(dp2506
g12
I206
sg13
Voligodendroglioma
p2507
sg14
I17
sg15
VC0028945
p2508
sg17
I1
sa(dp2509
g12
I123
sg13
g2488
sg14
I23
sg15
VC0334579
p2510
sg17
I2
sasg18
(lp2511
(dp2512
g12
I43
sg13
VSOX6
p2513
sg14
I4
sg22
VP35712
p2514
sg17
I1
sa(dp2515
g12
I38
sg13
Vanti-SOX6 antibody
p2516
sg14
I18
sg22
VP35712
p2517
sg17
I2
sa(dp2518
g12
I43
sg13
g2487
sg14
I4
sg22
VP35712
p2519
sg17
I1
sasa(dp2520
g2
VTo address these issues, we analyzed the production of proinflammatory mediators in mouse thyroid organs and demonstrate consistency with in vitro studies performed previously that Il1alpha, Il1beta, Il6, and Tnfalpha and the enzyme Cox2 are produced by RP3-transgenic thyroid tissue, but absent from nontransgenic thyroids.
p2521
sg4
(dp2522
(VIl1beta
p2523
VRP3
p2524
tp2525
I00
ssg9
(lp2526
(dp2527
g12
I254
sg13
g2524
sg14
I3
sg15
VC1845667
p2528
sg17
I1
sasg18
(lp2529
(dp2530
g12
I200
sg13
VIl6
p2531
sg14
I3
sg22
VP05231
p2532
sg17
I1
sa(dp2533
g12
I233
sg13
VCox2
p2534
sg14
I4
sg22
VP35354
p2535
sg17
I1
sa(dp2536
g12
I209
sg13
VTnfalpha
p2537
sg14
I8
sg22
VP01375
p2538
sg17
I1
sa(dp2539
g12
I181
sg13
VIl1alpha
p2540
sg14
I8
sg22
VP01583
p2541
sg17
I1
sa(dp2542
g12
I254
sg13
VRP3
p2543
sg14
I3
sg22
VP51808
p2544
sg17
I1
sa(dp2545
g12
I191
sg13
g2523
sg14
I7
sg22
VP01584
p2546
sg17
I1
sasa(dp2547
g2
VTo examine the association between the serum endostatin levels and subclinical atherosclerosis independent of traditional risk factors in a healthy Japanese population.
p2548
sg4
(dp2549
(Vserum endostatin
p2550
Vatherosclerosis
p2551
tp2552
I01
ssg9
(lp2553
(dp2554
g12
I79
sg13
g2551
sg14
I15
sg15
VC0004153
p2555
sg17
I1
sasg18
(lp2556
(dp2557
g12
I39
sg13
g2550
sg14
I16
sg22
VP39059
p2558
sg17
I2
sasa(dp2559
g2
VAmong these, 236 differentially expressed genes (DEGs) were statistically significant, including many DEGs that were novel in cervical cancer, including gastrulation brain homeobox 2,5-hydroxytryptamine receptor 1D and endothelin 3.
p2560
sg4
(dp2561
(Vbrain homeobox 2,5-hydroxytryptamine receptor 1D
p2562
Vcervical cancer
p2563
tp2564
I00
ssg9
(lp2565
(dp2566
g12
I126
sg13
g2563
sg14
I15
sg15
VC0302592
p2567
sg17
I2
sasg18
(lp2568
(dp2569
g12
I49
sg13
VDEGs
p2570
sg14
I4
sg22
g190
sg17
I1
sa(dp2571
g12
I219
sg13
Vendothelin 3
p2572
sg14
I12
sg22
VP14138
p2573
sg17
I2
sa(dp2574
g12
I166
sg13
g2562
sg14
I48
sg22
VP52954
p2575
sg17
I5
sa(dp2576
g12
I17
sg13
Vdifferentially expressed genes
p2577
sg14
I30
sg22
g190
sg17
I3
sasa(dp2578
g2
VA total of 5 overlapping genes [dipeptidyl peptidase 4 (DPP4); endothelin 3 (EDN3); fibroblast growth factor 14 (FGF14); tachykinin, precursor 1 (TAC1); and wingless-type MMTV integration site family, member 16 (WNT16)] between the 561 overlapping differentially methylated genes and the 242 DEGs were identified, which were downregulated and hypermethylated simultaneously in cervical cancer samples.
p2579
sg4
(dp2580
(VEDN3
p2581
Vcervical cancer
p2582
tp2583
I00
ssg9
(lp2584
(dp2585
g12
I377
sg13
g2582
sg14
I15
sg15
VC0302592
p2586
sg17
I2
sasg18
(lp2587
(dp2588
g12
I121
sg13
Vtachykinin, precursor 1
p2589
sg14
I23
sg22
VP29401
p2590
sg17
I3
sa(dp2591
g12
I157
sg13
Vwingless-type MMTV integration site family, member 16
p2592
sg14
I53
sg22
g190
sg17
I7
sa(dp2593
g12
I31
sg13
V[dipeptidyl peptidase 4
p2594
sg14
I23
sg22
VP27487
p2595
sg17
I3
sa(dp2596
g12
I56
sg13
VDPP4
p2597
sg14
I4
sg22
VP27487
p2598
sg17
I1
sa(dp2599
g12
I84
sg13
Vfibroblast growth factor 14
p2600
sg14
I27
sg22
g190
sg17
I4
sa(dp2601
g12
I212
sg13
VWNT16
p2602
sg14
I5
sg22
g190
sg17
I1
sa(dp2603
g12
I113
sg13
VFGF14
p2604
sg14
I5
sg22
g190
sg17
I1
sa(dp2605
g12
I63
sg13
Vendothelin 3
p2606
sg14
I12
sg22
VP14138
p2607
sg17
I2
sa(dp2608
g12
I77
sg13
g2581
sg14
I4
sg22
VP14138
p2609
sg17
I1
sasa(dp2610
g2
VTranscription factor MEF2C regulates multiple genes linked to autism spectrum disorder (ASD), and human MEF2C haploinsufficiency results in ASD, intellectual disability, and epilepsy.
p2611
sg4
(dp2612
(VTranscription factor MEF2C
p2613
Vautism spectrum disorder
p2614
tp2615
I01
ssg9
(lp2616
(dp2617
g12
I174
sg13
Vepilepsy
p2618
sg14
I8
sg15
VC0014544
p2619
sg17
I1
sa(dp2620
g12
I88
sg13
VASD
p2621
sg14
I3
sg15
VC1510586
p2622
sg17
I1
sa(dp2623
g12
I145
sg13
Vintellectual disability
p2624
sg14
I23
sg15
VC0025362
p2625
sg17
I2
sa(dp2626
g12
I88
sg13
VASD
p2627
sg14
I3
sg15
VC1510586
p2628
sg17
I1
sa(dp2629
g12
I62
sg13
g2614
sg14
I24
sg15
VC1510586
p2630
sg17
I3
sasg18
(lp2631
(dp2632
g12
I0
sg13
g2613
sg14
I26
sg22
VP35398
p2633
sg17
I3
sa(dp2634
g12
I98
sg13
Vhuman MEF2C
p2635
sg14
I11
sg22
g190
sg17
I2
sasa(dp2636
g2
VThe microRNAs target a group of genes enriched for synaptic signaling and epilepsy risk, including SLC12A5, SYT1, GRIN2A, GRIN2B, KCNB1, SCN2A, TSC1, and MEF2C.
p2637
sg4
(dp2638
(VSYT1
p2639
Vepilepsy
p2640
tp2641
I01
ssg9
(lp2642
(dp2643
g12
I144
sg13
VTSC1
p2644
sg14
I4
sg15
VC1854465
p2645
sg17
I1
sa(dp2646
g12
I74
sg13
g2640
sg14
I8
sg15
VC0014544
p2647
sg17
I1
sasg18
(lp2648
(dp2649
g12
I108
sg13
g2639
sg14
I4
sg22
VP21579
p2650
sg17
I1
sa(dp2651
g12
I122
sg13
VGRIN2B
p2652
sg14
I6
sg22
g190
sg17
I1
sa(dp2653
g12
I99
sg13
VSLC12A5
p2654
sg14
I7
sg22
g190
sg17
I1
sa(dp2655
g12
I137
sg13
VSCN2A
p2656
sg14
I5
sg22
g190
sg17
I1
sa(dp2657
g12
I154
sg13
VMEF2C
p2658
sg14
I5
sg22
g190
sg17
I1
sa(dp2659
g12
I114
sg13
VGRIN2A
p2660
sg14
I6
sg22
g190
sg17
I1
sa(dp2661
g12
I130
sg13
VKCNB1
p2662
sg14
I5
sg22
g190
sg17
I1
sa(dp2663
g12
I144
sg13
VTSC1
p2664
sg14
I4
sg22
g190
sg17
I1
sasa(dp2665
g2
VGenome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB1, HLA-DRB4, INPP5D, MEF2C, MS4A4A, MS4A4E, MS4A6E, NME8, PICALM, PLD3, PTK2B, RIN3, SLC24A4, SORL1, and ZCWPW1 genes.
p2666
sg4
(dp2667
(VCR1
p2668
VAD
p2669
tp2670
I00
ssg9
(lp2671
(dp2672
g12
I95
sg13
VAlzheimer's diseases
p2673
sg14
I20
sg15
VC0002395
p2674
sg17
I2
sa(dp2675
g12
I117
sg13
g2669
sg14
I2
sg15
VC0002395
p2676
sg17
I1
sasg18
(lp2677
(dp2678
g12
I292
sg13
VPICALM
p2679
sg14
I6
sg22
g190
sg17
I1
sa(dp2680
g12
I176
sg13
VCD2AP
p2681
sg14
I5
sg22
g190
sg17
I1
sa(dp2682
g12
I270
sg13
VMS4A4E
p2683
sg14
I6
sg22
g190
sg17
I1
sa(dp2684
g12
I255
sg13
VMEF2C
p2685
sg14
I5
sg22
g190
sg17
I1
sa(dp2686
g12
I227
sg13
VHLA
p2687
sg14
I3
sg22
VP30486
p2688
sg17
I1
sa(dp2689
g12
I206
sg13
VDSG2
p2690
sg14
I4
sg22
g190
sg17
I1
sa(dp2691
g12
I189
sg13
VCELF1
p2692
sg14
I5
sg22
g190
sg17
I1
sa(dp2693
g12
I157
sg13
VAPOE
p2694
sg14
I4
sg22
VP02649
p2695
sg17
I1
sa(dp2696
g12
I150
sg13
VABCA7
p2697
sg14
I5
sg22
g190
sg17
I1
sa(dp2698
g12
I313
sg13
VRIN3
p2699
sg14
I4
sg22
g190
sg17
I1
sa(dp2700
g12
I328
sg13
VSORL1
p2701
sg14
I5
sg22
g190
sg17
I1
sa(dp2702
g12
I319
sg13
VSLC24A4
p2703
sg14
I7
sg22
g190
sg17
I1
sa(dp2704
g12
I247
sg13
VINPP5D
p2705
sg14
I6
sg22
g190
sg17
I1
sa(dp2706
g12
I262
sg13
VMS4A4A
p2707
sg14
I6
sg22
g190
sg17
I1
sa(dp2708
g12
I183
sg13
VCD33
p2709
sg14
I4
sg22
VP20138
p2710
sg17
I1
sa(dp2711
g12
I300
sg13
VPLD3
p2712
sg14
I4
sg22
g190
sg17
I1
sa(dp2713
g12
I219
sg13
VFERMT2
p2714
sg14
I6
sg22
g190
sg17
I1
sa(dp2715
g12
I169
sg13
VCASS4
p2716
sg14
I5
sg22
g190
sg17
I1
sa(dp2717
g12
I196
sg13
VCLU
p2718
sg14
I3
sg22
VP10909
p2719
sg17
I1
sa(dp2720
g12
I306
sg13
VPTK2B
p2721
sg14
I5
sg22
g190
sg17
I1
sa(dp2722
g12
I212
sg13
VEPHA1
p2723
sg14
I5
sg22
VP21709
p2724
sg17
I1
sa(dp2725
g12
I278
sg13
VMS4A6E
p2726
sg14
I6
sg22
g190
sg17
I1
sa(dp2727
g12
I227
sg13
VHLA
p2728
sg14
I3
sg22
VP30486
p2729
sg17
I1
sa(dp2730
g12
I201
sg13
g2668
sg14
I3
sg22
VP17927
p2731
sg17
I1
sa(dp2732
g12
I339
sg13
VZCWPW1 genes
p2733
sg14
I12
sg22
g190
sg17
I2
sa(dp2734
g12
I286
sg13
VNME8
p2735
sg14
I4
sg22
g190
sg17
I1
sa(dp2736
g12
I231
sg13
VDRB1
p2737
sg14
I4
sg22
g190
sg17
I1
sasa(dp2738
g2
VA key factor protecting from oxidative stress in gestational diabetes mellitus (GDM) and in type 2 diabetes (T2D) is paraoxonase-1 (PON1).
p2739
sg4
(dp2740
(Vparaoxonase-1
p2741
Vtype 2 diabetes
p2742
tp2743
I00
ssg9
(lp2744
(dp2745
g12
I49
sg13
Vgestational diabetes mellitus
p2746
sg14
I29
sg15
VC0085207
p2747
sg17
I3
sa(dp2748
g12
I80
sg13
VGDM
p2749
sg14
I3
sg15
VC0085207
p2750
sg17
I1
sa(dp2751
g12
I109
sg13
VT2D
p2752
sg14
I3
sg15
VC0011860
p2753
sg17
I1
sa(dp2754
g12
I29
sg13
Voxidative stress
p2755
sg14
I16
sg15
VC0242606
p2756
sg17
I2
sa(dp2757
g12
I92
sg13
g2742
sg14
I15
sg15
VC0011860
p2758
sg17
I3
sasg18
(lp2759
(dp2760
g12
I132
sg13
VPON1
p2761
sg14
I4
sg22
VP27169
p2762
sg17
I1
sa(dp2763
g12
I117
sg13
g2741
sg14
I13
sg22
VP14222
p2764
sg17
I1
sasa(dp2765
g2
VIn this study our aim was to evaluate paraoxonase (PON1) activity and free sulfhydryl groups (-SH) as antioxidative parameters and lipid hydroperoxide (LOOH) as oxidative parameter in the serum of women with gestational diabetes mellitus (GDM) and determine their relation with the degree of subclinical atherosclerosis.
p2766
sg4
(dp2767
(VPON1
p2768
VGDM
p2769
tp2770
I00
ssg9
(lp2771
(dp2772
g12
I304
sg13
Vatherosclerosis
p2773
sg14
I15
sg15
VC0004153
p2774
sg17
I1
sa(dp2775
g12
I208
sg13
Vgestational diabetes mellitus
p2776
sg14
I29
sg15
VC0085207
p2777
sg17
I3
sa(dp2778
g12
I239
sg13
g2769
sg14
I3
sg15
VC0085207
p2779
sg17
I1
sasg18
(lp2780
(dp2781
g12
I38
sg13
Vparaoxonase
p2782
sg14
I11
sg22
VP14222
p2783
sg17
I1
sa(dp2784
g12
I51
sg13
g2768
sg14
I4
sg22
VP27169
p2785
sg17
I1
sasa(dp2786
g2
VTo clarify the levels of protein oxidation markers such as protein carbonyl (PCO), protein hydroperoxides (P-OOH), advanced oxidation protein products (AOPP) and nitrotyrosine (NT), as well as antioxidative enzymes such as paraoxonase (PON-1) in women with and without gestational diabetes mellitus (GDM).
p2787
sg4
(dp2788
(VPON-1
p2789
VPCO
p2790
tp2791
I00
ssg9
(lp2792
(dp2793
g12
I269
sg13
Vgestational diabetes mellitus
p2794
sg14
I29
sg15
VC0085207
p2795
sg17
I3
sa(dp2796
g12
I59
sg13
Vprotein carbonyl
p2797
sg14
I16
sg15
VC0032460
p2798
sg17
I2
sa(dp2799
g12
I300
sg13
VGDM
p2800
sg14
I3
sg15
VC0085207
p2801
sg17
I1
sa(dp2802
g12
I77
sg13
g2790
sg14
I3
sg15
VC0032460
p2803
sg17
I1
sasg18
(lp2804
(dp2805
g12
I223
sg13
Vparaoxonase
p2806
sg14
I11
sg22
VP14222
p2807
sg17
I1
sa(dp2808
g12
I236
sg13
g2789
sg14
I5
sg22
VP27169
p2809
sg17
I1
sasa(dp2810
g2
VTwenty-six (43.3%) PM/DM-ILD patients were anti-aminoacyl tRNA-synthetase antibody-positive (anti-ARS-positive), 15 (25.0%) were anti-melanoma differentiation-associated gene 5 antibody-positive (anti-MDA5-positive), 3 (5%) were anti-signal recognition particle antibody-positive, 1 (1.7%) was anti-transcriptional intermediary factor 1-gamma antibody-positive, and 15 (25%) were MSA-negative.
p2811
sg4
(dp2812
(Vanti-signal recognition particle antibody
p2813
VMSA
p2814
tp2815
I00
ssg9
(lp2816
(dp2817
g12
I134
sg13
Vmelanoma
p2818
sg14
I8
sg15
VC0025202
p2819
sg17
I1
sa(dp2820
g12
I380
sg13
g2814
sg14
I3
sg15
VC0393571
p2821
sg17
I1
sasg18
(lp2822
(dp2823
g12
I196
sg13
Vanti-MDA5
p2824
sg14
I9
sg22
g190
sg17
I1
sa(dp2825
g12
I129
sg13
Vanti-melanoma differentiation-associated gene 5 antibody
p2826
sg14
I56
sg22
g190
sg17
I5
sa(dp2827
g12
I229
sg13
g2813
sg14
I41
sg22
VP61011
p2828
sg17
I4
sa(dp2829
g12
I294
sg13
Vanti-transcriptional intermediary factor 1-gamma antibody
p2830
sg14
I57
sg22
g190
sg17
I5
sasa(dp2831
g2
VEach of the identified mutations altered the equilibrium between alternative GR conformations distinctively, indicating that the Hsp90 dependence of SRs may correlate with differences in the conformational dynamics of these receptors.
p2832
sg4
(dp2833
(VGR
p2834
VSRs
p2835
tp2836
I00
ssg9
(lp2837
(dp2838
g12
I135
sg13
Vdependence
p2839
sg14
I10
sg15
VC0439857
p2840
sg17
I1
sa(dp2841
g12
I149
sg13
g2835
sg14
I3
sg15
VC0175693
p2842
sg17
I1
sasg18
(lp2843
(dp2844
g12
I129
sg13
VHsp90
p2845
sg14
I5
sg22
VP07900
p2846
sg17
I1
sa(dp2847
g12
I149
sg13
VSRs
p2848
sg14
I3
sg22
VP35270
p2849
sg17
I1
sa(dp2850
g12
I77
sg13
g2834
sg14
I2
sg22
VP00390
p2851
sg17
I1
sasa(dp2852
g2
VThe ubiquitous heat shock protein 90 (hsp90) has been shown to participate directly in the function of a wide variety of cellular signal transduction components, including steroid receptors (SRs).
p2853
sg4
(dp2854
(VSRs
p2855
VSRs
p2856
tp2857
I00
ssg9
(lp2858
(dp2859
g12
I172
sg13
Vsteroid receptors
p2860
sg14
I17
sg15
VC0175693
p2861
sg17
I2
sa(dp2862
g12
I191
sg13
g2856
sg14
I3
sg15
VC0175693
p2863
sg17
I1
sasg18
(lp2864
(dp2865
g12
I172
sg13
Vsteroid receptors
p2866
sg14
I17
sg22
VP52788
p2867
sg17
I2
sa(dp2868
g12
I15
sg13
Vheat shock protein 90
p2869
sg14
I21
sg22
VP07900
p2870
sg17
I4
sa(dp2871
g12
I38
sg13
Vhsp90
p2872
sg14
I5
sg22
VP07900
p2873
sg17
I1
sa(dp2874
g12
I191
sg13
g2855
sg14
I3
sg22
VP35270
p2875
sg17
I1
sasa(dp2876
g2
VHowever, there is still no direct evidence for an in vivo association of SRs with hsp90.
p2877
sg4
(dp2878
(VSRs
p2879
VSRs
p2880
tp2881
I00
ssg9
(lp2882
(dp2883
g12
I73
sg13
g2880
sg14
I3
sg15
VC0175693
p2884
sg17
I1
sasg18
(lp2885
(dp2886
g12
I82
sg13
Vhsp90
p2887
sg14
I5
sg22
VP07900
p2888
sg17
I1
sa(dp2889
g12
I73
sg13
g2879
sg14
I3
sg22
VP35270
p2890
sg17
I1
sasa(dp2891
g2
VThe results suggest that the interaction of SRs with the hsp90 is minimal when compared to a bona fide type of interaction with the co-factors.
p2892
sg4
(dp2893
(VSRs
p2894
VSRs
p2895
tp2896
I00
ssg9
(lp2897
(dp2898
g12
I44
sg13
g2895
sg14
I3
sg15
VC0175693
p2899
sg17
I1
sasg18
(lp2900
(dp2901
g12
I57
sg13
Vhsp90
p2902
sg14
I5
sg22
VP07900
p2903
sg17
I1
sa(dp2904
g12
I44
sg13
g2894
sg14
I3
sg22
VP35270
p2905
sg17
I1
sasa(dp2906
g2
VTo address the role of endothelial Cx43 in this process, we analyzed Cx43 regulation in human umbilical vein endothelial cells in the proximity of Cx43high (DU-145 and MAT-LyLu) and Cx43low prostate cancer cells (PC-3 and AT-2).
p2907
sg4
(dp2908
(VCx43
p2909
Vprostate cancer
p2910
tp2911
I00
ssg9
(lp2912
(dp2913
g12
I190
sg13
g2910
sg14
I15
sg15
VC0600139
p2914
sg17
I2
sasg18
(lp2915
(dp2916
g12
I168
sg13
VMAT-LyLu
p2917
sg14
I8
sg22
VP24752
p2918
sg17
I1
sa(dp2919
g12
I35
sg13
VCx43
p2920
sg14
I4
sg22
VP17302
p2921
sg17
I1
sa(dp2922
g12
I35
sg13
g2909
sg14
I4
sg22
VP17302
p2923
sg17
I1
sa(dp2924
g12
I213
sg13
VPC-3
p2925
sg14
I4
sg22
g190
sg17
I1
sasa(dp2926
g2
VThe data on the nature of AT2-R expression in prostate tissue of prostate cancer patients may be considered as a tool for predicting biochemical recurrence after combined hormone and radiation therapy.
p2927
sg4
(dp2928
(VAT2-R
p2929
Vprostate cancer
p2930
tp2931
I01
ssg9
(lp2932
(dp2933
g12
I145
sg13
Vrecurrence
p2934
sg14
I10
sg15
VC1458156
p2935
sg17
I1
sa(dp2936
g12
I65
sg13
g2930
sg14
I15
sg15
VC0600139
p2937
sg17
I2
sasg18
(lp2938
(dp2939
g12
I26
sg13
g2929
sg14
I5
sg22
VP50052
p2940
sg17
I1
sasa(dp2941
g2
VThe present study found that, similarly to 5-fluorouracil, low concentrations (1-10 myM) of 9-aminoacridine (9-AAA) inhibited the growth of the two rat prostate cancer AT-2 and Mat-LyLu cell lines and the human melanoma A375 cell line.
p2942
sg4
(dp2943
(VMat
p2944
Vprostate cancer
p2945
tp2946
I00
ssg9
(lp2947
(dp2948
g12
I211
sg13
Vmelanoma
p2949
sg14
I8
sg15
VC0025202
p2950
sg17
I1
sa(dp2951
g12
I111
sg13
VAAA
p2952
sg14
I3
sg15
VC0162871
p2953
sg17
I1
sa(dp2954
g12
I152
sg13
g2945
sg14
I15
sg15
VC0600139
p2955
sg17
I2
sasg18
(lp2956
(dp2957
g12
I177
sg13
g2944
sg14
I3
sg22
VP24752
p2958
sg17
I1
sa(dp2959
g12
I148
sg13
Vrat prostate cancer AT-2
p2960
sg14
I24
sg22
g190
sg17
I4
sasa(dp2961
g2
VFurthermore, our previous studies indicate that increased expression of Ang II type 2 receptor (AT2R) alone induced apoptosis in human prostate cancer lines, an effect that did not require Ang II.
p2962
sg4
(dp2963
(VAT2R
p2964
Vprostate cancer
p2965
tp2966
I01
ssg9
(lp2967
(dp2968
g12
I135
sg13
g2965
sg14
I15
sg15
VC0600139
p2969
sg17
I2
sasg18
(lp2970
(dp2971
g12
I72
sg13
VAng II type 2 receptor
p2972
sg14
I22
sg22
VP01019
p2973
sg17
I5
sa(dp2974
g12
I72
sg13
VAng II
p2975
sg14
I6
sg22
VP01019
p2976
sg17
I2
sa(dp2977
g12
I96
sg13
g2964
sg14
I4
sg22
VP50052
p2978
sg17
I1
sasa(dp2979
g2
VHuman prostate cancer DU145 xenograft mouse model was used to assess the effect of AT2R on tumor growth in vivo.
p2980
sg4
(dp2981
(VAT2R
p2982
Vprostate cancer
p2983
tp2984
I01
ssg9
(lp2985
(dp2986
g12
I91
sg13
Vtumor growth
p2987
sg14
I12
sg15
VC0598934
p2988
sg17
I2
sa(dp2989
g12
I6
sg13
g2983
sg14
I15
sg15
VC0600139
p2990
sg17
I2
sasg18
(lp2991
(dp2992
g12
I83
sg13
g2982
sg14
I4
sg22
VP50052
p2993
sg17
I1
sasa(dp2994
g2
VThe results showed that AT2R overexpression can inhibit tumor growth of prostate cancer in vivo by inhibiting proliferation and inducing apoptosis of tumor cells.
p2995
sg4
(dp2996
(VAT2R
p2997
Vprostate cancer
p2998
tp2999
I01
ssg9
(lp3000
(dp3001
g12
I56
sg13
Vtumor growth
p3002
sg14
I12
sg15
VC0598934
p3003
sg17
I2
sa(dp3004
g12
I110
sg13
Vproliferation
p3005
sg14
I13
sg15
VC0334094
p3006
sg17
I1
sa(dp3007
g12
I72
sg13
g2998
sg14
I15
sg15
VC0600139
p3008
sg17
I2
sa(dp3009
g12
I56
sg13
Vtumor
p3010
sg14
I5
sg15
VC0027651
p3011
sg17
I1
sasg18
(lp3012
(dp3013
g12
I24
sg13
g2997
sg14
I4
sg22
VP50052
p3014
sg17
I1
sasa(dp3015
g2
VThe aim of the present study was the evaluation of AT1 and AT2 expressions in human prostate cancers.
p3016
sg4
(dp3017
(VAT2
p3018
Vprostate cancers
p3019
tp3020
I01
ssg9
(lp3021
(dp3022
g12
I51
sg13
VAT1
p3023
sg14
I3
sg15
VC0004135
p3024
sg17
I1
sa(dp3025
g12
I84
sg13
g3019
sg14
I16
sg15
VC0376358
p3026
sg17
I2
sasg18
(lp3027
(dp3028
g12
I51
sg13
VAT1
p3029
sg14
I3
sg22
VP30556
p3030
sg17
I1
sa(dp3031
g12
I59
sg13
g3018
sg14
I3
sg22
VP50052
p3032
sg17
I1
sasa(dp3033
g2
VThe data on AT1 and AT2 receptor expressions may suggest the involvement of RAS in prostate cancerogenesis.
p3034
sg4
(dp3035
(VAT1
p3036
VAT1
p3037
tp3038
I00
ssg9
(lp3039
(dp3040
g12
I12
sg13
g3037
sg14
I3
sg15
VC0004135
p3041
sg17
I1
sasg18
(lp3042
(dp3043
g12
I76
sg13
VRAS
p3044
sg14
I3
sg22
VP01116
p3045
sg17
I1
sa(dp3046
g12
I20
sg13
VAT2 receptor
p3047
sg14
I12
sg22
VP50052
p3048
sg17
I2
sa(dp3049
g12
I12
sg13
g3036
sg14
I3
sg22
VP30556
p3050
sg17
I1
sasa(dp3051
g2
VTo investigate the impact of genetic variants in CYP2C9, CYP2C19, CYP3A4, GSTT1, GSTM1 and GSTP1 on the efficacy of cyclophosphamide (CYC) therapy in patients with lupus nephritis.
p3052
sg4
(dp3053
(VCYP3A4
p3054
Vlupus nephritis
p3055
tp3056
I01
ssg9
(lp3057
(dp3058
g12
I164
sg13
g3055
sg14
I15
sg15
VC0024143
p3059
sg17
I2
sasg18
(lp3060
(dp3061
g12
I74
sg13
VGSTT1
p3062
sg14
I5
sg22
VP30711
p3063
sg17
I1
sa(dp3064
g12
I81
sg13
VGSTM1
p3065
sg14
I5
sg22
VP09488
p3066
sg17
I1
sa(dp3067
g12
I49
sg13
VCYP2C9
p3068
sg14
I6
sg22
VP11712
p3069
sg17
I1
sa(dp3070
g12
I91
sg13
VGSTP1
p3071
sg14
I5
sg22
VP09211
p3072
sg17
I1
sa(dp3073
g12
I57
sg13
VCYP2C19
p3074
sg14
I7
sg22
VP33261
p3075
sg17
I1
sa(dp3076
g12
I66
sg13
g3054
sg14
I6
sg22
VP08684
p3077
sg17
I1
sasa(dp3078
g2
VChronic kidney disease (CKD) complicates warfarin anticoagulation partially through its effect on CYP2C9 activity.
p3079
sg4
(dp3080
(VCYP2C9
p3081
VCKD
p3082
tp3083
I00
ssg9
(lp3084
(dp3085
g12
I0
sg13
VChronic kidney disease
p3086
sg14
I22
sg15
VC1561643
p3087
sg17
I3
sa(dp3088
g12
I24
sg13
g3082
sg14
I3
sg15
VC1561643
p3089
sg17
I1
sasg18
(lp3090
(dp3091
g12
I98
sg13
g3081
sg14
I6
sg22
VP11712
p3092
sg17
I1
sasa(dp3093
g2
VThe CYP2C9 pathway (4-hydroxyflurbiprofen formation clearance) was similar in all the patients with CKD and was concordant with previous reports of patients with end-stage renal disease (ESRD) and healthy controls.
p3094
sg4
(dp3095
(VCYP2C9
p3096
Vend-stage renal disease
p3097
tp3098
I01
ssg9
(lp3099
(dp3100
g12
I187
sg13
VESRD
p3101
sg14
I4
sg15
VC0022661
p3102
sg17
I1
sa(dp3103
g12
I162
sg13
g3097
sg14
I23
sg15
VC0022661
p3104
sg17
I3
sasg18
(lp3105
(dp3106
g12
I4
sg13
g3096
sg14
I6
sg22
VP11712
p3107
sg17
I1
sasa(dp3108
g2
VFor flurbiprofen, patients with glomerulonephritis had higher oral clearance than those with nonglomerular CKD, suggesting higher unbound fraction and enhanced metabolism through other (non-CYP2C9) routes.
p3109
sg4
(dp3110
(VCYP2C9
p3111
Vglomerulonephritis
p3112
tp3113
I00
ssg9
(lp3114
(dp3115
g12
I32
sg13
g3112
sg14
I18
sg15
VC0017658
p3116
sg17
I1
sasg18
(lp3117
(dp3118
g12
I190
sg13
g3111
sg14
I6
sg22
VP11712
p3119
sg17
I1
sasa(dp3120
g2
VThe current study suggests no statistically significant differences in the in vivo activity of CYP2C9 and CYP3A4 in patients with either glomerulonephritis or nonglomerular CKD.
p3121
sg4
(dp3122
(VCYP2C9 and CYP3A4
p3123
Vglomerulonephritis
p3124
tp3125
I00
ssg9
(lp3126
(dp3127
g12
I137
sg13
g3124
sg14
I18
sg15
VC0017658
p3128
sg17
I1
sasg18
(lp3129
(dp3130
g12
I95
sg13
g3123
sg14
I17
sg22
VP08684
p3131
sg17
I3
sasa(dp3132
g2
VWe examined whether the renin inhibitor, aliskiren, provides similar or greater protection than ACE inhibition from non-proliferative diabetic retinopathy and from the proliferative neoangiogenesis of oxygen-induced retinopathy.
p3133
sg4
(dp3134
(VACE
p3135
Vnon-proliferative diabetic retinopathy
p3136
tp3137
I01
ssg9
(lp3138
(dp3139
g12
I182
sg13
Vneoangiogenesis
p3140
sg14
I15
sg15
VC0027686
p3141
sg17
I1
sa(dp3142
g12
I143
sg13
Vretinopathy
p3143
sg14
I11
sg15
VC0035309
p3144
sg17
I1
sa(dp3145
g12
I120
sg13
Vproliferative
p3146
sg14
I13
sg15
VC0334094
p3147
sg17
I1
sa(dp3148
g12
I116
sg13
g3136
sg14
I38
sg15
VC0004606
p3149
sg17
I3
sasg18
(lp3150
(dp3151
g12
I24
sg13
Vrenin
p3152
sg14
I5
sg22
VP00797
p3153
sg17
I1
sa(dp3154
g12
I96
sg13
g3135
sg14
I3
sg22
VP12821
p3155
sg17
I1
sasa(dp3156
g2
VTo assess angiotensin-converting enzyme (ACE) levels in aqueous humor and plasma of patients with nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) as another potent ischemia-induced angiogenic factor.
p3157
sg4
(dp3158
(Vangiotensin-converting enzyme
p3159
Vproliferative diabetic retinopathy
p3160
tp3161
I00
ssg9
(lp3162
(dp3163
g12
I98
sg13
Vnonproliferative diabetic retinopathy
p3164
sg14
I37
sg15
VC0004606
p3165
sg17
I3
sa(dp3166
g12
I56
sg13
Vaqueous humor
p3167
sg14
I13
sg15
VC0595936
p3168
sg17
I2
sa(dp3169
g12
I137
sg13
VNPDR
p3170
sg14
I4
sg15
VC0004606
p3171
sg17
I1
sa(dp3172
g12
I138
sg13
VPDR
p3173
sg14
I3
sg15
VC0154830
p3174
sg17
I1
sa(dp3175
g12
I206
sg13
Vischemia
p3176
sg14
I8
sg15
VC0022116
p3177
sg17
I1
sa(dp3178
g12
I101
sg13
g3160
sg14
I34
sg15
VC0154830
p3179
sg17
I3
sasg18
(lp3180
(dp3181
g12
I41
sg13
VACE
p3182
sg14
I3
sg22
VP12821
p3183
sg17
I1
sa(dp3184
g12
I223
sg13
Vangiogenic factor
p3185
sg14
I17
sg22
g190
sg17
I2
sa(dp3186
g12
I10
sg13
g3159
sg14
I29
sg22
VP12821
p3187
sg17
I2
sasa(dp3188
g2
VWe observed significantly elevated ACE level in aqueous humor of patients with PDR compared with the patients with NPDR and normal subjects (P = 0.023), but no significant difference was detected between nonproliferative diabetics and control group (P = 0.239).
p3189
sg4
(dp3190
(VACE
p3191
Vaqueous humor
p3192
tp3193
I00
ssg9
(lp3194
(dp3195
g12
I79
sg13
VPDR
p3196
sg14
I3
sg15
VC1845050
p3197
sg17
I1
sa(dp3198
g12
I48
sg13
g3192
sg14
I13
sg15
VC0595936
p3199
sg17
I2
sasg18
(lp3200
(dp3201
g12
I35
sg13
g3191
sg14
I3
sg22
VP12821
p3202
sg17
I1
sasa(dp3203
g2
VStudies exploring the association between ACE I/D polymorphism and BDR or PDR may help us better understand the genetics of DR.
p3204
sg4
(dp3205
(VACE I/D
p3206
VPDR
p3207
tp3208
I01
ssg9
(lp3209
(dp3210
g12
I74
sg13
g3207
sg14
I3
sg15
VC1845050
p3211
sg17
I1
sasg18
(lp3212
(dp3213
g12
I42
sg13
g3206
sg14
I7
sg22
VP12821
p3214
sg17
I2
sasa(dp3215
g2
VTo evaluate the effects of angiotensin-converting enzyme inhibitors (ACE-I) in retarding progression of severe non-proliferative diabetic retinopathy (NPDR) in normotensive type 2 diabetic patients.
p3216
sg4
(dp3217
(Vangiotensin-converting enzyme inhibitors
p3218
VNPDR
p3219
tp3220
I01
ssg9
(lp3221
(dp3222
g12
I111
sg13
Vnon-proliferative diabetic retinopathy
p3223
sg14
I38
sg15
VC0004606
p3224
sg17
I3
sa(dp3225
g12
I151
sg13
g3219
sg14
I4
sg15
VC0004606
p3226
sg17
I1
sasg18
(lp3227
(dp3228
g12
I69
sg13
VACE-I
p3229
sg14
I5
sg22
VP12821
p3230
sg17
I1
sa(dp3231
g12
I27
sg13
g3218
sg14
I40
sg22
VP12821
p3232
sg17
I3
sasa(dp3233
g2
VThis was a retrospective case control study of 128 patients with normotensive type 2 diabetes with lower than +1 dipstick proteinuria and severe NPDR who were classified into either an ACE-I treated group (Enalapril maleate 10 mg, n=12 , Ramipril 5 mg, n=17) or an ACE-I untreated group (n=99).
p3234
sg4
(dp3235
(VACE-I
p3236
Vsevere NPDR
p3237
tp3238
I00
ssg9
(lp3239
(dp3240
g12
I78
sg13
Vtype 2 diabetes
p3241
sg14
I15
sg15
VC0011860
p3242
sg17
I3
sa(dp3243
g12
I138
sg13
g3237
sg14
I11
sg15
VC0730278
p3244
sg17
I2
sasg18
(lp3245
(dp3246
g12
I185
sg13
VACE-I
p3247
sg14
I5
sg22
VP12821
p3248
sg17
I1
sa(dp3249
g12
I185
sg13
g3236
sg14
I5
sg22
VP12821
p3250
sg17
I1
sasa(dp3251
g2
VSmall doses of ACE-I did not yield any beneficial effects in retarding the progression of severe NPDR.
p3252
sg4
(dp3253
(VACE-I
p3254
Vsevere NPDR
p3255
tp3256
I00
ssg9
(lp3257
(dp3258
g12
I90
sg13
g3255
sg14
I11
sg15
VC0730278
p3259
sg17
I2
sasg18
(lp3260
(dp3261
g12
I15
sg13
g3254
sg14
I5
sg22
VP12821
p3262
sg17
I1
sasa(dp3263
g2
VTo identify novel abnormally methylated genes in early stage non-small cell lung cancer (NSCLC), we analyzed the methylation status of 13 genes (ALX1, BCL2, FOXL2, HPP1, MYF6, OC2, PDGFRA, PHOX2A, PITX2, RARB, SIX6, SMPD3 and SOX1) in cancer tissues from 101 cases of stage I NSCLC patients and lung tissues from 30 cases of non-cancerous lung disease controls, using methylation-specific PCR (MSP).
p3264
sg4
(dp3265
(VFOXL2
p3266
Vstage I NSCLC
p3267
tp3268
I00
ssg9
(lp3269
(dp3270
g12
I89
sg13
VNSCLC
p3271
sg14
I5
sg15
VC0007131
p3272
sg17
I1
sa(dp3273
g12
I81
sg13
Vcancer
p3274
sg14
I6
sg15
VC0006826
p3275
sg17
I1
sa(dp3276
g12
I61
sg13
Vnon-small cell lung cancer
p3277
sg14
I26
sg15
VC0007131
p3278
sg17
I4
sa(dp3279
g12
I339
sg13
Vlung disease
p3280
sg14
I12
sg15
VC0024115
p3281
sg17
I2
sa(dp3282
g12
I268
sg13
g3267
sg14
I13
sg15
VC0278504
p3283
sg17
I3
sasg18
(lp3284
(dp3285
g12
I189
sg13
VPHOX2A
p3286
sg14
I6
sg22
g190
sg17
I1
sa(dp3287
g12
I176
sg13
VOC2
p3288
sg14
I3
sg22
VP43235
p3289
sg17
I1
sa(dp3290
g12
I197
sg13
VPITX2
p3291
sg14
I5
sg22
g190
sg17
I1
sa(dp3292
g12
I170
sg13
VMYF6
p3293
sg14
I4
sg22
VP23409
p3294
sg17
I1
sa(dp3295
g12
I181
sg13
VPDGFRA
p3296
sg14
I6
sg22
VP16234
p3297
sg17
I1
sa(dp3298
g12
I226
sg13
VSOX1
p3299
sg14
I4
sg22
g190
sg17
I1
sa(dp3300
g12
I216
sg13
VSMPD3
p3301
sg14
I5
sg22
g190
sg17
I1
sa(dp3302
g12
I204
sg13
VRARB
p3303
sg14
I4
sg22
VP10826
p3304
sg17
I1
sa(dp3305
g12
I164
sg13
VHPP1
p3306
sg14
I4
sg22
g190
sg17
I1
sa(dp3307
g12
I145
sg13
VALX1
p3308
sg14
I4
sg22
g190
sg17
I1
sa(dp3309
g12
I210
sg13
VSIX6
p3310
sg14
I4
sg22
g190
sg17
I1
sa(dp3311
g12
I151
sg13
VBCL2
p3312
sg14
I4
sg22
VP10415
p3313
sg17
I1
sa(dp3314
g12
I157
sg13
g3266
sg14
I5
sg22
VP58012
p3315
sg17
I1
sasa(dp3316
g2
VThe methylation frequencies (29.70-64.36%) of 7 genes (MYF6, SIX6, SOX1, RARB, BCL2, PHOX2A and FOLX2) in stage I NSCLC were significantly higher compared with those in non-cancerous lung disease controls (P&lt;0.05).
p3317
sg4
(dp3318
(VRARB
p3319
Vlung disease
p3320
tp3321
I00
ssg9
(lp3322
(dp3323
g12
I106
sg13
Vstage I NSCLC
p3324
sg14
I13
sg15
VC0278504
p3325
sg17
I3
sa(dp3326
g12
I183
sg13
g3320
sg14
I12
sg15
VC0024115
p3327
sg17
I2
sasg18
(lp3328
(dp3329
g12
I85
sg13
VPHOX2A
p3330
sg14
I6
sg22
g190
sg17
I1
sa(dp3331
g12
I55
sg13
VMYF6
p3332
sg14
I4
sg22
VP23409
p3333
sg17
I1
sa(dp3334
g12
I61
sg13
VSIX6
p3335
sg14
I4
sg22
g190
sg17
I1
sa(dp3336
g12
I79
sg13
VBCL2
p3337
sg14
I4
sg22
VP10415
p3338
sg17
I1
sa(dp3339
g12
I67
sg13
VSOX1
p3340
sg14
I4
sg22
g190
sg17
I1
sa(dp3341
g12
I73
sg13
g3319
sg14
I4
sg22
VP10826
p3342
sg17
I1
sasa(dp3343
g2
VFurthermore, we also detected the expression of 8 pathological markers (VEGF, HER-2, P53, P21, EGFR, CHGA, SYN and EMA) in cancer tissues of stage I NSCLC by immunohistochemistry, and found that high expression levels of p53 and CHGA were associated with the methylation of BCL2 (P=0.025) and PHOX2A (P=0.023), respectively.
p3344
sg4
(dp3345
(VEMA
p3346
VEMA
p3347
tp3348
I00
ssg9
(lp3349
(dp3350
g12
I141
sg13
Vstage I NSCLC
p3351
sg14
I13
sg15
VC0278504
p3352
sg17
I3
sa(dp3353
g12
I123
sg13
Vcancer
p3354
sg14
I6
sg15
VC0006826
p3355
sg17
I1
sa(dp3356
g12
I115
sg13
g3347
sg14
I3
sg15
VC0268596
p3357
sg17
I1
sasg18
(lp3358
(dp3359
g12
I90
sg13
VP21
p3360
sg14
I3
sg22
VP42857
p3361
sg17
I1
sa(dp3362
g12
I101
sg13
VCHGA
p3363
sg14
I4
sg22
VP10645
p3364
sg17
I1
sa(dp3365
g12
I274
sg13
VBCL2
p3366
sg14
I4
sg22
VP10415
p3367
sg17
I1
sa(dp3368
g12
I101
sg13
VCHGA
p3369
sg14
I4
sg22
VP10645
p3370
sg17
I1
sa(dp3371
g12
I107
sg13
VSYN
p3372
sg14
I3
sg22
VP17600
p3373
sg17
I1
sa(dp3374
g12
I293
sg13
VPHOX2A
p3375
sg14
I6
sg22
g190
sg17
I1
sa(dp3376
g12
I221
sg13
Vp53
p3377
sg14
I3
sg22
VP42771
p3378
sg17
I1
sa(dp3379
g12
I85
sg13
VP53
p3380
sg14
I3
sg22
VP42771
p3381
sg17
I1
sa(dp3382
g12
I78
sg13
VHER-2
p3383
sg14
I5
sg22
VP04626
p3384
sg17
I1
sa(dp3385
g12
I115
sg13
g3346
sg14
I3
sg22
VP13804
p3386
sg17
I1
sasa(dp3387
g2
VIn this study, among the 7 genes which demonstrated hypermethylation in stage I NSCLC compared with non-cancerous lung diseases, 5 genes (MYF6, SIX6, PHOX2A, FOLX2 and SOX1) were found for the first time to be abonormally methylated in NSCLC.
p3388
sg4
(dp3389
(VMYF6
p3390
VNSCLC
p3391
tp3392
I00
ssg9
(lp3393
(dp3394
g12
I72
sg13
Vstage I NSCLC
p3395
sg14
I13
sg15
VC0278504
p3396
sg17
I3
sa(dp3397
g12
I114
sg13
Vlung diseases
p3398
sg14
I13
sg15
VC0024115
p3399
sg17
I2
sa(dp3400
g12
I80
sg13
g3391
sg14
I5
sg15
VC0007131
p3401
sg17
I1
sasg18
(lp3402
(dp3403
g12
I168
sg13
VSOX1
p3404
sg14
I4
sg22
g190
sg17
I1
sa(dp3405
g12
I138
sg13
g3390
sg14
I4
sg22
VP23409
p3406
sg17
I1
sa(dp3407
g12
I144
sg13
VSIX6
p3408
sg14
I4
sg22
g190
sg17
I1
sa(dp3409
g12
I150
sg13
VPHOX2A
p3410
sg14
I6
sg22
g190
sg17
I1
sasa(dp3411
g2
VUsing homozygous mice for an autosomal dominant hypophosphatemic rickets-FGF23 mutation or animals treated with a furin inhibitor, we showed that cFGF23 and iFGF23 levels increased equivalently after PTH injection.
p3412
sg4
(dp3413
(VPTH
p3414
Vautosomal dominant hypophosphatemic rickets
p3415
tp3416
I00
ssg9
(lp3417
(dp3418
g12
I29
sg13
g3415
sg14
I43
sg15
VC0342642
p3419
sg17
I4
sasg18
(lp3420
(dp3421
g12
I114
sg13
Vfurin
p3422
sg14
I5
sg22
VP09958
p3423
sg17
I1
sa(dp3424
g12
I73
sg13
VFGF23
p3425
sg14
I5
sg22
g190
sg17
I1
sa(dp3426
g12
I200
sg13
g3414
sg14
I3
sg22
VP01270
p3427
sg17
I1
sasa(dp3428
g2
VTwo recent candidate genes, ErbB3 and Fgfr1, are growth factors whose mRNA levels have been found to be altered in the leukocytes of patients that are affected by bipolar disorder in a depressive state.
p3429
sg4
(dp3430
(VFgfr1
p3431
Vdepressive state
p3432
tp3433
I00
ssg9
(lp3434
(dp3435
g12
I163
sg13
Vbipolar disorder
p3436
sg14
I16
sg15
VC0005586
p3437
sg17
I2
sa(dp3438
g12
I185
sg13
g3432
sg14
I16
sg15
VC0011570
p3439
sg17
I2
sasg18
(lp3440
(dp3441
g12
I28
sg13
VErbB3
p3442
sg14
I5
sg22
VP21860
p3443
sg17
I1
sa(dp3444
g12
I38
sg13
g3431
sg14
I5
sg22
VP20930
p3445
sg17
I1
sasa(dp3446
g2
VMolecular genetics and developmental studies have identified 21 genes in this region (ADRA1A, ARHGEF10, CHRNA2, CHRNA6, CHRNB3, DKK4, DPYSL2, EGR3, FGF17, FGF20, FGFR1, FZD3, LDL, NAT2, NEF3, NRG1, PCM1, PLAT, PPP3CC, SFRP1 and VMAT1/SLC18A1) that are most likely to contribute to neuropsychiatric disorders (schizophrenia, autism, bipolar disorder and depression), neurodegenerative disorders (Parkinson's and Alzheimer's disease) and cancer.
p3447
sg4
(dp3448
(VFGFR1
p3449
Vdepression
p3450
tp3451
I00
ssg9
(lp3452
(dp3453
g12
I436
sg13
Vcancer
p3454
sg14
I6
sg15
VC0006826
p3455
sg17
I1
sa(dp3456
g12
I309
sg13
Vschizophrenia
p3457
sg14
I13
sg15
VC0036341
p3458
sg17
I1
sa(dp3459
g12
I332
sg13
Vbipolar disorder
p3460
sg14
I16
sg15
VC0005586
p3461
sg17
I2
sa(dp3462
g12
I324
sg13
Vautism
p3463
sg14
I6
sg15
VC0004352
p3464
sg17
I1
sa(dp3465
g12
I366
sg13
Vneurodegenerative disorders
p3466
sg14
I27
sg15
VC0524851
p3467
sg17
I2
sa(dp3468
g12
I353
sg13
g3450
sg14
I10
sg15
VC0011581
p3469
sg17
I1
sa(dp3470
g12
I411
sg13
VAlzheimer's disease
p3471
sg14
I19
sg15
VC1521724
p3472
sg17
I2
sasg18
(lp3473
(dp3474
g12
I94
sg13
VARHGEF10
p3475
sg14
I8
sg22
g190
sg17
I1
sa(dp3476
g12
I186
sg13
VNEF3
p3477
sg14
I4
sg22
VP07197
p3478
sg17
I1
sa(dp3479
g12
I210
sg13
VPPP3CC
p3480
sg14
I6
sg22
VP48454
p3481
sg17
I1
sa(dp3482
g12
I142
sg13
VEGR3
p3483
sg14
I4
sg22
g190
sg17
I1
sa(dp3484
g12
I120
sg13
VCHRNB3
p3485
sg14
I6
sg22
g190
sg17
I1
sa(dp3486
g12
I86
sg13
VADRA1A
p3487
sg14
I6
sg22
VP25100
p3488
sg17
I1
sa(dp3489
g12
I234
sg13
VSLC18A1
p3490
sg14
I7
sg22
VP54219
p3491
sg17
I1
sa(dp3492
g12
I228
sg13
VVMAT1
p3493
sg14
I5
sg22
VP54219
p3494
sg17
I1
sa(dp3495
g12
I180
sg13
VNAT2
p3496
sg14
I4
sg22
VP18440
p3497
sg17
I1
sa(dp3498
g12
I128
sg13
VDKK4
p3499
sg14
I4
sg22
g190
sg17
I1
sa(dp3500
g12
I162
sg13
g3449
sg14
I5
sg22
VP20930
p3501
sg17
I1
sa(dp3502
g12
I104
sg13
VCHRNA2
p3503
sg14
I6
sg22
g190
sg17
I1
sa(dp3504
g12
I134
sg13
VDPYSL2
p3505
sg14
I6
sg22
g190
sg17
I1
sa(dp3506
g12
I169
sg13
VFZD3
p3507
sg14
I4
sg22
g190
sg17
I1
sa(dp3508
g12
I148
sg13
VFGF17
p3509
sg14
I5
sg22
g190
sg17
I1
sa(dp3510
g12
I155
sg13
VFGF20
p3511
sg14
I5
sg22
g190
sg17
I1
sa(dp3512
g12
I218
sg13
VSFRP1
p3513
sg14
I5
sg22
g190
sg17
I1
sa(dp3514
g12
I198
sg13
VPCM1
p3515
sg14
I4
sg22
g190
sg17
I1
sa(dp3516
g12
I112
sg13
VCHRNA6
p3517
sg14
I6
sg22
g190
sg17
I1
sasa(dp3518
g2
VThe region on chromosome 3p13-p14 known to contain several chromosomal translocation breakpoints in families with "pure familial renal cell carcinoma" is quite proximal to the VHL locus in 3p25-p26 we have identified.
p3519
sg4
(dp3520
(Vp14
p3521
Vchromosomal translocation
p3522
tp3523
I00
ssg9
(lp3524
(dp3525
g12
I176
sg13
VVHL
p3526
sg14
I3
sg15
VC0019562
p3527
sg17
I1
sa(dp3528
g12
I120
sg13
Vfamilial renal cell carcinoma
p3529
sg14
I29
sg15
VC2931352
p3530
sg17
I4
sa(dp3531
g12
I59
sg13
g3522
sg14
I25
sg15
VC0040715
p3532
sg17
I2
sasg18
(lp3533
(dp3534
g12
I176
sg13
VVHL locus
p3535
sg14
I9
sg22
VP40337
p3536
sg17
I2
sa(dp3537
g12
I30
sg13
g3521
sg14
I3
sg22
VP03971
p3538
sg17
I1
sasa(dp3539
g2
VIn the unicellular parasite Trypanosoma brucei, which causes African sleeping sickness, TbISWI down-regulates RNA polymerase I (Pol I)-transcribed variant surface glycoprotein (VSG) gene expression sites (ESs), which are monoallelically expressed.
p3540
sg4
(dp3541
(VRNA polymerase I
p3542
VAfrican sleeping sickness
p3543
tp3544
I00
ssg9
(lp3545
(dp3546
g12
I61
sg13
g3543
sg14
I25
sg15
VC0041228
p3547
sg17
I3
sasg18
(lp3548
(dp3549
g12
I110
sg13
g3542
sg14
I16
sg22
VP24928
p3550
sg17
I3
sa(dp3551
g12
I128
sg13
VPol I
p3552
sg14
I5
sg22
VP10266
p3553
sg17
I2
sasa(dp3554
g2
VThis prospective study recruited 22 patients with ESRD who underwent a first living kidney allograft transplantation, comprising 12 patients with CYP3A5*1 allele (CYP3A5*1/*1 or *1/*3) and 10 patients without CYP3A5*1 allele (CYP3A5*3/*3).
p3555
sg4
(dp3556
(VCYP3A5*1 allele
p3557
VESRD
p3558
tp3559
I00
ssg9
(lp3560
(dp3561
g12
I50
sg13
g3558
sg14
I4
sg15
VC0022661
p3562
sg17
I1
sasg18
(lp3563
(dp3564
g12
I146
sg13
VCYP3A5*1
p3565
sg14
I8
sg22
VP20815
p3566
sg17
I1
sa(dp3567
g12
I226
sg13
VCYP3A5*3/*3
p3568
sg14
I11
sg22
VP20815
p3569
sg17
I1
sa(dp3570
g12
I146
sg13
VCYP3A5*1 allele
p3571
sg14
I15
sg22
VP20815
p3572
sg17
I2
sa(dp3573
g12
I146
sg13
g3557
sg14
I15
sg22
VP20815
p3574
sg17
I2
sasa(dp3575
g2
VNineteen SNPs in the ABCB1, NR1I2, UGT1A1, SLCO1B1 and CYP3A5 genes were examined in case patients with atazanavir/ritonavir-induced nephrolithiasis (n = 31) and controls (n = 47).
p3576
sg4
(dp3577
(VABCB1
p3578
Vnephrolithiasis
p3579
tp3580
I00
ssg9
(lp3581
(dp3582
g12
I133
sg13
g3579
sg14
I15
sg15
VC0392525
p3583
sg17
I1
sasg18
(lp3584
(dp3585
g12
I35
sg13
VUGT1A1
p3586
sg14
I6
sg22
VP35504
p3587
sg17
I1
sa(dp3588
g12
I55
sg13
VCYP3A5 genes
p3589
sg14
I12
sg22
VP20815
p3590
sg17
I2
sa(dp3591
g12
I21
sg13
g3578
sg14
I5
sg22
VP08183
p3592
sg17
I1
sa(dp3593
g12
I43
sg13
VSLCO1B1
p3594
sg14
I7
sg22
g190
sg17
I1
sasa(dp3595
g2
VIn conclusion, these results suggest that CYP3A5 polymorphism and plasma concentration of 3-INDS may account for the interindividual variability of CYP3A activity, and that plasma concentration of 3-INDS may partially explain the gap in CYP3A activity that cannot be explained by genetic contribution in patients with renal failure.
p3596
sg4
(dp3597
(VCYP3A
p3598
Vrenal failure
p3599
tp3600
I00
ssg9
(lp3601
(dp3602
g12
I318
sg13
g3599
sg14
I13
sg15
VC0035078
p3603
sg17
I2
sasg18
(lp3604
(dp3605
g12
I42
sg13
VCYP3A
p3606
sg14
I5
sg22
VP08684
p3607
sg17
I1
sa(dp3608
g12
I42
sg13
VCYP3A5
p3609
sg14
I6
sg22
VP20815
p3610
sg17
I1
sa(dp3611
g12
I42
sg13
g3598
sg14
I5
sg22
VP08684
p3612
sg17
I1
sasa(dp3613
g2
V#\u76ee#\u7684#\uff1a #\u63a2#\u8ba8FGD6  (faciogenital dysplasia) #\u57fa#\u56e0#\u5bf9#\u809d#\u5e72#\u7ec6#\u80de#\u5206#\u5316#\u8c03#\u63a7#\u7684#\u4f5c#\u7528#\u3002 #\u65b9#\u6cd5#\uff1a #\u9009#\u53d6FGD6#\u57fa#\u56e0#\u5e72#\u6270#\u9776#\u5e8f#\u5217, #\u4f7f#\u7528AdEasy#\u7cfb#\u7edf#\u6784#\u5efa#\u817a#\u75c5#\u6bd2#\u8f7d#\u4f53, #\u5305#\u88c5#\u5e76#\u6269#\u589e#\u91cd#\u7ec4#\u817a#\u75c5#\u6bd2#\u8f7d#\u4f53pSES-FGD6-siRNA, #\u611f#\u67d3HP14.5#\u7ec6#\u80de#\u3002#\u7ec6#\u80de#\u514d#\u75ab#\u8367#\u5149#\u68c0#\u6d4bFGD6#\u86cb#\u767d#\u5728HP14.5#\u7ec6#\u80de#\u4e2d#\u7684#\u8868#\u8fbe#\u6c34#\u5e73, #\u5b9e#\u65f6#\u8367#\u5149#\u5b9a#\u91cfPCR#\u68c0#\u6d4bFGD6#\u3001#\u7532#\u80ce#\u86cb#\u767d (AFP) #\u53ca#\u767d#\u86cb#\u767d (Alb) #\u7684mRNA#\u6c34#\u5e73, Western blot#\u68c0#\u6d4bFGD6#\u3001AFP#\u53caAlb#\u7684#\u86cb#\u767d#\u8868#\u8fbe#\u6c34#\u5e73#\u3002#\u6bcf#\u7ec4#\u7ec6#\u80de#\u5747#\u8bbe#\u7f6epSES-Ad-RFP#\u817a#\u75c5#\u6bd2#\u7a7a#\u8f7d#\u4f53#\u611f#\u67d3#\u8fdb#\u884c#\u5bf9#\u7167#\u3002#\u6240#\u6709#\u6570#\u636e#\u7528#\u5747#\u6570+/-#\u6807#\u51c6#\u5dee (x+/-s) #\u8868#\u793a, #\u91c7#\u7528#\u5355#\u56e0#\u7d20#\u65b9#\u5dee#\u5206#\u6790#\u3002 #\u7ed3#\u679c#\uff1a FGD6#\u86cb#\u767d#\u4e3b#\u8981#\u8868#\u8fbe#\u4e8eHP14.5#\u7ec6#\u80de#\u80de#\u6838#\u4e2d#\u3002#\u6210#\u529f#\u6784#\u5efa#\u817a#\u75c5#\u6bd2#\u8f7d#\u4f53pSES-FGD6-siRNA#\u3002#\u4e0b#\u8c03FGD6#\u57fa#\u56e0#\u5728HP14.5#\u7ec6#\u80de#\u4e2d#\u7684#\u8868#\u8fbe, #\u53ef#\u964d#\u4f4eAFP#\u7684mRNA#\u53ca#\u86cb#\u767d#\u7684#\u8868#\u8fbe, #\u800c#\u5347#\u9ad8Alb#\u7684mRNA#\u53ca#\u86cb#\u767d#\u7684#\u8868#\u8fbe (P&lt;0.01) #\u3002 #\u7ed3#\u8bba#\uff1a #\u6291#\u5236FGD6#\u57fa#\u56e0#\u5728HP14.5#\u7ec6#\u80de#\u4e2d#\u7684#\u8868#\u8fbe, #\u53ef#\u4f7fHP14.5#\u7ec6#\u80de#\u5411#\u809d#\u7ec6#\u80de#\u65b9#\u5411#\u5206#\u5316, #\u56e0#\u6b64, FGD6#\u57fa#\u56e0#\u5bf9#\u809d#\u5e72#\u7ec6#\u80de#\u5206#\u5316#\u8c03#\u63a7#\u53ef#\u80fd#\u8d77#\u7740#\u91cd#\u8981#\u4f5c#\u7528#\u3002.
p3614
sg4
(dp3615
(V\u3001AFP
p3616
Vfaciogenital dysplasia
p3617
tp3618
I00
ssg9
(lp3619
(dp3620
g12
I18
sg13
g3617
sg14
I22
sg15
VC0175701
p3621
sg17
I2
sasg18
(lp3622
(dp3623
g12
I11
sg13
VFGD6
p3624
sg14
I4
sg22
g190
sg17
I1
sa(dp3625
g12
I376
sg13
VRFP
p3626
sg14
I3
sg22
VP25090
p3627
sg17
I1
sa(dp3628
g12
I11
sg13
VFGD6
p3629
sg14
I4
sg22
g190
sg17
I1
sa(dp3630
g12
I329
sg13
g3616
sg14
I4
sg22
VP02771
p3631
sg17
I1
sa(dp3632
g12
I11
sg13
VFGD6
p3633
sg14
I4
sg22
g190
sg17
I1
sa(dp3634
g12
I11
sg13
VFGD6
p3635
sg14
I4
sg22
g190
sg17
I1
sasa(dp3636
g2
VFiltered albumin has been suggested to be a cause of the glomerular and tubular injuries observed at advanced stages of Alport syndrome.
p3637
sg4
(dp3638
(Valbumin
p3639
VAlport syndrome
p3640
tp3641
I00
ssg9
(lp3642
(dp3643
g12
I120
sg13
g3640
sg14
I15
sg15
VC1567741
p3644
sg17
I2
sasg18
(lp3645
(dp3646
g12
I9
sg13
g3639
sg14
I7
sg22
VP00441
p3647
sg17
I1
sasa(dp3648
g2
VTo directly investigate the role that albumin plays in the progression of disease in Alport syndrome, we generated albumin knockout (Alb(-/-)) mice to use as a tool for removing albuminuria as a component of kidney disease.
p3649
sg4
(dp3650
(Valbumin
p3651
Vkidney disease
p3652
tp3653
I00
ssg9
(lp3654
(dp3655
g12
I85
sg13
VAlport syndrome
p3656
sg14
I15
sg15
VC1567741
p3657
sg17
I2
sa(dp3658
g12
I208
sg13
g3652
sg14
I14
sg15
VC0022658
p3659
sg17
I2
sasg18
(lp3660
(dp3661
g12
I38
sg13
Valbumin
p3662
sg14
I7
sg22
VP00441
p3663
sg17
I1
sa(dp3664
g12
I38
sg13
g3651
sg14
I7
sg22
VP00441
p3665
sg17
I1
sa(dp3666
g12
I133
sg13
VAlb
p3667
sg14
I3
sg22
g190
sg17
I1
sasa(dp3668
g2
VWe conclude that filtered albumin is injurious to kidney cells in Alport syndrome and perhaps in other proteinuric kidney diseases, including diabetic nephropathy.
p3669
sg4
(dp3670
(Valbumin
p3671
VAlport syndrome
p3672
tp3673
I00
ssg9
(lp3674
(dp3675
g12
I142
sg13
Vdiabetic nephropathy
p3676
sg14
I20
sg15
VC0011881
p3677
sg17
I2
sa(dp3678
g12
I115
sg13
Vkidney diseases
p3679
sg14
I15
sg15
VC0022658
p3680
sg17
I2
sa(dp3681
g12
I66
sg13
g3672
sg14
I15
sg15
VC1567741
p3682
sg17
I2
sasg18
(lp3683
(dp3684
g12
I26
sg13
g3671
sg14
I7
sg22
VP00441
p3685
sg17
I1
sasa(dp3686
g2
VOn the other hand, we believe that tumor depth of invasion (&gt;=4 mm), POI, and VEGF-C expression all need to be considered in the preoperative and postoperative planning stages for tongue cancer treatment.
p3687
sg4
(dp3688
(VVEGF-C
p3689
Vtongue cancer
p3690
tp3691
I00
ssg9
(lp3692
(dp3693
g12
I183
sg13
g3690
sg14
I13
sg15
VC0558353
p3694
sg17
I2
sa(dp3695
g12
I35
sg13
Vtumor
p3696
sg14
I5
sg15
VC0027651
p3697
sg17
I1
sa(dp3698
g12
I50
sg13
Vinvasion
p3699
sg14
I8
sg15
VC2699153
p3700
sg17
I1
sasg18
(lp3701
(dp3702
g12
I81
sg13
g3689
sg14
I6
sg22
VP49767
p3703
sg17
I1
sasa(dp3704
g2
VThe use of a therapeutic approach which blocks lymphangiogenic factors, such as VEGF-C and VEGF-D, may be beneficial in suppressing the lymphatic spread of tongue cancer with intense intranodal lymphangiogenesis.
p3705
sg4
(dp3706
(VVEGF-C
p3707
Vtongue cancer
p3708
tp3709
I00
ssg9
(lp3710
(dp3711
g12
I156
sg13
g3708
sg14
I13
sg15
VC0558353
p3712
sg17
I2
sasg18
(lp3713
(dp3714
g12
I80
sg13
g3707
sg14
I6
sg22
VP49767
p3715
sg17
I1
sa(dp3716
g12
I91
sg13
VVEGF-D
p3717
sg14
I6
sg22
g190
sg17
I1
sasa(dp3718
g2
VVEGF, VEGF-C, VEGF-D and MIA expression levels of metastatic tongue cancer HSC-3 cells were higher than those with no metastatic HSC-4 cells, and VEGF, VEGF-C and VEGF-D expression levels were decreased by MIA siRNA treatment in both cells.
p3719
sg4
(dp3720
(VVEGF-C
p3721
Vtongue cancer
p3722
tp3723
I00
ssg9
(lp3724
(dp3725
g12
I61
sg13
g3722
sg14
I13
sg15
VC0558353
p3726
sg17
I2
sasg18
(lp3727
(dp3728
g12
I14
sg13
VVEGF-D
p3729
sg14
I6
sg22
g190
sg17
I1
sa(dp3730
g12
I6
sg13
VVEGF-C
p3731
sg14
I6
sg22
VP49767
p3732
sg17
I1
sa(dp3733
g12
I206
sg13
VMIA siRNA
p3734
sg14
I9
sg22
g190
sg17
I2
sa(dp3735
g12
I25
sg13
VMIA
p3736
sg14
I3
sg22
g190
sg17
I1
sa(dp3737
g12
I14
sg13
VVEGF-D
p3738
sg14
I6
sg22
g190
sg17
I1
sa(dp3739
g12
I6
sg13
g3721
sg14
I6
sg22
VP49767
p3740
sg17
I1
sasa(dp3741
g2
VVascular endothelial growth factor and Notch1 expression are significantly related to cervical lymph node metastasis and depth of invasion in tongue cancer patients.
p3742
sg4
(dp3743
(VNotch1
p3744
Vtongue cancer
p3745
tp3746
I01
ssg9
(lp3747
(dp3748
g12
I130
sg13
Vinvasion
p3749
sg14
I8
sg15
VC2699153
p3750
sg17
I1
sa(dp3751
g12
I95
sg13
Vlymph node metastasis
p3752
sg14
I21
sg15
VC0686619
p3753
sg17
I3
sa(dp3754
g12
I142
sg13
g3745
sg14
I13
sg15
VC0558353
p3755
sg17
I2
sasg18
(lp3756
(dp3757
g12
I0
sg13
VVascular endothelial growth factor
p3758
sg14
I34
sg22
g190
sg17
I4
sa(dp3759
g12
I39
sg13
g3744
sg14
I6
sg22
VP46531
p3760
sg17
I1
sasa(dp3761
g2
VWe observed the expression of maspin, mutant-type p53 and VEGF by immunohistochemistry in 33 patients with stages I and II oral tongue cancer.
p3762
sg4
(dp3763
(Vmaspin
p3764
Vtongue cancer
p3765
tp3766
I00
ssg9
(lp3767
(dp3768
g12
I128
sg13
g3765
sg14
I13
sg15
VC0558353
p3769
sg17
I2
sa(dp3770
g12
I38
sg13
Vmutant
p3771
sg14
I6
sg15
VC0596988
p3772
sg17
I1
sasg18
(lp3773
(dp3774
g12
I30
sg13
g3764
sg14
I6
sg22
VP36952
p3775
sg17
I1
sa(dp3776
g12
I38
sg13
Vmutant-type p53
p3777
sg14
I15
sg22
VP42771
p3778
sg17
I2
sasa(dp3779
g2
VIn an experimental autoimmune encephalomyelitis model of CNS autoimmunity, we found activation-induced cytidine deaminase, a GC-defining enzyme, in meningeal ELT (mELT) densely populated by B and T cells.
p3780
sg4
(dp3781
(Vcytidine deaminase
p3782
Vautoimmunity
p3783
tp3784
I00
ssg9
(lp3785
(dp3786
g12
I30
sg13
Vencephalomyelitis
p3787
sg14
I17
sg15
VC0014070
p3788
sg17
I1
sa(dp3789
g12
I61
sg13
g3783
sg14
I12
sg15
VC0004368
p3790
sg17
I1
sa(dp3791
g12
I19
sg13
Vautoimmune
p3792
sg14
I10
sg15
VC0443146
p3793
sg17
I1
sasg18
(lp3794
(dp3795
g12
I103
sg13
g3782
sg14
I18
sg22
VP32320
p3796
sg17
I2
sasa(dp3797
g2
VBradykinin type 1 receptor antagonism could represent a promising therapeutic tool in combination with TZD for the treatment of T2D, obesity and insulin resistance.
p3798
sg4
(dp3799
(Vinsulin
p3800
VT2D
p3801
tp3802
I00
ssg9
(lp3803
(dp3804
g12
I133
sg13
Vobesity
p3805
sg14
I7
sg15
VC0028754
p3806
sg17
I1
sa(dp3807
g12
I145
sg13
Vinsulin resistance
p3808
sg14
I18
sg15
VC0021655
p3809
sg17
I2
sa(dp3810
g12
I128
sg13
g3801
sg14
I3
sg15
VC0011860
p3811
sg17
I1
sasg18
(lp3812
(dp3813
g12
I0
sg13
VBradykinin type 1 receptor
p3814
sg14
I26
sg22
VP01042
p3815
sg17
I4
sa(dp3816
g12
I145
sg13
g3800
sg14
I7
sg22
VP01308
p3817
sg17
I1
sasa(dp3818
g2
VThe aim of this study was to analyze the acute responses of bradykinin, insulin, and glycemia to exercise performed above and below lactate threshold (LT) in individuals with type 2 diabetes mellitus (T2D).
p3819
sg4
(dp3820
(Vinsulin
p3821
VT2D
p3822
tp3823
I00
ssg9
(lp3824
(dp3825
g12
I175
sg13
Vtype 2 diabetes mellitus
p3826
sg14
I24
sg15
VC0011860
p3827
sg17
I4
sa(dp3828
g12
I201
sg13
g3822
sg14
I3
sg15
VC0011860
p3829
sg17
I1
sasg18
(lp3830
(dp3831
g12
I60
sg13
Vbradykinin
p3832
sg14
I10
sg22
VP01042
p3833
sg17
I1
sa(dp3834
g12
I72
sg13
g3821
sg14
I7
sg22
VP01308
p3835
sg17
I1
sasa(dp3836
g2
VTo examine the association of bradykinin and related peptides with the development of diabetic nephropathy lesions in 243 participants with type 1 diabetes (T1D) from the Renin-Angiotensin System Study who, at baseline, were normoalbuminuric, normotensive and had normal or increased glomerular filtration rate (GFR).
p3837
sg4
(dp3838
(VAngiotensin
p3839
Vtype 1 diabetes
p3840
tp3841
I00
ssg9
(lp3842
(dp3843
g12
I86
sg13
Vdiabetic nephropathy
p3844
sg14
I20
sg15
VC0011881
p3845
sg17
I2
sa(dp3846
g12
I157
sg13
VT1D
p3847
sg14
I3
sg15
VC0011854
p3848
sg17
I1
sa(dp3849
g12
I140
sg13
g3840
sg14
I15
sg15
VC0011854
p3850
sg17
I3
sasg18
(lp3851
(dp3852
g12
I30
sg13
Vbradykinin
p3853
sg14
I10
sg22
VP01042
p3854
sg17
I1
sa(dp3855
g12
I171
sg13
VRenin
p3856
sg14
I5
sg22
VP00797
p3857
sg17
I1
sa(dp3858
g12
I177
sg13
g3839
sg14
I11
sg22
VP21549
p3859
sg17
I1
sasa(dp3860
g2
VHeterozygosity for missense mutations in Seipin, namely N88S and S90L, leads to a broad spectrum of motor neuropathy, while a number of loss-of-function mutations in Seipin are associated with the Berardinelli-Seip congenital generalized lipodystrophy type 2 (CGL2, BSCL2), a condition that is characterized by severe lipoatrophy, insulin resistance, and intellectual impairment.
p3861
sg4
(dp3862
(Vcongenital generalized lipodystrophy type 2
p3863
Vintellectual impairment
p3864
tp3865
I00
ssg9
(lp3866
(dp3867
g12
I318
sg13
Vlipoatrophy
p3868
sg14
I11
sg15
VC1280433
p3869
sg17
I1
sa(dp3870
g12
I331
sg13
Vinsulin resistance
p3871
sg14
I18
sg15
VC0021655
p3872
sg17
I2
sa(dp3873
g12
I276
sg13
Vcondition
p3874
sg14
I9
sg15
VC0012634
p3875
sg17
I1
sa(dp3876
g12
I100
sg13
Vmotor neuropathy
p3877
sg14
I16
sg15
VC0235025
p3878
sg17
I2
sa(dp3879
g12
I260
sg13
VCGL2
p3880
sg14
I4
sg15
VC1720863
p3881
sg17
I1
sa(dp3882
g12
I215
sg13
Vcongenital generalized lipodystrophy type 2
p3883
sg14
I43
sg15
VC1720863
p3884
sg17
I5
sa(dp3885
g12
I355
sg13
g3864
sg14
I23
sg15
VC0683322
p3886
sg17
I2
sasg18
(lp3887
(dp3888
g12
I331
sg13
Vinsulin
p3889
sg14
I7
sg22
VP01308
p3890
sg17
I1
sa(dp3891
g12
I266
sg13
VBSCL2
p3892
sg14
I5
sg22
g190
sg17
I1
sa(dp3893
g12
I260
sg13
VCGL2
p3894
sg14
I4
sg22
VP20718
p3895
sg17
I1
sa(dp3896
g12
I41
sg13
VSeipin
p3897
sg14
I6
sg22
g190
sg17
I1
sa(dp3898
g12
I215
sg13
g3863
sg14
I43
sg22
VP20718
p3899
sg17
I5
sa(dp3900
g12
I41
sg13
VSeipin
p3901
sg14
I6
sg22
g190
sg17
I1
sasa(dp3902
g2
VIL-28A induced TH1 cytokine production by CD4+ T lymphocytes in a T-bet-dependent manner and was up-regulated in a murine model of T-cell-mediated hepatitis upon Con A administration.
p3903
sg4
(dp3904
(VCD4+
p3905
Vhepatitis
p3906
tp3907
I01
ssg9
(lp3908
(dp3909
g12
I147
sg13
g3906
sg14
I9
sg15
VC0019159
p3910
sg17
I1
sasg18
(lp3911
(dp3912
g12
I42
sg13
g3905
sg14
I4
sg22
VP01730
p3913
sg17
I1
sa(dp3914
g12
I15
sg13
VTH1 cytokine
p3915
sg14
I12
sg22
VP13236
p3916
sg17
I2
sasa(dp3917
g2
VIn addition, IL-28A-transgenic mice showed markedly augmented Con A-induced hepatitis with up-regulated interferon-gamma cytokine production, as compared with wild-type mice.
p3918
sg4
(dp3919
(Vinterferon-gamma
p3920
Vhepatitis
p3921
tp3922
I00
ssg9
(lp3923
(dp3924
g12
I76
sg13
g3921
sg14
I9
sg15
VC0019159
p3925
sg17
I1
sasg18
(lp3926
(dp3927
g12
I104
sg13
g3920
sg14
I16
sg22
VP01579
p3928
sg17
I1
sasa(dp3929
g2
VIn addition, in vivo blockade of interferon-gamma but not IL-4 suppressed augmented liver inflammation in transgenic mice, suggesting that IL-28A induces the T-bet signaling pathway in T-cell-induced hepatitis.
p3930
sg4
(dp3931
(Vinterferon-gamma
p3932
Vhepatitis
p3933
tp3934
I00
ssg9
(lp3935
(dp3936
g12
I90
sg13
Vinflammation
p3937
sg14
I12
sg15
VC0021368
p3938
sg17
I1
sa(dp3939
g12
I200
sg13
g3933
sg14
I9
sg15
VC0019159
p3940
sg17
I1
sasg18
(lp3941
(dp3942
g12
I58
sg13
VIL-4
p3943
sg14
I4
sg22
VP05112
p3944
sg17
I1
sa(dp3945
g12
I158
sg13
VT-bet
p3946
sg14
I5
sg22
g190
sg17
I1
sa(dp3947
g12
I33
sg13
g3932
sg14
I16
sg22
VP01579
p3948
sg17
I1
sasa(dp3949
g2
VThe present study therefore indicated that NOD receptor and TLR9 may modulate the inflammatory response and further impact upon intestinal injury of SAP, via the regulation of NF-KB expression and the oxidation/antioxidation balance, suggesting therapeutically targeting NOD receptor and TLR9 might be a useful approach for the treatment of severe acute pancreatitis.
p3950
sg4
(dp3951
(VNOD receptor
p3952
VNOD
p3953
tp3954
I00
ssg9
(lp3955
(dp3956
g12
I82
sg13
Vinflammatory response
p3957
sg14
I21
sg15
VC1155266
p3958
sg17
I2
sa(dp3959
g12
I43
sg13
VNOD
p3960
sg14
I3
sg15
VC0751781
p3961
sg17
I1
sa(dp3962
g12
I348
sg13
Vacute pancreatitis
p3963
sg14
I18
sg15
VC0001339
p3964
sg17
I2
sa(dp3965
g12
I43
sg13
g3953
sg14
I3
sg15
VC0751781
p3966
sg17
I1
sasg18
(lp3967
(dp3968
g12
I60
sg13
VTLR9
p3969
sg14
I4
sg22
g190
sg17
I1
sa(dp3970
g12
I60
sg13
VTLR9
p3971
sg14
I4
sg22
g190
sg17
I1
sa(dp3972
g12
I43
sg13
VNOD receptor
p3973
sg14
I12
sg22
VP54259
p3974
sg17
I2
sa(dp3975
g12
I43
sg13
g3952
sg14
I12
sg22
VP54259
p3976
sg17
I2
sasa(dp3977
g2
VAcute pancreatitis was induced by caerulein stimulation in wild-type mice and mice deficient in components of the inflammasome (apoptosis-associated speck-like protein containing a caspase recruitment domain [ASC], NLRP3, caspase-1), Toll-like receptor 9 (TLR9), or the purinergic receptor P2X(7).
p3978
sg4
(dp3979
(Vcaspase-1
p3980
VAcute pancreatitis
p3981
tp3982
I00
ssg9
(lp3983
(dp3984
g12
I189
sg13
Vrecruitment
p3985
sg14
I11
sg15
VC0271510
p3986
sg17
I1
sa(dp3987
g12
I0
sg13
g3981
sg14
I18
sg15
VC0001339
p3988
sg17
I2
sasg18
(lp3989
(dp3990
g12
I256
sg13
VTLR9
p3991
sg14
I4
sg22
g190
sg17
I1
sa(dp3992
g12
I270
sg13
Vpurinergic receptor P2X(7)
p3993
sg14
I26
sg22
VP51575
p3994
sg17
I3
sa(dp3995
g12
I234
sg13
VToll-like receptor 9
p3996
sg14
I20
sg22
g190
sg17
I3
sa(dp3997
g12
I181
sg13
Vcaspase
p3998
sg14
I7
sg22
VP39880
p3999
sg17
I1
sa(dp4000
g12
I222
sg13
g3980
sg14
I9
sg22
VP29466
p4001
sg17
I1
sasa(dp4002
g2
VTLR9 and P2X(7) are important DAMP receptors upstream of inflammasome activation, and their antagonism could provide a new therapeutic strategy for treating acute pancreatitis.
p4003
sg4
(dp4004
(VP2X(7)
p4005
Vacute pancreatitis
p4006
tp4007
I00
ssg9
(lp4008
(dp4009
g12
I157
sg13
g4006
sg14
I18
sg15
VC0001339
p4010
sg17
I2
sasg18
(lp4011
(dp4012
g12
I0
sg13
VTLR9
p4013
sg14
I4
sg22
g190
sg17
I1
sa(dp4014
g12
I9
sg13
g4005
sg14
I6
sg22
VP51575
p4015
sg17
I1
sasa(dp4016
g2
VWe are currently screening the 113 candidate DFNB79 genes for mutations and have excluded CACNA1B, EDF1, PTGDS, EHMT1, QSOX2, NOTCH1, MIR126 and MIR602.
p4017
sg4
(dp4018
(VPTGDS
p4019
VDFNB79
p4020
tp4021
I00
ssg9
(lp4022
(dp4023
g12
I45
sg13
g4020
sg14
I6
sg15
VC2750082
p4024
sg17
I1
sasg18
(lp4025
(dp4026
g12
I112
sg13
VEHMT1
p4027
sg14
I5
sg22
g190
sg17
I1
sa(dp4028
g12
I90
sg13
VCACNA1B
p4029
sg14
I7
sg22
g190
sg17
I1
sa(dp4030
g12
I119
sg13
VQSOX2
p4031
sg14
I5
sg22
g190
sg17
I1
sa(dp4032
g12
I99
sg13
VEDF1
p4033
sg14
I4
sg22
g190
sg17
I1
sa(dp4034
g12
I45
sg13
VDFNB79 genes
p4035
sg14
I12
sg22
g190
sg17
I2
sa(dp4036
g12
I126
sg13
VNOTCH1
p4037
sg14
I6
sg22
VP46531
p4038
sg17
I1
sa(dp4039
g12
I105
sg13
g4019
sg14
I5
sg22
VP41222
p4040
sg17
I1
sasa(dp4041
g2
VExposure to bone morphogenetic protein (BMP)-4 was found to enhance a TrkAhigh/CD15-/CD184- neuroblastoma cellular subset, accompanied by a reduction in doublecortin-positive neuroblasts and of NMYC protein expression in SH-SY5Y cells.
p4042
sg4
(dp4043
(VCD184
p4044
Vneuroblastoma
p4045
tp4046
I00
ssg9
(lp4047
(dp4048
g12
I92
sg13
g4045
sg14
I13
sg15
VC0027819
p4049
sg17
I1
sasg18
(lp4050
(dp4051
g12
I79
sg13
VCD15
p4052
sg14
I4
sg22
VP22083
p4053
sg17
I1
sa(dp4054
g12
I194
sg13
VNMYC protein
p4055
sg14
I12
sg22
VP04198
p4056
sg17
I2
sa(dp4057
g12
I17
sg13
Vmorphogenetic protein (BMP)-4
p4058
sg14
I29
sg22
VP18075
p4059
sg17
I3
sa(dp4060
g12
I85
sg13
g4044
sg14
I5
sg22
VP61073
p4061
sg17
I1
sasa(dp4062
g2
VRecent studies indicate that C-X-C motif chemokine receptor 4 (CXCR4) and its ligand, C-X-C motif chemokine ligand 12 (CXCL12), stimulate expression of the cell cycle regulatory protein Cyclin D1 in neurofibromatosis 1-associated malignant peripheral nerve sheath tumor (MPNST) cells and promote their proliferation.
p4063
sg4
(dp4064
(VCyclin D1
p4065
VMPNST
p4066
tp4067
I00
ssg9
(lp4068
(dp4069
g12
I230
sg13
Vmalignant peripheral nerve sheath tumor
p4070
sg14
I39
sg15
VC0751690
p4071
sg17
I5
sa(dp4072
g12
I199
sg13
Vneurofibromatosis 1
p4073
sg14
I19
sg15
VC0027831
p4074
sg17
I2
sa(dp4075
g12
I302
sg13
Vproliferation
p4076
sg14
I13
sg15
VC0334094
p4077
sg17
I1
sa(dp4078
g12
I271
sg13
g4066
sg14
I5
sg15
VC0751690
p4079
sg17
I1
sasg18
(lp4080
(dp4081
g12
I29
sg13
VC-X-C motif chemokine receptor 4
p4082
sg14
I32
sg22
VP51679
p4083
sg17
I5
sa(dp4084
g12
I119
sg13
VCXCL12
p4085
sg14
I6
sg22
VP48061
p4086
sg17
I1
sa(dp4087
g12
I63
sg13
VCXCR4
p4088
sg14
I5
sg22
VP61073
p4089
sg17
I1
sa(dp4090
g12
I86
sg13
VC-X-C motif chemokine ligand 12
p4091
sg14
I31
sg22
VP55773
p4092
sg17
I5
sa(dp4093
g12
I186
sg13
g4065
sg14
I9
sg22
VP24385
p4094
sg17
I2
sasa(dp4095
g2
VWestern blot analysis revealed the expression of multiple CXCR4 isoforms in neuroblastoma cells.
p4096
sg4
(dp4097
(VCXCR4 isoforms
p4098
Vneuroblastoma
p4099
tp4100
I00
ssg9
(lp4101
(dp4102
g12
I76
sg13
g4099
sg14
I13
sg15
VC0027819
p4103
sg17
I1
sasg18
(lp4104
(dp4105
g12
I58
sg13
g4098
sg14
I14
sg22
VP61073
p4106
sg17
I2
sasa(dp4107
g2
VOur data suggest a modulatory role of the MSC secretome on the expression of the 47 kDa CXCR4 isoform and invasion potential of the neuroblastoma cells to the bone marrow.
p4108
sg4
(dp4109
(V47 kDa CXCR4 isoform
p4110
Vneuroblastoma
p4111
tp4112
I00
ssg9
(lp4113
(dp4114
g12
I132
sg13
g4111
sg14
I13
sg15
VC0027819
p4115
sg17
I1
sa(dp4116
g12
I106
sg13
Vinvasion
p4117
sg14
I8
sg15
VC2699153
p4118
sg17
I1
sasg18
(lp4119
(dp4120
g12
I81
sg13
g4110
sg14
I20
sg22
VP61073
p4121
sg17
I4
sasa(dp4122
g2
VIn this study, we investigated the role of NF-KB signaling pathway in the regulation of CXC chemokine receptor-4 (CXCR4) in neuroblastoma metastasis.
p4123
sg4
(dp4124
(VCXC chemokine receptor-4
p4125
Vmetastasis
p4126
tp4127
I00
ssg9
(lp4128
(dp4129
g12
I124
sg13
Vneuroblastoma
p4130
sg14
I13
sg15
VC0027819
p4131
sg17
I1
sa(dp4132
g12
I138
sg13
g4126
sg14
I10
sg15
VC0027627
p4133
sg17
I1
sasg18
(lp4134
(dp4135
g12
I114
sg13
VCXCR4
p4136
sg14
I5
sg22
VP61073
p4137
sg17
I1
sa(dp4138
g12
I88
sg13
g4125
sg14
I24
sg22
VP61073
p4139
sg17
I3
sasa(dp4140
g2
VTargeting NF-KB signalling pathways and ultimately CXCR4 could be a strategy in neuroblastoma therapy.
p4141
sg4
(dp4142
(VCXCR4
p4143
Vneuroblastoma
p4144
tp4145
I00
ssg9
(lp4146
(dp4147
g12
I80
sg13
g4144
sg14
I13
sg15
VC0027819
p4148
sg17
I1
sasg18
(lp4149
(dp4150
g12
I51
sg13
g4143
sg14
I5
sg22
VP61073
p4151
sg17
I1
sasa(dp4152
g2
VThe FAM3C interleukin-like epithelial-to-mesenchymal-transition (EMT) inducer (ILEI) has been shown to be strongly up-regulated in several cancers and to be essential for tumor formation and metastasis in epithelial cells, correlating with a significant decrease in overall survival in colon and breast cancer patients.
p4153
sg4
(dp4154
(Vinterleukin-like
p4155
Vmetastasis
p4156
tp4157
I00
ssg9
(lp4158
(dp4159
g12
I139
sg13
Vcancers
p4160
sg14
I7
sg15
VC0006826
p4161
sg17
I1
sa(dp4162
g12
I296
sg13
Vbreast cancer
p4163
sg14
I13
sg15
VC0678222
p4164
sg17
I2
sa(dp4165
g12
I171
sg13
Vtumor
p4166
sg14
I5
sg15
VC0027651
p4167
sg17
I1
sa(dp4168
g12
I53
sg13
Vtransition
p4169
sg14
I10
sg15
VC0599156
p4170
sg17
I1
sa(dp4171
g12
I191
sg13
g4156
sg14
I10
sg15
VC0027627
p4172
sg17
I1
sasg18
(lp4173
(dp4174
g12
I79
sg13
VILEI
p4175
sg14
I4
sg22
g190
sg17
I1
sa(dp4176
g12
I4
sg13
VFAM3C
p4177
sg14
I5
sg22
g190
sg17
I1
sa(dp4178
g12
I10
sg13
g4155
sg14
I16
sg22
VP60568
p4179
sg17
I1
sasa(dp4180
g2
VInterleukin-like epithelial-to-mesenchymal transition inducer (ILEI) is an essential cytokine in tumor progression that is upregulated in several cancers, and its altered subcellular localization is a predictor of poor survival in human breast cancer.
p4181
sg4
(dp4182
(VInterleukin-like
p4183
Vtumor progression
p4184
tp4185
I01
ssg9
(lp4186
(dp4187
g12
I237
sg13
Vbreast cancer
p4188
sg14
I13
sg15
VC0678222
p4189
sg17
I2
sa(dp4190
g12
I97
sg13
g4184
sg14
I17
sg15
VC0178874
p4191
sg17
I2
sa(dp4192
g12
I43
sg13
Vtransition
p4193
sg14
I10
sg15
VC0599156
p4194
sg17
I1
sa(dp4195
g12
I146
sg13
Vcancers
p4196
sg14
I7
sg15
VC0006826
p4197
sg17
I1
sasg18
(lp4198
(dp4199
g12
I0
sg13
g4183
sg14
I16
sg22
VP60568
p4200
sg17
I1
sasa(dp4201
g2
VOur findings point out extracellular serine proteases, in particular plasmin, and uPAR as valuable therapeutic targets against ILEI-driven tumor progression and emphasize the prognostic relevance of ILEI localization and a combined ILEI-uPAR marker analysis in human breast cancer.
p4202
sg4
(dp4203
(Vplasmin
p4204
Vbreast cancer
p4205
tp4206
I00
ssg9
(lp4207
(dp4208
g12
I139
sg13
Vtumor progression
p4209
sg14
I17
sg15
VC0178874
p4210
sg17
I2
sa(dp4211
g12
I267
sg13
g4205
sg14
I13
sg15
VC0678222
p4212
sg17
I2
sasg18
(lp4213
(dp4214
g12
I127
sg13
VILEI
p4215
sg14
I4
sg22
g190
sg17
I1
sa(dp4216
g12
I23
sg13
Vextracellular serine proteases
p4217
sg14
I30
sg22
VP30740
p4218
sg17
I3
sa(dp4219
g12
I69
sg13
g4204
sg14
I7
sg22
VP00747
p4220
sg17
I1
sa(dp4221
g12
I127
sg13
VILEI
p4222
sg14
I4
sg22
g190
sg17
I1
sa(dp4223
g12
I127
sg13
VILEI
p4224
sg14
I4
sg22
g190
sg17
I1
sasa(dp4225
g2
VKeeping in view the fact that molecular basis of Burkitt's lymphoma (BL) is poorly understood, we attempted to explore the small interfering RNA (siRNA) mediated c-myc gene regulation using BL-derived EB-3 cell line as archetype cellular model.
p4226
sg4
(dp4227
(Vc-myc gene
p4228
VBL
p4229
tp4230
I00
ssg9
(lp4231
(dp4232
g12
I49
sg13
VBurkitt's lymphoma
p4233
sg14
I18
sg15
VC0006413
p4234
sg17
I2
sa(dp4235
g12
I69
sg13
VBL
p4236
sg14
I2
sg15
VC0006413
p4237
sg17
I1
sa(dp4238
g12
I69
sg13
g4229
sg14
I2
sg15
VC0006413
p4239
sg17
I1
sasg18
(lp4240
(dp4241
g12
I162
sg13
g4228
sg14
I10
sg22
VP12524
p4242
sg17
I2
sasa(dp4243
g2
VWith other procedures, as anti-complement immunoperoxidase (ACIP) and anti-IgG immunoperoxidase (AIIP) the Epstein-Barr Nuclear Antigen (EBNA) was detected precisely in EB3, Jijoye and Raji lymphocytes using anti-EBNA antibodies from patients with nasopharyngeal carcinoma or Burkitt lymphoma, in dilution 1:10-1:5120.
p4244
sg4
(dp4245
(Vanti-IgG immunoperoxidase (AIIP) the Epstein-Barr Nuclear Antigen
p4246
VBurkitt lymphoma
p4247
tp4248
I00
ssg9
(lp4249
(dp4250
g12
I248
sg13
Vnasopharyngeal carcinoma
p4251
sg14
I24
sg15
VC2931822
p4252
sg17
I2
sa(dp4253
g12
I276
sg13
g4247
sg14
I16
sg15
VC0006413
p4254
sg17
I2
sasg18
(lp4255
(dp4256
g12
I169
sg13
VEB3
p4257
sg14
I3
sg22
g190
sg17
I1
sa(dp4258
g12
I60
sg13
VACIP
p4259
sg14
I4
sg22
g190
sg17
I1
sa(dp4260
g12
I26
sg13
Vanti-complement immunoperoxidase
p4261
sg14
I32
sg22
g190
sg17
I2
sa(dp4262
g12
I70
sg13
g4246
sg14
I65
sg22
VP14209
p4263
sg17
I7
sasa(dp4264
g2
VCompared with baseline, rats resuscitated from cardiac arrest showed increased expression of CIRP, Bax, Caspase 9, and Caspase 3 and decreased expression of Bcl-2 in hippocampus (P &lt; 0.05).
p4265
sg4
(dp4266
(VCaspase 9
p4267
Vcardiac arrest
p4268
tp4269
I00
ssg9
(lp4270
(dp4271
g12
I47
sg13
g4268
sg14
I14
sg15
VC0018790
p4272
sg17
I2
sasg18
(lp4273
(dp4274
g12
I157
sg13
VBcl-2
p4275
sg14
I5
sg22
VP10415
p4276
sg17
I1
sa(dp4277
g12
I119
sg13
VCaspase 3
p4278
sg14
I9
sg22
VP42574
p4279
sg17
I2
sa(dp4280
g12
I93
sg13
VCIRP
p4281
sg14
I4
sg22
g190
sg17
I1
sa(dp4282
g12
I104
sg13
g4267
sg14
I9
sg22
VP55211
p4283
sg17
I2
sasa(dp4284
g2
VA previously reported expression signature of three genes (IGFBP3, F3 and VGLL3) was shown to have potential prognostic value in estimating overall and cancer-specific survivals at diagnosis of prostate cancer in a pilot cohort study using freshly frozen Fine Needle Aspiration (FNA) samples.
p4285
sg4
(dp4286
(VIGFBP3
p4287
VAspiration
p4288
tp4289
I00
ssg9
(lp4290
(dp4291
g12
I194
sg13
Vprostate cancer
p4292
sg14
I15
sg15
VC0600139
p4293
sg17
I2
sa(dp4294
g12
I267
sg13
g4288
sg14
I10
sg15
VC0700198
p4295
sg17
I1
sa(dp4296
g12
I152
sg13
Vcancer
p4297
sg14
I6
sg15
VC0006826
p4298
sg17
I1
sasg18
(lp4299
(dp4300
g12
I74
sg13
VVGLL3
p4301
sg14
I5
sg22
g190
sg17
I1
sa(dp4302
g12
I59
sg13
g4287
sg14
I6
sg22
VP17936
p4303
sg17
I1
sasa(dp4304
g2
VMultiple biopsy samples from 43 patients were evaluated using a previously reported gene signature of IGFBP3, F3 and VGLL3 with potential prognostic value in estimating overall survival at diagnosis of prostate cancer.
p4305
sg4
(dp4306
(VIGFBP3
p4307
Vprostate cancer
p4308
tp4309
I00
ssg9
(lp4310
(dp4311
g12
I202
sg13
g4308
sg14
I15
sg15
VC0600139
p4312
sg17
I2
sasg18
(lp4313
(dp4314
g12
I117
sg13
VVGLL3
p4315
sg14
I5
sg22
g190
sg17
I1
sa(dp4316
g12
I102
sg13
g4307
sg14
I6
sg22
VP17936
p4317
sg17
I1
sasa(dp4318
g2
VThe gene expression levels of IGFBP3 and F3 in prostate cancer epithelial cell-containing tissue representing the primary and secondary Gleason patterns were high and consistent, while the low expressed VGLL3 showed more variation in its expression levels.
p4319
sg4
(dp4320
(VIGFBP3
p4321
Vprostate cancer
p4322
tp4323
I00
ssg9
(lp4324
(dp4325
g12
I47
sg13
g4322
sg14
I15
sg15
VC0600139
p4326
sg17
I2
sasg18
(lp4327
(dp4328
g12
I203
sg13
VVGLL3
p4329
sg14
I5
sg22
g190
sg17
I1
sa(dp4330
g12
I30
sg13
g4321
sg14
I6
sg22
VP17936
p4331
sg17
I1
sasa(dp4332
g2
VPrevious studies have implicated vestigial like 3 (VGLL3), a chromosome 3p12.3 gene that encodes a putative transcription co-factor, as a candidate tumor suppressor gene (TSG) in high-grade serous ovarian carcinomas (HGSC), the most common type of epithelial ovarian cancer.
p4333
sg4
(dp4334
(Vtumor suppressor gene
p4335
Vovarian carcinomas
p4336
tp4337
I00
ssg9
(lp4338
(dp4339
g12
I248
sg13
Vepithelial ovarian cancer
p4340
sg14
I25
sg15
VC0677886
p4341
sg17
I3
sa(dp4342
g12
I148
sg13
Vtumor
p4343
sg14
I5
sg15
VC0027651
p4344
sg17
I1
sa(dp4345
g12
I197
sg13
g4336
sg14
I18
sg15
VC0029925
p4346
sg17
I2
sasg18
(lp4347
(dp4348
g12
I171
sg13
VTSG
p4349
sg14
I3
sg22
g190
sg17
I1
sa(dp4350
g12
I33
sg13
Vvestigial like 3
p4351
sg14
I16
sg22
g190
sg17
I3
sa(dp4352
g12
I148
sg13
g4335
sg14
I21
sg22
VP25054
p4353
sg17
I3
sa(dp4354
g12
I51
sg13
VVGLL3
p4355
sg14
I5
sg22
g190
sg17
I1
sasa(dp4356
g2
VWe tested the effects of the MEK inhibitor RDEA119, the Akt inhibitor perifosine, and the HDAC inhibitor SAHA on NIS expression in thirteen human cancer cell lines derived from melanoma, hepatic carcinoma, gastric carcinoma, colon carcinoma, breast carcinoma, and brain cancers.
p4357
sg4
(dp4358
(VMEK
p4359
Vbreast carcinoma
p4360
tp4361
I00
ssg9
(lp4362
(dp4363
g12
I206
sg13
Vgastric carcinoma
p4364
sg14
I17
sg15
VC0699791
p4365
sg17
I2
sa(dp4366
g12
I187
sg13
Vhepatic carcinoma
p4367
sg14
I17
sg15
VC2239176
p4368
sg17
I2
sa(dp4369
g12
I146
sg13
Vcancer
p4370
sg14
I6
sg15
VC0006826
p4371
sg17
I1
sa(dp4372
g12
I225
sg13
Vcolon carcinoma
p4373
sg14
I15
sg15
VC0699790
p4374
sg17
I2
sa(dp4375
g12
I177
sg13
Vmelanoma
p4376
sg14
I8
sg15
VC0025202
p4377
sg17
I1
sa(dp4378
g12
I264
sg13
Vbrain cancers
p4379
sg14
I13
sg15
VC0153633
p4380
sg17
I2
sa(dp4381
g12
I242
sg13
g4360
sg14
I16
sg15
VC0678222
p4382
sg17
I2
sasg18
(lp4383
(dp4384
g12
I90
sg13
VHDAC
p4385
sg14
I4
sg22
VP56524
p4386
sg17
I1
sa(dp4387
g12
I29
sg13
g4359
sg14
I3
sg22
VP45985
p4388
sg17
I1
sa(dp4389
g12
I56
sg13
VAkt
p4390
sg14
I3
sg22
g190
sg17
I1
sasa(dp4391
g2
VAPOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.
p4392
sg4
(dp4393
(VAPOBEC1
p4394
VBarrett's esophagus
p4395
tp4396
I01
ssg9
(lp4397
(dp4398
g12
I142
sg13
Vcondition
p4399
sg14
I9
sg15
VC0012634
p4400
sg17
I1
sa(dp4401
g12
I74
sg13
Vcarcinogenesis
p4402
sg14
I14
sg15
VC0596263
p4403
sg17
I1
sa(dp4404
g12
I29
sg13
Vcancer
p4405
sg14
I6
sg15
VC0006826
p4406
sg17
I1
sa(dp4407
g12
I174
sg13
Vesophageal adenocarcinoma
p4408
sg14
I25
sg15
VC0279628
p4409
sg17
I2
sa(dp4410
g12
I119
sg13
g4395
sg14
I19
sg15
VC0004763
p4411
sg17
I2
sasg18
(lp4412
(dp4413
g12
I0
sg13
g4394
sg14
I7
sg22
VP41238
p4414
sg17
I1
sasa(dp4415
g2
VSnake venom are known containing PLA2s (svPLA2s) which exhibit a wide variety of pharmacological effects including neurotoxicity, cardiotoxicity, myotoxicity and hemorrhage.
p4416
sg4
(dp4417
(VPLA2s
p4418
Vhemorrhage
p4419
tp4420
I00
ssg9
(lp4421
(dp4422
g12
I162
sg13
g4419
sg14
I10
sg15
VC0019080
p4423
sg17
I1
sasg18
(lp4424
(dp4425
g12
I33
sg13
g4418
sg14
I5
sg22
VP04054
p4426
sg17
I1
sasa(dp4427
g2
VThis study was aimed to assess regulation of surface-membrane enzymes such as Delta-6-desaturase (FADS2), secretory Phospholipase A2(sPLA2) by hemp seed and evening primrose oils as well as Hot-natured dietary intervention in relapsing remitting multiple sclerosis (RRMS) patients.
p4428
sg4
(dp4429
(VsPLA2
p4430
Vrelapsing remitting multiple sclerosis
p4431
tp4432
I00
ssg9
(lp4433
(dp4434
g12
I266
sg13
VRRMS
p4435
sg14
I4
sg15
VC0751967
p4436
sg17
I1
sa(dp4437
g12
I226
sg13
g4431
sg14
I38
sg15
VC0751967
p4438
sg17
I4
sasg18
(lp4439
(dp4440
g12
I78
sg13
VDelta-6-desaturase
p4441
sg14
I18
sg22
g190
sg17
I1
sa(dp4442
g12
I116
sg13
VPhospholipase A2
p4443
sg14
I16
sg22
VP04054
p4444
sg17
I2
sa(dp4445
g12
I133
sg13
g4430
sg14
I5
sg22
VP14555
p4446
sg17
I1
sa(dp4447
g12
I98
sg13
VFADS2
p4448
sg14
I5
sg22
g190
sg17
I1
sasa(dp4449
g2
VPhospholipases A2 (PLA2s) are enzymes responsible for inflammatory effects, edema formation, myotoxicity, neurotoxicity and other manifestations from envenoming.
p4450
sg4
(dp4451
(VPLA2s
p4452
Vedema
p4453
tp4454
I00
ssg9
(lp4455
(dp4456
g12
I76
sg13
g4453
sg14
I5
sg15
VC0013604
p4457
sg17
I1
sasg18
(lp4458
(dp4459
g12
I0
sg13
VPhospholipases A2
p4460
sg14
I17
sg22
VP04054
p4461
sg17
I2
sa(dp4462
g12
I19
sg13
g4452
sg14
I5
sg22
VP04054
p4463
sg17
I1
sasa(dp4464
g2
VCD9 expression obviously increased bortezomib sensitivity through inducing apoptosis, significantly inhibiting U266 cells' adhesion to HS-5 and primary bone marrow stromal cells, but increasing U266 cells' adhesion to fibronectin.
p4465
sg4
(dp4466
(VCD9
p4467
Vadhesion
p4468
tp4469
I00
ssg9
(lp4470
(dp4471
g12
I123
sg13
Vadhesion
p4472
sg14
I8
sg15
VC0001511
p4473
sg17
I1
sa(dp4474
g12
I123
sg13
g4468
sg14
I8
sg15
VC0001511
p4475
sg17
I1
sasg18
(lp4476
(dp4477
g12
I0
sg13
g4467
sg14
I3
sg22
VP21926
p4478
sg17
I1
sasa(dp4479
g2
VThe immunoprofiles of MOLP-6 and MOLP-7 correspond to that seen typically in primary MM cells: positive for cytoplasmic immunoglobulin (Ig) chains, a heavy and kappa light chains, CD9, CD28, CD40, CD44, CD45, CD56, and PCA-1; the cells were negative for surface Igs and various other B-cell, T-cell and myelomonocyte associated markers.
p4480
sg4
(dp4481
(VCD28
p4482
VPCA
p4483
tp4484
I00
ssg9
(lp4485
(dp4486
g12
I262
sg13
VIgs
p4487
sg14
I3
sg15
VC1306856
p4488
sg17
I1
sa(dp4489
g12
I219
sg13
g4483
sg14
I3
sg15
VC0268398
p4490
sg17
I1
sasg18
(lp4491
(dp4492
g12
I203
sg13
VCD45
p4493
sg14
I4
sg22
VP08575
p4494
sg17
I1
sa(dp4495
g12
I219
sg13
VPCA-1
p4496
sg14
I5
sg22
g190
sg17
I1
sa(dp4497
g12
I180
sg13
VCD9
p4498
sg14
I3
sg22
VP21926
p4499
sg17
I1
sa(dp4500
g12
I191
sg13
VCD40
p4501
sg14
I4
sg22
VP25942
p4502
sg17
I1
sa(dp4503
g12
I150
sg13
Vheavy and kappa light chains
p4504
sg14
I28
sg22
g190
sg17
I5
sa(dp4505
g12
I185
sg13
g4482
sg14
I4
sg22
VP33681
p4506
sg17
I1
sa(dp4507
g12
I262
sg13
VIgs
p4508
sg14
I3
sg22
g190
sg17
I1
sa(dp4509
g12
I108
sg13
Vcytoplasmic immunoglobulin (Ig) chains
p4510
sg14
I38
sg22
g190
sg17
I4
sasa(dp4511
g2
VThe univariate analysis showed that five parameters had an adverse effect on both complete remission (CR) and survival: advanced age (greater than 60 years), anemia (hemoglobin concentration (Hb) less than 10g/dl), the expression of the antigens detected by the anti-megakaryocytic antibodies (CDw41/CDw42), the monocytic antibodies (CD14), and the CD9 (FMC56, FMC8) antigen.
p4512
sg4
(dp4513
(VCD14
p4514
Vanemia
p4515
tp4516
I00
ssg9
(lp4517
(dp4518
g12
I59
sg13
Vadverse effect
p4519
sg14
I14
sg15
VC0879626
p4520
sg17
I2
sa(dp4521
g12
I158
sg13
g4515
sg14
I6
sg15
VC0002871
p4522
sg17
I1
sa(dp4523
g12
I91
sg13
Vremission
p4524
sg14
I9
sg15
VC0687702
p4525
sg17
I1
sasg18
(lp4526
(dp4527
g12
I166
sg13
Vhemoglobin
p4528
sg14
I10
sg22
g190
sg17
I1
sa(dp4529
g12
I349
sg13
VCD9
p4530
sg14
I3
sg22
VP21926
p4531
sg17
I1
sa(dp4532
g12
I334
sg13
g4514
sg14
I4
sg22
VP08571
p4533
sg17
I1
sasa(dp4534
g2
VIn this review, we consider the following paraneoplastic hormonal syndromes: malign hypercalcaemia, hyponatraemia (inappropiate secretion of the antidiuretic hormone), ectopic Cushing's syndrome, ectopic acromegaly, hypoglycaemia due to tumours different from those of the islet cells and paraneoplastic gynaecomastia; we make a brief final reference to other hormones (calcitonin, somatostatin, and VIP).
p4535
sg4
(dp4536
(VVIP
p4537
Vgynaecomastia
p4538
tp4539
I00
ssg9
(lp4540
(dp4541
g12
I216
sg13
Vhypoglycaemia
p4542
sg14
I13
sg15
VC0020615
p4543
sg17
I1
sa(dp4544
g12
I176
sg13
VCushing's syndrome
p4545
sg14
I18
sg15
VC0010481
p4546
sg17
I2
sa(dp4547
g12
I204
sg13
Vacromegaly
p4548
sg14
I10
sg15
VC0001206
p4549
sg17
I1
sa(dp4550
g12
I84
sg13
Vhypercalcaemia
p4551
sg14
I14
sg15
VC0020437
p4552
sg17
I1
sa(dp4553
g12
I66
sg13
Vsyndromes
p4554
sg14
I9
sg15
VC0039082
p4555
sg17
I1
sa(dp4556
g12
I237
sg13
Vtumours
p4557
sg14
I7
sg15
VC0027651
p4558
sg17
I1
sa(dp4559
g12
I304
sg13
g4538
sg14
I13
sg15
VC0018418
p4560
sg17
I1
sasg18
(lp4561
(dp4562
g12
I382
sg13
Vsomatostatin
p4563
sg14
I12
sg22
VP61278
p4564
sg17
I1
sa(dp4565
g12
I370
sg13
Vcalcitonin
p4566
sg14
I10
sg22
VP06881
p4567
sg17
I1
sa(dp4568
g12
I400
sg13
g4537
sg14
I3
sg22
VP01282
p4569
sg17
I1
sasa(dp4570
g2
VProtrudin was found to interact with other HSP-related proteins including myelin proteolipid protein 1 (SPG2), atlastin-1 (SPG3A), REEP1 (SPG31), REEP5 (similar to REEP1), Kif5A (SPG10), Kif5B, Kif5C, and reticulon 1, 3, and 4 (similar to reticulon 2, SPG12).
p4571
sg4
(dp4572
(VSPG2
p4573
VSPG12
p4574
tp4575
I00
ssg9
(lp4576
(dp4577
g12
I138
sg13
VSPG31
p4578
sg14
I5
sg15
VC1853247
p4579
sg17
I1
sa(dp4580
g12
I179
sg13
VSPG10
p4581
sg14
I5
sg15
VC1858712
p4582
sg17
I1
sa(dp4583
g12
I123
sg13
VSPG3A
p4584
sg14
I5
sg15
VC2931355
p4585
sg17
I1
sa(dp4586
g12
I104
sg13
VSPG2
p4587
sg14
I4
sg15
VC1839264
p4588
sg17
I1
sa(dp4589
g12
I43
sg13
VHSP
p4590
sg14
I3
sg15
VC0034152
p4591
sg17
I1
sa(dp4592
g12
I252
sg13
g4574
sg14
I5
sg15
VC1858106
p4593
sg17
I1
sasg18
(lp4594
(dp4595
g12
I138
sg13
VSPG31
p4596
sg14
I5
sg22
g190
sg17
I1
sa(dp4597
g12
I187
sg13
VKif5B
p4598
sg14
I5
sg22
VP33176
p4599
sg17
I1
sa(dp4600
g12
I146
sg13
VREEP5
p4601
sg14
I5
sg22
g190
sg17
I1
sa(dp4602
g12
I111
sg13
Vatlastin-1
p4603
sg14
I10
sg22
g190
sg17
I1
sa(dp4604
g12
I74
sg13
Vmyelin proteolipid protein 1
p4605
sg14
I28
sg22
VP60201
p4606
sg17
I4
sa(dp4607
g12
I43
sg13
VHSP-related proteins
p4608
sg14
I20
sg22
g190
sg17
I2
sa(dp4609
g12
I131
sg13
VREEP1
p4610
sg14
I5
sg22
g190
sg17
I1
sa(dp4611
g12
I179
sg13
VSPG10
p4612
sg14
I5
sg22
g190
sg17
I1
sa(dp4613
g12
I172
sg13
VKif5A
p4614
sg14
I5
sg22
g190
sg17
I1
sa(dp4615
g12
I123
sg13
VSPG3A
p4616
sg14
I5
sg22
g190
sg17
I1
sa(dp4617
g12
I131
sg13
VREEP1
p4618
sg14
I5
sg22
g190
sg17
I1
sa(dp4619
g12
I194
sg13
VKif5C
p4620
sg14
I5
sg22
g190
sg17
I1
sa(dp4621
g12
I104
sg13
g4573
sg14
I4
sg22
VP60201
p4622
sg17
I1
sasa(dp4623
g2
VSince, type 1 diabetes is characterised by hyperglycaemia we analysed 22 diabetic and 43 non-diabetic [(BB x SHR)FI x BB] backcross hybrids (28M:37F) which were already homozygous for Iddml and Iddm2 to search for quantitative trait loci (QTLs) affecting blood glucose in BB/OK rats.
p4624
sg4
(dp4625
(VIddm2
p4626
VIddm2
p4627
tp4628
I00
ssg9
(lp4629
(dp4630
g12
I43
sg13
Vhyperglycaemia
p4631
sg14
I14
sg15
VC0020456
p4632
sg17
I1
sa(dp4633
g12
I7
sg13
Vtype 1 diabetes
p4634
sg14
I15
sg15
VC0011854
p4635
sg17
I3
sa(dp4636
g12
I194
sg13
g4627
sg14
I5
sg15
VC1852092
p4637
sg17
I1
sasg18
(lp4638
(dp4639
g12
I194
sg13
g4626
sg14
I5
sg22
VP01308
p4640
sg17
I1
sasa(dp4641
g2
VLRRK2 selectively interacts with three Beta-tubulin isoforms: TUBB, TUBB4, and TUBB6, one of which (TUBB4) is mutated in the movement disorder dystonia type 4 (DYT4).
p4642
sg4
(dp4643
(VTUBB4
p4644
Vdystonia type 4
p4645
tp4646
I00
ssg9
(lp4647
(dp4648
g12
I125
sg13
Vmovement disorder
p4649
sg14
I17
sg15
VC0026650
p4650
sg17
I2
sa(dp4651
g12
I160
sg13
VDYT4
p4652
sg14
I4
sg15
VC1851943
p4653
sg17
I1
sa(dp4654
g12
I143
sg13
g4645
sg14
I15
sg15
VC1851943
p4655
sg17
I3
sasg18
(lp4656
(dp4657
g12
I79
sg13
VTUBB6
p4658
sg14
I5
sg22
g190
sg17
I1
sa(dp4659
g12
I0
sg13
VLRRK2
p4660
sg14
I5
sg22
g190
sg17
I1
sa(dp4661
g12
I39
sg13
VBeta-tubulin isoforms
p4662
sg14
I21
sg22
VP68371
p4663
sg17
I2
sa(dp4664
g12
I68
sg13
VTUBB4
p4665
sg14
I5
sg22
VP04350
p4666
sg17
I1
sa(dp4667
g12
I62
sg13
VTUBB
p4668
sg14
I4
sg22
VP04350
p4669
sg17
I1
sa(dp4670
g12
I68
sg13
g4644
sg14
I5
sg22
VP04350
p4671
sg17
I1
sasa(dp4672
g2
VIn this study, we aimed to analyze pairwise interactions that are associated with Body Mass Index (BMI) between SNPs from twelve genes robustly associated with obesity (BDNF, ETV5, FAIM2, FTO, GNPDA2, KCTD15, MC4R, MTCH2, NEGR1, SEC16B, SH2B1, and TMEM18).
p4673
sg4
(dp4674
(VETV5
p4675
Vobesity
p4676
tp4677
I00
ssg9
(lp4678
(dp4679
g12
I160
sg13
g4676
sg14
I7
sg15
VC0028754
p4680
sg17
I1
sasg18
(lp4681
(dp4682
g12
I209
sg13
VMC4R
p4683
sg14
I4
sg22
VP32245
p4684
sg17
I1
sa(dp4685
g12
I188
sg13
VFTO
p4686
sg14
I3
sg22
g190
sg17
I1
sa(dp4687
g12
I222
sg13
VNEGR1
p4688
sg14
I5
sg22
g190
sg17
I1
sa(dp4689
g12
I175
sg13
g4675
sg14
I4
sg22
VP41161
p4690
sg17
I1
sa(dp4691
g12
I229
sg13
VSEC16B
p4692
sg14
I6
sg22
g190
sg17
I1
sa(dp4693
g12
I181
sg13
VFAIM2
p4694
sg14
I5
sg22
g190
sg17
I1
sa(dp4695
g12
I193
sg13
VGNPDA2
p4696
sg14
I6
sg22
g190
sg17
I1
sa(dp4697
g12
I237
sg13
VSH2B1
p4698
sg14
I5
sg22
g190
sg17
I1
sa(dp4699
g12
I248
sg13
VTMEM18
p4700
sg14
I6
sg22
g190
sg17
I1
sa(dp4701
g12
I201
sg13
VKCTD15
p4702
sg14
I6
sg22
g190
sg17
I1
sa(dp4703
g12
I215
sg13
VMTCH2
p4704
sg14
I5
sg22
g190
sg17
I1
sasa(dp4705
g2
VIn total, 15 loci reached genome-wide significance (P-value &lt; 5 x 10(-8)) in the joint discovery and replication analysis, of which 12 are previously identified loci in or close to ADCY3, GNPDA2, TMEM18, SEC16B, FAIM2, FTO, TFAP2B, TNNI3K, MC4R, GPR61, LMX1B and OLFM4 associated with adult body mass index or childhood obesity.
p4706
sg4
(dp4707
(VADCY3
p4708
Vchildhood obesity
p4709
tp4710
I00
ssg9
(lp4711
(dp4712
g12
I313
sg13
g4709
sg14
I17
sg15
VC2362324
p4713
sg17
I2
sasg18
(lp4714
(dp4715
g12
I256
sg13
VLMX1B
p4716
sg14
I5
sg22
g190
sg17
I1
sa(dp4717
g12
I222
sg13
VFTO
p4718
sg14
I3
sg22
g190
sg17
I1
sa(dp4719
g12
I199
sg13
VTMEM18
p4720
sg14
I6
sg22
g190
sg17
I1
sa(dp4721
g12
I215
sg13
VFAIM2
p4722
sg14
I5
sg22
g190
sg17
I1
sa(dp4723
g12
I266
sg13
VOLFM4
p4724
sg14
I5
sg22
g190
sg17
I1
sa(dp4725
g12
I227
sg13
VTFAP2B
p4726
sg14
I6
sg22
g190
sg17
I1
sa(dp4727
g12
I243
sg13
VMC4R
p4728
sg14
I4
sg22
VP32245
p4729
sg17
I1
sa(dp4730
g12
I191
sg13
VGNPDA2
p4731
sg14
I6
sg22
g190
sg17
I1
sa(dp4732
g12
I207
sg13
VSEC16B
p4733
sg14
I6
sg22
g190
sg17
I1
sa(dp4734
g12
I184
sg13
g4708
sg14
I5
sg22
VP40145
p4735
sg17
I1
sa(dp4736
g12
I249
sg13
VGPR61
p4737
sg14
I5
sg22
g190
sg17
I1
sa(dp4738
g12
I235
sg13
VTNNI3K
p4739
sg14
I6
sg22
g190
sg17
I1
sasa(dp4740
g2
VThe association of FTO rs9939609-A, MC4R rs17782313-C, GNPDA2 rs10938397-G, and FAIM2 rs7138803-A with higher BMI, fat mass percentage, waist circumference, and waist-to height ratio and risk of obesity, and BDNF rs6265-G allele may increase BMI and obesity risk in Chinese children.
p4741
sg4
(dp4742
(VMC4R rs17782313-C
p4743
Vobesity
p4744
tp4745
I00
ssg9
(lp4746
(dp4747
g12
I195
sg13
Vobesity
p4748
sg14
I7
sg15
VC0028754
p4749
sg17
I1
sa(dp4750
g12
I195
sg13
g4744
sg14
I7
sg15
VC0028754
p4751
sg17
I1
sasg18
(lp4752
(dp4753
g12
I80
sg13
VFAIM2 rs7138803-A
p4754
sg14
I17
sg22
g190
sg17
I2
sa(dp4755
g12
I36
sg13
g4743
sg14
I17
sg22
VP32245
p4756
sg17
I2
sa(dp4757
g12
I55
sg13
VGNPDA2 rs10938397-G
p4758
sg14
I19
sg22
g190
sg17
I2
sa(dp4759
g12
I19
sg13
VFTO rs9939609-A
p4760
sg14
I15
sg22
g190
sg17
I2
sasa(dp4761
g2
VHere we aim to see whether variants in obesity-associated genes--NEGR1, FTO, MTCH2, MC4R, LRRN6C, MAP2K5, FAIM2, SEC16B, ETV5, BDNF-AS, ATXN2L, ATP2A1, KCTD15, and TNN13K--are associated with white matter microstructural properties, assessed by high angular resolution diffusion imaging (HARDI) in young healthy adults between 20 and 30 years of age from the Queensland Twin Imaging study (QTIM).
p4762
sg4
(dp4763
(VMC4R
p4764
Vobesity
p4765
tp4766
I00
ssg9
(lp4767
(dp4768
g12
I39
sg13
g4765
sg14
I7
sg15
VC0028754
p4769
sg17
I1
sasg18
(lp4770
(dp4771
g12
I65
sg13
VNEGR1
p4772
sg14
I5
sg22
g190
sg17
I1
sa(dp4773
g12
I144
sg13
VATP2A1
p4774
sg14
I6
sg22
g190
sg17
I1
sa(dp4775
g12
I72
sg13
VFTO
p4776
sg14
I3
sg22
g190
sg17
I1
sa(dp4777
g12
I98
sg13
VMAP2K5
p4778
sg14
I6
sg22
g190
sg17
I1
sa(dp4779
g12
I106
sg13
VFAIM2
p4780
sg14
I5
sg22
g190
sg17
I1
sa(dp4781
g12
I113
sg13
VSEC16B
p4782
sg14
I6
sg22
g190
sg17
I1
sa(dp4783
g12
I152
sg13
VKCTD15
p4784
sg14
I6
sg22
g190
sg17
I1
sa(dp4785
g12
I121
sg13
VETV5
p4786
sg14
I4
sg22
VP41161
p4787
sg17
I1
sa(dp4788
g12
I77
sg13
VMTCH2
p4789
sg14
I5
sg22
g190
sg17
I1
sa(dp4790
g12
I84
sg13
g4764
sg14
I4
sg22
VP32245
p4791
sg17
I1
sa(dp4792
g12
I90
sg13
VLRRN6C
p4793
sg14
I6
sg22
g190
sg17
I1
sasa(dp4794
g2
VHere, we report that ER-beta and pRb2/p130 proteins co-immunoprecipitate in both nucleus and cytoplasm of MCF-7 breast cancer cells.
p4795
sg4
(dp4796
(VpRb2
p4797
Vbreast cancer
p4798
tp4799
I00
ssg9
(lp4800
(dp4801
g12
I112
sg13
g4798
sg14
I13
sg15
VC0678222
p4802
sg17
I2
sasg18
(lp4803
(dp4804
g12
I38
sg13
Vp130
p4805
sg14
I4
sg22
g190
sg17
I1
sa(dp4806
g12
I33
sg13
g4797
sg14
I4
sg22
VP02812
p4807
sg17
I1
sasa(dp4808
g2
VHere we show a new molecular mechanism of ER-alpha gene inactivation mediated by pRb2/p130 in ER-negative breast cancer cells.
p4809
sg4
(dp4810
(VpRb2
p4811
Vbreast cancer
p4812
tp4813
I00
ssg9
(lp4814
(dp4815
g12
I106
sg13
g4812
sg14
I13
sg15
VC0678222
p4816
sg17
I2
sa(dp4817
g12
I56
sg13
Vinactivation
p4818
sg14
I12
sg15
VC0544461
p4819
sg17
I1
sasg18
(lp4820
(dp4821
g12
I81
sg13
g4811
sg14
I4
sg22
VP02812
p4822
sg17
I1
sa(dp4823
g12
I42
sg13
VER-alpha gene
p4824
sg14
I13
sg22
g190
sg17
I2
sa(dp4825
g12
I86
sg13
Vp130
p4826
sg14
I4
sg22
g190
sg17
I1
sasa(dp4827
g2
VThese findings suggest that pRb2/p130-multimolecular complexes can be key elements in the regulation of ER-alpha gene expression and may be viewed as promising targets for the development of novel therapeutic strategies in the treatment of breast cancer, especially for those tumors that are ER negative.
p4828
sg4
(dp4829
(VpRb2
p4830
Vbreast cancer
p4831
tp4832
I00
ssg9
(lp4833
(dp4834
g12
I240
sg13
g4831
sg14
I13
sg15
VC0678222
p4835
sg17
I2
sa(dp4836
g12
I276
sg13
Vtumors
p4837
sg14
I6
sg15
VC0027651
p4838
sg17
I1
sasg18
(lp4839
(dp4840
g12
I33
sg13
Vp130
p4841
sg14
I4
sg22
g190
sg17
I1
sa(dp4842
g12
I104
sg13
VER-alpha gene
p4843
sg14
I13
sg22
g190
sg17
I2
sa(dp4844
g12
I28
sg13
g4830
sg14
I4
sg22
VP02812
p4845
sg17
I1
sasa(dp4846
g2
VIn order to further analyze the role of CEACAM1 in the development of breast cancer, we performed Western-blot analysis and immunohistochemistry with highly specific monoclonal antibodies in a cohort of 68 mammary carcinomas which had also been analyzed for expression of cell-cycle regulatory proteins cyclin D1, cyclin E, p16, p21, p27, Rb, and Rb2, as well as for steroid hormone receptor status, Ki67, and HER2/neu immunoreactivity.
p4847
sg4
(dp4848
(Vsteroid hormone receptor
p4849
Vbreast cancer
p4850
tp4851
I00
ssg9
(lp4852
(dp4853
g12
I70
sg13
g4850
sg14
I13
sg15
VC0678222
p4854
sg17
I2
sa(dp4855
g12
I214
sg13
Vcarcinomas
p4856
sg14
I10
sg15
VC0007097
p4857
sg17
I1
sasg18
(lp4858
(dp4859
g12
I347
sg13
VRb2
p4860
sg14
I3
sg22
g190
sg17
I1
sa(dp4861
g12
I324
sg13
Vp16
p4862
sg14
I3
sg22
VP42771
p4863
sg17
I1
sa(dp4864
g12
I334
sg13
Vp27
p4865
sg14
I3
sg22
VP40305
p4866
sg17
I1
sa(dp4867
g12
I415
sg13
Vneu
p4868
sg14
I3
sg22
VP04626
p4869
sg17
I1
sa(dp4870
g12
I40
sg13
VCEACAM1
p4871
sg14
I7
sg22
VP13688
p4872
sg17
I1
sa(dp4873
g12
I329
sg13
Vp21
p4874
sg14
I3
sg22
VP42857
p4875
sg17
I1
sa(dp4876
g12
I314
sg13
Vcyclin E
p4877
sg14
I8
sg22
VP24864
p4878
sg17
I2
sa(dp4879
g12
I410
sg13
VHER2
p4880
sg14
I4
sg22
VP04626
p4881
sg17
I1
sa(dp4882
g12
I303
sg13
Vcyclin D1
p4883
sg14
I9
sg22
VP24385
p4884
sg17
I2
sa(dp4885
g12
I367
sg13
g4849
sg14
I24
sg22
VP22736
p4886
sg17
I3
sasa(dp4887
g2
VWe have developed a novel glycocancer biomarker, fucosylated haptoglobin (Fuc-Hpt), and have investigated its usefulness for the diagnosis of pancreatic cancer over approximately 10 years.
p4888
sg4
(dp4889
(Vfucosylated haptoglobin
p4890
Vpancreatic cancer
p4891
tp4892
I00
ssg9
(lp4893
(dp4894
g12
I142
sg13
g4891
sg14
I17
sg15
VC0235974
p4895
sg17
I2
sasg18
(lp4896
(dp4897
g12
I74
sg13
VFuc-Hpt
p4898
sg14
I7
sg22
VP00738
p4899
sg17
I1
sa(dp4900
g12
I49
sg13
g4890
sg14
I23
sg22
VP00738
p4901
sg17
I2
sasa(dp4902
g2
VIn this review, we provide a historical summary of our research on Fuc-Hpt as a cancer biomarker, and discuss a potential early detection system for pancreatic cancer.
p4903
sg4
(dp4904
(VFuc-Hpt
p4905
Vpancreatic cancer
p4906
tp4907
I00
ssg9
(lp4908
(dp4909
g12
I80
sg13
Vcancer
p4910
sg14
I6
sg15
VC0006826
p4911
sg17
I1
sa(dp4912
g12
I149
sg13
g4906
sg14
I17
sg15
VC0235974
p4913
sg17
I2
sasg18
(lp4914
(dp4915
g12
I67
sg13
g4905
sg14
I7
sg22
VP00738
p4916
sg17
I1
sasa(dp4917
g2
VWe developed a lectin-antibody ELISA kit using PhoSL to determine core-Fuc-Hpt levels in sera from colorectal or pancreatic cancer patients.
p4918
sg4
(dp4919
(Vcore-Fuc-Hpt
p4920
Vpancreatic cancer
p4921
tp4922
I00
ssg9
(lp4923
(dp4924
g12
I113
sg13
g4921
sg14
I17
sg15
VC0235974
p4925
sg17
I2
sasg18
(lp4926
(dp4927
g12
I66
sg13
g4920
sg14
I12
sg22
VP00738
p4928
sg17
I1
sa(dp4929
g12
I15
sg13
Vlectin-antibody
p4930
sg14
I15
sg22
g190
sg17
I1
sasa(dp4931
g2
VSerum levels of AAL-reactive Hpt are higher in pancreatic cancer patients, whereas those of PhoSL-reactive Hpt are higher in colorectal cancer patients.
p4932
sg4
(dp4933
(VAAL-reactive Hpt
p4934
Vcolorectal cancer
p4935
tp4936
I01
ssg9
(lp4937
(dp4938
g12
I47
sg13
Vpancreatic cancer
p4939
sg14
I17
sg15
VC0235974
p4940
sg17
I2
sa(dp4941
g12
I125
sg13
g4935
sg14
I17
sg15
VC1527249
p4942
sg17
I2
sasg18
(lp4943
(dp4944
g12
I92
sg13
VPhoSL-reactive Hpt
p4945
sg14
I18
sg22
VP00738
p4946
sg17
I2
sa(dp4947
g12
I16
sg13
g4934
sg14
I16
sg22
VP00738
p4948
sg17
I2
sasa(dp4949
g2
VFucosylated haptoglobin (Fuc-Hpt) has been identified as a novel biomarker for pancreatic cancer.
p4950
sg4
(dp4951
(VFucosylated haptoglobin
p4952
Vpancreatic cancer
p4953
tp4954
I00
ssg9
(lp4955
(dp4956
g12
I79
sg13
g4953
sg14
I17
sg15
VC0235974
p4957
sg17
I2
sasg18
(lp4958
(dp4959
g12
I25
sg13
VFuc-Hpt
p4960
sg14
I7
sg22
VP00738
p4961
sg17
I1
sa(dp4962
g12
I0
sg13
g4952
sg14
I23
sg22
VP00738
p4963
sg17
I2
sasa(dp4964
g2
VWe previously found that the level of Fuc-Hpt is increased in the sera of patients with pancreatic cancer, and established a lectin antibody ELISA using Aleuria aurantia lectin, which specifically binds to fucosylated residues on oligosaccharides.
p4965
sg4
(dp4966
(VFuc-Hpt
p4967
Vpancreatic cancer
p4968
tp4969
I00
ssg9
(lp4970
(dp4971
g12
I88
sg13
g4968
sg14
I17
sg15
VC0235974
p4972
sg17
I2
sasg18
(lp4973
(dp4974
g12
I38
sg13
g4967
sg14
I7
sg22
VP00738
p4975
sg17
I1
sa(dp4976
g12
I153
sg13
VAleuria aurantia lectin
p4977
sg14
I23
sg22
g190
sg17
I3
sa(dp4978
g12
I125
sg13
Vlectin antibody
p4979
sg14
I15
sg22
g190
sg17
I2
sasa(dp4980
g2
VTandem repeats of a novel, putative, zinc-binding motif (MYM) have been described within the products of two, highly homologous genes: ZNF198/RAMP/FIM and ZNF261/DXS6673E.
p4981
sg4
(dp4982
(VFIM
p4983
VFIM
p4984
tp4985
I00
ssg9
(lp4986
(dp4987
g12
I147
sg13
g4984
sg14
I3
sg15
VC0393929
p4988
sg17
I1
sasg18
(lp4989
(dp4990
g12
I155
sg13
VZNF261
p4991
sg14
I6
sg22
g190
sg17
I1
sa(dp4992
g12
I142
sg13
VRAMP
p4993
sg14
I4
sg22
g190
sg17
I1
sa(dp4994
g12
I147
sg13
g4983
sg14
I3
sg22
VP28329
p4995
sg17
I1
sa(dp4996
g12
I162
sg13
VDXS6673E
p4997
sg14
I8
sg22
g190
sg17
I1
sasa(dp4998
g2
VFrom 2005 to 2010, our unit performed testing for IL2RG, JAK3, IL7R, RAG1, RAG2, DCLRE1C, LIG4, AK2, and ZAP70 mutations in 42 Chinese and Southeast Asian infants with SCID adopting a candidate gene approach, based on patient's gender, immune phenotype, and inheritance pattern.
p4999
sg4
(dp5000
(VLIG4
p5001
VSCID
p5002
tp5003
I00
ssg9
(lp5004
(dp5005
g12
I168
sg13
g5002
sg14
I4
sg15
VC0085110
p5006
sg17
I1
sasg18
(lp5007
(dp5008
g12
I50
sg13
VIL2RG
p5009
sg14
I5
sg22
VP31785
p5010
sg17
I1
sa(dp5011
g12
I96
sg13
VAK2
p5012
sg14
I3
sg22
g190
sg17
I1
sa(dp5013
g12
I105
sg13
VZAP70 mutations
p5014
sg14
I15
sg22
VP43403
p5015
sg17
I2
sa(dp5016
g12
I69
sg13
VRAG1
p5017
sg14
I4
sg22
VP15918
p5018
sg17
I1
sa(dp5019
g12
I75
sg13
VRAG2
p5020
sg14
I4
sg22
VP55895
p5021
sg17
I1
sa(dp5022
g12
I57
sg13
VJAK3
p5023
sg14
I4
sg22
VP52333
p5024
sg17
I1
sa(dp5025
g12
I90
sg13
g5001
sg14
I4
sg22
VP49917
p5026
sg17
I1
sasa(dp5027
g2
VMutations in any of eight known genes: IL2RG, ARTEMIS, RAG1, RAG2, ADA, CD45, JAK3, and IL7R cause SCID.
p5028
sg4
(dp5029
(VRAG2
p5030
VSCID
p5031
tp5032
I00
ssg9
(lp5033
(dp5034
g12
I99
sg13
g5031
sg14
I4
sg15
VC0085110
p5035
sg17
I1
sasg18
(lp5036
(dp5037
g12
I39
sg13
VIL2RG
p5038
sg14
I5
sg22
VP31785
p5039
sg17
I1
sa(dp5040
g12
I78
sg13
VJAK3
p5041
sg14
I4
sg22
VP52333
p5042
sg17
I1
sa(dp5043
g12
I55
sg13
VRAG1
p5044
sg14
I4
sg22
VP15918
p5045
sg17
I1
sa(dp5046
g12
I72
sg13
VCD45
p5047
sg14
I4
sg22
VP08575
p5048
sg17
I1
sa(dp5049
g12
I67
sg13
VADA
p5050
sg14
I3
sg22
VP00813
p5051
sg17
I1
sa(dp5052
g12
I61
sg13
g5030
sg14
I4
sg22
VP55895
p5053
sg17
I1
sasa(dp5054
g2
VFurther investigation with an intracellular signaling array demonstrated that the depletion of NIT2 triggered the apoptosis of colon cancer cells through the caspase-3 and poly(ADP-ribose) polymerase (PARP) pathways.
p5055
sg4
(dp5056
(Vpoly(ADP-ribose) polymerase
p5057
Vcolon cancer
p5058
tp5059
I00
ssg9
(lp5060
(dp5061
g12
I127
sg13
g5058
sg14
I12
sg15
VC0699790
p5062
sg17
I2
sasg18
(lp5063
(dp5064
g12
I95
sg13
VNIT2
p5065
sg14
I4
sg22
g190
sg17
I1
sa(dp5066
g12
I201
sg13
VPARP
p5067
sg14
I4
sg22
VP09874
p5068
sg17
I1
sa(dp5069
g12
I158
sg13
Vcaspase-3
p5070
sg14
I9
sg22
VP42574
p5071
sg17
I1
sa(dp5072
g12
I172
sg13
g5057
sg14
I27
sg22
VP09874
p5073
sg17
I2
sasa(dp5074
g2
VWe recently characterized a stress and glucocorticoid-regulated gene, down-regulated in renal cell carcinoma - DRR1 (Fam107A).
p5075
sg4
(dp5076
(Vglucocorticoid-regulated gene
p5077
Vrenal cell carcinoma
p5078
tp5079
I00
ssg9
(lp5080
(dp5081
g12
I88
sg13
g5078
sg14
I20
sg15
VC0007134
p5082
sg17
I3
sasg18
(lp5083
(dp5084
g12
I117
sg13
VFam107A
p5085
sg14
I7
sg22
g190
sg17
I1
sa(dp5086
g12
I111
sg13
VDRR1
p5087
sg14
I4
sg22
g190
sg17
I1
sa(dp5088
g12
I39
sg13
g5077
sg14
I29
sg22
VP48506
p5089
sg17
I2
sasa(dp5090
g2
VFunction of E2F5 and p38 in prostate cancer was investigated using siRNA-treatment of PC3 cell-line followed by analyses of associated components and cell cycle.
p5091
sg4
(dp5092
(Vp38
p5093
Vprostate cancer
p5094
tp5095
I00
ssg9
(lp5096
(dp5097
g12
I28
sg13
g5094
sg14
I15
sg15
VC0600139
p5098
sg17
I2
sasg18
(lp5099
(dp5100
g12
I21
sg13
g5093
sg14
I3
sg22
VP46108
p5101
sg17
I1
sa(dp5102
g12
I12
sg13
VE2F5
p5103
sg14
I4
sg22
g190
sg17
I1
sasa(dp5104
g2
VOur findings unearthed that E2F5/p38 axis played a cardinal role in uncontrolled cellular proliferation in prostate cancer through pSMAD3L activation.
p5105
sg4
(dp5106
(Vp38
p5107
Vprostate cancer
p5108
tp5109
I00
ssg9
(lp5110
(dp5111
g12
I81
sg13
Vcellular proliferation
p5112
sg14
I22
sg15
VC0020507
p5113
sg17
I2
sa(dp5114
g12
I107
sg13
g5108
sg14
I15
sg15
VC0600139
p5115
sg17
I2
sasg18
(lp5116
(dp5117
g12
I33
sg13
g5107
sg14
I3
sg22
VP46108
p5118
sg17
I1
sa(dp5119
g12
I28
sg13
VE2F5
p5120
sg14
I4
sg22
g190
sg17
I1
sasa(dp5121
g2
VIn our per-SNP analysis, eight myopia gene associations were replicated successfully: GJD2, RASGRF1, BICC1, KCNQ5, CD55, CYP26A1, LRRC4C, and B4GALNT2.Seven additional gene associations were replicated in our gene-based analyses: GRIA4, BMP2, QKI, BMP4, SFRP1, SH3GL2, and EHBP1L1.
p5122
sg4
(dp5123
(VBMP4
p5124
Vmyopia
p5125
tp5126
I01
ssg9
(lp5127
(dp5128
g12
I31
sg13
g5125
sg14
I6
sg15
VC0027092
p5129
sg17
I1
sasg18
(lp5130
(dp5131
g12
I254
sg13
VSFRP1
p5132
sg14
I5
sg22
g190
sg17
I1
sa(dp5133
g12
I261
sg13
VSH3GL2
p5134
sg14
I6
sg22
g190
sg17
I1
sa(dp5135
g12
I130
sg13
VLRRC4C
p5136
sg14
I6
sg22
g190
sg17
I1
sa(dp5137
g12
I237
sg13
VBMP2
p5138
sg14
I4
sg22
VP12643
p5139
sg17
I1
sa(dp5140
g12
I86
sg13
VGJD2
p5141
sg14
I4
sg22
g190
sg17
I1
sa(dp5142
g12
I121
sg13
VCYP26A1
p5143
sg14
I7
sg22
g190
sg17
I1
sa(dp5144
g12
I273
sg13
VEHBP1L1
p5145
sg14
I7
sg22
g190
sg17
I1
sa(dp5146
g12
I108
sg13
VKCNQ5
p5147
sg14
I5
sg22
g190
sg17
I1
sa(dp5148
g12
I101
sg13
VBICC1
p5149
sg14
I5
sg22
g190
sg17
I1
sa(dp5150
g12
I115
sg13
VCD55
p5151
sg14
I4
sg22
VP08174
p5152
sg17
I1
sa(dp5153
g12
I230
sg13
VGRIA4
p5154
sg14
I5
sg22
VP48058
p5155
sg17
I1
sa(dp5156
g12
I248
sg13
g5124
sg14
I4
sg22
VP12644
p5157
sg17
I1
sa(dp5158
g12
I142
sg13
VB4GALNT2
p5159
sg14
I8
sg22
g190
sg17
I1
sa(dp5160
g12
I92
sg13
VRASGRF1
p5161
sg14
I7
sg22
g190
sg17
I1
sasa(dp5162
g2
VThe aims of the present study were to immunohistochemically examine S100A10 expression in surgically resected lung adenocarcinomas, and evaluate any relationships with clinicopathological parameters and prognosis of patients.
p5163
sg4
(dp5164
(VS100A10
p5165
Vadenocarcinomas
p5166
tp5167
I00
ssg9
(lp5168
(dp5169
g12
I115
sg13
g5166
sg14
I15
sg15
VC0001418
p5170
sg17
I1
sasg18
(lp5171
(dp5172
g12
I68
sg13
g5165
sg14
I7
sg22
VP60903
p5173
sg17
I1
sasa(dp5174
g2
VS100A10 expression was immunohistochemically studied in 202 consecutive resected lung adenocarcinomas, and its associations with clinicopathological parameters were evaluated.
p5175
sg4
(dp5176
(VS100A10
p5177
Vadenocarcinomas
p5178
tp5179
I00
ssg9
(lp5180
(dp5181
g12
I86
sg13
g5178
sg14
I15
sg15
VC0001418
p5182
sg17
I1
sasg18
(lp5183
(dp5184
g12
I0
sg13
g5177
sg14
I7
sg22
VP60903
p5185
sg17
I1
sasa(dp5186
g2
VS100A10 expression was detected in 65 of the 202 (32.2%) lung adenocarcinomas, being significantly correlated with poorer differentiation (P =0.015), a higher pathological TNM stage (stages II and III) (P=0.004), more frequent and severe intratumoral vascular invasion (P=0.001), and a poorer prognosis (P=0.030).
p5187
sg4
(dp5188
(VS100A10
p5189
Vadenocarcinomas
p5190
tp5191
I00
ssg9
(lp5192
(dp5193
g12
I62
sg13
g5190
sg14
I15
sg15
VC0001418
p5194
sg17
I1
sa(dp5195
g12
I260
sg13
Vinvasion
p5196
sg14
I8
sg15
VC2699153
p5197
sg17
I1
sasg18
(lp5198
(dp5199
g12
I0
sg13
g5189
sg14
I7
sg22
VP60903
p5200
sg17
I1
sasa(dp5201
g2
VThe present study reveals that S100A10 is expressed in a subset of lung adenocarcinomas, and this is related to some clinicopathological parameters, although further studies are required to confirm the correlation between S100A10 expression and prognosis of lung adenocarcinoma patients.
p5202
sg4
(dp5203
(VS100A10
p5204
Vlung adenocarcinoma
p5205
tp5206
I00
ssg9
(lp5207
(dp5208
g12
I72
sg13
Vadenocarcinomas
p5209
sg14
I15
sg15
VC0001418
p5210
sg17
I1
sa(dp5211
g12
I67
sg13
g5205
sg14
I19
sg15
VC0152013
p5212
sg17
I2
sasg18
(lp5213
(dp5214
g12
I31
sg13
VS100A10
p5215
sg14
I7
sg22
VP60903
p5216
sg17
I1
sa(dp5217
g12
I31
sg13
g5204
sg14
I7
sg22
VP60903
p5218
sg17
I1
sasa(dp5219
g2
VUsing mass spectrometry for protein identification and validating the results by immunohistochemistry on an independent validation set, we could identify two of 60 differentially expressed m/z species between Barrett's adenocarcinoma and the precursor lesion: COX7A2 and S100-A10.
p5220
sg4
(dp5221
(VS100
p5222
VBarrett's adenocarcinoma
p5223
tp5224
I00
ssg9
(lp5225
(dp5226
g12
I209
sg13
g5223
sg14
I24
sg15
VC1332460
p5227
sg17
I2
sasg18
(lp5228
(dp5229
g12
I260
sg13
VCOX7A2
p5230
sg14
I6
sg22
VP14406
p5231
sg17
I1
sa(dp5232
g12
I271
sg13
g5222
sg14
I4
sg22
VP04271
p5233
sg17
I1
sasa(dp5234
g2
VIn the validation set, we found a correlation of the expression levels of COX7A2 and TAGLN2 with a poor prognosis while S100-A10 was confirmed by multivariate analysis as a novel independent prognostic factor in Barrett's adenocarcinoma.
p5235
sg4
(dp5236
(VTAGLN2
p5237
VBarrett's adenocarcinoma
p5238
tp5239
I00
ssg9
(lp5240
(dp5241
g12
I212
sg13
g5238
sg14
I24
sg15
VC1332460
p5242
sg17
I2
sasg18
(lp5243
(dp5244
g12
I74
sg13
VCOX7A2
p5245
sg14
I6
sg22
VP14406
p5246
sg17
I1
sa(dp5247
g12
I85
sg13
g5237
sg14
I6
sg22
VP37802
p5248
sg17
I1
sasa(dp5249
g2
VS100A10, a member of the S100 family, forms a heterotetramer with annexin IIH and promotes carcinoma invasion and metastasis by plasminogen activation.
p5250
sg4
(dp5251
(Vplasminogen
p5252
Vmetastasis
p5253
tp5254
I00
ssg9
(lp5255
(dp5256
g12
I101
sg13
Vinvasion
p5257
sg14
I8
sg15
VC2699153
p5258
sg17
I1
sa(dp5259
g12
I114
sg13
g5253
sg14
I10
sg15
VC0027627
p5260
sg17
I1
sa(dp5261
g12
I91
sg13
Vcarcinoma
p5262
sg14
I9
sg15
VC0007097
p5263
sg17
I1
sasg18
(lp5264
(dp5265
g12
I25
sg13
VS100 family
p5266
sg14
I11
sg22
VP04271
p5267
sg17
I2
sa(dp5268
g12
I0
sg13
VS100A10
p5269
sg14
I7
sg22
VP60903
p5270
sg17
I1
sa(dp5271
g12
I128
sg13
g5252
sg14
I11
sg22
VP00747
p5272
sg17
I1
sasa(dp5273
g2
VS100A10 and annexin II were expressed in all papillary carcinomas, but 88.2% and 82.8% ofpapillary carcinomas were classified in the low group.
p5274
sg4
(dp5275
(VS100A10
p5276
Vpapillary carcinomas
p5277
tp5278
I01
ssg9
(lp5279
(dp5280
g12
I45
sg13
g5277
sg14
I20
sg15
VC0007133
p5281
sg17
I2
sa(dp5282
g12
I55
sg13
Vcarcinomas
p5283
sg14
I10
sg15
VC0007097
p5284
sg17
I1
sasg18
(lp5285
(dp5286
g12
I12
sg13
Vannexin II
p5287
sg14
I10
sg22
VP07355
p5288
sg17
I2
sa(dp5289
g12
I0
sg13
g5276
sg14
I7
sg22
VP60903
p5290
sg17
I1
sasa(dp5291
g2
VThese findings suggest that S100A10 and annexin II contribute to the aggressive characteristics of anaplastic carcinoma, while playing a constitutive role in papillary carcinoma.
p5292
sg4
(dp5293
(VS100A10
p5294
Vpapillary carcinoma
p5295
tp5296
I01
ssg9
(lp5297
(dp5298
g12
I69
sg13
Vaggressive
p5299
sg14
I10
sg15
VC0001807
p5300
sg17
I1
sa(dp5301
g12
I99
sg13
Vanaplastic carcinoma
p5302
sg14
I20
sg15
VC0205698
p5303
sg17
I2
sa(dp5304
g12
I158
sg13
g5295
sg14
I19
sg15
VC0007133
p5305
sg17
I2
sasg18
(lp5306
(dp5307
g12
I40
sg13
Vannexin II
p5308
sg14
I10
sg22
VP07355
p5309
sg17
I2
sa(dp5310
g12
I28
sg13
g5294
sg14
I7
sg22
VP60903
p5311
sg17
I1
sasa(dp5312
g2
VRemote parenchymal hemorrhage (rPH) after intravenous thrombolysis with recombinant tissue-type plasminogen activator may be associated with cerebral amyloid angiopathy, although supportive data are limited.
p5313
sg4
(dp5314
(Vtissue-type plasminogen activator
p5315
Vcerebral amyloid angiopathy
p5316
tp5317
I00
ssg9
(lp5318
(dp5319
g12
I141
sg13
g5316
sg14
I27
sg15
VC0085220
p5320
sg17
I3
sa(dp5321
g12
I7
sg13
Vparenchymal hemorrhage
p5322
sg14
I22
sg15
VC0747264
p5323
sg17
I2
sasg18
(lp5324
(dp5325
g12
I84
sg13
g5315
sg14
I33
sg22
VP00747
p5326
sg17
I3
sasa(dp5327
g2
VWe here review the data with respect to the activation of tPA by fibrin and its multiple other cofactors, in relation to tPA's role in pathophysiology, notably fibrinolysis and amyloidosis, with emphasis on Alzheimer's disease.
p5328
sg4
(dp5329
(Vfibrin
p5330
Vamyloidosis
p5331
tp5332
I00
ssg9
(lp5333
(dp5334
g12
I177
sg13
g5331
sg14
I11
sg15
VC0002726
p5335
sg17
I1
sa(dp5336
g12
I207
sg13
VAlzheimer's disease
p5337
sg14
I19
sg15
VC1521724
p5338
sg17
I2
sasg18
(lp5339
(dp5340
g12
I65
sg13
g5330
sg14
I6
sg22
VP22087
p5341
sg17
I1
sasa(dp5342
g2
VCerebral amyloid angiopathy (CAA) may be an important predisposing factor for the hemorrhagic complications of recombinant tissue-type plasminogen activator (rt-PA) therapy.
p5343
sg4
(dp5344
(Vrecombinant tissue-type plasminogen activator
p5345
VCerebral amyloid angiopathy
p5346
tp5347
I00
ssg9
(lp5348
(dp5349
g12
I29
sg13
VCAA
p5350
sg14
I3
sg15
VC1842937
p5351
sg17
I1
sa(dp5352
g12
I0
sg13
g5346
sg14
I27
sg15
VC0085220
p5353
sg17
I3
sasg18
(lp5354
(dp5355
g12
I158
sg13
Vrt-PA
p5356
sg14
I5
sg22
VP00747
p5357
sg17
I1
sa(dp5358
g12
I111
sg13
g5345
sg14
I45
sg22
VP00747
p5359
sg17
I4
sasa(dp5360
g2
VThe purpose of this study was to investigate the potential of intranasal immunization with non-ionic surfactant vesicles (NISV) containing either the secretory recombinant form of glycoprotein B (gBs) of herpes simplex virus type 1 or a related polylysine reach peptides (DTK) for induction of protective immunity against genital herpes infection in mice.
p5361
sg4
(dp5362
(Vglycoprotein B
p5363
Vherpes simplex
p5364
tp5365
I00
ssg9
(lp5366
(dp5367
g12
I196
sg13
VgBs
p5368
sg14
I3
sg15
VC1841700
p5369
sg17
I1
sa(dp5370
g12
I112
sg13
Vvesicles
p5371
sg14
I8
sg15
VC0333262
p5372
sg17
I1
sa(dp5373
g12
I330
sg13
Vherpes infection
p5374
sg14
I16
sg15
VC0019372
p5375
sg17
I2
sa(dp5376
g12
I204
sg13
g5364
sg14
I14
sg15
VC0019348
p5377
sg17
I2
sasg18
(lp5378
(dp5379
g12
I180
sg13
g5363
sg14
I14
sg22
VP36222
p5380
sg17
I2
sa(dp5381
g12
I196
sg13
VgBs
p5382
sg14
I3
sg22
g190
sg17
I1
sasa(dp5383
g2
VSeventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules.
p5384
sg4
(dp5385
(VCDK
p5386
Vrunt
p5387
tp5388
I00
ssg9
(lp5389
(dp5390
g12
I152
sg13
Vsarcoma
p5391
sg14
I7
sg15
VC1261473
p5392
sg17
I1
sa(dp5393
g12
I362
sg13
g5387
sg14
I4
sg15
VC0013336
p5394
sg17
I1
sasg18
(lp5395
(dp5396
g12
I57
sg13
VT-cell-specific transcription factor
p5397
sg14
I36
sg22
VP35398
p5398
sg17
I3
sa(dp5399
g12
I276
sg13
Vvitamin D receptor
p5400
sg14
I18
sg22
VP11473
p5401
sg17
I3
sa(dp5402
g12
I109
sg13
V"proto-oncogene tyrosine-protein kinase
p5403
sg14
I39
sg22
VP00519
p5404
sg17
I3
sa(dp5405
g12
I399
sg13
VPR domain zinc finger protein 1
p5406
sg14
I31
sg22
g190
sg17
I6
sa(dp5407
g12
I322
sg13
VERK
p5408
sg14
I3
sg22
VP29323
p5409
sg17
I1
sa(dp5410
g12
I362
sg13
Vrunt-related transcription factor 1
p5411
sg14
I35
sg22
VP20823
p5412
sg17
I4
sa(dp5413
g12
I477
sg13
Vinterleukin 1
p5414
sg14
I13
sg22
VP01584
p5415
sg17
I2
sa(dp5416
g12
I152
sg13
Vsarcoma"
p5417
sg14
I8
sg22
VP12931
p5418
sg17
I1
sa(dp5419
g12
I163
sg13
Vinterferon regulatory factor 1
p5420
sg14
I30
sg22
VP10914
p5421
sg17
I4
sa(dp5422
g12
I227
sg13
Vcyclin-dependent kinase (CDK) 4
p5423
sg14
I31
sg22
VP49336
p5424
sg17
I4
sa(dp5425
g12
I296
sg13
Vhistone deacetylase
p5426
sg14
I19
sg22
VP56524
p5427
sg17
I2
sa(dp5428
g12
I95
sg13
VSrc
p5429
sg14
I3
sg22
VP12931
p5430
sg17
I1
sa(dp5431
g12
I217
sg13
Vcyclin B
p5432
sg14
I8
sg22
VP14635
p5433
sg17
I2
sa(dp5434
g12
I334
sg13
Vbcl-2-associated X protein
p5435
sg14
I26
sg22
VP10415
p5436
sg17
I3
sa(dp5437
g12
I317
sg13
VMAPK
p5438
sg14
I4
sg22
VP53779
p5439
sg17
I1
sa(dp5440
g12
I432
sg13
Vplatelet-derived growth factor receptor
p5441
sg14
I39
sg22
VP09619
p5442
sg17
I4
sa(dp5443
g12
I265
sg13
Vcaspase-1
p5444
sg14
I9
sg22
VP29466
p5445
sg17
I1
sa(dp5446
g12
I195
sg13
Vthymidylate synthase
p5447
sg14
I20
sg22
VP04818
p5448
sg17
I2
sa(dp5449
g12
I252
sg13
g5386
sg14
I3
sg22
VP24941
p5450
sg17
I1
sasa(dp5451
g2
VHowever, the clinical significance and biological function of IRF1 in cholangiocarcinoma is poorly understood.
p5452
sg4
(dp5453
(VIRF1
p5454
Vcholangiocarcinoma
p5455
tp5456
I00
ssg9
(lp5457
(dp5458
g12
I70
sg13
g5455
sg14
I18
sg15
VC0206698
p5459
sg17
I1
sasg18
(lp5460
(dp5461
g12
I62
sg13
g5454
sg14
I4
sg22
VP10914
p5462
sg17
I1
sasa(dp5463
g2
VIn our results, IRF1 mRNA and protein expressions were decreased in cholangiocarcinoma tissues and cell lines compared with paired normal hepatic tissues and intrahepatic bile duct epithelial cell line.
p5464
sg4
(dp5465
(VIRF1 mRNA
p5466
Vcholangiocarcinoma
p5467
tp5468
I00
ssg9
(lp5469
(dp5470
g12
I68
sg13
g5467
sg14
I18
sg15
VC0206698
p5471
sg17
I1
sasg18
(lp5472
(dp5473
g12
I16
sg13
g5466
sg14
I9
sg22
VP10914
p5474
sg17
I2
sasa(dp5475
g2
VIRF1 protein low-expression was associated with tumor stage, tumor size, vascular invasion and metastasis and served as a poor independent prognostic parameter in cholangiocarcinoma patients.
p5476
sg4
(dp5477
(VIRF1
p5478
Vcholangiocarcinoma
p5479
tp5480
I00
ssg9
(lp5481
(dp5482
g12
I95
sg13
Vmetastasis
p5483
sg14
I10
sg15
VC0027627
p5484
sg17
I1
sa(dp5485
g12
I163
sg13
g5479
sg14
I18
sg15
VC0206698
p5486
sg17
I1
sa(dp5487
g12
I48
sg13
Vtumor
p5488
sg14
I5
sg15
VC0027651
p5489
sg17
I1
sa(dp5490
g12
I82
sg13
Vinvasion
p5491
sg14
I8
sg15
VC2699153
p5492
sg17
I1
sa(dp5493
g12
I48
sg13
Vtumor
p5494
sg14
I5
sg15
VC0027651
p5495
sg17
I1
sasg18
(lp5496
(dp5497
g12
I0
sg13
g5478
sg14
I4
sg22
VP10914
p5498
sg17
I1
sasa(dp5499
g2
VUp-regulation of IRF1 expression suppressed cholangiocarcinoma cells proliferation, migration and invasion, and blocked cell cycle progression, but has no effect on apoptosis.
p5500
sg4
(dp5501
(VIRF1
p5502
Vcholangiocarcinoma
p5503
tp5504
I00
ssg9
(lp5505
(dp5506
g12
I44
sg13
g5503
sg14
I18
sg15
VC0206698
p5507
sg17
I1
sa(dp5508
g12
I69
sg13
Vproliferation
p5509
sg14
I13
sg15
VC0334094
p5510
sg17
I1
sa(dp5511
g12
I98
sg13
Vinvasion
p5512
sg14
I8
sg15
VC2699153
p5513
sg17
I1
sasg18
(lp5514
(dp5515
g12
I17
sg13
g5502
sg14
I4
sg22
VP10914
p5516
sg17
I1
sasa(dp5517
g2
VIn conclusion, IRF1 is low-expressed in cholangiocarcinoma tissues and cell lines, and correlated with malignant status and prognosis in cholangiocarcinoma patients.
p5518
sg4
(dp5519
(VIRF1
p5520
Vcholangiocarcinoma
p5521
tp5522
I00
ssg9
(lp5523
(dp5524
g12
I40
sg13
Vcholangiocarcinoma
p5525
sg14
I18
sg15
VC0206698
p5526
sg17
I1
sa(dp5527
g12
I40
sg13
g5521
sg14
I18
sg15
VC0206698
p5528
sg17
I1
sasg18
(lp5529
(dp5530
g12
I15
sg13
g5520
sg14
I4
sg22
VP10914
p5531
sg17
I1
sasa(dp5532
g2
VIRF1 served as tumor suppressor in the regulation of cholangiocarcinoma cells proliferation, cell cycle, migration and invasion.
p5533
sg4
(dp5534
(VIRF1
p5535
Vcholangiocarcinoma
p5536
tp5537
I00
ssg9
(lp5538
(dp5539
g12
I119
sg13
Vinvasion
p5540
sg14
I8
sg15
VC2699153
p5541
sg17
I1
sa(dp5542
g12
I15
sg13
Vtumor
p5543
sg14
I5
sg15
VC0027651
p5544
sg17
I1
sa(dp5545
g12
I53
sg13
g5536
sg14
I18
sg15
VC0206698
p5546
sg17
I1
sa(dp5547
g12
I78
sg13
Vproliferation
p5548
sg14
I13
sg15
VC0334094
p5549
sg17
I1
sasg18
(lp5550
(dp5551
g12
I0
sg13
g5535
sg14
I4
sg22
VP10914
p5552
sg17
I1
sasa(dp5553
g2
VTo examine genetic defects of the IFNGamma-IRF1 pathway in non-small cell lung cancer (NSCLC), we analyzed The Cancer Genome Atlas (TCGA) lung adenocarcinoma (LuAd) and lung squamous cell carcinoma (LuSc) data.
p5554
sg4
(dp5555
(VIRF1
p5556
VLuAd
p5557
tp5558
I00
ssg9
(lp5559
(dp5560
g12
I111
sg13
VCancer
p5561
sg14
I6
sg15
VC0006826
p5562
sg17
I1
sa(dp5563
g12
I59
sg13
Vnon-small cell lung cancer
p5564
sg14
I26
sg15
VC0007131
p5565
sg17
I4
sa(dp5566
g12
I169
sg13
Vlung squamous cell carcinoma
p5567
sg14
I28
sg15
VC0149782
p5568
sg17
I4
sa(dp5569
g12
I199
sg13
VLuSc
p5570
sg14
I4
sg15
VC0149782
p5571
sg17
I1
sa(dp5572
g12
I138
sg13
Vlung adenocarcinoma
p5573
sg14
I19
sg15
VC0152013
p5574
sg17
I2
sa(dp5575
g12
I87
sg13
VNSCLC
p5576
sg14
I5
sg15
VC0007131
p5577
sg17
I1
sa(dp5578
g12
I159
sg13
g5557
sg14
I4
sg15
VC0152013
p5579
sg17
I1
sasg18
(lp5580
(dp5581
g12
I43
sg13
g5556
sg14
I4
sg22
VP10914
p5582
sg17
I1
sasa(dp5583
g2
VIRF1 expression was correlated with immune cytolytic activity markers GZMA and PRF1 in NSCLC.
p5584
sg4
(dp5585
(VIRF1
p5586
VNSCLC
p5587
tp5588
I00
ssg9
(lp5589
(dp5590
g12
I87
sg13
g5587
sg14
I5
sg15
VC0007131
p5591
sg17
I1
sasg18
(lp5592
(dp5593
g12
I79
sg13
VPRF1
p5594
sg14
I4
sg22
VP14222
p5595
sg17
I1
sa(dp5596
g12
I70
sg13
VGZMA
p5597
sg14
I4
sg22
VP12544
p5598
sg17
I1
sa(dp5599
g12
I0
sg13
g5586
sg14
I4
sg22
VP10914
p5600
sg17
I1
sasa(dp5601
g2
VDeletion of JAK2 or inhibition of the JAK2 kinase activity resulted in loss of IFNGamma-induced IRF1 and cell surface HLA-ABC in JAK2 wildtype NSCLC cells, whereas expression of exogenous JAK2 in H1573 cells restored the IFNGamma responses.
p5602
sg4
(dp5603
(VIRF1
p5604
VNSCLC
p5605
tp5606
I00
ssg9
(lp5607
(dp5608
g12
I143
sg13
g5605
sg14
I5
sg15
VC0007131
p5609
sg17
I1
sasg18
(lp5610
(dp5611
g12
I12
sg13
VJAK2
p5612
sg14
I4
sg22
g190
sg17
I1
sa(dp5613
g12
I96
sg13
g5604
sg14
I4
sg22
VP10914
p5614
sg17
I1
sa(dp5615
g12
I12
sg13
VJAK2
p5616
sg14
I4
sg22
g190
sg17
I1
sa(dp5617
g12
I118
sg13
VHLA-ABC
p5618
sg14
I7
sg22
VP30486
p5619
sg17
I1
sa(dp5620
g12
I12
sg13
VJAK2
p5621
sg14
I4
sg22
g190
sg17
I1
sa(dp5622
g12
I38
sg13
VJAK2 kinase
p5623
sg14
I11
sg22
g190
sg17
I2
sasa(dp5624
g2
VThese findings show that JAK2 deficiency is the major mechanism of genetic defects of the IFNGamma-IRF1 pathway in NSCLC and reveal a previously unrecognized significance of chromosome 9p deletion in NSCLC.
p5625
sg4
(dp5626
(VIFNGamma-IRF1
p5627
VNSCLC
p5628
tp5629
I00
ssg9
(lp5630
(dp5631
g12
I115
sg13
VNSCLC
p5632
sg14
I5
sg15
VC0007131
p5633
sg17
I1
sa(dp5634
g12
I115
sg13
g5628
sg14
I5
sg15
VC0007131
p5635
sg17
I1
sasg18
(lp5636
(dp5637
g12
I25
sg13
VJAK2
p5638
sg14
I4
sg22
g190
sg17
I1
sa(dp5639
g12
I90
sg13
g5627
sg14
I13
sg22
VP10914
p5640
sg17
I1
sasa(dp5641
g2
VPerformance of the investigational use only-labeled GeneXpert(R) (Cepheid, Sunnyvale, CA) Bladder Cancer Assay, an assay for detection of the five mRNAs (ABL1, CRH, IGF2, ANXA10, and UPK1B), was evaluated in an independent test cohort (n=450).
p5642
sg4
(dp5643
(VABL1
p5644
VBladder Cancer
p5645
tp5646
I00
ssg9
(lp5647
(dp5648
g12
I90
sg13
g5645
sg14
I14
sg15
VC0699885
p5649
sg17
I2
sasg18
(lp5650
(dp5651
g12
I171
sg13
VANXA10
p5652
sg14
I6
sg22
g190
sg17
I1
sa(dp5653
g12
I160
sg13
VCRH
p5654
sg14
I3
sg22
VP06850
p5655
sg17
I1
sa(dp5656
g12
I165
sg13
VIGF2
p5657
sg14
I4
sg22
VP01344
p5658
sg17
I1
sa(dp5659
g12
I183
sg13
VUPK1B
p5660
sg14
I5
sg22
g190
sg17
I1
sa(dp5661
g12
I154
sg13
g5644
sg14
I4
sg22
VP00519
p5662
sg17
I1
sasa(dp5663
g2
VOur previous mass spectrometry-based proteomics study revealed that annexin A10 (ANXA10) was uniquely overexpressed in pancreatic CD24+ adenocarcinoma cells that were dissected from clinical PDAC tissues but was absent in CD24- adjacent normal cells.
p5664
sg4
(dp5665
(VCD24
p5666
Vadenocarcinoma
p5667
tp5668
I00
ssg9
(lp5669
(dp5670
g12
I136
sg13
g5667
sg14
I14
sg15
VC0001418
p5671
sg17
I1
sasg18
(lp5672
(dp5673
g12
I81
sg13
VANXA10
p5674
sg14
I6
sg22
g190
sg17
I1
sa(dp5675
g12
I68
sg13
Vannexin A10
p5676
sg14
I11
sg22
g190
sg17
I2
sa(dp5677
g12
I130
sg13
g5666
sg14
I4
sg22
VP25063
p5678
sg17
I1
sasa(dp5679
g2
VNext, we found that up-regulation of ANXA10 in PC-3 resulted in down-regulation of S100 calcium binding protein A4 (S100A4), which is reportedly correlated with aggressiveness and a worse prognosis for patients with different types of carcinomas.
p5680
sg4
(dp5681
(VS100 calcium binding protein A4
p5682
Vaggressiveness
p5683
tp5684
I00
ssg9
(lp5685
(dp5686
g12
I235
sg13
Vcarcinomas
p5687
sg14
I10
sg15
VC0007097
p5688
sg17
I1
sa(dp5689
g12
I161
sg13
g5683
sg14
I14
sg15
VC0001807
p5690
sg17
I1
sasg18
(lp5691
(dp5692
g12
I116
sg13
VS100A4
p5693
sg14
I6
sg22
VP26447
p5694
sg17
I1
sa(dp5695
g12
I83
sg13
g5682
sg14
I31
sg22
VP26447
p5696
sg17
I5
sa(dp5697
g12
I47
sg13
VPC-3
p5698
sg14
I4
sg22
g190
sg17
I1
sa(dp5699
g12
I37
sg13
VANXA10
p5700
sg14
I6
sg22
g190
sg17
I1
sasa(dp5701
g2
VImmunohistochemistry for 7 gastric-type markers (ANXA10, VSIG1, CLDN18, CTSE, TFF2, MUC5AC, and MUC6) and 2 intestinal-type markers (CDX2 and CK20) was performed in 36 normal gastric/colorectal mucosa tissues, 163 colorectal polyps, and 175 microsatellite-unstable colorectal carcinomas (MSI-H CRCs).
p5702
sg4
(dp5703
(VCTSE
p5704
VMSI
p5705
tp5706
I00
ssg9
(lp5707
(dp5708
g12
I265
sg13
Vcolorectal carcinomas
p5709
sg14
I21
sg15
VC0009402
p5710
sg17
I2
sa(dp5711
g12
I214
sg13
Vcolorectal polyps
p5712
sg14
I17
sg15
VC0949059
p5713
sg17
I2
sa(dp5714
g12
I288
sg13
g5705
sg14
I3
sg15
VC0920269
p5715
sg17
I1
sasg18
(lp5716
(dp5717
g12
I133
sg13
VCDX2
p5718
sg14
I4
sg22
g190
sg17
I1
sa(dp5719
g12
I57
sg13
VVSIG1
p5720
sg14
I5
sg22
g190
sg17
I1
sa(dp5721
g12
I64
sg13
VCLDN18
p5722
sg14
I6
sg22
VP56856
p5723
sg17
I1
sa(dp5724
g12
I142
sg13
VCK20
p5725
sg14
I4
sg22
VP35900
p5726
sg17
I1
sa(dp5727
g12
I78
sg13
VTFF2
p5728
sg14
I4
sg22
g190
sg17
I1
sa(dp5729
g12
I72
sg13
g5704
sg14
I4
sg22
VP14091
p5730
sg17
I1
sa(dp5731
g12
I96
sg13
VMUC6
p5732
sg14
I4
sg22
g190
sg17
I1
sa(dp5733
g12
I49
sg13
VANXA10
p5734
sg14
I6
sg22
g190
sg17
I1
sasa(dp5735
g2
VTwo decades ago, Galectin-8 was described as a prostate carcinoma biomarker since it is only expressed in the neoplastic prostate, but not in the healthy tissue.
p5736
sg4
(dp5737
(VGalectin-8
p5738
Vprostate carcinoma
p5739
tp5740
I00
ssg9
(lp5741
(dp5742
g12
I47
sg13
g5739
sg14
I18
sg15
VC0600139
p5743
sg17
I2
sasg18
(lp5744
(dp5745
g12
I17
sg13
g5738
sg14
I10
sg22
VP09382
p5746
sg17
I1
sasa(dp5747
g2
VIn this study we silenced Galectin-8 in two human prostate cancer cell lines, PC3 and IGR-CaP1, and designed a pre-clinical experimental model that allows monitoring the pathology from its early steps to the long-term metastatic stages.
p5748
sg4
(dp5749
(VPC3
p5750
Vprostate cancer
p5751
tp5752
I00
ssg9
(lp5753
(dp5754
g12
I170
sg13
Vpathology
p5755
sg14
I9
sg15
VC0677042
p5756
sg17
I1
sa(dp5757
g12
I50
sg13
g5751
sg14
I15
sg15
VC0600139
p5758
sg17
I2
sasg18
(lp5759
(dp5760
g12
I26
sg13
VGalectin-8
p5761
sg14
I10
sg22
VP09382
p5762
sg17
I1
sa(dp5763
g12
I78
sg13
g5750
sg14
I3
sg22
VP42025
p5764
sg17
I1
sa(dp5765
g12
I86
sg13
VIGR-CaP1
p5766
sg14
I8
sg22
g190
sg17
I1
sasa(dp5767
g2
VWe show for the first time that the natural and conserved expression of Gal-8 in tumour cells is responsible for the metastatic evolution of prostate cancer.
p5768
sg4
(dp5769
(VGal-8
p5770
Vprostate cancer
p5771
tp5772
I00
ssg9
(lp5773
(dp5774
g12
I81
sg13
Vtumour
p5775
sg14
I6
sg15
VC0027651
p5776
sg17
I1
sa(dp5777
g12
I141
sg13
g5771
sg14
I15
sg15
VC0600139
p5778
sg17
I2
sasg18
(lp5779
(dp5780
g12
I72
sg13
g5770
sg14
I5
sg22
VP16278
p5781
sg17
I1
sasa(dp5782
g2
VCollectively, our results highlight Galectin-8 as a potential target for anti-metastatic therapy against prostate cancer.
p5783
sg4
(dp5784
(VGalectin-8
p5785
Vprostate cancer
p5786
tp5787
I00
ssg9
(lp5788
(dp5789
g12
I105
sg13
g5786
sg14
I15
sg15
VC0600139
p5790
sg17
I2
sasg18
(lp5791
(dp5792
g12
I36
sg13
g5785
sg14
I10
sg22
VP09382
p5793
sg17
I1
sasa(dp5794
g2
VImmunocytochemistry for prostate carcinoma tumour antigen (PCTA-1) was performed for culture purity evaluation.
p5795
sg4
(dp5796
(Vprostate carcinoma tumour antigen
p5797
Vprostate carcinoma
p5798
tp5799
I00
ssg9
(lp5800
(dp5801
g12
I24
sg13
g5798
sg14
I18
sg15
VC0600139
p5802
sg17
I2
sa(dp5803
g12
I43
sg13
Vtumour
p5804
sg14
I6
sg15
VC0027651
p5805
sg17
I1
sasg18
(lp5806
(dp5807
g12
I24
sg13
g5797
sg14
I33
sg22
VP49221
p5808
sg17
I4
sasa(dp5809
g2
VGalectin-8 levels of expression positively correlate with certain human neoplasms, prostate cancer being the best example studied thus far.
p5810
sg4
(dp5811
(VGalectin-8
p5812
Vneoplasms, prostate
p5813
tp5814
I01
ssg9
(lp5815
(dp5816
g12
I72
sg13
g5813
sg14
I19
sg15
VC0033578
p5817
sg17
I2
sa(dp5818
g12
I92
sg13
Vcancer
p5819
sg14
I6
sg15
VC0006826
p5820
sg17
I1
sasg18
(lp5821
(dp5822
g12
I0
sg13
g5812
sg14
I10
sg22
VP09382
p5823
sg17
I1
sasa(dp5824
g2
VThe Prostate Carcinoma Tumor Antigen-1 (PCTA-1) is located at the prostate cancer susceptibility locus on chromosome 1q42.2-43 (PCaP).
p5825
sg4
(dp5826
(VCarcinoma Tumor Antigen-1
p5827
VPCaP
p5828
tp5829
I00
ssg9
(lp5830
(dp5831
g12
I66
sg13
Vprostate cancer susceptibility locus on chromosome 1q42.2-43
p5832
sg14
I60
sg15
VC1864472
p5833
sg17
I7
sa(dp5834
g12
I23
sg13
VTumor
p5835
sg14
I5
sg15
VC0027651
p5836
sg17
I1
sa(dp5837
g12
I4
sg13
VProstate Carcinoma
p5838
sg14
I18
sg15
VC0600139
p5839
sg17
I2
sa(dp5840
g12
I128
sg13
g5828
sg14
I4
sg15
VC1864472
p5841
sg17
I1
sasg18
(lp5842
(dp5843
g12
I13
sg13
g5827
sg14
I25
sg22
VP14209
p5844
sg17
I3
sa(dp5845
g12
I66
sg13
Vprostate cancer susceptibility
p5846
sg14
I30
sg22
g190
sg17
I3
sasa(dp5847
g2
VThe isolation of Prostate Carcinoma Tumor Antigen-1 (PCTA-1), a cDNA closely related to rat and human Galectin-8, as a surface marker associated with prostate cancer was achieved using a previously described immunological subtraction approach, Surface Epitope Masking (SEM) approach, in combination with expression screening.
p5848
sg4
(dp5849
(VGalectin-8
p5850
VSEM
p5851
tp5852
I00
ssg9
(lp5853
(dp5854
g12
I36
sg13
VTumor
p5855
sg14
I5
sg15
VC0027651
p5856
sg17
I1
sa(dp5857
g12
I150
sg13
Vprostate cancer
p5858
sg14
I15
sg15
VC0600139
p5859
sg17
I2
sa(dp5860
g12
I244
sg13
VSurface Epitope Masking
p5861
sg14
I23
sg15
VC0432222
p5862
sg17
I3
sa(dp5863
g12
I17
sg13
VProstate Carcinoma
p5864
sg14
I18
sg15
VC0600139
p5865
sg17
I2
sa(dp5866
g12
I269
sg13
g5851
sg14
I3
sg15
VC0432222
p5867
sg17
I1
sasg18
(lp5868
(dp5869
g12
I26
sg13
VCarcinoma Tumor Antigen-1
p5870
sg14
I25
sg22
VP14209
p5871
sg17
I3
sa(dp5872
g12
I102
sg13
g5850
sg14
I10
sg22
VP09382
p5873
sg17
I1
sasa(dp5874
g2
VScreening a human LNCaP prostate cancer cDNA expression library with the Pro 1.5 mAb identifies a gene, prostate carcinoma tumor antigen-1 (PCTA-1).
p5875
sg4
(dp5876
(VPCTA-1
p5877
Vprostate carcinoma
p5878
tp5879
I00
ssg9
(lp5880
(dp5881
g12
I24
sg13
Vprostate cancer
p5882
sg14
I15
sg15
VC0600139
p5883
sg17
I2
sa(dp5884
g12
I123
sg13
Vtumor
p5885
sg14
I5
sg15
VC0027651
p5886
sg17
I1
sa(dp5887
g12
I104
sg13
g5878
sg14
I18
sg15
VC0600139
p5888
sg17
I2
sasg18
(lp5889
(dp5890
g12
I73
sg13
VPro 1.5 mAb
p5891
sg14
I11
sg22
VP63125
p5892
sg17
I3
sa(dp5893
g12
I104
sg13
Vprostate carcinoma tumor antigen-1
p5894
sg14
I34
sg22
VP49221
p5895
sg17
I4
sa(dp5896
g12
I140
sg13
g5877
sg14
I6
sg22
VP49221
p5897
sg17
I1
sasa(dp5898
g2
VMoreover, Foxp3 could interact with LMO2 and affect the expression level of TAL1, which was in accordance with the findings in T-cell acute lymphoblastic leukemia.
p5899
sg4
(dp5900
(VLMO2
p5901
VT-cell acute lymphoblastic leukemia
p5902
tp5903
I00
ssg9
(lp5904
(dp5905
g12
I127
sg13
g5902
sg14
I35
sg15
VC1961099
p5906
sg17
I4
sasg18
(lp5907
(dp5908
g12
I76
sg13
VTAL1
p5909
sg14
I4
sg22
VP17542
p5910
sg17
I1
sa(dp5911
g12
I36
sg13
g5901
sg14
I4
sg22
VP25791
p5912
sg17
I1
sa(dp5913
g12
I10
sg13
VFoxp3
p5914
sg14
I5
sg22
g190
sg17
I1
sasa(dp5915
g2
VOverexpression of LMO2 is known to be one of the causes of T-cell acute lymphoblastic leukemia (T-ALL) development; however, the mechanisms behind its oncogenic activity are incompletely understood.
p5916
sg4
(dp5917
(VLMO2
p5918
VT-cell acute lymphoblastic leukemia
p5919
tp5920
I00
ssg9
(lp5921
(dp5922
g12
I96
sg13
VT-ALL
p5923
sg14
I5
sg15
VC1961099
p5924
sg17
I1
sa(dp5925
g12
I59
sg13
g5919
sg14
I35
sg15
VC1961099
p5926
sg17
I4
sasg18
(lp5927
(dp5928
g12
I18
sg13
g5918
sg14
I4
sg22
VP25791
p5929
sg17
I1
sasa(dp5930
g2
VExpression of LMO2 has been evaluated in B-cell lymphoma, T-cell acute lymphoblastic leukemia and acute myeloid leukemia; however, information concerning its role in breakpoint cluster region/Abelson murine leukemia viral oncogene homolog 1 (BCR/ABL) negative B-cell acute lymphoblastic leukemia (B-ALL) remains limited.
p5931
sg4
(dp5932
(Vleukemia viral oncogene homolog 1
p5933
VT-cell acute lymphoblastic leukemia
p5934
tp5935
I00
ssg9
(lp5936
(dp5937
g12
I98
sg13
Vacute myeloid leukemia
p5938
sg14
I22
sg15
VC0023467
p5939
sg17
I3
sa(dp5940
g12
I85
sg13
Vleukemia
p5941
sg14
I8
sg15
VC0023418
p5942
sg17
I1
sa(dp5943
g12
I246
sg13
VABL
p5944
sg14
I3
sg15
VC0000744
p5945
sg17
I1
sa(dp5946
g12
I297
sg13
VB-ALL
p5947
sg14
I5
sg15
VC0006413
p5948
sg17
I1
sa(dp5949
g12
I260
sg13
VB-cell acute lymphoblastic leukemia
p5950
sg14
I35
sg15
VC1292769
p5951
sg17
I4
sa(dp5952
g12
I58
sg13
g5934
sg14
I35
sg15
VC1961099
p5953
sg17
I4
sasg18
(lp5954
(dp5955
g12
I14
sg13
VLMO2
p5956
sg14
I4
sg22
VP25791
p5957
sg17
I1
sa(dp5958
g12
I246
sg13
VABL
p5959
sg14
I3
sg22
VP55157
p5960
sg17
I1
sa(dp5961
g12
I242
sg13
VBCR
p5962
sg14
I3
sg22
VP11274
p5963
sg17
I1
sa(dp5964
g12
I207
sg13
g5933
sg14
I33
sg22
VP35125
p5965
sg17
I5
sasa(dp5966
g2
VOncogenic transcription factors are commonly activated in acute leukemias and subvert normal gene expression networks to reprogram hematopoietic progenitors into preleukemic stem cells, as exemplified by LIM-only 2 (LMO2) in T-cell acute lymphoblastic leukemia (T-ALL).
p5967
sg4
(dp5968
(VLMO2
p5969
VT-cell acute lymphoblastic leukemia
p5970
tp5971
I00
ssg9
(lp5972
(dp5973
g12
I58
sg13
Vacute leukemias
p5974
sg14
I15
sg15
VC0085669
p5975
sg17
I2
sa(dp5976
g12
I262
sg13
VT-ALL
p5977
sg14
I5
sg15
VC1961099
p5978
sg17
I1
sa(dp5979
g12
I225
sg13
g5970
sg14
I35
sg15
VC1961099
p5980
sg17
I4
sasg18
(lp5981
(dp5982
g12
I216
sg13
g5969
sg14
I4
sg22
VP25791
p5983
sg17
I1
sa(dp5984
g12
I204
sg13
VLIM-only 2
p5985
sg14
I10
sg22
g190
sg17
I2
sasa(dp5986
g2
VT-cell acute lymphoblastic leukemia (T-ALL) frequently involves aberrant expression of TAL1 (T-cell acute lymphocytic leukemia 1) and LMO2, oncogenic members of the TAL1 transcriptional complex.
p5987
sg4
(dp5988
(VTAL1 transcriptional complex
p5989
VT-cell acute lymphocytic leukemia
p5990
tp5991
I00
ssg9
(lp5992
(dp5993
g12
I0
sg13
VT-cell acute lymphoblastic leukemia
p5994
sg14
I35
sg15
VC1961099
p5995
sg17
I4
sa(dp5996
g12
I37
sg13
VT-ALL
p5997
sg14
I5
sg15
VC1961099
p5998
sg17
I1
sa(dp5999
g12
I93
sg13
g5990
sg14
I33
sg15
VC1961099
p6000
sg17
I4
sasg18
(lp6001
(dp6002
g12
I93
sg13
VT-cell acute lymphocytic leukemia 1
p6003
sg14
I35
sg22
VP17542
p6004
sg17
I5
sa(dp6005
g12
I134
sg13
VLMO2
p6006
sg14
I4
sg22
VP25791
p6007
sg17
I1
sa(dp6008
g12
I0
sg13
VT-cell acute
p6009
sg14
I12
sg22
g190
sg17
I2
sa(dp6010
g12
I87
sg13
VTAL1
p6011
sg14
I4
sg22
VP17542
p6012
sg17
I1
sa(dp6013
g12
I165
sg13
g5989
sg14
I28
sg22
VP17542
p6014
sg17
I3
sasa(dp6015
g2
VLmo2 is an oncogenic transcription factor that is frequently overexpressed in T-cell acute leukemias, in particular poor prognosis early T-cell precursor-like (ETP-) acute lymphoblastic leukemia (ALL).
p6016
sg4
(dp6017
(VLmo2
p6018
Vacute lymphoblastic leukemia
p6019
tp6020
I00
ssg9
(lp6021
(dp6022
g12
I85
sg13
Vacute leukemias
p6023
sg14
I15
sg15
VC0085669
p6024
sg17
I2
sa(dp6025
g12
I196
sg13
VALL
p6026
sg14
I3
sg15
VC1961102
p6027
sg17
I1
sa(dp6028
g12
I166
sg13
g6019
sg14
I28
sg15
VC1961102
p6029
sg17
I3
sasg18
(lp6030
(dp6031
g12
I160
sg13
VETP
p6032
sg14
I3
sg22
g190
sg17
I1
sa(dp6033
g12
I137
sg13
VT-cell precursor-like
p6034
sg14
I21
sg22
VP01275
p6035
sg17
I2
sa(dp6036
g12
I0
sg13
g6018
sg14
I4
sg22
VP25791
p6037
sg17
I1
sasa(dp6038
g2
VThe following associations were found: auto-immune thyroid disease (4.3% of DH patients and 6.0% of CD patients), insulin dependent diabetes (1.0% DH and 5.5% CD), lupus erythematosus (1.3% DH and 0.3% CD), Sjoegren's syndrome (1.0% DH and 2.9% CD), sarcoidosis (1.3% DH and 1.8% CD), and vitiligo or alopecia areata (1.6% DH and 0% CD).
p6039
sg4
(dp6040
(Vinsulin
p6041
Vvitiligo
p6042
tp6043
I00
ssg9
(lp6044
(dp6045
g12
I51
sg13
Vthyroid disease
p6046
sg14
I15
sg15
VC0040128
p6047
sg17
I2
sa(dp6048
g12
I114
sg13
Vinsulin dependent diabetes
p6049
sg14
I26
sg15
VC0011854
p6050
sg17
I3
sa(dp6051
g12
I164
sg13
Vlupus erythematosus
p6052
sg14
I19
sg15
VC0409974
p6053
sg17
I2
sa(dp6054
g12
I250
sg13
Vsarcoidosis
p6055
sg14
I11
sg15
VC0036202
p6056
sg17
I1
sa(dp6057
g12
I301
sg13
Valopecia areata
p6058
sg14
I15
sg15
VC0002171
p6059
sg17
I2
sa(dp6060
g12
I207
sg13
VSjoegren's syndrome
p6061
sg14
I19
sg15
VC1527336
p6062
sg17
I2
sa(dp6063
g12
I289
sg13
g6042
sg14
I8
sg15
VC0042900
p6064
sg17
I1
sasg18
(lp6065
(dp6066
g12
I114
sg13
g6041
sg14
I7
sg22
VP01308
p6067
sg17
I1
sasa(dp6068
g2
VRarely, an association of parkinsonism with PN may be encountered in other neurodegenerative diseases such as fragile X-associated tremor and ataxia syndrome related to premutation CGG repeat expansion in the fragile X mental retardation (FMR1) gene, Machado-Joseph disease related to an abnormal CAG repeat expansion in ataxin-3 (ATXN3) gene, Kufor-Rakeb syndrome caused by mutations in ATP13A2 gene, or in hereditary systemic disorders such as Gaucher disease due to mutations in the Beta-glucocerebrosidase (GBA) gene and Chediak-Higashi syndrome due to LYST gene mutations.
p6069
sg4
(dp6070
(VBeta-glucocerebrosidase
p6071
VGaucher disease
p6072
tp6073
I00
ssg9
(lp6074
(dp6075
g12
I344
sg13
VKufor-Rakeb syndrome
p6076
sg14
I20
sg15
VC1847640
p6077
sg17
I2
sa(dp6078
g12
I75
sg13
Vneurodegenerative diseases
p6079
sg14
I26
sg15
VC0524851
p6080
sg17
I2
sa(dp6081
g12
I525
sg13
VChediak-Higashi syndrome
p6082
sg14
I24
sg15
VC0007965
p6083
sg17
I2
sa(dp6084
g12
I149
sg13
Vsyndrome
p6085
sg14
I8
sg15
VC0039082
p6086
sg17
I1
sa(dp6087
g12
I219
sg13
Vmental retardation
p6088
sg14
I18
sg15
VC0025362
p6089
sg17
I2
sa(dp6090
g12
I142
sg13
Vataxia
p6091
sg14
I6
sg15
VC0004134
p6092
sg17
I1
sa(dp6093
g12
I26
sg13
Vparkinsonism
p6094
sg14
I12
sg15
VC0242422
p6095
sg17
I1
sa(dp6096
g12
I131
sg13
Vtremor
p6097
sg14
I6
sg15
VC0040822
p6098
sg17
I1
sa(dp6099
g12
I251
sg13
VMachado-Joseph disease
p6100
sg14
I22
sg15
VC0024408
p6101
sg17
I2
sa(dp6102
g12
I446
sg13
g6072
sg14
I15
sg15
VC0017205
p6103
sg17
I2
sasg18
(lp6104
(dp6105
g12
I331
sg13
VATXN3
p6106
sg14
I5
sg22
g190
sg17
I1
sa(dp6107
g12
I511
sg13
VGBA
p6108
sg14
I3
sg22
VP04062
p6109
sg17
I1
sa(dp6110
g12
I486
sg13
g6071
sg14
I23
sg22
VP02774
p6111
sg17
I1
sa(dp6112
g12
I557
sg13
VLYST gene
p6113
sg14
I9
sg22
g190
sg17
I2
sa(dp6114
g12
I388
sg13
VATP13A2 gene
p6115
sg14
I12
sg22
g190
sg17
I2
sa(dp6116
g12
I321
sg13
Vataxin-3
p6117
sg14
I8
sg22
g190
sg17
I1
sasa(dp6118
g2
VThese are classified into ten different types (NDNC1-10), which are described in OMIM.1 The genes described for isolated nail disorders include PLCD1 (MIM 602142), RSPO4 (MIM 610573), FZD6 (MIM 603409), COL7A1 (MIM 120120), HPGD (MIM 601688) and SLCO2A1 (MIM 601460).
p6119
sg4
(dp6120
(VPLCD1
p6121
Vnail disorders
p6122
tp6123
I00
ssg9
(lp6124
(dp6125
g12
I121
sg13
g6122
sg14
I14
sg15
VC0027339
p6126
sg17
I2
sa(dp6127
g12
I47
sg13
VNDNC1
p6128
sg14
I5
sg15
VC0406443
p6129
sg17
I1
sasg18
(lp6130
(dp6131
g12
I151
sg13
VMIM 602142
p6132
sg14
I10
sg22
g190
sg17
I2
sa(dp6133
g12
I255
sg13
VMIM 601460
p6134
sg14
I10
sg22
g190
sg17
I2
sa(dp6135
g12
I203
sg13
VCOL7A1
p6136
sg14
I6
sg22
g190
sg17
I1
sa(dp6137
g12
I190
sg13
VMIM 603409
p6138
sg14
I10
sg22
g190
sg17
I2
sa(dp6139
g12
I184
sg13
VFZD6
p6140
sg14
I4
sg22
g190
sg17
I1
sa(dp6141
g12
I211
sg13
VMIM 120120
p6142
sg14
I10
sg22
g190
sg17
I2
sa(dp6143
g12
I144
sg13
g6121
sg14
I5
sg22
VP51178
p6144
sg17
I1
sa(dp6145
g12
I171
sg13
VMIM 610573
p6146
sg14
I10
sg22
g190
sg17
I2
sa(dp6147
g12
I164
sg13
VRSPO4
p6148
sg14
I5
sg22
g190
sg17
I1
sa(dp6149
g12
I246
sg13
VSLCO2A1
p6150
sg14
I7
sg22
g190
sg17
I1
sasa(dp6151
g2
VTo investigate whether receipt of any antithrombin concentrate improves laboratory and clinical outcomes in children undergoing extracorporeal membrane oxygenation for respiratory failure during their hospitalization compared with those who did not receive antithrombin.
p6152
sg4
(dp6153
(Vantithrombin
p6154
Vrespiratory failure
p6155
tp6156
I00
ssg9
(lp6157
(dp6158
g12
I168
sg13
g6155
sg14
I19
sg15
VC1145670
p6159
sg17
I2
sasg18
(lp6160
(dp6161
g12
I38
sg13
Vantithrombin
p6162
sg14
I12
sg22
VP05546
p6163
sg17
I1
sa(dp6164
g12
I38
sg13
g6154
sg14
I12
sg22
VP05546
p6165
sg17
I1
sasa(dp6166
g2
VIntermittent, on-demand dosing of antithrombin concentrate in pediatric patients on extracorporeal membrane oxygenation for respiratory failure increased antithrombin levels, but not typically to the targeted level.
p6167
sg4
(dp6168
(Vantithrombin
p6169
Vrespiratory failure
p6170
tp6171
I00
ssg9
(lp6172
(dp6173
g12
I124
sg13
g6170
sg14
I19
sg15
VC1145670
p6174
sg17
I2
sasg18
(lp6175
(dp6176
g12
I34
sg13
Vantithrombin
p6177
sg14
I12
sg22
VP05546
p6178
sg17
I1
sa(dp6179
g12
I34
sg13
g6169
sg14
I12
sg22
VP05546
p6180
sg17
I1
sasa(dp6181
g2
VWe hypothesized that combining intravenous recombinant human antithrombin (rhAT), nebulized heparin, and nebulized tissue plasminogen activator (TPA) more effectively improves pulmonary gas exchange compared with a single rhAT infusion, while maintaining the anti-inflammatory properties of rhAT in ARDS.
p6182
sg4
(dp6183
(Vtissue plasminogen activator
p6184
VARDS
p6185
tp6186
I00
ssg9
(lp6187
(dp6188
g12
I299
sg13
g6185
sg14
I4
sg15
VC0035222
p6189
sg17
I1
sasg18
(lp6190
(dp6191
g12
I75
sg13
VrhAT
p6192
sg14
I4
sg22
VP05546
p6193
sg17
I1
sa(dp6194
g12
I75
sg13
VrhAT
p6195
sg14
I4
sg22
VP05546
p6196
sg17
I1
sa(dp6197
g12
I43
sg13
Vrecombinant human antithrombin
p6198
sg14
I30
sg22
VP05546
p6199
sg17
I3
sa(dp6200
g12
I145
sg13
VTPA
p6201
sg14
I3
sg22
VP00747
p6202
sg17
I1
sa(dp6203
g12
I75
sg13
VrhAT
p6204
sg14
I4
sg22
VP05546
p6205
sg17
I1
sa(dp6206
g12
I115
sg13
g6184
sg14
I28
sg22
VP00747
p6207
sg17
I3
sasa(dp6208
g2
VAfter 12 months, bonds fell from 43.9 +/- 9.5 MPa to 20.1 +/- 5.4 MPa and from 39.6 +/- 9.4 MPa to 14.2 +/- 5.0 MPa in control specimens for SB1 and XPB respectively, while bond fell only from 41.9 +/- 9.6MPa to 33.2 +/- 8.3 MPa and 38.3 +/- 8.9 MPa to 26.5 +/- 10.9 (for SB1 and XPB, respectively) when 0.2% CHX was previously used.
p6209
sg4
(dp6210
(VXPB
p6211
VXPB
p6212
tp6213
I00
ssg9
(lp6214
(dp6215
g12
I149
sg13
VXPB
p6216
sg14
I3
sg15
VC0268136
p6217
sg17
I1
sa(dp6218
g12
I149
sg13
g6212
sg14
I3
sg15
VC0268136
p6219
sg17
I1
sasg18
(lp6220
(dp6221
g12
I141
sg13
VSB1
p6222
sg14
I3
sg22
g190
sg17
I1
sa(dp6223
g12
I149
sg13
g6211
sg14
I3
sg22
VP19447
p6224
sg17
I1
sasa(dp6225
g2
VPrimary SFs from patients with rheumatoid arthritis (RA) were treated with recombinant human bone morphogenetic protein-2 or transduced with a constitutively active mutant of the ALK3 gene (ALK3CA) with or without TNF-Alfa, and then cultured in pellets.
p6226
sg4
(dp6227
(VTNF-Alfa
p6228
Vrheumatoid arthritis
p6229
tp6230
I00
ssg9
(lp6231
(dp6232
g12
I53
sg13
VRA
p6233
sg14
I2
sg15
VC0003873
p6234
sg17
I1
sa(dp6235
g12
I165
sg13
Vmutant
p6236
sg14
I6
sg15
VC0596988
p6237
sg17
I1
sa(dp6238
g12
I31
sg13
g6229
sg14
I20
sg15
VC0003873
p6239
sg17
I2
sasg18
(lp6240
(dp6241
g12
I179
sg13
VALK3 gene
p6242
sg14
I9
sg22
VP36894
p6243
sg17
I2
sa(dp6244
g12
I214
sg13
g6228
sg14
I8
sg22
VP01375
p6245
sg17
I1
sasa(dp6246
g2
VIn this study, the expression and regulation of two androgen-inactivating enzymes, the UDP-glucuronosyltransferases UGT2B15 and UGT2B17, was assessed in breast cancer.
p6247
sg4
(dp6248
(VUDP-glucuronosyltransferases UGT2B15
p6249
Vbreast cancer
p6250
tp6251
I00
ssg9
(lp6252
(dp6253
g12
I153
sg13
g6250
sg14
I13
sg15
VC0678222
p6254
sg17
I2
sasg18
(lp6255
(dp6256
g12
I128
sg13
VUGT2B17
p6257
sg14
I7
sg22
g190
sg17
I1
sa(dp6258
g12
I87
sg13
g6249
sg14
I36
sg22
VP54855
p6259
sg17
I2
sasa(dp6260
g2
VGlobal ablation of INSL3 hormone or its receptor RXFP2 in male mice results in cryptorchidism and infertility.
p6261
sg4
(dp6262
(VINSL3 hormone
p6263
Vcryptorchidism
p6264
tp6265
I00
ssg9
(lp6266
(dp6267
g12
I98
sg13
Vinfertility
p6268
sg14
I11
sg15
VC0021359
p6269
sg17
I1
sa(dp6270
g12
I79
sg13
g6264
sg14
I14
sg15
VC0010417
p6271
sg17
I1
sasg18
(lp6272
(dp6273
g12
I49
sg13
VRXFP2
p6274
sg14
I5
sg22
g190
sg17
I1
sa(dp6275
g12
I19
sg13
g6263
sg14
I13
sg22
VP51460
p6276
sg17
I2
sasa(dp6277
g2
VDeletion of Insl3 or Rxfp2 genes in mice caused cryptorchidism resulting from a failure of gubernaculum development.
p6278
sg4
(dp6279
(VInsl3
p6280
Vcryptorchidism
p6281
tp6282
I00
ssg9
(lp6283
(dp6284
g12
I48
sg13
g6281
sg14
I14
sg15
VC0010417
p6285
sg17
I1
sasg18
(lp6286
(dp6287
g12
I12
sg13
g6280
sg14
I5
sg22
VP51460
p6288
sg17
I1
sa(dp6289
g12
I21
sg13
VRxfp2 genes
p6290
sg14
I11
sg22
g190
sg17
I2
sasa(dp6291
g2
VUsing Cre transgene driven by retinoic acid receptor beta promoter, conditional gene targeting in gubernacular mesenchymal cells at early embryonic stages caused high intraabdominal cryptorchidism as in males with a global deletion of Rxfp2.
p6292
sg4
(dp6293
(Vretinoic acid receptor beta promoter
p6294
Vcryptorchidism
p6295
tp6296
I00
ssg9
(lp6297
(dp6298
g12
I182
sg13
g6295
sg14
I14
sg15
VC0010417
p6299
sg17
I1
sasg18
(lp6300
(dp6301
g12
I30
sg13
g6294
sg14
I36
sg22
VP10826
p6302
sg17
I5
sa(dp6303
g12
I6
sg13
VCre transgene
p6304
sg14
I13
sg22
g190
sg17
I2
sa(dp6305
g12
I235
sg13
VRxfp2
p6306
sg14
I5
sg22
g190
sg17
I1
sasa(dp6307
g2
VPrenatal exposure to diethylstilbestrol affected the expression of LGR8 mRNA in the mouse gubernaculum testis, which suggests that diethylstilbestrol may induce cryptorchidism by interfering with the INSL3-LGR8 signaling system and consequently the development of the gubernaculum testis.
p6308
sg4
(dp6309
(VLGR8 mRNA
p6310
Vcryptorchidism
p6311
tp6312
I00
ssg9
(lp6313
(dp6314
g12
I161
sg13
g6311
sg14
I14
sg15
VC0010417
p6315
sg17
I1
sasg18
(lp6316
(dp6317
g12
I67
sg13
VLGR8
p6318
sg14
I4
sg22
VP51460
p6319
sg17
I1
sa(dp6320
g12
I200
sg13
VINSL3
p6321
sg14
I5
sg22
VP51460
p6322
sg17
I1
sa(dp6323
g12
I67
sg13
g6310
sg14
I9
sg22
VP51460
p6324
sg17
I2
sasa(dp6325
g2
VProspectively collected cremaster muscle and/or hernia sac tissues from boys with congenital (79) or acquired (66) nonsyndromic cryptorchidism and hernia/hydrocele (controls, 84) were analyzed for hormone receptor (RXFP2, AR, ESR1, ESR2) and myosin heavy chain specific (MYH1, MYH2, MYH7) mRNA expression using real-time reverse transcriptase polymerase chain reaction.
p6326
sg4
(dp6327
(VMYH1
p6328
Vhydrocele
p6329
tp6330
I00
ssg9
(lp6331
(dp6332
g12
I48
sg13
Vhernia sac
p6333
sg14
I10
sg15
VC0333062
p6334
sg17
I2
sa(dp6335
g12
I128
sg13
Vcryptorchidism
p6336
sg14
I14
sg15
VC0010417
p6337
sg17
I1
sa(dp6338
g12
I48
sg13
Vhernia
p6339
sg14
I6
sg15
VC0019270
p6340
sg17
I1
sa(dp6341
g12
I154
sg13
g6329
sg14
I9
sg15
VC1720771
p6342
sg17
I1
sasg18
(lp6343
(dp6344
g12
I226
sg13
VESR1
p6345
sg14
I4
sg22
VP03372
p6346
sg17
I1
sa(dp6347
g12
I277
sg13
VMYH2
p6348
sg14
I4
sg22
g190
sg17
I1
sa(dp6349
g12
I242
sg13
Vmyosin heavy chain
p6350
sg14
I18
sg22
VP13535
p6351
sg17
I3
sa(dp6352
g12
I193
sg13
Vfor hormone receptor
p6353
sg14
I20
sg22
VP22736
p6354
sg17
I3
sa(dp6355
g12
I271
sg13
g6328
sg14
I4
sg22
VP12882
p6356
sg17
I1
sa(dp6357
g12
I215
sg13
VRXFP2
p6358
sg14
I5
sg22
g190
sg17
I1
sasa(dp6359
g2
VPatients with definite pneumonia at the time of admission, those with left-sided heart failure, pulmonary embolism and an identifiable cause of acute lung injury, and those whose albumin or C-reactive protein levels were not measured were excluded.
p6360
sg4
(dp6361
(Valbumin
p6362
Vleft-sided heart failure
p6363
tp6364
I00
ssg9
(lp6365
(dp6366
g12
I96
sg13
Vpulmonary embolism
p6367
sg14
I18
sg15
VC0034065
p6368
sg17
I2
sa(dp6369
g12
I23
sg13
Vpneumonia
p6370
sg14
I9
sg15
VC0032285
p6371
sg17
I1
sa(dp6372
g12
I70
sg13
g6363
sg14
I24
sg15
VC0023212
p6373
sg17
I3
sasg18
(lp6374
(dp6375
g12
I190
sg13
VC-reactive protein
p6376
sg14
I18
sg22
VP02741
p6377
sg17
I2
sa(dp6378
g12
I179
sg13
g6362
sg14
I7
sg22
VP00441
p6379
sg17
I1
sasa(dp6380
g2
VAnalyzing gene expression signatures in endometrial and stomach adenocarcinomas revealed that tumors with a JAK1 frameshift exhibited reduced expression of interferon response signatures and multiple anti-tumor immune signatures.
p6381
sg4
(dp6382
(VJAK1
p6383
Vadenocarcinomas
p6384
tp6385
I00
ssg9
(lp6386
(dp6387
g12
I64
sg13
g6384
sg14
I15
sg15
VC0001418
p6388
sg17
I1
sa(dp6389
g12
I113
sg13
Vframeshift
p6390
sg14
I10
sg15
VC0079380
p6391
sg17
I1
sa(dp6392
g12
I94
sg13
Vtumors
p6393
sg14
I6
sg15
VC0027651
p6394
sg17
I1
sa(dp6395
g12
I94
sg13
Vtumor
p6396
sg14
I5
sg15
VC0027651
p6397
sg17
I1
sasg18
(lp6398
(dp6399
g12
I156
sg13
Vinterferon
p6400
sg14
I10
sg22
VP01563
p6401
sg17
I1
sa(dp6402
g12
I108
sg13
g6383
sg14
I4
sg22
VP23458
p6403
sg17
I1
sasa(dp6404
g2
VFrom these data, we derive two primary conclusions: 1) JAK1 frameshifts are loss of function alterations that represent a potential pan-cancer adaptation to immune responses against tumors with microsatellite instability; 2) The mechanism by which JAK1 loss of function contributes to tumor immune evasion is likely associated with loss of the JAK1-mediated interferon response.
p6405
sg4
(dp6406
(VJAK1
p6407
Vmicrosatellite instability
p6408
tp6409
I00
ssg9
(lp6410
(dp6411
g12
I136
sg13
Vcancer
p6412
sg14
I6
sg15
VC0006826
p6413
sg17
I1
sa(dp6414
g12
I182
sg13
Vtumors
p6415
sg14
I6
sg15
VC0027651
p6416
sg17
I1
sa(dp6417
g12
I285
sg13
Vtumor immune evasion
p6418
sg14
I20
sg15
VC0282683
p6419
sg17
I3
sa(dp6420
g12
I194
sg13
g6408
sg14
I26
sg15
VC0920269
p6421
sg17
I2
sasg18
(lp6422
(dp6423
g12
I358
sg13
Vinterferon
p6424
sg14
I10
sg22
VP01563
p6425
sg17
I1
sa(dp6426
g12
I55
sg13
VJAK1
p6427
sg14
I4
sg22
VP23458
p6428
sg17
I1
sa(dp6429
g12
I55
sg13
VJAK1
p6430
sg14
I4
sg22
VP23458
p6431
sg17
I1
sa(dp6432
g12
I55
sg13
g6407
sg14
I4
sg22
VP23458
p6433
sg17
I1
sasa(dp6434
g2
VMAJIC (ISRCTN61925716) is a randomized phase 2 trial of ruxolitinib (JAK1/2 inhibitor) vs best available therapy (BAT) in ET and polycythemia vera patients resistant or intolerant to HC.
p6435
sg4
(dp6436
(VJAK1/2
p6437
Vpolycythemia vera
p6438
tp6439
I00
ssg9
(lp6440
(dp6441
g12
I129
sg13
g6438
sg14
I17
sg15
VC0032463
p6442
sg17
I2
sasg18
(lp6443
(dp6444
g12
I69
sg13
g6437
sg14
I6
sg22
VP23458
p6445
sg17
I1
sasa(dp6446
g2
VRuxolitinib (Rux), a JAK1/2 inhibitor, has been approved for patients with myelofibrosis and in polycythemia vera with inadequate response/intolerance to hydroxycarbamide.
p6447
sg4
(dp6448
(VJAK1/2
p6449
Vpolycythemia vera
p6450
tp6451
I00
ssg9
(lp6452
(dp6453
g12
I75
sg13
Vmyelofibrosis
p6454
sg14
I13
sg15
VC0001815
p6455
sg17
I1
sa(dp6456
g12
I96
sg13
g6450
sg14
I17
sg15
VC0032463
p6457
sg17
I2
sasg18
(lp6458
(dp6459
g12
I21
sg13
g6449
sg14
I6
sg22
VP23458
p6460
sg17
I1
sasa(dp6461
g2
VGain-of-function mutations in the Type I Bone Morphogenic Protein (BMP) receptor ACVR1 have been identified in two diseases: Fibrodysplasia Ossificans Progressiva (FOP), a rare autosomal dominant disorder characterized by genetically driven heterotopic ossification, and in 20-25% of Diffuse Intrinsic Pontine Gliomas (DIPGs), a pediatric brain tumor with no effective therapies and dismal median survival.
p6462
sg4
(dp6463
(VType I Bone Morphogenic Protein
p6464
VFibrodysplasia Ossificans Progressiva
p6465
tp6466
I00
ssg9
(lp6467
(dp6468
g12
I329
sg13
Vpediatric brain tumor
p6469
sg14
I21
sg15
VC0220603
p6470
sg17
I3
sa(dp6471
g12
I310
sg13
VGliomas
p6472
sg14
I7
sg15
VC0017638
p6473
sg17
I1
sa(dp6474
g12
I241
sg13
Vheterotopic ossification
p6475
sg14
I24
sg15
VC0029396
p6476
sg17
I2
sa(dp6477
g12
I164
sg13
VFOP
p6478
sg14
I3
sg15
VC0016037
p6479
sg17
I1
sa(dp6480
g12
I125
sg13
g6465
sg14
I37
sg15
VC0016037
p6481
sg17
I3
sasg18
(lp6482
(dp6483
g12
I34
sg13
g6464
sg14
I31
sg22
VP29475
p6484
sg17
I5
sasa(dp6485
g2
VData relative to the effectiveness of the knockdown together with the potentiality of the BCKDK-knockdown to increase the deficient branched-chain Alfa-ketoacid dehydrogenase activity detected in MSUD patients are also shown.
p6486
sg4
(dp6487
(VAlfa-ketoacid dehydrogenase
p6488
VMSUD
p6489
tp6490
I00
ssg9
(lp6491
(dp6492
g12
I196
sg13
g6489
sg14
I4
sg15
VC0024776
p6493
sg17
I1
sasg18
(lp6494
(dp6495
g12
I90
sg13
VBCKDK
p6496
sg14
I5
sg22
g190
sg17
I1
sa(dp6497
g12
I147
sg13
g6488
sg14
I27
sg22
VP49366
p6498
sg17
I2
sasa(dp6499
g2
VWe review the significance of elevated alpha-fetoprotein levels and discuss the clinical relevance of this unusual presentation of a possible primary Hodgkin's lymphoma.
p6500
sg4
(dp6501
(Valpha-fetoprotein
p6502
VHodgkin's lymphoma
p6503
tp6504
I00
ssg9
(lp6505
(dp6506
g12
I150
sg13
g6503
sg14
I18
sg15
VC0019829
p6507
sg17
I2
sasg18
(lp6508
(dp6509
g12
I39
sg13
g6502
sg14
I17
sg22
VP02771
p6510
sg17
I1
sasa(dp6511
g2
VHowever, we have found that exogenous 8-OHdG can paradoxically reduce ROS production, attenuate the nuclear factor-KB signaling pathway, and ameliorate the expression of proinflammatory mediators such as interleukin (IL)-1, IL-6, cyclo-oxygenase-2, and inducible nitric oxide synthase in addition to expression of nicotinamide adenine dinucleotide phosphate oxidase (NOX)-1, NOX organizer-1 and NOX activator-1 in various conditions of inflammation-based gastrointestinal (GI) diseases including gastritis, inflammatory bowel disease, pancreatitis, and even colitis-associated carcinogenesis.
p6512
sg4
(dp6513
(Vnuclear factor-KB
p6514
Vcolitis
p6515
tp6516
I00
ssg9
(lp6517
(dp6518
g12
I436
sg13
Vinflammation
p6519
sg14
I12
sg15
VC0021368
p6520
sg17
I1
sa(dp6521
g12
I535
sg13
Vpancreatitis
p6522
sg14
I12
sg15
VC0030305
p6523
sg17
I1
sa(dp6524
g12
I496
sg13
Vgastritis
p6525
sg14
I9
sg15
VC0017152
p6526
sg17
I1
sa(dp6527
g12
I577
sg13
Vcarcinogenesis
p6528
sg14
I14
sg15
VC0596263
p6529
sg17
I1
sa(dp6530
g12
I507
sg13
Vinflammatory bowel disease
p6531
sg14
I26
sg15
VC0021390
p6532
sg17
I3
sa(dp6533
g12
I558
sg13
g6515
sg14
I7
sg15
VC0009319
p6534
sg17
I1
sasg18
(lp6535
(dp6536
g12
I230
sg13
Vcyclo-oxygenase-2
p6537
sg14
I17
sg22
VP00403
p6538
sg17
I1
sa(dp6539
g12
I395
sg13
VNOX activator-1
p6540
sg14
I15
sg22
VP05154
p6541
sg17
I2
sa(dp6542
g12
I263
sg13
Vnitric oxide synthase
p6543
sg14
I21
sg22
VP29475
p6544
sg17
I3
sa(dp6545
g12
I204
sg13
Vinterleukin (IL)-1
p6546
sg14
I18
sg22
VP60568
p6547
sg17
I2
sa(dp6548
g12
I224
sg13
VIL-6
p6549
sg14
I4
sg22
VP05231
p6550
sg17
I1
sa(dp6551
g12
I100
sg13
g6514
sg14
I17
sg22
VP01160
p6552
sg17
I2
sa(dp6553
g12
I314
sg13
Vnicotinamide adenine dinucleotide phosphate oxidase (NOX)-1
p6554
sg14
I59
sg22
g190
sg17
I6
sasa(dp6555
g2
VTogether, our data suggest that suppression of miR-4262 in OS cells may promote OPN-mediated cancer invasion, highlighting miR-4262 as an intriguing therapeutic target to prevent OS metastases.
p6556
sg4
(dp6557
(VOPN
p6558
Vmetastases
p6559
tp6560
I00
ssg9
(lp6561
(dp6562
g12
I100
sg13
Vinvasion
p6563
sg14
I8
sg15
VC2699153
p6564
sg17
I1
sa(dp6565
g12
I32
sg13
Vsuppression
p6566
sg14
I11
sg15
VC0221103
p6567
sg17
I1
sa(dp6568
g12
I182
sg13
g6559
sg14
I10
sg15
VC0027627
p6569
sg17
I1
sa(dp6570
g12
I93
sg13
Vcancer
p6571
sg14
I6
sg15
VC0006826
p6572
sg17
I1
sasg18
(lp6573
(dp6574
g12
I80
sg13
g6558
sg14
I3
sg22
VP10451
p6575
sg17
I1
sasa(dp6576
g2
VThose can be classified into four groups: hypercalciuric hypomagnesemias (encompassing mutations in CLDN16, CLDN19, CASR, CLCNKB), Gitelman-like hypomagnesemias (CLCNKB, SLC12A3, BSND, KCNJ10, FYXD2, HNF1B, PCBD1), mitochondrial hypomagnesemias (SARS2, MT-TI, Kearns-Sayre syndrome) and other hypomagnesemias (TRPM6, CNMM2, EGF, EGFR, KCNA1, FAM111A).
p6577
sg4
(dp6578
(VCASR
p6579
VKearns-Sayre syndrome
p6580
tp6581
I00
ssg9
(lp6582
(dp6583
g12
I179
sg13
VBSND
p6584
sg14
I4
sg15
VC1865270
p6585
sg17
I1
sa(dp6586
g12
I260
sg13
g6580
sg14
I21
sg15
VC0022541
p6587
sg17
I2
sasg18
(lp6588
(dp6589
g12
I246
sg13
VSARS2
p6590
sg14
I5
sg22
g190
sg17
I1
sa(dp6591
g12
I324
sg13
VEGF
p6592
sg14
I3
sg22
VP01133
p6593
sg17
I1
sa(dp6594
g12
I108
sg13
VCLDN19
p6595
sg14
I6
sg22
g190
sg17
I1
sa(dp6596
g12
I310
sg13
VTRPM6
p6597
sg14
I5
sg22
g190
sg17
I1
sa(dp6598
g12
I122
sg13
VCLCNKB
p6599
sg14
I6
sg22
VP51801
p6600
sg17
I1
sa(dp6601
g12
I342
sg13
VFAM111A
p6602
sg14
I7
sg22
g190
sg17
I1
sa(dp6603
g12
I335
sg13
VKCNA1
p6604
sg14
I5
sg22
g190
sg17
I1
sa(dp6605
g12
I170
sg13
VSLC12A3
p6606
sg14
I7
sg22
VP55017
p6607
sg17
I1
sa(dp6608
g12
I207
sg13
VPCBD1
p6609
sg14
I5
sg22
VP61457
p6610
sg17
I1
sa(dp6611
g12
I200
sg13
VHNF1B
p6612
sg14
I5
sg22
VP35680
p6613
sg17
I1
sa(dp6614
g12
I179
sg13
VBSND
p6615
sg14
I4
sg22
g190
sg17
I1
sa(dp6616
g12
I185
sg13
VKCNJ10
p6617
sg14
I6
sg22
VP78508
p6618
sg17
I1
sa(dp6619
g12
I100
sg13
VCLDN16
p6620
sg14
I6
sg22
g190
sg17
I1
sa(dp6621
g12
I122
sg13
VCLCNKB
p6622
sg14
I6
sg22
VP51801
p6623
sg17
I1
sa(dp6624
g12
I116
sg13
g6579
sg14
I4
sg22
VP41180
p6625
sg17
I1
sasa(dp6626
g2
VAlthough some autoinflammatory diseases are due to gain-of-function mutations for caspase-1 activity, common diseases such as gout, type 2 diabetes, heart failure, recurrent pericarditis, rheumatoid arthritis, and smoldering myeloma also are responsive to IL-1Beta neutralization.
p6627
sg4
(dp6628
(VIL-1Beta
p6629
Vheart failure
p6630
tp6631
I00
ssg9
(lp6632
(dp6633
g12
I126
sg13
Vgout
p6634
sg14
I4
sg15
VC0018099
p6635
sg17
I1
sa(dp6636
g12
I214
sg13
Vsmoldering myeloma
p6637
sg14
I18
sg15
VC1531608
p6638
sg17
I2
sa(dp6639
g12
I188
sg13
Vrheumatoid arthritis
p6640
sg14
I20
sg15
VC0003873
p6641
sg17
I2
sa(dp6642
g12
I174
sg13
Vpericarditis
p6643
sg14
I12
sg15
VC0031046
p6644
sg17
I1
sa(dp6645
g12
I132
sg13
Vtype 2 diabetes
p6646
sg14
I15
sg15
VC0011860
p6647
sg17
I3
sa(dp6648
g12
I149
sg13
g6630
sg14
I13
sg15
VC0018802
p6649
sg17
I2
sasg18
(lp6650
(dp6651
g12
I82
sg13
Vcaspase-1
p6652
sg14
I9
sg22
VP29466
p6653
sg17
I1
sa(dp6654
g12
I256
sg13
g6629
sg14
I8
sg22
VP01584
p6655
sg17
I1
sasa(dp6656
g2
VInactivation of Ccl2 in an Lkb1-driven mouse model of endometrial cancer slowed tumor progression and increased survival.
p6657
sg4
(dp6658
(VCcl2
p6659
Vendometrial cancer
p6660
tp6661
I01
ssg9
(lp6662
(dp6663
g12
I80
sg13
Vtumor progression
p6664
sg14
I17
sg15
VC0178874
p6665
sg17
I2
sa(dp6666
g12
I54
sg13
g6660
sg14
I18
sg15
VC0476089
p6667
sg17
I2
sa(dp6668
g12
I0
sg13
VInactivation
p6669
sg14
I12
sg15
VC0544461
p6670
sg17
I1
sasg18
(lp6671
(dp6672
g12
I16
sg13
g6659
sg14
I4
sg22
VP13500
p6673
sg17
I1
sa(dp6674
g12
I27
sg13
VLkb1
p6675
sg14
I4
sg22
g190
sg17
I1
sasa(dp6676
g2
VIn human primary endometrial cancers, loss of LKB1 protein was strongly associated with increased CCL2 expression by tumor cells as well as increased macrophage density in the tumor microenvironment.
p6677
sg4
(dp6678
(VCCL2
p6679
Vendometrial cancers
p6680
tp6681
I01
ssg9
(lp6682
(dp6683
g12
I117
sg13
Vtumor
p6684
sg14
I5
sg15
VC0027651
p6685
sg17
I1
sa(dp6686
g12
I17
sg13
g6680
sg14
I19
sg15
VC0476089
p6687
sg17
I2
sa(dp6688
g12
I117
sg13
Vtumor
p6689
sg14
I5
sg15
VC0027651
p6690
sg17
I1
sasg18
(lp6691
(dp6692
g12
I46
sg13
VLKB1 protein
p6693
sg14
I12
sg22
g190
sg17
I2
sa(dp6694
g12
I98
sg13
g6679
sg14
I4
sg22
VP13500
p6695
sg17
I1
sasa(dp6696
g2
VThese data demonstrate that CCL2 is a potent effector of LKB1 loss in endometrial cancer, creating potential avenues for therapeutic opportunities.
p6697
sg4
(dp6698
(VCCL2
p6699
Vendometrial cancer
p6700
tp6701
I01
ssg9
(lp6702
(dp6703
g12
I70
sg13
g6700
sg14
I18
sg15
VC0476089
p6704
sg17
I2
sasg18
(lp6705
(dp6706
g12
I28
sg13
g6699
sg14
I4
sg22
VP13500
p6707
sg17
I1
sa(dp6708
g12
I57
sg13
VLKB1
p6709
sg14
I4
sg22
g190
sg17
I1
sasa(dp6710
g2
VOur results showed that in HEC-1-B (human endometrial cancer) cells, IL-17 stimulation induced mRNA level increases of CCL2, CCL5, CCL20, CXCL2, and IL-8.
p6711
sg4
(dp6712
(VCCL2
p6713
Vendometrial cancer
p6714
tp6715
I01
ssg9
(lp6716
(dp6717
g12
I42
sg13
g6714
sg14
I18
sg15
VC0476089
p6718
sg17
I2
sasg18
(lp6719
(dp6720
g12
I131
sg13
VCCL20
p6721
sg14
I5
sg22
VP78556
p6722
sg17
I1
sa(dp6723
g12
I27
sg13
VHEC-1-B
p6724
sg14
I7
sg22
g190
sg17
I1
sa(dp6725
g12
I138
sg13
VCXCL2
p6726
sg14
I5
sg22
VP19875
p6727
sg17
I1
sa(dp6728
g12
I125
sg13
VCCL5
p6729
sg14
I4
sg22
VP13501
p6730
sg17
I1
sa(dp6731
g12
I119
sg13
g6713
sg14
I4
sg22
VP13500
p6732
sg17
I1
sasa(dp6733
g2
VIn this study of Turkish women, the association of CCL2 A2518G and CCR2 V64I polymorphisms with endometrial cancer was investigated using 50 endometrial cancer patients and 211 controls.
p6734
sg4
(dp6735
(VCCL2 A2518G
p6736
Vendometrial cancer
p6737
tp6738
I01
ssg9
(lp6739
(dp6740
g12
I96
sg13
Vendometrial cancer
p6741
sg14
I18
sg15
VC0476089
p6742
sg17
I2
sa(dp6743
g12
I96
sg13
g6737
sg14
I18
sg15
VC0476089
p6744
sg17
I2
sasg18
(lp6745
(dp6746
g12
I67
sg13
VCCR2
p6747
sg14
I4
sg22
VP41597
p6748
sg17
I1
sa(dp6749
g12
I51
sg13
g6736
sg14
I11
sg22
VP13500
p6750
sg17
I2
sasa(dp6751
g2
VIn our study, individuals with CCL2 A2518G GG genotype showed a 6.7-fold increased risk for endometrial cancer (p&lt;0.0001) and individuals with CCL2 A2518G A allele had a 7.14-fold lower risk of endometrium cancer (p&lt;0.0001).
p6752
sg4
(dp6753
(VCCL2 A2518G A allele
p6754
Vendometrium cancer
p6755
tp6756
I01
ssg9
(lp6757
(dp6758
g12
I92
sg13
Vendometrial cancer
p6759
sg14
I18
sg15
VC0476089
p6760
sg17
I2
sa(dp6761
g12
I197
sg13
g6755
sg14
I18
sg15
VC0476089
p6762
sg17
I2
sasg18
(lp6763
(dp6764
g12
I31
sg13
VCCL2 A2518G GG genotype
p6765
sg14
I23
sg22
VP13500
p6766
sg17
I4
sa(dp6767
g12
I146
sg13
g6754
sg14
I20
sg22
VP13500
p6768
sg17
I4
sasa(dp6769
g2
VIn conclusion, we state that there appears to be an association between polymorphism of CCL2 and its receptor CCR2 and endometrial cancer.
p6770
sg4
(dp6771
(VCCL2
p6772
Vendometrial cancer
p6773
tp6774
I01
ssg9
(lp6775
(dp6776
g12
I119
sg13
g6773
sg14
I18
sg15
VC0476089
p6777
sg17
I2
sasg18
(lp6778
(dp6779
g12
I110
sg13
VCCR2
p6780
sg14
I4
sg22
VP41597
p6781
sg17
I1
sa(dp6782
g12
I88
sg13
g6772
sg14
I4
sg22
VP13500
p6783
sg17
I1
sasa(dp6784
g2
VIn this study the different applications and functionalities of the program are demonstrated such as: exhaustive assembly (rDNA region and mitochondrial genome), extracting homologous regions or genes (IGS, RPB1, RPB2 and TEF1a), as well as extracting multiple regions within a single run.
p6785
sg4
(dp6786
(VRPB2
p6787
VIGS
p6788
tp6789
I00
ssg9
(lp6790
(dp6791
g12
I202
sg13
g6788
sg14
I3
sg15
VC1306856
p6792
sg17
I1
sasg18
(lp6793
(dp6794
g12
I207
sg13
VRPB1
p6795
sg14
I4
sg22
VP24928
p6796
sg17
I1
sa(dp6797
g12
I213
sg13
g6787
sg14
I4
sg22
VP30876
p6798
sg17
I1
sa(dp6799
g12
I202
sg13
VIGS
p6800
sg14
I3
sg22
g190
sg17
I1
sasa(dp6801
g2
VSequences of the translation elongation factor 1Alfa (tef1Alfa), RNA polymerase II subunit B2 (rpb2), ATP citrate lyase subunit A (acla), and internal transcribed spacer (ITS) regions were monomorphic, while the intergenic spacer (IGS) region showed length polymorphisms at two minisatellites of 23 and 39 nucleotides (nt).
p6802
sg4
(dp6803
(VRNA polymerase II subunit B2
p6804
VIGS
p6805
tp6806
I00
ssg9
(lp6807
(dp6808
g12
I212
sg13
Vintergenic spacer
p6809
sg14
I17
sg15
VC1306856
p6810
sg17
I2
sa(dp6811
g12
I231
sg13
g6805
sg14
I3
sg15
VC1306856
p6812
sg17
I1
sasg18
(lp6813
(dp6814
g12
I102
sg13
VATP citrate lyase subunit A
p6815
sg14
I27
sg22
g190
sg17
I5
sa(dp6816
g12
I54
sg13
Vtef1Alfa
p6817
sg14
I8
sg22
g190
sg17
I1
sa(dp6818
g12
I95
sg13
Vrpb2
p6819
sg14
I4
sg22
VP30876
p6820
sg17
I1
sa(dp6821
g12
I131
sg13
Vacla
p6822
sg14
I4
sg22
g190
sg17
I1
sa(dp6823
g12
I65
sg13
g6804
sg14
I28
sg22
VP30876
p6824
sg17
I5
sa(dp6825
g12
I17
sg13
Vtranslation elongation factor 1Alfa
p6826
sg14
I35
sg22
g190
sg17
I4
sasa(dp6827
g2
VThe phylogenetic relationships of these species were determined using sequences from the ITS and IGS region of the nuclear rRNA gene complex, two nuclear genes ( Beta -tubulin (benA) and RNA polymerase II second largest subunit (rpb2)) and two mitochondrial genes (small rRNA subunit (rns) and cytochrome oxidase subunit I (cox1)) and, where available, related sequences from databases.
p6828
sg4
(dp6829
(VRNA polymerase II
p6830
VIGS
p6831
tp6832
I00
ssg9
(lp6833
(dp6834
g12
I285
sg13
Vrns
p6835
sg14
I3
sg15
VC1850106
p6836
sg17
I1
sa(dp6837
g12
I97
sg13
g6831
sg14
I3
sg15
VC1306856
p6838
sg17
I1
sasg18
(lp6839
(dp6840
g12
I324
sg13
Vcox1
p6841
sg14
I4
sg22
VP00395
p6842
sg17
I1
sa(dp6843
g12
I294
sg13
Vcytochrome oxidase subunit I
p6844
sg14
I28
sg22
VP00395
p6845
sg17
I4
sa(dp6846
g12
I229
sg13
Vrpb2
p6847
sg14
I4
sg22
VP30876
p6848
sg17
I1
sa(dp6849
g12
I187
sg13
g6830
sg14
I17
sg22
VP19388
p6850
sg17
I3
sasa(dp6851
g2
VThe combined use of the three commonly employed nuclear genes (benA, rpb2, and ITS), the IGS region, and two less often used mitochondrial gene sequences (rns and cox1) as a single unit resolved several taxonomic ambiguities.
p6852
sg4
(dp6853
(Vrpb2
p6854
Vrns
p6855
tp6856
I00
ssg9
(lp6857
(dp6858
g12
I89
sg13
VIGS
p6859
sg14
I3
sg15
VC1306856
p6860
sg17
I1
sa(dp6861
g12
I155
sg13
g6855
sg14
I3
sg15
VC1850106
p6862
sg17
I1
sasg18
(lp6863
(dp6864
g12
I155
sg13
Vrns
p6865
sg14
I3
sg22
g190
sg17
I1
sa(dp6866
g12
I163
sg13
Vcox1
p6867
sg14
I4
sg22
VP00395
p6868
sg17
I1
sa(dp6869
g12
I69
sg13
g6854
sg14
I4
sg22
VP30876
p6870
sg17
I1
sa(dp6871
g12
I89
sg13
VIGS region
p6872
sg14
I10
sg22
g190
sg17
I2
sasa(dp6873
g2
VIn order to find other markers that, in combination with the ITS rDNA region can be used for species identification in Cladonia, we studied the loci IGS rDNA, ef1Alfa, rpb2 and cox1.
p6874
sg4
(dp6875
(Vcox1
p6876
VIGS
p6877
tp6878
I00
ssg9
(lp6879
(dp6880
g12
I149
sg13
g6877
sg14
I3
sg15
VC1306856
p6881
sg17
I1
sasg18
(lp6882
(dp6883
g12
I149
sg13
VIGS rDNA
p6884
sg14
I8
sg22
g190
sg17
I2
sa(dp6885
g12
I168
sg13
Vrpb2
p6886
sg14
I4
sg22
VP30876
p6887
sg17
I1
sa(dp6888
g12
I177
sg13
g6876
sg14
I4
sg22
VP00395
p6889
sg17
I1
sasa(dp6890
g2
VSeven loci were analyzed: the translation elongation factor 1 alpha gene (EF-1Alfa); the nuclear rRNA internal transcribed spacer (ITS), large subunit (LSU), and intergenic spacer (IGS) regions; the second largest subunit of the RNA polymerase gene (RPB2); the calmodulin gene (CAM); and the mitochondrial small subunit (mtSSU) rRNA gene.
p6891
sg4
(dp6892
(VCAM
p6893
VCAM
p6894
tp6895
I00
ssg9
(lp6896
(dp6897
g12
I162
sg13
Vintergenic spacer
p6898
sg14
I17
sg15
VC1306856
p6899
sg17
I2
sa(dp6900
g12
I261
sg13
Vcalmodulin gene
p6901
sg14
I15
sg15
VC1861821
p6902
sg17
I2
sa(dp6903
g12
I181
sg13
VIGS
p6904
sg14
I3
sg15
VC1306856
p6905
sg17
I1
sa(dp6906
g12
I278
sg13
g6894
sg14
I3
sg15
VC1861821
p6907
sg17
I1
sasg18
(lp6908
(dp6909
g12
I30
sg13
Vtranslation elongation factor 1 alpha gene
p6910
sg14
I42
sg22
g190
sg17
I6
sa(dp6911
g12
I250
sg13
VRPB2
p6912
sg14
I4
sg22
VP30876
p6913
sg17
I1
sa(dp6914
g12
I278
sg13
g6893
sg14
I3
sg22
VP01768
p6915
sg17
I1
sa(dp6916
g12
I261
sg13
Vcalmodulin gene
p6917
sg14
I15
sg22
g190
sg17
I2
sasa(dp6918
g2
VComplete absence of STAT6 was most common in pleomorphic liposarcoma and alveolar soft part sarcoma (60% and 72% cases negative, respectively).
p6919
sg4
(dp6920
(VSTAT6
p6921
Valveolar soft part sarcoma
p6922
tp6923
I00
ssg9
(lp6924
(dp6925
g12
I45
sg13
Vpleomorphic liposarcoma
p6926
sg14
I23
sg15
VC0205825
p6927
sg17
I2
sa(dp6928
g12
I73
sg13
g6922
sg14
I26
sg15
VC0206657
p6929
sg17
I4
sasg18
(lp6930
(dp6931
g12
I20
sg13
g6921
sg14
I5
sg22
VP42226
p6932
sg17
I1
sasa(dp6933
g2
VPatients with ASC due to choledocholithiasis were allocated to two groups: Those who underwent EST immediately and those who underwent EBD followed by EST 1 wk later because they were under anticoagulant therapy, had a coagulopathy (international normalized ratio &gt; 1.3, partial thromboplastin time greater than twice that of control), or had a platelet count &lt; 50000 x 10(3)/myL.
p6934
sg4
(dp6935
(VmyL
p6936
Vcoagulopathy
p6937
tp6938
I00
ssg9
(lp6939
(dp6940
g12
I25
sg13
Vcholedocholithiasis
p6941
sg14
I19
sg15
VC0701818
p6942
sg17
I1
sa(dp6943
g12
I219
sg13
g6937
sg14
I12
sg15
VC0005779
p6944
sg17
I1
sasg18
(lp6945
(dp6946
g12
I282
sg13
Vthromboplastin
p6947
sg14
I14
sg22
VP13726
p6948
sg17
I1
sa(dp6949
g12
I382
sg13
g6936
sg14
I3
sg22
VP29590
p6950
sg17
I1
sasa(dp6951
g2
VA cross of the Asd-4 mutant with wild-type resulted in fruiting bodies that appeared to be normal macroscopically but which were complete devoid of asci and ascospores.
p6952
sg4
(dp6953
(VAsd-4 mutant
p6954
VAsd
p6955
tp6956
I00
ssg9
(lp6957
(dp6958
g12
I15
sg13
g6955
sg14
I3
sg15
VC1510586
p6959
sg17
I1
sa(dp6960
g12
I21
sg13
Vmutant
p6961
sg14
I6
sg15
VC0596988
p6962
sg17
I1
sasg18
(lp6963
(dp6964
g12
I15
sg13
g6954
sg14
I12
sg22
VP51689
p6965
sg17
I2
sasa(dp6966
g2
VA mutant strain (asd-1) with a recessive crossing defect (apparently caused by the RIP process) was isolated; in this strain, early development is normal and may asci are formed, but ascospores are never delineated.
p6967
sg4
(dp6968
(Vasd-1
p6969
Vasd
p6970
tp6971
I00
ssg9
(lp6972
(dp6973
g12
I17
sg13
g6970
sg14
I3
sg15
VC1510586
p6974
sg17
I1
sa(dp6975
g12
I2
sg13
Vmutant
p6976
sg14
I6
sg15
VC0596988
p6977
sg17
I1
sasg18
(lp6978
(dp6979
g12
I17
sg13
g6969
sg14
I5
sg22
VP51689
p6980
sg17
I1
sasa(dp6981
g2
VIL-19 is significantly positive correlated with UAE and Cystatin C. IL-19 may play an important role that contributes to the progression of diabetic nephropathy.
p6982
sg4
(dp6983
(VCystatin C
p6984
Vdiabetic nephropathy
p6985
tp6986
I01
ssg9
(lp6987
(dp6988
g12
I140
sg13
g6985
sg14
I20
sg15
VC0011881
p6989
sg17
I2
sasg18
(lp6990
(dp6991
g12
I0
sg13
VIL-19
p6992
sg14
I5
sg22
g190
sg17
I1
sa(dp6993
g12
I0
sg13
VIL-19
p6994
sg14
I5
sg22
g190
sg17
I1
sa(dp6995
g12
I56
sg13
g6984
sg14
I10
sg22
VP01034
p6996
sg17
I2
sasa(dp6997
g2
VThe PD-L1 mRNA and protein expression levels were measured in the bladder cancer T24 cell line and the human uroepithelial SV-HUC-1 cell line, following treatment with interleukin (IL)-2, interferon (IFN)-Alfa and IFN-Gamma, by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis, respectively.
p6998
sg4
(dp6999
(Vinterleukin (IL)-2
p7000
Vbladder cancer
p7001
tp7002
I00
ssg9
(lp7003
(dp7004
g12
I66
sg13
g7001
sg14
I14
sg15
VC0699885
p7005
sg17
I2
sasg18
(lp7006
(dp7007
g12
I200
sg13
VIFN
p7008
sg14
I3
sg22
VP01562
p7009
sg17
I1
sa(dp7010
g12
I188
sg13
Vinterferon
p7011
sg14
I10
sg22
VP01563
p7012
sg17
I1
sa(dp7013
g12
I214
sg13
VIFN-Gamma
p7014
sg14
I9
sg22
VP01579
p7015
sg17
I1
sa(dp7016
g12
I168
sg13
g7000
sg14
I18
sg22
VP60568
p7017
sg17
I2
sasa(dp7018
g2
VRT-qPCR and western blotting demonstrated that cytokines IL-2, IFN-Alfa and IFN-Gamma markedly upregulated PD-L1 mRNA expression rates and protein levels in bladder cancer T24 cells (P&lt;0.05), but had no significant effect in non-tumor SV-HUC-1 cells.
p7019
sg4
(dp7020
(VIFN-Gamma
p7021
Vbladder cancer
p7022
tp7023
I00
ssg9
(lp7024
(dp7025
g12
I157
sg13
g7022
sg14
I14
sg15
VC0699885
p7026
sg17
I2
sa(dp7027
g12
I232
sg13
Vtumor
p7028
sg14
I5
sg15
VC0027651
p7029
sg17
I1
sasg18
(lp7030
(dp7031
g12
I63
sg13
VIFN-Alfa
p7032
sg14
I8
sg22
VP01562
p7033
sg17
I1
sa(dp7034
g12
I57
sg13
VIL-2
p7035
sg14
I4
sg22
VP60568
p7036
sg17
I1
sa(dp7037
g12
I76
sg13
g7021
sg14
I9
sg22
VP01579
p7038
sg17
I1
sasa(dp7039
g2
VA primary deficiency of protein C or S is proposed which would produce cerebral thrombosis with exposure of phospholipids; this thrombosis then, like antigens, would generate antibodies acting on the thrombin-thrombomodulin complex, exacerbating the thrombotic process.
p7040
sg4
(dp7041
(Vthrombomodulin
p7042
Vthrombosis
p7043
tp7044
I00
ssg9
(lp7045
(dp7046
g12
I71
sg13
Vcerebral thrombosis
p7047
sg14
I19
sg15
VC0795687
p7048
sg17
I2
sa(dp7049
g12
I80
sg13
g7043
sg14
I10
sg15
VC0040053
p7050
sg17
I1
sasg18
(lp7051
(dp7052
g12
I24
sg13
Vprotein C
p7053
sg14
I9
sg22
VP02810
p7054
sg17
I2
sa(dp7055
g12
I200
sg13
Vthrombin
p7056
sg14
I8
sg22
VP00734
p7057
sg17
I1
sa(dp7058
g12
I209
sg13
g7042
sg14
I14
sg22
VP07204
p7059
sg17
I1
sasa(dp7060
g2
VThe frequencies of erythrocyte MNSs antigens and certain histocompatibility leukocyte antigen (HLA) specificities (HLA-A, HLA-B, and HLA-DR) were determined in white patients with meningitis or epiglottitis due to Haemophilus influenzae type b and in controls.
p7061
sg4
(dp7062
(Vcertain histocompatibility leukocyte antigen
p7063
Vmeningitis
p7064
tp7065
I00
ssg9
(lp7066
(dp7067
g12
I194
sg13
Vepiglottitis
p7068
sg14
I12
sg15
VC0014541
p7069
sg17
I1
sa(dp7070
g12
I180
sg13
g7064
sg14
I10
sg15
VC0025289
p7071
sg17
I1
sasg18
(lp7072
(dp7073
g12
I19
sg13
Verythrocyte MNSs antigens
p7074
sg14
I25
sg22
VP21333
p7075
sg17
I3
sa(dp7076
g12
I49
sg13
g7063
sg14
I44
sg22
VP14209
p7077
sg17
I4
sa(dp7078
g12
I122
sg13
VHLA-B
p7079
sg14
I5
sg22
VP30461
p7080
sg17
I1
sa(dp7081
g12
I133
sg13
VHLA-DR
p7082
sg14
I6
sg22
VP30486
p7083
sg17
I1
sa(dp7084
g12
I115
sg13
VHLA-A
p7085
sg14
I5
sg22
VP30447
p7086
sg17
I1
sa(dp7087
g12
I95
sg13
VHLA
p7088
sg14
I3
sg22
VP30486
p7089
sg17
I1
sasa(dp7090
g2
VAnalysis of antigen expression pattern, the presence or absence of T cell-associated antigen deletion, and the expression of CD10 and CD34 by 4-color flow cytometry can help differentiate thymoma from T-cell ALL/LBL.
p7091
sg4
(dp7092
(VT cell-associated antigen
p7093
Vthymoma
p7094
tp7095
I00
ssg9
(lp7096
(dp7097
g12
I188
sg13
g7094
sg14
I7
sg15
VC0040100
p7098
sg17
I1
sasg18
(lp7099
(dp7100
g12
I125
sg13
VCD10
p7101
sg14
I4
sg22
VP08473
p7102
sg17
I1
sa(dp7103
g12
I134
sg13
VCD34
p7104
sg14
I4
sg22
VP28906
p7105
sg17
I1
sa(dp7106
g12
I67
sg13
g7093
sg14
I25
sg22
VP14209
p7107
sg17
I3
sasa(dp7108
g2
VWe found that CYC1 was upregulated in breast tumor tissues, especially in tissues with lymph node metastasis.
p7109
sg4
(dp7110
(VCYC1
p7111
Vlymph node metastasis
p7112
tp7113
I00
ssg9
(lp7114
(dp7115
g12
I38
sg13
Vbreast tumor
p7116
sg14
I12
sg15
VC1458155
p7117
sg17
I2
sa(dp7118
g12
I87
sg13
g7112
sg14
I21
sg15
VC0686619
p7119
sg17
I3
sasg18
(lp7120
(dp7121
g12
I14
sg13
g7111
sg14
I4
sg22
VP08574
p7122
sg17
I1
sasa(dp7123
g2
VAnd higher expression of CYC1 correlates with poor prognosis in breast cancer patients using online databases and tools.
p7124
sg4
(dp7125
(VCYC1
p7126
Vbreast cancer
p7127
tp7128
I00
ssg9
(lp7129
(dp7130
g12
I64
sg13
g7127
sg14
I13
sg15
VC0678222
p7131
sg17
I2
sasg18
(lp7132
(dp7133
g12
I25
sg13
g7126
sg14
I4
sg22
VP08574
p7134
sg17
I1
sasa(dp7135
g2
VThen we confirmed that CYC1 contributed to metastasis and proliferation in two highly metastatic human breast cancer cell lines.
p7136
sg4
(dp7137
(VCYC1
p7138
Vbreast cancer
p7139
tp7140
I00
ssg9
(lp7141
(dp7142
g12
I43
sg13
Vmetastasis
p7143
sg14
I10
sg15
VC0027627
p7144
sg17
I1
sa(dp7145
g12
I58
sg13
Vproliferation
p7146
sg14
I13
sg15
VC0334094
p7147
sg17
I1
sa(dp7148
g12
I103
sg13
g7139
sg14
I13
sg15
VC0678222
p7149
sg17
I2
sasg18
(lp7150
(dp7151
g12
I23
sg13
g7138
sg14
I4
sg22
VP08574
p7152
sg17
I1
sasa(dp7153
g2
VOur results indicated that CYC1 plays crucial roles in breast cancer progression and might be a predictive factor assisting future patient diagnosis.
p7154
sg4
(dp7155
(VCYC1
p7156
Vcancer progression
p7157
tp7158
I00
ssg9
(lp7159
(dp7160
g12
I62
sg13
g7157
sg14
I18
sg15
VC0178874
p7161
sg17
I2
sasg18
(lp7162
(dp7163
g12
I27
sg13
g7156
sg14
I4
sg22
VP08574
p7164
sg17
I1
sasa(dp7165
g2
VUbiquinol-cytochrome c reductase hinge protein (UQCRH), as a connecter between cytochrome c1 with cytochrome c in complex III of respiratory chain, is top-ranked hypermethylated gene in clear cell renal cell carcinoma (ccRCC).
p7166
sg4
(dp7167
(VUbiquinol-cytochrome c reductase hinge protein
p7168
Vclear cell renal cell carcinoma
p7169
tp7170
I00
ssg9
(lp7171
(dp7172
g12
I219
sg13
VccRCC
p7173
sg14
I5
sg15
VC0279702
p7174
sg17
I1
sa(dp7175
g12
I186
sg13
g7169
sg14
I31
sg15
VC0279702
p7176
sg17
I5
sasg18
(lp7177
(dp7178
g12
I48
sg13
VUQCRH
p7179
sg14
I5
sg22
VP07919
p7180
sg17
I1
sa(dp7181
g12
I79
sg13
Vcytochrome c1
p7182
sg14
I13
sg22
VP08574
p7183
sg17
I2
sa(dp7184
g12
I10
sg13
Vcytochrome c
p7185
sg14
I12
sg22
VP99999
p7186
sg17
I2
sa(dp7187
g12
I0
sg13
g7168
sg14
I46
sg22
VP99999
p7188
sg17
I5
sasa(dp7189
g2
VThis study aimed at testing a panel of nine reference genes [beta-2-microglobulin, cytochrome c-1 (CYC1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hydroxymethylbilane synthase, hypoxanthine guanine phosphoribosyl transferase 1, ribosomal protein L13a (RPL13A), succinate dehydrogenase, TATA-box binding protein and 14-3-3 protein zeta] to identify and validate the most suitable reference genes for expression studies in human glioma of different grades (World Health Organization grades II-IV).
p7190
sg4
(dp7191
(Vsuccinate dehydrogenase
p7192
Vglioma
p7193
tp7194
I00
ssg9
(lp7195
(dp7196
g12
I436
sg13
g7193
sg14
I6
sg15
VC0017638
p7197
sg17
I1
sasg18
(lp7198
(dp7199
g12
I99
sg13
VCYC1
p7200
sg14
I4
sg22
VP08574
p7201
sg17
I1
sa(dp7202
g12
I61
sg13
Vbeta-2-microglobulin
p7203
sg14
I20
sg22
VP61769
p7204
sg17
I1
sa(dp7205
g12
I237
sg13
Vribosomal protein L13a
p7206
sg14
I22
sg22
VP40429
p7207
sg17
I3
sa(dp7208
g12
I295
sg13
VTATA-box binding protein
p7209
sg14
I24
sg22
VP20226
p7210
sg17
I3
sa(dp7211
g12
I83
sg13
Vcytochrome c-1
p7212
sg14
I14
sg22
VP99999
p7213
sg17
I2
sa(dp7214
g12
I261
sg13
VRPL13A
p7215
sg14
I6
sg22
VP40429
p7216
sg17
I1
sa(dp7217
g12
I106
sg13
Vglyceraldehyde-3-phosphate dehydrogenase
p7218
sg14
I40
sg22
VP04406
p7219
sg17
I2
sa(dp7220
g12
I186
sg13
Vhypoxanthine guanine phosphoribosyl transferase 1
p7221
sg14
I49
sg22
VP00492
p7222
sg17
I5
sa(dp7223
g12
I156
sg13
Vhydroxymethylbilane synthase
p7224
sg14
I28
sg22
VP08397
p7225
sg17
I2
sa(dp7226
g12
I148
sg13
VGAPDH
p7227
sg14
I5
sg22
VP04406
p7228
sg17
I1
sa(dp7229
g12
I270
sg13
g7192
sg14
I23
sg22
VP49366
p7230
sg17
I2
sasa(dp7231
g2
VAfter analysis of the stability values calculated using geNorm, NormFinder, and BestKeeper algorithms, GAPDH, RPL13A, and CYC1 can be indicated as reference genes applicable for accurate normalization of gene expression in glioma compared with normal brain and anaplastic astrocytoma or glioblastoma alone within this experimental setting.
p7232
sg4
(dp7233
(VGAPDH
p7234
Vglioma
p7235
tp7236
I00
ssg9
(lp7237
(dp7238
g12
I287
sg13
Vglioblastoma
p7239
sg14
I12
sg15
VC0017636
p7240
sg17
I1
sa(dp7241
g12
I261
sg13
Vanaplastic astrocytoma
p7242
sg14
I22
sg15
VC0334579
p7243
sg17
I2
sa(dp7244
g12
I223
sg13
g7235
sg14
I6
sg15
VC0017638
p7245
sg17
I1
sasg18
(lp7246
(dp7247
g12
I110
sg13
VRPL13A
p7248
sg14
I6
sg22
VP40429
p7249
sg17
I1
sa(dp7250
g12
I122
sg13
VCYC1
p7251
sg14
I4
sg22
VP08574
p7252
sg17
I1
sa(dp7253
g12
I103
sg13
g7234
sg14
I5
sg22
VP04406
p7254
sg17
I1
sasa(dp7255
g2
VKaplan-Meier plots identified correlations between individual or combined overexpression of E2F1, E2F3a, Mps1/TTK, Nek2, BubR1, or Hec1 and poor overall and relapse-free survival of breast cancer patients.
p7256
sg4
(dp7257
(VTTK
p7258
Vbreast cancer
p7259
tp7260
I00
ssg9
(lp7261
(dp7262
g12
I157
sg13
Vrelapse
p7263
sg14
I7
sg15
VC0277556
p7264
sg17
I1
sa(dp7265
g12
I182
sg13
g7259
sg14
I13
sg15
VC0678222
p7266
sg17
I2
sasg18
(lp7267
(dp7268
g12
I131
sg13
VHec1
p7269
sg14
I4
sg22
g190
sg17
I1
sa(dp7270
g12
I105
sg13
VMps1
p7271
sg14
I4
sg22
VP33981
p7272
sg17
I1
sa(dp7273
g12
I115
sg13
VNek2
p7274
sg14
I4
sg22
VP51955
p7275
sg17
I1
sa(dp7276
g12
I92
sg13
VE2F1
p7277
sg14
I4
sg22
g190
sg17
I1
sa(dp7278
g12
I110
sg13
g7258
sg14
I3
sg22
VP49841
p7279
sg17
I1
sa(dp7280
g12
I98
sg13
VE2F3a
p7281
sg14
I5
sg22
g190
sg17
I1
sasa(dp7282
g2
VBy interrogating the METABRIC database, we observed a significant correlation between p53 expression and that of c-Abl and TTK in basal-like breast cancers.
p7283
sg4
(dp7284
(VTTK
p7285
VAbl
p7286
tp7287
I00
ssg9
(lp7288
(dp7289
g12
I141
sg13
Vbreast cancers
p7290
sg14
I14
sg15
VC0006142
p7291
sg17
I2
sa(dp7292
g12
I115
sg13
g7286
sg14
I3
sg15
VC0000744
p7293
sg17
I1
sasg18
(lp7294
(dp7295
g12
I86
sg13
Vp53
p7296
sg14
I3
sg22
VP42771
p7297
sg17
I1
sa(dp7298
g12
I113
sg13
Vc-Abl
p7299
sg14
I5
sg22
VP00519
p7300
sg17
I1
sa(dp7301
g12
I123
sg13
g7285
sg14
I3
sg22
VP49841
p7302
sg17
I1
sasa(dp7303
g2
VThe protein kinase threonine tyrosine kinase (TTK; also known as Mps1) is a critical component of the spindle assembly checkpoint and a promising drug target for the treatment of aggressive cancers, such as triple negative breast cancer.
p7304
sg4
(dp7305
(VMps1
p7306
Vaggressive
p7307
tp7308
I00
ssg9
(lp7309
(dp7310
g12
I190
sg13
Vcancers
p7311
sg14
I7
sg15
VC0006826
p7312
sg17
I1
sa(dp7313
g12
I223
sg13
Vbreast cancer
p7314
sg14
I13
sg15
VC0678222
p7315
sg17
I2
sa(dp7316
g12
I179
sg13
g7307
sg14
I10
sg15
VC0001807
p7317
sg17
I1
sasg18
(lp7318
(dp7319
g12
I46
sg13
VTTK
p7320
sg14
I3
sg22
VP49841
p7321
sg17
I1
sa(dp7322
g12
I4
sg13
Vprotein kinase threonine tyrosine kinase
p7323
sg14
I40
sg22
VP29401
p7324
sg17
I5
sa(dp7325
g12
I65
sg13
g7306
sg14
I4
sg22
VP33981
p7326
sg17
I1
sasa(dp7327
g2
VHigh levels of the mitotic checkpoint kinase Mps1/TTK have correlated with high histologic grade in breast cancer, suggesting a potential new therapeutic target for aggressive breast cancers (BC).
p7328
sg4
(dp7329
(VMps1
p7330
VBC
p7331
tp7332
I00
ssg9
(lp7333
(dp7334
g12
I165
sg13
Vaggressive
p7335
sg14
I10
sg15
VC0001807
p7336
sg17
I1
sa(dp7337
g12
I176
sg13
Vbreast cancers
p7338
sg14
I14
sg15
VC0006142
p7339
sg17
I2
sa(dp7340
g12
I100
sg13
Vbreast cancer
p7341
sg14
I13
sg15
VC0006142
p7342
sg17
I2
sa(dp7343
g12
I192
sg13
g7331
sg14
I2
sg15
VC0006142
p7344
sg17
I1
sasg18
(lp7345
(dp7346
g12
I50
sg13
VTTK
p7347
sg14
I3
sg22
VP49841
p7348
sg17
I1
sa(dp7349
g12
I45
sg13
g7330
sg14
I4
sg22
VP33981
p7350
sg17
I1
sasa(dp7351
g2
VThese compounds were evaluated in anti-proliferative assays of a panel of 15 breast cancer cell lines and further examined for their ability to inhibit a variety of Mps1-dependent biological functions.
p7352
sg4
(dp7353
(VMps1
p7354
Vbreast cancer
p7355
tp7356
I00
ssg9
(lp7357
(dp7358
g12
I77
sg13
g7355
sg14
I13
sg15
VC0678222
p7359
sg17
I2
sa(dp7360
g12
I39
sg13
Vproliferative
p7361
sg14
I13
sg15
VC0334094
p7362
sg17
I1
sasg18
(lp7363
(dp7364
g12
I165
sg13
g7354
sg14
I4
sg22
VP33981
p7365
sg17
I1
sasa(dp7366
g2
VIn addition, the lead compounds 1 and 13 inhibit Mps1 kinase enzymatic activity with IC50 values from 0.356myM to 0.809myM, and inhibited Mps1-associated cellular functions such as centrosome duplication and the spindle checkpoint in triple negative breast cancer cells.
p7367
sg4
(dp7368
(VMps1 kinase
p7369
Vbreast cancer
p7370
tp7371
I00
ssg9
(lp7372
(dp7373
g12
I250
sg13
g7370
sg14
I13
sg15
VC0678222
p7374
sg17
I2
sa(dp7375
g12
I192
sg13
Vduplication
p7376
sg14
I11
sg15
VC1705960
p7377
sg17
I1
sasg18
(lp7378
(dp7379
g12
I49
sg13
VMps1
p7380
sg14
I4
sg22
VP33981
p7381
sg17
I1
sa(dp7382
g12
I49
sg13
g7369
sg14
I11
sg22
VP33981
p7383
sg17
I2
sasa(dp7384
g2
VUsing drug discovery technologies, computational modeling, medicinal chemistry, cell culture and in vivo assays, novel small molecule Mps1/TTK inhibitors have been identified as potential targeted therapies for breast cancers.
p7385
sg4
(dp7386
(VMps1
p7387
Vbreast cancers
p7388
tp7389
I00
ssg9
(lp7390
(dp7391
g12
I211
sg13
g7388
sg14
I14
sg15
VC0006142
p7392
sg17
I2
sasg18
(lp7393
(dp7394
g12
I139
sg13
VTTK
p7395
sg14
I3
sg22
VP49841
p7396
sg17
I1
sa(dp7397
g12
I134
sg13
g7387
sg14
I4
sg22
VP33981
p7398
sg17
I1
sasa(dp7399
g2
VHowever, high levels of Mps1 are found in many types of human malignancies, including glioblastoma, thyroid carcinoma, breast cancer, and other cancers.
p7400
sg4
(dp7401
(VMps1
p7402
Vbreast cancer
p7403
tp7404
I00
ssg9
(lp7405
(dp7406
g12
I100
sg13
Vthyroid carcinoma
p7407
sg14
I17
sg15
VC0549473
p7408
sg17
I2
sa(dp7409
g12
I86
sg13
Vglioblastoma
p7410
sg14
I12
sg15
VC0017636
p7411
sg17
I1
sa(dp7412
g12
I62
sg13
Vmalignancies
p7413
sg14
I12
sg15
VC0006826
p7414
sg17
I1
sa(dp7415
g12
I144
sg13
Vcancers
p7416
sg14
I7
sg15
VC0006826
p7417
sg17
I1
sa(dp7418
g12
I119
sg13
g7403
sg14
I13
sg15
VC0678222
p7419
sg17
I2
sasg18
(lp7420
(dp7421
g12
I24
sg13
g7402
sg14
I4
sg22
VP33981
p7422
sg17
I1
sasa(dp7423
g2
VHere, we employed amphiphilic polymers and silenced the expression of two cell cycle proteins, TTK and CDC20, and the anti-apoptosis protein survivin to determine the efficacy of polymer-mediated siRNA treatment in breast cancer cells as well as side effects in nonmalignant cells in vitro.
p7424
sg4
(dp7425
(VTTK
p7426
Vbreast cancer
p7427
tp7428
I00
ssg9
(lp7429
(dp7430
g12
I215
sg13
g7427
sg14
I13
sg15
VC0678222
p7431
sg17
I2
sasg18
(lp7432
(dp7433
g12
I95
sg13
g7426
sg14
I3
sg22
VP49841
p7434
sg17
I1
sa(dp7435
g12
I103
sg13
VCDC20
p7436
sg14
I5
sg22
g190
sg17
I1
sasa(dp7437
g2
VTo explore expressions of matrix metalloproteinase-1 (MMP-1), tissue inhibitor of metalloproteinases-1 (TIMP-1) and transforming growth factor-Beta1 (TGF-Beta1) in valve tissue of rheumatic heart disease (RHD), and to analyzed their roles in RHD.
p7438
sg4
(dp7439
(Vmatrix metalloproteinase-1
p7440
VRHD
p7441
tp7442
I00
ssg9
(lp7443
(dp7444
g12
I205
sg13
VRHD
p7445
sg14
I3
sg15
VC0035439
p7446
sg17
I1
sa(dp7447
g12
I180
sg13
Vrheumatic heart disease
p7448
sg14
I23
sg15
VC0035439
p7449
sg17
I3
sa(dp7450
g12
I205
sg13
g7441
sg14
I3
sg15
VC0035439
p7451
sg17
I1
sasg18
(lp7452
(dp7453
g12
I62
sg13
Vtissue inhibitor of metalloproteinases-1
p7454
sg14
I40
sg22
VP01033
p7455
sg17
I4
sa(dp7456
g12
I150
sg13
VTGF-Beta1
p7457
sg14
I9
sg22
VP01137
p7458
sg17
I1
sa(dp7459
g12
I116
sg13
Vtransforming growth factor-Beta1
p7460
sg14
I32
sg22
VP01137
p7461
sg17
I3
sa(dp7462
g12
I104
sg13
VTIMP-1
p7463
sg14
I6
sg22
VP01033
p7464
sg17
I1
sa(dp7465
g12
I54
sg13
VMMP-1
p7466
sg14
I5
sg22
VP03956
p7467
sg17
I1
sa(dp7468
g12
I26
sg13
g7440
sg14
I26
sg22
VP03956
p7469
sg17
I2
sasa(dp7470
g2
VPlasma vWF and vWF-CP activities were measured using enzyme-linked immunosorbent assay (ELISA) and residual collagen binding assay respectively in patients with lupus nephritis (n = 31), primary nephritic syndrome (n = 25), diabetic nephropathy (n = 45), chronic glomerulonephritis (n = 38) and 40 normal controls.
p7471
sg4
(dp7472
(VvWF
p7473
Vchronic glomerulonephritis
p7474
tp7475
I00
ssg9
(lp7476
(dp7477
g12
I195
sg13
Vnephritic syndrome
p7478
sg14
I18
sg15
VC0268732
p7479
sg17
I2
sa(dp7480
g12
I161
sg13
Vlupus nephritis
p7481
sg14
I15
sg15
VC0024143
p7482
sg17
I2
sa(dp7483
g12
I224
sg13
Vdiabetic nephropathy
p7484
sg14
I20
sg15
VC0011881
p7485
sg17
I2
sa(dp7486
g12
I255
sg13
g7474
sg14
I26
sg15
VC0152451
p7487
sg17
I2
sasg18
(lp7488
(dp7489
g12
I15
sg13
VvWF-CP
p7490
sg14
I6
sg22
VP04275
p7491
sg17
I1
sa(dp7492
g12
I7
sg13
g7473
sg14
I3
sg22
VP04275
p7493
sg17
I1
sasa(dp7494
g2
VRenal biopsy demonstrated that the vWF level in stage IV was higher than in stages II and III while vWF-CP activity was lower in patients with lupus nephritis.
p7495
sg4
(dp7496
(VvWF-CP
p7497
Vlupus nephritis
p7498
tp7499
I00
ssg9
(lp7500
(dp7501
g12
I143
sg13
g7498
sg14
I15
sg15
VC0024143
p7502
sg17
I2
sasg18
(lp7503
(dp7504
g12
I35
sg13
VvWF
p7505
sg14
I3
sg22
VP04275
p7506
sg17
I1
sa(dp7507
g12
I100
sg13
g7497
sg14
I6
sg22
VP04275
p7508
sg17
I1
sasa(dp7509
g2
VFurthermore the demonstration of a normal vWF-CP assay aided in the distinction between TTP and MAHA due to lupus nephritis.
p7510
sg4
(dp7511
(VvWF
p7512
VTTP
p7513
tp7514
I00
ssg9
(lp7515
(dp7516
g12
I108
sg13
Vlupus nephritis
p7517
sg14
I15
sg15
VC0024143
p7518
sg17
I2
sa(dp7519
g12
I88
sg13
g7513
sg14
I3
sg15
VC1268935
p7520
sg17
I1
sasg18
(lp7521
(dp7522
g12
I42
sg13
g7512
sg14
I3
sg22
VP04275
p7523
sg17
I1
sasa(dp7524
g2
VWe suggest that reduction of KLCs and DIC proteins in AD cortex results from both reduced expression and neuronal loss, and that these reductions and GSK-3Beta-mediated phosphorylation of KLC1 contribute to disturbances of axoplasmic flows and synaptic integrity in Alzheimer's disease.
p7525
sg4
(dp7526
(VGSK-3Beta
p7527
VDIC
p7528
tp7529
I00
ssg9
(lp7530
(dp7531
g12
I266
sg13
VAlzheimer's disease
p7532
sg14
I19
sg15
VC1521724
p7533
sg17
I2
sa(dp7534
g12
I38
sg13
g7528
sg14
I3
sg15
VC0012739
p7535
sg17
I1
sasg18
(lp7536
(dp7537
g12
I150
sg13
g7527
sg14
I9
sg22
VP49841
p7538
sg17
I1
sasa(dp7539
g2
VIn contrast to GTG banding, array CGH determined the exact number of deleted genes and thus allowed the identification of candidate genes for cleft palate (GREM1, CX36, MEIS2), congenital heart defect (ACTC, GREM1, CX36, MEIS2), and mental retardation (ARHGAP11A, CHRNA7, CHRM5).
p7540
sg4
(dp7541
(VACTC
p7542
Vcongenital heart defect
p7543
tp7544
I01
ssg9
(lp7545
(dp7546
g12
I233
sg13
Vmental retardation
p7547
sg14
I18
sg15
VC0025362
p7548
sg17
I2
sa(dp7549
g12
I142
sg13
Vcleft palate
p7550
sg14
I12
sg15
VC0008925
p7551
sg17
I2
sa(dp7552
g12
I34
sg13
VCGH
p7553
sg14
I3
sg15
VC1855900
p7554
sg17
I1
sa(dp7555
g12
I177
sg13
g7543
sg14
I23
sg15
VC0018798
p7556
sg17
I3
sasg18
(lp7557
(dp7558
g12
I169
sg13
VMEIS2
p7559
sg14
I5
sg22
g190
sg17
I1
sa(dp7560
g12
I163
sg13
VCX36
p7561
sg14
I4
sg22
g190
sg17
I1
sa(dp7562
g12
I272
sg13
VCHRM5
p7563
sg14
I5
sg22
VP08912
p7564
sg17
I1
sa(dp7565
g12
I202
sg13
g7542
sg14
I4
sg22
VP68032
p7566
sg17
I1
sa(dp7567
g12
I264
sg13
VCHRNA7
p7568
sg14
I6
sg22
VP36544
p7569
sg17
I1
sa(dp7570
g12
I169
sg13
VMEIS2
p7571
sg14
I5
sg22
g190
sg17
I1
sa(dp7572
g12
I156
sg13
VGREM1
p7573
sg14
I5
sg22
g190
sg17
I1
sa(dp7574
g12
I156
sg13
VGREM1
p7575
sg14
I5
sg22
g190
sg17
I1
sa(dp7576
g12
I163
sg13
VCX36
p7577
sg14
I4
sg22
g190
sg17
I1
sa(dp7578
g12
I253
sg13
VARHGAP11A
p7579
sg14
I9
sg22
g190
sg17
I1
sasa(dp7580
g2
VNon-progressive cerebellar ataxia with mental retardation (CANPMR, OMIM 614756) and chromosome 1p32-p31 deletion syndrome (OMIM 613735) are two very rare inherited disorders, which are caused by mono-allelic deficiency (haplo-insufficiency) of calmodulin-binding transcription activator 1 (CAMTA1) and, respectively, nuclear factor 1 A (NFIA) genes.
p7581
sg4
(dp7582
(Vnuclear factor 1 A
p7583
Vmono
p7584
tp7585
I00
ssg9
(lp7586
(dp7587
g12
I4
sg13
Vprogressive cerebellar ataxia
p7588
sg14
I29
sg15
VC0393525
p7589
sg17
I3
sa(dp7590
g12
I84
sg13
Vchromosome 1p32-p31 deletion syndrome
p7591
sg14
I37
sg15
VC3151036
p7592
sg17
I4
sa(dp7593
g12
I39
sg13
Vmental retardation
p7594
sg14
I18
sg15
VC0025362
p7595
sg17
I2
sa(dp7596
g12
I195
sg13
g7584
sg14
I4
sg15
VC0021345
p7597
sg17
I1
sasg18
(lp7598
(dp7599
g12
I244
sg13
Vcalmodulin-binding transcription activator 1
p7600
sg14
I44
sg22
g190
sg17
I4
sa(dp7601
g12
I317
sg13
g7583
sg14
I18
sg22
VP01160
p7602
sg17
I4
sa(dp7603
g12
I290
sg13
VCAMTA1
p7604
sg14
I6
sg22
g190
sg17
I1
sa(dp7605
g12
I337
sg13
VNFIA
p7606
sg14
I4
sg22
g190
sg17
I1
sasa(dp7607
g2
VAmong these 24 genes, four transcription factors Auts2, Nfia, Nr4a2, and Sox5 were found, suggesting that TBR1 controls a transcriptional cascade relevant to autism pathogenesis.
p7608
sg4
(dp7609
(VNr4a2
p7610
Vautism
p7611
tp7612
I00
ssg9
(lp7613
(dp7614
g12
I165
sg13
Vpathogenesis
p7615
sg14
I12
sg15
VC0699748
p7616
sg17
I1
sa(dp7617
g12
I158
sg13
g7611
sg14
I6
sg15
VC0004352
p7618
sg17
I1
sasg18
(lp7619
(dp7620
g12
I49
sg13
VAuts2
p7621
sg14
I5
sg22
g190
sg17
I1
sa(dp7622
g12
I56
sg13
VNfia
p7623
sg14
I4
sg22
g190
sg17
I1
sa(dp7624
g12
I106
sg13
VTBR1
p7625
sg14
I4
sg22
g190
sg17
I1
sa(dp7626
g12
I62
sg13
g7610
sg14
I5
sg22
VP43354
p7627
sg17
I1
sasa(dp7628
g2
VSome of these maternal and maternal-child associations were in or adjacent to autism candidate genes including: PCDH9, FOXP1, GABRB3, NRXN1, RELN, MACROD2, FHIT, RORA, CNTN4, CNTNAP2, FAM135B, LAMA1, NFIA, NLGN4X, RAPGEF4, and SDK1.
p7629
sg4
(dp7630
(VGABRB3
p7631
Vautism
p7632
tp7633
I00
ssg9
(lp7634
(dp7635
g12
I78
sg13
g7632
sg14
I6
sg15
VC0004352
p7636
sg17
I1
sasg18
(lp7637
(dp7638
g12
I200
sg13
VNFIA
p7639
sg14
I4
sg22
g190
sg17
I1
sa(dp7640
g12
I78
sg13
Vautism candidate genes
p7641
sg14
I22
sg22
VP27635
p7642
sg17
I3
sa(dp7643
g12
I162
sg13
VRORA
p7644
sg14
I4
sg22
VP35398
p7645
sg17
I1
sa(dp7646
g12
I227
sg13
VSDK1
p7647
sg14
I4
sg22
g190
sg17
I1
sa(dp7648
g12
I206
sg13
VNLGN4X
p7649
sg14
I6
sg22
g190
sg17
I1
sa(dp7650
g12
I112
sg13
VPCDH9
p7651
sg14
I5
sg22
g190
sg17
I1
sa(dp7652
g12
I156
sg13
VFHIT
p7653
sg14
I4
sg22
VP49789
p7654
sg17
I1
sa(dp7655
g12
I119
sg13
VFOXP1
p7656
sg14
I5
sg22
g190
sg17
I1
sa(dp7657
g12
I214
sg13
VRAPGEF4
p7658
sg14
I7
sg22
g190
sg17
I1
sa(dp7659
g12
I175
sg13
VCNTNAP2
p7660
sg14
I7
sg22
g190
sg17
I1
sa(dp7661
g12
I184
sg13
VFAM135B
p7662
sg14
I7
sg22
g190
sg17
I1
sa(dp7663
g12
I193
sg13
VLAMA1
p7664
sg14
I5
sg22
VP25391
p7665
sg17
I1
sa(dp7666
g12
I168
sg13
VCNTN4
p7667
sg14
I5
sg22
g190
sg17
I1
sa(dp7668
g12
I147
sg13
VMACROD2
p7669
sg14
I7
sg22
g190
sg17
I1
sa(dp7670
g12
I141
sg13
VRELN
p7671
sg14
I4
sg22
VP78509
p7672
sg17
I1
sa(dp7673
g12
I126
sg13
g7631
sg14
I6
sg22
VP28472
p7674
sg17
I1
sa(dp7675
g12
I134
sg13
VNRXN1
p7676
sg14
I5
sg22
VP58400
p7677
sg17
I1
sasa(dp7678
g2
VThese results provided a mechanistic linking between TRPM2-mediated Ca2+ influx and p47 phox signaling to induce excess ROS production and TXNIP-mediated NLRP3 inflammasome activation under HG, and suggested that TRPM2 represented a potential target for alleviating NLRP3 inflammasome activation related to hyperglycemia-induced oxidative stress in Type 2 diabetes Mellitus (T2DM).
p7679
sg4
(dp7680
(Vp47
p7681
Voxidative stress
p7682
tp7683
I00
ssg9
(lp7684
(dp7685
g12
I349
sg13
VType 2 diabetes Mellitus
p7686
sg14
I24
sg15
VC0011860
p7687
sg17
I4
sa(dp7688
g12
I375
sg13
VT2DM
p7689
sg14
I4
sg15
VC0011860
p7690
sg17
I1
sa(dp7691
g12
I307
sg13
Vhyperglycemia
p7692
sg14
I13
sg15
VC0020456
p7693
sg17
I1
sa(dp7694
g12
I329
sg13
g7682
sg14
I16
sg15
VC0242606
p7695
sg17
I2
sasg18
(lp7696
(dp7697
g12
I53
sg13
VTRPM2
p7698
sg14
I5
sg22
VP10909
p7699
sg17
I1
sa(dp7700
g12
I139
sg13
VTXNIP
p7701
sg14
I5
sg22
g190
sg17
I1
sa(dp7702
g12
I88
sg13
Vphox
p7703
sg14
I4
sg22
VP19878
p7704
sg17
I1
sa(dp7705
g12
I53
sg13
VTRPM2
p7706
sg14
I5
sg22
VP10909
p7707
sg17
I1
sa(dp7708
g12
I84
sg13
g7681
sg14
I3
sg22
VP08567
p7709
sg17
I1
sasa(dp7710
g2
VSOX3 mutations have been associated with growth hormone deficiency, variable degrees of additional pituitary hormone deficiencies, and mental retardation.
p7711
sg4
(dp7712
(VSOX3
p7713
Vmental retardation
p7714
tp7715
I00
ssg9
(lp7716
(dp7717
g12
I41
sg13
Vgrowth hormone deficiency
p7718
sg14
I25
sg15
VC0271561
p7719
sg17
I3
sa(dp7720
g12
I135
sg13
g7714
sg14
I18
sg15
VC0025362
p7721
sg17
I2
sasg18
(lp7722
(dp7723
g12
I41
sg13
Vgrowth hormone
p7724
sg14
I14
sg22
VP01242
p7725
sg17
I2
sa(dp7726
g12
I99
sg13
Vpituitary hormone
p7727
sg14
I17
sg22
VP18509
p7728
sg17
I2
sa(dp7729
g12
I0
sg13
g7713
sg14
I4
sg22
VP41225
p7730
sg17
I1
sasa(dp7731
g2
VSOX3 involvement should be considered in a male with short stature due to GH deficiency associated with intellectual disability.
p7732
sg4
(dp7733
(VSOX3
p7734
Vshort stature
p7735
tp7736
I00
ssg9
(lp7737
(dp7738
g12
I104
sg13
Vintellectual disability
p7739
sg14
I23
sg15
VC0025362
p7740
sg17
I2
sa(dp7741
g12
I53
sg13
g7735
sg14
I13
sg15
VC0013336
p7742
sg17
I2
sasg18
(lp7743
(dp7744
g12
I0
sg13
g7734
sg14
I4
sg22
VP41225
p7745
sg17
I1
sasa(dp7746
g2
VA further XX male, ascertained because of intellectual disability, carried a de novo cryptic duplication at Xq27.1, involving SOX3.
p7747
sg4
(dp7748
(VSOX3
p7749
VXX male
p7750
tp7751
I00
ssg9
(lp7752
(dp7753
g12
I42
sg13
Vintellectual disability
p7754
sg14
I23
sg15
VC0025362
p7755
sg17
I2
sa(dp7756
g12
I93
sg13
Vduplication
p7757
sg14
I11
sg15
VC1705960
p7758
sg17
I1
sa(dp7759
g12
I10
sg13
g7750
sg14
I7
sg15
VC0432475
p7760
sg17
I2
sasg18
(lp7761
(dp7762
g12
I126
sg13
g7749
sg14
I4
sg22
VP41225
p7763
sg17
I1
sasa(dp7764
g2
VIn humans, over- and underdosage of SOX3 is associated with X-linked hypopituitarism with variable phenotypes ranging from isolated GH deficiency (GHD) to panhypopituitarism, with or without mental retardation and, in most cases, with reported pituitary imaging, an ectopic/undescended posterior pituitary.
p7765
sg4
(dp7766
(VSOX3
p7767
VGH deficiency
p7768
tp7769
I00
ssg9
(lp7770
(dp7771
g12
I191
sg13
Vmental retardation
p7772
sg14
I18
sg15
VC0025362
p7773
sg17
I2
sa(dp7774
g12
I147
sg13
VGHD
p7775
sg14
I3
sg15
VC0271561
p7776
sg17
I1
sa(dp7777
g12
I155
sg13
Vpanhypopituitarism
p7778
sg14
I18
sg15
VC0242343
p7779
sg17
I1
sa(dp7780
g12
I69
sg13
Vhypopituitarism
p7781
sg14
I15
sg15
VC0020635
p7782
sg17
I1
sa(dp7783
g12
I132
sg13
g7768
sg14
I13
sg15
VC0271561
p7784
sg17
I2
sasg18
(lp7785
(dp7786
g12
I36
sg13
g7767
sg14
I4
sg22
VP41225
p7787
sg17
I1
sasa(dp7788
g2
VScreening for SOX3 should be advised not only for hypopituitary patients with an ectopic posterior pituitary, but also for those with a structurally normal pituitary and additional findings, including clefts and a persistent craniopharyngeal canal, with or without mental retardation.
p7789
sg4
(dp7790
(VSOX3
p7791
Vmental retardation
p7792
tp7793
I00
ssg9
(lp7794
(dp7795
g12
I265
sg13
g7792
sg14
I18
sg15
VC0025362
p7796
sg17
I2
sasg18
(lp7797
(dp7798
g12
I14
sg13
g7791
sg14
I4
sg22
VP41225
p7799
sg17
I1
sasa(dp7800
g2
VBoth duplications encompassing SOX3 and loss-of function mutations in SOX3 have been reported in a minor portion of X-linked isolated growth hormone deficiency (GHD) or combined pituitary hormone deficiency (CPHD) patients with or without mental retardation.
p7801
sg4
(dp7802
(VSOX3
p7803
VGHD
p7804
tp7805
I00
ssg9
(lp7806
(dp7807
g12
I239
sg13
Vmental retardation
p7808
sg14
I18
sg15
VC0025362
p7809
sg17
I2
sa(dp7810
g12
I161
sg13
g7804
sg14
I3
sg15
VC0271561
p7811
sg17
I1
sa(dp7812
g12
I141
sg13
Vhormone deficiency
p7813
sg14
I18
sg15
VC0599750
p7814
sg17
I2
sa(dp7815
g12
I125
sg13
Visolated growth hormone deficiency
p7816
sg14
I34
sg15
VC0271563
p7817
sg17
I4
sasg18
(lp7818
(dp7819
g12
I169
sg13
Vcombined pituitary hormone
p7820
sg14
I26
sg22
VP18509
p7821
sg17
I3
sa(dp7822
g12
I134
sg13
Vgrowth hormone
p7823
sg14
I14
sg22
VP01242
p7824
sg17
I2
sa(dp7825
g12
I31
sg13
g7803
sg14
I4
sg22
VP41225
p7826
sg17
I1
sasa(dp7827
g2
VIn humans, duplication of SOX3 and polyalanine expansions at its C-terminus may cause intellectual disability and hypopituitarism.
p7828
sg4
(dp7829
(VSOX3
p7830
Vintellectual disability
p7831
tp7832
I00
ssg9
(lp7833
(dp7834
g12
I11
sg13
Vduplication
p7835
sg14
I11
sg15
VC1705960
p7836
sg17
I1
sa(dp7837
g12
I114
sg13
Vhypopituitarism
p7838
sg14
I15
sg15
VC0020635
p7839
sg17
I1
sa(dp7840
g12
I86
sg13
g7831
sg14
I23
sg15
VC0025362
p7841
sg17
I2
sasg18
(lp7842
(dp7843
g12
I26
sg13
g7830
sg14
I4
sg22
VP41225
p7844
sg17
I1
sasa(dp7845
g2
VThe UNH159 marker as well as RNA-binding motif protein, X-linked (rbmx), SRY-box containing gene 3 (sox3) and alpha-thalassemia/mental retardation syndrome X-linked (atrx) genes were mapped to linkage group 2.
p7846
sg4
(dp7847
(VSRY-box containing gene 3
p7848
Vatrx
p7849
tp7850
I00
ssg9
(lp7851
(dp7852
g12
I110
sg13
Valpha-thalassemia/mental retardation syndrome X-linked
p7853
sg14
I54
sg15
VC1845055
p7854
sg17
I4
sa(dp7855
g12
I166
sg13
g7849
sg14
I4
sg15
VC1845055
p7856
sg17
I1
sasg18
(lp7857
(dp7858
g12
I100
sg13
Vsox3
p7859
sg14
I4
sg22
VP41225
p7860
sg17
I1
sa(dp7861
g12
I73
sg13
g7848
sg14
I25
sg22
VP41225
p7862
sg17
I4
sasa(dp7863
g2
VBoth overdosage of SOX3, as a result of gene duplication, and loss of function resulting from expansion of the first polyalanine (PA) tract are associated with variable degrees of hypopituitarism, with or without mental retardation.
p7864
sg4
(dp7865
(VSOX3
p7866
Vhypopituitarism
p7867
tp7868
I00
ssg9
(lp7869
(dp7870
g12
I213
sg13
Vmental retardation
p7871
sg14
I18
sg15
VC0025362
p7872
sg17
I2
sa(dp7873
g12
I180
sg13
g7867
sg14
I15
sg15
VC0020635
p7874
sg17
I1
sa(dp7875
g12
I40
sg13
Vgene duplication
p7876
sg14
I16
sg15
VC1705960
p7877
sg17
I2
sasg18
(lp7878
(dp7879
g12
I19
sg13
g7866
sg14
I4
sg22
VP41225
p7880
sg17
I1
sasa(dp7881
g2
VDuplications and polyalanine expansions within the transcription factor SOX3 have recently been described in association with infundibular hypoplasia, hypopituitarism and variable mental retardation, whilst mutations in SOX2 are associated with variable hypopituitarism in association with learning difficulties, oesophageal atresia and anophthalmia.
p7882
sg4
(dp7883
(VSOX3
p7884
Voesophageal atresia
p7885
tp7886
I00
ssg9
(lp7887
(dp7888
g12
I151
sg13
Vhypopituitarism
p7889
sg14
I15
sg15
VC0020635
p7890
sg17
I1
sa(dp7891
g12
I139
sg13
Vhypoplasia
p7892
sg14
I10
sg15
VC0243069
p7893
sg17
I1
sa(dp7894
g12
I337
sg13
Vanophthalmia
p7895
sg14
I12
sg15
VC0003119
p7896
sg17
I1
sa(dp7897
g12
I180
sg13
Vmental retardation
p7898
sg14
I18
sg15
VC0025362
p7899
sg17
I2
sa(dp7900
g12
I151
sg13
Vhypopituitarism
p7901
sg14
I15
sg15
VC0020635
p7902
sg17
I1
sa(dp7903
g12
I313
sg13
g7885
sg14
I19
sg15
VC0014850
p7904
sg17
I2
sasg18
(lp7905
(dp7906
g12
I220
sg13
VSOX2
p7907
sg14
I4
sg22
VP48431
p7908
sg17
I1
sa(dp7909
g12
I72
sg13
g7884
sg14
I4
sg22
VP41225
p7910
sg17
I1
sasa(dp7911
g2
VUsing mouse P19 embryonal carcinoma cells, which divide rapidly, yet in retinoic acid adopt a neuronal phenotype, admixed with occasional (approximately 10%) fibroblast-like cells, together with a panel of peptide-specific antibodies raised to 7 of the 8 CCT subunits we show that; (1) adoption of a post mitotic phenotype is accompanied by reduced CCT protein expression, significantly more so for CCTbeta, CCTdelta, CCTepsilon, and CCTtheta than for CCTalpha (TCP-1), CCTgamma and CCTzeta; (2) CCTalpha is detected preferentially over other subunits in neurites of P19 neurons; (3) small amounts of CCTalpha and gamma are localised in nuclei (i.e.
p7912
sg4
(dp7913
(VTCP-1
p7914
VTCP
p7915
tp7916
I00
ssg9
(lp7917
(dp7918
g12
I16
sg13
Vembryonal carcinoma
p7919
sg14
I19
sg15
VC0206659
p7920
sg17
I2
sa(dp7921
g12
I255
sg13
VCCT
p7922
sg14
I3
sg15
VC2752078
p7923
sg17
I1
sa(dp7924
g12
I462
sg13
g7915
sg14
I3
sg15
VC1842402
p7925
sg17
I1
sa(dp7926
g12
I255
sg13
VCCT
p7927
sg14
I3
sg15
VC2752078
p7928
sg17
I1
sasg18
(lp7929
(dp7930
g12
I462
sg13
g7914
sg14
I5
sg22
VP00995
p7931
sg17
I1
sa(dp7932
g12
I349
sg13
VCCT protein
p7933
sg14
I11
sg22
g190
sg17
I2
sasa(dp7934
g2
VIn line with these observations, in preclinical models, SIRT2 deficiency increases survival of mice with chronic staphylococcal infection, while having no effect on the course of toxic shock syndrome toxin-1, LPS or TNF-induced shock, fulminant Escherichia coli peritonitis, sub-lethal Klebsiella pneumoniae pneumonia, and chronic candidiasis.
p7935
sg4
(dp7936
(VTNF
p7937
Vstaphylococcal infection
p7938
tp7939
I01
ssg9
(lp7940
(dp7941
g12
I179
sg13
Vtoxic shock syndrome
p7942
sg14
I20
sg15
VC0600327
p7943
sg17
I3
sa(dp7944
g12
I262
sg13
Vperitonitis
p7945
sg14
I11
sg15
VC0031154
p7946
sg17
I1
sa(dp7947
g12
I209
sg13
VLPS
p7948
sg14
I3
sg15
VC0175697
p7949
sg17
I1
sa(dp7950
g12
I286
sg13
VKlebsiella pneumoniae pneumonia
p7951
sg14
I31
sg15
VC0519030
p7952
sg17
I3
sa(dp7953
g12
I323
sg13
Vchronic candidiasis
p7954
sg14
I19
sg15
VC0857069
p7955
sg17
I2
sa(dp7956
g12
I113
sg13
g7938
sg14
I24
sg15
VC0038160
p7957
sg17
I2
sasg18
(lp7958
(dp7959
g12
I216
sg13
g7937
sg14
I3
sg22
VP01375
p7960
sg17
I1
sa(dp7961
g12
I56
sg13
VSIRT2
p7962
sg14
I5
sg22
g190
sg17
I1
sasa(dp7963
g2
VLung injury was studied by measuring: vascular permeability-related pulmonary edema; histopathologic scores, neutrophil infiltration and concentrations of inflammatory cytokines in bronchoalveolar fluid; expression of inflammatory enzymes and sirtuin (SIRT) 1 as well as nuclear factor-kappa B (NF-KB) activity in pulmonary tissues.
p7964
sg4
(dp7965
(Vnuclear factor-kappa B
p7966
Vpulmonary edema
p7967
tp7968
I00
ssg9
(lp7969
(dp7970
g12
I120
sg13
Vinfiltration
p7971
sg14
I12
sg15
VC0332448
p7972
sg17
I1
sa(dp7973
g12
I68
sg13
g7967
sg14
I15
sg15
VC0034063
p7974
sg17
I2
sasg18
(lp7975
(dp7976
g12
I295
sg13
VNF-KB
p7977
sg14
I5
sg22
VP01160
p7978
sg17
I1
sa(dp7979
g12
I271
sg13
g7966
sg14
I22
sg22
VP01160
p7980
sg17
I3
sasa(dp7981
g2
VThe most significant changes common to HLHS-RV versus control-RV and control-LV sample groups is observed for Anti mullerian hormone receptor 2 (AMHR2) (+18.79 control-RV, +3.38 control-LV), and the BMP antagonist Inhibin alpha (INHA) (+11.47 control-RV, +5.73 control-LV).
p7982
sg4
(dp7983
(VBMP antagonist Inhibin alpha
p7984
VHLHS
p7985
tp7986
I00
ssg9
(lp7987
(dp7988
g12
I39
sg13
g7985
sg14
I4
sg15
VC0152101
p7989
sg17
I1
sasg18
(lp7990
(dp7991
g12
I110
sg13
VAnti mullerian hormone receptor 2
p7992
sg14
I33
sg22
VP22736
p7993
sg17
I5
sa(dp7994
g12
I145
sg13
VAMHR2
p7995
sg14
I5
sg22
g190
sg17
I1
sa(dp7996
g12
I229
sg13
VINHA
p7997
sg14
I4
sg22
VP05111
p7998
sg17
I1
sa(dp7999
g12
I39
sg13
VHLHS-RV
p8000
sg14
I7
sg22
VP17302
p8001
sg17
I1
sa(dp8002
g12
I199
sg13
g7984
sg14
I28
sg22
VP18075
p8003
sg17
I4
sasa(dp8004
g2
VWe have described previously the Ets family member ERM/ETV5 specifically upregulated in endometrial endometrioid carcinoma (EEC) associated with myometrial infiltration.
p8005
sg4
(dp8006
(VEts family member
p8007
Vendometrioid carcinoma
p8008
tp8009
I00
ssg9
(lp8010
(dp8011
g12
I156
sg13
Vinfiltration
p8012
sg14
I12
sg15
VC0332448
p8013
sg17
I1
sa(dp8014
g12
I124
sg13
VEEC
p8015
sg14
I3
sg15
VC1851841
p8016
sg17
I1
sa(dp8017
g12
I100
sg13
g8008
sg14
I22
sg15
VC0206687
p8018
sg17
I2
sasg18
(lp8019
(dp8020
g12
I55
sg13
VETV5
p8021
sg14
I4
sg22
VP41161
p8022
sg17
I1
sa(dp8023
g12
I51
sg13
VERM
p8024
sg14
I3
sg22
VP41161
p8025
sg17
I1
sa(dp8026
g12
I33
sg13
g8007
sg14
I17
sg22
VP20908
p8027
sg17
I3
sasa(dp8028
g2
VWe have described recently the Ets family transcription factor, ERM/ETV5, specifically up-regulated in endometrioid endometrial carcinoma (EEC) and associated with myometrial infiltration.
p8029
sg4
(dp8030
(VEts family transcription factor
p8031
VEEC
p8032
tp8033
I00
ssg9
(lp8034
(dp8035
g12
I175
sg13
Vinfiltration
p8036
sg14
I12
sg15
VC0332448
p8037
sg17
I1
sa(dp8038
g12
I116
sg13
Vendometrial carcinoma
p8039
sg14
I21
sg15
VC0476089
p8040
sg17
I2
sa(dp8041
g12
I139
sg13
g8032
sg14
I3
sg15
VC1851841
p8042
sg17
I1
sasg18
(lp8043
(dp8044
g12
I68
sg13
VETV5
p8045
sg14
I4
sg22
VP41161
p8046
sg17
I1
sa(dp8047
g12
I64
sg13
VERM
p8048
sg14
I3
sg22
VP41161
p8049
sg17
I1
sa(dp8050
g12
I31
sg13
g8031
sg14
I31
sg22
VP35398
p8051
sg17
I4
sasa(dp8052
g2
VFinally, the specific localization of ERM/ETV5 and MMP-2 at the invasive front of myometrial infiltrating human endometrial carcinomas further reinforced the hypothesis of a role for ERM/ETV5 in the early steps of endometrial dissemination.
p8053
sg4
(dp8054
(VETV5
p8055
Vendometrial carcinomas
p8056
tp8057
I00
ssg9
(lp8058
(dp8059
g12
I93
sg13
Vinfiltrating
p8060
sg14
I12
sg15
VC0332448
p8061
sg17
I1
sa(dp8062
g12
I112
sg13
g8056
sg14
I22
sg15
VC0476089
p8063
sg17
I2
sasg18
(lp8064
(dp8065
g12
I42
sg13
VETV5
p8066
sg14
I4
sg22
VP41161
p8067
sg17
I1
sa(dp8068
g12
I38
sg13
VERM
p8069
sg14
I3
sg22
VP41161
p8070
sg17
I1
sa(dp8071
g12
I38
sg13
VERM
p8072
sg14
I3
sg22
VP41161
p8073
sg17
I1
sa(dp8074
g12
I51
sg13
VMMP-2
p8075
sg14
I5
sg22
VP08253
p8076
sg17
I1
sa(dp8077
g12
I42
sg13
g8055
sg14
I4
sg22
VP41161
p8078
sg17
I1
sasa(dp8079
g2
VSTAT5 LKO caused hyperglycemia, hyperinsulinemia, hyperleptinemia and elevated free fatty acid and cholesterol concentrations under HFD feeding but induced only hyperglycemia on normal diet.
p8080
sg4
(dp8081
(VSTAT5
p8082
Vhyperglycemia
p8083
tp8084
I00
ssg9
(lp8085
(dp8086
g12
I32
sg13
Vhyperinsulinemia
p8087
sg14
I16
sg15
VC0020459
p8088
sg17
I1
sa(dp8089
g12
I17
sg13
Vhyperglycemia
p8090
sg14
I13
sg15
VC0020456
p8091
sg17
I1
sa(dp8092
g12
I17
sg13
g8083
sg14
I13
sg15
VC0020456
p8093
sg17
I1
sasg18
(lp8094
(dp8095
g12
I0
sg13
g8082
sg14
I5
sg22
VP42229
p8096
sg17
I1
sasa(dp8097
g2
VPrx2 is a key cytoprotector against IO that is induced either by iron supplementation or due to chronic hemolysis as in Beta-thalassemia.
p8098
sg4
(dp8099
(VPrx2
p8100
VBeta-thalassemia
p8101
tp8102
I01
ssg9
(lp8103
(dp8104
g12
I104
sg13
Vhemolysis
p8105
sg14
I9
sg15
VC0019054
p8106
sg17
I1
sa(dp8107
g12
I120
sg13
g8101
sg14
I16
sg15
VC0005283
p8108
sg17
I1
sasg18
(lp8109
(dp8110
g12
I0
sg13
g8100
sg14
I4
sg22
VP32119
p8111
sg17
I1
sasa(dp8112
g2
VPeroxiredoxin-2 (Prx2), a typical 2-cysteine peroxiredoxin, is upregulated during Beta-thalassemic erythropoiesis, but its contribution to stress erythropoiesis, a common feature of thalassemia, is yet to be fully defined.
p8113
sg4
(dp8114
(VPrx2
p8115
Vthalassemia
p8116
tp8117
I00
ssg9
(lp8118
(dp8119
g12
I182
sg13
g8116
sg14
I11
sg15
VC0039730
p8120
sg17
I1
sasg18
(lp8121
(dp8122
g12
I0
sg13
VPeroxiredoxin-2
p8123
sg14
I15
sg22
VP32119
p8124
sg17
I1
sa(dp8125
g12
I17
sg13
g8115
sg14
I4
sg22
VP32119
p8126
sg17
I1
sasa(dp8127
g2
VIn the present study, we aimed to investigate plasma levels of peroxiredoxin 2 (Prx2) and thioredoxin 1 (Trx1), and the activity of thioredoxin reductase (TrxR), in thalassemia major (TM) patients living in the Antalya region, Turkey.
p8128
sg4
(dp8129
(VTrxR
p8130
Vthalassemia major
p8131
tp8132
I00
ssg9
(lp8133
(dp8134
g12
I184
sg13
VTM
p8135
sg14
I2
sg15
VC0002875
p8136
sg17
I1
sa(dp8137
g12
I165
sg13
g8131
sg14
I17
sg15
VC0002875
p8138
sg17
I2
sasg18
(lp8139
(dp8140
g12
I80
sg13
VPrx2
p8141
sg14
I4
sg22
VP32119
p8142
sg17
I1
sa(dp8143
g12
I90
sg13
Vthioredoxin 1
p8144
sg14
I13
sg22
VP10599
p8145
sg17
I2
sa(dp8146
g12
I132
sg13
Vthioredoxin reductase
p8147
sg14
I21
sg22
VP10599
p8148
sg17
I2
sa(dp8149
g12
I105
sg13
VTrx1
p8150
sg14
I4
sg22
VP60606
p8151
sg17
I1
sa(dp8152
g12
I63
sg13
Vperoxiredoxin 2
p8153
sg14
I15
sg22
VP32119
p8154
sg17
I2
sa(dp8155
g12
I155
sg13
g8130
sg14
I4
sg22
VP30044
p8156
sg17
I1
sasa(dp8157
g2
VProteomic analysis of microparticles released from thalassemia intermedia erythrocytes indicated that, besides hemichromes and clustered band 3, the microparticles contain a characteristic set of proteins that includes catalase, heat shock protein 70, peroxiredoxin 2 and carbonic anhydrase.
p8158
sg4
(dp8159
(Vcarbonic anhydrase
p8160
Vthalassemia intermedia
p8161
tp8162
I00
ssg9
(lp8163
(dp8164
g12
I51
sg13
g8161
sg14
I22
sg15
VC0271979
p8165
sg17
I2
sasg18
(lp8166
(dp8167
g12
I219
sg13
Vcatalase
p8168
sg14
I8
sg22
VP04040
p8169
sg17
I1
sa(dp8170
g12
I229
sg13
Vheat shock protein 70
p8171
sg14
I21
sg22
VP34932
p8172
sg17
I4
sa(dp8173
g12
I252
sg13
Vperoxiredoxin 2
p8174
sg14
I15
sg22
VP32119
p8175
sg17
I2
sa(dp8176
g12
I272
sg13
g8160
sg14
I18
sg22
VP35218
p8177
sg17
I2
sasa(dp8178
g2
VInterestingly, Prx II interacted with Hb in mouse RBCs, and their interaction, in particular, was severely impaired in RBCs of patients with thalassemia (THAL) and sickle cell anemia (SCA).
p8179
sg4
(dp8180
(VPrx II
p8181
VTHAL
p8182
tp8183
I00
ssg9
(lp8184
(dp8185
g12
I141
sg13
Vthalassemia
p8186
sg14
I11
sg15
VC0039730
p8187
sg17
I1
sa(dp8188
g12
I184
sg13
VSCA
p8189
sg14
I3
sg15
VC0002895
p8190
sg17
I1
sa(dp8191
g12
I164
sg13
Vsickle cell anemia
p8192
sg14
I18
sg15
VC0002895
p8193
sg17
I3
sa(dp8194
g12
I154
sg13
g8182
sg14
I4
sg15
VC0039730
p8195
sg17
I1
sa(dp8196
g12
I107
sg13
Vimpaired
p8197
sg14
I8
sg15
VC0684336
p8198
sg17
I1
sasg18
(lp8199
(dp8200
g12
I15
sg13
g8181
sg14
I6
sg22
VP30041
p8201
sg17
I2
sasa(dp8202
g2
VFurthermore, ANGPTL2 deficiency in a mouse unilateral ureteral obstruction model significantly reduced renal fibrosis by decreasing TGF-Beta1 signal amplification in kidney.
p8203
sg4
(dp8204
(VTGF-Beta1
p8205
Vureteral obstruction
p8206
tp8207
I00
ssg9
(lp8208
(dp8209
g12
I103
sg13
Vrenal fibrosis
p8210
sg14
I14
sg15
VC0151650
p8211
sg17
I2
sa(dp8212
g12
I54
sg13
g8206
sg14
I20
sg15
VC0041956
p8213
sg17
I2
sa(dp8214
g12
I149
sg13
Vamplification
p8215
sg14
I13
sg15
VC1705759
p8216
sg17
I1
sasg18
(lp8217
(dp8218
g12
I132
sg13
g8205
sg14
I9
sg22
VP01137
p8219
sg17
I1
sa(dp8220
g12
I13
sg13
VANGPTL2
p8221
sg14
I7
sg22
g190
sg17
I1
sasa(dp8222
g2
VThus, ANGPTL2 and TGF-Beta1 positively regulate each other as renal fibrosis progresses.
p8223
sg4
(dp8224
(VTGF-Beta1
p8225
Vrenal fibrosis
p8226
tp8227
I00
ssg9
(lp8228
(dp8229
g12
I62
sg13
g8226
sg14
I14
sg15
VC0151650
p8230
sg17
I2
sasg18
(lp8231
(dp8232
g12
I6
sg13
VANGPTL2
p8233
sg14
I7
sg22
g190
sg17
I1
sa(dp8234
g12
I18
sg13
g8225
sg14
I9
sg22
VP01137
p8235
sg17
I1
sasa(dp8236
g2
Vdemonstrated that genetic depletion of Angptl2 confers amelioration of the mouse kidney fibrosis induced by a unilateral ureteral obstruction, implicating that ANGPTL2, predominantly in the renal tubular compartments, activates the transforming growth factor-Beta signaling and vice versa through miR-221.
p8237
sg4
(dp8238
(Vtransforming growth factor-Beta
p8239
Vureteral obstruction
p8240
tp8241
I00
ssg9
(lp8242
(dp8243
g12
I81
sg13
Vkidney fibrosis
p8244
sg14
I15
sg15
VC0151650
p8245
sg17
I2
sa(dp8246
g12
I121
sg13
g8240
sg14
I20
sg15
VC0041956
p8247
sg17
I2
sasg18
(lp8248
(dp8249
g12
I160
sg13
VANGPTL2
p8250
sg14
I7
sg22
g190
sg17
I1
sa(dp8251
g12
I39
sg13
VAngptl2
p8252
sg14
I7
sg22
g190
sg17
I1
sa(dp8253
g12
I232
sg13
g8239
sg14
I31
sg22
VP18075
p8254
sg17
I3
sasa(dp8255
g2
VThe present findings indicate ANGPTL2 may mediate the inflammation in murine mastitis through the activation of IL-6 and TNF-Alfa.
p8256
sg4
(dp8257
(VTNF-Alfa
p8258
Vinflammation
p8259
tp8260
I00
ssg9
(lp8261
(dp8262
g12
I54
sg13
g8259
sg14
I12
sg15
VC0021368
p8263
sg17
I1
sa(dp8264
g12
I77
sg13
Vmastitis
p8265
sg14
I8
sg15
VC3251795
p8266
sg17
I1
sasg18
(lp8267
(dp8268
g12
I112
sg13
VIL-6
p8269
sg14
I4
sg22
VP05231
p8270
sg17
I1
sa(dp8271
g12
I121
sg13
g8258
sg14
I8
sg22
VP01375
p8272
sg17
I1
sa(dp8273
g12
I30
sg13
VANGPTL2
p8274
sg14
I7
sg22
g190
sg17
I1
sasa(dp8275
g2
VImprovements to restriction fragment length polymorphism (RFLP)-based genotyping assays currently used for detection of mutations responsible for bovine ferrochelatase and myophosphorylase deficiencies, and equine hyperkalemic periodic paralysis (HYPP) are described.
p8276
sg4
(dp8277
(Vmyophosphorylase
p8278
Vhyperkalemic periodic paralysis
p8279
tp8280
I00
ssg9
(lp8281
(dp8282
g12
I247
sg13
VHYPP
p8283
sg14
I4
sg15
VC0238357
p8284
sg17
I1
sa(dp8285
g12
I214
sg13
g8279
sg14
I31
sg15
VC0238357
p8286
sg17
I3
sasg18
(lp8287
(dp8288
g12
I146
sg13
Vbovine ferrochelatase
p8289
sg14
I21
sg22
VP22830
p8290
sg17
I2
sa(dp8291
g12
I172
sg13
g8278
sg14
I16
sg22
VP11217
p8292
sg17
I1
sasa(dp8293
g2
VIn this study, we examined the pharmacological profile of KCL-440, a new PARP inhibitor, and its neuroprotective effects in the rat acute cerebral infarction model induced by photothrombotic middle cerebral artery (MCA) occlusion.
p8294
sg4
(dp8295
(VPARP
p8296
Vcerebral infarction
p8297
tp8298
I00
ssg9
(lp8299
(dp8300
g12
I220
sg13
Vocclusion
p8301
sg14
I9
sg15
VC0028778
p8302
sg17
I1
sa(dp8303
g12
I138
sg13
g8297
sg14
I19
sg15
VC0038454
p8304
sg17
I2
sasg18
(lp8305
(dp8306
g12
I73
sg13
g8296
sg14
I4
sg22
VP09874
p8307
sg17
I1
sasa(dp8308
g2
VOur data thus suggest that the tested PARP polymorphisms do not principally contribute to cerebral infarction, although extensive searches would be required to clarify whether the PARP gene plays an important role in the pathogenesis of human stroke.
p8309
sg4
(dp8310
(VPARP
p8311
Vstroke
p8312
tp8313
I00
ssg9
(lp8314
(dp8315
g12
I221
sg13
Vpathogenesis
p8316
sg14
I12
sg15
VC0699748
p8317
sg17
I1
sa(dp8318
g12
I90
sg13
Vcerebral infarction
p8319
sg14
I19
sg15
VC0038454
p8320
sg17
I2
sa(dp8321
g12
I243
sg13
g8312
sg14
I6
sg15
VC0038454
p8322
sg17
I1
sasg18
(lp8323
(dp8324
g12
I180
sg13
VPARP gene
p8325
sg14
I9
sg22
VP09874
p8326
sg17
I2
sa(dp8327
g12
I38
sg13
g8311
sg14
I4
sg22
VP09874
p8328
sg17
I1
sasa(dp8329
g2
VThe OR of breast cancer for the percentage BPE measure (BPE%) quantified from SUB1 was 3.5 (95% Confidence Interval: 1.3, 9.8; p = 0.015) for 20% increments.
p8330
sg4
(dp8331
(VSUB1
p8332
Vbreast cancer
p8333
tp8334
I01
ssg9
(lp8335
(dp8336
g12
I10
sg13
g8333
sg14
I13
sg15
VC0678222
p8337
sg17
I2
sasg18
(lp8338
(dp8339
g12
I78
sg13
g8332
sg14
I4
sg22
VP53999
p8340
sg17
I1
sasa(dp8341
g2
VIn this study, we show elevated expression of SUB1 in aggressive prostate cancer.
p8342
sg4
(dp8343
(VSUB1
p8344
Vprostate cancer
p8345
tp8346
I01
ssg9
(lp8347
(dp8348
g12
I54
sg13
Vaggressive
p8349
sg14
I10
sg15
VC0001807
p8350
sg17
I1
sa(dp8351
g12
I65
sg13
g8345
sg14
I15
sg15
VC0600139
p8352
sg17
I2
sasg18
(lp8353
(dp8354
g12
I46
sg13
g8344
sg14
I4
sg22
VP53999
p8355
sg17
I1
sasa(dp8356
g2
VKnockdown of SUB1 in prostate cancer cells resulted in reduced cell proliferation, invasion and migration in vitro, and tumor growth and metastasis in vivo.
p8357
sg4
(dp8358
(VSUB1
p8359
Vprostate cancer
p8360
tp8361
I01
ssg9
(lp8362
(dp8363
g12
I120
sg13
Vtumor growth
p8364
sg14
I12
sg15
VC0598934
p8365
sg17
I2
sa(dp8366
g12
I137
sg13
Vmetastasis
p8367
sg14
I10
sg15
VC0027627
p8368
sg17
I1
sa(dp8369
g12
I68
sg13
Vproliferation
p8370
sg14
I13
sg15
VC0334094
p8371
sg17
I1
sa(dp8372
g12
I21
sg13
g8360
sg14
I15
sg15
VC0600139
p8373
sg17
I2
sa(dp8374
g12
I83
sg13
Vinvasion
p8375
sg14
I8
sg15
VC2699153
p8376
sg17
I1
sasg18
(lp8377
(dp8378
g12
I13
sg13
g8359
sg14
I4
sg22
VP53999
p8379
sg17
I1
sasa(dp8380
g2
VPLK1 knockdown or use of PLK1 inhibitor can mitigate oncogenic function of SUB1 in benign prostate cancer cells.
p8381
sg4
(dp8382
(VPLK1
p8383
Vprostate cancer
p8384
tp8385
I00
ssg9
(lp8386
(dp8387
g12
I90
sg13
g8384
sg14
I15
sg15
VC0600139
p8388
sg17
I2
sasg18
(lp8389
(dp8390
g12
I75
sg13
VSUB1
p8391
sg14
I4
sg22
VP53999
p8392
sg17
I1
sa(dp8393
g12
I0
sg13
VPLK1
p8394
sg14
I4
sg22
VP53350
p8395
sg17
I1
sa(dp8396
g12
I0
sg13
g8383
sg14
I4
sg22
VP53350
p8397
sg17
I1
sasa(dp8398
g2
VThus, our study suggests that miR-101 loss results in increased SUB1 expression and subsequent activation of known oncogenes driving prostate cancer progression and metastasis.
p8399
sg4
(dp8400
(VSUB1
p8401
Vmetastasis
p8402
tp8403
I01
ssg9
(lp8404
(dp8405
g12
I142
sg13
Vcancer progression
p8406
sg14
I18
sg15
VC0178874
p8407
sg17
I2
sa(dp8408
g12
I165
sg13
g8402
sg14
I10
sg15
VC0027627
p8409
sg17
I1
sasg18
(lp8410
(dp8411
g12
I64
sg13
g8401
sg14
I4
sg22
VP53999
p8412
sg17
I1
sa(dp8413
g12
I30
sg13
VmiR-101 loss
p8414
sg14
I12
sg22
g190
sg17
I2
sasa(dp8415
g2
VThis study therefore demonstrates functional role of SUB1 in prostate cancer, and identifies its regulation and potential downstream therapeutic targets of SUB1 in prostate cancer.
p8416
sg4
(dp8417
(VSUB1
p8418
Vprostate cancer
p8419
tp8420
I01
ssg9
(lp8421
(dp8422
g12
I61
sg13
Vprostate cancer
p8423
sg14
I15
sg15
VC0600139
p8424
sg17
I2
sa(dp8425
g12
I61
sg13
g8419
sg14
I15
sg15
VC0600139
p8426
sg17
I2
sasg18
(lp8427
(dp8428
g12
I53
sg13
VSUB1
p8429
sg14
I4
sg22
VP53999
p8430
sg17
I1
sa(dp8431
g12
I53
sg13
g8418
sg14
I4
sg22
VP53999
p8432
sg17
I1
sasa(dp8433
g2
VThe proposed study aims to explore whether PC4 correlates with VEGF-C/VEGF-D/VEGFR-3 axis of lymphangiogenesis in the lymph node metastasis during lung adenocarcinoma.
p8434
sg4
(dp8435
(VVEGFR
p8436
Vlymph node metastasis
p8437
tp8438
I00
ssg9
(lp8439
(dp8440
g12
I147
sg13
Vlung adenocarcinoma
p8441
sg14
I19
sg15
VC0152013
p8442
sg17
I2
sa(dp8443
g12
I118
sg13
g8437
sg14
I21
sg15
VC0686619
p8444
sg17
I3
sasg18
(lp8445
(dp8446
g12
I63
sg13
VVEGF-C
p8447
sg14
I6
sg22
VP49767
p8448
sg17
I1
sa(dp8449
g12
I77
sg13
g8436
sg14
I5
sg22
VP35968
p8450
sg17
I1
sasa(dp8451
g2
VHere, small interfering RNA technique was employed to investigate the relationship of PC4 and the VEGF-C/VEGF-D/VEGFR-3 axis in lung adenocarcinoma cell lines as well as tumor xenografts of mice model.
p8452
sg4
(dp8453
(VVEGFR-3
p8454
Vlung adenocarcinoma
p8455
tp8456
I00
ssg9
(lp8457
(dp8458
g12
I128
sg13
g8455
sg14
I19
sg15
VC0152013
p8459
sg17
I2
sa(dp8460
g12
I170
sg13
Vtumor
p8461
sg14
I5
sg15
VC0027651
p8462
sg17
I1
sasg18
(lp8463
(dp8464
g12
I98
sg13
VVEGF-C
p8465
sg14
I6
sg22
VP49767
p8466
sg17
I1
sa(dp8467
g12
I86
sg13
VPC4
p8468
sg14
I3
sg22
VP53999
p8469
sg17
I1
sa(dp8470
g12
I112
sg13
g8454
sg14
I7
sg22
VP35916
p8471
sg17
I1
sasa(dp8472
g2
VPC4 expression correlated with the levels of VEGF-C, VEGF-D and VEGFR-3 during the development of lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma in vitro and in vivo, which may be a novel marker in the development of lymphangiogenesis and lymphatic metastasis of tumors.
p8473
sg4
(dp8474
(VVEGFR-3
p8475
Vlymphatic metastasis
p8476
tp8477
I00
ssg9
(lp8478
(dp8479
g12
I144
sg13
Vlung adenocarcinoma
p8480
sg14
I19
sg15
VC0152013
p8481
sg17
I2
sa(dp8482
g12
I282
sg13
Vtumors
p8483
sg14
I6
sg15
VC0027651
p8484
sg17
I1
sa(dp8485
g12
I120
sg13
Vlymphatic metastasis
p8486
sg14
I20
sg15
VC0024232
p8487
sg17
I2
sa(dp8488
g12
I120
sg13
g8476
sg14
I20
sg15
VC0024232
p8489
sg17
I2
sasg18
(lp8490
(dp8491
g12
I45
sg13
VVEGF-C
p8492
sg14
I6
sg22
VP49767
p8493
sg17
I1
sa(dp8494
g12
I53
sg13
VVEGF-D
p8495
sg14
I6
sg22
g190
sg17
I1
sa(dp8496
g12
I0
sg13
VPC4
p8497
sg14
I3
sg22
VP53999
p8498
sg17
I1
sa(dp8499
g12
I64
sg13
g8475
sg14
I7
sg22
VP35916
p8500
sg17
I1
sasa(dp8501
g2
VTo evaluate soluble E-cadherin (sE-cadherin) as a potential tumour marker in patients with transitional cell carcinoma (TCC) of the bladder (previously shown to correlate with tumour grade, number of Ta/T1 tumours at presentation and a positive 3-month check cystoscopy) by assessing its serum concentration in relation to transurethral resection of bladder tumour (TURBT).
p8502
sg4
(dp8503
(Vsoluble E-cadherin
p8504
Vtransitional cell carcinoma
p8505
tp8506
I00
ssg9
(lp8507
(dp8508
g12
I60
sg13
Vtumour
p8509
sg14
I6
sg15
VC0027651
p8510
sg17
I1
sa(dp8511
g12
I120
sg13
VTCC
p8512
sg14
I3
sg15
VC1861305
p8513
sg17
I1
sa(dp8514
g12
I60
sg13
Vtumour
p8515
sg14
I6
sg15
VC0027651
p8516
sg17
I1
sa(dp8517
g12
I91
sg13
g8505
sg14
I27
sg15
VC0007138
p8518
sg17
I3
sa(dp8519
g12
I60
sg13
Vtumour
p8520
sg14
I6
sg15
VC0027651
p8521
sg17
I1
sa(dp8522
g12
I206
sg13
Vtumours
p8523
sg14
I7
sg15
VC0027651
p8524
sg17
I1
sasg18
(lp8525
(dp8526
g12
I12
sg13
g8504
sg14
I18
sg22
VP35558
p8527
sg17
I2
sa(dp8528
g12
I32
sg13
VsE-cadherin
p8529
sg14
I11
sg22
g190
sg17
I1
sasa(dp8530
g2
VElevated mRNA expression of liver IL-6, IL-17A, IL-17F, TGF-Beta1, Alfa-SMA, TGR5, NTCP, OATP1a1, and ileum ASBT and decreased liver IL-10, FXR, CAR, VDR, BSEP, MRP2, MRP3, MRP4 was also observed in ANIT-induced cholestasis but were attenuated or normalized by YCHT.
p8531
sg4
(dp8532
(VTGF-Beta1
p8533
VSMA
p8534
tp8535
I00
ssg9
(lp8536
(dp8537
g12
I145
sg13
VCAR
p8538
sg14
I3
sg15
VC2607929
p8539
sg17
I1
sa(dp8540
g12
I212
sg13
Vcholestasis
p8541
sg14
I11
sg15
VC0008370
p8542
sg17
I1
sa(dp8543
g12
I72
sg13
g8534
sg14
I3
sg15
VC0026847
p8544
sg17
I1
sasg18
(lp8545
(dp8546
g12
I34
sg13
VIL-6
p8547
sg14
I4
sg22
VP05231
p8548
sg17
I1
sa(dp8549
g12
I67
sg13
VAlfa-SMA
p8550
sg14
I8
sg22
g190
sg17
I1
sa(dp8551
g12
I83
sg13
VNTCP
p8552
sg14
I4
sg22
g190
sg17
I1
sa(dp8553
g12
I140
sg13
VFXR
p8554
sg14
I3
sg22
VP23945
p8555
sg17
I1
sa(dp8556
g12
I155
sg13
VBSEP
p8557
sg14
I4
sg22
g190
sg17
I1
sa(dp8558
g12
I150
sg13
VVDR
p8559
sg14
I3
sg22
VP11473
p8560
sg17
I1
sa(dp8561
g12
I173
sg13
VMRP4
p8562
sg14
I4
sg22
g190
sg17
I1
sa(dp8563
g12
I56
sg13
g8533
sg14
I9
sg22
VP01137
p8564
sg17
I1
sa(dp8565
g12
I77
sg13
VTGR5
p8566
sg14
I4
sg22
g190
sg17
I1
sa(dp8567
g12
I161
sg13
VMRP2
p8568
sg14
I4
sg22
g190
sg17
I1
sasa(dp8569
g2
VThe objective of the present study is to evaluate whether IL-6, TNF-Alfa, IL-10 are associated with nutritional status in patients with cirrhosis secondary to biliary atresia and compare to healthy controls.
p8570
sg4
(dp8571
(VTNF-Alfa
p8572
Vbiliary atresia
p8573
tp8574
I01
ssg9
(lp8575
(dp8576
g12
I136
sg13
Vcirrhosis
p8577
sg14
I9
sg15
VC0023890
p8578
sg17
I1
sa(dp8579
g12
I159
sg13
g8573
sg14
I15
sg15
VC0005411
p8580
sg17
I2
sasg18
(lp8581
(dp8582
g12
I58
sg13
VIL-6
p8583
sg14
I4
sg22
VP05231
p8584
sg17
I1
sa(dp8585
g12
I64
sg13
g8572
sg14
I8
sg22
VP01375
p8586
sg17
I1
sasa(dp8587
g2
VThe authors suggest that, in patients with cirrhosis secondary to biliary atresia, IL-6 could be used as a possible supporting biomarker of deficient nutritional status and elevated IL-10 levels could be used as a possible early-stage supporting biomarker of deteriorating nutritional status.
p8588
sg4
(dp8589
(VIL-6
p8590
Vcirrhosis
p8591
tp8592
I00
ssg9
(lp8593
(dp8594
g12
I66
sg13
Vbiliary atresia
p8595
sg14
I15
sg15
VC0005411
p8596
sg17
I2
sa(dp8597
g12
I43
sg13
g8591
sg14
I9
sg15
VC0023890
p8598
sg17
I1
sasg18
(lp8599
(dp8600
g12
I83
sg13
g8590
sg14
I4
sg22
VP05231
p8601
sg17
I1
sasa(dp8602
g2
VIn a prospective study, 47 patients with obstructive jaundice secondary to malignant lesions were evaluated before, at the fifth hour after, and on the fifth day after PTBD for neopterin, nitrate, tumor necrosis factor (TNF)-Alfa, interleukin (IL)-6, IL-10, CRP levels, and liver function.
p8603
sg4
(dp8604
(VCRP
p8605
Vtumor necrosis
p8606
tp8607
I01
ssg9
(lp8608
(dp8609
g12
I41
sg13
Vobstructive jaundice
p8610
sg14
I20
sg15
VC0022354
p8611
sg17
I2
sa(dp8612
g12
I197
sg13
g8606
sg14
I14
sg15
VC0333516
p8613
sg17
I2
sasg18
(lp8614
(dp8615
g12
I197
sg13
Vtumor necrosis factor (TNF)-Alfa
p8616
sg14
I32
sg22
VP01375
p8617
sg17
I4
sa(dp8618
g12
I231
sg13
Vinterleukin (IL)-6
p8619
sg14
I18
sg22
VP60568
p8620
sg17
I2
sa(dp8621
g12
I258
sg13
g8605
sg14
I3
sg22
VP02741
p8622
sg17
I1
sasa(dp8623
g2
VIt has been reported that the hypermethylation of APAF-1, DAPK-1 and other tumor suppressive genes (TSGs) correlates with progression of renal cell carcinoma and exerts prognostic and diagnostic relevance in renal cell carcinoma.
p8624
sg4
(dp8625
(VDAPK-1
p8626
Vrenal cell carcinoma
p8627
tp8628
I00
ssg9
(lp8629
(dp8630
g12
I137
sg13
Vrenal cell carcinoma
p8631
sg14
I20
sg15
VC0007134
p8632
sg17
I3
sa(dp8633
g12
I137
sg13
g8627
sg14
I20
sg15
VC0007134
p8634
sg17
I3
sa(dp8635
g12
I75
sg13
Vtumor
p8636
sg14
I5
sg15
VC0027651
p8637
sg17
I1
sasg18
(lp8638
(dp8639
g12
I58
sg13
g8626
sg14
I6
sg22
VP53355
p8640
sg17
I1
sasa(dp8641
g2
VThe present study confirmed that DAC demethylated the CpGs, particularly APAF-1 in renal carcinoma cells, and that the demethylation synergized the cytotoxity of CDDP in renal carcinoma cells via enhancing the CDDP-induced apoptosis.
p8642
sg4
(dp8643
(VDAC
p8644
Vrenal carcinoma
p8645
tp8646
I01
ssg9
(lp8647
(dp8648
g12
I83
sg13
Vrenal carcinoma
p8649
sg14
I15
sg15
VC0007134
p8650
sg17
I2
sa(dp8651
g12
I83
sg13
g8645
sg14
I15
sg15
VC0007134
p8652
sg17
I2
sasg18
(lp8653
(dp8654
g12
I33
sg13
g8644
sg14
I3
sg22
VP57775
p8655
sg17
I1
sasa(dp8656
g2
VThe aim of this study was to investigate the occurrence and relevance of promoter methylation of the tumor suppressor DAPK-1, APAF-1 () and SPARC in relation to different pathological stages and histological grades of tumor progression that might act as possible independent prognostic factor in the susceptibility towards renal cell carcinoma (RCC) in North Indian population.
p8657
sg4
(dp8658
(VSPARC
p8659
VRCC
p8660
tp8661
I00
ssg9
(lp8662
(dp8663
g12
I101
sg13
Vtumor
p8664
sg14
I5
sg15
VC0027651
p8665
sg17
I1
sa(dp8666
g12
I323
sg13
Vrenal cell carcinoma
p8667
sg14
I20
sg15
VC0007134
p8668
sg17
I3
sa(dp8669
g12
I218
sg13
Vtumor progression
p8670
sg14
I17
sg15
VC0178874
p8671
sg17
I2
sa(dp8672
g12
I345
sg13
g8660
sg14
I3
sg15
VC0007134
p8673
sg17
I1
sasg18
(lp8674
(dp8675
g12
I118
sg13
VDAPK-1
p8676
sg14
I6
sg22
VP53355
p8677
sg17
I1
sa(dp8678
g12
I140
sg13
g8659
sg14
I5
sg22
VP09486
p8679
sg17
I1
sasa(dp8680
g2
VTo examine the significance of the methylation level of the p53 target and tumour suppressor genes apoptotic protease activating factor-1 (APAF-1) and death-associated protein kinase-1 (DAPK-1) in 80 microdissected tumour samples from transitional cell carcinoma (TCC) of the bladder and 80 tumour samples from clear-cell renal cell carcinoma (RCC) as well as from non-tumourous bladder and kidney tissue.
p8681
sg4
(dp8682
(Vdeath-associated protein kinase-1
p8683
Vrenal cell carcinoma
p8684
tp8685
I00
ssg9
(lp8686
(dp8687
g12
I75
sg13
Vtumour
p8688
sg14
I6
sg15
VC0027651
p8689
sg17
I1
sa(dp8690
g12
I75
sg13
Vtumour
p8691
sg14
I6
sg15
VC0027651
p8692
sg17
I1
sa(dp8693
g12
I344
sg13
VRCC
p8694
sg14
I3
sg15
VC0007134
p8695
sg17
I1
sa(dp8696
g12
I264
sg13
VTCC
p8697
sg14
I3
sg15
VC1861305
p8698
sg17
I1
sa(dp8699
g12
I235
sg13
Vtransitional cell carcinoma
p8700
sg14
I27
sg15
VC0007138
p8701
sg17
I3
sa(dp8702
g12
I75
sg13
Vtumour
p8703
sg14
I6
sg15
VC0027651
p8704
sg17
I1
sa(dp8705
g12
I322
sg13
g8684
sg14
I20
sg15
VC0007134
p8706
sg17
I3
sasg18
(lp8707
(dp8708
g12
I186
sg13
VDAPK-1
p8709
sg14
I6
sg22
VP53355
p8710
sg17
I1
sa(dp8711
g12
I60
sg13
Vp53 target and tumour suppressor genes apoptotic protease activating factor-1
p8712
sg14
I77
sg22
g190
sg17
I10
sa(dp8713
g12
I151
sg13
g8683
sg14
I33
sg22
VP53355
p8714
sg17
I3
sasa(dp8715
g2
VQuantification of mRNA expression of HNF1B, six of its potential target genes (PKHD1, PKD1, PKD2, IFT88, TMEM27 and UMOD) and three genes involved in the Mg(2+) renal homeostasis (ATP1A1, FXYD2 and CLDN16) in the urinary sediment of 11 individuals with mutation of HNF1B and in 9 controls (non-invasive assessment of the renal transcriptome).
p8716
sg4
(dp8717
(VPKD1
p8718
VPKD1
p8719
tp8720
I00
ssg9
(lp8721
(dp8722
g12
I79
sg13
VPKHD1
p8723
sg14
I5
sg15
VC0085548
p8724
sg17
I1
sa(dp8725
g12
I92
sg13
VPKD2
p8726
sg14
I4
sg15
VC2751306
p8727
sg17
I1
sa(dp8728
g12
I86
sg13
g8719
sg14
I4
sg15
VC3149841
p8729
sg17
I1
sasg18
(lp8730
(dp8731
g12
I105
sg13
VTMEM27
p8732
sg14
I6
sg22
g190
sg17
I1
sa(dp8733
g12
I188
sg13
VFXYD2
p8734
sg14
I5
sg22
VP54710
p8735
sg17
I1
sa(dp8736
g12
I37
sg13
VHNF1B
p8737
sg14
I5
sg22
VP35680
p8738
sg17
I1
sa(dp8739
g12
I92
sg13
VPKD2
p8740
sg14
I4
sg22
g190
sg17
I1
sa(dp8741
g12
I180
sg13
VATP1A1
p8742
sg14
I6
sg22
VP05023
p8743
sg17
I1
sa(dp8744
g12
I37
sg13
VHNF1B
p8745
sg14
I5
sg22
VP35680
p8746
sg17
I1
sa(dp8747
g12
I98
sg13
VIFT88
p8748
sg14
I5
sg22
g190
sg17
I1
sa(dp8749
g12
I116
sg13
VUMOD
p8750
sg14
I4
sg22
VP07911
p8751
sg17
I1
sa(dp8752
g12
I79
sg13
VPKHD1
p8753
sg14
I5
sg22
VP08F94
p8754
sg17
I1
sa(dp8755
g12
I198
sg13
VCLDN16
p8756
sg14
I6
sg22
g190
sg17
I1
sa(dp8757
g12
I86
sg13
g8718
sg14
I4
sg22
VP98161
p8758
sg17
I1
sasa(dp8759
g2
VCollectrin is a downstream target of the transcription factor hepatocyte nuclear factor-1alpha (HNF-1alpha), which is mutated in maturity-onset diabetes of the young subtype 3 (MODY3).
p8760
sg4
(dp8761
(Vmaturity-onset diabetes of the young subtype 3
p8762
Vmaturity-onset diabetes of the young subtype 3
p8763
tp8764
I00
ssg9
(lp8765
(dp8766
g12
I177
sg13
VMODY3
p8767
sg14
I5
sg15
VC1838100
p8768
sg17
I1
sa(dp8769
g12
I129
sg13
g8763
sg14
I46
sg15
VC1838100
p8770
sg17
I7
sasg18
(lp8771
(dp8772
g12
I62
sg13
Vhepatocyte nuclear factor-1alpha
p8773
sg14
I32
sg22
VP20823
p8774
sg17
I3
sa(dp8775
g12
I177
sg13
VMODY3
p8776
sg14
I5
sg22
VP20823
p8777
sg17
I1
sa(dp8778
g12
I0
sg13
VCollectrin
p8779
sg14
I10
sg22
g190
sg17
I1
sa(dp8780
g12
I96
sg13
VHNF-1alpha
p8781
sg14
I10
sg22
VP20823
p8782
sg17
I1
sa(dp8783
g12
I129
sg13
g8762
sg14
I46
sg22
VP20823
p8784
sg17
I7
sasa(dp8785
g2
VTo determine the difference in thrombomodulin expression in the myometrium and in myoma; and to understand the correlation of anticoagulation/fibrinolytic function and the mechanism of uterine artery occlusion in the treatment of leiomyoma.
p8786
sg4
(dp8787
(Vthrombomodulin
p8788
Vmyoma
p8789
tp8790
I00
ssg9
(lp8791
(dp8792
g12
I230
sg13
Vleiomyoma
p8793
sg14
I9
sg15
VC0023267
p8794
sg17
I1
sa(dp8795
g12
I82
sg13
g8789
sg14
I5
sg15
VC0027086
p8796
sg17
I1
sa(dp8797
g12
I193
sg13
Vartery occlusion
p8798
sg14
I16
sg15
VC0264995
p8799
sg17
I2
sasg18
(lp8800
(dp8801
g12
I31
sg13
g8788
sg14
I14
sg22
VP07204
p8802
sg17
I1
sasa(dp8803
g2
VSimilarly, leiomyoma-associated endometrium expressed less PAI-1 and thrombomodulin in vivo.
p8804
sg4
(dp8805
(Vthrombomodulin
p8806
Vleiomyoma
p8807
tp8808
I00
ssg9
(lp8809
(dp8810
g12
I11
sg13
g8807
sg14
I9
sg15
VC0023267
p8811
sg17
I1
sasg18
(lp8812
(dp8813
g12
I59
sg13
VPAI-1
p8814
sg14
I5
sg22
VP05121
p8815
sg17
I1
sa(dp8816
g12
I69
sg13
g8806
sg14
I14
sg22
VP07204
p8817
sg17
I1
sasa(dp8818
g2
VAlfa-methylacyl coenzyme A racemase (AMACR) and insulin-like growth factor-II mRNA-binding protein 3 (IMP3) are 2 markers helpful in detecting difficult cases of dysplasia in Barrett esophagus (BE).
p8819
sg4
(dp8820
(Vinsulin-like growth factor-II mRNA-binding protein 3
p8821
VBarrett esophagus
p8822
tp8823
I00
ssg9
(lp8824
(dp8825
g12
I194
sg13
VBE
p8826
sg14
I2
sg15
VC0004763
p8827
sg17
I1
sa(dp8828
g12
I162
sg13
Vdysplasia
p8829
sg14
I9
sg15
VC0334044
p8830
sg17
I1
sa(dp8831
g12
I175
sg13
g8822
sg14
I17
sg15
VC0004763
p8832
sg17
I2
sasg18
(lp8833
(dp8834
g12
I48
sg13
g8821
sg14
I52
sg22
VP01308
p8835
sg17
I6
sa(dp8836
g12
I102
sg13
VIMP3
p8837
sg14
I4
sg22
g190
sg17
I1
sa(dp8838
g12
I37
sg13
VAMACR
p8839
sg14
I5
sg22
g190
sg17
I1
sa(dp8840
g12
I0
sg13
VAlfa-methylacyl coenzyme A racemase
p8841
sg14
I35
sg22
g190
sg17
I4
sasa(dp8842
g2
VThese associations implicate genes related to apoptosis (HRK), development (WIF1), oxidative stress (MSR3B), ubiquitination (FBXW8) and neuronal migration (ASTN2), as well as enzymes targeted by new diabetes medications (DPP4), indicating new genetic influences on hippocampal size and possibly the risk of cognitive decline and dementia.
p8843
sg4
(dp8844
(VDPP4
p8845
Vcognitive decline
p8846
tp8847
I01
ssg9
(lp8848
(dp8849
g12
I199
sg13
Vdiabetes
p8850
sg14
I8
sg15
VC0011849
p8851
sg17
I1
sa(dp8852
g12
I329
sg13
Vdementia
p8853
sg14
I8
sg15
VC0497327
p8854
sg17
I1
sa(dp8855
g12
I83
sg13
Voxidative stress
p8856
sg14
I16
sg15
VC0242606
p8857
sg17
I2
sa(dp8858
g12
I307
sg13
g8846
sg14
I17
sg15
VC0338656
p8859
sg17
I2
sasg18
(lp8860
(dp8861
g12
I221
sg13
g8845
sg14
I4
sg22
VP27487
p8862
sg17
I1
sa(dp8863
g12
I125
sg13
VFBXW8
p8864
sg14
I5
sg22
g190
sg17
I1
sa(dp8865
g12
I76
sg13
VWIF1
p8866
sg14
I4
sg22
g190
sg17
I1
sasa(dp8867
g2
VIn a prospective randomized crossover trial, patients with acute renal failure received CRRT with either sodium bicarbonate (Bic) or sodium lactate (Lac) as a buffering agent over 2 consecutive 24-h periods.
p8868
sg4
(dp8869
(VLac
p8870
Vacute renal failure
p8871
tp8872
I00
ssg9
(lp8873
(dp8874
g12
I59
sg13
g8871
sg14
I19
sg15
VC0022660
p8875
sg17
I3
sasg18
(lp8876
(dp8877
g12
I140
sg13
Vlactate
p8878
sg14
I7
sg22
VP09848
p8879
sg17
I1
sa(dp8880
g12
I149
sg13
g8870
sg14
I3
sg22
VP09848
p8881
sg17
I1
sasa(dp8882
g2
VTo unmask weak inputs from outside the conventional RF (CRF), cell excitability was raised by iontophoretic application of glutamate (GLU) and/or bicuculline methiodide (BIC) or by light stimulation of the CRF.
p8883
sg4
(dp8884
(Vconventional RF
p8885
Vconventional RF
p8886
tp8887
I00
ssg9
(lp8888
(dp8889
g12
I56
sg13
VCRF
p8890
sg14
I3
sg15
VC0022661
p8891
sg17
I1
sa(dp8892
g12
I67
sg13
Vexcitability
p8893
sg14
I12
sg15
VC0235169
p8894
sg17
I1
sa(dp8895
g12
I56
sg13
VCRF
p8896
sg14
I3
sg15
VC0022661
p8897
sg17
I1
sa(dp8898
g12
I39
sg13
g8886
sg14
I15
sg15
VC0022661
p8899
sg17
I2
sasg18
(lp8900
(dp8901
g12
I56
sg13
VCRF
p8902
sg14
I3
sg22
VP06850
p8903
sg17
I1
sa(dp8904
g12
I39
sg13
g8885
sg14
I15
sg22
VP06850
p8905
sg17
I2
sasa(dp8906
g2
VIn an open, randomized, multicenter study, we investigated the effects of RF-bic and RF-lac on cardiovascular outcome in patients requiring CVVH following acute renal failure.
p8907
sg4
(dp8908
(VRF-lac
p8909
Vacute renal failure
p8910
tp8911
I00
ssg9
(lp8912
(dp8913
g12
I155
sg13
g8910
sg14
I19
sg15
VC0022660
p8914
sg17
I3
sasg18
(lp8915
(dp8916
g12
I85
sg13
g8909
sg14
I6
sg22
VP09848
p8917
sg17
I1
sasa(dp8918
g2
VThe primary influence of BIC and, to a lesser degree, 2-OH-S was to prolong the response duration of VPM neurons to CRF whisker stimulation.
p8919
sg4
(dp8920
(VCRF
p8921
VCRF
p8922
tp8923
I00
ssg9
(lp8924
(dp8925
g12
I116
sg13
g8922
sg14
I3
sg15
VC0022661
p8926
sg17
I1
sasg18
(lp8927
(dp8928
g12
I116
sg13
g8921
sg14
I3
sg22
VP06850
p8929
sg17
I1
sasa(dp8930
g2
VThe FGF9 subfamily, including FGF9, FGF16, and FGF20, in addition to rhFGF16, rhFGF9, and rhFGF20, were shown to stimulate the proliferation and migration of HuH7 human hepatocellular carcinoma (HCC) cells.
p8931
sg4
(dp8932
(VFGF9
p8933
VHCC
p8934
tp8935
I00
ssg9
(lp8936
(dp8937
g12
I169
sg13
Vhepatocellular carcinoma
p8938
sg14
I24
sg15
VC2239176
p8939
sg17
I2
sa(dp8940
g12
I195
sg13
g8934
sg14
I3
sg15
VC2239176
p8941
sg17
I1
sa(dp8942
g12
I127
sg13
Vproliferation
p8943
sg14
I13
sg15
VC0334094
p8944
sg17
I1
sasg18
(lp8945
(dp8946
g12
I4
sg13
VFGF9 subfamily
p8947
sg14
I14
sg22
VP31371
p8948
sg17
I2
sa(dp8949
g12
I4
sg13
g8933
sg14
I4
sg22
VP31371
p8950
sg17
I1
sa(dp8951
g12
I36
sg13
VFGF16
p8952
sg14
I5
sg22
g190
sg17
I1
sa(dp8953
g12
I47
sg13
VFGF20
p8954
sg14
I5
sg22
g190
sg17
I1
sasa(dp8955
g2
VFurthermore, the results indicate that exogenous rhFGF9- and rhFGF20-activated ERK/NF-KB signal transduction pathways play important roles in the regulation of HCC cell proliferation and migration, and this discovery helps to find the potential for new solutions of the treatment of liver cancer.
p8956
sg4
(dp8957
(VERK
p8958
Vliver cancer
p8959
tp8960
I00
ssg9
(lp8961
(dp8962
g12
I169
sg13
Vproliferation
p8963
sg14
I13
sg15
VC0334094
p8964
sg17
I1
sa(dp8965
g12
I160
sg13
VHCC
p8966
sg14
I3
sg15
VC2239176
p8967
sg17
I1
sa(dp8968
g12
I283
sg13
g8959
sg14
I12
sg15
VC0345904
p8969
sg17
I2
sasg18
(lp8970
(dp8971
g12
I79
sg13
g8958
sg14
I3
sg22
VP29323
p8972
sg17
I1
sasa(dp8973
g2
VThese include FGF3 in Michel aplasia; FGF8 in cleft lip/palate and in hypogonadotropic hypogonadism; FGF9 in carcinoma; FGF10 in the lacrimal/salivary glands aplasia, and lacrimo-auriculo-dento-digital syndrome; FGF14 in spinocerebellar ataxia; FGF20 in Parkinson disease; and FGF23 in tumoral calcinosis and hypophosphatemic rickets.
p8974
sg4
(dp8975
(VFGF3
p8976
Vspinocerebellar ataxia
p8977
tp8978
I00
ssg9
(lp8979
(dp8980
g12
I254
sg13
VParkinson disease
p8981
sg14
I17
sg15
VC0030567
p8982
sg17
I2
sa(dp8983
g12
I29
sg13
Vaplasia
p8984
sg14
I7
sg15
VC0243065
p8985
sg17
I1
sa(dp8986
g12
I171
sg13
Vlacrimo-auriculo-dento-digital syndrome
p8987
sg14
I39
sg15
VC0265269
p8988
sg17
I2
sa(dp8989
g12
I46
sg13
Vcleft lip/palate
p8990
sg14
I16
sg15
VC0158646
p8991
sg17
I2
sa(dp8992
g12
I309
sg13
Vhypophosphatemic rickets
p8993
sg14
I24
sg15
VC1704375
p8994
sg17
I2
sa(dp8995
g12
I286
sg13
Vtumoral calcinosis
p8996
sg14
I18
sg15
VC0263628
p8997
sg17
I2
sa(dp8998
g12
I109
sg13
Vcarcinoma
p8999
sg14
I9
sg15
VC0007097
p9000
sg17
I1
sa(dp9001
g12
I29
sg13
Vaplasia
p9002
sg14
I7
sg15
VC0243065
p9003
sg17
I1
sa(dp9004
g12
I70
sg13
Vhypogonadotropic hypogonadism
p9005
sg14
I29
sg15
VC0022735
p9006
sg17
I2
sa(dp9007
g12
I221
sg13
g8977
sg14
I22
sg15
VC0087012
p9008
sg17
I2
sasg18
(lp9009
(dp9010
g12
I120
sg13
VFGF10
p9011
sg14
I5
sg22
g190
sg17
I1
sa(dp9012
g12
I277
sg13
VFGF23
p9013
sg14
I5
sg22
g190
sg17
I1
sa(dp9014
g12
I38
sg13
VFGF8
p9015
sg14
I4
sg22
VP55075
p9016
sg17
I1
sa(dp9017
g12
I212
sg13
VFGF14
p9018
sg14
I5
sg22
g190
sg17
I1
sa(dp9019
g12
I101
sg13
VFGF9
p9020
sg14
I4
sg22
VP31371
p9021
sg17
I1
sa(dp9022
g12
I14
sg13
g8976
sg14
I4
sg22
VP11487
p9023
sg17
I1
sasa(dp9024
g2
VMolecular genetics and developmental studies have identified 21 genes in this region (ADRA1A, ARHGEF10, CHRNA2, CHRNA6, CHRNB3, DKK4, DPYSL2, EGR3, FGF17, FGF20, FGFR1, FZD3, LDL, NAT2, NEF3, NRG1, PCM1, PLAT, PPP3CC, SFRP1 and VMAT1/SLC18A1) that are most likely to contribute to neuropsychiatric disorders (schizophrenia, autism, bipolar disorder and depression), neurodegenerative disorders (Parkinson's and Alzheimer's disease) and cancer.
p9025
sg4
(dp9026
(VFGFR1
p9027
Vdepression
p9028
tp9029
I00
ssg9
(lp9030
(dp9031
g12
I436
sg13
Vcancer
p9032
sg14
I6
sg15
VC0006826
p9033
sg17
I1
sa(dp9034
g12
I309
sg13
Vschizophrenia
p9035
sg14
I13
sg15
VC0036341
p9036
sg17
I1
sa(dp9037
g12
I332
sg13
Vbipolar disorder
p9038
sg14
I16
sg15
VC0005586
p9039
sg17
I2
sa(dp9040
g12
I324
sg13
Vautism
p9041
sg14
I6
sg15
VC0004352
p9042
sg17
I1
sa(dp9043
g12
I366
sg13
Vneurodegenerative disorders
p9044
sg14
I27
sg15
VC0524851
p9045
sg17
I2
sa(dp9046
g12
I353
sg13
g9028
sg14
I10
sg15
VC0011581
p9047
sg17
I1
sa(dp9048
g12
I411
sg13
VAlzheimer's disease
p9049
sg14
I19
sg15
VC1521724
p9050
sg17
I2
sasg18
(lp9051
(dp9052
g12
I94
sg13
VARHGEF10
p9053
sg14
I8
sg22
g190
sg17
I1
sa(dp9054
g12
I186
sg13
VNEF3
p9055
sg14
I4
sg22
VP07197
p9056
sg17
I1
sa(dp9057
g12
I210
sg13
VPPP3CC
p9058
sg14
I6
sg22
VP48454
p9059
sg17
I1
sa(dp9060
g12
I142
sg13
VEGR3
p9061
sg14
I4
sg22
g190
sg17
I1
sa(dp9062
g12
I120
sg13
VCHRNB3
p9063
sg14
I6
sg22
g190
sg17
I1
sa(dp9064
g12
I86
sg13
VADRA1A
p9065
sg14
I6
sg22
VP25100
p9066
sg17
I1
sa(dp9067
g12
I234
sg13
VSLC18A1
p9068
sg14
I7
sg22
VP54219
p9069
sg17
I1
sa(dp9070
g12
I228
sg13
VVMAT1
p9071
sg14
I5
sg22
VP54219
p9072
sg17
I1
sa(dp9073
g12
I180
sg13
VNAT2
p9074
sg14
I4
sg22
VP18440
p9075
sg17
I1
sa(dp9076
g12
I128
sg13
VDKK4
p9077
sg14
I4
sg22
g190
sg17
I1
sa(dp9078
g12
I162
sg13
g9027
sg14
I5
sg22
VP20930
p9079
sg17
I1
sa(dp9080
g12
I104
sg13
VCHRNA2
p9081
sg14
I6
sg22
g190
sg17
I1
sa(dp9082
g12
I134
sg13
VDPYSL2
p9083
sg14
I6
sg22
g190
sg17
I1
sa(dp9084
g12
I169
sg13
VFZD3
p9085
sg14
I4
sg22
g190
sg17
I1
sa(dp9086
g12
I148
sg13
VFGF17
p9087
sg14
I5
sg22
g190
sg17
I1
sa(dp9088
g12
I155
sg13
VFGF20
p9089
sg14
I5
sg22
g190
sg17
I1
sa(dp9090
g12
I218
sg13
VSFRP1
p9091
sg14
I5
sg22
g190
sg17
I1
sa(dp9092
g12
I198
sg13
VPCM1
p9093
sg14
I4
sg22
g190
sg17
I1
sa(dp9094
g12
I112
sg13
VCHRNA6
p9095
sg14
I6
sg22
g190
sg17
I1
sasa(dp9096
g2
VEphrinB2 (erythropoietin-producing hepatoma interactor B2), a pivotal bidirectional signaling molecule ubiquitously expressed in mammals, is crucial in angiogenesis during development and disease progression.
p9097
sg4
(dp9098
(VEphrinB2
p9099
Vhepatoma
p9100
tp9101
I00
ssg9
(lp9102
(dp9103
g12
I35
sg13
g9100
sg14
I8
sg15
VC0023903
p9104
sg17
I1
sa(dp9105
g12
I188
sg13
Vdisease progression
p9106
sg14
I19
sg15
VC0242656
p9107
sg17
I2
sasg18
(lp9108
(dp9109
g12
I10
sg13
Verythropoietin
p9110
sg14
I14
sg22
VP01588
p9111
sg17
I1
sa(dp9112
g12
I0
sg13
g9099
sg14
I8
sg22
VP52799
p9113
sg17
I1
sasa(dp9114
g2
VThe aim of the present study was to detect the correlation between the expression of vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2), ephrinB2 and endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and carcinogenesis or portal vein tumor thrombus (PVTT) formation in human hepatocellular carcinoma (HCC).
p9115
sg4
(dp9116
(Vendocrine gland-derived vascular endothelial growth factor
p9117
Vhepatocellular carcinoma
p9118
tp9119
I00
ssg9
(lp9120
(dp9121
g12
I334
sg13
VHCC
p9122
sg14
I3
sg15
VC2239176
p9123
sg17
I1
sa(dp9124
g12
I237
sg13
Vcarcinogenesis
p9125
sg14
I14
sg15
VC0596263
p9126
sg17
I1
sa(dp9127
g12
I267
sg13
Vtumor thrombus
p9128
sg14
I14
sg15
VC3163918
p9129
sg17
I2
sa(dp9130
g12
I308
sg13
g9118
sg14
I24
sg15
VC2239176
p9131
sg17
I2
sasg18
(lp9132
(dp9133
g12
I128
sg13
Vangiopoietin 2
p9134
sg14
I14
sg22
g190
sg17
I2
sa(dp9135
g12
I85
sg13
Vvascular endothelial growth factor
p9136
sg14
I34
sg22
g190
sg17
I4
sa(dp9137
g12
I151
sg13
VephrinB2
p9138
sg14
I8
sg22
VP52799
p9139
sg17
I1
sa(dp9140
g12
I224
sg13
VEG-VEGF
p9141
sg14
I7
sg22
VP58294
p9142
sg17
I1
sa(dp9143
g12
I164
sg13
g9117
sg14
I58
sg22
VP58294
p9144
sg17
I6
sa(dp9145
g12
I144
sg13
VAng2
p9146
sg14
I4
sg22
g190
sg17
I1
sa(dp9147
g12
I121
sg13
VVEGF
p9148
sg14
I4
sg22
g190
sg17
I1
sasa(dp9149
g2
VTo study the possible involvement of the rod (SLC24A1) and cone (SLC24A2) Na-Ca+K exchanger (NCKX) genes in retinal diseases.
p9150
sg4
(dp9151
(Vrod
p9152
Vretinal diseases
p9153
tp9154
I00
ssg9
(lp9155
(dp9156
g12
I108
sg13
g9153
sg14
I16
sg15
VC0035309
p9157
sg17
I2
sasg18
(lp9158
(dp9159
g12
I74
sg13
VNa-Ca+K exchanger (NCKX) genes
p9160
sg14
I30
sg22
g190
sg17
I4
sa(dp9161
g12
I65
sg13
VSLC24A2
p9162
sg14
I7
sg22
g190
sg17
I1
sa(dp9163
g12
I41
sg13
g9152
sg14
I3
sg22
VP50748
p9164
sg17
I1
sa(dp9165
g12
I46
sg13
VSLC24A1
p9166
sg14
I7
sg22
g190
sg17
I1
sasa(dp9167
g2
VApproximately 23% of patients with metastatic castration-resistant prostate cancer exhibit somatic or germline aberrations in genes implicated in DNA repair, such as BRCA2, BRCA1, ATM, CHEK2, and PALB2, as well as mismatch repair genes.
p9168
sg4
(dp9169
(VBRCA1
p9170
Vprostate cancer
p9171
tp9172
I00
ssg9
(lp9173
(dp9174
g12
I67
sg13
g9171
sg14
I15
sg15
VC0600139
p9175
sg17
I2
sasg18
(lp9176
(dp9177
g12
I166
sg13
VBRCA2
p9178
sg14
I5
sg22
VP51587
p9179
sg17
I1
sa(dp9180
g12
I196
sg13
VPALB2
p9181
sg14
I5
sg22
g190
sg17
I1
sa(dp9182
g12
I180
sg13
VATM
p9183
sg14
I3
sg22
g190
sg17
I1
sa(dp9184
g12
I173
sg13
g9170
sg14
I5
sg22
VP38398
p9185
sg17
I1
sasa(dp9186
g2
VMen who inherit pathogenic germline mutations in BRCA2 and BRCA1 are at increased risk of developing aggressive prostate cancer, and those with germline mutations in other DNA repair genes such as ATM, CHEK2, and MSH2/MSH6 may also have increased risks.
p9187
sg4
(dp9188
(VMSH6
p9189
Vprostate cancer
p9190
tp9191
I00
ssg9
(lp9192
(dp9193
g12
I101
sg13
Vaggressive
p9194
sg14
I10
sg15
VC0001807
p9195
sg17
I1
sa(dp9196
g12
I112
sg13
g9190
sg14
I15
sg15
VC0600139
p9197
sg17
I2
sasg18
(lp9198
(dp9199
g12
I213
sg13
VMSH2
p9200
sg14
I4
sg22
VP43246
p9201
sg17
I1
sa(dp9202
g12
I197
sg13
VATM
p9203
sg14
I3
sg22
g190
sg17
I1
sa(dp9204
g12
I49
sg13
VBRCA2
p9205
sg14
I5
sg22
VP51587
p9206
sg17
I1
sa(dp9207
g12
I59
sg13
VBRCA1
p9208
sg14
I5
sg22
VP38398
p9209
sg17
I1
sa(dp9210
g12
I218
sg13
g9189
sg14
I4
sg22
VP52701
p9211
sg17
I1
sasa(dp9212
g2
VHuman limbal neurospheres expressed the neural lineage markers, Nestin, sex determining region box-2 and N-cadherin, and the retinal transcription factors microphthalmia-associated transcription factor, sex determining region box-2 and orthodentical homeobox-2.
p9213
sg4
(dp9214
(VN-cadherin
p9215
Vmicrophthalmia
p9216
tp9217
I00
ssg9
(lp9218
(dp9219
g12
I155
sg13
g9216
sg14
I14
sg15
VC0026010
p9220
sg17
I1
sasg18
(lp9221
(dp9222
g12
I250
sg13
Vhomeobox-2
p9223
sg14
I10
sg22
VP52954
p9224
sg17
I1
sa(dp9225
g12
I64
sg13
VNestin, sex determining region box-2
p9226
sg14
I36
sg22
VP48681
p9227
sg17
I5
sa(dp9228
g12
I105
sg13
g9215
sg14
I10
sg22
VP19022
p9229
sg17
I1
sa(dp9230
g12
I125
sg13
Vretinal transcription factors microphthalmia-associated transcription factor, sex determining region box-2
p9231
sg14
I106
sg22
g190
sg17
I10
sasa(dp9232
g2
VMutations of orthodentricle homeobox 2 (OTX2) in human and mice often cause retinal dystrophy and nyctalopia, suggesting a role of OTX2 in mature retina, in addition to its functions in the development of the eye and retina.
p9233
sg4
(dp9234
(VOTX2
p9235
Vnyctalopia
p9236
tp9237
I00
ssg9
(lp9238
(dp9239
g12
I76
sg13
Vretinal dystrophy
p9240
sg14
I17
sg15
VC0854723
p9241
sg17
I2
sa(dp9242
g12
I98
sg13
g9236
sg14
I10
sg15
VC0028077
p9243
sg17
I1
sasg18
(lp9244
(dp9245
g12
I40
sg13
VOTX2
p9246
sg14
I4
sg22
VP32243
p9247
sg17
I1
sa(dp9248
g12
I13
sg13
Vorthodentricle homeobox 2
p9249
sg14
I25
sg22
VP32243
p9250
sg17
I3
sa(dp9251
g12
I40
sg13
g9235
sg14
I4
sg22
VP32243
p9252
sg17
I1
sasa(dp9253
g2
VTHE ROLE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS: Angiotensin-converting enzyme inhibitors (ACE) affect the different mechanisms that lead to glomerulosclerosis: antihypertensive effect, with the normalisation of blood pressure having demonstrated its determining role in the production of nephrosis in various epidemiological studies; hemodynamic effect with a decrease in glomerular capillary pressure, in the filtration fraction, and inhibition of the bradykinin deterioration; antiproteinuric effect superior to that of other anti-hypertensive drugs (excepting angiotensin II-receptor antagonists).
p9254
sg4
(dp9255
(Vbradykinin
p9256
Vglomerulosclerosis
p9257
tp9258
I00
ssg9
(lp9259
(dp9260
g12
I294
sg13
Vnephrosis
p9261
sg14
I9
sg15
VC0027720
p9262
sg17
I1
sa(dp9263
g12
I146
sg13
g9257
sg14
I18
sg15
VC0178664
p9264
sg17
I1
sasg18
(lp9265
(dp9266
g12
I96
sg13
VACE
p9267
sg14
I3
sg22
VP12821
p9268
sg17
I1
sa(dp9269
g12
I569
sg13
Vangiotensin II-receptor
p9270
sg14
I23
sg22
VP01019
p9271
sg17
I2
sa(dp9272
g12
I54
sg13
VAngiotensin-converting enzyme inhibitors
p9273
sg14
I40
sg22
VP12821
p9274
sg17
I3
sa(dp9275
g12
I459
sg13
g9256
sg14
I10
sg22
VP01042
p9276
sg17
I1
sasa(dp9277
g2
VTo investigate whether the reduction in proteinuria is due to decreased generation of angiotensin II (AngII) or to decreased degradation of bradykinin, four series of experiments in established adriamycin nephrosis were performed.
p9278
sg4
(dp9279
(Vangiotensin II
p9280
Vnephrosis
p9281
tp9282
I01
ssg9
(lp9283
(dp9284
g12
I205
sg13
g9281
sg14
I9
sg15
VC0027720
p9285
sg17
I1
sasg18
(lp9286
(dp9287
g12
I140
sg13
Vbradykinin
p9288
sg14
I10
sg22
VP01042
p9289
sg17
I1
sa(dp9290
g12
I102
sg13
VAngII
p9291
sg14
I5
sg22
VP01019
p9292
sg17
I1
sa(dp9293
g12
I86
sg13
g9280
sg14
I14
sg22
VP01019
p9294
sg17
I2
sasa(dp9295
g2
VThere were few reports demonstrating behavior of kinin and kininogen in the nephrotic syndrome.
p9296
sg4
(dp9297
(Vkinin and kininogen
p9298
Vnephrotic syndrome
p9299
tp9300
I00
ssg9
(lp9301
(dp9302
g12
I76
sg13
g9299
sg14
I18
sg15
VC0027726
p9303
sg17
I2
sasg18
(lp9304
(dp9305
g12
I49
sg13
g9298
sg14
I19
sg22
VP01042
p9306
sg17
I3
sasa(dp9307
g2
VIn this paper, coagulation factors related to contact activation, such as factor XII (FXII), factor XI (FXI), prekallikrein (PK), high molecular weight kininogen (HMWKG), and kinins were measured in 15 cases of nephrotic syndrome, and clinical significance of these results were discussed.
p9308
sg4
(dp9309
(Vprekallikrein (PK), high molecular weight kininogen
p9310
Vnephrotic syndrome
p9311
tp9312
I00
ssg9
(lp9313
(dp9314
g12
I211
sg13
g9311
sg14
I18
sg15
VC0027726
p9315
sg17
I2
sasg18
(lp9316
(dp9317
g12
I74
sg13
Vfactor XII (FXII), factor XI
p9318
sg14
I28
sg22
VP00748
p9319
sg17
I5
sa(dp9320
g12
I86
sg13
VFXI
p9321
sg14
I3
sg22
g190
sg17
I1
sa(dp9322
g12
I110
sg13
g9310
sg14
I51
sg22
VP03952
p9323
sg17
I6
sasa(dp9324
g2
VTo investigate the role of anti-inflammatory TSG-6 in controlling MMP-1 and MMP-3, which have been shown to be upregulated in conjunctivochalasis (CCh).
p9325
sg4
(dp9326
(VMMP-1
p9327
VCCh
p9328
tp9329
I00
ssg9
(lp9330
(dp9331
g12
I126
sg13
Vconjunctivochalasis
p9332
sg14
I19
sg15
VC0878693
p9333
sg17
I1
sa(dp9334
g12
I147
sg13
g9328
sg14
I3
sg15
VC0878693
p9335
sg17
I1
sasg18
(lp9336
(dp9337
g12
I45
sg13
VTSG-6
p9338
sg14
I5
sg22
VP98066
p9339
sg17
I1
sa(dp9340
g12
I76
sg13
VMMP-3
p9341
sg14
I5
sg22
VP08254
p9342
sg17
I1
sa(dp9343
g12
I66
sg13
g9327
sg14
I5
sg22
VP03956
p9344
sg17
I1
sasa(dp9345
g2
VDirect sequencing analyses were performed in 19 genes, including ALS/frontotemporal lobar degeneration (FTLD)-related genes (SOD2, SOD3, ALS2/alsin, SMN1, PGRN, ANG, VEGF, VCP, VAPB, DCTN1, CHMP2B, and TARDBP or TDP-43), tauopathy-related gene (GSK3beta), and parkinsonism-related genes (alpha-synuclein, LRRK2, parkin, DJ-1, PINK1, and ATP13A2).
p9346
sg4
(dp9347
(VANG
p9348
VALS/frontotemporal lobar degeneration
p9349
tp9350
I00
ssg9
(lp9351
(dp9352
g12
I137
sg13
VALS2
p9353
sg14
I4
sg15
VC1859807
p9354
sg17
I1
sa(dp9355
g12
I104
sg13
VFTLD
p9356
sg14
I4
sg15
VC0751072
p9357
sg17
I1
sa(dp9358
g12
I260
sg13
Vparkinsonism
p9359
sg14
I12
sg15
VC0242422
p9360
sg17
I1
sa(dp9361
g12
I221
sg13
Vtauopathy
p9362
sg14
I9
sg15
VC0949664
p9363
sg17
I1
sa(dp9364
g12
I65
sg13
g9349
sg14
I37
sg15
VC0751072
p9365
sg17
I3
sasg18
(lp9366
(dp9367
g12
I305
sg13
VLRRK2
p9368
sg14
I5
sg22
g190
sg17
I1
sa(dp9369
g12
I260
sg13
Vparkinsonism-related genes
p9370
sg14
I26
sg22
VP01893
p9371
sg17
I2
sa(dp9372
g12
I202
sg13
VTARDBP
p9373
sg14
I6
sg22
g190
sg17
I1
sa(dp9374
g12
I183
sg13
VDCTN1
p9375
sg14
I5
sg22
g190
sg17
I1
sa(dp9376
g12
I125
sg13
VSOD2
p9377
sg14
I4
sg22
VP04179
p9378
sg17
I1
sa(dp9379
g12
I288
sg13
Valpha-synuclein
p9380
sg14
I15
sg22
VP37840
p9381
sg17
I1
sa(dp9382
g12
I190
sg13
VCHMP2B
p9383
sg14
I6
sg22
g190
sg17
I1
sa(dp9384
g12
I177
sg13
VVAPB
p9385
sg14
I4
sg22
g190
sg17
I1
sa(dp9386
g12
I149
sg13
VSMN1
p9387
sg14
I4
sg22
g190
sg17
I1
sa(dp9388
g12
I320
sg13
VDJ-1
p9389
sg14
I4
sg22
g190
sg17
I1
sa(dp9390
g12
I172
sg13
VVCP
p9391
sg14
I3
sg22
VP55072
p9392
sg17
I1
sa(dp9393
g12
I137
sg13
VALS2
p9394
sg14
I4
sg22
g190
sg17
I1
sa(dp9395
g12
I142
sg13
Valsin
p9396
sg14
I5
sg22
g190
sg17
I1
sa(dp9397
g12
I212
sg13
VTDP-43
p9398
sg14
I6
sg22
g190
sg17
I1
sa(dp9399
g12
I326
sg13
VPINK1
p9400
sg14
I5
sg22
g190
sg17
I1
sa(dp9401
g12
I337
sg13
VATP13A2
p9402
sg14
I7
sg22
g190
sg17
I1
sa(dp9403
g12
I131
sg13
VSOD3
p9404
sg14
I4
sg22
VP08294
p9405
sg17
I1
sa(dp9406
g12
I161
sg13
g9348
sg14
I3
sg22
VP03950
p9407
sg17
I1
sasa(dp9408
g2
VWe identified a set of PROs specific to ovarian cancer: abdominal pain, bloating, cramping, fear of recurrence/disease progression, indigestion, sexual dysfunction, vomiting, weight gain, and weight loss.
p9409
sg4
(dp9410
(VPROs
p9411
Vcramping
p9412
tp9413
I00
ssg9
(lp9414
(dp9415
g12
I132
sg13
Vindigestion
p9416
sg14
I11
sg15
VC0013395
p9417
sg17
I1
sa(dp9418
g12
I165
sg13
Vvomiting
p9419
sg14
I8
sg15
VC0042963
p9420
sg17
I1
sa(dp9421
g12
I72
sg13
Vbloating
p9422
sg14
I8
sg15
VC1291077
p9423
sg17
I1
sa(dp9424
g12
I56
sg13
Vabdominal pain
p9425
sg14
I14
sg15
VC0000737
p9426
sg17
I2
sa(dp9427
g12
I100
sg13
Vrecurrence
p9428
sg14
I10
sg15
VC1458156
p9429
sg17
I1
sa(dp9430
g12
I111
sg13
Vdisease progression
p9431
sg14
I19
sg15
VC0242656
p9432
sg17
I2
sa(dp9433
g12
I40
sg13
Vovarian cancer
p9434
sg14
I14
sg15
VC1140680
p9435
sg17
I2
sa(dp9436
g12
I145
sg13
Vsexual dysfunction
p9437
sg14
I18
sg15
VC0036877
p9438
sg17
I2
sa(dp9439
g12
I82
sg13
g9412
sg14
I8
sg15
VC1446787
p9440
sg17
I1
sasg18
(lp9441
(dp9442
g12
I23
sg13
g9411
sg14
I4
sg22
VP07225
p9443
sg17
I1
sasa(dp9444
g2
VTwo PRRT2 mutations were in familial hemiplegic migraine or episodic ataxia, one SLC2A1 family had episodic ataxia and one PNKD family had familial hemiplegic migraine alone.
p9445
sg4
(dp9446
(VSLC2A1
p9447
Vepisodic ataxia
p9448
tp9449
I01
ssg9
(lp9450
(dp9451
g12
I60
sg13
Vepisodic ataxia
p9452
sg14
I15
sg15
VC1720189
p9453
sg17
I2
sa(dp9454
g12
I28
sg13
Vfamilial hemiplegic migraine
p9455
sg14
I28
sg15
VC0338484
p9456
sg17
I3
sa(dp9457
g12
I28
sg13
Vfamilial hemiplegic migraine
p9458
sg14
I28
sg15
VC0338484
p9459
sg17
I3
sa(dp9460
g12
I60
sg13
g9448
sg14
I15
sg15
VC1720189
p9461
sg17
I2
sasg18
(lp9462
(dp9463
g12
I123
sg13
VPNKD family
p9464
sg14
I11
sg22
g190
sg17
I2
sa(dp9465
g12
I4
sg13
VPRRT2 mutations
p9466
sg14
I15
sg22
g190
sg17
I2
sa(dp9467
g12
I81
sg13
g9447
sg14
I6
sg22
VP11166
p9468
sg17
I1
sasa(dp9469
g2
VSLC2A1 mutations were associated with variable phenotypes including paroxysmal kinesigenic dyskinesia, paroxysmal non-kinesigenic dyskinesia, episodic ataxia and myotonia and we identified a novel PNKD gene deletion in familial hemiplegic migraine.
p9470
sg4
(dp9471
(VSLC2A1
p9472
Vfamilial hemiplegic migraine
p9473
tp9474
I01
ssg9
(lp9475
(dp9476
g12
I142
sg13
Vepisodic ataxia
p9477
sg14
I15
sg15
VC1720189
p9478
sg17
I2
sa(dp9479
g12
I68
sg13
Vparoxysmal kinesigenic dyskinesia
p9480
sg14
I33
sg15
VC1868682
p9481
sg17
I3
sa(dp9482
g12
I202
sg13
Vgene deletion
p9483
sg14
I13
sg15
VC1442161
p9484
sg17
I2
sa(dp9485
g12
I91
sg13
Vdyskinesia
p9486
sg14
I10
sg15
VC0013384
p9487
sg17
I1
sa(dp9488
g12
I219
sg13
g9473
sg14
I28
sg15
VC0338484
p9489
sg17
I3
sasg18
(lp9490
(dp9491
g12
I197
sg13
VPNKD gene
p9492
sg14
I9
sg22
g190
sg17
I2
sa(dp9493
g12
I0
sg13
g9472
sg14
I6
sg22
VP11166
p9494
sg17
I1
sasa(dp9495
g2
VThe onset of DSH is typically during infancy or childhood.
p9496
sg4
(dp9497
(VDSH
p9498
VDSH
p9499
tp9500
I00
ssg9
(lp9501
(dp9502
g12
I13
sg13
g9499
sg14
I3
sg15
VC0406775
p9503
sg17
I1
sasg18
(lp9504
(dp9505
g12
I13
sg13
g9498
sg14
I3
sg22
VP55265
p9506
sg17
I1
sasa(dp9507
g2
VAdditionally, there have been few significant non-cutaneous complications reported with DSH.
p9508
sg4
(dp9509
(VDSH
p9510
VDSH
p9511
tp9512
I00
ssg9
(lp9513
(dp9514
g12
I88
sg13
g9511
sg14
I3
sg15
VC0406775
p9515
sg17
I1
sasg18
(lp9516
(dp9517
g12
I88
sg13
g9510
sg14
I3
sg22
VP55265
p9518
sg17
I1
sasa(dp9519
g2
VThe present study reported two sporadic cases of patients born with DSH, confirmed by the identification of ADAR1 mutations.
p9520
sg4
(dp9521
(VADAR1
p9522
VDSH
p9523
tp9524
I00
ssg9
(lp9525
(dp9526
g12
I68
sg13
g9523
sg14
I3
sg15
VC0406775
p9527
sg17
I1
sasg18
(lp9528
(dp9529
g12
I68
sg13
VDSH
p9530
sg14
I3
sg22
VP55265
p9531
sg17
I1
sa(dp9532
g12
I108
sg13
g9522
sg14
I5
sg22
VP55265
p9533
sg17
I1
sasa(dp9534
g2
VAdditionally, comorbidity of DSH, congenital heart disease (CHD) and hemangioma disease were first reported.
p9535
sg4
(dp9536
(VDSH
p9537
VDSH
p9538
tp9539
I00
ssg9
(lp9540
(dp9541
g12
I69
sg13
Vhemangioma
p9542
sg14
I10
sg15
VC0018916
p9543
sg17
I1
sa(dp9544
g12
I60
sg13
VCHD
p9545
sg14
I3
sg15
VC0152021
p9546
sg17
I1
sa(dp9547
g12
I34
sg13
Vcongenital heart disease
p9548
sg14
I24
sg15
VC0152021
p9549
sg17
I3
sa(dp9550
g12
I29
sg13
g9538
sg14
I3
sg15
VC0406775
p9551
sg17
I1
sasg18
(lp9552
(dp9553
g12
I29
sg13
g9537
sg14
I3
sg22
VP55265
p9554
sg17
I1
sasa(dp9555
g2
VIn the patient with isolated DSH from birth, a nonsense mutation (p.Y1192X) was identified, whereas in the second patient with DSH, CHD and hemangioma from birth, a frameshift mutation (p.Glu673ValfsX652) in ADAR1 was identified.
p9556
sg4
(dp9557
(VDSH
p9558
VDSH
p9559
tp9560
I00
ssg9
(lp9561
(dp9562
g12
I47
sg13
Vnonsense mutation
p9563
sg14
I17
sg15
VC0544885
p9564
sg17
I2
sa(dp9565
g12
I140
sg13
Vhemangioma
p9566
sg14
I10
sg15
VC0018916
p9567
sg17
I1
sa(dp9568
g12
I29
sg13
VDSH
p9569
sg14
I3
sg15
VC0406775
p9570
sg17
I1
sa(dp9571
g12
I29
sg13
g9559
sg14
I3
sg15
VC0406775
p9572
sg17
I1
sa(dp9573
g12
I165
sg13
Vframeshift mutation
p9574
sg14
I19
sg15
VC0079380
p9575
sg17
I2
sasg18
(lp9576
(dp9577
g12
I208
sg13
VADAR1
p9578
sg14
I5
sg22
VP55265
p9579
sg17
I1
sa(dp9580
g12
I29
sg13
g9558
sg14
I3
sg22
VP55265
p9581
sg17
I1
sasa(dp9582
g2
VTo the best of the authors' knowledge, &gt;120 mutations in ADAR1 have been reported to cause DSH; however, no previous studies have reported mutations in ADAR1 in DSH at birth, with CHD and hemangioma.
p9583
sg4
(dp9584
(VADAR1
p9585
VDSH
p9586
tp9587
I00
ssg9
(lp9588
(dp9589
g12
I191
sg13
Vhemangioma
p9590
sg14
I10
sg15
VC0018916
p9591
sg17
I1
sa(dp9592
g12
I94
sg13
VDSH
p9593
sg14
I3
sg15
VC0406775
p9594
sg17
I1
sa(dp9595
g12
I94
sg13
g9586
sg14
I3
sg15
VC0406775
p9596
sg17
I1
sasg18
(lp9597
(dp9598
g12
I60
sg13
VADAR1
p9599
sg14
I5
sg22
VP55265
p9600
sg17
I1
sa(dp9601
g12
I94
sg13
VDSH
p9602
sg14
I3
sg22
VP55265
p9603
sg17
I1
sa(dp9604
g12
I60
sg13
g9585
sg14
I5
sg22
VP55265
p9605
sg17
I1
sasa(dp9606
g2
VThe novel variants described in the current study add to the current knowledge of ADAR1 mutations in DSH.
p9607
sg4
(dp9608
(VADAR1
p9609
VDSH
p9610
tp9611
I00
ssg9
(lp9612
(dp9613
g12
I101
sg13
g9610
sg14
I3
sg15
VC0406775
p9614
sg17
I1
sa(dp9615
g12
I50
sg13
Vadd
p9616
sg14
I3
sg15
VC0004269
p9617
sg17
I1
sasg18
(lp9618
(dp9619
g12
I101
sg13
VDSH
p9620
sg14
I3
sg22
VP55265
p9621
sg17
I1
sa(dp9622
g12
I82
sg13
g9609
sg14
I5
sg22
VP55265
p9623
sg17
I1
sasa(dp9624
g2
VPathogenic molecular variants in the ADAR gene are a known cause of rare diseases, autosomal recessive Aicardi- Goutieres syndrome type 6, severe infantile encephalopathy with intracranial calcifications and dominant dyschromatosis symmetrica hereditaria, demonstrated mainly in Asian adults.
p9625
sg4
(dp9626
(VADAR gene
p9627
Vencephalopathy
p9628
tp9629
I00
ssg9
(lp9630
(dp9631
g12
I122
sg13
Vsyndrome
p9632
sg14
I8
sg15
VC0039082
p9633
sg17
I1
sa(dp9634
g12
I217
sg13
Vdyschromatosis symmetrica hereditaria
p9635
sg14
I37
sg15
VC0406775
p9636
sg17
I3
sa(dp9637
g12
I68
sg13
Vrare diseases
p9638
sg14
I13
sg15
VC0678236
p9639
sg17
I2
sa(dp9640
g12
I156
sg13
g9628
sg14
I14
sg15
VC0085584
p9641
sg17
I1
sasg18
(lp9642
(dp9643
g12
I37
sg13
g9627
sg14
I9
sg22
VP55265
p9644
sg17
I2
sasa(dp9645
g2
VTo identify potential mutation of the ADAR1 gene in a Chinese family and a sporadic case affected with dyschromatosis symmetrica hereditaria(DSH).
p9646
sg4
(dp9647
(VADAR1 gene
p9648
Vdyschromatosis symmetrica hereditaria
p9649
tp9650
I00
ssg9
(lp9651
(dp9652
g12
I141
sg13
VDSH
p9653
sg14
I3
sg15
VC0406775
p9654
sg17
I1
sa(dp9655
g12
I103
sg13
g9649
sg14
I37
sg15
VC0406775
p9656
sg17
I3
sasg18
(lp9657
(dp9658
g12
I38
sg13
g9648
sg14
I10
sg22
VP55265
p9659
sg17
I2
sasa(dp9660
g2
VThe frame-shift mutation c.2638delG (p.Asp880ThrfsX15) and the nonsense mutation c.2867C&gt;A (p.Ser956X) in the ADAR1 gene probably underlie the DSH in our patients.
p9661
sg4
(dp9662
(VADAR1 gene
p9663
VDSH
p9664
tp9665
I00
ssg9
(lp9666
(dp9667
g12
I146
sg13
g9664
sg14
I3
sg15
VC0406775
p9668
sg17
I1
sa(dp9669
g12
I63
sg13
Vnonsense mutation
p9670
sg14
I17
sg15
VC0544885
p9671
sg17
I2
sasg18
(lp9672
(dp9673
g12
I146
sg13
VDSH
p9674
sg14
I3
sg22
VP55265
p9675
sg17
I1
sa(dp9676
g12
I113
sg13
g9663
sg14
I10
sg22
VP55265
p9677
sg17
I2
sasa(dp9678
g2
VDyschromatosis symmetrica hereditaria (DSH) is a rare autosomal dominant cutaneous disorder caused by the mutations of adenosine deaminase acting on RNA1 (ADAR1) gene.
p9679
sg4
(dp9680
(Vadenosine deaminase acting on RNA1
p9681
VDyschromatosis symmetrica hereditaria
p9682
tp9683
I00
ssg9
(lp9684
(dp9685
g12
I39
sg13
VDSH
p9686
sg14
I3
sg15
VC0406775
p9687
sg17
I1
sa(dp9688
g12
I73
sg13
Vcutaneous disorder
p9689
sg14
I18
sg15
VC0037274
p9690
sg17
I2
sa(dp9691
g12
I0
sg13
g9682
sg14
I37
sg15
VC0406775
p9692
sg17
I3
sasg18
(lp9693
(dp9694
g12
I155
sg13
VADAR1
p9695
sg14
I5
sg22
VP55265
p9696
sg17
I1
sa(dp9697
g12
I119
sg13
g9681
sg14
I34
sg22
VP55265
p9698
sg17
I5
sasa(dp9699
g2
VWe present a clinical and genetic study of seven unrelated families and two sporadic cases with DSH for mutations in the full coding sequence of ADAR1 gene.
p9700
sg4
(dp9701
(VADAR1 gene
p9702
VDSH
p9703
tp9704
I00
ssg9
(lp9705
(dp9706
g12
I96
sg13
g9703
sg14
I3
sg15
VC0406775
p9707
sg17
I1
sasg18
(lp9708
(dp9709
g12
I96
sg13
VDSH
p9710
sg14
I3
sg22
VP55265
p9711
sg17
I1
sa(dp9712
g12
I145
sg13
g9702
sg14
I10
sg22
VP55265
p9713
sg17
I2
sasa(dp9714
g2
VADAR1 gene was sequenced in seven unrelated families and two sporadic cases with DSH and 120 controls.
p9715
sg4
(dp9716
(VADAR1 gene
p9717
VDSH
p9718
tp9719
I00
ssg9
(lp9720
(dp9721
g12
I81
sg13
g9718
sg14
I3
sg15
VC0406775
p9722
sg17
I1
sasg18
(lp9723
(dp9724
g12
I0
sg13
g9717
sg14
I10
sg22
VP55265
p9725
sg17
I2
sasa(dp9726
g2
VWe describe six novel mutations of the ADAR1 gene in Chinese patients with DSH including a nonstop mutation p.Stop1227R, which was firstly reported in ADAR1 gene.
p9727
sg4
(dp9728
(VADAR1 gene
p9729
VDSH
p9730
tp9731
I00
ssg9
(lp9732
(dp9733
g12
I75
sg13
g9730
sg14
I3
sg15
VC0406775
p9734
sg17
I1
sasg18
(lp9735
(dp9736
g12
I39
sg13
VADAR1 gene
p9737
sg14
I10
sg22
VP55265
p9738
sg17
I2
sa(dp9739
g12
I39
sg13
g9729
sg14
I10
sg22
VP55265
p9740
sg17
I2
sasa(dp9741
g2
VA three-generation family exhibiting phenotypic variability with a single germline ADAR1 mutation suggests that chilblain might aggravate the clinical phenotypes of DSH.
p9742
sg4
(dp9743
(VADAR1
p9744
Vchilblain
p9745
tp9746
I00
ssg9
(lp9747
(dp9748
g12
I165
sg13
VDSH
p9749
sg14
I3
sg15
VC0406775
p9750
sg17
I1
sa(dp9751
g12
I112
sg13
g9745
sg14
I9
sg15
VC0008058
p9752
sg17
I1
sasg18
(lp9753
(dp9754
g12
I165
sg13
VDSH
p9755
sg14
I3
sg22
VP55265
p9756
sg17
I1
sa(dp9757
g12
I83
sg13
g9744
sg14
I5
sg22
VP55265
p9758
sg17
I1
sasa(dp9759
g2
VTTD is caused by mutations in DNA repair/transcription genes XPD, XPB or TTDA, and in TTDN1, a gene of unknown function.
p9760
sg4
(dp9761
(VXPD
p9762
VXPD
p9763
tp9764
I00
ssg9
(lp9765
(dp9766
g12
I66
sg13
VXPB
p9767
sg14
I3
sg15
VC0268136
p9768
sg17
I1
sa(dp9769
g12
I61
sg13
g9763
sg14
I3
sg15
VC0268138
p9770
sg17
I1
sa(dp9771
g12
I86
sg13
VTTDN1
p9772
sg14
I5
sg15
VC1961117
p9773
sg17
I1
sasg18
(lp9774
(dp9775
g12
I66
sg13
VXPB
p9776
sg14
I3
sg22
VP19447
p9777
sg17
I1
sa(dp9778
g12
I61
sg13
g9762
sg14
I3
sg22
VP18074
p9779
sg17
I1
sa(dp9780
g12
I73
sg13
VTTDA
p9781
sg14
I4
sg22
g190
sg17
I1
sa(dp9782
g12
I86
sg13
VTTDN1
p9783
sg14
I5
sg22
g190
sg17
I1
sasa(dp9784
g2
VTo date, four genes have been identified as responsible for TTD: XPD, XPB, p8/TTDA, and TTDN1.
p9785
sg4
(dp9786
(VXPB
p9787
VXPB
p9788
tp9789
I00
ssg9
(lp9790
(dp9791
g12
I65
sg13
VXPD
p9792
sg14
I3
sg15
VC0268138
p9793
sg17
I1
sa(dp9794
g12
I70
sg13
g9788
sg14
I3
sg15
VC0268136
p9795
sg17
I1
sa(dp9796
g12
I88
sg13
VTTDN1
p9797
sg14
I5
sg15
VC1961117
p9798
sg17
I1
sasg18
(lp9799
(dp9800
g12
I65
sg13
VXPD
p9801
sg14
I3
sg22
VP18074
p9802
sg17
I1
sa(dp9803
g12
I70
sg13
g9787
sg14
I3
sg22
VP19447
p9804
sg17
I1
sa(dp9805
g12
I88
sg13
VTTDN1
p9806
sg14
I5
sg22
g190
sg17
I1
sa(dp9807
g12
I78
sg13
VTTDA
p9808
sg14
I4
sg22
g190
sg17
I1
sasa(dp9809
g2
VWe analysed the gene expression and protein distribution of different members of the Hsp27, Hsp70, and Hsp90 families in the central nervous system of sheep naturally infected with scrapie.
p9810
sg4
(dp9811
(VHsp90 families
p9812
Vscrapie
p9813
tp9814
I00
ssg9
(lp9815
(dp9816
g12
I181
sg13
g9813
sg14
I7
sg15
VC0036457
p9817
sg17
I1
sa(dp9818
g12
I133
sg13
Vnervous
p9819
sg14
I7
sg15
VC0027769
p9820
sg17
I1
sasg18
(lp9821
(dp9822
g12
I92
sg13
VHsp70
p9823
sg14
I5
sg22
VP34932
p9824
sg17
I1
sa(dp9825
g12
I103
sg13
g9812
sg14
I14
sg22
VP19883
p9826
sg17
I2
sa(dp9827
g12
I85
sg13
VHsp27
p9828
sg14
I5
sg22
g190
sg17
I1
sasa(dp9829
g2
VWe have identified Receptor-interacting serine/threonine protein kinase 4 (RIP4) as a regulator of tumor differentiation in lung adenocarcinoma (AC).
p9830
sg4
(dp9831
(VRIP4
p9832
Vlung adenocarcinoma
p9833
tp9834
I00
ssg9
(lp9835
(dp9836
g12
I99
sg13
Vtumor
p9837
sg14
I5
sg15
VC0027651
p9838
sg17
I1
sa(dp9839
g12
I124
sg13
g9833
sg14
I19
sg15
VC0152013
p9840
sg17
I2
sasg18
(lp9841
(dp9842
g12
I75
sg13
g9832
sg14
I4
sg22
VP57078
p9843
sg17
I1
sa(dp9844
g12
I19
sg13
VReceptor-interacting serine/threonine protein kinase 4
p9845
sg14
I54
sg22
g190
sg17
I5
sasa(dp9846
g2
VAltogether, our work has identified that loss of RIP4 enhances STAT3 signaling in lung cancer cells, promoting the expression of ECM remodeling genes and cancer dedifferentiation.
p9847
sg4
(dp9848
(VRIP4
p9849
Vdedifferentiation
p9850
tp9851
I00
ssg9
(lp9852
(dp9853
g12
I82
sg13
Vlung cancer
p9854
sg14
I11
sg15
VC0684249
p9855
sg17
I2
sa(dp9856
g12
I87
sg13
Vcancer
p9857
sg14
I6
sg15
VC0006826
p9858
sg17
I1
sa(dp9859
g12
I161
sg13
g9850
sg14
I17
sg15
VC0002793
p9860
sg17
I1
sasg18
(lp9861
(dp9862
g12
I129
sg13
VECM remodeling genes
p9863
sg14
I20
sg22
g190
sg17
I3
sa(dp9864
g12
I63
sg13
VSTAT3
p9865
sg14
I5
sg22
VP40763
p9866
sg17
I1
sa(dp9867
g12
I49
sg13
g9849
sg14
I4
sg22
VP57078
p9868
sg17
I1
sasa(dp9869
g2
VIn conclusion, our data suggest that RIPK4/EZH2 markers might be used as potential predictors of prognosis in cervical cancer.
p9870
sg4
(dp9871
(VRIPK4
p9872
Vcervical cancer
p9873
tp9874
I01
ssg9
(lp9875
(dp9876
g12
I110
sg13
g9873
sg14
I15
sg15
VC0302592
p9877
sg17
I2
sasg18
(lp9878
(dp9879
g12
I43
sg13
VEZH2
p9880
sg14
I4
sg22
g190
sg17
I1
sa(dp9881
g12
I37
sg13
g9872
sg14
I5
sg22
VP57078
p9882
sg17
I1
sasa(dp9883
g2
VTo investigate the association between receptor-interacting kinase protein 4 (RIPK4) relative copy number (RCN) and prognosis of stage III( colorectal cancer (CRC) patients treated with oxaliplatin-based chemotherapy.
p9884
sg4
(dp9885
(VRIPK4
p9886
VCRC
p9887
tp9888
I00
ssg9
(lp9889
(dp9890
g12
I140
sg13
Vcolorectal cancer
p9891
sg14
I17
sg15
VC1527249
p9892
sg17
I2
sa(dp9893
g12
I159
sg13
g9887
sg14
I3
sg15
VC1527249
p9894
sg17
I1
sasg18
(lp9895
(dp9896
g12
I78
sg13
g9886
sg14
I5
sg22
VP57078
p9897
sg17
I1
sa(dp9898
g12
I39
sg13
Vreceptor-interacting kinase protein 4
p9899
sg14
I37
sg22
g190
sg17
I4
sasa(dp9900
g2
VIn colon cancer subgroup, high RIPK4 RCN was significantly associated with poor OS (median OS, 31.5 months vs. 56.6 months, P=0.015) but not with RFS (P=0.135).
p9901
sg4
(dp9902
(VRIPK4 RCN
p9903
VRFS
p9904
tp9905
I00
ssg9
(lp9906
(dp9907
g12
I3
sg13
Vcolon cancer
p9908
sg14
I12
sg15
VC0699790
p9909
sg17
I2
sa(dp9910
g12
I146
sg13
g9904
sg14
I3
sg15
VC0015624
p9911
sg17
I1
sasg18
(lp9912
(dp9913
g12
I31
sg13
g9903
sg14
I9
sg22
VP57078
p9914
sg17
I2
sasa(dp9915
g2
VIn rectal cancer subgroup, RIPK4 RCN was not associated with both OS and RFS (P=0.981, P=0.738).
p9916
sg4
(dp9917
(VRIPK4 RCN
p9918
VRFS
p9919
tp9920
I00
ssg9
(lp9921
(dp9922
g12
I3
sg13
Vrectal cancer
p9923
sg14
I13
sg15
VC0007113
p9924
sg17
I2
sa(dp9925
g12
I73
sg13
g9919
sg14
I3
sg15
VC0015624
p9926
sg17
I1
sasg18
(lp9927
(dp9928
g12
I27
sg13
g9918
sg14
I9
sg22
VP57078
p9929
sg17
I2
sasa(dp9930
g2
VRIPK4 RCN is significantly associated with OS in stage III( colon cancer patients receiving oxaliplatin-based chemotherapy and may be a novel biomarker that can predict the efficacy of oxaliplatin in colon cancer patients.
p9931
sg4
(dp9932
(VRIPK4 RCN
p9933
Vcolon cancer
p9934
tp9935
I00
ssg9
(lp9936
(dp9937
g12
I60
sg13
Vcolon cancer
p9938
sg14
I12
sg15
VC0699790
p9939
sg17
I2
sa(dp9940
g12
I60
sg13
g9934
sg14
I12
sg15
VC0699790
p9941
sg17
I2
sasg18
(lp9942
(dp9943
g12
I0
sg13
g9933
sg14
I9
sg22
VP57078
p9944
sg17
I2
sasa(dp9945
g2
VHere, we report the potential clinical implication and biological functions of RIPK4 in cervical squamous cell carcinoma (CSCC).
p9946
sg4
(dp9947
(VRIPK4
p9948
Vcervical squamous cell carcinoma
p9949
tp9950
I01
ssg9
(lp9951
(dp9952
g12
I122
sg13
VCSCC
p9953
sg14
I4
sg15
VC0279671
p9954
sg17
I1
sa(dp9955
g12
I88
sg13
g9949
sg14
I32
sg15
VC0279671
p9956
sg17
I4
sasg18
(lp9957
(dp9958
g12
I79
sg13
g9948
sg14
I5
sg22
VP57078
p9959
sg17
I1
sasa(dp9960
g2
VRIPK4 expression increased significantly with disease progression from 3.2% in chronic cervicitis, 19.3% in LSILs and 85.1% in HSILs to 94.4% in CSCCs (P &lt; 0.001).
p9961
sg4
(dp9962
(VRIPK4
p9963
Vchronic cervicitis
p9964
tp9965
I01
ssg9
(lp9966
(dp9967
g12
I79
sg13
g9964
sg14
I18
sg15
VC0269062
p9968
sg17
I2
sa(dp9969
g12
I46
sg13
Vdisease progression
p9970
sg14
I19
sg15
VC0242656
p9971
sg17
I2
sasg18
(lp9972
(dp9973
g12
I0
sg13
g9963
sg14
I5
sg22
VP57078
p9974
sg17
I1
sasa(dp9975
g2
VKnockdown of RIPK4 reduced cell migration and invasion via inhibition of Vimentin, MMP2 and Fibronectin expression in cervical cancer cells.
p9976
sg4
(dp9977
(VRIPK4
p9978
Vcervical cancer
p9979
tp9980
I01
ssg9
(lp9981
(dp9982
g12
I118
sg13
g9979
sg14
I15
sg15
VC0302592
p9983
sg17
I2
sa(dp9984
g12
I46
sg13
Vinvasion
p9985
sg14
I8
sg15
VC2699153
p9986
sg17
I1
sasg18
(lp9987
(dp9988
g12
I83
sg13
VMMP2
p9989
sg14
I4
sg22
VP08253
p9990
sg17
I1
sa(dp9991
g12
I13
sg13
g9978
sg14
I5
sg22
VP57078
p9992
sg17
I1
sasa(dp9993
g2
VWe previously showed that protein kinase C-associated kinase (PKK, also known as DIK/RIP4), which belongs to the receptor-interacting protein (RIP) kinase family, mediates the B cell activating factor of the TNF family (BAFF)-induced NF-KB activation in diffuse large B cell lymphoma (DLBCL) cell lines.
p9994
sg4
(dp9995
(VRIP4
p9996
Vdiffuse large B cell lymphoma
p9997
tp9998
I01
ssg9
(lp9999
(dp10000
g12
I285
sg13
VDLBCL
p10001
sg14
I5
sg15
VC0079744
p10002
sg17
I1
sa(dp10003
g12
I254
sg13
g9997
sg14
I29
sg15
VC0079744
p10004
sg17
I5
sasg18
(lp10005
(dp10006
g12
I113
sg13
Vreceptor-interacting protein
p10007
sg14
I28
sg22
g190
sg17
I2
sa(dp10008
g12
I26
sg13
Vprotein kinase C-associated kinase
p10009
sg14
I34
sg22
VP17252
p10010
sg17
I4
sa(dp10011
g12
I176
sg13
VB cell activating factor of the TNF family
p10012
sg14
I42
sg22
g190
sg17
I8
sa(dp10013
g12
I85
sg13
VRIP
p10014
sg14
I3
sg22
VP52594
p10015
sg17
I1
sa(dp10016
g12
I81
sg13
VDIK
p10017
sg14
I3
sg22
VP57078
p10018
sg17
I1
sa(dp10019
g12
I62
sg13
VPKK
p10020
sg14
I3
sg22
VP57078
p10021
sg17
I1
sa(dp10022
g12
I85
sg13
g9996
sg14
I4
sg22
VP57078
p10023
sg17
I1
sa(dp10024
g12
I220
sg13
VBAFF
p10025
sg14
I4
sg22
g190
sg17
I1
sasa(dp10026
g2
VThe better understanding of the molecular mechanism of RIPK4 in TSCC may provide a promising biomarker for tongue cancer prognosis and treatment.
p10027
sg4
(dp10028
(VRIPK4
p10029
Vtongue cancer
p10030
tp10031
I00
ssg9
(lp10032
(dp10033
g12
I107
sg13
g10030
sg14
I13
sg15
VC0558353
p10034
sg17
I2
sasg18
(lp10035
(dp10036
g12
I55
sg13
g10029
sg14
I5
sg22
VP57078
p10037
sg17
I1
sasa(dp10038
g2
VInterestingly, maladaptive ECM remodeling was observed in early AVM without AVD and worsened with late AVD, as evidenced by increased MMP-2 and MMP-9 expression and activity, as well as abnormalities in ADAMTS-mediated versican processing.
p10039
sg4
(dp10040
(VMMP-2
p10041
VAVM
p10042
tp10043
I00
ssg9
(lp10044
(dp10045
g12
I64
sg13
g10042
sg14
I3
sg15
VC0003857
p10046
sg17
I1
sasg18
(lp10047
(dp10048
g12
I144
sg13
VMMP-9
p10049
sg14
I5
sg22
VP14780
p10050
sg17
I1
sa(dp10051
g12
I134
sg13
g10041
sg14
I5
sg22
VP08253
p10052
sg17
I1
sasa(dp10053
g2
VIn patients with aortic stenosis or the hemolytic-uremic syndrome, abnormally high levels of shear stress across the stenotic valve or in the microcirculation inflicted with thrombosis may promote cleavage of vWF by ADAMTS13, contributing to the loss of large multimers commonly observed among these patients.
p10054
sg4
(dp10055
(VvWF
p10056
Vaortic stenosis
p10057
tp10058
I01
ssg9
(lp10059
(dp10060
g12
I174
sg13
Vthrombosis
p10061
sg14
I10
sg15
VC0040053
p10062
sg17
I1
sa(dp10063
g12
I40
sg13
Vhemolytic-uremic syndrome
p10064
sg14
I25
sg15
VC0019061
p10065
sg17
I2
sa(dp10066
g12
I17
sg13
g10057
sg14
I15
sg15
VC0003507
p10067
sg17
I2
sasg18
(lp10068
(dp10069
g12
I209
sg13
g10056
sg14
I3
sg22
VP04275
p10070
sg17
I1
sa(dp10071
g12
I216
sg13
VADAMTS13
p10072
sg14
I8
sg22
g190
sg17
I1
sasa(dp10073
g2
VThe gene and protein expression profiles and protein distribution of six potential genetic biomarkers (i.e., CAPN6, COL1A2, COL3A1, GALA1, MT2A and MTNR1B) are presented here for both the early and terminal stages of scrapie in five different brain regions.
p10074
sg4
(dp10075
(VMTNR1B
p10076
Vscrapie
p10077
tp10078
I00
ssg9
(lp10079
(dp10080
g12
I217
sg13
g10077
sg14
I7
sg15
VC0036457
p10081
sg17
I1
sasg18
(lp10082
(dp10083
g12
I109
sg13
VCAPN6
p10084
sg14
I5
sg22
g190
sg17
I1
sa(dp10085
g12
I139
sg13
VMT2A
p10086
sg14
I4
sg22
VP02795
p10087
sg17
I1
sa(dp10088
g12
I148
sg13
g10076
sg14
I6
sg22
VP49286
p10089
sg17
I1
sasa(dp10090
g2
VThe distribution of the GALA1 was identified in glial cells from the cerebellum of scrapie-infected animals, GALA1 protein expression was increased in clinical animals in the majority of regions, and the increase of MT2A was in agreement with previous reports.
p10091
sg4
(dp10092
(VMT2A
p10093
Vscrapie
p10094
tp10095
I00
ssg9
(lp10096
(dp10097
g12
I83
sg13
g10094
sg14
I7
sg15
VC0036457
p10098
sg17
I1
sasg18
(lp10099
(dp10100
g12
I216
sg13
g10093
sg14
I4
sg22
VP02795
p10101
sg17
I1
sasa(dp10102
g2
VIn conclusion, this study of gene transcription and protein expression and distribution confirm CAPN6, GALA1, MTNR1B and MT2A as potential targets for further prion disease research.
p10103
sg4
(dp10104
(VMT2A
p10105
Vprion disease
p10106
tp10107
I00
ssg9
(lp10108
(dp10109
g12
I159
sg13
g10106
sg14
I13
sg15
VC0162534
p10110
sg17
I2
sasg18
(lp10111
(dp10112
g12
I110
sg13
VMTNR1B
p10113
sg14
I6
sg22
VP49286
p10114
sg17
I1
sa(dp10115
g12
I96
sg13
VCAPN6
p10116
sg14
I5
sg22
g190
sg17
I1
sa(dp10117
g12
I121
sg13
g10105
sg14
I4
sg22
VP02795
p10118
sg17
I1
sasa(dp10119
g2
VLincRNA-p21 could lead to pulmonary fibrosis in ARDS by inhibition of the expression of Thy-1.
p10120
sg4
(dp10121
(Vp21
p10122
VARDS
p10123
tp10124
I00
ssg9
(lp10125
(dp10126
g12
I26
sg13
Vpulmonary fibrosis
p10127
sg14
I18
sg15
VC0034069
p10128
sg17
I2
sa(dp10129
g12
I48
sg13
g10123
sg14
I4
sg15
VC0035222
p10130
sg17
I1
sasg18
(lp10131
(dp10132
g12
I88
sg13
VThy-1
p10133
sg14
I5
sg22
VP04216
p10134
sg17
I1
sa(dp10135
g12
I8
sg13
g10122
sg14
I3
sg22
VP42857
p10136
sg17
I1
sasa(dp10137
g2
VLPS-induced pulmonary fibrosis was related with activation of HDAC, deacetylation of histone H3 and H4 and Thy-1 gene silencing.
p10138
sg4
(dp10139
(VHDAC
p10140
VLPS
p10141
tp10142
I00
ssg9
(lp10143
(dp10144
g12
I12
sg13
Vpulmonary fibrosis
p10145
sg14
I18
sg15
VC0034069
p10146
sg17
I2
sa(dp10147
g12
I0
sg13
g10141
sg14
I3
sg15
VC0175697
p10148
sg17
I1
sasg18
(lp10149
(dp10150
g12
I107
sg13
VThy-1 gene
p10151
sg14
I10
sg22
VP04216
p10152
sg17
I2
sa(dp10153
g12
I85
sg13
Vhistone H3
p10154
sg14
I10
sg22
g190
sg17
I2
sa(dp10155
g12
I62
sg13
g10140
sg14
I4
sg22
VP56524
p10156
sg17
I1
sasa(dp10157
g2
VHDAC inhibitor BA could inhibit LPS-induced pulmonary fibrosis and Thy-1 gene silencing through inhibiting activation of HDAC and deacetylation of histone H4.
p10158
sg4
(dp10159
(VHDAC
p10160
VLPS
p10161
tp10162
I00
ssg9
(lp10163
(dp10164
g12
I44
sg13
Vpulmonary fibrosis
p10165
sg14
I18
sg15
VC0034069
p10166
sg17
I2
sa(dp10167
g12
I32
sg13
g10161
sg14
I3
sg15
VC0175697
p10168
sg17
I1
sasg18
(lp10169
(dp10170
g12
I0
sg13
VHDAC
p10171
sg14
I4
sg22
VP56524
p10172
sg17
I1
sa(dp10173
g12
I147
sg13
Vhistone H4
p10174
sg14
I10
sg22
VP62805
p10175
sg17
I2
sa(dp10176
g12
I0
sg13
g10160
sg14
I4
sg22
VP56524
p10177
sg17
I1
sasa(dp10178
g2
VWhile planning genomics, we describe that 11 well-known type 2 diabetes genetic risk variants (in TCF7L2, PPARG-P12A, KCNJ11, FTO, IGF2BP2, DUSP9, CENTD2, THADA, HHEX, CDKAL1, KCNQ1) showed similar associations compared to literature.
p10179
sg4
(dp10180
(VKCNQ1
p10181
Vtype 2 diabetes
p10182
tp10183
I00
ssg9
(lp10184
(dp10185
g12
I56
sg13
g10182
sg14
I15
sg15
VC0011860
p10186
sg17
I3
sasg18
(lp10187
(dp10188
g12
I168
sg13
VCDKAL1
p10189
sg14
I6
sg22
g190
sg17
I1
sa(dp10190
g12
I131
sg13
VIGF2BP2
p10191
sg14
I7
sg22
g190
sg17
I1
sa(dp10192
g12
I118
sg13
VKCNJ11
p10193
sg14
I6
sg22
g190
sg17
I1
sa(dp10194
g12
I176
sg13
g10181
sg14
I5
sg22
VP51787
p10195
sg17
I1
sa(dp10196
g12
I162
sg13
VHHEX
p10197
sg14
I4
sg22
g190
sg17
I1
sa(dp10198
g12
I112
sg13
VP12A
p10199
sg14
I4
sg22
g190
sg17
I1
sa(dp10200
g12
I106
sg13
VPPARG
p10201
sg14
I5
sg22
g190
sg17
I1
sa(dp10202
g12
I126
sg13
VFTO
p10203
sg14
I3
sg22
g190
sg17
I1
sa(dp10204
g12
I140
sg13
VDUSP9
p10205
sg14
I5
sg22
g190
sg17
I1
sasa(dp10206
g2
VAssociations between insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) rs11705701, insulin receptor substrate 1 rs7578326, gastric inhibitory polypeptide receptor rs10423928 and transcription factor 7-like 2 rs12255372 gene polymorphisms with prediabetes and type 2 diabetes (T2D) have not been evaluated in the Han Chinese population.
p10207
sg4
(dp10208
(Vinsulin receptor substrate 1 rs7578326, gastric inhibitory polypeptide receptor rs10423928 and transcription factor 7-like 2 rs12255372 gene
p10209
VT2D
p10210
tp10211
I00
ssg9
(lp10212
(dp10213
g12
I271
sg13
Vtype 2 diabetes
p10214
sg14
I15
sg15
VC0011860
p10215
sg17
I3
sa(dp10216
g12
I255
sg13
Vprediabetes
p10217
sg14
I11
sg15
VC0362046
p10218
sg17
I1
sa(dp10219
g12
I288
sg13
g10210
sg14
I3
sg15
VC0011860
p10220
sg17
I1
sasg18
(lp10221
(dp10222
g12
I74
sg13
VIGF2BP2
p10223
sg14
I7
sg22
g190
sg17
I1
sa(dp10224
g12
I21
sg13
Vinsulin-like growth factor 2 mRNA-binding protein 2
p10225
sg14
I51
sg22
VP01308
p10226
sg17
I7
sa(dp10227
g12
I95
sg13
g10209
sg14
I140
sg22
VP35568
p10228
sg17
I17
sasa(dp10229
g2
VPhosphorylation also links HS1 to multiple signaling proteins, including Lck, PLCgamma1, and Vav1, and is essential for the stable recruitment of Vav1 to the IS.
p10230
sg4
(dp10231
(VVav1
p10232
VHS1
p10233
tp10234
I00
ssg9
(lp10235
(dp10236
g12
I27
sg13
g10233
sg14
I3
sg15
VC2674218
p10237
sg17
I1
sa(dp10238
g12
I131
sg13
Vrecruitment
p10239
sg14
I11
sg15
VC0271510
p10240
sg17
I1
sasg18
(lp10241
(dp10242
g12
I93
sg13
VVav1
p10243
sg14
I4
sg22
VP15498
p10244
sg17
I1
sa(dp10245
g12
I27
sg13
VHS1
p10246
sg14
I3
sg22
VP27348
p10247
sg17
I1
sa(dp10248
g12
I78
sg13
VPLCgamma1
p10249
sg14
I9
sg22
VP19174
p10250
sg17
I1
sa(dp10251
g12
I93
sg13
g10232
sg14
I4
sg22
VP15498
p10252
sg17
I1
sasa(dp10253
g2
VOn the other hand, we confirmed previously mapped Lck SH3 binding sites in ADAM15, HS1, SLP76, and NS5A, and identified putative Lck SH3 binding sites of Sam68, FasL, c-Cbl, and Cbl-b.
p10254
sg4
(dp10255
(VSH3 binding sites
p10256
VHS1
p10257
tp10258
I00
ssg9
(lp10259
(dp10260
g12
I83
sg13
g10257
sg14
I3
sg15
VC2674218
p10261
sg17
I1
sasg18
(lp10262
(dp10263
g12
I83
sg13
VHS1
p10264
sg14
I3
sg22
VP27348
p10265
sg17
I1
sa(dp10266
g12
I161
sg13
VFasL
p10267
sg14
I4
sg22
VP48023
p10268
sg17
I1
sa(dp10269
g12
I154
sg13
VSam68
p10270
sg14
I5
sg22
g190
sg17
I1
sa(dp10271
g12
I167
sg13
Vc-Cbl
p10272
sg14
I5
sg22
VP22681
p10273
sg17
I1
sa(dp10274
g12
I75
sg13
VADAM15
p10275
sg14
I6
sg22
g190
sg17
I1
sa(dp10276
g12
I54
sg13
VSH3 binding sites
p10277
sg14
I17
sg22
VP63244
p10278
sg17
I3
sa(dp10279
g12
I54
sg13
g10256
sg14
I17
sg22
VP63244
p10280
sg17
I3
sa(dp10281
g12
I88
sg13
VSLP76
p10282
sg14
I5
sg22
g190
sg17
I1
sa(dp10283
g12
I178
sg13
VCbl-b
p10284
sg14
I5
sg22
g190
sg17
I1
sasa(dp10285
g2
VThe SH2 domains of ZAP70, SHP-1 and PLC gamma 1 and the SH3 domains of lck, vav and HS1 did not bind to pp85--90.
p10286
sg4
(dp10287
(VSHP-1
p10288
VHS1
p10289
tp10290
I00
ssg9
(lp10291
(dp10292
g12
I84
sg13
g10289
sg14
I3
sg15
VC2674218
p10293
sg17
I1
sasg18
(lp10294
(dp10295
g12
I84
sg13
VHS1
p10296
sg14
I3
sg22
VP27348
p10297
sg17
I1
sa(dp10298
g12
I76
sg13
Vvav
p10299
sg14
I3
sg22
VP15498
p10300
sg17
I1
sa(dp10301
g12
I36
sg13
VPLC gamma 1
p10302
sg14
I11
sg22
VP98160
p10303
sg17
I3
sa(dp10304
g12
I19
sg13
VZAP70
p10305
sg14
I5
sg22
VP43403
p10306
sg17
I1
sa(dp10307
g12
I26
sg13
g10288
sg14
I5
sg22
VP29350
p10308
sg17
I1
sasa(dp10309
g2
VThese analyses identified several cellular proteins inside HIV-1: elongation factor 1alpha, glyceraldehyde-3-phosphate dehydrogenase, HS-1, phosphatidylethanolamine-binding protein, Pin1, Lck, Nm23-H1, and the C-terminal tail of CD43.
p10310
sg4
(dp10311
(Vglyceraldehyde-3-phosphate dehydrogenase
p10312
VHIV
p10313
tp10314
I00
ssg9
(lp10315
(dp10316
g12
I59
sg13
g10313
sg14
I3
sg15
VC0019693
p10317
sg17
I1
sasg18
(lp10318
(dp10319
g12
I59
sg13
VHIV-1: elongation factor 1alpha
p10320
sg14
I31
sg22
g190
sg17
I4
sa(dp10321
g12
I140
sg13
Vphosphatidylethanolamine-binding protein
p10322
sg14
I40
sg22
VP30086
p10323
sg17
I2
sa(dp10324
g12
I182
sg13
VPin1
p10325
sg14
I4
sg22
g190
sg17
I1
sa(dp10326
g12
I193
sg13
VNm23-H1
p10327
sg14
I7
sg22
VP22392
p10328
sg17
I1
sa(dp10329
g12
I229
sg13
VCD43
p10330
sg14
I4
sg22
VP16150
p10331
sg17
I1
sa(dp10332
g12
I92
sg13
g10312
sg14
I40
sg22
VP04406
p10333
sg17
I2
sasa(dp10334
g2
VWe find that the Src homology 3 domains of Grb2 directly associate, in vitro and in vivo, with murine hemopoietic specific protein 1 (HS1), a protein identical to Lck-binding protein 1.
p10335
sg4
(dp10336
(VHS1
p10337
VHS1
p10338
tp10339
I00
ssg9
(lp10340
(dp10341
g12
I102
sg13
Vhemopoietic specific protein 1
p10342
sg14
I30
sg15
VC2674218
p10343
sg17
I4
sa(dp10344
g12
I134
sg13
g10338
sg14
I3
sg15
VC2674218
p10345
sg17
I1
sasg18
(lp10346
(dp10347
g12
I43
sg13
VGrb2
p10348
sg14
I4
sg22
VP62993
p10349
sg17
I1
sa(dp10350
g12
I163
sg13
VLck-binding protein 1
p10351
sg14
I21
sg22
VP14222
p10352
sg17
I3
sa(dp10353
g12
I95
sg13
Vmurine hemopoietic specific protein 1
p10354
sg14
I37
sg22
VP14222
p10355
sg17
I5
sa(dp10356
g12
I17
sg13
VSrc homology 3
p10357
sg14
I14
sg22
VP12931
p10358
sg17
I3
sa(dp10359
g12
I134
sg13
g10337
sg14
I3
sg22
VP27348
p10360
sg17
I1
sasa(dp10361
g2
VBecause HS1 associates with the p56(lck) and p59(lyn) tyrosine kinases in vitro and in vivo, and becomes tyrosine phosphorylated upon various receptor stimulations, our present data suggest that HS1 mediates linkage between Lck or Lyn and Grb2 in lymphoid lineage cells.
p10362
sg4
(dp10363
(Vtyrosine kinases
p10364
VHS1
p10365
tp10366
I00
ssg9
(lp10367
(dp10368
g12
I8
sg13
VHS1
p10369
sg14
I3
sg15
VC2674218
p10370
sg17
I1
sa(dp10371
g12
I8
sg13
g10365
sg14
I3
sg15
VC2674218
p10372
sg17
I1
sasg18
(lp10373
(dp10374
g12
I8
sg13
VHS1
p10375
sg14
I3
sg22
VP27348
p10376
sg17
I1
sa(dp10377
g12
I49
sg13
Vlyn
p10378
sg14
I3
sg22
VP07948
p10379
sg17
I1
sa(dp10380
g12
I231
sg13
VLyn
p10381
sg14
I3
sg22
VP07948
p10382
sg17
I1
sa(dp10383
g12
I32
sg13
Vp56
p10384
sg14
I3
sg22
VP62191
p10385
sg17
I1
sa(dp10386
g12
I239
sg13
VGrb2
p10387
sg14
I4
sg22
VP62993
p10388
sg17
I1
sa(dp10389
g12
I45
sg13
Vp59
p10390
sg14
I3
sg22
g190
sg17
I1
sa(dp10391
g12
I54
sg13
g10364
sg14
I16
sg22
VP29401
p10392
sg17
I2
sasa(dp10393
g2
VWith this method, we previously isolated an Lck tyrosine kinase-associated protein, LckBP1, which is identical to HS1 (Kitamura et al., 1989, 1995; Takemoto et al., 1995).
p10394
sg4
(dp10395
(Vtyrosine kinase-associated protein
p10396
VHS1
p10397
tp10398
I00
ssg9
(lp10399
(dp10400
g12
I114
sg13
g10397
sg14
I3
sg15
VC2674218
p10401
sg17
I1
sasg18
(lp10402
(dp10403
g12
I84
sg13
VLckBP1
p10404
sg14
I6
sg22
VP14317
p10405
sg17
I1
sa(dp10406
g12
I48
sg13
g10396
sg14
I34
sg22
VP29401
p10407
sg17
I3
sasa(dp10408
g2
VWe additionally show that pulmonary fibrosis in MyD88-KO mice was associated with the accumulation of pro-fibrotic regulatory T lymphocytes (T regs) and pro-fibrotic cytokine expression (TGF-Beta, IL-10 and PDGF-B), not with T helper (Th) 17 cell influx.
p10409
sg4
(dp10410
(VPDGF-B
p10411
Vpulmonary fibrosis
p10412
tp10413
I01
ssg9
(lp10414
(dp10415
g12
I26
sg13
g10412
sg14
I18
sg15
VC0034069
p10416
sg17
I2
sasg18
(lp10417
(dp10418
g12
I187
sg13
VTGF-Beta
p10419
sg14
I8
sg22
VP18075
p10420
sg17
I1
sa(dp10421
g12
I207
sg13
g10411
sg14
I6
sg22
VP01127
p10422
sg17
I1
sa(dp10423
g12
I48
sg13
VMyD88-KO
p10424
sg14
I8
sg22
g190
sg17
I1
sasa(dp10425
g2
VThe aim of our investigation was to analyze the pattern of interleukin-1 (IL-1) family compounds: IL-1 beta, IL-1 receptor accessory protein (Acp), IL-1 receptor antagonist (IL-1Ra) and IL-1 receptor type II (IL-1RII) in the serum and cerebrospinal fluid (CSF) from 67 multiple sclerosis (MS) patients and 31 controls.
p10426
sg4
(dp10427
(VIL-1 beta
p10428
Vmultiple sclerosis
p10429
tp10430
I00
ssg9
(lp10431
(dp10432
g12
I123
sg13
Vaccessory protein
p10433
sg14
I17
sg15
VC0394005
p10434
sg17
I2
sa(dp10435
g12
I142
sg13
VAcp
p10436
sg14
I3
sg15
VC0394005
p10437
sg17
I1
sa(dp10438
g12
I289
sg13
VMS
p10439
sg14
I2
sg15
VC0026769
p10440
sg17
I1
sa(dp10441
g12
I269
sg13
g10429
sg14
I18
sg15
VC0026769
p10442
sg17
I2
sasg18
(lp10443
(dp10444
g12
I209
sg13
VIL-1RII
p10445
sg14
I7
sg22
g190
sg17
I1
sa(dp10446
g12
I109
sg13
VIL-1 receptor accessory protein
p10447
sg14
I31
sg22
g190
sg17
I4
sa(dp10448
g12
I59
sg13
Vinterleukin-1
p10449
sg14
I13
sg22
VP60568
p10450
sg17
I1
sa(dp10451
g12
I148
sg13
VIL-1 receptor antagonist
p10452
sg14
I24
sg22
g190
sg17
I3
sa(dp10453
g12
I174
sg13
VIL-1Ra
p10454
sg14
I6
sg22
VP18510
p10455
sg17
I1
sa(dp10456
g12
I235
sg13
Vcerebrospinal fluid (CSF)
p10457
sg14
I25
sg22
VP04141
p10458
sg17
I3
sa(dp10459
g12
I142
sg13
VAcp
p10460
sg14
I3
sg22
VP13686
p10461
sg17
I1
sa(dp10462
g12
I74
sg13
VIL-1
p10463
sg14
I4
sg22
VP01584
p10464
sg17
I1
sa(dp10465
g12
I98
sg13
g10428
sg14
I9
sg22
VP01584
p10466
sg17
I2
sa(dp10467
g12
I186
sg13
VIL-1 receptor type II
p10468
sg14
I21
sg22
g190
sg17
I4
sasa(dp10469
g2
VThe antigenic protein spots reacted against sera from clonorchiasis patients and were identified as cysteine proteases, glutathione transferases, gelsolin, propionyl-CoA carboxylase (PCC), prohibitin and 14-3-3 protein (14-3-3) using LC-coupled ESI-MS/MS and an EST database for C. sinensis.
p10470
sg4
(dp10471
(Vprohibitin
p10472
Vpropionyl-CoA carboxylase
p10473
tp10474
I00
ssg9
(lp10475
(dp10476
g12
I54
sg13
Vclonorchiasis
p10477
sg14
I13
sg15
VC0009021
p10478
sg17
I1
sa(dp10479
g12
I183
sg13
VPCC
p10480
sg14
I3
sg15
VC1832526
p10481
sg17
I1
sa(dp10482
g12
I22
sg13
Vspots
p10483
sg14
I5
sg15
VC0015230
p10484
sg17
I1
sa(dp10485
g12
I156
sg13
g10473
sg14
I25
sg15
VC1832526
p10486
sg17
I2
sasg18
(lp10487
(dp10488
g12
I183
sg13
VPCC
p10489
sg14
I3
sg22
VP07320
p10490
sg17
I1
sa(dp10491
g12
I120
sg13
Vglutathione transferases
p10492
sg14
I24
sg22
VP48637
p10493
sg17
I2
sa(dp10494
g12
I100
sg13
Vcysteine proteases
p10495
sg14
I18
sg22
VP49662
p10496
sg17
I2
sa(dp10497
g12
I146
sg13
Vgelsolin, propionyl-CoA carboxylase
p10498
sg14
I35
sg22
VP06396
p10499
sg17
I3
sa(dp10500
g12
I189
sg13
g10472
sg14
I10
sg22
VP35232
p10501
sg17
I1
sasa(dp10502
g2
VTo identify the possible biological roles of keratinocyte growth factor (KGF), connective tissue growth factor (CTGF) and transforming growth factor-Beta (TGF-Beta) in cyclosporine-A (CsA) and phenytoin (PNT)-induced gingival overgrowth (GO) and to correlate them with each other.
p10503
sg4
(dp10504
(Vtransforming growth factor-Beta
p10505
Vcyclosporine-A
p10506
tp10507
I00
ssg9
(lp10508
(dp10509
g12
I184
sg13
VCsA
p10510
sg14
I3
sg15
VC0751039
p10511
sg17
I1
sa(dp10512
g12
I168
sg13
g10506
sg14
I14
sg15
VC0751039
p10513
sg17
I1
sasg18
(lp10514
(dp10515
g12
I45
sg13
Vkeratinocyte growth factor
p10516
sg14
I26
sg22
VP21781
p10517
sg17
I3
sa(dp10518
g12
I112
sg13
VCTGF
p10519
sg14
I4
sg22
VP29279
p10520
sg17
I1
sa(dp10521
g12
I155
sg13
VTGF-Beta
p10522
sg14
I8
sg22
VP18075
p10523
sg17
I1
sa(dp10524
g12
I73
sg13
VKGF
p10525
sg14
I3
sg22
VP21781
p10526
sg17
I1
sa(dp10527
g12
I79
sg13
Vconnective tissue growth factor
p10528
sg14
I31
sg22
VP29279
p10529
sg17
I4
sa(dp10530
g12
I122
sg13
g10505
sg14
I31
sg22
VP18075
p10531
sg17
I3
sasa(dp10532
g2
VTwelve patients with classic radiologic and histologic features of MO, 6 with brown tumors, and 5 with cherubism diagnosed at our institution were studied for the presence of USP6 rearrangements using fluorescence in situ hybridization with probes flanking the USP6 locus on chromosome 17p13.
p10533
sg4
(dp10534
(VUSP6 locus
p10535
Vbrown tumors
p10536
tp10537
I00
ssg9
(lp10538
(dp10539
g12
I103
sg13
Vcherubism
p10540
sg14
I9
sg15
VC0008029
p10541
sg17
I1
sa(dp10542
g12
I78
sg13
g10536
sg14
I12
sg15
VC0029405
p10543
sg17
I2
sasg18
(lp10544
(dp10545
g12
I175
sg13
VUSP6 rearrangements
p10546
sg14
I19
sg22
VP35125
p10547
sg17
I2
sa(dp10548
g12
I261
sg13
g10535
sg14
I10
sg22
VP35125
p10549
sg17
I2
sasa(dp10550
g2
VNone of the patients with brown tumor or cherubism demonstrated USP6 rearrangements.
p10551
sg4
(dp10552
(VUSP6 rearrangements
p10553
Vcherubism
p10554
tp10555
I00
ssg9
(lp10556
(dp10557
g12
I26
sg13
Vbrown tumor
p10558
sg14
I11
sg15
VC0029405
p10559
sg17
I2
sa(dp10560
g12
I41
sg13
g10554
sg14
I9
sg15
VC0008029
p10561
sg17
I1
sasg18
(lp10562
(dp10563
g12
I64
sg13
g10553
sg14
I19
sg22
VP35125
p10564
sg17
I2
sasa(dp10565
g2
VIn contrast, no USP6 rearrangements were found in patients with cherubism or brown tumor, supporting the prevailing view that these lesions are distinct biologic entities.
p10566
sg4
(dp10567
(VUSP6 rearrangements
p10568
Vbrown tumor
p10569
tp10570
I00
ssg9
(lp10571
(dp10572
g12
I64
sg13
Vcherubism
p10573
sg14
I9
sg15
VC0008029
p10574
sg17
I1
sa(dp10575
g12
I77
sg13
g10569
sg14
I11
sg15
VC0029405
p10576
sg17
I2
sasg18
(lp10577
(dp10578
g12
I16
sg13
g10568
sg14
I19
sg22
VP35125
p10579
sg17
I2
sasa(dp10580
g2
VConsistent with findings in mice, marked alterations in nuclear envelope morphology, abnormal localization of RanGAP1, and nuclear accumulation of mRNA were found in cortex of Huntington's disease patients.
p10581
sg4
(dp10582
(VRanGAP1
p10583
VHuntington's disease
p10584
tp10585
I00
ssg9
(lp10586
(dp10587
g12
I176
sg13
g10584
sg14
I20
sg15
VC0020179
p10588
sg17
I2
sasg18
(lp10589
(dp10590
g12
I110
sg13
g10583
sg14
I7
sg22
VP46060
p10591
sg17
I1
sasa(dp10592
g2
VDouble immunofluorescent analyses revealed nuclear retention and apparent colocalization of RanGap1 with Nup205, Gp210 with Nup205, and partial colocalization of Nup205 with Nup107; most of the ischemic changes above were similar to those observed in patients with C9orf72-genetic amyotrophic lateral sclerosis.
p10593
sg4
(dp10594
(VNup107
p10595
Vamyotrophic lateral sclerosis
p10596
tp10597
I00
ssg9
(lp10598
(dp10599
g12
I281
sg13
g10596
sg14
I29
sg15
VC0002736
p10600
sg17
I3
sasg18
(lp10601
(dp10602
g12
I105
sg13
VNup205
p10603
sg14
I6
sg22
g190
sg17
I1
sa(dp10604
g12
I92
sg13
VRanGap1
p10605
sg14
I7
sg22
VP46060
p10606
sg17
I1
sa(dp10607
g12
I174
sg13
g10595
sg14
I6
sg22
VP57740
p10608
sg17
I1
sa(dp10609
g12
I105
sg13
VNup205
p10610
sg14
I6
sg22
g190
sg17
I1
sa(dp10611
g12
I105
sg13
VNup205
p10612
sg14
I6
sg22
g190
sg17
I1
sa(dp10613
g12
I113
sg13
VGp210
p10614
sg14
I5
sg22
g190
sg17
I1
sasa(dp10615
g2
VDetection of the expression of these proteins and genes encoding these proteins in human gastric cancer tissues by real-time PCR (RT-qPCR) and western blot revealed that the expression of Beta-ACTIN, LDH, DLD, PRPF19 and CaM genes were up-regulated and RanGAP was down-regulated in gastric cancer tissues and/or metastatic lymph nodes compared to peri-cancerous tissues.
p10616
sg4
(dp10617
(VCaM genes
p10618
VCaM
p10619
tp10620
I00
ssg9
(lp10621
(dp10622
g12
I89
sg13
Vgastric cancer
p10623
sg14
I14
sg15
VC0024623
p10624
sg17
I2
sa(dp10625
g12
I89
sg13
Vgastric cancer
p10626
sg14
I14
sg15
VC0024623
p10627
sg17
I2
sa(dp10628
g12
I221
sg13
g10619
sg14
I3
sg15
VC1861821
p10629
sg17
I1
sasg18
(lp10630
(dp10631
g12
I205
sg13
VDLD
p10632
sg14
I3
sg22
VP98173
p10633
sg17
I1
sa(dp10634
g12
I200
sg13
VLDH
p10635
sg14
I3
sg22
g190
sg17
I1
sa(dp10636
g12
I188
sg13
VBeta-ACTIN
p10637
sg14
I10
sg22
VP63261
p10638
sg17
I1
sa(dp10639
g12
I221
sg13
g10618
sg14
I9
sg22
VP01768
p10640
sg17
I2
sa(dp10641
g12
I210
sg13
VPRPF19
p10642
sg14
I6
sg22
g190
sg17
I1
sasa(dp10643
g2
VStable coronary artery disease (SCAD) patients scheduled for PCI were randomized to one of the three study arms: 1) genotyping, 2) PFT, and 3) control and evaluated by the CYP2C19 allele genotyping and PFT with P2Y12 assay.
p10644
sg4
(dp10645
(VCYP2C19 allele
p10646
VSCAD
p10647
tp10648
I00
ssg9
(lp10649
(dp10650
g12
I0
sg13
VStable coronary artery disease
p10651
sg14
I30
sg15
VC0342783
p10652
sg17
I4
sa(dp10653
g12
I107
sg13
Varms
p10654
sg14
I4
sg15
VC0206655
p10655
sg17
I1
sa(dp10656
g12
I32
sg13
g10647
sg14
I4
sg15
VC0342783
p10657
sg17
I1
sasg18
(lp10658
(dp10659
g12
I172
sg13
g10646
sg14
I14
sg22
VP33261
p10660
sg17
I2
sasa(dp10661
g2
VTo assess the association of CYP2C19 G681A, P2RY12 H1/H2, and ITGB3 T1565C polymorphisms with the extent of platelet aggregation in patients with coronary heart disease (CHD) during antiplatelet therapy.
p10662
sg4
(dp10663
(VITGB3 T1565C
p10664
Vcoronary heart disease
p10665
tp10666
I00
ssg9
(lp10667
(dp10668
g12
I170
sg13
VCHD
p10669
sg14
I3
sg15
VC0010054
p10670
sg17
I1
sa(dp10671
g12
I146
sg13
g10665
sg14
I22
sg15
VC0010054
p10672
sg17
I3
sasg18
(lp10673
(dp10674
g12
I44
sg13
VP2RY12 H1/H2
p10675
sg14
I12
sg22
g190
sg17
I2
sa(dp10676
g12
I29
sg13
VCYP2C19 G681A
p10677
sg14
I13
sg22
VP33261
p10678
sg17
I2
sa(dp10679
g12
I62
sg13
g10664
sg14
I12
sg22
VP05106
p10680
sg17
I2
sasa(dp10681
g2
VThis shortening of the HuR mRNA 3'-UTR via alternative polyadenylation (APA) was observed to be dependent on cleavage stimulation factor subunit 2 (CSTF2/CstF-64), which is up-regulated in the TAMR breast cancer cells.
p10682
sg4
(dp10683
(VCstF-64
p10684
Vbreast cancer
p10685
tp10686
I00
ssg9
(lp10687
(dp10688
g12
I198
sg13
g10685
sg14
I13
sg15
VC0678222
p10689
sg17
I2
sasg18
(lp10690
(dp10691
g12
I148
sg13
VCSTF2
p10692
sg14
I5
sg22
VP33240
p10693
sg17
I1
sa(dp10694
g12
I23
sg13
VHuR mRNA 3'-UTR
p10695
sg14
I15
sg22
g190
sg17
I3
sa(dp10696
g12
I154
sg13
g10684
sg14
I7
sg22
VP33240
p10697
sg17
I1
sa(dp10698
g12
I130
sg13
Vfactor subunit 2
p10699
sg14
I16
sg22
g190
sg17
I3
sasa(dp10700
g2
VMoreover, CSTF2, POLA1, HMOX2, and EFNB2 may be associated with the prognosis of bladder cancer patient.
p10701
sg4
(dp10702
(VCSTF2
p10703
Vbladder cancer
p10704
tp10705
I00
ssg9
(lp10706
(dp10707
g12
I81
sg13
g10704
sg14
I14
sg15
VC0699885
p10708
sg17
I2
sasg18
(lp10709
(dp10710
g12
I24
sg13
VHMOX2
p10711
sg14
I5
sg22
VP30519
p10712
sg17
I1
sa(dp10713
g12
I17
sg13
VPOLA1
p10714
sg14
I5
sg22
VP09884
p10715
sg17
I1
sa(dp10716
g12
I35
sg13
VEFNB2
p10717
sg14
I5
sg22
VP52799
p10718
sg17
I1
sa(dp10719
g12
I10
sg13
g10703
sg14
I5
sg22
VP33240
p10720
sg17
I1
sasa(dp10721
g2
VImmunohistochemical staining using tissue microarray consisting of 327 lung cancers was applied to examine the expression of CSTF2 protein and its prognostic value.
p10722
sg4
(dp10723
(VCSTF2 protein
p10724
Vlung cancers
p10725
tp10726
I01
ssg9
(lp10727
(dp10728
g12
I71
sg13
g10725
sg14
I12
sg15
VC0242379
p10729
sg17
I2
sasg18
(lp10730
(dp10731
g12
I125
sg13
g10724
sg14
I13
sg22
VP33240
p10732
sg17
I2
sasa(dp10733
g2
VImmunohistochemical analysis using tissue microarray showed an association of strong CSTF2 expression with poor prognosis of patients with non-small cell lung cancer (P = 0.0079), and multivariate analysis showed that CSTF2 positivity is an independent prognostic factor.
p10734
sg4
(dp10735
(VCSTF2
p10736
Vnon-small cell lung cancer
p10737
tp10738
I01
ssg9
(lp10739
(dp10740
g12
I139
sg13
g10737
sg14
I26
sg15
VC0007131
p10741
sg17
I4
sasg18
(lp10742
(dp10743
g12
I85
sg13
VCSTF2
p10744
sg14
I5
sg22
VP33240
p10745
sg17
I1
sa(dp10746
g12
I85
sg13
g10736
sg14
I5
sg22
VP33240
p10747
sg17
I1
sasa(dp10748
g2
VImmunohistochemistry analysis of cellular immune parameters (CD4+ or CD8+ T cells, CIITA, MHC-II and CD68) was performed on NMU-induced rat mammary tumor nodules, followed by evaluation of the serum level of 34 cytokines using the cytokine antibody array.
p10749
sg4
(dp10750
(VCD68
p10751
Vmammary tumor
p10752
tp10753
I01
ssg9
(lp10754
(dp10755
g12
I154
sg13
Vnodules
p10756
sg14
I7
sg15
VC0028259
p10757
sg17
I1
sa(dp10758
g12
I140
sg13
g10752
sg14
I13
sg15
VC1458155
p10759
sg17
I2
sasg18
(lp10760
(dp10761
g12
I90
sg13
VMHC-II
p10762
sg14
I6
sg22
VP13747
p10763
sg17
I1
sa(dp10764
g12
I69
sg13
VCD8+
p10765
sg14
I4
sg22
VP01732
p10766
sg17
I1
sa(dp10767
g12
I83
sg13
VCIITA
p10768
sg14
I5
sg22
VP33076
p10769
sg17
I1
sa(dp10770
g12
I61
sg13
VCD4+
p10771
sg14
I4
sg22
VP01730
p10772
sg17
I1
sa(dp10773
g12
I101
sg13
g10751
sg14
I4
sg22
VP34810
p10774
sg17
I1
sasa(dp10775
g2
VImmunohistochemistry was performed to determine PD-L1 tumor cell expression and to enumerate CD8, CD4 and CD68 tumor-infiltrating leucocytes (TIL) in a cohort of 443 breast cancers categorized by molecular subtype.
p10776
sg4
(dp10777
(VCD4
p10778
Vbreast cancers
p10779
tp10780
I01
ssg9
(lp10781
(dp10782
g12
I54
sg13
Vtumor
p10783
sg14
I5
sg15
VC0027651
p10784
sg17
I1
sa(dp10785
g12
I54
sg13
Vtumor
p10786
sg14
I5
sg15
VC0027651
p10787
sg17
I1
sa(dp10788
g12
I117
sg13
Vinfiltrating
p10789
sg14
I12
sg15
VC0332448
p10790
sg17
I1
sa(dp10791
g12
I166
sg13
g10779
sg14
I14
sg15
VC0006142
p10792
sg17
I2
sasg18
(lp10793
(dp10794
g12
I106
sg13
VCD68
p10795
sg14
I4
sg22
VP34810
p10796
sg17
I1
sa(dp10797
g12
I142
sg13
VTIL
p10798
sg14
I3
sg22
VP01765
p10799
sg17
I1
sa(dp10800
g12
I93
sg13
VCD8
p10801
sg14
I3
sg22
VP01732
p10802
sg17
I1
sa(dp10803
g12
I98
sg13
g10778
sg14
I3
sg22
VP01730
p10804
sg17
I1
sa(dp10805
g12
I111
sg13
Vtumor-infiltrating leucocytes
p10806
sg14
I29
sg22
VP01765
p10807
sg17
I2
sasa(dp10808
g2
VThese findings demonstrate, for the first time, a novel capacity of a P-Alexa647-FA conjugate to colocalize to CD11b+CD68+ TAMs in both primary and metastatic breast tumors.
p10809
sg4
(dp10810
(VCD11b+CD68+ TAMs
p10811
Vbreast tumors
p10812
tp10813
I00
ssg9
(lp10814
(dp10815
g12
I159
sg13
g10812
sg14
I13
sg15
VC1458155
p10816
sg17
I2
sasg18
(lp10817
(dp10818
g12
I111
sg13
g10811
sg14
I16
sg22
VP11215
p10819
sg17
I2
sasa(dp10820
g2
VWe used breast tumor tissues from each patient to make tissue microarrays that were then stained for leukocyte and myeloid markers including CD4, CD8, CD20, CD25, CD68, and CD163 using immunohistochemical techniques.
p10821
sg4
(dp10822
(VCD4
p10823
Vbreast tumor
p10824
tp10825
I01
ssg9
(lp10826
(dp10827
g12
I8
sg13
g10824
sg14
I12
sg15
VC1458155
p10828
sg17
I2
sasg18
(lp10829
(dp10830
g12
I151
sg13
VCD20
p10831
sg14
I4
sg22
VP35900
p10832
sg17
I1
sa(dp10833
g12
I173
sg13
VCD163
p10834
sg14
I5
sg22
g190
sg17
I1
sa(dp10835
g12
I146
sg13
VCD8
p10836
sg14
I3
sg22
VP01732
p10837
sg17
I1
sa(dp10838
g12
I157
sg13
VCD25
p10839
sg14
I4
sg22
VP01589
p10840
sg17
I1
sa(dp10841
g12
I163
sg13
VCD68
p10842
sg14
I4
sg22
VP34810
p10843
sg17
I1
sa(dp10844
g12
I141
sg13
g10823
sg14
I3
sg22
VP01730
p10845
sg17
I1
sasa(dp10846
g2
VFurthermore, high density of CD163+ and CD68+ TAMs was observed in ovarian cancer with advanced TNM stage.
p10847
sg4
(dp10848
(VCD68+
p10849
Vovarian cancer
p10850
tp10851
I00
ssg9
(lp10852
(dp10853
g12
I67
sg13
g10850
sg14
I14
sg15
VC1140680
p10854
sg17
I2
sasg18
(lp10855
(dp10856
g12
I29
sg13
VCD163+
p10857
sg14
I6
sg22
g190
sg17
I1
sa(dp10858
g12
I40
sg13
g10849
sg14
I5
sg22
VP34810
p10859
sg17
I1
sasa(dp10860
g2
VThe number of CD68+CD163+ M2-like macrophages was significantly higher in breast cancer tissues than in benign tissues.
p10861
sg4
(dp10862
(VCD68+CD163+ M2-like
p10863
Vbreast cancer
p10864
tp10865
I00
ssg9
(lp10866
(dp10867
g12
I74
sg13
g10864
sg14
I13
sg15
VC0678222
p10868
sg17
I2
sasg18
(lp10869
(dp10870
g12
I14
sg13
g10863
sg14
I19
sg22
VP34810
p10871
sg17
I2
sasa(dp10872
S'line'
p10873
VCharacterisation of most mutations found in CLCN2 in patients with CC2L leukodystrophy show that they cause a reduction in function of the chloride channel ClC-2.
p10874
sg4
(dp10875
(Vchloride channel ClC-2
p10876
Vleukodystrophy
p10877
tp10878
I00
ssS'diseases'
p10879
(lp10880
(dp10881
S'index'
p10882
I72
sS'name'
p10883
g10877
sS'lengthInChars'
p10884
I14
sS'cui'
p10885
VC0023520
p10886
sS'lengthInWords'
p10887
I1
sasS'genes'
p10888
(lp10889
(dp10890
g10882
I139
sg10883
g10876
sg10884
I22
sS'uniprot'
p10891
VP51800
p10892
sg10887
I3
sasa(dp10893
g10873
VGlialCAM, a regulatory subunit of ClC-2 in glial cells and involved in the leukodystrophy megalencephalic leukoencephalopathy with subcortical cysts (MLC), increases the activity of a ClC-2 mutant by affecting ClC-2 gating and by stabilising the mutant at the plasma membrane.
p10894
sg4
(dp10895
(VClC-2
p10896
VMLC
p10897
tp10898
I00
ssg10879
(lp10899
(dp10900
g10882
I90
sg10883
Vmegalencephalic leukoencephalopathy with subcortical cysts
p10901
sg10884
I58
sg10885
VC1858854
p10902
sg10887
I5
sa(dp10903
g10882
I190
sg10883
Vmutant
p10904
sg10884
I6
sg10885
VC0596988
p10905
sg10887
I1
sa(dp10906
g10882
I75
sg10883
Vleukodystrophy
p10907
sg10884
I14
sg10885
VC0023520
p10908
sg10887
I1
sa(dp10909
g10882
I190
sg10883
Vmutant
p10910
sg10884
I6
sg10885
VC0596988
p10911
sg10887
I1
sa(dp10912
g10882
I150
sg10883
g10897
sg10884
I3
sg10885
VC1858854
p10913
sg10887
I1
sasg10888
(lp10914
(dp10915
g10882
I0
sg10883
VGlialCAM
p10916
sg10884
I8
sg10891
g190
sg10887
I1
sa(dp10917
g10882
I184
sg10883
VClC-2 mutant
p10918
sg10884
I12
sg10891
VP51788
p10919
sg10887
I2
sa(dp10920
g10882
I34
sg10883
g10896
sg10884
I5
sg10891
VP51788
p10921
sg10887
I1
sasa(dp10922
g10873
VWe suggest that leukodystrophy-causing CLCN2 mutations reduce the functional expression of ClC-2, which is partly counteracted by GlialCAM/MLC1-mediated increase in the gating and stability of the channel.
p10923
sg4
(dp10924
(VCLCN2 mutations
p10925
Vleukodystrophy
p10926
tp10927
I00
ssg10879
(lp10928
(dp10929
g10882
I139
sg10883
VMLC1
p10930
sg10884
I4
sg10885
VC1858854
p10931
sg10887
I1
sa(dp10932
g10882
I16
sg10883
g10926
sg10884
I14
sg10885
VC0023520
p10933
sg10887
I1
sasg10888
(lp10934
(dp10935
g10882
I139
sg10883
VMLC1
p10936
sg10884
I4
sg10891
VP12829
p10937
sg10887
I1
sa(dp10938
g10882
I130
sg10883
VGlialCAM
p10939
sg10884
I8
sg10891
g190
sg10887
I1
sa(dp10940
g10882
I91
sg10883
VClC-2
p10941
sg10884
I5
sg10891
VP51788
p10942
sg10887
I1
sa(dp10943
g10882
I39
sg10883
g10925
sg10884
I15
sg10891
VP51788
p10944
sg10887
I2
sasa(dp10945
g10873
VThe review then discusses the diseases associated with ClC-2, including degeneration of the retina, Sjoegren's syndrome, age-related cataracts, degeneration of the testes, azoospermia, lung cancer, constipation, repair of impaired intestinal mucosa barrier, leukemia, cystic fibrosis, leukoencephalopathy, epilepsy and diabetes mellitus.
p10946
sg4
(dp10947
(VClC-2
p10948
Vdiabetes mellitus
p10949
tp10950
I00
ssg10879
(lp10951
(dp10952
g10882
I268
sg10883
Vcystic fibrosis
p10953
sg10884
I15
sg10885
VC0010674
p10954
sg10887
I2
sa(dp10955
g10882
I306
sg10883
Vepilepsy
p10956
sg10884
I8
sg10885
VC0014544
p10957
sg10887
I1
sa(dp10958
g10882
I285
sg10883
Vleukoencephalopathy
p10959
sg10884
I19
sg10885
VC0270612
p10960
sg10887
I1
sa(dp10961
g10882
I133
sg10883
Vcataracts
p10962
sg10884
I9
sg10885
VC0521707
p10963
sg10887
I1
sa(dp10964
g10882
I72
sg10883
Vdegeneration
p10965
sg10884
I12
sg10885
VC0011164
p10966
sg10887
I1
sa(dp10967
g10882
I185
sg10883
Vlung cancer
p10968
sg10884
I11
sg10885
VC0684249
p10969
sg10887
I2
sa(dp10970
g10882
I258
sg10883
Vleukemia
p10971
sg10884
I8
sg10885
VC0023418
p10972
sg10887
I1
sa(dp10973
g10882
I100
sg10883
VSjoegren's syndrome
p10974
sg10884
I19
sg10885
VC1527336
p10975
sg10887
I2
sa(dp10976
g10882
I222
sg10883
Vimpaired
p10977
sg10884
I8
sg10885
VC0684336
p10978
sg10887
I1
sa(dp10979
g10882
I72
sg10883
Vdegeneration
p10980
sg10884
I12
sg10885
VC0011164
p10981
sg10887
I1
sa(dp10982
g10882
I198
sg10883
Vconstipation
p10983
sg10884
I12
sg10885
VC0009806
p10984
sg10887
I1
sa(dp10985
g10882
I172
sg10883
Vazoospermia
p10986
sg10884
I11
sg10885
VC1321542
p10987
sg10887
I1
sa(dp10988
g10882
I319
sg10883
g10949
sg10884
I17
sg10885
VC0011849
p10989
sg10887
I2
sasg10888
(lp10990
(dp10991
g10882
I55
sg10883
g10948
sg10884
I5
sg10891
VP51788
p10992
sg10887
I1
sasa(dp10993
g10873
VA subset of these genes has been implicated in other neurobehavioral disorders including depression (SLIT3), epilepsy (CLCN2, PRICKLE1), intellectual disability (AP4M1), schizophrenia (WDR60), and Tourette syndrome (OFCC1).
p10994
sg4
(dp10995
(VCLCN2
p10996
VTourette syndrome
p10997
tp10998
I00
ssg10879
(lp10999
(dp11000
g10882
I137
sg10883
Vintellectual disability
p11001
sg10884
I23
sg10885
VC0025362
p11002
sg10887
I2
sa(dp11003
g10882
I170
sg10883
Vschizophrenia
p11004
sg10884
I13
sg10885
VC0036341
p11005
sg10887
I1
sa(dp11006
g10882
I109
sg10883
Vepilepsy
p11007
sg10884
I8
sg10885
VC0014544
p11008
sg10887
I1
sa(dp11009
g10882
I89
sg10883
Vdepression
p11010
sg10884
I10
sg10885
VC0011581
p11011
sg10887
I1
sa(dp11012
g10882
I197
sg10883
g10997
sg10884
I17
sg10885
VC0040517
p11013
sg10887
I2
sasg10888
(lp11014
(dp11015
g10882
I126
sg10883
VPRICKLE1
p11016
sg10884
I8
sg10891
g190
sg10887
I1
sa(dp11017
g10882
I162
sg10883
VAP4M1
p11018
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp11019
g10882
I101
sg10883
VSLIT3
p11020
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp11021
g10882
I185
sg10883
VWDR60
p11022
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp11023
g10882
I109
sg10883
Vepilepsy
p11024
sg10884
I8
sg10891
VP10646
p11025
sg10887
I1
sa(dp11026
g10882
I119
sg10883
g10996
sg10884
I5
sg10891
VP51788
p11027
sg10887
I1
sasa(dp11028
g10873
VEffective silencing of Runx2 by short interfering RNA (siRNA) demonstrated downregulation of EMT-related molecules (SNAI2, SNAI3 and TWIST1), MMP2 and vasculogenic factors (VEGFA and VEGFC) in thyroid carcinoma cells.
p11029
sg4
(dp11030
(Vvasculogenic factors
p11031
Vthyroid carcinoma
p11032
tp11033
I00
ssg10879
(lp11034
(dp11035
g10882
I193
sg10883
g11032
sg10884
I17
sg10885
VC0549473
p11036
sg10887
I2
sasg10888
(lp11037
(dp11038
g10882
I123
sg10883
VSNAI3
p11039
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp11040
g10882
I142
sg10883
VMMP2
p11041
sg10884
I4
sg10891
VP08253
p11042
sg10887
I1
sa(dp11043
g10882
I133
sg10883
VTWIST1
p11044
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp11045
g10882
I93
sg10883
VEMT-related molecules
p11046
sg10884
I21
sg10891
g190
sg10887
I2
sa(dp11047
g10882
I23
sg10883
VRunx2
p11048
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp11049
g10882
I183
sg10883
VVEGFC
p11050
sg10884
I5
sg10891
VP49767
p11051
sg10887
I1
sa(dp11052
g10882
I116
sg10883
VSNAI2
p11053
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp11054
g10882
I151
sg10883
g11031
sg10884
I20
sg10891
VP19883
p11055
sg10887
I2
sasa(dp11056
g10873
VThyroid-stimulating hormone levels, goiter and thyroid dysfunction were higher in children who were anti-TPO1 than in diabetic children without thyroid autoimmunity.
p11057
sg4
(dp11058
(VThyroid-stimulating hormone
p11059
Vautoimmunity
p11060
tp11061
I00
ssg10879
(lp11062
(dp11063
g10882
I36
sg10883
Vgoiter
p11064
sg10884
I6
sg10885
VC0018021
p11065
sg10887
I1
sa(dp11066
g10882
I152
sg10883
g11060
sg10884
I12
sg10885
VC0004368
p11067
sg10887
I1
sa(dp11068
g10882
I47
sg10883
Vthyroid dysfunction
p11069
sg10884
I19
sg10885
VC0348024
p11070
sg10887
I2
sasg10888
(lp11071
(dp11072
g10882
I0
sg10883
g11059
sg10884
I27
sg10891
VP01222
p11073
sg10887
I2
sa(dp11074
g10882
I100
sg10883
Vanti-TPO1
p11075
sg10884
I9
sg10891
g190
sg10887
I1
sasa(dp11076
g10873
VThe impact of urinary VDBP and KIM-1 on MARE was independent of known CIN risk factors such as anemia, preexisting renal failure, preexisting heart failure, and diabetes.
p11077
sg4
(dp11078
(VVDBP
p11079
Vdiabetes
p11080
tp11081
I01
ssg10879
(lp11082
(dp11083
g10882
I95
sg10883
Vanemia
p11084
sg10884
I6
sg10885
VC0002871
p11085
sg10887
I1
sa(dp11086
g10882
I70
sg10883
VCIN
p11087
sg10884
I3
sg10885
VC0206708
p11088
sg10887
I1
sa(dp11089
g10882
I142
sg10883
Vheart failure
p11090
sg10884
I13
sg10885
VC0018802
p11091
sg10887
I2
sa(dp11092
g10882
I115
sg10883
Vrenal failure
p11093
sg10884
I13
sg10885
VC0035078
p11094
sg10887
I2
sa(dp11095
g10882
I161
sg10883
g11080
sg10884
I8
sg10885
VC0011849
p11096
sg10887
I1
sasg10888
(lp11097
(dp11098
g10882
I40
sg10883
VMARE
p11099
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp11100
g10882
I31
sg10883
VKIM-1
p11101
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp11102
g10882
I22
sg10883
g11079
sg10884
I4
sg10891
VP02774
p11103
sg10887
I1
sasa(dp11104
g10873
VNext, we demonstrate that CD172a(+)Slan DCs that produced IL-1Beta and TNF-Alfa accumulated in mLNs and colons of CD patients.
p11105
sg4
(dp11106
(VIL-1Beta
p11107
VDCs
p11108
tp11109
I00
ssg10879
(lp11110
(dp11111
g10882
I95
sg10883
VmLNs
p11112
sg10884
I4
sg10885
VC0026691
p11113
sg10887
I1
sa(dp11114
g10882
I40
sg10883
g11108
sg10884
I3
sg10885
VC0268238
p11115
sg10887
I1
sasg10888
(lp11116
(dp11117
g10882
I71
sg10883
VTNF-Alfa
p11118
sg10884
I8
sg10891
VP01375
p11119
sg10887
I1
sa(dp11120
g10882
I58
sg10883
g11107
sg10884
I8
sg10891
VP01584
p11121
sg10887
I1
sasa(dp11122
g10873
VIn conclusion, we propose that proinflammatory CD14(bright)CD172a(+)Slan DCs are a distinguishing feature between CD and UC, as these cells accumulate uniquely in mLNs and colonic mucosa of CD patients.
p11123
sg4
(dp11124
(VCD14(bright)CD172a(+)Slan DCs
p11125
VmLNs
p11126
tp11127
I00
ssg10879
(lp11128
(dp11129
g10882
I73
sg10883
VDCs
p11130
sg10884
I3
sg10885
VC0268238
p11131
sg10887
I1
sa(dp11132
g10882
I163
sg10883
g11126
sg10884
I4
sg10885
VC0026691
p11133
sg10887
I1
sasg10888
(lp11134
(dp11135
g10882
I47
sg10883
g11125
sg10884
I29
sg10891
VP08571
p11136
sg10887
I2
sasa(dp11137
g10873
VHere, we show that CD172a(+)CD11c(+) cells accumulate in the mesenteric lymph nodes (mLNs) and inflamed intestinal mucosa in patients with Crohn's disease (CD).
p11138
sg4
(dp11139
(VCD172a(+)CD11c
p11140
VCD
p11141
tp11142
I00
ssg10879
(lp11143
(dp11144
g10882
I85
sg10883
VmLNs
p11145
sg10884
I4
sg10885
VC0026691
p11146
sg10887
I1
sa(dp11147
g10882
I139
sg10883
VCrohn's disease
p11148
sg10884
I15
sg10885
VC0010346
p11149
sg10887
I2
sa(dp11150
g10882
I61
sg10883
Vmesenteric lymph nodes
p11151
sg10884
I22
sg10885
VC0026691
p11152
sg10887
I3
sa(dp11153
g10882
I19
sg10883
g11141
sg10884
I2
sg10885
VC0010346
p11154
sg10887
I1
sasg10888
(lp11155
(dp11156
g10882
I19
sg10883
g11140
sg10884
I14
sg10891
VP20702
p11157
sg10887
I1
sasa(dp11158
g10873
VWe first show that mucosal CD103(-) DCs selectively express SIRPalpha and that their frequency was augmented in the lamina propria and mLNs of mice that developed Th17-biased colitis in response to trinitrobenzene sulfonic acid.
p11159
sg4
(dp11160
(VCD103(-) DCs
p11161
Vcolitis
p11162
tp11163
I00
ssg10879
(lp11164
(dp11165
g10882
I135
sg10883
VmLNs
p11166
sg10884
I4
sg10885
VC0026691
p11167
sg10887
I1
sa(dp11168
g10882
I36
sg10883
VDCs
p11169
sg10884
I3
sg10885
VC0268238
p11170
sg10887
I1
sa(dp11171
g10882
I175
sg10883
g11162
sg10884
I7
sg10885
VC0009319
p11172
sg10887
I1
sasg10888
(lp11173
(dp11174
g10882
I27
sg10883
g11161
sg10884
I12
sg10891
VP38570
p11175
sg10887
I2
sasa(dp11176
g10873
VCD47 expression was required on the SIRPalpha(+)CD103(-) DCs for efficient trafficking to mLNs in vivo, whereas it was dispensable on both DCs and T cells for Th17 polarization in vitro.
p11177
sg4
(dp11178
(VSIRPalpha(+)CD103(-)
p11179
VmLNs
p11180
tp11181
I00
ssg10879
(lp11182
(dp11183
g10882
I57
sg10883
VDCs
p11184
sg10884
I3
sg10885
VC0268238
p11185
sg10887
I1
sa(dp11186
g10882
I57
sg10883
VDCs
p11187
sg10884
I3
sg10885
VC0268238
p11188
sg10887
I1
sa(dp11189
g10882
I90
sg10883
g11180
sg10884
I4
sg10885
VC0026691
p11190
sg10887
I1
sasg10888
(lp11191
(dp11192
g10882
I36
sg10883
g11179
sg10884
I20
sg10891
VP38570
p11193
sg10887
I1
sa(dp11194
g10882
I0
sg10883
VCD47
p11195
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp11196
g10873
VEffects of Ca2+ and calmodulin on the adenylate cyclase activity of a prolactin and growth hormone-producing pituitary tumor cell strain (GH3) were examined.
p11197
sg4
(dp11198
(Vprolactin
p11199
Vgrowth hormone-producing pituitary tumor
p11200
tp11201
I00
ssg10879
(lp11202
(dp11203
g10882
I84
sg10883
g11200
sg10884
I40
sg10885
VC0278864
p11204
sg10887
I4
sasg10888
(lp11205
(dp11206
g10882
I38
sg10883
Vadenylate cyclase
p11207
sg10884
I17
sg10891
g190
sg10887
I2
sa(dp11208
g10882
I84
sg10883
Vgrowth hormone
p11209
sg10884
I14
sg10891
VP01242
p11210
sg10887
I2
sa(dp11211
g10882
I20
sg10883
Vcalmodulin
p11212
sg10884
I10
sg10891
g190
sg10887
I1
sa(dp11213
g10882
I70
sg10883
g11199
sg10884
I9
sg10891
VP01236
p11214
sg10887
I1
sasa(dp11215
g10873
VX-linked hypophosphatemia (XLH), autosomal dominant HR (ADHR), and autosomal recessive HR (ARHR) are examples of hereditary forms of HR, which are mainly caused by mutations in the phosphate regulating endopeptidase homolog, X-linked (PHEX), FGF23, and, dentin matrix protein-1 (DMP1) and ecto-nucleotide pyro phosphatase/phosphodiesterase 1 (ENPP1) genes, respectively.
p11216
sg4
(dp11217
(Vecto-nucleotide pyro phosphatase/phosphodiesterase 1
p11218
Vautosomal recessive HR
p11219
tp11220
I01
ssg10879
(lp11221
(dp11222
g10882
I0
sg10883
VX-linked hypophosphatemia
p11223
sg10884
I25
sg10885
VC0733682
p11224
sg10887
I2
sa(dp11225
g10882
I91
sg10883
VARHR
p11226
sg10884
I4
sg10885
VC0342643
p11227
sg10887
I1
sa(dp11228
g10882
I33
sg10883
Vautosomal dominant HR
p11229
sg10884
I21
sg10885
VC0342642
p11230
sg10887
I3
sa(dp11231
g10882
I56
sg10883
VADHR
p11232
sg10884
I4
sg10885
VC0342642
p11233
sg10887
I1
sa(dp11234
g10882
I27
sg10883
VXLH
p11235
sg10884
I3
sg10885
VC0733682
p11236
sg10887
I1
sa(dp11237
g10882
I67
sg10883
g11219
sg10884
I22
sg10885
VC0342643
p11238
sg10887
I3
sasg10888
(lp11239
(dp11240
g10882
I242
sg10883
VFGF23
p11241
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp11242
g10882
I202
sg10883
Vendopeptidase homolog, X-linked
p11243
sg10884
I31
sg10891
g190
sg10887
I3
sa(dp11244
g10882
I33
sg10883
Vautosomal dominant HR
p11245
sg10884
I21
sg10891
VP56715
p11246
sg10887
I3
sa(dp11247
g10882
I254
sg10883
Vdentin matrix protein-1
p11248
sg10884
I23
sg10891
g190
sg10887
I3
sa(dp11249
g10882
I56
sg10883
VADHR
p11250
sg10884
I4
sg10891
VP30518
p11251
sg10887
I1
sa(dp11252
g10882
I279
sg10883
VDMP1
p11253
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp11254
g10882
I343
sg10883
VENPP1
p11255
sg10884
I5
sg10891
VP22413
p11256
sg10887
I1
sa(dp11257
g10882
I235
sg10883
VPHEX
p11258
sg10884
I4
sg10891
VP78562
p11259
sg10887
I1
sa(dp11260
g10882
I289
sg10883
g11218
sg10884
I52
sg10891
VP22413
p11261
sg10887
I4
sasa(dp11262
g10873
VAmong various causes of low serum phosphorous are inherited disorders associated with increased urinary excretion of phosphate, including autosomal dominant hypophosphatemic rickets (ADHR), X-linked hypophosphatemia (XLH), autosomal recessive hypophosphatemia (ARHP), and hereditary hypophosphatemic rickets with hypercalciuria (HHRH).
p11263
sg4
(dp11264
(Vautosomal dominant hypophosphatemic rickets
p11265
VX-linked hypophosphatemia
p11266
tp11267
I00
ssg10879
(lp11268
(dp11269
g10882
I261
sg10883
VARHP
p11270
sg10884
I4
sg10885
VC0342643
p11271
sg10887
I1
sa(dp11272
g10882
I138
sg10883
Vautosomal dominant hypophosphatemic rickets
p11273
sg10884
I43
sg10885
VC0342642
p11274
sg10887
I4
sa(dp11275
g10882
I283
sg10883
Vhypophosphatemic rickets with hypercalciuria
p11276
sg10884
I44
sg10885
VC0342645
p11277
sg10887
I4
sa(dp11278
g10882
I329
sg10883
VHHRH
p11279
sg10884
I4
sg10885
VC0342645
p11280
sg10887
I1
sa(dp11281
g10882
I217
sg10883
VXLH
p11282
sg10884
I3
sg10885
VC0733682
p11283
sg10887
I1
sa(dp11284
g10882
I223
sg10883
Vautosomal recessive hypophosphatemia
p11285
sg10884
I36
sg10885
VC0342643
p11286
sg10887
I3
sa(dp11287
g10882
I183
sg10883
VADHR
p11288
sg10884
I4
sg10885
VC0342642
p11289
sg10887
I1
sa(dp11290
g10882
I190
sg10883
g11266
sg10884
I25
sg10885
VC0733682
p11291
sg10887
I2
sasg10888
(lp11292
(dp11293
g10882
I183
sg10883
VADHR
p11294
sg10884
I4
sg10891
VP30518
p11295
sg10887
I1
sa(dp11296
g10882
I138
sg10883
g11265
sg10884
I43
sg10891
VP30518
p11297
sg10887
I4
sasa(dp11298
g10873
VRecently, positional cloning approaches furthermore led to the identification of homozygous inactivating mutations in dentin matrix protein 1 (DMP1) as the cause of an autosomal recessive form of hypophosphatemia.
p11299
sg4
(dp11300
(Vdentin matrix protein 1
p11301
Vhypophosphatemia
p11302
tp11303
I00
ssg10879
(lp11304
(dp11305
g10882
I196
sg10883
g11302
sg10884
I16
sg10885
VC0085682
p11306
sg10887
I1
sasg10888
(lp11307
(dp11308
g10882
I118
sg10883
g11301
sg10884
I23
sg10891
VP14222
p11309
sg10887
I4
sa(dp11310
g10882
I143
sg10883
VDMP1
p11311
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp11312
g10873
VSeventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules.
p11313
sg4
(dp11314
(VCDK
p11315
Vrunt
p11316
tp11317
I00
ssg10879
(lp11318
(dp11319
g10882
I152
sg10883
Vsarcoma
p11320
sg10884
I7
sg10885
VC1261473
p11321
sg10887
I1
sa(dp11322
g10882
I362
sg10883
g11316
sg10884
I4
sg10885
VC0013336
p11323
sg10887
I1
sasg10888
(lp11324
(dp11325
g10882
I57
sg10883
VT-cell-specific transcription factor
p11326
sg10884
I36
sg10891
VP35398
p11327
sg10887
I3
sa(dp11328
g10882
I276
sg10883
Vvitamin D receptor
p11329
sg10884
I18
sg10891
VP11473
p11330
sg10887
I3
sa(dp11331
g10882
I109
sg10883
V"proto-oncogene tyrosine-protein kinase
p11332
sg10884
I39
sg10891
VP00519
p11333
sg10887
I3
sa(dp11334
g10882
I399
sg10883
VPR domain zinc finger protein 1
p11335
sg10884
I31
sg10891
g190
sg10887
I6
sa(dp11336
g10882
I322
sg10883
VERK
p11337
sg10884
I3
sg10891
VP29323
p11338
sg10887
I1
sa(dp11339
g10882
I362
sg10883
Vrunt-related transcription factor 1
p11340
sg10884
I35
sg10891
VP20823
p11341
sg10887
I4
sa(dp11342
g10882
I477
sg10883
Vinterleukin 1
p11343
sg10884
I13
sg10891
VP01584
p11344
sg10887
I2
sa(dp11345
g10882
I152
sg10883
Vsarcoma"
p11346
sg10884
I8
sg10891
VP12931
p11347
sg10887
I1
sa(dp11348
g10882
I163
sg10883
Vinterferon regulatory factor 1
p11349
sg10884
I30
sg10891
VP10914
p11350
sg10887
I4
sa(dp11351
g10882
I227
sg10883
Vcyclin-dependent kinase (CDK) 4
p11352
sg10884
I31
sg10891
VP49336
p11353
sg10887
I4
sa(dp11354
g10882
I296
sg10883
Vhistone deacetylase
p11355
sg10884
I19
sg10891
VP56524
p11356
sg10887
I2
sa(dp11357
g10882
I95
sg10883
VSrc
p11358
sg10884
I3
sg10891
VP12931
p11359
sg10887
I1
sa(dp11360
g10882
I217
sg10883
Vcyclin B
p11361
sg10884
I8
sg10891
VP14635
p11362
sg10887
I2
sa(dp11363
g10882
I334
sg10883
Vbcl-2-associated X protein
p11364
sg10884
I26
sg10891
VP10415
p11365
sg10887
I3
sa(dp11366
g10882
I317
sg10883
VMAPK
p11367
sg10884
I4
sg10891
VP53779
p11368
sg10887
I1
sa(dp11369
g10882
I432
sg10883
Vplatelet-derived growth factor receptor
p11370
sg10884
I39
sg10891
VP09619
p11371
sg10887
I4
sa(dp11372
g10882
I265
sg10883
Vcaspase-1
p11373
sg10884
I9
sg10891
VP29466
p11374
sg10887
I1
sa(dp11375
g10882
I195
sg10883
Vthymidylate synthase
p11376
sg10884
I20
sg10891
VP04818
p11377
sg10887
I2
sa(dp11378
g10882
I252
sg10883
g11315
sg10884
I3
sg10891
VP24941
p11379
sg10887
I1
sasa(dp11380
g10873
VTherefore, targeting the caspase-1/PPARGamma/MCAD pathway might be a promising therapeutic approach to prevent tumor progression.Tumor associated macrophages (TAMs) promote cancer progression.
p11381
sg4
(dp11382
(Vcaspase-1
p11383
Vtumor progression
p11384
tp11385
I00
ssg10879
(lp11386
(dp11387
g10882
I173
sg10883
Vcancer progression
p11388
sg10884
I18
sg10885
VC0178874
p11389
sg10887
I2
sa(dp11390
g10882
I45
sg10883
VMCAD
p11391
sg10884
I4
sg10885
VC0220710
p11392
sg10887
I1
sa(dp11393
g10882
I129
sg10883
VTumor
p11394
sg10884
I5
sg10885
VC0027651
p11395
sg10887
I1
sa(dp11396
g10882
I111
sg10883
g11384
sg10884
I17
sg10885
VC0178874
p11397
sg10887
I2
sasg10888
(lp11398
(dp11399
g10882
I45
sg10883
VMCAD
p11400
sg10884
I4
sg10891
VP11310
p11401
sg10887
I1
sa(dp11402
g10882
I25
sg10883
g11383
sg10884
I9
sg10891
VP29466
p11403
sg10887
I1
sasa(dp11404
g10873
VHere, the author show that caspase-1 promotes TAMs differentiation by attenuating medium-chain acyl-CoA dehydrogenase activity and that inhibition of this axis results in suppression of tumour growth in a transgenic mouse model of breast cancer.
p11405
sg4
(dp11406
(Vcaspase-1
p11407
Vbreast cancer
p11408
tp11409
I01
ssg10879
(lp11410
(dp11411
g10882
I100
sg10883
VCoA
p11412
sg10884
I3
sg10885
VC2678439
p11413
sg10887
I1
sa(dp11414
g10882
I231
sg10883
g11408
sg10884
I13
sg10885
VC0678222
p11415
sg10887
I2
sa(dp11416
g10882
I171
sg10883
Vsuppression
p11417
sg10884
I11
sg10885
VC0221103
p11418
sg10887
I1
sa(dp11419
g10882
I186
sg10883
Vtumour
p11420
sg10884
I6
sg10885
VC0027651
p11421
sg10887
I1
sasg10888
(lp11422
(dp11423
g10882
I95
sg10883
Vacyl-CoA dehydrogenase
p11424
sg10884
I22
sg10891
VP49366
p11425
sg10887
I2
sa(dp11426
g10882
I27
sg10883
g11407
sg10884
I9
sg10891
VP29466
p11427
sg10887
I1
sasa(dp11428
g10873
VA total of 104 patients (89.4% females) fulfilling the 1990 ACR criteria for FMS and the Rome III criteria for IBS classification and 125 unrelated age- and sex-matched IBS patients without FMS underwent the following studies: haematological, coagulation and biochemistry tests, serological and genetic markers for CD (i.e., tissue transglutaminase 2 (tTG-2) and major histocompatibility complex HLA-DQ2/HLA-DQ8), multiple gastric and duodenal biopsies, FMS tender points (TPs), Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire (HAQ), 36-Item Short Form Health Survey (SF-36) and Visual Analogue Scales (VASs) for tiredness and gastrointestinal complaints.
p11429
sg4
(dp11430
(VtTG-2
p11431
VIBS
p11432
tp11433
I00
ssg10879
(lp11434
(dp11435
g10882
I111
sg10883
VIBS
p11436
sg10884
I3
sg10885
VC0022104
p11437
sg10887
I1
sa(dp11438
g10882
I77
sg10883
VFMS
p11439
sg10884
I3
sg10885
VC0016053
p11440
sg10887
I1
sa(dp11441
g10882
I638
sg10883
Vtiredness
p11442
sg10884
I9
sg10885
VC0015672
p11443
sg10887
I1
sa(dp11444
g10882
I479
sg10883
VFibromyalgia
p11445
sg10884
I12
sg10885
VC0016053
p11446
sg10887
I1
sa(dp11447
g10882
I77
sg10883
VFMS
p11448
sg10884
I3
sg10885
VC0016053
p11449
sg10887
I1
sa(dp11450
g10882
I77
sg10883
VFMS
p11451
sg10884
I3
sg10885
VC0016053
p11452
sg10887
I1
sa(dp11453
g10882
I111
sg10883
g11432
sg10884
I3
sg10885
VC0022104
p11454
sg10887
I1
sasg10888
(lp11455
(dp11456
g10882
I325
sg10883
Vtissue transglutaminase 2
p11457
sg10884
I25
sg10891
VP21980
p11458
sg10887
I3
sa(dp11459
g10882
I400
sg10883
VDQ2
p11460
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp11461
g10882
I363
sg10883
Vmajor histocompatibility complex HLA
p11462
sg10884
I36
sg10891
VP18464
p11463
sg10887
I4
sa(dp11464
g10882
I352
sg10883
g11431
sg10884
I5
sg10891
VP21980
p11465
sg10887
I1
sa(dp11466
g10882
I404
sg10883
VHLA-DQ8
p11467
sg10884
I7
sg10891
VP30486
p11468
sg10887
I1
sasa(dp11469
g10873
VGFD effectiveness was assessed at baseline and after 1 year, examining the score changes in the Tender Points (TPs) test, Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire (HAQ), Short Form Health Survey (SF-36), Visual Analogue Scales (VAS) for gastrointestinal complaints, pain and tiredness, drug prescriptions and tissue-Trans-Glutaminase (tTG) serum levels.
p11470
sg4
(dp11471
(VtTG
p11472
VFibromyalgia
p11473
tp11474
I00
ssg10879
(lp11475
(dp11476
g10882
I307
sg10883
Vtiredness
p11477
sg10884
I9
sg10885
VC0015672
p11478
sg10887
I1
sa(dp11479
g10882
I0
sg10883
VGFD
p11480
sg10884
I3
sg10885
VC1851112
p11481
sg10887
I1
sa(dp11482
g10882
I122
sg10883
g11473
sg10884
I12
sg10885
VC0016053
p11483
sg10887
I1
sasg10888
(lp11484
(dp11485
g10882
I367
sg10883
g11472
sg10884
I3
sg10891
VP21980
p11486
sg10887
I1
sa(dp11487
g10882
I341
sg10883
Vtissue-Trans-Glutaminase
p11488
sg10884
I24
sg10891
g190
sg10887
I1
sasa(dp11489
g10873
VNon-organ specific AAb (ANA, anti-Ro52, anti-Ro60, anti-La, anti-RNP) but not anti-thyroid peroxidase, anti-tissue transglutaminase or myositis-specific antibodies, were more frequent in s-IBM patients, and 14/51 (27%) had another autoimmune disease (Sjoegren's syndrome, thyroiditis, psoriasis, vitiligo).
p11490
sg4
(dp11491
(Vanti-tissue transglutaminase
p11492
Vpsoriasis
p11493
tp11494
I01
ssg10879
(lp11495
(dp11496
g10882
I189
sg10883
VIBM
p11497
sg10884
I3
sg10885
VC0238190
p11498
sg10887
I1
sa(dp11499
g10882
I251
sg10883
VSjoegren's syndrome
p11500
sg10884
I19
sg10885
VC1527336
p11501
sg10887
I2
sa(dp11502
g10882
I231
sg10883
Vautoimmune disease
p11503
sg10884
I18
sg10885
VC0004364
p11504
sg10887
I2
sa(dp11505
g10882
I296
sg10883
Vvitiligo
p11506
sg10884
I8
sg10885
VC0042900
p11507
sg10887
I1
sa(dp11508
g10882
I135
sg10883
Vmyositis
p11509
sg10884
I8
sg10885
VC0027121
p11510
sg10887
I1
sa(dp11511
g10882
I272
sg10883
Vthyroiditis
p11512
sg10884
I11
sg10885
VC0040147
p11513
sg10887
I1
sa(dp11514
g10882
I285
sg10883
g11493
sg10884
I9
sg10885
VC0033860
p11515
sg10887
I1
sasg10888
(lp11516
(dp11517
g10882
I40
sg10883
Vanti-Ro60
p11518
sg10884
I9
sg10891
VP10155
p11519
sg10887
I1
sa(dp11520
g10882
I78
sg10883
Vanti-thyroid peroxidase
p11521
sg10884
I23
sg10891
VP40225
p11522
sg10887
I2
sa(dp11523
g10882
I60
sg10883
Vanti-RNP
p11524
sg10884
I8
sg10891
g190
sg10887
I1
sa(dp11525
g10882
I135
sg10883
Vmyositis-specific antibodies
p11526
sg10884
I28
sg10891
VP04280
p11527
sg10887
I2
sa(dp11528
g10882
I24
sg10883
VANA
p11529
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp11530
g10882
I29
sg10883
Vanti-Ro52
p11531
sg10884
I9
sg10891
VP19474
p11532
sg10887
I1
sa(dp11533
g10882
I103
sg10883
g11492
sg10884
I28
sg10891
VP21980
p11534
sg10887
I2
sasa(dp11535
g10873
VBy applying CD146 and CD105 antibodies on human retinas from glaucomatous eyes, CD146-positive retinal ganglion cells (RGCs) were found, some being placed in perivascular positions; ongoing processes of neurites extension were related to these neurons.
p11536
sg4
(dp11537
(VCD105
p11538
Vganglion
p11539
tp11540
I00
ssg10879
(lp11541
(dp11542
g10882
I103
sg10883
g11539
sg10884
I8
sg10885
VC1258666
p11543
sg10887
I1
sasg10888
(lp11544
(dp11545
g10882
I12
sg10883
VCD146
p11546
sg10884
I5
sg10891
VP43121
p11547
sg10887
I1
sa(dp11548
g10882
I12
sg10883
VCD146
p11549
sg10884
I5
sg10891
VP43121
p11550
sg10887
I1
sa(dp11551
g10882
I22
sg10883
g11538
sg10884
I5
sg10891
VP17813
p11552
sg10887
I1
sasa(dp11553
g10873
VThese results support the hypothesis that in glaucoma eyes the CD146-positive RGCs result from regenerative processes driven by stem cells in the retinal perivascular niches.
p11554
sg4
(dp11555
(VCD146-positive RGCs
p11556
Vglaucoma
p11557
tp11558
I00
ssg10879
(lp11559
(dp11560
g10882
I45
sg10883
g11557
sg10884
I8
sg10885
VC0017601
p11561
sg10887
I1
sasg10888
(lp11562
(dp11563
g10882
I63
sg10883
g11556
sg10884
I19
sg10891
VP43121
p11564
sg10887
I2
sasa(dp11565
g10873
VTwo new and potentially promising melanocytic markers, microphthalmia transcription factor (MiTF) and melanoma cell adhesion molecule (Mel-CAM), have been shown to be sensitive markers of epithelioid melanoma, but have not been tested in desmoplastic/spindle cell melanoma or in other rare melanocytic neuroectodermal tumors such as clear cell sarcoma.
p11566
sg4
(dp11567
(Vmelanoma cell adhesion molecule
p11568
Vadhesion
p11569
tp11570
I00
ssg10879
(lp11571
(dp11572
g10882
I238
sg10883
Vdesmoplastic
p11573
sg10884
I12
sg10885
VC1511789
p11574
sg10887
I1
sa(dp11575
g10882
I55
sg10883
Vmicrophthalmia
p11576
sg10884
I14
sg10885
VC0026010
p11577
sg10887
I1
sa(dp11578
g10882
I333
sg10883
Vclear cell sarcoma
p11579
sg10884
I18
sg10885
VC0206651
p11580
sg10887
I3
sa(dp11581
g10882
I139
sg10883
VCAM
p11582
sg10884
I3
sg10885
VC1861821
p11583
sg10887
I1
sa(dp11584
g10882
I135
sg10883
VMel
p11585
sg10884
I3
sg10885
VC3149631
p11586
sg10887
I1
sa(dp11587
g10882
I188
sg10883
Vepithelioid melanoma
p11588
sg10884
I20
sg10885
VC0334443
p11589
sg10887
I2
sa(dp11590
g10882
I302
sg10883
Vneuroectodermal tumors
p11591
sg10884
I22
sg10885
VC0206093
p11592
sg10887
I2
sa(dp11593
g10882
I102
sg10883
Vmelanoma
p11594
sg10884
I8
sg10885
VC0025202
p11595
sg10887
I1
sa(dp11596
g10882
I251
sg10883
Vspindle cell melanoma
p11597
sg10884
I21
sg10885
VC0334444
p11598
sg10887
I3
sa(dp11599
g10882
I116
sg10883
g11569
sg10884
I8
sg10885
VC0001511
p11600
sg10887
I1
sasg10888
(lp11601
(dp11602
g10882
I55
sg10883
Vmicrophthalmia transcription factor
p11603
sg10884
I35
sg10891
VP35398
p11604
sg10887
I3
sa(dp11605
g10882
I135
sg10883
VMel-CAM
p11606
sg10884
I7
sg10891
VP61006
p11607
sg10887
I1
sa(dp11608
g10882
I92
sg10883
VMiTF
p11609
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp11610
g10882
I102
sg10883
g11568
sg10884
I31
sg10891
VP43121
p11611
sg10887
I4
sasa(dp11612
g10873
VWe investigated the effect of carnosine as an adjuvant therapy on urinary albumin excretion (UAE), the tubular damage marker alpha 1-microglobulin (A1M), and oxidative stress in pediatric patients with type 1 diabetes and nephropathy.
p11613
sg4
(dp11614
(VA1M
p11615
Vnephropathy
p11616
tp11617
I00
ssg10879
(lp11618
(dp11619
g10882
I158
sg10883
Voxidative stress
p11620
sg10884
I16
sg10885
VC0242606
p11621
sg10887
I2
sa(dp11622
g10882
I202
sg10883
Vtype 1 diabetes
p11623
sg10884
I15
sg10885
VC0011854
p11624
sg10887
I3
sa(dp11625
g10882
I222
sg10883
g11616
sg10884
I11
sg10885
VC0022658
p11626
sg10887
I1
sasg10888
(lp11627
(dp11628
g10882
I74
sg10883
Valbumin
p11629
sg10884
I7
sg10891
VP00441
p11630
sg10887
I1
sa(dp11631
g10882
I125
sg10883
Valpha 1-microglobulin
p11632
sg10884
I21
sg10891
VP25100
p11633
sg10887
I2
sa(dp11634
g10882
I148
sg10883
g11615
sg10884
I3
sg10891
VP02760
p11635
sg10887
I1
sasa(dp11636
g10873
VThe following parameters were measured in 377 patients with type 2 diabetes: HbA1c, serum concentrations of 1,5-AG, GA and creatinine, hemoglobin, urinary albumin/creatinine ratio, and urinary excretion of Alfa1 -microglobulin (A1M).
p11637
sg4
(dp11638
(VA1M
p11639
Vtype 2 diabetes
p11640
tp11641
I00
ssg10879
(lp11642
(dp11643
g10882
I60
sg10883
g11640
sg10884
I15
sg10885
VC0011860
p11644
sg10887
I3
sasg10888
(lp11645
(dp11646
g10882
I206
sg10883
VAlfa1 -microglobulin
p11647
sg10884
I20
sg10891
VP02760
p11648
sg10887
I2
sa(dp11649
g10882
I135
sg10883
Vhemoglobin
p11650
sg10884
I10
sg10891
g190
sg10887
I1
sa(dp11651
g10882
I155
sg10883
Valbumin
p11652
sg10884
I7
sg10891
VP00441
p11653
sg10887
I1
sa(dp11654
g10882
I228
sg10883
g11639
sg10884
I3
sg10891
VP02760
p11655
sg10887
I1
sasa(dp11656
g10873
VVonoprazan Fumarate (TAK-438F) is a new and effective drug approved in Japan in 2014 for treatment and prevention of acid-related diseases (ARDs), which exhibits many advantages compared with traditional proton-pump inhibitors (PPIs).
p11657
sg4
(dp11658
(VTAK-438F
p11659
VARDs
p11660
tp11661
I00
ssg10879
(lp11662
(dp11663
g10882
I117
sg10883
Vacid-related diseases
p11664
sg10884
I21
sg10885
VC0035222
p11665
sg10887
I2
sa(dp11666
g10882
I140
sg10883
g11660
sg10884
I4
sg10885
VC0035222
p11667
sg10887
I1
sasg10888
(lp11668
(dp11669
g10882
I21
sg10883
g11659
sg10884
I8
sg10891
VP50750
p11670
sg10887
I1
sasa(dp11671
g10873
VANO3 encodes anoctamin-3, a Ca+2-dependent phospholipid scramblase expressed in striatal-neurons, that has been implicated in autosomal dominant craniocervical dystonia (Dystonia-24, DYT24, MIM# 615034).
p11672
sg4
(dp11673
(VCa+2-dependent phospholipid scramblase
p11674
VDystonia
p11675
tp11676
I01
ssg10879
(lp11677
(dp11678
g10882
I160
sg10883
Vdystonia
p11679
sg10884
I8
sg10885
VC0393593
p11680
sg10887
I1
sa(dp11681
g10882
I170
sg10883
g11675
sg10884
I8
sg10885
VC0393593
p11682
sg10887
I1
sasg10888
(lp11683
(dp11684
g10882
I13
sg10883
Vanoctamin-3
p11685
sg10884
I11
sg10891
g190
sg10887
I1
sa(dp11686
g10882
I0
sg10883
VANO3
p11687
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp11688
g10882
I28
sg10883
g11674
sg10884
I38
sg10891
VP19525
p11689
sg10887
I3
sasa(dp11690
g10873
VThree genes (GCH1, THAP1, TOR1A) were associated with isolated generalized dystonia, whereas 2 (ANO3, ADCY5) gave rise to combined dystonia-myoclonus phenotypes.
p11691
sg4
(dp11692
(VGCH1
p11693
Vmyoclonus
p11694
tp11695
I01
ssg10879
(lp11696
(dp11697
g10882
I75
sg10883
Vdystonia
p11698
sg10884
I8
sg10885
VC0393593
p11699
sg10887
I1
sa(dp11700
g10882
I63
sg10883
Vgeneralized dystonia
p11701
sg10884
I20
sg10885
VC1848954
p11702
sg10887
I2
sa(dp11703
g10882
I140
sg10883
g11694
sg10884
I9
sg10885
VC0027066
p11704
sg10887
I1
sasg10888
(lp11705
(dp11706
g10882
I102
sg10883
VADCY5
p11707
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp11708
g10882
I13
sg10883
g11693
sg10884
I4
sg10891
VP30793
p11709
sg10887
I1
sa(dp11710
g10882
I26
sg10883
VTOR1A
p11711
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp11712
g10882
I19
sg10883
VTHAP1
p11713
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp11714
g10882
I96
sg10883
VANO3
p11715
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp11716
g10873
VSome genes, such as ANO3, GNAL and CIZ1, have been discovered for isolated dystonia, but they are probably not a common cause of classic cervical dystonia.
p11717
sg4
(dp11718
(VGNAL
p11719
Vcervical dystonia
p11720
tp11721
I00
ssg10879
(lp11722
(dp11723
g10882
I75
sg10883
Vdystonia
p11724
sg10884
I8
sg10885
VC0393593
p11725
sg10887
I1
sa(dp11726
g10882
I137
sg10883
g11720
sg10884
I17
sg10885
VC0949445
p11727
sg10887
I2
sasg10888
(lp11728
(dp11729
g10882
I20
sg10883
VANO3
p11730
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp11731
g10882
I35
sg10883
VCIZ1
p11732
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp11733
g10882
I26
sg10883
g11719
sg10884
I4
sg10891
VP38405
p11734
sg10887
I1
sasa(dp11735
g10873
VClinical and genetic heterogeneity also characterizes myoclonus-dystonia, which includes not only the classical phenotype associated with epsilon-sarcoglycan mutations but rarely also presentation of ANO3 gene mutations, TITF1 gene mutations typically underlying benign hereditary chorea, and some dopamine synthesis pathway conditions due to GCH1 and TH mutations.
p11736
sg4
(dp11737
(VGCH1
p11738
Vbenign hereditary chorea
p11739
tp11740
I01
ssg10879
(lp11741
(dp11742
g10882
I54
sg10883
Vmyoclonus
p11743
sg10884
I9
sg10885
VC0027066
p11744
sg10887
I1
sa(dp11745
g10882
I64
sg10883
Vdystonia
p11746
sg10884
I8
sg10885
VC0393593
p11747
sg10887
I1
sa(dp11748
g10882
I263
sg10883
g11739
sg10884
I24
sg10885
VC0393584
p11749
sg10887
I3
sasg10888
(lp11750
(dp11751
g10882
I221
sg10883
VTITF1 gene
p11752
sg10884
I10
sg10891
VP43699
p11753
sg10887
I2
sa(dp11754
g10882
I200
sg10883
VANO3 gene
p11755
sg10884
I9
sg10891
g190
sg10887
I2
sa(dp11756
g10882
I343
sg10883
g11738
sg10884
I4
sg10891
VP30793
p11757
sg10887
I1
sasa(dp11758
g10873
VThe individual diagnostic marker positivity was 98% for GATA-binding protein 3, 95% for androgen receptor, 90% for progesterone receptor, 88% for deleted in pancreatic cancer 4, 75% for gross cystic disease fluid protein 15, 72% for cytokeratin 7, 55% for mammaglobin, and 15% for vimentin and Wilms tumor protein 1.
p11759
sg4
(dp11760
(VWilms tumor protein 1
p11761
VWilms tumor
p11762
tp11763
I00
ssg10879
(lp11764
(dp11765
g10882
I192
sg10883
Vcystic disease
p11766
sg10884
I14
sg10885
VC0334054
p11767
sg10887
I2
sa(dp11768
g10882
I157
sg10883
Vpancreatic cancer
p11769
sg10884
I17
sg10885
VC0235974
p11770
sg10887
I2
sa(dp11771
g10882
I294
sg10883
g11762
sg10884
I11
sg10885
VC0027708
p11772
sg10887
I2
sasg10888
(lp11773
(dp11774
g10882
I56
sg10883
VGATA-binding protein 3
p11775
sg10884
I22
sg10891
VP23771
p11776
sg10887
I3
sa(dp11777
g10882
I256
sg10883
Vmammaglobin
p11778
sg10884
I11
sg10891
g190
sg10887
I1
sa(dp11779
g10882
I115
sg10883
Vprogesterone receptor
p11780
sg10884
I21
sg10891
VP06401
p11781
sg10887
I2
sa(dp11782
g10882
I88
sg10883
Vandrogen receptor
p11783
sg10884
I17
sg10891
VP10275
p11784
sg10887
I2
sa(dp11785
g10882
I294
sg10883
g11761
sg10884
I21
sg10891
VP14222
p11786
sg10887
I4
sasa(dp11787
g10873
VAstrocyte loss may be caused by cytotoxic T cells as seen in Rasmussen encephalitis, auto-antibodies such as in neuromyelitis optica (aquaporin-4 antibodies), or cytokines such as TNF-Alfa in major depressive disorder.
p11788
sg4
(dp11789
(Vaquaporin-4 antibodies
p11790
Vmajor depressive disorder
p11791
tp11792
I00
ssg10879
(lp11793
(dp11794
g10882
I112
sg10883
Vneuromyelitis optica
p11795
sg10884
I20
sg10885
VC0027873
p11796
sg10887
I2
sa(dp11797
g10882
I61
sg10883
VRasmussen encephalitis
p11798
sg10884
I22
sg10885
VC0393484
p11799
sg10887
I2
sa(dp11800
g10882
I192
sg10883
g11791
sg10884
I25
sg10885
VC1269683
p11801
sg10887
I3
sasg10888
(lp11802
(dp11803
g10882
I180
sg10883
VTNF-Alfa
p11804
sg10884
I8
sg10891
VP01375
p11805
sg10887
I1
sa(dp11806
g10882
I134
sg10883
g11790
sg10884
I22
sg10891
VP55087
p11807
sg10887
I2
sasa(dp11808
g10873
VMutations in KCNJ5, ATP1A1, ATP2B3 and CACNA1D are found in aldosterone producing adenoma (APA) and familial hyperaldosteronism (FH).
p11809
sg4
(dp11810
(VATP1A1
p11811
Vhyperaldosteronism
p11812
tp11813
I01
ssg10879
(lp11814
(dp11815
g10882
I82
sg10883
Vadenoma
p11816
sg10884
I7
sg10885
VC0001430
p11817
sg10887
I1
sa(dp11818
g10882
I109
sg10883
g11812
sg10884
I18
sg10885
VC0020428
p11819
sg10887
I1
sasg10888
(lp11820
(dp11821
g10882
I13
sg10883
VKCNJ5
p11822
sg10884
I5
sg10891
VP48544
p11823
sg10887
I1
sa(dp11824
g10882
I39
sg10883
VCACNA1D
p11825
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp11826
g10882
I20
sg10883
g11811
sg10884
I6
sg10891
VP05023
p11827
sg10887
I1
sa(dp11828
g10882
I28
sg10883
VATP2B3
p11829
sg10884
I6
sg10891
g190
sg10887
I1
sasa(dp11830
g10873
VOur results suggest that these mutations, in addition to mutations in the KCNJ5 gene and other genes such as ATP1A1, ATP2B3 and CACNA1D, may be responsible for the tumorigenesis of APAs and CPAs with subclinical Cushing's syndrome.
p11831
sg4
(dp11832
(VATP1A1
p11833
VCushing's syndrome
p11834
tp11835
I00
ssg10879
(lp11836
(dp11837
g10882
I164
sg10883
Vtumorigenesis
p11838
sg10884
I13
sg10885
VC0007621
p11839
sg10887
I1
sa(dp11840
g10882
I212
sg10883
g11834
sg10884
I18
sg10885
VC0010481
p11841
sg10887
I2
sasg10888
(lp11842
(dp11843
g10882
I74
sg10883
VKCNJ5 gene
p11844
sg10884
I10
sg10891
VP48544
p11845
sg10887
I2
sa(dp11846
g10882
I117
sg10883
VATP2B3
p11847
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp11848
g10882
I128
sg10883
VCACNA1D
p11849
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp11850
g10882
I109
sg10883
g11833
sg10884
I6
sg10891
VP05023
p11851
sg10887
I1
sasa(dp11852
g10873
VScreening of SOX2 was completed in 89 patients with a variety of ocular anomalies, including 28 with A/M and 61 with normal eye size and anterior segment dysgenesis (28), cataract (14), isolated coloboma (5), or other eye disorders (14).
p11853
sg4
(dp11854
(VSOX2
p11855
Vcataract
p11856
tp11857
I00
ssg10879
(lp11858
(dp11859
g10882
I218
sg10883
Veye disorders
p11860
sg10884
I13
sg10885
VC0015397
p11861
sg10887
I2
sa(dp11862
g10882
I195
sg10883
Vcoloboma
p11863
sg10884
I8
sg10885
VC0009363
p11864
sg10887
I1
sa(dp11865
g10882
I137
sg10883
Vanterior segment dysgenesis
p11866
sg10884
I27
sg10885
VC0266525
p11867
sg10887
I3
sa(dp11868
g10882
I171
sg10883
g11856
sg10884
I8
sg10885
VC0086543
p11869
sg10887
I1
sasg10888
(lp11870
(dp11871
g10882
I13
sg10883
g11855
sg10884
I4
sg10891
VP48431
p11872
sg10887
I1
sasa(dp11873
g10873
VThe overexpression of Kir3.2, a subunit of the G protein-gated inwardly rectifying K(+) channel, is implicated in some of the neurological phenotypes of Down syndrome (DS).
p11874
sg4
(dp11875
(VKir3.2
p11876
VDS
p11877
tp11878
I00
ssg10879
(lp11879
(dp11880
g10882
I153
sg10883
VDown syndrome
p11881
sg10884
I13
sg10885
VC0013080
p11882
sg10887
I2
sa(dp11883
g10882
I168
sg10883
g11877
sg10884
I2
sg10885
VC0013080
p11884
sg10887
I1
sasg10888
(lp11885
(dp11886
g10882
I47
sg10883
VG protein
p11887
sg10884
I9
sg10891
g190
sg10887
I2
sa(dp11888
g10882
I22
sg10883
g11876
sg10884
I6
sg10891
VP48051
p11889
sg10887
I1
sasa(dp11890
g10873
VWe sequenced the exomes of three unrelated individuals affected by KPLBS and found de novo heterozygous mutations in KCNJ6 (GIRK2), which encodes an inwardly rectifying potassium channel and maps to the Down syndrome critical region between DIRK1A and DSCR4.
p11891
sg4
(dp11892
(VGIRK2
p11893
VDown syndrome critical region
p11894
tp11895
I01
ssg10879
(lp11896
(dp11897
g10882
I67
sg10883
VKPLBS
p11898
sg10884
I5
sg10885
VC3279800
p11899
sg10887
I1
sa(dp11900
g10882
I203
sg10883
g11894
sg10884
I29
sg10885
VC1860787
p11901
sg10887
I4
sasg10888
(lp11902
(dp11903
g10882
I104
sg10883
Vmutations in KCNJ6
p11904
sg10884
I18
sg10891
VP48051
p11905
sg10887
I3
sa(dp11906
g10882
I252
sg10883
VDSCR4
p11907
sg10884
I5
sg10891
VP56555
p11908
sg10887
I1
sa(dp11909
g10882
I124
sg10883
g11893
sg10884
I5
sg10891
VP48051
p11910
sg10887
I1
sasa(dp11911
g10873
VGlc-Lys MRPs ameliorate DSS-induced colitis, as determined by a decrease in disease index activity, colon weight/length ratio, nitric oxide levels in serum, recovery of body weight loss, colon length and serum lysozyme levels.
p11912
sg4
(dp11913
(Vcolon length and serum lysozyme
p11914
Vcolitis
p11915
tp11916
I01
ssg10879
(lp11917
(dp11918
g10882
I24
sg10883
VDSS
p11919
sg10884
I3
sg10885
VC0011195
p11920
sg10887
I1
sa(dp11921
g10882
I36
sg10883
g11915
sg10884
I7
sg10885
VC0009319
p11922
sg10887
I1
sasg10888
(lp11923
(dp11924
g10882
I0
sg10883
VGlc-Lys MRPs
p11925
sg10884
I12
sg10891
g190
sg10887
I2
sa(dp11926
g10882
I187
sg10883
g11914
sg10884
I31
sg10891
VP61626
p11927
sg10887
I5
sasa(dp11928
g10873
VThe dimeric hybrid-IgG/IgA inhibited the binding of digoxigenin-conjugated Stx1B to natural ligands (CD77) displayed on Burkitt's lymphoma cell line Ramos.
p11929
sg4
(dp11930
(VIgA
p11931
VBurkitt's lymphoma
p11932
tp11933
I01
ssg10879
(lp11934
(dp11935
g10882
I120
sg10883
g11932
sg10884
I18
sg10885
VC0006413
p11936
sg10887
I2
sasg10888
(lp11937
(dp11938
g10882
I75
sg10883
VStx1B
p11939
sg10884
I5
sg10891
VP61266
p11940
sg10887
I1
sa(dp11941
g10882
I23
sg10883
g11931
sg10884
I3
sg10891
VP11912
p11942
sg10887
I1
sasa(dp11943
g10873
VFurthermore, we found that Mcl-1 could be a potential therapeutic target of MECK-induced apoptosis and its stability is regulated by extracellular signal-regulated kinases 1/2 (ERK1/2) signaling MECK can be used as a safe and efficient therapeutic alternative for the treatment of salivary gland cancer.
p11944
sg4
(dp11945
(VMcl-1
p11946
VMcl
p11947
tp11948
I00
ssg10879
(lp11949
(dp11950
g10882
I281
sg10883
Vsalivary gland cancer
p11951
sg10884
I21
sg10885
VC0220636
p11952
sg10887
I3
sa(dp11953
g10882
I27
sg10883
g11947
sg10884
I3
sg10885
VC1708350
p11954
sg10887
I1
sasg10888
(lp11955
(dp11956
g10882
I177
sg10883
VERK1/2
p11957
sg10884
I6
sg10891
VP27361
p11958
sg10887
I1
sa(dp11959
g10882
I133
sg10883
Vextracellular signal-regulated kinases 1/2
p11960
sg10884
I42
sg10891
g190
sg10887
I4
sa(dp11961
g10882
I27
sg10883
g11946
sg10884
I5
sg10891
VP07954
p11962
sg10887
I1
sasa(dp11963
g10873
VAlthough NF-KB RelA (p65) is essential for the expression of many cytokines during pneumonia, its targeted mutation in the lung epithelium was inconsequential for pneumonia-driven LIF induction.
p11964
sg4
(dp11965
(Vp65
p11966
Vpneumonia
p11967
tp11968
I00
ssg10879
(lp11969
(dp11970
g10882
I83
sg10883
Vpneumonia
p11971
sg10884
I9
sg10885
VC0032285
p11972
sg10887
I1
sa(dp11973
g10882
I83
sg10883
g11967
sg10884
I9
sg10885
VC0032285
p11974
sg10887
I1
sasg10888
(lp11975
(dp11976
g10882
I9
sg10883
VNF-KB RelA
p11977
sg10884
I10
sg10891
g190
sg10887
I2
sa(dp11978
g10882
I21
sg10883
g11966
sg10884
I3
sg10891
VP21579
p11979
sg10887
I1
sasa(dp11980
g10873
VOverall, our data suggest a signaling axis whereby activation of NF-KB RelA in myeloid cells promotes epithelial LIF induction during lung infections, representing a means through which these two cell types collaborate to improve tissue resilience during pneumonia.
p11981
sg4
(dp11982
(Vepithelial LIF
p11983
Vpneumonia
p11984
tp11985
I00
ssg10879
(lp11986
(dp11987
g10882
I139
sg10883
Vinfections
p11988
sg10884
I10
sg10885
VC0021311
p11989
sg10887
I1
sa(dp11990
g10882
I255
sg10883
g11984
sg10884
I9
sg10885
VC0032285
p11991
sg10887
I1
sasg10888
(lp11992
(dp11993
g10882
I102
sg10883
g11983
sg10884
I14
sg10891
VP15018
p11994
sg10887
I2
sa(dp11995
g10882
I65
sg10883
VNF-KB RelA
p11996
sg10884
I10
sg10891
g190
sg10887
I2
sasa(dp11997
g10873
VTo determine the functional significance of the hepatic APR during pneumonia, we challenged APR-null mice lacking hepatocyte signal transducer and activator of transcription 3 (STAT3) and v-rel avian reticuloendotheliosis viral oncogene homolog A (RelA) with Escherichia coli in the airspaces.
p11998
sg4
(dp11999
(VSTAT3
p12000
Vpneumonia
p12001
tp12002
I00
ssg10879
(lp12003
(dp12004
g10882
I67
sg10883
g12001
sg10884
I9
sg10885
VC0032285
p12005
sg10887
I1
sa(dp12006
g10882
I194
sg10883
Vavian reticuloendotheliosis
p12007
sg10884
I27
sg10885
VC0276487
p12008
sg10887
I2
sasg10888
(lp12009
(dp12010
g10882
I114
sg10883
Vhepatocyte signal transducer and activator of transcription 3
p12011
sg10884
I61
sg10891
VP40763
p12012
sg10887
I8
sa(dp12013
g10882
I188
sg10883
Vv-rel avian reticuloendotheliosis viral oncogene homolog A
p12014
sg10884
I58
sg10891
g190
sg10887
I7
sa(dp12015
g10882
I248
sg10883
VRelA
p12016
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp12017
g10882
I177
sg10883
g12000
sg10884
I5
sg10891
VP40763
p12018
sg10887
I1
sasa(dp12019
g10873
VEpithelial RelA mutation decreased whole lung levels of CXCL5 and GM-CSF during pneumococcal pneumonia, whereas lung levels of other neutrophil-recruiting factors were unaffected.
p12020
sg4
(dp12021
(VCXCL5
p12022
Vpneumococcal pneumonia
p12023
tp12024
I00
ssg10879
(lp12025
(dp12026
g10882
I80
sg10883
g12023
sg10884
I22
sg10885
VC0155862
p12027
sg10887
I2
sasg10888
(lp12028
(dp12029
g10882
I66
sg10883
VGM-CSF
p12030
sg10884
I6
sg10891
VP04141
p12031
sg10887
I1
sa(dp12032
g10882
I56
sg10883
g12022
sg10884
I5
sg10891
VP42830
p12033
sg10887
I1
sa(dp12034
g10882
I11
sg10883
VRelA
p12035
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp12036
g10873
VBecause innate immunity gene induction depends on NF-KB RelA (also known as p65) during pneumonia, we generated a murine model of RelA mutated throughout the alveolar epithelium.
p12037
sg4
(dp12038
(Vp65
p12039
Vpneumonia
p12040
tp12041
I00
ssg10879
(lp12042
(dp12043
g10882
I88
sg10883
g12040
sg10884
I9
sg10885
VC0032285
p12044
sg10887
I1
sasg10888
(lp12045
(dp12046
g10882
I76
sg10883
g12039
sg10884
I3
sg10891
VP21579
p12047
sg10887
I1
sa(dp12048
g10882
I56
sg10883
VRelA
p12049
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp12050
g10882
I50
sg10883
VNF-KB RelA
p12051
sg10884
I10
sg10891
g190
sg10887
I2
sasa(dp12052
g10873
VSorted cell populations from mouse lungs revealed that CXCL5 was induced during pneumonia in type I cells, which did not require RelA.
p12053
sg4
(dp12054
(VCXCL5
p12055
Vpneumonia
p12056
tp12057
I00
ssg10879
(lp12058
(dp12059
g10882
I80
sg10883
g12056
sg10884
I9
sg10885
VC0032285
p12060
sg10887
I1
sasg10888
(lp12061
(dp12062
g10882
I129
sg10883
VRelA
p12063
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp12064
g10882
I55
sg10883
g12055
sg10884
I5
sg10891
VP42830
p12065
sg10887
I1
sasa(dp12066
g10873
VWe review the literature of genetic PD autopsies from cases with molecularly confirmed PD or parkinsonism and summarize main findings on SNCA (n = 25), Parkin (n = 20, 17 bi-allelic and 3 heterozygotes), PINK1 (n = 5, 1 bi-allelic and 4 heterozygotes), DJ-1 (n = 1), LRRK2 (n = 55), GBA (n = 10 Gaucher disease patients with parkinsonism), DNAJC13, GCH1, ATP13A2, PLA2G6 (n = 8 patients, 2 with PD), MPAN (n = 2), FBXO7, RAB39B, and ATXN2 (SCA2), as well as on 22q deletion syndrome (n = 3).
p12067
sg4
(dp12068
(VGCH1
p12069
VSCA2
p12070
tp12071
I00
ssg10879
(lp12072
(dp12073
g10882
I295
sg10883
VGaucher disease
p12074
sg10884
I15
sg10885
VC0017205
p12075
sg10887
I2
sa(dp12076
g10882
I93
sg10883
Vparkinsonism
p12077
sg10884
I12
sg10885
VC0242422
p12078
sg10887
I1
sa(dp12079
g10882
I461
sg10883
V22q deletion syndrome
p12080
sg10884
I21
sg10885
VC0795880
p12081
sg10887
I3
sa(dp12082
g10882
I93
sg10883
Vparkinsonism
p12083
sg10884
I12
sg10885
VC0242422
p12084
sg10887
I1
sa(dp12085
g10882
I440
sg10883
g12070
sg10884
I4
sg10885
VC0752121
p12086
sg10887
I1
sasg10888
(lp12087
(dp12088
g10882
I421
sg10883
VRAB39B
p12089
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp12090
g10882
I204
sg10883
VPINK1
p12091
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12092
g10882
I440
sg10883
VSCA2
p12093
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp12094
g10882
I267
sg10883
VLRRK2
p12095
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12096
g10882
I349
sg10883
g12069
sg10884
I4
sg10891
VP30793
p12097
sg10887
I1
sa(dp12098
g10882
I414
sg10883
VFBXO7
p12099
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12100
g10882
I355
sg10883
VATP13A2
p12101
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp12102
g10882
I364
sg10883
VPLA2G6
p12103
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp12104
g10882
I433
sg10883
VATXN2
p12105
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp12106
g10873
VPathological developments leading to amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are associated with misbehavior of several key proteins, such as SOD1 (superoxide dismutase 1), TARDBP/TDP-43, FUS, C9orf72, and dipeptide repeat proteins generated as a result of the translation of the intronic hexanucleotide expansions in the C9orf72 gene, PFN1 (profilin 1), GLE1 (GLE1, RNA export mediator), PURA (purine rich element binding protein A), FLCN (folliculin), RBM45 (RNA binding motif protein 45), SS18L1/CREST, HNRNPA1 (heterogeneous nuclear ribonucleoprotein A1), HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1), ATXN2 (ataxin 2), MAPT (microtubule associated protein tau), and TIA1 (TIA1 cytotoxic granule associated RNA binding protein).
p12107
sg4
(dp12108
(VHNRNPA1
p12109
Vamyotrophic lateral sclerosis
p12110
tp12111
I00
ssg10879
(lp12112
(dp12113
g10882
I68
sg10883
VALS
p12114
sg10884
I3
sg10885
VC0002736
p12115
sg10887
I1
sa(dp12116
g10882
I77
sg10883
Vfrontotemporal lobar degeneration
p12117
sg10884
I33
sg10885
VC0751072
p12118
sg10887
I3
sa(dp12119
g10882
I540
sg10883
VCREST
p12120
sg10884
I5
sg10885
VC0206138
p12121
sg10887
I1
sa(dp12122
g10882
I112
sg10883
VFTLD
p12123
sg10884
I4
sg10885
VC0751072
p12124
sg10887
I1
sa(dp12125
g10882
I37
sg10883
g12110
sg10884
I29
sg10885
VC0002736
p12126
sg10887
I3
sasg10888
(lp12127
(dp12128
g10882
I556
sg10883
Vheterogeneous nuclear ribonucleoprotein A1
p12129
sg10884
I42
sg10891
VP09651
p12130
sg10887
I4
sa(dp12131
g10882
I684
sg10883
Vmicrotubule associated protein tau
p12132
sg10884
I34
sg10891
g190
sg10887
I4
sa(dp12133
g10882
I396
sg10883
VGLE1
p12134
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp12135
g10882
I430
sg10883
VPURA
p12136
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp12137
g10882
I383
sg10883
Vprofilin 1
p12138
sg10884
I10
sg10891
VP07737
p12139
sg10887
I2
sa(dp12140
g10882
I482
sg10883
Vfolliculin
p12141
sg10884
I10
sg10891
g190
sg10887
I1
sa(dp12142
g10882
I436
sg10883
Vpurine rich element binding protein A
p12143
sg10884
I37
sg10891
g190
sg10887
I6
sa(dp12144
g10882
I725
sg10883
VTIA1
p12145
sg10884
I4
sg10891
VP31483
p12146
sg10887
I1
sa(dp12147
g10882
I183
sg10883
VSOD1
p12148
sg10884
I4
sg10891
VP00441
p12149
sg10887
I1
sa(dp12150
g10882
I229
sg10883
VFUS
p12151
sg10884
I3
sg10891
VP35637
p12152
sg10887
I1
sa(dp12153
g10882
I189
sg10883
Vsuperoxide dismutase 1
p12154
sg10884
I22
sg10891
VP00441
p12155
sg10887
I3
sa(dp12156
g10882
I678
sg10883
VMAPT
p12157
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp12158
g10882
I396
sg10883
VGLE1
p12159
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp12160
g10882
I667
sg10883
Vataxin 2
p12161
sg10884
I8
sg10891
g190
sg10887
I2
sa(dp12162
g10882
I612
sg10883
Vheterogeneous nuclear ribonucleoprotein A2/B1
p12163
sg10884
I45
sg10891
VP22626
p12164
sg10887
I4
sa(dp12165
g10882
I234
sg10883
VC9orf72
p12166
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp12167
g10882
I214
sg10883
VTARDBP/TDP-43
p12168
sg10884
I13
sg10891
g190
sg10887
I1
sa(dp12169
g10882
I731
sg10883
VTIA1 cytotoxic granule associated RNA binding protein
p12170
sg10884
I53
sg10891
VP00390
p12171
sg10887
I7
sa(dp12172
g10882
I601
sg10883
VHNRNPA2B1
p12173
sg10884
I9
sg10891
VP22626
p12174
sg10887
I1
sa(dp12175
g10882
I377
sg10883
VPFN1
p12176
sg10884
I4
sg10891
VP07737
p12177
sg10887
I1
sa(dp12178
g10882
I363
sg10883
VC9orf72 gene
p12179
sg10884
I12
sg10891
g190
sg10887
I2
sa(dp12180
g10882
I476
sg10883
VFLCN
p12181
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp12182
g10882
I660
sg10883
VATXN2
p12183
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12184
g10882
I547
sg10883
g12109
sg10884
I7
sg10891
VP09651
p12185
sg10887
I1
sasa(dp12186
g10873
VRecent studies have identified the RNA-binding protein Ataxin-2 as a genetic determinant or risk factor for various diseases including spinocerebellar ataxia type II (SCA2) and amyotrophic lateral sclerosis (ALS), amongst others.
p12187
sg4
(dp12188
(Vataxia type II
p12189
Vspinocerebellar ataxia
p12190
tp12191
I00
ssg10879
(lp12192
(dp12193
g10882
I167
sg10883
VSCA2
p12194
sg10884
I4
sg10885
VC0752121
p12195
sg10887
I1
sa(dp12196
g10882
I177
sg10883
Vamyotrophic lateral sclerosis
p12197
sg10884
I29
sg10885
VC0002736
p12198
sg10887
I3
sa(dp12199
g10882
I208
sg10883
VALS
p12200
sg10884
I3
sg10885
VC0002736
p12201
sg10887
I1
sa(dp12202
g10882
I135
sg10883
g12190
sg10884
I22
sg10885
VC0087012
p12203
sg10887
I2
sasg10888
(lp12204
(dp12205
g10882
I167
sg10883
VSCA2
p12206
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp12207
g10882
I55
sg10883
VAtaxin-2
p12208
sg10884
I8
sg10891
g190
sg10887
I1
sa(dp12209
g10882
I151
sg10883
g12189
sg10884
I14
sg10891
VP27037
p12210
sg10887
I3
sasa(dp12211
g10873
VHere we show that synaptobrevin 2 sorting involves determinants within its SNARE motif that are recognized by the ANTH domains of the endocytic adaptors AP180 and clathrin assembly lymphoid myeloid leukemia (CALM).
p12212
sg4
(dp12213
(Vsynaptobrevin 2
p12214
Vmyeloid leukemia
p12215
tp12216
I00
ssg10879
(lp12217
(dp12218
g10882
I190
sg10883
g12215
sg10884
I16
sg10885
VC0023470
p12219
sg10887
I2
sasg10888
(lp12220
(dp12221
g10882
I18
sg10883
g12214
sg10884
I15
sg10891
VP63027
p12222
sg10887
I2
sa(dp12223
g10882
I153
sg10883
VAP180
p12224
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp12225
g10873
VSpecifically, fibroblast growth factor receptor 3 (FGFR3), desmoglein 2 (DSG2), E3 ubiquitin ligase c-CBL (casitas B-cell lymphoma), cancer/testis antigen NY-ESO-1 (CTAG1A/B), undifferentiated embryonic cell transcription factor 1 (UTF1) and synaptosomal-associated protein, 91 kDa homolog (SNAP91) were shown to represent specific biomarkers of human spermatogonia.
p12226
sg4
(dp12227
(VE3 ubiquitin
p12228
VB-cell lymphoma
p12229
tp12230
I00
ssg10879
(lp12231
(dp12232
g10882
I115
sg10883
g12229
sg10884
I15
sg10885
VC0079731
p12233
sg10887
I2
sa(dp12234
g10882
I133
sg10883
Vcancer
p12235
sg10884
I6
sg10885
VC0006826
p12236
sg10887
I1
sasg10888
(lp12237
(dp12238
g10882
I51
sg10883
VFGFR3
p12239
sg10884
I5
sg10891
VP22607
p12240
sg10887
I1
sa(dp12241
g10882
I100
sg10883
Vc-CBL
p12242
sg10884
I5
sg10891
VP22681
p12243
sg10887
I1
sa(dp12244
g10882
I59
sg10883
Vdesmoglein 2
p12245
sg10884
I12
sg10891
g190
sg10887
I2
sa(dp12246
g10882
I155
sg10883
VNY-ESO-1
p12247
sg10884
I8
sg10891
VP78358
p12248
sg10887
I1
sa(dp12249
g10882
I80
sg10883
g12228
sg10884
I12
sg10891
VP62979
p12250
sg10887
I2
sa(dp12251
g10882
I14
sg10883
Vfibroblast growth factor receptor 3
p12252
sg10884
I35
sg10891
g190
sg10887
I5
sa(dp12253
g10882
I176
sg10883
Vundifferentiated embryonic cell transcription factor 1
p12254
sg10884
I54
sg10891
g190
sg10887
I6
sa(dp12255
g10882
I291
sg10883
VSNAP91
p12256
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp12257
g10882
I73
sg10883
VDSG2
p12258
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp12259
g10882
I275
sg10883
V91 kDa homolog
p12260
sg10884
I14
sg10891
g190
sg10887
I3
sa(dp12261
g10882
I165
sg10883
VCTAG1A/B
p12262
sg10884
I8
sg10891
VP78358
p12263
sg10887
I1
sa(dp12264
g10882
I232
sg10883
VUTF1
p12265
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp12266
g10873
VThe expression level of ERp57 was also elevated in rat insulinoma INS-1 cells by inducible knock-down of the atg7-gene.
p12267
sg4
(dp12268
(VERp57
p12269
Vinsulinoma
p12270
tp12271
I00
ssg10879
(lp12272
(dp12273
g10882
I66
sg10883
VINS
p12274
sg10884
I3
sg10885
VC1533172
p12275
sg10887
I1
sa(dp12276
g10882
I55
sg10883
g12270
sg10884
I10
sg10885
VC0021670
p12277
sg10887
I1
sasg10888
(lp12278
(dp12279
g10882
I51
sg10883
Vrat insulinoma INS-1
p12280
sg10884
I20
sg10891
VP01308
p12281
sg10887
I3
sa(dp12282
g10882
I109
sg10883
Vatg7-gene
p12283
sg10884
I9
sg10891
g190
sg10887
I1
sa(dp12284
g10882
I24
sg10883
g12269
sg10884
I5
sg10891
VP30101
p12285
sg10887
I1
sasa(dp12286
g10873
VTissue specimens of nine dental follicles and 69 ameloblastomas were immunohistochemically examined with antibodies against ATG7, LC3, and p62.
p12287
sg4
(dp12288
(Vp62
p12289
Vameloblastomas
p12290
tp12291
I00
ssg10879
(lp12292
(dp12293
g10882
I49
sg10883
g12290
sg10884
I14
sg10885
VC0002448
p12294
sg10887
I1
sasg10888
(lp12295
(dp12296
g10882
I130
sg10883
VLC3
p12297
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp12298
g10882
I139
sg10883
g12289
sg10884
I3
sg10891
VP37198
p12299
sg10887
I1
sa(dp12300
g10882
I124
sg10883
VATG7
p12301
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp12302
g10873
VImmunohistochemical reactivity for ATG7, LC3, and p62 was detected in many odontogenic epithelial cells and several endothelial cells and fibroblasts in dental follicles and ameloblastomas.
p12303
sg4
(dp12304
(Vp62
p12305
Vameloblastomas
p12306
tp12307
I00
ssg10879
(lp12308
(dp12309
g10882
I174
sg10883
g12306
sg10884
I14
sg10885
VC0002448
p12310
sg10887
I1
sasg10888
(lp12311
(dp12312
g10882
I35
sg10883
VATG7
p12313
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp12314
g10882
I41
sg10883
VLC3
p12315
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp12316
g10882
I50
sg10883
g12305
sg10884
I3
sg10891
VP37198
p12317
sg10887
I1
sasa(dp12318
g10873
VExpression of ATG7, LC3, and p62 was found markedly in neoplastic cells near the basement membrane rather than central polyhedral cells in ameloblastomas.
p12319
sg4
(dp12320
(Vp62
p12321
Vameloblastomas
p12322
tp12323
I00
ssg10879
(lp12324
(dp12325
g10882
I139
sg10883
g12322
sg10884
I14
sg10885
VC0002448
p12326
sg10887
I1
sasg10888
(lp12327
(dp12328
g10882
I29
sg10883
g12321
sg10884
I3
sg10891
VP37198
p12329
sg10887
I1
sa(dp12330
g10882
I20
sg10883
VLC3
p12331
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp12332
g10882
I14
sg10883
VATG7
p12333
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp12334
g10873
VExpression of ATG7, LC3, and p62 in dental follicles and ameloblastomas suggests that autophagy regulation might be affected by microenvironment alterations during tumorigenesis.
p12335
sg4
(dp12336
(Vp62
p12337
Vameloblastomas
p12338
tp12339
I00
ssg10879
(lp12340
(dp12341
g10882
I164
sg10883
Vtumorigenesis
p12342
sg10884
I13
sg10885
VC0007621
p12343
sg10887
I1
sa(dp12344
g10882
I57
sg10883
g12338
sg10884
I14
sg10885
VC0002448
p12345
sg10887
I1
sasg10888
(lp12346
(dp12347
g10882
I29
sg10883
g12337
sg10884
I3
sg10891
VP37198
p12348
sg10887
I1
sa(dp12349
g10882
I20
sg10883
VLC3
p12350
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp12351
g10882
I14
sg10883
VATG7
p12352
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp12353
g10873
VUsing genetically engineered mouse models (GEMMs) for human non-small-cell lung cancer (NSCLC), we found that deletion of the essential autophagy gene, Atg7, in KRAS(G12D)-driven NSCLC inhibits tumor growth and converts adenomas and adenocarcinomas to benign oncocytomas characterized by the accumulation of respiration-defective mitochondria.
p12354
sg4
(dp12355
(VKRAS
p12356
Vadenocarcinomas
p12357
tp12358
I00
ssg10879
(lp12359
(dp12360
g10882
I194
sg10883
Vtumor growth
p12361
sg10884
I12
sg10885
VC0598934
p12362
sg10887
I2
sa(dp12363
g10882
I88
sg10883
VNSCLC
p12364
sg10884
I5
sg10885
VC0007131
p12365
sg10887
I1
sa(dp12366
g10882
I220
sg10883
Vadenomas
p12367
sg10884
I8
sg10885
VC0001430
p12368
sg10887
I1
sa(dp12369
g10882
I259
sg10883
Voncocytomas
p12370
sg10884
I11
sg10885
VC0949541
p12371
sg10887
I1
sa(dp12372
g10882
I88
sg10883
VNSCLC
p12373
sg10884
I5
sg10885
VC0007131
p12374
sg10887
I1
sa(dp12375
g10882
I60
sg10883
Vnon-small-cell lung cancer
p12376
sg10884
I26
sg10885
VC0007131
p12377
sg10887
I3
sa(dp12378
g10882
I233
sg10883
g12357
sg10884
I15
sg10885
VC0001418
p12379
sg10887
I1
sasg10888
(lp12380
(dp12381
g10882
I152
sg10883
VAtg7
p12382
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp12383
g10882
I161
sg10883
g12356
sg10884
I4
sg10891
VP01116
p12384
sg10887
I1
sasa(dp12385
g10873
Vp15RS is a ubiquitously expressed nuclear protein that is positively regulated by p15 and, in turn, inhibits the expression of cyclin D and cyclin E. To determine whether p15RS has malignancy inhibitory functions in addition to its inhibitory effects on cell cycle entry, we ectopically expressed p15RS in metastatic melanoma A375 cells, in which p15 gene is deleted and p15RS expression is dramatically downregulated, and examined the effect on various malignant phenotypes.
p12386
sg4
(dp12387
(Vcyclin D
p12388
Vmetastatic melanoma
p12389
tp12390
I01
ssg10879
(lp12391
(dp12392
g10882
I181
sg10883
Vmalignancy
p12393
sg10884
I10
sg10885
VC0006826
p12394
sg10887
I1
sa(dp12395
g10882
I306
sg10883
g12389
sg10884
I19
sg10885
VC0278883
p12396
sg10887
I2
sasg10888
(lp12397
(dp12398
g10882
I0
sg10883
Vp15RS
p12399
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12400
g10882
I0
sg10883
Vp15RS
p12401
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12402
g10882
I0
sg10883
Vp15RS
p12403
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12404
g10882
I0
sg10883
Vp15RS
p12405
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12406
g10882
I347
sg10883
Vp15 gene
p12407
sg10884
I8
sg10891
VP53999
p12408
sg10887
I2
sa(dp12409
g10882
I0
sg10883
Vp15
p12410
sg10884
I3
sg10891
VP53999
p12411
sg10887
I1
sa(dp12412
g10882
I140
sg10883
Vcyclin E
p12413
sg10884
I8
sg10891
VP24864
p12414
sg10887
I2
sa(dp12415
g10882
I127
sg10883
g12388
sg10884
I8
sg10891
VP24385
p12416
sg10887
I2
sasa(dp12417
g10873
VWe discuss known inborn errors of CTGM, including deficiencies of: AGPAT2 (a form of generalized lipodystrophy), LPIN1 (childhood rhabdomyolysis), LPIN2 (an inflammatory condition, Majeed syndrome, described elsewhere in this issue), DGAT1 (protein loosing enteropathy), perilipin 1 (partial lipodystrophy), CGI-58 (gene ABHD5, neutral lipid storage disease (NLSD) with ichthyosis and "Jordan's anomaly" of vacuolated polymorphonuclear leukocytes), adipose triglyceride lipase (ATGL, gene PNPLA2, NLSD with myopathy, cardiomyopathy and Jordan's anomaly), hormone-sensitive lipase (HSL, gene LIPE, hypertriglyceridemia, and insulin resistance).
p12418
sg4
(dp12419
(Vadipose triglyceride lipase
p12420
Vinsulin resistance
p12421
tp12422
I00
ssg10879
(lp12423
(dp12424
g10882
I507
sg10883
Vmyopathy
p12425
sg10884
I8
sg10885
VC0026848
p12426
sg10887
I1
sa(dp12427
g10882
I359
sg10883
VNLSD
p12428
sg10884
I4
sg10885
VC0268238
p12429
sg10887
I1
sa(dp12430
g10882
I181
sg10883
VMajeed syndrome
p12431
sg10884
I15
sg10885
VC1864997
p12432
sg10887
I2
sa(dp12433
g10882
I359
sg10883
VNLSD
p12434
sg10884
I4
sg10885
VC0268238
p12435
sg10887
I1
sa(dp12436
g10882
I370
sg10883
Vichthyosis
p12437
sg10884
I10
sg10885
VC0020758
p12438
sg10887
I1
sa(dp12439
g10882
I328
sg10883
Vneutral lipid storage disease
p12440
sg10884
I29
sg10885
VC0268238
p12441
sg10887
I4
sa(dp12442
g10882
I517
sg10883
Vcardiomyopathy
p12443
sg10884
I14
sg10885
VC0878544
p12444
sg10887
I1
sa(dp12445
g10882
I130
sg10883
Vrhabdomyolysis
p12446
sg10884
I14
sg10885
VC0035410
p12447
sg10887
I1
sa(dp12448
g10882
I85
sg10883
Vgeneralized lipodystrophy
p12449
sg10884
I25
sg10885
VC0221032
p12450
sg10887
I2
sa(dp12451
g10882
I257
sg10883
Venteropathy
p12452
sg10884
I11
sg10885
VC0021831
p12453
sg10887
I1
sa(dp12454
g10882
I170
sg10883
Vcondition
p12455
sg10884
I9
sg10885
VC0012634
p12456
sg10887
I1
sa(dp12457
g10882
I284
sg10883
Vpartial lipodystrophy
p12458
sg10884
I21
sg10885
VC0220989
p12459
sg10887
I2
sa(dp12460
g10882
I623
sg10883
g12421
sg10884
I18
sg10885
VC0021655
p12461
sg10887
I2
sasg10888
(lp12462
(dp12463
g10882
I623
sg10883
Vinsulin
p12464
sg10884
I7
sg10891
VP01308
p12465
sg10887
I1
sa(dp12466
g10882
I586
sg10883
Vgene LIPE
p12467
sg10884
I9
sg10891
g190
sg10887
I2
sa(dp12468
g10882
I478
sg10883
VATGL
p12469
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp12470
g10882
I581
sg10883
VHSL
p12471
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp12472
g10882
I484
sg10883
Vgene PNPLA2
p12473
sg10884
I11
sg10891
g190
sg10887
I2
sa(dp12474
g10882
I555
sg10883
Vhormone-sensitive lipase
p12475
sg10884
I24
sg10891
g190
sg10887
I2
sa(dp12476
g10882
I321
sg10883
VABHD5
p12477
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12478
g10882
I271
sg10883
Vperilipin 1
p12479
sg10884
I11
sg10891
g190
sg10887
I2
sa(dp12480
g10882
I234
sg10883
VDGAT1
p12481
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12482
g10882
I67
sg10883
VAGPAT2
p12483
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp12484
g10882
I449
sg10883
g12420
sg10884
I27
sg10891
VP04118
p12485
sg10887
I3
sa(dp12486
g10882
I113
sg10883
VLPIN1
p12487
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp12488
g10873
VWnt-signaling hyperactivation, albeit in GSK-3Beta independent manner, differentiated colon cancer in claudin-3-/- mice versus WT-mice.
p12489
sg4
(dp12490
(VGSK-3Beta
p12491
Vcolon cancer
p12492
tp12493
I00
ssg10879
(lp12494
(dp12495
g10882
I86
sg10883
g12492
sg10884
I12
sg10885
VC0699790
p12496
sg10887
I2
sasg10888
(lp12497
(dp12498
g10882
I41
sg10883
g12491
sg10884
I9
sg10891
VP49841
p12499
sg10887
I1
sasa(dp12500
g10873
VGenetic and pharmacological studies confirmed that claudin-3 loss induces Wnt/Beta-catenin activation, which is further exacerbated by Stat-3-activation and help promote colon cancer.
p12501
sg4
(dp12502
(VBeta-catenin
p12503
Vcolon cancer
p12504
tp12505
I00
ssg10879
(lp12506
(dp12507
g10882
I170
sg10883
g12504
sg10884
I12
sg10885
VC0699790
p12508
sg10887
I2
sasg10888
(lp12509
(dp12510
g10882
I51
sg10883
Vclaudin-3 loss
p12511
sg10884
I14
sg10891
g190
sg10887
I2
sa(dp12512
g10882
I135
sg10883
VStat-3
p12513
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp12514
g10882
I78
sg10883
g12503
sg10884
I12
sg10891
VP35222
p12515
sg10887
I1
sasa(dp12516
g10873
VHere, we report that epidermal growth factor (EGF) increases the expression of claudin-3 in human colorectal adenocarcinoma HT-29 cells.
p12517
sg4
(dp12518
(Vepidermal growth factor
p12519
Vcolorectal adenocarcinoma
p12520
tp12521
I00
ssg10879
(lp12522
(dp12523
g10882
I98
sg10883
g12520
sg10884
I25
sg10885
VC1319315
p12524
sg10887
I2
sasg10888
(lp12525
(dp12526
g10882
I79
sg10883
Vclaudin-3
p12527
sg10884
I9
sg10891
g190
sg10887
I1
sa(dp12528
g10882
I46
sg10883
VEGF
p12529
sg10884
I3
sg10891
VP01133
p12530
sg10887
I1
sa(dp12531
g10882
I21
sg10883
g12519
sg10884
I23
sg10891
VP01133
p12532
sg10887
I3
sasa(dp12533
g10873
VIn conclusion, our results show a novel role for claudin-3 overexpression in promoting the malignant potential of colorectal cancer cells, which is potentially regulated by the EGF-activated ERK1/2 and PI3K-Akt pathways.
p12534
sg4
(dp12535
(VERK1/2
p12536
Vcolorectal cancer
p12537
tp12538
I00
ssg10879
(lp12539
(dp12540
g10882
I114
sg10883
g12537
sg10884
I17
sg10885
VC1527249
p12541
sg10887
I2
sasg10888
(lp12542
(dp12543
g10882
I49
sg10883
Vclaudin-3
p12544
sg10884
I9
sg10891
g190
sg10887
I1
sa(dp12545
g10882
I177
sg10883
VEGF
p12546
sg10884
I3
sg10891
VP01133
p12547
sg10887
I1
sa(dp12548
g10882
I202
sg10883
VPI3K
p12549
sg10884
I4
sg10891
VP42336
p12550
sg10887
I1
sa(dp12551
g10882
I207
sg10883
VAkt
p12552
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp12553
g10882
I191
sg10883
g12536
sg10884
I6
sg10891
VP27361
p12554
sg10887
I1
sasa(dp12555
g10873
VPatients with essential thrombocythemia (ET) and polycythemia vera (PV), complicated by microvascular ischemic or thrombotic events, have shortened platelet survival, increased beta-thromboglobulin, platelet factor 4, and thrombomodulin levels, and increased urinary thromboxane B2 excretion.
p12556
sg4
(dp12557
(Vthrombomodulin
p12558
Vpolycythemia vera
p12559
tp12560
I00
ssg10879
(lp12561
(dp12562
g10882
I68
sg10883
VPV
p12563
sg10884
I2
sg10885
VC0032463
p12564
sg10887
I1
sa(dp12565
g10882
I14
sg10883
Vessential thrombocythemia
p12566
sg10884
I25
sg10885
VC0040028
p12567
sg10887
I2
sa(dp12568
g10882
I41
sg10883
VET
p12569
sg10884
I2
sg10885
VC0040028
p12570
sg10887
I1
sa(dp12571
g10882
I49
sg10883
g12559
sg10884
I17
sg10885
VC0032463
p12572
sg10887
I2
sasg10888
(lp12573
(dp12574
g10882
I177
sg10883
Vbeta-thromboglobulin
p12575
sg10884
I20
sg10891
VP02775
p12576
sg10887
I1
sa(dp12577
g10882
I199
sg10883
Vplatelet factor 4
p12578
sg10884
I17
sg10891
VP02776
p12579
sg10887
I3
sa(dp12580
g10882
I222
sg10883
g12558
sg10884
I14
sg10891
VP07204
p12581
sg10887
I1
sasa(dp12582
g10873
VWhether fibroblast growth factor 19 (FGF19) or farnesoid X receptor (FXR) dependent signaling are involved in the regulation of BA homeostasis in primary biliary cirrhosis (PBC) remains unknown.
p12583
sg4
(dp12584
(VFXR
p12585
Vprimary biliary cirrhosis
p12586
tp12587
I00
ssg10879
(lp12588
(dp12589
g10882
I173
sg10883
VPBC
p12590
sg10884
I3
sg10885
VC0008312
p12591
sg10887
I1
sa(dp12592
g10882
I146
sg10883
g12586
sg10884
I25
sg10885
VC0008312
p12593
sg10887
I3
sasg10888
(lp12594
(dp12595
g10882
I8
sg10883
Vfibroblast growth factor 19
p12596
sg10884
I27
sg10891
g190
sg10887
I4
sa(dp12597
g10882
I69
sg10883
g12585
sg10884
I3
sg10891
VP23945
p12598
sg10887
I1
sa(dp12599
g10882
I47
sg10883
Vfarnesoid X receptor
p12600
sg10884
I20
sg10891
g190
sg10887
I3
sa(dp12601
g10882
I37
sg10883
VFGF19
p12602
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp12603
g10873
VPrevious studies have resulted in the isolation of the human HSST gene from within the Treacher Collins syndrome locus (TCOF1) critical region on 5q.
p12604
sg4
(dp12605
(Vhuman HSST gene
p12606
VTreacher Collins syndrome
p12607
tp12608
I00
ssg10879
(lp12609
(dp12610
g10882
I87
sg10883
g12607
sg10884
I25
sg10885
VC0242387
p12611
sg10887
I3
sasg10888
(lp12612
(dp12613
g10882
I120
sg10883
VTCOF1
p12614
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12615
g10882
I55
sg10883
g12606
sg10884
I15
sg10891
VP52848
p12616
sg10887
I3
sasa(dp12617
g10873
VIn this study, we show that hyperinsulinemia in the Rag/MKR mice increases the expression of mesenchymal transcription factors, TWIST1 and ZEB1, and increases the expression of the angiogenesis marker, vascular endothelial growth factor A (VEGFA).
p12618
sg4
(dp12619
(VMKR
p12620
Vhyperinsulinemia
p12621
tp12622
I00
ssg10879
(lp12623
(dp12624
g10882
I28
sg10883
g12621
sg10884
I16
sg10885
VC0020459
p12625
sg10887
I1
sasg10888
(lp12626
(dp12627
g10882
I240
sg10883
VVEGFA
p12628
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12629
g10882
I52
sg10883
VRag
p12630
sg10884
I3
sg10891
VP52803
p12631
sg10887
I1
sa(dp12632
g10882
I139
sg10883
VZEB1
p12633
sg10884
I4
sg10891
VP37275
p12634
sg10887
I1
sa(dp12635
g10882
I56
sg10883
g12620
sg10884
I3
sg10891
VP33032
p12636
sg10887
I1
sa(dp12637
g10882
I128
sg10883
VTWIST1
p12638
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp12639
g10882
I202
sg10883
Vvascular endothelial growth factor A
p12640
sg10884
I36
sg10891
g190
sg10887
I5
sasa(dp12641
g10873
VIn summary, the results suggest that eupatolide suppresses the migration and invasion of breast cancer cells by blocking the canonical ALK5-SMAD3 signaling pathway and the non-canonical ERK and AKT signaling pathways.
p12642
sg4
(dp12643
(VALK5
p12644
Vbreast cancer
p12645
tp12646
I00
ssg10879
(lp12647
(dp12648
g10882
I77
sg10883
Vinvasion
p12649
sg10884
I8
sg10885
VC2699153
p12650
sg10887
I1
sa(dp12651
g10882
I112
sg10883
Vblocking
p12652
sg10884
I8
sg10885
VC0233660
p12653
sg10887
I1
sa(dp12654
g10882
I89
sg10883
g12645
sg10884
I13
sg10885
VC0678222
p12655
sg10887
I2
sasg10888
(lp12656
(dp12657
g10882
I186
sg10883
VERK
p12658
sg10884
I3
sg10891
VP29323
p12659
sg10887
I1
sa(dp12660
g10882
I135
sg10883
g12644
sg10884
I4
sg10891
VP36897
p12661
sg10887
I1
sa(dp12662
g10882
I194
sg10883
VAKT
p12663
sg10884
I3
sg10891
g190
sg10887
I1
sasa(dp12664
g10873
VRecent studies show that IL-16, soluble ST2 or anti-IL-33 reduce type 2 cytokines (such as IL-5) and eosinophilia in murine models of allergic asthma or allergic rhinitis respectively.
p12665
sg4
(dp12666
(VIL-5
p12667
Veosinophilia
p12668
tp12669
I00
ssg10879
(lp12670
(dp12671
g10882
I134
sg10883
Vallergic asthma
p12672
sg10884
I15
sg10885
VC0155877
p12673
sg10887
I2
sa(dp12674
g10882
I153
sg10883
Vallergic rhinitis
p12675
sg10884
I17
sg10885
VC2607914
p12676
sg10887
I2
sa(dp12677
g10882
I101
sg10883
g12668
sg10884
I12
sg10885
VC0014457
p12678
sg10887
I1
sasg10888
(lp12679
(dp12680
g10882
I65
sg10883
Vtype 2 cytokines
p12681
sg10884
I16
sg10891
VP01374
p12682
sg10887
I3
sa(dp12683
g10882
I91
sg10883
g12667
sg10884
I4
sg10891
VP05113
p12684
sg10887
I1
sa(dp12685
g10882
I25
sg10883
VIL-16, soluble ST2
p12686
sg10884
I18
sg10891
g190
sg10887
I3
sasa(dp12687
g10873
VIn this study, we studied the release of IL-5, IL-16, IL-33 and soluble ST2 in allergic rhinitis patients after nasal allergen challenge and natural pollen exposure.
p12688
sg4
(dp12689
(VIL-5
p12690
Vallergic rhinitis
p12691
tp12692
I00
ssg10879
(lp12693
(dp12694
g10882
I79
sg10883
g12691
sg10884
I17
sg10885
VC2607914
p12695
sg10887
I2
sasg10888
(lp12696
(dp12697
g10882
I47
sg10883
VIL-16
p12698
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12699
g10882
I41
sg10883
g12690
sg10884
I4
sg10891
VP05113
p12700
sg10887
I1
sasa(dp12701
g10873
VThe observed upregulation of soluble ST2 and IL-16 after nasal allergen challenge and during peak pollination season suggests potential regulatory roles of these cytokines in the inflammatory reaction in allergic rhinitis.
p12702
sg4
(dp12703
(VST2
p12704
Vinflammatory reaction
p12705
tp12706
I00
ssg10879
(lp12707
(dp12708
g10882
I204
sg10883
Vallergic rhinitis
p12709
sg10884
I17
sg10885
VC2607914
p12710
sg10887
I2
sa(dp12711
g10882
I179
sg10883
g12705
sg10884
I21
sg10885
VC0021368
p12712
sg10887
I2
sasg10888
(lp12713
(dp12714
g10882
I45
sg10883
VIL-16
p12715
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12716
g10882
I37
sg10883
g12704
sg10884
I3
sg10891
VP10767
p12717
sg10887
I1
sasa(dp12718
g10873
VTo detect the expression and distribution of the lung surfactant protein D (surfactant protein D,SP-D ) and IL-16 in nasal mucosa of allergic rhinitis and nasal polyps, and then probe into their significance in the pathology of allergic rhinitis and nasal polyps.
p12719
sg4
(dp12720
(Vsurfactant protein D
p12721
Vallergic rhinitis
p12722
tp12723
I00
ssg10879
(lp12724
(dp12725
g10882
I215
sg10883
Vpathology
p12726
sg10884
I9
sg10885
VC0677042
p12727
sg10887
I1
sa(dp12728
g10882
I155
sg10883
Vnasal polyps
p12729
sg10884
I12
sg10885
VC0027430
p12730
sg10887
I2
sa(dp12731
g10882
I133
sg10883
Vallergic rhinitis
p12732
sg10884
I17
sg10885
VC2607914
p12733
sg10887
I2
sa(dp12734
g10882
I155
sg10883
Vnasal polyps
p12735
sg10884
I12
sg10885
VC0027430
p12736
sg10887
I2
sa(dp12737
g10882
I133
sg10883
g12722
sg10884
I17
sg10885
VC2607914
p12738
sg10887
I2
sasg10888
(lp12739
(dp12740
g10882
I97
sg10883
VSP-D
p12741
sg10884
I4
sg10891
VP35247
p12742
sg10887
I1
sa(dp12743
g10882
I54
sg10883
Vsurfactant protein D
p12744
sg10884
I20
sg10891
VP35247
p12745
sg10887
I3
sa(dp12746
g10882
I54
sg10883
g12721
sg10884
I20
sg10891
VP35247
p12747
sg10887
I3
sa(dp12748
g10882
I108
sg10883
VIL-16
p12749
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp12750
g10873
VFifteen cases of allergic rhinitis, fifteen cases of nasal polyps and fifteen cases of inferior turbinate mucosa were studied to detect the expression of SP-D and IL-16 by immunohistochemistry method.
p12751
sg4
(dp12752
(VSP-D
p12753
Vnasal polyps
p12754
tp12755
I00
ssg10879
(lp12756
(dp12757
g10882
I17
sg10883
Vallergic rhinitis
p12758
sg10884
I17
sg10885
VC2607914
p12759
sg10887
I2
sa(dp12760
g10882
I53
sg10883
g12754
sg10884
I12
sg10885
VC0027430
p12761
sg10887
I2
sasg10888
(lp12762
(dp12763
g10882
I154
sg10883
g12753
sg10884
I4
sg10891
VP35247
p12764
sg10887
I1
sa(dp12765
g10882
I163
sg10883
VIL-16
p12766
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp12767
g10873
VThe expression of SP-D and IL-16 in allergic rhinitis and nasal polyps were dramatically higher in controls (P &lt; 0.01).
p12768
sg4
(dp12769
(VSP-D
p12770
Vnasal polyps
p12771
tp12772
I00
ssg10879
(lp12773
(dp12774
g10882
I36
sg10883
Vallergic rhinitis
p12775
sg10884
I17
sg10885
VC2607914
p12776
sg10887
I2
sa(dp12777
g10882
I58
sg10883
g12771
sg10884
I12
sg10885
VC0027430
p12778
sg10887
I2
sasg10888
(lp12779
(dp12780
g10882
I27
sg10883
VIL-16
p12781
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12782
g10882
I18
sg10883
g12770
sg10884
I4
sg10891
VP35247
p12783
sg10887
I1
sasa(dp12784
g10873
VThere was no remarkable difference in the expression of SP-D and IL-16 between allergic rhinitis and nasal polyps (P &gt; 0.05).
p12785
sg4
(dp12786
(VSP-D
p12787
Vallergic rhinitis
p12788
tp12789
I00
ssg10879
(lp12790
(dp12791
g10882
I101
sg10883
Vnasal polyps
p12792
sg10884
I12
sg10885
VC0027430
p12793
sg10887
I2
sa(dp12794
g10882
I79
sg10883
g12788
sg10884
I17
sg10885
VC2607914
p12795
sg10887
I2
sasg10888
(lp12796
(dp12797
g10882
I65
sg10883
VIL-16
p12798
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12799
g10882
I56
sg10883
g12787
sg10884
I4
sg10891
VP35247
p12800
sg10887
I1
sasa(dp12801
g10873
VThough a chemotactin for CD4(+) cells and eosinophils, IL-16 also modulates their production of factors that influence inflammatory lung diseases, e.g., asthma and allergic rhinitis.
p12802
sg4
(dp12803
(VCD4
p12804
Vallergic rhinitis
p12805
tp12806
I00
ssg10879
(lp12807
(dp12808
g10882
I153
sg10883
Vasthma
p12809
sg10884
I6
sg10885
VC0004096
p12810
sg10887
I1
sa(dp12811
g10882
I132
sg10883
Vlung diseases
p12812
sg10884
I13
sg10885
VC0024115
p12813
sg10887
I2
sa(dp12814
g10882
I164
sg10883
g12805
sg10884
I17
sg10885
VC2607914
p12815
sg10887
I2
sasg10888
(lp12816
(dp12817
g10882
I55
sg10883
VIL-16
p12818
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12819
g10882
I25
sg10883
g12804
sg10884
I3
sg10891
VP01730
p12820
sg10887
I1
sasa(dp12821
g10873
VInterleukin-16 (IL-16) is a cytokine that induces selective migration of CD4+ cells and participates in inflammatory diseases including allergic rhinitis.
p12822
sg4
(dp12823
(VCD4+
p12824
Vallergic rhinitis
p12825
tp12826
I00
ssg10879
(lp12827
(dp12828
g10882
I136
sg10883
g12825
sg10884
I17
sg10885
VC2607914
p12829
sg10887
I2
sasg10888
(lp12830
(dp12831
g10882
I16
sg10883
VIL-16
p12832
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12833
g10882
I0
sg10883
VInterleukin-16
p12834
sg10884
I14
sg10891
g190
sg10887
I1
sa(dp12835
g10882
I73
sg10883
g12824
sg10884
I4
sg10891
VP01730
p12836
sg10887
I1
sasa(dp12837
g10873
VThe results showed abnormally increased levels of IL-16 (294.4 +/- 15.24 pg/ml), serum eosinophils with absolute count (510.0 +/- 93.57, P&gt;0.05), and total serum IgE (287.9 +/- 61.22 IU/ml) using ELFA in patients of combined asthma and rhinitis, than in each of them alone.
p12838
sg4
(dp12839
(Vserum IgE
p12840
Vasthma
p12841
tp12842
I00
ssg10879
(lp12843
(dp12844
g10882
I239
sg10883
Vrhinitis
p12845
sg10884
I8
sg10885
VC0035455
p12846
sg10887
I1
sa(dp12847
g10882
I165
sg10883
VIgE
p12848
sg10884
I3
sg10885
VC0270850
p12849
sg10887
I1
sa(dp12850
g10882
I228
sg10883
g12841
sg10884
I6
sg10885
VC0004096
p12851
sg10887
I1
sasg10888
(lp12852
(dp12853
g10882
I159
sg10883
g12840
sg10884
I9
sg10891
VP01854
p12854
sg10887
I2
sa(dp12855
g10882
I50
sg10883
VIL-16
p12856
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp12857
g10873
VExpression of several genes associated with schizophrenia or autism including Sema3a, Trfr2 and Vldlr were found to be altered as were protein levels of Foxp2.
p12858
sg4
(dp12859
(VVldlr
p12860
Vautism
p12861
tp12862
I00
ssg10879
(lp12863
(dp12864
g10882
I44
sg10883
Vschizophrenia
p12865
sg10884
I13
sg10885
VC0036341
p12866
sg10887
I1
sa(dp12867
g10882
I61
sg10883
g12861
sg10884
I6
sg10885
VC0004352
p12868
sg10887
I1
sasg10888
(lp12869
(dp12870
g10882
I96
sg10883
g12860
sg10884
I5
sg10891
VP98155
p12871
sg10887
I1
sa(dp12872
g10882
I78
sg10883
VSema3a
p12873
sg10884
I6
sg10891
g190
sg10887
I1
sasa(dp12874
g10873
VAn increase in the ratio of Abeta(WT)/Abeta(MUT(Arctic)), therefore, may result in the accumulation of potential neurotoxic protofibrils and acceleration of disease progression in familial Alzheimer's disease mutation carriers.
p12875
sg4
(dp12876
(VMUT
p12877
Vfamilial Alzheimer's disease
p12878
tp12879
I01
ssg10879
(lp12880
(dp12881
g10882
I157
sg10883
Vdisease progression
p12882
sg10884
I19
sg10885
VC0242656
p12883
sg10887
I2
sa(dp12884
g10882
I180
sg10883
g12878
sg10884
I28
sg10885
VC0276496
p12885
sg10887
I3
sasg10888
(lp12886
(dp12887
g10882
I44
sg10883
g12877
sg10884
I3
sg10891
VP22033
p12888
sg10887
I1
sa(dp12889
g10882
I28
sg10883
VAbeta
p12890
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp12891
g10882
I28
sg10883
VAbeta
p12892
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp12893
g10873
VTo gain insight into the pathogenesis of these tumors we have analyzed the immunophenotype (ARID1A, MLH1, PMS2, MSH2, MSH6, p53, b-catenin, SMARCB1, synaptophysin, chromogranin A, and CD56) and mutational status (PTEN, KRAS, PIK3CA, TP53 and POLE) of 4 dedifferentiated endometrial carcinomas with strong and diffuse neuroendocrine expression.
p12894
sg4
(dp12895
(VKRAS
p12896
Vendometrial carcinomas
p12897
tp12898
I00
ssg10879
(lp12899
(dp12900
g10882
I270
sg10883
g12897
sg10884
I22
sg10885
VC0476089
p12901
sg10887
I2
sa(dp12902
g10882
I47
sg10883
Vtumors
p12903
sg10884
I6
sg10885
VC0027651
p12904
sg10887
I1
sa(dp12905
g10882
I25
sg10883
Vpathogenesis
p12906
sg10884
I12
sg10885
VC0699748
p12907
sg10887
I1
sasg10888
(lp12908
(dp12909
g10882
I140
sg10883
VSMARCB1
p12910
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp12911
g10882
I112
sg10883
VMSH2
p12912
sg10884
I4
sg10891
VP43246
p12913
sg10887
I1
sa(dp12914
g10882
I164
sg10883
Vchromogranin A
p12915
sg10884
I14
sg10891
VP10645
p12916
sg10887
I2
sa(dp12917
g10882
I149
sg10883
Vsynaptophysin
p12918
sg10884
I13
sg10891
VP08247
p12919
sg10887
I1
sa(dp12920
g10882
I100
sg10883
VMLH1
p12921
sg10884
I4
sg10891
VP40692
p12922
sg10887
I1
sa(dp12923
g10882
I124
sg10883
Vp53
p12924
sg10884
I3
sg10891
VP42771
p12925
sg10887
I1
sa(dp12926
g10882
I225
sg10883
VPIK3CA
p12927
sg10884
I6
sg10891
VP42336
p12928
sg10887
I1
sa(dp12929
g10882
I118
sg10883
VMSH6
p12930
sg10884
I4
sg10891
VP52701
p12931
sg10887
I1
sa(dp12932
g10882
I106
sg10883
VPMS2
p12933
sg10884
I4
sg10891
VP25054
p12934
sg10887
I1
sa(dp12935
g10882
I213
sg10883
VPTEN
p12936
sg10884
I4
sg10891
VP60484
p12937
sg10887
I1
sa(dp12938
g10882
I219
sg10883
g12896
sg10884
I4
sg10891
VP01116
p12939
sg10887
I1
sa(dp12940
g10882
I242
sg10883
VPOLE
p12941
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp12942
g10873
VWe recently identified 3 mutually exclusive mechanisms of switch/sucrose nonfermentable (SWI/SNF) complex inactivation (BRG1 inactivation, INI1 inactivation or ARID1A/ARID1B co-inactivation) that are associated with histologic dedifferentiation in the majority of dedifferentiated endometrial carcinoma.
p12943
sg4
(dp12944
(VBRG1
p12945
Vdedifferentiation
p12946
tp12947
I01
ssg10879
(lp12948
(dp12949
g10882
I106
sg10883
Vinactivation
p12950
sg10884
I12
sg10885
VC0544461
p12951
sg10887
I1
sa(dp12952
g10882
I281
sg10883
Vendometrial carcinoma
p12953
sg10884
I21
sg10885
VC0476089
p12954
sg10887
I2
sa(dp12955
g10882
I106
sg10883
Vinactivation
p12956
sg10884
I12
sg10885
VC0544461
p12957
sg10887
I1
sa(dp12958
g10882
I227
sg10883
g12946
sg10884
I17
sg10885
VC0002793
p12959
sg10887
I1
sa(dp12960
g10882
I106
sg10883
Vinactivation
p12961
sg10884
I12
sg10885
VC0544461
p12962
sg10887
I1
sa(dp12963
g10882
I106
sg10883
Vinactivation
p12964
sg10884
I12
sg10885
VC0544461
p12965
sg10887
I1
sasg10888
(lp12966
(dp12967
g10882
I89
sg10883
VSWI
p12968
sg10884
I3
sg10891
VP28370
p12969
sg10887
I1
sa(dp12970
g10882
I120
sg10883
g12945
sg10884
I4
sg10891
VP51532
p12971
sg10887
I1
sa(dp12972
g10882
I139
sg10883
VINI1
p12973
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp12974
g10882
I167
sg10883
VARID1B
p12975
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp12976
g10882
I93
sg10883
VSNF
p12977
sg10884
I3
sg10891
g190
sg10887
I1
sasa(dp12978
g10873
VThe current study aimed to evaluate serum levels of MFAP4 in patients with pulmonary fibrosis in order to test its potential as biomarker in clinical practice.
p12979
sg4
(dp12980
(VMFAP4
p12981
Vpulmonary fibrosis
p12982
tp12983
I00
ssg10879
(lp12984
(dp12985
g10882
I75
sg10883
g12982
sg10884
I18
sg10885
VC0034069
p12986
sg10887
I2
sasg10888
(lp12987
(dp12988
g10882
I52
sg10883
g12981
sg10884
I5
sg10891
VP55083
p12989
sg10887
I1
sasa(dp12990
g10873
VA further aim was to determine whether MFAP4 deficiency in mice affects the formation of pulmonary fibrosis in the bleomycin model of lung fibrosis.
p12991
sg4
(dp12992
(VMFAP4
p12993
Vlung fibrosis
p12994
tp12995
I00
ssg10879
(lp12996
(dp12997
g10882
I89
sg10883
Vpulmonary fibrosis
p12998
sg10884
I18
sg10885
VC0034069
p12999
sg10887
I2
sa(dp13000
g10882
I134
sg10883
g12994
sg10884
I13
sg10885
VC0034069
p13001
sg10887
I2
sasg10888
(lp13002
(dp13003
g10882
I39
sg10883
g12993
sg10884
I5
sg10891
VP55083
p13004
sg10887
I1
sasa(dp13005
g10873
VMFAP4 levels were increased in BAL of bleomycin treated mice with pulmonary fibrosis.
p13006
sg4
(dp13007
(VMFAP4
p13008
Vpulmonary fibrosis
p13009
tp13010
I00
ssg10879
(lp13011
(dp13012
g10882
I66
sg10883
g13009
sg10884
I18
sg10885
VC0034069
p13013
sg10887
I2
sasg10888
(lp13014
(dp13015
g10882
I0
sg10883
g13008
sg10884
I5
sg10891
VP55083
p13016
sg10887
I1
sasa(dp13017
g10873
VMFAP4 is not elevated in sera of patients with pulmonary fibrosis or bleomycin treated mice with pulmonary fibrosis.
p13018
sg4
(dp13019
(VMFAP4
p13020
Vpulmonary fibrosis
p13021
tp13022
I00
ssg10879
(lp13023
(dp13024
g10882
I47
sg10883
Vpulmonary fibrosis
p13025
sg10884
I18
sg10885
VC0034069
p13026
sg10887
I2
sa(dp13027
g10882
I47
sg10883
g13021
sg10884
I18
sg10885
VC0034069
p13028
sg10887
I2
sasg10888
(lp13029
(dp13030
g10882
I0
sg10883
g13020
sg10884
I5
sg10891
VP55083
p13031
sg10887
I1
sasa(dp13032
g10873
VThe aim of this study was to test the hypothesis that plasma MFAP4 (pMFAP4) reflects clinical outcomes in chronic obstructive pulmonary disease (COPD).
p13033
sg4
(dp13034
(VMFAP4
p13035
Vchronic obstructive pulmonary disease
p13036
tp13037
I01
ssg10879
(lp13038
(dp13039
g10882
I145
sg10883
VCOPD
p13040
sg10884
I4
sg10885
VC0024117
p13041
sg10887
I1
sa(dp13042
g10882
I106
sg10883
g13036
sg10884
I37
sg10885
VC0024117
p13043
sg10887
I4
sasg10888
(lp13044
(dp13045
g10882
I61
sg10883
g13035
sg10884
I5
sg10891
VP55083
p13046
sg10887
I1
sasa(dp13047
g10873
VFor essential thrombocythemia, reported risk factors for leukemic transformation include advanced age, extreme thrombocytosis, anemia, leukocytosis, and sequence variants/mutations involving TP53 and EZH2 (for expansion of gene symbols, see www.genenames.org); for polycythemia vera, advanced age, leukocytosis, abnormal karyotype, mutations involving SRSF2 and IDH2, and treatment with pipobroman, chlorambucil, or P32; and for PMF, increased blast percentage, thrombocytopenia, abnormal karyotype, triple-negative driver mutational status, and sequence variants/mutations involving SRSF2, RUNX1, CEBPA, and SH2B3.
p13048
sg4
(dp13049
(VIDH2
p13050
Vthrombocytosis
p13051
tp13052
I00
ssg10879
(lp13053
(dp13054
g10882
I265
sg10883
Vpolycythemia vera
p13055
sg10884
I17
sg10885
VC0032463
p13056
sg10887
I2
sa(dp13057
g10882
I4
sg10883
Vessential thrombocythemia
p13058
sg10884
I25
sg10885
VC0040028
p13059
sg10887
I2
sa(dp13060
g10882
I66
sg10883
Vtransformation
p13061
sg10884
I14
sg10885
VC1510411
p13062
sg10887
I1
sa(dp13063
g10882
I135
sg10883
Vleukocytosis
p13064
sg10884
I12
sg10885
VC0023518
p13065
sg10887
I1
sa(dp13066
g10882
I127
sg10883
Vanemia
p13067
sg10884
I6
sg10885
VC0002871
p13068
sg10887
I1
sa(dp13069
g10882
I135
sg10883
Vleukocytosis
p13070
sg10884
I12
sg10885
VC0023518
p13071
sg10887
I1
sa(dp13072
g10882
I111
sg10883
g13051
sg10884
I14
sg10885
VC0836924
p13073
sg10887
I1
sasg10888
(lp13074
(dp13075
g10882
I598
sg10883
VCEBPA
p13076
sg10884
I5
sg10891
VP49715
p13077
sg10887
I1
sa(dp13078
g10882
I200
sg10883
VEZH2
p13079
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp13080
g10882
I362
sg10883
g13050
sg10884
I4
sg10891
VP48735
p13081
sg10887
I1
sa(dp13082
g10882
I609
sg10883
VSH2B3
p13083
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp13084
g10873
VHistopathological examination (HPE) of excised gland showed multiple Hurthle cell adenomas in both lobes of thyroid along with foci of papillary thyroid carcinoma which on immunohistochemistry were thyroglobulin positive and PSA negative.
p13085
sg4
(dp13086
(VPSA
p13087
Vadenomas
p13088
tp13089
I00
ssg10879
(lp13090
(dp13091
g10882
I225
sg10883
VPSA
p13092
sg10884
I3
sg10885
VC1519176
p13093
sg10887
I1
sa(dp13094
g10882
I135
sg10883
Vpapillary thyroid carcinoma
p13095
sg10884
I27
sg10885
VC0238463
p13096
sg10887
I3
sa(dp13097
g10882
I82
sg10883
g13088
sg10884
I8
sg10885
VC0001430
p13098
sg10887
I1
sasg10888
(lp13099
(dp13100
g10882
I225
sg10883
g13087
sg10884
I3
sg10891
VP55786
p13101
sg10887
I1
sa(dp13102
g10882
I198
sg10883
Vthyroglobulin
p13103
sg10884
I13
sg10891
g190
sg10887
I1
sasa(dp13104
g10873
VAfter immunohistochemical characterization using a panel of chromogranin A, thyroglobulin, and calcitonin, 7 of the former thyroid neoplasms were diagnosed as thyroid adenomas, 1 was diagnosed as a thyroid carcinoma, and 4 were diagnosed as parathyroid adenomas.
p13105
sg4
(dp13106
(Vchromogranin A
p13107
Vadenomas
p13108
tp13109
I00
ssg10879
(lp13110
(dp13111
g10882
I123
sg10883
Vthyroid neoplasms
p13112
sg10884
I17
sg10885
VC0040136
p13113
sg10887
I2
sa(dp13114
g10882
I198
sg10883
Vthyroid carcinoma
p13115
sg10884
I17
sg10885
VC0549473
p13116
sg10887
I2
sa(dp13117
g10882
I241
sg10883
Vparathyroid adenomas
p13118
sg10884
I20
sg10885
VC0262587
p13119
sg10887
I2
sa(dp13120
g10882
I167
sg10883
g13108
sg10884
I8
sg10885
VC0001430
p13121
sg10887
I1
sasg10888
(lp13122
(dp13123
g10882
I95
sg10883
Vcalcitonin
p13124
sg10884
I10
sg10891
VP06881
p13125
sg10887
I1
sa(dp13126
g10882
I60
sg10883
g13107
sg10884
I14
sg10891
VP10645
p13127
sg10887
I2
sa(dp13128
g10882
I76
sg10883
Vthyroglobulin
p13129
sg10884
I13
sg10891
g190
sg10887
I1
sasa(dp13130
g10873
VFew of the substrates of Tankyrases are Telomeric Repeat binding Factor protein (TRF1), Axis Inhibitory protein (AXIN 1&amp;amp;2), Insulin Responsive Amino Peptidase (IRAP), Nuclear Mitotic Apparatus protein (NuMa), that become aberrantly active due to the apparent overexpression of the enzyme during hyper proliferative disease conditions like cancer, fibrosis and metabolic disorders like diabetes.
p13131
sg4
(dp13132
(VTRF1
p13133
Vdiabetes
p13134
tp13135
I00
ssg10879
(lp13136
(dp13137
g10882
I309
sg10883
Vproliferative
p13138
sg10884
I13
sg10885
VC0334094
p13139
sg10887
I1
sa(dp13140
g10882
I368
sg10883
Vmetabolic disorders
p13141
sg10884
I19
sg10885
VC0025517
p13142
sg10887
I2
sa(dp13143
g10882
I355
sg10883
Vfibrosis
p13144
sg10884
I8
sg10885
VC0016059
p13145
sg10887
I1
sa(dp13146
g10882
I393
sg10883
g13134
sg10884
I8
sg10885
VC0011849
p13147
sg10887
I1
sa(dp13148
g10882
I347
sg10883
Vcancer
p13149
sg10884
I6
sg10885
VC0006826
p13150
sg10887
I1
sasg10888
(lp13151
(dp13152
g10882
I168
sg10883
VIRAP
p13153
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp13154
g10882
I25
sg10883
VTankyrases
p13155
sg10884
I10
sg10891
g190
sg10887
I1
sa(dp13156
g10882
I132
sg10883
VInsulin Responsive Amino Peptidase
p13157
sg10884
I34
sg10891
g190
sg10887
I4
sa(dp13158
g10882
I40
sg10883
VTelomeric Repeat binding Factor protein
p13159
sg10884
I39
sg10891
VP54274
p13160
sg10887
I5
sa(dp13161
g10882
I-1
sg10883
VAXIN 1&2
p13162
sg10884
I8
sg10891
g190
sg10887
I2
sa(dp13163
g10882
I81
sg10883
g13133
sg10884
I4
sg10891
VP54274
p13164
sg10887
I1
sasa(dp13165
g10873
VSIN3B was required for PTEN-induced cellular senescence and prevented progression to invasive prostate adenocarcinoma.
p13166
sg4
(dp13167
(VPTEN
p13168
Vprostate adenocarcinoma
p13169
tp13170
I00
ssg10879
(lp13171
(dp13172
g10882
I94
sg10883
g13169
sg10884
I23
sg10885
VC0007112
p13173
sg10887
I2
sasg10888
(lp13174
(dp13175
g10882
I0
sg10883
VSIN3B
p13176
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp13177
g10882
I23
sg10883
g13168
sg10884
I4
sg10891
VP60484
p13178
sg10887
I1
sasa(dp13179
g10873
VFinally, by immunohistochemical staining of primary breast tissue microarrays we find that EMSY/KDM5A/SIN3B complex subunits are frequently overexpressed in primary breast cancer cases in a correlative manner.
p13180
sg4
(dp13181
(VKDM5A
p13182
Vbreast cancer
p13183
tp13184
I01
ssg10879
(lp13185
(dp13186
g10882
I165
sg10883
g13183
sg10884
I13
sg10885
VC0678222
p13187
sg10887
I2
sasg10888
(lp13188
(dp13189
g10882
I96
sg10883
g13182
sg10884
I5
sg10891
VP29375
p13190
sg10887
I1
sa(dp13191
g10882
I102
sg10883
VSIN3B
p13192
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp13193
g10882
I91
sg10883
VEMSY
p13194
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp13195
g10873
VHere, using a mouse model of pancreatic cancer, we have demonstrated that SIN3B is required for activated KRAS-induced senescence in vivo.
p13196
sg4
(dp13197
(VKRAS
p13198
Vpancreatic cancer
p13199
tp13200
I00
ssg10879
(lp13201
(dp13202
g10882
I29
sg10883
g13199
sg10884
I17
sg10885
VC0235974
p13203
sg10887
I2
sasg10888
(lp13204
(dp13205
g10882
I106
sg10883
g13198
sg10884
I4
sg10891
VP01116
p13206
sg10887
I1
sa(dp13207
g10882
I74
sg10883
VSIN3B
p13208
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp13209
g10873
VAmong proteins in the c-Myc/Max/Mad/Sin3 regulatory complex, Mad4 and Sin3B are routinely detected in human glioblastoma multiforme (GBM) cell lines.
p13210
sg4
(dp13211
(VMad
p13212
Vglioblastoma multiforme
p13213
tp13214
I00
ssg10879
(lp13215
(dp13216
g10882
I133
sg10883
VGBM
p13217
sg10884
I3
sg10885
VC1621958
p13218
sg10887
I1
sa(dp13219
g10882
I108
sg10883
g13213
sg10884
I23
sg10885
VC1621958
p13220
sg10887
I2
sasg10888
(lp13221
(dp13222
g10882
I36
sg10883
VSin3
p13223
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp13224
g10882
I61
sg10883
VMad4
p13225
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp13226
g10882
I22
sg10883
Vc-Myc
p13227
sg10884
I5
sg10891
VP12524
p13228
sg10887
I1
sa(dp13229
g10882
I70
sg10883
VSin3B
p13230
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp13231
g10882
I32
sg10883
g13212
sg10884
I3
sg10891
VP23109
p13232
sg10887
I1
sasa(dp13233
g10873
VUsing the Drosophila heart as a platform for identifying novel gene interactions leading to heart disease, we found that the Rho-GTPase Cdc42 cooperates with the cardiac transcription factor Tinman/Nkx2-5.
p13234
sg4
(dp13235
(Vcardiac transcription factor
p13236
Vheart disease
p13237
tp13238
I00
ssg10879
(lp13239
(dp13240
g10882
I92
sg10883
g13237
sg10884
I13
sg10885
VC0018799
p13241
sg10887
I2
sasg10888
(lp13242
(dp13243
g10882
I198
sg10883
VNkx2-5
p13244
sg10884
I6
sg10891
VP52952
p13245
sg10887
I1
sa(dp13246
g10882
I125
sg10883
VRho-GTPase
p13247
sg10884
I10
sg10891
VP08100
p13248
sg10887
I1
sa(dp13249
g10882
I136
sg10883
VCdc42
p13250
sg10884
I5
sg10891
VP60953
p13251
sg10887
I1
sa(dp13252
g10882
I162
sg10883
g13236
sg10884
I28
sg10891
VP35398
p13253
sg10887
I3
sasa(dp13254
g10873
VThe atypical E3 ubiquitin ligase RNF31 is highly expressed in human breast cancer, the most frequent neoplastic lethality among women.
p13255
sg4
(dp13256
(VE3 ubiquitin
p13257
Vbreast cancer
p13258
tp13259
I01
ssg10879
(lp13260
(dp13261
g10882
I68
sg10883
g13258
sg10884
I13
sg10885
VC0678222
p13262
sg10887
I2
sasg10888
(lp13263
(dp13264
g10882
I13
sg10883
g13257
sg10884
I12
sg10891
VP62979
p13265
sg10887
I2
sa(dp13266
g10882
I33
sg10883
VRNF31
p13267
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp13268
g10873
VBy examining the kinetics of pathway activation in TRAIL-sensitive lymphoma cells wild-type or deficient for RIP1, TRAF2, cIAP1/2 or HOIP, we report here that TRAIL induces two phases of JNK and NF-KB activation.
p13269
sg4
(dp13270
(VTRAIL
p13271
Vlymphoma
p13272
tp13273
I00
ssg10879
(lp13274
(dp13275
g10882
I67
sg10883
g13272
sg10884
I8
sg10885
VC0024299
p13276
sg10887
I1
sasg10888
(lp13277
(dp13278
g10882
I115
sg10883
VTRAF2
p13279
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp13280
g10882
I109
sg10883
VRIP1
p13281
sg10884
I4
sg10891
VP47985
p13282
sg10887
I1
sa(dp13283
g10882
I122
sg10883
VcIAP1/2
p13284
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp13285
g10882
I187
sg10883
VJNK
p13286
sg10884
I3
sg10891
VP53779
p13287
sg10887
I1
sa(dp13288
g10882
I51
sg10883
g13271
sg10884
I5
sg10891
VP50591
p13289
sg10887
I1
sasa(dp13290
g10873
VLiterature search included the terms adrenergic, noradrenergic, reuptake, inhibitors, analgesia, NET, norepinephrine transporter, and pain using Medline, Google scholar, Web of Knowledge, www.clinicaltrials.gov, and Pharmaprojects (Informa UK Ltd. 2012).
p13291
sg4
(dp13292
(Vnorepinephrine transporter
p13293
Vanalgesia
p13294
tp13295
I00
ssg10879
(lp13296
(dp13297
g10882
I170
sg10883
VWeb
p13298
sg10884
I3
sg10885
VC0332875
p13299
sg10887
I1
sa(dp13300
g10882
I86
sg10883
g13294
sg10884
I9
sg10885
VC0344307
p13301
sg10887
I1
sasg10888
(lp13302
(dp13303
g10882
I102
sg10883
g13293
sg10884
I26
sg10891
VP23975
p13304
sg10887
I2
sasa(dp13305
g10873
VTo identify mutation in SCNN1B and SCNN1G genes in an adolescent with suspicious Liddle syndrome and his family members and to explore the screening target subjects of Liddle syndrome.
p13306
sg4
(dp13307
(VSCNN1G genes
p13308
VLiddle syndrome
p13309
tp13310
I00
ssg10879
(lp13311
(dp13312
g10882
I81
sg10883
VLiddle syndrome
p13313
sg10884
I15
sg10885
VC0221043
p13314
sg10887
I2
sa(dp13315
g10882
I81
sg10883
g13309
sg10884
I15
sg10885
VC0221043
p13316
sg10887
I2
sasg10888
(lp13317
(dp13318
g10882
I24
sg10883
VSCNN1B
p13319
sg10884
I6
sg10891
VP51168
p13320
sg10887
I1
sa(dp13321
g10882
I35
sg10883
g13308
sg10884
I12
sg10891
VP51168
p13322
sg10887
I2
sasa(dp13323
g10873
VGenetic analysis of the C-terminus of SCNN1B and SCNN1G genes was conducted in an adolescent, with treatment-resistant hypertension and hypokalemia, who was suspected of having Liddle syndrome, and his family members.
p13324
sg4
(dp13325
(VSCNN1G genes
p13326
VLiddle syndrome
p13327
tp13328
I00
ssg10879
(lp13329
(dp13330
g10882
I119
sg10883
Vhypertension
p13331
sg10884
I12
sg10885
VC0020538
p13332
sg10887
I1
sa(dp13333
g10882
I177
sg10883
g13327
sg10884
I15
sg10885
VC0221043
p13334
sg10887
I2
sasg10888
(lp13335
(dp13336
g10882
I38
sg10883
VSCNN1B
p13337
sg10884
I6
sg10891
VP51168
p13338
sg10887
I1
sa(dp13339
g10882
I49
sg10883
g13326
sg10884
I12
sg10891
VP51168
p13340
sg10887
I2
sasa(dp13341
g10873
VIn adulthood, an induced nephron-specific deficiency of AlfaENaC (Scnn1a) resulted in pseudohypoaldosteronism type 1 (PHA-1) with sodium loss, hyperkalemia, and metabolic acidosis that is rescued through high-sodium/low-potassium (HNa+/LK+) diet.
p13342
sg4
(dp13343
(VScnn1a
p13344
Vmetabolic acidosis
p13345
tp13346
I01
ssg10879
(lp13347
(dp13348
g10882
I86
sg10883
Vpseudohypoaldosteronism type 1
p13349
sg10884
I30
sg10885
VC0268436
p13350
sg10887
I3
sa(dp13351
g10882
I118
sg10883
VPHA-1
p13352
sg10884
I5
sg10885
VC0268436
p13353
sg10887
I1
sa(dp13354
g10882
I161
sg10883
g13345
sg10884
I18
sg10885
VC0220981
p13355
sg10887
I2
sasg10888
(lp13356
(dp13357
g10882
I86
sg10883
Vpseudohypoaldosteronism type 1
p13358
sg10884
I30
sg10891
VP37088
p13359
sg10887
I3
sa(dp13360
g10882
I66
sg10883
g13344
sg10884
I6
sg10891
VP37088
p13361
sg10887
I1
sa(dp13362
g10882
I118
sg10883
VPHA-1
p13363
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp13364
g10873
VLiddle syndrome is an autosomal dominant genetic condition that causes hypertension and hypokalemia due to a gain-of-function mutation in the SCNN1B or SCNN1G genes which code for the epithelial sodium channel in the kidney.
p13365
sg4
(dp13366
(VSCNN1G genes
p13367
Vhypertension
p13368
tp13369
I00
ssg10879
(lp13370
(dp13371
g10882
I41
sg10883
Vgenetic condition
p13372
sg10884
I17
sg10885
VC0019247
p13373
sg10887
I2
sa(dp13374
g10882
I0
sg10883
VLiddle syndrome
p13375
sg10884
I15
sg10885
VC0221043
p13376
sg10887
I2
sa(dp13377
g10882
I71
sg10883
g13368
sg10884
I12
sg10885
VC0020538
p13378
sg10887
I1
sasg10888
(lp13379
(dp13380
g10882
I142
sg10883
VSCNN1B
p13381
sg10884
I6
sg10891
VP51168
p13382
sg10887
I1
sa(dp13383
g10882
I152
sg10883
g13367
sg10884
I12
sg10891
VP51168
p13384
sg10887
I2
sasa(dp13385
g10873
VLoss-of-function mutations of the MR are responsible for renal pseudohypoaldosteronism type 1 (PHA1), a rare disease of mineralocorticoid resistance presenting in the newborn with weight loss, failure to thrive, vomiting and dehydration, associated with hyperkalemia and metabolic acidosis, despite extremely elevated levels of plasma renin and aldosterone.
p13386
sg4
(dp13387
(VPHA1
p13388
Vdehydration
p13389
tp13390
I01
ssg10879
(lp13391
(dp13392
g10882
I212
sg10883
Vvomiting
p13393
sg10884
I8
sg10885
VC0042963
p13394
sg10887
I1
sa(dp13395
g10882
I104
sg10883
Vrare disease
p13396
sg10884
I12
sg10885
VC0678236
p13397
sg10887
I2
sa(dp13398
g10882
I271
sg10883
Vmetabolic acidosis
p13399
sg10884
I18
sg10885
VC0220981
p13400
sg10887
I2
sa(dp13401
g10882
I193
sg10883
Vfailure to thrive
p13402
sg10884
I17
sg10885
VC0015544
p13403
sg10887
I3
sa(dp13404
g10882
I95
sg10883
VPHA1
p13405
sg10884
I4
sg10885
VC0268436
p13406
sg10887
I1
sa(dp13407
g10882
I63
sg10883
Vpseudohypoaldosteronism type 1
p13408
sg10884
I30
sg10885
VC0268436
p13409
sg10887
I3
sa(dp13410
g10882
I225
sg10883
g13389
sg10884
I11
sg10885
VC0011175
p13411
sg10887
I1
sasg10888
(lp13412
(dp13413
g10882
I57
sg10883
Vrenal pseudohypoaldosteronism type 1
p13414
sg10884
I36
sg10891
VP37088
p13415
sg10887
I4
sa(dp13416
g10882
I328
sg10883
Vplasma renin
p13417
sg10884
I12
sg10891
VP00797
p13418
sg10887
I2
sa(dp13419
g10882
I95
sg10883
g13388
sg10884
I4
sg10891
VP37088
p13420
sg10887
I1
sasa(dp13421
g10873
VPseudohypoaldosteronism type 1 (PHA1) is a rare genetic disease characterized by resistance to aldosterone, and the renal form of PHA1 is associated with heterozygous inactivating mutations in NR3C2, which encodes mineralocorticoid receptor (MR).
p13422
sg4
(dp13423
(VPseudohypoaldosteronism type 1
p13424
VPseudohypoaldosteronism type 1
p13425
tp13426
I00
ssg10879
(lp13427
(dp13428
g10882
I32
sg10883
VPHA1
p13429
sg10884
I4
sg10885
VC0268436
p13430
sg10887
I1
sa(dp13431
g10882
I32
sg10883
VPHA1
p13432
sg10884
I4
sg10885
VC0268436
p13433
sg10887
I1
sa(dp13434
g10882
I0
sg10883
g13425
sg10884
I30
sg10885
VC0268436
p13435
sg10887
I3
sa(dp13436
g10882
I48
sg10883
Vgenetic disease
p13437
sg10884
I15
sg10885
VC0019247
p13438
sg10887
I2
sasg10888
(lp13439
(dp13440
g10882
I32
sg10883
VPHA1
p13441
sg10884
I4
sg10891
VP37088
p13442
sg10887
I1
sa(dp13443
g10882
I32
sg10883
VPHA1
p13444
sg10884
I4
sg10891
VP37088
p13445
sg10887
I1
sa(dp13446
g10882
I193
sg10883
VNR3C2
p13447
sg10884
I5
sg10891
VP08235
p13448
sg10887
I1
sa(dp13449
g10882
I0
sg10883
g13424
sg10884
I30
sg10891
VP37088
p13450
sg10887
I3
sasa(dp13451
g10873
VOur results unravel a functional link between CD81 and cholesterol during infection by malaria parasites, and illustrate that tetraspanin microdomains constitute a novel type of membrane microdomains that could be used by pathogens for infection.
p13452
sg4
(dp13453
(VCD81
p13454
Vmalaria
p13455
tp13456
I00
ssg10879
(lp13457
(dp13458
g10882
I87
sg10883
g13455
sg10884
I7
sg10885
VC0024530
p13459
sg10887
I1
sa(dp13460
g10882
I74
sg10883
Vinfection
p13461
sg10884
I9
sg10885
VC0009450
p13462
sg10887
I1
sa(dp13463
g10882
I74
sg10883
Vinfection
p13464
sg10884
I9
sg10885
VC0009450
p13465
sg10887
I1
sasg10888
(lp13466
(dp13467
g10882
I46
sg10883
g13454
sg10884
I4
sg10891
VP60033
p13468
sg10887
I1
sa(dp13469
g10882
I126
sg10883
Vtetraspanin microdomains
p13470
sg10884
I24
sg10891
g190
sg10887
I2
sasa(dp13471
g10873
VTaken together, the results indicated that sorafenib had protective effects against renal fibrosis; its mechanism of action was associated with inhibition of macrophage infiltration via the CXCR3/CXCL11 pathway.
p13472
sg4
(dp13473
(VCXCR3
p13474
Vrenal fibrosis
p13475
tp13476
I01
ssg10879
(lp13477
(dp13478
g10882
I169
sg10883
Vinfiltration
p13479
sg10884
I12
sg10885
VC0332448
p13480
sg10887
I1
sa(dp13481
g10882
I84
sg10883
g13475
sg10884
I14
sg10885
VC0151650
p13482
sg10887
I2
sasg10888
(lp13483
(dp13484
g10882
I190
sg10883
g13474
sg10884
I5
sg10891
VP49682
p13485
sg10887
I1
sa(dp13486
g10882
I196
sg10883
VCXCL11
p13487
sg10884
I6
sg10891
g190
sg10887
I1
sasa(dp13488
g10873
VUrinary mRNA levels of CXCL10 and CXCL11 are decreased, and those of collagen I A1 chain and fibronectin are increased in diabetic nephropathy.
p13489
sg4
(dp13490
(VCXCL10
p13491
Vdiabetic nephropathy
p13492
tp13493
I01
ssg10879
(lp13494
(dp13495
g10882
I122
sg10883
g13492
sg10884
I20
sg10885
VC0011881
p13496
sg10887
I2
sasg10888
(lp13497
(dp13498
g10882
I23
sg10883
g13491
sg10884
I6
sg10891
VP02778
p13499
sg10887
I1
sa(dp13500
g10882
I34
sg10883
VCXCL11
p13501
sg10884
I6
sg10891
g190
sg10887
I1
sasa(dp13502
g10873
VFor this purpose, serum concentration of interleukin 2 (IL2), interleukin 10 (IL10), interferon-gamma (IFNG), Toll-like receptor 2 (TLR2) and Toll-like receptor 9 (TLR9) were measured in blood samples obtained from F(2) piglets (n = 334) of a Duroc x Pietrain resource population (DUPI) after Mycoplasma hypopneumoniae (Mh), tetanus toxoid (TT) and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccination at 6, 9 and 15 weeks of age.
p13503
sg4
(dp13504
(Vinterleukin 10
p13505
VMycoplasma
p13506
tp13507
I00
ssg10879
(lp13508
(dp13509
g10882
I325
sg10883
Vtetanus
p13510
sg10884
I7
sg10885
VC0039614
p13511
sg10887
I1
sa(dp13512
g10882
I349
sg10883
VPorcine Reproductive and Respiratory Syndrome
p13513
sg10884
I45
sg10885
VC0376538
p13514
sg10887
I5
sa(dp13515
g10882
I293
sg10883
g13506
sg10884
I10
sg10885
VC0026936
p13516
sg10887
I1
sasg10888
(lp13517
(dp13518
g10882
I78
sg10883
VIL10
p13519
sg10884
I4
sg10891
VP22301
p13520
sg10887
I1
sa(dp13521
g10882
I164
sg10883
VTLR9
p13522
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp13523
g10882
I56
sg10883
VIL2
p13524
sg10884
I3
sg10891
VP60568
p13525
sg10887
I1
sa(dp13526
g10882
I142
sg10883
VToll-like receptor 9
p13527
sg10884
I20
sg10891
g190
sg10887
I3
sa(dp13528
g10882
I41
sg10883
Vinterleukin 2
p13529
sg10884
I13
sg10891
VP60568
p13530
sg10887
I2
sa(dp13531
g10882
I110
sg10883
VToll-like receptor 2
p13532
sg10884
I20
sg10891
g190
sg10887
I3
sa(dp13533
g10882
I132
sg10883
VTLR2
p13534
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp13535
g10882
I85
sg10883
Vinterferon-gamma
p13536
sg10884
I16
sg10891
VP01579
p13537
sg10887
I1
sa(dp13538
g10882
I103
sg10883
VIFNG
p13539
sg10884
I4
sg10891
VP01579
p13540
sg10887
I1
sa(dp13541
g10882
I62
sg10883
g13505
sg10884
I14
sg10891
VP22301
p13542
sg10887
I2
sasa(dp13543
g10873
VNot only TLR-2 gene polymorphisms but also immunoglobulins (IgG, IgM, IgA), IgG subsets (G1, G2, G3), and specific antibody levels (anti-tetanus and anti-hemophilus influenza) were determined to exclude humoral immunodeficiencies.
p13544
sg4
(dp13545
(VIgA
p13546
Vimmunodeficiencies
p13547
tp13548
I01
ssg10879
(lp13549
(dp13550
g10882
I165
sg10883
Vinfluenza
p13551
sg10884
I9
sg10885
VC0021400
p13552
sg10887
I1
sa(dp13553
g10882
I211
sg10883
g13547
sg10884
I18
sg10885
VC0021051
p13554
sg10887
I1
sa(dp13555
g10882
I137
sg10883
Vtetanus
p13556
sg10884
I7
sg10885
VC0039614
p13557
sg10887
I1
sasg10888
(lp13558
(dp13559
g10882
I65
sg10883
VIgM
p13560
sg10884
I3
sg10891
VP29965
p13561
sg10887
I1
sa(dp13562
g10882
I9
sg10883
VTLR-2 gene
p13563
sg10884
I10
sg10891
g190
sg10887
I2
sa(dp13564
g10882
I70
sg10883
g13546
sg10884
I3
sg10891
VP11912
p13565
sg10887
I1
sa(dp13566
g10882
I43
sg10883
Vimmunoglobulins
p13567
sg10884
I15
sg10891
g190
sg10887
I1
sasa(dp13568
g10873
VPeripheral blood monocyte surface marker (CD14, CD16, CD163, CSF1R, CCR2, CCR4, CCR5, CXCR3, CXCR4, CX3CR1, HLA-DR, CD62L, SIGLEC-1) expression and capacity for phagocytosis, oxidative burst and LPS-stimulated TNF production were assessed in patients with hepatitis C (HCV) (n = 39) or non-alcoholic fatty liver disease (NAFLD) (n = 34) (classified as non-advanced disease, compensated cirrhosis and decompensated cirrhosis) and healthy controls (n = 11) by flow cytometry.
p13569
sg4
(dp13570
(VCD14
p13571
Vnon-alcoholic fatty liver disease
p13572
tp13573
I01
ssg10879
(lp13574
(dp13575
g10882
I374
sg10883
Vcompensated cirrhosis
p13576
sg10884
I21
sg10885
VC1608426
p13577
sg10887
I2
sa(dp13578
g10882
I400
sg10883
Vdecompensated cirrhosis
p13579
sg10884
I23
sg10885
VC1619727
p13580
sg10887
I2
sa(dp13581
g10882
I321
sg10883
VNAFLD
p13582
sg10884
I5
sg10885
VC0400966
p13583
sg10887
I1
sa(dp13584
g10882
I195
sg10883
VLPS
p13585
sg10884
I3
sg10885
VC0175697
p13586
sg10887
I1
sa(dp13587
g10882
I256
sg10883
Vhepatitis C
p13588
sg10884
I11
sg10885
VC0019196
p13589
sg10887
I2
sa(dp13590
g10882
I286
sg10883
g13572
sg10884
I33
sg10885
VC0400966
p13591
sg10887
I4
sasg10888
(lp13592
(dp13593
g10882
I48
sg10883
VCD16
p13594
sg10884
I4
sg10891
VP08637
p13595
sg10887
I1
sa(dp13596
g10882
I100
sg10883
VCX3CR1
p13597
sg10884
I6
sg10891
VP78423
p13598
sg10887
I1
sa(dp13599
g10882
I80
sg10883
VCCR5
p13600
sg10884
I4
sg10891
VP32302
p13601
sg10887
I1
sa(dp13602
g10882
I74
sg10883
VCCR4
p13603
sg10884
I4
sg10891
VP51679
p13604
sg10887
I1
sa(dp13605
g10882
I86
sg10883
VCXCR3
p13606
sg10884
I5
sg10891
VP49682
p13607
sg10887
I1
sa(dp13608
g10882
I54
sg10883
VCD163
p13609
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp13610
g10882
I210
sg10883
VTNF
p13611
sg10884
I3
sg10891
VP01375
p13612
sg10887
I1
sa(dp13613
g10882
I61
sg10883
VCSF1R
p13614
sg10884
I5
sg10891
VP09619
p13615
sg10887
I1
sa(dp13616
g10882
I108
sg10883
VHLA-DR
p13617
sg10884
I6
sg10891
VP30486
p13618
sg10887
I1
sa(dp13619
g10882
I93
sg10883
VCXCR4
p13620
sg10884
I5
sg10891
VP61073
p13621
sg10887
I1
sa(dp13622
g10882
I123
sg10883
VSIGLEC-1
p13623
sg10884
I8
sg10891
g190
sg10887
I1
sa(dp13624
g10882
I116
sg10883
VCD62L
p13625
sg10884
I5
sg10891
VP14151
p13626
sg10887
I1
sa(dp13627
g10882
I68
sg10883
VCCR2
p13628
sg10884
I4
sg10891
VP41597
p13629
sg10887
I1
sa(dp13630
g10882
I42
sg10883
g13571
sg10884
I4
sg10891
VP08571
p13631
sg10887
I1
sasa(dp13632
g10873
VTo study the effect of B lymphocyte-induced mature protein-1(Blimp1) expression in bone marrow mononuclear cells on the prognosis of patients with multiple myeloma.
p13633
sg4
(dp13634
(Vmature protein-1
p13635
Vmultiple myeloma
p13636
tp13637
I00
ssg10879
(lp13638
(dp13639
g10882
I147
sg10883
g13636
sg10884
I16
sg10885
VC0026764
p13640
sg10887
I2
sasg10888
(lp13641
(dp13642
g10882
I61
sg10883
VBlimp1
p13643
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp13644
g10882
I44
sg10883
g13635
sg10884
I16
sg10891
VP17980
p13645
sg10887
I2
sasa(dp13646
g10873
VHere we further dissect the anti-myeloma mechanisms mediated by EZH2 inhibition and show that pharmacological inhibition of EZH2 reduces the expression of MM-associated oncogenes; IRF-4, XBP-1, PRDM1/BLIMP-1 and c-MYC.
p13647
sg4
(dp13648
(Vc-MYC
p13649
Vmyeloma
p13650
tp13651
I00
ssg10879
(lp13652
(dp13653
g10882
I33
sg10883
g13650
sg10884
I7
sg10885
VC0026764
p13654
sg10887
I1
sasg10888
(lp13655
(dp13656
g10882
I64
sg10883
VEZH2
p13657
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp13658
g10882
I187
sg10883
VXBP-1
p13659
sg10884
I5
sg10891
VP17861
p13660
sg10887
I1
sa(dp13661
g10882
I64
sg10883
VEZH2
p13662
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp13663
g10882
I194
sg10883
VPRDM1
p13664
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp13665
g10882
I212
sg10883
g13649
sg10884
I5
sg10891
VP12524
p13666
sg10887
I1
sa(dp13667
g10882
I200
sg10883
VBLIMP-1
p13668
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp13669
g10882
I180
sg10883
VIRF-4
p13670
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp13671
g10873
VTo investigate the expression level of B lymphocyte-induced maturation protein-1(Blimp-1) mRNA in bone marrow mononuclear cells(BMMNC) of multiple myeloma(MM) patients and its clinical significance.
p13672
sg4
(dp13673
(Vmaturation protein-1
p13674
Vmultiple myeloma
p13675
tp13676
I00
ssg10879
(lp13677
(dp13678
g10882
I138
sg10883
g13675
sg10884
I16
sg10885
VC0026764
p13679
sg10887
I2
sasg10888
(lp13680
(dp13681
g10882
I60
sg10883
g13674
sg10884
I20
sg10891
VP17980
p13682
sg10887
I2
sasa(dp13683
g10873
VMeanwhile, plasma could promote myeloma differentiation by up-regulating Blimp-1 and XBP-1 expression.
p13684
sg4
(dp13685
(VXBP-1
p13686
Vmyeloma
p13687
tp13688
I00
ssg10879
(lp13689
(dp13690
g10882
I32
sg10883
g13687
sg10884
I7
sg10885
VC0026764
p13691
sg10887
I1
sasg10888
(lp13692
(dp13693
g10882
I85
sg10883
g13686
sg10884
I5
sg10891
VP17861
p13694
sg10887
I1
sa(dp13695
g10882
I73
sg10883
VBlimp-1
p13696
sg10884
I7
sg10891
g190
sg10887
I1
sasa(dp13697
g10873
VMost IgAD and CVID patients in our clinic population in the Southeastern United States have inherited part or all of two extended MHC haplotypes, referred to as haplotype 1 (HLA-DQB1 0201, HLA-DR3, C4B-Sf, C4A-0, G1-15, Bf-0.4, C2-a, HSP-7.5, TNF alpha-5, HLA-B8, HLA-A1) and haplotype 2 (HLA-DQB1 0201, HLA-DR-7, C4B-S, C4A-L, G11-4.5, Bf-0.6, C2-b, HSP-9, TNF alpha-9, HLA-B44, HLA-A29).
p13698
sg4
(dp13699
(VG11-4.5
p13700
VCVID
p13701
tp13702
I00
ssg10879
(lp13703
(dp13704
g10882
I234
sg10883
VHSP
p13705
sg10884
I3
sg10885
VC0034152
p13706
sg10887
I1
sa(dp13707
g10882
I234
sg10883
VHSP
p13708
sg10884
I3
sg10885
VC0034152
p13709
sg10887
I1
sa(dp13710
g10882
I14
sg10883
g13701
sg10884
I4
sg10885
VC0009447
p13711
sg10887
I1
sasg10888
(lp13712
(dp13713
g10882
I371
sg10883
VHLA-B44
p13714
sg10884
I7
sg10891
VP30486
p13715
sg10887
I1
sa(dp13716
g10882
I243
sg10883
VTNF alpha-5
p13717
sg10884
I11
sg10891
VP01375
p13718
sg10887
I2
sa(dp13719
g10882
I351
sg10883
VHSP-9
p13720
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp13721
g10882
I358
sg10883
VTNF alpha-9
p13722
sg10884
I11
sg10891
VP01375
p13723
sg10887
I2
sa(dp13724
g10882
I174
sg10883
VHLA-DQB1 0201
p13725
sg10884
I13
sg10891
VP09471
p13726
sg10887
I2
sa(dp13727
g10882
I380
sg10883
VHLA-A29
p13728
sg10884
I7
sg10891
VP30486
p13729
sg10887
I1
sa(dp13730
g10882
I130
sg10883
VMHC haplotypes
p13731
sg10884
I14
sg10891
VP13747
p13732
sg10887
I2
sa(dp13733
g10882
I198
sg10883
VC4B
p13734
sg10884
I3
sg10891
VP04003
p13735
sg10887
I1
sa(dp13736
g10882
I189
sg10883
VHLA-DR3
p13737
sg10884
I7
sg10891
VP30486
p13738
sg10887
I1
sa(dp13739
g10882
I198
sg10883
VC4B-S
p13740
sg10884
I5
sg10891
VP04003
p13741
sg10887
I1
sa(dp13742
g10882
I234
sg10883
VHSP-7.5
p13743
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp13744
g10882
I304
sg10883
VHLA-DR-7
p13745
sg10884
I8
sg10891
VP30486
p13746
sg10887
I1
sa(dp13747
g10882
I256
sg10883
VHLA-B8
p13748
sg10884
I6
sg10891
VP30486
p13749
sg10887
I1
sa(dp13750
g10882
I174
sg10883
VHLA-DQB1 0201
p13751
sg10884
I13
sg10891
VP09471
p13752
sg10887
I2
sa(dp13753
g10882
I328
sg10883
g13700
sg10884
I7
sg10891
VP56715
p13754
sg10887
I1
sasa(dp13755
g10873
VIn search of a genetic linkage between the two immunodeficiencies, we examined the major histocompatibility complex (MHC) class III genes encoding complement components C2, C4A, and C4B and steroid 21-hydroxylase in addition to the HLA serotypes in individuals with either common variable immunodeficiency or IgA deficiency.
p13756
sg4
(dp13757
(Vsteroid 21-hydroxylase
p13758
VIgA deficiency
p13759
tp13760
I01
ssg10879
(lp13761
(dp13762
g10882
I47
sg10883
Vimmunodeficiencies
p13763
sg10884
I18
sg10885
VC0021051
p13764
sg10887
I1
sa(dp13765
g10882
I273
sg10883
Vcommon variable immunodeficiency
p13766
sg10884
I32
sg10885
VC0009447
p13767
sg10887
I3
sa(dp13768
g10882
I309
sg10883
g13759
sg10884
I14
sg10885
VC0162538
p13769
sg10887
I2
sasg10888
(lp13770
(dp13771
g10882
I232
sg10883
VHLA
p13772
sg10884
I3
sg10891
VP30486
p13773
sg10887
I1
sa(dp13774
g10882
I309
sg10883
VIgA
p13775
sg10884
I3
sg10891
VP11912
p13776
sg10887
I1
sa(dp13777
g10882
I182
sg10883
VC4B
p13778
sg10884
I3
sg10891
VP04003
p13779
sg10887
I1
sa(dp13780
g10882
I190
sg10883
g13758
sg10884
I22
sg10891
VP08686
p13781
sg10887
I2
sa(dp13782
g10882
I83
sg10883
Vmajor histocompatibility complex (MHC) class III genes encoding complement
p13783
sg10884
I74
sg10891
g190
sg10887
I9
sasa(dp13784
g10873
VTwelve of 19 patients with common variable immunodeficiency (63%, P less than 0.001) and 9 of 16 patients with IgA deficiency (56%, P less than 0.01) had rare C2 alleles and/or C4A and 21-hydroxylase A deletions, whereas these gene features were seen in only 5 of 34 healthy individuals (15%) in the control group.
p13785
sg4
(dp13786
(VIgA
p13787
VIgA deficiency
p13788
tp13789
I00
ssg10879
(lp13790
(dp13791
g10882
I27
sg10883
Vcommon variable immunodeficiency
p13792
sg10884
I32
sg10885
VC0009447
p13793
sg10887
I3
sa(dp13794
g10882
I111
sg10883
g13788
sg10884
I14
sg10885
VC0162538
p13795
sg10887
I2
sasg10888
(lp13796
(dp13797
g10882
I185
sg10883
V21-hydroxylase A
p13798
sg10884
I16
sg10891
VP08686
p13799
sg10887
I2
sa(dp13800
g10882
I111
sg10883
g13787
sg10884
I3
sg10891
VP11912
p13801
sg10887
I1
sasa(dp13802
g10873
VLiver sections from patients with biliary atresia were evaluated to detect antigen for the BECs marker 4 and cytokeratin-7 (CK-7), proteins (fibroblast-specific protein 1, also known S100A4; the collagen chaperone heat shock protein 47, HSP47) characteristically expressed by cells undergoing EMT, as well as myofibroblasts marker a-smooth muscle actin (a-SMA).
p13803
sg4
(dp13804
(VS100A4
p13805
VSMA
p13806
tp13807
I00
ssg10879
(lp13808
(dp13809
g10882
I34
sg10883
Vbiliary atresia
p13810
sg10884
I15
sg10885
VC0005411
p13811
sg10887
I2
sa(dp13812
g10882
I356
sg10883
g13806
sg10884
I3
sg10885
VC0026847
p13813
sg10887
I1
sasg10888
(lp13814
(dp13815
g10882
I124
sg10883
VCK-7), proteins (fibroblast-specific protein 1
p13816
sg10884
I46
sg10891
VP14222
p13817
sg10887
I5
sa(dp13818
g10882
I109
sg10883
Vcytokeratin-7
p13819
sg10884
I13
sg10891
VP08729
p13820
sg10887
I1
sa(dp13821
g10882
I237
sg10883
VHSP47
p13822
sg10884
I5
sg10891
VP50454
p13823
sg10887
I1
sa(dp13824
g10882
I195
sg10883
Vcollagen chaperone heat shock protein 47
p13825
sg10884
I40
sg10891
VP34931
p13826
sg10887
I6
sa(dp13827
g10882
I183
sg10883
g13805
sg10884
I6
sg10891
VP26447
p13828
sg10887
I1
sa(dp13829
g10882
I354
sg10883
Va-SMA
p13830
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp13831
g10882
I331
sg10883
Va-smooth muscle actin
p13832
sg10884
I21
sg10891
g190
sg10887
I3
sasa(dp13833
g10873
VHowever, BECs from biliary atresia resulted in increased expression of a-SMA, S100A4, with concurrent transition to a fibroblast-like morphology and decreased expression of AK-7.
p13834
sg4
(dp13835
(VS100A4
p13836
VSMA
p13837
tp13838
I00
ssg10879
(lp13839
(dp13840
g10882
I102
sg10883
Vtransition
p13841
sg10884
I10
sg10885
VC0599156
p13842
sg10887
I1
sa(dp13843
g10882
I19
sg10883
Vbiliary atresia
p13844
sg10884
I15
sg10885
VC0005411
p13845
sg10887
I2
sa(dp13846
g10882
I73
sg10883
g13837
sg10884
I3
sg10885
VC0026847
p13847
sg10887
I1
sasg10888
(lp13848
(dp13849
g10882
I173
sg10883
VAK-7
p13850
sg10884
I4
sg10891
VP55263
p13851
sg10887
I1
sa(dp13852
g10882
I78
sg10883
g13836
sg10884
I6
sg10891
VP26447
p13853
sg10887
I1
sa(dp13854
g10882
I73
sg10883
VSMA
p13855
sg10884
I3
sg10891
g190
sg10887
I1
sasa(dp13856
g10873
VConsequently, there has been considerable interest in the pharmaceutical industry to develop selective TPL-2 inhibitors as drugs for the treatment of TNF-dependent inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.
p13857
sg4
(dp13858
(VTPL-2
p13859
Vrheumatoid arthritis
p13860
tp13861
I00
ssg10879
(lp13862
(dp13863
g10882
I220
sg10883
Vinflammatory bowel disease
p13864
sg10884
I26
sg10885
VC0021390
p13865
sg10887
I3
sa(dp13866
g10882
I195
sg10883
g13860
sg10884
I20
sg10885
VC0003873
p13867
sg10887
I2
sasg10888
(lp13868
(dp13869
g10882
I150
sg10883
VTNF
p13870
sg10884
I3
sg10891
VP01375
p13871
sg10887
I1
sa(dp13872
g10882
I103
sg10883
g13859
sg10884
I5
sg10891
VP41279
p13873
sg10887
I1
sasa(dp13874
g10873
VThus, pharmacologic inhibition of Tpl2 should be a valid approach to therapeutic intervention in the pathogenesis of rheumatoid arthritis and other inflammatory diseases in humans.
p13875
sg4
(dp13876
(VTpl2
p13877
Vrheumatoid arthritis
p13878
tp13879
I00
ssg10879
(lp13880
(dp13881
g10882
I117
sg10883
g13878
sg10884
I20
sg10885
VC0003873
p13882
sg10887
I2
sa(dp13883
g10882
I101
sg10883
Vpathogenesis
p13884
sg10884
I12
sg10885
VC0699748
p13885
sg10887
I1
sasg10888
(lp13886
(dp13887
g10882
I34
sg10883
g13877
sg10884
I4
sg10891
VP41279
p13888
sg10887
I1
sasa(dp13889
g10873
VTaken together, our results show that inhibition of Tpl2 in primary human cell types can decrease the production of TNFalpha and other pro-inflammatory mediators during inflammatory events, and they further support the notion that Tpl2 is an appropriate therapeutic target for rheumatoid arthritis and other human inflammatory diseases.
p13890
sg4
(dp13891
(VTpl2
p13892
Vrheumatoid arthritis
p13893
tp13894
I00
ssg10879
(lp13895
(dp13896
g10882
I277
sg10883
g13893
sg10884
I20
sg10885
VC0003873
p13897
sg10887
I2
sasg10888
(lp13898
(dp13899
g10882
I116
sg10883
VTNFalpha
p13900
sg10884
I8
sg10891
VP01375
p13901
sg10887
I1
sa(dp13902
g10882
I52
sg10883
VTpl2
p13903
sg10884
I4
sg10891
VP41279
p13904
sg10887
I1
sa(dp13905
g10882
I52
sg10883
g13892
sg10884
I4
sg10891
VP41279
p13906
sg10887
I1
sasa(dp13907
g10873
VRecent studies using Tpl2 knockout mice have indicated an important role for Tpl2 in the lipopolysaccharide (LPS) induced production of tumor necrosis factor alpha (TNF-alpha) and other proinflammatory cytokines involved in diseases such as rheumatoid arthritis.
p13908
sg4
(dp13909
(VTNF-alpha
p13910
Vrheumatoid arthritis
p13911
tp13912
I00
ssg10879
(lp13913
(dp13914
g10882
I136
sg10883
Vtumor necrosis
p13915
sg10884
I14
sg10885
VC0333516
p13916
sg10887
I2
sa(dp13917
g10882
I89
sg10883
Vlipopolysaccharide
p13918
sg10884
I18
sg10885
VC0175697
p13919
sg10887
I1
sa(dp13920
g10882
I109
sg10883
VLPS
p13921
sg10884
I3
sg10885
VC0175697
p13922
sg10887
I1
sa(dp13923
g10882
I241
sg10883
g13911
sg10884
I20
sg10885
VC0003873
p13924
sg10887
I2
sasg10888
(lp13925
(dp13926
g10882
I136
sg10883
Vtumor necrosis factor alpha
p13927
sg10884
I27
sg10891
VP01375
p13928
sg10887
I4
sa(dp13929
g10882
I21
sg10883
VTpl2
p13930
sg10884
I4
sg10891
VP41279
p13931
sg10887
I1
sa(dp13932
g10882
I21
sg10883
VTpl2
p13933
sg10884
I4
sg10891
VP41279
p13934
sg10887
I1
sa(dp13935
g10882
I165
sg10883
g13910
sg10884
I9
sg10891
VP01375
p13936
sg10887
I1
sasa(dp13937
g10873
VTarget genes (e.g., cyclin-dependent kinase 6) of hsa-miR-942-5p were mainly enriched in cancer-related pathways, whereas target genes (e.g., CRK-Like Proto-Oncogene, Adaptor Protein) of hsa-miR-940 were enriched in the ErbB signaling pathway.
p13938
sg4
(dp13939
(VCRK-Like Proto-Oncogene, Adaptor Protein
p13940
Vhsa
p13941
tp13942
I00
ssg10879
(lp13943
(dp13944
g10882
I89
sg10883
Vcancer
p13945
sg10884
I6
sg10885
VC0006826
p13946
sg10887
I1
sa(dp13947
g10882
I50
sg10883
Vhsa
p13948
sg10884
I3
sg10885
VC0393754
p13949
sg10887
I1
sa(dp13950
g10882
I50
sg10883
g13941
sg10884
I3
sg10885
VC0393754
p13951
sg10887
I1
sasg10888
(lp13952
(dp13953
g10882
I142
sg10883
g13940
sg10884
I40
sg10891
VP46108
p13954
sg10887
I4
sa(dp13955
g10882
I187
sg10883
Vhsa-miR-940
p13956
sg10884
I11
sg10891
g190
sg10887
I1
sa(dp13957
g10882
I50
sg10883
Vhsa-miR-942-5p
p13958
sg10884
I14
sg10891
g190
sg10887
I1
sa(dp13959
g10882
I220
sg10883
VErbB
p13960
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp13961
g10882
I20
sg10883
Vcyclin-dependent kinase 6
p13962
sg10884
I25
sg10891
g190
sg10887
I3
sasa(dp13963
g10873
Vp27 and PTEN were evidenced as direct targets for miR-940 and inhibition of p27 and PTEN recovered the suppressive function of miR-940-silenced cell towards to proliferation and tumorigenicity in cervical cancer cells.
p13964
sg4
(dp13965
(VPTEN
p13966
Vcervical cancer
p13967
tp13968
I00
ssg10879
(lp13969
(dp13970
g10882
I196
sg10883
g13967
sg10884
I15
sg10885
VC0302592
p13971
sg10887
I2
sa(dp13972
g10882
I160
sg10883
Vproliferation
p13973
sg10884
I13
sg10885
VC0334094
p13974
sg10887
I1
sa(dp13975
g10882
I178
sg10883
Vtumorigenicity
p13976
sg10884
I14
sg10885
VC1519697
p13977
sg10887
I1
sasg10888
(lp13978
(dp13979
g10882
I0
sg10883
Vp27
p13980
sg10884
I3
sg10891
VP40305
p13981
sg10887
I1
sa(dp13982
g10882
I8
sg10883
VPTEN
p13983
sg10884
I4
sg10891
VP60484
p13984
sg10887
I1
sa(dp13985
g10882
I0
sg10883
Vp27
p13986
sg10884
I3
sg10891
VP40305
p13987
sg10887
I1
sa(dp13988
g10882
I8
sg10883
g13966
sg10884
I4
sg10891
VP60484
p13989
sg10887
I1
sasa(dp13990
g10873
VIn addition, miR-940 expression was inversely associated with p27 and PTEN expression levels and actively with cyclin D1 in cervical cancer specimens.
p13991
sg4
(dp13992
(VPTEN
p13993
Vcervical cancer
p13994
tp13995
I00
ssg10879
(lp13996
(dp13997
g10882
I124
sg10883
g13994
sg10884
I15
sg10885
VC0302592
p13998
sg10887
I2
sasg10888
(lp13999
(dp14000
g10882
I111
sg10883
Vcyclin D1
p14001
sg10884
I9
sg10891
VP24385
p14002
sg10887
I2
sa(dp14003
g10882
I62
sg10883
Vp27
p14004
sg10884
I3
sg10891
VP40305
p14005
sg10887
I1
sa(dp14006
g10882
I70
sg10883
g13993
sg10884
I4
sg10891
VP60484
p14007
sg10887
I1
sasa(dp14008
g10873
VThe results from our study demonstrated that miR-940 regulated p27 and PTEN post-transcriptionally and might play a significant role in cervical cancer development and progression.
p14009
sg4
(dp14010
(Vp27
p14011
Vcervical cancer
p14012
tp14013
I01
ssg10879
(lp14014
(dp14015
g10882
I136
sg10883
g14012
sg10884
I15
sg10885
VC0302592
p14016
sg10887
I2
sasg10888
(lp14017
(dp14018
g10882
I45
sg10883
VmiR-940
p14019
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp14020
g10882
I71
sg10883
VPTEN
p14021
sg10884
I4
sg10891
VP60484
p14022
sg10887
I1
sa(dp14023
g10882
I63
sg10883
g14011
sg10884
I3
sg10891
VP40305
p14024
sg10887
I1
sasa(dp14025
g10873
VOvarian cancer OVCAR3 cells were transfected with the miR-940 vector, miR-940 inhibitor, and/or small interfering RNA (siRNA) targeting PKC-Delta (si-PKC-Delta), respectively.
p14026
sg4
(dp14027
(VPKC-Delta
p14028
VPKC
p14029
tp14030
I00
ssg10879
(lp14031
(dp14032
g10882
I0
sg10883
VOvarian cancer
p14033
sg10884
I14
sg10885
VC1140680
p14034
sg10887
I2
sa(dp14035
g10882
I136
sg10883
VPKC
p14036
sg10884
I3
sg10885
VC1868682
p14037
sg10887
I1
sa(dp14038
g10882
I136
sg10883
g14029
sg10884
I3
sg10885
VC1868682
p14039
sg10887
I1
sasg10888
(lp14040
(dp14041
g10882
I147
sg10883
Vsi-PKC-Delta
p14042
sg10884
I12
sg10891
VP17252
p14043
sg10887
I1
sa(dp14044
g10882
I136
sg10883
g14028
sg10884
I9
sg10891
VP17252
p14045
sg10887
I1
sasa(dp14046
g10873
VTaken together, the results of our study suggest that upregulation of miR-940 may function as a suppressor in the progression of ovarian cancer by inhibiting cell proliferation and inducing apoptosis by targeting PKC-Delta.
p14047
sg4
(dp14048
(VPKC-Delta
p14049
VPKC
p14050
tp14051
I00
ssg10879
(lp14052
(dp14053
g10882
I129
sg10883
Vovarian cancer
p14054
sg10884
I14
sg10885
VC1140680
p14055
sg10887
I2
sa(dp14056
g10882
I213
sg10883
g14050
sg10884
I3
sg10885
VC1868682
p14057
sg10887
I1
sa(dp14058
g10882
I163
sg10883
Vproliferation
p14059
sg10884
I13
sg10885
VC0334094
p14060
sg10887
I1
sasg10888
(lp14061
(dp14062
g10882
I213
sg10883
g14049
sg10884
I9
sg10891
VP17252
p14063
sg10887
I1
sa(dp14064
g10882
I70
sg10883
VmiR-940
p14065
sg10884
I7
sg10891
g190
sg10887
I1
sasa(dp14066
g10873
VGene variants known to contribute to Autoimmune Addison's disease (AAD) susceptibility include those at the MHC, MICA, CIITA, CTLA4, PTPN22, CYP27B1, NLRP-1 and CD274 loci.
p14067
sg4
(dp14068
(VCIITA
p14069
VAutoimmune Addison's disease
p14070
tp14071
I01
ssg10879
(lp14072
(dp14073
g10882
I67
sg10883
VAAD
p14074
sg10884
I3
sg10885
VC0271737
p14075
sg10887
I1
sa(dp14076
g10882
I37
sg10883
g14070
sg10884
I28
sg10885
VC0271737
p14077
sg10887
I3
sa(dp14078
g10882
I113
sg10883
VMICA
p14079
sg10884
I4
sg10885
VC0700319
p14080
sg10887
I1
sasg10888
(lp14081
(dp14082
g10882
I108
sg10883
VMHC
p14083
sg10884
I3
sg10891
VP13747
p14084
sg10887
I1
sa(dp14085
g10882
I161
sg10883
VCD274 loci
p14086
sg10884
I10
sg10891
g190
sg10887
I2
sa(dp14087
g10882
I126
sg10883
VCTLA4
p14088
sg10884
I5
sg10891
VP16410
p14089
sg10887
I1
sa(dp14090
g10882
I141
sg10883
VCYP27B1
p14091
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp14092
g10882
I150
sg10883
VNLRP-1
p14093
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp14094
g10882
I119
sg10883
g14069
sg10884
I5
sg10891
VP33076
p14095
sg10887
I1
sa(dp14096
g10882
I133
sg10883
VPTPN22
p14097
sg10884
I6
sg10891
g190
sg10887
I1
sasa(dp14098
g10873
VThe most frequent acupoints of acupuncture for PCOS were Sanyinjiao (SP 6), Guanyuan (CV 4), Zigong (EX-CA 1), Zhongji (CV 3) and Qihai (CV 6).
p14099
sg4
(dp14100
(VEX-CA 1
p14101
VPCOS
p14102
tp14103
I00
ssg10879
(lp14104
(dp14105
g10882
I47
sg10883
g14102
sg10884
I4
sg10885
VC0032460
p14106
sg10887
I1
sasg10888
(lp14107
(dp14108
g10882
I101
sg10883
g14101
sg10884
I7
sg10891
VP00915
p14109
sg10887
I2
sasa(dp14110
g10873
VIn the modern treatment of acupuncture for PCOS, Sanyinjiao (SP 6), Guanyuan (CV 4), Zigong (EX-CA 1), Zhongii (CV 3) and Qihai (CV 6) are most used.
p14111
sg4
(dp14112
(VEX-CA 1
p14113
VPCOS
p14114
tp14115
I00
ssg10879
(lp14116
(dp14117
g10882
I43
sg10883
g14114
sg10884
I4
sg10885
VC0032460
p14118
sg10887
I1
sasg10888
(lp14119
(dp14120
g10882
I93
sg10883
g14113
sg10884
I7
sg10891
VP00915
p14121
sg10887
I2
sasa(dp14122
g10873
VCarbonic anhydrase II (CA II) has an important role in thyroid hormone synthesis via regulating iodide (I-) transport across thyroidal cell membranes and the existence of autoantibodies against CA I and/or CA II have been shown in sera from patient with various autoimmune diseases such as Sjoegren's Syndrome, Systemic Lupus Erythmatosus, type 1 diabetes, primary biliary cirrhosis and ulcerative colitis.
p14123
sg4
(dp14124
(VCA II
p14125
Vprimary biliary cirrhosis
p14126
tp14127
I00
ssg10879
(lp14128
(dp14129
g10882
I340
sg10883
Vtype 1 diabetes
p14130
sg10884
I15
sg10885
VC0011854
p14131
sg10887
I3
sa(dp14132
g10882
I387
sg10883
Vulcerative colitis
p14133
sg10884
I18
sg10885
VC0009324
p14134
sg10887
I2
sa(dp14135
g10882
I320
sg10883
VLupus
p14136
sg10884
I5
sg10885
VC0024131
p14137
sg10887
I1
sa(dp14138
g10882
I290
sg10883
VSjoegren's Syndrome
p14139
sg10884
I19
sg10885
VC1527336
p14140
sg10887
I2
sa(dp14141
g10882
I262
sg10883
Vautoimmune diseases
p14142
sg10884
I19
sg10885
VC0004364
p14143
sg10887
I2
sa(dp14144
g10882
I357
sg10883
g14126
sg10884
I25
sg10885
VC0008312
p14145
sg10887
I3
sasg10888
(lp14146
(dp14147
g10882
I23
sg10883
VCA I
p14148
sg10884
I4
sg10891
VP00915
p14149
sg10887
I2
sa(dp14150
g10882
I0
sg10883
VCarbonic anhydrase II
p14151
sg10884
I21
sg10891
VP00918
p14152
sg10887
I3
sa(dp14153
g10882
I23
sg10883
VCA II
p14154
sg10884
I5
sg10891
VP00918
p14155
sg10887
I2
sa(dp14156
g10882
I23
sg10883
g14125
sg10884
I5
sg10891
VP00918
p14157
sg10887
I2
sasa(dp14158
g10873
VEfforts to inhibit the chemokine receptor CCR9 using the agent CCX282-B in Crohn's disease were not successful.
p14159
sg4
(dp14160
(Vchemokine receptor CCR9
p14161
VCrohn's disease
p14162
tp14163
I01
ssg10879
(lp14164
(dp14165
g10882
I75
sg10883
g14162
sg10884
I15
sg10885
VC0010346
p14166
sg10887
I2
sasg10888
(lp14167
(dp14168
g10882
I23
sg10883
g14161
sg10884
I23
sg10891
VP51686
p14169
sg10887
I3
sasa(dp14170
g10873
VOther therapeuticals that might find their way to the market the coming years include the anti-mucosal vascular addressin cell adhesion molecule (MAdCAM) PF-00547659, small molecules (including laquinimod and the CCR9 antagonist Vercirnon), as well as an orally active SMAD7 antisense oligonucleotide that showed clinical benefit in Crohn's disease patients.
p14171
sg4
(dp14172
(VCCR9
p14173
VCrohn's disease
p14174
tp14175
I01
ssg10879
(lp14176
(dp14177
g10882
I127
sg10883
Vadhesion
p14178
sg10884
I8
sg10885
VC0001511
p14179
sg10887
I1
sa(dp14180
g10882
I333
sg10883
g14174
sg10884
I15
sg10885
VC0010346
p14181
sg10887
I2
sasg10888
(lp14182
(dp14183
g10882
I112
sg10883
Vaddressin cell adhesion molecule
p14184
sg10884
I32
sg10891
g190
sg10887
I4
sa(dp14185
g10882
I213
sg10883
g14173
sg10884
I4
sg10891
VP51686
p14186
sg10887
I1
sa(dp14187
g10882
I269
sg10883
VSMAD7 antisense oligonucleotide
p14188
sg10884
I31
sg10891
g190
sg10887
I3
sasa(dp14189
g10873
VThe chemokine CCL25, and its receptor CCR9, constitute a unique chemokine/receptor pair, which regulates trafficking of T lymphocytes to the small intestine under physiological conditions and is an attractive target for small bowel Crohn's disease drug development.
p14190
sg4
(dp14191
(VCCR9
p14192
VCrohn's disease
p14193
tp14194
I01
ssg10879
(lp14195
(dp14196
g10882
I232
sg10883
g14193
sg10884
I15
sg10885
VC0010346
p14197
sg10887
I2
sasg10888
(lp14198
(dp14199
g10882
I14
sg10883
VCCL25
p14200
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp14201
g10882
I38
sg10883
g14192
sg10884
I4
sg10891
VP51686
p14202
sg10887
I1
sasa(dp14203
g10873
VVercirnon is a CCR9 chemokine receptor antagonist being developed for the treatment of Crohn's disease.
p14204
sg4
(dp14205
(VCCR9 chemokine receptor
p14206
VCrohn's disease
p14207
tp14208
I01
ssg10879
(lp14209
(dp14210
g10882
I87
sg10883
g14207
sg10884
I15
sg10885
VC0010346
p14211
sg10887
I2
sasg10888
(lp14212
(dp14213
g10882
I15
sg10883
g14206
sg10884
I23
sg10891
VP51686
p14214
sg10887
I3
sasa(dp14215
g10873
VIt is well established that the passive trans-placental passage of anti-Ro/SSA antibodies from mother to foetus is associated with the risk to develop an uncommon syndrome named neonatal lupus (NLE), where the congenital heart block represents the most severe clinical feature.
p14216
sg4
(dp14217
(Vanti-Ro/SSA antibodies
p14218
Vcongenital heart block
p14219
tp14220
I00
ssg10879
(lp14221
(dp14222
g10882
I178
sg10883
Vneonatal lupus
p14223
sg10884
I14
sg10885
VC0409979
p14224
sg10887
I2
sa(dp14225
g10882
I210
sg10883
g14219
sg10884
I22
sg10885
VC0149530
p14226
sg10887
I3
sa(dp14227
g10882
I163
sg10883
Vsyndrome
p14228
sg10884
I8
sg10885
VC0039082
p14229
sg10887
I1
sasg10888
(lp14230
(dp14231
g10882
I67
sg10883
g14218
sg10884
I22
sg10891
VP19474
p14232
sg10887
I2
sasa(dp14233
g10873
VSera from patients known to frequently produce precipitating anti-SS-A/Ro antibody (subacute cutaneous lupus erythematosus [SCLE], 56 patients; Sjoegren's syndrome [SS], 41 patients; mothers of infants with neonatal LE [NLE], 10 individuals; infants with congenital heart block [CHB], 5 patients) were tested for reactivity to RoSP7-24 in ELISA.
p14234
sg4
(dp14235
(Vanti-SS-A/Ro antibody
p14236
Vsubacute cutaneous lupus erythematosus
p14237
tp14238
I00
ssg10879
(lp14239
(dp14240
g10882
I279
sg10883
VCHB
p14241
sg10884
I3
sg10885
VC0151517
p14242
sg10887
I1
sa(dp14243
g10882
I144
sg10883
VSjoegren's syndrome
p14244
sg10884
I19
sg10885
VC1527336
p14245
sg10887
I2
sa(dp14246
g10882
I255
sg10883
Vcongenital heart block
p14247
sg10884
I22
sg10885
VC0149530
p14248
sg10887
I3
sa(dp14249
g10882
I84
sg10883
g14237
sg10884
I38
sg10885
VC0024140
p14250
sg10887
I4
sasg10888
(lp14251
(dp14252
g10882
I61
sg10883
g14236
sg10884
I21
sg10891
VP37268
p14253
sg10887
I2
sasa(dp14254
g10873
VOur findings also suggested that the inhibitory effects of AC-93253 iodide on lung cancer progression may be attributable to its ability to modulate multiple proteins, including Src, PI3K, JNK, Paxillin, p130cas, MEK, ERK, and EGFR.
p14255
sg4
(dp14256
(VMEK
p14257
Vcancer progression
p14258
tp14259
I00
ssg10879
(lp14260
(dp14261
g10882
I83
sg10883
g14258
sg10884
I18
sg10885
VC0178874
p14262
sg10887
I2
sasg10888
(lp14263
(dp14264
g10882
I178
sg10883
VSrc
p14265
sg10884
I3
sg10891
VP12931
p14266
sg10887
I1
sa(dp14267
g10882
I204
sg10883
Vp130cas
p14268
sg10884
I7
sg10891
VP56945
p14269
sg10887
I1
sa(dp14270
g10882
I183
sg10883
VPI3K
p14271
sg10884
I4
sg10891
VP42336
p14272
sg10887
I1
sa(dp14273
g10882
I189
sg10883
VJNK
p14274
sg10884
I3
sg10891
VP53779
p14275
sg10887
I1
sa(dp14276
g10882
I218
sg10883
VERK
p14277
sg10884
I3
sg10891
VP29323
p14278
sg10887
I1
sa(dp14279
g10882
I194
sg10883
VPaxillin
p14280
sg10884
I8
sg10891
VP49023
p14281
sg10887
I1
sa(dp14282
g10882
I213
sg10883
g14257
sg10884
I3
sg10891
VP45985
p14283
sg10887
I1
sasa(dp14284
g10873
VPaxillin and FAK activity are reduced in lung cancer cell lines following wiskostatin and nWASP knockdown as shown by immunofluorescence and western blot.
p14285
sg4
(dp14286
(VPaxillin
p14287
Vlung cancer
p14288
tp14289
I00
ssg10879
(lp14290
(dp14291
g10882
I41
sg10883
g14288
sg10884
I11
sg10885
VC0684249
p14292
sg10887
I2
sasg10888
(lp14293
(dp14294
g10882
I13
sg10883
VFAK
p14295
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp14296
g10882
I90
sg10883
VnWASP
p14297
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp14298
g10882
I0
sg10883
g14287
sg10884
I8
sg10891
VP49023
p14299
sg10887
I1
sasa(dp14300
g10873
VTaken together, these results suggested that treatment with DBL may act as a potential candidate to inhibit lung cancer metastasis by inhibiting MMP-2 and -9 via affecting PI3K/AKT, MAPKs, FAK/paxillin, EMT/Snail and Slug, Nrf2/antioxidant enzymes, and NFKB signaling pathways.
p14301
sg4
(dp14302
(Vpaxillin
p14303
Vmetastasis
p14304
tp14305
I00
ssg10879
(lp14306
(dp14307
g10882
I108
sg10883
Vlung cancer
p14308
sg10884
I11
sg10885
VC0684249
p14309
sg10887
I2
sa(dp14310
g10882
I120
sg10883
g14304
sg10884
I10
sg10885
VC0027627
p14311
sg10887
I1
sasg10888
(lp14312
(dp14313
g10882
I189
sg10883
VFAK
p14314
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp14315
g10882
I145
sg10883
VMMP-2
p14316
sg10884
I5
sg10891
VP08253
p14317
sg10887
I1
sa(dp14318
g10882
I217
sg10883
VSlug
p14319
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp14320
g10882
I177
sg10883
VAKT
p14321
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp14322
g10882
I203
sg10883
VEMT
p14323
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp14324
g10882
I172
sg10883
VPI3K
p14325
sg10884
I4
sg10891
VP42336
p14326
sg10887
I1
sa(dp14327
g10882
I223
sg10883
VNrf2
p14328
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp14329
g10882
I253
sg10883
VNFKB
p14330
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp14331
g10882
I182
sg10883
VMAPKs
p14332
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp14333
g10882
I207
sg10883
VSnail
p14334
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp14335
g10882
I193
sg10883
g14303
sg10884
I8
sg10891
VP49023
p14336
sg10887
I1
sasa(dp14337
g10873
VEL decreased phosphorylation of FAK and its downstream targets, Src, paxillin, and decreased mRNA expression of cell motility-related genes, RhoA, Rac1, and Cdc42 in lung cancer cells.
p14338
sg4
(dp14339
(Vpaxillin
p14340
Vlung cancer
p14341
tp14342
I00
ssg10879
(lp14343
(dp14344
g10882
I166
sg10883
g14341
sg10884
I11
sg10885
VC0684249
p14345
sg10887
I2
sasg10888
(lp14346
(dp14347
g10882
I147
sg10883
VRac1
p14348
sg10884
I4
sg10891
VP63000
p14349
sg10887
I1
sa(dp14350
g10882
I141
sg10883
VRhoA
p14351
sg10884
I4
sg10891
VP61586
p14352
sg10887
I1
sa(dp14353
g10882
I32
sg10883
VFAK
p14354
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp14355
g10882
I64
sg10883
VSrc
p14356
sg10884
I3
sg10891
VP12931
p14357
sg10887
I1
sa(dp14358
g10882
I157
sg10883
VCdc42
p14359
sg10884
I5
sg10891
VP60953
p14360
sg10887
I1
sa(dp14361
g10882
I69
sg10883
g14340
sg10884
I8
sg10891
VP49023
p14362
sg10887
I1
sasa(dp14363
g10873
VIt efficiently inhibits metastasis on NSCLC by reducing vascularization, and eliciting depression of the PI3K-AKT and FAK-Paxillin signaling pathways.
p14364
sg4
(dp14365
(VPI3K
p14366
Vvascularization
p14367
tp14368
I00
ssg10879
(lp14369
(dp14370
g10882
I38
sg10883
VNSCLC
p14371
sg10884
I5
sg10885
VC0007131
p14372
sg10887
I1
sa(dp14373
g10882
I24
sg10883
Vmetastasis
p14374
sg10884
I10
sg10885
VC0027627
p14375
sg10887
I1
sa(dp14376
g10882
I87
sg10883
Vdepression
p14377
sg10884
I10
sg10885
VC0011581
p14378
sg10887
I1
sa(dp14379
g10882
I56
sg10883
g14367
sg10884
I15
sg10885
VC0027686
p14380
sg10887
I1
sasg10888
(lp14381
(dp14382
g10882
I122
sg10883
VPaxillin
p14383
sg10884
I8
sg10891
VP49023
p14384
sg10887
I1
sa(dp14385
g10882
I110
sg10883
VAKT
p14386
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp14387
g10882
I105
sg10883
g14366
sg10884
I4
sg10891
VP42336
p14388
sg10887
I1
sa(dp14389
g10882
I118
sg10883
VFAK
p14390
sg10884
I3
sg10891
g190
sg10887
I1
sasa(dp14391
g10873
VUsing a T-cell transfer model of chronic colitis, we found that in recipients of naive T cells from CD101(+/+) donors up to 30% of the recovered lymphocytes expressed CD101, correlating with an increased interleukin (IL)-2-mediated FoxP3 expression.
p14392
sg4
(dp14393
(Vinterleukin (IL)-2
p14394
Vchronic colitis
p14395
tp14396
I00
ssg10879
(lp14397
(dp14398
g10882
I33
sg10883
g14395
sg10884
I15
sg10885
VC0267375
p14399
sg10887
I2
sasg10888
(lp14400
(dp14401
g10882
I204
sg10883
g14394
sg10884
I18
sg10891
VP60568
p14402
sg10887
I2
sa(dp14403
g10882
I232
sg10883
VFoxP3
p14404
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp14405
g10882
I100
sg10883
VCD101
p14406
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp14407
g10873
VSubgroups of T cells (Th : CD4(+) or Tc : CD8(+) ); naive (CD27(+) CD28(+) CD45RA(+) CCR7(+) ), central memory (CD27(+) CD28(+) CD45RA(-) CCR7(+) ), effector memory (early differentiated; CD27(+) CD28(+) CD45RA(-) CCR7(-) and late differentiated; CD27(-) CD28(-) CD45RA(-) CCR7(-) ), terminally differentiated effector cells (TEMRA; CD27(-) CD28(-) CD45RA(+) CCR7(-) ) and Treg (CD4(+) CD25(+) FOXP3(+) CD127(-) ) cells, and their expression of CD39, CD45RA, CD101 and CD129, were studied by flow cytometry in T1D and/or coeliac disease children or without any of these diseases (reference group).
p14408
sg4
(dp14409
(VCD4(+) CD25(+) FOXP3(+) CD127
p14410
Vcoeliac disease
p14411
tp14412
I00
ssg10879
(lp14413
(dp14414
g10882
I521
sg10883
g14411
sg10884
I15
sg10885
VC0007570
p14415
sg10887
I2
sasg10888
(lp14416
(dp14417
g10882
I247
sg10883
VCD27(-)
p14418
sg10884
I7
sg10891
VP26842
p14419
sg10887
I1
sa(dp14420
g10882
I445
sg10883
VCD39
p14421
sg10884
I4
sg10891
VP49961
p14422
sg10887
I1
sa(dp14423
g10882
I255
sg10883
VCD28(-) CD45RA(-) CCR7
p14424
sg10884
I22
sg10891
VP33681
p14425
sg10887
I3
sa(dp14426
g10882
I27
sg10883
VCD4
p14427
sg10884
I3
sg10891
VP01730
p14428
sg10887
I1
sa(dp14429
g10882
I341
sg10883
VCD28(-) CD45RA(+) CCR7
p14430
sg10884
I22
sg10891
VP33681
p14431
sg10887
I3
sa(dp14432
g10882
I247
sg10883
VCD27(-)
p14433
sg10884
I7
sg10891
VP26842
p14434
sg10887
I1
sa(dp14435
g10882
I112
sg10883
VCD27(+) CD28(+) CD45RA(-) CCR7
p14436
sg10884
I30
sg10891
VP26842
p14437
sg10887
I4
sa(dp14438
g10882
I42
sg10883
VCD8
p14439
sg10884
I3
sg10891
VP01732
p14440
sg10887
I1
sa(dp14441
g10882
I59
sg10883
VCD27(+) CD28(+) CD45RA(+) CCR7
p14442
sg10884
I30
sg10891
VP26842
p14443
sg10887
I4
sa(dp14444
g10882
I188
sg10883
VCD27(+) CD28(+) CD45RA(-) CCR7(-)
p14445
sg10884
I33
sg10891
VP26842
p14446
sg10887
I4
sa(dp14447
g10882
I459
sg10883
VCD101
p14448
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp14449
g10882
I469
sg10883
VCD129
p14450
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp14451
g10882
I379
sg10883
g14410
sg10884
I29
sg10891
VP01730
p14452
sg10887
I4
sasa(dp14453
g10873
VChildren with exclusively coeliac disease had a higher MFI of CD101 (P &lt; 0*01), as well as a higher percentage of CD129(+) (P &lt; 0*05), in the CD4(+) CD25(hi) lymphocyte population, compared to references.
p14454
sg4
(dp14455
(VCD4(+) CD25
p14456
Vcoeliac disease
p14457
tp14458
I00
ssg10879
(lp14459
(dp14460
g10882
I26
sg10883
g14457
sg10884
I15
sg10885
VC0007570
p14461
sg10887
I2
sasg10888
(lp14462
(dp14463
g10882
I62
sg10883
VCD101
p14464
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp14465
g10882
I148
sg10883
g14456
sg10884
I11
sg10891
VP01730
p14466
sg10887
I2
sasa(dp14467
g10873
VFurther, to define the mechanism of action that explains the differential ability of C57BL/6 Treg versus dnTGF-BetaRII Treg on the ability to down-regulate autoimmune cholangitis, we noted significant differential expression of glycoprotein A repetitions predominant (GARP), CD73, CD101 and CD103 and a functionally significant increase in interleukin (IL)-10 in Treg from C57BL/6 compared to dnTGF-BetaRII mice.
p14468
sg4
(dp14469
(VGARP
p14470
Vcholangitis
p14471
tp14472
I00
ssg10879
(lp14473
(dp14474
g10882
I167
sg10883
g14471
sg10884
I11
sg10885
VC0008311
p14475
sg10887
I1
sa(dp14476
g10882
I156
sg10883
Vautoimmune
p14477
sg10884
I10
sg10885
VC0443146
p14478
sg10887
I1
sasg10888
(lp14479
(dp14480
g10882
I340
sg10883
Vinterleukin (IL)-10
p14481
sg10884
I19
sg10891
VP60568
p14482
sg10887
I2
sa(dp14483
g10882
I275
sg10883
VCD73
p14484
sg10884
I4
sg10891
VP21589
p14485
sg10887
I1
sa(dp14486
g10882
I291
sg10883
VCD103
p14487
sg10884
I5
sg10891
VP38570
p14488
sg10887
I1
sa(dp14489
g10882
I281
sg10883
VCD101
p14490
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp14491
g10882
I228
sg10883
Vglycoprotein A repetitions predominant
p14492
sg10884
I38
sg10891
VP55822
p14493
sg10887
I4
sa(dp14494
g10882
I268
sg10883
g14470
sg10884
I4
sg10891
VP55822
p14495
sg10887
I1
sasa(dp14496
g10873
VCD101-knockout mice generated on the B6 background also exhibit substantially more severe N. aromaticivorans-induced liver disease correlating with increased IFN-Gamma and IL-17 responses compared with wild-type mice.
p14497
sg4
(dp14498
(VIFN-Gamma
p14499
Vliver disease
p14500
tp14501
I00
ssg10879
(lp14502
(dp14503
g10882
I117
sg10883
g14500
sg10884
I13
sg10885
VC0023895
p14504
sg10887
I2
sasg10888
(lp14505
(dp14506
g10882
I0
sg10883
VCD101
p14507
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp14508
g10882
I158
sg10883
g14499
sg10884
I9
sg10891
VP01579
p14509
sg10887
I1
sasa(dp14510
g10873
VGastric juice from 15 normals, 20 patients with gastric ulcer and 14 patients with erosive haemorrhagic gastroduodenitis was investigated in respect of its activity on unheated and heated fibrin plates and its content of FDP and plasminogen or plasmin with immunochemical methods.
p14511
sg4
(dp14512
(Vplasmin
p14513
Vgastroduodenitis
p14514
tp14515
I00
ssg10879
(lp14516
(dp14517
g10882
I48
sg10883
Vgastric ulcer
p14518
sg10884
I13
sg10885
VC0038358
p14519
sg10887
I2
sa(dp14520
g10882
I104
sg10883
g14514
sg10884
I16
sg10885
VC0267166
p14521
sg10887
I1
sasg10888
(lp14522
(dp14523
g10882
I188
sg10883
Vfibrin
p14524
sg10884
I6
sg10891
VP22087
p14525
sg10887
I1
sa(dp14526
g10882
I221
sg10883
VFDP
p14527
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp14528
g10882
I229
sg10883
Vplasminogen
p14529
sg10884
I11
sg10891
VP00747
p14530
sg10887
I1
sa(dp14531
g10882
I229
sg10883
g14513
sg10884
I7
sg10891
VP00747
p14532
sg10887
I1
sasa(dp14533
g10873
VThe patients with erosive haemorrhagic gastroduodenitis showed no increase in fibrinolysis in the blood, but low values for plasminogen and alpha2-M, and the serum contained FDP.
p14534
sg4
(dp14535
(Vplasminogen
p14536
Vgastroduodenitis
p14537
tp14538
I00
ssg10879
(lp14539
(dp14540
g10882
I39
sg10883
g14537
sg10884
I16
sg10885
VC0267166
p14541
sg10887
I1
sasg10888
(lp14542
(dp14543
g10882
I174
sg10883
VFDP
p14544
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp14545
g10882
I124
sg10883
g14536
sg10884
I11
sg10891
VP00747
p14546
sg10887
I1
sasa(dp14547
g10873
VActivin BA, follistatin, and activin receptor type IIA proteins were observed in normal and cleft palate tissues throughout pregnancy (gestational weeks 11 to 40).
p14548
sg4
(dp14549
(Vactivin receptor type IIA proteins
p14550
Vcleft palate
p14551
tp14552
I00
ssg10879
(lp14553
(dp14554
g10882
I92
sg10883
g14551
sg10884
I12
sg10885
VC0008925
p14555
sg10887
I2
sasg10888
(lp14556
(dp14557
g10882
I0
sg10883
VActivin
p14558
sg10884
I7
sg10891
VP58166
p14559
sg10887
I1
sa(dp14560
g10882
I29
sg10883
g14550
sg10884
I34
sg10891
VP27037
p14561
sg10887
I5
sasa(dp14562
g10873
VWe have previously shown that follistatin-deficient mice have numerous embryonic defects including shiny, taut skin, growth retardation, and cleft palate leading to death within hours of birth.
p14563
sg4
(dp14564
(Vfollistatin
p14565
Vcleft palate
p14566
tp14567
I00
ssg10879
(lp14568
(dp14569
g10882
I117
sg10883
Vgrowth retardation
p14570
sg10884
I18
sg10885
VC0151686
p14571
sg10887
I2
sa(dp14572
g10882
I141
sg10883
g14566
sg10884
I12
sg10885
VC0008925
p14573
sg10887
I2
sasg10888
(lp14574
(dp14575
g10882
I30
sg10883
g14565
sg10884
I11
sg10891
VP19883
p14576
sg10887
I1
sasa(dp14577
g10873
VTwo rheumatic disease patients had a relatively high titer of IgG(2)anti-p80-coilin antibodies.
p14578
sg4
(dp14579
(VIgG(2)anti-p80-coilin antibodies
p14580
Vrheumatic disease
p14581
tp14582
I00
ssg10879
(lp14583
(dp14584
g10882
I4
sg10883
g14581
sg10884
I17
sg10885
VC0035435
p14585
sg10887
I2
sasg10888
(lp14586
(dp14587
g10882
I62
sg10883
g14580
sg10884
I32
sg10891
VP38432
p14588
sg10887
I2
sasa(dp14589
g10873
VThe patients with localized scleroderma who were positive for anti-p80-coilin antibody had all been classified as having linear scleroderma.
p14590
sg4
(dp14591
(Vanti-p80-coilin antibody
p14592
Vlinear scleroderma
p14593
tp14594
I00
ssg10879
(lp14595
(dp14596
g10882
I18
sg10883
Vlocalized scleroderma
p14597
sg10884
I21
sg10885
VC0036420
p14598
sg10887
I2
sa(dp14599
g10882
I121
sg10883
g14593
sg10884
I18
sg10885
VC0263409
p14600
sg10887
I2
sasg10888
(lp14601
(dp14602
g10882
I62
sg10883
g14592
sg10884
I24
sg10891
VP38432
p14603
sg10887
I2
sasa(dp14604
g10873
VOur data indicate that anti-p80-coilin antibody is uncommon in skin diseases: however, this antibody is present in patients with a milder form of linear scleroderma, although the incidence of positivity may not be high.
p14605
sg4
(dp14606
(Vanti-p80-coilin antibody
p14607
Vlinear scleroderma
p14608
tp14609
I00
ssg10879
(lp14610
(dp14611
g10882
I63
sg10883
Vskin diseases
p14612
sg10884
I13
sg10885
VC0037274
p14613
sg10887
I2
sa(dp14614
g10882
I146
sg10883
g14608
sg10884
I18
sg10885
VC0263409
p14615
sg10887
I2
sasg10888
(lp14616
(dp14617
g10882
I23
sg10883
g14607
sg10884
I24
sg10891
VP38432
p14618
sg10887
I2
sasa(dp14619
g10873
VWe also discuss several of the antigen-autoantibody systems found in systemic lupus erythematosus (Smith antigen, U1-nuclear ribonucleoprotein, SS-A/Ro, SS-B/La, proliferating cell nuclear antigen ribosomal ribonucleoprotein, double-strand DNA, histones, antiphospholipids, Ku, Ki/SL), systemic sclerosis (centromere, topo I, RNA polymerases, fibrillarin, polymyositis-Scl, Th/To), polymyositis/dermatomyositis (transferRNA synthetases, signal recognition particle, and others), and SS (SS-A/Ro, SS-B/La, nucleolar organizing region-90, p80-coilin), addressing their clinical significance, common detection methods, immunogenetic associations, and the molecular and cellular biology of the cognate antigens.
p14620
sg4
(dp14621
(VSS-B
p14622
Vdermatomyositis
p14623
tp14624
I00
ssg10879
(lp14625
(dp14626
g10882
I286
sg10883
Vsystemic sclerosis
p14627
sg10884
I18
sg10885
VC0036421
p14628
sg10887
I2
sa(dp14629
g10882
I356
sg10883
Vpolymyositis
p14630
sg10884
I12
sg10885
VC0085655
p14631
sg10887
I1
sa(dp14632
g10882
I69
sg10883
Vsystemic lupus erythematosus
p14633
sg10884
I28
sg10885
VC0024141
p14634
sg10887
I3
sa(dp14635
g10882
I356
sg10883
Vpolymyositis
p14636
sg10884
I12
sg10885
VC0085655
p14637
sg10887
I1
sa(dp14638
g10882
I395
sg10883
g14623
sg10884
I15
sg10885
VC0221056
p14639
sg10887
I1
sasg10888
(lp14640
(dp14641
g10882
I162
sg10883
Vproliferating cell nuclear antigen ribosomal ribonucleoprotein
p14642
sg10884
I62
sg10891
VP12004
p14643
sg10887
I6
sa(dp14644
g10882
I144
sg10883
VSS-A
p14645
sg10884
I4
sg10891
VP37268
p14646
sg10887
I1
sa(dp14647
g10882
I326
sg10883
VRNA polymerases
p14648
sg10884
I15
sg10891
g190
sg10887
I2
sa(dp14649
g10882
I343
sg10883
Vfibrillarin
p14650
sg10884
I11
sg10891
VP22087
p14651
sg10887
I1
sa(dp14652
g10882
I537
sg10883
Vp80
p14653
sg10884
I3
sg10891
VP20333
p14654
sg10887
I1
sa(dp14655
g10882
I153
sg10883
VSS-B
p14656
sg10884
I4
sg10891
VP37268
p14657
sg10887
I1
sa(dp14658
g10882
I114
sg10883
VU1-nuclear ribonucleoprotein
p14659
sg10884
I28
sg10891
VP26599
p14660
sg10887
I2
sa(dp14661
g10882
I541
sg10883
Vcoilin
p14662
sg10884
I6
sg10891
VP38432
p14663
sg10887
I1
sa(dp14664
g10882
I99
sg10883
VSmith antigen
p14665
sg10884
I13
sg10891
VP14209
p14666
sg10887
I2
sa(dp14667
g10882
I153
sg10883
g14622
sg10884
I4
sg10891
VP37268
p14668
sg10887
I1
sasa(dp14669
g10873
VThe development of arthritis and aortitis was significantly suppressed by the deficiency of TNFalpha or IL-17.
p14670
sg4
(dp14671
(VTNFalpha
p14672
Varthritis
p14673
tp14674
I00
ssg10879
(lp14675
(dp14676
g10882
I19
sg10883
g14673
sg10884
I9
sg10885
VC0003864
p14677
sg10887
I1
sa(dp14678
g10882
I33
sg10883
Vaortitis
p14679
sg10884
I8
sg10885
VC0003509
p14680
sg10887
I1
sasg10888
(lp14681
(dp14682
g10882
I92
sg10883
g14672
sg10884
I8
sg10891
VP01375
p14683
sg10887
I1
sasa(dp14684
g10873
VObjective To evaluate the efficacy of Ganoderma lucidum preparation on the behaviors,biochemistry,and autoimmunity parameters of mouse models of APP/PS-1 double transgenic Alzheimer's disease(AD).Methods A total of 44 4-month-old APP/PS-1 double transgenic AD mice were randomly divided into AD model group,Aricept group,Ganoderma lucidum middle-dose(LZ-M)group,and Ganoderma lucidum high-dose(LZ-H)group,with 11 mice in each group.In addition,10 4-month-old C57BL/6 mice were used as the control group.Water maze test was conducted to observe the behavior changes,and the protein expressions in brain tissues were detected by Western blot analysis.The autoimmune indicators were detected by indirect immunofluorescence method.Results In the navigation experiment,the time of finding the platform was gradually shortened since the 2nd day in the control,LZ-H,and LZ-M groups,and the time of searching the platform in the AD model group gradually increased.On the 5th day,the time of finding platform was significantly shorter in control group (t=5.607,P=0.000) and LZ-H group(t=2.750,P=0.010)than AD model group.In the space exploration experiment,the number of crossing the target platform(t=2.452,P=0.025)and the residence time in the target quadrant(t=2.530,P=0.020)in AD model group mice was significantly smaller/shorter than those in control group;in addition,the number of crossing the target platform in the AD model group was significantly smaller than that in LZ-H group(t=2.317,P=0.030)and LZ-M group(t=2.443,P=0.030),while the residence time in target quadrant decreased significantly(t=2.770,P=0.020)compared with LZ-H group;the number of crossing through the target platform quadrant(t=2.493,P=0.022)and residence time in the target quadrant(t=2.683,P=0.015)in LZ-H group were significantly higher than in Aricept group.Western blot analysis showed that the expression of ApoA1 in the brain tissues of mice in LZ-H and LZ-M groups were significantly higher than those in AD model group(P&lt;0.01,P&lt;0.05);ABeta-40 expression in LZ-H group was significantly lower than that in AD model group(P&lt;0.05);the expressions of Syt1,ApoE,and ABCA1 in brain tissues of mice in LZ-H group were significantly higher than those in model group(P&lt;0.01,P&lt;0.05).The plasma IgG level in Aricept group(t=30.945,P=0.000),LZ-M group(t=25.639,P=0.000)and LZ-H group(t=4.689,P=0.001)were significantly higher than that in the control group.Conclusion Ganoderma lucidum preparation can improve behavior disorders of AD model mice,promote the expressions of ApoA1,ApoE and Syt1,inhibit the expression of ABeta-40 protein,and improve the autoimmune function.
p14685
sg4
(dp14686
(VSyt1
p14687
Vbehavior disorders
p14688
tp14689
I00
ssg10879
(lp14690
(dp14691
g10882
I102
sg10883
Vautoimmunity
p14692
sg10884
I12
sg10885
VC0004368
p14693
sg10887
I1
sa(dp14694
g10882
I172
sg10883
VAlzheimer's disease
p14695
sg10884
I19
sg10885
VC1521724
p14696
sg10887
I2
sa(dp14697
g10882
I2494
sg10883
g14688
sg10884
I18
sg10885
VC0004930
p14698
sg10887
I2
sa(dp14699
g10882
I653
sg10883
Vautoimmune
p14700
sg10884
I10
sg10885
VC0443146
p14701
sg10887
I1
sa(dp14702
g10882
I653
sg10883
Vautoimmune
p14703
sg10884
I10
sg10885
VC0443146
p14704
sg10887
I1
sasg10888
(lp14705
(dp14706
g10882
I2137
sg10883
VSyt1
p14707
sg10884
I4
sg10891
VP21579
p14708
sg10887
I1
sa(dp14709
g10882
I1886
sg10883
VApoA1
p14710
sg10884
I5
sg10891
VP02647
p14711
sg10887
I1
sa(dp14712
g10882
I1065
sg10883
VLZ-H group
p14713
sg10884
I10
sg10891
VP00390
p14714
sg10887
I2
sa(dp14715
g10882
I2142
sg10883
VApoE
p14716
sg10884
I4
sg10891
VP02649
p14717
sg10887
I1
sa(dp14718
g10882
I145
sg10883
VAPP/PS-1
p14719
sg10884
I8
sg10891
VP48651
p14720
sg10887
I1
sa(dp14721
g10882
I2142
sg10883
VApoE
p14722
sg10884
I4
sg10891
VP02649
p14723
sg10887
I1
sa(dp14724
g10882
I2603
sg10883
VABeta-40 protein
p14725
sg10884
I16
sg10891
g190
sg10887
I2
sa(dp14726
g10882
I1886
sg10883
VApoA1
p14727
sg10884
I5
sg10891
VP02647
p14728
sg10887
I1
sa(dp14729
g10882
I2021
sg10883
VABeta-40
p14730
sg10884
I8
sg10891
g190
sg10887
I1
sa(dp14731
g10882
I1065
sg10883
VLZ-H group
p14732
sg10884
I10
sg10891
VP00390
p14733
sg10887
I2
sa(dp14734
g10882
I145
sg10883
VAPP
p14735
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp14736
g10882
I1065
sg10883
VLZ-H group
p14737
sg10884
I10
sg10891
VP00390
p14738
sg10887
I2
sa(dp14739
g10882
I149
sg10883
VPS-1
p14740
sg10884
I4
sg10891
VP48651
p14741
sg10887
I1
sa(dp14742
g10882
I2137
sg10883
g14687
sg10884
I4
sg10891
VP21579
p14743
sg10887
I1
sasa(dp14744
g10873
VThese findings suggest that the p185 neu may be a prognostic indicator not only for breast adenocarcinomas but also for lymphoproliferative disorders, and that the transforming p185 protein may be involved in the mechanisms of aggressive expansion of lymphoid neoplasias.
p14745
sg4
(dp14746
(Vneu
p14747
Vlymphoproliferative disorders
p14748
tp14749
I01
ssg10879
(lp14750
(dp14751
g10882
I227
sg10883
Vaggressive
p14752
sg10884
I10
sg10885
VC0001807
p14753
sg10887
I1
sa(dp14754
g10882
I91
sg10883
Vadenocarcinomas
p14755
sg10884
I15
sg10885
VC0001418
p14756
sg10887
I1
sa(dp14757
g10882
I120
sg10883
g14748
sg10884
I29
sg10885
VC0024314
p14758
sg10887
I2
sa(dp14759
g10882
I260
sg10883
Vneoplasias
p14760
sg10884
I10
sg10885
VC0027651
p14761
sg10887
I1
sasg10888
(lp14762
(dp14763
g10882
I37
sg10883
g14747
sg10884
I3
sg10891
VP04626
p14764
sg10887
I1
sa(dp14765
g10882
I32
sg10883
Vp185
p14766
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp14767
g10882
I177
sg10883
Vp185 protein
p14768
sg10884
I12
sg10891
g190
sg10887
I2
sasa(dp14769
g10873
VThe authors investigated the correlation between clinicopathologic factors and the overexpression of the p185(HER2) in Korean gastric adenocarcinoma patients, and determined whether the antiproliferative effects of anti- p185(HER2) antibody can also be observed on gastric cancer cell lines that overexpress this growth factor receptor.
p14770
sg4
(dp14771
(VHER2
p14772
Vgastric adenocarcinoma
p14773
tp14774
I00
ssg10879
(lp14775
(dp14776
g10882
I265
sg10883
Vgastric cancer
p14777
sg10884
I14
sg10885
VC0024623
p14778
sg10887
I2
sa(dp14779
g10882
I126
sg10883
g14773
sg10884
I22
sg10885
VC0278701
p14780
sg10887
I2
sasg10888
(lp14781
(dp14782
g10882
I215
sg10883
Vanti- p185
p14783
sg10884
I10
sg10891
g190
sg10887
I2
sa(dp14784
g10882
I110
sg10883
VHER2
p14785
sg10884
I4
sg10891
VP04626
p14786
sg10887
I1
sa(dp14787
g10882
I105
sg10883
Vp185
p14788
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp14789
g10882
I313
sg10883
Vgrowth factor receptor
p14790
sg10884
I22
sg10891
g190
sg10887
I3
sa(dp14791
g10882
I110
sg10883
g14772
sg10884
I4
sg10891
VP04626
p14792
sg10887
I1
sasa(dp14793
g10873
VWe evaluated the relationship between p185(HER2) overexpression and clinicopathological features in 94 (M: F=52: 42) gastric adenocarcinoma patients (median age 59 years).
p14794
sg4
(dp14795
(VHER2
p14796
Vgastric adenocarcinoma
p14797
tp14798
I00
ssg10879
(lp14799
(dp14800
g10882
I117
sg10883
g14797
sg10884
I22
sg10885
VC0278701
p14801
sg10887
I2
sasg10888
(lp14802
(dp14803
g10882
I43
sg10883
g14796
sg10884
I4
sg10891
VP04626
p14804
sg10887
I1
sa(dp14805
g10882
I38
sg10883
Vp185
p14806
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp14807
g10873
VTo explore the role of humanized anti-p185(HER2) monoclonal antibody trastuzumab (Herceptin ) in vitro, the growth curve of Korean gastric cancer cells that overexpress the p185(HER2) protein was studied and a cell cycle analysis was performed.
p14808
sg4
(dp14809
(VHER2
p14810
Vgastric cancer
p14811
tp14812
I00
ssg10879
(lp14813
(dp14814
g10882
I131
sg10883
g14811
sg10884
I14
sg10885
VC0024623
p14815
sg10887
I2
sasg10888
(lp14816
(dp14817
g10882
I43
sg10883
VHER2
p14818
sg10884
I4
sg10891
VP04626
p14819
sg10887
I1
sa(dp14820
g10882
I23
sg10883
Vhumanized anti-p185
p14821
sg10884
I19
sg10891
g190
sg10887
I2
sa(dp14822
g10882
I43
sg10883
g14810
sg10884
I4
sg10891
VP04626
p14823
sg10887
I1
sa(dp14824
g10882
I38
sg10883
Vp185
p14825
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp14826
g10873
Vp185(HER2) overexpression was found to be more frequent in advanced gastric cancer than early gastric cancer (54.1% vs 24.2%, p=0.008).
p14827
sg4
(dp14828
(VHER2
p14829
Vgastric cancer
p14830
tp14831
I00
ssg10879
(lp14832
(dp14833
g10882
I88
sg10883
Vearly gastric cancer
p14834
sg10884
I20
sg10885
VC0349530
p14835
sg10887
I3
sa(dp14836
g10882
I68
sg10883
g14830
sg10884
I14
sg10885
VC0024623
p14837
sg10887
I2
sasg10888
(lp14838
(dp14839
g10882
I5
sg10883
g14829
sg10884
I4
sg10891
VP04626
p14840
sg10887
I1
sa(dp14841
g10882
I0
sg10883
Vp185
p14842
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp14843
g10873
VAmong several Korean gastric cancer cell lines, SNU-1, SNU-5, and SNU-620 overexpress p185(HER2).
p14844
sg4
(dp14845
(VHER2
p14846
Vgastric cancer
p14847
tp14848
I00
ssg10879
(lp14849
(dp14850
g10882
I21
sg10883
g14847
sg10884
I14
sg10885
VC0024623
p14851
sg10887
I2
sasg10888
(lp14852
(dp14853
g10882
I86
sg10883
Vp185
p14854
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp14855
g10882
I91
sg10883
g14846
sg10884
I4
sg10891
VP04626
p14856
sg10887
I1
sasa(dp14857
g10873
VTrastuzumab inhibited the proliferation of p185(HER2) overexpressed Korean gastric cancer cell line by 21% with down-regulation of p185(HER2) protein expression.
p14858
sg4
(dp14859
(VHER2
p14860
Vgastric cancer
p14861
tp14862
I00
ssg10879
(lp14863
(dp14864
g10882
I75
sg10883
g14861
sg10884
I14
sg10885
VC0024623
p14865
sg10887
I2
sa(dp14866
g10882
I26
sg10883
Vproliferation
p14867
sg10884
I13
sg10885
VC0334094
p14868
sg10887
I1
sasg10888
(lp14869
(dp14870
g10882
I43
sg10883
Vp185
p14871
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp14872
g10882
I48
sg10883
VHER2
p14873
sg10884
I4
sg10891
VP04626
p14874
sg10887
I1
sa(dp14875
g10882
I48
sg10883
g14860
sg10884
I4
sg10891
VP04626
p14876
sg10887
I1
sa(dp14877
g10882
I43
sg10883
Vp185
p14878
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp14879
g10873
VS: Taken together, our observations suggest the potential prognostic significance of p185(HER2) overexpression in Korean gastric adenocarcinoma patients and point to the need for further research on this mechanism.
p14880
sg4
(dp14881
(VHER2
p14882
Vgastric adenocarcinoma
p14883
tp14884
I00
ssg10879
(lp14885
(dp14886
g10882
I121
sg10883
g14883
sg10884
I22
sg10885
VC0278701
p14887
sg10887
I2
sasg10888
(lp14888
(dp14889
g10882
I85
sg10883
Vp185
p14890
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp14891
g10882
I90
sg10883
g14882
sg10884
I4
sg10891
VP04626
p14892
sg10887
I1
sasa(dp14893
g10873
VThis suggests the possible use of p185(HER2) as a therapeutic target in gastric cancer.
p14894
sg4
(dp14895
(VHER2
p14896
Vgastric cancer
p14897
tp14898
I00
ssg10879
(lp14899
(dp14900
g10882
I72
sg10883
g14897
sg10884
I14
sg10885
VC0024623
p14901
sg10887
I2
sasg10888
(lp14902
(dp14903
g10882
I39
sg10883
g14896
sg10884
I4
sg10891
VP04626
p14904
sg10887
I1
sa(dp14905
g10882
I34
sg10883
Vp185
p14906
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp14907
g10873
VAdministration of trastuzumab, a fully humanized monoclonal antibody targeted to the human epidermal growth factor receptor 2 (HER2, p185), has improved outcomes for patients with HER2-positive gastric cancer (GC), but some relevant issues remain to be investigated and will emerge with new anti-GC drugs.
p14908
sg4
(dp14909
(VHER2
p14910
VGC
p14911
tp14912
I00
ssg10879
(lp14913
(dp14914
g10882
I194
sg10883
Vgastric cancer
p14915
sg10884
I14
sg10885
VC0024623
p14916
sg10887
I2
sa(dp14917
g10882
I210
sg10883
VGC
p14918
sg10884
I2
sg10885
VC0024623
p14919
sg10887
I1
sa(dp14920
g10882
I210
sg10883
g14911
sg10884
I2
sg10885
VC0024623
p14921
sg10887
I1
sasg10888
(lp14922
(dp14923
g10882
I85
sg10883
Vhuman epidermal growth factor receptor 2
p14924
sg10884
I40
sg10891
VP01133
p14925
sg10887
I6
sa(dp14926
g10882
I127
sg10883
VHER2
p14927
sg10884
I4
sg10891
VP04626
p14928
sg10887
I1
sa(dp14929
g10882
I133
sg10883
Vp185
p14930
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp14931
g10882
I127
sg10883
g14910
sg10884
I4
sg10891
VP04626
p14932
sg10887
I1
sasa(dp14933
g10873
VTo investigate the correlation between eukaryotic translation initiation factor 3, subunit A (eIF3a) and human epididymis protein 4 (HE4) expression and ovarian cancer.
p14934
sg4
(dp14935
(Vhuman epididymis protein 4
p14936
Vovarian cancer
p14937
tp14938
I00
ssg10879
(lp14939
(dp14940
g10882
I153
sg10883
g14937
sg10884
I14
sg10885
VC1140680
p14941
sg10887
I2
sasg10888
(lp14942
(dp14943
g10882
I133
sg10883
VHE4
p14944
sg10884
I3
sg10891
VP01031
p14945
sg10887
I1
sa(dp14946
g10882
I105
sg10883
g14936
sg10884
I26
sg10891
VP01031
p14947
sg10887
I4
sa(dp14948
g10882
I94
sg10883
VeIF3a
p14949
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp14950
g10873
VThe expressions of eIF3a and HE4 are associated with ovarian cancer, and extracellular regulated protein kinases may play a role in the interaction between eIF3a and HE4.
p14951
sg4
(dp14952
(Vextracellular regulated protein kinases
p14953
Vovarian cancer
p14954
tp14955
I00
ssg10879
(lp14956
(dp14957
g10882
I53
sg10883
g14954
sg10884
I14
sg10885
VC1140680
p14958
sg10887
I2
sasg10888
(lp14959
(dp14960
g10882
I19
sg10883
VeIF3a
p14961
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp14962
g10882
I73
sg10883
g14953
sg10884
I39
sg10891
VP10398
p14963
sg10887
I4
sa(dp14964
g10882
I19
sg10883
VeIF3a
p14965
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp14966
g10873
VWe describe an ultrasensitive electrochemical nucleic acid assay amplified by carbon nanotubes (CNTs)-based labels for the detection of human acute lymphocytic leukemia (ALL)-related p185 BCR-ABL fusion transcript.
p14967
sg4
(dp14968
(VBCR
p14969
VALL
p14970
tp14971
I00
ssg10879
(lp14972
(dp14973
g10882
I192
sg10883
VABL
p14974
sg10884
I3
sg10885
VC0000744
p14975
sg10887
I1
sa(dp14976
g10882
I142
sg10883
Vacute lymphocytic leukemia
p14977
sg10884
I26
sg10885
VC1961102
p14978
sg10887
I3
sa(dp14979
g10882
I170
sg10883
g14970
sg10884
I3
sg10885
VC1961102
p14980
sg10887
I1
sasg10888
(lp14981
(dp14982
g10882
I192
sg10883
VABL
p14983
sg10884
I3
sg10891
VP55157
p14984
sg10887
I1
sa(dp14985
g10882
I183
sg10883
Vp185
p14986
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp14987
g10882
I188
sg10883
g14969
sg10884
I3
sg10891
VP11274
p14988
sg10887
I1
sasa(dp14989
g10873
VPlasma levels of annexin V-MP, endothelial-derived MP, platelet-derived MP (CD61+ and P-Selectin+), leukocyte-derived MP, tissue factor-bearing (TF+) and CD36+MP were prospectively measured in 20 patients with III degree obesity (BMI &gt;= 40 kg/m(2)) before (T0) and 3 (T3) and 12 (T12) months after sleeve gastrectomy (SLG).
p14990
sg4
(dp14991
(VCD61+
p14992
Vobesity
p14993
tp14994
I00
ssg10879
(lp14995
(dp14996
g10882
I221
sg10883
g14993
sg10884
I7
sg10885
VC0028754
p14997
sg10887
I1
sasg10888
(lp14998
(dp14999
g10882
I100
sg10883
Vleukocyte-derived MP, tissue factor-bearing (TF+)
p15000
sg10884
I49
sg10891
VP13726
p15001
sg10887
I5
sa(dp15002
g10882
I17
sg10883
Vannexin V-MP, endothelial-derived MP, platelet-derived MP
p15003
sg10884
I57
sg10891
VP08758
p15004
sg10887
I6
sa(dp15005
g10882
I76
sg10883
g14992
sg10884
I5
sg10891
VP05106
p15006
sg10887
I1
sasa(dp15007
g10873
VKey messages Bilirubin levels are inversely related to cardiovascular disease, and overexpression of heme oxygenase-1 (the enzyme that determines bilirubin production) has prevented post-infarction ventricular remodeling in experimental animals, but the association between bilirubin levels and the progression of ventricular volumes and function in patients with acute myocardial infarction remained unexplored.
p15008
sg4
(dp15009
(Vheme oxygenase-1
p15010
Vacute myocardial infarction
p15011
tp15012
I00
ssg10879
(lp15013
(dp15014
g10882
I187
sg10883
Vinfarction
p15015
sg10884
I10
sg10885
VC0021308
p15016
sg10887
I1
sa(dp15017
g10882
I55
sg10883
Vcardiovascular disease
p15018
sg10884
I22
sg10885
VC0007222
p15019
sg10887
I2
sa(dp15020
g10882
I364
sg10883
g15011
sg10884
I27
sg10885
VC0155626
p15021
sg10887
I3
sasg10888
(lp15022
(dp15023
g10882
I101
sg10883
g15010
sg10884
I16
sg10891
VP09601
p15024
sg10887
I2
sasa(dp15025
g10873
VHO-1 is known to be protective in the setting of acute myocardial infarction.
p15026
sg4
(dp15027
(VHO-1
p15028
Vacute myocardial infarction
p15029
tp15030
I00
ssg10879
(lp15031
(dp15032
g10882
I49
sg10883
g15029
sg10884
I27
sg10885
VC0155626
p15033
sg10887
I3
sasg10888
(lp15034
(dp15035
g10882
I0
sg10883
g15028
sg10884
I4
sg10891
VP09601
p15036
sg10887
I1
sasa(dp15037
g10873
VIn vitro experiments revealed enteropeptidase as a putative substrate for Bace1 suggesting a role in acute pancreatitis.
p15038
sg4
(dp15039
(Venteropeptidase
p15040
Vacute pancreatitis
p15041
tp15042
I00
ssg10879
(lp15043
(dp15044
g10882
I101
sg10883
g15041
sg10884
I18
sg10885
VC0001339
p15045
sg10887
I2
sasg10888
(lp15046
(dp15047
g10882
I74
sg10883
VBace1
p15048
sg10884
I5
sg10891
VP56817
p15049
sg10887
I1
sa(dp15050
g10882
I30
sg10883
g15040
sg10884
I15
sg10891
VP98073
p15051
sg10887
I1
sasa(dp15052
g10873
Vacute necrotizing pancreatitis was induced in anesthetized pigs by the retrograde infusion of 1 ml/kg of 5% sodium taurocholate and 8 U/kg enterokinase in the pancreatic duct.
p15053
sg4
(dp15054
(VU/kg enterokinase
p15055
Vacute necrotizing pancreatitis
p15056
tp15057
I00
ssg10879
(lp15058
(dp15059
g10882
I0
sg10883
g15056
sg10884
I30
sg10885
VC0267941
p15060
sg10887
I3
sasg10888
(lp15061
(dp15062
g10882
I134
sg10883
g15055
sg10884
I17
sg10891
VP98073
p15063
sg10887
I2
sasa(dp15064
g10873
VConversely, duodenopancreatic reflux of proteolytically active enteropeptidase may cause acute and chronic pancreatitis.
p15065
sg4
(dp15066
(Venteropeptidase
p15067
Vreflux
p15068
tp15069
I00
ssg10879
(lp15070
(dp15071
g10882
I99
sg10883
Vchronic pancreatitis
p15072
sg10884
I20
sg10885
VC0149521
p15073
sg10887
I2
sa(dp15074
g10882
I30
sg10883
g15068
sg10884
I6
sg10885
VC0017168
p15075
sg10887
I1
sasg10888
(lp15076
(dp15077
g10882
I63
sg10883
g15067
sg10884
I15
sg10891
VP98073
p15078
sg10887
I1
sasa(dp15079
g10873
VA noninvasive model of necrohemorrhagic pancreatitis induced by simultaneous intravenous cerulein/enterokinase (EK) infusion has recently been established in rats.
p15080
sg4
(dp15081
(Vcerulein/enterokinase
p15082
Vpancreatitis
p15083
tp15084
I00
ssg10879
(lp15085
(dp15086
g10882
I40
sg10883
g15083
sg10884
I12
sg10885
VC0030305
p15087
sg10887
I1
sasg10888
(lp15088
(dp15089
g10882
I112
sg10883
VEK
p15090
sg10884
I2
sg10891
VP98073
p15091
sg10887
I1
sa(dp15092
g10882
I89
sg10883
g15082
sg10884
I21
sg10891
VP98073
p15093
sg10887
I1
sasa(dp15094
g10873
VStudy hemodynamic pattern and lipoperoxidation during methylene blue (MB) treatment on taurocholate - enterokinase induced acute pancreatitis (AP).
p15095
sg4
(dp15096
(Vtaurocholate - enterokinase
p15097
VAP
p15098
tp15099
I00
ssg10879
(lp15100
(dp15101
g10882
I123
sg10883
Vacute pancreatitis
p15102
sg10884
I18
sg10885
VC0001339
p15103
sg10887
I2
sa(dp15104
g10882
I143
sg10883
g15098
sg10884
I2
sg10885
VC0001339
p15105
sg10887
I1
sasg10888
(lp15106
(dp15107
g10882
I87
sg10883
g15097
sg10884
I27
sg10891
VP98073
p15108
sg10887
I3
sasa(dp15109
g10873
VThe HLA-B47,DR7 haplotype in congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency contains a deletion of most of the active CYP21 gene and the entire adjacent C4B gene.
p15110
sg4
(dp15111
(V21-hydroxylase
p15112
V21-hydroxylase deficiency
p15113
tp15114
I00
ssg10879
(lp15115
(dp15116
g10882
I61
sg10883
VCAH
p15117
sg10884
I3
sg10885
VC0520463
p15118
sg10887
I1
sa(dp15119
g10882
I29
sg10883
Vcongenital adrenal hyperplasia
p15120
sg10884
I30
sg10885
VC0001627
p15121
sg10887
I3
sa(dp15122
g10882
I73
sg10883
g15113
sg10884
I25
sg10885
VC0852654
p15123
sg10887
I2
sasg10888
(lp15124
(dp15125
g10882
I141
sg10883
VCYP21 gene
p15126
sg10884
I10
sg10891
VP08686
p15127
sg10887
I2
sa(dp15128
g10882
I176
sg10883
VC4B gene
p15129
sg10884
I8
sg10891
VP04003
p15130
sg10887
I2
sa(dp15131
g10882
I12
sg10883
VDR7 haplotype
p15132
sg10884
I13
sg10891
VP13761
p15133
sg10887
I2
sa(dp15134
g10882
I4
sg10883
VHLA-B47
p15135
sg10884
I7
sg10891
VP30486
p15136
sg10887
I1
sa(dp15137
g10882
I73
sg10883
g15112
sg10884
I14
sg10891
VP08686
p15138
sg10887
I1
sasa(dp15139
g10873
VThe HLA haplotype A3-Cw6-B47-C4A91-BQ0-DR7 is associated with congenital adrenal hyperplasia (CAH), since it only carries the dysfunctional steroid 21-hydroxylase A pseudogene as well as the 5' adjacent complement C4A gene.
p15140
sg4
(dp15141
(Vsteroid 21-hydroxylase A pseudogene
p15142
VCAH
p15143
tp15144
I00
ssg10879
(lp15145
(dp15146
g10882
I62
sg10883
Vcongenital adrenal hyperplasia
p15147
sg10884
I30
sg10885
VC0001627
p15148
sg10887
I3
sa(dp15149
g10882
I94
sg10883
g15143
sg10884
I3
sg10885
VC0520463
p15150
sg10887
I1
sasg10888
(lp15151
(dp15152
g10882
I4
sg10883
VHLA haplotype A3-Cw6-B47-C4A91-BQ0-DR7
p15153
sg10884
I38
sg10891
VP30486
p15154
sg10887
I3
sa(dp15155
g10882
I140
sg10883
g15142
sg10884
I35
sg10891
VP08686
p15156
sg10887
I4
sa(dp15157
g10882
I191
sg10883
V5' adjacent complement C4A gene
p15158
sg10884
I31
sg10891
g190
sg10887
I5
sasa(dp15159
g10873
VWnt3a and Wnt5a are ligands orchestrating the canonical and non-canonical pathways, respectively, with involvement in hepatocellular carcinoma (HCC).
p15160
sg4
(dp15161
(VWnt3a
p15162
Vhepatocellular carcinoma
p15163
tp15164
I00
ssg10879
(lp15165
(dp15166
g10882
I144
sg10883
VHCC
p15167
sg10884
I3
sg10885
VC2239176
p15168
sg10887
I1
sa(dp15169
g10882
I118
sg10883
g15163
sg10884
I24
sg10885
VC2239176
p15170
sg10887
I2
sasg10888
(lp15171
(dp15172
g10882
I10
sg10883
VWnt5a
p15173
sg10884
I5
sg10891
VP41221
p15174
sg10887
I1
sa(dp15175
g10882
I0
sg10883
g15162
sg10884
I5
sg10891
VP56704
p15176
sg10887
I1
sasa(dp15177
g10873
VTo investigate member 3a of Wingless-type MMTV integration site family (Wnt3a) expression in cancerous and surrounding tissues and the relationship between clinicopathologic features of hepatocellular carcinoma (HCC) and Wnt3a expression.
p15178
sg4
(dp15179
(VWnt3a
p15180
Vhepatocellular carcinoma
p15181
tp15182
I00
ssg10879
(lp15183
(dp15184
g10882
I212
sg10883
VHCC
p15185
sg10884
I3
sg10885
VC2239176
p15186
sg10887
I1
sa(dp15187
g10882
I186
sg10883
g15181
sg10884
I24
sg10885
VC2239176
p15188
sg10887
I2
sasg10888
(lp15189
(dp15190
g10882
I15
sg10883
Vmember 3a
p15191
sg10884
I9
sg10891
VP61587
p15192
sg10887
I2
sa(dp15193
g10882
I72
sg10883
VWnt3a
p15194
sg10884
I5
sg10891
VP56704
p15195
sg10887
I1
sa(dp15196
g10882
I28
sg10883
VWingless-type MMTV integration site family
p15197
sg10884
I42
sg10891
g190
sg10887
I5
sa(dp15198
g10882
I72
sg10883
g15180
sg10884
I5
sg10891
VP56704
p15199
sg10887
I1
sasa(dp15200
g10873
VWe then use a realistic GENESIS model to test two hypothesis about interneuron hypofunction and conclude that a reduction in GAD67 is the most likely candidate as the cause for hypofrontality as observed in Schizophrenia.
p15201
sg4
(dp15202
(VGAD67
p15203
VSchizophrenia
p15204
tp15205
I01
ssg10879
(lp15206
(dp15207
g10882
I79
sg10883
Vhypofunction
p15208
sg10884
I12
sg10885
VC0679221
p15209
sg10887
I1
sa(dp15210
g10882
I207
sg10883
g15204
sg10884
I13
sg10885
VC0036341
p15211
sg10887
I1
sasg10888
(lp15212
(dp15213
g10882
I125
sg10883
g15203
sg10884
I5
sg10891
VP49419
p15214
sg10887
I1
sasa(dp15215
g10873
VThe objective of this study was to determine the effect of the CYP3A5 and ATP binding cassette subfamily B member 1 (ABCB1) single-nucleotide polymorphisms on the disposition of sunitinib and SU12662, on clinical response, and on the manifestation of toxicities in Asian metastatic renal cell carcinoma patients.
p15216
sg4
(dp15217
(VCYP3A5
p15218
Vmetastatic renal cell carcinoma
p15219
tp15220
I01
ssg10879
(lp15221
(dp15222
g10882
I271
sg10883
g15219
sg10884
I31
sg10885
VC0278678
p15223
sg10887
I4
sasg10888
(lp15224
(dp15225
g10882
I74
sg10883
VATP binding cassette subfamily B member 1
p15226
sg10884
I41
sg10891
g190
sg10887
I7
sa(dp15227
g10882
I117
sg10883
VABCB1
p15228
sg10884
I5
sg10891
VP08183
p15229
sg10887
I1
sa(dp15230
g10882
I63
sg10883
g15218
sg10884
I6
sg10891
VP20815
p15231
sg10887
I1
sasa(dp15232
g10873
VTo examine whether common genetic variation at the SLC10A1 locus is associated with risk of persistent HBV infection, haplotype-tagging and imputed single nucleotide polymorphisms (SNPs) were assessed in two case-control sample sets, totally including 2,550 cases (persistently HBV infected subjects, PIs) and 2,124 controls (spontaneously recovered subjects, SRs) of Southern Chinese ancestry.
p15233
sg4
(dp15234
(VSRs
p15235
VSRs
p15236
tp15237
I00
ssg10879
(lp15238
(dp15239
g10882
I107
sg10883
Vinfection
p15240
sg10884
I9
sg10885
VC0009450
p15241
sg10887
I1
sa(dp15242
g10882
I103
sg10883
VHBV
p15243
sg10884
I3
sg10885
VC0019163
p15244
sg10887
I1
sa(dp15245
g10882
I103
sg10883
VHBV
p15246
sg10884
I3
sg10885
VC0019163
p15247
sg10887
I1
sa(dp15248
g10882
I360
sg10883
g15236
sg10884
I3
sg10885
VC0175693
p15249
sg10887
I1
sasg10888
(lp15250
(dp15251
g10882
I360
sg10883
g15235
sg10884
I3
sg10891
VP35270
p15252
sg10887
I1
sa(dp15253
g10882
I51
sg10883
VSLC10A1 locus
p15254
sg10884
I13
sg10891
g190
sg10887
I2
sasa(dp15255
g10873
VThis is in accordance with clinical and epidemiological findings demonstrating that defects in three RecQL helicases, i.e., WRN, BLM, RECQL4, are related to human progeroid and cancer predisposition syndromes, i.e., Werner, Bloom, and Rothmund Thomson syndrome, respectively.
p15256
sg4
(dp15257
(VBLM
p15258
VBLM
p15259
tp15260
I00
ssg10879
(lp15261
(dp15262
g10882
I235
sg10883
VRothmund Thomson syndrome
p15263
sg10884
I25
sg10885
VC0032339
p15264
sg10887
I3
sa(dp15265
g10882
I199
sg10883
Vsyndromes
p15266
sg10884
I9
sg10885
VC0039082
p15267
sg10887
I1
sa(dp15268
g10882
I124
sg10883
VWRN
p15269
sg10884
I3
sg10885
VC0043119
p15270
sg10887
I1
sa(dp15271
g10882
I177
sg10883
Vcancer
p15272
sg10884
I6
sg10885
VC0006826
p15273
sg10887
I1
sa(dp15274
g10882
I129
sg10883
g15259
sg10884
I3
sg10885
VC0005859
p15275
sg10887
I1
sasg10888
(lp15276
(dp15277
g10882
I101
sg10883
VRecQL helicases
p15278
sg10884
I15
sg10891
VP46063
p15279
sg10887
I2
sa(dp15280
g10882
I129
sg10883
g15258
sg10884
I3
sg10891
VP54132
p15281
sg10887
I1
sa(dp15282
g10882
I134
sg10883
VRECQL4
p15283
sg10884
I6
sg10891
g190
sg10887
I1
sasa(dp15284
g10873
VHuman RecQ homologs include RECQ1, BLM, WRN, RECQ4, and RECQ5Beta, three of which have been linked to diseases with elevated risk of cancer and growth defects (Bloom Syndrome and Rothmund-Thomson Syndrome) or premature aging (Werner Syndrome).
p15285
sg4
(dp15286
(VBLM
p15287
VWRN
p15288
tp15289
I00
ssg10879
(lp15290
(dp15291
g10882
I226
sg10883
VWerner Syndrome
p15292
sg10884
I15
sg10885
VC0043119
p15293
sg10887
I2
sa(dp15294
g10882
I209
sg10883
Vpremature aging
p15295
sg10884
I15
sg10885
VC0231341
p15296
sg10887
I2
sa(dp15297
g10882
I35
sg10883
VBLM
p15298
sg10884
I3
sg10885
VC0005859
p15299
sg10887
I1
sa(dp15300
g10882
I133
sg10883
Vcancer
p15301
sg10884
I6
sg10885
VC0006826
p15302
sg10887
I1
sa(dp15303
g10882
I160
sg10883
VBloom Syndrome
p15304
sg10884
I14
sg10885
VC0005859
p15305
sg10887
I2
sa(dp15306
g10882
I179
sg10883
VRothmund-Thomson Syndrome
p15307
sg10884
I25
sg10885
VC0032339
p15308
sg10887
I2
sa(dp15309
g10882
I40
sg10883
g15288
sg10884
I3
sg10885
VC0043119
p15310
sg10887
I1
sasg10888
(lp15311
(dp15312
g10882
I45
sg10883
VRECQ4
p15313
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp15314
g10882
I40
sg10883
VWRN
p15315
sg10884
I3
sg10891
VP02545
p15316
sg10887
I1
sa(dp15317
g10882
I0
sg10883
VHuman RecQ homologs
p15318
sg10884
I19
sg10891
g190
sg10887
I3
sa(dp15319
g10882
I28
sg10883
VRECQ1
p15320
sg10884
I5
sg10891
VP46063
p15321
sg10887
I1
sa(dp15322
g10882
I35
sg10883
g15287
sg10884
I3
sg10891
VP54132
p15323
sg10887
I1
sasa(dp15324
g10873
VWe propose that pharmacological inhibition of components within this network, such as PAICS, may be used in conjunction with the Fra-1 prognostic classifier towards personalized management of poor prognosis breast cancer.
p15325
sg4
(dp15326
(VPAICS
p15327
VFra
p15328
tp15329
I00
ssg10879
(lp15330
(dp15331
g10882
I207
sg10883
Vbreast cancer
p15332
sg10884
I13
sg10885
VC0678222
p15333
sg10887
I2
sa(dp15334
g10882
I129
sg10883
g15328
sg10884
I3
sg10885
VC1858361
p15335
sg10887
I1
sasg10888
(lp15336
(dp15337
g10882
I129
sg10883
VFra-1
p15338
sg10884
I5
sg10891
VP15407
p15339
sg10887
I1
sa(dp15340
g10882
I86
sg10883
g15327
sg10884
I5
sg10891
VP22234
p15341
sg10887
I1
sasa(dp15342
g10873
VNext-generation sequencing, qRTPCR and immunoblot analysis revealed an elevated expression of a de novo purine biosynthetic gene, Phosphoribosylaminoimidazole Carboxylase, Phosphoribosylaminoimidazole Succinocarboxamide Synthetase (PAICS) in a progressive manner in prostate cancer.
p15343
sg4
(dp15344
(VPhosphoribosylaminoimidazole Succinocarboxamide Synthetase
p15345
Vprostate cancer
p15346
tp15347
I00
ssg10879
(lp15348
(dp15349
g10882
I266
sg10883
g15346
sg10884
I15
sg10885
VC0600139
p15350
sg10887
I2
sasg10888
(lp15351
(dp15352
g10882
I130
sg10883
VPhosphoribosylaminoimidazole Carboxylase
p15353
sg10884
I40
sg10891
VP22234
p15354
sg10887
I2
sa(dp15355
g10882
I232
sg10883
VPAICS
p15356
sg10884
I5
sg10891
VP22234
p15357
sg10887
I1
sa(dp15358
g10882
I172
sg10883
g15345
sg10884
I58
sg10891
VP22234
p15359
sg10887
I3
sasa(dp15360
g10873
VThrough several in vitro and in vivo functional studies, we show that PAICS is necessary for proliferation and invasion in prostate cancer cells.
p15361
sg4
(dp15362
(VPAICS
p15363
Vprostate cancer
p15364
tp15365
I00
ssg10879
(lp15366
(dp15367
g10882
I93
sg10883
Vproliferation
p15368
sg10884
I13
sg10885
VC0334094
p15369
sg10887
I1
sa(dp15370
g10882
I123
sg10883
g15364
sg10884
I15
sg10885
VC0600139
p15371
sg10887
I2
sa(dp15372
g10882
I111
sg10883
Vinvasion
p15373
sg10884
I8
sg10885
VC2699153
p15374
sg10887
I1
sasg10888
(lp15375
(dp15376
g10882
I70
sg10883
g15363
sg10884
I5
sg10891
VP22234
p15377
sg10887
I1
sasa(dp15378
g10873
VWe identified JQ1, a BET bromodomain inhibitor previously implicated in regulating MYC expression and demonstrated role in prostate cancer, abrogates PAICS expression in several prostate cancer cells.
p15379
sg4
(dp15380
(VPAICS
p15381
Vprostate cancer
p15382
tp15383
I00
ssg10879
(lp15384
(dp15385
g10882
I123
sg10883
Vprostate cancer
p15386
sg10884
I15
sg10885
VC0600139
p15387
sg10887
I2
sa(dp15388
g10882
I123
sg10883
g15382
sg10884
I15
sg10885
VC0600139
p15389
sg10887
I2
sasg10888
(lp15390
(dp15391
g10882
I83
sg10883
VMYC
p15392
sg10884
I3
sg10891
VP12524
p15393
sg10887
I1
sa(dp15394
g10882
I150
sg10883
g15381
sg10884
I5
sg10891
VP22234
p15395
sg10887
I1
sasa(dp15396
g10873
VWe discovered increased expression of phosphoribosyl amidotransferase (PPAT) and phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase (PAICS) enzymes of de novo purine biosynthetic pathway in lung adenocarcinomas.
p15397
sg4
(dp15398
(Vphosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase
p15399
Vadenocarcinomas
p15400
tp15401
I00
ssg10879
(lp15402
(dp15403
g10882
I245
sg10883
g15400
sg10884
I15
sg10885
VC0001418
p15404
sg10887
I1
sasg10888
(lp15405
(dp15406
g10882
I71
sg10883
VPPAT
p15407
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp15408
g10882
I183
sg10883
VPAICS
p15409
sg10884
I5
sg10891
VP22234
p15410
sg10887
I1
sa(dp15411
g10882
I38
sg10883
Vphosphoribosyl amidotransferase
p15412
sg10884
I31
sg10891
g190
sg10887
I2
sa(dp15413
g10882
I81
sg10883
g15399
sg10884
I100
sg10891
VP22234
p15414
sg10887
I5
sasa(dp15415
g10873
VTranscript analyses from next-generation RNA sequencing and gene expression profiling studies suggested that PPAT and PAICS can serve as prognostic biomarkers for aggressive lung adenocarcinoma.
p15416
sg4
(dp15417
(VPAICS
p15418
Vaggressive
p15419
tp15420
I00
ssg10879
(lp15421
(dp15422
g10882
I174
sg10883
Vlung adenocarcinoma
p15423
sg10884
I19
sg10885
VC0152013
p15424
sg10887
I2
sa(dp15425
g10882
I163
sg10883
g15419
sg10884
I10
sg10885
VC0001807
p15426
sg10887
I1
sasg10888
(lp15427
(dp15428
g10882
I109
sg10883
VPPAT
p15429
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp15430
g10882
I118
sg10883
g15418
sg10884
I5
sg10891
VP22234
p15431
sg10887
I1
sasa(dp15432
g10873
VFurthermore we identified genomic amplification and aneuploidy of the divergently transcribed PPAT-PAICS genomic region in a subset of lung cancers.
p15433
sg4
(dp15434
(VPAICS
p15435
Vaneuploidy
p15436
tp15437
I00
ssg10879
(lp15438
(dp15439
g10882
I135
sg10883
Vlung cancers
p15440
sg10884
I12
sg10885
VC0242379
p15441
sg10887
I2
sa(dp15442
g10882
I52
sg10883
g15436
sg10884
I10
sg10885
VC0002938
p15443
sg10887
I1
sa(dp15444
g10882
I34
sg10883
Vamplification
p15445
sg10884
I13
sg10885
VC1705759
p15446
sg10887
I1
sasg10888
(lp15447
(dp15448
g10882
I99
sg10883
g15435
sg10884
I5
sg10891
VP22234
p15449
sg10887
I1
sa(dp15450
g10882
I94
sg10883
VPPAT
p15451
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp15452
g10873
VIn summary, this study reveals the regulatory mechanisms by which purine biosynthetic pathway enzymes PPAT and PAICS, and pyruvate kinase activity is increased and exposes an existing metabolic vulnerability in lung cancer cells that can be explored for pharmacological intervention.
p15453
sg4
(dp15454
(VPAICS
p15455
Vlung cancer
p15456
tp15457
I00
ssg10879
(lp15458
(dp15459
g10882
I211
sg10883
g15456
sg10884
I11
sg10885
VC0684249
p15460
sg10887
I2
sasg10888
(lp15461
(dp15462
g10882
I102
sg10883
VPPAT
p15463
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp15464
g10882
I122
sg10883
Vpyruvate kinase
p15465
sg10884
I15
sg10891
VP30613
p15466
sg10887
I2
sa(dp15467
g10882
I111
sg10883
g15455
sg10884
I5
sg10891
VP22234
p15468
sg10887
I1
sasa(dp15469
g10873
VWe also identified mutations in four genes (MUC19, PAICS, RBMXL1, KIF23) never reported in melanoma, which might deserve further investigations.
p15470
sg4
(dp15471
(VPAICS
p15472
Vmelanoma
p15473
tp15474
I00
ssg10879
(lp15475
(dp15476
g10882
I91
sg10883
g15473
sg10884
I8
sg10885
VC0025202
p15477
sg10887
I1
sasg10888
(lp15478
(dp15479
g10882
I58
sg10883
VRBMXL1
p15480
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp15481
g10882
I44
sg10883
VMUC19
p15482
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp15483
g10882
I51
sg10883
g15472
sg10884
I5
sg10891
VP22234
p15484
sg10887
I1
sa(dp15485
g10882
I66
sg10883
VKIF23
p15486
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp15487
g10873
VAn IST1 clone, detected for the first time in 2000, was the most prevalent and responsible for the shigellosis epidemic in 2001 to 2003.
p15488
sg4
(dp15489
(VIST1
p15490
Vshigellosis
p15491
tp15492
I00
ssg10879
(lp15493
(dp15494
g10882
I99
sg10883
g15491
sg10884
I11
sg10885
VC0013371
p15495
sg10887
I1
sasg10888
(lp15496
(dp15497
g10882
I3
sg10883
g15490
sg10884
I4
sg10891
VP53990
p15498
sg10887
I1
sasa(dp15499
g10873
VIn this observational, cross-sectional study, circulating levels of sclerostin and other laboratory parameters of mineral and bone disease, including intact parathyroid hormone (PTH), calcium, phosphate, magnesium, 25(OH) D-vitamin, 1,25 (OH)2 D-vitamin, and bone specific alkaline phosphatase (BALP) were assessed in 100 patients with end-stage renal disease recruited from an ongoing longitudinal cohort study in Stockholm, Sweden.
p15500
sg4
(dp15501
(VBALP
p15502
Vbone disease
p15503
tp15504
I00
ssg10879
(lp15505
(dp15506
g10882
I336
sg10883
Vend-stage renal disease
p15507
sg10884
I23
sg10885
VC0022661
p15508
sg10887
I3
sa(dp15509
g10882
I126
sg10883
g15503
sg10884
I12
sg10885
VC0005940
p15510
sg10887
I2
sasg10888
(lp15511
(dp15512
g10882
I259
sg10883
Vbone specific alkaline phosphatase
p15513
sg10884
I34
sg10891
VP10696
p15514
sg10887
I4
sa(dp15515
g10882
I178
sg10883
VPTH
p15516
sg10884
I3
sg10891
VP01270
p15517
sg10887
I1
sa(dp15518
g10882
I150
sg10883
Vintact parathyroid hormone
p15519
sg10884
I26
sg10891
VP01270
p15520
sg10887
I3
sa(dp15521
g10882
I295
sg10883
g15502
sg10884
I4
sg10891
VP10696
p15522
sg10887
I1
sasa(dp15523
g10873
VFindings from research into mineral bone disorder associated with CKD (CKD-MBD) could help the medical community to better understand the vascular actions of certain molecules, such as phosphates, fibroblast growth factor 23, parathyroid hormone, sclerostin, or vitamin D and their relevance to the management of different pathologies in the general population.
p15524
sg4
(dp15525
(Vparathyroid hormone
p15526
Vbone disorder
p15527
tp15528
I00
ssg10879
(lp15529
(dp15530
g10882
I36
sg10883
g15527
sg10884
I13
sg10885
VC0005940
p15531
sg10887
I2
sasg10888
(lp15532
(dp15533
g10882
I197
sg10883
Vfibroblast growth factor 23
p15534
sg10884
I27
sg10891
g190
sg10887
I4
sa(dp15535
g10882
I226
sg10883
g15526
sg10884
I19
sg10891
VP01270
p15536
sg10887
I2
sasa(dp15537
g10873
V(3) Compared with the control group, the expression of CD63 in basophils increased in anaphylactic shock lung tissue.
p15538
sg4
(dp15539
(VCD63
p15540
Vshock lung
p15541
tp15542
I00
ssg10879
(lp15543
(dp15544
g10882
I86
sg10883
Vanaphylactic shock
p15545
sg10884
I18
sg10885
VC0002792
p15546
sg10887
I2
sa(dp15547
g10882
I99
sg10883
g15541
sg10884
I10
sg10885
VC0035222
p15548
sg10887
I2
sasg10888
(lp15549
(dp15550
g10882
I55
sg10883
g15540
sg10884
I4
sg10891
VP08962
p15551
sg10887
I1
sasa(dp15552
g10873
VWe report here that trichostatin-A (TSA) specifically induces the transcription of Cend1, a neuronal-lineage specific regulator of cell cycle exit and differentiation, in neuroblastoma Neuro2A cells, but not in non-neuronal cells.
p15553
sg4
(dp15554
(Vtrichostatin-A
p15555
Vneuroblastoma
p15556
tp15557
I00
ssg10879
(lp15558
(dp15559
g10882
I171
sg10883
g15556
sg10884
I13
sg10885
VC0027819
p15560
sg10887
I1
sasg10888
(lp15561
(dp15562
g10882
I36
sg10883
VTSA
p15563
sg10884
I3
sg10891
VP32119
p15564
sg10887
I1
sa(dp15565
g10882
I83
sg10883
VCend1
p15566
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp15567
g10882
I20
sg10883
g15555
sg10884
I14
sg10891
VP32119
p15568
sg10887
I1
sasa(dp15569
g10873
VBM88 overexpression also results in increased levels of the cell cycle regulatory protein p53, and accumulation of the hypophosphorylated form of the retinoblastoma protein leading to cell cycle arrest, with concomitant decreased levels and, in many cells, cytoplasmic localization of cyclin D1.
p15570
sg4
(dp15571
(Vcyclin D1
p15572
Vretinoblastoma
p15573
tp15574
I00
ssg10879
(lp15575
(dp15576
g10882
I150
sg10883
g15573
sg10884
I14
sg10885
VC0035335
p15577
sg10887
I1
sasg10888
(lp15578
(dp15579
g10882
I0
sg10883
VBM88
p15580
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp15581
g10882
I285
sg10883
g15572
sg10884
I9
sg10891
VP24385
p15582
sg10887
I2
sa(dp15583
g10882
I150
sg10883
Vretinoblastoma protein
p15584
sg10884
I22
sg10891
g190
sg10887
I2
sa(dp15585
g10882
I82
sg10883
Vprotein p53
p15586
sg10884
I11
sg10891
VP42771
p15587
sg10887
I2
sasa(dp15588
g10873
VIn conclusion, our findings show that overexpression of the neuron-specific antigen BM88 in neuroblastoma cells modifies their properties with respect to growth factor sensitivity, and, hence, the Neuro 2a and Neuro 2a-BM88 are suitable cell models to examine the role of growth factors in neuronal differentiation.
p15589
sg4
(dp15590
(Vneuron-specific antigen BM88
p15591
Vneuroblastoma
p15592
tp15593
I00
ssg10879
(lp15594
(dp15595
g10882
I92
sg10883
g15592
sg10884
I13
sg10885
VC0027819
p15596
sg10887
I1
sasg10888
(lp15597
(dp15598
g10882
I60
sg10883
g15591
sg10884
I28
sg10891
VP14209
p15599
sg10887
I3
sa(dp15600
g10882
I210
sg10883
VNeuro 2a-BM88
p15601
sg10884
I13
sg10891
g190
sg10887
I2
sasa(dp15602
g10873
VHere, we investigated the expression stabilities of ten previously recommended reference genes (ABCT, CYP, EF1A, FBOX, GPDH, RPL30, TUA4, TUB4, TUA5, and UNK2) in soybean under biotic stress from Bean pod mottle virus (BPMV), powdery mildew (PMD), soybean aphid (SBA), and two-spotted spider mite (TSSM).
p15603
sg4
(dp15604
(VEF1A
p15605
Vpowdery mildew
p15606
tp15607
I00
ssg10879
(lp15608
(dp15609
g10882
I242
sg10883
VPMD
p15610
sg10884
I3
sg10885
VC1832661
p15611
sg10887
I1
sa(dp15612
g10882
I226
sg10883
g15606
sg10884
I14
sg10885
VC1832661
p15613
sg10887
I2
sasg10888
(lp15614
(dp15615
g10882
I102
sg10883
VCYP
p15616
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp15617
g10882
I125
sg10883
VRPL30
p15618
sg10884
I5
sg10891
VP62888
p15619
sg10887
I1
sa(dp15620
g10882
I107
sg10883
g15605
sg10884
I4
sg10891
VP68104
p15621
sg10887
I1
sasa(dp15622
g10873
VThe surface expression of T cell costimulatory molecules CTLA-4 and CD28 and their counter-ligands, B7 molecules (CD80, CD86), is differentially induced for T cell activation and expansion in allergic asthma.
p15623
sg4
(dp15624
(VCD80
p15625
Vallergic asthma
p15626
tp15627
I00
ssg10879
(lp15628
(dp15629
g10882
I192
sg10883
g15626
sg10884
I15
sg10885
VC0155877
p15630
sg10887
I2
sasg10888
(lp15631
(dp15632
g10882
I68
sg10883
VCD28
p15633
sg10884
I4
sg10891
VP33681
p15634
sg10887
I1
sa(dp15635
g10882
I120
sg10883
VCD86
p15636
sg10884
I4
sg10891
VP42081
p15637
sg10887
I1
sa(dp15638
g10882
I26
sg10883
VT cell costimulatory molecules CTLA-4
p15639
sg10884
I37
sg10891
VP16410
p15640
sg10887
I5
sa(dp15641
g10882
I114
sg10883
g15625
sg10884
I4
sg10891
VP33681
p15642
sg10887
I1
sasa(dp15643
g10873
VPlasma concentrations of soluble CTLA-4 (sCTLA-4), CD28, CD80 and CD86 in 51 children with chronic allergic asthma with or without inhaled corticosteroid treatment, and 22 sex- and age-matched control subjects were measured by enzyme-linked immunosorbent assay.
p15644
sg4
(dp15645
(VCTLA-4
p15646
Vallergic asthma
p15647
tp15648
I00
ssg10879
(lp15649
(dp15650
g10882
I99
sg10883
g15647
sg10884
I15
sg10885
VC0155877
p15651
sg10887
I2
sasg10888
(lp15652
(dp15653
g10882
I57
sg10883
VCD80
p15654
sg10884
I4
sg10891
VP33681
p15655
sg10887
I1
sa(dp15656
g10882
I66
sg10883
VCD86
p15657
sg10884
I4
sg10891
VP42081
p15658
sg10887
I1
sa(dp15659
g10882
I51
sg10883
VCD28
p15660
sg10884
I4
sg10891
VP33681
p15661
sg10887
I1
sa(dp15662
g10882
I33
sg10883
g15646
sg10884
I6
sg10891
VP16410
p15663
sg10887
I1
sasa(dp15664
g10873
VThe percentage of myoglobin denaturation (PMD) of the CA groups was also increased according to the level of CA during storage.
p15665
sg4
(dp15666
(Vmyoglobin
p15667
Vpercentage of myoglobin denaturation
p15668
tp15669
I00
ssg10879
(lp15670
(dp15671
g10882
I42
sg10883
VPMD
p15672
sg10884
I3
sg10885
VC1832661
p15673
sg10887
I1
sa(dp15674
g10882
I4
sg10883
g15668
sg10884
I36
sg10885
VC1832661
p15675
sg10887
I4
sasg10888
(lp15676
(dp15677
g10882
I18
sg10883
g15667
sg10884
I9
sg10891
VP02144
p15678
sg10887
I1
sasa(dp15679
g10873
VLow expression of (or IHC-negative) COX2, miR-200c, ERCC1 and TS, or high expression of (or IHC-positive) CDC25B and p16 are potential biomarkers for predicting the response of esophageal cancer patients treated with chemo(radio)therapy.
p15680
sg4
(dp15681
(VERCC1
p15682
Vesophageal cancer
p15683
tp15684
I00
ssg10879
(lp15685
(dp15686
g10882
I177
sg10883
g15683
sg10884
I17
sg10885
VC0014859
p15687
sg10887
I2
sasg10888
(lp15688
(dp15689
g10882
I36
sg10883
VCOX2
p15690
sg10884
I4
sg10891
VP35354
p15691
sg10887
I1
sa(dp15692
g10882
I117
sg10883
Vp16
p15693
sg10884
I3
sg10891
VP42771
p15694
sg10887
I1
sa(dp15695
g10882
I42
sg10883
VmiR-200c
p15696
sg10884
I8
sg10891
g190
sg10887
I1
sa(dp15697
g10882
I106
sg10883
VCDC25B
p15698
sg10884
I6
sg10891
VP30305
p15699
sg10887
I1
sa(dp15700
g10882
I52
sg10883
g15682
sg10884
I5
sg10891
VP07992
p15701
sg10887
I1
sasa(dp15702
g10873
VERCC1-SNP in combination with mRNA ERCC1, DPYD, and ERBB2 from pretherapeutic endoscopic biopsies can predict minor response to chemoradiation, as a basis for individualized therapy of advanced esophageal cancer.
p15703
sg4
(dp15704
(VERCC1
p15705
Vesophageal cancer
p15706
tp15707
I00
ssg10879
(lp15708
(dp15709
g10882
I194
sg10883
g15706
sg10884
I17
sg10885
VC0014859
p15710
sg10887
I2
sasg10888
(lp15711
(dp15712
g10882
I6
sg10883
VSNP
p15713
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp15714
g10882
I0
sg10883
VERCC1
p15715
sg10884
I5
sg10891
VP07992
p15716
sg10887
I1
sa(dp15717
g10882
I52
sg10883
VERBB2
p15718
sg10884
I5
sg10891
VP04626
p15719
sg10887
I1
sa(dp15720
g10882
I0
sg10883
g15705
sg10884
I5
sg10891
VP07992
p15721
sg10887
I1
sasa(dp15722
g10873
VERCC1 C118T could be a predictive factor for the response to radiotherapy and chemotherapy, but not a prognostic factor for OS in esophageal cancer patients after surgery.
p15723
sg4
(dp15724
(VERCC1
p15725
Vesophageal cancer
p15726
tp15727
I00
ssg10879
(lp15728
(dp15729
g10882
I130
sg10883
g15726
sg10884
I17
sg10885
VC0014859
p15730
sg10887
I2
sasg10888
(lp15731
(dp15732
g10882
I0
sg10883
g15725
sg10884
I5
sg10891
VP07992
p15733
sg10887
I1
sasa(dp15734
g10873
VIn the present meta-analysis, we demonstrated that the ERCC1 rs3212986 polymorphism was significantly correlated with the response rate of esophageal cancer patients to neoadjuvant therapy (OR =  .49, 95% CI = 0.31-0.76, heterogeneity P = 0.480).
p15735
sg4
(dp15736
(VERCC1 rs3212986
p15737
Vesophageal cancer
p15738
tp15739
I00
ssg10879
(lp15740
(dp15741
g10882
I139
sg10883
g15738
sg10884
I17
sg10885
VC0014859
p15742
sg10887
I2
sasg10888
(lp15743
(dp15744
g10882
I55
sg10883
g15737
sg10884
I15
sg10891
VP07992
p15745
sg10887
I2
sasa(dp15746
g10873
VFurthermore, a considerable correlation was observed between ERCC1 rs11615 and the response rate of esophageal cancer patients to neoadjuvant therapy (OR = 0.228, 95% CI = 0.125-0.418, heterogeneity P = 0.291).
p15747
sg4
(dp15748
(VERCC1
p15749
Vesophageal cancer
p15750
tp15751
I00
ssg10879
(lp15752
(dp15753
g10882
I100
sg10883
g15750
sg10884
I17
sg10885
VC0014859
p15754
sg10887
I2
sasg10888
(lp15755
(dp15756
g10882
I61
sg10883
g15749
sg10884
I5
sg10891
VP07992
p15757
sg10887
I1
sasa(dp15758
g10873
VThese findings indicate that the ERCC1 rs11615 and ERCC1 rs312986 polymorphisms may be candidate pharmacogenomic factors capable of predicting the response rate of esophageal cancer patients who accept neoadjuvant therapy.
p15759
sg4
(dp15760
(VERCC1
p15761
Vesophageal cancer
p15762
tp15763
I00
ssg10879
(lp15764
(dp15765
g10882
I164
sg10883
g15762
sg10884
I17
sg10885
VC0014859
p15766
sg10887
I2
sasg10888
(lp15767
(dp15768
g10882
I33
sg10883
VERCC1 rs11615
p15769
sg10884
I13
sg10891
VP07992
p15770
sg10887
I2
sa(dp15771
g10882
I33
sg10883
g15761
sg10884
I5
sg10891
VP07992
p15772
sg10887
I1
sasa(dp15773
g10873
VIn patients with colon cancer, the expression of TSP50, MAGE-A(1-6), and SSX1,2,4 genes was associated with a poor prognosis, that of MAGE-C1 and XAGE1 was related to a favorable prognosis.
p15774
sg4
(dp15775
(VMAGE
p15776
Vcolon cancer
p15777
tp15778
I00
ssg10879
(lp15779
(dp15780
g10882
I17
sg10883
g15777
sg10884
I12
sg10885
VC0699790
p15781
sg10887
I2
sasg10888
(lp15782
(dp15783
g10882
I73
sg10883
VSSX1,2,4 genes
p15784
sg10884
I14
sg10891
g190
sg10887
I2
sa(dp15785
g10882
I49
sg10883
VTSP50
p15786
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp15787
g10882
I146
sg10883
VXAGE1
p15788
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp15789
g10882
I56
sg10883
g15776
sg10884
I4
sg10891
VP43355
p15790
sg10887
I1
sasa(dp15791
g10873
VConsequently, the expression of CT antigens MAGE-A1, MAGE-A4, CT7/MAGE-C1, NY-ESO-1, and GAGE was analyzed in a series of pediatric melanomas.
p15792
sg4
(dp15793
(VMAGE-A4
p15794
Vmelanomas
p15795
tp15796
I00
ssg10879
(lp15797
(dp15798
g10882
I132
sg10883
g15795
sg10884
I9
sg10885
VC0025202
p15799
sg10887
I1
sasg10888
(lp15800
(dp15801
g10882
I32
sg10883
VCT antigens MAGE-A1
p15802
sg10884
I19
sg10891
VP43355
p15803
sg10887
I3
sa(dp15804
g10882
I44
sg10883
VMAGE
p15805
sg10884
I4
sg10891
VP43355
p15806
sg10887
I1
sa(dp15807
g10882
I62
sg10883
VCT7
p15808
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp15809
g10882
I75
sg10883
VNY-ESO-1
p15810
sg10884
I8
sg10891
VP78358
p15811
sg10887
I1
sa(dp15812
g10882
I53
sg10883
g15794
sg10884
I7
sg10891
VP43355
p15813
sg10887
I1
sasa(dp15814
g10873
VIn this study, we show that the dying myeloma cells treated with chaetocin resulted in the induction of heat shock protein (HSP) 90, which was inhibited by antioxidant N-acetyl cysteine, and showed an increase in the expression of MAGE-A3 and MAGE-C1/CT7.
p15815
sg4
(dp15816
(VMAGE-A3
p15817
Vheat shock protein
p15818
tp15819
I00
ssg10879
(lp15820
(dp15821
g10882
I124
sg10883
VHSP
p15822
sg10884
I3
sg10885
VC0034152
p15823
sg10887
I1
sa(dp15824
g10882
I38
sg10883
Vmyeloma
p15825
sg10884
I7
sg10885
VC0026764
p15826
sg10887
I1
sa(dp15827
g10882
I104
sg10883
g15818
sg10884
I18
sg10885
VC0034152
p15828
sg10887
I3
sasg10888
(lp15829
(dp15830
g10882
I104
sg10883
Vheat shock protein (HSP) 90
p15831
sg10884
I27
sg10891
VP34931
p15832
sg10887
I5
sa(dp15833
g10882
I251
sg10883
VCT7
p15834
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp15835
g10882
I231
sg10883
VMAGE
p15836
sg10884
I4
sg10891
VP43355
p15837
sg10887
I1
sa(dp15838
g10882
I231
sg10883
g15817
sg10884
I7
sg10891
VP43355
p15839
sg10887
I1
sasa(dp15840
g10873
VWe used immunohistochemistry to examine the expression of four CTAs (MAGE-A, NY-ESO-1, CT7, and GAGE7) in various types of salivary gland carcinoma (n = 95).
p15841
sg4
(dp15842
(VMAGE-A
p15843
Vsalivary gland carcinoma
p15844
tp15845
I00
ssg10879
(lp15846
(dp15847
g10882
I123
sg10883
g15844
sg10884
I24
sg10885
VC0948750
p15848
sg10887
I3
sasg10888
(lp15849
(dp15850
g10882
I77
sg10883
VNY-ESO-1
p15851
sg10884
I8
sg10891
VP78358
p15852
sg10887
I1
sa(dp15853
g10882
I96
sg10883
VGAGE7
p15854
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp15855
g10882
I87
sg10883
VCT7
p15856
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp15857
g10882
I69
sg10883
g15843
sg10884
I6
sg10891
VP43355
p15858
sg10887
I1
sasa(dp15859
g10873
VThe expression of cancer testis antigen MAGE C1 has been linked to the malignant stem cell in this disease, and thus, we investigated the use of both flow cytometric and qRTPCR approaches to monitor its expression as an alternative monitoring methodology in this pilot study.
p15860
sg4
(dp15861
(Vtestis antigen MAGE C1
p15862
Vcancer testis
p15863
tp15864
I00
ssg10879
(lp15865
(dp15866
g10882
I18
sg10883
g15863
sg10884
I13
sg10885
VC0153594
p15867
sg10887
I2
sasg10888
(lp15868
(dp15869
g10882
I25
sg10883
g15862
sg10884
I22
sg10891
VP15735
p15870
sg10887
I4
sasa(dp15871
g10873
VOur study aims to analyze the expression pattern, mechanism, and prognostic significance of melanoma-associated antigen MAGE-C1 and MAGE-C2 in breast cancer.
p15872
sg4
(dp15873
(VMAGE
p15874
Vbreast cancer
p15875
tp15876
I01
ssg10879
(lp15877
(dp15878
g10882
I92
sg10883
Vmelanoma
p15879
sg10884
I8
sg10885
VC0025202
p15880
sg10887
I1
sa(dp15881
g10882
I143
sg10883
g15875
sg10884
I13
sg10885
VC0678222
p15882
sg10887
I2
sasg10888
(lp15883
(dp15884
g10882
I132
sg10883
VMAGE-C2
p15885
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp15886
g10882
I120
sg10883
g15874
sg10884
I4
sg10891
VP43355
p15887
sg10887
I1
sasa(dp15888
g10873
VReverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry were used to investigate the expressions of MAGE-C1 and MAGE-C2 in breast benign disease specimens, tumor-free breast specimens, and breast cancer specimens; their correlation with clinicopathologic parameters and recurrence-free survival was elucidated.
p15889
sg4
(dp15890
(VMAGE
p15891
Vbreast cancer
p15892
tp15893
I01
ssg10879
(lp15894
(dp15895
g10882
I215
sg10883
g15892
sg10884
I13
sg10885
VC0678222
p15896
sg10887
I2
sa(dp15897
g10882
I182
sg10883
Vtumor
p15898
sg10884
I5
sg10885
VC0027651
p15899
sg10887
I1
sa(dp15900
g10882
I296
sg10883
Vrecurrence
p15901
sg10884
I10
sg10885
VC1458156
p15902
sg10887
I1
sasg10888
(lp15903
(dp15904
g10882
I126
sg10883
VMAGE
p15905
sg10884
I4
sg10891
VP43355
p15906
sg10887
I1
sa(dp15907
g10882
I126
sg10883
g15891
sg10884
I4
sg10891
VP43355
p15908
sg10887
I1
sasa(dp15909
g10873
VWe examined the influence of DNA methylase inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR) together with histone deacetylase inhibitor trichostatin A on the expression of MAGE-C1 and MAGE-C2 in breast cancer cell lines.
p15910
sg4
(dp15911
(Vhistone deacetylase
p15912
Vbreast cancer
p15913
tp15914
I00
ssg10879
(lp15915
(dp15916
g10882
I191
sg10883
g15913
sg10884
I13
sg10885
VC0678222
p15917
sg10887
I2
sasg10888
(lp15918
(dp15919
g10882
I122
sg10883
Vinhibitor trichostatin A
p15920
sg10884
I24
sg10891
VP32119
p15921
sg10887
I3
sa(dp15922
g10882
I168
sg10883
VMAGE
p15923
sg10884
I4
sg10891
VP43355
p15924
sg10887
I1
sa(dp15925
g10882
I102
sg10883
g15912
sg10884
I19
sg10891
VP56524
p15926
sg10887
I2
sa(dp15927
g10882
I180
sg10883
VMAGE-C2
p15928
sg10884
I7
sg10891
g190
sg10887
I1
sasa(dp15929
g10873
VProteins for MAGE-C1 and MAGE-C2 expressions were 38.3% and 58.3% in breast cancer specimens, messenger RNA for MAGE-C1 and MAGE-C2 expressions were 43.3% and 61.7%, respectively.
p15930
sg4
(dp15931
(VMAGE
p15932
Vbreast cancer
p15933
tp15934
I01
ssg10879
(lp15935
(dp15936
g10882
I69
sg10883
g15933
sg10884
I13
sg10885
VC0678222
p15937
sg10887
I2
sasg10888
(lp15938
(dp15939
g10882
I13
sg10883
VMAGE
p15940
sg10884
I4
sg10891
VP43355
p15941
sg10887
I1
sa(dp15942
g10882
I13
sg10883
VMAGE
p15943
sg10884
I4
sg10891
VP43355
p15944
sg10887
I1
sa(dp15945
g10882
I13
sg10883
VMAGE
p15946
sg10884
I4
sg10891
VP43355
p15947
sg10887
I1
sa(dp15948
g10882
I13
sg10883
g15932
sg10884
I4
sg10891
VP43355
p15949
sg10887
I1
sasa(dp15950
g10873
VMAGE-C1 and MAGE-C2 maybe potential targets for tumor immunotherapy, and their expressions are associated with advanced breast cancer and poor outcome.
p15951
sg4
(dp15952
(VMAGE
p15953
Vbreast cancer
p15954
tp15955
I01
ssg10879
(lp15956
(dp15957
g10882
I120
sg10883
g15954
sg10884
I13
sg10885
VC0678222
p15958
sg10887
I2
sa(dp15959
g10882
I48
sg10883
Vtumor
p15960
sg10884
I5
sg10885
VC0027651
p15961
sg10887
I1
sasg10888
(lp15962
(dp15963
g10882
I0
sg10883
VMAGE
p15964
sg10884
I4
sg10891
VP43355
p15965
sg10887
I1
sa(dp15966
g10882
I0
sg10883
g15953
sg10884
I4
sg10891
VP43355
p15967
sg10887
I1
sasa(dp15968
g10873
VMRI represents the gold standard tool for differential diagnosis (with schwannoma, paraganglioma and haemangioma) and correct staging, while immunohistochemical and cytomorphologic analysis (bcl-2 and CD34 positivity in 90% of cases) is needed for definitive diagnosis.
p15969
sg4
(dp15970
(VCD34
p15971
Vparaganglioma
p15972
tp15973
I00
ssg10879
(lp15974
(dp15975
g10882
I101
sg10883
Vhaemangioma
p15976
sg10884
I11
sg10885
VC0018916
p15977
sg10887
I1
sa(dp15978
g10882
I71
sg10883
Vschwannoma
p15979
sg10884
I10
sg10885
VC0027809
p15980
sg10887
I1
sa(dp15981
g10882
I83
sg10883
g15972
sg10884
I13
sg10885
VC0030421
p15982
sg10887
I1
sasg10888
(lp15983
(dp15984
g10882
I191
sg10883
Vbcl-2
p15985
sg10884
I5
sg10891
VP10415
p15986
sg10887
I1
sa(dp15987
g10882
I201
sg10883
g15971
sg10884
I4
sg10891
VP28906
p15988
sg10887
I1
sasa(dp15989
g10873
VL'RMN rappresenta l'esame principale per escludere altre diagnosi (schwannoma, paragangliome ed emangioma) e per una corretta stadiazione mentre l'immunoistochimica e l'analisi citomorfologica (bcl-2 e CD34 positiva nel 90% dei casi) e la base per una diagnosi definitiva.
p15990
sg4
(dp15991
(Vbcl-2
p15992
Vschwannoma
p15993
tp15994
I00
ssg10879
(lp15995
(dp15996
g10882
I67
sg10883
g15993
sg10884
I10
sg10885
VC0027809
p15997
sg10887
I1
sasg10888
(lp15998
(dp15999
g10882
I202
sg10883
VCD34
p16000
sg10884
I4
sg10891
VP28906
p16001
sg10887
I1
sa(dp16002
g10882
I194
sg10883
g15992
sg10884
I5
sg10891
VP10415
p16003
sg10887
I1
sasa(dp16004
g10873
VDisease-specific iPS cells were generated from skin fibroblasts obtained from the indicated PMD patient and two other PMD patients having a 637-kb chromosomal duplication including entire PLP1 and a novel missense mutation (W212C) of PLP1, by transfections of OCT3/4, C-MYC, KLF4 and SOX2 using retro-virus vectors.
p16005
sg4
(dp16006
(VSOX2
p16007
VPMD
p16008
tp16009
I00
ssg10879
(lp16010
(dp16011
g10882
I147
sg10883
Vchromosomal duplication
p16012
sg10884
I23
sg10885
VC1516516
p16013
sg10887
I2
sa(dp16014
g10882
I17
sg10883
ViPS
p16015
sg10884
I3
sg10885
VC1837610
p16016
sg10887
I1
sa(dp16017
g10882
I92
sg10883
VPMD
p16018
sg10884
I3
sg10885
VC1832661
p16019
sg10887
I1
sa(dp16020
g10882
I92
sg10883
g16008
sg10884
I3
sg10885
VC1832661
p16021
sg10887
I1
sasg10888
(lp16022
(dp16023
g10882
I188
sg10883
VPLP1
p16024
sg10884
I4
sg10891
VP60201
p16025
sg10887
I1
sa(dp16026
g10882
I188
sg10883
VPLP1
p16027
sg10884
I4
sg10891
VP60201
p16028
sg10887
I1
sa(dp16029
g10882
I275
sg10883
VKLF4
p16030
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp16031
g10882
I268
sg10883
VC-MYC
p16032
sg10884
I5
sg10891
VP12524
p16033
sg10887
I1
sa(dp16034
g10882
I284
sg10883
g16007
sg10884
I4
sg10891
VP48431
p16035
sg10887
I1
sa(dp16036
g10882
I260
sg10883
VOCT3/4
p16037
sg10884
I6
sg10891
g190
sg10887
I1
sasa(dp16038
g10873
VOur findings further reveal that activated Akt and STAT3 pathways induce the upregulation of HIF1Alfa and its downstream targets (LDHA and PDK1), leading to increased glycolysis in myeloma cells.
p16039
sg4
(dp16040
(VSTAT3
p16041
Vmyeloma
p16042
tp16043
I00
ssg10879
(lp16044
(dp16045
g10882
I181
sg10883
g16042
sg10884
I7
sg10885
VC0026764
p16046
sg10887
I1
sasg10888
(lp16047
(dp16048
g10882
I43
sg10883
VAkt
p16049
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp16050
g10882
I139
sg10883
VPDK1
p16051
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp16052
g10882
I130
sg10883
VLDHA
p16053
sg10884
I4
sg10891
VP00338
p16054
sg10887
I1
sa(dp16055
g10882
I51
sg10883
g16041
sg10884
I5
sg10891
VP40763
p16056
sg10887
I1
sasa(dp16057
g10873
VWe show the unprecedented role of the metabolic phenotype in inducing drug resistance through LDHA and HIF1A in multiple myeloma, and that specific inhibition of LDHA and HIF1A can restore sensitivity to therapeutic agents such as bortezomib and can also inhibit tumor growth induced by altered metabolism.
p16058
sg4
(dp16059
(VLDHA
p16060
Vmultiple myeloma
p16061
tp16062
I01
ssg10879
(lp16063
(dp16064
g10882
I263
sg10883
Vtumor growth
p16065
sg10884
I12
sg10885
VC0598934
p16066
sg10887
I2
sa(dp16067
g10882
I112
sg10883
g16061
sg10884
I16
sg10885
VC0026764
p16068
sg10887
I2
sasg10888
(lp16069
(dp16070
g10882
I94
sg10883
VLDHA
p16071
sg10884
I4
sg10891
VP00338
p16072
sg10887
I1
sa(dp16073
g10882
I103
sg10883
VHIF1A
p16074
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp16075
g10882
I103
sg10883
VHIF1A
p16076
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp16077
g10882
I94
sg10883
g16060
sg10884
I4
sg10891
VP00338
p16078
sg10887
I1
sasa(dp16079
g10873
VNovel drugs that regulate metabolic pathways in multiple myeloma, specifically targeting LDHA, can be beneficial to inhibit tumor growth and overcome drug resistance.
p16080
sg4
(dp16081
(VLDHA
p16082
Vmultiple myeloma
p16083
tp16084
I01
ssg10879
(lp16085
(dp16086
g10882
I48
sg10883
g16083
sg10884
I16
sg10885
VC0026764
p16087
sg10887
I2
sa(dp16088
g10882
I124
sg10883
Vtumor growth
p16089
sg10884
I12
sg10885
VC0598934
p16090
sg10887
I2
sasg10888
(lp16091
(dp16092
g10882
I89
sg10883
g16082
sg10884
I4
sg10891
VP00338
p16093
sg10887
I1
sasa(dp16094
g10873
VA 36,000-Mr protein purified from mouse myeloma on the basis of selective binding to a single-stranded DNA (ssDNA)-cellulose column has been identified as the lactate dehydrogenase A (LDH-A) subunit.
p16095
sg4
(dp16096
(Vlactate dehydrogenase A
p16097
Vmyeloma
p16098
tp16099
I00
ssg10879
(lp16100
(dp16101
g10882
I40
sg10883
g16098
sg10884
I7
sg10885
VC0026764
p16102
sg10887
I1
sasg10888
(lp16103
(dp16104
g10882
I184
sg10883
VLDH-A
p16105
sg10884
I5
sg10891
VP00338
p16106
sg10887
I1
sa(dp16107
g10882
I159
sg10883
g16097
sg10884
I23
sg10891
VP49366
p16108
sg10887
I3
sasa(dp16109
g10873
VA homogeneous preparation of this mouse myeloma ssDNA-binding protein, termed the 'low-salt-eluting protein', was found to possess LDH activity, and rabbit antiserum prepared against this protein was shown to cross-react with purified 36,000-Mr LDH-A subunits from mouse and bovine sources.
p16110
sg4
(dp16111
(VLDH-A subunits
p16112
Vmyeloma
p16113
tp16114
I01
ssg10879
(lp16115
(dp16116
g10882
I40
sg10883
g16113
sg10884
I7
sg10885
VC0026764
p16117
sg10887
I1
sa(dp16118
g10882
I123
sg10883
Vpossess
p16119
sg10884
I7
sg10885
VC0850310
p16120
sg10887
I1
sasg10888
(lp16121
(dp16122
g10882
I131
sg10883
VLDH
p16123
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp16124
g10882
I245
sg10883
g16112
sg10884
I14
sg10891
VP00338
p16125
sg10887
I2
sa(dp16126
g10882
I34
sg10883
Vmouse myeloma ssDNA-binding protein
p16127
sg10884
I35
sg10891
g190
sg10887
I4
sasa(dp16128
g10873
VThese enzymic and immunological identities with LDH-A were not observed with purified helix-destabilizing protein 1 from mouse myeloma.
p16129
sg4
(dp16130
(VLDH-A
p16131
Vmyeloma
p16132
tp16133
I01
ssg10879
(lp16134
(dp16135
g10882
I127
sg10883
g16132
sg10884
I7
sg10885
VC0026764
p16136
sg10887
I1
sasg10888
(lp16137
(dp16138
g10882
I48
sg10883
g16131
sg10884
I5
sg10891
VP00338
p16139
sg10887
I1
sasa(dp16140
g10873
VConcentrations of total lactate dehydrogenase (LDH; EC 1.1.1.27) and LDH isoenzyme patterns were studied in serum of 19 patients with multiple myeloma and in 19 healthy controls.
p16141
sg4
(dp16142
(Vlactate dehydrogenase
p16143
Vmultiple myeloma
p16144
tp16145
I00
ssg10879
(lp16146
(dp16147
g10882
I134
sg10883
g16144
sg10884
I16
sg10885
VC0026764
p16148
sg10887
I2
sasg10888
(lp16149
(dp16150
g10882
I24
sg10883
g16143
sg10884
I21
sg10891
VP49366
p16151
sg10887
I2
sa(dp16152
g10882
I47
sg10883
VLDH
p16153
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp16154
g10882
I69
sg10883
VLDH isoenzyme
p16155
sg10884
I13
sg10891
g190
sg10887
I2
sasa(dp16156
g10873
VDefective DNA repair is tightly correlated with worse neurological outcomes after stroke, whereas upregulation of DNA repair enzymes, such as APE1, OGG1, and XRCC1, improves long-term functional recovery following stroke.
p16157
sg4
(dp16158
(VAPE1
p16159
Vstroke
p16160
tp16161
I00
ssg10879
(lp16162
(dp16163
g10882
I184
sg10883
Vfunctional recovery
p16164
sg10884
I19
sg10885
VC0599766
p16165
sg10887
I2
sa(dp16166
g10882
I82
sg10883
Vstroke
p16167
sg10884
I6
sg10885
VC0038454
p16168
sg10887
I1
sa(dp16169
g10882
I82
sg10883
g16160
sg10884
I6
sg10885
VC0038454
p16170
sg10887
I1
sasg10888
(lp16171
(dp16172
g10882
I158
sg10883
VXRCC1
p16173
sg10884
I5
sg10891
VP18887
p16174
sg10887
I1
sa(dp16175
g10882
I142
sg10883
g16159
sg10884
I4
sg10891
VP27695
p16176
sg10887
I1
sasa(dp16177
g10873
VOur data showed that OGG1 Ser326Cys and XRCC1 Arg399Gln gene polymorphisms had impacts on the development of stroke.
p16178
sg4
(dp16179
(VXRCC1 Arg399Gln gene
p16180
Vstroke
p16181
tp16182
I00
ssg10879
(lp16183
(dp16184
g10882
I109
sg10883
g16181
sg10884
I6
sg10885
VC0038454
p16185
sg10887
I1
sasg10888
(lp16186
(dp16187
g10882
I40
sg10883
g16180
sg10884
I20
sg10891
VP18887
p16188
sg10887
I3
sasa(dp16189
g10873
VGenotyping of polymorphisms of the OGG1 (Ser326Cys), XRCC1 (Arg399Gln), ERCC2 (Lys751Gln), and ERCC5 (Asp1104His) genes was performed and used to evaluate LAA stroke susceptibility.
p16190
sg4
(dp16191
(VXRCC1
p16192
Vstroke
p16193
tp16194
I00
ssg10879
(lp16195
(dp16196
g10882
I159
sg10883
g16193
sg10884
I6
sg10885
VC0038454
p16197
sg10887
I1
sasg10888
(lp16198
(dp16199
g10882
I95
sg10883
VERCC5 (Asp1104His) genes
p16200
sg10884
I24
sg10891
VP28715
p16201
sg10887
I3
sa(dp16202
g10882
I72
sg10883
VERCC2
p16203
sg10884
I5
sg10891
VP18074
p16204
sg10887
I1
sa(dp16205
g10882
I53
sg10883
g16192
sg10884
I5
sg10891
VP18887
p16206
sg10887
I1
sasa(dp16207
g10873
VA joint effect on risk elevation of LAA stroke was seen in those patients with OGG1 and ERCC2 polymorphisms (OR: 2.75, 95%CI: 1.26-6.00).
p16208
sg4
(dp16209
(VERCC2
p16210
Vstroke
p16211
tp16212
I00
ssg10879
(lp16213
(dp16214
g10882
I40
sg10883
g16211
sg10884
I6
sg10885
VC0038454
p16215
sg10887
I1
sasg10888
(lp16216
(dp16217
g10882
I88
sg10883
g16210
sg10884
I5
sg10891
VP18074
p16218
sg10887
I1
sasa(dp16219
g10873
VMoreover, among smokers carrying the OGG1 Ser326Cys polymorphism, there was a tendency toward an increased risk of LAA stroke in those patients who had a greater number of high-risk genotypes of XRCC1, ERCC2, and ERCC5 polymorphisms (p(trend)=0.010).
p16220
sg4
(dp16221
(VXRCC1
p16222
Vstroke
p16223
tp16224
I00
ssg10879
(lp16225
(dp16226
g10882
I119
sg10883
g16223
sg10884
I6
sg10885
VC0038454
p16227
sg10887
I1
sasg10888
(lp16228
(dp16229
g10882
I202
sg10883
VERCC2
p16230
sg10884
I5
sg10891
VP18074
p16231
sg10887
I1
sa(dp16232
g10882
I213
sg10883
VERCC5
p16233
sg10884
I5
sg10891
VP28715
p16234
sg10887
I1
sa(dp16235
g10882
I195
sg10883
g16222
sg10884
I5
sg10891
VP18887
p16236
sg10887
I1
sasa(dp16237
g10873
VTwo thousand four hundred ninety-three consecutive dermatitis patients in 9 dermatology clinics were patch tested with a TDM 6.6%, consisting of Disperse (D) Blue 35, D Yellow 3, D Orange 1 and 3, D Red 1 and 17, all 1.0% each, and D Blue 106 and D Blue 124, each 0.3%.
p16238
sg4
(dp16239
(VDisperse (D) Blue 35, D Yellow 3, D Orange 1 and 3, D Red 1
p16240
Vdermatitis
p16241
tp16242
I00
ssg10879
(lp16243
(dp16244
g10882
I51
sg10883
g16241
sg10884
I10
sg10885
VC0011603
p16245
sg10887
I1
sasg10888
(lp16246
(dp16247
g10882
I145
sg10883
g16240
sg10884
I59
sg10891
VP16435
p16248
sg10887
I15
sasa(dp16249
g10873
VIn this study, we evaluated the feasibility of combining p53-DC vaccine and rAd-p53 gene therapy, using the p53-overexpressing and non-expressing prostate cancer cells in vitro.
p16250
sg4
(dp16251
(VrAd
p16252
Vprostate cancer
p16253
tp16254
I01
ssg10879
(lp16255
(dp16256
g10882
I146
sg10883
g16253
sg10884
I15
sg10885
VC0600139
p16257
sg10887
I2
sasg10888
(lp16258
(dp16259
g10882
I57
sg10883
Vp53-DC
p16260
sg10884
I6
sg10891
VP42771
p16261
sg10887
I1
sa(dp16262
g10882
I57
sg10883
Vp53-
p16263
sg10884
I4
sg10891
VP42771
p16264
sg10887
I1
sa(dp16265
g10882
I57
sg10883
Vp53
p16266
sg10884
I3
sg10891
VP42771
p16267
sg10887
I1
sa(dp16268
g10882
I76
sg10883
g16252
sg10884
I3
sg10891
VP55042
p16269
sg10887
I1
sasa(dp16270
g10873
VIn addition, rAd-p53 infection can induce overexpression of p53 and thus the cytotoxicity of CTLs differentiated by the p53-DC vaccine in p53 non-expressing prostate cancer cells.
p16271
sg4
(dp16272
(VrAd-p53
p16273
Vprostate cancer
p16274
tp16275
I01
ssg10879
(lp16276
(dp16277
g10882
I77
sg10883
Vcytotoxicity
p16278
sg10884
I12
sg10885
VC0596402
p16279
sg10887
I1
sa(dp16280
g10882
I21
sg10883
Vinfection
p16281
sg10884
I9
sg10885
VC0009450
p16282
sg10887
I1
sa(dp16283
g10882
I157
sg10883
g16274
sg10884
I15
sg10885
VC0600139
p16284
sg10887
I2
sasg10888
(lp16285
(dp16286
g10882
I17
sg10883
Vp53
p16287
sg10884
I3
sg10891
VP42771
p16288
sg10887
I1
sa(dp16289
g10882
I120
sg10883
Vp53-DC
p16290
sg10884
I6
sg10891
VP42771
p16291
sg10887
I1
sa(dp16292
g10882
I13
sg10883
g16273
sg10884
I7
sg10891
VP55042
p16293
sg10887
I1
sa(dp16294
g10882
I17
sg10883
Vp53
p16295
sg10884
I3
sg10891
VP42771
p16296
sg10887
I1
sasa(dp16297
g10873
VThis study detected the migration of MSCs to high metastasis liver carcinoma cells MHCC-97H in vitro, investigated the inhibitory effect of rAd-NK4-MSCs on the growth and metastasis of MHCC-97H cells, further explored the inhibitory mechanism of rAd-NK4-MSCs to MHCC-97H cell metastasis, and examined the inhibitory effect of rAd-NK4-MSCs on the migration of human umbilical vein endothelial cells (HUVECs) in vitro.
p16298
sg4
(dp16299
(VNK4
p16300
Vmetastasis
p16301
tp16302
I00
ssg10879
(lp16303
(dp16304
g10882
I50
sg10883
Vmetastasis
p16305
sg10884
I10
sg10885
VC0027627
p16306
sg10887
I1
sa(dp16307
g10882
I50
sg10883
Vmetastasis
p16308
sg10884
I10
sg10885
VC0027627
p16309
sg10887
I1
sa(dp16310
g10882
I61
sg10883
Vliver carcinoma
p16311
sg10884
I15
sg10885
VC2239176
p16312
sg10887
I2
sa(dp16313
g10882
I50
sg10883
g16301
sg10884
I10
sg10885
VC0027627
p16314
sg10887
I1
sasg10888
(lp16315
(dp16316
g10882
I140
sg10883
VrAd-NK4-MSCs
p16317
sg10884
I12
sg10891
VP55042
p16318
sg10887
I1
sa(dp16319
g10882
I140
sg10883
VrAd
p16320
sg10884
I3
sg10891
VP55042
p16321
sg10887
I1
sa(dp16322
g10882
I140
sg10883
VrAd-NK4-MSCs
p16323
sg10884
I12
sg10891
VP55042
p16324
sg10887
I1
sa(dp16325
g10882
I144
sg10883
g16300
sg10884
I3
sg10891
VP24001
p16326
sg10887
I1
sasa(dp16327
g10873
VThe present study was conducted to identify the anti-tumor effects of rAd/p53, which is a recombinant human serotype 5 adenovirus, in cutaneous squamous cell carcinoma (cSCC).
p16328
sg4
(dp16329
(VrAd
p16330
VcSCC
p16331
tp16332
I00
ssg10879
(lp16333
(dp16334
g10882
I134
sg10883
Vcutaneous squamous cell carcinoma
p16335
sg10884
I33
sg10885
VC0553723
p16336
sg10887
I4
sa(dp16337
g10882
I119
sg10883
Vadenovirus
p16338
sg10884
I10
sg10885
VC0001486
p16339
sg10887
I1
sa(dp16340
g10882
I169
sg10883
g16331
sg10884
I4
sg10885
VC0553723
p16341
sg10887
I1
sa(dp16342
g10882
I53
sg10883
Vtumor
p16343
sg10884
I5
sg10885
VC0027651
p16344
sg10887
I1
sasg10888
(lp16345
(dp16346
g10882
I70
sg10883
g16330
sg10884
I3
sg10891
VP55042
p16347
sg10887
I1
sa(dp16348
g10882
I74
sg10883
Vp53
p16349
sg10884
I3
sg10891
VP42771
p16350
sg10887
I1
sasa(dp16351
g10873
VFinally, the mechanistic experiments indicate that DUXAP10 could interact with Histone demethylase Lysine specific demethylase1 (LSD1) and repress tumor suppressors Large tumor suppressor 2 (LATS2) and Ras-related associated with diabetes (RRAD) transcription in NSCLC cells.
p16352
sg4
(dp16353
(VRas
p16354
VNSCLC
p16355
tp16356
I00
ssg10879
(lp16357
(dp16358
g10882
I147
sg10883
Vtumor
p16359
sg10884
I5
sg10885
VC0027651
p16360
sg10887
I1
sa(dp16361
g10882
I230
sg10883
Vdiabetes
p16362
sg10884
I8
sg10885
VC0011849
p16363
sg10887
I1
sa(dp16364
g10882
I147
sg10883
Vtumor
p16365
sg10884
I5
sg10885
VC0027651
p16366
sg10887
I1
sa(dp16367
g10882
I263
sg10883
g16355
sg10884
I5
sg10885
VC0007131
p16368
sg10887
I1
sasg10888
(lp16369
(dp16370
g10882
I79
sg10883
VHistone demethylase Lysine specific demethylase1
p16371
sg10884
I48
sg10891
g190
sg10887
I5
sa(dp16372
g10882
I165
sg10883
VLarge tumor suppressor 2
p16373
sg10884
I24
sg10891
g190
sg10887
I4
sa(dp16374
g10882
I191
sg10883
VLATS2
p16375
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp16376
g10882
I202
sg10883
g16354
sg10884
I3
sg10891
VP01116
p16377
sg10887
I1
sasa(dp16378
g10873
VTo compare clinical curative effects and toxicity of recombinant human adenovirus-p53 injection (rAd-p53, Gendicine) combining chemoradiotherapy (CRT)/radiotherapy (RT) with those obtained with CRT/RT alone in nasopharyngeal carcinoma (NPC).
p16379
sg4
(dp16380
(Vchemoradiotherapy
p16381
VNPC
p16382
tp16383
I00
ssg10879
(lp16384
(dp16385
g10882
I71
sg10883
Vadenovirus
p16386
sg10884
I10
sg10885
VC0001486
p16387
sg10887
I1
sa(dp16388
g10882
I210
sg10883
Vnasopharyngeal carcinoma
p16389
sg10884
I24
sg10885
VC2931822
p16390
sg10887
I2
sa(dp16391
g10882
I236
sg10883
g16382
sg10884
I3
sg10885
VC2931822
p16392
sg10887
I1
sasg10888
(lp16393
(dp16394
g10882
I97
sg10883
VrAd-p53
p16395
sg10884
I7
sg10891
VP55042
p16396
sg10887
I1
sa(dp16397
g10882
I146
sg10883
VCRT
p16398
sg10884
I3
sg10891
VP27797
p16399
sg10887
I1
sa(dp16400
g10882
I53
sg10883
Vrecombinant human adenovirus-p53 injection
p16401
sg10884
I42
sg10891
VP55042
p16402
sg10887
I4
sa(dp16403
g10882
I127
sg10883
g16381
sg10884
I17
sg10891
VP27797
p16404
sg10887
I1
sasa(dp16405
g10873
VConsistent with these findings, we observed that in an IL-33-administered asthmatic airway inflammation model, IL-13 levels were markedly increased in bronchoalveolar lavage fluid, but its levels were markedly suppressed by treatment with inhibitors of 5-LO, 12-LO or BLT2, further suggesting roles of 5-/12-LO in IL-33-induced IL-13 production.
p16406
sg4
(dp16407
(VIL-13
p16408
Vasthmatic
p16409
tp16410
I00
ssg10879
(lp16411
(dp16412
g10882
I91
sg10883
Vinflammation
p16413
sg10884
I12
sg10885
VC0021368
p16414
sg10887
I1
sa(dp16415
g10882
I74
sg10883
g16409
sg10884
I9
sg10885
VC0004096
p16416
sg10887
I1
sasg10888
(lp16417
(dp16418
g10882
I268
sg10883
VBLT2
p16419
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp16420
g10882
I111
sg10883
VIL-13
p16421
sg10884
I5
sg10891
VP35225
p16422
sg10887
I1
sa(dp16423
g10882
I111
sg10883
g16408
sg10884
I5
sg10891
VP35225
p16424
sg10887
I1
sasa(dp16425
g10873
VOur results suggest that "MyD88-5-/12-LO-BLT2-NF-KB" cascade significantly contributes to the IL-33-induced synthesis of IL-13 in mast cells, thus potentially contributing to asthmatic development and exacerbation.
p16426
sg4
(dp16427
(VIL-13
p16428
Vasthmatic
p16429
tp16430
I00
ssg10879
(lp16431
(dp16432
g10882
I175
sg10883
g16429
sg10884
I9
sg10885
VC0004096
p16433
sg10887
I1
sasg10888
(lp16434
(dp16435
g10882
I41
sg10883
VBLT2
p16436
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp16437
g10882
I26
sg10883
VMyD88
p16438
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp16439
g10882
I121
sg10883
g16428
sg10884
I5
sg10891
VP35225
p16440
sg10887
I1
sasa(dp16441
g10873
VDNA methylation changes at a number of these genes have been linked to various forms of human disease, including cancers, such as asthma and acute myeloid leukemia (ALOX12), gastric cancer (EBF3), breast cancer (NAV1), colon cancer and acute lymphoid leukemia (KCNK15), Wilms tumor (protocadherin gene cluster; PCDHAs) and colorectal cancer (TCERG1L), suggesting a potential etiologic role for MEs in tumorigenesis and underscoring the possible developmental origins of these malignancies.
p16442
sg4
(dp16443
(Vgastric cancer (EBF3), breast cancer (NAV1), colon cancer and acute lymphoid leukemia
p16444
VWilms tumor
p16445
tp16446
I00
ssg10879
(lp16447
(dp16448
g10882
I197
sg10883
Vbreast cancer
p16449
sg10884
I13
sg10885
VC0678222
p16450
sg10887
I2
sa(dp16451
g10882
I401
sg10883
Vtumorigenesis
p16452
sg10884
I13
sg10885
VC0007621
p16453
sg10887
I1
sa(dp16454
g10882
I174
sg10883
Vgastric cancer
p16455
sg10884
I14
sg10885
VC0024623
p16456
sg10887
I2
sa(dp16457
g10882
I141
sg10883
Vacute myeloid leukemia
p16458
sg10884
I22
sg10885
VC0023467
p16459
sg10887
I3
sa(dp16460
g10882
I236
sg10883
Vacute lymphoid leukemia
p16461
sg10884
I23
sg10885
VC1961102
p16462
sg10887
I3
sa(dp16463
g10882
I219
sg10883
Vcolon cancer
p16464
sg10884
I12
sg10885
VC0699790
p16465
sg10887
I2
sa(dp16466
g10882
I130
sg10883
Vasthma
p16467
sg10884
I6
sg10885
VC0004096
p16468
sg10887
I1
sa(dp16469
g10882
I476
sg10883
Vmalignancies
p16470
sg10884
I12
sg10885
VC0006826
p16471
sg10887
I1
sa(dp16472
g10882
I323
sg10883
Vcolorectal cancer
p16473
sg10884
I17
sg10885
VC1527249
p16474
sg10887
I2
sa(dp16475
g10882
I394
sg10883
VMEs
p16476
sg10884
I3
sg10885
VC0265215
p16477
sg10887
I1
sa(dp16478
g10882
I113
sg10883
Vcancers
p16479
sg10884
I7
sg10885
VC0006826
p16480
sg10887
I1
sa(dp16481
g10882
I270
sg10883
g16445
sg10884
I11
sg10885
VC0027708
p16482
sg10887
I2
sasg10888
(lp16483
(dp16484
g10882
I174
sg10883
g16444
sg10884
I85
sg10891
VP12830
p16485
sg10887
I12
sa(dp16486
g10882
I270
sg10883
VWilms tumor (protocadherin gene cluster; PCDHAs) and colorectal cancer (TCERG1L)
p16487
sg10884
I80
sg10891
g190
sg10887
I10
sa(dp16488
g10882
I261
sg10883
VKCNK15
p16489
sg10884
I6
sg10891
g190
sg10887
I1
sasa(dp16490
g10873
VDNA methylation of ALOX12 may be an epigenetic biomarker for the risk of asthma-related phenotypes.
p16491
sg4
(dp16492
(VALOX12
p16493
Vasthma
p16494
tp16495
I01
ssg10879
(lp16496
(dp16497
g10882
I73
sg10883
g16494
sg10884
I6
sg10885
VC0004096
p16498
sg10887
I1
sasg10888
(lp16499
(dp16500
g10882
I19
sg10883
g16493
sg10884
I6
sg10891
VP18054
p16501
sg10887
I1
sasa(dp16502
g10873
VWe provide evidence that MJD in five pedigrees of Azorean descent is also linked to chromosome 14q in an 18-cM region between the markers D14S67 and AACT (multipoint lod score +7.00 near D14S81).
p16503
sg4
(dp16504
(VAACT
p16505
VMJD
p16506
tp16507
I00
ssg10879
(lp16508
(dp16509
g10882
I25
sg10883
g16506
sg10884
I3
sg10885
VC0024408
p16510
sg10887
I1
sasg10888
(lp16511
(dp16512
g10882
I149
sg10883
g16505
sg10884
I4
sg10891
VP05154
p16513
sg10887
I1
sasa(dp16514
g10873
VThe present study deals with CTLA-4 gene selected polymorphisms (rs11571317 C/T and rs3087243G/A) to explore their relation with breast cancer susceptibility and progression in BC patients.
p16515
sg4
(dp16516
(VCTLA-4 gene
p16517
Vbreast cancer
p16518
tp16519
I00
ssg10879
(lp16520
(dp16521
g10882
I129
sg10883
g16518
sg10884
I13
sg10885
VC0678222
p16522
sg10887
I2
sasg10888
(lp16523
(dp16524
g10882
I29
sg10883
g16517
sg10884
I11
sg10891
VP16410
p16525
sg10887
I2
sasa(dp16526
g10873
VClinical experience with checkpoint inhibitors in hepatocellular carcinoma includes early trials with the anti-CTLA-4 agent tremelimumab, and a large phase 2 trial with the anti-PD-1 agent nivolumab.
p16527
sg4
(dp16528
(Vanti-CTLA-4
p16529
Vhepatocellular carcinoma
p16530
tp16531
I00
ssg10879
(lp16532
(dp16533
g10882
I50
sg10883
g16530
sg10884
I24
sg10885
VC1512411
p16534
sg10887
I2
sasg10888
(lp16535
(dp16536
g10882
I106
sg10883
g16529
sg10884
I11
sg10891
VP16410
p16537
sg10887
I1
sasa(dp16538
g10873
VSeveral immune checkpoint inhibitors that target programmed cell death protein 1 (PD1), its ligand PDL1, and cytotoxic T lymphocyte-associated protein 4 (CTLA4) have already been approved for use in bladder cancer, representing the most important change to the urological oncologist's tool-kit in over a decade.
p16539
sg4
(dp16540
(Vprogrammed cell death protein 1
p16541
Vbladder cancer
p16542
tp16543
I00
ssg10879
(lp16544
(dp16545
g10882
I199
sg10883
g16542
sg10884
I14
sg10885
VC0699885
p16546
sg10887
I2
sasg10888
(lp16547
(dp16548
g10882
I154
sg10883
VCTLA4
p16549
sg10884
I5
sg10891
VP16410
p16550
sg10887
I1
sa(dp16551
g10882
I99
sg10883
VPDL1
p16552
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp16553
g10882
I82
sg10883
VPD1
p16554
sg10884
I3
sg10891
VP37840
p16555
sg10887
I1
sa(dp16556
g10882
I109
sg10883
Vcytotoxic T lymphocyte-associated protein 4
p16557
sg10884
I43
sg10891
VP16410
p16558
sg10887
I5
sa(dp16559
g10882
I49
sg10883
g16541
sg10884
I31
sg10891
VP37840
p16560
sg10887
I5
sasa(dp16561
g10873
VOur model predicts survival in anti-CTLA-4-treated patients with melanoma and anti-PD-1-treated patients with lung cancer.
p16562
sg4
(dp16563
(Vanti-PD-1
p16564
Vlung cancer
p16565
tp16566
I00
ssg10879
(lp16567
(dp16568
g10882
I65
sg10883
Vmelanoma
p16569
sg10884
I8
sg10885
VC0025202
p16570
sg10887
I1
sa(dp16571
g10882
I110
sg10883
g16565
sg10884
I11
sg10885
VC0684249
p16572
sg10887
I2
sasg10888
(lp16573
(dp16574
g10882
I31
sg10883
Vanti-CTLA-4
p16575
sg10884
I11
sg10891
VP16410
p16576
sg10887
I1
sa(dp16577
g10882
I78
sg10883
g16564
sg10884
I9
sg10891
VP18621
p16578
sg10887
I1
sasa(dp16579
g10873
VSmall animal PET/CT studies showed that 89Zr-C4 detected antigen levels on a patient derived xenograft (PDX) established from a non-small-cell lung cancer (NSCLC) patient before an 8-month response to anti-PD-1 and anti-CTLA4 therapy.
p16580
sg4
(dp16581
(Vanti-CTLA4
p16582
VNSCLC
p16583
tp16584
I00
ssg10879
(lp16585
(dp16586
g10882
I128
sg10883
Vnon-small-cell lung cancer
p16587
sg10884
I26
sg10885
VC0007131
p16588
sg10887
I3
sa(dp16589
g10882
I156
sg10883
g16583
sg10884
I5
sg10885
VC0007131
p16590
sg10887
I1
sasg10888
(lp16591
(dp16592
g10882
I201
sg10883
Vanti-PD-1
p16593
sg10884
I9
sg10891
VP18621
p16594
sg10887
I1
sa(dp16595
g10882
I215
sg10883
g16582
sg10884
I10
sg10891
VP16410
p16596
sg10887
I1
sasa(dp16597
g10873
VAutosomal disorders such as mutations of the phosphomannomutase 2 (PMM2) gene, the galactose-1-phosphate uridyltransferase (GALT) gene, the FSH receptor (FSHR) gene, chromosome 3q containing the Blepharophimosis gene and the autoimmune regulator (AIRE) gene, responsible for polyendocrinopathy-candidiasis-ectodermal dystrophy, have been identified in patients with POF.
p16598
sg4
(dp16599
(VFSH receptor
p16600
VPOF
p16601
tp16602
I00
ssg10879
(lp16603
(dp16604
g10882
I294
sg10883
Vcandidiasis
p16605
sg10884
I11
sg10885
VC0006840
p16606
sg10887
I1
sa(dp16607
g10882
I317
sg10883
Vdystrophy
p16608
sg10884
I9
sg10885
VC0333606
p16609
sg10887
I1
sa(dp16610
g10882
I195
sg10883
VBlepharophimosis
p16611
sg10884
I16
sg10885
VC0005744
p16612
sg10887
I1
sa(dp16613
g10882
I225
sg10883
Vautoimmune
p16614
sg10884
I10
sg10885
VC0443146
p16615
sg10887
I1
sa(dp16616
g10882
I366
sg10883
g16601
sg10884
I3
sg10885
VC0085215
p16617
sg10887
I1
sasg10888
(lp16618
(dp16619
g10882
I124
sg10883
VGALT
p16620
sg10884
I4
sg10891
VP15291
p16621
sg10887
I1
sa(dp16622
g10882
I154
sg10883
VFSHR
p16623
sg10884
I4
sg10891
VP23945
p16624
sg10887
I1
sa(dp16625
g10882
I140
sg10883
g16600
sg10884
I12
sg10891
VP23945
p16626
sg10887
I2
sa(dp16627
g10882
I67
sg10883
VPMM2
p16628
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp16629
g10882
I83
sg10883
Vgalactose-1-phosphate uridyltransferase
p16630
sg10884
I39
sg10891
g190
sg10887
I2
sa(dp16631
g10882
I45
sg10883
Vphosphomannomutase 2
p16632
sg10884
I20
sg10891
g190
sg10887
I2
sasa(dp16633
g10873
VOsteoclast-specific genes such as Trap, osteopetrosis-associated transmembrane protein 1 (Ostm1), chloride channel 7 (Clcn7), cathepsin K (Ctsk) as well as osteoclast-specific transcription factor and microphthalmia transcription factor (MITF) were up-regulated in the treated cells, whilst the messenger RNA (mRNA) levels of Dspp, Dmp1 and Opg were reduced in the induced cells.
p16634
sg4
(dp16635
(VCtsk
p16636
Vmicrophthalmia
p16637
tp16638
I00
ssg10879
(lp16639
(dp16640
g10882
I40
sg10883
Vosteopetrosis
p16641
sg10884
I13
sg10885
VC0029454
p16642
sg10887
I1
sa(dp16643
g10882
I201
sg10883
g16637
sg10884
I14
sg10885
VC0026010
p16644
sg10887
I1
sasg10888
(lp16645
(dp16646
g10882
I332
sg10883
VDmp1
p16647
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp16648
g10882
I126
sg10883
Vcathepsin K
p16649
sg10884
I11
sg10891
VP43235
p16650
sg10887
I2
sa(dp16651
g10882
I118
sg10883
VClcn7
p16652
sg10884
I5
sg10891
VP51798
p16653
sg10887
I1
sa(dp16654
g10882
I201
sg10883
Vmicrophthalmia transcription factor
p16655
sg10884
I35
sg10891
VP35398
p16656
sg10887
I3
sa(dp16657
g10882
I326
sg10883
VDspp
p16658
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp16659
g10882
I139
sg10883
g16636
sg10884
I4
sg10891
VP43235
p16660
sg10887
I1
sa(dp16661
g10882
I238
sg10883
VMITF
p16662
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp16663
g10882
I34
sg10883
VTrap, osteopetrosis-associated transmembrane protein 1 (Ostm1), chloride channel 7
p16664
sg10884
I82
sg10891
g190
sg10887
I9
sa(dp16665
g10882
I341
sg10883
VOpg
p16666
sg10884
I3
sg10891
g190
sg10887
I1
sasa(dp16667
g10873
VCathepsin K is a protease whose expression is driven by microphthalmia transcription factor (MITF) in osteoclasts.
p16668
sg4
(dp16669
(Vmicrophthalmia transcription factor
p16670
Vmicrophthalmia
p16671
tp16672
I00
ssg10879
(lp16673
(dp16674
g10882
I56
sg10883
g16671
sg10884
I14
sg10885
VC0026010
p16675
sg10887
I1
sasg10888
(lp16676
(dp16677
g10882
I0
sg10883
VCathepsin K
p16678
sg10884
I11
sg10891
VP43235
p16679
sg10887
I2
sa(dp16680
g10882
I56
sg10883
g16670
sg10884
I35
sg10891
VP35398
p16681
sg10887
I3
sa(dp16682
g10882
I93
sg10883
VMITF
p16683
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp16684
g10873
VAmong cell species that infiltrated in perichondral granulation, LCA, CD68 (monocytes/macrophages), and CD4 cells were dominant in number; MMP-8, MMP-9, and elastase were expressed only in the perichondral granulation; whereas MMP-3 and cathepsin K and L were detected in both chondrocytes and granulations.
p16685
sg4
(dp16686
(VCD68
p16687
VLCA
p16688
tp16689
I00
ssg10879
(lp16690
(dp16691
g10882
I24
sg10883
Vinfiltrated
p16692
sg10884
I11
sg10885
VC0332448
p16693
sg10887
I1
sa(dp16694
g10882
I65
sg10883
g16688
sg10884
I3
sg10885
VC0339527
p16695
sg10887
I1
sasg10888
(lp16696
(dp16697
g10882
I146
sg10883
VMMP-9
p16698
sg10884
I5
sg10891
VP14780
p16699
sg10887
I1
sa(dp16700
g10882
I139
sg10883
VMMP-8
p16701
sg10884
I5
sg10891
VP22894
p16702
sg10887
I1
sa(dp16703
g10882
I237
sg10883
Vcathepsin K and L
p16704
sg10884
I17
sg10891
VP43235
p16705
sg10887
I4
sa(dp16706
g10882
I104
sg10883
VCD4
p16707
sg10884
I3
sg10891
VP01730
p16708
sg10887
I1
sa(dp16709
g10882
I157
sg10883
Velastase
p16710
sg10884
I8
sg10891
VP30740
p16711
sg10887
I1
sa(dp16712
g10882
I227
sg10883
VMMP-3
p16713
sg10884
I5
sg10891
VP08254
p16714
sg10887
I1
sa(dp16715
g10882
I65
sg10883
VLCA
p16716
sg10884
I3
sg10891
VP09496
p16717
sg10887
I1
sa(dp16718
g10882
I70
sg10883
g16687
sg10884
I4
sg10891
VP34810
p16719
sg10887
I1
sasa(dp16720
g10873
VOverexpression of microphthalmia transcription factor has been shown to mediate the expression of cathepsin-K in osteoclasts.
p16721
sg4
(dp16722
(Vcathepsin-K
p16723
Vmicrophthalmia
p16724
tp16725
I00
ssg10879
(lp16726
(dp16727
g10882
I18
sg10883
g16724
sg10884
I14
sg10885
VC0026010
p16728
sg10887
I1
sasg10888
(lp16729
(dp16730
g10882
I18
sg10883
Vmicrophthalmia transcription factor
p16731
sg10884
I35
sg10891
VP35398
p16732
sg10887
I3
sa(dp16733
g10882
I98
sg10883
g16723
sg10884
I11
sg10891
VP43235
p16734
sg10887
I1
sasa(dp16735
g10873
VWe studied cathepsin-K in 17 cytogenetically confirmed microphthalmia transcription factor/TFE-family translocation renal cell carcinomas.
p16736
sg4
(dp16737
(Vmicrophthalmia transcription factor
p16738
Vtranslocation
p16739
tp16740
I00
ssg10879
(lp16741
(dp16742
g10882
I116
sg10883
Vrenal cell carcinomas
p16743
sg10884
I21
sg10885
VC0007134
p16744
sg10887
I3
sa(dp16745
g10882
I55
sg10883
Vmicrophthalmia
p16746
sg10884
I14
sg10885
VC0026010
p16747
sg10887
I1
sa(dp16748
g10882
I102
sg10883
g16739
sg10884
I13
sg10885
VC0040715
p16749
sg10887
I1
sasg10888
(lp16750
(dp16751
g10882
I55
sg10883
g16738
sg10884
I35
sg10891
VP35398
p16752
sg10887
I3
sasa(dp16753
g10873
VRadiographs of the hands of 60 patients with cartilage hair hypoplasia (CHH), 69 with trichorhinophalangeal syndrome I (TRP I) and 11 with TRP II were examined, including 26 longitudinal observations.
p16754
sg4
(dp16755
(VTRP II
p16756
Vtrichorhinophalangeal syndrome I
p16757
tp16758
I00
ssg10879
(lp16759
(dp16760
g10882
I120
sg10883
VTRP I
p16761
sg10884
I5
sg10885
VC0432233
p16762
sg10887
I2
sa(dp16763
g10882
I45
sg10883
Vcartilage hair hypoplasia
p16764
sg10884
I25
sg10885
VC0220748
p16765
sg10887
I3
sa(dp16766
g10882
I72
sg10883
VCHH
p16767
sg10884
I3
sg10885
VC0220748
p16768
sg10887
I1
sa(dp16769
g10882
I86
sg10883
g16757
sg10884
I32
sg10885
VC0432233
p16770
sg10887
I3
sasg10888
(lp16771
(dp16772
g10882
I139
sg10883
g16756
sg10884
I6
sg10891
VP13686
p16773
sg10887
I2
sasa(dp16774
g10873
VHowever, the effects of the potential herb-drug interactions (HDIs) between LCA and therapeutic drugs on the inhibition of human cytochrome P450 (CYP) enzymes remain unclear.
p16775
sg4
(dp16776
(Vhuman cytochrome P450
p16777
VLCA
p16778
tp16779
I00
ssg10879
(lp16780
(dp16781
g10882
I76
sg10883
g16778
sg10884
I3
sg10885
VC0339527
p16782
sg10887
I1
sasg10888
(lp16783
(dp16784
g10882
I146
sg10883
VCYP
p16785
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp16786
g10882
I123
sg10883
g16777
sg10884
I21
sg10891
VP20853
p16787
sg10887
I3
sasa(dp16788
g10873
VIn the present study, the inhibitory effects of LCA on seven major human CYP isoforms, including CYP1A2, 2D6, 2E1, 2C19, 2C8, 2C9 and 3A4, were investigated in human liver microsomes (HLMs).
p16789
sg4
(dp16790
(VCYP1A2
p16791
VLCA
p16792
tp16793
I00
ssg10879
(lp16794
(dp16795
g10882
I48
sg10883
g16792
sg10884
I3
sg10885
VC0339527
p16796
sg10887
I1
sasg10888
(lp16797
(dp16798
g10882
I61
sg10883
Vmajor human CYP isoforms
p16799
sg10884
I24
sg10891
g190
sg10887
I4
sa(dp16800
g10882
I97
sg10883
g16791
sg10884
I6
sg10891
VP05177
p16801
sg10887
I1
sasa(dp16802
g10873
VThe results demonstrated that LCA significantly inhibited the activities of CYP1A2, 2C19, 2C8, 2C9 and 3A4 and exhibited weak inhibitory effects on CYP2E1 and CYP2D6.
p16803
sg4
(dp16804
(VCYP2D6
p16805
VLCA
p16806
tp16807
I00
ssg10879
(lp16808
(dp16809
g10882
I30
sg10883
g16806
sg10884
I3
sg10885
VC0339527
p16810
sg10887
I1
sasg10888
(lp16811
(dp16812
g10882
I76
sg10883
VCYP1A2
p16813
sg10884
I6
sg10891
VP05177
p16814
sg10887
I1
sa(dp16815
g10882
I148
sg10883
VCYP2E1
p16816
sg10884
I6
sg10891
VP05181
p16817
sg10887
I1
sa(dp16818
g10882
I159
sg10883
g16805
sg10884
I6
sg10891
VP10635
p16819
sg10887
I1
sasa(dp16820
g10873
VDixon and Lineweaver-Burk plots revealed that the inhibition types of LCA against CYP1A2, 2C9, 2C19 and 2C8 were best fit as mixed-type inhibitions, while LCA was a competitive inhibitor towards CYP3A4.
p16821
sg4
(dp16822
(VCYP1A2
p16823
Vfit
p16824
tp16825
I00
ssg10879
(lp16826
(dp16827
g10882
I70
sg10883
VLCA
p16828
sg10884
I3
sg10885
VC0339527
p16829
sg10887
I1
sa(dp16830
g10882
I70
sg10883
VLCA
p16831
sg10884
I3
sg10885
VC0339527
p16832
sg10887
I1
sa(dp16833
g10882
I118
sg10883
g16824
sg10884
I3
sg10885
VC0036572
p16834
sg10887
I1
sasg10888
(lp16835
(dp16836
g10882
I195
sg10883
VCYP3A4
p16837
sg10884
I6
sg10891
VP08684
p16838
sg10887
I1
sa(dp16839
g10882
I82
sg10883
g16823
sg10884
I6
sg10891
VP05177
p16840
sg10887
I1
sasa(dp16841
g10873
VDiabetes significantly changed the kidney expression of Rage, Sod2, Tgfb1 and Ctgf, Pdp2, nephrin, and Lias.
p16842
sg4
(dp16843
(VCtgf
p16844
VDiabetes
p16845
tp16846
I00
ssg10879
(lp16847
(dp16848
g10882
I0
sg10883
g16845
sg10884
I8
sg10885
VC0011849
p16849
sg10887
I1
sasg10888
(lp16850
(dp16851
g10882
I68
sg10883
VTgfb1
p16852
sg10884
I5
sg10891
VP01137
p16853
sg10887
I1
sa(dp16854
g10882
I103
sg10883
VLias
p16855
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp16856
g10882
I56
sg10883
VRage
p16857
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp16858
g10882
I62
sg10883
VSod2
p16859
sg10884
I4
sg10891
VP04179
p16860
sg10887
I1
sa(dp16861
g10882
I84
sg10883
VPdp2
p16862
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp16863
g10882
I78
sg10883
g16844
sg10884
I4
sg10891
VP29279
p16864
sg10887
I1
sa(dp16865
g10882
I90
sg10883
Vnephrin
p16866
sg10884
I7
sg10891
g190
sg10887
I1
sasa(dp16867
g10873
VThis study analyzed protein expression and DNA alterations for the KRAS, CDKN2A, SMAD4, and TP53 genes by immunohistochemistry and next-generation sequencing in formalin-fixed, paraffin-embedded tumors in 356 patients with resected pancreatic adenocarcinoma who were treated at the Dana-Farber/Brigham and Women's Cancer Center (October 26, 2002, to May 21, 2012), University of Rochester Medical Center (March 1, 2006, to November 1, 2013), or Stanford Cancer Institute (September 26, 1995, to May 22, 2013).
p16868
sg4
(dp16869
(VTP53 genes
p16870
Vpancreatic adenocarcinoma
p16871
tp16872
I00
ssg10879
(lp16873
(dp16874
g10882
I195
sg10883
Vtumors
p16875
sg10884
I6
sg10885
VC0027651
p16876
sg10887
I1
sa(dp16877
g10882
I232
sg10883
g16871
sg10884
I25
sg10885
VC0281361
p16878
sg10887
I2
sa(dp16879
g10882
I314
sg10883
VCancer
p16880
sg10884
I6
sg10885
VC0006826
p16881
sg10887
I1
sa(dp16882
g10882
I314
sg10883
VCancer
p16883
sg10884
I6
sg10885
VC0006826
p16884
sg10887
I1
sasg10888
(lp16885
(dp16886
g10882
I73
sg10883
VCDKN2A
p16887
sg10884
I6
sg10891
VP42771
p16888
sg10887
I1
sa(dp16889
g10882
I81
sg10883
VSMAD4
p16890
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp16891
g10882
I67
sg10883
VKRAS
p16892
sg10884
I4
sg10891
VP01116
p16893
sg10887
I1
sa(dp16894
g10882
I92
sg10883
g16870
sg10884
I10
sg10891
VP01893
p16895
sg10887
I2
sasa(dp16896
g10873
VWe are now performing molecular testing of the HSP patients using Sanger sequencing (SPG4, SPG11, SPG31, and ARSACS), comparative genomic hybridization (CGH) array (SPG1, 2, 3A, 4, 5, 6, 7, 8, 10, 11, 13, 15, 17, 20, 21, 31, 33, 39, 42, ABCD1, alsin, and ARSACS), and resequencing microarray (SPG1, 2, 3A, 4, 5, 6, 7, 8, 10, 11, 13, 17, 20, 21, 31, 33, and ABCD1).
p16897
sg4
(dp16898
(VABCD1
p16899
VHSP
p16900
tp16901
I00
ssg10879
(lp16902
(dp16903
g10882
I118
sg10883
Vcomparative genomic hybridization
p16904
sg10884
I33
sg10885
VC1855900
p16905
sg10887
I3
sa(dp16906
g10882
I98
sg10883
VSPG31
p16907
sg10884
I5
sg10885
VC1853247
p16908
sg10887
I1
sa(dp16909
g10882
I153
sg10883
VCGH
p16910
sg10884
I3
sg10885
VC1855900
p16911
sg10887
I1
sa(dp16912
g10882
I109
sg10883
VARSACS
p16913
sg10884
I6
sg10885
VC1849140
p16914
sg10887
I1
sa(dp16915
g10882
I91
sg10883
VSPG1
p16916
sg10884
I4
sg10885
VC0795953
p16917
sg10887
I1
sa(dp16918
g10882
I85
sg10883
VSPG4
p16919
sg10884
I4
sg10885
VC1866855
p16920
sg10887
I1
sa(dp16921
g10882
I91
sg10883
VSPG1
p16922
sg10884
I4
sg10885
VC0795953
p16923
sg10887
I1
sa(dp16924
g10882
I91
sg10883
VSPG11
p16925
sg10884
I5
sg10885
VC1858479
p16926
sg10887
I1
sa(dp16927
g10882
I109
sg10883
VARSACS
p16928
sg10884
I6
sg10885
VC1849140
p16929
sg10887
I1
sa(dp16930
g10882
I47
sg10883
g16900
sg10884
I3
sg10885
VC0034152
p16931
sg10887
I1
sasg10888
(lp16932
(dp16933
g10882
I237
sg10883
VABCD1
p16934
sg10884
I5
sg10891
VP33897
p16935
sg10887
I1
sa(dp16936
g10882
I244
sg10883
Valsin
p16937
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp16938
g10882
I98
sg10883
VSPG31
p16939
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp16940
g10882
I85
sg10883
VSPG4
p16941
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp16942
g10882
I237
sg10883
g16899
sg10884
I5
sg10891
VP33897
p16943
sg10887
I1
sasa(dp16944
g10873
VWe are now performing molecular testing for the HSP patients using direct sequencing (SPG4, SPG31, and ARSACS), comparative genomic hybridization (CGH) array (SPG1/2/3A/4/5/6/7/8/10/11/13/15/17/20/21/31/33/39/42/ABCD1/alsin/SACS), and resequencing microarray (SPG1/2/3A/4/5/6/7/8/10/11/13/17/20/21/31/33/ABCD1).
p16945
sg4
(dp16946
(VABCD1
p16947
VSPG4
p16948
tp16949
I00
ssg10879
(lp16950
(dp16951
g10882
I92
sg10883
VSPG31
p16952
sg10884
I5
sg10885
VC1853247
p16953
sg10887
I1
sa(dp16954
g10882
I103
sg10883
VARSACS
p16955
sg10884
I6
sg10885
VC1849140
p16956
sg10887
I1
sa(dp16957
g10882
I112
sg10883
Vcomparative genomic hybridization
p16958
sg10884
I33
sg10885
VC1855900
p16959
sg10887
I3
sa(dp16960
g10882
I147
sg10883
VCGH
p16961
sg10884
I3
sg10885
VC1855900
p16962
sg10887
I1
sa(dp16963
g10882
I48
sg10883
VHSP
p16964
sg10884
I3
sg10885
VC0034152
p16965
sg10887
I1
sa(dp16966
g10882
I159
sg10883
VSPG1
p16967
sg10884
I4
sg10885
VC0795953
p16968
sg10887
I1
sa(dp16969
g10882
I159
sg10883
VSPG1
p16970
sg10884
I4
sg10885
VC0795953
p16971
sg10887
I1
sa(dp16972
g10882
I105
sg10883
VSACS
p16973
sg10884
I4
sg10885
VC1849140
p16974
sg10887
I1
sa(dp16975
g10882
I86
sg10883
g16948
sg10884
I4
sg10885
VC1866855
p16976
sg10887
I1
sasg10888
(lp16977
(dp16978
g10882
I92
sg10883
VSPG31
p16979
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp16980
g10882
I212
sg10883
VABCD1
p16981
sg10884
I5
sg10891
VP33897
p16982
sg10887
I1
sa(dp16983
g10882
I212
sg10883
g16947
sg10884
I5
sg10891
VP33897
p16984
sg10887
I1
sa(dp16985
g10882
I86
sg10883
VSPG4
p16986
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp16987
g10882
I105
sg10883
VSACS
p16988
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp16989
g10882
I218
sg10883
Valsin
p16990
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp16991
g10873
VExpression of KIR3DL2 on NK and T cells was quantified in peripheral blood (PB) from 35 patients with SpA and 5 patients with juvenile enthesitis-related arthritis (juvenile ERA); samples were compared with samples from healthy and rheumatoid arthritis (RA) controls.
p16992
sg4
(dp16993
(VKIR3DL2
p16994
Varthritis
p16995
tp16996
I01
ssg10879
(lp16997
(dp16998
g10882
I175
sg10883
VRA
p16999
sg10884
I2
sg10885
VC0003873
p17000
sg10887
I1
sa(dp17001
g10882
I135
sg10883
Venthesitis
p17002
sg10884
I10
sg10885
VC1282952
p17003
sg10887
I1
sa(dp17004
g10882
I232
sg10883
Vrheumatoid arthritis
p17005
sg10884
I20
sg10885
VC0003873
p17006
sg10887
I2
sa(dp17007
g10882
I154
sg10883
g16995
sg10884
I9
sg10885
VC0003864
p17008
sg10887
I1
sasg10888
(lp17009
(dp17010
g10882
I14
sg10883
g16994
sg10884
I7
sg10891
VP43630
p17011
sg10887
I1
sasa(dp17012
g10873
VNKB1 inhibits cytoxic activity of T lymphocytes mediated by superantigens, which is one of the contributing factors in the pathogenesis of rheumatoid arthritis (RA).
p17013
sg4
(dp17014
(VNKB1
p17015
VRA
p17016
tp17017
I01
ssg10879
(lp17018
(dp17019
g10882
I139
sg10883
Vrheumatoid arthritis
p17020
sg10884
I20
sg10885
VC0003873
p17021
sg10887
I2
sa(dp17022
g10882
I123
sg10883
Vpathogenesis
p17023
sg10884
I12
sg10885
VC0699748
p17024
sg10887
I1
sa(dp17025
g10882
I161
sg10883
g17016
sg10884
I2
sg10885
VC0003873
p17026
sg10887
I1
sasg10888
(lp17027
(dp17028
g10882
I0
sg10883
g17015
sg10884
I4
sg10891
VP43629
p17029
sg10887
I1
sasa(dp17030
g10873
VKiller Ig-like receptors (KIRs) are expressed on CD4(+)CD28(null) T cells, a highly oligoclonal subset of T cells that is expanded in patients with rheumatoid arthritis.
p17031
sg4
(dp17032
(VCD4
p17033
Vrheumatoid arthritis
p17034
tp17035
I00
ssg10879
(lp17036
(dp17037
g10882
I148
sg10883
g17034
sg10884
I20
sg10885
VC0003873
p17038
sg10887
I2
sasg10888
(lp17039
(dp17040
g10882
I0
sg10883
VKiller Ig-like receptors
p17041
sg10884
I24
sg10891
g190
sg10887
I3
sa(dp17042
g10882
I26
sg10883
VKIRs
p17043
sg10884
I4
sg10891
VP55040
p17044
sg10887
I1
sa(dp17045
g10882
I55
sg10883
VCD28
p17046
sg10884
I4
sg10891
VP33681
p17047
sg10887
I1
sa(dp17048
g10882
I49
sg10883
g17033
sg10884
I3
sg10891
VP01730
p17049
sg10887
I1
sasa(dp17050
g10873
VSerial samples of serum Cystatin C and urine NGAL were collected from 139 consecutive patients with congenital heart defects aged 3 days to 30 years after admission to the intensive care unit, 2 and 6 hours after the end of cardiopulmonary bypass.
p17051
sg4
(dp17052
(VCystatin C
p17053
Vcongenital heart defects
p17054
tp17055
I01
ssg10879
(lp17056
(dp17057
g10882
I100
sg10883
g17054
sg10884
I24
sg10885
VC0018798
p17058
sg10887
I3
sasg10888
(lp17059
(dp17060
g10882
I39
sg10883
Vurine NGAL
p17061
sg10884
I10
sg10891
VP80188
p17062
sg10887
I2
sa(dp17063
g10882
I24
sg10883
g17053
sg10884
I10
sg10891
VP01034
p17064
sg10887
I2
sasa(dp17065
g10873
VHyper-IgE syndrome (HIES) is a very rare primary immune deficiency characterized by elevated serum IgE levels, recurrent bacterial infections, chronic dermatitis, and connective tissue abnormalities.
p17066
sg4
(dp17067
(Vserum IgE
p17068
Vrecurrent bacterial infections
p17069
tp17070
I00
ssg10879
(lp17071
(dp17072
g10882
I6
sg10883
VIgE
p17073
sg10884
I3
sg10885
VC0270850
p17074
sg10887
I1
sa(dp17075
g10882
I0
sg10883
VHyper-IgE syndrome
p17076
sg10884
I18
sg10885
VC0022398
p17077
sg10887
I2
sa(dp17078
g10882
I20
sg10883
VHIES
p17079
sg10884
I4
sg10885
VC0022398
p17080
sg10887
I1
sa(dp17081
g10882
I143
sg10883
Vchronic dermatitis
p17082
sg10884
I18
sg10885
VC0262975
p17083
sg10887
I2
sa(dp17084
g10882
I49
sg10883
Vimmune deficiency
p17085
sg10884
I17
sg10885
VC0850497
p17086
sg10887
I2
sa(dp17087
g10882
I111
sg10883
g17069
sg10884
I30
sg10885
VC1844383
p17088
sg10887
I3
sasg10888
(lp17089
(dp17090
g10882
I0
sg10883
VHyper-IgE
p17091
sg10884
I9
sg10891
VP01854
p17092
sg10887
I1
sa(dp17093
g10882
I93
sg10883
g17068
sg10884
I9
sg10891
VP01854
p17094
sg10887
I2
sasa(dp17095
g10873
VWe describe the clinical course of a 2-month-old infant who was evaluated for autosomal dominant Hyper IgE Syndrome based on eczema, periorbital cellulitis, skin abscesses, increased total IgE levels and blood eosinophilia.
p17096
sg4
(dp17097
(Vdominant Hyper IgE
p17098
Vperiorbital cellulitis
p17099
tp17100
I00
ssg10879
(lp17101
(dp17102
g10882
I97
sg10883
VHyper IgE Syndrome
p17103
sg10884
I18
sg10885
VC0022398
p17104
sg10887
I3
sa(dp17105
g10882
I125
sg10883
Veczema
p17106
sg10884
I6
sg10885
VC0013595
p17107
sg10887
I1
sa(dp17108
g10882
I210
sg10883
Veosinophilia
p17109
sg10884
I12
sg10885
VC0014457
p17110
sg10887
I1
sa(dp17111
g10882
I157
sg10883
Vskin abscesses
p17112
sg10884
I14
sg10885
VC0149777
p17113
sg10887
I2
sa(dp17114
g10882
I103
sg10883
VIgE
p17115
sg10884
I3
sg10885
VC0270850
p17116
sg10887
I1
sa(dp17117
g10882
I133
sg10883
g17099
sg10884
I22
sg10885
VC0149754
p17118
sg10887
I2
sasg10888
(lp17119
(dp17120
g10882
I103
sg10883
VIgE
p17121
sg10884
I3
sg10891
VP01854
p17122
sg10887
I1
sa(dp17123
g10882
I88
sg10883
g17098
sg10884
I18
sg10891
VP01854
p17124
sg10887
I3
sasa(dp17125
g10873
VIL-22 induces STAT3 phosphorylation and mediates psoriasis-related gene expression.
p17126
sg4
(dp17127
(VSTAT3
p17128
Vpsoriasis
p17129
tp17130
I00
ssg10879
(lp17131
(dp17132
g10882
I49
sg10883
g17129
sg10884
I9
sg10885
VC0033860
p17133
sg10887
I1
sasg10888
(lp17134
(dp17135
g10882
I14
sg10883
g17128
sg10884
I5
sg10891
VP40763
p17136
sg10887
I1
sa(dp17137
g10882
I0
sg10883
VIL-22
p17138
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp17139
g10873
VSequencing of genes known to be causative for WS [microphthalmia transcription factor (MITF), Pax3, Sox10, SNAI2 ] failed to show any candidate mutations to explain this complex cutaneous depigmentation phenotype.
p17140
sg4
(dp17141
(VPax3
p17142
Vdepigmentation
p17143
tp17144
I00
ssg10879
(lp17145
(dp17146
g10882
I50
sg10883
Vmicrophthalmia
p17147
sg10884
I14
sg10885
VC0026010
p17148
sg10887
I1
sa(dp17149
g10882
I188
sg10883
g17143
sg10884
I14
sg10885
VC0162835
p17150
sg10887
I1
sasg10888
(lp17151
(dp17152
g10882
I87
sg10883
VMITF
p17153
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp17154
g10882
I100
sg10883
VSox10
p17155
sg10884
I5
sg10891
VP56693
p17156
sg10887
I1
sa(dp17157
g10882
I49
sg10883
V[microphthalmia transcription factor
p17158
sg10884
I36
sg10891
g190
sg10887
I3
sa(dp17159
g10882
I107
sg10883
VSNAI2
p17160
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp17161
g10882
I94
sg10883
g17142
sg10884
I4
sg10891
VP23760
p17162
sg10887
I1
sasa(dp17163
g10873
VThe mice include splotch (Sp), microphthalmia (mi), Slugh-/-, WS4, JF1, lethal-spotting (ls), and Dominant megacolon (Dom).
p17164
sg4
(dp17165
(VWS4
p17166
Vmicrophthalmia
p17167
tp17168
I00
ssg10879
(lp17169
(dp17170
g10882
I4
sg10883
Vmi
p17171
sg10884
I2
sg10885
VC0026010
p17172
sg10887
I1
sa(dp17173
g10882
I62
sg10883
VWS4
p17174
sg10884
I3
sg10885
VC1848519
p17175
sg10887
I1
sa(dp17176
g10882
I79
sg10883
Vspotting
p17177
sg10884
I8
sg10885
VC0025874
p17178
sg10887
I1
sa(dp17179
g10882
I107
sg10883
Vmegacolon
p17180
sg10884
I9
sg10885
VC0235904
p17181
sg10887
I1
sa(dp17182
g10882
I31
sg10883
g17167
sg10884
I14
sg10885
VC0026010
p17183
sg10887
I1
sasg10888
(lp17184
(dp17185
g10882
I62
sg10883
g17166
sg10884
I3
sg10891
VP56693
p17186
sg10887
I1
sasa(dp17187
g10873
VMoreover, the Etv5 mutation resulted in several developmental abnormalities including an increased incidence of embryonic and perinatal lethality, postnatal growth restriction, polydactyly and renal asymmetry.
p17188
sg4
(dp17189
(VEtv5 mutation
p17190
Vpolydactyly
p17191
tp17192
I00
ssg10879
(lp17193
(dp17194
g10882
I177
sg10883
g17191
sg10884
I11
sg10885
VC0152427
p17195
sg10887
I1
sasg10888
(lp17196
(dp17197
g10882
I14
sg10883
g17190
sg10884
I13
sg10891
VP41161
p17198
sg10887
I2
sasa(dp17199
g10873
VHere, we show that conditional knockout of the FGF-activated transcription factor genes Etv4 and Etv5 in mouse led to ectopic Shh expression in the anterior limb bud and a preaxial polydactyly (PPD) skeletal phenotype.
p17200
sg4
(dp17201
(VEtv5
p17202
VPPD
p17203
tp17204
I01
ssg10879
(lp17205
(dp17206
g10882
I172
sg10883
Vpreaxial polydactyly
p17207
sg10884
I20
sg10885
VC0345354
p17208
sg10887
I2
sa(dp17209
g10882
I194
sg10883
g17203
sg10884
I3
sg10885
VC0432215
p17210
sg10887
I1
sasg10888
(lp17211
(dp17212
g10882
I126
sg10883
VShh
p17213
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp17214
g10882
I172
sg10883
Vpreaxial polydactyly
p17215
sg10884
I20
sg10891
VP32754
p17216
sg10887
I2
sa(dp17217
g10882
I194
sg10883
VPPD
p17218
sg10884
I3
sg10891
VP32754
p17219
sg10887
I1
sa(dp17220
g10882
I47
sg10883
VFGF-activated transcription factor genes Etv4
p17221
sg10884
I45
sg10891
VP35398
p17222
sg10887
I5
sa(dp17223
g10882
I97
sg10883
g17202
sg10884
I4
sg10891
VP41161
p17224
sg10887
I1
sasa(dp17225
g10873
VMechanistic studies showed that inducible expression of CD82 in highly metastatic melanoma cells significantly increased p21 expression upon binding of Duffy antigen receptor group (DARC), inducing tumor cell senescence and interrupting IL-8-mediated vascular endothelial (VE)-cadherin disassembly.
p17226
sg4
(dp17227
(VCD82
p17228
Vmetastatic melanoma
p17229
tp17230
I00
ssg10879
(lp17231
(dp17232
g10882
I198
sg10883
Vtumor
p17233
sg10884
I5
sg10885
VC0027651
p17234
sg10887
I1
sa(dp17235
g10882
I71
sg10883
g17229
sg10884
I19
sg10885
VC0278883
p17236
sg10887
I2
sasg10888
(lp17237
(dp17238
g10882
I182
sg10883
VDARC
p17239
sg10884
I4
sg10891
VP00390
p17240
sg10887
I1
sa(dp17241
g10882
I152
sg10883
VDuffy antigen receptor group
p17242
sg10884
I28
sg10891
VP00390
p17243
sg10887
I4
sa(dp17244
g10882
I121
sg10883
Vp21
p17245
sg10884
I3
sg10891
VP42857
p17246
sg10887
I1
sa(dp17247
g10882
I56
sg10883
g17228
sg10884
I4
sg10891
VP27701
p17248
sg10887
I1
sa(dp17249
g10882
I237
sg10883
VIL-8-mediated vascular endothelial (VE)-cadherin
p17250
sg10884
I48
sg10891
g190
sg10887
I4
sasa(dp17251
g10873
VOur oneway ANOVA analysis results showed that in all cases from benign diseases to invasive carcinoma, the concentration of CXCL8, CXCR4 and CXCL12 was significantly different; in benign subgroups (benign change, benign change with proliferation, atypia), the concentration of CCL2 and CCR5 was significantly different; in invasive carcinoma cases, DARC concentration was significantly correlated with the relapse risk of patients.
p17252
sg4
(dp17253
(VCXCL12
p17254
Vinvasive carcinoma
p17255
tp17256
I00
ssg10879
(lp17257
(dp17258
g10882
I83
sg10883
Vinvasive carcinoma
p17259
sg10884
I18
sg10885
VC1334274
p17260
sg10887
I2
sa(dp17261
g10882
I83
sg10883
g17255
sg10884
I18
sg10885
VC1334274
p17262
sg10887
I2
sa(dp17263
g10882
I232
sg10883
Vproliferation
p17264
sg10884
I13
sg10885
VC0334094
p17265
sg10887
I1
sa(dp17266
g10882
I406
sg10883
Vrelapse
p17267
sg10884
I7
sg10885
VC0277556
p17268
sg10887
I1
sasg10888
(lp17269
(dp17270
g10882
I286
sg10883
VCCR5
p17271
sg10884
I4
sg10891
VP32302
p17272
sg10887
I1
sa(dp17273
g10882
I131
sg10883
VCXCR4
p17274
sg10884
I5
sg10891
VP61073
p17275
sg10887
I1
sa(dp17276
g10882
I277
sg10883
VCCL2
p17277
sg10884
I4
sg10891
VP13500
p17278
sg10887
I1
sa(dp17279
g10882
I141
sg10883
g17254
sg10884
I6
sg10891
VP48061
p17280
sg10887
I1
sasa(dp17281
g10873
V177Lu-DOTATATE = lutetium octreotate; ACO = aconitase; Ad = adenine; AD = autosomal dominant; ATRX = ATRX chromatin remodeler; ccRCC = clear cell renal cell carcinoma; c-MYC = MYC proto oncognene; CoA = coenzyme A; COMT = catechol-O-methyl transferase; CPE = carboxypeptidase E; CS = citrate synthase; CT = computed tomography; DH = pyruvate dehydrogenase; DOTATATE = DOTA-octreotate; EGLN1/2 = egl-9 family hypoxia inducible factor 1/2; EGLN2/PHD1 = egl-9 family hypoxia inducible factor 2; elF-4E = eukaryotic initiation factor 4E; EMT = epithelial-to-mesenchymal transition; EPAS1/HIF2A = endothelial PAS domain protein 2/hypoxia-inducible factor 2Alfa; ERK = extracellular signal-regulated kinase; FH = fumarate hydroxylase; GSH = glutathione; H3F3A = histone 3.3 encoding gene; HIFs = Hypoxia-inducible factors; HIF-Alfa = hypoxia-inducible factor alpha; HNPGLs = head and neck paragangliomas; HRAS = HRas protooncogene; IDH = isocitrate dehydrogenase; IGF-1R = growth factor 1 receptor; KIF1B = kinesin family member 1B; MAX = myc-associated factor X; MDH2 = malate dehydrogenase; MN = metanephrine; MRI = magnetic resonance imaging; mTORC1 = mammalian target of rapamycin complex 1; MTY = methoxytyramine; NAd = nicotinamide adenine dinucleotide; NETs = neuroendocrine tumors; NF1 = neurofibromin 1; NMN = normetanephrine; OPLS-DA = orthogonal partial least square discriminant analysis; PFS = progression free survival; PHD = prolyl hydroxylase domain protein; PPGLs = Pheochromocytoma and Paragangliomas; PRRT = peptide receptor radionuclide therapy; Pvhl = von Hippel-Lindau protein; Raptor = regulatory associated protein of mTOR; RAS = rat sarcoma oncogene; RET = rearranged during transfection proto-oncogene; ROS = reactive oxygen species; S6K = S6 kinase; SDH = succinate dehydrogenase; SDHA, -B, -C, -D, = succinate dehydrogenase subunits A, B, C, D; SDHAF2 = succinate dehydrogenase complex assembly factor 2; SDHB, C, D = succinate dehydrogenase subunits B, C, D; SDHx = succinate dehydrogenase subunits; SSTRs = somatostatin receptors; SUCLG = succinyl-CoA synthase; TERRA = Telomeric Repeat-containing RNA; TET = ten-eleven-translocation methylcytosine dioxygenase; TMEM127 = transmembrane protein 127; VEGF = vascular endothelial growth factor; VHL = von Hippel-Lindau; Alfa-KGDH = alpha-ketoglutarate dehydrogenase.
p17282
sg4
(dp17283
(VMAX = myc-associated factor X
p17284
Vhypoxia
p17285
tp17286
I00
ssg10879
(lp17287
(dp17288
g10882
I1771
sg10883
VSDH
p17289
sg10884
I3
sg10885
VC0018946
p17290
sg10887
I1
sa(dp17291
g10882
I1261
sg10883
Vneuroendocrine tumors
p17292
sg10884
I21
sg10885
VC0206754
p17293
sg10887
I2
sa(dp17294
g10882
I1477
sg10883
VPheochromocytoma
p17295
sg10884
I16
sg10885
VC0031511
p17296
sg10887
I1
sa(dp17297
g10882
I1648
sg10883
Vrat sarcoma
p17298
sg10884
I11
sg10885
VC1882848
p17299
sg10887
I2
sa(dp17300
g10882
I408
sg10883
Vhypoxia
p17301
sg10884
I7
sg10885
VC0242184
p17302
sg10887
I1
sa(dp17303
g10882
I790
sg10883
VHypoxia
p17304
sg10884
I7
sg10885
VC0242184
p17305
sg10887
I1
sa(dp17306
g10882
I1213
sg10883
VNAd
p17307
sg10884
I3
sg10885
VC1850380
p17308
sg10887
I1
sa(dp17309
g10882
I94
sg10883
VATRX
p17310
sg10884
I4
sg10885
VC1845055
p17311
sg10887
I1
sa(dp17312
g10882
I197
sg10883
VCoA
p17313
sg10884
I3
sg10885
VC2678439
p17314
sg10887
I1
sa(dp17315
g10882
I1498
sg10883
VParagangliomas
p17316
sg10884
I14
sg10885
VC0030421
p17317
sg10887
I1
sa(dp17318
g10882
I883
sg10883
Vparagangliomas
p17319
sg10884
I14
sg10885
VC0030421
p17320
sg10887
I1
sa(dp17321
g10882
I408
sg10883
Vhypoxia
p17322
sg10884
I7
sg10885
VC0242184
p17323
sg10887
I1
sa(dp17324
g10882
I1284
sg10883
VNF1
p17325
sg10884
I3
sg10885
VC0027831
p17326
sg10887
I1
sa(dp17327
g10882
I408
sg10883
Vhypoxia
p17328
sg10884
I7
sg10885
VC0242184
p17329
sg10887
I1
sa(dp17330
g10882
I2266
sg10883
VVHL
p17331
sg10884
I3
sg10885
VC0019562
p17332
sg10887
I1
sa(dp17333
g10882
I729
sg10883
VGSH
p17334
sg10884
I3
sg10885
VC1260386
p17335
sg10887
I1
sa(dp17336
g10882
I135
sg10883
Vclear cell renal cell carcinoma
p17337
sg10884
I31
sg10885
VC0279702
p17338
sg10887
I5
sa(dp17339
g10882
I566
sg10883
Vtransition
p17340
sg10884
I10
sg10885
VC0599156
p17341
sg10887
I1
sa(dp17342
g10882
I94
sg10883
VATRX
p17343
sg10884
I4
sg10885
VC1845055
p17344
sg10887
I1
sa(dp17345
g10882
I2144
sg10883
Vtranslocation
p17346
sg10884
I13
sg10885
VC0040715
p17347
sg10887
I1
sa(dp17348
g10882
I197
sg10883
VCoA
p17349
sg10884
I3
sg10885
VC2678439
p17350
sg10887
I1
sa(dp17351
g10882
I408
sg10883
g17285
sg10884
I7
sg10885
VC0242184
p17352
sg10887
I1
sasg10888
(lp17353
(dp17354
g10882
I1876
sg10883
Vsuccinate dehydrogenase complex assembly factor 2
p17355
sg10884
I49
sg10891
VP49366
p17356
sg10887
I6
sa(dp17357
g10882
I1927
sg10883
VSDHB
p17358
sg10884
I4
sg10891
VP21912
p17359
sg10887
I1
sa(dp17360
g10882
I1771
sg10883
VSDH
p17361
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp17362
g10882
I2023
sg10883
VSSTRs = somatostatin receptors
p17363
sg10884
I30
sg10891
VP61278
p17364
sg10887
I4
sa(dp17365
g10882
I438
sg10883
VEGLN2
p17366
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp17367
g10882
I2266
sg10883
VVHL
p17368
sg10884
I3
sg10891
VP40337
p17369
sg10887
I1
sa(dp17370
g10882
I1802
sg10883
VSDHA
p17371
sg10884
I4
sg10891
VP31040
p17372
sg10887
I1
sa(dp17373
g10882
I1760
sg10883
VS6 kinase
p17374
sg10884
I9
sg10891
VP33981
p17375
sg10887
I2
sa(dp17376
g10882
I578
sg10883
VEPAS1
p17377
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp17378
g10882
I1434
sg10883
Vprolyl hydroxylase domain protein
p17379
sg10884
I33
sg10891
VP13674
p17380
sg10887
I4
sa(dp17381
g10882
I2303
sg10883
Valpha-ketoglutarate dehydrogenase
p17382
sg10884
I33
sg10891
VP49366
p17383
sg10887
I2
sa(dp17384
g10882
I464
sg10883
Vhypoxia inducible factor 2
p17385
sg10884
I26
sg10891
g190
sg10887
I4
sa(dp17386
g10882
I1140
sg10883
VmTOR
p17387
sg10884
I4
sg10891
VP42345
p17388
sg10887
I1
sa(dp17389
g10882
I1754
sg10883
VS6K
p17390
sg10884
I3
sg10891
VP62753
p17391
sg10887
I1
sa(dp17392
g10882
I592
sg10883
Vendothelial PAS domain protein 2
p17393
sg10884
I32
sg10891
g190
sg10887
I5
sa(dp17394
g10882
I492
sg10883
VelF
p17395
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp17396
g10882
I584
sg10883
VHIF2A
p17397
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp17398
g10882
I2063
sg10883
Vsuccinyl-CoA synthase
p17399
sg10884
I21
sg10891
g190
sg10887
I2
sa(dp17400
g10882
I231
sg10883
VO-methyl transferase
p17401
sg10884
I20
sg10891
VP31947
p17402
sg10887
I2
sa(dp17403
g10882
I958
sg10883
VIGF-1R = growth factor 1 receptor
p17404
sg10884
I33
sg10891
g190
sg10887
I6
sa(dp17405
g10882
I1777
sg10883
Vsuccinate dehydrogenase
p17406
sg10884
I23
sg10891
VP49366
p17407
sg10887
I2
sa(dp17408
g10882
I926
sg10883
VIDH = isocitrate dehydrogenase
p17409
sg10884
I30
sg10891
VP48735
p17410
sg10887
I4
sa(dp17411
g10882
I748
sg10883
VH3F3A
p17412
sg10884
I5
sg10891
VP84243
p17413
sg10887
I1
sa(dp17414
g10882
I900
sg10883
VRAS
p17415
sg10884
I3
sg10891
VP01116
p17416
sg10887
I1
sa(dp17417
g10882
I1058
sg10883
VMDH2 = malate dehydrogenase
p17418
sg10884
I27
sg10891
VP49366
p17419
sg10887
I4
sa(dp17420
g10882
I385
sg10883
VEGLN1/2
p17421
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp17422
g10882
I253
sg10883
VCPE = carboxypeptidase E
p17423
sg10884
I24
sg10891
VP16870
p17424
sg10887
I4
sa(dp17425
g10882
I1001
sg10883
Vkinesin
p17426
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp17427
g10882
I756
sg10883
Vhistone 3.3 encoding gene
p17428
sg10884
I25
sg10891
VP62805
p17429
sg10887
I4
sa(dp17430
g10882
I625
sg10883
Vhypoxia-inducible factor 2Alfa
p17431
sg10884
I30
sg10891
g190
sg10887
I3
sa(dp17432
g10882
I1648
sg10883
Vrat sarcoma oncogene
p17433
sg10884
I20
sg10891
VP35125
p17434
sg10887
I3
sa(dp17435
g10882
I1670
sg10883
VRET
p17436
sg10884
I3
sg10891
VP07949
p17437
sg10887
I1
sa(dp17438
g10882
I657
sg10883
VERK
p17439
sg10884
I3
sg10891
VP29323
p17440
sg10887
I1
sa(dp17441
g10882
I1027
sg10883
g17284
sg10884
I29
sg10891
VP61244
p17442
sg10887
I5
sa(dp17443
g10882
I408
sg10883
Vhypoxia inducible factor 1/2
p17444
sg10884
I28
sg10891
g190
sg10887
I4
sa(dp17445
g10882
I2230
sg10883
Vvascular endothelial growth factor
p17446
sg10884
I34
sg10891
g190
sg10887
I4
sa(dp17447
g10882
I444
sg10883
VPHD1
p17448
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp17449
g10873
VImmunohistochemistry for phosphorylated-S6, phosphorylated-mTOR, mTOR, phosphorylated-AKT, hypoxia inducible factor-1Alfa, Raptor, phosphatase and tensin homolog (PTEN), phosphoinositide 3-kinase (PI3K), and phosphorylated 4E-binding protein-1 was performed on tissue microarray constructs of patients treated for nonmetastatic kidney cancer from 1997 to 2010.
p17450
sg4
(dp17451
(VmTOR
p17452
Vkidney cancer
p17453
tp17454
I00
ssg10879
(lp17455
(dp17456
g10882
I91
sg10883
Vhypoxia
p17457
sg10884
I7
sg10885
VC0242184
p17458
sg10887
I1
sa(dp17459
g10882
I328
sg10883
g17453
sg10884
I13
sg10885
VC0740457
p17460
sg10887
I2
sasg10888
(lp17461
(dp17462
g10882
I86
sg10883
VAKT
p17463
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp17464
g10882
I163
sg10883
VPTEN
p17465
sg10884
I4
sg10891
VP60484
p17466
sg10887
I1
sa(dp17467
g10882
I59
sg10883
VmTOR
p17468
sg10884
I4
sg10891
VP42345
p17469
sg10887
I1
sa(dp17470
g10882
I197
sg10883
VPI3K
p17471
sg10884
I4
sg10891
VP42336
p17472
sg10887
I1
sa(dp17473
g10882
I123
sg10883
VRaptor, phosphatase
p17474
sg10884
I19
sg10891
g190
sg10887
I2
sa(dp17475
g10882
I131
sg10883
Vphosphatase and tensin homolog
p17476
sg10884
I30
sg10891
VP60484
p17477
sg10887
I4
sa(dp17478
g10882
I59
sg10883
g17452
sg10884
I4
sg10891
VP42345
p17479
sg10887
I1
sa(dp17480
g10882
I91
sg10883
Vhypoxia inducible factor-1Alfa
p17481
sg10884
I30
sg10891
g190
sg10887
I3
sa(dp17482
g10882
I208
sg10883
Vphosphorylated 4E-binding protein-1
p17483
sg10884
I35
sg10891
g190
sg10887
I3
sa(dp17484
g10882
I170
sg10883
Vphosphoinositide 3-kinase
p17485
sg10884
I25
sg10891
g190
sg10887
I2
sasa(dp17486
g10873
VOur goal was to characterize PD-L1 expression in intra-hepatic (iCCA) and perihilar (pCCA) cholangiocarcinomas, and to correlate our results with clinicopathological features, density of tumor-infiltrating lymphocytes (TILs) and PD-1 expression.A series of 58 iCCAs and 41 pCCAs was included in the study.
p17487
sg4
(dp17488
(VPD-1
p17489
ViCCA
p17490
tp17491
I00
ssg10879
(lp17492
(dp17493
g10882
I91
sg10883
Vcholangiocarcinomas
p17494
sg10884
I19
sg10885
VC0206698
p17495
sg10887
I1
sa(dp17496
g10882
I193
sg10883
Vinfiltrating
p17497
sg10884
I12
sg10885
VC0332448
p17498
sg10887
I1
sa(dp17499
g10882
I85
sg10883
VpCCA
p17500
sg10884
I4
sg10885
VC3151140
p17501
sg10887
I1
sa(dp17502
g10882
I64
sg10883
g17490
sg10884
I4
sg10885
VC1865926
p17503
sg10887
I1
sa(dp17504
g10882
I187
sg10883
Vtumor
p17505
sg10884
I5
sg10885
VC0027651
p17506
sg10887
I1
sasg10888
(lp17507
(dp17508
g10882
I229
sg10883
g17489
sg10884
I4
sg10891
VP18621
p17509
sg10887
I1
sasa(dp17510
g10873
VBTC are sub-classified as intrahepatic cholangiocarcinoma (iCCA), perhilar/hilar cholangiocarcinoma (pCCA), distal cholangiocarcinoma (dCCA), and gallbladder carcinoma.
p17511
sg4
(dp17512
(VBTC
p17513
ViCCA
p17514
tp17515
I00
ssg10879
(lp17516
(dp17517
g10882
I39
sg10883
Vcholangiocarcinoma
p17518
sg10884
I18
sg10885
VC0206698
p17519
sg10887
I1
sa(dp17520
g10882
I66
sg10883
Vperhilar/hilar cholangiocarcinoma
p17521
sg10884
I33
sg10885
VC3151140
p17522
sg10887
I2
sa(dp17523
g10882
I146
sg10883
Vgallbladder carcinoma
p17524
sg10884
I21
sg10885
VC0235782
p17525
sg10887
I2
sa(dp17526
g10882
I26
sg10883
Vintrahepatic cholangiocarcinoma
p17527
sg10884
I31
sg10885
VC0345905
p17528
sg10887
I2
sa(dp17529
g10882
I101
sg10883
VpCCA
p17530
sg10884
I4
sg10885
VC3151140
p17531
sg10887
I1
sa(dp17532
g10882
I59
sg10883
g17514
sg10884
I4
sg10885
VC1865926
p17533
sg10887
I1
sasg10888
(lp17534
(dp17535
g10882
I0
sg10883
g17513
sg10884
I3
sg10891
VP35070
p17536
sg10887
I1
sasa(dp17537
g10873
VClinical data were collected and analyzed from 71 cases of primary nephrotic syndrome with glucocorticoid-induced ocular hypertension, glaucoma or cataract from Jun.
p17538
sg4
(dp17539
(VJun
p17540
Vocular hypertension
p17541
tp17542
I01
ssg10879
(lp17543
(dp17544
g10882
I147
sg10883
Vcataract
p17545
sg10884
I8
sg10885
VC0086543
p17546
sg10887
I1
sa(dp17547
g10882
I135
sg10883
Vglaucoma
p17548
sg10884
I8
sg10885
VC0017601
p17549
sg10887
I1
sa(dp17550
g10882
I67
sg10883
Vnephrotic syndrome
p17551
sg10884
I18
sg10885
VC0027726
p17552
sg10887
I2
sa(dp17553
g10882
I114
sg10883
g17541
sg10884
I19
sg10885
VC0028840
p17554
sg10887
I2
sasg10888
(lp17555
(dp17556
g10882
I161
sg10883
g17540
sg10884
I3
sg10891
VP05412
p17557
sg10887
I1
sasa(dp17558
g10873
Vc-Jun, c-Jun N-terminal kinase(JNK) and endothelin B (ETB) receptor have been shown to contribute to the pathogenesis of glaucoma.
p17559
sg4
(dp17560
(Vc-Jun N-terminal kinase
p17561
Vglaucoma
p17562
tp17563
I00
ssg10879
(lp17564
(dp17565
g10882
I105
sg10883
Vpathogenesis
p17566
sg10884
I12
sg10885
VC0699748
p17567
sg10887
I1
sa(dp17568
g10882
I121
sg10883
g17562
sg10884
I8
sg10885
VC0017601
p17569
sg10887
I1
sasg10888
(lp17570
(dp17571
g10882
I0
sg10883
Vc-Jun
p17572
sg10884
I5
sg10891
VP05412
p17573
sg10887
I1
sa(dp17574
g10882
I31
sg10883
VJNK
p17575
sg10884
I3
sg10891
VP53779
p17576
sg10887
I1
sa(dp17577
g10882
I40
sg10883
Vendothelin B (ETB) receptor
p17578
sg10884
I27
sg10891
g190
sg10887
I4
sa(dp17579
g10882
I7
sg10883
g17561
sg10884
I23
sg10891
VP53779
p17580
sg10887
I3
sasa(dp17581
g10873
VOcular hypertension also caused upregulations in the iron-regulating protein ceruloplasmin, the anaerobic glycolytic enzyme lactate dehydrogenase, and the transcription factors cFos and p-cJun.
p17582
sg4
(dp17583
(VcFos
p17584
VOcular hypertension
p17585
tp17586
I00
ssg10879
(lp17587
(dp17588
g10882
I0
sg10883
g17585
sg10884
I19
sg10885
VC0028840
p17589
sg10887
I2
sasg10888
(lp17590
(dp17591
g10882
I53
sg10883
Viron-regulating protein ceruloplasmin
p17592
sg10884
I37
sg10891
VP00450
p17593
sg10887
I3
sa(dp17594
g10882
I124
sg10883
Vlactate dehydrogenase
p17595
sg10884
I21
sg10891
VP49366
p17596
sg10887
I2
sa(dp17597
g10882
I177
sg10883
g17584
sg10884
I4
sg10891
VP01100
p17598
sg10887
I1
sasa(dp17599
g10873
VJUN is expressed after glaucoma-relevant injuries and Jun deficiency protects RGCs after mechanical injury to the optic nerve.
p17600
sg4
(dp17601
(VJUN
p17602
Vglaucoma
p17603
tp17604
I00
ssg10879
(lp17605
(dp17606
g10882
I23
sg10883
g17603
sg10884
I8
sg10885
VC0017601
p17607
sg10887
I1
sasg10888
(lp17608
(dp17609
g10882
I54
sg10883
VJun
p17610
sg10884
I3
sg10891
VP05412
p17611
sg10887
I1
sa(dp17612
g10882
I0
sg10883
g17602
sg10884
I3
sg10891
VP05412
p17613
sg10887
I1
sasa(dp17614
g10873
VHere, we tested the importance of JNK-JUN signaling for RGC death after ocular hypertensive axonal injury in an age-related, mouse model of ocular hypertension.
p17615
sg4
(dp17616
(VJNK
p17617
Vocular hypertension
p17618
tp17619
I00
ssg10879
(lp17620
(dp17621
g10882
I140
sg10883
g17618
sg10884
I19
sg10885
VC0028840
p17622
sg10887
I2
sasg10888
(lp17623
(dp17624
g10882
I38
sg10883
VJUN
p17625
sg10884
I3
sg10891
VP05412
p17626
sg10887
I1
sa(dp17627
g10882
I34
sg10883
g17617
sg10884
I3
sg10891
VP53779
p17628
sg10887
I1
sasa(dp17629
g10873
VTo determine the importance of JUN in ocular hypertension-induced RGC death, a floxed allele of Jun and a retinal expressed cre recombinase (Six3-cre) were backcrossed onto the DBA/2J background.
p17630
sg4
(dp17631
(VJun
p17632
Vocular hypertension
p17633
tp17634
I01
ssg10879
(lp17635
(dp17636
g10882
I177
sg10883
VDBA
p17637
sg10884
I3
sg10885
VC0398550
p17638
sg10887
I1
sa(dp17639
g10882
I38
sg10883
g17633
sg10884
I19
sg10885
VC0028840
p17640
sg10887
I2
sasg10888
(lp17641
(dp17642
g10882
I124
sg10883
Vcre recombinase
p17643
sg10884
I15
sg10891
g190
sg10887
I2
sa(dp17644
g10882
I141
sg10883
VSix3-cre
p17645
sg10884
I8
sg10891
g190
sg10887
I1
sa(dp17646
g10882
I96
sg10883
g17632
sg10884
I3
sg10891
VP05412
p17647
sg10887
I1
sasa(dp17648
g10873
VJun deficiency protected RGC somas from ocular hypertensive injury, but did not protect RGC axons from glaucomatous neurodegeneration.
p17649
sg4
(dp17650
(VJun
p17651
Vneurodegeneration
p17652
tp17653
I00
ssg10879
(lp17654
(dp17655
g10882
I116
sg10883
g17652
sg10884
I17
sg10885
VC0027746
p17656
sg10887
I1
sasg10888
(lp17657
(dp17658
g10882
I0
sg10883
g17651
sg10884
I3
sg10891
VP05412
p17659
sg10887
I1
sasa(dp17660
g10873
VThese results suggest in glaucomatous neurodegeneration, JNK-JUN signaling has a major role as a pro-death signaling pathway between axonal injury and somal degeneration.
p17661
sg4
(dp17662
(VJNK
p17663
Vneurodegeneration
p17664
tp17665
I00
ssg10879
(lp17666
(dp17667
g10882
I43
sg10883
Vdegeneration
p17668
sg10884
I12
sg10885
VC0011164
p17669
sg10887
I1
sa(dp17670
g10882
I38
sg10883
g17664
sg10884
I17
sg10885
VC0027746
p17671
sg10887
I1
sasg10888
(lp17672
(dp17673
g10882
I61
sg10883
VJUN
p17674
sg10884
I3
sg10891
VP05412
p17675
sg10887
I1
sa(dp17676
g10882
I57
sg10883
g17663
sg10884
I3
sg10891
VP53779
p17677
sg10887
I1
sasa(dp17678
g10873
VVarious genes involved in the control of cell proliferation and invasion (p16INK4A, RASSF1A, PTEN, Rap1GAP, TIMP3, DAPK, RARBeta2, E-cadherin, and CITED1) as well as genes specific of thyroid differentiation (Na+/I- symport, TSH receptor, pendrin, SL5A8, and TTF-1) present aberrant methylation in thyroid cancer.
p17679
sg4
(dp17680
(VE-cadherin
p17681
Vthyroid cancer
p17682
tp17683
I00
ssg10879
(lp17684
(dp17685
g10882
I298
sg10883
g17682
sg10884
I14
sg10885
VC0007115
p17686
sg10887
I2
sa(dp17687
g10882
I46
sg10883
Vproliferation
p17688
sg10884
I13
sg10885
VC0334094
p17689
sg10887
I1
sa(dp17690
g10882
I64
sg10883
Vinvasion
p17691
sg10884
I8
sg10885
VC2699153
p17692
sg10887
I1
sasg10888
(lp17693
(dp17694
g10882
I93
sg10883
VPTEN
p17695
sg10884
I4
sg10891
VP60484
p17696
sg10887
I1
sa(dp17697
g10882
I115
sg10883
VDAPK
p17698
sg10884
I4
sg10891
VP53355
p17699
sg10887
I1
sa(dp17700
g10882
I225
sg10883
VTSH receptor
p17701
sg10884
I12
sg10891
VP16473
p17702
sg10887
I2
sa(dp17703
g10882
I74
sg10883
Vp16INK4A
p17704
sg10884
I8
sg10891
VP42771
p17705
sg10887
I1
sa(dp17706
g10882
I108
sg10883
VTIMP3
p17707
sg10884
I5
sg10891
VP35625
p17708
sg10887
I1
sa(dp17709
g10882
I147
sg10883
VCITED1
p17710
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp17711
g10882
I99
sg10883
VRap1GAP
p17712
sg10884
I7
sg10891
VP47736
p17713
sg10887
I1
sa(dp17714
g10882
I259
sg10883
VTTF-1
p17715
sg10884
I5
sg10891
VP43699
p17716
sg10887
I1
sa(dp17717
g10882
I131
sg10883
g17681
sg10884
I10
sg10891
VP12830
p17718
sg10887
I1
sa(dp17719
g10882
I239
sg10883
Vpendrin
p17720
sg10884
I7
sg10891
g190
sg10887
I1
sasa(dp17721
g10873
VThese analyses showed that several antibodies were useful in distinguishing follicular adenomas from follicular variant of papillary thyroid carcinomas including HBME-1, CITED1, galectin-3, cytokeratin 19, and S100A4 (p &lt; 0.0001).
p17722
sg4
(dp17723
(VS100A4
p17724
Vfollicular adenomas
p17725
tp17726
I01
ssg10879
(lp17727
(dp17728
g10882
I76
sg10883
g17725
sg10884
I19
sg10885
VC0205647
p17729
sg10887
I2
sa(dp17730
g10882
I141
sg10883
Vcarcinomas
p17731
sg10884
I10
sg10885
VC0007097
p17732
sg10887
I1
sasg10888
(lp17733
(dp17734
g10882
I178
sg10883
Vgalectin-3, cytokeratin 19
p17735
sg10884
I26
sg10891
VP17931
p17736
sg10887
I3
sa(dp17737
g10882
I210
sg10883
g17724
sg10884
I6
sg10891
VP26447
p17738
sg10887
I1
sa(dp17739
g10882
I170
sg10883
VCITED1
p17740
sg10884
I6
sg10891
g190
sg10887
I1
sasa(dp17741
g10873
VA combination of markers consisting of a panel of HBME-1, galectin-3, and CK19 or a panel of HBME-1, CITED1, and galectin-3 was usually most effective in distinguishing follicular adenoma from follicular variant of papillary thyroid carcinoma.
p17742
sg4
(dp17743
(Vgalectin-3
p17744
Vfollicular adenoma
p17745
tp17746
I00
ssg10879
(lp17747
(dp17748
g10882
I215
sg10883
Vpapillary thyroid carcinoma
p17749
sg10884
I27
sg10885
VC0238463
p17750
sg10887
I3
sa(dp17751
g10882
I169
sg10883
g17745
sg10884
I18
sg10885
VC0205647
p17752
sg10887
I2
sasg10888
(lp17753
(dp17754
g10882
I58
sg10883
Vgalectin-3
p17755
sg10884
I10
sg10891
VP17931
p17756
sg10887
I1
sa(dp17757
g10882
I101
sg10883
VCITED1
p17758
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp17759
g10882
I58
sg10883
g17744
sg10884
I10
sg10891
VP17931
p17760
sg10887
I1
sasa(dp17761
g10873
VWe examined acetylcholinesterase, plasma neuronal proteins, secreted beta-amyloid precursor protein (APP), and amyloid-beta 40 and amyloid-beta 42 peptides in children with and without autism.
p17762
sg4
(dp17763
(Vplasma neuronal proteins, secreted beta-amyloid precursor protein
p17764
Vautism
p17765
tp17766
I00
ssg10879
(lp17767
(dp17768
g10882
I185
sg10883
g17765
sg10884
I6
sg10885
VC0004352
p17769
sg10887
I1
sa(dp17770
g10882
I74
sg10883
Vamyloid
p17771
sg10884
I7
sg10885
VC0011560
p17772
sg10887
I1
sa(dp17773
g10882
I74
sg10883
Vamyloid
p17774
sg10884
I7
sg10885
VC0011560
p17775
sg10887
I1
sa(dp17776
g10882
I74
sg10883
Vamyloid
p17777
sg10884
I7
sg10885
VC0011560
p17778
sg10887
I1
sasg10888
(lp17779
(dp17780
g10882
I101
sg10883
VAPP
p17781
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp17782
g10882
I12
sg10883
Vacetylcholinesterase
p17783
sg10884
I20
sg10891
VP12821
p17784
sg10887
I1
sa(dp17785
g10882
I34
sg10883
g17764
sg10884
I65
sg10891
VP29475
p17786
sg10887
I7
sa(dp17787
g10882
I111
sg10883
Vamyloid-beta 40 and amyloid-beta 42 peptides
p17788
sg10884
I44
sg10891
g190
sg10887
I6
sasa(dp17789
g10873
VHere we showed that miR-342-5p and miR-608 suppressed the tumorigenesis of colon cancer cells in vitro and in vivo by targeting NAA10 mRNA for degradation.
p17790
sg4
(dp17791
(VNAA10 mRNA
p17792
Vtumorigenesis
p17793
tp17794
I00
ssg10879
(lp17795
(dp17796
g10882
I75
sg10883
Vcolon cancer
p17797
sg10884
I12
sg10885
VC0699790
p17798
sg10887
I2
sa(dp17799
g10882
I58
sg10883
g17793
sg10884
I13
sg10885
VC0007621
p17800
sg10887
I1
sasg10888
(lp17801
(dp17802
g10882
I20
sg10883
VmiR-342-5p
p17803
sg10884
I10
sg10891
g190
sg10887
I1
sa(dp17804
g10882
I128
sg10883
g17792
sg10884
I10
sg10891
VP41227
p17805
sg10887
I2
sasa(dp17806
g10873
VOur results implicate miR-342-5p and miR-608 in colon cancer development and unveil the underlying mechanism of this phenomenon, which involves NAA10.
p17807
sg4
(dp17808
(VNAA10
p17809
Vcolon cancer
p17810
tp17811
I00
ssg10879
(lp17812
(dp17813
g10882
I48
sg10883
g17810
sg10884
I12
sg10885
VC0699790
p17814
sg10887
I2
sasg10888
(lp17815
(dp17816
g10882
I22
sg10883
VmiR-342-5p
p17817
sg10884
I10
sg10891
g190
sg10887
I1
sa(dp17818
g10882
I144
sg10883
g17809
sg10884
I5
sg10891
VP41227
p17819
sg10887
I1
sa(dp17820
g10882
I37
sg10883
VmiR-608
p17821
sg10884
I7
sg10891
g190
sg10887
I1
sasa(dp17822
g10873
VWe demonstrated the clinical relevance of the miRNAs and identified miR-342-5p and miR-744* as significantly down-regulated in HER2-positive breast tumors as compared to HER2-negative tumors from two cohorts of breast cancer patients (101 and 1302 cases).
p17823
sg4
(dp17824
(VHER2
p17825
Vbreast tumors
p17826
tp17827
I00
ssg10879
(lp17828
(dp17829
g10882
I211
sg10883
Vbreast cancer
p17830
sg10884
I13
sg10885
VC0678222
p17831
sg10887
I2
sa(dp17832
g10882
I141
sg10883
g17826
sg10884
I13
sg10885
VC1458155
p17833
sg10887
I2
sa(dp17834
g10882
I148
sg10883
Vtumors
p17835
sg10884
I6
sg10885
VC0027651
p17836
sg10887
I1
sasg10888
(lp17837
(dp17838
g10882
I127
sg10883
VHER2
p17839
sg10884
I4
sg10891
VP04626
p17840
sg10887
I1
sa(dp17841
g10882
I83
sg10883
VmiR-744*
p17842
sg10884
I8
sg10891
g190
sg10887
I1
sa(dp17843
g10882
I127
sg10883
g17825
sg10884
I4
sg10891
VP04626
p17844
sg10887
I1
sa(dp17845
g10882
I68
sg10883
VmiR-342-5p
p17846
sg10884
I10
sg10891
g190
sg10887
I1
sasa(dp17847
g10873
VCompromised CN function is a significant cause of erectile dysfunction development following prostatectomy and serves as the primary target for potential neuroprotective or regenerative strategies utilizing NGFs such as BDNF, GDF-5, and NTN, and/or targeted novel therapeutics modulating signaling pathways.
p17848
sg4
(dp17849
(VGDF-5
p17850
Verectile dysfunction
p17851
tp17852
I00
ssg10879
(lp17853
(dp17854
g10882
I50
sg10883
g17851
sg10884
I20
sg10885
VC0242350
p17855
sg10887
I2
sasg10888
(lp17856
(dp17857
g10882
I226
sg10883
g17850
sg10884
I5
sg10891
VP43026
p17858
sg10887
I1
sasa(dp17859
g10873
VMT-ND4: mitochondrially encoded NADH dehydrogenase 4; MT-TL1: mitochondrially encoded tRNA leucine 1 (UUA/G); PCR: polymerase chain reaction; OXPHOS: mitochondrial oxidative phosphorylation; ATP: adenosine triphosphate; mtDNA: mitochondrial DNA; SNPs: single nucleotide substitutions; AD: alzheimer's disease; PD: parkinson's disease; MELAS: mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes; ROS: reactive oxygen species.
p17860
sg4
(dp17861
(VMT-ND4
p17862
VMELAS
p17863
tp17864
I00
ssg10879
(lp17865
(dp17866
g10882
I314
sg10883
Vparkinson's disease
p17867
sg10884
I19
sg10885
VC0030567
p17868
sg10887
I2
sa(dp17869
g10882
I342
sg10883
Vmitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes
p17870
sg10884
I77
sg10885
VC1964017
p17871
sg10887
I8
sa(dp17872
g10882
I335
sg10883
g17863
sg10884
I5
sg10885
VC0162671
p17873
sg10887
I1
sa(dp17874
g10882
I289
sg10883
Valzheimer's disease
p17875
sg10884
I19
sg10885
VC1521724
p17876
sg10887
I2
sasg10888
(lp17877
(dp17878
g10882
I54
sg10883
VMT-TL1
p17879
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp17880
g10882
I62
sg10883
Vmitochondrially encoded tRNA leucine 1
p17881
sg10884
I38
sg10891
VP30740
p17882
sg10887
I5
sa(dp17883
g10882
I8
sg10883
Vmitochondrially encoded NADH dehydrogenase 4
p17884
sg10884
I44
sg10891
VP49366
p17885
sg10887
I5
sa(dp17886
g10882
I0
sg10883
g17862
sg10884
I6
sg10891
VP03905
p17887
sg10887
I1
sasa(dp17888
g10873
VThe role of oxidative stress in the five most common inherited mitochondrial diseases, Friedreich ataxia, LHON, MELAS, MERRF, and Leigh syndrome (LS), is discussed.
p17889
sg4
(dp17890
(VMERRF
p17891
VMERRF
p17892
tp17893
I01
ssg10879
(lp17894
(dp17895
g10882
I63
sg10883
Vmitochondrial diseases
p17896
sg10884
I22
sg10885
VC0751651
p17897
sg10887
I2
sa(dp17898
g10882
I112
sg10883
VMELAS
p17899
sg10884
I5
sg10885
VC0162671
p17900
sg10887
I1
sa(dp17901
g10882
I130
sg10883
VLeigh syndrome
p17902
sg10884
I14
sg10885
VC0023264
p17903
sg10887
I2
sa(dp17904
g10882
I12
sg10883
Voxidative stress
p17905
sg10884
I16
sg10885
VC0242606
p17906
sg10887
I2
sa(dp17907
g10882
I146
sg10883
VLS
p17908
sg10884
I2
sg10885
VC0023264
p17909
sg10887
I1
sa(dp17910
g10882
I87
sg10883
VFriedreich ataxia
p17911
sg10884
I17
sg10885
VC0016719
p17912
sg10887
I2
sa(dp17913
g10882
I106
sg10883
VLHON
p17914
sg10884
I4
sg10885
VC0917796
p17915
sg10887
I1
sa(dp17916
g10882
I119
sg10883
g17892
sg10884
I5
sg10885
VC0162672
p17917
sg10887
I1
sasg10888
(lp17918
(dp17919
g10882
I112
sg10883
VMELAS
p17920
sg10884
I5
sg10891
VP03886
p17921
sg10887
I1
sa(dp17922
g10882
I119
sg10883
g17891
sg10884
I5
sg10891
VP03915
p17923
sg10887
I1
sasa(dp17924
g10873
VMutations in the retinitis pigmentosa 1 (RP1) gene are a common cause of retinitis pigmentosa (RP).
p17925
sg4
(dp17926
(VRP1
p17927
VRP1
p17928
tp17929
I00
ssg10879
(lp17930
(dp17931
g10882
I17
sg10883
Vretinitis pigmentosa 1
p17932
sg10884
I22
sg10885
VC0220701
p17933
sg10887
I3
sa(dp17934
g10882
I41
sg10883
VRP
p17935
sg10884
I2
sg10885
VC0035334
p17936
sg10887
I1
sa(dp17937
g10882
I17
sg10883
Vretinitis pigmentosa
p17938
sg10884
I20
sg10885
VC0035334
p17939
sg10887
I2
sa(dp17940
g10882
I41
sg10883
g17928
sg10884
I3
sg10885
VC0220701
p17941
sg10887
I1
sasg10888
(lp17942
(dp17943
g10882
I17
sg10883
Vretinitis pigmentosa 1
p17944
sg10884
I22
sg10891
VP56715
p17945
sg10887
I3
sa(dp17946
g10882
I41
sg10883
g17927
sg10884
I3
sg10891
VP56715
p17947
sg10887
I1
sasa(dp17948
g10873
VFurthermore, these findings indicate that the RP1 form of inherited retinal degeneration is part of the larger class of neurodegenerative diseases caused by MAP dysfunction.
p17949
sg4
(dp17950
(VRP1
p17951
Vretinal degeneration
p17952
tp17953
I00
ssg10879
(lp17954
(dp17955
g10882
I46
sg10883
VRP1
p17956
sg10884
I3
sg10885
VC0220701
p17957
sg10887
I1
sa(dp17958
g10882
I120
sg10883
Vneurodegenerative diseases
p17959
sg10884
I26
sg10885
VC0524851
p17960
sg10887
I2
sa(dp17961
g10882
I68
sg10883
g17952
sg10884
I20
sg10885
VC0035304
p17962
sg10887
I2
sasg10888
(lp17963
(dp17964
g10882
I46
sg10883
g17951
sg10884
I3
sg10891
VP56715
p17965
sg10887
I1
sasa(dp17966
g10873
VA recent article explored protective modifiers, including plastin 3 (PLS3) and coronin 1C (CORO1C), in spinal muscular atrophy (SMA).
p17967
sg4
(dp17968
(VPLS3
p17969
VSMA
p17970
tp17971
I00
ssg10879
(lp17972
(dp17973
g10882
I103
sg10883
Vspinal muscular atrophy
p17974
sg10884
I23
sg10885
VC0026847
p17975
sg10887
I3
sa(dp17976
g10882
I128
sg10883
g17970
sg10884
I3
sg10885
VC0026847
p17977
sg10887
I1
sasg10888
(lp17978
(dp17979
g10882
I58
sg10883
Vplastin 3
p17980
sg10884
I9
sg10891
VP13797
p17981
sg10887
I2
sa(dp17982
g10882
I69
sg10883
g17969
sg10884
I4
sg10891
VP13797
p17983
sg10887
I1
sa(dp17984
g10882
I79
sg10883
Vcoronin 1C
p17985
sg10884
I10
sg10891
g190
sg10887
I2
sa(dp17986
g10882
I91
sg10883
VCORO1C
p17987
sg10884
I6
sg10891
g190
sg10887
I1
sasa(dp17988
g10873
VIn the present study we chose to investigate 7 genes involved in the synthesis, degradation and transportation of RA, ALDH1A1, ALDH1A2, ALDH1A3, CYP26A1, CYP26B1, CYP26C1 and Transthyretin (TTR), for their roles in the development of schizophrenia.
p17989
sg4
(dp17990
(VALDH1A1
p17991
Vschizophrenia
p17992
tp17993
I00
ssg10879
(lp17994
(dp17995
g10882
I234
sg10883
g17992
sg10884
I13
sg10885
VC0036341
p17996
sg10887
I1
sasg10888
(lp17997
(dp17998
g10882
I136
sg10883
VALDH1A3
p17999
sg10884
I7
sg10891
VP47895
p18000
sg10887
I1
sa(dp18001
g10882
I190
sg10883
VTTR
p18002
sg10884
I3
sg10891
VP02766
p18003
sg10887
I1
sa(dp18004
g10882
I175
sg10883
VTransthyretin
p18005
sg10884
I13
sg10891
VP02766
p18006
sg10887
I1
sa(dp18007
g10882
I163
sg10883
VCYP26C1
p18008
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp18009
g10882
I154
sg10883
VCYP26B1
p18010
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp18011
g10882
I145
sg10883
VCYP26A1
p18012
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp18013
g10882
I127
sg10883
VALDH1A2
p18014
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp18015
g10882
I118
sg10883
g17991
sg10884
I7
sg10891
VP00352
p18016
sg10887
I1
sasa(dp18017
g10873
VBACKGROUND To examine changes of mRNA and protein expressions of MMP-2, Bcl-2, and BAX in atrial fibrillation (AF) patients, and investigate the correlations among these 3 biomarkers.
p18018
sg4
(dp18019
(VBcl-2
p18020
VAF
p18021
tp18022
I00
ssg10879
(lp18023
(dp18024
g10882
I90
sg10883
Vatrial fibrillation
p18025
sg10884
I19
sg10885
VC0004238
p18026
sg10887
I2
sa(dp18027
g10882
I111
sg10883
g18021
sg10884
I2
sg10885
VC0004238
p18028
sg10887
I1
sasg10888
(lp18029
(dp18030
g10882
I65
sg10883
VMMP-2
p18031
sg10884
I5
sg10891
VP08253
p18032
sg10887
I1
sa(dp18033
g10882
I72
sg10883
g18020
sg10884
I5
sg10891
VP10415
p18034
sg10887
I1
sasa(dp18035
g10873
VWe investigated the localization of KCNJ10 and the homologous KCNJ16 in kidney and the functional consequences of KCNJ10 mutations found in our patients with EAST syndrome.
p18036
sg4
(dp18037
(VKCNJ10 mutations
p18038
VEAST syndrome
p18039
tp18040
I00
ssg10879
(lp18041
(dp18042
g10882
I158
sg10883
g18039
sg10884
I13
sg10885
VC2748572
p18043
sg10887
I2
sasg10888
(lp18044
(dp18045
g10882
I62
sg10883
VKCNJ16
p18046
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp18047
g10882
I36
sg10883
VKCNJ10
p18048
sg10884
I6
sg10891
VP78508
p18049
sg10887
I1
sa(dp18050
g10882
I114
sg10883
g18038
sg10884
I16
sg10891
VP78508
p18051
sg10887
I2
sasa(dp18052
g10873
VThus, we evaluated the effect of serum availability on the expression of commonly used HKG (ACTB, B2M, GAPDH, GUSB, HPRT1, IPO8, MRPL19, PGK1, PPIA, RPLP0, RPS23, SDHA, TBP, UBC, and YWHAZ) in seven colon adenocarcinoma cell lines (Caco-2, DLD-1, HCT116, HT29, Lovo, SW480, and SW620).
p18053
sg4
(dp18054
(VSDHA
p18055
Vcolon adenocarcinoma
p18056
tp18057
I00
ssg10879
(lp18058
(dp18059
g10882
I199
sg10883
g18056
sg10884
I20
sg10885
VC0338106
p18060
sg10887
I2
sasg10888
(lp18061
(dp18062
g10882
I110
sg10883
VGUSB
p18063
sg10884
I4
sg10891
VP08236
p18064
sg10887
I1
sa(dp18065
g10882
I98
sg10883
VB2M
p18066
sg10884
I3
sg10891
VP61769
p18067
sg10887
I1
sa(dp18068
g10882
I123
sg10883
VIPO8
p18069
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp18070
g10882
I169
sg10883
VTBP
p18071
sg10884
I3
sg10891
VP20226
p18072
sg10887
I1
sa(dp18073
g10882
I240
sg10883
VDLD-1
p18074
sg10884
I5
sg10891
VP98173
p18075
sg10887
I1
sa(dp18076
g10882
I137
sg10883
VPGK1
p18077
sg10884
I4
sg10891
VP00558
p18078
sg10887
I1
sa(dp18079
g10882
I103
sg10883
VGAPDH
p18080
sg10884
I5
sg10891
VP04406
p18081
sg10887
I1
sa(dp18082
g10882
I156
sg10883
VRPS23
p18083
sg10884
I5
sg10891
VP62266
p18084
sg10887
I1
sa(dp18085
g10882
I92
sg10883
VACTB
p18086
sg10884
I4
sg10891
VP63261
p18087
sg10887
I1
sa(dp18088
g10882
I149
sg10883
VRPLP0
p18089
sg10884
I5
sg10891
VP05388
p18090
sg10887
I1
sa(dp18091
g10882
I143
sg10883
VPPIA
p18092
sg10884
I4
sg10891
VP62937
p18093
sg10887
I1
sa(dp18094
g10882
I116
sg10883
VHPRT1
p18095
sg10884
I5
sg10891
VP55884
p18096
sg10887
I1
sa(dp18097
g10882
I129
sg10883
VMRPL19
p18098
sg10884
I6
sg10891
VP49406
p18099
sg10887
I1
sa(dp18100
g10882
I163
sg10883
g18055
sg10884
I4
sg10891
VP31040
p18101
sg10887
I1
sa(dp18102
g10882
I174
sg10883
VUBC
p18103
sg10884
I3
sg10891
g190
sg10887
I1
sasa(dp18104
g10873
VWe investigated whether the expression of PGK1 varies between metastatic and non-metastatic colon cancer.
p18105
sg4
(dp18106
(VPGK1
p18107
Vmetastatic colon cancer
p18108
tp18109
I01
ssg10879
(lp18110
(dp18111
g10882
I81
sg10883
g18108
sg10884
I23
sg10885
VC0278484
p18112
sg10887
I3
sasg10888
(lp18113
(dp18114
g10882
I42
sg10883
g18107
sg10884
I4
sg10891
VP00558
p18115
sg10887
I1
sasa(dp18116
g10873
VWe compared PGK1 expression in colon cancer patients either with or without metastasis via polymerase chain reaction (PCR) and immunohistochemistry.
p18117
sg4
(dp18118
(VPGK1
p18119
Vmetastasis
p18120
tp18121
I00
ssg10879
(lp18122
(dp18123
g10882
I31
sg10883
Vcolon cancer
p18124
sg10884
I12
sg10885
VC0699790
p18125
sg10887
I2
sa(dp18126
g10882
I76
sg10883
g18120
sg10884
I10
sg10885
VC0027627
p18127
sg10887
I1
sasg10888
(lp18128
(dp18129
g10882
I12
sg10883
g18119
sg10884
I4
sg10891
VP00558
p18130
sg10887
I1
sasa(dp18131
g10873
VPCR results showed an increased expression of PGK1 in colon cancer tissue from metastatic patients in comparison to patients with no metastasis (fold change 2.6, p&lt;0.001).
p18132
sg4
(dp18133
(VPGK1
p18134
Vcolon cancer
p18135
tp18136
I00
ssg10879
(lp18137
(dp18138
g10882
I133
sg10883
Vmetastasis
p18139
sg10884
I10
sg10885
VC0027627
p18140
sg10887
I1
sa(dp18141
g10882
I54
sg10883
g18135
sg10884
I12
sg10885
VC0699790
p18142
sg10887
I2
sasg10888
(lp18143
(dp18144
g10882
I46
sg10883
g18134
sg10884
I4
sg10891
VP00558
p18145
sg10887
I1
sasa(dp18146
g10873
VThe results indicate that increased expression of PGK1 in colon cancer tissue is associated with metastasis.
p18147
sg4
(dp18148
(VPGK1
p18149
Vmetastasis
p18150
tp18151
I00
ssg10879
(lp18152
(dp18153
g10882
I58
sg10883
Vcolon cancer
p18154
sg10884
I12
sg10885
VC0699790
p18155
sg10887
I2
sa(dp18156
g10882
I97
sg10883
g18150
sg10884
I10
sg10885
VC0027627
p18157
sg10887
I1
sasg10888
(lp18158
(dp18159
g10882
I50
sg10883
g18149
sg10884
I4
sg10891
VP00558
p18160
sg10887
I1
sasa(dp18161
g10873
VTYMS and PGK1, as well as their epitope peptides, might be appropriate target molecules for specific immunotherapy of HLA-A2(+) colon cancer patients because of the positive role of TYMS and PGK1 in chemoresistance (5-fluorouracil) and angiogenesis of tumor cells, respectively.
p18162
sg4
(dp18163
(VTYMS
p18164
Vcolon cancer
p18165
tp18166
I00
ssg10879
(lp18167
(dp18168
g10882
I128
sg10883
g18165
sg10884
I12
sg10885
VC0699790
p18169
sg10887
I2
sa(dp18170
g10882
I252
sg10883
Vtumor
p18171
sg10884
I5
sg10885
VC0027651
p18172
sg10887
I1
sasg10888
(lp18173
(dp18174
g10882
I9
sg10883
VPGK1
p18175
sg10884
I4
sg10891
VP00558
p18176
sg10887
I1
sa(dp18177
g10882
I9
sg10883
VPGK1
p18178
sg10884
I4
sg10891
VP00558
p18179
sg10887
I1
sa(dp18180
g10882
I0
sg10883
VTYMS
p18181
sg10884
I4
sg10891
VP04818
p18182
sg10887
I1
sa(dp18183
g10882
I118
sg10883
VHLA-A2(+)
p18184
sg10884
I9
sg10891
VP30486
p18185
sg10887
I1
sa(dp18186
g10882
I0
sg10883
g18164
sg10884
I4
sg10891
VP04818
p18187
sg10887
I1
sasa(dp18188
g10873
VIn one sample we sequenced 7231 contiguous base pairs that covered completely the region from the 5'end of the 16S rRNA gene to the 5'end of the 23S rRNA gene comprising the whole 16S rRNA (rrs), and the following genes: Ala tRNA (alaT), Ile tRNA (ileT), adenylosuccinate lyase (purB), adenylosuccinate synthetase (purA), methylpurine-DNA glycosylase (mag), hypoxanthine-guanine phosphoribosyltransferase (hpt), an hydrolase (HAD superfamily) and a 135 bp 5' fragment of the 23S rRNA (rrlA) genes.
p18189
sg4
(dp18190
(Vhypoxanthine-guanine phosphoribosyltransferase
p18191
Vrrs
p18192
tp18193
I00
ssg10879
(lp18194
(dp18195
g10882
I190
sg10883
g18192
sg10884
I3
sg10885
VC1849334
p18196
sg10887
I1
sasg10888
(lp18197
(dp18198
g10882
I315
sg10883
VpurA
p18199
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp18200
g10882
I352
sg10883
Vmag
p18201
sg10884
I3
sg10891
VP20916
p18202
sg10887
I1
sa(dp18203
g10882
I279
sg10883
VpurB
p18204
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp18205
g10882
I322
sg10883
Vmethylpurine-DNA glycosylase
p18206
sg10884
I28
sg10891
g190
sg10887
I2
sa(dp18207
g10882
I255
sg10883
Vadenylosuccinate lyase
p18208
sg10884
I22
sg10891
VP30566
p18209
sg10887
I2
sa(dp18210
g10882
I406
sg10883
Vhpt
p18211
sg10884
I3
sg10891
VP00738
p18212
sg10887
I1
sa(dp18213
g10882
I221
sg10883
VAla tRNA (alaT), Ile tRNA
p18214
sg10884
I25
sg10891
VP00709
p18215
sg10887
I5
sa(dp18216
g10882
I190
sg10883
Vrrs
p18217
sg10884
I3
sg10891
VP49788
p18218
sg10887
I1
sa(dp18219
g10882
I475
sg10883
V23S rRNA (rrlA) genes
p18220
sg10884
I21
sg10891
VP01893
p18221
sg10887
I4
sa(dp18222
g10882
I286
sg10883
Vadenylosuccinate synthetase
p18223
sg10884
I27
sg10891
VP30520
p18224
sg10887
I2
sa(dp18225
g10882
I358
sg10883
g18191
sg10884
I46
sg10891
VP00492
p18226
sg10887
I2
sasa(dp18227
g10873
VLow expression of NOLC1 in hepatoma cell lines and liver cancer tissues was associated with cyclin D3.
p18228
sg4
(dp18229
(Vcyclin D3
p18230
Vliver cancer
p18231
tp18232
I00
ssg10879
(lp18233
(dp18234
g10882
I27
sg10883
Vhepatoma
p18235
sg10884
I8
sg10885
VC0023903
p18236
sg10887
I1
sa(dp18237
g10882
I51
sg10883
g18231
sg10884
I12
sg10885
VC0345904
p18238
sg10887
I2
sasg10888
(lp18239
(dp18240
g10882
I92
sg10883
g18230
sg10884
I9
sg10891
VP30281
p18241
sg10887
I2
sa(dp18242
g10882
I18
sg10883
VNOLC1
p18243
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp18244
g10873
VThe aim of the study was to examine the effects of endurance exercise on circulating vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) in sickle cell trait (SCT) athletes with or without alpha-thalassemia.
p18245
sg4
(dp18246
(Vvascular cell adhesion molecule-1
p18247
Valpha-thalassemia
p18248
tp18249
I01
ssg10879
(lp18250
(dp18251
g10882
I180
sg10883
Vsickle cell trait
p18252
sg10884
I17
sg10885
VC0037054
p18253
sg10887
I3
sa(dp18254
g10882
I199
sg10883
VSCT
p18255
sg10884
I3
sg10885
VC1848934
p18256
sg10887
I1
sa(dp18257
g10882
I99
sg10883
Vadhesion
p18258
sg10884
I8
sg10885
VC0001511
p18259
sg10887
I1
sa(dp18260
g10882
I99
sg10883
Vadhesion
p18261
sg10884
I8
sg10885
VC0001511
p18262
sg10887
I1
sa(dp18263
g10882
I229
sg10883
g18248
sg10884
I17
sg10885
VC0002312
p18264
sg10887
I1
sasg10888
(lp18265
(dp18266
g10882
I133
sg10883
Vintercellular adhesion molecule-1
p18267
sg10884
I33
sg10891
VP05362
p18268
sg10887
I3
sa(dp18269
g10882
I85
sg10883
g18247
sg10884
I33
sg10891
VP19320
p18270
sg10887
I4
sasa(dp18271
g10873
VThe aim of the study was to examine the effects of exercise on soluble vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) in sickle cell trait (SCT) athletes with or without alpha-thalassemia.
p18272
sg4
(dp18273
(Vvascular cell adhesion molecule-1
p18274
VSCT
p18275
tp18276
I01
ssg10879
(lp18277
(dp18278
g10882
I85
sg10883
Vadhesion
p18279
sg10884
I8
sg10885
VC0001511
p18280
sg10887
I1
sa(dp18281
g10882
I85
sg10883
Vadhesion
p18282
sg10884
I8
sg10885
VC0001511
p18283
sg10887
I1
sa(dp18284
g10882
I215
sg10883
Valpha-thalassemia
p18285
sg10884
I17
sg10885
VC0002312
p18286
sg10887
I1
sa(dp18287
g10882
I166
sg10883
Vsickle cell trait
p18288
sg10884
I17
sg10885
VC0037054
p18289
sg10887
I3
sa(dp18290
g10882
I185
sg10883
g18275
sg10884
I3
sg10885
VC1848934
p18291
sg10887
I1
sasg10888
(lp18292
(dp18293
g10882
I119
sg10883
Vintercellular adhesion molecule-1
p18294
sg10884
I33
sg10891
VP05362
p18295
sg10887
I3
sa(dp18296
g10882
I71
sg10883
g18274
sg10884
I33
sg10891
VP19320
p18297
sg10887
I4
sasa(dp18298
g10873
VAs compared to normal, increased sICAM-1 was found in beta-thal/HbE patients with non-splenectomy; BE-NS (p = 0.002), increased ELAM-1 in beta-thal/HbE patients with splenectomy; BE-S (p = 0.01) and HbH with Hb Constant Spring; HbH/CS (p = 0.001), and increased sVCAM-1 in BE-NS; (p = &lt; 0.0001) and BE-S (p = 0.002).
p18299
sg4
(dp18300
(VELAM-1
p18301
VHbH
p18302
tp18303
I00
ssg10879
(lp18304
(dp18305
g10882
I199
sg10883
VHbH
p18306
sg10884
I3
sg10885
VC3161174
p18307
sg10887
I1
sa(dp18308
g10882
I199
sg10883
g18302
sg10884
I3
sg10885
VC3161174
p18309
sg10887
I1
sasg10888
(lp18310
(dp18311
g10882
I64
sg10883
VHbE
p18312
sg10884
I3
sg10891
VP02100
p18313
sg10887
I1
sa(dp18314
g10882
I128
sg10883
g18301
sg10884
I6
sg10891
VP16581
p18315
sg10887
I1
sa(dp18316
g10882
I208
sg10883
VHb Constant Spring
p18317
sg10884
I18
sg10891
g190
sg10887
I3
sasa(dp18318
g10873
VFurthermore, treatment with AST or DEX significantly suppressed the mRNA and protein expression levels of the transcription factor GATA-3 and retinoic acid receptor-related orphan nuclear receptor (ROR)Gammat in tissue samples isolated from the spleen and nasal mucosa of mice with allergic rhinitis.
p18319
sg4
(dp18320
(Vretinoic acid receptor
p18321
Vallergic rhinitis
p18322
tp18323
I00
ssg10879
(lp18324
(dp18325
g10882
I282
sg10883
g18322
sg10884
I17
sg10885
VC2607914
p18326
sg10887
I2
sasg10888
(lp18327
(dp18328
g10882
I173
sg10883
Vorphan nuclear receptor
p18329
sg10884
I23
sg10891
VP51843
p18330
sg10887
I3
sa(dp18331
g10882
I110
sg10883
Vtranscription factor GATA-3
p18332
sg10884
I27
sg10891
VP23771
p18333
sg10887
I3
sa(dp18334
g10882
I142
sg10883
g18321
sg10884
I22
sg10891
VP10826
p18335
sg10887
I3
sasa(dp18336
g10873
VThe present results suggested that treatment with AST may attenuate OVA-induced allergic rhinitis via regulating the expression of the transcription factors GATA-3, RORGammat, T-bet and Foxp3, which commit T helper cells to the Th1 phenotype.
p18337
sg4
(dp18338
(Vtranscription factors GATA-3
p18339
Vallergic rhinitis
p18340
tp18341
I00
ssg10879
(lp18342
(dp18343
g10882
I80
sg10883
g18340
sg10884
I17
sg10885
VC2607914
p18344
sg10887
I2
sasg10888
(lp18345
(dp18346
g10882
I50
sg10883
VAST
p18347
sg10884
I3
sg10891
VP51689
p18348
sg10887
I1
sa(dp18349
g10882
I135
sg10883
g18339
sg10884
I28
sg10891
VP19883
p18350
sg10887
I3
sa(dp18351
g10882
I176
sg10883
VT-bet
p18352
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp18353
g10882
I186
sg10883
VFoxp3
p18354
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp18355
g10873
VCanagliflozin was associated with a low incidence of hypoglycemia when not used in conjunction with AHAs associated with hypoglycemia (i.e., insulin or sulfonylurea).
p18356
sg4
(dp18357
(Vinsulin
p18358
Vhypoglycemia
p18359
tp18360
I00
ssg10879
(lp18361
(dp18362
g10882
I53
sg10883
Vhypoglycemia
p18363
sg10884
I12
sg10885
VC0020615
p18364
sg10887
I1
sa(dp18365
g10882
I53
sg10883
g18359
sg10884
I12
sg10885
VC0020615
p18366
sg10887
I1
sasg10888
(lp18367
(dp18368
g10882
I141
sg10883
g18358
sg10884
I7
sg10891
VP01308
p18369
sg10887
I1
sasa(dp18370
g10873
VIt has been shown at least four mutations of mitochondrial genome, namely, A1555G in MT-RNR1 gene, C3256T in MT-TL1 gene, G12315A in MT-TL2 gene, and G15059A in MT-CYB gene have significantly higher prevalence and mean value in lipofibrous plaques as compared to non-atherosclerotic intima, and therefore are associated with atherosclerosis.
p18371
sg4
(dp18372
(VMT-TL2 gene
p18373
Vatherosclerosis
p18374
tp18375
I00
ssg10879
(lp18376
(dp18377
g10882
I240
sg10883
Vplaques
p18378
sg10884
I7
sg10885
VC0333463
p18379
sg10887
I1
sa(dp18380
g10882
I325
sg10883
g18374
sg10884
I15
sg10885
VC0004153
p18381
sg10887
I1
sasg10888
(lp18382
(dp18383
g10882
I85
sg10883
VMT-RNR1 gene
p18384
sg10884
I12
sg10891
VP43354
p18385
sg10887
I2
sa(dp18386
g10882
I133
sg10883
g18373
sg10884
I11
sg10891
VP50591
p18387
sg10887
I2
sa(dp18388
g10882
I109
sg10883
VMT-TL1 gene
p18389
sg10884
I11
sg10891
g190
sg10887
I2
sa(dp18390
g10882
I161
sg10883
VMT-CYB gene
p18391
sg10884
I11
sg10891
g190
sg10887
I2
sasa(dp18392
g10873
VTen mitochondrial mutations belonging to mitochondrial genes MT-RNR1 (rRNA 12S); MT-TL1 (tRNA-Leu, recognizes UUR); MT-TL2 (tRNA-Leu, recognizes CUN); MT-ND1, MT-ND2, MT-ND5, and MT-ND6 (subunits 1, 2, 5, and 6, respectively, of NADH dehydrogenase); and MT-CYB (cytochrome b) were potentially associated with atherosclerosis.
p18393
sg4
(dp18394
(VMT-ND1
p18395
Vatherosclerosis
p18396
tp18397
I00
ssg10879
(lp18398
(dp18399
g10882
I309
sg10883
g18396
sg10884
I15
sg10885
VC0004153
p18400
sg10887
I1
sasg10888
(lp18401
(dp18402
g10882
I81
sg10883
VMT-TL1
p18403
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp18404
g10882
I116
sg10883
VMT-TL2
p18405
sg10884
I6
sg10891
VP50591
p18406
sg10887
I1
sa(dp18407
g10882
I254
sg10883
VMT-CYB
p18408
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp18409
g10882
I167
sg10883
VMT-ND5
p18410
sg10884
I6
sg10891
VP03915
p18411
sg10887
I1
sa(dp18412
g10882
I159
sg10883
VMT-ND2
p18413
sg10884
I6
sg10891
VP03891
p18414
sg10887
I1
sa(dp18415
g10882
I229
sg10883
VNADH dehydrogenase
p18416
sg10884
I18
sg10891
VP49366
p18417
sg10887
I2
sa(dp18418
g10882
I61
sg10883
VMT-RNR1
p18419
sg10884
I7
sg10891
VP43354
p18420
sg10887
I1
sa(dp18421
g10882
I124
sg10883
VtRNA-Leu, recognizes CUN
p18422
sg10884
I24
sg10891
VP30740
p18423
sg10887
I3
sa(dp18424
g10882
I89
sg10883
VtRNA-Leu, recognizes UUR
p18425
sg10884
I24
sg10891
VP30740
p18426
sg10887
I3
sa(dp18427
g10882
I151
sg10883
g18395
sg10884
I6
sg10891
VP03886
p18428
sg10887
I1
sasa(dp18429
g10873
VThe results of an examination of a paraffin block histopathology specimen by fluorescence in-situ hybridization (FISH) showed no mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1) (18q21.1), B-cell lymphoma 2 (BCL2) (18q21.3), or BCL6 (3q27) split signals in either the uterus or the greater omentum, however, trisomy 18 was detected in approximately 50%-70% of the tumor cells in both the uterus and the greater omentum.
p18430
sg4
(dp18431
(VB-cell lymphoma 2
p18432
Vtrisomy 18
p18433
tp18434
I00
ssg10879
(lp18435
(dp18436
g10882
I172
sg10883
Vtranslocation
p18437
sg10884
I13
sg10885
VC0040715
p18438
sg10887
I1
sa(dp18439
g10882
I387
sg10883
Vtumor
p18440
sg10884
I5
sg10885
VC0027651
p18441
sg10887
I1
sa(dp18442
g10882
I129
sg10883
Vmucosa associated lymphoid tissue lymphoma
p18443
sg10884
I42
sg10885
VC0242647
p18444
sg10887
I5
sa(dp18445
g10882
I212
sg10883
VB-cell lymphoma
p18446
sg10884
I15
sg10885
VC0079731
p18447
sg10887
I2
sa(dp18448
g10882
I331
sg10883
g18433
sg10884
I10
sg10885
VC0152096
p18449
sg10887
I2
sasg10888
(lp18450
(dp18451
g10882
I251
sg10883
VBCL6
p18452
sg10884
I4
sg10891
VP41182
p18453
sg10887
I1
sa(dp18454
g10882
I231
sg10883
VBCL2
p18455
sg10884
I4
sg10891
VP10415
p18456
sg10887
I1
sa(dp18457
g10882
I212
sg10883
g18432
sg10884
I17
sg10891
VP10415
p18458
sg10887
I3
sasa(dp18459
g10873
VPassive avoidance test showed four Group rats shuttle times were 6.8+/-0.6, 1.2+/-0.2, 5.4+/-0.5, 3.6+/-0.3, incubation period were 26.1+/-3.9, 152.2+/-12.9, 65.8+/-7.0, 91.2+/-9.1, and water maze test had the same trend, with values in epilepsy groups significantly lower than the normal group of rats, which meant cognitive dysfunction.The above results also showed Baclofen further inhibited the learning and memory ability of the rats and CGP35348 promoted the learning and memory ability.The results of the Arc/Arg3.1 and GB1, GB2 level detection showed that epilepsy groups had significantly higher expression levels of Arc/Arg3.1 and GB1, GB2 than the normal group.Comparison among epilepsy groups showed that Baclofen group expressed lower levels of Arc/Arg3.1 and expressed higher levels of GB1, GB2, however CGP35348 group expressed higher levels of Arc/Arg3.1 and expressed lower levels of GB1, GB2.
p18460
sg4
(dp18461
(VGB1
p18462
VArc
p18463
tp18464
I00
ssg10879
(lp18465
(dp18466
g10882
I237
sg10883
Vepilepsy
p18467
sg10884
I8
sg10885
VC0014544
p18468
sg10887
I1
sa(dp18469
g10882
I512
sg10883
VArc
p18470
sg10884
I3
sg10885
VC0001857
p18471
sg10887
I1
sa(dp18472
g10882
I237
sg10883
Vepilepsy
p18473
sg10884
I8
sg10885
VC0014544
p18474
sg10887
I1
sa(dp18475
g10882
I512
sg10883
VArc
p18476
sg10884
I3
sg10885
VC0001857
p18477
sg10887
I1
sa(dp18478
g10882
I512
sg10883
VArc
p18479
sg10884
I3
sg10885
VC0001857
p18480
sg10887
I1
sa(dp18481
g10882
I316
sg10883
Vcognitive dysfunction
p18482
sg10884
I21
sg10885
VC0338656
p18483
sg10887
I2
sa(dp18484
g10882
I237
sg10883
Vepilepsy
p18485
sg10884
I8
sg10885
VC0014544
p18486
sg10887
I1
sa(dp18487
g10882
I512
sg10883
g18463
sg10884
I3
sg10885
VC0001857
p18488
sg10887
I1
sasg10888
(lp18489
(dp18490
g10882
I516
sg10883
VArg3.1
p18491
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp18492
g10882
I532
sg10883
VGB2
p18493
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp18494
g10882
I527
sg10883
VGB1
p18495
sg10884
I3
sg10891
VP62873
p18496
sg10887
I1
sa(dp18497
g10882
I516
sg10883
VArg3.1
p18498
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp18499
g10882
I532
sg10883
VGB2
p18500
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp18501
g10882
I532
sg10883
VGB2
p18502
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp18503
g10882
I512
sg10883
VArc
p18504
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp18505
g10882
I516
sg10883
VArg3.1
p18506
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp18507
g10882
I512
sg10883
VArc
p18508
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp18509
g10882
I512
sg10883
VArc
p18510
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp18511
g10882
I527
sg10883
VGB1
p18512
sg10884
I3
sg10891
VP62873
p18513
sg10887
I1
sa(dp18514
g10882
I527
sg10883
VGB1
p18515
sg10884
I3
sg10891
VP62873
p18516
sg10887
I1
sa(dp18517
g10882
I532
sg10883
VGB2
p18518
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp18519
g10882
I818
sg10883
VCGP35348 group
p18520
sg10884
I14
sg10891
VP00390
p18521
sg10887
I2
sa(dp18522
g10882
I512
sg10883
VArc
p18523
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp18524
g10882
I516
sg10883
VArg3.1
p18525
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp18526
g10882
I527
sg10883
g18462
sg10884
I3
sg10891
VP62873
p18527
sg10887
I1
sasa(dp18528
g10873
VTo search for the mechanism causing clinically silent corticotroph adenoma, we immunohistochemically examined the expression of prohormone convertase 1/3 (PC1/3) in this type of adenoma and compared our results with those obtained for Cushing's disease.
p18529
sg4
(dp18530
(Vprohormone convertase 1/3
p18531
VPC1
p18532
tp18533
I00
ssg10879
(lp18534
(dp18535
g10882
I67
sg10883
Vadenoma
p18536
sg10884
I7
sg10885
VC0001430
p18537
sg10887
I1
sa(dp18538
g10882
I54
sg10883
Vcorticotroph adenoma
p18539
sg10884
I20
sg10885
VC1306214
p18540
sg10887
I2
sa(dp18541
g10882
I235
sg10883
VCushing's disease
p18542
sg10884
I17
sg10885
VC0221406
p18543
sg10887
I2
sa(dp18544
g10882
I155
sg10883
g18532
sg10884
I3
sg10885
VC1706595
p18545
sg10887
I1
sasg10888
(lp18546
(dp18547
g10882
I155
sg10883
VPC1/3
p18548
sg10884
I5
sg10891
VP29120
p18549
sg10887
I1
sa(dp18550
g10882
I128
sg10883
g18531
sg10884
I25
sg10891
VP29120
p18551
sg10887
I3
sasa(dp18552
g10873
VOur objective in this work was to investigate the anti-inflammatory effects of the Ras inhibitor farnesylthiosalicylic acid (FTS) on adjuvant-induced arthritis (AIA) in rats, an experimental model for RA.
p18553
sg4
(dp18554
(VRas
p18555
Varthritis
p18556
tp18557
I00
ssg10879
(lp18558
(dp18559
g10882
I150
sg10883
g18556
sg10884
I9
sg10885
VC0003864
p18560
sg10887
I1
sasg10888
(lp18561
(dp18562
g10882
I83
sg10883
g18555
sg10884
I3
sg10891
VP01116
p18563
sg10887
I1
sasa(dp18564
g10873
VData from several studies suggest that the gastrin family of growth factors potentiates colorectal cancer tumourigenesis.
p18565
sg4
(dp18566
(Vgrowth factors
p18567
Vcolorectal cancer
p18568
tp18569
I00
ssg10879
(lp18570
(dp18571
g10882
I88
sg10883
g18568
sg10884
I17
sg10885
VC1527249
p18572
sg10887
I2
sasg10888
(lp18573
(dp18574
g10882
I43
sg10883
Vgastrin family
p18575
sg10884
I14
sg10891
VP01350
p18576
sg10887
I2
sa(dp18577
g10882
I61
sg10883
g18567
sg10884
I14
sg10891
VP19883
p18578
sg10887
I2
sasa(dp18579
g10873
VThe aim of this study was to analyze plasma concentrations of enterohormones (motilin, ghrelin, gastrin and pancreatic polypeptide) and to verify if their abnormal levels may contribute to the severity of dyspeptic symptoms in colorectal cancer patients.
p18580
sg4
(dp18581
(Vmotilin
p18582
Vcolorectal cancer
p18583
tp18584
I00
ssg10879
(lp18585
(dp18586
g10882
I227
sg10883
g18583
sg10884
I17
sg10885
VC1527249
p18587
sg10887
I2
sasg10888
(lp18588
(dp18589
g10882
I87
sg10883
Vghrelin
p18590
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp18591
g10882
I96
sg10883
Vgastrin
p18592
sg10884
I7
sg10891
VP01350
p18593
sg10887
I1
sa(dp18594
g10882
I78
sg10883
g18582
sg10884
I7
sg10891
VP12872
p18595
sg10887
I1
sasa(dp18596
g10873
VThis study examined the expression level, subcellular localization, and binding activity of CacyBP/SIP in human colon cancer cells in the presence and absence of the hormone gastrin.
p18597
sg4
(dp18598
(Vgastrin
p18599
Vcolon cancer
p18600
tp18601
I00
ssg10879
(lp18602
(dp18603
g10882
I112
sg10883
g18600
sg10884
I12
sg10885
VC0699790
p18604
sg10887
I2
sasg10888
(lp18605
(dp18606
g10882
I99
sg10883
VSIP
p18607
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp18608
g10882
I92
sg10883
VCacyBP
p18609
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp18610
g10882
I174
sg10883
g18599
sg10884
I7
sg10891
VP01350
p18611
sg10887
I1
sasa(dp18612
g10873
VCacyBP/SIP promoted the cell proliferation of colon cancer cells under both basal and gastrin stimulated conditions as shown by knockdown studies.
p18613
sg4
(dp18614
(Vgastrin
p18615
Vcolon cancer
p18616
tp18617
I00
ssg10879
(lp18618
(dp18619
g10882
I46
sg10883
g18616
sg10884
I12
sg10885
VC0699790
p18620
sg10887
I2
sa(dp18621
g10882
I29
sg10883
Vproliferation
p18622
sg10884
I13
sg10885
VC0334094
p18623
sg10887
I1
sasg10888
(lp18624
(dp18625
g10882
I86
sg10883
g18615
sg10884
I7
sg10891
VP01350
p18626
sg10887
I1
sa(dp18627
g10882
I0
sg10883
VCacyBP
p18628
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp18629
g10882
I7
sg10883
VSIP
p18630
sg10884
I3
sg10891
g190
sg10887
I1
sasa(dp18631
g10873
VAs treatment with proton pump inhibitors (PPIs) increases the biosynthesis and secretion of gastrin, it has been postulated that treatment with PPIs could increase the risk of cancer, especially in Barrett's esophagus, gastric carcinoids, and colorectal cancer (CRC).
p18632
sg4
(dp18633
(Vgastrin
p18634
VCRC
p18635
tp18636
I00
ssg10879
(lp18637
(dp18638
g10882
I198
sg10883
VBarrett's esophagus
p18639
sg10884
I19
sg10885
VC0004763
p18640
sg10887
I2
sa(dp18641
g10882
I243
sg10883
Vcolorectal cancer
p18642
sg10884
I17
sg10885
VC1527249
p18643
sg10887
I2
sa(dp18644
g10882
I227
sg10883
Vcarcinoids
p18645
sg10884
I10
sg10885
VC0007095
p18646
sg10887
I1
sa(dp18647
g10882
I262
sg10883
g18635
sg10884
I3
sg10885
VC1527249
p18648
sg10887
I1
sa(dp18649
g10882
I176
sg10883
Vcancer
p18650
sg10884
I6
sg10885
VC0006826
p18651
sg10887
I1
sasg10888
(lp18652
(dp18653
g10882
I92
sg10883
g18634
sg10884
I7
sg10891
VP01350
p18654
sg10887
I1
sasa(dp18655
g10873
VA progressive increase in the expression of PD-1 and B7-H1/B7-DC on T cells and APC, respectively, was observed in the pancreatic lymph nodes of female non-obese diabetic (NOD) mice as they developed diabetes.
p18656
sg4
(dp18657
(VPD-1
p18658
Vnon-obese diabetic
p18659
tp18660
I00
ssg10879
(lp18661
(dp18662
g10882
I172
sg10883
VNOD
p18663
sg10884
I3
sg10885
VC0751781
p18664
sg10887
I1
sa(dp18665
g10882
I80
sg10883
VAPC
p18666
sg10884
I3
sg10885
VC0033036
p18667
sg10887
I1
sa(dp18668
g10882
I200
sg10883
Vdiabetes
p18669
sg10884
I8
sg10885
VC0011849
p18670
sg10887
I1
sa(dp18671
g10882
I152
sg10883
g18659
sg10884
I18
sg10885
VC0751781
p18672
sg10887
I2
sasg10888
(lp18673
(dp18674
g10882
I53
sg10883
VB7-H1
p18675
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp18676
g10882
I80
sg10883
VAPC
p18677
sg10884
I3
sg10891
VP25054
p18678
sg10887
I1
sa(dp18679
g10882
I44
sg10883
g18658
sg10884
I4
sg10891
VP18621
p18680
sg10887
I1
sa(dp18681
g10882
I59
sg10883
VB7-DC
p18682
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp18683
g10873
VB7-H1 and B7-DC have negative regulatory effects upon binding PD-1 on activated T cells and B7-H1 deficiency increases severity of both diabetes and EAE.
p18684
sg4
(dp18685
(VPD-1
p18686
Vdiabetes
p18687
tp18688
I00
ssg10879
(lp18689
(dp18690
g10882
I136
sg10883
g18687
sg10884
I8
sg10885
VC0011849
p18691
sg10887
I1
sasg10888
(lp18692
(dp18693
g10882
I10
sg10883
VB7-DC
p18694
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp18695
g10882
I0
sg10883
VB7-H1
p18696
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp18697
g10882
I62
sg10883
g18686
sg10884
I4
sg10891
VP18621
p18698
sg10887
I1
sa(dp18699
g10882
I0
sg10883
VB7-H1
p18700
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp18701
g10873
VThese characteristics have implicated KIR3DL2 in several pathologies: ankylosing spondylitis and cutaneous T-cell lymphomas such as Sezary syndrome, CD30+ cutaneous lymphoma, and transformed mycosis fungoides.
p18702
sg4
(dp18703
(VKIR3DL2
p18704
Vmycosis fungoides
p18705
tp18706
I00
ssg10879
(lp18707
(dp18708
g10882
I132
sg10883
VSezary syndrome
p18709
sg10884
I15
sg10885
VC0036920
p18710
sg10887
I2
sa(dp18711
g10882
I97
sg10883
Vcutaneous T-cell lymphomas
p18712
sg10884
I26
sg10885
VC0079773
p18713
sg10887
I3
sa(dp18714
g10882
I70
sg10883
Vankylosing spondylitis
p18715
sg10884
I22
sg10885
VC0038013
p18716
sg10887
I2
sa(dp18717
g10882
I155
sg10883
Vcutaneous lymphoma
p18718
sg10884
I18
sg10885
VC1276146
p18719
sg10887
I2
sa(dp18720
g10882
I191
sg10883
g18705
sg10884
I17
sg10885
VC0026948
p18721
sg10887
I2
sasg10888
(lp18722
(dp18723
g10882
I38
sg10883
g18704
sg10884
I7
sg10891
VP43630
p18724
sg10887
I1
sasa(dp18725
g10873
VKIR3DL2, an inhibitory receptor expressed by natural killer cells and a subset of normal CD8(+) T cells, is aberrantly expressed in neoplastic cells in transformed mycosis fungoides and Sezary syndrome.
p18726
sg4
(dp18727
(VCD8
p18728
Vmycosis fungoides and Sezary syndrome
p18729
tp18730
I00
ssg10879
(lp18731
(dp18732
g10882
I164
sg10883
g18729
sg10884
I37
sg10885
VC0862196
p18733
sg10887
I5
sasg10888
(lp18734
(dp18735
g10882
I0
sg10883
VKIR3DL2
p18736
sg10884
I7
sg10891
VP43630
p18737
sg10887
I1
sa(dp18738
g10882
I89
sg10883
g18728
sg10884
I3
sg10891
VP01732
p18739
sg10887
I1
sasa(dp18740
g10873
VNot only we confirmed the expression of this marker in the blood and/or skin of mycosis fungoides patients but we also show for the first time CD158k expression (often associated with CD160) on cutaneous CD4+ T cells from healthy individuals (25.3 +/- 15%).
p18741
sg4
(dp18742
(VCD158k
p18743
Vmycosis fungoides
p18744
tp18745
I00
ssg10879
(lp18746
(dp18747
g10882
I80
sg10883
g18744
sg10884
I17
sg10885
VC0026948
p18748
sg10887
I2
sasg10888
(lp18749
(dp18750
g10882
I184
sg10883
VCD160
p18751
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp18752
g10882
I143
sg10883
g18743
sg10884
I6
sg10891
VP43627
p18753
sg10887
I1
sasa(dp18754
g10873
VTherefore, CD4+ CD160+ T cells expressing CD158k might represent specialized cutaneous lymphocytes devoted to immune surveillance, from which could originate cutaneous T-cell lymphomas such as mycosis fungoides.
p18755
sg4
(dp18756
(VCD158k
p18757
Vmycosis fungoides
p18758
tp18759
I00
ssg10879
(lp18760
(dp18761
g10882
I158
sg10883
Vcutaneous T-cell lymphomas
p18762
sg10884
I26
sg10885
VC0079773
p18763
sg10887
I3
sa(dp18764
g10882
I193
sg10883
g18758
sg10884
I17
sg10885
VC0026948
p18765
sg10887
I2
sasg10888
(lp18766
(dp18767
g10882
I11
sg10883
VCD4+
p18768
sg10884
I4
sg10891
VP01730
p18769
sg10887
I1
sa(dp18770
g10882
I42
sg10883
g18757
sg10884
I6
sg10891
VP43627
p18771
sg10887
I1
sasa(dp18772
g10873
Vp140/KIR3DL2 has been identified in malignant cell lines isolated from the skin and blood of patients with transformed mycosis fungoides (MF) and Sezary's syndrome (SS).
p18773
sg4
(dp18774
(Vp140
p18775
Vmycosis fungoides
p18776
tp18777
I00
ssg10879
(lp18778
(dp18779
g10882
I146
sg10883
VSezary's syndrome
p18780
sg10884
I17
sg10885
VC0036920
p18781
sg10887
I2
sa(dp18782
g10882
I119
sg10883
g18776
sg10884
I17
sg10885
VC0026948
p18783
sg10887
I2
sasg10888
(lp18784
(dp18785
g10882
I5
sg10883
VKIR3DL2
p18786
sg10884
I7
sg10891
VP43630
p18787
sg10887
I1
sa(dp18788
g10882
I0
sg10883
g18775
sg10884
I4
sg10891
VP43630
p18789
sg10887
I1
sasa(dp18790
g10873
VThe Fxn KO/Mck model reproduces some key features of patients with Friedreich ataxia and provides an opportunity of ameliorating their symptoms with experimental therapies.
p18791
sg4
(dp18792
(VFxn KO
p18793
VFriedreich ataxia
p18794
tp18795
I00
ssg10879
(lp18796
(dp18797
g10882
I67
sg10883
g18794
sg10884
I17
sg10885
VC0016719
p18798
sg10887
I2
sasg10888
(lp18799
(dp18800
g10882
I4
sg10883
g18793
sg10884
I6
sg10891
VP51587
p18801
sg10887
I2
sasa(dp18802
g10873
VFurther confirmation is obtained with identification of two mutations in the ARSB gene for MPS VI or mutations in the GALNS gene for MPS IVA.We report slowly progressing patients, one with MPS VI and two with MPS IVA, who presented with skeletal changes and hip findings resembling Legg-Calve-Perthes disease or spondyloepiphyseal dysplasia and normal/near normal urine GAG levels.
p18803
sg4
(dp18804
(VMPS VI
p18805
VMPS VI
p18806
tp18807
I00
ssg10879
(lp18808
(dp18809
g10882
I133
sg10883
VMPS IVA
p18810
sg10884
I7
sg10885
VC0086651
p18811
sg10887
I2
sa(dp18812
g10882
I91
sg10883
VMPS VI
p18813
sg10884
I6
sg10885
VC0026709
p18814
sg10887
I2
sa(dp18815
g10882
I312
sg10883
Vspondyloepiphyseal dysplasia
p18816
sg10884
I28
sg10885
VC2745959
p18817
sg10887
I2
sa(dp18818
g10882
I282
sg10883
VLegg-Calve-Perthes disease
p18819
sg10884
I26
sg10885
VC0023234
p18820
sg10887
I2
sa(dp18821
g10882
I133
sg10883
VMPS IVA
p18822
sg10884
I7
sg10885
VC0086651
p18823
sg10887
I2
sa(dp18824
g10882
I91
sg10883
g18806
sg10884
I6
sg10885
VC0026709
p18825
sg10887
I2
sasg10888
(lp18826
(dp18827
g10882
I118
sg10883
VGALNS gene
p18828
sg10884
I10
sg10891
VP34059
p18829
sg10887
I2
sa(dp18830
g10882
I133
sg10883
VMPS IVA
p18831
sg10884
I7
sg10891
VP05164
p18832
sg10887
I2
sa(dp18833
g10882
I91
sg10883
g18805
sg10884
I6
sg10891
VP05164
p18834
sg10887
I2
sasa(dp18835
g10873
VData were collected retrospectively from medical records included age, gender, predisposing factors for ABPA, chronic pulmonary aspergillosis, or Aspergillus bronchitis; presence of nocturnal reflux, nausea, epigastric pain, Medical Research Council dyspnea scale score, pH manometry data, endoscopic results (ulcers, Barrett's esophagus), treatment of GORD [proton-pump inhibitors (PPIs), surgical operation]; history of smoking, alcohol consumption; concomitant COPD; serological markers (anti-Aspergillus IgG, anti-Aspergillus IgE), and antifungal treatment.
p18836
sg4
(dp18837
(Vanti-Aspergillus IgE
p18838
VABPA
p18839
tp18840
I00
ssg10879
(lp18841
(dp18842
g10882
I310
sg10883
Vulcers
p18843
sg10884
I6
sg10885
VC0041582
p18844
sg10887
I1
sa(dp18845
g10882
I200
sg10883
Vnausea
p18846
sg10884
I6
sg10885
VC0027497
p18847
sg10887
I1
sa(dp18848
g10882
I208
sg10883
Vepigastric pain
p18849
sg10884
I15
sg10885
VC0232493
p18850
sg10887
I2
sa(dp18851
g10882
I192
sg10883
Vreflux
p18852
sg10884
I6
sg10885
VC0017168
p18853
sg10887
I1
sa(dp18854
g10882
I530
sg10883
VIgE
p18855
sg10884
I3
sg10885
VC0270850
p18856
sg10887
I1
sa(dp18857
g10882
I250
sg10883
Vdyspnea
p18858
sg10884
I7
sg10885
VC0013404
p18859
sg10887
I1
sa(dp18860
g10882
I118
sg10883
Vpulmonary aspergillosis
p18861
sg10884
I23
sg10885
VC2350529
p18862
sg10887
I2
sa(dp18863
g10882
I464
sg10883
VCOPD
p18864
sg10884
I4
sg10885
VC0024117
p18865
sg10887
I1
sa(dp18866
g10882
I146
sg10883
VAspergillus bronchitis
p18867
sg10884
I22
sg10885
VC2919277
p18868
sg10887
I2
sa(dp18869
g10882
I318
sg10883
VBarrett's esophagus
p18870
sg10884
I19
sg10885
VC0004763
p18871
sg10887
I2
sa(dp18872
g10882
I104
sg10883
g18839
sg10884
I4
sg10885
VC0004031
p18873
sg10887
I1
sasg10888
(lp18874
(dp18875
g10882
I513
sg10883
g18838
sg10884
I20
sg10891
VP01854
p18876
sg10887
I2
sasa(dp18877
g10873
VOn the other hand, a widespread positive reaction for CK 5/8, CK 7, CK 19, and negative reaction for CK 10, was a helpful feature in the differentiation of Paget's disease from Bowen's disease and BAK.
p18878
sg4
(dp18879
(VCK 10
p18880
VPaget's disease
p18881
tp18882
I00
ssg10879
(lp18883
(dp18884
g10882
I177
sg10883
VBowen's disease
p18885
sg10884
I15
sg10885
VC0006079
p18886
sg10887
I2
sa(dp18887
g10882
I156
sg10883
g18881
sg10884
I15
sg10885
VC0029401
p18888
sg10887
I2
sasg10888
(lp18889
(dp18890
g10882
I54
sg10883
VCK 5/8
p18891
sg10884
I6
sg10891
VP02533
p18892
sg10887
I2
sa(dp18893
g10882
I62
sg10883
VCK 7
p18894
sg10884
I4
sg10891
VP08729
p18895
sg10887
I2
sa(dp18896
g10882
I101
sg10883
g18880
sg10884
I5
sg10891
VP13645
p18897
sg10887
I2
sasa(dp18898
g10873
VTo date, the relation between serum leptin levels of dialysis patients and renal osteodystrophy, defined by histomorphometric and histodynamic parameters of bone, has not been studied.
p18899
sg4
(dp18900
(Vleptin
p18901
Vrenal osteodystrophy
p18902
tp18903
I00
ssg10879
(lp18904
(dp18905
g10882
I75
sg10883
g18902
sg10884
I20
sg10885
VC0035086
p18906
sg10887
I2
sasg10888
(lp18907
(dp18908
g10882
I36
sg10883
g18901
sg10884
I6
sg10891
VP41159
p18909
sg10887
I1
sasa(dp18910
g10873
VHere, we evaluated the potency of highly active NK cells derived from human CD34+ haematopoietic stem and progenitor cells (HSPC) to infiltrate and mediate killing of human ovarian cancer spheroids using an in vivo-like model system and mouse xenograft model.
p18911
sg4
(dp18912
(Vhuman CD34+
p18913
Vovarian cancer
p18914
tp18915
I00
ssg10879
(lp18916
(dp18917
g10882
I173
sg10883
g18914
sg10884
I14
sg10885
VC1140680
p18918
sg10887
I2
sa(dp18919
g10882
I133
sg10883
Vinfiltrate
p18920
sg10884
I10
sg10885
VC0332448
p18921
sg10887
I1
sasg10888
(lp18922
(dp18923
g10882
I70
sg10883
g18913
sg10884
I11
sg10891
VP28906
p18924
sg10887
I2
sasa(dp18925
g10873
VThese CD56+Perforin+ HSPC-NK cells were generated under stroma-free conditions in the presence of StemRegenin-1, IL-15, and IL-12, and exerted efficient cytolytic activity and IFNGamma production toward ovarian cancer monolayer cultures.
p18926
sg4
(dp18927
(VIL-15
p18928
Vovarian cancer
p18929
tp18930
I00
ssg10879
(lp18931
(dp18932
g10882
I203
sg10883
g18929
sg10884
I14
sg10885
VC1140680
p18933
sg10887
I2
sasg10888
(lp18934
(dp18935
g10882
I6
sg10883
VCD56+Perforin+ HSPC-NK
p18936
sg10884
I22
sg10891
VP14222
p18937
sg10887
I2
sa(dp18938
g10882
I113
sg10883
g18928
sg10884
I5
sg10891
VP40933
p18939
sg10887
I1
sasa(dp18940
g10873
VFurthermore, intraperitoneal HSPC-NK cell infusions in NOD/SCID-IL2RGammanull (NSG) mice bearing ovarian carcinoma significantly reduced tumor progression.
p18941
sg4
(dp18942
(VNOD
p18943
Vtumor progression
p18944
tp18945
I00
ssg10879
(lp18946
(dp18947
g10882
I97
sg10883
Vovarian carcinoma
p18948
sg10884
I17
sg10885
VC0029925
p18949
sg10887
I2
sa(dp18950
g10882
I55
sg10883
VNOD
p18951
sg10884
I3
sg10885
VC0751781
p18952
sg10887
I1
sa(dp18953
g10882
I59
sg10883
VSCID
p18954
sg10884
I4
sg10885
VC0085110
p18955
sg10887
I1
sa(dp18956
g10882
I137
sg10883
g18944
sg10884
I17
sg10885
VC0178874
p18957
sg10887
I2
sasg10888
(lp18958
(dp18959
g10882
I59
sg10883
VSCID-IL2RGammanull
p18960
sg10884
I18
sg10891
VP31785
p18961
sg10887
I1
sa(dp18962
g10882
I55
sg10883
g18943
sg10884
I3
sg10891
VP54259
p18963
sg10887
I1
sasa(dp18964
g10873
VIn asthmatic children with positive ETC, monocyte hemotactic protein-1 (MCP-1) and IL-16 adjusted to pre-EBC forced expiratory volume in 1 s (FEV1) were significantly higher compared to children with negative ETC (p = 0.022 and p = 0.017 respectively).
p18965
sg4
(dp18966
(VETC, monocyte hemotactic protein-1
p18967
Vasthmatic
p18968
tp18969
I00
ssg10879
(lp18970
(dp18971
g10882
I3
sg10883
g18968
sg10884
I9
sg10885
VC0004096
p18972
sg10887
I1
sasg10888
(lp18973
(dp18974
g10882
I83
sg10883
VIL-16
p18975
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp18976
g10882
I72
sg10883
VMCP-1
p18977
sg10884
I5
sg10891
VP41597
p18978
sg10887
I1
sa(dp18979
g10882
I36
sg10883
g18967
sg10884
I34
sg10891
VP17980
p18980
sg10887
I4
sasa(dp18981
g10873
VAs silicosis biomarkers, TNF-alpha, TGF-beta, IL-16, PDGF, MMP-2, MMP-9 and MCP-1 have certain significance, further suggesting that early detection rate of patients with silicosis can be improved by employing the multiple indexes discriminate equation.
p18982
sg4
(dp18983
(VTGF-beta
p18984
Vsilicosis
p18985
tp18986
I01
ssg10879
(lp18987
(dp18988
g10882
I3
sg10883
Vsilicosis
p18989
sg10884
I9
sg10885
VC0037116
p18990
sg10887
I1
sa(dp18991
g10882
I3
sg10883
g18985
sg10884
I9
sg10885
VC0037116
p18992
sg10887
I1
sasg10888
(lp18993
(dp18994
g10882
I66
sg10883
VMMP-9
p18995
sg10884
I5
sg10891
VP14780
p18996
sg10887
I1
sa(dp18997
g10882
I53
sg10883
VPDGF
p18998
sg10884
I4
sg10891
VP04085
p18999
sg10887
I1
sa(dp19000
g10882
I46
sg10883
VIL-16
p19001
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp19002
g10882
I25
sg10883
VTNF-alpha
p19003
sg10884
I9
sg10891
VP01375
p19004
sg10887
I1
sa(dp19005
g10882
I59
sg10883
VMMP-2
p19006
sg10884
I5
sg10891
VP08253
p19007
sg10887
I1
sa(dp19008
g10882
I76
sg10883
VMCP-1
p19009
sg10884
I5
sg10891
VP41597
p19010
sg10887
I1
sa(dp19011
g10882
I36
sg10883
g18984
sg10884
I8
sg10891
VP18075
p19012
sg10887
I1
sasa(dp19013
g10873
VBy contrast, compared to eosinophil-normal asthma (eosinophils&lt;=0.3%), eosinophil-high asthma (eosinophils&gt;0.3%) had higher levels of IL-5, IL-13, IL-16, and PDGF-bb, but same neutrophil percentage, IL-8, and FEV1.
p19014
sg4
(dp19015
(VIL-5
p19016
Vasthma
p19017
tp19018
I00
ssg10879
(lp19019
(dp19020
g10882
I43
sg10883
Vasthma
p19021
sg10884
I6
sg10885
VC0004096
p19022
sg10887
I1
sa(dp19023
g10882
I43
sg10883
g19017
sg10884
I6
sg10885
VC0004096
p19024
sg10887
I1
sasg10888
(lp19025
(dp19026
g10882
I146
sg10883
VIL-13
p19027
sg10884
I5
sg10891
VP35225
p19028
sg10887
I1
sa(dp19029
g10882
I164
sg10883
VPDGF-bb
p19030
sg10884
I7
sg10891
VP04085
p19031
sg10887
I1
sa(dp19032
g10882
I153
sg10883
VIL-16
p19033
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp19034
g10882
I140
sg10883
g19016
sg10884
I4
sg10891
VP05113
p19035
sg10887
I1
sasa(dp19036
g10873
VTo this end, we describe the identification of developmentally regulated GTP-binding protein 1 (DRG-1) as a melanoma-associated antigen recognized by HLA-DR11-restricted CD4(+) Th1 cells.
p19037
sg4
(dp19038
(VCD4
p19039
Vmelanoma
p19040
tp19041
I00
ssg10879
(lp19042
(dp19043
g10882
I108
sg10883
g19040
sg10884
I8
sg10885
VC0025202
p19044
sg10887
I1
sasg10888
(lp19045
(dp19046
g10882
I96
sg10883
VDRG-1
p19047
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp19048
g10882
I150
sg10883
VHLA-DR11
p19049
sg10884
I8
sg10891
VP30486
p19050
sg10887
I1
sa(dp19051
g10882
I108
sg10883
Vmelanoma-associated antigen
p19052
sg10884
I27
sg10891
VP08962
p19053
sg10887
I2
sa(dp19054
g10882
I47
sg10883
Vdevelopmentally regulated GTP-binding protein 1
p19055
sg10884
I47
sg10891
g190
sg10887
I5
sa(dp19056
g10882
I170
sg10883
g19039
sg10884
I3
sg10891
VP01730
p19057
sg10887
I1
sasa(dp19058
g10873
VTaken together, these data suggest that DRG-1 plays an important role in melanoma cell growth and transformation, indicating that DRG1 may represent a novel target for CD4(+) T cell-mediated immunotherapy in melanoma.
p19059
sg4
(dp19060
(VCD4
p19061
Vmelanoma
p19062
tp19063
I00
ssg10879
(lp19064
(dp19065
g10882
I98
sg10883
Vtransformation
p19066
sg10884
I14
sg10885
VC1510411
p19067
sg10887
I1
sa(dp19068
g10882
I73
sg10883
Vmelanoma
p19069
sg10884
I8
sg10885
VC0025202
p19070
sg10887
I1
sa(dp19071
g10882
I73
sg10883
g19062
sg10884
I8
sg10885
VC0025202
p19072
sg10887
I1
sasg10888
(lp19073
(dp19074
g10882
I168
sg10883
g19061
sg10884
I3
sg10891
VP01730
p19075
sg10887
I1
sa(dp19076
g10882
I40
sg10883
VDRG-1
p19077
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp19078
g10882
I130
sg10883
VDRG1
p19079
sg10884
I4
sg10891
VP55039
p19080
sg10887
I1
sasa(dp19081
g10873
VSubsequently, miR-15/16 activities are reduced and many of their direct targets are de-repressed, including ubiquitin ligase FBXW7 that destabilizes Cyclin E. Conversely, GBM cells expressing low p21 level, or after p21 knock-down, exhibit weaker or no E2F1 response to miR-10b inhibition.
p19082
sg4
(dp19083
(VCyclin E
p19084
VGBM
p19085
tp19086
I01
ssg10879
(lp19087
(dp19088
g10882
I171
sg10883
g19085
sg10884
I3
sg10885
VC0017636
p19089
sg10887
I1
sasg10888
(lp19090
(dp19091
g10882
I270
sg10883
VmiR-10b
p19092
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp19093
g10882
I14
sg10883
VmiR-15/16
p19094
sg10884
I9
sg10891
g190
sg10887
I1
sa(dp19095
g10882
I108
sg10883
Vubiquitin ligase FBXW7
p19096
sg10884
I22
sg10891
g190
sg10887
I3
sa(dp19097
g10882
I196
sg10883
Vp21
p19098
sg10884
I3
sg10891
VP42857
p19099
sg10887
I1
sa(dp19100
g10882
I253
sg10883
VE2F1
p19101
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp19102
g10882
I216
sg10883
Vp21 knock
p19103
sg10884
I9
sg10891
VP42857
p19104
sg10887
I2
sa(dp19105
g10882
I149
sg10883
g19084
sg10884
I8
sg10891
VP24864
p19106
sg10887
I2
sasa(dp19107
g10873
VNotch pathway genes are overexpressed in ependymomas and gliomas along with FBXW7 downregulation.
p19108
sg4
(dp19109
(VNotch pathway genes
p19110
Vgliomas
p19111
tp19112
I00
ssg10879
(lp19113
(dp19114
g10882
I41
sg10883
Vependymomas
p19115
sg10884
I11
sg10885
VC0014474
p19116
sg10887
I1
sa(dp19117
g10882
I57
sg10883
g19111
sg10884
I7
sg10885
VC0017638
p19118
sg10887
I1
sasg10888
(lp19119
(dp19120
g10882
I0
sg10883
g19110
sg10884
I19
sg10891
VP01893
p19121
sg10887
I3
sa(dp19122
g10882
I76
sg10883
VFBXW7
p19123
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp19124
g10873
VPMD is located adjacent and medial to the nucleus prepositus hypoglossi (PH) in the dorsal medulla and is distinguished by the pattern of immunoreactivity of cells and fibers to several markers including calcium-binding proteins, a synthetic enzyme for nitric oxide (neuronal nitric oxide synthase, nNOS) and a nonphosphorylated neurofilament protein (antibody SMI-32).
p19125
sg4
(dp19126
(VnNOS
p19127
VPMD
p19128
tp19129
I00
ssg10879
(lp19130
(dp19131
g10882
I0
sg10883
g19128
sg10884
I3
sg10885
VC1832661
p19132
sg10887
I1
sasg10888
(lp19133
(dp19134
g10882
I42
sg10883
Vnucleus prepositus hypoglossi
p19135
sg10884
I29
sg10891
VP61457
p19136
sg10887
I3
sa(dp19137
g10882
I299
sg10883
g19127
sg10884
I4
sg10891
VP29475
p19138
sg10887
I1
sasa(dp19139
g10873
VCells in PMD are also immunoreactive to nNOS, and immunoreactivity to a neurofilament protein shows many labeled cells and fibers.
p19140
sg4
(dp19141
(VnNOS
p19142
VPMD
p19143
tp19144
I00
ssg10879
(lp19145
(dp19146
g10882
I9
sg10883
g19143
sg10884
I3
sg10885
VC1832661
p19147
sg10887
I1
sasg10888
(lp19148
(dp19149
g10882
I40
sg10883
g19142
sg10884
I4
sg10891
VP29475
p19150
sg10887
I1
sasa(dp19151
g10873
VRegardless of the type of surgery (PRE-OP, POS-OP1, POS-OP2), the prevalence of periodontitis proved to be high (81.45%).
p19152
sg4
(dp19153
(VPOS-OP2
p19154
Vperiodontitis
p19155
tp19156
I00
ssg10879
(lp19157
(dp19158
g10882
I80
sg10883
g19155
sg10884
I13
sg10885
VC0031099
p19159
sg10887
I1
sasg10888
(lp19160
(dp19161
g10882
I43
sg10883
VPOS-OP1
p19162
sg10884
I7
sg10891
VP18075
p19163
sg10887
I1
sa(dp19164
g10882
I52
sg10883
g19154
sg10884
I7
sg10891
VP34820
p19165
sg10887
I1
sasa(dp19166
g10873
VThere was a statistically significant difference in the prevalence of periodontitis among the PRE-OP, POS-OP1, and POS-OP2 groups (P = 0.040).
p19167
sg4
(dp19168
(VPOS-OP1
p19169
Vperiodontitis
p19170
tp19171
I00
ssg10879
(lp19172
(dp19173
g10882
I70
sg10883
g19170
sg10884
I13
sg10885
VC0031099
p19174
sg10887
I1
sasg10888
(lp19175
(dp19176
g10882
I94
sg10883
VPRE-OP
p19177
sg10884
I6
sg10891
VP58743
p19178
sg10887
I1
sa(dp19179
g10882
I102
sg10883
g19169
sg10884
I7
sg10891
VP18075
p19180
sg10887
I1
sasa(dp19181
g10873
VBone morphogenetic protein-7 (BMP 7) induces cementogenesis in periodontitis-associated periodontal ligament (PDL) defects.
p19182
sg4
(dp19183
(VBMP 7
p19184
Vperiodontitis
p19185
tp19186
I00
ssg10879
(lp19187
(dp19188
g10882
I63
sg10883
g19185
sg10884
I13
sg10885
VC0031099
p19189
sg10887
I1
sasg10888
(lp19190
(dp19191
g10882
I0
sg10883
VBone morphogenetic protein-7
p19192
sg10884
I28
sg10891
VP18075
p19193
sg10887
I3
sa(dp19194
g10882
I30
sg10883
g19184
sg10884
I5
sg10891
VP18075
p19195
sg10887
I2
sasa(dp19196
g10873
VNone of the NF1 glioblastomas harbored isocitrate dehydrogenase 1 (IDH1) gene mutation, v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) gene mutation, and telomerase reverse transcriptase (TERT) gene promoter mutation.
p19197
sg4
(dp19198
(Vv-RAF murine sarcoma viral oncogene homolog B1
p19199
Vglioblastomas
p19200
tp19201
I00
ssg10879
(lp19202
(dp19203
g10882
I101
sg10883
Vsarcoma
p19204
sg10884
I7
sg10885
VC1261473
p19205
sg10887
I1
sa(dp19206
g10882
I12
sg10883
VNF1
p19207
sg10884
I3
sg10885
VC0027831
p19208
sg10887
I1
sa(dp19209
g10882
I16
sg10883
g19200
sg10884
I13
sg10885
VC0017636
p19210
sg10887
I1
sasg10888
(lp19211
(dp19212
g10882
I161
sg10883
Vtelomerase reverse transcriptase
p19213
sg10884
I32
sg10891
g190
sg10887
I3
sa(dp19214
g10882
I39
sg10883
Visocitrate dehydrogenase 1
p19215
sg10884
I26
sg10891
VP48735
p19216
sg10887
I3
sa(dp19217
g10882
I136
sg10883
VBRAF
p19218
sg10884
I4
sg10891
VP15056
p19219
sg10887
I1
sa(dp19220
g10882
I67
sg10883
VIDH1
p19221
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp19222
g10882
I195
sg10883
VTERT
p19223
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp19224
g10882
I12
sg10883
VNF1 glioblastomas
p19225
sg10884
I17
sg10891
VP21359
p19226
sg10887
I2
sa(dp19227
g10882
I88
sg10883
g19199
sg10884
I46
sg10891
VP15056
p19228
sg10887
I7
sasa(dp19229
g10873
VSomatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis.
p19230
sg4
(dp19231
(VSomatic v-Raf murine sarcoma viral oncogene homolog B
p19232
Vmetastatic colorectal cancer
p19233
tp19234
I00
ssg10879
(lp19235
(dp19236
g10882
I21
sg10883
Vsarcoma
p19237
sg10884
I7
sg10885
VC1261473
p19238
sg10887
I1
sa(dp19239
g10882
I133
sg10883
VmCRC
p19240
sg10884
I4
sg10885
VC0948380
p19241
sg10887
I1
sa(dp19242
g10882
I103
sg10883
g19233
sg10884
I28
sg10885
VC0948380
p19243
sg10887
I3
sasg10888
(lp19244
(dp19245
g10882
I55
sg10883
VBRAF
p19246
sg10884
I4
sg10891
VP15056
p19247
sg10887
I1
sa(dp19248
g10882
I0
sg10883
g19232
sg10884
I53
sg10891
VP04049
p19249
sg10887
I8
sasa(dp19250
g10873
VAll colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified.
p19251
sg4
(dp19252
(VBRAF
p19253
Vcolorectal cancer
p19254
tp19255
I00
ssg10879
(lp19256
(dp19257
g10882
I4
sg10883
g19254
sg10884
I17
sg10885
VC1527249
p19258
sg10887
I2
sasg10888
(lp19259
(dp19260
g10882
I42
sg10883
g19253
sg10884
I4
sg10891
VP15056
p19261
sg10887
I1
sasa(dp19262
g10873
VWe highlight common mechanistic themes underpinning resistance to targeted therapies that are shared by NSCLC subtypes, including those with oncogenic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1), serine/threonine-protein kinase b-raf (BRAF) and other less established oncoproteins.
p19263
sg4
(dp19264
(Vserine/threonine-protein kinase b-raf
p19265
VNSCLC
p19266
tp19267
I00
ssg10879
(lp19268
(dp19269
g10882
I207
sg10883
Vanaplastic lymphoma
p19270
sg10884
I19
sg10885
VC1321546
p19271
sg10887
I2
sa(dp19272
g10882
I104
sg10883
g19266
sg10884
I5
sg10885
VC0007131
p19273
sg10887
I1
sasg10888
(lp19274
(dp19275
g10882
I333
sg10883
VBRAF
p19276
sg10884
I4
sg10891
VP15056
p19277
sg10887
I1
sa(dp19278
g10882
I241
sg10883
VROS1 proto-oncogene receptor tyrosine kinase
p19279
sg10884
I44
sg10891
VP29401
p19280
sg10887
I5
sa(dp19281
g10882
I200
sg10883
VEGFR
p19282
sg10884
I4
sg10891
VP01133
p19283
sg10887
I1
sa(dp19284
g10882
I241
sg10883
VROS1
p19285
sg10884
I4
sg10891
VP08922
p19286
sg10887
I1
sa(dp19287
g10882
I166
sg10883
Vepidermal growth factor receptor
p19288
sg10884
I32
sg10891
VP01133
p19289
sg10887
I4
sa(dp19290
g10882
I294
sg10883
g19265
sg10884
I37
sg10891
VP15056
p19291
sg10887
I3
sa(dp19292
g10882
I235
sg10883
VALK
p19293
sg10884
I3
sg10891
g190
sg10887
I1
sa(dp19294
g10882
I207
sg10883
Vanaplastic lymphoma kinase
p19295
sg10884
I26
sg10891
g190
sg10887
I3
sasa(dp19296
g10873
VHere, we investigated the response of normal human keratinocytes to the MEK inhibitors trametinib and cobimetinib, alone and in combination with the v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors dabrafenib and vemurafenib, in terms of signal transduction and de novo gene expression.
p19297
sg4
(dp19298
(VMEK
p19299
Vsarcoma
p19300
tp19301
I00
ssg10879
(lp19302
(dp19303
g10882
I162
sg10883
g19300
sg10884
I7
sg10885
VC1261473
p19304
sg10887
I1
sasg10888
(lp19305
(dp19306
g10882
I196
sg10883
VBRAF
p19307
sg10884
I4
sg10891
VP15056
p19308
sg10887
I1
sa(dp19309
g10882
I149
sg10883
Vv-Raf murine sarcoma viral oncogene homolog B
p19310
sg10884
I45
sg10891
VP04049
p19311
sg10887
I7
sa(dp19312
g10882
I72
sg10883
g19299
sg10884
I3
sg10891
VP45985
p19313
sg10887
I1
sasa(dp19314
g10873
VThe prognostic role of the V600E mutation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC) is well established, but the therapeutic regimen targeting this disease is lacking.
p19315
sg4
(dp19316
(Vv-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC)
p19317
Vsarcoma
p19318
tp19319
I00
ssg10879
(lp19320
(dp19321
g10882
I132
sg10883
VmCRC
p19322
sg10884
I4
sg10885
VC0948380
p19323
sg10887
I1
sa(dp19324
g10882
I102
sg10883
Vmetastatic colorectal cancer
p19325
sg10884
I28
sg10885
VC0948380
p19326
sg10887
I3
sa(dp19327
g10882
I58
sg10883
g19318
sg10884
I7
sg10885
VC1261473
p19328
sg10887
I1
sasg10888
(lp19329
(dp19330
g10882
I45
sg10883
g19317
sg10884
I92
sg10891
VP15056
p19331
sg10887
I13
sasa(dp19332
g10873
VKirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and BRAF mutational status was assayed using direct sequencing.
p19333
sg4
(dp19334
(VKRAS
p19335
Vneuroblastoma
p19336
tp19337
I00
ssg10879
(lp19338
(dp19339
g10882
I51
sg10883
g19336
sg10884
I13
sg10885
VC0027819
p19340
sg10887
I1
sa(dp19341
g10882
I8
sg10883
Vrat sarcoma
p19342
sg10884
I11
sg10885
VC1882848
p19343
sg10887
I2
sasg10888
(lp19344
(dp19345
g10882
I104
sg10883
VBRAF
p19346
sg10884
I4
sg10891
VP15056
p19347
sg10887
I1
sa(dp19348
g10882
I51
sg10883
Vneuroblastoma RAS viral oncogene homolog
p19349
sg10884
I40
sg10891
VP01116
p19350
sg10887
I5
sa(dp19351
g10882
I0
sg10883
VKirsten rat sarcoma viral oncogene homolog
p19352
sg10884
I42
sg10891
VP35125
p19353
sg10887
I6
sa(dp19354
g10882
I93
sg10883
VNRAS
p19355
sg10884
I4
sg10891
VP01111
p19356
sg10887
I1
sa(dp19357
g10882
I44
sg10883
g19335
sg10884
I4
sg10891
VP01116
p19358
sg10887
I1
sasa(dp19359
g10873
VWe performed an unbiased CRISPR-Cas9 knockout screen on melanoma cells that were both resistant and addicted to inhibition of the serine/threonine-protein kinase BRAF, in order to functionally mine their genome for 'addiction genes'.
p19360
sg4
(dp19361
(VBRAF
p19362
V'addiction
p19363
tp19364
I00
ssg10879
(lp19365
(dp19366
g10882
I56
sg10883
Vmelanoma
p19367
sg10884
I8
sg10885
VC0025202
p19368
sg10887
I1
sa(dp19369
g10882
I215
sg10883
g19363
sg10884
I10
sg10885
VC0085281
p19370
sg10887
I1
sasg10888
(lp19371
(dp19372
g10882
I130
sg10883
Vserine/threonine-protein kinase
p19373
sg10884
I31
sg10891
g190
sg10887
I2
sa(dp19374
g10882
I162
sg10883
g19362
sg10884
I4
sg10891
VP15056
p19375
sg10887
I1
sasa(dp19376
g10873
VIn patients with melanoma that had progressed during treatment with a BRAF inhibitor, treatment cessation was followed by increased expression of the receptor tyrosine kinase AXL, which is associated with the phenotype switch.
p19377
sg4
(dp19378
(VAXL
p19379
Vmelanoma
p19380
tp19381
I00
ssg10879
(lp19382
(dp19383
g10882
I17
sg10883
g19380
sg10884
I8
sg10885
VC0025202
p19384
sg10887
I1
sasg10888
(lp19385
(dp19386
g10882
I150
sg10883
Vreceptor tyrosine kinase
p19387
sg10884
I24
sg10891
VP29401
p19388
sg10887
I3
sa(dp19389
g10882
I70
sg10883
VBRAF
p19390
sg10884
I4
sg10891
VP15056
p19391
sg10887
I1
sa(dp19392
g10882
I175
sg10883
g19379
sg10884
I3
sg10891
VP30530
p19393
sg10887
I1
sasa(dp19394
g10873
Vv-raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutant anaplastic xanthoastrocytomas and gangliogliomas may benefit from BRAF and mitogen-activated protein kinase inhibitors.
p19395
sg4
(dp19396
(Vmitogen-activated protein kinase
p19397
Vgangliogliomas
p19398
tp19399
I00
ssg10879
(lp19400
(dp19401
g10882
I13
sg10883
Vsarcoma
p19402
sg10884
I7
sg10885
VC1261473
p19403
sg10887
I1
sa(dp19404
g10882
I54
sg10883
Vmutant
p19405
sg10884
I6
sg10885
VC0596988
p19406
sg10887
I1
sa(dp19407
g10882
I95
sg10883
g19398
sg10884
I14
sg10885
VC0206716
p19408
sg10887
I1
sasg10888
(lp19409
(dp19410
g10882
I0
sg10883
Vv-raf murine sarcoma viral oncogene homolog B1
p19411
sg10884
I46
sg10891
VP15056
p19412
sg10887
I7
sa(dp19413
g10882
I48
sg10883
VBRAF
p19414
sg10884
I4
sg10891
VP15056
p19415
sg10887
I1
sa(dp19416
g10882
I48
sg10883
VBRAF
p19417
sg10884
I4
sg10891
VP15056
p19418
sg10887
I1
sa(dp19419
g10882
I136
sg10883
g19397
sg10884
I32
sg10891
VP53779
p19420
sg10887
I3
sasa(dp19421
g10873
VMutations in the proto-oncogene B-raf (BRAF) occur in approximately 3% of NSCLC cases.
p19422
sg4
(dp19423
(Vproto-oncogene B-raf
p19424
VNSCLC
p19425
tp19426
I00
ssg10879
(lp19427
(dp19428
g10882
I74
sg10883
g19425
sg10884
I5
sg10885
VC0007131
p19429
sg10887
I1
sasg10888
(lp19430
(dp19431
g10882
I39
sg10883
VBRAF
p19432
sg10884
I4
sg10891
VP15056
p19433
sg10887
I1
sa(dp19434
g10882
I17
sg10883
g19424
sg10884
I20
sg10891
VP15056
p19435
sg10887
I2
sasa(dp19436
g10873
VChanges in the epidermal growth factor receptor (EGFR) gene, Kirsten rat sarcoma viral oncogene (KRAS), v-Raf murine sarcoma viral oncogene homolog B (BRAF), gene encoding neurofibromin (NF1), anaplastic lymphoma kinase (ALK) and ROS1 are the main genes that suffer alterations in the tumors of patients with ADC.
p19437
sg4
(dp19438
(Vepidermal growth factor receptor
p19439
Vanaplastic lymphoma
p19440
tp19441
I00
ssg10879
(lp19442
(dp19443
g10882
I187
sg10883
VNF1
p19444
sg10884
I3
sg10885
VC0027831
p19445
sg10887
I1
sa(dp19446
g10882
I69
sg10883
Vrat sarcoma
p19447
sg10884
I11
sg10885
VC1882848
p19448
sg10887
I2
sa(dp19449
g10882
I73
sg10883
Vsarcoma
p19450
sg10884
I7
sg10885
VC1261473
p19451
sg10887
I1
sa(dp19452
g10882
I259
sg10883
Vsuffer
p19453
sg10884
I6
sg10885
VC0683278
p19454
sg10887
I1
sa(dp19455
g10882
I285
sg10883
Vtumors
p19456
sg10884
I6
sg10885
VC0027651
p19457
sg10887
I1
sa(dp19458
g10882
I193
sg10883
g19440
sg10884
I19
sg10885
VC1321546
p19459
sg10887
I2
sasg10888
(lp19460
(dp19461
g10882
I187
sg10883
VNF1
p19462
sg10884
I3
sg10891
VP21359
p19463
sg10887
I1
sa(dp19464
g10882
I104
sg10883
Vv-Raf murine sarcoma viral oncogene homolog B
p19465
sg10884
I45
sg10891
VP04049
p19466
sg10887
I7
sa(dp19467
g10882
I230
sg10883
VROS1
p19468
sg10884
I4
sg10891
VP08922
p19469
sg10887
I1
sa(dp19470
g10882
I97
sg10883
VKRAS
p19471
sg10884
I4
sg10891
VP01116
p19472
sg10887
I1
sa(dp19473
g10882
I61
sg10883
VKirsten rat sarcoma viral oncogene
p19474
sg10884
I34
sg10891
VP35125
p19475
sg10887
I5
sa(dp19476
g10882
I172
sg10883
Vneurofibromin
p19477
sg10884
I13
sg10891
VP21359
p19478
sg10887
I1
sa(dp19479
g10882
I49
sg10883
VEGFR
p19480
sg10884
I4
sg10891
VP01133
p19481
sg10887
I1
sa(dp19482
g10882
I151
sg10883
VBRAF
p19483
sg10884
I4
sg10891
VP15056
p19484
sg10887
I1
sa(dp19485
g10882
I15
sg10883
g19439
sg10884
I32
sg10891
VP01133
p19486
sg10887
I4
sasa(dp19487
g10873
VAPL are significantly influenced by azole dose, age, cystic fibrosis, type of LTx, and comedication with proton-pump inhibitors.
p19488
sg4
(dp19489
(VAPL
p19490
VAPL
p19491
tp19492
I00
ssg10879
(lp19493
(dp19494
g10882
I53
sg10883
Vcystic fibrosis
p19495
sg10884
I15
sg10885
VC0010674
p19496
sg10887
I2
sa(dp19497
g10882
I0
sg10883
g19491
sg10884
I3
sg10885
VC0023487
p19498
sg10887
I1
sasg10888
(lp19499
(dp19500
g10882
I0
sg10883
g19490
sg10884
I3
sg10891
VP10276
p19501
sg10887
I1
sasa(dp19502
g10873
VAPL are significantly influenced by azole dose, age, cystic fibrosis, type of LTx, and co-medication with proton-pump inhibitors.
p19503
sg4
(dp19504
(VAPL
p19505
VAPL
p19506
tp19507
I00
ssg10879
(lp19508
(dp19509
g10882
I53
sg10883
Vcystic fibrosis
p19510
sg10884
I15
sg10885
VC0010674
p19511
sg10887
I2
sa(dp19512
g10882
I0
sg10883
g19506
sg10884
I3
sg10885
VC0023487
p19513
sg10887
I1
sasg10888
(lp19514
(dp19515
g10882
I0
sg10883
g19505
sg10884
I3
sg10891
VP10276
p19516
sg10887
I1
sasa(dp19517
g10873
VMutation screening and phenotypic profiling of 2 amyotrophic lateral sclerosis-(ALS) and frontotemporal dementia-(FTD) associated genes, CHCHD10 and TUBA4A, were performed in a Belgian cohort of 459 FTD, 28 FTD-ALS, and 429 ALS patients.
p19518
sg4
(dp19519
(VTUBA4A
p19520
VFTD
p19521
tp19522
I00
ssg10879
(lp19523
(dp19524
g10882
I207
sg10883
VFTD-ALS
p19525
sg10884
I7
sg10885
VC1862937
p19526
sg10887
I1
sa(dp19527
g10882
I114
sg10883
VFTD
p19528
sg10884
I3
sg10885
VC0338451
p19529
sg10887
I1
sa(dp19530
g10882
I49
sg10883
Vamyotrophic lateral sclerosis
p19531
sg10884
I29
sg10885
VC0002736
p19532
sg10887
I3
sa(dp19533
g10882
I80
sg10883
VALS
p19534
sg10884
I3
sg10885
VC0002736
p19535
sg10887
I1
sa(dp19536
g10882
I80
sg10883
VALS
p19537
sg10884
I3
sg10885
VC0002736
p19538
sg10887
I1
sa(dp19539
g10882
I89
sg10883
Vfrontotemporal dementia
p19540
sg10884
I23
sg10885
VC0338451
p19541
sg10887
I2
sa(dp19542
g10882
I114
sg10883
g19521
sg10884
I3
sg10885
VC0338451
p19543
sg10887
I1
sasg10888
(lp19544
(dp19545
g10882
I137
sg10883
VCHCHD10
p19546
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp19547
g10882
I149
sg10883
g19520
sg10884
I6
sg10891
VP68366
p19548
sg10887
I1
sasa(dp19549
g10873
VIn TUBA4A, we detected a novel frameshift mutation (p.Arg64Glyfs*90) leading to a truncated protein in 1 FTD patient (1/459 of 0.22%) with family history of Parkinson's disease and cognitive impairment, and a novel missense mutation (p.Thr381Met) in 2 sibs with familial ALS and memory problems (1 index patient/429, 0.23%) in whom we previously identified a pathogenic Chromosome 9 open reading frame 72 repeat expansion mutation.
p19550
sg4
(dp19551
(VTUBA4A
p19552
VParkinson's disease
p19553
tp19554
I00
ssg10879
(lp19555
(dp19556
g10882
I105
sg10883
VFTD
p19557
sg10884
I3
sg10885
VC0338451
p19558
sg10887
I1
sa(dp19559
g10882
I31
sg10883
Vframeshift mutation
p19560
sg10884
I19
sg10885
VC0079380
p19561
sg10887
I2
sa(dp19562
g10882
I181
sg10883
Vcognitive impairment
p19563
sg10884
I20
sg10885
VC0338656
p19564
sg10887
I2
sa(dp19565
g10882
I279
sg10883
Vmemory problems
p19566
sg10884
I15
sg10885
VC0233794
p19567
sg10887
I2
sa(dp19568
g10882
I271
sg10883
VALS
p19569
sg10884
I3
sg10885
VC0002736
p19570
sg10887
I1
sa(dp19571
g10882
I157
sg10883
g19553
sg10884
I19
sg10885
VC0030567
p19572
sg10887
I2
sasg10888
(lp19573
(dp19574
g10882
I3
sg10883
g19552
sg10884
I6
sg10891
VP68366
p19575
sg10887
I1
sasa(dp19576
g10873
VThe present study confirms the role of CHCHD10 and TUBA4A in the FTD-ALS spectrum, although genetic variations in these 2 genes are extremely rare in the Belgian population and often associated with symptomatology of related neurodegenerative diseases including Parkinson's disease and Alzheimer's disease.
p19577
sg4
(dp19578
(VTUBA4A
p19579
VParkinson's disease
p19580
tp19581
I00
ssg10879
(lp19582
(dp19583
g10882
I225
sg10883
Vneurodegenerative diseases
p19584
sg10884
I26
sg10885
VC0524851
p19585
sg10887
I2
sa(dp19586
g10882
I262
sg10883
g19580
sg10884
I19
sg10885
VC0030567
p19587
sg10887
I2
sa(dp19588
g10882
I65
sg10883
VFTD-ALS
p19589
sg10884
I7
sg10885
VC1862937
p19590
sg10887
I1
sa(dp19591
g10882
I286
sg10883
VAlzheimer's disease
p19592
sg10884
I19
sg10885
VC1521724
p19593
sg10887
I2
sasg10888
(lp19594
(dp19595
g10882
I51
sg10883
g19579
sg10884
I6
sg10891
VP68366
p19596
sg10887
I1
sa(dp19597
g10882
I39
sg10883
VCHCHD10
p19598
sg10884
I7
sg10891
g190
sg10887
I1
sasa(dp19599
g10873
VThe tubulin alpha 4a (TUBA4A) gene has been recently associated with amyotrophic lateral sclerosis.
p19600
sg4
(dp19601
(Vtubulin alpha 4a
p19602
Vamyotrophic lateral sclerosis
p19603
tp19604
I00
ssg10879
(lp19605
(dp19606
g10882
I69
sg10883
g19603
sg10884
I29
sg10885
VC0002736
p19607
sg10887
I3
sasg10888
(lp19608
(dp19609
g10882
I22
sg10883
VTUBA4A
p19610
sg10884
I6
sg10891
VP68366
p19611
sg10887
I1
sa(dp19612
g10882
I4
sg10883
g19602
sg10884
I16
sg10891
VP68366
p19613
sg10887
I3
sasa(dp19614
g10873
VTUBA4A gene has recently been identified as a potential candidate amyotrophic lateral sclerosis(ALS)-associated gene using exome-wide rare variant burden analysis.
p19615
sg4
(dp19616
(VTUBA4A gene
p19617
VALS
p19618
tp19619
I00
ssg10879
(lp19620
(dp19621
g10882
I66
sg10883
Vamyotrophic lateral sclerosis
p19622
sg10884
I29
sg10885
VC0002736
p19623
sg10887
I3
sa(dp19624
g10882
I96
sg10883
g19618
sg10884
I3
sg10885
VC0002736
p19625
sg10887
I1
sasg10888
(lp19626
(dp19627
g10882
I0
sg10883
g19617
sg10884
I11
sg10891
VP68366
p19628
sg10887
I2
sasa(dp19629
g10873
VCollagen XXV alpha 1 (COL25A1) is a collagenous type II transmembrane protein purified from senile plaques of Alzheimer's disease (AD) brains.
p19630
sg4
(dp19631
(Vcollagenous type II transmembrane protein
p19632
Vsenile plaques
p19633
tp19634
I00
ssg10879
(lp19635
(dp19636
g10882
I131
sg10883
VAD
p19637
sg10884
I2
sg10885
VC1521724
p19638
sg10887
I1
sa(dp19639
g10882
I92
sg10883
g19633
sg10884
I14
sg10885
VC0333463
p19640
sg10887
I2
sa(dp19641
g10882
I110
sg10883
VAlzheimer's disease
p19642
sg10884
I19
sg10885
VC1521724
p19643
sg10887
I2
sasg10888
(lp19644
(dp19645
g10882
I0
sg10883
VCollagen XXV alpha 1
p19646
sg10884
I20
sg10891
VP25100
p19647
sg10887
I4
sa(dp19648
g10882
I36
sg10883
g19632
sg10884
I41
sg10891
VP27037
p19649
sg10887
I5
sa(dp19650
g10882
I22
sg10883
VCOL25A1
p19651
sg10884
I7
sg10891
g190
sg10887
I1
sasa(dp19652
g10873
VOf the 289 patients, prostate cancer was detected in 128 (44%) with 88 (30%) having sPCa.
p19653
sg4
(dp19654
(VsPCa
p19655
Vprostate cancer
p19656
tp19657
I00
ssg10879
(lp19658
(dp19659
g10882
I21
sg10883
g19656
sg10884
I15
sg10885
VC0600139
p19660
sg10887
I2
sasg10888
(lp19661
(dp19662
g10882
I84
sg10883
g19655
sg10884
I4
sg10891
VP08709
p19663
sg10887
I1
sasa(dp19664
g10873
VFactor VII (FVII) activating protease (FSAP) is a circulating serine protease that is likely to be involved in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer.
p19665
sg4
(dp19666
(Vserine protease
p19667
Vthrombosis
p19668
tp19669
I00
ssg10879
(lp19670
(dp19671
g10882
I150
sg10883
Vstroke
p19672
sg10884
I6
sg10885
VC0038454
p19673
sg10887
I1
sa(dp19674
g10882
I158
sg10883
Vatherosclerosis
p19675
sg10884
I15
sg10885
VC0004153
p19676
sg10887
I1
sa(dp19677
g10882
I175
sg10883
Vliver fibrosis
p19678
sg10884
I14
sg10885
VC0239946
p19679
sg10887
I2
sa(dp19680
g10882
I206
sg10883
Vcancer
p19681
sg10884
I6
sg10885
VC0006826
p19682
sg10887
I1
sa(dp19683
g10882
I191
sg10883
g19668
sg10884
I10
sg10885
VC0040053
p19684
sg10887
I1
sasg10888
(lp19685
(dp19686
g10882
I0
sg10883
VFactor VII (FVII) activating protease
p19687
sg10884
I37
sg10891
VP08709
p19688
sg10887
I5
sa(dp19689
g10882
I39
sg10883
VFSAP
p19690
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp19691
g10882
I62
sg10883
g19667
sg10884
I15
sg10891
VP57727
p19692
sg10887
I2
sasa(dp19693
g10873
VIn the absence of factor VII in platelet-free plasma, thrombin generation in solid pancreatic cancer cell lines was significantly reduced unlike in haematological cell lines.
p19694
sg4
(dp19695
(Vthrombin
p19696
Vpancreatic cancer
p19697
tp19698
I00
ssg10879
(lp19699
(dp19700
g10882
I83
sg10883
g19697
sg10884
I17
sg10885
VC0235974
p19701
sg10887
I2
sasg10888
(lp19702
(dp19703
g10882
I54
sg10883
g19696
sg10884
I8
sg10891
VP00734
p19704
sg10887
I1
sasa(dp19705
g10873
VSPCA gene expression is significantly elevated in breast cancer subtypes that are associated with microcalcifications.
p19706
sg4
(dp19707
(VSPCA gene
p19708
Vbreast cancer
p19709
tp19710
I00
ssg10879
(lp19711
(dp19712
g10882
I50
sg10883
g19709
sg10884
I13
sg10885
VC0678222
p19713
sg10887
I2
sa(dp19714
g10882
I98
sg10883
Vmicrocalcifications
p19715
sg10884
I19
sg10885
VC0521174
p19716
sg10887
I1
sasg10888
(lp19717
(dp19718
g10882
I0
sg10883
g19708
sg10884
I9
sg10891
VP08709
p19719
sg10887
I2
sasa(dp19720
g10873
VPatients with severe atopic dermatitis had a decreased CD4+CD29+: CD4+CD45RA+ ratio (p &lt; 0.01).
p19721
sg4
(dp19722
(VCD4+CD29+
p19723
Vatopic dermatitis
p19724
tp19725
I00
ssg10879
(lp19726
(dp19727
g10882
I21
sg10883
g19724
sg10884
I17
sg10885
VC0011615
p19728
sg10887
I2
sasg10888
(lp19729
(dp19730
g10882
I66
sg10883
VCD4+CD45RA+
p19731
sg10884
I11
sg10891
VP01730
p19732
sg10887
I1
sa(dp19733
g10882
I55
sg10883
g19723
sg10884
I9
sg10891
VP01730
p19734
sg10887
I1
sasa(dp19735
g10873
VNo significant changes in the CD4+CD29+: CD4+CD45RA+ ratio were found in the peripheral blood of patients with clinically mild or moderate atopic dermatitis.
p19736
sg4
(dp19737
(VCD4+CD45RA+
p19738
Vatopic dermatitis
p19739
tp19740
I00
ssg10879
(lp19741
(dp19742
g10882
I139
sg10883
g19739
sg10884
I17
sg10885
VC0011615
p19743
sg10887
I2
sasg10888
(lp19744
(dp19745
g10882
I30
sg10883
VCD4+CD29+
p19746
sg10884
I9
sg10891
VP01730
p19747
sg10887
I1
sa(dp19748
g10882
I41
sg10883
g19738
sg10884
I11
sg10891
VP01730
p19749
sg10887
I1
sasa(dp19750
g10873
VTissue sections from the skin of patients with atopic dermatitis were investigated by means of hematoxylin-eosin staining, the avidin-biotin-peroxidase complex method, and double-labeling immunofluorescence using monoclonal antibodies to cell-surface antigens, including CD45R and CD29.
p19751
sg4
(dp19752
(Vperoxidase
p19753
Vatopic dermatitis
p19754
tp19755
I00
ssg10879
(lp19756
(dp19757
g10882
I47
sg10883
g19754
sg10884
I17
sg10885
VC0011615
p19758
sg10887
I2
sasg10888
(lp19759
(dp19760
g10882
I271
sg10883
VCD45R
p19761
sg10884
I5
sg10891
VP08575
p19762
sg10887
I1
sa(dp19763
g10882
I141
sg10883
g19753
sg10884
I10
sg10891
VP05164
p19764
sg10887
I1
sasa(dp19765
g10873
VThe mRNA levels of cholesterol transport regulators ABCA1 and ABCG1 were markedly downregulated by UVB, parallel to the lamellar ichthyosis related glucosylceramide transporter ABCA12 and the suspected sphingosine-1-phosphate and cholesterol sulfate transporter ABCC1.
p19766
sg4
(dp19767
(Vcholesterol sulfate transporter ABCC1
p19768
Vlamellar ichthyosis
p19769
tp19770
I00
ssg10879
(lp19771
(dp19772
g10882
I120
sg10883
g19769
sg10884
I19
sg10885
VC0020758
p19773
sg10887
I2
sasg10888
(lp19774
(dp19775
g10882
I230
sg10883
g19768
sg10884
I37
sg10891
VP50443
p19776
sg10887
I4
sasa(dp19777
g10873
VIn contrast, serum and plasma kallikrein 10 values in uterine serous papillary carcinoma patients (1.2 +/- 0.1) were significantly higher than those in the non-cancer group (P = .002), benign group (P = .002), and endometrioid carcinoma patients (P = .005).
p19778
sg4
(dp19779
(Vplasma kallikrein
p19780
Vendometrioid carcinoma
p19781
tp19782
I00
ssg10879
(lp19783
(dp19784
g10882
I160
sg10883
Vcancer
p19785
sg10884
I6
sg10885
VC0006826
p19786
sg10887
I1
sa(dp19787
g10882
I69
sg10883
Vpapillary carcinoma
p19788
sg10884
I19
sg10885
VC0007133
p19789
sg10887
I2
sa(dp19790
g10882
I214
sg10883
g19781
sg10884
I22
sg10885
VC0206687
p19791
sg10887
I2
sasg10888
(lp19792
(dp19793
g10882
I23
sg10883
g19780
sg10884
I17
sg10891
VP03952
p19794
sg10887
I2
sasa(dp19795
g10873
VKallikrein 10 is highly expressed in uterine serous papillary carcinoma, and it is released in the plasma and serum of uterine serous papillary carcinoma patients.
p19796
sg4
(dp19797
(VKallikrein
p19798
Vpapillary carcinoma
p19799
tp19800
I00
ssg10879
(lp19801
(dp19802
g10882
I52
sg10883
Vpapillary carcinoma
p19803
sg10884
I19
sg10885
VC0007133
p19804
sg10887
I2
sa(dp19805
g10882
I52
sg10883
g19799
sg10884
I19
sg10885
VC0007133
p19806
sg10887
I2
sasg10888
(lp19807
(dp19808
g10882
I0
sg10883
g19798
sg10884
I10
sg10891
VP06870
p19809
sg10887
I1
sasa(dp19810
g10873
VKallikrein 10 may represent a novel biomarker for uterine serous papillary carcinoma.
p19811
sg4
(dp19812
(VKallikrein
p19813
Vpapillary carcinoma
p19814
tp19815
I00
ssg10879
(lp19816
(dp19817
g10882
I65
sg10883
g19814
sg10884
I19
sg10885
VC0007133
p19818
sg10887
I2
sasg10888
(lp19819
(dp19820
g10882
I0
sg10883
g19813
sg10884
I10
sg10891
VP06870
p19821
sg10887
I1
sasa(dp19822
g10873
VAt the same time, it functions as a transcriptional regulator of particular genes and as a cytokine: HMGB-1 released from a defective cell has been reported to induce damage to the adjacent cells.With a view to examine the relationship between neuronal damage caused by hydrocephalus and HMGB-1, we analyzed the expression of HMGB-1 in the cerebellum, cerebrum, and hippocampus of 1-day-old congenitally hydrocephalic H-Tx rats.As opposed to nonhydrocephalic H-Tx rats, the hydrocephalic H-Tx rats were observed to show stronger expression of HMGB-1 in the cerebellum, cerebrum, and hippocampus.
p19823
sg4
(dp19824
(VHMGB-1
p19825
Vhydrocephalus
p19826
tp19827
I00
ssg10879
(lp19828
(dp19829
g10882
I270
sg10883
g19826
sg10884
I13
sg10885
VC0020255
p19830
sg10887
I1
sasg10888
(lp19831
(dp19832
g10882
I101
sg10883
VHMGB-1
p19833
sg10884
I6
sg10891
VP09429
p19834
sg10887
I1
sa(dp19835
g10882
I101
sg10883
VHMGB-1
p19836
sg10884
I6
sg10891
VP09429
p19837
sg10887
I1
sa(dp19838
g10882
I101
sg10883
VHMGB-1
p19839
sg10884
I6
sg10891
VP09429
p19840
sg10887
I1
sa(dp19841
g10882
I101
sg10883
g19825
sg10884
I6
sg10891
VP09429
p19842
sg10887
I1
sasa(dp19843
g10873
VAll studies utilized an animal model such as AQP4-knockout mice, H-Tx rats, and kaolin and L-Alfa-lysophosphatidylcholine (LPC) stearoyl injection models of hydrocephalus.
p19844
sg4
(dp19845
(VAQP4
p19846
Vhydrocephalus
p19847
tp19848
I01
ssg10879
(lp19849
(dp19850
g10882
I157
sg10883
g19847
sg10884
I13
sg10885
VC0020255
p19851
sg10887
I1
sasg10888
(lp19852
(dp19853
g10882
I45
sg10883
g19846
sg10884
I4
sg10891
VP55087
p19854
sg10887
I1
sasa(dp19855
g10873
VRenal fibrosis was consequently attenuated in the UUO+VEGF-C group.
p19856
sg4
(dp19857
(VUUO+VEGF-C
p19858
VRenal fibrosis
p19859
tp19860
I00
ssg10879
(lp19861
(dp19862
g10882
I0
sg10883
g19859
sg10884
I14
sg10885
VC0151650
p19863
sg10887
I2
sasg10888
(lp19864
(dp19865
g10882
I50
sg10883
g19858
sg10884
I10
sg10891
VP49767
p19866
sg10887
I1
sasa(dp19867
g10873
VEnhancement of the VEGF-C signaling pathway in LECs may be a therapeutic strategy for renal fibrosis.Laboratory Investigation advance online publication, 30 October 2017; doi:10.1038/labinvest.2017.77.
p19868
sg4
(dp19869
(VVEGF-C
p19870
Vrenal fibrosis
p19871
tp19872
I00
ssg10879
(lp19873
(dp19874
g10882
I86
sg10883
g19871
sg10884
I14
sg10885
VC0151650
p19875
sg10887
I2
sasg10888
(lp19876
(dp19877
g10882
I19
sg10883
g19870
sg10884
I6
sg10891
VP49767
p19878
sg10887
I1
sasa(dp19879
g10873
VBy using a novel, advanced, multicolor fluorescence in situ hybridization approach, we enumerated copy numbers of six genes previously identified by array comparative genomic hybridization to be involved in aggressive prostate cancer [TBL1XR1, CTTNBP2, MYC (alias c-myc), PTEN, MEN1, and PDGFB] in six nonrecurrent and seven recurrent radical prostatectomy cases.
p19880
sg4
(dp19881
(VPTEN
p19882
Vaggressive
p19883
tp19884
I00
ssg10879
(lp19885
(dp19886
g10882
I278
sg10883
VMEN1
p19887
sg10884
I4
sg10885
VC0025267
p19888
sg10887
I1
sa(dp19889
g10882
I218
sg10883
Vprostate cancer
p19890
sg10884
I15
sg10885
VC0600139
p19891
sg10887
I2
sa(dp19892
g10882
I207
sg10883
g19883
sg10884
I10
sg10885
VC0001807
p19893
sg10887
I1
sasg10888
(lp19894
(dp19895
g10882
I264
sg10883
Vc-myc
p19896
sg10884
I5
sg10891
VP12524
p19897
sg10887
I1
sa(dp19898
g10882
I253
sg10883
VMYC
p19899
sg10884
I3
sg10891
VP12524
p19900
sg10887
I1
sa(dp19901
g10882
I244
sg10883
VCTTNBP2
p19902
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp19903
g10882
I235
sg10883
VTBL1XR1
p19904
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp19905
g10882
I272
sg10883
g19882
sg10884
I4
sg10891
VP60484
p19906
sg10887
I1
sa(dp19907
g10882
I278
sg10883
VMEN1
p19908
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp19909
g10873
VThe identification of higher NIHSS scores, higher HAMD scores, lower dopamine level, lower 5-hydroxytryptamine level, higher tumor necrosis factor-Alfa level, and lower nerve growth factor level might be useful for clinicians in recognizing and treating depression in patients after a stroke.
p19910
sg4
(dp19911
(Vnerve growth factor
p19912
Vstroke
p19913
tp19914
I00
ssg10879
(lp19915
(dp19916
g10882
I254
sg10883
Vdepression
p19917
sg10884
I10
sg10885
VC0011581
p19918
sg10887
I1
sa(dp19919
g10882
I125
sg10883
Vtumor necrosis
p19920
sg10884
I14
sg10885
VC0333516
p19921
sg10887
I2
sa(dp19922
g10882
I285
sg10883
g19913
sg10884
I6
sg10885
VC0038454
p19923
sg10887
I1
sasg10888
(lp19924
(dp19925
g10882
I125
sg10883
Vtumor necrosis factor-Alfa
p19926
sg10884
I26
sg10891
VP01375
p19927
sg10887
I3
sa(dp19928
g10882
I169
sg10883
g19912
sg10884
I19
sg10891
VP01138
p19929
sg10887
I3
sasa(dp19930
g10873
VOther effects include a reduction in the platelet levels of adenosine triphosphate (ATP), serotonin (5-hydroxytryptamine), platelet factor 3 (PF3), PF4 and Beta-thromboglobulin (BTG), decreased platelet adhesiveness in platelets from healthy volunteers and from atherosclerotic patients and an improvement in red blood cell deformability in patients with occlusive vascular disease.
p19931
sg4
(dp19932
(VBeta-thromboglobulin
p19933
Vocclusive vascular disease
p19934
tp19935
I00
ssg10879
(lp19936
(dp19937
g10882
I355
sg10883
g19934
sg10884
I26
sg10885
VC0750145
p19938
sg10887
I3
sasg10888
(lp19939
(dp19940
g10882
I148
sg10883
VPF4
p19941
sg10884
I3
sg10891
VP02776
p19942
sg10887
I1
sa(dp19943
g10882
I178
sg10883
VBTG
p19944
sg10884
I3
sg10891
VP02775
p19945
sg10887
I1
sa(dp19946
g10882
I123
sg10883
Vplatelet factor 3
p19947
sg10884
I17
sg10891
VP14770
p19948
sg10887
I3
sa(dp19949
g10882
I142
sg10883
VPF3
p19950
sg10884
I3
sg10891
VP14770
p19951
sg10887
I1
sa(dp19952
g10882
I156
sg10883
g19933
sg10884
I20
sg10891
VP02775
p19953
sg10887
I1
sasa(dp19954
g10873
VObjective: To explore the effect of trimetazidine pre-treatments on serum 5-hydroxytryptamine (5-HT) and serotonin transporter (SERT), platelet 5-HT and SERT in the Sprague Dawley rats with myocardial infarction(MI), depression, and myocardial infarction co-exist with depression (MI+ depression) and in sham operated rats.
p19955
sg4
(dp19956
(VSERT
p19957
Vmyocardial infarction
p19958
tp19959
I00
ssg10879
(lp19960
(dp19961
g10882
I217
sg10883
Vdepression
p19962
sg10884
I10
sg10885
VC0011581
p19963
sg10887
I1
sa(dp19964
g10882
I217
sg10883
Vdepression
p19965
sg10884
I10
sg10885
VC0011581
p19966
sg10887
I1
sa(dp19967
g10882
I217
sg10883
Vdepression
p19968
sg10884
I10
sg10885
VC0011581
p19969
sg10887
I1
sa(dp19970
g10882
I190
sg10883
Vmyocardial infarction
p19971
sg10884
I21
sg10885
VC0027051
p19972
sg10887
I2
sa(dp19973
g10882
I190
sg10883
g19958
sg10884
I21
sg10885
VC0027051
p19974
sg10887
I2
sasg10888
(lp19975
(dp19976
g10882
I128
sg10883
VSERT
p19977
sg10884
I4
sg10891
VP31645
p19978
sg10887
I1
sa(dp19979
g10882
I105
sg10883
Vserotonin transporter
p19980
sg10884
I21
sg10891
VP31645
p19981
sg10887
I2
sa(dp19982
g10882
I128
sg10883
g19957
sg10884
I4
sg10891
VP31645
p19983
sg10887
I1
sasa(dp19984
g10873
VThe role of histone deacetylase-3 (HDAC3) in allergic skin inflammation was reported.
p19985
sg4
(dp19986
(Vhistone deacetylase-3
p19987
Vskin inflammation
p19988
tp19989
I00
ssg10879
(lp19990
(dp19991
g10882
I54
sg10883
g19988
sg10884
I17
sg10885
VC0011603
p19992
sg10887
I2
sasg10888
(lp19993
(dp19994
g10882
I35
sg10883
VHDAC3
p19995
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp19996
g10882
I12
sg10883
g19987
sg10884
I21
sg10891
VP56524
p19997
sg10887
I2
sasa(dp19998
g10873
VTo investigate the expression and prognostic value of Alfa1-ACT (Alpha1-antichymotrypsin) in patients with HCC (hepatocellular carcinoma) and identify the mechanism by which Alfa1-ACT inhibits proliferation and promotes apoptosis of HCC.
p19999
sg4
(dp20000
(Vantichymotrypsin
p20001
VHCC
p20002
tp20003
I00
ssg10879
(lp20004
(dp20005
g10882
I112
sg10883
Vhepatocellular carcinoma
p20006
sg10884
I24
sg10885
VC2239176
p20007
sg10887
I2
sa(dp20008
g10882
I107
sg10883
VHCC
p20009
sg10884
I3
sg10885
VC2239176
p20010
sg10887
I1
sa(dp20011
g10882
I193
sg10883
Vproliferation
p20012
sg10884
I13
sg10885
VC0334094
p20013
sg10887
I1
sa(dp20014
g10882
I107
sg10883
g20002
sg10884
I3
sg10885
VC2239176
p20015
sg10887
I1
sasg10888
(lp20016
(dp20017
g10882
I54
sg10883
VAlfa1-ACT
p20018
sg10884
I9
sg10891
VP63267
p20019
sg10887
I1
sa(dp20020
g10882
I54
sg10883
VAlfa1-ACT
p20021
sg10884
I9
sg10891
VP63267
p20022
sg10887
I1
sa(dp20023
g10882
I72
sg10883
g20001
sg10884
I16
sg10891
VP05154
p20024
sg10887
I1
sasa(dp20025
g10873
VDeletions were found in LEC1 (9.5% versus 14.3%), LEC2 (4.8% versus 14.3%), cagT (33.3% versus 28.6%), cagE (28.6% versus 28.6%) and the promoter region of the cagA (19.0% versus 42.9%) of gastritis and PUD strains, respectively.
p20026
sg4
(dp20027
(VcagA
p20028
Vgastritis
p20029
tp20030
I00
ssg10879
(lp20031
(dp20032
g10882
I203
sg10883
VPUD
p20033
sg10884
I3
sg10885
VC0030920
p20034
sg10887
I1
sa(dp20035
g10882
I189
sg10883
g20029
sg10884
I9
sg10885
VC0017152
p20036
sg10887
I1
sasg10888
(lp20037
(dp20038
g10882
I103
sg10883
VcagE
p20039
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp20040
g10882
I50
sg10883
VLEC2
p20041
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp20042
g10882
I24
sg10883
VLEC1
p20043
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp20044
g10882
I160
sg10883
g20028
sg10884
I4
sg10891
VP05109
p20045
sg10887
I1
sasa(dp20046
g10873
VUsher syndrome type III (USH3), characterized by progressive deafness, variable balance disorder and blindness, is caused by destabilizing mutations in the gene encoding the clarin-1 (CLRN1) protein.
p20047
sg4
(dp20048
(Vclarin-1
p20049
Vbalance disorder
p20050
tp20051
I00
ssg10879
(lp20052
(dp20053
g10882
I25
sg10883
VUSH3
p20054
sg10884
I4
sg10885
VC1568248
p20055
sg10887
I1
sa(dp20056
g10882
I61
sg10883
Vdeafness
p20057
sg10884
I8
sg10885
VC0011053
p20058
sg10887
I1
sa(dp20059
g10882
I101
sg10883
Vblindness
p20060
sg10884
I9
sg10885
VC0456909
p20061
sg10887
I1
sa(dp20062
g10882
I0
sg10883
VUsher syndrome
p20063
sg10884
I14
sg10885
VC0271097
p20064
sg10887
I2
sa(dp20065
g10882
I80
sg10883
g20050
sg10884
I16
sg10885
VC0575090
p20066
sg10887
I2
sasg10888
(lp20067
(dp20068
g10882
I25
sg10883
VUSH3
p20069
sg10884
I4
sg10891
VP58418
p20070
sg10887
I1
sa(dp20071
g10882
I184
sg10883
VCLRN1
p20072
sg10884
I5
sg10891
VP58418
p20073
sg10887
I1
sa(dp20074
g10882
I174
sg10883
g20049
sg10884
I8
sg10891
VP58418
p20075
sg10887
I1
sasa(dp20076
g10873
VMutations in the CLRN1 gene cause Usher syndrome type 3 (USH3), a human disease characterized by progressive blindness and deafness.
p20077
sg4
(dp20078
(VUsher syndrome type 3
p20079
Vdeafness
p20080
tp20081
I00
ssg10879
(lp20082
(dp20083
g10882
I109
sg10883
Vblindness
p20084
sg10884
I9
sg10885
VC0456909
p20085
sg10887
I1
sa(dp20086
g10882
I34
sg10883
VUsher syndrome type 3
p20087
sg10884
I21
sg10885
VC1568248
p20088
sg10887
I4
sa(dp20089
g10882
I57
sg10883
VUSH3
p20090
sg10884
I4
sg10885
VC1568248
p20091
sg10887
I1
sa(dp20092
g10882
I123
sg10883
g20080
sg10884
I8
sg10885
VC0011053
p20093
sg10887
I1
sasg10888
(lp20094
(dp20095
g10882
I57
sg10883
VUSH3
p20096
sg10884
I4
sg10891
VP58418
p20097
sg10887
I1
sa(dp20098
g10882
I17
sg10883
VCLRN1 gene
p20099
sg10884
I10
sg10891
VP58418
p20100
sg10887
I2
sa(dp20101
g10882
I34
sg10883
g20079
sg10884
I21
sg10891
VP58418
p20102
sg10887
I4
sasa(dp20103
g10873
VTaken together, CD47 might be a novel target to enhance anti-PD-1 and CLTA-4 efficacy in esophageal squamous cell cancer.
p20104
sg4
(dp20105
(Vanti-PD-1
p20106
Vsquamous cell cancer
p20107
tp20108
I00
ssg10879
(lp20109
(dp20110
g10882
I100
sg10883
g20107
sg10884
I20
sg10885
VC0007137
p20111
sg10887
I3
sasg10888
(lp20112
(dp20113
g10882
I16
sg10883
VCD47
p20114
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp20115
g10882
I70
sg10883
VCLTA-4
p20116
sg10884
I6
sg10891
VP09496
p20117
sg10887
I1
sa(dp20118
g10882
I56
sg10883
g20106
sg10884
I9
sg10891
VP18621
p20119
sg10887
I1
sasa(dp20120
g10873
VIpilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma.
p20121
sg4
(dp20122
(VCLTA-4 antibody
p20123
Vmelanoma
p20124
tp20125
I00
ssg10879
(lp20126
(dp20127
g10882
I91
sg10883
g20124
sg10884
I8
sg10885
VC0025202
p20128
sg10887
I1
sasg10888
(lp20129
(dp20130
g10882
I24
sg10883
g20123
sg10884
I15
sg10891
VP09496
p20131
sg10887
I2
sasa(dp20132
g10873
VThe most prominent example of this shift is the management of metastatic melanoma, where BRAF and MEK inhibition and CLTA-4 blockade have established an entirely new standard of care in the last 3 years.
p20133
sg4
(dp20134
(VMEK
p20135
Vmetastatic melanoma
p20136
tp20137
I00
ssg10879
(lp20138
(dp20139
g10882
I62
sg10883
g20136
sg10884
I19
sg10885
VC0278883
p20140
sg10887
I2
sasg10888
(lp20141
(dp20142
g10882
I89
sg10883
VBRAF
p20143
sg10884
I4
sg10891
VP15056
p20144
sg10887
I1
sa(dp20145
g10882
I117
sg10883
VCLTA-4
p20146
sg10884
I6
sg10891
VP09496
p20147
sg10887
I1
sa(dp20148
g10882
I98
sg10883
g20135
sg10884
I3
sg10891
VP45985
p20149
sg10887
I1
sasa(dp20150
g10873
VThis was associated with the decreased protein expression of Notch1, Notch2, Notch3 and Hey1, and the increased expression of the tumor suppressor microRNA (miR or miRNA)-200 family members (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) that are typically downregulated in colon cancer.
p20151
sg4
(dp20152
(VNotch1
p20153
Vcolon cancer
p20154
tp20155
I00
ssg10879
(lp20156
(dp20157
g10882
I130
sg10883
Vtumor
p20158
sg10884
I5
sg10885
VC0027651
p20159
sg10887
I1
sa(dp20160
g10882
I278
sg10883
g20154
sg10884
I12
sg10885
VC0699790
p20161
sg10887
I2
sasg10888
(lp20162
(dp20163
g10882
I211
sg10883
VmiR-200c
p20164
sg10884
I8
sg10891
g190
sg10887
I1
sa(dp20165
g10882
I88
sg10883
VHey1
p20166
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp20167
g10882
I233
sg10883
VmiR-429
p20168
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp20169
g10882
I221
sg10883
VmiR-141
p20170
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp20171
g10882
I201
sg10883
VmiR-200b
p20172
sg10884
I8
sg10891
g190
sg10887
I1
sa(dp20173
g10882
I77
sg10883
VNotch3
p20174
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp20175
g10882
I61
sg10883
g20153
sg10884
I6
sg10891
VP46531
p20176
sg10887
I1
sa(dp20177
g10882
I191
sg10883
VmiR-200a
p20178
sg10884
I8
sg10891
g190
sg10887
I1
sa(dp20179
g10882
I69
sg10883
VNotch2
p20180
sg10884
I6
sg10891
g190
sg10887
I1
sasa(dp20181
g10873
VPhosphorylated IGF-IR/IR (P-IGF-IR/IR) and its downstream signaling partner phospho-S6 (P-S6) were evaluated immunohistochemically in tumor tissue microarrays representing 438 cases of invasive breast cancer.
p20182
sg4
(dp20183
(VIR
p20184
Vinvasive breast cancer
p20185
tp20186
I00
ssg10879
(lp20187
(dp20188
g10882
I185
sg10883
g20185
sg10884
I22
sg10885
VC0853879
p20189
sg10887
I3
sa(dp20190
g10882
I134
sg10883
Vtumor
p20191
sg10884
I5
sg10885
VC0027651
p20192
sg10887
I1
sasg10888
(lp20193
(dp20194
g10882
I15
sg10883
VIGF-IR
p20195
sg10884
I6
sg10891
VP06213
p20196
sg10887
I1
sa(dp20197
g10882
I19
sg10883
VIR
p20198
sg10884
I2
sg10891
VP06213
p20199
sg10887
I1
sa(dp20200
g10882
I26
sg10883
VP-IGF-IR
p20201
sg10884
I8
sg10891
VP06213
p20202
sg10887
I1
sa(dp20203
g10882
I19
sg10883
g20184
sg10884
I2
sg10891
VP06213
p20204
sg10887
I1
sasa(dp20205
g10873
VImportantly, P-IGF-IR/IR was detected in all breast cancer subtypes (luminal, 48.1%; triple negative, 41.9%; and HER2, 64.3%).
p20206
sg4
(dp20207
(VIR
p20208
Vbreast cancer
p20209
tp20210
I00
ssg10879
(lp20211
(dp20212
g10882
I45
sg10883
g20209
sg10884
I13
sg10885
VC0678222
p20213
sg10887
I2
sasg10888
(lp20214
(dp20215
g10882
I13
sg10883
VP-IGF-IR
p20216
sg10884
I8
sg10891
VP06213
p20217
sg10887
I1
sa(dp20218
g10882
I19
sg10883
g20208
sg10884
I2
sg10891
VP06213
p20219
sg10887
I1
sasa(dp20220
g10873
VThus, we can determine which patients have the activated receptor and provide evidence that P-IGF-IR/IR is a prognostic factor for breast cancer.
p20221
sg4
(dp20222
(VIR
p20223
Vbreast cancer
p20224
tp20225
I00
ssg10879
(lp20226
(dp20227
g10882
I131
sg10883
g20224
sg10884
I13
sg10885
VC0678222
p20228
sg10887
I2
sasg10888
(lp20229
(dp20230
g10882
I92
sg10883
VP-IGF-IR
p20231
sg10884
I8
sg10891
VP06213
p20232
sg10887
I1
sa(dp20233
g10882
I98
sg10883
g20223
sg10884
I2
sg10891
VP06213
p20234
sg10887
I1
sasa(dp20235
g10873
VBeyond this, P-IGF-IR/IR could be a predictive marker for response to IGF-IR and/or IR-targeted therapies, as these inhibitors may be of benefit in all breast cancer subtypes including those with acquired resistance to tamoxifen.
p20236
sg4
(dp20237
(VIR
p20238
Vbreast cancer
p20239
tp20240
I00
ssg10879
(lp20241
(dp20242
g10882
I152
sg10883
g20239
sg10884
I13
sg10885
VC0678222
p20243
sg10887
I2
sasg10888
(lp20244
(dp20245
g10882
I13
sg10883
VP-IGF-IR
p20246
sg10884
I8
sg10891
VP06213
p20247
sg10887
I1
sa(dp20248
g10882
I15
sg10883
VIGF-IR
p20249
sg10884
I6
sg10891
VP06213
p20250
sg10887
I1
sa(dp20251
g10882
I19
sg10883
g20238
sg10884
I2
sg10891
VP06213
p20252
sg10887
I1
sasa(dp20253
g10873
VWe examined the expression of CT-1, leukemia inhibitory factor (LIF), and gp130 by competitive RT-PCR and Western blotting in Dahl salt-sensitive (DS) rats with a high-salt diet, which showed a distinct transition from left ventricular hypertrophy (LVH) to congestive heart failure (CHF).
p20254
sg4
(dp20255
(Vgp130
p20256
VCHF
p20257
tp20258
I00
ssg10879
(lp20259
(dp20260
g10882
I249
sg10883
VLVH
p20261
sg10884
I3
sg10885
VC0149721
p20262
sg10887
I1
sa(dp20263
g10882
I36
sg10883
Vleukemia
p20264
sg10884
I8
sg10885
VC0023418
p20265
sg10887
I1
sa(dp20266
g10882
I257
sg10883
Vcongestive heart failure
p20267
sg10884
I24
sg10885
VC0018802
p20268
sg10887
I3
sa(dp20269
g10882
I203
sg10883
Vtransition
p20270
sg10884
I10
sg10885
VC0599156
p20271
sg10887
I1
sa(dp20272
g10882
I219
sg10883
Vleft ventricular hypertrophy
p20273
sg10884
I28
sg10885
VC0149721
p20274
sg10887
I3
sa(dp20275
g10882
I283
sg10883
g20257
sg10884
I3
sg10885
VC0018802
p20276
sg10887
I1
sasg10888
(lp20277
(dp20278
g10882
I36
sg10883
Vleukemia inhibitory factor
p20279
sg10884
I26
sg10891
VP15018
p20280
sg10887
I3
sa(dp20281
g10882
I64
sg10883
VLIF
p20282
sg10884
I3
sg10891
VP15018
p20283
sg10887
I1
sa(dp20284
g10882
I74
sg10883
g20256
sg10884
I5
sg10891
VP40189
p20285
sg10887
I1
sa(dp20286
g10882
I30
sg10883
VCT-1
p20287
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp20288
g10873
VWe propose a model in which P-Rex1 acts as a crucial node for the integration of upstream inputs from HER/ErbB receptors and CXCR4 in luminal breast cancer cells.
p20289
sg4
(dp20290
(VCXCR4
p20291
Vbreast cancer
p20292
tp20293
I00
ssg10879
(lp20294
(dp20295
g10882
I142
sg10883
g20292
sg10884
I13
sg10885
VC0678222
p20296
sg10887
I2
sasg10888
(lp20297
(dp20298
g10882
I125
sg10883
g20291
sg10884
I5
sg10891
VP61073
p20299
sg10887
I1
sa(dp20300
g10882
I28
sg10883
VP-Rex1
p20301
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp20302
g10882
I106
sg10883
VErbB receptors
p20303
sg10884
I14
sg10891
g190
sg10887
I2
sasa(dp20304
g10873
VNotably, there is a significant association in the expression of P-Rex1 and MMP10 in human luminal breast cancer, and their co-expression is indicative of poor prognosis.
p20305
sg4
(dp20306
(VMMP10
p20307
Vbreast cancer
p20308
tp20309
I01
ssg10879
(lp20310
(dp20311
g10882
I99
sg10883
g20308
sg10884
I13
sg10885
VC0678222
p20312
sg10887
I2
sasg10888
(lp20313
(dp20314
g10882
I76
sg10883
g20307
sg10884
I5
sg10891
VP09238
p20315
sg10887
I1
sa(dp20316
g10882
I65
sg10883
VP-Rex1
p20317
sg10884
I6
sg10891
g190
sg10887
I1
sasa(dp20318
g10873
VTreatment of normal MCF-10A or basal-like cancer cells, MDA-MB-231 with the demethylating agent 5-aza-2'-deoxycitidine in combination with the histone deacetylase inhibitor trichostatin A restores P-REX1 levels to those observed in luminal breast cancer cell lines, suggesting that aberrant expression of P-REX1 in luminal breast cancer is a consequence of PREX1 promoter demethylation.
p20319
sg4
(dp20320
(Vhistone deacetylase
p20321
Vbreast cancer
p20322
tp20323
I00
ssg10879
(lp20324
(dp20325
g10882
I240
sg10883
Vbreast cancer
p20326
sg10884
I13
sg10885
VC0678222
p20327
sg10887
I2
sa(dp20328
g10882
I42
sg10883
Vcancer
p20329
sg10884
I6
sg10885
VC0006826
p20330
sg10887
I1
sa(dp20331
g10882
I240
sg10883
g20322
sg10884
I13
sg10885
VC0678222
p20332
sg10887
I2
sasg10888
(lp20333
(dp20334
g10882
I197
sg10883
VP-REX1
p20335
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp20336
g10882
I197
sg10883
VP-REX1
p20337
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp20338
g10882
I163
sg10883
Vinhibitor trichostatin A
p20339
sg10884
I24
sg10891
VP32119
p20340
sg10887
I3
sa(dp20341
g10882
I143
sg10883
g20321
sg10884
I19
sg10891
VP56524
p20342
sg10887
I2
sasa(dp20343
g10873
VWe identify 112 candidate ciliogenesis and ciliopathy genes, including 44 components of the ubiquitin-proteasome system, 12 G-protein-coupled receptors, and 3 pre-mRNA processing factors (PRPF6, PRPF8 and PRPF31) mutated in autosomal dominant retinitis pigmentosa.
p20344
sg4
(dp20345
(Vubiquitin
p20346
Vautosomal dominant retinitis pigmentosa
p20347
tp20348
I00
ssg10879
(lp20349
(dp20350
g10882
I224
sg10883
g20347
sg10884
I39
sg10885
VC0339525
p20351
sg10887
I4
sasg10888
(lp20352
(dp20353
g10882
I195
sg10883
VPRPF8
p20354
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp20355
g10882
I121
sg10883
V12 G-protein-coupled receptors
p20356
sg10884
I30
sg10891
g190
sg10887
I3
sa(dp20357
g10882
I205
sg10883
VPRPF31
p20358
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp20359
g10882
I188
sg10883
VPRPF6
p20360
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp20361
g10882
I92
sg10883
g20346
sg10884
I9
sg10891
VP62979
p20362
sg10887
I1
sasa(dp20363
g10873
VLoss of the lysosomal ClC-7/Ostm1 2Cl(-)/H(+) exchanger causes lysosomal storage disease and osteopetrosis in humans and additionally changes fur colour in mice.
p20364
sg4
(dp20365
(Vlysosomal ClC-7
p20366
Vosteopetrosis
p20367
tp20368
I00
ssg10879
(lp20369
(dp20370
g10882
I63
sg10883
Vlysosomal storage disease
p20371
sg10884
I25
sg10885
VC0085078
p20372
sg10887
I3
sa(dp20373
g10882
I93
sg10883
g20367
sg10884
I13
sg10885
VC0029454
p20374
sg10887
I1
sasg10888
(lp20375
(dp20376
g10882
I12
sg10883
g20366
sg10884
I15
sg10891
VP51798
p20377
sg10887
I2
sa(dp20378
g10882
I28
sg10883
VOstm1
p20379
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp20380
g10873
VMice lacking either ClC-7 or Ostm1 develop a lysosomal storage disease and mutations in either protein have been found to underlie osteopetrosis in mice and humans.
p20381
sg4
(dp20382
(VClC-7
p20383
Vosteopetrosis
p20384
tp20385
I00
ssg10879
(lp20386
(dp20387
g10882
I45
sg10883
Vlysosomal storage disease
p20388
sg10884
I25
sg10885
VC0085078
p20389
sg10887
I3
sa(dp20390
g10882
I131
sg10883
g20384
sg10884
I13
sg10885
VC0029454
p20391
sg10887
I1
sasg10888
(lp20392
(dp20393
g10882
I20
sg10883
g20383
sg10884
I5
sg10891
VP51798
p20394
sg10887
I1
sa(dp20395
g10882
I29
sg10883
VOstm1
p20396
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp20397
g10873
VMice or humans lacking ClC-7 or Ostm1 display osteopetrosis and lysosomal storage disease.
p20398
sg4
(dp20399
(VClC-7
p20400
Vosteopetrosis
p20401
tp20402
I00
ssg10879
(lp20403
(dp20404
g10882
I64
sg10883
Vlysosomal storage disease
p20405
sg10884
I25
sg10885
VC0085078
p20406
sg10887
I3
sa(dp20407
g10882
I46
sg10883
g20401
sg10884
I13
sg10885
VC0029454
p20408
sg10887
I1
sasg10888
(lp20409
(dp20410
g10882
I32
sg10883
VOstm1
p20411
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp20412
g10882
I23
sg10883
g20400
sg10884
I5
sg10891
VP51798
p20413
sg10887
I1
sasa(dp20414
g10873
VOur findings are summarized as follows: i) BPY2 (testis basic protein on Y, 2), DAZ1 (deleted in azoospermia 1), TTY4 (testis transcript Y 4) mRNAs and 23 ESTs were found; ii) Eighteen of 23 ESTs were transcripts of the DAZ gene(s), one EST was a transcript of TTY4 gene, and the remaining 4 probably corresponded to 4 different pseudogenes; iii) DAZ gene(s) were expressed not only in testis, but also in lung carcinoma cells, stomach and Ewing's sarcoma cells; iv) beta-satellite clusters were present around and within the BPY2 and TTY4 gene region; v) In this study, TTY4, BPY2 and DAZ1 genes were mapped precisely to the AC010088 region.
p20415
sg4
(dp20416
(Vtestis basic protein
p20417
VEwing's sarcoma
p20418
tp20419
I00
ssg10879
(lp20420
(dp20421
g10882
I406
sg10883
Vlung carcinoma
p20422
sg10884
I14
sg10885
VC0684249
p20423
sg10887
I2
sa(dp20424
g10882
I440
sg10883
g20418
sg10884
I15
sg10885
VC0553580
p20425
sg10887
I2
sa(dp20426
g10882
I97
sg10883
Vazoospermia
p20427
sg10884
I11
sg10885
VC1321542
p20428
sg10887
I1
sasg10888
(lp20429
(dp20430
g10882
I80
sg10883
VDAZ1
p20431
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp20432
g10882
I49
sg10883
g20417
sg10884
I20
sg10891
VP15735
p20433
sg10887
I3
sa(dp20434
g10882
I43
sg10883
VBPY2
p20435
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp20436
g10882
I220
sg10883
VDAZ gene
p20437
sg10884
I8
sg10891
g190
sg10887
I2
sa(dp20438
g10882
I220
sg10883
VDAZ gene(s)
p20439
sg10884
I11
sg10891
g190
sg10887
I2
sa(dp20440
g10882
I43
sg10883
VBPY2
p20441
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp20442
g10882
I586
sg10883
VDAZ1 genes
p20443
sg10884
I10
sg10891
g190
sg10887
I2
sa(dp20444
g10882
I43
sg10883
VBPY2
p20445
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp20446
g10882
I86
sg10883
Vdeleted in azoospermia 1
p20447
sg10884
I24
sg10891
g190
sg10887
I4
sasa(dp20448
g10873
VLowered POMC and heightened TRPV3 expressions in the HN and mNTS are involved in development of hyperphagia and obesity in OP rats.
p20449
sg4
(dp20450
(VPOMC
p20451
Vhyperphagia
p20452
tp20453
I01
ssg10879
(lp20454
(dp20455
g10882
I112
sg10883
Vobesity
p20456
sg10884
I7
sg10885
VC0028754
p20457
sg10887
I1
sa(dp20458
g10882
I96
sg10883
g20452
sg10884
I11
sg10885
VC0020505
p20459
sg10887
I1
sasg10888
(lp20460
(dp20461
g10882
I8
sg10883
g20451
sg10884
I4
sg10891
VP01189
p20462
sg10887
I1
sa(dp20463
g10882
I28
sg10883
VTRPV3
p20464
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp20465
g10873
VTen patients with colorectal carcinoma expressing carcinoembryonic antigen received antibody-directed enzyme prodrug therapy with A5B7 F(ab')2 antibody to carcinoembryonic antigen conjugated to carboxypeptidase G2 (CPG2).
p20466
sg4
(dp20467
(VCPG2
p20468
Vcolorectal carcinoma
p20469
tp20470
I00
ssg10879
(lp20471
(dp20472
g10882
I18
sg10883
g20469
sg10884
I20
sg10885
VC0009402
p20473
sg10887
I2
sasg10888
(lp20474
(dp20475
g10882
I194
sg10883
Vcarboxypeptidase G2
p20476
sg10884
I19
sg10891
VP10619
p20477
sg10887
I2
sa(dp20478
g10882
I50
sg10883
Vcarcinoembryonic antigen
p20479
sg10884
I24
sg10891
VP40198
p20480
sg10887
I2
sa(dp20481
g10882
I215
sg10883
g20468
sg10884
I4
sg10891
VP10619
p20482
sg10887
I1
sasa(dp20483
g10873
VHuman tumor cell lines A2780, SK-OV-3 (ovarian adenocarcinomas), LS174T, and WiDr (colon carcinomas) were engineered to express constitutively either CPG2 or bacterial beta-galactosidase.
p20484
sg4
(dp20485
(Vbacterial beta-galactosidase
p20486
Vadenocarcinomas
p20487
tp20488
I01
ssg10879
(lp20489
(dp20490
g10882
I6
sg10883
Vtumor
p20491
sg10884
I5
sg10885
VC0027651
p20492
sg10887
I1
sa(dp20493
g10882
I47
sg10883
g20487
sg10884
I15
sg10885
VC0001418
p20494
sg10887
I1
sa(dp20495
g10882
I52
sg10883
Vcarcinomas
p20496
sg10884
I10
sg10885
VC0007097
p20497
sg10887
I1
sasg10888
(lp20498
(dp20499
g10882
I158
sg10883
g20486
sg10884
I28
sg10891
VP16278
p20500
sg10887
I2
sasa(dp20501
g10873
VThey have been used to treat mouse models of connective tissue disease such as lumican-null (Lum) and mucopolysaccharidosis (Gusb) mice.
p20502
sg4
(dp20503
(Vlumican-null
p20504
Vmucopolysaccharidosis
p20505
tp20506
I00
ssg10879
(lp20507
(dp20508
g10882
I45
sg10883
Vconnective tissue disease
p20509
sg10884
I25
sg10885
VC0009782
p20510
sg10887
I3
sa(dp20511
g10882
I102
sg10883
g20505
sg10884
I21
sg10885
VC0026703
p20512
sg10887
I1
sasg10888
(lp20513
(dp20514
g10882
I93
sg10883
VLum
p20515
sg10884
I3
sg10891
VP51884
p20516
sg10887
I1
sa(dp20517
g10882
I79
sg10883
g20504
sg10884
I12
sg10891
VP51884
p20518
sg10887
I1
sasa(dp20519
g10873
VExpression of fibromodulin was significantly higher in plaques obtained from patients with diabetes and a high fibromodulin expression was associated with a higher incidence of post-operative cerebrovascular events, whereas no such associations were seen for lumican.
p20520
sg4
(dp20521
(Vlumican
p20522
Vdiabetes
p20523
tp20524
I00
ssg10879
(lp20525
(dp20526
g10882
I55
sg10883
Vplaques
p20527
sg10884
I7
sg10885
VC0333463
p20528
sg10887
I1
sa(dp20529
g10882
I91
sg10883
g20523
sg10884
I8
sg10885
VC0011849
p20530
sg10887
I1
sasg10888
(lp20531
(dp20532
g10882
I14
sg10883
Vfibromodulin
p20533
sg10884
I12
sg10891
g190
sg10887
I1
sa(dp20534
g10882
I259
sg10883
g20522
sg10884
I7
sg10891
VP51884
p20535
sg10887
I1
sa(dp20536
g10882
I14
sg10883
Vfibromodulin
p20537
sg10884
I12
sg10891
g190
sg10887
I1
sasa(dp20538
g10873
VThis study aimed to identify which myometrial ECM components are affected by diabetes, including fibril-forming collagen types I, III and V, as well as proteoglycans, decorin, lumican, fibromodulin and biglycan.
p20539
sg4
(dp20540
(Vdecorin
p20541
Vdiabetes
p20542
tp20543
I00
ssg10879
(lp20544
(dp20545
g10882
I77
sg10883
g20542
sg10884
I8
sg10885
VC0011849
p20546
sg10887
I1
sasg10888
(lp20547
(dp20548
g10882
I185
sg10883
Vfibromodulin
p20549
sg10884
I12
sg10891
g190
sg10887
I1
sa(dp20550
g10882
I176
sg10883
Vlumican
p20551
sg10884
I7
sg10891
VP51884
p20552
sg10887
I1
sa(dp20553
g10882
I35
sg10883
Vmyometrial ECM components
p20554
sg10884
I25
sg10891
g190
sg10887
I3
sa(dp20555
g10882
I167
sg10883
g20541
sg10884
I7
sg10891
VP07585
p20556
sg10887
I1
sasa(dp20557
g10873
VUsing the polymicrobial model of murine sepsis, we investigated the role of C5a receptors in septic lymphopenia.
p20558
sg4
(dp20559
(VC5a receptors
p20560
Vlymphopenia
p20561
tp20562
I00
ssg10879
(lp20563
(dp20564
g10882
I40
sg10883
Vsepsis
p20565
sg10884
I6
sg10885
VC0243026
p20566
sg10887
I1
sa(dp20567
g10882
I100
sg10883
g20561
sg10884
I11
sg10885
VC0024312
p20568
sg10887
I1
sasg10888
(lp20569
(dp20570
g10882
I76
sg10883
g20560
sg10884
I13
sg10891
VP21730
p20571
sg10887
I2
sasa(dp20572
g10873
VIn wild-type mice, cecal ligation and puncture resulted in splenocyte apoptosis and significant lymphopenia after 3 d, which was not observed in C5aR1(-/-) or C5aR2(-/-) mice.
p20573
sg4
(dp20574
(VC5aR1
p20575
Vlymphopenia
p20576
tp20577
I00
ssg10879
(lp20578
(dp20579
g10882
I96
sg10883
g20576
sg10884
I11
sg10885
VC0024312
p20580
sg10887
I1
sasg10888
(lp20581
(dp20582
g10882
I145
sg10883
g20575
sg10884
I5
sg10891
VP21730
p20583
sg10887
I1
sasa(dp20584
g10873
VNonetheless, topical application of C5aR antagonists produced circulating levels of the drugs that antagonized the LPS-induced systemic responses of neutropenia and hypotension.
p20585
sg4
(dp20586
(VC5aR
p20587
VLPS
p20588
tp20589
I00
ssg10879
(lp20590
(dp20591
g10882
I115
sg10883
g20588
sg10884
I3
sg10885
VC0175697
p20592
sg10887
I1
sasg10888
(lp20593
(dp20594
g10882
I36
sg10883
g20587
sg10884
I4
sg10891
VP21730
p20595
sg10887
I1
sasa(dp20596
g10873
VSeveral of these antigens (CD2, CD25, CD35, CD88, CD203c) appear to be upregulated on MCs in patients with systemic mastocytosis and therefore are used as diagnostic markers.
p20597
sg4
(dp20598
(VCD35
p20599
Vsystemic mastocytosis
p20600
tp20601
I00
ssg10879
(lp20602
(dp20603
g10882
I86
sg10883
VMCs
p20604
sg10884
I3
sg10885
VC0036221
p20605
sg10887
I1
sa(dp20606
g10882
I107
sg10883
g20600
sg10884
I21
sg10885
VC0221013
p20607
sg10887
I2
sasg10888
(lp20608
(dp20609
g10882
I27
sg10883
VCD2
p20610
sg10884
I3
sg10891
VP06729
p20611
sg10887
I1
sa(dp20612
g10882
I50
sg10883
VCD203c
p20613
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp20614
g10882
I32
sg10883
VCD25
p20615
sg10884
I4
sg10891
VP01589
p20616
sg10887
I1
sa(dp20617
g10882
I44
sg10883
VCD88
p20618
sg10884
I4
sg10891
VP21730
p20619
sg10887
I1
sa(dp20620
g10882
I38
sg10883
g20599
sg10884
I4
sg10891
VP11274
p20621
sg10887
I1
sasa(dp20622
g10873
VThis study analysed the expression of various complement-related cell surface antigens (CD11b/CR3, CD11c/CR4, CD35/CR1, CD55/DAF, CD59/MIRL, CD88/C5aR) on bone marrow mast cells (BMMC) in patients suffering from systemic mastocytosis (SM), other haematological diseases and non-haematological disorders (control groups).
p20623
sg4
(dp20624
(VCD88
p20625
Vsystemic mastocytosis
p20626
tp20627
I00
ssg10879
(lp20628
(dp20629
g10882
I278
sg10883
Vhaematological disorders
p20630
sg10884
I24
sg10885
VC0018939
p20631
sg10887
I2
sa(dp20632
g10882
I197
sg10883
Vsuffering
p20633
sg10884
I9
sg10885
VC0683278
p20634
sg10887
I1
sa(dp20635
g10882
I235
sg10883
VSM
p20636
sg10884
I2
sg10885
VC0221013
p20637
sg10887
I1
sa(dp20638
g10882
I212
sg10883
g20626
sg10884
I21
sg10885
VC0221013
p20639
sg10887
I2
sasg10888
(lp20640
(dp20641
g10882
I125
sg10883
VDAF
p20642
sg10884
I3
sg10891
VP08174
p20643
sg10887
I1
sa(dp20644
g10882
I146
sg10883
VC5aR
p20645
sg10884
I4
sg10891
VP21730
p20646
sg10887
I1
sa(dp20647
g10882
I46
sg10883
Vcomplement-related cell surface antigens
p20648
sg10884
I40
sg10891
g190
sg10887
I4
sa(dp20649
g10882
I130
sg10883
VCD59
p20650
sg10884
I4
sg10891
VP13987
p20651
sg10887
I1
sa(dp20652
g10882
I115
sg10883
VCR1
p20653
sg10884
I3
sg10891
VP17927
p20654
sg10887
I1
sa(dp20655
g10882
I105
sg10883
VCR4
p20656
sg10884
I3
sg10891
VP20702
p20657
sg10887
I1
sa(dp20658
g10882
I88
sg10883
VCD11b
p20659
sg10884
I5
sg10891
VP11215
p20660
sg10887
I1
sa(dp20661
g10882
I110
sg10883
VCD35
p20662
sg10884
I4
sg10891
VP11274
p20663
sg10887
I1
sa(dp20664
g10882
I120
sg10883
VCD55
p20665
sg10884
I4
sg10891
VP08174
p20666
sg10887
I1
sa(dp20667
g10882
I94
sg10883
VCR3
p20668
sg10884
I3
sg10891
VP51864
p20669
sg10887
I1
sa(dp20670
g10882
I135
sg10883
VMIRL
p20671
sg10884
I4
sg10891
VP13987
p20672
sg10887
I1
sa(dp20673
g10882
I99
sg10883
VCD11c
p20674
sg10884
I5
sg10891
VP20702
p20675
sg10887
I1
sa(dp20676
g10882
I141
sg10883
g20625
sg10884
I4
sg10891
VP21730
p20677
sg10887
I1
sasa(dp20678
g10873
VA cyclic peptide, Phe-[Orn-Pro-D-Cyclohexylalanine-Trp-Arg] (F-[OPdChaWR]), was recently shown in vitro to antagonise the binding of C5a to its receptor (CD88) on human polymorphonuclear leukocytes (PMNs) and in vivo to inhibit the neutropenia associated with septic shock induced by lipopolysaccharide (LPS) in rats.
p20679
sg4
(dp20680
(VC5a
p20681
Vlipopolysaccharide
p20682
tp20683
I00
ssg10879
(lp20684
(dp20685
g10882
I260
sg10883
Vseptic shock
p20686
sg10884
I12
sg10885
VC0036983
p20687
sg10887
I2
sa(dp20688
g10882
I304
sg10883
VLPS
p20689
sg10884
I3
sg10885
VC0175697
p20690
sg10887
I1
sa(dp20691
g10882
I284
sg10883
g20682
sg10884
I18
sg10885
VC0175697
p20692
sg10887
I1
sasg10888
(lp20693
(dp20694
g10882
I154
sg10883
VCD88
p20695
sg10884
I4
sg10891
VP21730
p20696
sg10887
I1
sa(dp20697
g10882
I133
sg10883
g20681
sg10884
I3
sg10891
VP21730
p20698
sg10887
I1
sasa(dp20699
g10873
VThe abnormal C5aR expression on eosinophils and neutrophils became normal after spontaneous resolution of symptoms and blood eosinophilia.
p20700
sg4
(dp20701
(VC5aR
p20702
Veosinophilia
p20703
tp20704
I00
ssg10879
(lp20705
(dp20706
g10882
I125
sg10883
g20703
sg10884
I12
sg10885
VC0014457
p20707
sg10887
I1
sasg10888
(lp20708
(dp20709
g10882
I13
sg10883
g20702
sg10884
I4
sg10891
VP21730
p20710
sg10887
I1
sasa(dp20711
g10873
VThe therapeutic potential of DPPSC was tested in a wound healing mouse model and in two genetic mouse models of muscular dystrophy (Scid/mdx and Sgcb-null Rag2-null Gammac-null).
p20712
sg4
(dp20713
(VSgcb-null Rag2-null Gammac-null
p20714
VScid
p20715
tp20716
I00
ssg10879
(lp20717
(dp20718
g10882
I112
sg10883
Vmuscular dystrophy
p20719
sg10884
I18
sg10885
VC0026850
p20720
sg10887
I2
sa(dp20721
g10882
I137
sg10883
Vmdx
p20722
sg10884
I3
sg10885
VC1839839
p20723
sg10887
I1
sa(dp20724
g10882
I132
sg10883
g20715
sg10884
I4
sg10885
VC0085110
p20725
sg10887
I1
sasg10888
(lp20726
(dp20727
g10882
I145
sg10883
g20714
sg10884
I31
sg10891
VP55895
p20728
sg10887
I3
sasa(dp20729
g10873
VMutations in the RAG1/RAG2 genes are associated with a broad spectrum of clinical phenotypes, ranging from severe combined immunodeficiency to various autoimmune diseases.
p20730
sg4
(dp20731
(VRAG1
p20732
Vautoimmune diseases
p20733
tp20734
I00
ssg10879
(lp20735
(dp20736
g10882
I107
sg10883
Vsevere combined immunodeficiency
p20737
sg10884
I32
sg10885
VC0085110
p20738
sg10887
I3
sa(dp20739
g10882
I151
sg10883
g20733
sg10884
I19
sg10885
VC0004364
p20740
sg10887
I2
sasg10888
(lp20741
(dp20742
g10882
I22
sg10883
VRAG2
p20743
sg10884
I4
sg10891
VP55895
p20744
sg10887
I1
sa(dp20745
g10882
I17
sg10883
g20732
sg10884
I4
sg10891
VP15918
p20746
sg10887
I1
sasa(dp20747
g10873
VIn this review, the molecular pathology of diseases caused by RAG1/RAG2 mutations, in particular Omenn syndrome, will be discussed.
p20748
sg4
(dp20749
(VRAG2
p20750
VOmenn syndrome
p20751
tp20752
I00
ssg10879
(lp20753
(dp20754
g10882
I30
sg10883
Vpathology
p20755
sg10884
I9
sg10885
VC0677042
p20756
sg10887
I1
sa(dp20757
g10882
I97
sg10883
g20751
sg10884
I14
sg10885
VC1801959
p20758
sg10887
I2
sasg10888
(lp20759
(dp20760
g10882
I62
sg10883
VRAG1
p20761
sg10884
I4
sg10891
VP15918
p20762
sg10887
I1
sa(dp20763
g10882
I67
sg10883
g20750
sg10884
I4
sg10891
VP55895
p20764
sg10887
I1
sasa(dp20765
g10873
VSevere combined immunodeficiency (SCID) is a potentially fatal primary immunodeficiency (PID) that is caused by mutations in genes such as IL2RG, JAK3, IL7RA, RAG1, RAG2, and ADA.
p20766
sg4
(dp20767
(VJAK3
p20768
VPID
p20769
tp20770
I00
ssg10879
(lp20771
(dp20772
g10882
I34
sg10883
VSCID
p20773
sg10884
I4
sg10885
VC0085110
p20774
sg10887
I1
sa(dp20775
g10882
I63
sg10883
Vprimary immunodeficiency
p20776
sg10884
I24
sg10885
VC0398686
p20777
sg10887
I2
sa(dp20778
g10882
I0
sg10883
VSevere combined immunodeficiency
p20779
sg10884
I32
sg10885
VC0085110
p20780
sg10887
I3
sa(dp20781
g10882
I89
sg10883
g20769
sg10884
I3
sg10885
VC0242172
p20782
sg10887
I1
sasg10888
(lp20783
(dp20784
g10882
I159
sg10883
VRAG1
p20785
sg10884
I4
sg10891
VP15918
p20786
sg10887
I1
sa(dp20787
g10882
I139
sg10883
VIL2RG
p20788
sg10884
I5
sg10891
VP31785
p20789
sg10887
I1
sa(dp20790
g10882
I175
sg10883
VADA
p20791
sg10884
I3
sg10891
VP00813
p20792
sg10887
I1
sa(dp20793
g10882
I165
sg10883
VRAG2
p20794
sg10884
I4
sg10891
VP55895
p20795
sg10887
I1
sa(dp20796
g10882
I146
sg10883
g20768
sg10884
I4
sg10891
VP52333
p20797
sg10887
I1
sasa(dp20798
g10873
VSevere combined immunodeficiency can be caused by loss-of-function mutations in genes involved in the DNA recombination machinery, such as recombination-activating gene 1 (RAG1), RAG2, or DNA cross-link repair 1C (DCLRE1C).
p20799
sg4
(dp20800
(VRAG1
p20801
VSevere combined immunodeficiency
p20802
tp20803
I00
ssg10879
(lp20804
(dp20805
g10882
I0
sg10883
g20802
sg10884
I32
sg10885
VC0085110
p20806
sg10887
I3
sasg10888
(lp20807
(dp20808
g10882
I139
sg10883
Vrecombination-activating gene 1
p20809
sg10884
I31
sg10891
VP15918
p20810
sg10887
I3
sa(dp20811
g10882
I179
sg10883
VRAG2
p20812
sg10884
I4
sg10891
VP55895
p20813
sg10887
I1
sa(dp20814
g10882
I172
sg10883
g20801
sg10884
I4
sg10891
VP15918
p20815
sg10887
I1
sasa(dp20816
g10873
VHere, we evaluated the effects of 15d-PGJ2 alone and in combination with the tyrosine kinas inhibitor (TKI) dasatinib in uterine sarcoma cell lines (MES-SA, MES-SA/DX5 and SKN).
p20817
sg4
(dp20818
(VTKI
p20819
VMES
p20820
tp20821
I00
ssg10879
(lp20822
(dp20823
g10882
I149
sg10883
VMES
p20824
sg10884
I3
sg10885
VC0265215
p20825
sg10887
I1
sa(dp20826
g10882
I121
sg10883
Vuterine sarcoma
p20827
sg10884
I15
sg10885
VC0338113
p20828
sg10887
I2
sa(dp20829
g10882
I149
sg10883
g20820
sg10884
I3
sg10885
VC0265215
p20830
sg10887
I1
sasg10888
(lp20831
(dp20832
g10882
I149
sg10883
VMES-SA
p20833
sg10884
I6
sg10891
VP31947
p20834
sg10887
I1
sa(dp20835
g10882
I77
sg10883
Vtyrosine kinas inhibitor
p20836
sg10884
I24
sg10891
VP14679
p20837
sg10887
I3
sa(dp20838
g10882
I103
sg10883
g20819
sg10884
I3
sg10891
VP14679
p20839
sg10887
I1
sa(dp20840
g10882
I172
sg10883
VSKN
p20841
sg10884
I3
sg10891
g190
sg10887
I1
sasa(dp20842
g10873
VPrevious studies have shown that N(1),N(12)-bis(all-trans-retinoyl)spermine (RASP), a retinoid analog, inhibits RNase P activity and angiogenesis in the chicken embryo chorioallantoic membrane, demonstrates anti-tumor activity on prostate cancer cells, and acts as anti-inflammatory agent, being more effective and less toxic than all-trans retinoic acid.
p20843
sg4
(dp20844
(VRNase P
p20845
Vprostate cancer
p20846
tp20847
I00
ssg10879
(lp20848
(dp20849
g10882
I212
sg10883
Vtumor
p20850
sg10884
I5
sg10885
VC0027651
p20851
sg10887
I1
sa(dp20852
g10882
I230
sg10883
g20846
sg10884
I15
sg10885
VC0600139
p20853
sg10887
I2
sasg10888
(lp20854
(dp20855
g10882
I112
sg10883
g20845
sg10884
I7
sg10891
VP07998
p20856
sg10887
I2
sasa(dp20857
g10873
VTo determine the functional significance of Hhat expression in breast cancer, we used a panel of breast cancer cell lines that included estrogen receptor (ER) positive, HER2 amplified, triple negative, and tamoxifen resistant cells.
p20858
sg4
(dp20859
(Vestrogen receptor
p20860
Vbreast cancer
p20861
tp20862
I00
ssg10879
(lp20863
(dp20864
g10882
I63
sg10883
Vbreast cancer
p20865
sg10884
I13
sg10885
VC0678222
p20866
sg10887
I2
sa(dp20867
g10882
I63
sg10883
g20861
sg10884
I13
sg10885
VC0678222
p20868
sg10887
I2
sasg10888
(lp20869
(dp20870
g10882
I155
sg10883
VER
p20871
sg10884
I2
sg10891
VP03372
p20872
sg10887
I1
sa(dp20873
g10882
I169
sg10883
VHER2
p20874
sg10884
I4
sg10891
VP04626
p20875
sg10887
I1
sa(dp20876
g10882
I136
sg10883
g20860
sg10884
I17
sg10891
VP03372
p20877
sg10887
I2
sasa(dp20878
g10873
VThese data suggest that Hhat plays a critical role in ER positive, HER2 amplified, and hormone resistant breast cancer proliferation and highlights the potential promise of Hhat inhibitors for therapeutic benefit in breast cancer.
p20879
sg4
(dp20880
(VHER2
p20881
Vbreast cancer
p20882
tp20883
I00
ssg10879
(lp20884
(dp20885
g10882
I105
sg10883
Vbreast cancer
p20886
sg10884
I13
sg10885
VC0678222
p20887
sg10887
I2
sa(dp20888
g10882
I119
sg10883
Vproliferation
p20889
sg10884
I13
sg10885
VC0334094
p20890
sg10887
I1
sa(dp20891
g10882
I105
sg10883
g20882
sg10884
I13
sg10885
VC0678222
p20892
sg10887
I2
sasg10888
(lp20893
(dp20894
g10882
I67
sg10883
g20881
sg10884
I4
sg10891
VP04626
p20895
sg10887
I1
sasa(dp20896
g10873
VThe STARD3 gene belongs to the minimal amplicon in HER2-positive breast cancers and encodes a cholesterol-binding membrane protein.
p20897
sg4
(dp20898
(Vcholesterol-binding membrane protein
p20899
Vbreast cancers
p20900
tp20901
I00
ssg10879
(lp20902
(dp20903
g10882
I65
sg10883
g20900
sg10884
I14
sg10885
VC0006142
p20904
sg10887
I2
sasg10888
(lp20905
(dp20906
g10882
I51
sg10883
VHER2
p20907
sg10884
I4
sg10891
VP04626
p20908
sg10887
I1
sa(dp20909
g10882
I4
sg10883
VSTARD3 gene
p20910
sg10884
I11
sg10891
g190
sg10887
I2
sa(dp20911
g10882
I94
sg10883
g20899
sg10884
I36
sg10891
VP63244
p20912
sg10887
I3
sasa(dp20913
g10873
VIn two Finnish nationwide patient cohorts, approximately 10% (212/2220) breast cancers exhibited high StARD3 protein levels, which was strongly associated with HER2 amplification; several factors related to poor disease outcome and poor breast cancer-specific survival.
p20914
sg4
(dp20915
(VHER2
p20916
Vbreast cancer
p20917
tp20918
I00
ssg10879
(lp20919
(dp20920
g10882
I165
sg10883
Vamplification
p20921
sg10884
I13
sg10885
VC1705759
p20922
sg10887
I1
sa(dp20923
g10882
I72
sg10883
Vbreast cancers
p20924
sg10884
I14
sg10885
VC0006142
p20925
sg10887
I2
sa(dp20926
g10882
I72
sg10883
g20917
sg10884
I13
sg10885
VC0006142
p20927
sg10887
I2
sasg10888
(lp20928
(dp20929
g10882
I160
sg10883
g20916
sg10884
I4
sg10891
VP04626
p20930
sg10887
I1
sa(dp20931
g10882
I102
sg10883
VStARD3 protein
p20932
sg10884
I14
sg10891
g190
sg10887
I2
sasa(dp20933
g10873
VIn addition, high StARD3 levels in breast cancers were associated with elevated 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA levels and anti-Src-Tyr416 immunoreactivity.
p20934
sg4
(dp20935
(Vanti-Src
p20936
Vbreast cancers
p20937
tp20938
I00
ssg10879
(lp20939
(dp20940
g10882
I35
sg10883
g20937
sg10884
I14
sg10885
VC0006142
p20941
sg10887
I2
sasg10888
(lp20942
(dp20943
g10882
I80
sg10883
V3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA
p20944
sg10884
I52
sg10891
VP04035
p20945
sg10887
I4
sa(dp20946
g10882
I144
sg10883
g20936
sg10884
I8
sg10891
VP12931
p20947
sg10887
I1
sa(dp20948
g10882
I18
sg10883
VStARD3
p20949
sg10884
I6
sg10891
g190
sg10887
I1
sasa(dp20950
g10873
VThese results provide evidence that StARD3 overexpression results in increased cholesterol biosynthesis and Src kinase activity in breast cancer cells and suggest that elevated StARD3 expression may contribute to breast cancer aggressiveness by increasing membrane cholesterol and enhancing oncogenic signaling.
p20951
sg4
(dp20952
(VSrc kinase
p20953
Vbreast cancer
p20954
tp20955
I00
ssg10879
(lp20956
(dp20957
g10882
I227
sg10883
Vaggressiveness
p20958
sg10884
I14
sg10885
VC0001807
p20959
sg10887
I1
sa(dp20960
g10882
I131
sg10883
Vbreast cancer
p20961
sg10884
I13
sg10885
VC0678222
p20962
sg10887
I2
sa(dp20963
g10882
I131
sg10883
g20954
sg10884
I13
sg10885
VC0678222
p20964
sg10887
I2
sasg10888
(lp20965
(dp20966
g10882
I36
sg10883
VStARD3
p20967
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp20968
g10882
I108
sg10883
g20953
sg10884
I10
sg10891
VP12931
p20969
sg10887
I2
sa(dp20970
g10882
I36
sg10883
VStARD3
p20971
sg10884
I6
sg10891
g190
sg10887
I1
sasa(dp20972
g10873
VIn addition it will discuss the clinical and biological implications of the amplification of ten other genes at this locus (MED1, STARD3, GRB7, THRA, RARA, IGFPB4, CCR7, KRT20, KRT19 and GAST) in breast cancer.
p20973
sg4
(dp20974
(VKRT20
p20975
Vbreast cancer
p20976
tp20977
I00
ssg10879
(lp20978
(dp20979
g10882
I196
sg10883
g20976
sg10884
I13
sg10885
VC0678222
p20980
sg10887
I2
sa(dp20981
g10882
I76
sg10883
Vamplification
p20982
sg10884
I13
sg10885
VC1705759
p20983
sg10887
I1
sasg10888
(lp20984
(dp20985
g10882
I124
sg10883
VMED1
p20986
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp20987
g10882
I138
sg10883
VGRB7
p20988
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp20989
g10882
I144
sg10883
VTHRA
p20990
sg10884
I4
sg10891
VP10827
p20991
sg10887
I1
sa(dp20992
g10882
I187
sg10883
VGAST
p20993
sg10884
I4
sg10891
VP01350
p20994
sg10887
I1
sa(dp20995
g10882
I130
sg10883
VSTARD3
p20996
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp20997
g10882
I164
sg10883
VCCR7
p20998
sg10884
I4
sg10891
VP32248
p20999
sg10887
I1
sa(dp21000
g10882
I150
sg10883
VRARA
p21001
sg10884
I4
sg10891
VP10276
p21002
sg10887
I1
sa(dp21003
g10882
I170
sg10883
g20975
sg10884
I5
sg10891
VP35900
p21004
sg10887
I1
sasa(dp21005
g10873
VUsing a quantitative polymerase chain reaction method and DNA extracted from frozen tumor specimens, 11 genes (MED1, STARD3, HER2, GRB7, THRA, RARA, TOP2A, IGFBP4, CCR7, KRT20, KRT19 and GAS), which are localized within Chr17q12-q21 and have a putative role in breast cancer development, were quantified.
p21006
sg4
(dp21007
(VRARA
p21008
Vbreast cancer
p21009
tp21010
I00
ssg10879
(lp21011
(dp21012
g10882
I261
sg10883
g21009
sg10884
I13
sg10885
VC0678222
p21013
sg10887
I2
sa(dp21014
g10882
I84
sg10883
Vtumor
p21015
sg10884
I5
sg10885
VC0027651
p21016
sg10887
I1
sasg10888
(lp21017
(dp21018
g10882
I156
sg10883
VIGFBP4
p21019
sg10884
I6
sg10891
VP22692
p21020
sg10887
I1
sa(dp21021
g10882
I131
sg10883
VGRB7
p21022
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp21023
g10882
I111
sg10883
VMED1
p21024
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp21025
g10882
I117
sg10883
VSTARD3
p21026
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp21027
g10882
I170
sg10883
VKRT20
p21028
sg10884
I5
sg10891
VP35900
p21029
sg10887
I1
sa(dp21030
g10882
I149
sg10883
VTOP2A
p21031
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp21032
g10882
I164
sg10883
VCCR7
p21033
sg10884
I4
sg10891
VP32248
p21034
sg10887
I1
sa(dp21035
g10882
I125
sg10883
VHER2
p21036
sg10884
I4
sg10891
VP04626
p21037
sg10887
I1
sa(dp21038
g10882
I137
sg10883
VTHRA
p21039
sg10884
I4
sg10891
VP10827
p21040
sg10887
I1
sa(dp21041
g10882
I187
sg10883
VGAS
p21042
sg10884
I3
sg10891
VP01350
p21043
sg10887
I1
sa(dp21044
g10882
I143
sg10883
g21008
sg10884
I4
sg10891
VP10276
p21045
sg10887
I1
sasa(dp21046
g10873
VSTARD3 and RARA also hold clinical relevance, the former having been shown to function in steroidogenesis and therefore implicated in hormone-receptor-positive breast cancer.
p21047
sg4
(dp21048
(VRARA
p21049
Vbreast cancer
p21050
tp21051
I00
ssg10879
(lp21052
(dp21053
g10882
I160
sg10883
g21050
sg10884
I13
sg10885
VC0678222
p21054
sg10887
I2
sasg10888
(lp21055
(dp21056
g10882
I0
sg10883
VSTARD3
p21057
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp21058
g10882
I11
sg10883
g21049
sg10884
I4
sg10891
VP10276
p21059
sg10887
I1
sasa(dp21060
g10873
VWe used a genetic association study design to determine if common genetic variation (frequency&gt;or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk.
p21061
sg4
(dp21062
(VERBB2
p21063
Vbreast cancer
p21064
tp21065
I00
ssg10879
(lp21066
(dp21067
g10882
I280
sg10883
g21064
sg10884
I13
sg10885
VC0678222
p21068
sg10887
I2
sasg10888
(lp21069
(dp21070
g10882
I169
sg10883
VCRK7
p21071
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp21072
g10882
I175
sg10883
VNEUROD2
p21073
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp21074
g10882
I207
sg10883
VPNMT
p21075
sg10884
I4
sg10891
VP11086
p21076
sg10887
I1
sa(dp21077
g10882
I226
sg10883
VC17ORF37
p21078
sg10884
I8
sg10891
g190
sg10887
I1
sa(dp21079
g10882
I184
sg10883
VPPP1R1B
p21080
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp21081
g10882
I236
sg10883
VGRB7
p21082
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp21083
g10882
I161
sg10883
VPPARBP
p21084
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp21085
g10882
I213
sg10883
VCAB2
p21086
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp21087
g10882
I245
sg10883
VZNFN1A3 genes
p21088
sg10884
I13
sg10891
g190
sg10887
I2
sa(dp21089
g10882
I193
sg10883
VSTARD3
p21090
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp21091
g10882
I136
sg10883
VERBB2
p21092
sg10884
I5
sg10891
VP04626
p21093
sg10887
I1
sa(dp21094
g10882
I136
sg10883
g21063
sg10884
I5
sg10891
VP04626
p21095
sg10887
I1
sa(dp21096
g10882
I201
sg10883
VTCAP
p21097
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp21098
g10873
VAs a well-defined antagonist in FGFR2-induced RAS/ERK activation, ectopic expression of sprouty (SPRY) family was reported in several kinds of cancers except gastric cancer.
p21099
sg4
(dp21100
(VRAS
p21101
Vgastric cancer
p21102
tp21103
I00
ssg10879
(lp21104
(dp21105
g10882
I143
sg10883
Vcancers
p21106
sg10884
I7
sg10885
VC0006826
p21107
sg10887
I1
sa(dp21108
g10882
I158
sg10883
g21102
sg10884
I14
sg10885
VC0024623
p21109
sg10887
I2
sasg10888
(lp21110
(dp21111
g10882
I50
sg10883
VERK
p21112
sg10884
I3
sg10891
VP29323
p21113
sg10887
I1
sa(dp21114
g10882
I46
sg10883
g21101
sg10884
I3
sg10891
VP01116
p21115
sg10887
I1
sasa(dp21116
g10873
VWe show that these retained super-enhancers are essential for rhabdoid tumor survival, including some that are shared by all subtypes, such as SPRY1, and other lineage-specific super-enhancers, such as SOX2 in brain-derived rhabdoid tumors.
p21117
sg4
(dp21118
(VSOX2
p21119
Vrhabdoid tumor
p21120
tp21121
I00
ssg10879
(lp21122
(dp21123
g10882
I224
sg10883
Vrhabdoid tumors
p21124
sg10884
I15
sg10885
VC0206743
p21125
sg10887
I2
sa(dp21126
g10882
I62
sg10883
g21120
sg10884
I14
sg10885
VC0206743
p21127
sg10887
I2
sasg10888
(lp21128
(dp21129
g10882
I202
sg10883
g21119
sg10884
I4
sg10891
VP48431
p21130
sg10887
I1
sa(dp21131
g10882
I143
sg10883
VSPRY1
p21132
sg10884
I5
sg10891
g190
sg10887
I1
sasa(dp21133
g10873
VIn this issue of Blood, Dietrich et al make the first observation of the presence of deleterious CDKN1B mutation in 16% of patients with hairy cell leukemia (HCL).
p21134
sg4
(dp21135
(VCDKN1B mutation
p21136
VHCL
p21137
tp21138
I00
ssg10879
(lp21139
(dp21140
g10882
I137
sg10883
Vhairy cell leukemia
p21141
sg10884
I19
sg10885
VC0023443
p21142
sg10887
I3
sa(dp21143
g10882
I158
sg10883
g21137
sg10884
I3
sg10885
VC0023443
p21144
sg10887
I1
sasg10888
(lp21145
(dp21146
g10882
I97
sg10883
g21136
sg10884
I15
sg10891
VP46527
p21147
sg10887
I2
sasa(dp21148
g10873
VAdult CypD(-/-) developed hyperglycemia, insulin resistance and glucose intolerance albeit resistant to DIO.
p21149
sg4
(dp21150
(Vinsulin
p21151
Vinsulin resistance
p21152
tp21153
I00
ssg10879
(lp21154
(dp21155
g10882
I64
sg10883
Vglucose intolerance
p21156
sg10884
I19
sg10885
VC0271650
p21157
sg10887
I2
sa(dp21158
g10882
I26
sg10883
Vhyperglycemia
p21159
sg10884
I13
sg10885
VC0020456
p21160
sg10887
I1
sa(dp21161
g10882
I41
sg10883
g21152
sg10884
I18
sg10885
VC0021655
p21162
sg10887
I2
sasg10888
(lp21163
(dp21164
g10882
I6
sg10883
VCypD
p21165
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp21166
g10882
I41
sg10883
g21151
sg10884
I7
sg10891
VP01308
p21167
sg10887
I1
sasa(dp21168
g10873
Vvon Willebrand factor (VWF) is an independent risk factor for adverse events in patients with non-valvular atrial fibrillation (NVAF).
p21169
sg4
(dp21170
(Vvon Willebrand factor
p21171
Vatrial fibrillation
p21172
tp21173
I00
ssg10879
(lp21174
(dp21175
g10882
I107
sg10883
g21172
sg10884
I19
sg10885
VC0004238
p21176
sg10887
I2
sasg10888
(lp21177
(dp21178
g10882
I23
sg10883
VVWF
p21179
sg10884
I3
sg10891
VP04275
p21180
sg10887
I1
sa(dp21181
g10882
I0
sg10883
g21171
sg10884
I21
sg10891
VP04275
p21182
sg10887
I3
sasa(dp21183
g10873
VPatients with atrial fibrillation (AF) exhibit higher plasma vWF and lower ADAMTS13 levels.
p21184
sg4
(dp21185
(VvWF
p21186
Vatrial fibrillation
p21187
tp21188
I00
ssg10879
(lp21189
(dp21190
g10882
I35
sg10883
VAF
p21191
sg10884
I2
sg10885
VC0004238
p21192
sg10887
I1
sa(dp21193
g10882
I14
sg10883
g21187
sg10884
I19
sg10885
VC0004238
p21194
sg10887
I2
sasg10888
(lp21195
(dp21196
g10882
I61
sg10883
g21186
sg10884
I3
sg10891
VP04275
p21197
sg10887
I1
sasa(dp21198
g10873
VIn a multicenter case-control association study, we studied the SNPs rs11136000 (clusterin, CLU), rs541458 (phosphatidylinositol binding clatrin assembly protein, PICALM), and rs1554948 (transcription factor A, and tyrosine kinase, non-receptor, 1, TNK1) according to the three age groups 50-65 years (group 1), 66-80 years (group 2), and 80+ years (group 3) in 569 older subjects without cognitive impairment (NoCI) and 520 Alzheimer's disease (AD) patients.
p21199
sg4
(dp21200
(Vphosphatidylinositol binding clatrin
p21201
Vcognitive impairment
p21202
tp21203
I00
ssg10879
(lp21204
(dp21205
g10882
I446
sg10883
VAD
p21206
sg10884
I2
sg10885
VC1521724
p21207
sg10887
I1
sa(dp21208
g10882
I389
sg10883
g21202
sg10884
I20
sg10885
VC0338656
p21209
sg10887
I2
sa(dp21210
g10882
I425
sg10883
VAlzheimer's disease
p21211
sg10884
I19
sg10885
VC1521724
p21212
sg10887
I2
sasg10888
(lp21213
(dp21214
g10882
I215
sg10883
Vtyrosine kinase
p21215
sg10884
I15
sg10891
VP29401
p21216
sg10887
I2
sa(dp21217
g10882
I108
sg10883
g21201
sg10884
I36
sg10891
VP63244
p21218
sg10887
I3
sa(dp21219
g10882
I232
sg10883
Vnon-receptor, 1
p21220
sg10884
I15
sg10891
g190
sg10887
I2
sa(dp21221
g10882
I249
sg10883
VTNK1
p21222
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp21223
g10873
VGenome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB1, HLA-DRB4, INPP5D, MEF2C, MS4A4A, MS4A4E, MS4A6E, NME8, PICALM, PLD3, PTK2B, RIN3, SLC24A4, SORL1, and ZCWPW1 genes.
p21224
sg4
(dp21225
(VCR1
p21226
VAD
p21227
tp21228
I00
ssg10879
(lp21229
(dp21230
g10882
I95
sg10883
VAlzheimer's diseases
p21231
sg10884
I20
sg10885
VC0002395
p21232
sg10887
I2
sa(dp21233
g10882
I117
sg10883
g21227
sg10884
I2
sg10885
VC0002395
p21234
sg10887
I1
sasg10888
(lp21235
(dp21236
g10882
I292
sg10883
VPICALM
p21237
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp21238
g10882
I176
sg10883
VCD2AP
p21239
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp21240
g10882
I270
sg10883
VMS4A4E
p21241
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp21242
g10882
I255
sg10883
VMEF2C
p21243
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp21244
g10882
I227
sg10883
VHLA
p21245
sg10884
I3
sg10891
VP30486
p21246
sg10887
I1
sa(dp21247
g10882
I206
sg10883
VDSG2
p21248
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp21249
g10882
I189
sg10883
VCELF1
p21250
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp21251
g10882
I157
sg10883
VAPOE
p21252
sg10884
I4
sg10891
VP02649
p21253
sg10887
I1
sa(dp21254
g10882
I150
sg10883
VABCA7
p21255
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp21256
g10882
I313
sg10883
VRIN3
p21257
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp21258
g10882
I328
sg10883
VSORL1
p21259
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp21260
g10882
I319
sg10883
VSLC24A4
p21261
sg10884
I7
sg10891
g190
sg10887
I1
sa(dp21262
g10882
I247
sg10883
VINPP5D
p21263
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp21264
g10882
I262
sg10883
VMS4A4A
p21265
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp21266
g10882
I183
sg10883
VCD33
p21267
sg10884
I4
sg10891
VP20138
p21268
sg10887
I1
sa(dp21269
g10882
I300
sg10883
VPLD3
p21270
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp21271
g10882
I219
sg10883
VFERMT2
p21272
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp21273
g10882
I169
sg10883
VCASS4
p21274
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp21275
g10882
I196
sg10883
VCLU
p21276
sg10884
I3
sg10891
VP10909
p21277
sg10887
I1
sa(dp21278
g10882
I306
sg10883
VPTK2B
p21279
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp21280
g10882
I212
sg10883
VEPHA1
p21281
sg10884
I5
sg10891
VP21709
p21282
sg10887
I1
sa(dp21283
g10882
I278
sg10883
VMS4A6E
p21284
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp21285
g10882
I227
sg10883
VHLA
p21286
sg10884
I3
sg10891
VP30486
p21287
sg10887
I1
sa(dp21288
g10882
I201
sg10883
g21226
sg10884
I3
sg10891
VP17927
p21289
sg10887
I1
sa(dp21290
g10882
I339
sg10883
VZCWPW1 genes
p21291
sg10884
I12
sg10891
g190
sg10887
I2
sa(dp21292
g10882
I286
sg10883
VNME8
p21293
sg10884
I4
sg10891
g190
sg10887
I1
sa(dp21294
g10882
I231
sg10883
VDRB1
p21295
sg10884
I4
sg10891
g190
sg10887
I1
sasa(dp21296
g10873
VIn vivo, depletion of GDF-15 in Ras-driven tumor xenografts and in an orthotopic model of pancreatic cancer delayed tumor development.
p21297
sg4
(dp21298
(VRas
p21299
Vpancreatic cancer
p21300
tp21301
I00
ssg10879
(lp21302
(dp21303
g10882
I43
sg10883
Vtumor
p21304
sg10884
I5
sg10885
VC0027651
p21305
sg10887
I1
sa(dp21306
g10882
I90
sg10883
g21300
sg10884
I17
sg10885
VC0235974
p21307
sg10887
I2
sa(dp21308
g10882
I43
sg10883
Vtumor
p21309
sg10884
I5
sg10885
VC0027651
p21310
sg10887
I1
sasg10888
(lp21311
(dp21312
g10882
I22
sg10883
VGDF-15
p21313
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp21314
g10882
I32
sg10883
g21299
sg10884
I3
sg10891
VP01116
p21315
sg10887
I1
sasa(dp21316
g10873
VThe aim of the present case-control study was to compare the diagnostic value of ULBP2, MIC-1 and carbohydrate antigen 19-9 (CA19-9) in 359 serum samples, consisting of 152 cases of PC, 20 cases of pre-pancreatic cancer, 91 cases of chronic pancreatitis (CP) and 96 normal controls (NC).
p21317
sg4
(dp21318
(Vcarbohydrate antigen 19-9
p21319
Vchronic pancreatitis
p21320
tp21321
I00
ssg10879
(lp21322
(dp21323
g10882
I202
sg10883
Vpancreatic cancer
p21324
sg10884
I17
sg10885
VC0235974
p21325
sg10887
I2
sa(dp21326
g10882
I255
sg10883
VCP
p21327
sg10884
I2
sg10885
VC0149521
p21328
sg10887
I1
sa(dp21329
g10882
I233
sg10883
g21320
sg10884
I20
sg10885
VC0149521
p21330
sg10887
I2
sasg10888
(lp21331
(dp21332
g10882
I125
sg10883
VCA19-9
p21333
sg10884
I6
sg10891
VP14209
p21334
sg10887
I1
sa(dp21335
g10882
I88
sg10883
VMIC-1
p21336
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp21337
g10882
I81
sg10883
VULBP2
p21338
sg10884
I5
sg10891
g190
sg10887
I1
sa(dp21339
g10882
I98
sg10883
g21319
sg10884
I25
sg10891
VP14209
p21340
sg10887
I3
sasa(dp21341
g10873
VCD30 ligand/TNFSF8, chordin-like 2, FGF-10/KGF-2, growth/differentiation factor 15, I-TAC/CXCL11, OSM, and SCF might represent as predictive biomarkers for gemcitabine and erlotinib response of patients with pancreatic cancer.
p21342
sg4
(dp21343
(VTNFSF8
p21344
Vpancreatic cancer
p21345
tp21346
I00
ssg10879
(lp21347
(dp21348
g10882
I208
sg10883
g21345
sg10884
I17
sg10885
VC0235974
p21349
sg10887
I2
sasg10888
(lp21350
(dp21351
g10882
I43
sg10883
VKGF-2
p21352
sg10884
I5
sg10891
VP21781
p21353
sg10887
I1
sa(dp21354
g10882
I107
sg10883
VSCF
p21355
sg10884
I3
sg10891
VP21583
p21356
sg10887
I1
sa(dp21357
g10882
I98
sg10883
VOSM
p21358
sg10884
I3
sg10891
VP13725
p21359
sg10887
I1
sa(dp21360
g10882
I20
sg10883
Vchordin-like 2
p21361
sg10884
I14
sg10891
g190
sg10887
I2
sa(dp21362
g10882
I50
sg10883
Vgrowth/differentiation factor
p21363
sg10884
I29
sg10891
g190
sg10887
I2
sa(dp21364
g10882
I0
sg10883
VCD30 ligand
p21365
sg10884
I11
sg10891
VP32971
p21366
sg10887
I2
sa(dp21367
g10882
I90
sg10883
VCXCL11
p21368
sg10884
I6
sg10891
g190
sg10887
I1
sa(dp21369
g10882
I12
sg10883
g21344
sg10884
I6
sg10891
VP32971
p21370
sg10887
I1
sasa(dp21371
g10873
VImmunohistochemistry analysis showed a significant increase of RHBDD2 protein expression in association with breast cancer samples negative for progesterone receptor (p = 0.015).
p21372
sg4
(dp21373
(Vprogesterone receptor
p21374
Vbreast cancer
p21375
tp21376
I00
ssg10879
(lp21377
(dp21378
g10882
I109
sg10883
g21375
sg10884
I13
sg10885
VC0678222
p21379
sg10887
I2
sasg10888
(lp21380
(dp21381
g10882
I63
sg10883
VRHBDD2 protein
p21382
sg10884
I14
sg10891
g190
sg10887
I2
sa(dp21383
g10882
I144
sg10883
g21374
sg10884
I21
sg10891
VP06401
p21384
sg10887
I2
sasa(dp21385
S'line'
p21386
VThese effects could also be exerted via the upregulation of eight specific target genes, the subsequent over-activation of the PKC and PI3 K-Akt pathways, and the eventual abnormal cardiac development and VSD.
p21387
sg4
(dp21388
(VPI3 K
p21389
VPKC
p21390
tp21391
I00
ssS'diseases'
p21392
(lp21393
(dp21394
S'index'
p21395
I205
sS'name'
p21396
VVSD
p21397
sS'lengthInChars'
p21398
I3
sS'cui'
p21399
VC0018818
p21400
sS'lengthInWords'
p21401
I1
sa(dp21402
g21395
I127
sg21396
g21390
sg21398
I3
sg21399
VC1868682
p21403
sg21401
I1
sasS'genes'
p21404
(lp21405
(dp21406
g21395
I141
sg21396
VAkt
p21407
sg21398
I3
sS'uniprot'
p21408
g190
sg21401
I1
sa(dp21409
g21395
I127
sg21396
VPKC
p21410
sg21398
I3
sg21408
VP17252
p21411
sg21401
I1
sa(dp21412
g21395
I135
sg21396
g21389
sg21398
I5
sg21408
VP19957
p21413
sg21401
I2
sasa(dp21414
g21386
VReduced translation of CEBPA mRNA has been associated with increased proliferation of bronchial smooth muscle (BSM) cells of asthma patients.
p21415
sg4
(dp21416
(VCEBPA mRNA
p21417
Vasthma
p21418
tp21419
I01
ssg21392
(lp21420
(dp21421
g21395
I125
sg21396
g21418
sg21398
I6
sg21399
VC0004096
p21422
sg21401
I1
sa(dp21423
g21395
I69
sg21396
Vproliferation
p21424
sg21398
I13
sg21399
VC0334094
p21425
sg21401
I1
sasg21404
(lp21426
(dp21427
g21395
I23
sg21396
g21417
sg21398
I10
sg21408
VP49715
p21428
sg21401
I2
sasa(dp21429
g21386
VHDM extract reduced the C/EBPAlfa expression in BSM cells of asthma patients, which coincided with significantly increased levels of calreticulin (CRT) protein, an inhibitor of CEBPA mRNA translation.
p21430
sg4
(dp21431
(VCRT
p21432
Vasthma
p21433
tp21434
I00
ssg21392
(lp21435
(dp21436
g21395
I61
sg21396
g21433
sg21398
I6
sg21399
VC0004096
p21437
sg21401
I1
sasg21404
(lp21438
(dp21439
g21395
I133
sg21396
Vcalreticulin
p21440
sg21398
I12
sg21408
VP27797
p21441
sg21401
I1
sa(dp21442
g21395
I177
sg21396
VCEBPA mRNA
p21443
sg21398
I10
sg21408
VP49715
p21444
sg21401
I2
sa(dp21445
g21395
I147
sg21396
g21432
sg21398
I3
sg21408
VP27797
p21446
sg21401
I1
sasa(dp21447
g21386
VIn conclusion, HDM extract reduced CEBPA mRNA translation, specifically in asthmatic BSM cells, and 1) upregulated CRT, 2) activated PAR2, and increased 3) IL-6 expression and 4) the proliferation of asthmatic BSM cells.
p21448
sg4
(dp21449
(VPAR2
p21450
Vasthmatic
p21451
tp21452
I00
ssg21392
(lp21453
(dp21454
g21395
I183
sg21396
Vproliferation
p21455
sg21398
I13
sg21399
VC0334094
p21456
sg21401
I1
sa(dp21457
g21395
I75
sg21396
Vasthmatic
p21458
sg21398
I9
sg21399
VC0004096
p21459
sg21401
I1
sa(dp21460
g21395
I75
sg21396
g21451
sg21398
I9
sg21399
VC0004096
p21461
sg21401
I1
sasg21404
(lp21462
(dp21463
g21395
I35
sg21396
VCEBPA mRNA
p21464
sg21398
I10
sg21408
VP49715
p21465
sg21401
I2
sa(dp21466
g21395
I156
sg21396
VIL-6
p21467
sg21398
I4
sg21408
VP05231
p21468
sg21401
I1
sa(dp21469
g21395
I133
sg21396
g21450
sg21398
I4
sg21408
VP55085
p21470
sg21401
I1
sasa(dp21471
g21386
VCCAAT/enhancer-binding proteins (C/EBPs) control cell proliferation; lack of C/EBPalpha correlates with increased proliferation of bronchial smooth muscle cells (BSMCs) of asthmatic patients.
p21472
sg4
(dp21473
(VCCAAT/enhancer-binding proteins
p21474
Vasthmatic
p21475
tp21476
I01
ssg21392
(lp21477
(dp21478
g21395
I54
sg21396
Vproliferation
p21479
sg21398
I13
sg21399
VC0334094
p21480
sg21401
I1
sa(dp21481
g21395
I54
sg21396
Vproliferation
p21482
sg21398
I13
sg21399
VC0334094
p21483
sg21401
I1
sa(dp21484
g21395
I172
sg21396
g21475
sg21398
I9
sg21399
VC0004096
p21485
sg21401
I1
sasg21404
(lp21486
(dp21487
g21395
I33
sg21396
VC/EBPs
p21488
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp21489
g21395
I0
sg21396
g21474
sg21398
I31
sg21408
VP63244
p21490
sg21401
I2
sasa(dp21491
g21386
VFurther, FDA-approved arsenic trioxide (ATO) and the ND2-SmoA1 mouse model of Medulloblastoma (MB) were used to extend our analyses of combined MRI and Reverse Phase Protein Microarray (RPMA) data to assess tumor responses to ATO and to uncover the complexity of therapeutic molecular biology.
p21492
sg4
(dp21493
(VND2-SmoA1
p21494
VMedulloblastoma
p21495
tp21496
I00
ssg21392
(lp21497
(dp21498
g21395
I95
sg21396
VMB
p21499
sg21398
I2
sg21399
VC0025149
p21500
sg21401
I1
sa(dp21501
g21395
I78
sg21396
g21495
sg21398
I15
sg21399
VC0025149
p21502
sg21401
I1
sa(dp21503
g21395
I207
sg21396
Vtumor
p21504
sg21398
I5
sg21399
VC0027651
p21505
sg21401
I1
sasg21404
(lp21506
(dp21507
g21395
I53
sg21396
g21494
sg21398
I9
sg21408
VP03891
p21508
sg21401
I1
sasa(dp21509
g21386
VImportantly, while ASC deficiency did not affect normal cerebellar development, ASC knockout mice on the Smoothened (ND2:SmoA1) transgenic model of medulloblastoma exhibited a profound reduction in medulloblastoma incidence and a delayed tumor onset.
p21510
sg4
(dp21511
(VASC
p21512
Vmedulloblastoma
p21513
tp21514
I00
ssg21392
(lp21515
(dp21516
g21395
I148
sg21396
Vmedulloblastoma
p21517
sg21398
I15
sg21399
VC0025149
p21518
sg21401
I1
sa(dp21519
g21395
I148
sg21396
g21513
sg21398
I15
sg21399
VC0025149
p21520
sg21401
I1
sa(dp21521
g21395
I238
sg21396
Vtumor
p21522
sg21398
I5
sg21399
VC0027651
p21523
sg21401
I1
sasg21404
(lp21524
(dp21525
g21395
I117
sg21396
VND2
p21526
sg21398
I3
sg21408
VP03891
p21527
sg21401
I1
sa(dp21528
g21395
I19
sg21396
g21512
sg21398
I3
sg21408
VP08842
p21529
sg21401
I1
sasa(dp21530
g21386
VWe report the use of IRDye 800CW chlorotoxin (CLTX) as a targeted imaging agent for brain tumors in a spontaneous mouse model of medulloblastoma, ND2:SmoA1.
p21531
sg4
(dp21532
(VND2
p21533
Vbrain tumors
p21534
tp21535
I00
ssg21392
(lp21536
(dp21537
g21395
I129
sg21396
Vmedulloblastoma
p21538
sg21398
I15
sg21399
VC0025149
p21539
sg21401
I1
sa(dp21540
g21395
I84
sg21396
g21534
sg21398
I12
sg21399
VC0006118
p21541
sg21401
I2
sasg21404
(lp21542
(dp21543
g21395
I146
sg21396
g21533
sg21398
I3
sg21408
VP03891
p21544
sg21401
I1
sasa(dp21545
g21386
VImportantly, genetic deletion of Bax in medulloblastoma-prone ND2:SmoA1 transgenic mice greatly accelerated tumorigenesis.
p21546
sg4
(dp21547
(VND2
p21548
Vmedulloblastoma
p21549
tp21550
I00
ssg21392
(lp21551
(dp21552
g21395
I108
sg21396
Vtumorigenesis
p21553
sg21398
I13
sg21399
VC0007621
p21554
sg21401
I1
sa(dp21555
g21395
I40
sg21396
g21549
sg21398
I15
sg21399
VC0025149
p21556
sg21401
I1
sasg21404
(lp21557
(dp21558
g21395
I62
sg21396
g21548
sg21398
I3
sg21408
VP03891
p21559
sg21401
I1
sasa(dp21560
g21386
VFive common variants were associated with pancreatic cancer at nominal statistical significance (P &lt; 0.05) with the strongest finding for mt5460g in the ND2 gene [OR = 3.9; 95% confidence interval (CI), 1.5-10; P = 0.004] which encodes an A331T substitution.
p21561
sg4
(dp21562
(VND2 gene
p21563
Vpancreatic cancer
p21564
tp21565
I01
ssg21392
(lp21566
(dp21567
g21395
I42
sg21396
g21564
sg21398
I17
sg21399
VC0235974
p21568
sg21401
I2
sasg21404
(lp21569
(dp21570
g21395
I156
sg21396
g21563
sg21398
I8
sg21408
VP03891
p21571
sg21401
I2
sasa(dp21572
g21386
VOur findings indicate a critical role of HspBP1 in differential CHIP/Hsp70 activities in neuronal and glial cells and the greater neuronal vulnerability to misfolded proteins in neurodegenerative diseases.
p21573
sg4
(dp21574
(VHsp70
p21575
Vneurodegenerative diseases
p21576
tp21577
I00
ssg21392
(lp21578
(dp21579
g21395
I178
sg21396
g21576
sg21398
I26
sg21399
VC0524851
p21580
sg21401
I2
sasg21404
(lp21581
(dp21582
g21395
I41
sg21396
VHspBP1
p21583
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp21584
g21395
I69
sg21396
g21575
sg21398
I5
sg21408
VP34932
p21585
sg21401
I1
sa(dp21586
g21395
I64
sg21396
VCHIP
p21587
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp21588
g21386
VIn this study the adenoviral mediated over-expression of HSP70 interacting protein (HIP) alone was shown to significantly reduce inclusion formation in both an in vitro model of Spinal Bulbar Muscular Atrophy and a primary neuronal model of polyglutamine disease.
p21589
sg4
(dp21590
(VHIP
p21591
VMuscular Atrophy
p21592
tp21593
I00
ssg21392
(lp21594
(dp21595
g21395
I192
sg21396
g21592
sg21398
I16
sg21399
VC0026846
p21596
sg21401
I2
sasg21404
(lp21597
(dp21598
g21395
I57
sg21396
VHSP70 interacting protein
p21599
sg21398
I25
sg21408
VP50502
p21600
sg21401
I3
sa(dp21601
g21395
I84
sg21396
g21591
sg21398
I3
sg21408
VP47914
p21602
sg21401
I1
sasa(dp21603
g21386
VTo explore the relationship of telomerase, MYC and JAK2 in chronic myeloproliferative diseases, we investigated hTERT and MYC expression in bone marrow cells of essential thrombocythemia (ET) and polycythemia vera (PV).
p21604
sg4
(dp21605
(VMYC
p21606
VPV
p21607
tp21608
I00
ssg21392
(lp21609
(dp21610
g21395
I161
sg21396
Vessential thrombocythemia
p21611
sg21398
I25
sg21399
VC0040028
p21612
sg21401
I2
sa(dp21613
g21395
I188
sg21396
VET
p21614
sg21398
I2
sg21399
VC0040028
p21615
sg21401
I1
sa(dp21616
g21395
I196
sg21396
Vpolycythemia vera
p21617
sg21398
I17
sg21399
VC0032463
p21618
sg21401
I2
sa(dp21619
g21395
I215
sg21396
g21607
sg21398
I2
sg21399
VC0032463
p21620
sg21401
I1
sasg21404
(lp21621
(dp21622
g21395
I112
sg21396
VhTERT
p21623
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp21624
g21395
I51
sg21396
VJAK2
p21625
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp21626
g21395
I43
sg21396
VMYC
p21627
sg21398
I3
sg21408
VP12524
p21628
sg21401
I1
sa(dp21629
g21395
I43
sg21396
g21606
sg21398
I3
sg21408
VP12524
p21630
sg21401
I1
sasa(dp21631
g21386
VWoodhouse-Sakati syndrome (WSS) is a rare autosomal recessive disorder characterized by alopecia, hypogonadism, diabetes mellitus, intellectual disability, sensorineural deafness, extrapyramidal signs, and low insulinlike growth factor 1 levels.
p21632
sg4
(dp21633
(Vlow insulinlike growth factor 1
p21634
Vdiabetes mellitus
p21635
tp21636
I00
ssg21392
(lp21637
(dp21638
g21395
I180
sg21396
Vextrapyramidal signs
p21639
sg21398
I20
sg21399
VC0234133
p21640
sg21401
I2
sa(dp21641
g21395
I98
sg21396
Vhypogonadism
p21642
sg21398
I12
sg21399
VC0020619
p21643
sg21401
I1
sa(dp21644
g21395
I0
sg21396
VWoodhouse-Sakati syndrome
p21645
sg21398
I25
sg21399
VC0342286
p21646
sg21401
I2
sa(dp21647
g21395
I27
sg21396
VWSS
p21648
sg21398
I3
sg21399
VC0406587
p21649
sg21401
I1
sa(dp21650
g21395
I156
sg21396
Vsensorineural deafness
p21651
sg21398
I22
sg21399
VC0018784
p21652
sg21401
I2
sa(dp21653
g21395
I131
sg21396
Vintellectual disability
p21654
sg21398
I23
sg21399
VC0025362
p21655
sg21401
I2
sa(dp21656
g21395
I112
sg21396
g21635
sg21398
I17
sg21399
VC0011849
p21657
sg21401
I2
sasg21404
(lp21658
(dp21659
g21395
I206
sg21396
g21634
sg21398
I31
sg21408
VP05019
p21660
sg21401
I5
sasa(dp21661
g21386
VA population of CD80+Gr-1+ myeloid cells was found to be expanded in conventional as well as in bone marrow-transplanted mice with disseminated candidiasis, but its depletion increased the IFN-gamma-mediated antifungal resistance.
p21662
sg4
(dp21663
(VIFN-gamma
p21664
Vdisseminated candidiasis
p21665
tp21666
I00
ssg21392
(lp21667
(dp21668
g21395
I131
sg21396
g21665
sg21398
I24
sg21399
VC0153252
p21669
sg21401
I2
sasg21404
(lp21670
(dp21671
g21395
I16
sg21396
VCD80+Gr-1+
p21672
sg21398
I10
sg21408
VP00390
p21673
sg21401
I1
sa(dp21674
g21395
I189
sg21396
g21664
sg21398
I9
sg21408
VP01579
p21675
sg21401
I1
sasa(dp21676
g21386
VThe patients with esophageal candidiasis had lower CD4+ cell counts (129/microliter) and CD4:CD8 ratios (0.23) than those with oropharyngeal candidiasis (CD4 179/microliter; CD4:CD8 0.35).
p21677
sg4
(dp21678
(VCD4
p21679
Voropharyngeal candidiasis
p21680
tp21681
I00
ssg21392
(lp21682
(dp21683
g21395
I18
sg21396
Vesophageal candidiasis
p21684
sg21398
I22
sg21399
VC0239295
p21685
sg21401
I2
sa(dp21686
g21395
I127
sg21396
g21680
sg21398
I25
sg21399
VC0919659
p21687
sg21401
I2
sasg21404
(lp21688
(dp21689
g21395
I178
sg21396
VCD8 0.35
p21690
sg21398
I8
sg21408
VP01732
p21691
sg21401
I2
sa(dp21692
g21395
I51
sg21396
VCD4
p21693
sg21398
I3
sg21408
VP01730
p21694
sg21401
I1
sa(dp21695
g21395
I51
sg21396
VCD4+
p21696
sg21398
I4
sg21408
VP01730
p21697
sg21401
I1
sa(dp21698
g21395
I51
sg21396
VCD4
p21699
sg21398
I3
sg21408
VP01730
p21700
sg21401
I1
sa(dp21701
g21395
I93
sg21396
VCD8
p21702
sg21398
I3
sg21408
VP01732
p21703
sg21401
I1
sa(dp21704
g21395
I51
sg21396
g21679
sg21398
I3
sg21408
VP01730
p21705
sg21401
I1
sasa(dp21706
g21386
VThe current study provides novel evidence that TGFBeta upregulates the expression of multiple receptor tyrosine kinases (RTKs), including IGF1R, EGFR, PDGFBetaR, and FGFR1 in human hepatocellular carcinoma (HCC) cells.
p21707
sg4
(dp21708
(VIGF1R
p21709
Vhepatocellular carcinoma
p21710
tp21711
I00
ssg21392
(lp21712
(dp21713
g21395
I207
sg21396
VHCC
p21714
sg21398
I3
sg21399
VC2239176
p21715
sg21401
I1
sa(dp21716
g21395
I181
sg21396
g21710
sg21398
I24
sg21399
VC2239176
p21717
sg21401
I2
sasg21404
(lp21718
(dp21719
g21395
I47
sg21396
VTGFBeta
p21720
sg21398
I7
sg21408
VP01137
p21721
sg21401
I1
sa(dp21722
g21395
I166
sg21396
VFGFR1
p21723
sg21398
I5
sg21408
VP20930
p21724
sg21401
I1
sa(dp21725
g21395
I94
sg21396
Vreceptor tyrosine kinases
p21726
sg21398
I25
sg21408
VP29401
p21727
sg21401
I3
sa(dp21728
g21395
I121
sg21396
VRTKs
p21729
sg21398
I4
sg21408
VP35968
p21730
sg21401
I1
sa(dp21731
g21395
I138
sg21396
g21709
sg21398
I5
sg21408
VP08069
p21732
sg21401
I1
sasa(dp21733
g21386
VWhile numerical and functional defects of invariant NKT cells have been demonstrated in rheumatoid arthritis (RA), the detailed characterization of proliferative and secretory responses following CD1d-mediated presentation is lacking; the presence of non-invariant populations has never been assessed in human autoimmunity.
p21734
sg4
(dp21735
(VCD1d
p21736
Vrheumatoid arthritis
p21737
tp21738
I01
ssg21392
(lp21739
(dp21740
g21395
I310
sg21396
Vautoimmunity
p21741
sg21398
I12
sg21399
VC0004368
p21742
sg21401
I1
sa(dp21743
g21395
I110
sg21396
VRA
p21744
sg21398
I2
sg21399
VC0003873
p21745
sg21401
I1
sa(dp21746
g21395
I148
sg21396
Vproliferative
p21747
sg21398
I13
sg21399
VC0334094
p21748
sg21401
I1
sa(dp21749
g21395
I88
sg21396
g21737
sg21398
I20
sg21399
VC0003873
p21750
sg21401
I2
sasg21404
(lp21751
(dp21752
g21395
I196
sg21396
g21736
sg21398
I4
sg21408
VP15813
p21753
sg21401
I1
sasa(dp21754
g21386
VIn adults, angiopoietin-2 (Ang-2) and its soluble receptor (sTie-2) are associated with diabetes, hypertension, and obesity and could be increased in children with OSA and obesity, particularly those with evidence of cardiometabolic alterations.
p21755
sg4
(dp21756
(VAng-2
p21757
VOSA
p21758
tp21759
I00
ssg21392
(lp21760
(dp21761
g21395
I98
sg21396
Vhypertension
p21762
sg21398
I12
sg21399
VC0020538
p21763
sg21401
I1
sa(dp21764
g21395
I88
sg21396
Vdiabetes
p21765
sg21398
I8
sg21399
VC0011849
p21766
sg21401
I1
sa(dp21767
g21395
I116
sg21396
Vobesity
p21768
sg21398
I7
sg21399
VC0028754
p21769
sg21401
I1
sa(dp21770
g21395
I116
sg21396
Vobesity
p21771
sg21398
I7
sg21399
VC0028754
p21772
sg21401
I1
sa(dp21773
g21395
I164
sg21396
g21758
sg21398
I3
sg21399
VC0520679
p21774
sg21401
I1
sasg21404
(lp21775
(dp21776
g21395
I27
sg21396
g21757
sg21398
I5
sg21408
VP03950
p21777
sg21401
I1
sa(dp21778
g21395
I11
sg21396
Vangiopoietin-2
p21779
sg21398
I14
sg21408
g190
sg21401
I1
sasa(dp21780
g21386
VChildren with obesity and OSA had significantly elevated plasma Ang-2 and sTie-2 levels compared to corresponding controls with and without obesity.
p21781
sg4
(dp21782
(Vplasma Ang-2
p21783
VOSA
p21784
tp21785
I00
ssg21392
(lp21786
(dp21787
g21395
I14
sg21396
Vobesity
p21788
sg21398
I7
sg21399
VC0028754
p21789
sg21401
I1
sa(dp21790
g21395
I14
sg21396
Vobesity
p21791
sg21398
I7
sg21399
VC0028754
p21792
sg21401
I1
sa(dp21793
g21395
I26
sg21396
g21784
sg21398
I3
sg21399
VC0520679
p21794
sg21401
I1
sasg21404
(lp21795
(dp21796
g21395
I57
sg21396
g21783
sg21398
I12
sg21408
VP03950
p21797
sg21401
I2
sasa(dp21798
g21386
VAng-2 and sTie-2 plasma levels are increased in pediatric OSA and obesity, particularly when endothelial dysfunction or insulin resistance is detectable, and appear to decrease upon OSA treatment.
p21799
sg4
(dp21800
(VAng-2
p21801
Vendothelial dysfunction
p21802
tp21803
I00
ssg21392
(lp21804
(dp21805
g21395
I58
sg21396
VOSA
p21806
sg21398
I3
sg21399
VC0520679
p21807
sg21401
I1
sa(dp21808
g21395
I66
sg21396
Vobesity
p21809
sg21398
I7
sg21399
VC0028754
p21810
sg21401
I1
sa(dp21811
g21395
I58
sg21396
VOSA
p21812
sg21398
I3
sg21399
VC0520679
p21813
sg21401
I1
sa(dp21814
g21395
I120
sg21396
Vinsulin resistance
p21815
sg21398
I18
sg21399
VC0021655
p21816
sg21401
I2
sa(dp21817
g21395
I93
sg21396
g21802
sg21398
I23
sg21399
VC0856169
p21818
sg21401
I2
sasg21404
(lp21819
(dp21820
g21395
I120
sg21396
Vinsulin
p21821
sg21398
I7
sg21408
VP01308
p21822
sg21401
I1
sa(dp21823
g21395
I0
sg21396
g21801
sg21398
I5
sg21408
VP03950
p21824
sg21401
I1
sasa(dp21825
g21386
VANG-2 overexpressing mice show increased sWAT vascularization and are resistant to HFD-induced obesity.
p21826
sg4
(dp21827
(VANG-2
p21828
Vvascularization
p21829
tp21830
I00
ssg21392
(lp21831
(dp21832
g21395
I95
sg21396
Vobesity
p21833
sg21398
I7
sg21399
VC0028754
p21834
sg21401
I1
sa(dp21835
g21395
I46
sg21396
g21829
sg21398
I15
sg21399
VC0027686
p21836
sg21401
I1
sasg21404
(lp21837
(dp21838
g21395
I0
sg21396
g21828
sg21398
I5
sg21408
VP03950
p21839
sg21401
I1
sasa(dp21840
g21386
VWe have previously shown that the ethanol extract of dried Angelica gigas Nakai (AGN) root exerts anticancer activity against androgen receptor (AR)-negative human DU145 and PC-3 prostate cancer xenografts and primary carcinogenesis in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
p21841
sg4
(dp21842
(VAR
p21843
Vprostate cancer
p21844
tp21845
I00
ssg21392
(lp21846
(dp21847
g21395
I251
sg21396
Vadenocarcinoma
p21848
sg21398
I14
sg21399
VC0001418
p21849
sg21401
I1
sa(dp21850
g21395
I218
sg21396
Vcarcinogenesis
p21851
sg21398
I14
sg21399
VC0596263
p21852
sg21401
I1
sa(dp21853
g21395
I179
sg21396
g21844
sg21398
I15
sg21399
VC0600139
p21854
sg21401
I2
sasg21404
(lp21855
(dp21856
g21395
I126
sg21396
Vandrogen receptor
p21857
sg21398
I17
sg21408
VP10275
p21858
sg21401
I2
sa(dp21859
g21395
I145
sg21396
g21843
sg21398
I2
sg21408
VP10275
p21860
sg21401
I1
sasa(dp21861
g21386
VWe showed previously that nuclear localization of the androgen receptor (AR) and expression of the androgen-responsive gene FK506-binding protein 5 (FKBP5) in esophageal adenocarcinoma (EAC) tissues were associated with decreased patient survival, suggesting a role for androgens in this cancer.
p21862
sg4
(dp21863
(Vandrogen receptor
p21864
VEAC
p21865
tp21866
I00
ssg21392
(lp21867
(dp21868
g21395
I159
sg21396
Vesophageal adenocarcinoma
p21869
sg21398
I25
sg21399
VC0279628
p21870
sg21401
I2
sa(dp21871
g21395
I288
sg21396
Vcancer
p21872
sg21398
I6
sg21399
VC0006826
p21873
sg21401
I1
sa(dp21874
g21395
I186
sg21396
g21865
sg21398
I3
sg21399
VC1275122
p21875
sg21401
I1
sasg21404
(lp21876
(dp21877
g21395
I73
sg21396
VAR
p21878
sg21398
I2
sg21408
VP10275
p21879
sg21401
I1
sa(dp21880
g21395
I99
sg21396
Vandrogen-responsive gene FK506-binding protein 5
p21881
sg21398
I48
sg21408
g190
sg21401
I5
sa(dp21882
g21395
I149
sg21396
VFKBP5
p21883
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp21884
g21395
I54
sg21396
g21864
sg21398
I17
sg21408
VP10275
p21885
sg21401
I2
sasa(dp21886
g21386
VOnly 5 samples were ERG-/AR- corresponding to adenocarcinoma GS of 6.
p21887
sg4
(dp21888
(Vadenocarcinoma GS
p21889
Vadenocarcinoma
p21890
tp21891
I00
ssg21392
(lp21892
(dp21893
g21395
I46
sg21396
g21890
sg21398
I14
sg21399
VC0001418
p21894
sg21401
I1
sasg21404
(lp21895
(dp21896
g21395
I46
sg21396
g21889
sg21398
I17
sg21408
VP15104
p21897
sg21401
I2
sasa(dp21898
g21386
VIL-6 and the MSC markers CD166 and nestin were colocalized in macroscopically normal human cartilage taken from the lateral femoral compartment of knees with medial tibiofemoral osteoarthritis.
p21899
sg4
(dp21900
(VIL-6
p21901
Vosteoarthritis
p21902
tp21903
I00
ssg21392
(lp21904
(dp21905
g21395
I178
sg21396
g21902
sg21398
I14
sg21399
VC0029408
p21906
sg21401
I1
sasg21404
(lp21907
(dp21908
g21395
I35
sg21396
Vnestin
p21909
sg21398
I6
sg21408
VP48681
p21910
sg21401
I1
sa(dp21911
g21395
I25
sg21396
VCD166
p21912
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp21913
g21395
I13
sg21396
VMSC
p21914
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp21915
g21395
I0
sg21396
g21901
sg21398
I4
sg21408
VP05231
p21916
sg21401
I1
sasa(dp21917
g21386
VPlasma YKL-40 levels were significantly higher in subjects with asbestosis (n = 19) than in those with no fibrotic findings in HRCT following asbestos exposure (n = 66) or in unexposed healthy controls.
p21918
sg4
(dp21919
(VPlasma YKL-40
p21920
Vasbestosis
p21921
tp21922
I00
ssg21392
(lp21923
(dp21924
g21395
I64
sg21396
g21921
sg21398
I10
sg21399
VC0003949
p21925
sg21401
I1
sasg21404
(lp21926
(dp21927
g21395
I0
sg21396
g21920
sg21398
I13
sg21408
VP36222
p21928
sg21401
I2
sasa(dp21929
g21386
VYKL-40 is a promising marker of cardiovascular disease and liver siderosis in Beta-TM patients.
p21930
sg4
(dp21931
(VYKL-40
p21932
Vcardiovascular disease
p21933
tp21934
I00
ssg21392
(lp21935
(dp21936
g21395
I65
sg21396
Vsiderosis
p21937
sg21398
I9
sg21399
VC0037061
p21938
sg21401
I1
sa(dp21939
g21395
I32
sg21396
g21933
sg21398
I22
sg21399
VC0007222
p21940
sg21401
I2
sasg21404
(lp21941
(dp21942
g21395
I0
sg21396
g21932
sg21398
I6
sg21408
VP36222
p21943
sg21401
I1
sasa(dp21944
g21386
VThe aim of the study was to analyse the level of serum YKL-40 and plasma chitotriosidase activity of patients with beta-thalassemia to assess whether their expression correlates with liver disease and degree of liver siderosis.
p21945
sg4
(dp21946
(Vserum YKL-40
p21947
Vliver disease
p21948
tp21949
I00
ssg21392
(lp21950
(dp21951
g21395
I115
sg21396
Vbeta-thalassemia
p21952
sg21398
I16
sg21399
VC0005283
p21953
sg21401
I1
sa(dp21954
g21395
I217
sg21396
Vsiderosis
p21955
sg21398
I9
sg21399
VC0037061
p21956
sg21401
I1
sa(dp21957
g21395
I183
sg21396
g21948
sg21398
I13
sg21399
VC0023895
p21958
sg21401
I2
sasg21404
(lp21959
(dp21960
g21395
I49
sg21396
g21947
sg21398
I12
sg21408
VP36222
p21961
sg21401
I2
sa(dp21962
g21395
I66
sg21396
Vplasma chitotriosidase
p21963
sg21398
I22
sg21408
g190
sg21401
I2
sasa(dp21964
g21386
VTen prognostic and diagnostic epigenetic breast cancer biomarkers (PITX2, RASSF1A, PLAU, LHX3, PITX3, LIMK1, SLITRK1, SLIT2, HS3ST2, and TFF1) were analyzed in tissue samples obtained from two patients with invasive ductal carcinoma of the breast.
p21965
sg4
(dp21966
(VPLAU
p21967
Vinvasive ductal carcinoma of the breast
p21968
tp21969
I01
ssg21392
(lp21970
(dp21971
g21395
I41
sg21396
Vbreast cancer
p21972
sg21398
I13
sg21399
VC0678222
p21973
sg21401
I2
sa(dp21974
g21395
I207
sg21396
g21968
sg21398
I39
sg21399
VC1134719
p21975
sg21401
I6
sasg21404
(lp21976
(dp21977
g21395
I102
sg21396
VLIMK1
p21978
sg21398
I5
sg21408
VP53667
p21979
sg21401
I1
sa(dp21980
g21395
I137
sg21396
VTFF1
p21981
sg21398
I4
sg21408
VP04155
p21982
sg21401
I1
sa(dp21983
g21395
I125
sg21396
VHS3ST2
p21984
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp21985
g21395
I83
sg21396
g21967
sg21398
I4
sg21408
VP00749
p21986
sg21401
I1
sa(dp21987
g21395
I109
sg21396
VSLITRK1
p21988
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp21989
g21395
I89
sg21396
VLHX3
p21990
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp21991
g21395
I67
sg21396
VPITX2
p21992
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp21993
g21395
I118
sg21396
VSLIT2
p21994
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp21995
g21395
I95
sg21396
VPITX3
p21996
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp21997
g21386
VThe aim of this study is to determine the correlation between methylation status of multiple cancer genes, p16(INK4A), p14(ARF), Cyclin D2 and Slit2 in invasive ductal carcinoma of the breast and paired serum DNA and clinicopathological parameters.
p21998
sg4
(dp21999
(VCyclin D2
p22000
Vmultiple cancer
p22001
tp22002
I01
ssg21392
(lp22003
(dp22004
g21395
I123
sg21396
VARF
p22005
sg21398
I3
sg21399
VC0264490
p22006
sg21401
I1
sa(dp22007
g21395
I152
sg21396
Vinvasive ductal carcinoma of the breast
p22008
sg21398
I39
sg21399
VC1134719
p22009
sg21401
I6
sa(dp22010
g21395
I84
sg21396
g22001
sg21398
I15
sg21399
VC0346429
p22011
sg21401
I2
sasg21404
(lp22012
(dp22013
g21395
I119
sg21396
Vp14
p22014
sg21398
I3
sg21408
VP03971
p22015
sg21401
I1
sa(dp22016
g21395
I129
sg21396
g22000
sg21398
I9
sg21408
VP30279
p22017
sg21401
I2
sa(dp22018
g21395
I107
sg21396
Vp16
p22019
sg21398
I3
sg21408
VP42771
p22020
sg21401
I1
sa(dp22021
g21395
I123
sg21396
VARF
p22022
sg21398
I3
sg21408
VP42771
p22023
sg21401
I1
sa(dp22024
g21395
I143
sg21396
VSlit2
p22025
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp22026
g21395
I111
sg21396
VINK4A
p22027
sg21398
I5
sg21408
VP42771
p22028
sg21401
I1
sasa(dp22029
g21386
VIn trichoblastic fibroma (three cases), CK1/5/10/14, CK7, CK8/18, CK10/11, CK14, CK17 and CK19 were expressed in the basaloid nests, and CK6 and involucrin were detected in the inner layers of keratinous cysts.
p22030
sg4
(dp22031
(VCK1/5/10/14
p22032
Vcysts
p22033
tp22034
I00
ssg21392
(lp22035
(dp22036
g21395
I3
sg21396
Vtrichoblastic fibroma
p22037
sg21398
I21
sg21399
VC1704236
p22038
sg21401
I2
sa(dp22039
g21395
I204
sg21396
g22033
sg21398
I5
sg21399
VC0010709
p22040
sg21401
I1
sasg21404
(lp22041
(dp22042
g21395
I75
sg21396
VCK14
p22043
sg21398
I4
sg21408
VP02533
p22044
sg21401
I1
sa(dp22045
g21395
I145
sg21396
Vinvolucrin
p22046
sg21398
I10
sg21408
VP07476
p22047
sg21401
I1
sa(dp22048
g21395
I66
sg21396
VCK10/11
p22049
sg21398
I7
sg21408
VP13645
p22050
sg21401
I1
sa(dp22051
g21395
I53
sg21396
VCK7
p22052
sg21398
I3
sg21408
VP08729
p22053
sg21401
I1
sa(dp22054
g21395
I40
sg21396
g22032
sg21398
I11
sg21408
VP48729
p22055
sg21401
I1
sasa(dp22056
g21386
VPlasma membrane NADH oxidoreductase activity, studied using cytosolic NADH as substrate and assayed with DCIP as acceptor, was significantly increased in IDDM patients, suggesting a response to a deficient mitochondrial energetic activity.
p22057
sg4
(dp22058
(VPlasma membrane NADH oxidoreductase
p22059
VIDDM
p22060
tp22061
I00
ssg21392
(lp22062
(dp22063
g21395
I154
sg21396
g22060
sg21398
I4
sg21399
VC0011854
p22064
sg21401
I1
sasg21404
(lp22065
(dp22066
g21395
I60
sg21396
Vcytosolic NADH
p22067
sg21398
I14
sg21408
VP0C870
p22068
sg21401
I2
sa(dp22069
g21395
I0
sg21396
g22059
sg21398
I35
sg21408
VP28331
p22070
sg21401
I4
sasa(dp22071
g21386
VNon insulin-dependent diabetic (NIDDM) mortality is 1.4 to 3.7 times that of non-diabetics.
p22072
sg4
(dp22073
(Vinsulin
p22074
VNIDDM
p22075
tp22076
I00
ssg21392
(lp22077
(dp22078
g21395
I32
sg21396
g22075
sg21398
I5
sg21399
VC0011860
p22079
sg21401
I1
sasg21404
(lp22080
(dp22081
g21395
I4
sg21396
g22074
sg21398
I7
sg21408
VP01308
p22082
sg21401
I1
sasa(dp22083
g21386
VThe differences in eCO levels among various asthmatic phenotypes and the correlations between eCO and other measured parameters (spirometric indices, Asthma Control Test score, exhaled nitric oxide, total IgE, blood eosinophils and marker of oxidative damage of proteins) were analysed.
p22084
sg4
(dp22085
(VIgE
p22086
VIgE
p22087
tp22088
I01
ssg21392
(lp22089
(dp22090
g21395
I19
sg21396
VeCO
p22091
sg21398
I3
sg21399
VC2675227
p22092
sg21401
I1
sa(dp22093
g21395
I44
sg21396
Vasthmatic
p22094
sg21398
I9
sg21399
VC0004096
p22095
sg21401
I1
sa(dp22096
g21395
I19
sg21396
VeCO
p22097
sg21398
I3
sg21399
VC2675227
p22098
sg21401
I1
sa(dp22099
g21395
I150
sg21396
VAsthma
p22100
sg21398
I6
sg21399
VC0004096
p22101
sg21401
I1
sa(dp22102
g21395
I205
sg21396
g22087
sg21398
I3
sg21399
VC0270850
p22103
sg21401
I1
sasg21404
(lp22104
(dp22105
g21395
I19
sg21396
VeCO
p22106
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp22107
g21395
I19
sg21396
VeCO
p22108
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp22109
g21395
I205
sg21396
g22086
sg21398
I3
sg21408
VP01854
p22110
sg21401
I1
sasa(dp22111
g21386
VTo investigate the role of SphK2 in TNF-Alfa-induced arthritis, we developed SphK2 deficient hTNF-Alfa overexpressing mice and separately treated hTNF-Alfa mice with ABC294640, a SphK2-specific inhibitor.
p22112
sg4
(dp22113
(VTNF
p22114
Varthritis
p22115
tp22116
I00
ssg21392
(lp22117
(dp22118
g21395
I53
sg21396
g22115
sg21398
I9
sg21399
VC0003864
p22119
sg21401
I1
sasg21404
(lp22120
(dp22121
g21395
I27
sg21396
VSphK2
p22122
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp22123
g21395
I27
sg21396
VSphK2
p22124
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp22125
g21395
I27
sg21396
VSphK2
p22126
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp22127
g21395
I36
sg21396
g22114
sg21398
I3
sg21408
VP01375
p22128
sg21401
I1
sasa(dp22129
g21386
VWe show that the number of parvalbumin+ interneurons in these 3 cortical areas-BA46, BA47, and BA9-is significantly reduced in autism compared with controls.
p22130
sg4
(dp22131
(Vparvalbumin+
p22132
Vautism
p22133
tp22134
I01
ssg21392
(lp22135
(dp22136
g21395
I127
sg21396
g22133
sg21398
I6
sg21399
VC0004352
p22137
sg21401
I1
sasg21404
(lp22138
(dp22139
g21395
I27
sg21396
g22132
sg21398
I12
sg21408
VP20472
p22140
sg21401
I1
sasa(dp22141
g21386
VAt the site of disease in leprosy, we found that S100A12 was more strongly expressed in skin lesions from tuberculoid leprosy (T-lep), the self-limiting form of the disease, compared to lepromatous leprosy (L-lep), the progressive form of the disease.
p22142
sg4
(dp22143
(VS100A12
p22144
VL-lep
p22145
tp22146
I00
ssg21392
(lp22147
(dp22148
g21395
I26
sg21396
Vleprosy
p22149
sg21398
I7
sg21399
VC0023343
p22150
sg21401
I1
sa(dp22151
g21395
I127
sg21396
VT-lep
p22152
sg21398
I5
sg21399
VC0023351
p22153
sg21401
I1
sa(dp22154
g21395
I186
sg21396
Vlepromatous leprosy
p22155
sg21398
I19
sg21399
VC0023348
p22156
sg21401
I2
sa(dp22157
g21395
I106
sg21396
Vtuberculoid leprosy
p22158
sg21398
I19
sg21399
VC0023351
p22159
sg21401
I2
sa(dp22160
g21395
I207
sg21396
g22145
sg21398
I5
sg21399
VC0023348
p22161
sg21401
I1
sasg21404
(lp22162
(dp22163
g21395
I49
sg21396
g22144
sg21398
I7
sg21408
VP80511
p22164
sg21401
I1
sasa(dp22165
g21386
VThe aim of this study was to predict right ventricular dysfunction (RVD) using plasma concentration of D-dimer, pro-atrial natriuretic peptide (pro-ANP), brain natriuretic peptide (BNP), endothelin-1 (ET-1) and cardiac troponin I (TNI) in patients with pulmonary embolism (PE).
p22166
sg4
(dp22167
(Vcardiac troponin I
p22168
Vpulmonary embolism
p22169
tp22170
I00
ssg21392
(lp22171
(dp22172
g21395
I37
sg21396
Vright ventricular dysfunction
p22173
sg21398
I29
sg21399
VC0242707
p22174
sg21401
I3
sa(dp22175
g21395
I273
sg21396
VPE
p22176
sg21398
I2
sg21399
VC0034065
p22177
sg21401
I1
sa(dp22178
g21395
I68
sg21396
VRVD
p22179
sg21398
I3
sg21399
VC0242707
p22180
sg21401
I1
sa(dp22181
g21395
I253
sg21396
g22169
sg21398
I18
sg21399
VC0034065
p22182
sg21401
I2
sasg21404
(lp22183
(dp22184
g21395
I201
sg21396
VET-1
p22185
sg21398
I4
sg21408
VP05305
p22186
sg21401
I1
sa(dp22187
g21395
I187
sg21396
Vendothelin-1
p22188
sg21398
I12
sg21408
VP20800
p22189
sg21401
I1
sa(dp22190
g21395
I231
sg21396
VTNI
p22191
sg21398
I3
sg21408
VP48788
p22192
sg21401
I1
sa(dp22193
g21395
I103
sg21396
VD-dimer, pro-atrial natriuretic peptide (pro-ANP), brain natriuretic peptide
p22194
sg21398
I76
sg21408
VP16066
p22195
sg21401
I8
sa(dp22196
g21395
I181
sg21396
VBNP
p22197
sg21398
I3
sg21408
VP16860
p22198
sg21401
I1
sa(dp22199
g21395
I211
sg21396
g22168
sg21398
I18
sg21408
VP24821
p22200
sg21401
I3
sasa(dp22201
g21386
VAtrial natriuretic petide (ANP), brain natriuretic peptide (BNP) and endothelin-1 (ET-1) may reflect the severity of right ventricular dysfunction (RVD) in patients with pulmonary embolism (PE).
p22202
sg4
(dp22203
(VAtrial natriuretic petide
p22204
Vpulmonary embolism
p22205
tp22206
I00
ssg21392
(lp22207
(dp22208
g21395
I190
sg21396
VPE
p22209
sg21398
I2
sg21399
VC0034065
p22210
sg21401
I1
sa(dp22211
g21395
I148
sg21396
VRVD
p22212
sg21398
I3
sg21399
VC0242707
p22213
sg21401
I1
sa(dp22214
g21395
I117
sg21396
Vright ventricular dysfunction
p22215
sg21398
I29
sg21399
VC0242707
p22216
sg21401
I3
sa(dp22217
g21395
I170
sg21396
g22205
sg21398
I18
sg21399
VC0034065
p22218
sg21401
I2
sasg21404
(lp22219
(dp22220
g21395
I27
sg21396
VANP
p22221
sg21398
I3
sg21408
VP16066
p22222
sg21401
I1
sa(dp22223
g21395
I83
sg21396
VET-1
p22224
sg21398
I4
sg21408
VP05305
p22225
sg21401
I1
sa(dp22226
g21395
I69
sg21396
Vendothelin-1
p22227
sg21398
I12
sg21408
VP20800
p22228
sg21401
I1
sa(dp22229
g21395
I0
sg21396
g22204
sg21398
I25
sg21408
VP16066
p22230
sg21401
I3
sasa(dp22231
g21386
VAcute pulmonary embolism (PE) is a life-threatening disease, and several vasoconstrictors, including endothelin-1 (ET-1), play a key role in vasoconstriction and hypoxemia during the development of PE.
p22232
sg4
(dp22233
(VET-1
p22234
Vvasoconstriction
p22235
tp22236
I01
ssg21392
(lp22237
(dp22238
g21395
I6
sg21396
Vpulmonary embolism
p22239
sg21398
I18
sg21399
VC0034065
p22240
sg21401
I2
sa(dp22241
g21395
I26
sg21396
VPE
p22242
sg21398
I2
sg21399
VC0034065
p22243
sg21401
I1
sa(dp22244
g21395
I26
sg21396
VPE
p22245
sg21398
I2
sg21399
VC0034065
p22246
sg21401
I1
sa(dp22247
g21395
I141
sg21396
g22235
sg21398
I16
sg21399
VC1456863
p22248
sg21401
I1
sasg21404
(lp22249
(dp22250
g21395
I101
sg21396
Vendothelin-1
p22251
sg21398
I12
sg21408
VP20800
p22252
sg21401
I1
sa(dp22253
g21395
I115
sg21396
g22234
sg21398
I4
sg21408
VP05305
p22254
sg21401
I1
sasa(dp22255
g21386
VRE repeats encoded (RERE) was identified recently as a protein with high homology to the atrophin-1 protein, which appears to be causal in the hereditary neurodegenerative disorder termed dentatorubral-pallidoluysian atrophy (DRPLA) caused by an abnormal glutamine expansion.
p22256
sg4
(dp22257
(Vatrophin-1 protein
p22258
Vhereditary neurodegenerative disorder
p22259
tp22260
I00
ssg21392
(lp22261
(dp22262
g21395
I188
sg21396
Vdentatorubral-pallidoluysian atrophy
p22263
sg21398
I36
sg21399
VC0751781
p22264
sg21401
I2
sa(dp22265
g21395
I226
sg21396
VDRPLA
p22266
sg21398
I5
sg21399
VC0751781
p22267
sg21401
I1
sa(dp22268
g21395
I143
sg21396
g22259
sg21398
I37
sg21399
VC3273225
p22269
sg21401
I3
sasg21404
(lp22270
(dp22271
g21395
I89
sg21396
g22258
sg21398
I18
sg21408
VP54259
p22272
sg21401
I2
sasa(dp22273
g21386
VThe gene isolated, designated RERE, has an open reading frame of 1566 amino acids, of which the C-terminal portion has 67% homology to DRPLA, whereas the N-terminal portion is distinctive.
p22274
sg4
(dp22275
(VDRPLA
p22276
VDRPLA
p22277
tp22278
I00
ssg21392
(lp22279
(dp22280
g21395
I135
sg21396
g22277
sg21398
I5
sg21399
VC0751781
p22281
sg21401
I1
sasg21404
(lp22282
(dp22283
g21395
I135
sg21396
g22276
sg21398
I5
sg21408
VP54259
p22284
sg21401
I1
sa(dp22285
g21395
I30
sg21396
VRERE
p22286
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp22287
g21386
VImmunoprecipitation and in vitro binding assays demonstrate that the DRPLA and RERE proteins bind each other, for which one of the RE repeats has a primary role, and extended polyglutamine enhances the binding.
p22288
sg4
(dp22289
(VDRPLA
p22290
VDRPLA
p22291
tp22292
I00
ssg21392
(lp22293
(dp22294
g21395
I69
sg21396
g22291
sg21398
I5
sg21399
VC0751781
p22295
sg21401
I1
sasg21404
(lp22296
(dp22297
g21395
I79
sg21396
VRERE proteins
p22298
sg21398
I13
sg21408
g190
sg21401
I2
sa(dp22299
g21395
I69
sg21396
g22290
sg21398
I5
sg21408
VP54259
p22300
sg21401
I1
sasa(dp22301
g21386
VMoreover, when RERE is overexpressed, the distribution of endogenous DRPLA protein alters from the diffused to the speckled pattern in the nucleus so as to co-localize with RERE.
p22302
sg4
(dp22303
(Vendogenous DRPLA protein
p22304
VDRPLA
p22305
tp22306
I00
ssg21392
(lp22307
(dp22308
g21395
I69
sg21396
g22305
sg21398
I5
sg21399
VC0751781
p22309
sg21401
I1
sasg21404
(lp22310
(dp22311
g21395
I15
sg21396
VRERE
p22312
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp22313
g21395
I58
sg21396
g22304
sg21398
I24
sg21408
VP54259
p22314
sg21401
I3
sasa(dp22315
g21386
VMore RERE protein is recruited into nuclear aggregates of the DRPLA protein with extended polyglutamine than into those of pure polyglutamine.
p22316
sg4
(dp22317
(VDRPLA protein
p22318
VDRPLA
p22319
tp22320
I00
ssg21392
(lp22321
(dp22322
g21395
I62
sg21396
g22319
sg21398
I5
sg21399
VC0751781
p22323
sg21401
I1
sasg21404
(lp22324
(dp22325
g21395
I62
sg21396
g22318
sg21398
I13
sg21408
VP54259
p22326
sg21401
I2
sasa(dp22327
g21386
VThe DNB1/ARPh gene, which was found to be ubiquitously expressed in human adult and fetal tissues, is highly related to the DRPLA gene, in which expansion of a CAG triplet appears to be causal in the dentatorubral and pallidolysian atrophy disease phenotype.
p22328
sg4
(dp22329
(VDNB1
p22330
Vatrophy
p22331
tp22332
I00
ssg21392
(lp22333
(dp22334
g21395
I124
sg21396
VDRPLA
p22335
sg21398
I5
sg21399
VC0751781
p22336
sg21401
I1
sa(dp22337
g21395
I232
sg21396
g22331
sg21398
I7
sg21399
VC0333641
p22338
sg21401
I1
sasg21404
(lp22339
(dp22340
g21395
I124
sg21396
VDRPLA gene
p22341
sg21398
I10
sg21408
VP54259
p22342
sg21401
I2
sa(dp22343
g21395
I4
sg21396
g22330
sg21398
I4
sg21408
VP55145
p22344
sg21401
I1
sasa(dp22345
g21386
VTherefore, we evaluated the roles of CSNK2A1, SIRT6, and phosphorylated SIRT6 and their relationships in breast carcinoma.
p22346
sg4
(dp22347
(VCSNK2A1
p22348
Vbreast carcinoma
p22349
tp22350
I01
ssg21392
(lp22351
(dp22352
g21395
I105
sg21396
g22349
sg21398
I16
sg21399
VC0678222
p22353
sg21401
I2
sasg21404
(lp22354
(dp22355
g21395
I37
sg21396
g22348
sg21398
I7
sg21408
VP19784
p22356
sg21401
I1
sasa(dp22357
g21386
VThis study demonstrates that CSNK2A1 and SIRT6 are indicators of poor prognosis for breast carcinomas and that CSNK2A1-mediated phosphorylation of SIRT6 might be involved in the progression of breast carcinoma.
p22358
sg4
(dp22359
(VCSNK2A1
p22360
Vbreast carcinomas
p22361
tp22362
I01
ssg21392
(lp22363
(dp22364
g21395
I84
sg21396
Vbreast carcinoma
p22365
sg21398
I16
sg21399
VC0678222
p22366
sg21401
I2
sa(dp22367
g21395
I84
sg21396
g22361
sg21398
I17
sg21399
VC0678222
p22368
sg21401
I2
sasg21404
(lp22369
(dp22370
g21395
I29
sg21396
VCSNK2A1
p22371
sg21398
I7
sg21408
VP19784
p22372
sg21401
I1
sa(dp22373
g21395
I29
sg21396
g22360
sg21398
I7
sg21408
VP19784
p22374
sg21401
I1
sasa(dp22375
g21386
VRNA expression levels of CDC2L1, CDC2L2, CCNL1, CCNL2, CSNK2A1, CSNK2A2, and CSNK2B genes in breast cancer subtypes were analyzed.
p22376
sg4
(dp22377
(VCSNK2A1
p22378
Vbreast cancer
p22379
tp22380
I01
ssg21392
(lp22381
(dp22382
g21395
I93
sg21396
g22379
sg21398
I13
sg21399
VC0678222
p22383
sg21401
I2
sasg21404
(lp22384
(dp22385
g21395
I77
sg21396
VCSNK2B genes
p22386
sg21398
I12
sg21408
VP67870
p22387
sg21401
I2
sa(dp22388
g21395
I64
sg21396
VCSNK2A2
p22389
sg21398
I7
sg21408
VP19784
p22390
sg21401
I1
sa(dp22391
g21395
I41
sg21396
VCCNL1
p22392
sg21398
I5
sg21408
VP49736
p22393
sg21401
I1
sa(dp22394
g21395
I55
sg21396
g22378
sg21398
I7
sg21408
VP19784
p22395
sg21401
I1
sasa(dp22396
g21386
VRecent evidence suggests the role of Wnt signaling in human breast cancer involves elevated levels of nuclear and/or cytoplasmic beta-catenin using immunohistochemistry, overexpression or downregulation of specific Wnt proteins, overexpression of CKII and sFRP4, downregulation of WIF-1 and sFRP1, as well as amplification of DVL-1.
p22397
sg4
(dp22398
(VDVL-1
p22399
Vbreast cancer
p22400
tp22401
I01
ssg21392
(lp22402
(dp22403
g21395
I60
sg21396
g22400
sg21398
I13
sg21399
VC0678222
p22404
sg21401
I2
sa(dp22405
g21395
I309
sg21396
Vamplification
p22406
sg21398
I13
sg21399
VC1705759
p22407
sg21401
I1
sasg21404
(lp22408
(dp22409
g21395
I117
sg21396
Vcytoplasmic beta-catenin
p22410
sg21398
I24
sg21408
g190
sg21401
I2
sa(dp22411
g21395
I247
sg21396
VCKII
p22412
sg21398
I4
sg21408
VP68400
p22413
sg21401
I1
sa(dp22414
g21395
I326
sg21396
g22399
sg21398
I5
sg21408
VP54792
p22415
sg21401
I1
sa(dp22416
g21395
I291
sg21396
VsFRP1
p22417
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp22418
g21395
I256
sg21396
VsFRP4
p22419
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp22420
g21386
VBy combining the mutational data in the Catalogue of Somatic Mutations in Cancer (COSMIC) and the spatial information in the Protein Data Bank (PDB), SpacePAC is able to identify novel mutation clusters in many proteins such as FGFR3 and CHRM2.
p22421
sg4
(dp22422
(VCHRM2
p22423
VPDB
p22424
tp22425
I00
ssg21392
(lp22426
(dp22427
g21395
I53
sg21396
VSomatic Mutations
p22428
sg21398
I17
sg21399
VC0544886
p22429
sg21401
I2
sa(dp22430
g21395
I125
sg21396
VProtein Data Bank
p22431
sg21398
I17
sg21399
VC0029401
p22432
sg21401
I3
sa(dp22433
g21395
I179
sg21396
Vnovel mutation
p22434
sg21398
I14
sg21399
VC2985438
p22435
sg21401
I2
sa(dp22436
g21395
I74
sg21396
VCancer
p22437
sg21398
I6
sg21399
VC0006826
p22438
sg21401
I1
sa(dp22439
g21395
I144
sg21396
g22424
sg21398
I3
sg21399
VC0029401
p22440
sg21401
I1
sasg21404
(lp22441
(dp22442
g21395
I228
sg21396
VFGFR3
p22443
sg21398
I5
sg21408
VP22607
p22444
sg21401
I1
sa(dp22445
g21395
I238
sg21396
g22423
sg21398
I5
sg21408
VP08172
p22446
sg21401
I1
sasa(dp22447
g21386
VColorectal cancer (HCT 116, LoVo, C 170 HM 2, CaCO-2), fibroblast (46-BR.IGI, CCD-18 Co) and fibrosarcoma (HT1080) cell lines were irradiated at 4 gray (4 Gy) and matrix metalloproteinase gene and protein expression examined over a 96 h period by real time polymerase chain reaction and gelatin zymography.
p22448
sg4
(dp22449
(VIGI
p22450
VCCD
p22451
tp22452
I00
ssg21392
(lp22453
(dp22454
g21395
I0
sg21396
VColorectal cancer
p22455
sg21398
I17
sg21399
VC1527249
p22456
sg21401
I2
sa(dp22457
g21395
I93
sg21396
Vfibrosarcoma
p22458
sg21398
I12
sg21399
VC0016057
p22459
sg21401
I1
sa(dp22460
g21395
I78
sg21396
g22451
sg21398
I3
sg21399
VC0008928
p22461
sg21401
I1
sasg21404
(lp22462
(dp22463
g21395
I78
sg21396
VCCD-18 Co
p22464
sg21398
I9
sg21408
VP21817
p22465
sg21401
I2
sa(dp22466
g21395
I163
sg21396
Vmatrix metalloproteinase gene
p22467
sg21398
I29
sg21408
g190
sg21401
I3
sa(dp22468
g21395
I73
sg21396
g22450
sg21398
I3
sg21408
VP12018
p22469
sg21401
I1
sasa(dp22470
g21386
VIn addition, because HBL is a major enterotoxin, we also designed HBL gene-specific polymerase chain reaction (PCR) primers, i.e., Hm1 and Hm2, that generated the same results as those of the hemolysis and BCET-RPLA assays.
p22471
sg4
(dp22472
(VHm2
p22473
Vhemolysis
p22474
tp22475
I00
ssg21392
(lp22476
(dp22477
g21395
I192
sg21396
g22474
sg21398
I9
sg21399
VC0019054
p22478
sg21401
I1
sasg21404
(lp22479
(dp22480
g21395
I66
sg21396
VHBL gene
p22481
sg21398
I8
sg21408
VP09382
p22482
sg21401
I2
sa(dp22483
g21395
I131
sg21396
VHm1
p22484
sg21398
I3
sg21408
VP11229
p22485
sg21401
I1
sa(dp22486
g21395
I21
sg21396
VHBL
p22487
sg21398
I3
sg21408
VP09382
p22488
sg21401
I1
sa(dp22489
g21395
I139
sg21396
g22473
sg21398
I3
sg21408
VP08172
p22490
sg21401
I1
sasa(dp22491
g21386
VPositive cancer invasion in the cut end was classified as hm2 or dm2 in 8 patients and em2 in 13.
p22492
sg4
(dp22493
(Vhm2
p22494
Vdm2
p22495
tp22496
I00
ssg21392
(lp22497
(dp22498
g21395
I16
sg21396
Vinvasion
p22499
sg21398
I8
sg21399
VC2699153
p22500
sg21401
I1
sa(dp22501
g21395
I65
sg21396
g22495
sg21398
I3
sg21399
VC2931689
p22502
sg21401
I1
sa(dp22503
g21395
I9
sg21396
Vcancer
p22504
sg21398
I6
sg21399
VC0006826
p22505
sg21401
I1
sasg21404
(lp22506
(dp22507
g21395
I58
sg21396
g22494
sg21398
I3
sg21408
VP08172
p22508
sg21401
I1
sasa(dp22509
g21386
VBiopsy samples from five acquired immune deficiency syndrome (AIDS)-Kaposi's sarcomas and one non-AIDS-associated Kaposi's sarcoma were assayed by in situ RNA hybridization onto paraformaldehyde-fixed, paraffin-embedded skin sections for the presence of two fibroblast growth factor gene transcripts, FGFB and FGF5.
p22510
sg4
(dp22511
(VFGF5
p22512
VAIDS
p22513
tp22514
I01
ssg21392
(lp22515
(dp22516
g21395
I25
sg21396
Vacquired immune deficiency syndrome
p22517
sg21398
I35
sg21399
VC0001175
p22518
sg21401
I4
sa(dp22519
g21395
I62
sg21396
VAIDS
p22520
sg21398
I4
sg21399
VC0001175
p22521
sg21401
I1
sa(dp22522
g21395
I77
sg21396
Vsarcomas
p22523
sg21398
I8
sg21399
VC1261473
p22524
sg21401
I1
sa(dp22525
g21395
I68
sg21396
VKaposi's sarcoma
p22526
sg21398
I16
sg21399
VC0036220
p22527
sg21401
I2
sa(dp22528
g21395
I62
sg21396
g22513
sg21398
I4
sg21399
VC0001175
p22529
sg21401
I1
sasg21404
(lp22530
(dp22531
g21395
I258
sg21396
Vfibroblast growth factor gene transcripts
p22532
sg21398
I41
sg21408
g190
sg21401
I5
sa(dp22533
g21395
I310
sg21396
g22512
sg21398
I4
sg21408
VP12034
p22534
sg21401
I1
sasa(dp22535
g21386
VFGF5 gene expression was detected in the characteristic Kaposi's sarcoma spindle-shaped cells in the five samples from human immunodeficiency-positive (HIV+) patients.
p22536
sg4
(dp22537
(VFGF5 gene
p22538
VKaposi's sarcoma
p22539
tp22540
I01
ssg21392
(lp22541
(dp22542
g21395
I125
sg21396
Vimmunodeficiency
p22543
sg21398
I16
sg21399
VC0021051
p22544
sg21401
I1
sa(dp22545
g21395
I56
sg21396
g22539
sg21398
I16
sg21399
VC0036220
p22546
sg21401
I2
sasg21404
(lp22547
(dp22548
g21395
I0
sg21396
g22538
sg21398
I9
sg21408
VP12034
p22549
sg21401
I2
sasa(dp22550
g21386
VFurthermore, they demonstrate a contrasting expression pattern of FGF5 and FGFB genes, both involved in the growth factor pathogenic cascade leading to Kaposi's sarcoma.
p22551
sg4
(dp22552
(VFGF5
p22553
VKaposi's sarcoma
p22554
tp22555
I01
ssg21392
(lp22556
(dp22557
g21395
I152
sg21396
g22554
sg21398
I16
sg21399
VC0036220
p22558
sg21401
I2
sasg21404
(lp22559
(dp22560
g21395
I75
sg21396
VFGFB genes
p22561
sg21398
I10
sg21408
VP01893
p22562
sg21401
I2
sa(dp22563
g21395
I66
sg21396
g22553
sg21398
I4
sg21408
VP12034
p22564
sg21401
I1
sasa(dp22565
g21386
VObjective To evaluate the efficacy of Ganoderma lucidum preparation on the behaviors,biochemistry,and autoimmunity parameters of mouse models of APP/PS-1 double transgenic Alzheimer's disease(AD).Methods A total of 44 4-month-old APP/PS-1 double transgenic AD mice were randomly divided into AD model group,Aricept group,Ganoderma lucidum middle-dose(LZ-M)group,and Ganoderma lucidum high-dose(LZ-H)group,with 11 mice in each group.In addition,10 4-month-old C57BL/6 mice were used as the control group.Water maze test was conducted to observe the behavior changes,and the protein expressions in brain tissues were detected by Western blot analysis.The autoimmune indicators were detected by indirect immunofluorescence method.Results In the navigation experiment,the time of finding the platform was gradually shortened since the 2nd day in the control,LZ-H,and LZ-M groups,and the time of searching the platform in the AD model group gradually increased.On the 5th day,the time of finding platform was significantly shorter in control group (t=5.607,P=0.000) and LZ-H group(t=2.750,P=0.010)than AD model group.In the space exploration experiment,the number of crossing the target platform(t=2.452,P=0.025)and the residence time in the target quadrant(t=2.530,P=0.020)in AD model group mice was significantly smaller/shorter than those in control group;in addition,the number of crossing the target platform in the AD model group was significantly smaller than that in LZ-H group(t=2.317,P=0.030)and LZ-M group(t=2.443,P=0.030),while the residence time in target quadrant decreased significantly(t=2.770,P=0.020)compared with LZ-H group;the number of crossing through the target platform quadrant(t=2.493,P=0.022)and residence time in the target quadrant(t=2.683,P=0.015)in LZ-H group were significantly higher than in Aricept group.Western blot analysis showed that the expression of ApoA1 in the brain tissues of mice in LZ-H and LZ-M groups were significantly higher than those in AD model group(P&lt;0.01,P&lt;0.05);ABeta-40 expression in LZ-H group was significantly lower than that in AD model group(P&lt;0.05);the expressions of Syt1,ApoE,and ABCA1 in brain tissues of mice in LZ-H group were significantly higher than those in model group(P&lt;0.01,P&lt;0.05).The plasma IgG level in Aricept group(t=30.945,P=0.000),LZ-M group(t=25.639,P=0.000)and LZ-H group(t=4.689,P=0.001)were significantly higher than that in the control group.Conclusion Ganoderma lucidum preparation can improve behavior disorders of AD model mice,promote the expressions of ApoA1,ApoE and Syt1,inhibit the expression of ABeta-40 protein,and improve the autoimmune function.
p22566
sg4
(dp22567
(VSyt1
p22568
Vbehavior disorders
p22569
tp22570
I00
ssg21392
(lp22571
(dp22572
g21395
I102
sg21396
Vautoimmunity
p22573
sg21398
I12
sg21399
VC0004368
p22574
sg21401
I1
sa(dp22575
g21395
I172
sg21396
VAlzheimer's disease
p22576
sg21398
I19
sg21399
VC1521724
p22577
sg21401
I2
sa(dp22578
g21395
I2494
sg21396
g22569
sg21398
I18
sg21399
VC0004930
p22579
sg21401
I2
sa(dp22580
g21395
I653
sg21396
Vautoimmune
p22581
sg21398
I10
sg21399
VC0443146
p22582
sg21401
I1
sa(dp22583
g21395
I653
sg21396
Vautoimmune
p22584
sg21398
I10
sg21399
VC0443146
p22585
sg21401
I1
sasg21404
(lp22586
(dp22587
g21395
I2137
sg21396
VSyt1
p22588
sg21398
I4
sg21408
VP21579
p22589
sg21401
I1
sa(dp22590
g21395
I1886
sg21396
VApoA1
p22591
sg21398
I5
sg21408
VP02647
p22592
sg21401
I1
sa(dp22593
g21395
I1065
sg21396
VLZ-H group
p22594
sg21398
I10
sg21408
VP00390
p22595
sg21401
I2
sa(dp22596
g21395
I2142
sg21396
VApoE
p22597
sg21398
I4
sg21408
VP02649
p22598
sg21401
I1
sa(dp22599
g21395
I145
sg21396
VAPP/PS-1
p22600
sg21398
I8
sg21408
VP48651
p22601
sg21401
I1
sa(dp22602
g21395
I2142
sg21396
VApoE
p22603
sg21398
I4
sg21408
VP02649
p22604
sg21401
I1
sa(dp22605
g21395
I2603
sg21396
VABeta-40 protein
p22606
sg21398
I16
sg21408
g190
sg21401
I2
sa(dp22607
g21395
I1886
sg21396
VApoA1
p22608
sg21398
I5
sg21408
VP02647
p22609
sg21401
I1
sa(dp22610
g21395
I2021
sg21396
VABeta-40
p22611
sg21398
I8
sg21408
g190
sg21401
I1
sa(dp22612
g21395
I1065
sg21396
VLZ-H group
p22613
sg21398
I10
sg21408
VP00390
p22614
sg21401
I2
sa(dp22615
g21395
I145
sg21396
VAPP
p22616
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp22617
g21395
I1065
sg21396
VLZ-H group
p22618
sg21398
I10
sg21408
VP00390
p22619
sg21401
I2
sa(dp22620
g21395
I149
sg21396
VPS-1
p22621
sg21398
I4
sg21408
VP48651
p22622
sg21401
I1
sa(dp22623
g21395
I2137
sg21396
g22568
sg21398
I4
sg21408
VP21579
p22624
sg21401
I1
sasa(dp22625
g21386
VSomatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis.
p22626
sg4
(dp22627
(VSomatic v-Raf murine sarcoma viral oncogene homolog B
p22628
Vmetastatic colorectal cancer
p22629
tp22630
I00
ssg21392
(lp22631
(dp22632
g21395
I21
sg21396
Vsarcoma
p22633
sg21398
I7
sg21399
VC1261473
p22634
sg21401
I1
sa(dp22635
g21395
I133
sg21396
VmCRC
p22636
sg21398
I4
sg21399
VC0948380
p22637
sg21401
I1
sa(dp22638
g21395
I103
sg21396
g22629
sg21398
I28
sg21399
VC0948380
p22639
sg21401
I3
sasg21404
(lp22640
(dp22641
g21395
I55
sg21396
VBRAF
p22642
sg21398
I4
sg21408
VP15056
p22643
sg21401
I1
sa(dp22644
g21395
I0
sg21396
g22628
sg21398
I53
sg21408
VP04049
p22645
sg21401
I8
sasa(dp22646
g21386
VAll colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified.
p22647
sg4
(dp22648
(VBRAF
p22649
Vcolorectal cancer
p22650
tp22651
I00
ssg21392
(lp22652
(dp22653
g21395
I4
sg21396
g22650
sg21398
I17
sg21399
VC1527249
p22654
sg21401
I2
sasg21404
(lp22655
(dp22656
g21395
I42
sg21396
g22649
sg21398
I4
sg21408
VP15056
p22657
sg21401
I1
sasa(dp22658
g21386
VThe prognostic role of the V600E mutation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC) is well established, but the therapeutic regimen targeting this disease is lacking.
p22659
sg4
(dp22660
(Vv-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC)
p22661
Vsarcoma
p22662
tp22663
I00
ssg21392
(lp22664
(dp22665
g21395
I132
sg21396
VmCRC
p22666
sg21398
I4
sg21399
VC0948380
p22667
sg21401
I1
sa(dp22668
g21395
I102
sg21396
Vmetastatic colorectal cancer
p22669
sg21398
I28
sg21399
VC0948380
p22670
sg21401
I3
sa(dp22671
g21395
I58
sg21396
g22662
sg21398
I7
sg21399
VC1261473
p22672
sg21401
I1
sasg21404
(lp22673
(dp22674
g21395
I45
sg21396
g22661
sg21398
I92
sg21408
VP15056
p22675
sg21401
I13
sasa(dp22676
g21386
VThe aim of our study was to evaluate the incidence of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving first line oxaliplatin based chemotherapy with or without bevacizumab and to evaluate their prognostic and predictive significance.
p22677
sg4
(dp22678
(VKRAS
p22679
Vmetastatic colorectal cancer
p22680
tp22681
I00
ssg21392
(lp22682
(dp22683
g21395
I95
sg21396
g22680
sg21398
I28
sg21399
VC0948380
p22684
sg21401
I3
sasg21404
(lp22685
(dp22686
g21395
I66
sg21396
VBRAF
p22687
sg21398
I4
sg21408
VP15056
p22688
sg21401
I1
sa(dp22689
g21395
I60
sg21396
VNRAS
p22690
sg21398
I4
sg21408
VP01111
p22691
sg21401
I1
sa(dp22692
g21395
I75
sg21396
VPIK3CA
p22693
sg21398
I6
sg21408
VP42336
p22694
sg21401
I1
sa(dp22695
g21395
I54
sg21396
g22679
sg21398
I4
sg21408
VP01116
p22696
sg21401
I1
sasa(dp22697
g21386
VActivating BRAF (V-raf murine sarcoma viral oncogene homolog B) mutations occur in approximately 5% to 10% of patients with metastatic colorectal cancer, mostly V600E mutation, and it is associated with distinct clinical and pathological features.
p22698
sg4
(dp22699
(VV-raf murine sarcoma viral oncogene homolog B
p22700
Vmetastatic colorectal cancer
p22701
tp22702
I00
ssg21392
(lp22703
(dp22704
g21395
I30
sg21396
Vsarcoma
p22705
sg21398
I7
sg21399
VC1261473
p22706
sg21401
I1
sa(dp22707
g21395
I124
sg21396
g22701
sg21398
I28
sg21399
VC0948380
p22708
sg21401
I3
sasg21404
(lp22709
(dp22710
g21395
I11
sg21396
VBRAF
p22711
sg21398
I4
sg21408
VP15056
p22712
sg21401
I1
sa(dp22713
g21395
I17
sg21396
g22700
sg21398
I45
sg21408
VP04049
p22714
sg21401
I7
sasa(dp22715
g21386
VThis review aims to provide data about new strategies to target to BRAF gene mutation in metastatic colorectal cancer.
p22716
sg4
(dp22717
(VBRAF gene
p22718
Vmetastatic colorectal cancer
p22719
tp22720
I00
ssg21392
(lp22721
(dp22722
g21395
I89
sg21396
g22719
sg21398
I28
sg21399
VC0948380
p22723
sg21401
I3
sa(dp22724
g21395
I67
sg21396
VBRAF gene mutation
p22725
sg21398
I18
sg21399
VC1511021
p22726
sg21401
I3
sasg21404
(lp22727
(dp22728
g21395
I67
sg21396
g22718
sg21398
I9
sg21408
VP15056
p22729
sg21401
I2
sasa(dp22730
g21386
VThe variables of age, incidence of autoimmune hepatitis, model of end-stage liver disease (MELD) score, values for total bilirubin and prothrombin time-international ratio (PT-INR), and Japan Hepatic Encephalopathy Prediction Model (JHEPM) probability at registration were significantly higher in ALF patients than in ALI patients.
p22731
sg4
(dp22732
(Vprothrombin
p22733
VHepatic Encephalopathy
p22734
tp22735
I01
ssg21392
(lp22736
(dp22737
g21395
I35
sg21396
Vautoimmune hepatitis
p22738
sg21398
I20
sg21399
VC0241910
p22739
sg21401
I2
sa(dp22740
g21395
I76
sg21396
Vliver disease
p22741
sg21398
I13
sg21399
VC0023895
p22742
sg21401
I2
sa(dp22743
g21395
I192
sg21396
g22734
sg21398
I22
sg21399
VC0019151
p22744
sg21401
I2
sasg21404
(lp22745
(dp22746
g21395
I135
sg21396
g22733
sg21398
I11
sg21408
VP00734
p22747
sg21401
I1
sasa(dp22748
g21386
VOn the other hand, the multivariate Cox proportional hazard model showed that positivity for serum anti-PD-1 antibody, probable diagnosis based on the revised scoring system proposed by the International Autoimmune Hepatitis Group, and prothrombin activity of less than 60% were associated with the later normalization of serum transaminase levels.
p22749
sg4
(dp22750
(Vprothrombin
p22751
VAutoimmune Hepatitis
p22752
tp22753
I00
ssg21392
(lp22754
(dp22755
g21395
I204
sg21396
g22752
sg21398
I20
sg21399
VC0241910
p22756
sg21401
I2
sasg21404
(lp22757
(dp22758
g21395
I93
sg21396
Vserum anti-PD-1 antibody
p22759
sg21398
I24
sg21408
VP18621
p22760
sg21401
I3
sa(dp22761
g21395
I322
sg21396
Vserum transaminase
p22762
sg21398
I18
sg21408
g190
sg21401
I2
sa(dp22763
g21395
I236
sg21396
g22751
sg21398
I11
sg21408
VP00734
p22764
sg21401
I1
sasa(dp22765
g21386
VMyeloma cell maturity was classified via immunophenotyping: myeloma cells showing mature plasma cell 1 (MPC-1)-positive and CD49e-positive cells were considered mature type; MPC-1-positive and CD49e-negative cells were considered intermediate type; and MPC-1-negative cells were considered immature type.
p22766
sg4
(dp22767
(VCD49e
p22768
VMyeloma
p22769
tp22770
I00
ssg21392
(lp22771
(dp22772
g21395
I60
sg21396
Vmyeloma
p22773
sg21398
I7
sg21399
VC0026764
p22774
sg21401
I1
sa(dp22775
g21395
I0
sg21396
g22769
sg21398
I7
sg21399
VC0026764
p22776
sg21401
I1
sasg21404
(lp22777
(dp22778
g21395
I124
sg21396
VCD49e
p22779
sg21398
I5
sg21408
VP08648
p22780
sg21401
I1
sa(dp22781
g21395
I124
sg21396
g22768
sg21398
I5
sg21408
VP08648
p22782
sg21401
I1
sasa(dp22783
g21386
VThe findings of this study demonstrate the clinical importance of myeloma cell classification according to immunophenotyping using MPC-1 and CD49e antibodies to determine patient prognosis in this era of novel therapeutic agents.
p22784
sg4
(dp22785
(VCD49e antibodies
p22786
Vmyeloma
p22787
tp22788
I00
ssg21392
(lp22789
(dp22790
g21395
I66
sg21396
g22787
sg21398
I7
sg21399
VC0026764
p22791
sg21401
I1
sasg21404
(lp22792
(dp22793
g21395
I131
sg21396
VMPC-1
p22794
sg21398
I5
sg21408
VP28062
p22795
sg21401
I1
sa(dp22796
g21395
I141
sg21396
g22786
sg21398
I16
sg21408
VP08648
p22797
sg21401
I2
sasa(dp22798
g21386
VOn the basis of biopsies of the masses in the pharynx and finger, he was diagnosed with extramedullary plasmablastic plasmacytoma, with somewhat immature CD45(+), MPC-1(-), and CD49e(-).
p22799
sg4
(dp22800
(VMPC-1
p22801
Vplasmacytoma
p22802
tp22803
I00
ssg21392
(lp22804
(dp22805
g21395
I117
sg21396
g22802
sg21398
I12
sg21399
VC0032131
p22806
sg21401
I1
sasg21404
(lp22807
(dp22808
g21395
I177
sg21396
VCD49e
p22809
sg21398
I5
sg21408
VP08648
p22810
sg21401
I1
sa(dp22811
g21395
I154
sg21396
VCD45(+)
p22812
sg21398
I7
sg21408
VP08575
p22813
sg21401
I1
sa(dp22814
g21395
I163
sg21396
g22801
sg21398
I5
sg21408
VP28062
p22815
sg21401
I1
sasa(dp22816
g21386
VChanges to CD45 negativity and MPC-1 partial positivity were seen, while CD49e negativity persisted, suggesting that the plasmablastic plasmacytoma had reverted to a more immature state.
p22817
sg4
(dp22818
(VCD45 negativity
p22819
Vplasmacytoma
p22820
tp22821
I00
ssg21392
(lp22822
(dp22823
g21395
I135
sg21396
g22820
sg21398
I12
sg21399
VC0032131
p22824
sg21401
I1
sasg21404
(lp22825
(dp22826
g21395
I31
sg21396
VMPC-1
p22827
sg21398
I5
sg21408
VP28062
p22828
sg21401
I1
sa(dp22829
g21395
I73
sg21396
VCD49e
p22830
sg21398
I5
sg21408
VP08648
p22831
sg21401
I1
sa(dp22832
g21395
I11
sg21396
g22819
sg21398
I15
sg21408
VP08575
p22833
sg21401
I2
sasa(dp22834
g21386
VHe had the following poor prognostic factors: 1) multiple extramedullary plasmacytomas, 2) massive myelomatous effusion, 3) increasing immature myeloma cells with plasmablastic morphology, and 4) predominance of MPC1-CD49e-CD45+ phenotype immature myeloma cells.
p22835
sg4
(dp22836
(VCD49e
p22837
Vplasmacytomas
p22838
tp22839
I00
ssg21392
(lp22840
(dp22841
g21395
I99
sg21396
Vmyeloma
p22842
sg21398
I7
sg21399
VC0026764
p22843
sg21401
I1
sa(dp22844
g21395
I111
sg21396
Veffusion
p22845
sg21398
I8
sg21399
VC0013687
p22846
sg21401
I1
sa(dp22847
g21395
I99
sg21396
Vmyeloma
p22848
sg21398
I7
sg21399
VC0026764
p22849
sg21401
I1
sa(dp22850
g21395
I73
sg21396
g22838
sg21398
I13
sg21399
VC0032131
p22851
sg21401
I1
sasg21404
(lp22852
(dp22853
g21395
I212
sg21396
VMPC1
p22854
sg21398
I4
sg21408
VP28062
p22855
sg21401
I1
sa(dp22856
g21395
I223
sg21396
VCD45+
p22857
sg21398
I5
sg21408
VP08575
p22858
sg21401
I1
sa(dp22859
g21395
I217
sg21396
g22837
sg21398
I5
sg21408
VP08648
p22860
sg21401
I1
sasa(dp22861
g21386
VCD32 was significantly expressed on primary myeloma cells, but immature, MPC-1- myeloma cells expressed CD32 more weakly than mature, MPC-1+ cells.
p22862
sg4
(dp22863
(VCD32
p22864
Vmyeloma
p22865
tp22866
I00
ssg21392
(lp22867
(dp22868
g21395
I44
sg21396
Vmyeloma
p22869
sg21398
I7
sg21399
VC0026764
p22870
sg21401
I1
sa(dp22871
g21395
I44
sg21396
g22865
sg21398
I7
sg21399
VC0026764
p22872
sg21401
I1
sasg21404
(lp22873
(dp22874
g21395
I0
sg21396
VCD32
p22875
sg21398
I4
sg21408
VP12318
p22876
sg21401
I1
sa(dp22877
g21395
I73
sg21396
VMPC-1
p22878
sg21398
I5
sg21408
VP28062
p22879
sg21401
I1
sa(dp22880
g21395
I0
sg21396
g22864
sg21398
I4
sg21408
VP12318
p22881
sg21401
I1
sasa(dp22882
g21386
VTreatment with anti-CD32 antibody decreased the viability of normal plasma cells (CD38++ CD19+) more than that of myeloma cells (CD38++ CD19-); CD32-mediated growth suppression was greater in mature MPC-1+ cells than in immature MPC-1- cells.
p22883
sg4
(dp22884
(VCD32
p22885
Vmyeloma
p22886
tp22887
I00
ssg21392
(lp22888
(dp22889
g21395
I158
sg21396
Vgrowth suppression
p22890
sg21398
I18
sg21399
VC0151686
p22891
sg21401
I2
sa(dp22892
g21395
I114
sg21396
g22886
sg21398
I7
sg21399
VC0026764
p22893
sg21401
I1
sasg21404
(lp22894
(dp22895
g21395
I15
sg21396
Vanti-CD32 antibody
p22896
sg21398
I18
sg21408
VP12318
p22897
sg21401
I2
sa(dp22898
g21395
I82
sg21396
VCD38++ CD19+
p22899
sg21398
I12
sg21408
VP28907
p22900
sg21401
I2
sa(dp22901
g21395
I20
sg21396
g22885
sg21398
I4
sg21408
VP12318
p22902
sg21401
I1
sasa(dp22903
g21386
VTo date, at least 5 subpopulations of plasma cells have been identified in the bone marrow of multiple myeloma (MM) patients with regard to the expression of MPC-1, CD49e (VLA-5), and CD45: MPC-1(-)CD49e(-)CD45(+) proliferative immature cells, MPC-1(-)CD49e(-)CD45(-) immature myeloma cells, MPC-1(+)CD49e(-)CD45(-) and MPC-1(+)CD49e(-)CD45(+) intermediate myeloma cells, and MPC-1(+)CD49e(+)CD45(+) mature myeloma cells.
p22904
sg4
(dp22905
(VMPC-1(+)CD49e(-)CD45(+)
p22906
Vmyeloma
p22907
tp22908
I00
ssg21392
(lp22909
(dp22910
g21395
I103
sg21396
Vmyeloma
p22911
sg21398
I7
sg21399
VC0026764
p22912
sg21401
I1
sa(dp22913
g21395
I94
sg21396
Vmultiple myeloma
p22914
sg21398
I16
sg21399
VC0026764
p22915
sg21401
I2
sa(dp22916
g21395
I214
sg21396
Vproliferative
p22917
sg21398
I13
sg21399
VC0334094
p22918
sg21401
I1
sa(dp22919
g21395
I112
sg21396
VMM
p22920
sg21398
I2
sg21399
VC0026764
p22921
sg21401
I1
sa(dp22922
g21395
I103
sg21396
Vmyeloma
p22923
sg21398
I7
sg21399
VC0026764
p22924
sg21401
I1
sa(dp22925
g21395
I103
sg21396
g22907
sg21398
I7
sg21399
VC0026764
p22926
sg21401
I1
sasg21404
(lp22927
(dp22928
g21395
I376
sg21396
VMPC-1(+)CD49e(+)CD45(+)
p22929
sg21398
I23
sg21408
VP28062
p22930
sg21401
I1
sa(dp22931
g21395
I184
sg21396
VCD45: MPC-1(-)CD49e(-)CD45
p22932
sg21398
I26
sg21408
VP08575
p22933
sg21401
I2
sa(dp22934
g21395
I158
sg21396
VMPC-1
p22935
sg21398
I5
sg21408
VP28062
p22936
sg21401
I1
sa(dp22937
g21395
I260
sg21396
VCD45(-)
p22938
sg21398
I7
sg21408
VP08575
p22939
sg21401
I1
sa(dp22940
g21395
I190
sg21396
VMPC-1(-)CD49e(-)
p22941
sg21398
I16
sg21408
VP28062
p22942
sg21401
I1
sa(dp22943
g21395
I292
sg21396
VMPC-1(+)CD49e(-)CD45(-)
p22944
sg21398
I23
sg21408
VP28062
p22945
sg21401
I1
sa(dp22946
g21395
I172
sg21396
VVLA-5
p22947
sg21398
I5
sg21408
VP08648
p22948
sg21401
I1
sa(dp22949
g21395
I165
sg21396
VCD49e
p22950
sg21398
I5
sg21408
VP08648
p22951
sg21401
I1
sa(dp22952
g21395
I320
sg21396
g22906
sg21398
I23
sg21408
VP28062
p22953
sg21401
I1
sasa(dp22954
g21386
VIn 31 cases of progressive MM disease, MPC-1(-) immature and MPC-1(-)CD45(+) proliferative immature myeloma cells were significantly increased up to &gt;25% and &gt;10%, respectively, of the plasma cell fractions (CD38(++) cells), whereas there were no increases in MPC-1(-) or MPC-1(-)CD45(+) proliferative immature myeloma cells in 15 cases of stable disease.
p22955
sg4
(dp22956
(VMPC-1(-)
p22957
Vmyeloma
p22958
tp22959
I00
ssg21392
(lp22960
(dp22961
g21395
I77
sg21396
Vproliferative
p22962
sg21398
I13
sg21399
VC0334094
p22963
sg21401
I1
sa(dp22964
g21395
I77
sg21396
Vproliferative
p22965
sg21398
I13
sg21399
VC0334094
p22966
sg21401
I1
sa(dp22967
g21395
I100
sg21396
Vmyeloma
p22968
sg21398
I7
sg21399
VC0026764
p22969
sg21401
I1
sa(dp22970
g21395
I100
sg21396
g22958
sg21398
I7
sg21399
VC0026764
p22971
sg21401
I1
sasg21404
(lp22972
(dp22973
g21395
I61
sg21396
VMPC-1(-)CD45(+)
p22974
sg21398
I15
sg21408
VP28062
p22975
sg21401
I1
sa(dp22976
g21395
I214
sg21396
VCD38
p22977
sg21398
I4
sg21408
VP28907
p22978
sg21401
I1
sa(dp22979
g21395
I61
sg21396
VMPC-1(-)CD45(+)
p22980
sg21398
I15
sg21408
VP28062
p22981
sg21401
I1
sa(dp22982
g21395
I39
sg21396
g22957
sg21398
I8
sg21408
VP28062
p22983
sg21401
I1
sasa(dp22984
g21386
VInterestingly, the proportions of MPC-1(-) and MPC-1(-)CD45(+) immature monoclonal plasma cells also increased in the 7 progressive cases of MGUS.
p22985
sg4
(dp22986
(VMPC-1
p22987
VMGUS
p22988
tp22989
I00
ssg21392
(lp22990
(dp22991
g21395
I141
sg21396
g22988
sg21398
I4
sg21399
VC0026470
p22992
sg21401
I1
sasg21404
(lp22993
(dp22994
g21395
I47
sg21396
VMPC-1(-)CD45(+)
p22995
sg21398
I15
sg21408
VP28062
p22996
sg21401
I1
sa(dp22997
g21395
I34
sg21396
g22987
sg21398
I5
sg21408
VP28062
p22998
sg21401
I1
sasa(dp22999
g21386
VResults with flow cytometry using a combination of MPC1, CD49e, and CD45 supported the morphologic findings for the myeloma cells.
p23000
sg4
(dp23001
(VCD45
p23002
Vmyeloma
p23003
tp23004
I00
ssg21392
(lp23005
(dp23006
g21395
I116
sg21396
g23003
sg21398
I7
sg21399
VC0026764
p23007
sg21401
I1
sasg21404
(lp23008
(dp23009
g21395
I51
sg21396
VMPC1
p23010
sg21398
I4
sg21408
VP28062
p23011
sg21401
I1
sa(dp23012
g21395
I57
sg21396
VCD49e
p23013
sg21398
I5
sg21408
VP08648
p23014
sg21401
I1
sa(dp23015
g21395
I68
sg21396
g23002
sg21398
I4
sg21408
VP08575
p23016
sg21401
I1
sasa(dp23017
g21386
VOn the other hand, a significant increase was demonstrated in CD14-positive cells at 3 weeks after immunization in only arthritis-developed monkeys regardless of sex.
p23018
sg4
(dp23019
(VCD14
p23020
Varthritis
p23021
tp23022
I01
ssg21392
(lp23023
(dp23024
g21395
I120
sg21396
g23021
sg21398
I9
sg21399
VC0003864
p23025
sg21401
I1
sasg21404
(lp23026
(dp23027
g21395
I62
sg21396
g23020
sg21398
I4
sg21408
VP08571
p23028
sg21401
I1
sasa(dp23029
g21386
VWe previously reported the accumulation of abnormal myeloid cell populations reacting with CD14 (MY4) monoclonal antibody in the iliac and epiphyseal bone marrow of patients with severe rheumatoid arthritis (RA).
p23030
sg4
(dp23031
(VCD14
p23032
Vrheumatoid arthritis
p23033
tp23034
I00
ssg21392
(lp23035
(dp23036
g21395
I208
sg21396
VRA
p23037
sg21398
I2
sg21399
VC0003873
p23038
sg21401
I1
sa(dp23039
g21395
I186
sg21396
g23033
sg21398
I20
sg21399
VC0003873
p23040
sg21401
I2
sasg21404
(lp23041
(dp23042
g21395
I91
sg21396
g23032
sg21398
I4
sg21408
VP08571
p23043
sg21401
I1
sasa(dp23044
g21386
VPrior to treatment, monocyte-macrophage activation in rheumatoid arthritis was signified by an increased expression of HLA-class II antigens and the CD14 antigen, and by an increased production of neopterin and interleukin-1.
p23045
sg4
(dp23046
(Vinterleukin-1
p23047
Vrheumatoid arthritis
p23048
tp23049
I00
ssg21392
(lp23050
(dp23051
g21395
I54
sg21396
g23048
sg21398
I20
sg21399
VC0003873
p23052
sg21401
I2
sasg21404
(lp23053
(dp23054
g21395
I149
sg21396
VCD14 antigen
p23055
sg21398
I12
sg21408
VP08571
p23056
sg21401
I2
sa(dp23057
g21395
I211
sg21396
g23047
sg21398
I13
sg21408
VP60568
p23058
sg21401
I1
sa(dp23059
g21395
I119
sg21396
VHLA-class II antigens
p23060
sg21398
I21
sg21408
VP30486
p23061
sg21401
I3
sasa(dp23062
g21386
VMonocytes, defined by staining with the Mo-2 and Leu-M3 monoclonal antibodies which both detect the CD14 antigen, were studied in peripheral blood of control subjects and patients with rheumatoid arthritis as well as in rheumatoid synovial fluid of the latter for expression of activation/differentiation markers.
p23063
sg4
(dp23064
(VCD14 antigen
p23065
Vrheumatoid arthritis
p23066
tp23067
I00
ssg21392
(lp23068
(dp23069
g21395
I185
sg21396
g23066
sg21398
I20
sg21399
VC0003873
p23070
sg21401
I2
sasg21404
(lp23071
(dp23072
g21395
I49
sg21396
VLeu-M3 monoclonal antibodies
p23073
sg21398
I28
sg21408
VP30740
p23074
sg21401
I3
sa(dp23075
g21395
I100
sg21396
g23065
sg21398
I12
sg21408
VP08571
p23076
sg21401
I2
sasa(dp23077
g21386
VWe review recent findings implicating variants of FCRL3 (gene for FC receptor-like-3 protein), SCGB3A2 (gene for secretory uteroglobin-related protein 1- UGRP1) as well as other unverified possible candidate genes for GD selected through their documented association with type 1 diabetes mellitus: Tenr-IL2-IL21, CAPSL (encoding calcyphosine-like protein), IFIH1(gene for interferon-induced helicase C domain 1), AFF3, CD226 and PTPN2.
p23078
sg4
(dp23079
(VIL2
p23080
Vtype 1 diabetes mellitus
p23081
tp23082
I00
ssg21392
(lp23083
(dp23084
g21395
I272
sg21396
g23081
sg21398
I24
sg21399
VC0011854
p23085
sg21401
I4
sasg21404
(lp23086
(dp23087
g21395
I413
sg21396
VAFF3
p23088
sg21398
I4
sg21408
VP51826
p23089
sg21401
I1
sa(dp23090
g21395
I307
sg21396
VIL21
p23091
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp23092
g21395
I113
sg21396
Vsecretory uteroglobin-related protein 1- UGRP1
p23093
sg21398
I46
sg21408
VP11684
p23094
sg21401
I5
sa(dp23095
g21395
I50
sg21396
VFCRL3
p23096
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23097
g21395
I329
sg21396
Vcalcyphosine-like protein
p23098
sg21398
I25
sg21408
g190
sg21401
I2
sa(dp23099
g21395
I429
sg21396
VPTPN2
p23100
sg21398
I5
sg21408
VP17706
p23101
sg21401
I1
sa(dp23102
g21395
I66
sg21396
VFC receptor-like-3 protein
p23103
sg21398
I26
sg21408
g190
sg21401
I3
sa(dp23104
g21395
I372
sg21396
Vinterferon-induced helicase C domain 1
p23105
sg21398
I38
sg21408
VP01563
p23106
sg21401
I5
sa(dp23107
g21395
I357
sg21396
VIFIH1
p23108
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23109
g21395
I95
sg21396
VSCGB3A2
p23110
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp23111
g21395
I303
sg21396
g23080
sg21398
I3
sg21408
VP60568
p23112
sg21401
I1
sa(dp23113
g21395
I419
sg21396
VCD226
p23114
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23115
g21395
I313
sg21396
VCAPSL
p23116
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp23117
g21386
VIn vivo, in a model of experimental autoimmune encephalomyelitis, we show that an agonist of DR3 suppressed disease, correlating with expansion of CD4+Foxp3+ Tregs, and this protective effect was lost in Galectin-9-/- mice.
p23118
sg4
(dp23119
(VCD4+Foxp3+
p23120
Vencephalomyelitis
p23121
tp23122
I00
ssg21392
(lp23123
(dp23124
g21395
I36
sg21396
Vautoimmune
p23125
sg21398
I10
sg21399
VC0443146
p23126
sg21401
I1
sa(dp23127
g21395
I47
sg21396
g23121
sg21398
I17
sg21399
VC0014070
p23128
sg21401
I1
sasg21404
(lp23129
(dp23130
g21395
I147
sg21396
g23120
sg21398
I10
sg21408
VP01730
p23131
sg21401
I1
sa(dp23132
g21395
I204
sg21396
VGalectin-9
p23133
sg21398
I10
sg21408
g190
sg21401
I1
sasa(dp23134
g21386
VOur objective is to identify phenotypically the position of CD43(+) B cells among peripheral B-lineage cell compartments in healthy donors, with reference to B-cell subsets from patients with systemic lupus erythematosus (SLE).
p23135
sg4
(dp23136
(VCD43
p23137
VSLE
p23138
tp23139
I00
ssg21392
(lp23140
(dp23141
g21395
I192
sg21396
Vsystemic lupus erythematosus
p23142
sg21398
I28
sg21399
VC0024141
p23143
sg21401
I3
sa(dp23144
g21395
I222
sg21396
g23138
sg21398
I3
sg21399
VC0024141
p23145
sg21401
I1
sasg21404
(lp23146
(dp23147
g21395
I60
sg21396
g23137
sg21398
I4
sg21408
VP16150
p23148
sg21401
I1
sasa(dp23149
g21386
VPrevious studies indicate that CD43 plays a role in regulating the adhesion of lymphocytes, cell mutation and activation, however, little is known about its effect on systemic lupus erythematosus (SLE).
p23150
sg4
(dp23151
(VCD43
p23152
Vsystemic lupus erythematosus
p23153
tp23154
I00
ssg21392
(lp23155
(dp23156
g21395
I197
sg21396
VSLE
p23157
sg21398
I3
sg21399
VC0024141
p23158
sg21401
I1
sa(dp23159
g21395
I67
sg21396
Vadhesion
p23160
sg21398
I8
sg21399
VC0001511
p23161
sg21401
I1
sa(dp23162
g21395
I167
sg21396
g23153
sg21398
I28
sg21399
VC0024141
p23163
sg21401
I3
sasg21404
(lp23164
(dp23165
g21395
I31
sg21396
g23152
sg21398
I4
sg21408
VP16150
p23166
sg21401
I1
sasa(dp23167
g21386
VIt is suggested that elevated plasma nociceptin level found in Wilson disease patients is due to inhibition of nociceptin-inactivating Zn-metallopeptidases (aminopeptidase N (APN) and endopeptidase 24.15) by the toxic copper deposits in liver and/or brain.
p23168
sg4
(dp23169
(Vaminopeptidase N
p23170
VWilson disease
p23171
tp23172
I00
ssg21392
(lp23173
(dp23174
g21395
I63
sg21396
g23171
sg21398
I14
sg21399
VC0019202
p23175
sg21401
I2
sasg21404
(lp23176
(dp23177
g21395
I175
sg21396
VAPN
p23178
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp23179
g21395
I111
sg21396
Vnociceptin-inactivating Zn-metallopeptidases
p23180
sg21398
I44
sg21408
g190
sg21401
I2
sa(dp23181
g21395
I184
sg21396
Vendopeptidase 24.15
p23182
sg21398
I19
sg21408
VP52888
p23183
sg21401
I2
sa(dp23184
g21395
I157
sg21396
g23170
sg21398
I16
sg21408
VP15144
p23185
sg21401
I2
sa(dp23186
g21395
I30
sg21396
Vplasma nociceptin
p23187
sg21398
I17
sg21408
g190
sg21401
I2
sasa(dp23188
g21386
VIt is evident from the study that body iron (serum iron, TIBC &amp; transferrin saturation) level significantly increases among acute myocardial infarction patients in Bangladesh.
p23189
sg4
(dp23190
(Vtransferrin
p23191
Vacute myocardial infarction
p23192
tp23193
I00
ssg21392
(lp23194
(dp23195
g21395
I128
sg21396
g23192
sg21398
I27
sg21399
VC0155626
p23196
sg21401
I3
sasg21404
(lp23197
(dp23198
g21395
I68
sg21396
g23191
sg21398
I11
sg21408
VP02787
p23199
sg21401
I1
sasa(dp23200
g21386
VWe investigated the relation of NTBI, serum iron, transferrin saturation, and serum ferritin with risk of CHD and acute myocardial infarction (AMI).
p23201
sg4
(dp23202
(Vtransferrin
p23203
VAMI
p23204
tp23205
I00
ssg21392
(lp23206
(dp23207
g21395
I114
sg21396
Vacute myocardial infarction
p23208
sg21398
I27
sg21399
VC0155626
p23209
sg21401
I3
sa(dp23210
g21395
I143
sg21396
g23204
sg21398
I3
sg21399
VC0155626
p23211
sg21401
I1
sasg21404
(lp23212
(dp23213
g21395
I78
sg21396
Vserum ferritin
p23214
sg21398
I14
sg21408
VP02794
p23215
sg21401
I2
sa(dp23216
g21395
I50
sg21396
g23203
sg21398
I11
sg21408
VP02787
p23217
sg21401
I1
sasa(dp23218
g21386
VIn this study, the effects of chiral pesticide metalaxyl on CYP1A1, CYP1A2, CYP2B1, CYP2B2, CYP2E1 and CYP3A were investigated in human hepatoma HepG2, rat hepatic H4IIE, chicken hepatic LMH and grass carp hepatic L8824 cells.
p23219
sg4
(dp23220
(VCYP3A
p23221
Vhepatoma
p23222
tp23223
I00
ssg21392
(lp23224
(dp23225
g21395
I201
sg21396
Vcarp
p23226
sg21398
I4
sg21399
VC0263385
p23227
sg21401
I1
sa(dp23228
g21395
I136
sg21396
g23222
sg21398
I8
sg21399
VC0023903
p23229
sg21401
I1
sasg21404
(lp23230
(dp23231
g21395
I171
sg21396
Vchicken hepatic LMH
p23232
sg21398
I19
sg21408
g190
sg21401
I3
sa(dp23233
g21395
I68
sg21396
VCYP1A2
p23234
sg21398
I6
sg21408
VP05177
p23235
sg21401
I1
sa(dp23236
g21395
I92
sg21396
VCYP2E1
p23237
sg21398
I6
sg21408
VP05181
p23238
sg21401
I1
sa(dp23239
g21395
I60
sg21396
VCYP1A1
p23240
sg21398
I6
sg21408
VP04798
p23241
sg21401
I1
sa(dp23242
g21395
I103
sg21396
g23221
sg21398
I5
sg21408
VP08684
p23243
sg21401
I1
sasa(dp23244
g21386
VThe mechanisms were investigated by detecting levels of NADPH Oxidase 4 (NOX4),p22phox, cytochrome P4502E1 (CYP2E1),Bax,B-cell lymphoma 2 (Bcl-2),cleaved-caspase 3 and 9 and phosphorylated extracellular regulated protein kinases(ERK),phosphorylated c-Jun N-terminal kinase (JNK), and phosphorylated p38 mitogen-activated protein kinase (MAPK) using real-time polymerase chain reaction (PCR) and Western blotting.
p23245
sg4
(dp23246
(VBcl-2
p23247
VB-cell lymphoma
p23248
tp23249
I00
ssg21392
(lp23250
(dp23251
g21395
I120
sg21396
g23248
sg21398
I15
sg21399
VC0079731
p23252
sg21401
I2
sasg21404
(lp23253
(dp23254
g21395
I337
sg21396
VMAPK
p23255
sg21398
I4
sg21408
VP53779
p23256
sg21401
I1
sa(dp23257
g21395
I249
sg21396
Vc-Jun N-terminal kinase
p23258
sg21398
I23
sg21408
VP53779
p23259
sg21401
I3
sa(dp23260
g21395
I79
sg21396
Vp22phox
p23261
sg21398
I7
sg21408
VP13498
p23262
sg21401
I1
sa(dp23263
g21395
I299
sg21396
Vp38 mitogen-activated protein kinase
p23264
sg21398
I36
sg21408
g190
sg21401
I4
sa(dp23265
g21395
I108
sg21396
VCYP2E1
p23266
sg21398
I6
sg21408
VP05181
p23267
sg21401
I1
sa(dp23268
g21395
I274
sg21396
VJNK
p23269
sg21398
I3
sg21408
VP53779
p23270
sg21401
I1
sa(dp23271
g21395
I88
sg21396
Vcytochrome P4502E1
p23272
sg21398
I18
sg21408
VP05181
p23273
sg21401
I2
sa(dp23274
g21395
I154
sg21396
Vcaspase
p23275
sg21398
I7
sg21408
VP39880
p23276
sg21401
I1
sa(dp23277
g21395
I115
sg21396
V,Bax,B-cell lymphoma 2
p23278
sg21398
I22
sg21408
VP10415
p23279
sg21401
I3
sa(dp23280
g21395
I56
sg21396
VNADPH Oxidase 4
p23281
sg21398
I15
sg21408
g190
sg21401
I3
sa(dp23282
g21395
I189
sg21396
Vextracellular regulated protein kinases
p23283
sg21398
I39
sg21408
VP10398
p23284
sg21401
I4
sa(dp23285
g21395
I73
sg21396
VNOX4
p23286
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp23287
g21395
I229
sg21396
VERK
p23288
sg21398
I3
sg21408
VP29323
p23289
sg21401
I1
sa(dp23290
g21395
I139
sg21396
g23247
sg21398
I5
sg21408
VP10415
p23291
sg21401
I1
sasa(dp23292
g21386
VTwenty-two variants from 21 genes (APEX1 rs1130409 and rs1760944, ATM rs664677, AXIN2 rs2240308, CHRNA3 rs6495309, CHRNA5 rs16969968, CLPTM1L rs402710, CXCR2 rs1126579, CYP1A1 rs4646903, CYP2E1 rs6413432, ERCC1 rs11615, ERCC2 rs13181, FGFR4 rs351855, HYKK rs931794, MIR146A rs2910164, MIR196A2 rs11614913, OGG1 rs1052133, PON1 rs662, REV3L rs462779, SOD2 rs4880, TERT rs2736098, and TP53 rs1042522) showed significant associations with lung cancer susceptibility with strong cumulative epidemiological evidence.
p23293
sg4
(dp23294
(VCXCR2 rs1126579
p23295
Vlung cancer
p23296
tp23297
I00
ssg21392
(lp23298
(dp23299
g21395
I436
sg21396
g23296
sg21398
I11
sg21399
VC0684249
p23300
sg21401
I2
sasg21404
(lp23301
(dp23302
g21395
I322
sg21396
VPON1 rs662
p23303
sg21398
I10
sg21408
VP27169
p23304
sg21401
I2
sa(dp23305
g21395
I35
sg21396
VAPEX1 rs1130409
p23306
sg21398
I15
sg21408
VP27695
p23307
sg21401
I2
sa(dp23308
g21395
I205
sg21396
VERCC1 rs11615
p23309
sg21398
I13
sg21408
VP07992
p23310
sg21401
I2
sa(dp23311
g21395
I334
sg21396
VREV3L rs462779
p23312
sg21398
I14
sg21408
g190
sg21401
I2
sa(dp23313
g21395
I436
sg21396
Vlung cancer susceptibility
p23314
sg21398
I26
sg21408
g190
sg21401
I3
sa(dp23315
g21395
I363
sg21396
VTERT rs2736098
p23316
sg21398
I14
sg21408
g190
sg21401
I2
sa(dp23317
g21395
I80
sg21396
VAXIN2 rs2240308
p23318
sg21398
I15
sg21408
g190
sg21401
I2
sa(dp23319
g21395
I350
sg21396
VSOD2 rs4880
p23320
sg21398
I11
sg21408
VP04179
p23321
sg21401
I2
sa(dp23322
g21395
I169
sg21396
VCYP1A1 rs4646903
p23323
sg21398
I16
sg21408
VP04798
p23324
sg21401
I2
sa(dp23325
g21395
I235
sg21396
VFGFR4 rs351855
p23326
sg21398
I14
sg21408
VP22455
p23327
sg21401
I2
sa(dp23328
g21395
I97
sg21396
VCHRNA3 rs6495309
p23329
sg21398
I16
sg21408
VP32297
p23330
sg21401
I2
sa(dp23331
g21395
I66
sg21396
VATM rs664677
p23332
sg21398
I12
sg21408
g190
sg21401
I2
sa(dp23333
g21395
I187
sg21396
VCYP2E1 rs6413432
p23334
sg21398
I16
sg21408
VP05181
p23335
sg21401
I2
sa(dp23336
g21395
I115
sg21396
VCHRNA5 rs16969968
p23337
sg21398
I17
sg21408
VP30532
p23338
sg21401
I2
sa(dp23339
g21395
I134
sg21396
VCLPTM1L rs402710
p23340
sg21398
I16
sg21408
g190
sg21401
I2
sa(dp23341
g21395
I220
sg21396
VERCC2 rs13181
p23342
sg21398
I13
sg21408
VP18074
p23343
sg21401
I2
sa(dp23344
g21395
I152
sg21396
g23295
sg21398
I15
sg21408
VP25025
p23345
sg21401
I2
sasa(dp23346
g21386
VAs compared with major IIPs such as idiopathic pulmonary fibrosis and fibrotic nonspecific interstitial pneumonia, IPPFE significantly showed higher frequency of cases with a unique pattern of serum biomarkers, which is characterized by an elevated level of SP-D with a normal range of KL-6.
p23347
sg4
(dp23348
(VSP-D
p23349
Vnonspecific interstitial pneumonia
p23350
tp23351
I00
ssg21392
(lp23352
(dp23353
g21395
I36
sg21396
Vidiopathic pulmonary fibrosis
p23354
sg21398
I29
sg21399
VC3161101
p23355
sg21401
I3
sa(dp23356
g21395
I79
sg21396
g23350
sg21398
I34
sg21399
VC1290344
p23357
sg21401
I3
sasg21404
(lp23358
(dp23359
g21395
I258
sg21396
g23349
sg21398
I4
sg21408
VP35247
p23360
sg21401
I1
sasa(dp23361
g21386
VHowever, associations of serum KL-6 and SP-D with radiologic findings in nonspecific interstitial pneumonia (NSIP) remain unclear.
p23362
sg4
(dp23363
(VSP-D
p23364
Vnonspecific interstitial pneumonia
p23365
tp23366
I00
ssg21392
(lp23367
(dp23368
g21395
I109
sg21396
VNSIP
p23369
sg21398
I4
sg21399
VC1290344
p23370
sg21401
I1
sa(dp23371
g21395
I73
sg21396
g23365
sg21398
I34
sg21399
VC1290344
p23372
sg21401
I3
sasg21404
(lp23373
(dp23374
g21395
I25
sg21396
Vserum KL-6
p23375
sg21398
I10
sg21408
g190
sg21401
I2
sa(dp23376
g21395
I40
sg21396
g23364
sg21398
I4
sg21408
VP35247
p23377
sg21401
I1
sasa(dp23378
g21386
VExpression of ARHGAP11A in cancer cells suppressed RhoA-dependent mechanisms, such as stress fiber formation and focal adhesion, which made the cells more prone to migrate.
p23379
sg4
(dp23380
(VRhoA
p23381
Vadhesion
p23382
tp23383
I00
ssg21392
(lp23384
(dp23385
g21395
I119
sg21396
g23382
sg21398
I8
sg21399
VC0001511
p23386
sg21401
I1
sa(dp23387
g21395
I27
sg21396
Vcancer
p23388
sg21398
I6
sg21399
VC0006826
p23389
sg21401
I1
sasg21404
(lp23390
(dp23391
g21395
I14
sg21396
VARHGAP11A
p23392
sg21398
I9
sg21408
g190
sg21401
I1
sa(dp23393
g21395
I51
sg21396
g23381
sg21398
I4
sg21408
VP61586
p23394
sg21401
I1
sasa(dp23395
g21386
VIdentified genome-wide significant loci: 1) corroborated genes implicated in other studies (MTNR1B, ZNF259/APOA5, XPA/FOXE1 (TTF-2), DARC, CCR3, ABO); 2) localized novel genes in plausible biological pathways (PCSK2, ARHGAP11A, CHRNA3); and 3) revealed novel genes with unknown function in obesity pathogenesis (MATK, COL4A1).
p23396
sg4
(dp23397
(VCHRNA3
p23398
Vobesity
p23399
tp23400
I00
ssg21392
(lp23401
(dp23402
g21395
I290
sg21396
g23399
sg21398
I7
sg21399
VC0028754
p23403
sg21401
I1
sa(dp23404
g21395
I298
sg21396
Vpathogenesis
p23405
sg21398
I12
sg21399
VC0699748
p23406
sg21401
I1
sasg21404
(lp23407
(dp23408
g21395
I312
sg21396
VMATK
p23409
sg21398
I4
sg21408
VP42679
p23410
sg21401
I1
sa(dp23411
g21395
I114
sg21396
VXPA
p23412
sg21398
I3
sg21408
VP23025
p23413
sg21401
I1
sa(dp23414
g21395
I139
sg21396
VCCR3
p23415
sg21398
I4
sg21408
VP51677
p23416
sg21401
I1
sa(dp23417
g21395
I118
sg21396
VFOXE1
p23418
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23419
g21395
I125
sg21396
VTTF-2
p23420
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23421
g21395
I318
sg21396
VCOL4A1
p23422
sg21398
I6
sg21408
VP02462
p23423
sg21401
I1
sa(dp23424
g21395
I210
sg21396
VPCSK2
p23425
sg21398
I5
sg21408
VP16519
p23426
sg21401
I1
sa(dp23427
g21395
I217
sg21396
VARHGAP11A
p23428
sg21398
I9
sg21408
g190
sg21401
I1
sa(dp23429
g21395
I100
sg21396
VZNF259
p23430
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp23431
g21395
I92
sg21396
VMTNR1B
p23432
sg21398
I6
sg21408
VP49286
p23433
sg21401
I1
sa(dp23434
g21395
I228
sg21396
g23398
sg21398
I6
sg21408
VP32297
p23435
sg21401
I1
sa(dp23436
g21395
I107
sg21396
VAPOA5
p23437
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp23438
g21386
VIn contrast to GTG banding, array CGH determined the exact number of deleted genes and thus allowed the identification of candidate genes for cleft palate (GREM1, CX36, MEIS2), congenital heart defect (ACTC, GREM1, CX36, MEIS2), and mental retardation (ARHGAP11A, CHRNA7, CHRM5).
p23439
sg4
(dp23440
(VACTC
p23441
Vcongenital heart defect
p23442
tp23443
I01
ssg21392
(lp23444
(dp23445
g21395
I233
sg21396
Vmental retardation
p23446
sg21398
I18
sg21399
VC0025362
p23447
sg21401
I2
sa(dp23448
g21395
I142
sg21396
Vcleft palate
p23449
sg21398
I12
sg21399
VC0008925
p23450
sg21401
I2
sa(dp23451
g21395
I34
sg21396
VCGH
p23452
sg21398
I3
sg21399
VC1855900
p23453
sg21401
I1
sa(dp23454
g21395
I177
sg21396
g23442
sg21398
I23
sg21399
VC0018798
p23455
sg21401
I3
sasg21404
(lp23456
(dp23457
g21395
I169
sg21396
VMEIS2
p23458
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23459
g21395
I163
sg21396
VCX36
p23460
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp23461
g21395
I272
sg21396
VCHRM5
p23462
sg21398
I5
sg21408
VP08912
p23463
sg21401
I1
sa(dp23464
g21395
I202
sg21396
g23441
sg21398
I4
sg21408
VP68032
p23465
sg21401
I1
sa(dp23466
g21395
I264
sg21396
VCHRNA7
p23467
sg21398
I6
sg21408
VP36544
p23468
sg21401
I1
sa(dp23469
g21395
I169
sg21396
VMEIS2
p23470
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23471
g21395
I156
sg21396
VGREM1
p23472
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23473
g21395
I156
sg21396
VGREM1
p23474
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23475
g21395
I163
sg21396
VCX36
p23476
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp23477
g21395
I253
sg21396
VARHGAP11A
p23478
sg21398
I9
sg21408
g190
sg21401
I1
sasa(dp23479
g21386
VThe expression levels of four genes identified by microarray screening (PLCB2, HVCN1, CTSS, and DEF8) and one purine/thiopurine related gene (NME6) correlated significantly with the clinical activity of Crohn's disease.
p23480
sg4
(dp23481
(VCTSS
p23482
VCrohn's disease
p23483
tp23484
I01
ssg21392
(lp23485
(dp23486
g21395
I203
sg21396
g23483
sg21398
I15
sg21399
VC0010346
p23487
sg21401
I2
sasg21404
(lp23488
(dp23489
g21395
I86
sg21396
g23482
sg21398
I4
sg21408
VP25774
p23490
sg21401
I1
sa(dp23491
g21395
I110
sg21396
Vpurine/thiopurine related gene
p23492
sg21398
I30
sg21408
g190
sg21401
I3
sa(dp23493
g21395
I79
sg21396
VHVCN1
p23494
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23495
g21395
I96
sg21396
VDEF8
p23496
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp23497
g21395
I142
sg21396
VNME6
p23498
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp23499
g21395
I72
sg21396
VPLCB2
p23500
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp23501
g21386
VRecently, we have identified DC-SCRIPT (ZNF366) as a co-suppressor of ERAlfa and as a strong and independent prognostic marker in ESR1 (ERAlfa gene)-positive breast cancer patients.
p23502
sg4
(dp23503
(VESR1
p23504
Vbreast cancer
p23505
tp23506
I00
ssg21392
(lp23507
(dp23508
g21395
I158
sg21396
g23505
sg21398
I13
sg21399
VC0678222
p23509
sg21401
I2
sasg21404
(lp23510
(dp23511
g21395
I29
sg21396
VDC-SCRIPT
p23512
sg21398
I9
sg21408
g190
sg21401
I1
sa(dp23513
g21395
I40
sg21396
VZNF366
p23514
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp23515
g21395
I130
sg21396
g23504
sg21398
I4
sg21408
VP03372
p23516
sg21401
I1
sasa(dp23517
g21386
VIn the primary ESR1-positive breast tumors, DC-SCRIPT expression negatively correlated with several cell cycle gene ontologies and pathways.
p23518
sg4
(dp23519
(VESR1
p23520
Vbreast tumors
p23521
tp23522
I00
ssg21392
(lp23523
(dp23524
g21395
I29
sg21396
g23521
sg21398
I13
sg21399
VC1458155
p23525
sg21401
I2
sasg21404
(lp23526
(dp23527
g21395
I15
sg21396
g23520
sg21398
I4
sg21408
VP03372
p23528
sg21401
I1
sasa(dp23529
g21386
VMoreover, in 1,132 primary ESR1-positive breast tumors, DC-SCRIPT expression also correlated with CDKN2B expression.
p23530
sg4
(dp23531
(VESR1
p23532
Vbreast tumors
p23533
tp23534
I00
ssg21392
(lp23535
(dp23536
g21395
I41
sg21396
g23533
sg21398
I13
sg21399
VC1458155
p23537
sg21401
I2
sasg21404
(lp23538
(dp23539
g21395
I98
sg21396
VCDKN2B
p23540
sg21398
I6
sg21408
VP42772
p23541
sg21401
I1
sa(dp23542
g21395
I27
sg21396
g23532
sg21398
I4
sg21408
VP03372
p23543
sg21401
I1
sasa(dp23544
g21386
VCollectively, these data show that DC-SCRIPT acts as a novel regulator of CDKN2B and induces cell cycle arrest in ESR1-positive breast cancer cells.
p23545
sg4
(dp23546
(VESR1
p23547
Vbreast cancer
p23548
tp23549
I00
ssg21392
(lp23550
(dp23551
g21395
I128
sg21396
g23548
sg21398
I13
sg21399
VC0678222
p23552
sg21401
I2
sasg21404
(lp23553
(dp23554
g21395
I74
sg21396
VCDKN2B
p23555
sg21398
I6
sg21408
VP42772
p23556
sg21401
I1
sa(dp23557
g21395
I114
sg21396
g23547
sg21398
I4
sg21408
VP03372
p23558
sg21401
I1
sasa(dp23559
g21386
VThe prognostic value of tumor DC-SCRIPT mRNA expression was assessed in three independent cohorts of breast cancer patients: a discovery group (n = 47) and a validation group (n = 97) (neither of which had received systemic adjuvant therapy) and in a tamoxifen-treated validation group (n = 68) by using a DC-SCRIPT to porphobilinogen deaminase transcript ratio cutoff of 0.15 determined in the discovery group.
p23560
sg4
(dp23561
(Vporphobilinogen deaminase transcript
p23562
Vbreast cancer
p23563
tp23564
I01
ssg21392
(lp23565
(dp23566
g21395
I101
sg21396
g23563
sg21398
I13
sg21399
VC0678222
p23567
sg21401
I2
sa(dp23568
g21395
I24
sg21396
Vtumor
p23569
sg21398
I5
sg21399
VC0027651
p23570
sg21401
I1
sasg21404
(lp23571
(dp23572
g21395
I319
sg21396
g23562
sg21398
I36
sg21408
VP08397
p23573
sg21401
I3
sa(dp23574
g21395
I30
sg21396
VDC-SCRIPT
p23575
sg21398
I9
sg21408
g190
sg21401
I1
sasa(dp23576
g21386
VBoth SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.
p23577
sg4
(dp23578
(VKLK2
p23579
Vbreast cancer
p23580
tp23581
I00
ssg21392
(lp23582
(dp23583
g21395
I68
sg21396
g23580
sg21398
I13
sg21399
VC0678222
p23584
sg21401
I2
sasg21404
(lp23585
(dp23586
g21395
I140
sg21396
VKLKB1
p23587
sg21398
I5
sg21408
VP03952
p23588
sg21401
I1
sa(dp23589
g21395
I176
sg21396
VKLK4
p23590
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp23591
g21395
I189
sg21396
VNCF2
p23592
sg21398
I4
sg21408
VP19878
p23593
sg21401
I1
sa(dp23594
g21395
I195
sg21396
VCCL1
p23595
sg21398
I4
sg21408
VP22362
p23596
sg21401
I1
sa(dp23597
g21395
I201
sg21396
VC1QR1
p23598
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23599
g21395
I182
sg21396
VSTAT6
p23600
sg21398
I5
sg21408
VP42226
p23601
sg21401
I1
sa(dp23602
g21395
I169
sg21396
VIRAK3
p23603
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23604
g21395
I123
sg21396
VCNTNAP1
p23605
sg21398
I7
sg21408
VP78357
p23606
sg21401
I1
sa(dp23607
g21395
I132
sg21396
VCTNNB1
p23608
sg21398
I6
sg21408
VP35222
p23609
sg21401
I1
sa(dp23610
g21395
I147
sg21396
VITGB2
p23611
sg21398
I5
sg21408
VP05107
p23612
sg21401
I1
sa(dp23613
g21395
I109
sg21396
VFCER1A
p23614
sg21398
I6
sg21408
VP12319
p23615
sg21401
I1
sa(dp23616
g21395
I117
sg21396
VNCF4
p23617
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp23618
g21395
I208
sg21396
VMBP
p23619
sg21398
I3
sg21408
VP13727
p23620
sg21401
I1
sa(dp23621
g21395
I101
sg21396
VOR10J3
p23622
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp23623
g21395
I216
sg21396
VNOS1
p23624
sg21398
I4
sg21408
VP29475
p23625
sg21401
I1
sa(dp23626
g21395
I154
sg21396
VALOX12B
p23627
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp23628
g21395
I163
sg21396
g23579
sg21398
I4
sg21408
VP20151
p23629
sg21401
I1
sasa(dp23630
g21386
VWhen the data were divided by menopausal status, the optimal models to predict breast cancer, which included NAF hK2 or PSA and age, were 100% sensitive and 41% specific in pre- vs. 93% sensitive and 12% specific in postmenopausal women.
p23631
sg4
(dp23632
(VNAF hK2
p23633
Vbreast cancer
p23634
tp23635
I00
ssg21392
(lp23636
(dp23637
g21395
I120
sg21396
VPSA
p23638
sg21398
I3
sg21399
VC1519176
p23639
sg21401
I1
sa(dp23640
g21395
I79
sg21396
g23634
sg21398
I13
sg21399
VC0678222
p23641
sg21401
I2
sasg21404
(lp23642
(dp23643
g21395
I120
sg21396
VPSA
p23644
sg21398
I3
sg21408
VP55786
p23645
sg21401
I1
sa(dp23646
g21395
I109
sg21396
g23633
sg21398
I7
sg21408
VP20151
p23647
sg21401
I2
sasa(dp23648
g21386
VSeveral lines of evidence suggest that members of the kallikrein family are involved in various malignancies such as prostate (PSA, KLK2, KLK15), ovarian (KLK4, KLK5, KLK6, KLK8, KLK10), and breast cancer (KLK10, KLK13, KLK14).
p23649
sg4
(dp23650
(VPSA
p23651
Vprostate
p23652
tp23653
I00
ssg21392
(lp23654
(dp23655
g21395
I127
sg21396
VPSA
p23656
sg21398
I3
sg21399
VC1519176
p23657
sg21401
I1
sa(dp23658
g21395
I191
sg21396
Vbreast cancer
p23659
sg21398
I13
sg21399
VC0678222
p23660
sg21401
I2
sa(dp23661
g21395
I96
sg21396
Vmalignancies
p23662
sg21398
I12
sg21399
VC0006826
p23663
sg21401
I1
sa(dp23664
g21395
I117
sg21396
g23652
sg21398
I8
sg21399
VC1519176
p23665
sg21401
I1
sasg21404
(lp23666
(dp23667
g21395
I173
sg21396
VKLK8
p23668
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp23669
g21395
I155
sg21396
VKLK4
p23670
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp23671
g21395
I179
sg21396
VKLK10
p23672
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23673
g21395
I213
sg21396
VKLK13
p23674
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23675
g21395
I132
sg21396
VKLK2
p23676
sg21398
I4
sg21408
VP20151
p23677
sg21401
I1
sa(dp23678
g21395
I54
sg21396
Vkallikrein family
p23679
sg21398
I17
sg21408
VP06870
p23680
sg21401
I2
sa(dp23681
g21395
I167
sg21396
VKLK6
p23682
sg21398
I4
sg21408
VP06870
p23683
sg21401
I1
sa(dp23684
g21395
I138
sg21396
VKLK15
p23685
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23686
g21395
I220
sg21396
VKLK14
p23687
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23688
g21395
I179
sg21396
VKLK10
p23689
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23690
g21395
I161
sg21396
VKLK5
p23691
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp23692
g21395
I117
sg21396
Vprostate
p23693
sg21398
I8
sg21408
VP55786
p23694
sg21401
I1
sa(dp23695
g21395
I127
sg21396
g23651
sg21398
I3
sg21408
VP55786
p23696
sg21401
I1
sasa(dp23697
g21386
VWe examined previously the steroid hormone regulation of 2 known androgen-regulated kallikreins, KLK3 (encoding PSA) and KLK2 (encoding human kallikrein 2 or hK2) in BT-474, T-47D, ZR75-1, MCF-7, MFM-223 and BT-20 human breast cancer cells and found that they were differentially regulated, with the cells showing variable responses to androgen.
p23698
sg4
(dp23699
(Vhuman kallikrein 2
p23700
VPSA
p23701
tp23702
I00
ssg21392
(lp23703
(dp23704
g21395
I220
sg21396
Vbreast cancer
p23705
sg21398
I13
sg21399
VC0678222
p23706
sg21401
I2
sa(dp23707
g21395
I112
sg21396
g23701
sg21398
I3
sg21399
VC1519176
p23708
sg21401
I1
sasg21404
(lp23709
(dp23710
g21395
I121
sg21396
VKLK2
p23711
sg21398
I4
sg21408
VP20151
p23712
sg21401
I1
sa(dp23713
g21395
I142
sg21396
Vkallikrein 2 or hK2
p23714
sg21398
I19
sg21408
VP20151
p23715
sg21401
I4
sa(dp23716
g21395
I65
sg21396
Vandrogen-regulated kallikreins
p23717
sg21398
I30
sg21408
VP10398
p23718
sg21401
I2
sa(dp23719
g21395
I136
sg21396
g23700
sg21398
I18
sg21408
VP20151
p23720
sg21401
I3
sasa(dp23721
g21386
VEvery breast cancer cell line exhibited a distinct expression pattern of the nuclear receptor co-regulators examined raising the possibility that the relative levels of these co-activators/-repressors might differentially modulate androgen receptor transcriptional activity within the promoter/enhancer region of KLK2 and KLK3 of these cells.
p23722
sg4
(dp23723
(VKLK2
p23724
Vbreast cancer
p23725
tp23726
I00
ssg21392
(lp23727
(dp23728
g21395
I6
sg21396
g23725
sg21398
I13
sg21399
VC0678222
p23729
sg21401
I2
sasg21404
(lp23730
(dp23731
g21395
I231
sg21396
Vandrogen receptor
p23732
sg21398
I17
sg21408
VP10275
p23733
sg21401
I2
sa(dp23734
g21395
I322
sg21396
VKLK3
p23735
sg21398
I4
sg21408
VP03952
p23736
sg21401
I1
sa(dp23737
g21395
I313
sg21396
g23724
sg21398
I4
sg21408
VP20151
p23738
sg21401
I1
sasa(dp23739
g21386
VLike KLK2 and KLK3, the KLK5 gene is regulated by steroid hormones in the BT-474 breast cancer cell line.
p23740
sg4
(dp23741
(VKLK3
p23742
Vbreast cancer
p23743
tp23744
I00
ssg21392
(lp23745
(dp23746
g21395
I81
sg21396
g23743
sg21398
I13
sg21399
VC0678222
p23747
sg21401
I2
sasg21404
(lp23748
(dp23749
g21395
I5
sg21396
VKLK2
p23750
sg21398
I4
sg21408
VP20151
p23751
sg21401
I1
sa(dp23752
g21395
I14
sg21396
g23742
sg21398
I4
sg21408
VP03952
p23753
sg21401
I1
sa(dp23754
g21395
I24
sg21396
VKLK5 gene
p23755
sg21398
I9
sg21408
g190
sg21401
I2
sasa(dp23756
g21386
VKLK2 and KLK3 have important applications in prostate cancer diagnostics and, more recently, in breast cancer diagnostics.
p23757
sg4
(dp23758
(VKLK2
p23759
Vprostate cancer
p23760
tp23761
I00
ssg21392
(lp23762
(dp23763
g21395
I96
sg21396
Vbreast cancer
p23764
sg21398
I13
sg21399
VC0678222
p23765
sg21401
I2
sa(dp23766
g21395
I45
sg21396
g23760
sg21398
I15
sg21399
VC0600139
p23767
sg21401
I2
sasg21404
(lp23768
(dp23769
g21395
I9
sg21396
VKLK3
p23770
sg21398
I4
sg21408
VP03952
p23771
sg21401
I1
sa(dp23772
g21395
I0
sg21396
g23759
sg21398
I4
sg21408
VP20151
p23773
sg21401
I1
sasa(dp23774
g21386
VTo observe the effect of Bushen Huoxue Recipe (BHR) on inhibiting vascular calcification (VC) in chronic renal failure (CRF) rats by regulating BMP-2/Runx2/Osterix signal pathway, and to explore its possible mechanism.
p23775
sg4
(dp23776
(VBMP-2
p23777
VCRF
p23778
tp23779
I01
ssg21392
(lp23780
(dp23781
g21395
I90
sg21396
VVC
p23782
sg21398
I2
sg21399
VC0342649
p23783
sg21401
I1
sa(dp23784
g21395
I66
sg21396
Vvascular calcification
p23785
sg21398
I22
sg21399
VC0342649
p23786
sg21401
I2
sa(dp23787
g21395
I97
sg21396
Vchronic renal failure
p23788
sg21398
I21
sg21399
VC0022661
p23789
sg21401
I3
sa(dp23790
g21395
I120
sg21396
g23778
sg21398
I3
sg21399
VC0022661
p23791
sg21401
I1
sasg21404
(lp23792
(dp23793
g21395
I144
sg21396
g23777
sg21398
I5
sg21408
VP12643
p23794
sg21401
I1
sa(dp23795
g21395
I150
sg21396
VRunx2
p23796
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp23797
g21395
I156
sg21396
VOsterix
p23798
sg21398
I7
sg21408
g190
sg21401
I1
sasa(dp23799
g21386
VHere, we report that inhibition of Src significantly reduced survival of H37Rv as well as multidrug-resistant (MDR) and extremely drug-resistant (XDR) strains of M. tuberculosis in THP-1 macrophages.
p23800
sg4
(dp23801
(VSrc
p23802
Vtuberculosis
p23803
tp23804
I00
ssg21392
(lp23805
(dp23806
g21395
I165
sg21396
g23803
sg21398
I12
sg21399
VC0041296
p23807
sg21401
I1
sasg21404
(lp23808
(dp23809
g21395
I35
sg21396
g23802
sg21398
I3
sg21408
VP12931
p23810
sg21401
I1
sasa(dp23811
g21386
VSrc inhibition was also effective in controlling M. tuberculosis infection in guinea pigs.
p23812
sg4
(dp23813
(VSrc
p23814
Vtuberculosis infection
p23815
tp23816
I00
ssg21392
(lp23817
(dp23818
g21395
I52
sg21396
g23815
sg21398
I22
sg21399
VC0041296
p23819
sg21401
I2
sasg21404
(lp23820
(dp23821
g21395
I0
sg21396
g23814
sg21398
I3
sg21408
VP12931
p23822
sg21401
I1
sasa(dp23823
g21386
VIn guinea pigs, reduced M. tuberculosis burden due to Src inhibition also led to a marked decline in the disease pathology.
p23824
sg4
(dp23825
(VSrc
p23826
Vtuberculosis
p23827
tp23828
I00
ssg21392
(lp23829
(dp23830
g21395
I27
sg21396
g23827
sg21398
I12
sg21399
VC0041296
p23831
sg21401
I1
sa(dp23832
g21395
I113
sg21396
Vpathology
p23833
sg21398
I9
sg21399
VC0677042
p23834
sg21401
I1
sasg21404
(lp23835
(dp23836
g21395
I54
sg21396
g23826
sg21398
I3
sg21408
VP12931
p23837
sg21401
I1
sasa(dp23838
g21386
VWe propose that Src inhibitors could be developed into effective host-directed anti-TB drugs, which could be indiscriminately used against both drug-sensitive and drug-resistant strains of M. tuberculosis.
p23839
sg4
(dp23840
(VSrc
p23841
Vtuberculosis
p23842
tp23843
I00
ssg21392
(lp23844
(dp23845
g21395
I192
sg21396
g23842
sg21398
I12
sg21399
VC0041296
p23846
sg21401
I1
sasg21404
(lp23847
(dp23848
g21395
I16
sg21396
g23841
sg21398
I3
sg21408
VP12931
p23849
sg21401
I1
sasa(dp23850
g21386
VWe explored tyrosine kinase Src as a host factor exploited by virulent M. tuberculosis for intracellular survival.
p23851
sg4
(dp23852
(Vtyrosine kinase Src
p23853
Vtuberculosis
p23854
tp23855
I00
ssg21392
(lp23856
(dp23857
g21395
I74
sg21396
g23854
sg21398
I12
sg21399
VC0041296
p23858
sg21401
I1
sasg21404
(lp23859
(dp23860
g21395
I12
sg21396
g23853
sg21398
I19
sg21408
VP29401
p23861
sg21401
I3
sasa(dp23862
g21386
VWe show that Src inhibition can effectively control tuberculosis in infected guinea pigs.
p23863
sg4
(dp23864
(VSrc
p23865
Vtuberculosis
p23866
tp23867
I00
ssg21392
(lp23868
(dp23869
g21395
I52
sg21396
g23866
sg21398
I12
sg21399
VC0041296
p23870
sg21401
I1
sasg21404
(lp23871
(dp23872
g21395
I13
sg21396
g23865
sg21398
I3
sg21408
VP12931
p23873
sg21401
I1
sasa(dp23874
g21386
VAmong them, the human Cytokine-inducible Src homology 2(SH2) domain protein (CISH) gene has been very recently reported to be involved in T cell activation and differentiation in response to Mycobacterium tuberculosis infection.
p23875
sg4
(dp23876
(VSrc homology 2
p23877
Vtuberculosis infection
p23878
tp23879
I00
ssg21392
(lp23880
(dp23881
g21395
I205
sg21396
g23878
sg21398
I22
sg21399
VC0041296
p23882
sg21401
I2
sasg21404
(lp23883
(dp23884
g21395
I41
sg21396
g23877
sg21398
I14
sg21408
VP12931
p23885
sg21401
I3
sasa(dp23886
g21386
VAlthough there are conflicting data regarding prognostic implications of isolated MYC aberrancy in these non-BLs, the co-occurrence of MYC rearrangements and either the antiapoptotic gene B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) or the transcriptional repressor BCL6 leads to an entity termed double-hit B-cell lymphoma (DHL) (or triple-hit if all 3 abnormalities are observed) with a particularly poor prognosis and no established treatment paradigms.
p23887
sg4
(dp23888
(VB-cell chronic lymphocytic leukemia/lymphoma 2
p23889
Vlymphoma
p23890
tp23891
I00
ssg21392
(lp23892
(dp23893
g21395
I317
sg21396
VB-cell lymphoma
p23894
sg21398
I15
sg21399
VC0079731
p23895
sg21401
I2
sa(dp23896
g21395
I188
sg21396
VB-cell chronic lymphocytic leukemia
p23897
sg21398
I35
sg21399
VC1868683
p23898
sg21401
I4
sa(dp23899
g21395
I109
sg21396
VBLs
p23900
sg21398
I3
sg21399
VC0005859
p23901
sg21401
I1
sa(dp23902
g21395
I224
sg21396
g23890
sg21398
I8
sg21399
VC0024299
p23903
sg21401
I1
sasg21404
(lp23904
(dp23905
g21395
I275
sg21396
VBCL6
p23906
sg21398
I4
sg21408
VP41182
p23907
sg21401
I1
sa(dp23908
g21395
I236
sg21396
VBCL2
p23909
sg21398
I4
sg21408
VP10415
p23910
sg21401
I1
sa(dp23911
g21395
I82
sg21396
VMYC
p23912
sg21398
I3
sg21408
VP12524
p23913
sg21401
I1
sa(dp23914
g21395
I188
sg21396
g23889
sg21398
I46
sg21408
VP10415
p23915
sg21401
I5
sasa(dp23916
g21386
VThe clinicopathologic findings in Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) may show significant overlap, and MYC abnormalities, found in all BLs, also occur in a subset of DLBCL.
p23917
sg4
(dp23918
(VMYC
p23919
VBLs
p23920
tp23921
I00
ssg21392
(lp23922
(dp23923
g21395
I34
sg21396
VBurkitt lymphoma
p23924
sg21398
I16
sg21399
VC0006413
p23925
sg21401
I2
sa(dp23926
g21395
I91
sg21396
VDLBCL
p23927
sg21398
I5
sg21399
VC0079744
p23928
sg21401
I1
sa(dp23929
g21395
I91
sg21396
VDLBCL
p23930
sg21398
I5
sg21399
VC0079744
p23931
sg21401
I1
sa(dp23932
g21395
I60
sg21396
Vdiffuse large B-cell lymphoma
p23933
sg21398
I29
sg21399
VC0079744
p23934
sg21401
I4
sa(dp23935
g21395
I52
sg21396
VBL
p23936
sg21398
I2
sg21399
VC0006413
p23937
sg21401
I1
sa(dp23938
g21395
I164
sg21396
g23920
sg21398
I3
sg21399
VC0005859
p23939
sg21401
I1
sasg21404
(lp23940
(dp23941
g21395
I132
sg21396
g23919
sg21398
I3
sg21408
VP12524
p23942
sg21401
I1
sasa(dp23943
g21386
VIn particular, we determined the expression and production of several angiogenic factors including tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), Leptin, connective tissue growth factor (CTGF), meningioma-associated complimentary DNA (Mac25), basic fibroblast growth factor (bFGF), and Midkine.
p23944
sg4
(dp23945
(VLeptin
p23946
Vmeningioma
p23947
tp23948
I00
ssg21392
(lp23949
(dp23950
g21395
I205
sg21396
g23947
sg21398
I10
sg21399
VC0025286
p23951
sg21401
I1
sasg21404
(lp23952
(dp23953
g21395
I70
sg21396
Vangiogenic factors including tissue inhibitor of matrix metalloproteinases-1
p23954
sg21398
I76
sg21408
VP19883
p23955
sg21401
I8
sa(dp23956
g21395
I254
sg21396
Vbasic fibroblast growth factor
p23957
sg21398
I30
sg21408
VP53370
p23958
sg21401
I4
sa(dp23959
g21395
I148
sg21396
VTIMP-1
p23960
sg21398
I6
sg21408
VP01033
p23961
sg21401
I1
sa(dp23962
g21395
I286
sg21396
VbFGF
p23963
sg21398
I4
sg21408
VP53370
p23964
sg21401
I1
sa(dp23965
g21395
I198
sg21396
VCTGF
p23966
sg21398
I4
sg21408
VP29279
p23967
sg21401
I1
sa(dp23968
g21395
I165
sg21396
Vconnective tissue growth factor
p23969
sg21398
I31
sg21408
VP29279
p23970
sg21401
I4
sa(dp23971
g21395
I157
sg21396
g23946
sg21398
I6
sg21408
VP41159
p23972
sg21401
I1
sasa(dp23973
g21386
VAltered expression levels of several genes identified in this study have been previously noted in meningiomas (eg, growth hormone receptor, IGFBP-7, endothelin receptor A, IGF2).
p23974
sg4
(dp23975
(Vgrowth hormone receptor
p23976
Vmeningiomas
p23977
tp23978
I00
ssg21392
(lp23979
(dp23980
g21395
I98
sg21396
g23977
sg21398
I11
sg21399
VC0025286
p23981
sg21401
I1
sasg21404
(lp23982
(dp23983
g21395
I149
sg21396
Vendothelin receptor A
p23984
sg21398
I21
sg21408
g190
sg21401
I3
sa(dp23985
g21395
I172
sg21396
VIGF2
p23986
sg21398
I4
sg21408
VP01344
p23987
sg21401
I1
sa(dp23988
g21395
I115
sg21396
g23976
sg21398
I23
sg21408
VP10912
p23989
sg21401
I3
sasa(dp23990
g21386
VTaken together, the results of the present study concluded that human FAT2 may function as a key molecule that governs not only PCP, but also NF2-Hpo signaling in arachnoid cells; thus, a mutation in this gene may result in spinal meningioma.
p23991
sg4
(dp23992
(VPCP
p23993
Vspinal meningioma
p23994
tp23995
I00
ssg21392
(lp23996
(dp23997
g21395
I142
sg21396
VNF2
p23998
sg21398
I3
sg21399
VC0027832
p23999
sg21401
I1
sa(dp24000
g21395
I128
sg21396
VPCP
p24001
sg21398
I3
sg21399
VC2919094
p24002
sg21401
I1
sa(dp24003
g21395
I224
sg21396
g23994
sg21398
I17
sg21399
VC0347515
p24004
sg21401
I2
sasg21404
(lp24005
(dp24006
g21395
I146
sg21396
VHpo
p24007
sg21398
I3
sg21408
VP55789
p24008
sg21401
I1
sa(dp24009
g21395
I70
sg21396
VFAT2
p24010
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp24011
g21395
I128
sg21396
g23993
sg21398
I3
sg21408
VP42785
p24012
sg21401
I1
sasa(dp24013
g21386
VPsoriasis area and severity index (PASI), serum P-selectin and interleukin (IL)-6 were monitored throughout the treatment.
p24014
sg4
(dp24015
(Vinterleukin (IL)-6
p24016
VPsoriasis
p24017
tp24018
I00
ssg21392
(lp24019
(dp24020
g21395
I0
sg21396
g24017
sg21398
I9
sg21399
VC0033860
p24021
sg21401
I1
sasg21404
(lp24022
(dp24023
g21395
I42
sg21396
Vserum P-selectin
p24024
sg21398
I16
sg21408
VP16109
p24025
sg21401
I2
sa(dp24026
g21395
I63
sg21396
g24016
sg21398
I18
sg21408
VP60568
p24027
sg21401
I2
sasa(dp24028
g21386
VWe aimed to study the association of the endothelial activation biomarkers monocyte chemoattractant protein 1 (MCP-1), soluble (s) E-selectin and P-selectin with disease activity and severity in psoriasis patients treated with anti-TNF-Alfa therapy.
p24029
sg4
(dp24030
(VP-selectin
p24031
Vpsoriasis
p24032
tp24033
I00
ssg21392
(lp24034
(dp24035
g21395
I195
sg21396
g24032
sg21398
I9
sg21399
VC0033860
p24036
sg21401
I1
sasg21404
(lp24037
(dp24038
g21395
I41
sg21396
Vendothelial activation biomarkers monocyte chemoattractant protein 1
p24039
sg21398
I68
sg21408
VP14222
p24040
sg21401
I7
sa(dp24041
g21395
I227
sg21396
Vanti-TNF-Alfa
p24042
sg21398
I13
sg21408
VP01375
p24043
sg21401
I1
sa(dp24044
g21395
I146
sg21396
g24031
sg21398
I10
sg21408
VP16109
p24045
sg21401
I1
sasa(dp24046
g21386
VPlasma soluble P-selectin concentrations, PDMP and platelet aggregation were significantly elevated in patients with psoriasis, as compared to controls.
p24047
sg4
(dp24048
(VPlasma soluble P-selectin
p24049
Vpsoriasis
p24050
tp24051
I00
ssg21392
(lp24052
(dp24053
g21395
I117
sg21396
g24050
sg21398
I9
sg21399
VC0033860
p24054
sg21401
I1
sasg21404
(lp24055
(dp24056
g21395
I0
sg21396
g24049
sg21398
I25
sg21408
VP16109
p24057
sg21401
I3
sasa(dp24058
g21386
VThese results identify SOXN as a major player in regulating the sensitization of neuroblastoma cells for IFN-gamma-induced apoptosis.
p24059
sg4
(dp24060
(VIFN-gamma
p24061
Vneuroblastoma
p24062
tp24063
I00
ssg21392
(lp24064
(dp24065
g21395
I81
sg21396
g24062
sg21398
I13
sg21399
VC0027819
p24066
sg21401
I1
sasg21404
(lp24067
(dp24068
g21395
I105
sg21396
g24061
sg21398
I9
sg21408
VP01579
p24069
sg21401
I1
sa(dp24070
g21395
I23
sg21396
VSOXN
p24071
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp24072
g21386
VIn this study, we demonstrated that osteopontin (OPN) was dramatically reduced by loss of TSC1/TSC2 complex in Tsc2-null mouse embryonic fibroblasts (MEFs), rat uterine leiomyoma-derived Tsc2-deficient cells, genetically modified mouse TSC models, and clinical samples.
p24073
sg4
(dp24074
(VTSC2
p24075
VTSC2
p24076
tp24077
I00
ssg21392
(lp24078
(dp24079
g21395
I111
sg21396
VTsc2
p24080
sg21398
I4
sg21399
VC1860707
p24081
sg21401
I1
sa(dp24082
g21395
I161
sg21396
Vuterine leiomyoma
p24083
sg21398
I17
sg21399
VC0042133
p24084
sg21401
I2
sa(dp24085
g21395
I90
sg21396
VTSC1
p24086
sg21398
I4
sg21399
VC1854465
p24087
sg21401
I1
sa(dp24088
g21395
I90
sg21396
VTSC
p24089
sg21398
I3
sg21399
VC0041341
p24090
sg21401
I1
sa(dp24091
g21395
I111
sg21396
VTsc2
p24092
sg21398
I4
sg21399
VC1860707
p24093
sg21401
I1
sa(dp24094
g21395
I95
sg21396
g24076
sg21398
I4
sg21399
VC1860707
p24095
sg21401
I1
sasg21404
(lp24096
(dp24097
g21395
I111
sg21396
VTsc2
p24098
sg21398
I4
sg21408
VP49815
p24099
sg21401
I1
sa(dp24100
g21395
I49
sg21396
VOPN
p24101
sg21398
I3
sg21408
VP10451
p24102
sg21401
I1
sa(dp24103
g21395
I90
sg21396
VTSC1
p24104
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp24105
g21395
I36
sg21396
Vosteopontin
p24106
sg21398
I11
sg21408
VP10451
p24107
sg21401
I1
sa(dp24108
g21395
I111
sg21396
VTsc2
p24109
sg21398
I4
sg21408
VP49815
p24110
sg21401
I1
sa(dp24111
g21395
I95
sg21396
g24075
sg21398
I4
sg21408
VP49815
p24112
sg21401
I1
sasa(dp24113
g21386
VTSC2-deficient Eker rat uterine leiomyoma ELT3 cells were stably transfected with empty vector or plasmid for the expression of TSC2.
p24114
sg4
(dp24115
(VTSC2
p24116
VTSC2
p24117
tp24118
I00
ssg21392
(lp24119
(dp24120
g21395
I0
sg21396
VTSC2
p24121
sg21398
I4
sg21399
VC1860707
p24122
sg21401
I1
sa(dp24123
g21395
I24
sg21396
Vuterine leiomyoma
p24124
sg21398
I17
sg21399
VC0042133
p24125
sg21401
I2
sa(dp24126
g21395
I0
sg21396
g24117
sg21398
I4
sg21399
VC1860707
p24127
sg21401
I1
sasg21404
(lp24128
(dp24129
g21395
I0
sg21396
VTSC2
p24130
sg21398
I4
sg21408
VP49815
p24131
sg21401
I1
sa(dp24132
g21395
I0
sg21396
g24116
sg21398
I4
sg21408
VP49815
p24133
sg21401
I1
sasa(dp24134
g21386
VBy analyzing Tsc2-null mouse embryonic fibroblasts (MEFs) and rat uterine leiomyoma-derived Tsc2-null ELT3 cells, we detected evidence for the involvement of cyclooxygenase 2 (COX2) as a downstream target of mTORC1 in the development of TSC tumors.
p24135
sg4
(dp24136
(Vcyclooxygenase 2
p24137
VTsc2
p24138
tp24139
I00
ssg21392
(lp24140
(dp24141
g21395
I66
sg21396
Vuterine leiomyoma
p24142
sg21398
I17
sg21399
VC0042133
p24143
sg21401
I2
sa(dp24144
g21395
I237
sg21396
VTSC
p24145
sg21398
I3
sg21399
VC0041341
p24146
sg21401
I1
sa(dp24147
g21395
I13
sg21396
VTsc2
p24148
sg21398
I4
sg21399
VC1860707
p24149
sg21401
I1
sa(dp24150
g21395
I13
sg21396
g24138
sg21398
I4
sg21399
VC1860707
p24151
sg21401
I1
sa(dp24152
g21395
I241
sg21396
Vtumors
p24153
sg21398
I6
sg21399
VC0027651
p24154
sg21401
I1
sasg21404
(lp24155
(dp24156
g21395
I13
sg21396
VTsc2
p24157
sg21398
I4
sg21408
VP49815
p24158
sg21401
I1
sa(dp24159
g21395
I13
sg21396
VTsc2
p24160
sg21398
I4
sg21408
VP49815
p24161
sg21401
I1
sa(dp24162
g21395
I176
sg21396
VCOX2
p24163
sg21398
I4
sg21408
VP35354
p24164
sg21401
I1
sa(dp24165
g21395
I158
sg21396
g24137
sg21398
I16
sg21408
VP35354
p24166
sg21401
I2
sasa(dp24167
g21386
VTSC2-positive and TSC2-negative mouse embryonic fibroblasts (MEF), 323-TSC2-positive and 323-TSC2-null MEF and Eker rat uterine leiomyoma (ELT3) cells were treated with doxycycline or rapamycin alone, or in combination.
p24168
sg4
(dp24169
(VTSC2
p24170
VTSC2
p24171
tp24172
I00
ssg21392
(lp24173
(dp24174
g21395
I0
sg21396
VTSC2
p24175
sg21398
I4
sg21399
VC1860707
p24176
sg21401
I1
sa(dp24177
g21395
I0
sg21396
VTSC2
p24178
sg21398
I4
sg21399
VC1860707
p24179
sg21401
I1
sa(dp24180
g21395
I0
sg21396
VTSC2
p24181
sg21398
I4
sg21399
VC1860707
p24182
sg21401
I1
sa(dp24183
g21395
I120
sg21396
Vuterine leiomyoma
p24184
sg21398
I17
sg21399
VC0042133
p24185
sg21401
I2
sa(dp24186
g21395
I0
sg21396
g24171
sg21398
I4
sg21399
VC1860707
p24187
sg21401
I1
sasg21404
(lp24188
(dp24189
g21395
I0
sg21396
VTSC2
p24190
sg21398
I4
sg21408
VP49815
p24191
sg21401
I1
sa(dp24192
g21395
I0
sg21396
VTSC2
p24193
sg21398
I4
sg21408
VP49815
p24194
sg21401
I1
sa(dp24195
g21395
I0
sg21396
VTSC2
p24196
sg21398
I4
sg21408
VP49815
p24197
sg21401
I1
sa(dp24198
g21395
I0
sg21396
g24170
sg21398
I4
sg21408
VP49815
p24199
sg21401
I1
sasa(dp24200
g21386
VImportantly, rapamycin treatment did not affect the expression of AdPLA2 and the production of PGE2 by TSC2-deficient mouse embryonic fibroblast (Tsc2-/-MEFs), rat uterine leiomyoma-derived ELT3 cells, and LAM patient-associated renal angiomyolipoma-derived "mesenchymal" cells.
p24201
sg4
(dp24202
(VTSC2-deficient mouse embryonic fibroblast
p24203
VTsc2
p24204
tp24205
I00
ssg21392
(lp24206
(dp24207
g21395
I229
sg21396
Vrenal angiomyolipoma
p24208
sg21398
I20
sg21399
VC0241961
p24209
sg21401
I2
sa(dp24210
g21395
I206
sg21396
VLAM
p24211
sg21398
I3
sg21399
VC0751674
p24212
sg21401
I1
sa(dp24213
g21395
I164
sg21396
Vuterine leiomyoma
p24214
sg21398
I17
sg21399
VC0042133
p24215
sg21401
I2
sa(dp24216
g21395
I103
sg21396
VTSC2
p24217
sg21398
I4
sg21399
VC1860707
p24218
sg21401
I1
sa(dp24219
g21395
I146
sg21396
g24204
sg21398
I4
sg21399
VC1860707
p24220
sg21401
I1
sasg21404
(lp24221
(dp24222
g21395
I146
sg21396
VTsc2-/-MEFs
p24223
sg21398
I11
sg21408
VP49815
p24224
sg21401
I1
sa(dp24225
g21395
I103
sg21396
g24203
sg21398
I41
sg21408
VP49815
p24226
sg21401
I4
sasa(dp24227
g21386
VLoss of the Tuberous Sclerosis 2 (TSC2) tumor suppressor has been proposed as a mechanism important for the etiology of uterine leiomyomata based on the Eker rat model.
p24228
sg4
(dp24229
(VTuberous Sclerosis 2
p24230
VTuberous Sclerosis 2
p24231
tp24232
I00
ssg21392
(lp24233
(dp24234
g21395
I120
sg21396
Vuterine leiomyomata
p24235
sg21398
I19
sg21399
VC0042133
p24236
sg21401
I2
sa(dp24237
g21395
I34
sg21396
VTSC2
p24238
sg21398
I4
sg21399
VC1860707
p24239
sg21401
I1
sa(dp24240
g21395
I12
sg21396
g24231
sg21398
I20
sg21399
VC1860707
p24241
sg21401
I3
sa(dp24242
g21395
I40
sg21396
Vtumor
p24243
sg21398
I5
sg21399
VC0027651
p24244
sg21401
I1
sasg21404
(lp24245
(dp24246
g21395
I34
sg21396
VTSC2
p24247
sg21398
I4
sg21408
VP49815
p24248
sg21401
I1
sa(dp24249
g21395
I12
sg21396
g24230
sg21398
I20
sg21408
VP49815
p24250
sg21401
I3
sasa(dp24251
g21386
VHowever, conflicting evidence showing increased TSC2 expression has been reported in human uterine leiomyomata, suggesting that TSC2 might not be involved in the pathogenesis of this disorder.
p24252
sg4
(dp24253
(VTSC2
p24254
VTSC2
p24255
tp24256
I00
ssg21392
(lp24257
(dp24258
g21395
I162
sg21396
Vpathogenesis
p24259
sg21398
I12
sg21399
VC0699748
p24260
sg21401
I1
sa(dp24261
g21395
I91
sg21396
Vuterine leiomyomata
p24262
sg21398
I19
sg21399
VC0042133
p24263
sg21401
I2
sa(dp24264
g21395
I48
sg21396
VTSC2
p24265
sg21398
I4
sg21399
VC1860707
p24266
sg21401
I1
sa(dp24267
g21395
I48
sg21396
g24255
sg21398
I4
sg21399
VC1860707
p24268
sg21401
I1
sasg21404
(lp24269
(dp24270
g21395
I48
sg21396
VTSC2
p24271
sg21398
I4
sg21408
VP49815
p24272
sg21401
I1
sa(dp24273
g21395
I48
sg21396
g24254
sg21398
I4
sg21408
VP49815
p24274
sg21401
I1
sasa(dp24275
g21386
VIn cell culture models of TSC2-deficient LAM patient-derived and rat uterine leiomyoma-derived cells, we found that progesterone treatment or progesterone plus estradiol resulted in increased phosphorylation of Protein Kinase B (Akt) and Extracellular signal-regulated kinases1/2 (ERK1/2), induced the proliferation, and enhanced the migration and invasiveness.
p24276
sg4
(dp24277
(VERK1/2
p24278
Vuterine leiomyoma
p24279
tp24280
I00
ssg21392
(lp24281
(dp24282
g21395
I41
sg21396
VLAM
p24283
sg21398
I3
sg21399
VC0751674
p24284
sg21401
I1
sa(dp24285
g21395
I302
sg21396
Vproliferation
p24286
sg21398
I13
sg21399
VC0334094
p24287
sg21401
I1
sa(dp24288
g21395
I26
sg21396
VTSC2
p24289
sg21398
I4
sg21399
VC1860707
p24290
sg21401
I1
sa(dp24291
g21395
I69
sg21396
g24279
sg21398
I17
sg21399
VC0042133
p24292
sg21401
I2
sasg21404
(lp24293
(dp24294
g21395
I211
sg21396
VProtein Kinase B
p24295
sg21398
I16
sg21408
VP31749
p24296
sg21401
I3
sa(dp24297
g21395
I26
sg21396
VTSC2
p24298
sg21398
I4
sg21408
VP49815
p24299
sg21401
I1
sa(dp24300
g21395
I238
sg21396
VExtracellular signal-regulated kinases1/2
p24301
sg21398
I41
sg21408
VP35555
p24302
sg21401
I3
sa(dp24303
g21395
I229
sg21396
VAkt
p24304
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp24305
g21395
I281
sg21396
g24278
sg21398
I6
sg21408
VP27361
p24306
sg21401
I1
sasa(dp24307
g21386
VWe report here that expression of AlfaB-crystallin was upregulated in Tsc1-/- or Tsc2-/- mouse embryonic fibroblasts, Eker rat uterine leiomyoma-derived Tsc2-deficient ELT3 cells, mutant Tsc2-associated mouse kidney tumors, and human lung lymphangioleiomyomatosis nodules.
p24308
sg4
(dp24309
(VTsc2
p24310
Vlung lymphangioleiomyomatosis
p24311
tp24312
I00
ssg21392
(lp24313
(dp24314
g21395
I81
sg21396
VTsc2
p24315
sg21398
I4
sg21399
VC1860707
p24316
sg21401
I1
sa(dp24317
g21395
I70
sg21396
VTsc1
p24318
sg21398
I4
sg21399
VC1854465
p24319
sg21401
I1
sa(dp24320
g21395
I209
sg21396
Vkidney tumors
p24321
sg21398
I13
sg21399
VC0022665
p24322
sg21401
I2
sa(dp24323
g21395
I81
sg21396
VTsc2
p24324
sg21398
I4
sg21399
VC1860707
p24325
sg21401
I1
sa(dp24326
g21395
I264
sg21396
Vnodules
p24327
sg21398
I7
sg21399
VC0028259
p24328
sg21401
I1
sa(dp24329
g21395
I127
sg21396
Vuterine leiomyoma
p24330
sg21398
I17
sg21399
VC0042133
p24331
sg21401
I2
sa(dp24332
g21395
I81
sg21396
VTsc2
p24333
sg21398
I4
sg21399
VC1860707
p24334
sg21401
I1
sa(dp24335
g21395
I180
sg21396
Vmutant
p24336
sg21398
I6
sg21399
VC0596988
p24337
sg21401
I1
sa(dp24338
g21395
I234
sg21396
g24311
sg21398
I29
sg21399
VC0349649
p24339
sg21401
I2
sasg21404
(lp24340
(dp24341
g21395
I81
sg21396
VTsc2
p24342
sg21398
I4
sg21408
VP49815
p24343
sg21401
I1
sa(dp24344
g21395
I34
sg21396
VAlfaB-crystallin
p24345
sg21398
I16
sg21408
VP22914
p24346
sg21401
I1
sa(dp24347
g21395
I81
sg21396
VTsc2
p24348
sg21398
I4
sg21408
VP49815
p24349
sg21401
I1
sa(dp24350
g21395
I81
sg21396
g24310
sg21398
I4
sg21408
VP49815
p24351
sg21401
I1
sa(dp24352
g21395
I70
sg21396
VTsc1
p24353
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp24354
g21386
VFemale Eker rats harboring an insertional deletion in one copy of the tuberous sclerosis complex 2 (Tsc2) gene develop uterine leiomyoma, but the underlying mechanism of human uterine leiomyoma is not completely understood.
p24355
sg4
(dp24356
(Vtuberous sclerosis complex 2
p24357
Vuterine leiomyoma
p24358
tp24359
I00
ssg21392
(lp24360
(dp24361
g21395
I119
sg21396
Vuterine leiomyoma
p24362
sg21398
I17
sg21399
VC0042133
p24363
sg21401
I2
sa(dp24364
g21395
I100
sg21396
VTsc2
p24365
sg21398
I4
sg21399
VC1860707
p24366
sg21401
I1
sa(dp24367
g21395
I70
sg21396
Vtuberous sclerosis complex 2
p24368
sg21398
I28
sg21399
VC1860707
p24369
sg21401
I4
sa(dp24370
g21395
I119
sg21396
g24358
sg21398
I17
sg21399
VC0042133
p24371
sg21401
I2
sasg21404
(lp24372
(dp24373
g21395
I100
sg21396
VTsc2
p24374
sg21398
I4
sg21408
VP49815
p24375
sg21401
I1
sa(dp24376
g21395
I70
sg21396
g24357
sg21398
I28
sg21408
VP49815
p24377
sg21401
I4
sasa(dp24378
g21386
VTo examine whether down-regulation of tuberin, a TSC2 gene product, is present in human uterine leiomyoma, we analyzed leiomyoma and matched myometrium tissues from 22 Chinese patients with Western blotting and real-time polymerase chain reaction analyses, and found that the expression of tuberin was significantly increased in leiomyoma tissues compared with matched myometrium tissues with inhibition of both the mammalian target of rapacmycin pathway and mitogen-activated protein kinase pathways.
p24379
sg4
(dp24380
(Vmitogen-activated protein kinase
p24381
VTSC2
p24382
tp24383
I00
ssg21392
(lp24384
(dp24385
g21395
I96
sg21396
Vleiomyoma
p24386
sg21398
I9
sg21399
VC0042133
p24387
sg21401
I1
sa(dp24388
g21395
I88
sg21396
Vuterine leiomyoma
p24389
sg21398
I17
sg21399
VC0042133
p24390
sg21401
I2
sa(dp24391
g21395
I96
sg21396
Vleiomyoma
p24392
sg21398
I9
sg21399
VC0042133
p24393
sg21401
I1
sa(dp24394
g21395
I49
sg21396
g24382
sg21398
I4
sg21399
VC1860707
p24395
sg21401
I1
sasg21404
(lp24396
(dp24397
g21395
I38
sg21396
Vtuberin
p24398
sg21398
I7
sg21408
VP49815
p24399
sg21401
I1
sa(dp24400
g21395
I49
sg21396
VTSC2 gene product
p24401
sg21398
I17
sg21408
VP49815
p24402
sg21401
I3
sa(dp24403
g21395
I38
sg21396
Vtuberin
p24404
sg21398
I7
sg21408
VP49815
p24405
sg21401
I1
sa(dp24406
g21395
I459
sg21396
g24381
sg21398
I32
sg21408
VP53779
p24407
sg21401
I3
sasa(dp24408
g21386
VCells derived from an Eker rat uterine leiomyoma (ELT3 cells) are Tsc2-null and these have been used in a rodent cell models for LAM.
p24409
sg4
(dp24410
(VTsc2-null
p24411
VTsc2
p24412
tp24413
I00
ssg21392
(lp24414
(dp24415
g21395
I129
sg21396
VLAM
p24416
sg21398
I3
sg21399
VC0751674
p24417
sg21401
I1
sa(dp24418
g21395
I31
sg21396
Vuterine leiomyoma
p24419
sg21398
I17
sg21399
VC0042133
p24420
sg21401
I2
sa(dp24421
g21395
I66
sg21396
g24412
sg21398
I4
sg21399
VC1860707
p24422
sg21401
I1
sasg21404
(lp24423
(dp24424
g21395
I66
sg21396
g24411
sg21398
I9
sg21408
VP49815
p24425
sg21401
I1
sasa(dp24426
g21386
VIn patients with rheumatoid arthritis, furin is reported to be highly expressed in the synovial pannus compared with healthy persons.
p24427
sg4
(dp24428
(Vfurin
p24429
Vrheumatoid arthritis
p24430
tp24431
I00
ssg21392
(lp24432
(dp24433
g21395
I96
sg21396
Vpannus
p24434
sg21398
I6
sg21399
VC0155094
p24435
sg21401
I1
sa(dp24436
g21395
I17
sg21396
g24430
sg21398
I20
sg21399
VC0003873
p24437
sg21401
I2
sasg21404
(lp24438
(dp24439
g21395
I39
sg21396
g24429
sg21398
I5
sg21408
VP09958
p24440
sg21401
I1
sasa(dp24441
g21386
VInhibition of furin enhances invasive phenotype of synoviocytes from patients with rheumatoid arthritis, implying a protective role of furin.
p24442
sg4
(dp24443
(Vfurin
p24444
Vrheumatoid arthritis
p24445
tp24446
I00
ssg21392
(lp24447
(dp24448
g21395
I83
sg21396
g24445
sg21398
I20
sg21399
VC0003873
p24449
sg21401
I2
sasg21404
(lp24450
(dp24451
g21395
I14
sg21396
Vfurin
p24452
sg21398
I5
sg21408
VP09958
p24453
sg21401
I1
sa(dp24454
g21395
I14
sg21396
g24444
sg21398
I5
sg21408
VP09958
p24455
sg21401
I1
sasa(dp24456
g21386
VAgents targeting upregulation of furin may have therapeutic potential for rheumatoid arthritis.
p24457
sg4
(dp24458
(Vfurin
p24459
Vrheumatoid arthritis
p24460
tp24461
I00
ssg21392
(lp24462
(dp24463
g21395
I74
sg21396
g24460
sg21398
I20
sg21399
VC0003873
p24464
sg21401
I2
sasg21404
(lp24465
(dp24466
g21395
I33
sg21396
g24459
sg21398
I5
sg21408
VP09958
p24467
sg21401
I1
sasa(dp24468
g21386
VThe effect of furin and its inhibitor Alfa1-PDX was tested in mice with collagen-induced arthritis (CIA).
p24469
sg4
(dp24470
(Vfurin
p24471
Varthritis
p24472
tp24473
I00
ssg21392
(lp24474
(dp24475
g21395
I89
sg21396
g24472
sg21398
I9
sg21399
VC0003864
p24476
sg21401
I1
sasg21404
(lp24477
(dp24478
g21395
I14
sg21396
g24471
sg21398
I5
sg21408
VP09958
p24479
sg21401
I1
sasa(dp24480
g21386
VSystemic administration of furin prevented increases in the arthritis score, joint destruction, and bone loss, in contrast to systemic administration of the furin inhibitor Alfa1-PDX, which enhanced these parameters.
p24481
sg4
(dp24482
(Vfurin
p24483
Vbone loss
p24484
tp24485
I00
ssg21392
(lp24486
(dp24487
g21395
I60
sg21396
Varthritis
p24488
sg21398
I9
sg21399
VC0003864
p24489
sg21401
I1
sa(dp24490
g21395
I100
sg21396
g24484
sg21398
I9
sg21399
VC0029453
p24491
sg21401
I2
sasg21404
(lp24492
(dp24493
g21395
I27
sg21396
Vfurin
p24494
sg21398
I5
sg21408
VP09958
p24495
sg21401
I1
sa(dp24496
g21395
I27
sg21396
g24483
sg21398
I5
sg21408
VP09958
p24497
sg21401
I1
sasa(dp24498
g21386
VThey also suggest that Adamts5 induction in joint components other than cartilage, and its post-translational activation by PACE4 and/or furin may be important in the pathophysiology of arthritis.
p24499
sg4
(dp24500
(Vfurin
p24501
Varthritis
p24502
tp24503
I00
ssg21392
(lp24504
(dp24505
g21395
I186
sg21396
g24502
sg21398
I9
sg21399
VC0003864
p24506
sg21401
I1
sasg21404
(lp24507
(dp24508
g21395
I23
sg21396
VAdamts5
p24509
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp24510
g21395
I137
sg21396
g24501
sg21398
I5
sg21408
VP09958
p24511
sg21401
I1
sasa(dp24512
g21386
VWhen comparing the chorioamniotic membranes from women in spontaneous preterm labor with acute histologic chorioamnionitis to those without this placental lesion, we found that (1) the mRNA of NLR family pyrin domain-containing protein ( NLRP) 1, NLRP3, NLR family CARD domain-containing protein 4 ( NLRC4), and NOD2 were higher; (2) the NLRP3 protein was increased; (3) the mRNA and active form (p10) of CASP-1 were greater; (4) the mRNA and active form of CASP-4 were increased; (5) the mRNA and mature form of IL-1Beta were higher; (6) the mature form of IL-18 was elevated; and (7) ASC/CASP-1 complex formation was increased.
p24513
sg4
(dp24514
(Vp10
p24515
Vpreterm labor
p24516
tp24517
I00
ssg21392
(lp24518
(dp24519
g21395
I106
sg21396
Vchorioamnionitis
p24520
sg21398
I16
sg21399
VC0008495
p24521
sg21401
I1
sa(dp24522
g21395
I70
sg21396
g24516
sg21398
I13
sg21399
VC0022876
p24523
sg21401
I2
sasg21404
(lp24524
(dp24525
g21395
I193
sg21396
VNLR family pyrin domain-containing protein ( NLRP) 1
p24526
sg21398
I52
sg21408
g190
sg21401
I8
sa(dp24527
g21395
I513
sg21396
VIL-1Beta
p24528
sg21398
I8
sg21408
VP01584
p24529
sg21401
I1
sa(dp24530
g21395
I300
sg21396
VNLRC4
p24531
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp24532
g21395
I254
sg21396
VNLR family CARD domain-containing protein 4
p24533
sg21398
I43
sg21408
g190
sg21401
I6
sa(dp24534
g21395
I458
sg21396
VCASP-4
p24535
sg21398
I6
sg21408
VP39880
p24536
sg21401
I1
sa(dp24537
g21395
I405
sg21396
VCASP-1
p24538
sg21398
I6
sg21408
VP39880
p24539
sg21401
I1
sa(dp24540
g21395
I312
sg21396
VNOD2
p24541
sg21398
I4
sg21408
VP22301
p24542
sg21401
I1
sa(dp24543
g21395
I397
sg21396
g24515
sg21398
I3
sg21408
VP60903
p24544
sg21401
I1
sasa(dp24545
g21386
VWhen comparing the chorioamniotic membranes from women in spontaneous labor at term with acute histologic chorioamnionitis to those without this placental lesion, we found that (1) the messenger RNA (mRNA) abundance of NLR family pyrin domain containing 3 ( NLRP3), NLR family CARD domain containing 4 ( NLRC4), absent in melanoma 2 ( AIM2), and nucleotide binding oligomerization domain 2 ( NOD2) was higher; (2) the NLRP3 and NLRC4 protein quantities were increased; (3) the mRNA and protein expressions of CASP-1 and its active forms were greater; (4) CASP-4 was increased at the mRNA level only; (5) the mRNA and protein expressions of IL-1Beta and its mature form were higher; and (6) a modest increase in the total protein concentration and abundance of the mature form of IL-18 was observed.
p24546
sg4
(dp24547
(VNOD2
p24548
Vmelanoma
p24549
tp24550
I00
ssg21392
(lp24551
(dp24552
g21395
I106
sg21396
Vchorioamnionitis
p24553
sg21398
I16
sg21399
VC0008495
p24554
sg21401
I1
sa(dp24555
g21395
I322
sg21396
g24549
sg21398
I8
sg21399
VC0025202
p24556
sg21401
I1
sasg21404
(lp24557
(dp24558
g21395
I335
sg21396
VAIM2
p24559
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp24560
g21395
I266
sg21396
VNLR family CARD domain containing 4
p24561
sg21398
I35
sg21408
g190
sg21401
I6
sa(dp24562
g21395
I640
sg21396
VIL-1Beta
p24563
sg21398
I8
sg21408
VP01584
p24564
sg21401
I1
sa(dp24565
g21395
I304
sg21396
VNLRC4
p24566
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp24567
g21395
I509
sg21396
VCASP-1
p24568
sg21398
I6
sg21408
VP39880
p24569
sg21401
I1
sa(dp24570
g21395
I219
sg21396
VNLR family pyrin domain containing 3
p24571
sg21398
I36
sg21408
g190
sg21401
I6
sa(dp24572
g21395
I346
sg21396
Vnucleotide binding oligomerization domain 2
p24573
sg21398
I43
sg21408
VP63244
p24574
sg21401
I5
sa(dp24575
g21395
I428
sg21396
VNLRC4 protein
p24576
sg21398
I13
sg21408
g190
sg21401
I2
sa(dp24577
g21395
I392
sg21396
g24548
sg21398
I4
sg21408
VP22301
p24578
sg21401
I1
sasa(dp24579
g21386
VMutations in NLRP7 (NOD-like-receptor family, pyrin domain containing 7) are responsible for a type of recurrent pregnancy loss known as recurrent hydatidiform mole (HYDM1).
p24580
sg4
(dp24581
(VNOD-like-receptor family
p24582
VHYDM1
p24583
tp24584
I01
ssg21392
(lp24585
(dp24586
g21395
I20
sg21396
VNOD
p24587
sg21398
I3
sg21399
VC0751781
p24588
sg21401
I1
sa(dp24589
g21395
I103
sg21396
Vrecurrent pregnancy loss
p24590
sg21398
I24
sg21399
VC2921106
p24591
sg21401
I3
sa(dp24592
g21395
I147
sg21396
Vhydatidiform mole
p24593
sg21398
I17
sg21399
VC0020217
p24594
sg21401
I2
sa(dp24595
g21395
I166
sg21396
g24583
sg21398
I5
sg21399
VC3463897
p24596
sg21401
I1
sasg21404
(lp24597
(dp24598
g21395
I20
sg21396
g24582
sg21398
I24
sg21408
VP54259
p24599
sg21401
I2
sa(dp24600
g21395
I13
sg21396
VNLRP7
p24601
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp24602
g21395
I46
sg21396
Vpyrin domain containing 7
p24603
sg21398
I25
sg21408
g190
sg21401
I4
sasa(dp24604
g21386
VIn patient 1 an SDC4-NRG1 gene fusion was detected, similar gene fusions having been described in lung cancers previously.
p24605
sg4
(dp24606
(VSDC4
p24607
Vlung cancers
p24608
tp24609
I00
ssg21392
(lp24610
(dp24611
g21395
I26
sg21396
Vgene fusion
p24612
sg21398
I11
sg21399
VC1705736
p24613
sg21401
I2
sa(dp24614
g21395
I98
sg21396
g24608
sg21398
I12
sg21399
VC0242379
p24615
sg21401
I2
sasg21404
(lp24616
(dp24617
g21395
I60
sg21396
Vgene fusions
p24618
sg21398
I12
sg21408
VP35637
p24619
sg21401
I2
sa(dp24620
g21395
I16
sg21396
g24607
sg21398
I4
sg21408
VP31431
p24621
sg21401
I1
sasa(dp24622
g21386
VWe highlight the current knowledge about the ErbB network and NRG1 deregulation in lung cancer and their merger into the ErbB/PI3K-AKT axis modulation and current therapeutic strategies.
p24623
sg4
(dp24624
(VPI3K
p24625
Vlung cancer
p24626
tp24627
I00
ssg21392
(lp24628
(dp24629
g21395
I83
sg21396
g24626
sg21398
I11
sg21399
VC0684249
p24630
sg21401
I2
sasg21404
(lp24631
(dp24632
g21395
I45
sg21396
VErbB
p24633
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp24634
g21395
I131
sg21396
VAKT
p24635
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp24636
g21395
I126
sg21396
g24625
sg21398
I4
sg21408
VP42336
p24637
sg21401
I1
sa(dp24638
g21395
I45
sg21396
VErbB network
p24639
sg21398
I12
sg21408
g190
sg21401
I2
sasa(dp24640
g21386
VMore advances in knowledge of crosstalk between NRG1, ErbB3 and PI3K-AKT pathways may increase and strongly support the therapeutic choice for lung cancer patients.
p24641
sg4
(dp24642
(VErbB3
p24643
Vlung cancer
p24644
tp24645
I00
ssg21392
(lp24646
(dp24647
g21395
I143
sg21396
g24644
sg21398
I11
sg21399
VC0684249
p24648
sg21401
I2
sasg21404
(lp24649
(dp24650
g21395
I64
sg21396
VPI3K
p24651
sg21398
I4
sg21408
VP42336
p24652
sg21401
I1
sa(dp24653
g21395
I54
sg21396
g24643
sg21398
I5
sg21408
VP21860
p24654
sg21401
I1
sa(dp24655
g21395
I69
sg21396
VAKT
p24656
sg21398
I3
sg21408
g190
sg21401
I1
sasa(dp24657
g21386
VAll coding exons of SCN1B, GABRG2, and CACNB4 genes were screened for mutations in 38 SCN1A-mutation-positive SMEI probands.
p24658
sg4
(dp24659
(VGABRG2
p24660
VSMEI
p24661
tp24662
I00
ssg21392
(lp24663
(dp24664
g21395
I110
sg21396
g24661
sg21398
I4
sg21399
VC0751122
p24665
sg21401
I1
sasg21404
(lp24666
(dp24667
g21395
I86
sg21396
VSCN1A
p24668
sg21398
I5
sg21408
VP35498
p24669
sg21401
I1
sa(dp24670
g21395
I20
sg21396
VSCN1B
p24671
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp24672
g21395
I39
sg21396
VCACNB4 genes
p24673
sg21398
I12
sg21408
g190
sg21401
I2
sa(dp24674
g21395
I27
sg21396
g24660
sg21398
I6
sg21408
VP18507
p24675
sg21401
I1
sasa(dp24676
g21386
VFurthermore, we demonstrated that the activation of COX-2 expression by hnRNPA2/B1 was mediated through the cooperation with p300, a transcriptional co-activator, in NSCLC cells.
p24677
sg4
(dp24678
(VCOX-2
p24679
VNSCLC
p24680
tp24681
I00
ssg21392
(lp24682
(dp24683
g21395
I166
sg21396
g24680
sg21398
I5
sg21399
VC0007131
p24684
sg21401
I1
sasg21404
(lp24685
(dp24686
g21395
I72
sg21396
VhnRNPA2
p24687
sg21398
I7
sg21408
VP22626
p24688
sg21401
I1
sa(dp24689
g21395
I52
sg21396
g24679
sg21398
I5
sg21408
VP35354
p24690
sg21401
I1
sa(dp24691
g21395
I125
sg21396
Vp300
p24692
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp24693
g21386
VFurthermore, eight of the 17 CpG sites reside in genes (FSTL1, SORCS2, NRF1, DLC1, PPARGC1B, CHN2, NXPH1) that have prior known associations with obesity, diabetes, and the insulin pathway.
p24694
sg4
(dp24695
(VNXPH1
p24696
Vobesity
p24697
tp24698
I00
ssg21392
(lp24699
(dp24700
g21395
I155
sg21396
Vdiabetes
p24701
sg21398
I8
sg21399
VC0011849
p24702
sg21401
I1
sa(dp24703
g21395
I146
sg21396
g24697
sg21398
I7
sg21399
VC0028754
p24704
sg21401
I1
sasg21404
(lp24705
(dp24706
g21395
I63
sg21396
VSORCS2
p24707
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp24708
g21395
I93
sg21396
VCHN2
p24709
sg21398
I4
sg21408
VP52757
p24710
sg21401
I1
sa(dp24711
g21395
I71
sg21396
VNRF1
p24712
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp24713
g21395
I56
sg21396
VFSTL1
p24714
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp24715
g21395
I77
sg21396
VDLC1
p24716
sg21398
I4
sg21408
VP63167
p24717
sg21401
I1
sa(dp24718
g21395
I173
sg21396
Vinsulin
p24719
sg21398
I7
sg21408
VP01308
p24720
sg21401
I1
sa(dp24721
g21395
I99
sg21396
g24696
sg21398
I5
sg21408
VP58417
p24722
sg21401
I1
sasa(dp24723
g21386
VNo significant associations were found, although the top significant CpGs in boys were located in the LRPAP1, HAGH, PPARGC1B, KCNQ1 and KCNQ1DN genes, previously associated to birth weight, Type 2 diabetes, obesity or steroid hormone signaling.
p24724
sg4
(dp24725
(VLRPAP1
p24726
Vobesity
p24727
tp24728
I00
ssg21392
(lp24729
(dp24730
g21395
I190
sg21396
VType 2 diabetes
p24731
sg21398
I15
sg21399
VC0011860
p24732
sg21401
I3
sa(dp24733
g21395
I207
sg21396
g24727
sg21398
I7
sg21399
VC0028754
p24734
sg21401
I1
sasg21404
(lp24735
(dp24736
g21395
I136
sg21396
VKCNQ1DN genes
p24737
sg21398
I13
sg21408
g190
sg21401
I2
sa(dp24738
g21395
I126
sg21396
VKCNQ1
p24739
sg21398
I5
sg21408
VP51787
p24740
sg21401
I1
sa(dp24741
g21395
I102
sg21396
g24726
sg21398
I6
sg21408
VP30533
p24742
sg21401
I1
sa(dp24743
g21395
I110
sg21396
VHAGH
p24744
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp24745
g21386
VWe used a two-stage study design to evaluate whether variations in the peroxisome proliferator-activated receptors (PPAR) and the PPAR gamma co-activator 1 (PGC1) gene families (PPARA, PPARG, PPARD, PPARGC1A, and PPARGC1B) are associated with type 2 diabetes (T2D) risk.
p24746
sg4
(dp24747
(Vgene families
p24748
Vtype 2 diabetes
p24749
tp24750
I00
ssg21392
(lp24751
(dp24752
g21395
I260
sg21396
VT2D
p24753
sg21398
I3
sg21399
VC0011860
p24754
sg21401
I1
sa(dp24755
g21395
I243
sg21396
g24749
sg21398
I15
sg21399
VC0011860
p24756
sg21401
I3
sasg21404
(lp24757
(dp24758
g21395
I163
sg21396
g24748
sg21398
I13
sg21408
VP19883
p24759
sg21401
I2
sa(dp24760
g21395
I157
sg21396
VPGC1
p24761
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp24762
g21395
I199
sg21396
VPPARGC1A
p24763
sg21398
I8
sg21408
g190
sg21401
I1
sa(dp24764
g21395
I116
sg21396
VPPAR
p24765
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp24766
g21395
I71
sg21396
Vperoxisome proliferator-activated receptors
p24767
sg21398
I43
sg21408
g190
sg21401
I3
sa(dp24768
g21395
I130
sg21396
VPPAR gamma co-activator 1
p24769
sg21398
I25
sg21408
g190
sg21401
I4
sa(dp24770
g21395
I185
sg21396
VPPARG
p24771
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp24772
g21395
I192
sg21396
VPPARD
p24773
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp24774
g21395
I178
sg21396
VPPARA
p24775
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp24776
g21386
VA recently identified muscular dystrophy gene TOR1AIP1 was detected as a hub gene in dysferlinopathy.
p24777
sg4
(dp24778
(Vmuscular dystrophy gene TOR1AIP1
p24779
Vdysferlinopathy
p24780
tp24781
I00
ssg21392
(lp24782
(dp24783
g21395
I22
sg21396
Vmuscular dystrophy
p24784
sg21398
I18
sg21399
VC0026850
p24785
sg21401
I2
sa(dp24786
g21395
I85
sg21396
g24780
sg21398
I15
sg21399
VC2931687
p24787
sg21401
I1
sasg21404
(lp24788
(dp24789
g21395
I73
sg21396
Vhub gene
p24790
sg21398
I8
sg21408
g190
sg21401
I2
sa(dp24791
g21395
I22
sg21396
g24779
sg21398
I32
sg21408
VP43034
p24792
sg21401
I4
sasa(dp24793
g21386
VTorsinA-interacting protein 1 (TOR1AIP1) gene is a novel gene that has recently been described to cause limb-girdle muscular dystrophy (LGMD) with mild dilated cardiomyopathy.
p24794
sg4
(dp24795
(VTorsinA-interacting protein 1
p24796
VLGMD
p24797
tp24798
I00
ssg21392
(lp24799
(dp24800
g21395
I152
sg21396
Vdilated cardiomyopathy
p24801
sg21398
I22
sg21399
VC0007193
p24802
sg21401
I2
sa(dp24803
g21395
I104
sg21396
Vlimb-girdle muscular dystrophy
p24804
sg21398
I30
sg21399
VC0686353
p24805
sg21401
I3
sa(dp24806
g21395
I136
sg21396
g24797
sg21398
I4
sg21399
VC0686353
p24807
sg21401
I1
sasg21404
(lp24808
(dp24809
g21395
I0
sg21396
g24796
sg21398
I29
sg21408
VP14222
p24810
sg21401
I3
sasa(dp24811
g21386
VThese scientific contributions strengthen the role of LAP1 in DYT1 dystonia and muscular dystrophy.
p24812
sg4
(dp24813
(VLAP1
p24814
Vmuscular dystrophy
p24815
tp24816
I00
ssg21392
(lp24817
(dp24818
g21395
I62
sg21396
VDYT1
p24819
sg21398
I4
sg21399
VC1851945
p24820
sg21401
I1
sa(dp24821
g21395
I67
sg21396
Vdystonia
p24822
sg21398
I8
sg21399
VC0393593
p24823
sg21401
I1
sa(dp24824
g21395
I80
sg21396
g24815
sg21398
I18
sg21399
VC0026850
p24825
sg21401
I2
sasg21404
(lp24826
(dp24827
g21395
I62
sg21396
VDYT1 dystonia
p24828
sg21398
I13
sg21408
g190
sg21401
I2
sa(dp24829
g21395
I54
sg21396
g24814
sg21398
I4
sg21408
VP15144
p24830
sg21401
I1
sasa(dp24831
g21386
VMoreover, LAP1 also interacts with torsinA and emerin, proteins involved in DYT1 dystonia and X-linked Emery-Dreifuss muscular dystrophy disorder, respectively.
p24832
sg4
(dp24833
(VLAP1
p24834
Vdystonia
p24835
tp24836
I00
ssg21392
(lp24837
(dp24838
g21395
I76
sg21396
VDYT1
p24839
sg21398
I4
sg21399
VC1851945
p24840
sg21401
I1
sa(dp24841
g21395
I94
sg21396
VX-linked Emery-Dreifuss muscular dystrophy
p24842
sg21398
I42
sg21399
VC0751337
p24843
sg21401
I4
sa(dp24844
g21395
I81
sg21396
g24835
sg21398
I8
sg21399
VC0393593
p24845
sg21401
I1
sasg21404
(lp24846
(dp24847
g21395
I76
sg21396
VDYT1
p24848
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp24849
g21395
I47
sg21396
Vemerin
p24850
sg21398
I6
sg21408
VP50402
p24851
sg21401
I1
sa(dp24852
g21395
I35
sg21396
VtorsinA
p24853
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp24854
g21395
I10
sg21396
g24834
sg21398
I4
sg21408
VP15144
p24855
sg21401
I1
sasa(dp24856
g21386
VThus, the transcriptional targets normally activated by RANKL that promote a proliferative response in luminal progenitors can contribute to the susceptibility of mammary epithelial cells to BRCA1-mutated breast cancers as a consequence of DDR-induced NF-kappaB.
p24857
sg4
(dp24858
(VNF-kappaB
p24859
Vbreast cancers
p24860
tp24861
I00
ssg21392
(lp24862
(dp24863
g21395
I77
sg21396
Vproliferative
p24864
sg21398
I13
sg21399
VC0334094
p24865
sg21401
I1
sa(dp24866
g21395
I205
sg21396
g24860
sg21398
I14
sg21399
VC0006142
p24867
sg21401
I2
sasg21404
(lp24868
(dp24869
g21395
I191
sg21396
VBRCA1
p24870
sg21398
I5
sg21408
VP38398
p24871
sg21401
I1
sa(dp24872
g21395
I252
sg21396
g24859
sg21398
I9
sg21408
VP19838
p24873
sg21401
I1
sa(dp24874
g21395
I56
sg21396
VRANKL
p24875
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp24876
g21386
VTCGA data analyses revealed that expression of APOBEC3D and APOBEC3H also correlates with CD3D across multiple cancer types.
p24877
sg4
(dp24878
(VCD3D
p24879
Vmultiple cancer
p24880
tp24881
I00
ssg21392
(lp24882
(dp24883
g21395
I102
sg21396
g24880
sg21398
I15
sg21399
VC0346429
p24884
sg21401
I2
sasg21404
(lp24885
(dp24886
g21395
I90
sg21396
g24879
sg21398
I4
sg21408
VP04234
p24887
sg21401
I1
sa(dp24888
g21395
I60
sg21396
VAPOBEC3H
p24889
sg21398
I8
sg21408
g190
sg21401
I1
sa(dp24890
g21395
I47
sg21396
VAPOBEC3D
p24891
sg21398
I8
sg21408
g190
sg21401
I1
sasa(dp24892
g21386
VHere, we address the contribution of the EP3 receptor in dictating early outcomes after transient cerebral ischemia.
p24893
sg4
(dp24894
(VEP3 receptor
p24895
Vtransient cerebral ischemia
p24896
tp24897
I00
ssg21392
(lp24898
(dp24899
g21395
I88
sg21396
g24896
sg21398
I27
sg21399
VC0917805
p24900
sg21401
I3
sasg21404
(lp24901
(dp24902
g21395
I41
sg21396
g24895
sg21398
I12
sg21408
VP43115
p24903
sg21401
I2
sasa(dp24904
g21386
VConversely, patients with endometriosis had significantly shortened activated partial thromboplastin time (APTT) when compared to controls (1.08 +/- 0.06 and 1.12 +/- 0.19, respectively; P &lt; .01).
p24905
sg4
(dp24906
(Vthromboplastin
p24907
Vendometriosis
p24908
tp24909
I01
ssg21392
(lp24910
(dp24911
g21395
I26
sg21396
g24908
sg21398
I13
sg21399
VC0014175
p24912
sg21401
I1
sasg21404
(lp24913
(dp24914
g21395
I86
sg21396
g24907
sg21398
I14
sg21408
VP13726
p24915
sg21401
I1
sasa(dp24916
g21386
VActivated partial thromboplastin time is shorter in women with endometriosis but still in the normal range.
p24917
sg4
(dp24918
(Vthromboplastin
p24919
Vendometriosis
p24920
tp24921
I01
ssg21392
(lp24922
(dp24923
g21395
I63
sg21396
g24920
sg21398
I13
sg21399
VC0014175
p24924
sg21401
I1
sasg21404
(lp24925
(dp24926
g21395
I18
sg21396
g24919
sg21398
I14
sg21408
VP13726
p24927
sg21401
I1
sasa(dp24928
g21386
VAre the levels of total circulating cell-derived microparticles (cMPs) and circulating tissue factor-containing microparticles (cMP-TF) increased in patients with endometriosis?
p24929
sg4
(dp24930
(VcMP-TF
p24931
Vendometriosis
p24932
tp24933
I00
ssg21392
(lp24934
(dp24935
g21395
I163
sg21396
g24932
sg21398
I13
sg21399
VC0014175
p24936
sg21401
I1
sasg21404
(lp24937
(dp24938
g21395
I128
sg21396
g24931
sg21398
I6
sg21408
VP21941
p24939
sg21401
I1
sasa(dp24940
g21386
VIncreased expression of tissue factor (a transmembrane receptor for Factor VII/VIIa) in eutopic and ectopic endometrium from patients with endometriosis has been described.
p24941
sg4
(dp24942
(VFactor VII/VIIa
p24943
Vendometriosis
p24944
tp24945
I00
ssg21392
(lp24946
(dp24947
g21395
I139
sg21396
g24944
sg21398
I13
sg21399
VC0014175
p24948
sg21401
I1
sasg21404
(lp24949
(dp24950
g21395
I68
sg21396
g24943
sg21398
I15
sg21408
VP08709
p24951
sg21401
I2
sasa(dp24952
g21386
VOverexpressing miR-378 in ovarian cancer cells altered expression of genes associated with angiogenesis (ALCAM, EHD1, ELK3, TLN1), apoptosis (RPN2, HIPK3), and cell cycle regulation (SWAP-70, LSM14A, RDX).
p24953
sg4
(dp24954
(VELK3
p24955
Vovarian cancer
p24956
tp24957
I00
ssg21392
(lp24958
(dp24959
g21395
I26
sg21396
g24956
sg21398
I14
sg21399
VC1140680
p24960
sg21401
I2
sasg21404
(lp24961
(dp24962
g21395
I148
sg21396
VHIPK3
p24963
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp24964
g21395
I15
sg21396
VmiR-378
p24965
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp24966
g21395
I105
sg21396
VALCAM
p24967
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp24968
g21395
I192
sg21396
VLSM14A
p24969
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp24970
g21395
I142
sg21396
VRPN2
p24971
sg21398
I4
sg21408
VP04844
p24972
sg21401
I1
sa(dp24973
g21395
I200
sg21396
VRDX
p24974
sg21398
I3
sg21408
VP35241
p24975
sg21401
I1
sa(dp24976
g21395
I183
sg21396
VSWAP-70
p24977
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp24978
g21395
I118
sg21396
g24955
sg21398
I4
sg21408
VP41970
p24979
sg21401
I1
sa(dp24980
g21395
I124
sg21396
VTLN1
p24981
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp24982
g21395
I112
sg21396
VEHD1
p24983
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp24984
g21386
VActivated leukocyte cell adhesion molecule (ALCAM) is expressed at the surface of epithelial ovarian cancer (EOC) cells and is released in a soluble form (sALCAM) by ADAM-17-mediated shedding.
p24985
sg4
(dp24986
(VADAM-17
p24987
Vepithelial ovarian cancer
p24988
tp24989
I01
ssg21392
(lp24990
(dp24991
g21395
I109
sg21396
VEOC
p24992
sg21398
I3
sg21399
VC0677886
p24993
sg21401
I1
sa(dp24994
g21395
I25
sg21396
Vadhesion
p24995
sg21398
I8
sg21399
VC0001511
p24996
sg21401
I1
sa(dp24997
g21395
I82
sg21396
g24988
sg21398
I25
sg21399
VC0677886
p24998
sg21401
I3
sasg21404
(lp24999
(dp25000
g21395
I44
sg21396
VALCAM
p25001
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp25002
g21395
I166
sg21396
g24987
sg21398
I7
sg21408
VP78536
p25003
sg21401
I1
sa(dp25004
g21395
I0
sg21396
VActivated leukocyte cell adhesion molecule
p25005
sg21398
I42
sg21408
g190
sg21401
I5
sasa(dp25006
g21386
VThe present study aimed to investigate the correlation of ubiquitin-specific peptidase 22 (USP22) with acquired resistance to cisplatin in lung adenocarcinoma.
p25007
sg4
(dp25008
(Vubiquitin-specific peptidase 22
p25009
Vlung adenocarcinoma
p25010
tp25011
I00
ssg21392
(lp25012
(dp25013
g21395
I139
sg21396
g25010
sg21398
I19
sg21399
VC0152013
p25014
sg21401
I2
sasg21404
(lp25015
(dp25016
g21395
I58
sg21396
g25009
sg21398
I31
sg21408
VP62979
p25017
sg21401
I3
sa(dp25018
g21395
I91
sg21396
VUSP22
p25019
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp25020
g21386
VIn this study, we explored the functional role of USP22 in modulating c-Myc stability and its physiological relevance in breast cancer progression.
p25021
sg4
(dp25022
(Vc-Myc
p25023
Vcancer progression
p25024
tp25025
I00
ssg21392
(lp25026
(dp25027
g21395
I128
sg21396
g25024
sg21398
I18
sg21399
VC0178874
p25028
sg21401
I2
sasg21404
(lp25029
(dp25030
g21395
I70
sg21396
g25023
sg21398
I5
sg21408
VP12524
p25031
sg21401
I1
sa(dp25032
g21395
I50
sg21396
VUSP22
p25033
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp25034
g21386
VWe found that USP22 promotes deubiquitination of c-Myc in several breast cancer cell lines, resulting in increased levels of c-Myc.
p25035
sg4
(dp25036
(Vc-Myc
p25037
Vbreast cancer
p25038
tp25039
I00
ssg21392
(lp25040
(dp25041
g21395
I66
sg21396
g25038
sg21398
I13
sg21399
VC0678222
p25042
sg21401
I2
sasg21404
(lp25043
(dp25044
g21395
I49
sg21396
Vc-Myc
p25045
sg21398
I5
sg21408
VP12524
p25046
sg21401
I1
sa(dp25047
g21395
I14
sg21396
VUSP22
p25048
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp25049
g21395
I49
sg21396
g25037
sg21398
I5
sg21408
VP12524
p25050
sg21401
I1
sasa(dp25051
g21386
VIn conclusion, the present study reveals that USP22 in breast cancer cell lines increases c-Myc stability through c-Myc deubiquitination, which is closely correlated with breast cancer progression.
p25052
sg4
(dp25053
(Vc-Myc
p25054
Vbreast cancer
p25055
tp25056
I00
ssg21392
(lp25057
(dp25058
g21395
I178
sg21396
Vcancer progression
p25059
sg21398
I18
sg21399
VC0178874
p25060
sg21401
I2
sa(dp25061
g21395
I55
sg21396
g25055
sg21398
I13
sg21399
VC0678222
p25062
sg21401
I2
sasg21404
(lp25063
(dp25064
g21395
I90
sg21396
Vc-Myc
p25065
sg21398
I5
sg21408
VP12524
p25066
sg21401
I1
sa(dp25067
g21395
I90
sg21396
g25054
sg21398
I5
sg21408
VP12524
p25068
sg21401
I1
sa(dp25069
g21395
I46
sg21396
VUSP22
p25070
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp25071
g21386
VCurcumin might have therapeutic potential in breast cancer through regulating breast cancer-related genes, including SERPINE1, PGAP3, MAP3K1, MAPK1, GSTO2, VIM, SPARC, and FGF2.
p25072
sg4
(dp25073
(VSERPINE1
p25074
Vbreast cancer
p25075
tp25076
I00
ssg21392
(lp25077
(dp25078
g21395
I45
sg21396
Vbreast cancer
p25079
sg21398
I13
sg21399
VC0678222
p25080
sg21401
I2
sa(dp25081
g21395
I45
sg21396
g25075
sg21398
I13
sg21399
VC0678222
p25082
sg21401
I2
sasg21404
(lp25083
(dp25084
g21395
I161
sg21396
VSPARC
p25085
sg21398
I5
sg21408
VP09486
p25086
sg21401
I1
sa(dp25087
g21395
I142
sg21396
VMAPK1
p25088
sg21398
I5
sg21408
VP28482
p25089
sg21401
I1
sa(dp25090
g21395
I134
sg21396
VMAP3K1
p25091
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp25092
g21395
I78
sg21396
Vbreast cancer-related genes
p25093
sg21398
I27
sg21408
VP01893
p25094
sg21401
I3
sa(dp25095
g21395
I117
sg21396
g25074
sg21398
I8
sg21408
VP05121
p25096
sg21401
I1
sa(dp25097
g21395
I149
sg21396
VGSTO2
p25098
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp25099
g21395
I127
sg21396
VPGAP3
p25100
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp25101
g21395
I172
sg21396
VFGF2
p25102
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp25103
g21386
VOur data showed that the level of CENPE, BAG2, SOD2, GDI2, CORO1C, CFL1, DSTN, CALD1, PHGDH, PDHA1, AKR1B1, TST and TBCA proteins were significantly up-regulated in the fibroblasts co-cultured with ovarian cancer cells, whereas HSPB1, P4HB and VIM were significantly down-regulated.
p25104
sg4
(dp25105
(VP4HB
p25106
Vovarian cancer
p25107
tp25108
I01
ssg21392
(lp25109
(dp25110
g21395
I198
sg21396
g25107
sg21398
I14
sg21399
VC1140680
p25111
sg21401
I2
sasg21404
(lp25112
(dp25113
g21395
I93
sg21396
VPDHA1
p25114
sg21398
I5
sg21408
VP08559
p25115
sg21401
I1
sa(dp25116
g21395
I100
sg21396
VAKR1B1
p25117
sg21398
I6
sg21408
VP15121
p25118
sg21401
I1
sa(dp25119
g21395
I79
sg21396
VCALD1
p25120
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp25121
g21395
I67
sg21396
VCFL1
p25122
sg21398
I4
sg21408
VP23528
p25123
sg21401
I1
sa(dp25124
g21395
I59
sg21396
VCORO1C
p25125
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp25126
g21395
I116
sg21396
VTBCA proteins
p25127
sg21398
I13
sg21408
g190
sg21401
I2
sa(dp25128
g21395
I73
sg21396
VDSTN
p25129
sg21398
I4
sg21408
VP60981
p25130
sg21401
I1
sa(dp25131
g21395
I47
sg21396
VSOD2
p25132
sg21398
I4
sg21408
VP04179
p25133
sg21401
I1
sa(dp25134
g21395
I53
sg21396
VGDI2
p25135
sg21398
I4
sg21408
VP50395
p25136
sg21401
I1
sa(dp25137
g21395
I235
sg21396
g25106
sg21398
I4
sg21408
VP07237
p25138
sg21401
I1
sa(dp25139
g21395
I108
sg21396
VTST
p25140
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp25141
g21395
I41
sg21396
VBAG2
p25142
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp25143
g21395
I86
sg21396
VPHGDH
p25144
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp25145
g21395
I34
sg21396
VCENPE
p25146
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp25147
g21386
VPreviously, using systems biology approach and cancer signaling networks, we identified top-5 highly expressed and connected proteins (HSP90AB1, CSNK2B, TK1, YWHAB and VIM) in the invasive MDA-MB-231 breast cancer cell line.
p25148
sg4
(dp25149
(VCSNK2B
p25150
Vbreast cancer
p25151
tp25152
I01
ssg21392
(lp25153
(dp25154
g21395
I200
sg21396
g25151
sg21398
I13
sg21399
VC0678222
p25155
sg21401
I2
sa(dp25156
g21395
I47
sg21396
Vcancer
p25157
sg21398
I6
sg21399
VC0006826
p25158
sg21401
I1
sasg21404
(lp25159
(dp25160
g21395
I158
sg21396
VYWHAB
p25161
sg21398
I5
sg21408
VP31946
p25162
sg21401
I1
sa(dp25163
g21395
I135
sg21396
VHSP90AB1
p25164
sg21398
I8
sg21408
VP08238
p25165
sg21401
I1
sa(dp25166
g21395
I153
sg21396
VTK1
p25167
sg21398
I3
sg21408
VP04183
p25168
sg21401
I1
sa(dp25169
g21395
I145
sg21396
g25150
sg21398
I6
sg21408
VP67870
p25170
sg21401
I1
sasa(dp25171
g21386
VElevated cAMP levels increased cell size and altered expression levels of cardiac genes and micro-RNAs associated with hypertrophic cardiomyopathy (HCM), including Myh6, Myh7, Myh7b, Tnni3, Anp, Bnp, Gata4, Mef2c, Mef2d, Nfatc1, miR208a, and miR208b.
p25172
sg4
(dp25173
(VBnp
p25174
VHCM
p25175
tp25176
I00
ssg21392
(lp25177
(dp25178
g21395
I119
sg21396
Vhypertrophic cardiomyopathy
p25179
sg21398
I27
sg21399
VC0007194
p25180
sg21401
I2
sa(dp25181
g21395
I148
sg21396
g25175
sg21398
I3
sg21399
VC0007194
p25182
sg21401
I1
sasg21404
(lp25183
(dp25184
g21395
I221
sg21396
VNfatc1
p25185
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp25186
g21395
I214
sg21396
VMef2d
p25187
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp25188
g21395
I176
sg21396
VMyh7b
p25189
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp25190
g21395
I183
sg21396
VTnni3
p25191
sg21398
I5
sg21408
VP19429
p25192
sg21401
I1
sa(dp25193
g21395
I200
sg21396
VGata4
p25194
sg21398
I5
sg21408
VP43694
p25195
sg21401
I1
sa(dp25196
g21395
I190
sg21396
VAnp
p25197
sg21398
I3
sg21408
VP16066
p25198
sg21401
I1
sa(dp25199
g21395
I164
sg21396
VMyh6
p25200
sg21398
I4
sg21408
VP13533
p25201
sg21401
I1
sa(dp25202
g21395
I195
sg21396
g25174
sg21398
I3
sg21408
VP16860
p25203
sg21401
I1
sa(dp25204
g21395
I207
sg21396
VMef2c
p25205
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp25206
g21386
VThe aim of this study was to determine whether miR-208, miR-208b, and miR-499 are expressed with MHC mRNA in human dilated cardiomyopathy (DCM), and whether these levels are related to left ventricular (LV) function and to clinical outcomes.
p25207
sg4
(dp25208
(VMHC mRNA
p25209
Vdilated cardiomyopathy
p25210
tp25211
I00
ssg21392
(lp25212
(dp25213
g21395
I139
sg21396
VDCM
p25214
sg21398
I3
sg21399
VC0007193
p25215
sg21401
I1
sa(dp25216
g21395
I115
sg21396
g25210
sg21398
I22
sg21399
VC0007193
p25217
sg21401
I2
sasg21404
(lp25218
(dp25219
g21395
I56
sg21396
VmiR-208b
p25220
sg21398
I8
sg21408
g190
sg21401
I1
sa(dp25221
g21395
I47
sg21396
VmiR-208
p25222
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp25223
g21395
I70
sg21396
VmiR-499
p25224
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp25225
g21395
I97
sg21396
g25209
sg21398
I8
sg21408
VP13747
p25226
sg21401
I2
sasa(dp25227
g21386
VOur results indicated that LIS1 and TSNAX genes are not associated with susceptibility to bipolar I disorder in Chinese Han population.
p25228
sg4
(dp25229
(VLIS1
p25230
Vbipolar I disorder
p25231
tp25232
I00
ssg21392
(lp25233
(dp25234
g21395
I27
sg21396
VLIS1
p25235
sg21398
I4
sg21399
VC1843916
p25236
sg21401
I1
sa(dp25237
g21395
I90
sg21396
g25231
sg21398
I18
sg21399
VC0853193
p25238
sg21401
I3
sasg21404
(lp25239
(dp25240
g21395
I27
sg21396
g25230
sg21398
I4
sg21408
VP43034
p25241
sg21401
I1
sa(dp25242
g21395
I36
sg21396
VTSNAX genes
p25243
sg21398
I11
sg21408
g190
sg21401
I2
sasa(dp25244
g21386
VThe Translin-associated factor X/Disrupted in Schizophrenia 1 (TRAX/DISC) region was first implicated as a susceptibility locus for schizophrenia by analysis of a large Scottish family in which a t(1;11) translocation cosegregates with schizophrenia, bipolar disorder and recurrent major depression.
p25245
sg4
(dp25246
(VSchizophrenia 1
p25247
VSchizophrenia 1
p25248
tp25249
I00
ssg21392
(lp25250
(dp25251
g21395
I272
sg21396
Vrecurrent major depression
p25252
sg21398
I26
sg21399
VC0154409
p25253
sg21401
I3
sa(dp25254
g21395
I132
sg21396
Vschizophrenia
p25255
sg21398
I13
sg21399
VC0036341
p25256
sg21401
I1
sa(dp25257
g21395
I132
sg21396
Vschizophrenia
p25258
sg21398
I13
sg21399
VC0036341
p25259
sg21401
I1
sa(dp25260
g21395
I204
sg21396
Vtranslocation
p25261
sg21398
I13
sg21399
VC0040715
p25262
sg21401
I1
sa(dp25263
g21395
I251
sg21396
Vbipolar disorder
p25264
sg21398
I16
sg21399
VC0005586
p25265
sg21401
I2
sa(dp25266
g21395
I46
sg21396
g25248
sg21398
I15
sg21399
VC0220702
p25267
sg21401
I2
sasg21404
(lp25268
(dp25269
g21395
I4
sg21396
VTranslin-associated factor X
p25270
sg21398
I28
sg21408
g190
sg21401
I3
sa(dp25271
g21395
I46
sg21396
g25247
sg21398
I15
sg21408
VP35462
p25272
sg21401
I2
sa(dp25273
g21395
I63
sg21396
VTRAX
p25274
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp25275
g21386
VThe data showed age-related upregulation of downstream signaling molecules such as mitogen activated protein kinases (MAPKs), activator protein-1 (AP-1), NF-KB, and COX-2 in a cell culture cell system.Taken together, the results of this study show that the formation of adducts between 4-HNE and Src activates inflammatory signaling pathways in the aged kidney, contributing to age-related nephropathy.
p25276
sg4
(dp25277
(Vmitogen activated protein kinases (MAPKs), activator protein-1
p25278
Vnephropathy
p25279
tp25280
I00
ssg21392
(lp25281
(dp25282
g21395
I390
sg21396
g25279
sg21398
I11
sg21399
VC0022658
p25283
sg21401
I1
sasg21404
(lp25284
(dp25285
g21395
I165
sg21396
VCOX-2
p25286
sg21398
I5
sg21408
VP35354
p25287
sg21401
I1
sa(dp25288
g21395
I296
sg21396
VSrc
p25289
sg21398
I3
sg21408
VP12931
p25290
sg21401
I1
sa(dp25291
g21395
I147
sg21396
VAP-1
p25292
sg21398
I4
sg21408
VP01100
p25293
sg21401
I1
sa(dp25294
g21395
I288
sg21396
VHNE
p25295
sg21398
I3
sg21408
VP08246
p25296
sg21401
I1
sa(dp25297
g21395
I83
sg21396
g25278
sg21398
I62
sg21408
VP17980
p25298
sg21401
I7
sasa(dp25299
g21386
VElevated plasma 4-HNE has been associated with renal failure, septic shock and cardiopulmonary bypass surgery.
p25300
sg4
(dp25301
(Vplasma 4-HNE
p25302
Vrenal failure
p25303
tp25304
I00
ssg21392
(lp25305
(dp25306
g21395
I62
sg21396
Vseptic shock
p25307
sg21398
I12
sg21399
VC0036983
p25308
sg21401
I2
sa(dp25309
g21395
I47
sg21396
g25303
sg21398
I13
sg21399
VC0035078
p25310
sg21401
I2
sasg21404
(lp25311
(dp25312
g21395
I9
sg21396
g25302
sg21398
I12
sg21408
VP08246
p25313
sg21401
I2
sasa(dp25314
g21386
VAdditionally, the effect of PlGF (inhibition) on IOP was investigated, since aqueous PlGF is known to be upregulated in glaucoma patients.
p25315
sg4
(dp25316
(VPlGF
p25317
Vglaucoma
p25318
tp25319
I00
ssg21392
(lp25320
(dp25321
g21395
I120
sg21396
g25318
sg21398
I8
sg21399
VC0017601
p25322
sg21401
I1
sasg21404
(lp25323
(dp25324
g21395
I28
sg21396
VPlGF
p25325
sg21398
I4
sg21408
VP49763
p25326
sg21401
I1
sa(dp25327
g21395
I28
sg21396
g25317
sg21398
I4
sg21408
VP49763
p25328
sg21401
I1
sasa(dp25329
g21386
VInhibition of PlGF also might open alternative perspectives as IOP-lowering strategy for glaucoma patients with increased aqueous PlGF levels.
p25330
sg4
(dp25331
(VPlGF
p25332
Vglaucoma
p25333
tp25334
I00
ssg21392
(lp25335
(dp25336
g21395
I89
sg21396
g25333
sg21398
I8
sg21399
VC0017601
p25337
sg21401
I1
sasg21404
(lp25338
(dp25339
g21395
I14
sg21396
VPlGF
p25340
sg21398
I4
sg21408
VP49763
p25341
sg21401
I1
sa(dp25342
g21395
I14
sg21396
g25332
sg21398
I4
sg21408
VP49763
p25343
sg21401
I1
sasa(dp25344
g21386
VTo evaluate changes in the concentrations of placental growth factor (PlGF) and vascular endothelial growth factor-A (VEGF-A) in aqueous humor of patients with neovascular glaucoma (NVG) before and after an intravitreal injection of ranibizumab (IVR) and to determine the underlying correlation between the levels.
p25345
sg4
(dp25346
(Vplacental growth factor
p25347
VNVG
p25348
tp25349
I00
ssg21392
(lp25350
(dp25351
g21395
I160
sg21396
Vneovascular glaucoma
p25352
sg21398
I20
sg21399
VC0017609
p25353
sg21401
I2
sa(dp25354
g21395
I129
sg21396
Vaqueous humor
p25355
sg21398
I13
sg21399
VC0595936
p25356
sg21401
I2
sa(dp25357
g21395
I182
sg21396
g25348
sg21398
I3
sg21399
VC0017609
p25358
sg21401
I1
sasg21404
(lp25359
(dp25360
g21395
I80
sg21396
Vvascular endothelial growth factor-A
p25361
sg21398
I36
sg21408
g190
sg21401
I4
sa(dp25362
g21395
I118
sg21396
VVEGF-A
p25363
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp25364
g21395
I70
sg21396
VPlGF
p25365
sg21398
I4
sg21408
VP49763
p25366
sg21401
I1
sa(dp25367
g21395
I45
sg21396
g25347
sg21398
I23
sg21408
VP49763
p25368
sg21401
I3
sasa(dp25369
g21386
VELISA experiments showed that PlGF levels were significantly increased in aqueous humour of glaucoma patients and after VEGF treatment, which may indicate an important contribution of this growth factor to wound healing after trabeculectomy.
p25370
sg4
(dp25371
(VPlGF
p25372
Vglaucoma
p25373
tp25374
I00
ssg21392
(lp25375
(dp25376
g21395
I92
sg21396
g25373
sg21398
I8
sg21399
VC0017601
p25377
sg21401
I1
sasg21404
(lp25378
(dp25379
g21395
I30
sg21396
g25372
sg21398
I4
sg21408
VP49763
p25380
sg21401
I1
sasa(dp25381
g21386
VUsing a mouse model of glaucoma filtration surgery, we were able to show that intracameral injection of a previously characterized anti-PlGF antibody (ThromboGenics NV) significantly improved surgical outcome by increasing bleb survival and bleb area.
p25382
sg4
(dp25383
(Vanti-PlGF antibody
p25384
Vglaucoma
p25385
tp25386
I00
ssg21392
(lp25387
(dp25388
g21395
I223
sg21396
Vbleb
p25389
sg21398
I4
sg21399
VC0005758
p25390
sg21401
I1
sa(dp25391
g21395
I223
sg21396
Vbleb
p25392
sg21398
I4
sg21399
VC0005758
p25393
sg21401
I1
sa(dp25394
g21395
I23
sg21396
g25385
sg21398
I8
sg21399
VC0017601
p25395
sg21401
I1
sasg21404
(lp25396
(dp25397
g21395
I131
sg21396
g25384
sg21398
I18
sg21408
VP49763
p25398
sg21401
I2
sasa(dp25399
g21386
VThe aim of this study was to investigate the mannose-binding lectin 2 (MBL-2), interleukin (IL)-4, Toll-like receptor 4 (TLR-4), angiotensin converting enzyme (ACE), chemokine receptor 5 (CCR-5), and IL-1 receptor antagonist (RA) gene polymorphisms (GPs) in acute leukemias (ALs) and to evaluate their roles in febrile neutropenia (FN) resulting from chemotherapy.
p25400
sg4
(dp25401
(VACE
p25402
Vfebrile neutropenia
p25403
tp25404
I00
ssg21392
(lp25405
(dp25406
g21395
I332
sg21396
VFN
p25407
sg21398
I2
sg21399
VC0746883
p25408
sg21401
I1
sa(dp25409
g21395
I250
sg21396
VGPs
p25410
sg21398
I3
sg21399
VC0272302
p25411
sg21401
I1
sa(dp25412
g21395
I230
sg21396
Vgene polymorphisms
p25413
sg21398
I18
sg21399
VC0272302
p25414
sg21401
I2
sa(dp25415
g21395
I258
sg21396
Vacute leukemias
p25416
sg21398
I15
sg21399
VC0085669
p25417
sg21401
I2
sa(dp25418
g21395
I275
sg21396
VALs
p25419
sg21398
I3
sg21399
VC0002736
p25420
sg21401
I1
sa(dp25421
g21395
I311
sg21396
g25403
sg21398
I19
sg21399
VC0746883
p25422
sg21401
I2
sasg21404
(lp25423
(dp25424
g21395
I45
sg21396
Vmannose-binding lectin 2
p25425
sg21398
I24
sg21408
VP11226
p25426
sg21401
I3
sa(dp25427
g21395
I71
sg21396
VMBL-2
p25428
sg21398
I5
sg21408
VP11226
p25429
sg21401
I1
sa(dp25430
g21395
I200
sg21396
VIL-1 receptor
p25431
sg21398
I13
sg21408
g190
sg21401
I2
sa(dp25432
g21395
I79
sg21396
Vinterleukin (IL)-4
p25433
sg21398
I18
sg21408
VP60568
p25434
sg21401
I2
sa(dp25435
g21395
I129
sg21396
Vangiotensin converting enzyme
p25436
sg21398
I29
sg21408
VP12821
p25437
sg21401
I3
sa(dp25438
g21395
I188
sg21396
VCCR-5
p25439
sg21398
I5
sg21408
VP61073
p25440
sg21401
I1
sa(dp25441
g21395
I121
sg21396
VTLR-4
p25442
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp25443
g21395
I166
sg21396
Vchemokine receptor 5
p25444
sg21398
I20
sg21408
VP61073
p25445
sg21401
I3
sa(dp25446
g21395
I99
sg21396
VToll-like receptor 4
p25447
sg21398
I20
sg21408
g190
sg21401
I3
sa(dp25448
g21395
I160
sg21396
g25402
sg21398
I3
sg21408
VP12821
p25449
sg21401
I1
sasa(dp25450
g21386
VIn a multivariate analysis, adjusted for occurrence of graft-versus-host-disease, Cytomegalovirus serostatus and duration of neutropenia, paired presence of the TLR4 1063A&gt;G and IFNG 874T&gt;A single nucleotide polymorphisms showed a trend towards increased susceptibility to invasive aspergillosis (p = 0.04).
p25451
sg4
(dp25452
(VIFNG 874T
p25453
Vinvasive aspergillosis
p25454
tp25455
I00
ssg21392
(lp25456
(dp25457
g21395
I55
sg21396
Vgraft-versus-host-disease
p25458
sg21398
I25
sg21399
VC0018133
p25459
sg21401
I1
sa(dp25460
g21395
I279
sg21396
g25454
sg21398
I22
sg21399
VC0238013
p25461
sg21401
I2
sasg21404
(lp25462
(dp25463
g21395
I181
sg21396
g25453
sg21398
I9
sg21408
VP01579
p25464
sg21401
I2
sasa(dp25465
g21386
VRecently, it was shown that some CSPGs members like aggrecan, versican, and neurocan were strongly involved in brain disorders like bipolar disorder (BD), schizophrenia, and ADHD.
p25466
sg4
(dp25467
(Vaggrecan
p25468
Vschizophrenia
p25469
tp25470
I01
ssg21392
(lp25471
(dp25472
g21395
I174
sg21396
VADHD
p25473
sg21398
I4
sg21399
VC1263846
p25474
sg21401
I1
sa(dp25475
g21395
I111
sg21396
Vbrain disorders
p25476
sg21398
I15
sg21399
VC0006111
p25477
sg21401
I2
sa(dp25478
g21395
I132
sg21396
Vbipolar disorder
p25479
sg21398
I16
sg21399
VC0005586
p25480
sg21401
I2
sa(dp25481
g21395
I150
sg21396
VBD
p25482
sg21398
I2
sg21399
VC0005586
p25483
sg21401
I1
sa(dp25484
g21395
I155
sg21396
g25469
sg21398
I13
sg21399
VC0036341
p25485
sg21401
I1
sasg21404
(lp25486
(dp25487
g21395
I52
sg21396
g25468
sg21398
I8
sg21408
VP16112
p25488
sg21401
I1
sa(dp25489
g21395
I174
sg21396
VADHD
p25490
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp25491
g21386
VIn contrast, studies have associated primary biliary cirrhosis and primary sclerosing cholangitis with genes encoding major histocompatibility complex proteins and identified loci associated with microbial sensing and immune regulatory pathways outside this region, such as genes encoding IL12, STAT4, IRF5, IL2 and its receptor (IL2R), CD28, and CD80.
p25492
sg4
(dp25493
(VCD28
p25494
Vprimary sclerosing cholangitis
p25495
tp25496
I01
ssg21392
(lp25497
(dp25498
g21395
I37
sg21396
Vprimary biliary cirrhosis
p25499
sg21398
I25
sg21399
VC0008312
p25500
sg21401
I3
sa(dp25501
g21395
I67
sg21396
g25495
sg21398
I30
sg21399
VC0566602
p25502
sg21401
I3
sasg21404
(lp25503
(dp25504
g21395
I308
sg21396
VIL2 and its receptor
p25505
sg21398
I20
sg21408
VP01589
p25506
sg21401
I4
sa(dp25507
g21395
I330
sg21396
VIL2R
p25508
sg21398
I4
sg21408
VP01589
p25509
sg21401
I1
sa(dp25510
g21395
I302
sg21396
VIRF5
p25511
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp25512
g21395
I118
sg21396
Vmajor histocompatibility complex proteins
p25513
sg21398
I41
sg21408
VP18464
p25514
sg21401
I4
sa(dp25515
g21395
I347
sg21396
VCD80
p25516
sg21398
I4
sg21408
VP33681
p25517
sg21401
I1
sa(dp25518
g21395
I295
sg21396
VSTAT4
p25519
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp25520
g21395
I337
sg21396
g25494
sg21398
I4
sg21408
VP33681
p25521
sg21401
I1
sasa(dp25522
g21386
VIn this condition, 8CR inhibited edema and myonecrosis induced by the sPLA2 activity of Crotalus durissus terrificus in a dose-dependent manner by decreasing interleukin-1Beta (IL-1Beta), tumor necrosis factor Alfa (TNF-Alfa), prostaglandin E2 (PGE2), and lipid peroxidation.
p25523
sg4
(dp25524
(VsPLA2
p25525
Vtumor necrosis
p25526
tp25527
I00
ssg21392
(lp25528
(dp25529
g21395
I8
sg21396
Vcondition
p25530
sg21398
I9
sg21399
VC0012634
p25531
sg21401
I1
sa(dp25532
g21395
I43
sg21396
Vmyonecrosis
p25533
sg21398
I11
sg21399
VC0235957
p25534
sg21401
I1
sa(dp25535
g21395
I33
sg21396
Vedema
p25536
sg21398
I5
sg21399
VC0013604
p25537
sg21401
I1
sa(dp25538
g21395
I188
sg21396
g25526
sg21398
I14
sg21399
VC0333516
p25539
sg21401
I2
sasg21404
(lp25540
(dp25541
g21395
I216
sg21396
VTNF-Alfa
p25542
sg21398
I8
sg21408
VP01375
p25543
sg21401
I1
sa(dp25544
g21395
I177
sg21396
VIL-1Beta
p25545
sg21398
I8
sg21408
VP01584
p25546
sg21401
I1
sa(dp25547
g21395
I158
sg21396
Vinterleukin-1Beta
p25548
sg21398
I17
sg21408
VP01584
p25549
sg21401
I1
sa(dp25550
g21395
I188
sg21396
Vtumor necrosis factor Alfa
p25551
sg21398
I26
sg21408
VP01375
p25552
sg21401
I4
sa(dp25553
g21395
I70
sg21396
g25525
sg21398
I5
sg21408
VP14555
p25554
sg21401
I1
sasa(dp25555
g21386
VIn addition, it was shown that Crotalus durissus terrificus sPLA2 increases cell oxidative stress during edema and myonecrosis, and the antioxidant properties of the polyphenolic compound may be significant in mitigating the pharmacological effect induced by sPLA2 and other snake venom toxins.
p25556
sg4
(dp25557
(VsPLA2
p25558
Voxidative stress
p25559
tp25560
I00
ssg21392
(lp25561
(dp25562
g21395
I115
sg21396
Vmyonecrosis
p25563
sg21398
I11
sg21399
VC0235957
p25564
sg21401
I1
sa(dp25565
g21395
I105
sg21396
Vedema
p25566
sg21398
I5
sg21399
VC0013604
p25567
sg21401
I1
sa(dp25568
g21395
I81
sg21396
g25559
sg21398
I16
sg21399
VC0242606
p25569
sg21401
I2
sasg21404
(lp25570
(dp25571
g21395
I60
sg21396
g25558
sg21398
I5
sg21408
VP14555
p25572
sg21401
I1
sasa(dp25573
g21386
VThe changes in the levels of mast cell tryptase, PAF and the activity of sPLA2 were determined throughout the course of illness in 13 adult patients with DHF, and 30 patients with dengue fever (DF).
p25574
sg4
(dp25575
(VsPLA2
p25576
VDF
p25577
tp25578
I00
ssg21392
(lp25579
(dp25580
g21395
I49
sg21396
VPAF
p25581
sg21398
I3
sg21399
VC0235480
p25582
sg21401
I1
sa(dp25583
g21395
I180
sg21396
Vdengue fever
p25584
sg21398
I12
sg21399
VC0011311
p25585
sg21401
I2
sa(dp25586
g21395
I110
sg21396
Vcourse of illness
p25587
sg21398
I17
sg21399
VC0242656
p25588
sg21401
I3
sa(dp25589
g21395
I194
sg21396
g25577
sg21398
I2
sg21399
VC0011311
p25590
sg21401
I1
sasg21404
(lp25591
(dp25592
g21395
I49
sg21396
VPAF
p25593
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp25594
g21395
I73
sg21396
g25576
sg21398
I5
sg21408
VP14555
p25595
sg21401
I1
sa(dp25596
g21395
I29
sg21396
Vmast cell tryptase
p25597
sg21398
I18
sg21408
VP15157
p25598
sg21401
I3
sasa(dp25599
g21386
VThe difference in serum levels of PLA2G2A was analyzed among chronic hepatitis B (CHB), LC, and HCC patients.
p25600
sg4
(dp25601
(VPLA2G2A
p25602
VHCC
p25603
tp25604
I00
ssg21392
(lp25605
(dp25606
g21395
I82
sg21396
VCHB
p25607
sg21398
I3
sg21399
VC0151517
p25608
sg21401
I1
sa(dp25609
g21395
I61
sg21396
Vchronic hepatitis B
p25610
sg21398
I19
sg21399
VC0524909
p25611
sg21401
I3
sa(dp25612
g21395
I96
sg21396
g25603
sg21398
I3
sg21399
VC2239176
p25613
sg21401
I1
sasg21404
(lp25614
(dp25615
g21395
I34
sg21396
g25602
sg21398
I7
sg21408
VP14555
p25616
sg21401
I1
sasa(dp25617
g21386
VWe have previously shown that secreted phospholipases A2 (sPLA2s) from animal venoms inhibit the in vitro development of Plasmodium falciparum, the agent of malaria.
p25618
sg4
(dp25619
(Vphospholipases A2
p25620
Vmalaria
p25621
tp25622
I00
ssg21392
(lp25623
(dp25624
g21395
I157
sg21396
g25621
sg21398
I7
sg21399
VC0024530
p25625
sg21401
I1
sasg21404
(lp25626
(dp25627
g21395
I58
sg21396
VsPLA2s
p25628
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp25629
g21395
I39
sg21396
g25620
sg21398
I17
sg21408
VP04054
p25630
sg21401
I2
sasa(dp25631
g21386
VIn addition, the inflammatory-type human group IIA (hGIIA) sPLA2 circulates at high levels in the serum of malaria patients.
p25632
sg4
(dp25633
(VsPLA2
p25634
Vmalaria
p25635
tp25636
I00
ssg21392
(lp25637
(dp25638
g21395
I107
sg21396
g25635
sg21398
I7
sg21399
VC0024530
p25639
sg21401
I1
sasg21404
(lp25640
(dp25641
g21395
I59
sg21396
g25634
sg21398
I5
sg21408
VP14555
p25642
sg21401
I1
sasa(dp25643
g21386
VFinally, anisomycin was the highest correlation with DEGs.MiR-124a might be involved in the pathogenesis of hypertension via targeting Ebf3 and Rgs7 bp, which possibly represent a novel and effective strategy for treatment of hypertension.
p25644
sg4
(dp25645
(VRgs7
p25646
Vhypertension
p25647
tp25648
I00
ssg21392
(lp25649
(dp25650
g21395
I92
sg21396
Vpathogenesis
p25651
sg21398
I12
sg21399
VC0699748
p25652
sg21401
I1
sa(dp25653
g21395
I108
sg21396
Vhypertension
p25654
sg21398
I12
sg21399
VC0020538
p25655
sg21401
I1
sa(dp25656
g21395
I108
sg21396
g25647
sg21398
I12
sg21399
VC0020538
p25657
sg21401
I1
sasg21404
(lp25658
(dp25659
g21395
I135
sg21396
VEbf3
p25660
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp25661
g21395
I53
sg21396
VDEGs.MiR-124a
p25662
sg21398
I13
sg21408
g190
sg21401
I1
sa(dp25663
g21395
I144
sg21396
g25646
sg21398
I4
sg21408
VP49802
p25664
sg21401
I1
sasa(dp25665
g21386
VIt was also demonstrated that miR-124-3p expression was positively associated with mTOR signaling and this relationship was dependent on the tuberous sclerosis proteins 1/2 complex.
p25666
sg4
(dp25667
(VmTOR
p25668
Vtuberous sclerosis
p25669
tp25670
I00
ssg21392
(lp25671
(dp25672
g21395
I141
sg21396
g25669
sg21398
I18
sg21399
VC0041341
p25673
sg21401
I2
sasg21404
(lp25674
(dp25675
g21395
I30
sg21396
VmiR-124-3p
p25676
sg21398
I10
sg21408
g190
sg21401
I1
sa(dp25677
g21395
I83
sg21396
g25668
sg21398
I4
sg21408
VP42345
p25678
sg21401
I1
sasa(dp25679
g21386
VThis study aimed to evaluate fibrosis and elastin destruction in childhood interstitial lung disease (chILD) patients.
p25680
sg4
(dp25681
(Velastin
p25682
Vfibrosis
p25683
tp25684
I00
ssg21392
(lp25685
(dp25686
g21395
I75
sg21396
Vinterstitial lung disease
p25687
sg21398
I25
sg21399
VC0206062
p25688
sg21401
I3
sa(dp25689
g21395
I29
sg21396
g25683
sg21398
I8
sg21399
VC0016059
p25690
sg21401
I1
sasg21404
(lp25691
(dp25692
g21395
I42
sg21396
g25682
sg21398
I7
sg21408
VP49918
p25693
sg21401
I1
sasa(dp25694
g21386
VInhibitors of the cGMP-degrading phosphodiesterase (PDE) 5 have achieved blockbuster status in the treatment of penile erectile dysfunction (PED).
p25695
sg4
(dp25696
(VcGMP-degrading phosphodiesterase
p25697
Verectile dysfunction
p25698
tp25699
I00
ssg21392
(lp25700
(dp25701
g21395
I52
sg21396
VPDE
p25702
sg21398
I3
sg21399
VC1849508
p25703
sg21401
I1
sa(dp25704
g21395
I33
sg21396
Vphosphodiesterase
p25705
sg21398
I17
sg21399
VC1849508
p25706
sg21401
I1
sa(dp25707
g21395
I119
sg21396
g25698
sg21398
I20
sg21399
VC0242350
p25708
sg21401
I2
sasg21404
(lp25709
(dp25710
g21395
I52
sg21396
VPDE
p25711
sg21398
I3
sg21408
VP49419
p25712
sg21401
I1
sa(dp25713
g21395
I18
sg21396
g25697
sg21398
I32
sg21408
VP22413
p25714
sg21401
I2
sasa(dp25715
g21386
VTo compare the effectiveness of the phosphodiesterase type 5 inhibitor (PDE-5i) tadalafil alone and in combination with a biologically active dietary supplement (BADS) NeyroDoz, containing the precursors of serotonin in patients with erectile dysfunction (ED) associated with secondary premature ejaculation (SPE).
p25716
sg4
(dp25717
(VPDE-5i
p25718
Verectile dysfunction
p25719
tp25720
I01
ssg21392
(lp25721
(dp25722
g21395
I72
sg21396
VPDE
p25723
sg21398
I3
sg21399
VC1849508
p25724
sg21401
I1
sa(dp25725
g21395
I286
sg21396
Vpremature ejaculation
p25726
sg21398
I21
sg21399
VC0033038
p25727
sg21401
I2
sa(dp25728
g21395
I256
sg21396
VED
p25729
sg21398
I2
sg21399
VC0242350
p25730
sg21401
I1
sa(dp25731
g21395
I234
sg21396
g25719
sg21398
I20
sg21399
VC0242350
p25732
sg21401
I2
sasg21404
(lp25733
(dp25734
g21395
I36
sg21396
Vphosphodiesterase type 5 inhibitor
p25735
sg21398
I34
sg21408
VP22413
p25736
sg21401
I4
sa(dp25737
g21395
I72
sg21396
g25718
sg21398
I6
sg21408
VP49419
p25738
sg21401
I1
sasa(dp25739
g21386
VPhosphodiesterase (PDE) 5 inhibitor induced muscle relaxation in corporal smooth muscle cells and was used to treat erectile dysfunction by inhibiting cGMP degradation.
p25740
sg4
(dp25741
(VPhosphodiesterase (PDE) 5
p25742
Verectile dysfunction
p25743
tp25744
I00
ssg21392
(lp25745
(dp25746
g21395
I0
sg21396
VPhosphodiesterase
p25747
sg21398
I17
sg21399
VC1849508
p25748
sg21401
I1
sa(dp25749
g21395
I19
sg21396
VPDE
p25750
sg21398
I3
sg21399
VC1849508
p25751
sg21401
I1
sa(dp25752
g21395
I44
sg21396
Vmuscle relaxation
p25753
sg21398
I17
sg21399
VC0700323
p25754
sg21401
I2
sa(dp25755
g21395
I116
sg21396
g25743
sg21398
I20
sg21399
VC0242350
p25756
sg21401
I2
sasg21404
(lp25757
(dp25758
g21395
I0
sg21396
g25742
sg21398
I25
sg21408
VP22413
p25759
sg21401
I3
sasa(dp25760
g21386
VCyclic guanosine monophosphate (cGMP)-specific phosphodiesterase (PDE) inhibitors are hypothesized to improve cognition in schizophrenia and Alzheimer disease by increasing cGMP levels in certain brain regions.
p25761
sg4
(dp25762
(VCyclic guanosine monophosphate (cGMP)-specific phosphodiesterase
p25763
VPDE
p25764
tp25765
I00
ssg21392
(lp25766
(dp25767
g21395
I47
sg21396
Vphosphodiesterase
p25768
sg21398
I17
sg21399
VC1849508
p25769
sg21401
I1
sa(dp25770
g21395
I141
sg21396
VAlzheimer disease
p25771
sg21398
I17
sg21399
VC0002395
p25772
sg21401
I2
sa(dp25773
g21395
I123
sg21396
Vschizophrenia
p25774
sg21398
I13
sg21399
VC0036341
p25775
sg21401
I1
sa(dp25776
g21395
I66
sg21396
g25764
sg21398
I3
sg21399
VC1849508
p25777
sg21401
I1
sasg21404
(lp25778
(dp25779
g21395
I66
sg21396
VPDE
p25780
sg21398
I3
sg21408
VP49419
p25781
sg21401
I1
sa(dp25782
g21395
I0
sg21396
g25763
sg21398
I64
sg21408
VP22413
p25783
sg21401
I5
sasa(dp25784
g21386
VPhosphodiesterase (PDE) inhibitors are currently under evaluation as agents that may facilitate the improvement of cognitive impairment associated with Alzheimer's disease.
p25785
sg4
(dp25786
(VPhosphodiesterase (PDE)
p25787
Vcognitive impairment
p25788
tp25789
I00
ssg21392
(lp25790
(dp25791
g21395
I0
sg21396
VPhosphodiesterase
p25792
sg21398
I17
sg21399
VC1849508
p25793
sg21401
I1
sa(dp25794
g21395
I152
sg21396
VAlzheimer's disease
p25795
sg21398
I19
sg21399
VC1521724
p25796
sg21401
I2
sa(dp25797
g21395
I19
sg21396
VPDE
p25798
sg21398
I3
sg21399
VC1849508
p25799
sg21401
I1
sa(dp25800
g21395
I115
sg21396
g25788
sg21398
I20
sg21399
VC0338656
p25801
sg21401
I2
sasg21404
(lp25802
(dp25803
g21395
I0
sg21396
g25787
sg21398
I23
sg21408
VP22413
p25804
sg21401
I2
sasa(dp25805
g21386
VIntriguingly, both Cst6(-/-)Ctsl(-/-) and Cst6(-/-)Ctsl(+/-) mice were viable, but the absence of cystatin M/E caused scarring alopecia in adult animals.
p25806
sg4
(dp25807
(VCst6
p25808
Vscarring alopecia
p25809
tp25810
I00
ssg21392
(lp25811
(dp25812
g21395
I118
sg21396
g25809
sg21398
I17
sg21399
VC2936846
p25813
sg21401
I2
sasg21404
(lp25814
(dp25815
g21395
I19
sg21396
VCst6
p25816
sg21398
I4
sg21408
VP04080
p25817
sg21401
I1
sa(dp25818
g21395
I19
sg21396
g25808
sg21398
I4
sg21408
VP04080
p25819
sg21401
I1
sa(dp25820
g21395
I98
sg21396
Vcystatin M/E
p25821
sg21398
I12
sg21408
g190
sg21401
I2
sasa(dp25822
g21386
VTranscription factor 4 (TCF-4) was recently identified as a candidate gene for the cause of type 2 diabetes, although the mechanisms have not been fully elucidated.
p25823
sg4
(dp25824
(VTCF-4
p25825
Vtype 2 diabetes
p25826
tp25827
I00
ssg21392
(lp25828
(dp25829
g21395
I92
sg21396
g25826
sg21398
I15
sg21399
VC0011860
p25830
sg21401
I3
sasg21404
(lp25831
(dp25832
g21395
I0
sg21396
VTranscription factor 4
p25833
sg21398
I22
sg21408
VP15884
p25834
sg21401
I3
sa(dp25835
g21395
I24
sg21396
g25825
sg21398
I5
sg21408
VP15884
p25836
sg21401
I1
sasa(dp25837
g21386
VCollectively, these observations demonstrate a disease-promoting role of E2-2 dependent pDCs in the pancreas during autoimmune diabetes in the NOD mouse.
p25838
sg4
(dp25839
(VE2-2
p25840
Vautoimmune diabetes
p25841
tp25842
I00
ssg21392
(lp25843
(dp25844
g21395
I143
sg21396
VNOD
p25845
sg21398
I3
sg21399
VC0751781
p25846
sg21401
I1
sa(dp25847
g21395
I116
sg21396
g25841
sg21398
I19
sg21399
VC0205734
p25848
sg21401
I2
sasg21404
(lp25849
(dp25850
g21395
I73
sg21396
g25840
sg21398
I4
sg21408
VP15884
p25851
sg21401
I1
sasa(dp25852
g21386
VIn primates, a PGBD3 element inserted into the Cockayne syndrome group B (CSB) gene over 43 Mya serves as an alternative 3' terminal exon, enabling the CSB gene to generate both full length CSB and a conserved CSB-PGBD3 fusion protein that joins an N-terminal CSB domain to the C-terminal transposase domain.
p25853
sg4
(dp25854
(VCSB
p25855
VCSB
p25856
tp25857
I00
ssg21392
(lp25858
(dp25859
g21395
I74
sg21396
VCSB
p25860
sg21398
I3
sg21399
VC1858160
p25861
sg21401
I1
sa(dp25862
g21395
I74
sg21396
VCSB
p25863
sg21398
I3
sg21399
VC1858160
p25864
sg21401
I1
sa(dp25865
g21395
I74
sg21396
VCSB
p25866
sg21398
I3
sg21399
VC1858160
p25867
sg21401
I1
sa(dp25868
g21395
I47
sg21396
VCockayne syndrome group B
p25869
sg21398
I25
sg21399
VC1858160
p25870
sg21401
I4
sa(dp25871
g21395
I74
sg21396
VCSB
p25872
sg21398
I3
sg21399
VC1858160
p25873
sg21401
I1
sa(dp25874
g21395
I74
sg21396
g25856
sg21398
I3
sg21399
VC1858160
p25875
sg21401
I1
sasg21404
(lp25876
(dp25877
g21395
I152
sg21396
VCSB gene
p25878
sg21398
I8
sg21408
VP35548
p25879
sg21401
I2
sa(dp25880
g21395
I278
sg21396
VC-terminal transposase domain
p25881
sg21398
I29
sg21408
g190
sg21401
I3
sa(dp25882
g21395
I74
sg21396
VCSB
p25883
sg21398
I3
sg21408
VP35548
p25884
sg21401
I1
sa(dp25885
g21395
I15
sg21396
VPGBD3 element
p25886
sg21398
I13
sg21408
g190
sg21401
I2
sa(dp25887
g21395
I15
sg21396
VPGBD3
p25888
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp25889
g21395
I47
sg21396
VCockayne syndrome group B
p25890
sg21398
I25
sg21408
VP35548
p25891
sg21401
I4
sa(dp25892
g21395
I74
sg21396
g25855
sg21398
I3
sg21408
VP35548
p25893
sg21401
I1
sasa(dp25894
g21386
VThe CSB-PGBD3 fusion protein arose more than 43 million years ago when a 2.5-kb piggyBac 3 (PGBD3) transposon inserted into intron 5 of the Cockayne syndrome Group B (CSB) gene in the common ancestor of all higher primates.
p25895
sg4
(dp25896
(VCockayne syndrome Group B
p25897
VCSB
p25898
tp25899
I00
ssg21392
(lp25900
(dp25901
g21395
I4
sg21396
VCSB
p25902
sg21398
I3
sg21399
VC1858160
p25903
sg21401
I1
sa(dp25904
g21395
I140
sg21396
VCockayne syndrome Group B
p25905
sg21398
I25
sg21399
VC1858160
p25906
sg21401
I4
sa(dp25907
g21395
I4
sg21396
g25898
sg21398
I3
sg21399
VC1858160
p25908
sg21401
I1
sasg21404
(lp25909
(dp25910
g21395
I4
sg21396
VCSB
p25911
sg21398
I3
sg21408
VP35548
p25912
sg21401
I1
sa(dp25913
g21395
I8
sg21396
VPGBD3
p25914
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp25915
g21395
I8
sg21396
VPGBD3
p25916
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp25917
g21395
I4
sg21396
VCSB
p25918
sg21398
I3
sg21408
VP35548
p25919
sg21401
I1
sa(dp25920
g21395
I140
sg21396
g25897
sg21398
I25
sg21408
VP35548
p25921
sg21401
I4
sasa(dp25922
g21386
VOur data suggest that the CSB-PGBD3 fusion protein is important in both health and disease, and could play a role in Cockayne syndrome.
p25923
sg4
(dp25924
(VCSB
p25925
VCSB
p25926
tp25927
I00
ssg21392
(lp25928
(dp25929
g21395
I117
sg21396
VCockayne syndrome
p25930
sg21398
I17
sg21399
VC0009207
p25931
sg21401
I2
sa(dp25932
g21395
I26
sg21396
g25926
sg21398
I3
sg21399
VC1858160
p25933
sg21401
I1
sasg21404
(lp25934
(dp25935
g21395
I30
sg21396
VPGBD3
p25936
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp25937
g21395
I26
sg21396
g25925
sg21398
I3
sg21408
VP35548
p25938
sg21401
I1
sasa(dp25939
g21386
VAt stimulation, the tubulovesicles fuse with the apical canaliculi and the HK-ATPase is incorporated into the apical membrane where it actively pumps H ions in exchange for K. Acute infection with Helicobacter pylori results in hypochlorhydria, whereas chronic infection can cause either hypo- or hyperchlorhydria, depending on the distribution of the infection and the degree of corpus gastritis.
p25940
sg4
(dp25941
(VHK-ATPase
p25942
Vgastritis
p25943
tp25944
I00
ssg21392
(lp25945
(dp25946
g21395
I176
sg21396
VAcute infection
p25947
sg21398
I15
sg21399
VC0275518
p25948
sg21401
I2
sa(dp25949
g21395
I297
sg21396
Vhyperchlorhydria
p25950
sg21398
I16
sg21399
VC0151713
p25951
sg21401
I1
sa(dp25952
g21395
I253
sg21396
Vchronic infection
p25953
sg21398
I17
sg21399
VC0151317
p25954
sg21401
I2
sa(dp25955
g21395
I182
sg21396
Vinfection
p25956
sg21398
I9
sg21399
VC0009450
p25957
sg21401
I1
sa(dp25958
g21395
I387
sg21396
g25943
sg21398
I9
sg21399
VC0017152
p25959
sg21401
I1
sa(dp25960
g21395
I228
sg21396
Vhypochlorhydria
p25961
sg21398
I15
sg21399
VC0079581
p25962
sg21401
I1
sasg21404
(lp25963
(dp25964
g21395
I75
sg21396
g25942
sg21398
I9
sg21408
VP38606
p25965
sg21401
I1
sasa(dp25966
g21386
VThe results directly confirm that the gastric H+/K(+)-ATPase is the causative autoantigen in the genesis of autoimmune gastritis.
p25967
sg4
(dp25968
(Vgastric H+/K(+)-ATPase
p25969
Vautoimmune gastritis
p25970
tp25971
I00
ssg21392
(lp25972
(dp25973
g21395
I108
sg21396
g25970
sg21398
I20
sg21399
VC0017154
p25974
sg21401
I2
sasg21404
(lp25975
(dp25976
g21395
I38
sg21396
g25969
sg21398
I22
sg21408
VP38606
p25977
sg21401
I2
sasa(dp25978
g21386
VWe conclude that the beta subunit of the gastric H/K ATPase is a major T cell target in autoimmune gastritis and that thymic expression of a single autoantigen can abrogate an autoimmune response to multiple autoantigens.
p25979
sg4
(dp25980
(Vgastric H/K ATPase
p25981
Vautoimmune gastritis
p25982
tp25983
I00
ssg21392
(lp25984
(dp25985
g21395
I176
sg21396
Vautoimmune response
p25986
sg21398
I19
sg21399
VC0004366
p25987
sg21401
I2
sa(dp25988
g21395
I88
sg21396
g25982
sg21398
I20
sg21399
VC0017154
p25989
sg21401
I2
sasg21404
(lp25990
(dp25991
g21395
I41
sg21396
g25981
sg21398
I18
sg21408
VP38606
p25992
sg21401
I3
sasa(dp25993
g21386
V8 cases of pneumophathia osteoplastica (ppo) of branching type observed at patients having no vascular deformities and one case of a focal ppo at a patient with mitral stenosis are reported.
p25994
sg4
(dp25995
(Vppo
p25996
Vdeformities
p25997
tp25998
I00
ssg21392
(lp25999
(dp26000
g21395
I161
sg21396
Vmitral stenosis
p26001
sg21398
I15
sg21399
VC0026269
p26002
sg21401
I2
sa(dp26003
g21395
I103
sg21396
g25997
sg21398
I11
sg21399
VC0000768
p26004
sg21401
I1
sasg21404
(lp26005
(dp26006
g21395
I40
sg21396
g25996
sg21398
I3
sg21408
VP50336
p26007
sg21401
I1
sasa(dp26008
g21386
VDetection of cell cycle marker expression showed that CDKN3 knockdown promotes cell cycle arrest by decreasing the expression of CDK2, CDC25A, CCNB1, and CCNB2 in human gastric cancer cells.
p26009
sg4
(dp26010
(VCDC25A
p26011
Vgastric cancer
p26012
tp26013
I01
ssg21392
(lp26014
(dp26015
g21395
I169
sg21396
g26012
sg21398
I14
sg21399
VC0024623
p26016
sg21401
I2
sasg21404
(lp26017
(dp26018
g21395
I129
sg21396
VCDK2
p26019
sg21398
I4
sg21408
VP24941
p26020
sg21401
I1
sa(dp26021
g21395
I154
sg21396
VCCNB2
p26022
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp26023
g21395
I143
sg21396
VCCNB1
p26024
sg21398
I5
sg21408
VP14635
p26025
sg21401
I1
sa(dp26026
g21395
I135
sg21396
g26011
sg21398
I6
sg21408
VP30304
p26027
sg21401
I1
sasa(dp26028
g21386
VThe cyclin-dependent kinase inhibitor 3 (CDKN3) gene, involved in mitosis, is upregulated in cervical cancer (CC).
p26029
sg4
(dp26030
(VCDKN3
p26031
Vcervical cancer
p26032
tp26033
I00
ssg21392
(lp26034
(dp26035
g21395
I93
sg21396
g26032
sg21398
I15
sg21399
VC0302592
p26036
sg21401
I2
sasg21404
(lp26037
(dp26038
g21395
I4
sg21396
Vcyclin-dependent kinase inhibitor 3
p26039
sg21398
I35
sg21408
VP38936
p26040
sg21401
I4
sa(dp26041
g21395
I41
sg21396
g26031
sg21398
I5
sg21408
VP38936
p26042
sg21401
I1
sasa(dp26043
g21386
VWe first discovered the pro-tumor effect of a controversial cell cycle regulator, cylin-dependent kinase inhibitor 3 (CDKN3), which is highly expressed in colorectal cancer, and the possible related signaling pathways, by bioinformatics tools.
p26044
sg4
(dp26045
(VCDKN3
p26046
Vcolorectal cancer
p26047
tp26048
I00
ssg21392
(lp26049
(dp26050
g21395
I28
sg21396
Vtumor
p26051
sg21398
I5
sg21399
VC0027651
p26052
sg21401
I1
sa(dp26053
g21395
I155
sg21396
g26047
sg21398
I17
sg21399
VC1527249
p26054
sg21401
I2
sasg21404
(lp26055
(dp26056
g21395
I82
sg21396
Vcylin-dependent kinase inhibitor 3
p26057
sg21398
I34
sg21408
VP19525
p26058
sg21401
I4
sa(dp26059
g21395
I118
sg21396
g26046
sg21398
I5
sg21408
VP19525
p26060
sg21401
I1
sasa(dp26061
g21386
VHowever, the role of CDKN3 in Bcr-Abl-mediated chronic myelogenous leukemia (CML) remains unknown.
p26062
sg4
(dp26063
(VAbl
p26064
VAbl
p26065
tp26066
I00
ssg21392
(lp26067
(dp26068
g21395
I47
sg21396
Vchronic myelogenous leukemia
p26069
sg21398
I28
sg21399
VC0023473
p26070
sg21401
I3
sa(dp26071
g21395
I77
sg21396
VCML
p26072
sg21398
I3
sg21399
VC0023473
p26073
sg21401
I1
sa(dp26074
g21395
I34
sg21396
g26065
sg21398
I3
sg21399
VC0000744
p26075
sg21401
I1
sasg21404
(lp26076
(dp26077
g21395
I30
sg21396
VBcr
p26078
sg21398
I3
sg21408
VP11274
p26079
sg21401
I1
sa(dp26080
g21395
I34
sg21396
g26064
sg21398
I3
sg21408
VP55157
p26081
sg21401
I1
sasa(dp26082
g21386
VOur results highlight the importance of CDKN3 in Bcr-Abl-mediated leukemogenesis, and provide new insights into diagnostics and therapeutics of the leukemia.
p26083
sg4
(dp26084
(VAbl
p26085
VAbl
p26086
tp26087
I00
ssg21392
(lp26088
(dp26089
g21395
I148
sg21396
Vleukemia
p26090
sg21398
I8
sg21399
VC0023418
p26091
sg21401
I1
sa(dp26092
g21395
I66
sg21396
Vleukemogenesis
p26093
sg21398
I14
sg21399
VC0598766
p26094
sg21401
I1
sa(dp26095
g21395
I53
sg21396
g26086
sg21398
I3
sg21399
VC0000744
p26096
sg21401
I1
sasg21404
(lp26097
(dp26098
g21395
I49
sg21396
VBcr
p26099
sg21398
I3
sg21408
VP11274
p26100
sg21401
I1
sa(dp26101
g21395
I53
sg21396
g26085
sg21398
I3
sg21408
VP55157
p26102
sg21401
I1
sasa(dp26103
g21386
VUsing in situ hybridization, the expression of key clock genes, including period circadian protein homolog (Per) 1 and 2, cryptochrome 1 (Cry1), circadian locomoter output cycles protein kaput (Clock), brain and muscle ARNT-like protein 1 (Bmal1) and casein kinase 1Epsilon (CK1Epsilon) were retrospectively examined in 51 cases of colorectal carcinoma and 10 cases of adenoma.
p26104
sg4
(dp26105
(Vcasein kinase 1Epsilon
p26106
Vcolorectal carcinoma
p26107
tp26108
I01
ssg21392
(lp26109
(dp26110
g21395
I369
sg21396
Vadenoma
p26111
sg21398
I7
sg21399
VC0001430
p26112
sg21401
I1
sa(dp26113
g21395
I332
sg21396
g26107
sg21398
I20
sg21399
VC0009402
p26114
sg21401
I2
sasg21404
(lp26115
(dp26116
g21395
I219
sg21396
VARNT-like protein 1
p26117
sg21398
I19
sg21408
VP14222
p26118
sg21401
I3
sa(dp26119
g21395
I275
sg21396
VCK1Epsilon
p26120
sg21398
I10
sg21408
VP48729
p26121
sg21401
I1
sa(dp26122
g21395
I138
sg21396
VCry1
p26123
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp26124
g21395
I122
sg21396
Vcryptochrome 1
p26125
sg21398
I14
sg21408
g190
sg21401
I2
sa(dp26126
g21395
I81
sg21396
Vcircadian protein homolog (Per) 1 and 2
p26127
sg21398
I39
sg21408
g190
sg21401
I7
sa(dp26128
g21395
I251
sg21396
g26106
sg21398
I22
sg21408
VP48729
p26129
sg21401
I3
sasa(dp26130
g21386
VStudy distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.
p26131
sg4
(dp26132
(VPER3
p26133
Vcolorectal cancer
p26134
tp26135
I00
ssg21392
(lp26136
(dp26137
g21395
I219
sg21396
Vnon-small cell lung cancer
p26138
sg21398
I26
sg21399
VC0007131
p26139
sg21401
I4
sa(dp26140
g21395
I144
sg21396
Vglioma
p26141
sg21398
I6
sg21399
VC0017638
p26142
sg21401
I1
sa(dp26143
g21395
I22
sg21396
Vtumor
p26144
sg21398
I5
sg21399
VC0027651
p26145
sg21401
I1
sa(dp26146
g21395
I44
sg21396
Vbreast cancer
p26147
sg21398
I13
sg21399
VC0678222
p26148
sg21401
I2
sa(dp26149
g21395
I44
sg21396
Vbreast cancer
p26150
sg21398
I13
sg21399
VC0678222
p26151
sg21401
I2
sa(dp26152
g21395
I44
sg21396
Vbreast cancer
p26153
sg21398
I13
sg21399
VC0678222
p26154
sg21401
I2
sa(dp26155
g21395
I51
sg21396
Vcancer
p26156
sg21398
I6
sg21399
VC0006826
p26157
sg21401
I1
sa(dp26158
g21395
I89
sg21396
Vpancreatic cancer
p26159
sg21398
I17
sg21399
VC0235974
p26160
sg21401
I2
sa(dp26161
g21395
I256
sg21396
Vovarian cancer
p26162
sg21398
I14
sg21399
VC1140680
p26163
sg21401
I2
sa(dp26164
g21395
I44
sg21396
Vbreast cancer
p26165
sg21398
I13
sg21399
VC0678222
p26166
sg21401
I2
sa(dp26167
g21395
I44
sg21396
Vbreast cancer
p26168
sg21398
I13
sg21399
VC0678222
p26169
sg21401
I2
sa(dp26170
g21395
I158
sg21396
Vchronic lymphocytic leukemia
p26171
sg21398
I28
sg21399
VC0023434
p26172
sg21401
I3
sa(dp26173
g21395
I114
sg21396
Vnon-Hodgkin's lymphoma
p26174
sg21398
I22
sg21399
VC0024305
p26175
sg21401
I2
sa(dp26176
g21395
I66
sg21396
Vprostate cancer
p26177
sg21398
I15
sg21399
VC0600139
p26178
sg21401
I2
sa(dp26179
g21395
I194
sg21396
g26134
sg21398
I17
sg21399
VC1527249
p26180
sg21401
I2
sasg21404
(lp26181
(dp26182
g21395
I495
sg21396
VCLOCK rs3749474
p26183
sg21398
I15
sg21408
g190
sg21401
I2
sa(dp26184
g21395
I376
sg21396
VNPAS2 rs10165970
p26185
sg21398
I16
sg21408
g190
sg21401
I2
sa(dp26186
g21395
I671
sg21396
g26133
sg21398
I4
sg21408
VP56645
p26187
sg21401
I1
sa(dp26188
g21395
I624
sg21396
VRORB rs7867494
p26189
sg21398
I14
sg21408
g190
sg21401
I2
sasa(dp26190
g21386
VWe summarize fifteen epidemiological studies, including five studies on shift work that have indicated BMAL1, BMAL2, CLOCK, NPAS2, CRY1, CRY2, PER1, PER3 and TIMELESS as a candidate breast cancer risk variants.
p26191
sg4
(dp26192
(VTIMELESS
p26193
Vbreast cancer
p26194
tp26195
I01
ssg21392
(lp26196
(dp26197
g21395
I182
sg21396
g26194
sg21398
I13
sg21399
VC0678222
p26198
sg21401
I2
sasg21404
(lp26199
(dp26200
g21395
I149
sg21396
VPER3
p26201
sg21398
I4
sg21408
VP56645
p26202
sg21401
I1
sa(dp26203
g21395
I131
sg21396
VCRY1
p26204
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp26205
g21395
I124
sg21396
VNPAS2
p26206
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp26207
g21395
I158
sg21396
g26193
sg21398
I8
sg21408
VP60174
p26208
sg21401
I1
sa(dp26209
g21395
I143
sg21396
VPER1
p26210
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp26211
g21395
I117
sg21396
VCLOCK
p26212
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp26213
g21395
I137
sg21396
VCRY2
p26214
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp26215
g21386
VThe tumor necrosis factor receptor-associated factor family member-associated nuclear factor-KB (NF-KB) activator (TANK) takes part in the tumor necrosis factor-Alfa (TNF-Alfa)-mediated NF-KB signaling pathway and the interferon (IFN)-induction pathways that have relevance to HBV-related liver disease.
p26216
sg4
(dp26217
(VTNF-Alfa
p26218
VHBV
p26219
tp26220
I00
ssg21392
(lp26221
(dp26222
g21395
I4
sg21396
Vtumor necrosis
p26223
sg21398
I14
sg21399
VC0333516
p26224
sg21401
I2
sa(dp26225
g21395
I289
sg21396
Vliver disease
p26226
sg21398
I13
sg21399
VC0023895
p26227
sg21401
I2
sa(dp26228
g21395
I4
sg21396
Vtumor necrosis
p26229
sg21398
I14
sg21399
VC0333516
p26230
sg21401
I2
sa(dp26231
g21395
I277
sg21396
g26219
sg21398
I3
sg21399
VC0019163
p26232
sg21401
I1
sasg21404
(lp26233
(dp26234
g21395
I4
sg21396
Vtumor necrosis factor receptor-associated factor family member-associated nuclear factor-KB
p26235
sg21398
I91
sg21408
VP01375
p26236
sg21401
I9
sa(dp26237
g21395
I218
sg21396
Vinterferon
p26238
sg21398
I10
sg21408
VP01563
p26239
sg21401
I1
sa(dp26240
g21395
I115
sg21396
VTANK
p26241
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp26242
g21395
I139
sg21396
Vtumor necrosis factor-Alfa
p26243
sg21398
I26
sg21408
VP01375
p26244
sg21401
I3
sa(dp26245
g21395
I167
sg21396
g26218
sg21398
I8
sg21408
VP01375
p26246
sg21401
I1
sa(dp26247
g21395
I230
sg21396
VIFN
p26248
sg21398
I3
sg21408
VP01562
p26249
sg21401
I1
sasa(dp26250
g21386
VThese results indicate that treatment with TUDCA may be helpful to counteract obesity-induced hyperinsulinemia through increasing insulin clearance, likely through enhanced liver IDE expression in a mechanism dependent on S1PR2-Insulin pathway activation.
p26251
sg4
(dp26252
(VIDE
p26253
Vhyperinsulinemia
p26254
tp26255
I00
ssg21392
(lp26256
(dp26257
g21395
I78
sg21396
Vobesity
p26258
sg21398
I7
sg21399
VC0028754
p26259
sg21401
I1
sa(dp26260
g21395
I119
sg21396
Vincreasing insulin
p26261
sg21398
I18
sg21399
VC0020459
p26262
sg21401
I2
sa(dp26263
g21395
I94
sg21396
g26254
sg21398
I16
sg21399
VC0020459
p26264
sg21401
I1
sasg21404
(lp26265
(dp26266
g21395
I228
sg21396
VInsulin
p26267
sg21398
I7
sg21408
VP01308
p26268
sg21401
I1
sa(dp26269
g21395
I99
sg21396
Vinsulin
p26270
sg21398
I7
sg21408
VP01308
p26271
sg21401
I1
sa(dp26272
g21395
I179
sg21396
g26253
sg21398
I3
sg21408
VP14735
p26273
sg21401
I1
sa(dp26274
g21395
I222
sg21396
VS1PR2
p26275
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp26276
g21386
VInsulin-degrading enzyme (IDE) is a ubiquitous zinc peptidase of the inverzincin family, which has been initially discovered as the enzyme responsible for insulin catabolism; therefore, its involvement in the onset of diabetes has been largely investigated.
p26277
sg4
(dp26278
(Vinsulin
p26279
Vdiabetes
p26280
tp26281
I00
ssg21392
(lp26282
(dp26283
g21395
I218
sg21396
g26280
sg21398
I8
sg21399
VC0011849
p26284
sg21401
I1
sasg21404
(lp26285
(dp26286
g21395
I0
sg21396
VInsulin-degrading enzyme
p26287
sg21398
I24
sg21408
VP14735
p26288
sg21401
I2
sa(dp26289
g21395
I47
sg21396
Vzinc peptidase
p26290
sg21398
I14
sg21408
g190
sg21401
I2
sa(dp26291
g21395
I26
sg21396
VIDE
p26292
sg21398
I3
sg21408
VP14735
p26293
sg21401
I1
sa(dp26294
g21395
I155
sg21396
g26279
sg21398
I7
sg21408
VP01308
p26295
sg21401
I1
sasa(dp26296
g21386
VImpairment of the insulin-degrading enzyme (IDE) is associated with obesity and type 2 diabetes mellitus (T2DM).
p26297
sg4
(dp26298
(VIDE
p26299
Vobesity
p26300
tp26301
I00
ssg21392
(lp26302
(dp26303
g21395
I106
sg21396
VT2DM
p26304
sg21398
I4
sg21399
VC0011860
p26305
sg21401
I1
sa(dp26306
g21395
I80
sg21396
Vtype 2 diabetes mellitus
p26307
sg21398
I24
sg21399
VC0011860
p26308
sg21401
I4
sa(dp26309
g21395
I0
sg21396
VImpairment
p26310
sg21398
I10
sg21399
VC0684336
p26311
sg21401
I1
sa(dp26312
g21395
I68
sg21396
g26300
sg21398
I7
sg21399
VC0028754
p26313
sg21401
I1
sasg21404
(lp26314
(dp26315
g21395
I18
sg21396
Vinsulin-degrading enzyme
p26316
sg21398
I24
sg21408
VP14735
p26317
sg21401
I2
sa(dp26318
g21395
I44
sg21396
g26299
sg21398
I3
sg21408
VP14735
p26319
sg21401
I1
sasa(dp26320
g21386
VSeveral mechanisms have been reported underlying the association of the two disorders, diabetes and dementia, one among which is the insulin-degrading enzyme (IDE) which is known to degrade insulin as well beta-amyloid peptides.
p26321
sg4
(dp26322
(Vinsulin
p26323
Vdiabetes
p26324
tp26325
I00
ssg21392
(lp26326
(dp26327
g21395
I100
sg21396
Vdementia
p26328
sg21398
I8
sg21399
VC0497327
p26329
sg21401
I1
sa(dp26330
g21395
I211
sg21396
Vamyloid
p26331
sg21398
I7
sg21399
VC0011560
p26332
sg21401
I1
sa(dp26333
g21395
I87
sg21396
g26324
sg21398
I8
sg21399
VC0011849
p26334
sg21401
I1
sasg21404
(lp26335
(dp26336
g21395
I159
sg21396
VIDE
p26337
sg21398
I3
sg21408
VP14735
p26338
sg21401
I1
sa(dp26339
g21395
I133
sg21396
Vinsulin-degrading enzyme
p26340
sg21398
I24
sg21408
VP14735
p26341
sg21401
I2
sa(dp26342
g21395
I133
sg21396
g26323
sg21398
I7
sg21408
VP01308
p26343
sg21401
I1
sasa(dp26344
g21386
VWe concluded that vitamin D3 ameliorated insulin resistance and hyperinsulinemia in diabetic rat model received HFW through reduction of IDE and activation of insulin receptor phosphorylation.
p26345
sg4
(dp26346
(Vinsulin receptor
p26347
Vinsulin resistance
p26348
tp26349
I00
ssg21392
(lp26350
(dp26351
g21395
I64
sg21396
Vhyperinsulinemia
p26352
sg21398
I16
sg21399
VC0020459
p26353
sg21401
I1
sa(dp26354
g21395
I41
sg21396
g26348
sg21398
I18
sg21399
VC0021655
p26355
sg21401
I2
sasg21404
(lp26356
(dp26357
g21395
I41
sg21396
Vinsulin
p26358
sg21398
I7
sg21408
VP01308
p26359
sg21401
I1
sa(dp26360
g21395
I159
sg21396
g26347
sg21398
I16
sg21408
VP01308
p26361
sg21401
I2
sasa(dp26362
g21386
VTo verify the association of transforming growth factor-beta1(TGF-beta1) (C-509T and T869C), CD14 (C-159T), IL-4 (C-590T), IL-4R (ILe50Val) and ADAM33 (S_2) gene polymorphisms with asthma severity in a sample of patients with mild, moderate and severe persistent atopic asthma.
p26363
sg4
(dp26364
(VCD14
p26365
Vasthma
p26366
tp26367
I00
ssg21392
(lp26368
(dp26369
g21395
I263
sg21396
Vatopic asthma
p26370
sg21398
I13
sg21399
VC0155877
p26371
sg21401
I2
sa(dp26372
g21395
I181
sg21396
g26366
sg21398
I6
sg21399
VC0004096
p26373
sg21401
I1
sasg21404
(lp26374
(dp26375
g21395
I108
sg21396
VIL-4
p26376
sg21398
I4
sg21408
VP05112
p26377
sg21401
I1
sa(dp26378
g21395
I29
sg21396
Vtransforming growth factor-beta1
p26379
sg21398
I32
sg21408
VP01137
p26380
sg21401
I3
sa(dp26381
g21395
I144
sg21396
VADAM33
p26382
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp26383
g21395
I62
sg21396
VTGF-beta1
p26384
sg21398
I9
sg21408
VP01137
p26385
sg21401
I1
sa(dp26386
g21395
I93
sg21396
g26365
sg21398
I4
sg21408
VP08571
p26387
sg21401
I1
sasa(dp26388
g21386
VChlamydia pneumoniae (Cpn) infection may play a role in the pathogenesis of chronic obstructive pulmonary disease (COPD).
p26389
sg4
(dp26390
(VCpn
p26391
Vchronic obstructive pulmonary disease
p26392
tp26393
I00
ssg21392
(lp26394
(dp26395
g21395
I27
sg21396
Vinfection
p26396
sg21398
I9
sg21399
VC0009450
p26397
sg21401
I1
sa(dp26398
g21395
I115
sg21396
VCOPD
p26399
sg21398
I4
sg21399
VC0024117
p26400
sg21401
I1
sa(dp26401
g21395
I76
sg21396
g26392
sg21398
I37
sg21399
VC0024117
p26402
sg21401
I4
sa(dp26403
g21395
I60
sg21396
Vpathogenesis
p26404
sg21398
I12
sg21399
VC0699748
p26405
sg21401
I1
sasg21404
(lp26406
(dp26407
g21395
I0
sg21396
VChlamydia pneumoniae
p26408
sg21398
I20
sg21408
VP15169
p26409
sg21401
I2
sa(dp26410
g21395
I22
sg21396
g26391
sg21398
I3
sg21408
VP15169
p26411
sg21401
I1
sasa(dp26412
g21386
VTo determine the possible association between Chlamydiae pneumoniae (Cpn) infection and chronic obstructive pulmonary disease (COPD).
p26413
sg4
(dp26414
(VCpn
p26415
Vchronic obstructive pulmonary disease
p26416
tp26417
I00
ssg21392
(lp26418
(dp26419
g21395
I127
sg21396
VCOPD
p26420
sg21398
I4
sg21399
VC0024117
p26421
sg21401
I1
sa(dp26422
g21395
I88
sg21396
g26416
sg21398
I37
sg21399
VC0024117
p26423
sg21401
I4
sa(dp26424
g21395
I74
sg21396
Vinfection
p26425
sg21398
I9
sg21399
VC0009450
p26426
sg21401
I1
sasg21404
(lp26427
(dp26428
g21395
I46
sg21396
VChlamydiae pneumoniae
p26429
sg21398
I21
sg21408
VP15169
p26430
sg21401
I2
sa(dp26431
g21395
I69
sg21396
g26415
sg21398
I3
sg21408
VP15169
p26432
sg21401
I1
sasa(dp26433
g21386
VThe objective of the study was to investigate the possible association of Chlamydia pneumoniae (Cpn) in acute exacerbations of chronic obstructive pulmonary disease (COPD) patients.
p26434
sg4
(dp26435
(VChlamydia pneumoniae
p26436
VCOPD
p26437
tp26438
I00
ssg21392
(lp26439
(dp26440
g21395
I127
sg21396
Vchronic obstructive pulmonary disease
p26441
sg21398
I37
sg21399
VC0024117
p26442
sg21401
I4
sa(dp26443
g21395
I166
sg21396
g26437
sg21398
I4
sg21399
VC0024117
p26444
sg21401
I1
sasg21404
(lp26445
(dp26446
g21395
I96
sg21396
VCpn
p26447
sg21398
I3
sg21408
VP15169
p26448
sg21401
I1
sa(dp26449
g21395
I74
sg21396
g26436
sg21398
I20
sg21408
VP15169
p26450
sg21401
I2
sasa(dp26451
g21386
VReading this article will familiarize the reader with (1) the unique chlamydial intracellular life cycle and the propensity for human chlamydial infections to become persistent and to result in immunopathologic (inflammatory) damage in target organs and (2) current evidence linking Chlamydia pneumoniae (Cpn) infection to obstructive lung diseases (asthma and chronic obstructive pulmonary disease, COPD).
p26452
sg4
(dp26453
(VChlamydia pneumoniae
p26454
Vasthma
p26455
tp26456
I00
ssg21392
(lp26457
(dp26458
g21395
I400
sg21396
VCOPD
p26459
sg21398
I4
sg21399
VC0024117
p26460
sg21401
I1
sa(dp26461
g21395
I145
sg21396
Vinfection
p26462
sg21398
I9
sg21399
VC0009450
p26463
sg21401
I1
sa(dp26464
g21395
I323
sg21396
Vobstructive lung diseases
p26465
sg21398
I25
sg21399
VC0600260
p26466
sg21401
I3
sa(dp26467
g21395
I134
sg21396
Vchlamydial infections
p26468
sg21398
I21
sg21399
VC0008149
p26469
sg21401
I2
sa(dp26470
g21395
I361
sg21396
Vchronic obstructive pulmonary disease
p26471
sg21398
I37
sg21399
VC0024117
p26472
sg21401
I4
sa(dp26473
g21395
I350
sg21396
g26455
sg21398
I6
sg21399
VC0004096
p26474
sg21401
I1
sasg21404
(lp26475
(dp26476
g21395
I305
sg21396
VCpn
p26477
sg21398
I3
sg21408
VP15169
p26478
sg21401
I1
sa(dp26479
g21395
I283
sg21396
g26454
sg21398
I20
sg21408
VP15169
p26480
sg21401
I2
sasa(dp26481
g21386
VIn this study we used 115 NSCLC tissues to examine the immunohistochemical expression of four distinct molecules - the major regulator of autophagy Beclin 1, the anti-apoptotic and anti-autophagic protein Bcl-2, the pro-apoptotic and pro-autophagic protein BNIP3, and a marker of hypoxia and glucolysis, the glucose transporter Glut 1.
p26482
sg4
(dp26483
(Vanti-autophagic protein Bcl-2
p26484
VNSCLC
p26485
tp26486
I00
ssg21392
(lp26487
(dp26488
g21395
I280
sg21396
Vhypoxia
p26489
sg21398
I7
sg21399
VC0242184
p26490
sg21401
I1
sa(dp26491
g21395
I26
sg21396
g26485
sg21398
I5
sg21399
VC0007131
p26492
sg21401
I1
sasg21404
(lp26493
(dp26494
g21395
I138
sg21396
Vautophagy Beclin 1
p26495
sg21398
I18
sg21408
g190
sg21401
I3
sa(dp26496
g21395
I181
sg21396
g26484
sg21398
I29
sg21408
VP10415
p26497
sg21401
I3
sa(dp26498
g21395
I234
sg21396
Vpro-autophagic protein BNIP3
p26499
sg21398
I28
sg21408
g190
sg21401
I3
sasa(dp26500
g21386
VIn conclusion, the accelerated autophagic status in NSCLC is unrelated to Beclin 1 and BNIP3 expression, but does show significant association with Bcl-2 reactivity.
p26501
sg4
(dp26502
(VBcl-2
p26503
VNSCLC
p26504
tp26505
I00
ssg21392
(lp26506
(dp26507
g21395
I52
sg21396
g26504
sg21398
I5
sg21399
VC0007131
p26508
sg21401
I1
sasg21404
(lp26509
(dp26510
g21395
I74
sg21396
VBeclin 1
p26511
sg21398
I8
sg21408
g190
sg21401
I2
sa(dp26512
g21395
I87
sg21396
VBNIP3
p26513
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp26514
g21395
I148
sg21396
g26503
sg21398
I5
sg21408
VP10415
p26515
sg21401
I1
sasa(dp26516
g21386
VThis study was designed to determine the pattern and correlation between expression of the HIF-1Alfa transcriptional targets TGM2 and BNIP3 in laryngeal cancer, and investigate the association of BNIP3 and TGM2 with clinical outcome in laryngeal squamous cell carcinoma (SCC) patients receiving postoperative radiotherapy.
p26517
sg4
(dp26518
(VTGM2
p26519
Vlaryngeal cancer
p26520
tp26521
I00
ssg21392
(lp26522
(dp26523
g21395
I236
sg21396
Vlaryngeal squamous cell carcinoma
p26524
sg21398
I33
sg21399
VC0280324
p26525
sg21401
I4
sa(dp26526
g21395
I143
sg21396
g26520
sg21398
I16
sg21399
VC0595989
p26527
sg21401
I2
sasg21404
(lp26528
(dp26529
g21395
I134
sg21396
VBNIP3
p26530
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp26531
g21395
I125
sg21396
VTGM2
p26532
sg21398
I4
sg21408
VP21980
p26533
sg21401
I1
sa(dp26534
g21395
I125
sg21396
g26519
sg21398
I4
sg21408
VP21980
p26535
sg21401
I1
sa(dp26536
g21395
I134
sg21396
VBNIP3
p26537
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp26538
g21386
VConsidering tumors with telomere shortening, expression for BNIP3, DAPK1, NDRG1, EGFR, and CDKN2A was significantly higher in NSCLC than in CRC, whereas TP53 was overexpressed in CRC with respect to NSCLC.
p26539
sg4
(dp26540
(VCRC
p26541
VNSCLC
p26542
tp26543
I00
ssg21392
(lp26544
(dp26545
g21395
I24
sg21396
Vtelomere shortening
p26546
sg21398
I19
sg21399
VC1515263
p26547
sg21401
I2
sa(dp26548
g21395
I140
sg21396
VCRC
p26549
sg21398
I3
sg21399
VC1527249
p26550
sg21401
I1
sa(dp26551
g21395
I12
sg21396
Vtumors
p26552
sg21398
I6
sg21399
VC0027651
p26553
sg21401
I1
sa(dp26554
g21395
I126
sg21396
VNSCLC
p26555
sg21398
I5
sg21399
VC0007131
p26556
sg21401
I1
sa(dp26557
g21395
I140
sg21396
VCRC
p26558
sg21398
I3
sg21399
VC1527249
p26559
sg21401
I1
sa(dp26560
g21395
I126
sg21396
g26542
sg21398
I5
sg21399
VC0007131
p26561
sg21401
I1
sasg21404
(lp26562
(dp26563
g21395
I140
sg21396
VCRC, whereas TP53
p26564
sg21398
I17
sg21408
VP31749
p26565
sg21401
I3
sa(dp26566
g21395
I91
sg21396
VCDKN2A
p26567
sg21398
I6
sg21408
VP42771
p26568
sg21401
I1
sa(dp26569
g21395
I67
sg21396
VDAPK1
p26570
sg21398
I5
sg21408
VP53355
p26571
sg21401
I1
sa(dp26572
g21395
I140
sg21396
g26541
sg21398
I3
sg21408
VP31749
p26573
sg21401
I1
sa(dp26574
g21395
I74
sg21396
VNDRG1
p26575
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp26576
g21395
I60
sg21396
VBNIP3
p26577
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp26578
g21386
VObesity is a heritable disorder, and some of the many obesity susceptible genes are fat mass and obesity (FTO), leptin, and Melanocortin-4 receptor (MC4R).
p26579
sg4
(dp26580
(Vleptin
p26581
Vobesity
p26582
tp26583
I00
ssg21392
(lp26584
(dp26585
g21395
I0
sg21396
VObesity
p26586
sg21398
I7
sg21399
VC0028754
p26587
sg21401
I1
sa(dp26588
g21395
I54
sg21396
Vobesity
p26589
sg21398
I7
sg21399
VC0028754
p26590
sg21401
I1
sa(dp26591
g21395
I54
sg21396
g26582
sg21398
I7
sg21399
VC0028754
p26592
sg21401
I1
sasg21404
(lp26593
(dp26594
g21395
I124
sg21396
VMelanocortin-4 receptor
p26595
sg21398
I23
sg21408
VP32245
p26596
sg21401
I2
sa(dp26597
g21395
I149
sg21396
VMC4R
p26598
sg21398
I4
sg21408
VP32245
p26599
sg21401
I1
sa(dp26600
g21395
I112
sg21396
g26581
sg21398
I6
sg21408
VP41159
p26601
sg21401
I1
sasa(dp26602
g21386
VWe showed that: (1) there was a significant association between the biased usage of IGHV4-34 (binds to the carbohydrate I/i antigens) and inactivating mutation of TNFAIP3 [encoding a global negative regulator of the canonical nuclear factor-KB (NF-KB) pathway] in ocular adnexal MALT lymphoma; (2) IGHV1-69 was significantly overrepresented (54%) in MALT lymphoma of the salivary gland, but was not associated with mutation in any of the 17 genes investigated; and (3) MALT lymphoma lacked mutations that are frequently seen in other B-cell lymphomas characterized by constitutive NF-KB activities, including mutations in CD79B, CARD11, MYD88, TNFRSF11A, and TRAF3.
p26603
sg4
(dp26604
(VCD79B
p26605
VMALT lymphoma
p26606
tp26607
I01
ssg21392
(lp26608
(dp26609
g21395
I279
sg21396
VMALT lymphoma
p26610
sg21398
I13
sg21399
VC0242647
p26611
sg21401
I2
sa(dp26612
g21395
I534
sg21396
VB-cell lymphomas
p26613
sg21398
I16
sg21399
VC0079731
p26614
sg21401
I2
sa(dp26615
g21395
I264
sg21396
Vocular adnexal MALT lymphoma
p26616
sg21398
I28
sg21399
VC1335103
p26617
sg21401
I4
sa(dp26618
g21395
I279
sg21396
g26606
sg21398
I13
sg21399
VC0242647
p26619
sg21401
I2
sasg21404
(lp26620
(dp26621
g21395
I637
sg21396
VMYD88
p26622
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp26623
g21395
I644
sg21396
VTNFRSF11A
p26624
sg21398
I9
sg21408
g190
sg21401
I1
sa(dp26625
g21395
I226
sg21396
Vnuclear factor-KB
p26626
sg21398
I17
sg21408
VP01160
p26627
sg21401
I2
sa(dp26628
g21395
I629
sg21396
VCARD11
p26629
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp26630
g21395
I245
sg21396
VNF-KB
p26631
sg21398
I5
sg21408
VP01160
p26632
sg21401
I1
sa(dp26633
g21395
I659
sg21396
VTRAF3
p26634
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp26635
g21395
I245
sg21396
VNF-KB
p26636
sg21398
I5
sg21408
VP01160
p26637
sg21401
I1
sa(dp26638
g21395
I107
sg21396
Vcarbohydrate I/i antigens
p26639
sg21398
I25
sg21408
g190
sg21401
I3
sa(dp26640
g21395
I163
sg21396
VTNFAIP3
p26641
sg21398
I7
sg21408
VP21580
p26642
sg21401
I1
sa(dp26643
g21395
I622
sg21396
g26605
sg21398
I5
sg21408
VP40259
p26644
sg21401
I1
sasa(dp26645
g21386
VTherefore, we aim to assess the correlation of endothelin-1 concentrations with the development and severity of knee osteoarthritis (OA).
p26646
sg4
(dp26647
(Vendothelin-1
p26648
Vknee osteoarthritis
p26649
tp26650
I00
ssg21392
(lp26651
(dp26652
g21395
I112
sg21396
g26649
sg21398
I19
sg21399
VC0409959
p26653
sg21401
I2
sasg21404
(lp26654
(dp26655
g21395
I47
sg21396
g26648
sg21398
I12
sg21408
VP20800
p26656
sg21401
I1
sasa(dp26657
g21386
VTogether, the results here demonstrate that the febrile response in zymosan-induced arthritis in rats depends on the centrally acting pyrogenic cytokines TNF-Alfa, IL-1Beta, and IL-6, but does not depend on either CRF or ET-1.
p26658
sg4
(dp26659
(Vcytokines TNF-Alfa
p26660
VCRF
p26661
tp26662
I00
ssg21392
(lp26663
(dp26664
g21395
I84
sg21396
Varthritis
p26665
sg21398
I9
sg21399
VC0003864
p26666
sg21401
I1
sa(dp26667
g21395
I214
sg21396
g26661
sg21398
I3
sg21399
VC0022661
p26668
sg21401
I1
sasg21404
(lp26669
(dp26670
g21395
I221
sg21396
VET-1
p26671
sg21398
I4
sg21408
VP05305
p26672
sg21401
I1
sa(dp26673
g21395
I178
sg21396
VIL-6
p26674
sg21398
I4
sg21408
VP05231
p26675
sg21401
I1
sa(dp26676
g21395
I164
sg21396
VIL-1Beta
p26677
sg21398
I8
sg21408
VP01584
p26678
sg21401
I1
sa(dp26679
g21395
I214
sg21396
VCRF
p26680
sg21398
I3
sg21408
VP06850
p26681
sg21401
I1
sa(dp26682
g21395
I144
sg21396
g26660
sg21398
I18
sg21408
VP01375
p26683
sg21401
I2
sasa(dp26684
g21386
VAntibodies to AQP4 and AQP1 are detected in neuromyelitis optica and are believed to play a pathogenic role.
p26685
sg4
(dp26686
(VAQP1
p26687
Vneuromyelitis optica
p26688
tp26689
I01
ssg21392
(lp26690
(dp26691
g21395
I44
sg21396
g26688
sg21398
I20
sg21399
VC0027873
p26692
sg21401
I2
sasg21404
(lp26693
(dp26694
g21395
I14
sg21396
VAQP4
p26695
sg21398
I4
sg21408
VP55087
p26696
sg21401
I1
sa(dp26697
g21395
I23
sg21396
g26687
sg21398
I4
sg21408
VP29972
p26698
sg21401
I1
sasa(dp26699
g21386
VAmong thirteen different mammalian AQPs, AQP1 and AQP4 have been mainly studied in the CNS and evidence has been presented that they play important roles in the pathogenesis of CNS injury, edema and multiple diseases such as multiple sclerosis, neuromyelitis optica spectrum disorders, amyotrophic lateral sclerosis, glioblastoma multiforme, Alzheimer's disease and Parkinson's disease.
p26700
sg4
(dp26701
(VAQP1
p26702
Vedema
p26703
tp26704
I00
ssg21392
(lp26705
(dp26706
g21395
I161
sg21396
Vpathogenesis
p26707
sg21398
I12
sg21399
VC0699748
p26708
sg21401
I1
sa(dp26709
g21395
I366
sg21396
VParkinson's disease
p26710
sg21398
I19
sg21399
VC0030567
p26711
sg21401
I2
sa(dp26712
g21395
I317
sg21396
Vglioblastoma multiforme
p26713
sg21398
I23
sg21399
VC1621958
p26714
sg21401
I2
sa(dp26715
g21395
I286
sg21396
Vamyotrophic lateral sclerosis
p26716
sg21398
I29
sg21399
VC0002736
p26717
sg21401
I3
sa(dp26718
g21395
I245
sg21396
Vneuromyelitis optica
p26719
sg21398
I20
sg21399
VC0027873
p26720
sg21401
I2
sa(dp26721
g21395
I342
sg21396
VAlzheimer's disease
p26722
sg21398
I19
sg21399
VC1521724
p26723
sg21401
I2
sa(dp26724
g21395
I225
sg21396
Vmultiple sclerosis
p26725
sg21398
I18
sg21399
VC0026769
p26726
sg21401
I2
sa(dp26727
g21395
I189
sg21396
g26703
sg21398
I5
sg21399
VC0013604
p26728
sg21401
I1
sasg21404
(lp26729
(dp26730
g21395
I50
sg21396
VAQP4
p26731
sg21398
I4
sg21408
VP55087
p26732
sg21401
I1
sa(dp26733
g21395
I41
sg21396
g26702
sg21398
I4
sg21408
VP29972
p26734
sg21401
I1
sasa(dp26735
g21386
VThe ICOS-ICOSL signaling has a regulatory effect on CD154-CD40 signaling pathway, and may play an important role in the hepatic egg granuloma formation of Schistosomiasis.
p26736
sg4
(dp26737
(VICOS-ICOSL
p26738
VSchistosomiasis
p26739
tp26740
I00
ssg21392
(lp26741
(dp26742
g21395
I132
sg21396
Vgranuloma
p26743
sg21398
I9
sg21399
VC0018188
p26744
sg21401
I1
sa(dp26745
g21395
I155
sg21396
g26739
sg21398
I15
sg21399
VC0036323
p26746
sg21401
I1
sasg21404
(lp26747
(dp26748
g21395
I52
sg21396
VCD154
p26749
sg21398
I5
sg21408
VP29965
p26750
sg21401
I1
sa(dp26751
g21395
I58
sg21396
VCD40
p26752
sg21398
I4
sg21408
VP25942
p26753
sg21401
I1
sa(dp26754
g21395
I4
sg21396
g26738
sg21398
I10
sg21408
VP16410
p26755
sg21401
I1
sasa(dp26756
g21386
VUsing models of schistosomiasis in ICOSL KO and the C57BL/6 WT mice, we studied the role of the ICOSL/ICOS interaction in the mediation of the Th17 response in host granulomatous inflammation, particularly in liver fibrosis during S. japonicum infection, and investigated the immune responses and pathology of ICOSL KO mice in these models.
p26757
sg4
(dp26758
(VICOS
p26759
Vliver fibrosis
p26760
tp26761
I00
ssg21392
(lp26762
(dp26763
g21395
I16
sg21396
Vschistosomiasis
p26764
sg21398
I15
sg21399
VC0036323
p26765
sg21401
I1
sa(dp26766
g21395
I209
sg21396
g26760
sg21398
I14
sg21399
VC0239946
p26767
sg21401
I2
sa(dp26768
g21395
I244
sg21396
Vinfection
p26769
sg21398
I9
sg21399
VC0009450
p26770
sg21401
I1
sa(dp26771
g21395
I165
sg21396
Vgranulomatous inflammation
p26772
sg21398
I26
sg21399
VC0553697
p26773
sg21401
I2
sa(dp26774
g21395
I297
sg21396
Vpathology
p26775
sg21398
I9
sg21399
VC0677042
p26776
sg21401
I1
sasg21404
(lp26777
(dp26778
g21395
I35
sg21396
VICOSL KO
p26779
sg21398
I8
sg21408
g190
sg21401
I2
sa(dp26780
g21395
I35
sg21396
g26759
sg21398
I4
sg21408
VP16410
p26781
sg21401
I1
sa(dp26782
g21395
I35
sg21396
VICOSL KO
p26783
sg21398
I8
sg21408
g190
sg21401
I2
sa(dp26784
g21395
I35
sg21396
VICOSL
p26785
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp26786
g21386
VLncRNA ZEB1 Antisense 1 (ZEB1-AS1) has been suggested to be an oncogenic role in human hepatocellular carcinoma, osteosarcoma, glioma and esophageal carcinoma progression.
p26787
sg4
(dp26788
(VLncRNA ZEB1 Antisense 1
p26789
Vglioma
p26790
tp26791
I00
ssg21392
(lp26792
(dp26793
g21395
I87
sg21396
Vhepatocellular carcinoma
p26794
sg21398
I24
sg21399
VC1512411
p26795
sg21401
I2
sa(dp26796
g21395
I138
sg21396
Vesophageal carcinoma
p26797
sg21398
I20
sg21399
VC0152018
p26798
sg21401
I2
sa(dp26799
g21395
I30
sg21396
VAS1
p26800
sg21398
I3
sg21399
VC1846534
p26801
sg21401
I1
sa(dp26802
g21395
I113
sg21396
Vosteosarcoma
p26803
sg21398
I12
sg21399
VC0029463
p26804
sg21401
I1
sa(dp26805
g21395
I127
sg21396
g26790
sg21398
I6
sg21399
VC0017638
p26806
sg21401
I1
sasg21404
(lp26807
(dp26808
g21395
I7
sg21396
VZEB1
p26809
sg21398
I4
sg21408
VP37275
p26810
sg21401
I1
sa(dp26811
g21395
I30
sg21396
VAS1
p26812
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp26813
g21395
I0
sg21396
g26789
sg21398
I23
sg21408
VP37275
p26814
sg21401
I4
sasa(dp26815
g21386
VZEB1-AS1 acts as an oncogene in hepatocellular carcinoma, accelerating tumor growth and promoting metastasis.
p26816
sg4
(dp26817
(VZEB1
p26818
VAS1
p26819
tp26820
I00
ssg21392
(lp26821
(dp26822
g21395
I32
sg21396
Vhepatocellular carcinoma
p26823
sg21398
I24
sg21399
VC1512411
p26824
sg21401
I2
sa(dp26825
g21395
I98
sg21396
Vmetastasis
p26826
sg21398
I10
sg21399
VC0027627
p26827
sg21401
I1
sa(dp26828
g21395
I5
sg21396
g26819
sg21398
I3
sg21399
VC1846534
p26829
sg21401
I1
sa(dp26830
g21395
I71
sg21396
Vtumor growth
p26831
sg21398
I12
sg21399
VC0598934
p26832
sg21401
I2
sasg21404
(lp26833
(dp26834
g21395
I0
sg21396
g26818
sg21398
I4
sg21408
VP37275
p26835
sg21401
I1
sa(dp26836
g21395
I5
sg21396
VAS1
p26837
sg21398
I3
sg21408
g190
sg21401
I1
sasa(dp26838
g21386
VLncRNA ZEB1-AS1 has been identified as a tumor oncogene in hepatocellular carcinoma.
p26839
sg4
(dp26840
(VZEB1
p26841
Vhepatocellular carcinoma
p26842
tp26843
I00
ssg21392
(lp26844
(dp26845
g21395
I12
sg21396
VAS1
p26846
sg21398
I3
sg21399
VC1846534
p26847
sg21401
I1
sa(dp26848
g21395
I59
sg21396
g26842
sg21398
I24
sg21399
VC1512411
p26849
sg21401
I2
sa(dp26850
g21395
I41
sg21396
Vtumor
p26851
sg21398
I5
sg21399
VC0027651
p26852
sg21401
I1
sasg21404
(lp26853
(dp26854
g21395
I12
sg21396
VAS1
p26855
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp26856
g21395
I7
sg21396
g26841
sg21398
I4
sg21408
VP37275
p26857
sg21401
I1
sasa(dp26858
g21386
VWe analyzed the outcome of allo-SCT in a population of FLT3-positive AML patients according to molecular MRD at the pretransplantation workup, assessed by the quantitative expression evaluation of the panleukemic marker Wilms' tumor (WT1) gene.
p26859
sg4
(dp26860
(VFLT3
p26861
VAML
p26862
tp26863
I00
ssg21392
(lp26864
(dp26865
g21395
I220
sg21396
VWilms' tumor
p26866
sg21398
I12
sg21399
VC0027708
p26867
sg21401
I2
sa(dp26868
g21395
I32
sg21396
VSCT
p26869
sg21398
I3
sg21399
VC1848934
p26870
sg21401
I1
sa(dp26871
g21395
I105
sg21396
VMRD
p26872
sg21398
I3
sg21399
VC1840451
p26873
sg21401
I1
sa(dp26874
g21395
I234
sg21396
VWT1
p26875
sg21398
I3
sg21399
VC0027708
p26876
sg21401
I1
sa(dp26877
g21395
I69
sg21396
g26862
sg21398
I3
sg21399
VC0023467
p26878
sg21401
I1
sasg21404
(lp26879
(dp26880
g21395
I55
sg21396
g26861
sg21398
I4
sg21408
VP36888
p26881
sg21401
I1
sasa(dp26882
g21386
VTo determine the chemokine receptor expression profile in gastric mucosa-associated lymphoid tissue (MALT) lymphoma, we performed an expression analysis of 19 chemokine receptors at mRNA levels by using real-time RT-PCR, as well as of five chemokine receptors--CCR8, CCR9, CXCR4, CXCR6 and CXCR7--by immunohistochemistry on human tissue samples of Helicobacter pylori-associated gastritis, gastric MALT lymphoma and gastric extranodal diffuse large B-cell lymphoma originating from MALT lymphoma (transformed MALT lymphoma).
p26883
sg4
(dp26884
(VCXCR7
p26885
VHelicobacter pylori-associated gastritis
p26886
tp26887
I00
ssg21392
(lp26888
(dp26889
g21395
I398
sg21396
VMALT lymphoma
p26890
sg21398
I13
sg21399
VC0242647
p26891
sg21401
I2
sa(dp26892
g21395
I107
sg21396
Vlymphoma
p26893
sg21398
I8
sg21399
VC0024299
p26894
sg21401
I1
sa(dp26895
g21395
I435
sg21396
Vdiffuse large B-cell lymphoma
p26896
sg21398
I29
sg21399
VC0079744
p26897
sg21401
I4
sa(dp26898
g21395
I398
sg21396
VMALT lymphoma
p26899
sg21398
I13
sg21399
VC0242647
p26900
sg21401
I2
sa(dp26901
g21395
I390
sg21396
Vgastric MALT lymphoma
p26902
sg21398
I21
sg21399
VC1333782
p26903
sg21401
I3
sa(dp26904
g21395
I348
sg21396
g26886
sg21398
I40
sg21399
VC0343378
p26905
sg21401
I3
sasg21404
(lp26906
(dp26907
g21395
I261
sg21396
VCCR8
p26908
sg21398
I4
sg21408
VP51685
p26909
sg21401
I1
sa(dp26910
g21395
I267
sg21396
VCCR9
p26911
sg21398
I4
sg21408
VP51686
p26912
sg21401
I1
sa(dp26913
g21395
I273
sg21396
VCXCR4
p26914
sg21398
I5
sg21408
VP61073
p26915
sg21401
I1
sa(dp26916
g21395
I290
sg21396
g26885
sg21398
I5
sg21408
VP25106
p26917
sg21401
I1
sa(dp26918
g21395
I280
sg21396
VCXCR6
p26919
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp26920
g21386
VThe transformation of gastric MALT lymphomas to gastric extranodal diffuse large B-cell lymphoma was accompanied by upregulation of CCR1, CCR5, CCR7, CCR8, CCR9, CXCR3, CXCR6, CXCR7 and XCR1.
p26921
sg4
(dp26922
(VCCR7
p26923
VMALT lymphomas
p26924
tp26925
I00
ssg21392
(lp26926
(dp26927
g21395
I67
sg21396
Vdiffuse large B-cell lymphoma
p26928
sg21398
I29
sg21399
VC0079744
p26929
sg21401
I4
sa(dp26930
g21395
I4
sg21396
Vtransformation
p26931
sg21398
I14
sg21399
VC1510411
p26932
sg21401
I1
sa(dp26933
g21395
I30
sg21396
g26924
sg21398
I14
sg21399
VC0242647
p26934
sg21401
I2
sasg21404
(lp26935
(dp26936
g21395
I162
sg21396
VCXCR3
p26937
sg21398
I5
sg21408
VP49682
p26938
sg21401
I1
sa(dp26939
g21395
I169
sg21396
VCXCR6
p26940
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp26941
g21395
I138
sg21396
VCCR5
p26942
sg21398
I4
sg21408
VP32302
p26943
sg21401
I1
sa(dp26944
g21395
I132
sg21396
VCCR1
p26945
sg21398
I4
sg21408
VP32246
p26946
sg21401
I1
sa(dp26947
g21395
I176
sg21396
VCXCR7
p26948
sg21398
I5
sg21408
VP25106
p26949
sg21401
I1
sa(dp26950
g21395
I156
sg21396
VCCR9
p26951
sg21398
I4
sg21408
VP51686
p26952
sg21401
I1
sa(dp26953
g21395
I150
sg21396
VCCR8
p26954
sg21398
I4
sg21408
VP51685
p26955
sg21401
I1
sa(dp26956
g21395
I186
sg21396
VXCR1
p26957
sg21398
I4
sg21408
VP46094
p26958
sg21401
I1
sa(dp26959
g21395
I144
sg21396
g26923
sg21398
I4
sg21408
VP32248
p26960
sg21401
I1
sasa(dp26961
g21386
VFeline leukemia virus (FeLV) p27 or gp70 antigen was detected in 21 lymphomas (54%).
p26962
sg4
(dp26963
(Vp27
p26964
VFeline leukemia
p26965
tp26966
I00
ssg21392
(lp26967
(dp26968
g21395
I68
sg21396
Vlymphomas
p26969
sg21398
I9
sg21399
VC0024299
p26970
sg21401
I1
sa(dp26971
g21395
I0
sg21396
g26965
sg21398
I15
sg21399
VC0085164
p26972
sg21401
I2
sasg21404
(lp26973
(dp26974
g21395
I29
sg21396
g26964
sg21398
I3
sg21408
VP40305
p26975
sg21401
I1
sa(dp26976
g21395
I36
sg21396
Vgp70 antigen
p26977
sg21398
I12
sg21408
g190
sg21401
I2
sasa(dp26978
g21386
VVaccines to large B cell lymphoma were made by the covalent attachment of an epitope from the gp70 glycoprotein (SSWDFITV) to the N-termini of the conformationally biased, response-selective C5a agonists EP54 (YSFKPMPLaR) and EP67 (YSFKDMP(MeL)aR).
p26979
sg4
(dp26980
(VMeL
p26981
VMeL
p26982
tp26983
I00
ssg21392
(lp26984
(dp26985
g21395
I18
sg21396
VB cell lymphoma
p26986
sg21398
I15
sg21399
VC0079731
p26987
sg21401
I3
sa(dp26988
g21395
I240
sg21396
g26982
sg21398
I3
sg21399
VC3149631
p26989
sg21401
I1
sasg21404
(lp26990
(dp26991
g21395
I94
sg21396
Vgp70 glycoprotein
p26992
sg21398
I17
sg21408
g190
sg21401
I2
sa(dp26993
g21395
I191
sg21396
VC5a
p26994
sg21398
I3
sg21408
VP21730
p26995
sg21401
I1
sa(dp26996
g21395
I240
sg21396
g26981
sg21398
I3
sg21408
VP61006
p26997
sg21401
I1
sasa(dp26998
g21386
VCD8(+) T lymphocytes activated in response to Vaccines 2 and 3 express cytotoxic specificity for gp70-expressing RAW117-H10 lymphoma cells, but not antigen-irrelevant MDA-MB231A human breast cancer cells.
p26999
sg4
(dp27000
(VCD8
p27001
Vbreast cancer
p27002
tp27003
I00
ssg21392
(lp27004
(dp27005
g21395
I124
sg21396
Vlymphoma
p27006
sg21398
I8
sg21399
VC0024299
p27007
sg21401
I1
sa(dp27008
g21395
I184
sg21396
g27002
sg21398
I13
sg21399
VC0678222
p27009
sg21401
I2
sasg21404
(lp27010
(dp27011
g21395
I0
sg21396
g27001
sg21398
I3
sg21408
VP01732
p27012
sg21401
I1
sa(dp27013
g21395
I97
sg21396
Vgp70
p27014
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp27015
g21386
VOur strategy relies on the fact that feline leukemia virus subgroup B (FeLV-B) and amphotropic murine leukemia virus (A-MLV) have closely related gp70 surface envelope glycoproteins and use related Na(+)-dependent phosphate symporters, Pit1 and Pit2, respectively, as their receptors.
p27016
sg4
(dp27017
(VNa(+)-dependent phosphate symporters
p27018
Vleukemia
p27019
tp27020
I00
ssg21392
(lp27021
(dp27022
g21395
I37
sg21396
Vfeline leukemia
p27023
sg21398
I15
sg21399
VC0085164
p27024
sg21401
I2
sa(dp27025
g21395
I44
sg21396
g27019
sg21398
I8
sg21399
VC0023418
p27026
sg21401
I1
sasg21404
(lp27027
(dp27028
g21395
I245
sg21396
VPit2
p27029
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp27030
g21395
I236
sg21396
VPit1
p27031
sg21398
I4
sg21408
VP28069
p27032
sg21401
I1
sa(dp27033
g21395
I146
sg21396
Vgp70 surface envelope glycoproteins
p27034
sg21398
I35
sg21408
g190
sg21401
I4
sa(dp27035
g21395
I198
sg21396
g27018
sg21398
I36
sg21408
VP19525
p27036
sg21401
I3
sasa(dp27037
g21386
VNumerous studies have investigated the utility of serum intestinal fatty-acid binding protein (I-FABP) in differentiating acute intestinal ischemia from acute abdomen.
p27038
sg4
(dp27039
(VI-FABP
p27040
Vacute abdomen
p27041
tp27042
I00
ssg21392
(lp27043
(dp27044
g21395
I122
sg21396
Vacute intestinal ischemia
p27045
sg21398
I25
sg21399
VC0001363
p27046
sg21401
I3
sa(dp27047
g21395
I153
sg21396
g27041
sg21398
I13
sg21399
VC0000727
p27048
sg21401
I2
sasg21404
(lp27049
(dp27050
g21395
I56
sg21396
Vintestinal fatty-acid binding protein
p27051
sg21398
I37
sg21408
VP12104
p27052
sg21401
I4
sa(dp27053
g21395
I95
sg21396
g27040
sg21398
I6
sg21408
VP12104
p27054
sg21401
I1
sasa(dp27055
g21386
VThe meta-analysis carried out in this report suggests that the I-FABP may be a useful diagnostic tool to confirm acute intestinal ischemia in acute abdomen, but better-designed trials are still required to confirm our findings.
p27056
sg4
(dp27057
(VI-FABP
p27058
Vacute abdomen
p27059
tp27060
I00
ssg21392
(lp27061
(dp27062
g21395
I142
sg21396
g27059
sg21398
I13
sg21399
VC0000727
p27063
sg21401
I2
sa(dp27064
g21395
I113
sg21396
Vacute intestinal ischemia
p27065
sg21398
I25
sg21399
VC0001363
p27066
sg21401
I3
sasg21404
(lp27067
(dp27068
g21395
I63
sg21396
g27058
sg21398
I6
sg21408
VP12104
p27069
sg21401
I1
sasa(dp27070
g21386
VEcoptic expression of miR-330-5p suppressed Pdia3 expression and overexpression of EWSAT1 promoted Pdia3 expression in ovarian cancer cell.
p27071
sg4
(dp27072
(VPdia3
p27073
Vovarian cancer
p27074
tp27075
I01
ssg21392
(lp27076
(dp27077
g21395
I119
sg21396
g27074
sg21398
I14
sg21399
VC1140680
p27078
sg21401
I2
sasg21404
(lp27079
(dp27080
g21395
I22
sg21396
VmiR-330-5p
p27081
sg21398
I10
sg21408
g190
sg21401
I1
sa(dp27082
g21395
I44
sg21396
VPdia3
p27083
sg21398
I5
sg21408
VP30101
p27084
sg21401
I1
sa(dp27085
g21395
I44
sg21396
g27073
sg21398
I5
sg21408
VP30101
p27086
sg21401
I1
sasa(dp27087
g21386
VRecently, lncRNA Ewing sarcoma-associated transcript 1 (EWSAT1) was functionally identified in Ewing sarcoma, a highly aggressive primary pediatric bone tumor.
p27088
sg4
(dp27089
(VlncRNA Ewing sarcoma-associated transcript 1
p27090
VEwing sarcoma
p27091
tp27092
I00
ssg21392
(lp27093
(dp27094
g21395
I148
sg21396
Vbone tumor
p27095
sg21398
I10
sg21399
VC0005967
p27096
sg21401
I2
sa(dp27097
g21395
I17
sg21396
VEwing sarcoma
p27098
sg21398
I13
sg21399
VC0553580
p27099
sg21401
I2
sa(dp27100
g21395
I119
sg21396
Vaggressive
p27101
sg21398
I10
sg21399
VC0001807
p27102
sg21401
I1
sa(dp27103
g21395
I17
sg21396
g27091
sg21398
I13
sg21399
VC0553580
p27104
sg21401
I2
sasg21404
(lp27105
(dp27106
g21395
I10
sg21396
g27090
sg21398
I44
sg21408
VP11308
p27107
sg21401
I5
sasa(dp27108
g21386
VResults: The data show that the expression of MZF-1/Elk-1 is correlated with that of PKCAlfa in hepatocellular carcinoma (HCC), but not in bladder and lung cancers.
p27109
sg4
(dp27110
(VMZF-1
p27111
Vhepatocellular carcinoma
p27112
tp27113
I00
ssg21392
(lp27114
(dp27115
g21395
I122
sg21396
VHCC
p27116
sg21398
I3
sg21399
VC2239176
p27117
sg21401
I1
sa(dp27118
g21395
I151
sg21396
Vlung cancers
p27119
sg21398
I12
sg21399
VC0242379
p27120
sg21401
I2
sa(dp27121
g21395
I96
sg21396
g27112
sg21398
I24
sg21399
VC2239176
p27122
sg21401
I2
sasg21404
(lp27123
(dp27124
g21395
I52
sg21396
VElk-1
p27125
sg21398
I5
sg21408
VP54762
p27126
sg21401
I1
sa(dp27127
g21395
I46
sg21396
g27111
sg21398
I5
sg21408
VP28698
p27128
sg21401
I1
sasa(dp27129
g21386
VHere, using PEI-Mn0.5Zn0.5Fe2O4 nanoparticles (PEI-MZF-NPs) as magnetic media for MFH (magnetic fluid hyperthermia) and gene transfer vector for gene-therapy, a combined therapy, pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH, for hepatoma is developed.
p27130
sg4
(dp27131
(VPEI-MZF-NPs
p27132
VNPs
p27133
tp27134
I00
ssg21392
(lp27135
(dp27136
g21395
I228
sg21396
Vhepatoma
p27137
sg21398
I8
sg21399
VC0023903
p27138
sg21401
I1
sa(dp27139
g21395
I55
sg21396
g27133
sg21398
I3
sg21399
VC0027341
p27140
sg21401
I1
sasg21404
(lp27141
(dp27142
g21395
I179
sg21396
VpHRE-Egr1-HSV-TK
p27143
sg21398
I16
sg21408
VP29401
p27144
sg21401
I1
sa(dp27145
g21395
I12
sg21396
VPEI-Mn0.5Zn0.5Fe2O4 nanoparticles
p27146
sg21398
I33
sg21408
g190
sg21401
I2
sa(dp27147
g21395
I47
sg21396
g27132
sg21398
I11
sg21408
VP28698
p27148
sg21401
I1
sasa(dp27149
g21386
VTo explore a new combination of thermal treatment and gene therapy for hepatoma, a heat-inducible herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) gene therapy system was developed in which thermal energy generated by Mn0.5Zn0.5Fe2O4 nanoparticles (MZF-NPs) under an alternating magnetic field was used to activate gene expression.
p27150
sg4
(dp27151
(VMZF-NPs
p27152
VNPs
p27153
tp27154
I00
ssg21392
(lp27155
(dp27156
g21395
I71
sg21396
Vhepatoma
p27157
sg21398
I8
sg21399
VC0023903
p27158
sg21401
I1
sa(dp27159
g21395
I98
sg21396
Vherpes simplex
p27160
sg21398
I14
sg21399
VC0019348
p27161
sg21401
I2
sa(dp27162
g21395
I267
sg21396
g27153
sg21398
I3
sg21399
VC0027341
p27163
sg21401
I1
sasg21404
(lp27164
(dp27165
g21395
I232
sg21396
VMn0.5Zn0.5Fe2O4 nanoparticles
p27166
sg21398
I29
sg21408
g190
sg21401
I2
sa(dp27167
g21395
I156
sg21396
VGCV
p27168
sg21398
I3
sg21408
VP23434
p27169
sg21401
I1
sa(dp27170
g21395
I153
sg21396
VTK
p27171
sg21398
I2
sg21408
VP29401
p27172
sg21401
I1
sa(dp27173
g21395
I263
sg21396
g27152
sg21398
I7
sg21408
VP28698
p27174
sg21401
I1
sasa(dp27175
g21386
VMagnet-induced heating was then applied to cells to assess the antihepatoma effects of the polyethylenimine (PEI)-MZF-NPs/pHsp 70-HSV-TK/GCV complex, in vitro and in vivo.
p27176
sg4
(dp27177
(VTK
p27178
VNPs
p27179
tp27180
I00
ssg21392
(lp27181
(dp27182
g21395
I118
sg21396
g27179
sg21398
I3
sg21399
VC0027341
p27183
sg21401
I1
sasg21404
(lp27184
(dp27185
g21395
I137
sg21396
VGCV
p27186
sg21398
I3
sg21408
VP23434
p27187
sg21401
I1
sa(dp27188
g21395
I118
sg21396
VNPs
p27189
sg21398
I3
sg21408
VP0C0P6
p27190
sg21401
I1
sa(dp27191
g21395
I114
sg21396
VMZF
p27192
sg21398
I3
sg21408
VP28698
p27193
sg21401
I1
sa(dp27194
g21395
I134
sg21396
g27178
sg21398
I2
sg21408
VP29401
p27195
sg21401
I1
sasa(dp27196
g21386
VIn this study, the molecular mechanism of protein kinase C alpha (PKCAlfa) gene regulation in hepatocellular carcinoma (HCC) involving Ets-like protein-1 (Elk-1) and myeloid zinc finger-1 (MZF-1) was investigated.
p27197
sg4
(dp27198
(VMZF-1
p27199
Vhepatocellular carcinoma
p27200
tp27201
I00
ssg21392
(lp27202
(dp27203
g21395
I120
sg21396
VHCC
p27204
sg21398
I3
sg21399
VC2239176
p27205
sg21401
I1
sa(dp27206
g21395
I94
sg21396
g27200
sg21398
I24
sg21399
VC2239176
p27207
sg21401
I2
sasg21404
(lp27208
(dp27209
g21395
I166
sg21396
Vmyeloid zinc finger-1
p27210
sg21398
I21
sg21408
VP28698
p27211
sg21401
I3
sa(dp27212
g21395
I155
sg21396
VElk-1
p27213
sg21398
I5
sg21408
VP54762
p27214
sg21401
I1
sa(dp27215
g21395
I135
sg21396
VEts-like protein-1
p27216
sg21398
I18
sg21408
VP17980
p27217
sg21401
I2
sa(dp27218
g21395
I42
sg21396
Vprotein kinase C alpha
p27219
sg21398
I22
sg21408
VP17252
p27220
sg21401
I4
sa(dp27221
g21395
I189
sg21396
g27199
sg21398
I5
sg21408
VP28698
p27222
sg21401
I1
sasa(dp27223
g21386
VBesides, PEI-MZF-NPs were used as magnetic media for thermotherapy to treat hepatoma by magnet-induced heating, combined with radiation-gene therapy.
p27224
sg4
(dp27225
(VPEI-MZF-NPs
p27226
Vhepatoma
p27227
tp27228
I00
ssg21392
(lp27229
(dp27230
g21395
I17
sg21396
VNPs
p27231
sg21398
I3
sg21399
VC0027341
p27232
sg21401
I1
sa(dp27233
g21395
I76
sg21396
g27227
sg21398
I8
sg21399
VC0023903
p27234
sg21401
I1
sasg21404
(lp27235
(dp27236
g21395
I9
sg21396
g27226
sg21398
I11
sg21408
VP28698
p27237
sg21401
I1
sasa(dp27238
g21386
VIn a recent study on hepatocellular carcinoma (HCC), we have shown that the transcription factors Myeloid Zinc Finger-1 (MZF-1) and Ets-like-protein 1 (Elk-1) are significantly related to protein kinase C alpha (PKCAlfa) expression.
p27239
sg4
(dp27240
(VElk-1
p27241
VHCC
p27242
tp27243
I00
ssg21392
(lp27244
(dp27245
g21395
I21
sg21396
Vhepatocellular carcinoma
p27246
sg21398
I24
sg21399
VC2239176
p27247
sg21401
I2
sa(dp27248
g21395
I47
sg21396
g27242
sg21398
I3
sg21399
VC2239176
p27249
sg21401
I1
sasg21404
(lp27250
(dp27251
g21395
I121
sg21396
VMZF-1
p27252
sg21398
I5
sg21408
VP28698
p27253
sg21401
I1
sa(dp27254
g21395
I132
sg21396
VEts-like-protein 1
p27255
sg21398
I18
sg21408
VP14222
p27256
sg21401
I2
sa(dp27257
g21395
I188
sg21396
Vprotein kinase C alpha
p27258
sg21398
I22
sg21408
VP17252
p27259
sg21401
I4
sa(dp27260
g21395
I98
sg21396
VMyeloid Zinc Finger-1
p27261
sg21398
I21
sg21408
VP28698
p27262
sg21401
I3
sa(dp27263
g21395
I152
sg21396
g27241
sg21398
I5
sg21408
VP54762
p27264
sg21401
I1
sasa(dp27265
g21386
VRecently, our research into hepatocellular carcinoma (HCC) has shown that the transcription factors Myeloid Zinc Finger-1 (MZF-1) and Ets-like-protein 1 are related to protein kinase C alpha (PKCAlfa) expression.
p27266
sg4
(dp27267
(VEts-like-protein 1
p27268
Vhepatocellular carcinoma
p27269
tp27270
I01
ssg21392
(lp27271
(dp27272
g21395
I54
sg21396
VHCC
p27273
sg21398
I3
sg21399
VC2239176
p27274
sg21401
I1
sa(dp27275
g21395
I28
sg21396
g27269
sg21398
I24
sg21399
VC2239176
p27276
sg21401
I2
sasg21404
(lp27277
(dp27278
g21395
I100
sg21396
VMyeloid Zinc Finger-1
p27279
sg21398
I21
sg21408
VP28698
p27280
sg21401
I3
sa(dp27281
g21395
I123
sg21396
VMZF-1
p27282
sg21398
I5
sg21408
VP28698
p27283
sg21401
I1
sa(dp27284
g21395
I168
sg21396
Vprotein kinase C alpha
p27285
sg21398
I22
sg21408
VP17252
p27286
sg21401
I4
sa(dp27287
g21395
I134
sg21396
g27268
sg21398
I18
sg21408
VP14222
p27288
sg21401
I2
sasa(dp27289
g21386
VUsing immunocytochemistry, we investigated the distribution of chromogranin A, chromogranin B, secretoneurin, and, for comparison, dynorphin in hippocampal specimens removed at routine surgery from patients with drug-resistant mesial temporal lobe epilepsy and in autopsy tissues from nonneurologically deceased subjects.
p27290
sg4
(dp27291
(Vchromogranin A
p27292
Vtemporal lobe epilepsy
p27293
tp27294
I00
ssg21392
(lp27295
(dp27296
g21395
I234
sg21396
g27293
sg21398
I22
sg21399
VC0014556
p27297
sg21401
I3
sasg21404
(lp27298
(dp27299
g21395
I79
sg21396
Vchromogranin B
p27300
sg21398
I14
sg21408
VP08311
p27301
sg21401
I2
sa(dp27302
g21395
I131
sg21396
Vdynorphin
p27303
sg21398
I9
sg21408
VP01213
p27304
sg21401
I1
sa(dp27305
g21395
I95
sg21396
Vsecretoneurin
p27306
sg21398
I13
sg21408
VP13521
p27307
sg21401
I1
sa(dp27308
g21395
I63
sg21396
g27292
sg21398
I14
sg21408
VP10645
p27309
sg21401
I2
sasa(dp27310
g21386
VThe most intriguing change seen in human temporal lobe epilepsy specimens and in the kainic acid model of the rat was the prominent staining of the inner molecular layer, indicating storage of chromogranins A and B and secretoneurin in terminals of reorganized mossy fibers, from which they may be released upon nerve stimulation.
p27311
sg4
(dp27312
(Vchromogranins A and B and secretoneurin
p27313
Vtemporal lobe epilepsy
p27314
tp27315
I00
ssg21392
(lp27316
(dp27317
g21395
I41
sg21396
g27314
sg21398
I22
sg21399
VC0014556
p27318
sg21401
I3
sasg21404
(lp27319
(dp27320
g21395
I193
sg21396
g27313
sg21398
I39
sg21408
VP08311
p27321
sg21401
I6
sasa(dp27322
g21386
VTransition of control prediabetic ZDF rats to diabetes was associated with reduced plasma insulin levels, reduced islet insulin content and GSIS, reduced stearoyl-CoA desaturase 2 (SCD 2) expression, and increased islet TAG, diacylglyceride (DAG) and ceramides species containing saturated FA.
p27323
sg4
(dp27324
(Vplasma insulin
p27325
VSCD
p27326
tp27327
I00
ssg21392
(lp27328
(dp27329
g21395
I46
sg21396
Vdiabetes
p27330
sg21398
I8
sg21399
VC0011849
p27331
sg21401
I1
sa(dp27332
g21395
I0
sg21396
VTransition
p27333
sg21398
I10
sg21399
VC0599156
p27334
sg21401
I1
sa(dp27335
g21395
I163
sg21396
VCoA
p27336
sg21398
I3
sg21399
VC2678439
p27337
sg21401
I1
sa(dp27338
g21395
I220
sg21396
VTAG
p27339
sg21398
I3
sg21399
VC0037293
p27340
sg21401
I1
sa(dp27341
g21395
I181
sg21396
g27326
sg21398
I3
sg21399
VC0002895
p27342
sg21401
I1
sasg21404
(lp27343
(dp27344
g21395
I114
sg21396
Vislet insulin
p27345
sg21398
I13
sg21408
VP01308
p27346
sg21401
I2
sa(dp27347
g21395
I154
sg21396
Vstearoyl-CoA desaturase 2
p27348
sg21398
I25
sg21408
g190
sg21401
I3
sa(dp27349
g21395
I83
sg21396
g27325
sg21398
I14
sg21408
VP01308
p27350
sg21401
I2
sa(dp27351
g21395
I181
sg21396
VSCD 2
p27352
sg21398
I5
sg21408
g190
sg21401
I2
sasa(dp27353
g21386
VIn the subgroup of non-vomiting drinkers with Wernicke's encephalopathy (WE), the slope of the linear regression of AETK on ETK was 1.21, so that apoTK decreased as ETK decreased.
p27354
sg4
(dp27355
(VETK
p27356
VWE
p27357
tp27358
I00
ssg21392
(lp27359
(dp27360
g21395
I46
sg21396
VWernicke's encephalopathy
p27361
sg21398
I25
sg21399
VC0043121
p27362
sg21401
I2
sa(dp27363
g21395
I23
sg21396
Vvomiting
p27364
sg21398
I8
sg21399
VC0042963
p27365
sg21401
I1
sa(dp27366
g21395
I73
sg21396
g27357
sg21398
I2
sg21399
VC0043121
p27367
sg21401
I1
sasg21404
(lp27368
(dp27369
g21395
I117
sg21396
VETK
p27370
sg21398
I3
sg21408
VP51813
p27371
sg21401
I1
sa(dp27372
g21395
I117
sg21396
g27356
sg21398
I3
sg21408
VP51813
p27373
sg21401
I1
sasa(dp27374
g21386
VIn pancreatic ductal adenocarcinoma, the CCL2-CCR2 chemokine axis is used to recruit tumour-associated macrophages for construction of an immunosuppressive tumour microenvironment.
p27375
sg4
(dp27376
(VCCR2
p27377
Vpancreatic ductal adenocarcinoma
p27378
tp27379
I00
ssg21392
(lp27380
(dp27381
g21395
I3
sg21396
g27378
sg21398
I32
sg21399
VC1335302
p27382
sg21401
I3
sa(dp27383
g21395
I85
sg21396
Vtumour
p27384
sg21398
I6
sg21399
VC0027651
p27385
sg21401
I1
sa(dp27386
g21395
I85
sg21396
Vtumour
p27387
sg21398
I6
sg21399
VC0027651
p27388
sg21401
I1
sasg21404
(lp27389
(dp27390
g21395
I41
sg21396
VCCL2
p27391
sg21398
I4
sg21408
VP13500
p27392
sg21401
I1
sa(dp27393
g21395
I46
sg21396
g27377
sg21398
I4
sg21408
VP41597
p27394
sg21401
I1
sasa(dp27395
g21386
VThis pathway has prognostic implications in pancreatic cancer, and blockade of CCR2 restores anti-tumour immunity in preclinical models.
p27396
sg4
(dp27397
(VCCR2
p27398
Vpancreatic cancer
p27399
tp27400
I01
ssg21392
(lp27401
(dp27402
g21395
I44
sg21396
g27399
sg21398
I17
sg21399
VC0235974
p27403
sg21401
I2
sa(dp27404
g21395
I98
sg21396
Vtumour
p27405
sg21398
I6
sg21399
VC0027651
p27406
sg21401
I1
sasg21404
(lp27407
(dp27408
g21395
I79
sg21396
g27398
sg21398
I4
sg21408
VP41597
p27409
sg21401
I1
sasa(dp27410
g21386
VTo determine the role of the CCL2/CCR2 axis and inflammatory monocytes (CCR2(+)/CD14(+)) as immunotherapeutic targets in the treatment of pancreatic cancer.
p27411
sg4
(dp27412
(VCD14
p27413
Vpancreatic cancer
p27414
tp27415
I01
ssg21392
(lp27416
(dp27417
g21395
I138
sg21396
g27414
sg21398
I17
sg21399
VC0235974
p27418
sg21401
I2
sasg21404
(lp27419
(dp27420
g21395
I29
sg21396
VCCL2
p27421
sg21398
I4
sg21408
VP13500
p27422
sg21401
I1
sa(dp27423
g21395
I34
sg21396
VCCR2
p27424
sg21398
I4
sg21408
VP41597
p27425
sg21401
I1
sa(dp27426
g21395
I34
sg21396
VCCR2
p27427
sg21398
I4
sg21408
VP41597
p27428
sg21401
I1
sa(dp27429
g21395
I80
sg21396
g27413
sg21398
I4
sg21408
VP08571
p27430
sg21401
I1
sasa(dp27431
g21386
VA novel CCR2 inhibitor (PF-04136309) was tested in an orthotopic model of murine pancreatic cancer.
p27432
sg4
(dp27433
(VCCR2
p27434
Vpancreatic cancer
p27435
tp27436
I01
ssg21392
(lp27437
(dp27438
g21395
I81
sg21396
g27435
sg21398
I17
sg21399
VC0235974
p27439
sg21401
I2
sasg21404
(lp27440
(dp27441
g21395
I8
sg21396
g27434
sg21398
I4
sg21408
VP41597
p27442
sg21401
I1
sasa(dp27443
g21386
VHuman pancreatic cancer produces CCL2, and immunosuppressive CCR2(+) macrophages infiltrate these tumors.
p27444
sg4
(dp27445
(VCCL2
p27446
Vpancreatic cancer
p27447
tp27448
I00
ssg21392
(lp27449
(dp27450
g21395
I6
sg21396
g27447
sg21398
I17
sg21399
VC0235974
p27451
sg21401
I2
sa(dp27452
g21395
I98
sg21396
Vtumors
p27453
sg21398
I6
sg21399
VC0027651
p27454
sg21401
I1
sa(dp27455
g21395
I81
sg21396
Vinfiltrate
p27456
sg21398
I10
sg21399
VC0332448
p27457
sg21401
I1
sasg21404
(lp27458
(dp27459
g21395
I33
sg21396
g27446
sg21398
I4
sg21408
VP13500
p27460
sg21401
I1
sasa(dp27461
g21386
VInflammatory monocyte recruitment is critical to pancreatic cancer progression, and targeting CCR2 may be an effective immunotherapeutic strategy in this disease.
p27462
sg4
(dp27463
(VCCR2
p27464
Vcancer progression
p27465
tp27466
I00
ssg21392
(lp27467
(dp27468
g21395
I22
sg21396
Vrecruitment
p27469
sg21398
I11
sg21399
VC0271510
p27470
sg21401
I1
sa(dp27471
g21395
I60
sg21396
g27465
sg21398
I18
sg21399
VC0178874
p27472
sg21401
I2
sasg21404
(lp27473
(dp27474
g21395
I94
sg21396
g27464
sg21398
I4
sg21408
VP41597
p27475
sg21401
I1
sasa(dp27476
g21386
VWe evaluated the associations of six nonsynonymous SNPs in the MMP3, MMP8, and MMP9 genes with skin cancer risk in a nested case-control study of Caucasians within the Nurses' Health Study among 218 melanoma cases, 285 squamous cell carcinoma (SCC) cases, 300 basal cell carcinoma (BCC) cases, and 870 normal controls.
p27477
sg4
(dp27478
(VMMP8
p27479
Vbasal cell carcinoma
p27480
tp27481
I01
ssg21392
(lp27482
(dp27483
g21395
I199
sg21396
Vmelanoma
p27484
sg21398
I8
sg21399
VC0025202
p27485
sg21401
I1
sa(dp27486
g21395
I244
sg21396
VSCC
p27487
sg21398
I3
sg21399
VC0007137
p27488
sg21401
I1
sa(dp27489
g21395
I95
sg21396
Vskin cancer
p27490
sg21398
I11
sg21399
VC0007114
p27491
sg21401
I2
sa(dp27492
g21395
I219
sg21396
Vsquamous cell carcinoma
p27493
sg21398
I23
sg21399
VC0007137
p27494
sg21401
I3
sa(dp27495
g21395
I282
sg21396
VBCC
p27496
sg21398
I3
sg21399
VC0007117
p27497
sg21401
I1
sa(dp27498
g21395
I260
sg21396
g27480
sg21398
I20
sg21399
VC0007117
p27499
sg21401
I3
sasg21404
(lp27500
(dp27501
g21395
I79
sg21396
VMMP9 genes
p27502
sg21398
I10
sg21408
VP14780
p27503
sg21401
I2
sa(dp27504
g21395
I63
sg21396
VMMP3
p27505
sg21398
I4
sg21408
VP08254
p27506
sg21401
I1
sa(dp27507
g21395
I69
sg21396
g27479
sg21398
I4
sg21408
VP22894
p27508
sg21401
I1
sasa(dp27509
g21386
VNinety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
p27510
sg4
(dp27511
(VKi-67
p27512
Vbasal cell carcinoma
p27513
tp27514
I00
ssg21392
(lp27515
(dp27516
g21395
I21
sg21396
Vsquamous cell carcinoma
p27517
sg21398
I23
sg21399
VC0007137
p27518
sg21401
I3
sa(dp27519
g21395
I62
sg21396
g27513
sg21398
I20
sg21399
VC0007117
p27520
sg21401
I3
sasg21404
(lp27521
(dp27522
g21395
I199
sg21396
VMMP-3
p27523
sg21398
I5
sg21408
VP08254
p27524
sg21401
I1
sa(dp27525
g21395
I189
sg21396
VMMP-1
p27526
sg21398
I5
sg21408
VP03956
p27527
sg21401
I1
sa(dp27528
g21395
I170
sg21396
Vp53
p27529
sg21398
I3
sg21408
VP42771
p27530
sg21401
I1
sa(dp27531
g21395
I163
sg21396
g27512
sg21398
I5
sg21408
VP46013
p27532
sg21401
I1
sasa(dp27533
g21386
VA novel zinc oxide-binding peptide (ZBP), FPYPGGDA, with high affinity to ZNP (K a  = 2.26 x 106 M-1) was isolated from a random peptide library and fused with a bacterial antigen, ScaA of Orientia tsutsugamushi, the causative agent of scrub typhus.
p27534
sg4
(dp27535
(Vzinc oxide-binding peptide
p27536
Vscrub typhus
p27537
tp27538
I00
ssg21392
(lp27539
(dp27540
g21395
I198
sg21396
Vtsutsugamushi
p27541
sg21398
I13
sg21399
VC0036472
p27542
sg21401
I1
sa(dp27543
g21395
I236
sg21396
g27537
sg21398
I12
sg21399
VC0036472
p27544
sg21401
I2
sasg21404
(lp27545
(dp27546
g21395
I36
sg21396
VZBP
p27547
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp27548
g21395
I8
sg21396
g27536
sg21398
I26
sg21408
VP10070
p27549
sg21401
I3
sa(dp27550
g21395
I162
sg21396
Vbacterial antigen
p27551
sg21398
I17
sg21408
g190
sg21401
I2
sasa(dp27552
g21386
VOne hundred and one consecutive patients of Han nationality with rheumatic heart disease undergoing valve surgery were enrolled and randomly assigned to an experimental group (n=50, based on CYP2C9 and VKORC1 genotypes, pharmacogenetic-based "predicted warfarin dose" for 3 days and then was adjusted to INR until stable warfarin maintenance dose) or a control group (n=51, 2.5mg/d for 3 days and then was adjusted to INR until stable warfarin maintenance dose).
p27553
sg4
(dp27554
(VCYP2C9
p27555
Vrheumatic heart disease
p27556
tp27557
I00
ssg21392
(lp27558
(dp27559
g21395
I65
sg21396
g27556
sg21398
I23
sg21399
VC0035439
p27560
sg21401
I3
sasg21404
(lp27561
(dp27562
g21395
I191
sg21396
g27555
sg21398
I6
sg21408
VP11712
p27563
sg21401
I1
sa(dp27564
g21395
I202
sg21396
VVKORC1
p27565
sg21398
I6
sg21408
g190
sg21401
I1
sasa(dp27566
g21386
Vto investigate the molecular mechanisms and morphological substrate of reduced uterine leiomyoma in patients receiving the selective progesterone receptor modulator (SPRM) ulipristal acetate for 3 months, by estimating the immunohistochemical expression of the markers steroid receptor coactivator 1 (SRC-1), nuclear receptor corepressor 1 (NCoR-1), ER, PgR, Ki-67, p16, TGF-Beta, and VEGF in tumor tissue.
p27567
sg4
(dp27568
(Vprogesterone receptor
p27569
Vuterine leiomyoma
p27570
tp27571
I00
ssg21392
(lp27572
(dp27573
g21395
I79
sg21396
g27570
sg21398
I17
sg21399
VC0042133
p27574
sg21401
I2
sa(dp27575
g21395
I393
sg21396
Vtumor
p27576
sg21398
I5
sg21399
VC0027651
p27577
sg21401
I1
sasg21404
(lp27578
(dp27579
g21395
I371
sg21396
VTGF-Beta
p27580
sg21398
I8
sg21408
VP18075
p27581
sg21401
I1
sa(dp27582
g21395
I354
sg21396
VPgR
p27583
sg21398
I3
sg21408
VP06401
p27584
sg21401
I1
sa(dp27585
g21395
I301
sg21396
VSRC-1
p27586
sg21398
I5
sg21408
VP12931
p27587
sg21401
I1
sa(dp27588
g21395
I341
sg21396
VNCoR-1
p27589
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp27590
g21395
I366
sg21396
Vp16
p27591
sg21398
I3
sg21408
VP42771
p27592
sg21401
I1
sa(dp27593
g21395
I309
sg21396
Vnuclear receptor corepressor 1
p27594
sg21398
I30
sg21408
g190
sg21401
I4
sa(dp27595
g21395
I359
sg21396
VKi-67
p27596
sg21398
I5
sg21408
VP46013
p27597
sg21401
I1
sa(dp27598
g21395
I269
sg21396
Vsteroid receptor coactivator 1
p27599
sg21398
I30
sg21408
g190
sg21401
I4
sa(dp27600
g21395
I133
sg21396
g27569
sg21398
I21
sg21408
VP06401
p27601
sg21401
I2
sasa(dp27602
g21386
VThe morphological substrate of partial leiomyoma reduction was leiomyocyte apoptosis and dystrophy, tumor stroma sclerosis and hyalinosis with diminished Ki-67 expression and elevated p16 in the smooth muscle cells, trophic nodular tissue disorders exhibited by vascular wall sclerosis and lower VEGF and TGF-Beta expression, and leiomyocyte hormonal reception dysregulation that made itself evident through the reduced expression of SRC-1 with the unchanged expression of PR and ER and the maintained level of NCoR-1.
p27603
sg4
(dp27604
(VSRC-1
p27605
Vsclerosis
p27606
tp27607
I00
ssg21392
(lp27608
(dp27609
g21395
I113
sg21396
Vsclerosis
p27610
sg21398
I9
sg21399
VC0036429
p27611
sg21401
I1
sa(dp27612
g21395
I89
sg21396
Vdystrophy
p27613
sg21398
I9
sg21399
VC0333606
p27614
sg21401
I1
sa(dp27615
g21395
I100
sg21396
Vtumor
p27616
sg21398
I5
sg21399
VC0027651
p27617
sg21401
I1
sa(dp27618
g21395
I39
sg21396
Vleiomyoma
p27619
sg21398
I9
sg21399
VC0023267
p27620
sg21401
I1
sa(dp27621
g21395
I127
sg21396
Vhyalinosis
p27622
sg21398
I10
sg21399
VC0333438
p27623
sg21401
I1
sa(dp27624
g21395
I113
sg21396
g27606
sg21398
I9
sg21399
VC0036429
p27625
sg21401
I1
sasg21404
(lp27626
(dp27627
g21395
I305
sg21396
VTGF-Beta
p27628
sg21398
I8
sg21408
VP18075
p27629
sg21401
I1
sa(dp27630
g21395
I511
sg21396
VNCoR-1
p27631
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp27632
g21395
I184
sg21396
Vp16
p27633
sg21398
I3
sg21408
VP42771
p27634
sg21401
I1
sa(dp27635
g21395
I434
sg21396
g27605
sg21398
I5
sg21408
VP12931
p27636
sg21401
I1
sasa(dp27637
g21386
VWhile SDHD has been more frequently associated with the pathogenesis of head and neck paragangliomas, SDHB mutations were mainly associated with malignant and/or extra-adrenal pheochromocytoma/paraganglioma.
p27638
sg4
(dp27639
(VSDHB mutations
p27640
Vparagangliomas
p27641
tp27642
I00
ssg21392
(lp27643
(dp27644
g21395
I56
sg21396
Vpathogenesis
p27645
sg21398
I12
sg21399
VC0699748
p27646
sg21401
I1
sa(dp27647
g21395
I162
sg21396
Vextra-adrenal pheochromocytoma
p27648
sg21398
I30
sg21399
VC1257877
p27649
sg21401
I2
sa(dp27650
g21395
I86
sg21396
Vparaganglioma
p27651
sg21398
I13
sg21399
VC0030421
p27652
sg21401
I1
sa(dp27653
g21395
I86
sg21396
g27641
sg21398
I14
sg21399
VC0030421
p27654
sg21401
I1
sasg21404
(lp27655
(dp27656
g21395
I102
sg21396
g27640
sg21398
I14
sg21408
VP21912
p27657
sg21401
I2
sa(dp27658
g21395
I6
sg21396
VSDHD
p27659
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp27660
g21386
VSDHB mutation carriers were more likely than SDHD mutation carriers to develop extraadrenal pheochromocytomas and malignant disease, whereas SDHD mutation carriers had a greater propensity to develop head and neck paragangliomas and multiple tumors.
p27661
sg4
(dp27662
(VSDHB
p27663
Vparagangliomas
p27664
tp27665
I00
ssg21392
(lp27666
(dp27667
g21395
I92
sg21396
Vpheochromocytomas
p27668
sg21398
I17
sg21399
VC0031511
p27669
sg21401
I1
sa(dp27670
g21395
I233
sg21396
Vmultiple tumors
p27671
sg21398
I15
sg21399
VC0260037
p27672
sg21401
I2
sa(dp27673
g21395
I114
sg21396
Vmalignant disease
p27674
sg21398
I17
sg21399
VC0442867
p27675
sg21401
I2
sa(dp27676
g21395
I214
sg21396
g27664
sg21398
I14
sg21399
VC0030421
p27677
sg21401
I1
sasg21404
(lp27678
(dp27679
g21395
I45
sg21396
VSDHD
p27680
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp27681
g21395
I45
sg21396
VSDHD mutation
p27682
sg21398
I13
sg21408
g190
sg21401
I2
sa(dp27683
g21395
I0
sg21396
g27663
sg21398
I4
sg21408
VP21912
p27684
sg21401
I1
sasa(dp27685
g21386
VHowever, in the presence of extra-adrenal pheochromocytoma, it may be more useful to screen for VHL, SDHD and SDHB mutations.
p27686
sg4
(dp27687
(VVHL
p27688
VVHL
p27689
tp27690
I00
ssg21392
(lp27691
(dp27692
g21395
I28
sg21396
Vextra-adrenal pheochromocytoma
p27693
sg21398
I30
sg21399
VC1257877
p27694
sg21401
I2
sa(dp27695
g21395
I96
sg21396
g27689
sg21398
I3
sg21399
VC0019562
p27696
sg21401
I1
sasg21404
(lp27697
(dp27698
g21395
I110
sg21396
VSDHB
p27699
sg21398
I4
sg21408
VP21912
p27700
sg21401
I1
sa(dp27701
g21395
I96
sg21396
g27688
sg21398
I3
sg21408
VP40337
p27702
sg21401
I1
sa(dp27703
g21395
I101
sg21396
VSDHD
p27704
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp27705
g21386
VHere we show, using two different techniques, FISH and quantitative PCR that SHFM3 is caused by a minimal 325 kb duplication containing only two genes (BTRC and POLL).
p27706
sg4
(dp27707
(VSHFM3
p27708
VSHFM3
p27709
tp27710
I00
ssg21392
(lp27711
(dp27712
g21395
I77
sg21396
g27709
sg21398
I5
sg21399
VC1838652
p27713
sg21401
I1
sa(dp27714
g21395
I113
sg21396
Vduplication
p27715
sg21398
I11
sg21399
VC1705960
p27716
sg21401
I1
sasg21404
(lp27717
(dp27718
g21395
I161
sg21396
VPOLL
p27719
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp27720
g21395
I152
sg21396
VBTRC
p27721
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp27722
g21395
I77
sg21396
g27708
sg21398
I5
sg21408
VP57775
p27723
sg21401
I1
sasa(dp27724
g21386
VThe smaller duplication in the second patient contained the LBX1, BTRC, POLL, and DPCD genes and a disrupted extra copy of the dactylin gene, and was nearly identical to the smallest known duplicated region of SHFM3.
p27725
sg4
(dp27726
(VLBX1
p27727
VSHFM3
p27728
tp27729
I00
ssg21392
(lp27730
(dp27731
g21395
I210
sg21396
g27728
sg21398
I5
sg21399
VC1838652
p27732
sg21401
I1
sa(dp27733
g21395
I12
sg21396
Vduplication
p27734
sg21398
I11
sg21399
VC1705960
p27735
sg21401
I1
sasg21404
(lp27736
(dp27737
g21395
I82
sg21396
VDPCD genes
p27738
sg21398
I10
sg21408
g190
sg21401
I2
sa(dp27739
g21395
I127
sg21396
Vdactylin gene
p27740
sg21398
I13
sg21408
VP57775
p27741
sg21401
I2
sa(dp27742
g21395
I72
sg21396
VPOLL
p27743
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp27744
g21395
I210
sg21396
VSHFM3
p27745
sg21398
I5
sg21408
VP57775
p27746
sg21401
I1
sa(dp27747
g21395
I60
sg21396
g27727
sg21398
I4
sg21408
VP52954
p27748
sg21401
I1
sa(dp27749
g21395
I66
sg21396
VBTRC
p27750
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp27751
g21386
VThe values of the relative risks for hospitalization for pneumonia and asthma were significant for lag 0 (RR=1.051, 95%CI; 1.016 to 1.088); lag 2 (RR=1.066, 95%CI: 1.023 to 1.113); lag 3 (RR=1.053, 95%CI: 1.015 to 1.092); lag 4 (RR=1.043, 95%CI: 1.004 to 1.088) and lag 5 (RR=1.061, 95%CI: 1.018 to 1.106).
p27752
sg4
(dp27753
(Vlag 4
p27754
Vasthma
p27755
tp27756
I00
ssg21392
(lp27757
(dp27758
g21395
I57
sg21396
Vpneumonia
p27759
sg21398
I9
sg21399
VC0032285
p27760
sg21401
I1
sa(dp27761
g21395
I71
sg21396
g27755
sg21398
I6
sg21399
VC0004096
p27762
sg21401
I1
sasg21404
(lp27763
(dp27764
g21395
I140
sg21396
Vlag 2
p27765
sg21398
I5
sg21408
VP16949
p27766
sg21401
I2
sa(dp27767
g21395
I266
sg21396
Vlag 5
p27768
sg21398
I5
sg21408
VP16949
p27769
sg21401
I2
sa(dp27770
g21395
I181
sg21396
Vlag 3
p27771
sg21398
I5
sg21408
VP16949
p27772
sg21401
I2
sa(dp27773
g21395
I99
sg21396
Vlag 0
p27774
sg21398
I5
sg21408
VP16949
p27775
sg21401
I2
sa(dp27776
g21395
I222
sg21396
g27754
sg21398
I5
sg21408
VP16949
p27777
sg21401
I2
sasa(dp27778
g21386
VA 10 microg/m increase in bushfire PM10 was associated with a 1.24% (95% confidence interval = 0.22% to 2.27%) increase in all respiratory disease admissions (at lag 0), a 3.80% (1.40% to 6.26%) increase in chronic obstructive pulmonary disease admissions (at lag 2), and a 5.02% (1.77% to 8.37%) increase in adult asthma admissions (at lag 0).
p27779
sg4
(dp27780
(Vlag 2
p27781
Vchronic obstructive pulmonary disease
p27782
tp27783
I00
ssg21392
(lp27784
(dp27785
g21395
I315
sg21396
Vasthma
p27786
sg21398
I6
sg21399
VC0004096
p27787
sg21401
I1
sa(dp27788
g21395
I127
sg21396
Vrespiratory disease
p27789
sg21398
I19
sg21399
VC0035242
p27790
sg21401
I2
sa(dp27791
g21395
I207
sg21396
g27782
sg21398
I37
sg21399
VC0024117
p27792
sg21401
I4
sasg21404
(lp27793
(dp27794
g21395
I260
sg21396
g27781
sg21398
I5
sg21408
VP16949
p27795
sg21401
I2
sasa(dp27796
g21386
VIn CD4(+) T cell- and dextran sodium sulfate-induced models of colitis, Trem1(-/-) mice displayed significantly attenuated disease that was associated with reduced inflammatory infiltrates and diminished expression of pro-inflammatory cytokines.
p27797
sg4
(dp27798
(VCD4
p27799
Vcolitis
p27800
tp27801
I00
ssg21392
(lp27802
(dp27803
g21395
I63
sg21396
g27800
sg21398
I7
sg21399
VC0009319
p27804
sg21401
I1
sa(dp27805
g21395
I177
sg21396
Vinfiltrates
p27806
sg21398
I11
sg21399
VC0332448
p27807
sg21401
I1
sasg21404
(lp27808
(dp27809
g21395
I3
sg21396
g27799
sg21398
I3
sg21408
VP01730
p27810
sg21401
I1
sa(dp27811
g21395
I72
sg21396
VTrem1
p27812
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp27813
g21386
VIn ulcerative colitis, sTREM-1 level was correlated more strongly with the endoscopic activity (r=0.498) than the C-reactive protein level (r=0.386) or erythrocyte sedimentation rate (r=0.272), although not superior to the partial Mayo score (r=0.611).
p27814
sg4
(dp27815
(VC-reactive protein
p27816
Vulcerative colitis
p27817
tp27818
I00
ssg21392
(lp27819
(dp27820
g21395
I3
sg21396
g27817
sg21398
I18
sg21399
VC0009324
p27821
sg21401
I2
sasg21404
(lp27822
(dp27823
g21395
I114
sg21396
g27816
sg21398
I18
sg21408
VP02741
p27824
sg21401
I2
sasa(dp27825
g21386
VOn the basis of biopsies of the masses in the pharynx and finger, he was diagnosed with extramedullary plasmablastic plasmacytoma, with somewhat immature CD45(+), MPC-1(-), and CD49e(-).
p27826
sg4
(dp27827
(VMPC-1
p27828
Vplasmacytoma
p27829
tp27830
I00
ssg21392
(lp27831
(dp27832
g21395
I117
sg21396
g27829
sg21398
I12
sg21399
VC0032131
p27833
sg21401
I1
sasg21404
(lp27834
(dp27835
g21395
I177
sg21396
VCD49e
p27836
sg21398
I5
sg21408
VP08648
p27837
sg21401
I1
sa(dp27838
g21395
I154
sg21396
VCD45(+)
p27839
sg21398
I7
sg21408
VP08575
p27840
sg21401
I1
sa(dp27841
g21395
I163
sg21396
g27828
sg21398
I5
sg21408
VP28062
p27842
sg21401
I1
sasa(dp27843
g21386
VChanges to CD45 negativity and MPC-1 partial positivity were seen, while CD49e negativity persisted, suggesting that the plasmablastic plasmacytoma had reverted to a more immature state.
p27844
sg4
(dp27845
(VCD45 negativity
p27846
Vplasmacytoma
p27847
tp27848
I00
ssg21392
(lp27849
(dp27850
g21395
I135
sg21396
g27847
sg21398
I12
sg21399
VC0032131
p27851
sg21401
I1
sasg21404
(lp27852
(dp27853
g21395
I31
sg21396
VMPC-1
p27854
sg21398
I5
sg21408
VP28062
p27855
sg21401
I1
sa(dp27856
g21395
I73
sg21396
VCD49e
p27857
sg21398
I5
sg21408
VP08648
p27858
sg21401
I1
sa(dp27859
g21395
I11
sg21396
g27846
sg21398
I15
sg21408
VP08575
p27860
sg21401
I2
sasa(dp27861
g21386
VHe had the following poor prognostic factors: 1) multiple extramedullary plasmacytomas, 2) massive myelomatous effusion, 3) increasing immature myeloma cells with plasmablastic morphology, and 4) predominance of MPC1-CD49e-CD45+ phenotype immature myeloma cells.
p27862
sg4
(dp27863
(VCD49e
p27864
Vplasmacytomas
p27865
tp27866
I00
ssg21392
(lp27867
(dp27868
g21395
I99
sg21396
Vmyeloma
p27869
sg21398
I7
sg21399
VC0026764
p27870
sg21401
I1
sa(dp27871
g21395
I111
sg21396
Veffusion
p27872
sg21398
I8
sg21399
VC0013687
p27873
sg21401
I1
sa(dp27874
g21395
I99
sg21396
Vmyeloma
p27875
sg21398
I7
sg21399
VC0026764
p27876
sg21401
I1
sa(dp27877
g21395
I73
sg21396
g27865
sg21398
I13
sg21399
VC0032131
p27878
sg21401
I1
sasg21404
(lp27879
(dp27880
g21395
I212
sg21396
VMPC1
p27881
sg21398
I4
sg21408
VP28062
p27882
sg21401
I1
sa(dp27883
g21395
I223
sg21396
VCD45+
p27884
sg21398
I5
sg21408
VP08575
p27885
sg21401
I1
sa(dp27886
g21395
I217
sg21396
g27864
sg21398
I5
sg21408
VP08648
p27887
sg21401
I1
sasa(dp27888
g21386
VInterestingly, the proportions of MPC-1(-) and MPC-1(-)CD45(+) immature monoclonal plasma cells also increased in the 7 progressive cases of MGUS.
p27889
sg4
(dp27890
(VMPC-1
p27891
VMGUS
p27892
tp27893
I00
ssg21392
(lp27894
(dp27895
g21395
I141
sg21396
g27892
sg21398
I4
sg21399
VC0026470
p27896
sg21401
I1
sasg21404
(lp27897
(dp27898
g21395
I47
sg21396
VMPC-1(-)CD45(+)
p27899
sg21398
I15
sg21408
VP28062
p27900
sg21401
I1
sa(dp27901
g21395
I34
sg21396
g27891
sg21398
I5
sg21408
VP28062
p27902
sg21401
I1
sasa(dp27903
g21386
VMoreover, lyso-Gb3 suppressed expression of class II phosphatidylinositol 3-kinase C2Beta (PI3KC2Beta) by PKA activation, which reduces the production of phosphatidylinositol 3-phosphate [PI(3)P], and the reduced membrane surface expression of KCa3.1 channel was recovered by increasing the intracellular levels of PI(3)P. Consequently, our findings that lyso-Gb3 inhibited both KCa3.1 channel synthesis and surface expression by increasing intracellular cAMP, and controlled surface expression through changes in PI3KC2Beta-mediated PI(3)P production, suggest that modulation of PKA and PI3KC2Beta activity to control of KCa3.1 channel expression can be an alternative important target to attenuate ascending thoracic aortic aneurysms in Fabry disease.
p27904
sg4
(dp27905
(VPKA
p27906
Vthoracic aortic aneurysms
p27907
tp27908
I00
ssg21392
(lp27909
(dp27910
g21395
I739
sg21396
VFabry disease
p27911
sg21398
I13
sg21399
VC0002986
p27912
sg21401
I2
sa(dp27913
g21395
I710
sg21396
g27907
sg21398
I25
sg21399
VC0162872
p27914
sg21401
I3
sasg21404
(lp27915
(dp27916
g21395
I244
sg21396
VKCa3.1
p27917
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp27918
g21395
I44
sg21396
Vclass II phosphatidylinositol 3-kinase C2Beta
p27919
sg21398
I45
sg21408
g190
sg21401
I5
sa(dp27920
g21395
I244
sg21396
VKCa3.1
p27921
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp27922
g21395
I244
sg21396
VKCa3.1
p27923
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp27924
g21395
I106
sg21396
VPKA
p27925
sg21398
I3
sg21408
VP17612
p27926
sg21401
I1
sa(dp27927
g21395
I154
sg21396
Vphosphatidylinositol 3-phosphate [PI(3)P]
p27928
sg21398
I41
sg21408
VP48426
p27929
sg21401
I3
sa(dp27930
g21395
I106
sg21396
g27906
sg21398
I3
sg21408
VP17612
p27931
sg21401
I1
sasa(dp27932
g21386
VWe sequenced BCAs in patients with autism or related NDDs, revealing disruption of 33 loci in four general categories: (1) genes previously associated with abnormal neurodevelopment (e.g., AUTS2, FOXP1, and CDKL5), (2) single-gene contributors to microdeletion syndromes (MBD5, SATB2, EHMT1, and SNURF-SNRPN), (3) novel risk loci (e.g., CHD8, KIRREL3, and ZNF507), and (4) genes associated with later-onset psychiatric disorders (e.g., TCF4, ZNF804A, PDE10A, GRIN2B, and ANK3).
p27933
sg4
(dp27934
(VTCF4
p27935
Vpsychiatric disorders
p27936
tp27937
I00
ssg21392
(lp27938
(dp27939
g21395
I35
sg21396
Vautism
p27940
sg21398
I6
sg21399
VC0004352
p27941
sg21401
I1
sa(dp27942
g21395
I407
sg21396
g27936
sg21398
I21
sg21399
VC0004936
p27943
sg21401
I2
sa(dp27944
g21395
I261
sg21396
Vsyndromes
p27945
sg21398
I9
sg21399
VC0039082
p27946
sg21401
I1
sasg21404
(lp27947
(dp27948
g21395
I436
sg21396
g27935
sg21398
I4
sg21408
VP15884
p27949
sg21401
I1
sa(dp27950
g21395
I459
sg21396
VGRIN2B
p27951
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp27952
g21395
I189
sg21396
VAUTS2
p27953
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp27954
g21395
I296
sg21396
VSNURF-SNRPN
p27955
sg21398
I11
sg21408
VP63162
p27956
sg21401
I1
sa(dp27957
g21395
I196
sg21396
VFOXP1
p27958
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp27959
g21395
I471
sg21396
VANK3
p27960
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp27961
g21395
I278
sg21396
VSATB2
p27962
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp27963
g21395
I356
sg21396
VZNF507
p27964
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp27965
g21395
I207
sg21396
VCDKL5
p27966
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp27967
g21395
I285
sg21396
VEHMT1
p27968
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp27969
g21395
I272
sg21396
VMBD5
p27970
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp27971
g21395
I343
sg21396
VKIRREL3
p27972
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp27973
g21395
I442
sg21396
VZNF804A
p27974
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp27975
g21395
I451
sg21396
VPDE10A
p27976
sg21398
I6
sg21408
g190
sg21401
I1
sasa(dp27977
g21386
VTheir protein products listed below immediately suggest cell signalling pathways/processes worthy of further investigation in elucidating the mechanism of CpG 5mer activity: caspase 2, the transcription factors Atf4, Hic, HoxB3 and Rqcd1, the splicing factors Rbmx, Sfrs5 and Sfrs7, the DNA replication factors Mcm5 and Brd4, phosphoinositide-3-kinase, annexin A1, mucosa-associated lymphoid tissue lymphoma translocation 1 and three enzymes involved in protein ubiquitylation, Siah1, Gsa7 and Nin283.
p27978
sg4
(dp27979
(Vphosphoinositide-3-kinase
p27980
Vtranslocation
p27981
tp27982
I00
ssg21392
(lp27983
(dp27984
g21395
I365
sg21396
Vmucosa-associated lymphoid tissue lymphoma
p27985
sg21398
I42
sg21399
VC0242647
p27986
sg21401
I4
sa(dp27987
g21395
I408
sg21396
g27981
sg21398
I13
sg21399
VC0040715
p27988
sg21401
I1
sasg21404
(lp27989
(dp27990
g21395
I266
sg21396
VSfrs5
p27991
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp27992
g21395
I211
sg21396
VAtf4
p27993
sg21398
I4
sg21408
VP18848
p27994
sg21401
I1
sa(dp27995
g21395
I276
sg21396
VSfrs7
p27996
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp27997
g21395
I232
sg21396
VRqcd1
p27998
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp27999
g21395
I485
sg21396
VGsa7
p28000
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp28001
g21395
I217
sg21396
VHic
p28002
sg21398
I3
sg21408
VP18136
p28003
sg21401
I1
sa(dp28004
g21395
I311
sg21396
VMcm5
p28005
sg21398
I4
sg21408
VP33992
p28006
sg21401
I1
sa(dp28007
g21395
I222
sg21396
VHoxB3
p28008
sg21398
I5
sg21408
VP14651
p28009
sg21401
I1
sa(dp28010
g21395
I320
sg21396
VBrd4
p28011
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp28012
g21395
I494
sg21396
VNin283
p28013
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp28014
g21395
I353
sg21396
Vannexin A1
p28015
sg21398
I10
sg21408
VP04083
p28016
sg21401
I2
sa(dp28017
g21395
I260
sg21396
VRbmx
p28018
sg21398
I4
sg21408
VP38159
p28019
sg21401
I1
sa(dp28020
g21395
I478
sg21396
VSiah1
p28021
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp28022
g21395
I174
sg21396
Vcaspase 2
p28023
sg21398
I9
sg21408
VP42575
p28024
sg21401
I2
sa(dp28025
g21395
I326
sg21396
g27980
sg21398
I25
sg21408
VP33981
p28026
sg21401
I1
sasa(dp28027
g21386
VHere, we investigated inherited cylindromas from several families with germline CYLD mutations for the presence of MYB activation.
p28028
sg4
(dp28029
(VMYB
p28030
Vcylindromas
p28031
tp28032
I00
ssg21392
(lp28033
(dp28034
g21395
I32
sg21396
g28031
sg21398
I11
sg21399
VC0010606
p28035
sg21401
I1
sasg21404
(lp28036
(dp28037
g21395
I115
sg21396
g28030
sg21398
I3
sg21408
VP10243
p28038
sg21401
I1
sa(dp28039
g21395
I80
sg21396
VCYLD
p28040
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp28041
g21386
VThe aims of this study were to perform a whole-exome sequencing analysis of a breast cylindroma and to investigate the role of molecular analyses in the differentiation between breast cylindroma, a benign tumour that displays MYB expression, and CYLD gene mutations, and its main differential diagnosis, the breast solid-basaloid adenoid cystic carcinoma, a malignant tumour that is characterized by the presence of the MYB-NFIB fusion gene and MYB overexpression.
p28042
sg4
(dp28043
(VMYB
p28044
Vcylindroma
p28045
tp28046
I00
ssg21392
(lp28047
(dp28048
g21395
I330
sg21396
Vadenoid cystic carcinoma
p28049
sg21398
I24
sg21399
VC0010606
p28050
sg21401
I3
sa(dp28051
g21395
I358
sg21396
Vmalignant tumour
p28052
sg21398
I16
sg21399
VC0006826
p28053
sg21401
I2
sa(dp28054
g21395
I85
sg21396
Vcylindroma
p28055
sg21398
I10
sg21399
VC0010606
p28056
sg21401
I1
sa(dp28057
g21395
I198
sg21396
Vbenign tumour
p28058
sg21398
I13
sg21399
VC0086692
p28059
sg21401
I2
sa(dp28060
g21395
I85
sg21396
g28045
sg21398
I10
sg21399
VC0010606
p28061
sg21401
I1
sasg21404
(lp28062
(dp28063
g21395
I424
sg21396
VNFIB fusion gene
p28064
sg21398
I16
sg21408
g190
sg21401
I3
sa(dp28065
g21395
I226
sg21396
VMYB
p28066
sg21398
I3
sg21408
VP10243
p28067
sg21401
I1
sa(dp28068
g21395
I226
sg21396
VMYB
p28069
sg21398
I3
sg21408
VP10243
p28070
sg21401
I1
sa(dp28071
g21395
I246
sg21396
VCYLD gene
p28072
sg21398
I9
sg21408
g190
sg21401
I2
sa(dp28073
g21395
I226
sg21396
g28044
sg21398
I3
sg21408
VP10243
p28074
sg21401
I1
sasa(dp28075
g21386
VWe investigated frequencies of single nucleotide polymorphisms (SNPs) in the candidate genes protein tyrosine phosphatase, non-receptor type 22 (PTPN22), B-cell scaffold protein with ankyrin repeats (BANK1), B lymphocyte kinase (Blk), and Fc gamma receptor class IIB (FCGR2B), which have been found to be associated with other autoimmune diseases, CD1A and CD1E, important for antigen presentation of glycolipids, and transient axonal glycoprotein 1 (TAG-1), which is associated with responsiveness to intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy.
p28076
sg4
(dp28077
(VBlk
p28078
Vautoimmune diseases
p28079
tp28080
I00
ssg21392
(lp28081
(dp28082
g21395
I546
sg21396
Vchronic inflammatory demyelinating polyneuropathy
p28083
sg21398
I49
sg21399
VC0393819
p28084
sg21401
I4
sa(dp28085
g21395
I451
sg21396
VTAG
p28086
sg21398
I3
sg21399
VC0037293
p28087
sg21401
I1
sa(dp28088
g21395
I327
sg21396
g28079
sg21398
I19
sg21399
VC0004364
p28089
sg21401
I2
sasg21404
(lp28090
(dp28091
g21395
I348
sg21396
VCD1A
p28092
sg21398
I4
sg21408
VP15813
p28093
sg21401
I1
sa(dp28094
g21395
I200
sg21396
VBANK1
p28095
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp28096
g21395
I514
sg21396
Vimmunoglobulin
p28097
sg21398
I14
sg21408
g190
sg21401
I1
sa(dp28098
g21395
I208
sg21396
VB lymphocyte kinase
p28099
sg21398
I19
sg21408
VP51451
p28100
sg21401
I3
sa(dp28101
g21395
I87
sg21396
Vgenes protein tyrosine phosphatase
p28102
sg21398
I34
sg21408
VP60484
p28103
sg21401
I4
sa(dp28104
g21395
I418
sg21396
Vtransient axonal glycoprotein 1
p28105
sg21398
I31
sg21408
g190
sg21401
I4
sa(dp28106
g21395
I268
sg21396
VFCGR2B
p28107
sg21398
I6
sg21408
VP31995
p28108
sg21401
I1
sa(dp28109
g21395
I239
sg21396
VFc gamma receptor class IIB
p28110
sg21398
I27
sg21408
VP12314
p28111
sg21401
I5
sa(dp28112
g21395
I145
sg21396
VPTPN22
p28113
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp28114
g21395
I183
sg21396
Vankyrin
p28115
sg21398
I7
sg21408
VP16157
p28116
sg21401
I1
sa(dp28117
g21395
I451
sg21396
VTAG-1
p28118
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp28119
g21395
I229
sg21396
g28078
sg21398
I3
sg21408
VP51451
p28120
sg21401
I1
sa(dp28121
g21395
I123
sg21396
Vnon-receptor type 22
p28122
sg21398
I20
sg21408
g190
sg21401
I3
sasa(dp28123
g21386
VExpressions of GluRs and CaBPs (i.e., parvalbumin and calbindin D-28k) were observed to be increased in the retinal ganglion cell layer (GCL) and inner nuclear layer (INL) at 3 days and 1 week after the onset of glaucoma.
p28124
sg4
(dp28125
(Vcalbindin D-28k
p28126
VGCL
p28127
tp28128
I00
ssg21392
(lp28129
(dp28130
g21395
I116
sg21396
Vganglion cell layer
p28131
sg21398
I19
sg21399
VC0023521
p28132
sg21401
I3
sa(dp28133
g21395
I212
sg21396
Vglaucoma
p28134
sg21398
I8
sg21399
VC0017601
p28135
sg21401
I1
sa(dp28136
g21395
I137
sg21396
g28127
sg21398
I3
sg21399
VC0023521
p28137
sg21401
I1
sasg21404
(lp28138
(dp28139
g21395
I38
sg21396
Vparvalbumin
p28140
sg21398
I11
sg21408
VP20472
p28141
sg21401
I1
sa(dp28142
g21395
I54
sg21396
g28126
sg21398
I15
sg21408
VP05937
p28143
sg21401
I2
sasa(dp28144
g21386
VUSP45 associates with ERCC1, a subunit of the DNA repair endonuclease XPF-ERCC1, via a short acidic motif outside of the USP45 catalytic domain.
p28145
sg4
(dp28146
(VERCC1
p28147
VXPF
p28148
tp28149
I00
ssg21392
(lp28150
(dp28151
g21395
I70
sg21396
g28148
sg21398
I3
sg21399
VC0268140
p28152
sg21401
I1
sasg21404
(lp28153
(dp28154
g21395
I22
sg21396
VERCC1
p28155
sg21398
I5
sg21408
VP07992
p28156
sg21401
I1
sa(dp28157
g21395
I46
sg21396
VDNA repair endonuclease XPF
p28158
sg21398
I27
sg21408
g190
sg21401
I4
sa(dp28159
g21395
I22
sg21396
g28147
sg21398
I5
sg21408
VP07992
p28160
sg21401
I1
sa(dp28161
g21395
I0
sg21396
VUSP45
p28162
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp28163
g21395
I121
sg21396
VUSP45 catalytic domain
p28164
sg21398
I22
sg21408
g190
sg21401
I3
sasa(dp28165
g21386
VFinally, USP45 localises to sites of DNA damage in a manner dependent on its deubiquitylase activity, but independent of its ability to bind ERCC1-XPF.
p28166
sg4
(dp28167
(VERCC1
p28168
VXPF
p28169
tp28170
I00
ssg21392
(lp28171
(dp28172
g21395
I37
sg21396
VDNA damage
p28173
sg21398
I10
sg21399
VC0012860
p28174
sg21401
I2
sa(dp28175
g21395
I147
sg21396
g28169
sg21398
I3
sg21399
VC0268140
p28176
sg21401
I1
sasg21404
(lp28177
(dp28178
g21395
I147
sg21396
VXPF
p28179
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp28180
g21395
I141
sg21396
g28168
sg21398
I5
sg21408
VP07992
p28181
sg21401
I1
sa(dp28182
g21395
I9
sg21396
VUSP45
p28183
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp28184
g21386
VWe used a polycistronic lentiviral vector (hSTEMCCA-loxP) encoding OCT4, SOX2, KLF4, and cMYC genes and containing loxP sites, excisible by Cre recombinase, to reprogram patient-specific fetal cells derived from prenatal diagnosis for several genetic disorders, such as myotonic dystrophy type 1 (DM1), Beta-thalassemia (Beta-Thal), lymphedema-distichiasis syndrome (LDS), spinal muscular atrophy (SMA), cystic fibrosis (CF), as well as from wild-type (WT) fetal cells.
p28185
sg4
(dp28186
(VSOX2
p28187
VBeta-Thal
p28188
tp28189
I00
ssg21392
(lp28190
(dp28191
g21395
I333
sg21396
Vlymphedema-distichiasis syndrome
p28192
sg21398
I32
sg21399
VC0265345
p28193
sg21401
I2
sa(dp28194
g21395
I421
sg21396
VCF
p28195
sg21398
I2
sg21399
VC0010674
p28196
sg21401
I1
sa(dp28197
g21395
I270
sg21396
Vmyotonic dystrophy
p28198
sg21398
I18
sg21399
VC0027126
p28199
sg21401
I2
sa(dp28200
g21395
I404
sg21396
Vcystic fibrosis
p28201
sg21398
I15
sg21399
VC0010674
p28202
sg21401
I2
sa(dp28203
g21395
I243
sg21396
Vgenetic disorders
p28204
sg21398
I17
sg21399
VC0019247
p28205
sg21401
I2
sa(dp28206
g21395
I297
sg21396
VDM1
p28207
sg21398
I3
sg21399
VC2931688
p28208
sg21401
I1
sa(dp28209
g21395
I303
sg21396
VBeta-thalassemia
p28210
sg21398
I16
sg21399
VC0005283
p28211
sg21401
I1
sa(dp28212
g21395
I398
sg21396
VSMA
p28213
sg21398
I3
sg21399
VC0026847
p28214
sg21401
I1
sa(dp28215
g21395
I373
sg21396
Vspinal muscular atrophy
p28216
sg21398
I23
sg21399
VC0026847
p28217
sg21401
I3
sa(dp28218
g21395
I367
sg21396
VLDS
p28219
sg21398
I3
sg21399
VC0265345
p28220
sg21401
I1
sa(dp28221
g21395
I321
sg21396
g28188
sg21398
I9
sg21399
VC0005283
p28222
sg21401
I1
sasg21404
(lp28223
(dp28224
g21395
I297
sg21396
VDM1
p28225
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp28226
g21395
I140
sg21396
VCre recombinase
p28227
sg21398
I15
sg21408
g190
sg21401
I2
sa(dp28228
g21395
I79
sg21396
VKLF4
p28229
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp28230
g21395
I270
sg21396
Vmyotonic dystrophy type 1
p28231
sg21398
I25
sg21408
g190
sg21401
I4
sa(dp28232
g21395
I89
sg21396
VcMYC genes
p28233
sg21398
I10
sg21408
VP01893
p28234
sg21401
I2
sa(dp28235
g21395
I73
sg21396
g28187
sg21398
I4
sg21408
VP48431
p28236
sg21401
I1
sasa(dp28237
g21386
VThe objective of this study was to determine the combined influence of alpha thalassemia, fetal hemoglobin, and the UGT1A1 polymorphism on serum bilirubin levels and cholelithiasis in patients with sickle cell disease.
p28238
sg4
(dp28239
(VUGT1A1
p28240
Valpha thalassemia
p28241
tp28242
I00
ssg21392
(lp28243
(dp28244
g21395
I198
sg21396
Vsickle cell disease
p28245
sg21398
I19
sg21399
VC0002895
p28246
sg21401
I3
sa(dp28247
g21395
I166
sg21396
Vcholelithiasis
p28248
sg21398
I14
sg21399
VC0008350
p28249
sg21401
I1
sa(dp28250
g21395
I71
sg21396
g28241
sg21398
I17
sg21399
VC0002312
p28251
sg21401
I2
sasg21404
(lp28252
(dp28253
g21395
I90
sg21396
Vfetal hemoglobin
p28254
sg21398
I16
sg21408
VP14207
p28255
sg21401
I2
sa(dp28256
g21395
I116
sg21396
g28240
sg21398
I6
sg21408
VP35504
p28257
sg21401
I1
sasa(dp28258
g21386
VWe explored the potential relationship between steady state serum bilirubin levels and the incidence of cholelithiasis in the context of UGT1A1 gene A(TA)nTAA promoter polymorphism in Omani sickle cell anemia (SCA) patients, homozygotes for African (Benin and Bantu) and Arab-Indian Beta(S) haplotypes, but sharing the same microgeographical environment and comparable life style factors.
p28259
sg4
(dp28260
(VUGT1A1 gene A
p28261
Vcholelithiasis
p28262
tp28263
I00
ssg21392
(lp28264
(dp28265
g21395
I210
sg21396
VSCA
p28266
sg21398
I3
sg21399
VC0002895
p28267
sg21401
I1
sa(dp28268
g21395
I190
sg21396
Vsickle cell anemia
p28269
sg21398
I18
sg21399
VC0002895
p28270
sg21401
I3
sa(dp28271
g21395
I104
sg21396
g28262
sg21398
I14
sg21399
VC0008350
p28272
sg21401
I1
sasg21404
(lp28273
(dp28274
g21395
I137
sg21396
g28261
sg21398
I13
sg21408
VP35504
p28275
sg21401
I3
sasa(dp28276
g21386
VThus, not cholelithiasis but total serum bilirubin was influenced by UGT1A1 polymorphism in this SCA cohort.
p28277
sg4
(dp28278
(VUGT1A1
p28279
Vcholelithiasis
p28280
tp28281
I00
ssg21392
(lp28282
(dp28283
g21395
I10
sg21396
g28280
sg21398
I14
sg21399
VC0008350
p28284
sg21401
I1
sasg21404
(lp28285
(dp28286
g21395
I69
sg21396
g28279
sg21398
I6
sg21408
VP35504
p28287
sg21401
I1
sasa(dp28288
g21386
VAltogether our data provide the implication of UGT1A1 and SLCO1A2 in sickle cell anemia-related cholelithiasis.
p28289
sg4
(dp28290
(VUGT1A1
p28291
Vcholelithiasis
p28292
tp28293
I00
ssg21392
(lp28294
(dp28295
g21395
I69
sg21396
Vsickle cell anemia
p28296
sg21398
I18
sg21399
VC0002895
p28297
sg21401
I3
sa(dp28298
g21395
I96
sg21396
g28292
sg21398
I14
sg21399
VC0008350
p28299
sg21401
I1
sasg21404
(lp28300
(dp28301
g21395
I58
sg21396
VSLCO1A2
p28302
sg21398
I7
sg21408
VP46721
p28303
sg21401
I1
sa(dp28304
g21395
I47
sg21396
g28291
sg21398
I6
sg21408
VP35504
p28305
sg21401
I1
sasa(dp28306
g21386
VPresent study was aimed to explore the effect of (TA)n UGT1A1 gene promoter polymorphism on bilirubin metabolism, bilirubinaemia, predisposition to cholelithiasis and subsequent cholecystectomy, in Sickle-Cell Anemia (SCA) and beta-Thalasemia major (bTH) in Kuwaiti subjects compared to other population.
p28307
sg4
(dp28308
(VUGT1A1 gene promoter
p28309
VSCA
p28310
tp28311
I00
ssg21392
(lp28312
(dp28313
g21395
I198
sg21396
VSickle-Cell Anemia
p28314
sg21398
I18
sg21399
VC0002895
p28315
sg21401
I2
sa(dp28316
g21395
I114
sg21396
Vbilirubinaemia
p28317
sg21398
I14
sg21399
VC0020433
p28318
sg21401
I1
sa(dp28319
g21395
I148
sg21396
Vcholelithiasis
p28320
sg21398
I14
sg21399
VC0008350
p28321
sg21401
I1
sa(dp28322
g21395
I218
sg21396
g28310
sg21398
I3
sg21399
VC0002895
p28323
sg21401
I1
sasg21404
(lp28324
(dp28325
g21395
I55
sg21396
g28309
sg21398
I20
sg21408
VP35504
p28326
sg21401
I3
sasa(dp28327
g21386
VOur results confirm UGT1A1 (TA)7 allele as one of the factors accounting for the hyperbilirubinemia and cholelithiasis observed in SCA and bTH.
p28328
sg4
(dp28329
(VUGT1A1
p28330
Vcholelithiasis
p28331
tp28332
I00
ssg21392
(lp28333
(dp28334
g21395
I81
sg21396
Vhyperbilirubinemia
p28335
sg21398
I18
sg21399
VC0020433
p28336
sg21401
I1
sa(dp28337
g21395
I104
sg21396
g28331
sg21398
I14
sg21399
VC0008350
p28338
sg21401
I1
sasg21404
(lp28339
(dp28340
g21395
I20
sg21396
g28330
sg21398
I6
sg21408
VP35504
p28341
sg21401
I1
sasa(dp28342
g21386
VWe analyzed the polymorphism A(TA)nTAA at the UGT1A1 promoter and the relationships between the various A(TA)nTAA genotypes and alleles and bilirubin levels and occurrence of cholelithiasis.
p28343
sg4
(dp28344
(VUGT1A1 promoter
p28345
Vcholelithiasis
p28346
tp28347
I00
ssg21392
(lp28348
(dp28349
g21395
I175
sg21396
g28346
sg21398
I14
sg21399
VC0008350
p28350
sg21401
I1
sasg21404
(lp28351
(dp28352
g21395
I46
sg21396
g28345
sg21398
I15
sg21408
VP35504
p28353
sg21401
I2
sasa(dp28354
g21386
VWe analyzed the polymorphism A(TA)&lt;formula&gt;_{n}&lt;/formula&gt; TAA at the UGT1A1 promoter and the relationships between the various A(TA)&lt;formula&gt;_{n}&lt;/formula&gt; TAA genotypes and alleles and bilirubin levels and occurrence of cholelithiasis.
p28355
sg4
(dp28356
(VUGT1A1 promoter
p28357
VTAA
p28358
tp28359
I00
ssg21392
(lp28360
(dp28361
g21395
I245
sg21396
Vcholelithiasis
p28362
sg21398
I14
sg21399
VC0008350
p28363
sg21401
I1
sa(dp28364
g21395
I70
sg21396
VTAA
p28365
sg21398
I3
sg21399
VC0162872
p28366
sg21401
I1
sa(dp28367
g21395
I70
sg21396
g28358
sg21398
I3
sg21399
VC0162872
p28368
sg21401
I1
sasg21404
(lp28369
(dp28370
g21395
I81
sg21396
g28357
sg21398
I15
sg21408
VP35504
p28371
sg21401
I2
sasa(dp28372
g21386
VHereditary spherocytosis stems from mutations in one of the genes encoding ankyrin-1 (ANKI), alpha spectrin (SPTA1) and beta spectrin (SPTB), the anion exchanger 1 (SLC4A 1), and protein 4.2 (EPB42).
p28373
sg4
(dp28374
(Vanion exchanger 1
p28375
VHereditary spherocytosis
p28376
tp28377
I00
ssg21392
(lp28378
(dp28379
g21395
I0
sg21396
g28376
sg21398
I24
sg21399
VC0037889
p28380
sg21401
I2
sasg21404
(lp28381
(dp28382
g21395
I120
sg21396
Vbeta spectrin
p28383
sg21398
I13
sg21408
VP11277
p28384
sg21401
I2
sa(dp28385
g21395
I93
sg21396
Valpha spectrin
p28386
sg21398
I14
sg21408
VP02549
p28387
sg21401
I2
sa(dp28388
g21395
I192
sg21396
VEPB42
p28389
sg21398
I5
sg21408
VP16452
p28390
sg21401
I1
sa(dp28391
g21395
I86
sg21396
VANKI
p28392
sg21398
I4
sg21408
VP16157
p28393
sg21401
I1
sa(dp28394
g21395
I135
sg21396
VSPTB
p28395
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp28396
g21395
I109
sg21396
VSPTA1
p28397
sg21398
I5
sg21408
VP02549
p28398
sg21401
I1
sa(dp28399
g21395
I75
sg21396
Vankyrin-1
p28400
sg21398
I9
sg21408
VP16157
p28401
sg21401
I1
sa(dp28402
g21395
I179
sg21396
Vprotein 4.2
p28403
sg21398
I11
sg21408
VP01031
p28404
sg21401
I2
sa(dp28405
g21395
I146
sg21396
g28375
sg21398
I17
sg21408
VP02730
p28406
sg21401
I3
sasa(dp28407
g21386
VWe also investigated methylation profiles in peripheral blood mononuclear cells from patients with red cell membrane diseases, such as complete protein 4.2 deficiency due to ELB42 mutations, hereditary spherocytosis with EPB3 mutations, and hereditary elliptocytosis with SPTB mutations.
p28408
sg4
(dp28409
(Vprotein 4.2
p28410
Vhereditary spherocytosis
p28411
tp28412
I00
ssg21392
(lp28413
(dp28414
g21395
I241
sg21396
Vhereditary elliptocytosis
p28415
sg21398
I25
sg21399
VC0013902
p28416
sg21401
I2
sa(dp28417
g21395
I191
sg21396
g28411
sg21398
I24
sg21399
VC0037889
p28418
sg21401
I2
sasg21404
(lp28419
(dp28420
g21395
I221
sg21396
VEPB3 mutations
p28421
sg21398
I14
sg21408
VP02730
p28422
sg21401
I2
sa(dp28423
g21395
I272
sg21396
VSPTB
p28424
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp28425
g21395
I144
sg21396
g28410
sg21398
I11
sg21408
VP01031
p28426
sg21401
I2
sasa(dp28427
g21386
VThe mutations of most cases of hereditary spherocytosis (HS) are located in the following genes: ANK1, SPTB, SLC4A1, EPB42 and SPTA1, which encode ankyrin, spectrin beta-chain, the anion exchanger 1 (band 3), protein 4.2 and spectrin alpha-chain, respectively.
p28428
sg4
(dp28429
(Vankyrin
p28430
VHS
p28431
tp28432
I00
ssg21392
(lp28433
(dp28434
g21395
I31
sg21396
Vhereditary spherocytosis
p28435
sg21398
I24
sg21399
VC0037889
p28436
sg21401
I2
sa(dp28437
g21395
I57
sg21396
g28431
sg21398
I2
sg21399
VC0037889
p28438
sg21401
I1
sasg21404
(lp28439
(dp28440
g21395
I97
sg21396
VANK1
p28441
sg21398
I4
sg21408
VP16157
p28442
sg21401
I1
sa(dp28443
g21395
I156
sg21396
Vspectrin beta-chain
p28444
sg21398
I19
sg21408
g190
sg21401
I2
sa(dp28445
g21395
I109
sg21396
VSLC4A1
p28446
sg21398
I6
sg21408
VP02730
p28447
sg21401
I1
sa(dp28448
g21395
I209
sg21396
Vprotein 4.2
p28449
sg21398
I11
sg21408
VP01031
p28450
sg21401
I2
sa(dp28451
g21395
I117
sg21396
VEPB42
p28452
sg21398
I5
sg21408
VP16452
p28453
sg21401
I1
sa(dp28454
g21395
I225
sg21396
Vspectrin alpha-chain
p28455
sg21398
I20
sg21408
VP55899
p28456
sg21401
I2
sa(dp28457
g21395
I127
sg21396
VSPTA1
p28458
sg21398
I5
sg21408
VP02549
p28459
sg21401
I1
sa(dp28460
g21395
I147
sg21396
g28430
sg21398
I7
sg21408
VP16157
p28461
sg21401
I1
sa(dp28462
g21395
I103
sg21396
VSPTB
p28463
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp28464
g21386
VMutations in bone morphogenetic protein 1 (BMP1) in humans or deletion of BMP1 and related protease tolloid like 1 (TLL1) in mice lead to osteogenesis imperfecta (OI).
p28465
sg4
(dp28466
(Vbone morphogenetic protein 1
p28467
Vosteogenesis imperfecta
p28468
tp28469
I00
ssg21392
(lp28470
(dp28471
g21395
I163
sg21396
VOI
p28472
sg21398
I2
sg21399
VC0029434
p28473
sg21401
I1
sa(dp28474
g21395
I138
sg21396
g28468
sg21398
I23
sg21399
VC0029434
p28475
sg21401
I2
sasg21404
(lp28476
(dp28477
g21395
I43
sg21396
VBMP1
p28478
sg21398
I4
sg21408
VP14222
p28479
sg21401
I1
sa(dp28480
g21395
I100
sg21396
Vtolloid like 1
p28481
sg21398
I14
sg21408
g190
sg21401
I3
sa(dp28482
g21395
I116
sg21396
VTLL1
p28483
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp28484
g21395
I74
sg21396
VBMP1 and related protease
p28485
sg21398
I25
sg21408
VP63123
p28486
sg21401
I4
sa(dp28487
g21395
I13
sg21396
g28467
sg21398
I28
sg21408
VP14222
p28488
sg21401
I4
sasa(dp28489
g21386
VAutosomal recessive osteogenesis imperfecta (OI) accounts for 10% of all OI cases, and, currently, mutations in 10 genes (CRTAP, LEPRE1, PPIB, SERPINH1, FKBP10, SERPINF1, SP7, BMP1, TMEM38B, and WNT1) are known to be responsible for this form of the disease.
p28490
sg4
(dp28491
(VWNT1
p28492
VOI
p28493
tp28494
I00
ssg21392
(lp28495
(dp28496
g21395
I20
sg21396
Vosteogenesis imperfecta
p28497
sg21398
I23
sg21399
VC0029434
p28498
sg21401
I2
sa(dp28499
g21395
I45
sg21396
VOI
p28500
sg21398
I2
sg21399
VC0029434
p28501
sg21401
I1
sa(dp28502
g21395
I45
sg21396
g28493
sg21398
I2
sg21399
VC0029434
p28503
sg21401
I1
sasg21404
(lp28504
(dp28505
g21395
I171
sg21396
VSP7
p28506
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp28507
g21395
I182
sg21396
VTMEM38B
p28508
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp28509
g21395
I122
sg21396
VCRTAP
p28510
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp28511
g21395
I137
sg21396
VPPIB
p28512
sg21398
I4
sg21408
VP23284
p28513
sg21401
I1
sa(dp28514
g21395
I143
sg21396
VSERPINH1
p28515
sg21398
I8
sg21408
VP50454
p28516
sg21401
I1
sa(dp28517
g21395
I153
sg21396
VFKBP10
p28518
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp28519
g21395
I161
sg21396
VSERPINF1
p28520
sg21398
I8
sg21408
VP36955
p28521
sg21401
I1
sa(dp28522
g21395
I195
sg21396
g28492
sg21398
I4
sg21408
VP04628
p28523
sg21401
I1
sasa(dp28524
g21386
VIsolated 3-methylcrotonyl-CoA carboxylase (MCC) deficiency is an autosomal recessive disorder of leucine metabolism caused by mutations in MCCC1 or MCCC2 encoding the Alfa and Beta subunit of MCC, respectively.
p28525
sg4
(dp28526
(VMCC
p28527
V3-methylcrotonyl-CoA carboxylase
p28528
tp28529
I00
ssg21392
(lp28530
(dp28531
g21395
I43
sg21396
VMCC
p28532
sg21398
I3
sg21399
VC0007129
p28533
sg21401
I1
sa(dp28534
g21395
I43
sg21396
VMCC
p28535
sg21398
I3
sg21399
VC0007129
p28536
sg21401
I1
sa(dp28537
g21395
I9
sg21396
g28528
sg21398
I32
sg21399
VC0007129
p28538
sg21401
I2
sasg21404
(lp28539
(dp28540
g21395
I0
sg21396
VIsolated 3-methylcrotonyl-CoA carboxylase
p28541
sg21398
I41
sg21408
g190
sg21401
I3
sa(dp28542
g21395
I43
sg21396
VMCC
p28543
sg21398
I3
sg21408
VP23508
p28544
sg21401
I1
sa(dp28545
g21395
I139
sg21396
VMCCC1
p28546
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp28547
g21395
I148
sg21396
VMCCC2
p28548
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp28549
g21395
I43
sg21396
g28527
sg21398
I3
sg21408
VP23508
p28550
sg21401
I1
sasa(dp28551
g21386
VWe performed mutational analysis in the four main HPE causing genes (SHH, SIX3, TGIF, and ZIC2) and GLI3, a gene associated with polydactyly as well as fluorescent in situ hybridization (FISH) to search for microdeletions in these genes and two candidate HPE genes (DISP1 and FOXA2).
p28552
sg4
(dp28553
(VTGIF
p28554
Vpolydactyly
p28555
tp28556
I00
ssg21392
(lp28557
(dp28558
g21395
I129
sg21396
g28555
sg21398
I11
sg21399
VC0152427
p28559
sg21401
I1
sasg21404
(lp28560
(dp28561
g21395
I90
sg21396
VZIC2
p28562
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp28563
g21395
I69
sg21396
VSHH
p28564
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp28565
g21395
I276
sg21396
VFOXA2
p28566
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp28567
g21395
I255
sg21396
VHPE genes
p28568
sg21398
I9
sg21408
VP01893
p28569
sg21401
I2
sa(dp28570
g21395
I100
sg21396
VGLI3
p28571
sg21398
I4
sg21408
VP10071
p28572
sg21401
I1
sa(dp28573
g21395
I266
sg21396
VDISP1
p28574
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp28575
g21395
I74
sg21396
VSIX3
p28576
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp28577
g21395
I80
sg21396
g28554
sg21398
I4
sg21408
VP22301
p28578
sg21401
I1
sasa(dp28579
g21386
VAlthough the CCK-1 receptor has been shown to be highly expressed in resected human pancreatic cancer samples, its role is less clear.
p28580
sg4
(dp28581
(VCCK-1 receptor
p28582
Vpancreatic cancer
p28583
tp28584
I00
ssg21392
(lp28585
(dp28586
g21395
I84
sg21396
g28583
sg21398
I17
sg21399
VC0235974
p28587
sg21401
I2
sasg21404
(lp28588
(dp28589
g21395
I13
sg21396
g28582
sg21398
I14
sg21408
VP06307
p28590
sg21401
I2
sasa(dp28591
g21386
VThe aim of this in vitro study was to investigate the CCK-1 receptor expression and the function of the CCK-CCK-1 receptor pathway in the human pancreatic adenocarcinoma cell line, Mia PaCa-2.
p28592
sg4
(dp28593
(VCCK-CCK-1 receptor
p28594
Vpancreatic adenocarcinoma
p28595
tp28596
I01
ssg21392
(lp28597
(dp28598
g21395
I185
sg21396
VPaCa
p28599
sg21398
I4
sg21399
VC1836780
p28600
sg21401
I1
sa(dp28601
g21395
I144
sg21396
g28595
sg21398
I25
sg21399
VC0281361
p28602
sg21401
I2
sasg21404
(lp28603
(dp28604
g21395
I54
sg21396
VCCK-1 receptor
p28605
sg21398
I14
sg21408
VP06307
p28606
sg21401
I2
sa(dp28607
g21395
I104
sg21396
g28594
sg21398
I18
sg21408
VP06307
p28608
sg21401
I2
sa(dp28609
g21395
I181
sg21396
VMia PaCa-2
p28610
sg21398
I10
sg21408
g190
sg21401
I2
sasa(dp28611
g21386
VHowever, the main source of CCK receptors in the pancreatic tumor samples consisted of CCK2-expressing islets and/or CCK1-expressing nerves rather than neoplastic tissue.
p28612
sg4
(dp28613
(VCCK receptors
p28614
Vpancreatic tumor
p28615
tp28616
I01
ssg21392
(lp28617
(dp28618
g21395
I49
sg21396
g28615
sg21398
I16
sg21399
VC0030297
p28619
sg21401
I2
sasg21404
(lp28620
(dp28621
g21395
I28
sg21396
g28614
sg21398
I13
sg21408
VP06307
p28622
sg21401
I2
sa(dp28623
g21395
I117
sg21396
VCCK1
p28624
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp28625
g21386
VThese data indicate that the presence of CCK receptors in human ductal pancreatic tumor samples is mainly due to CCK2 expression in residual pancreatic islets and CCK1 in pancreatic nerves.
p28626
sg4
(dp28627
(VCCK receptors
p28628
Vpancreatic tumor
p28629
tp28630
I01
ssg21392
(lp28631
(dp28632
g21395
I71
sg21396
g28629
sg21398
I16
sg21399
VC0030297
p28633
sg21401
I2
sasg21404
(lp28634
(dp28635
g21395
I41
sg21396
g28628
sg21398
I13
sg21408
VP06307
p28636
sg21401
I2
sa(dp28637
g21395
I163
sg21396
VCCK1
p28638
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp28639
g21386
VThe aim of this study was to evaluate the association of the polymorphisms in TCN2 (rs1801198) gene and in MTRR (rs1801394) gene with nonsyndromic cleft lip and/or palate (NSCL/P) in a Brazilian population.
p28640
sg4
(dp28641
(VTCN2 (rs1801198) gene
p28642
Vcleft lip
p28643
tp28644
I00
ssg21392
(lp28645
(dp28646
g21395
I147
sg21396
g28643
sg21398
I9
sg21399
VC0008924
p28647
sg21401
I2
sasg21404
(lp28648
(dp28649
g21395
I78
sg21396
g28642
sg21398
I21
sg21408
VP20062
p28650
sg21401
I3
sasa(dp28651
g21386
VIn conclusion, clonidine could improve the learning and memory ability of rats with cerebral ischemia, and NR2B, ERK1/2, CREB, NF-KB were involved in this effect.
p28652
sg4
(dp28653
(VERK1/2
p28654
Vcerebral ischemia
p28655
tp28656
I00
ssg21392
(lp28657
(dp28658
g21395
I84
sg21396
g28655
sg21398
I17
sg21399
VC0917798
p28659
sg21401
I2
sasg21404
(lp28660
(dp28661
g21395
I121
sg21396
VCREB
p28662
sg21398
I4
sg21408
VP16220
p28663
sg21401
I1
sa(dp28664
g21395
I113
sg21396
g28654
sg21398
I6
sg21408
VP27361
p28665
sg21401
I1
sa(dp28666
g21395
I107
sg21396
VNR2B
p28667
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp28668
g21386
VTaken together, our results demonstrated that LBP is neuroprotective against ischemic injury by its dual roles in activation of NR2A and inhibition of NR2B signaling pathways, which suggests that LBP may be a superior therapeutic candidate for targeting glutamate excitotoxicity for the treatment of ischemic stroke.
p28669
sg4
(dp28670
(VLBP
p28671
VLBP
p28672
tp28673
I00
ssg21392
(lp28674
(dp28675
g21395
I300
sg21396
Vischemic stroke
p28676
sg21398
I15
sg21399
VC3272363
p28677
sg21401
I2
sa(dp28678
g21395
I46
sg21396
VLBP
p28679
sg21398
I3
sg21399
VC0024031
p28680
sg21401
I1
sa(dp28681
g21395
I46
sg21396
g28672
sg21398
I3
sg21399
VC0024031
p28682
sg21401
I1
sasg21404
(lp28683
(dp28684
g21395
I151
sg21396
VNR2B
p28685
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp28686
g21395
I128
sg21396
VNR2A
p28687
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp28688
g21395
I46
sg21396
VLBP
p28689
sg21398
I3
sg21408
VP18428
p28690
sg21401
I1
sa(dp28691
g21395
I46
sg21396
g28671
sg21398
I3
sg21408
VP18428
p28692
sg21401
I1
sasa(dp28693
g21386
VThe obesity-induced changes in adipose tissue macrophage numbers are mainly due to increases in the triple-positive CD11b+ F4/80+ CD11c+ adipose tissue macrophage subpopulation.
p28694
sg4
(dp28695
(VCD11b+ F4/80+ CD11c+
p28696
Vobesity
p28697
tp28698
I00
ssg21392
(lp28699
(dp28700
g21395
I4
sg21396
g28697
sg21398
I7
sg21399
VC0028754
p28701
sg21401
I1
sasg21404
(lp28702
(dp28703
g21395
I116
sg21396
g28696
sg21398
I20
sg21408
VP11215
p28704
sg21401
I3
sasa(dp28705
g21386
VContrary to our hypothesis that obesity-mediated white AT inflammation is Nlrp3-dependent, we found that Western diet-induced expression of AT inflammatory markers (i.e., Cd68, Cd11c, Emr1, Itgam, Lgals, Il18, Mcp1, Tnf, Ccr2, Ccl5 mRNAs, and Mac-2 protein) were not accompanied by increased caspase-1 cleavage, a hallmark feature of NLRP3 inflammasome activation.
p28706
sg4
(dp28707
(VCd11c
p28708
Vinflammation
p28709
tp28710
I00
ssg21392
(lp28711
(dp28712
g21395
I32
sg21396
Vobesity
p28713
sg21398
I7
sg21399
VC0028754
p28714
sg21401
I1
sa(dp28715
g21395
I58
sg21396
g28709
sg21398
I12
sg21399
VC0021368
p28716
sg21401
I1
sasg21404
(lp28717
(dp28718
g21395
I227
sg21396
VCcl5 mRNAs
p28719
sg21398
I10
sg21408
VP13501
p28720
sg21401
I2
sa(dp28721
g21395
I292
sg21396
Vcaspase-1
p28722
sg21398
I9
sg21408
VP29466
p28723
sg21401
I1
sa(dp28724
g21395
I221
sg21396
VCcr2
p28725
sg21398
I4
sg21408
VP41597
p28726
sg21401
I1
sa(dp28727
g21395
I210
sg21396
VMcp1
p28728
sg21398
I4
sg21408
VP13500
p28729
sg21401
I1
sa(dp28730
g21395
I190
sg21396
VItgam
p28731
sg21398
I5
sg21408
VP11215
p28732
sg21401
I1
sa(dp28733
g21395
I243
sg21396
VMac-2 protein
p28734
sg21398
I13
sg21408
VP17931
p28735
sg21401
I2
sa(dp28736
g21395
I216
sg21396
VTnf
p28737
sg21398
I3
sg21408
VP01375
p28738
sg21401
I1
sa(dp28739
g21395
I184
sg21396
VEmr1
p28740
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp28741
g21395
I171
sg21396
VCd68
p28742
sg21398
I4
sg21408
VP34810
p28743
sg21401
I1
sa(dp28744
g21395
I177
sg21396
g28708
sg21398
I5
sg21408
VP20702
p28745
sg21401
I1
sa(dp28746
g21395
I204
sg21396
VIl18
p28747
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp28748
g21386
VAlthough heterogenous staining patterns were seen within individual cases, use of the PIN-4 cocktail effectively discriminates NA from prostate cancer because of the high frequency of coexpression of AMACR and CK903 within NA.
p28749
sg4
(dp28750
(VPIN-4
p28751
Vprostate cancer
p28752
tp28753
I00
ssg21392
(lp28754
(dp28755
g21395
I86
sg21396
VPIN
p28756
sg21398
I3
sg21399
VC0282612
p28757
sg21401
I1
sa(dp28758
g21395
I135
sg21396
g28752
sg21398
I15
sg21399
VC0600139
p28759
sg21401
I2
sasg21404
(lp28760
(dp28761
g21395
I86
sg21396
g28751
sg21398
I5
sg21408
VP63167
p28762
sg21401
I1
sasa(dp28763
g21386
VKidney and prostate cancer tumor and benign biopsies were stained with hemotoxylin and eosin and prostate biopsies were subjected to PIN-4 immunohistochemistry.
p28764
sg4
(dp28765
(VPIN-4
p28766
VPIN
p28767
tp28768
I00
ssg21392
(lp28769
(dp28770
g21395
I11
sg21396
Vprostate cancer
p28771
sg21398
I15
sg21399
VC0600139
p28772
sg21401
I2
sa(dp28773
g21395
I133
sg21396
g28767
sg21398
I3
sg21399
VC0282612
p28774
sg21401
I1
sa(dp28775
g21395
I27
sg21396
Vtumor
p28776
sg21398
I5
sg21399
VC0027651
p28777
sg21401
I1
sasg21404
(lp28778
(dp28779
g21395
I133
sg21396
g28766
sg21398
I5
sg21408
VP63167
p28780
sg21401
I1
sasa(dp28781
g21386
VElevated serum levels of Ang-2 and high values for the Ang-2/Ang-1 ratio may potentially be used as predictors of worst-case prognoses for P. vivax malaria, especially in patients with thrombocytopenia.
p28782
sg4
(dp28783
(VAng-1
p28784
Vvivax malaria
p28785
tp28786
I00
ssg21392
(lp28787
(dp28788
g21395
I142
sg21396
g28785
sg21398
I13
sg21399
VC0024537
p28789
sg21401
I2
sasg21404
(lp28790
(dp28791
g21395
I25
sg21396
VAng-2
p28792
sg21398
I5
sg21408
VP03950
p28793
sg21401
I1
sa(dp28794
g21395
I25
sg21396
VAng-2
p28795
sg21398
I5
sg21408
VP03950
p28796
sg21401
I1
sa(dp28797
g21395
I61
sg21396
g28784
sg21398
I5
sg21408
VP03950
p28798
sg21401
I1
sasa(dp28799
g21386
VIt has been previously reported that mutations in retinal G protein coupled receptor (RGR) are associated with retinitis pigmentosa.
p28800
sg4
(dp28801
(Vretinal G protein coupled receptor
p28802
Vretinitis pigmentosa
p28803
tp28804
I00
ssg21392
(lp28805
(dp28806
g21395
I111
sg21396
g28803
sg21398
I20
sg21399
VC0035334
p28807
sg21401
I2
sasg21404
(lp28808
(dp28809
g21395
I86
sg21396
VRGR
p28810
sg21398
I3
sg21408
VP47804
p28811
sg21401
I1
sa(dp28812
g21395
I50
sg21396
g28802
sg21398
I34
sg21408
VP47804
p28813
sg21401
I5
sasa(dp28814
g21386
VThe present study aims to systemically analyze the potential role of variants of RGR in retinal diseases.
p28815
sg4
(dp28816
(VRGR
p28817
Vretinal diseases
p28818
tp28819
I01
ssg21392
(lp28820
(dp28821
g21395
I88
sg21396
g28818
sg21398
I16
sg21399
VC0035309
p28822
sg21401
I2
sasg21404
(lp28823
(dp28824
g21395
I81
sg21396
g28817
sg21398
I3
sg21408
VP47804
p28825
sg21401
I1
sasa(dp28826
g21386
VThese data suggest that the recessive retinal disorder previously reported to be due to homozygous mutation in RGR is, at least in part, due to variants in CDHR1 and that the true consequences of RGR knock-out on human retinal structure and function are yet to be determined.
p28827
sg4
(dp28828
(VRGR knock-out
p28829
Vretinal disorder
p28830
tp28831
I01
ssg21392
(lp28832
(dp28833
g21395
I38
sg21396
g28830
sg21398
I16
sg21399
VC0035309
p28834
sg21401
I2
sasg21404
(lp28835
(dp28836
g21395
I111
sg21396
VRGR
p28837
sg21398
I3
sg21408
VP47804
p28838
sg21401
I1
sa(dp28839
g21395
I196
sg21396
g28829
sg21398
I13
sg21408
VP47804
p28840
sg21401
I2
sa(dp28841
g21395
I156
sg21396
VCDHR1
p28842
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp28843
g21386
VRare mutations in the human RGR gene lead to autosomal recessive retinitis pigmentosa or dominantly inherited peripapillary choroidal atrophy.
p28844
sg4
(dp28845
(Vhuman RGR gene
p28846
Vautosomal recessive retinitis pigmentosa
p28847
tp28848
I00
ssg21392
(lp28849
(dp28850
g21395
I134
sg21396
Vatrophy
p28851
sg21398
I7
sg21399
VC0333641
p28852
sg21401
I1
sa(dp28853
g21395
I45
sg21396
g28847
sg21398
I40
sg21399
VC0339526
p28854
sg21401
I4
sasg21404
(lp28855
(dp28856
g21395
I22
sg21396
g28846
sg21398
I14
sg21408
VP47804
p28857
sg21401
I3
sasa(dp28858
g21386
VIn Western blot assays, the RGR-d protein was detected in retinas of a large proportion ( approximately 53%) of individual donors, including patients with age-related macular degeneration (AMD).
p28859
sg4
(dp28860
(VRGR-d protein
p28861
VAMD
p28862
tp28863
I01
ssg21392
(lp28864
(dp28865
g21395
I155
sg21396
Vage-related macular degeneration
p28866
sg21398
I32
sg21399
VC0242383
p28867
sg21401
I3
sa(dp28868
g21395
I189
sg21396
g28862
sg21398
I3
sg21399
VC0242383
p28869
sg21401
I1
sasg21404
(lp28870
(dp28871
g21395
I28
sg21396
g28861
sg21398
I13
sg21408
VP47804
p28872
sg21401
I2
sasa(dp28873
g21386
VMutations in the human gene encoding RGR are associated with retinitis pigmentosa.
p28874
sg4
(dp28875
(Vhuman gene encoding RGR
p28876
Vretinitis pigmentosa
p28877
tp28878
I00
ssg21392
(lp28879
(dp28880
g21395
I61
sg21396
g28877
sg21398
I20
sg21399
VC0035334
p28881
sg21401
I2
sasg21404
(lp28882
(dp28883
g21395
I17
sg21396
g28876
sg21398
I23
sg21408
VP47804
p28884
sg21401
I4
sasa(dp28885
g21386
VoH(E)mT-DCN treatment also attenuated the expression of major ECM components, such as collagen I/III, elastin and fibronectin and induced tumor cell apoptosis, leading to extensive viral dispersion within orthotopic pancreatic tumors and pancreatic cancer patient-derived tumor spheroids.
p28886
sg4
(dp28887
(Velastin
p28888
Vpancreatic tumors
p28889
tp28890
I00
ssg21392
(lp28891
(dp28892
g21395
I138
sg21396
Vtumor
p28893
sg21398
I5
sg21399
VC0027651
p28894
sg21401
I1
sa(dp28895
g21395
I138
sg21396
Vtumor
p28896
sg21398
I5
sg21399
VC0027651
p28897
sg21401
I1
sa(dp28898
g21395
I238
sg21396
Vpancreatic cancer
p28899
sg21398
I17
sg21399
VC0235974
p28900
sg21401
I2
sa(dp28901
g21395
I216
sg21396
g28889
sg21398
I17
sg21399
VC0030297
p28902
sg21401
I2
sasg21404
(lp28903
(dp28904
g21395
I102
sg21396
g28888
sg21398
I7
sg21408
VP49918
p28905
sg21401
I1
sasa(dp28906
g21386
VDysregulation of cysteinyl cathepsins and their inhibitors, cystatins (stefins), were implied in progression of tumorgenesis; nevertheless, their role in sinonasal inverted papilloma (IP) is still unrecognized.
p28907
sg4
(dp28908
(Vcysteinyl cathepsins
p28909
Vinverted papilloma
p28910
tp28911
I00
ssg21392
(lp28912
(dp28913
g21395
I184
sg21396
VIP
p28914
sg21398
I2
sg21399
VC1881254
p28915
sg21401
I1
sa(dp28916
g21395
I164
sg21396
g28910
sg21398
I18
sg21399
VC1881254
p28917
sg21401
I2
sasg21404
(lp28918
(dp28919
g21395
I17
sg21396
g28909
sg21398
I20
sg21408
VP25774
p28920
sg21401
I2
sasa(dp28921
g21386
VDespite fundamental limitations applying to these models, such as the distinct immune system and the different metabolism regulating liver homeostasis in rodents when compared to humans, multiple approaches, such as surgery (bile duct ligation), chemical-induced (3,5-diethoxycarbonyl-1,4-dihydrocollidine, DDC, Alfa-naphthylisothiocyanate, ANIT), viral infections (Rhesus rotavirustype A, RRV-A), and genetic manipulation (Mdr2, Cftr, Pkd1, Pkd2, Prkcsh, Sec63, Pkhd1) have been developed.
p28922
sg4
(dp28923
(VPrkcsh
p28924
VPkd1
p28925
tp28926
I00
ssg21392
(lp28927
(dp28928
g21395
I442
sg21396
VPkd2
p28929
sg21398
I4
sg21399
VC2751306
p28930
sg21401
I1
sa(dp28931
g21395
I463
sg21396
VPkhd1
p28932
sg21398
I5
sg21399
VC0085548
p28933
sg21401
I1
sa(dp28934
g21395
I348
sg21396
Vviral infections
p28935
sg21398
I16
sg21399
VC0042769
p28936
sg21401
I2
sa(dp28937
g21395
I436
sg21396
g28925
sg21398
I4
sg21399
VC3149841
p28938
sg21401
I1
sasg21404
(lp28939
(dp28940
g21395
I424
sg21396
VMdr2
p28941
sg21398
I4
sg21408
VP21439
p28942
sg21401
I1
sa(dp28943
g21395
I442
sg21396
VPkd2
p28944
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp28945
g21395
I463
sg21396
VPkhd1
p28946
sg21398
I5
sg21408
VP08F94
p28947
sg21401
I1
sa(dp28948
g21395
I436
sg21396
VPkd1
p28949
sg21398
I4
sg21408
VP98161
p28950
sg21401
I1
sa(dp28951
g21395
I456
sg21396
VSec63
p28952
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp28953
g21395
I430
sg21396
VCftr
p28954
sg21398
I4
sg21408
VP13569
p28955
sg21401
I1
sa(dp28956
g21395
I448
sg21396
g28924
sg21398
I6
sg21408
VP14314
p28957
sg21401
I1
sasa(dp28958
g21386
VProgressive familial intrahepatic cholestasis type 3 (PFIC3) is an autosomal recessive disorder of cholestasis of hepatocellular origin, typically seen in infancy or childhood caused by a defect in the ABCB4 located on chromosome 7.
p28959
sg4
(dp28960
(VABCB4
p28961
VProgressive familial intrahepatic cholestasis type 3
p28962
tp28963
I00
ssg21392
(lp28964
(dp28965
g21395
I54
sg21396
VPFIC3
p28966
sg21398
I5
sg21399
VC1865643
p28967
sg21401
I1
sa(dp28968
g21395
I34
sg21396
Vcholestasis
p28969
sg21398
I11
sg21399
VC0008370
p28970
sg21401
I1
sa(dp28971
g21395
I0
sg21396
g28962
sg21398
I52
sg21399
VC1865643
p28972
sg21401
I6
sasg21404
(lp28973
(dp28974
g21395
I54
sg21396
VPFIC3
p28975
sg21398
I5
sg21408
VP21439
p28976
sg21401
I1
sa(dp28977
g21395
I0
sg21396
VProgressive familial intrahepatic cholestasis type 3
p28978
sg21398
I52
sg21408
VP21439
p28979
sg21401
I6
sa(dp28980
g21395
I202
sg21396
g28961
sg21398
I5
sg21408
VP21439
p28981
sg21401
I1
sasa(dp28982
g21386
VFor example, mutations in ABCA1 cause Tangier disease associated with defective efflux of cholesterol and phosphatidylcholine from the plasma membrane to the lipid acceptor protein apoA1 (apolipoprotein AI), mutations in ABCA3 cause neonatal surfactant deficiency associated with a loss in secretion of the lipid pulmonary surfactants from lungs of newborns, mutations in ABCA4 cause Stargardt macular degeneration, a retinal degenerative disease linked to the reduced clearance of retinoid compounds from photoreceptor cells, mutations in ABCA12 cause harlequin and lamellar ichthyosis, skin diseases associated with defective lipid trafficking in keratinocytes, and mutations in ABCB4 and ABCG5/ABCG8 are responsible for progressive intrafamilial hepatic disease and sitosterolaemia associated with defective phospholipid and sterol transport respectively.
p28983
sg4
(dp28984
(VABCB4
p28985
Vsitosterolaemia
p28986
tp28987
I00
ssg21392
(lp28988
(dp28989
g21395
I38
sg21396
VTangier disease
p28990
sg21398
I15
sg21399
VC0039292
p28991
sg21401
I2
sa(dp28992
g21395
I588
sg21396
Vskin diseases
p28993
sg21398
I13
sg21399
VC0037274
p28994
sg21401
I2
sa(dp28995
g21395
I426
sg21396
Vdegenerative disease
p28996
sg21398
I20
sg21399
VC1285162
p28997
sg21401
I2
sa(dp28998
g21395
I394
sg21396
Vmacular degeneration
p28999
sg21398
I20
sg21399
VC0242383
p29000
sg21401
I2
sa(dp29001
g21395
I749
sg21396
Vhepatic disease
p29002
sg21398
I15
sg21399
VC0023895
p29003
sg21401
I2
sa(dp29004
g21395
I567
sg21396
Vlamellar ichthyosis
p29005
sg21398
I19
sg21399
VC0020758
p29006
sg21401
I2
sa(dp29007
g21395
I769
sg21396
g28986
sg21398
I15
sg21399
VC0342907
p29008
sg21401
I1
sasg21404
(lp29009
(dp29010
g21395
I188
sg21396
Vapolipoprotein AI
p29011
sg21398
I17
sg21408
VP02656
p29012
sg21401
I2
sa(dp29013
g21395
I181
sg21396
VapoA1
p29014
sg21398
I5
sg21408
VP02647
p29015
sg21401
I1
sa(dp29016
g21395
I372
sg21396
VABCA4
p29017
sg21398
I5
sg21408
VP78363
p29018
sg21401
I1
sa(dp29019
g21395
I221
sg21396
VABCA3
p29020
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp29021
g21395
I540
sg21396
VABCA12
p29022
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp29023
g21395
I681
sg21396
g28985
sg21398
I5
sg21408
VP21439
p29024
sg21401
I1
sa(dp29025
g21395
I697
sg21396
VABCG8
p29026
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp29027
g21395
I691
sg21396
VABCG5
p29028
sg21398
I5
sg21408
g190
sg21401
I1
sasa(dp29029
g21386
VWe further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.
p29030
sg4
(dp29031
(VITGB6
p29032
Vbreast cancer
p29033
tp29034
I01
ssg21392
(lp29035
(dp29036
g21395
I35
sg21396
g29033
sg21398
I13
sg21399
VC0678222
p29037
sg21401
I2
sasg21404
(lp29038
(dp29039
g21395
I122
sg21396
VKLHDC9
p29040
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp29041
g21395
I93
sg21396
VIGF2BP2
p29042
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp29043
g21395
I111
sg21396
g29032
sg21398
I5
sg21408
VP18564
p29044
sg21401
I1
sa(dp29045
g21395
I102
sg21396
VNECTIN4
p29046
sg21398
I7
sg21408
g190
sg21401
I1
sasa(dp29047
g21386
VBackground: Serum autoantibodies against tumor-associated antigens (TAAs) are detectable in early-stage gastric cancer patients; however, the time point during cancerogenesis when they appear in circulation is still obscure.Methods: In this study, we developed a recombinant antigen microarray and analyzed the prevalence of autoantibodies against 102 TAAs in 829 gastric cancer patients and 929 healthy controls from Caucasian and Asian populations, as well as 100 patients with chronic atrophic gastritis and 775 individuals staged according to different grades of intestinal metaplasia.Results: Six antigens, including CTAG1B/CTAG2, DDX53, IGF2BP2, TP53, and MAGEA3, were predominantly reacting with sera from gastric cancer patients when compared with healthy controls, and the seroreactivity was associated with intestinal-type gastric cancer, but not with patients' Helicobacter pylori status, grade, age, gender, or stage of gastric cancer.
p29048
sg4
(dp29049
(VTAAs
p29050
Vchronic atrophic gastritis
p29051
tp29052
I00
ssg21392
(lp29053
(dp29054
g21395
I104
sg21396
Vgastric cancer
p29055
sg21398
I14
sg21399
VC0024623
p29056
sg21401
I2
sa(dp29057
g21395
I104
sg21396
Vgastric cancer
p29058
sg21398
I14
sg21399
VC0024623
p29059
sg21401
I2
sa(dp29060
g21395
I567
sg21396
Vintestinal metaplasia
p29061
sg21398
I21
sg21399
VC0334037
p29062
sg21401
I2
sa(dp29063
g21395
I41
sg21396
Vtumor
p29064
sg21398
I5
sg21399
VC0027651
p29065
sg21401
I1
sa(dp29066
g21395
I104
sg21396
Vgastric cancer
p29067
sg21398
I14
sg21399
VC0024623
p29068
sg21401
I2
sa(dp29069
g21395
I104
sg21396
Vgastric cancer
p29070
sg21398
I14
sg21399
VC0024623
p29071
sg21401
I2
sa(dp29072
g21395
I104
sg21396
Vgastric cancer
p29073
sg21398
I14
sg21399
VC0024623
p29074
sg21401
I2
sa(dp29075
g21395
I480
sg21396
g29051
sg21398
I26
sg21399
VC0017154
p29076
sg21401
I3
sasg21404
(lp29077
(dp29078
g21395
I643
sg21396
VIGF2BP2
p29079
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp29080
g21395
I636
sg21396
VDDX53
p29081
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp29082
g21395
I41
sg21396
Vtumor-associated antigens
p29083
sg21398
I25
sg21408
VP51572
p29084
sg21401
I2
sa(dp29085
g21395
I68
sg21396
VTAAs
p29086
sg21398
I4
sg21408
VP51572
p29087
sg21401
I1
sa(dp29088
g21395
I629
sg21396
VCTAG2
p29089
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp29090
g21395
I68
sg21396
g29050
sg21398
I4
sg21408
VP51572
p29091
sg21401
I1
sa(dp29092
g21395
I622
sg21396
VCTAG1B
p29093
sg21398
I6
sg21408
VP78358
p29094
sg21401
I1
sasa(dp29095
g21386
VNew genes HTRP5, CAPN6, STPK, 14-3-3PKR, and CALM1 and previously known genes including BTK, DDP, GLA, PLP, COL4A5, COL4A6, PAK3, and DCX are localized; candidate loci for other disorders for which genes have not yet been identified, including DFN-2, POF, megalocornea, and syndromic and nonsyndromic mental retardation, are also mapped in the region.
p29096
sg4
(dp29097
(VCOL4A5
p29098
Vmegalocornea
p29099
tp29100
I00
ssg21392
(lp29101
(dp29102
g21395
I251
sg21396
VPOF
p29103
sg21398
I3
sg21399
VC0085215
p29104
sg21401
I1
sa(dp29105
g21395
I93
sg21396
VDDP
p29106
sg21398
I3
sg21399
VC0796074
p29107
sg21401
I1
sa(dp29108
g21395
I301
sg21396
Vmental retardation
p29109
sg21398
I18
sg21399
VC0025362
p29110
sg21401
I2
sa(dp29111
g21395
I256
sg21396
g29099
sg21398
I12
sg21399
VC0344530
p29112
sg21401
I1
sasg21404
(lp29113
(dp29114
g21395
I134
sg21396
VDCX
p29115
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp29116
g21395
I98
sg21396
VGLA
p29117
sg21398
I3
sg21408
VP06280
p29118
sg21401
I1
sa(dp29119
g21395
I251
sg21396
VPOF
p29120
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp29121
g21395
I0
sg21396
VNew genes HTRP5
p29122
sg21398
I15
sg21408
VP01701
p29123
sg21401
I3
sa(dp29124
g21395
I17
sg21396
VCAPN6
p29125
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp29126
g21395
I103
sg21396
VPLP
p29127
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp29128
g21395
I24
sg21396
VSTPK
p29129
sg21398
I4
sg21408
VP53350
p29130
sg21401
I1
sa(dp29131
g21395
I88
sg21396
VBTK
p29132
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp29133
g21395
I108
sg21396
g29098
sg21398
I6
sg21408
VP29400
p29134
sg21401
I1
sa(dp29135
g21395
I93
sg21396
VDDP
p29136
sg21398
I3
sg21408
g190
sg21401
I1
sasa(dp29137
g21386
VTo study the expression status of Ras-association domain family 7 (RASSF7) and Ras-association domain family 8 (RASSF8) in nodular thyroid goiter (NTG), medullary thyroid carcinoma (MTC), and papillary thyroid carcinoma (PTC) and establish whether a correlation exists between the presence of RASSF7 and RASSF8 proteins and clinicopathological parameters of the disease.
p29138
sg4
(dp29139
(VRas-association domain family 7
p29140
Vmedullary thyroid carcinoma
p29141
tp29142
I00
ssg21392
(lp29143
(dp29144
g21395
I131
sg21396
Vthyroid goiter
p29145
sg21398
I14
sg21399
VC0018021
p29146
sg21401
I2
sa(dp29147
g21395
I192
sg21396
Vpapillary thyroid carcinoma
p29148
sg21398
I27
sg21399
VC0238463
p29149
sg21401
I3
sa(dp29150
g21395
I221
sg21396
VPTC
p29151
sg21398
I3
sg21399
VC0238463
p29152
sg21401
I1
sa(dp29153
g21395
I182
sg21396
VMTC
p29154
sg21398
I3
sg21399
VC1833921
p29155
sg21401
I1
sa(dp29156
g21395
I153
sg21396
g29141
sg21398
I27
sg21399
VC0238462
p29157
sg21401
I3
sasg21404
(lp29158
(dp29159
g21395
I67
sg21396
VRASSF7
p29160
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp29161
g21395
I67
sg21396
VRASSF7
p29162
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp29163
g21395
I304
sg21396
VRASSF8 proteins
p29164
sg21398
I15
sg21408
g190
sg21401
I2
sa(dp29165
g21395
I79
sg21396
VRas-association domain family 8
p29166
sg21398
I31
sg21408
VP01116
p29167
sg21401
I4
sa(dp29168
g21395
I112
sg21396
VRASSF8
p29169
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp29170
g21395
I34
sg21396
g29140
sg21398
I31
sg21408
VP01116
p29171
sg21401
I4
sasa(dp29172
g21386
VMoreover, HO-1 diminished ischemia-induced expression of MyoD involved in satellite cell differentiation in HO-1 KO mice.
p29173
sg4
(dp29174
(VMyoD
p29175
Vischemia
p29176
tp29177
I00
ssg21392
(lp29178
(dp29179
g21395
I26
sg21396
g29176
sg21398
I8
sg21399
VC0022116
p29180
sg21401
I1
sasg21404
(lp29181
(dp29182
g21395
I57
sg21396
g29175
sg21398
I4
sg21408
VP15172
p29183
sg21401
I1
sasa(dp29184
g21386
VCoprecipitation of CD36, CD9, and alpha6beta1 was also observed on platelets from a patient with Glanzmann thrombasthenia, indicating that alphaII(b)beta3 is not required for the other proteins to associate.
p29185
sg4
(dp29186
(VCD9
p29187
VGlanzmann thrombasthenia
p29188
tp29189
I00
ssg21392
(lp29190
(dp29191
g21395
I97
sg21396
g29188
sg21398
I24
sg21399
VC0040015
p29192
sg21401
I2
sasg21404
(lp29193
(dp29194
g21395
I25
sg21396
g29187
sg21398
I3
sg21408
VP21926
p29195
sg21401
I1
sasa(dp29196
g21386
VTo rule out a cross-reactivity of the two polyclonal antibodies with GPIIb/IIIa, we studied PECAM1 and CD9 expression on the platelets from a patient with type I Glanzmann's thrombasthenia whose platelets are devoid of GPIIb/IIIa.
p29197
sg4
(dp29198
(VCD9
p29199
VGlanzmann's thrombasthenia
p29200
tp29201
I00
ssg21392
(lp29202
(dp29203
g21395
I162
sg21396
g29200
sg21398
I26
sg21399
VC0040015
p29204
sg21401
I2
sasg21404
(lp29205
(dp29206
g21395
I69
sg21396
VGPIIb/IIIa
p29207
sg21398
I10
sg21408
VP08514
p29208
sg21401
I1
sa(dp29209
g21395
I69
sg21396
VGPIIb/IIIa
p29210
sg21398
I10
sg21408
VP08514
p29211
sg21401
I1
sa(dp29212
g21395
I103
sg21396
g29199
sg21398
I3
sg21408
VP21926
p29213
sg21401
I1
sasa(dp29214
g21386
VIn contrast to TASK-1, which was not differentially expressed in lung cancer vs. normal lung tissue, we found the Na+-coupled nutrient transporters, SLC5A3, SLC5A6, and SLC38A1, transporters for myo-inositol, biotin and glutamine, respectively, to be significantly overexpressed in lung adenocarcinomas.
p29215
sg4
(dp29216
(VSLC5A3
p29217
Vadenocarcinomas
p29218
tp29219
I00
ssg21392
(lp29220
(dp29221
g21395
I65
sg21396
Vlung cancer
p29222
sg21398
I11
sg21399
VC0684249
p29223
sg21401
I2
sa(dp29224
g21395
I287
sg21396
g29218
sg21398
I15
sg21399
VC0001418
p29225
sg21401
I1
sasg21404
(lp29226
(dp29227
g21395
I15
sg21396
VTASK-1
p29228
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp29229
g21395
I114
sg21396
VNa+-coupled nutrient transporters
p29230
sg21398
I33
sg21408
g190
sg21401
I3
sa(dp29231
g21395
I157
sg21396
VSLC5A6
p29232
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp29233
g21395
I169
sg21396
VSLC38A1
p29234
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp29235
g21395
I149
sg21396
g29217
sg21398
I6
sg21408
VP53794
p29236
sg21401
I1
sasa(dp29237
g21386
VqPCR analysis showed elevated expression of efflux transporters (P-glycoprotein, multidrug resistant protein 2, breast cancer resistant protein) and influx transporters (folate receptor-Alfa, cationic and neutral amino acid transporter, sodium dependent multivitamin transporter) in a time dependent manner.
p29238
sg4
(dp29239
(VP-glycoprotein
p29240
Vbreast cancer
p29241
tp29242
I00
ssg21392
(lp29243
(dp29244
g21395
I112
sg21396
g29241
sg21398
I13
sg21399
VC0678222
p29245
sg21401
I2
sasg21404
(lp29246
(dp29247
g21395
I237
sg21396
Vsodium dependent multivitamin transporter
p29248
sg21398
I41
sg21408
VP19525
p29249
sg21401
I4
sa(dp29250
g21395
I44
sg21396
Vefflux transporters
p29251
sg21398
I19
sg21408
g190
sg21401
I2
sa(dp29252
g21395
I213
sg21396
Vamino acid transporter
p29253
sg21398
I22
sg21408
g190
sg21401
I3
sa(dp29254
g21395
I65
sg21396
g29240
sg21398
I14
sg21408
VP08183
p29255
sg21401
I1
sasa(dp29256
g21386
VImmunoblot analysis further confirmed elevated expression of breast cancer resistant protein and sodium dependent multivitamin transporter.
p29257
sg4
(dp29258
(Vsodium dependent multivitamin transporter
p29259
Vbreast cancer
p29260
tp29261
I00
ssg21392
(lp29262
(dp29263
g21395
I61
sg21396
g29260
sg21398
I13
sg21399
VC0678222
p29264
sg21401
I2
sasg21404
(lp29265
(dp29266
g21395
I97
sg21396
g29259
sg21398
I41
sg21408
VP19525
p29267
sg21401
I4
sasa(dp29268
g21386
VAll these studies demonstrated for the first time the functional and molecular expression of sodium dependent multivitamin transporter (SMVT), a specific carrier-mediated system for biotin uptake, in human derived breast cancer (T47D) cells.
p29269
sg4
(dp29270
(Vsodium dependent multivitamin transporter
p29271
Vbreast cancer
p29272
tp29273
I00
ssg21392
(lp29274
(dp29275
g21395
I214
sg21396
g29272
sg21398
I13
sg21399
VC0678222
p29276
sg21401
I2
sasg21404
(lp29277
(dp29278
g21395
I93
sg21396
g29271
sg21398
I41
sg21408
VP19525
p29279
sg21401
I4
sa(dp29280
g21395
I136
sg21396
VSMVT
p29281
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp29282
g21386
VThe overall objective of this study was to investigate the differential expression of folate receptor-alpha (FR-Alfa), sodium-dependent multivitamin transporter (SMVT), and amino acid transporter [B ((0, +))] in retinoblastoma (Y-79) and retinal pigment epithelial (ARPE-19) cells.
p29283
sg4
(dp29284
(Vfolate receptor-alpha
p29285
Vretinoblastoma
p29286
tp29287
I00
ssg21392
(lp29288
(dp29289
g21395
I212
sg21396
g29286
sg21398
I14
sg21399
VC0035335
p29290
sg21401
I1
sasg21404
(lp29291
(dp29292
g21395
I86
sg21396
g29285
sg21398
I21
sg21408
VP15328
p29293
sg21401
I2
sa(dp29294
g21395
I162
sg21396
VSMVT
p29295
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp29296
g21395
I119
sg21396
Vsodium-dependent multivitamin transporter
p29297
sg21398
I41
sg21408
g190
sg21401
I3
sasa(dp29298
g21386
VGiven the biologic properties of interleukin-16 and the parallel activation of the interleukin-2/CD25 pathway, interleukin-16 might be involved in the recruitment and stimulation of CD4+ lymphocytes in mycosis fungoides lesions and therefore contribute to the perpetuation of the associated cutaneous inflammation.
p29299
sg4
(dp29300
(VCD25
p29301
Vinflammation
p29302
tp29303
I00
ssg21392
(lp29304
(dp29305
g21395
I202
sg21396
Vmycosis fungoides
p29306
sg21398
I17
sg21399
VC0026948
p29307
sg21401
I2
sa(dp29308
g21395
I151
sg21396
Vrecruitment
p29309
sg21398
I11
sg21399
VC0271510
p29310
sg21401
I1
sa(dp29311
g21395
I301
sg21396
g29302
sg21398
I12
sg21399
VC0021368
p29312
sg21401
I1
sasg21404
(lp29313
(dp29314
g21395
I182
sg21396
VCD4+
p29315
sg21398
I4
sg21408
VP01730
p29316
sg21401
I1
sa(dp29317
g21395
I83
sg21396
Vinterleukin-2
p29318
sg21398
I13
sg21408
VP60568
p29319
sg21401
I1
sa(dp29320
g21395
I33
sg21396
Vinterleukin-16
p29321
sg21398
I14
sg21408
g190
sg21401
I1
sa(dp29322
g21395
I33
sg21396
Vinterleukin-16
p29323
sg21398
I14
sg21408
g190
sg21401
I1
sa(dp29324
g21395
I97
sg21396
g29301
sg21398
I4
sg21408
VP01589
p29325
sg21401
I1
sasa(dp29326
g21386
VThree additional patients with possible parathyroid adenomas at 11C-choline PET/CT were ultimately found to have thyroid lesions on the basis of tissue diagnosis; however, none of these patients had abnormal calcium or parathyroid hormone levels.
p29327
sg4
(dp29328
(Vparathyroid hormone
p29329
Vparathyroid adenomas
p29330
tp29331
I00
ssg21392
(lp29332
(dp29333
g21395
I40
sg21396
g29330
sg21398
I20
sg21399
VC0262587
p29334
sg21401
I2
sasg21404
(lp29335
(dp29336
g21395
I219
sg21396
g29329
sg21398
I19
sg21408
VP01270
p29337
sg21401
I2
sasa(dp29338
g21386
VPatients with primary hyperparathyroidism generally have a single parathyroid adenoma that causes excessive excretion of parathyroid hormone.
p29339
sg4
(dp29340
(Vparathyroid hormone
p29341
Vprimary hyperparathyroidism
p29342
tp29343
I00
ssg21392
(lp29344
(dp29345
g21395
I66
sg21396
Vparathyroid adenoma
p29346
sg21398
I19
sg21399
VC0262587
p29347
sg21401
I2
sa(dp29348
g21395
I14
sg21396
g29342
sg21398
I27
sg21399
VC0221002
p29349
sg21401
I2
sasg21404
(lp29350
(dp29351
g21395
I121
sg21396
g29341
sg21398
I19
sg21408
VP01270
p29352
sg21401
I2
sasa(dp29353
g21386
VAlthough double adenomas are not yet widely acknowledged, presurgical imaging and nuclear scans can help to localize multiple lesions, and intraoperative parathyroid hormone assays can confirm the diagnosis and cure.
p29354
sg4
(dp29355
(Vparathyroid hormone
p29356
Vadenomas
p29357
tp29358
I00
ssg21392
(lp29359
(dp29360
g21395
I16
sg21396
g29357
sg21398
I8
sg21399
VC0001430
p29361
sg21401
I1
sasg21404
(lp29362
(dp29363
g21395
I154
sg21396
g29356
sg21398
I19
sg21408
VP01270
p29364
sg21401
I2
sasa(dp29365
g21386
VFinally, MMGP analysis revealed a positive correlation between the transcript levels of B7-H4 and proliferation-related genes including MKI67, CCNA1, and Myc in several patients with multiple myeloma.
p29366
sg4
(dp29367
(Vproliferation-related genes
p29368
Vmultiple myeloma
p29369
tp29370
I00
ssg21392
(lp29371
(dp29372
g21395
I98
sg21396
Vproliferation
p29373
sg21398
I13
sg21399
VC0334094
p29374
sg21401
I1
sa(dp29375
g21395
I183
sg21396
g29369
sg21398
I16
sg21399
VC0026764
p29376
sg21401
I2
sasg21404
(lp29377
(dp29378
g21395
I154
sg21396
VMyc
p29379
sg21398
I3
sg21408
VP12524
p29380
sg21401
I1
sa(dp29381
g21395
I143
sg21396
VCCNA1
p29382
sg21398
I5
sg21408
VP78396
p29383
sg21401
I1
sa(dp29384
g21395
I88
sg21396
VB7-H4
p29385
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp29386
g21395
I136
sg21396
VMKI67
p29387
sg21398
I5
sg21408
VP46013
p29388
sg21401
I1
sa(dp29389
g21395
I98
sg21396
g29368
sg21398
I27
sg21408
VP01893
p29390
sg21401
I2
sasa(dp29391
g21386
VThe purpose of this study was to evaluate the expression of cyclin A1 mRNA in patients with myelodysplastic syndrome (MDS) and its clinical significance.
p29392
sg4
(dp29393
(Vcyclin A1 mRNA
p29394
VMDS
p29395
tp29396
I00
ssg21392
(lp29397
(dp29398
g21395
I92
sg21396
Vmyelodysplastic syndrome
p29399
sg21398
I24
sg21399
VC3463824
p29400
sg21401
I2
sa(dp29401
g21395
I118
sg21396
g29395
sg21398
I3
sg21399
VC0265219
p29402
sg21401
I1
sasg21404
(lp29403
(dp29404
g21395
I60
sg21396
g29394
sg21398
I14
sg21408
VP78396
p29405
sg21401
I3
sasa(dp29406
g21386
VCyclin A1 mRNA was detectable in 11 of 11 patients with acute myeloid leukemia, three of three patients with acute biphenotypic leukemia, eight of eight patients with myelodysplastic syndrome, 59 of 69 patients with chronic myelogenous leukemia (CML) at diagnosis, 13 of 15 patients with CML in blastic transformation, 10 of 18 patients with chronic lymphocytic leukemia, two of nine patients with essential thrombocythemia, and only two of 10 patients with acute lymphoblastic leukemia (ALL) with both cyclin A1 RT-PCR positive ALL leukemias being undifferentiated relapses.
p29407
sg4
(dp29408
(Vcyclin A1 RT
p29409
Vleukemias
p29410
tp29411
I00
ssg21392
(lp29412
(dp29413
g21395
I488
sg21396
VALL
p29414
sg21398
I3
sg21399
VC1961102
p29415
sg21401
I1
sa(dp29416
g21395
I246
sg21396
VCML
p29417
sg21398
I3
sg21399
VC0023473
p29418
sg21401
I1
sa(dp29419
g21395
I109
sg21396
Vacute biphenotypic leukemia
p29420
sg21398
I27
sg21399
VC0023464
p29421
sg21401
I3
sa(dp29422
g21395
I246
sg21396
VCML
p29423
sg21398
I3
sg21399
VC0023473
p29424
sg21401
I1
sa(dp29425
g21395
I342
sg21396
Vchronic lymphocytic leukemia
p29426
sg21398
I28
sg21399
VC0023434
p29427
sg21401
I3
sa(dp29428
g21395
I56
sg21396
Vacute myeloid leukemia
p29429
sg21398
I22
sg21399
VC0023467
p29430
sg21401
I3
sa(dp29431
g21395
I167
sg21396
Vmyelodysplastic syndrome
p29432
sg21398
I24
sg21399
VC0033027
p29433
sg21401
I2
sa(dp29434
g21395
I398
sg21396
Vessential thrombocythemia
p29435
sg21398
I25
sg21399
VC0040028
p29436
sg21401
I2
sa(dp29437
g21395
I303
sg21396
Vtransformation
p29438
sg21398
I14
sg21399
VC1510411
p29439
sg21401
I1
sa(dp29440
g21395
I216
sg21396
Vchronic myelogenous leukemia
p29441
sg21398
I28
sg21399
VC0023473
p29442
sg21401
I3
sa(dp29443
g21395
I458
sg21396
Vacute lymphoblastic leukemia
p29444
sg21398
I28
sg21399
VC1961102
p29445
sg21401
I3
sa(dp29446
g21395
I488
sg21396
VALL
p29447
sg21398
I3
sg21399
VC1961102
p29448
sg21401
I1
sa(dp29449
g21395
I533
sg21396
g29410
sg21398
I9
sg21399
VC0023418
p29450
sg21401
I1
sasg21404
(lp29451
(dp29452
g21395
I0
sg21396
VCyclin A1 mRNA
p29453
sg21398
I14
sg21408
VP78396
p29454
sg21401
I3
sa(dp29455
g21395
I503
sg21396
g29409
sg21398
I12
sg21408
VP78396
p29456
sg21401
I3
sasa(dp29457
g21386
VMice with ANP showed increased apoptosis of pancreatic acinar cells, pancreatic myeloperoxidase activity, serum lactate dehydrogenase activity, amylase, tumor necrosis factor-Alfa (TNF-Alfa), interleukin-6 (IL-6) levels as well as decreased serum IL-10 level, pancreatic expression of heat shock factor 1 (HSF1), sirtuin 1 (SIRT1) and p53, but the ratio of acetylated HSF1 and p53 was markedly increased.
p29458
sg4
(dp29459
(VIL-6
p29460
Vtumor necrosis
p29461
tp29462
I01
ssg21392
(lp29463
(dp29464
g21395
I153
sg21396
g29461
sg21398
I14
sg21399
VC0333516
p29465
sg21401
I2
sasg21404
(lp29466
(dp29467
g21395
I80
sg21396
Vmyeloperoxidase
p29468
sg21398
I15
sg21408
VP05164
p29469
sg21401
I1
sa(dp29470
g21395
I324
sg21396
VSIRT1
p29471
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp29472
g21395
I335
sg21396
Vp53
p29473
sg21398
I3
sg21408
VP42771
p29474
sg21401
I1
sa(dp29475
g21395
I144
sg21396
Vamylase
p29476
sg21398
I7
sg21408
VP04746
p29477
sg21401
I1
sa(dp29478
g21395
I313
sg21396
Vsirtuin 1
p29479
sg21398
I9
sg21408
g190
sg21401
I2
sa(dp29480
g21395
I306
sg21396
VHSF1
p29481
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp29482
g21395
I153
sg21396
Vtumor necrosis factor-Alfa
p29483
sg21398
I26
sg21408
VP01375
p29484
sg21401
I3
sa(dp29485
g21395
I285
sg21396
Vheat shock factor 1
p29486
sg21398
I19
sg21408
g190
sg21401
I4
sa(dp29487
g21395
I192
sg21396
Vinterleukin-6
p29488
sg21398
I13
sg21408
VP05231
p29489
sg21401
I1
sa(dp29490
g21395
I335
sg21396
Vp53
p29491
sg21398
I3
sg21408
VP42771
p29492
sg21401
I1
sa(dp29493
g21395
I306
sg21396
VHSF1
p29494
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp29495
g21395
I106
sg21396
Vserum lactate dehydrogenase
p29496
sg21398
I27
sg21408
VP49366
p29497
sg21401
I3
sa(dp29498
g21395
I241
sg21396
Vserum IL-10
p29499
sg21398
I11
sg21408
g190
sg21401
I2
sa(dp29500
g21395
I10
sg21396
VANP
p29501
sg21398
I3
sg21408
VP16066
p29502
sg21401
I1
sa(dp29503
g21395
I181
sg21396
VTNF-Alfa
p29504
sg21398
I8
sg21408
VP01375
p29505
sg21401
I1
sa(dp29506
g21395
I207
sg21396
g29460
sg21398
I4
sg21408
VP05231
p29507
sg21401
I1
sasa(dp29508
g21386
VHNRNPL directly regulates the alternative splicing of a set of RNAs, including those encoding the androgen receptor, the key lineage-specific prostate cancer oncogene.
p29509
sg4
(dp29510
(Vandrogen receptor
p29511
Vprostate cancer
p29512
tp29513
I00
ssg21392
(lp29514
(dp29515
g21395
I142
sg21396
g29512
sg21398
I15
sg21399
VC0600139
p29516
sg21401
I2
sasg21404
(lp29517
(dp29518
g21395
I0
sg21396
VHNRNPL
p29519
sg21398
I6
sg21408
VP14866
p29520
sg21401
I1
sa(dp29521
g21395
I98
sg21396
g29511
sg21398
I17
sg21408
VP10275
p29522
sg21401
I2
sasa(dp29523
g21386
VHeterogeneous nuclear ribonucleoprotein L (hnRNP-L) is a promoter of various kinds of cancers, but its actions in bladder cancer (BC) are unclear.
p29524
sg4
(dp29525
(VhnRNP-L
p29526
VBC
p29527
tp29528
I00
ssg21392
(lp29529
(dp29530
g21395
I86
sg21396
Vcancers
p29531
sg21398
I7
sg21399
VC0006826
p29532
sg21401
I1
sa(dp29533
g21395
I114
sg21396
Vbladder cancer
p29534
sg21398
I14
sg21399
VC0699885
p29535
sg21401
I2
sa(dp29536
g21395
I130
sg21396
g29527
sg21398
I2
sg21399
VC0699885
p29537
sg21401
I1
sasg21404
(lp29538
(dp29539
g21395
I0
sg21396
VHeterogeneous nuclear ribonucleoprotein L
p29540
sg21398
I41
sg21408
VP14866
p29541
sg21401
I4
sa(dp29542
g21395
I43
sg21396
g29526
sg21398
I7
sg21408
VP14866
p29543
sg21401
I1
sasa(dp29544
g21386
VIn this study, we examined the role of HnRNP-L in prostate cancer (Pca).
p29545
sg4
(dp29546
(VHnRNP-L in prostate cancer
p29547
VPca
p29548
tp29549
I00
ssg21392
(lp29550
(dp29551
g21395
I50
sg21396
Vprostate cancer
p29552
sg21398
I15
sg21399
VC0600139
p29553
sg21401
I2
sa(dp29554
g21395
I67
sg21396
g29548
sg21398
I3
sg21399
VC0268398
p29555
sg21401
I1
sasg21404
(lp29556
(dp29557
g21395
I39
sg21396
g29547
sg21398
I26
sg21408
VP14866
p29558
sg21401
I4
sa(dp29559
g21395
I67
sg21396
VPca
p29560
sg21398
I3
sg21408
g190
sg21401
I1
sasa(dp29561
g21386
VThis study investigated the presence of CA I and II autoantibodies in patients with iron deficiency anemia (IDA).
p29562
sg4
(dp29563
(VCA I and II autoantibodies
p29564
Viron deficiency anemia
p29565
tp29566
I00
ssg21392
(lp29567
(dp29568
g21395
I108
sg21396
VIDA
p29569
sg21398
I3
sg21399
VC0162316
p29570
sg21401
I1
sa(dp29571
g21395
I84
sg21396
g29565
sg21398
I22
sg21399
VC0162316
p29572
sg21401
I3
sasg21404
(lp29573
(dp29574
g21395
I40
sg21396
g29564
sg21398
I26
sg21408
VP00915
p29575
sg21401
I5
sasa(dp29576
g21386
VCompared with controls, CAIII concentration was lower in iron deficiency anemia (P&lt;0.01), but higher in beta-thalassemia anemia (P&lt;0.001).
p29577
sg4
(dp29578
(VCAIII
p29579
Viron deficiency anemia
p29580
tp29581
I00
ssg21392
(lp29582
(dp29583
g21395
I73
sg21396
Vanemia
p29584
sg21398
I6
sg21399
VC0002871
p29585
sg21401
I1
sa(dp29586
g21395
I107
sg21396
Vbeta-thalassemia
p29587
sg21398
I16
sg21399
VC0005283
p29588
sg21401
I1
sa(dp29589
g21395
I57
sg21396
g29580
sg21398
I22
sg21399
VC0162316
p29590
sg21401
I3
sasg21404
(lp29591
(dp29592
g21395
I24
sg21396
g29579
sg21398
I5
sg21408
VP07451
p29593
sg21401
I1
sasa(dp29594
g21386
VThe levels of erythrocyte carbonic anhydrase isozymes (CA-B and CA-C) were determined by a quantitative immunochemical technique in order to elucidate their clinical significances in patients with iron deficiency anemia.
p29595
sg4
(dp29596
(Verythrocyte carbonic anhydrase isozymes
p29597
Viron deficiency anemia
p29598
tp29599
I00
ssg21392
(lp29600
(dp29601
g21395
I197
sg21396
g29598
sg21398
I22
sg21399
VC0162316
p29602
sg21401
I3
sasg21404
(lp29603
(dp29604
g21395
I14
sg21396
g29597
sg21398
I39
sg21408
VP35218
p29605
sg21401
I4
sasa(dp29606
g21386
VInhibition of inducible T-cell kinase (ITK), a nonreceptor tyrosine kinase, may represent a novel treatment for allergic asthma.
p29607
sg4
(dp29608
(Vinducible T-cell kinase
p29609
Vallergic asthma
p29610
tp29611
I00
ssg21392
(lp29612
(dp29613
g21395
I112
sg21396
g29610
sg21398
I15
sg21399
VC0155877
p29614
sg21401
I2
sasg21404
(lp29615
(dp29616
g21395
I39
sg21396
VITK
p29617
sg21398
I3
sg21408
VP19823
p29618
sg21401
I1
sa(dp29619
g21395
I14
sg21396
g29609
sg21398
I23
sg21408
VP19823
p29620
sg21401
I3
sasa(dp29621
g21386
VHere we show that Itk, a mediator of T cell receptor signalling required for Th2 immune responses and the development of asthma, is a positive regulator of Th9 differentiation.
p29622
sg4
(dp29623
(VItk
p29624
Vasthma
p29625
tp29626
I00
ssg21392
(lp29627
(dp29628
g21395
I121
sg21396
g29625
sg21398
I6
sg21399
VC0004096
p29629
sg21401
I1
sasg21404
(lp29630
(dp29631
g21395
I37
sg21396
VT cell receptor
p29632
sg21398
I15
sg21408
g190
sg21401
I3
sa(dp29633
g21395
I18
sg21396
g29624
sg21398
I3
sg21408
VP19823
p29634
sg21401
I1
sasa(dp29635
g21386
VUnexpectedly, inhibition of the kinase activity of ITK during or after antigen rechallenge in an ovalbumin-induced mouse model of asthma failed to reduce airway hyperresponsiveness and inflammation.
p29636
sg4
(dp29637
(VITK
p29638
Vinflammation
p29639
tp29640
I01
ssg21392
(lp29641
(dp29642
g21395
I130
sg21396
Vasthma
p29643
sg21398
I6
sg21399
VC0004096
p29644
sg21401
I1
sa(dp29645
g21395
I185
sg21396
g29639
sg21398
I12
sg21399
VC0021368
p29646
sg21401
I1
sasg21404
(lp29647
(dp29648
g21395
I51
sg21396
g29638
sg21398
I3
sg21408
VP19823
p29649
sg21401
I1
sasa(dp29650
g21386
VThus, our studies predict that inhibition of the kinase activity of ITK may not be therapeutic in patients with asthma.
p29651
sg4
(dp29652
(VITK
p29653
Vasthma
p29654
tp29655
I00
ssg21392
(lp29656
(dp29657
g21395
I112
sg21396
g29654
sg21398
I6
sg21399
VC0004096
p29658
sg21401
I1
sasg21404
(lp29659
(dp29660
g21395
I68
sg21396
g29653
sg21398
I3
sg21408
VP19823
p29661
sg21401
I1
sasa(dp29662
g21386
VThe medicinal chemistry community has directed considerable efforts toward the discovery of selective inhibitors of interleukin-2 inducible T-cell kinase (ITK), given its role in T-cell signaling downstream of the T-cell receptor (TCR) and the implications of this target for inflammatory disorders such as asthma.
p29663
sg4
(dp29664
(VITK
p29665
Vasthma
p29666
tp29667
I00
ssg21392
(lp29668
(dp29669
g21395
I307
sg21396
g29666
sg21398
I6
sg21399
VC0004096
p29670
sg21401
I1
sasg21404
(lp29671
(dp29672
g21395
I130
sg21396
Vinducible T-cell kinase
p29673
sg21398
I23
sg21408
VP19823
p29674
sg21401
I3
sa(dp29675
g21395
I214
sg21396
VT-cell receptor
p29676
sg21398
I15
sg21408
g190
sg21401
I2
sa(dp29677
g21395
I116
sg21396
Vinterleukin-2
p29678
sg21398
I13
sg21408
VP60568
p29679
sg21401
I1
sa(dp29680
g21395
I231
sg21396
VTCR
p29681
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp29682
g21395
I155
sg21396
g29665
sg21398
I3
sg21408
VP19823
p29683
sg21401
I1
sasa(dp29684
g21386
VThe caspase-3 apoptotic index was a strong risk factor for subsequent gestational trophoblastic neoplasia development.
p29685
sg4
(dp29686
(Vcaspase-3
p29687
Vgestational trophoblastic neoplasia
p29688
tp29689
I00
ssg21392
(lp29690
(dp29691
g21395
I70
sg21396
g29688
sg21398
I35
sg21399
VC1135868
p29692
sg21401
I3
sasg21404
(lp29693
(dp29694
g21395
I4
sg21396
g29687
sg21398
I9
sg21408
VP42574
p29695
sg21401
I1
sasa(dp29696
g21386
VThe two genes were CXCL6 (chemokine (C-X-C motif) ligand 6) and BBS5 (Bardet-Biedl syndrome 5).
p29697
sg4
(dp29698
(V(C-X-C motif) ligand 6
p29699
VBardet-Biedl syndrome
p29700
tp29701
I00
ssg21392
(lp29702
(dp29703
g21395
I70
sg21396
g29700
sg21398
I21
sg21399
VC0752166
p29704
sg21401
I2
sasg21404
(lp29705
(dp29706
g21395
I19
sg21396
VCXCL6
p29707
sg21398
I5
sg21408
VP80162
p29708
sg21401
I1
sa(dp29709
g21395
I64
sg21396
VBBS5
p29710
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp29711
g21395
I70
sg21396
VBardet-Biedl syndrome 5
p29712
sg21398
I23
sg21408
g190
sg21401
I3
sa(dp29713
g21395
I36
sg21396
g29699
sg21398
I22
sg21408
VP80162
p29714
sg21401
I4
sasa(dp29715
g21386
VHowever, aberrant expression of class III Beta-tubulin has been observed in passaged RPE cells and RPE cells with dedifferentiated morphology in pathologic epiretinal membranes from idiopathic macular pucker, proliferative vitreoretinopathy (PVR) and proliferative diabetic retinopathy (PDR).
p29716
sg4
(dp29717
(VBeta-tubulin
p29718
Vepiretinal membranes
p29719
tp29720
I00
ssg21392
(lp29721
(dp29722
g21395
I251
sg21396
Vproliferative diabetic retinopathy
p29723
sg21398
I34
sg21399
VC0154830
p29724
sg21401
I3
sa(dp29725
g21395
I209
sg21396
Vproliferative vitreoretinopathy
p29726
sg21398
I31
sg21399
VC1860404
p29727
sg21401
I2
sa(dp29728
g21395
I242
sg21396
VPVR
p29729
sg21398
I3
sg21399
VC1860404
p29730
sg21401
I1
sa(dp29731
g21395
I287
sg21396
VPDR
p29732
sg21398
I3
sg21399
VC0154830
p29733
sg21401
I1
sa(dp29734
g21395
I156
sg21396
g29719
sg21398
I20
sg21399
VC0339543
p29735
sg21401
I2
sa(dp29736
g21395
I193
sg21396
Vmacular pucker
p29737
sg21398
I14
sg21399
VC0154853
p29738
sg21401
I2
sasg21404
(lp29739
(dp29740
g21395
I42
sg21396
g29718
sg21398
I12
sg21408
VP68371
p29741
sg21401
I1
sasa(dp29742
g21386
VDisorders in the ability ofleukocytes to produce IFN-alpha and IFN-gamma were detected in patients with bronchial asthma and allergic rhinitis.
p29743
sg4
(dp29744
(VIFN-gamma
p29745
Vbronchial asthma
p29746
tp29747
I00
ssg21392
(lp29748
(dp29749
g21395
I125
sg21396
Vallergic rhinitis
p29750
sg21398
I17
sg21399
VC2607914
p29751
sg21401
I2
sa(dp29752
g21395
I104
sg21396
g29746
sg21398
I16
sg21399
VC0004096
p29753
sg21401
I2
sasg21404
(lp29754
(dp29755
g21395
I63
sg21396
g29745
sg21398
I9
sg21408
VP01579
p29756
sg21401
I1
sa(dp29757
g21395
I49
sg21396
VIFN-alpha
p29758
sg21398
I9
sg21408
VP01562
p29759
sg21401
I1
sasa(dp29760
g21386
VFactors underlying the 'exacerbation-prone' phenotype are incompletely understood but include extrinsic factors: cigarette smoking, medication non-compliance, psychosocial factors, and co-morbidities such as gastroesophageal reflux disease, rhinosinusitis, obesity, and intolerance to non-steroidal anti-inflammatory medications; as well as intrinsic factors such as deficient epithelial cell production of the anti-viral type I interferons (IFN-alpha and IFN-beta).
p29761
sg4
(dp29762
(VIFN-beta
p29763
Vrhinosinusitis
p29764
tp29765
I00
ssg21392
(lp29766
(dp29767
g21395
I257
sg21396
Vobesity
p29768
sg21398
I7
sg21399
VC0028754
p29769
sg21401
I1
sa(dp29770
g21395
I208
sg21396
Vgastroesophageal reflux disease
p29771
sg21398
I31
sg21399
VC0017168
p29772
sg21401
I3
sa(dp29773
g21395
I241
sg21396
g29764
sg21398
I14
sg21399
VC0948780
p29774
sg21401
I1
sasg21404
(lp29775
(dp29776
g21395
I411
sg21396
Vanti-viral type I interferons
p29777
sg21398
I29
sg21408
VP29475
p29778
sg21401
I4
sa(dp29779
g21395
I442
sg21396
VIFN-alpha
p29780
sg21398
I9
sg21408
VP01562
p29781
sg21401
I1
sa(dp29782
g21395
I456
sg21396
g29763
sg21398
I8
sg21408
VP01574
p29783
sg21401
I1
sasa(dp29784
g21386
VThese data indicate that therapeutic strategies using SAHPs targeting CD36, but not necessarily mimicking all apolipoprotein A-I functions, may be considered a possible new treatment approach for inflammation-induced ALI and pulmonary edema.
p29785
sg4
(dp29786
(Vapolipoprotein A-I
p29787
Vpulmonary edema
p29788
tp29789
I00
ssg21392
(lp29790
(dp29791
g21395
I196
sg21396
Vinflammation
p29792
sg21398
I12
sg21399
VC0021368
p29793
sg21401
I1
sa(dp29794
g21395
I225
sg21396
g29788
sg21398
I15
sg21399
VC0034063
p29795
sg21401
I2
sasg21404
(lp29796
(dp29797
g21395
I110
sg21396
g29787
sg21398
I18
sg21408
VP02647
p29798
sg21401
I2
sasa(dp29799
g21386
VThe enhanced expression of IL-17 that is observed in patients with Crohn's disease could act on intestinal fibroblasts to induce expression of transcription factor NFKBIZ and proinflammatory chemokine CXCL1.
p29800
sg4
(dp29801
(Vtranscription factor NFKBIZ and proinflammatory chemokine CXCL1
p29802
VCrohn's disease
p29803
tp29804
I00
ssg21392
(lp29805
(dp29806
g21395
I67
sg21396
g29803
sg21398
I15
sg21399
VC0010346
p29807
sg21401
I2
sasg21404
(lp29808
(dp29809
g21395
I143
sg21396
g29802
sg21398
I63
sg21408
VP35398
p29810
sg21401
I7
sasa(dp29811
g21386
VThe morphological similarity and resemblance of keratin 1, 10, and 14 profiles, and p63 and Beta-catenin expression between mixed epidermal and inner root sheath hybrid cysts and keratoacanthomas suggests that hybrid cysts progressed to keratoacanthomas, and the cells from infundibular cells to inner root sheath cells of the pilar segment seem to be the origin of rat keratoacanthomas.
p29812
sg4
(dp29813
(VBeta-catenin
p29814
Vcysts
p29815
tp29816
I00
ssg21392
(lp29817
(dp29818
g21395
I179
sg21396
Vkeratoacanthomas
p29819
sg21398
I16
sg21399
VC0022572
p29820
sg21401
I1
sa(dp29821
g21395
I179
sg21396
Vkeratoacanthomas
p29822
sg21398
I16
sg21399
VC0022572
p29823
sg21401
I1
sa(dp29824
g21395
I169
sg21396
Vcysts
p29825
sg21398
I5
sg21399
VC0010709
p29826
sg21401
I1
sa(dp29827
g21395
I179
sg21396
Vkeratoacanthomas
p29828
sg21398
I16
sg21399
VC0022572
p29829
sg21401
I1
sa(dp29830
g21395
I169
sg21396
g29815
sg21398
I5
sg21399
VC0010709
p29831
sg21401
I1
sasg21404
(lp29832
(dp29833
g21395
I48
sg21396
Vkeratin 1
p29834
sg21398
I9
sg21408
VP04264
p29835
sg21401
I2
sa(dp29836
g21395
I84
sg21396
Vp63
p29837
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp29838
g21395
I92
sg21396
g29814
sg21398
I12
sg21408
VP35222
p29839
sg21401
I1
sasa(dp29840
g21386
VUCDs include a spectrum of enzyme deficiencies, namely n-acetylglutamate synthase deficiency (NAGS), carbamoyl phosphate synthetase I deficiency (CPS1), ornithine transcarbamylase deficiency (OTC), argininosuccinate lyase deficiency (ASL), citrullinemia type I (ASS1), and argininemia (ARG).
p29841
sg4
(dp29842
(Vargininosuccinate lyase
p29843
VOTC
p29844
tp29845
I00
ssg21392
(lp29846
(dp29847
g21395
I153
sg21396
Vornithine transcarbamylase deficiency
p29848
sg21398
I37
sg21399
VC0268542
p29849
sg21401
I3
sa(dp29850
g21395
I286
sg21396
VARG
p29851
sg21398
I3
sg21399
VC0268548
p29852
sg21401
I1
sa(dp29853
g21395
I101
sg21396
Vcarbamoyl phosphate synthetase I deficiency
p29854
sg21398
I43
sg21399
VC0751753
p29855
sg21401
I5
sa(dp29856
g21395
I240
sg21396
Vcitrullinemia
p29857
sg21398
I13
sg21399
VC0175683
p29858
sg21401
I1
sa(dp29859
g21395
I55
sg21396
Vn-acetylglutamate synthase deficiency
p29860
sg21398
I37
sg21399
VC0268543
p29861
sg21401
I3
sa(dp29862
g21395
I234
sg21396
VASL
p29863
sg21398
I3
sg21399
VC0268547
p29864
sg21401
I1
sa(dp29865
g21395
I273
sg21396
Vargininemia
p29866
sg21398
I11
sg21399
VC0268548
p29867
sg21401
I1
sa(dp29868
g21395
I94
sg21396
VNAGS
p29869
sg21398
I4
sg21399
VC0268543
p29870
sg21401
I1
sa(dp29871
g21395
I198
sg21396
Vargininosuccinate lyase deficiency
p29872
sg21398
I34
sg21399
VC0268547
p29873
sg21401
I3
sa(dp29874
g21395
I192
sg21396
g29844
sg21398
I3
sg21399
VC0268542
p29875
sg21401
I1
sasg21404
(lp29876
(dp29877
g21395
I55
sg21396
Vn-acetylglutamate synthase
p29878
sg21398
I26
sg21408
g190
sg21401
I2
sa(dp29879
g21395
I153
sg21396
Vornithine transcarbamylase
p29880
sg21398
I26
sg21408
VP00480
p29881
sg21401
I2
sa(dp29882
g21395
I146
sg21396
VCPS1
p29883
sg21398
I4
sg21408
VP31327
p29884
sg21401
I1
sa(dp29885
g21395
I101
sg21396
Vcarbamoyl phosphate synthetase I
p29886
sg21398
I32
sg21408
VP31327
p29887
sg21401
I4
sa(dp29888
g21395
I262
sg21396
VASS1
p29889
sg21398
I4
sg21408
VP00966
p29890
sg21401
I1
sa(dp29891
g21395
I240
sg21396
Vcitrullinemia type I
p29892
sg21398
I20
sg21408
VP00966
p29893
sg21401
I3
sa(dp29894
g21395
I198
sg21396
g29843
sg21398
I23
sg21408
VP04424
p29895
sg21401
I2
sasa(dp29896
g21386
VArgininosuccinic acid lyase (ASL) deficiency, caused by mutations in the ASL gene (OMIM: 608310) is a urea cycle disorder that has pleiotropic presentations.
p29897
sg4
(dp29898
(VASL
p29899
Vurea cycle disorder
p29900
tp29901
I00
ssg21392
(lp29902
(dp29903
g21395
I102
sg21396
g29900
sg21398
I19
sg21399
VC0154246
p29904
sg21401
I3
sasg21404
(lp29905
(dp29906
g21395
I73
sg21396
VASL gene
p29907
sg21398
I8
sg21408
VP30566
p29908
sg21401
I2
sa(dp29909
g21395
I29
sg21396
g29899
sg21398
I3
sg21408
VP30566
p29910
sg21401
I1
sa(dp29911
g21395
I0
sg21396
VArgininosuccinic acid lyase
p29912
sg21398
I27
sg21408
g190
sg21401
I3
sasa(dp29913
g21386
VThese include N-acetylglutamate synthase deficiency (NAGSD); Carbamyl phosphate synthetase 1 deficiency (CPS1D); Ornithine transcarbamylase deficiency (OTCD); Argininosuccinate synthetase deficiency (ASSD) (Citrullinemia); Argininosuccinate lyase deficiency (ASLD) (Argininosuccinic aciduria); Arginase deficiency (ARGD, Argininemia); Hyperornithinemia, hyperammonemia, homocitrullinuria (HHH) syndrome (or mitochondrial ornithine transporter 1 deficiency [ORNT1D]); and Citrullinemia type II (mitochondrial aspartate/glutamate carrier deficiency [CITRIN]).
p29914
sg4
(dp29915
(VArgininosuccinate synthetase
p29916
VArginase deficiency
p29917
tp29918
I00
ssg21392
(lp29919
(dp29920
g21395
I389
sg21396
VHHH
p29921
sg21398
I3
sg21399
VC0268540
p29922
sg21401
I1
sa(dp29923
g21395
I335
sg21396
VHyperornithinemia
p29924
sg21398
I17
sg21399
VC0599035
p29925
sg21401
I1
sa(dp29926
g21395
I394
sg21396
Vsyndrome
p29927
sg21398
I8
sg21399
VC0039082
p29928
sg21401
I1
sa(dp29929
g21395
I159
sg21396
VArgininosuccinate synthetase deficiency
p29930
sg21398
I39
sg21399
VC0175683
p29931
sg21401
I3
sa(dp29932
g21395
I14
sg21396
VN-acetylglutamate synthase deficiency
p29933
sg21398
I37
sg21399
VC0268543
p29934
sg21401
I3
sa(dp29935
g21395
I315
sg21396
VARGD
p29936
sg21398
I4
sg21399
VC0268548
p29937
sg21401
I1
sa(dp29938
g21395
I223
sg21396
VArgininosuccinate lyase deficiency
p29939
sg21398
I34
sg21399
VC0268547
p29940
sg21401
I3
sa(dp29941
g21395
I207
sg21396
VCitrullinemia
p29942
sg21398
I13
sg21399
VC0175683
p29943
sg21401
I1
sa(dp29944
g21395
I152
sg21396
VOTCD
p29945
sg21398
I4
sg21399
VC0268542
p29946
sg21401
I1
sa(dp29947
g21395
I53
sg21396
VNAGSD
p29948
sg21398
I5
sg21399
VC0268543
p29949
sg21401
I1
sa(dp29950
g21395
I200
sg21396
VASSD
p29951
sg21398
I4
sg21399
VC0175683
p29952
sg21401
I1
sa(dp29953
g21395
I259
sg21396
VASLD
p29954
sg21398
I4
sg21399
VC0268547
p29955
sg21401
I1
sa(dp29956
g21395
I207
sg21396
VCitrullinemia
p29957
sg21398
I13
sg21399
VC0175683
p29958
sg21401
I1
sa(dp29959
g21395
I321
sg21396
VArgininemia
p29960
sg21398
I11
sg21399
VC0268548
p29961
sg21401
I1
sa(dp29962
g21395
I266
sg21396
VArgininosuccinic aciduria
p29963
sg21398
I25
sg21399
VC0268547
p29964
sg21401
I2
sa(dp29965
g21395
I354
sg21396
Vhyperammonemia
p29966
sg21398
I14
sg21399
VC0220994
p29967
sg21401
I1
sa(dp29968
g21395
I113
sg21396
VOrnithine transcarbamylase deficiency
p29969
sg21398
I37
sg21399
VC0268542
p29970
sg21401
I3
sa(dp29971
g21395
I294
sg21396
g29917
sg21398
I19
sg21399
VC0268548
p29972
sg21401
I2
sasg21404
(lp29973
(dp29974
g21395
I407
sg21396
Vmitochondrial ornithine transporter 1
p29975
sg21398
I37
sg21408
g190
sg21401
I4
sa(dp29976
g21395
I61
sg21396
VCarbamyl phosphate synthetase 1
p29977
sg21398
I31
sg21408
g190
sg21401
I4
sa(dp29978
g21395
I223
sg21396
VArgininosuccinate lyase
p29979
sg21398
I23
sg21408
VP04424
p29980
sg21401
I2
sa(dp29981
g21395
I294
sg21396
VArginase
p29982
sg21398
I8
sg21408
VP05089
p29983
sg21401
I1
sa(dp29984
g21395
I113
sg21396
VOrnithine transcarbamylase
p29985
sg21398
I26
sg21408
VP00480
p29986
sg21401
I2
sa(dp29987
g21395
I159
sg21396
g29916
sg21398
I28
sg21408
VP00966
p29988
sg21401
I2
sa(dp29989
g21395
I14
sg21396
VN-acetylglutamate synthase
p29990
sg21398
I26
sg21408
g190
sg21401
I2
sa(dp29991
g21395
I494
sg21396
Vmitochondrial aspartate/glutamate carrier deficiency [CITRIN]
p29992
sg21398
I61
sg21408
g190
sg21401
I5
sasa(dp29993
g21386
VCardiomyopathy [methylmalonic (MMA) and propionic aciduria (PA)], prolonged QTc interval (PA), optic nerve atrophy [MMA, isovaleric aciduria (IVA)], pancytopenia (PA), and macrocephaly [glutaric aciduria type 1 (GA1)] were exclusively found in OAD patients, whereas hepatic involvement was more frequent in UCD patients, in particular in argininosuccinate lyase (ASL) deficiency.
p29994
sg4
(dp29995
(Vargininosuccinate lyase
p29996
VIVA
p29997
tp29998
I00
ssg21392
(lp29999
(dp30000
g21395
I186
sg21396
Vglutaric aciduria type 1
p30001
sg21398
I24
sg21399
VC0268595
p30002
sg21401
I4
sa(dp30003
g21395
I60
sg21396
VPA
p30004
sg21398
I2
sg21399
VC2717876
p30005
sg21401
I1
sa(dp30006
g21395
I149
sg21396
Vpancytopenia
p30007
sg21398
I12
sg21399
VC0030312
p30008
sg21401
I1
sa(dp30009
g21395
I121
sg21396
Visovaleric aciduria
p30010
sg21398
I19
sg21399
VC0268575
p30011
sg21401
I2
sa(dp30012
g21395
I31
sg21396
VMMA
p30013
sg21398
I3
sg21399
VC0276096
p30014
sg21401
I1
sa(dp30015
g21395
I60
sg21396
VPA
p30016
sg21398
I2
sg21399
VC2717876
p30017
sg21401
I1
sa(dp30018
g21395
I0
sg21396
VCardiomyopathy
p30019
sg21398
I14
sg21399
VC0878544
p30020
sg21401
I1
sa(dp30021
g21395
I95
sg21396
Voptic nerve atrophy
p30022
sg21398
I19
sg21399
VC0029124
p30023
sg21401
I3
sa(dp30024
g21395
I40
sg21396
Vpropionic aciduria
p30025
sg21398
I18
sg21399
VC2717876
p30026
sg21401
I2
sa(dp30027
g21395
I60
sg21396
VPA
p30028
sg21398
I2
sg21399
VC2717876
p30029
sg21401
I1
sa(dp30030
g21395
I172
sg21396
Vmacrocephaly
p30031
sg21398
I12
sg21399
VC0221355
p30032
sg21401
I1
sa(dp30033
g21395
I15
sg21396
V[methylmalonic
p30034
sg21398
I14
sg21399
VC0276096
p30035
sg21401
I1
sa(dp30036
g21395
I31
sg21396
VMMA
p30037
sg21398
I3
sg21399
VC0276096
p30038
sg21401
I1
sa(dp30039
g21395
I66
sg21396
Vprolonged QTc interval
p30040
sg21398
I22
sg21399
VC1560305
p30041
sg21401
I3
sa(dp30042
g21395
I142
sg21396
g29997
sg21398
I3
sg21399
VC0268575
p30043
sg21401
I1
sasg21404
(lp30044
(dp30045
g21395
I363
sg21396
VASL
p30046
sg21398
I3
sg21408
VP30566
p30047
sg21401
I1
sa(dp30048
g21395
I338
sg21396
g29996
sg21398
I23
sg21408
VP04424
p30049
sg21401
I2
sasa(dp30050
g21386
VFifteen patients (8 argininosuccinate lyase deficiency, 3 argininosuccinic acid synthetase deficiency, 3 ornithine transcarbamylase deficiency, 1 arginase deficiency) ages 2 months through 5 years enrolled in and completed the study.
p30051
sg4
(dp30052
(V3 ornithine transcarbamylase deficiency, 1 arginase
p30053
Vargininosuccinate lyase deficiency
p30054
tp30055
I00
ssg21392
(lp30056
(dp30057
g21395
I105
sg21396
Vornithine transcarbamylase deficiency
p30058
sg21398
I37
sg21399
VC0268542
p30059
sg21401
I3
sa(dp30060
g21395
I146
sg21396
Varginase deficiency
p30061
sg21398
I19
sg21399
VC0268548
p30062
sg21401
I2
sa(dp30063
g21395
I58
sg21396
Vargininosuccinic acid synthetase deficiency
p30064
sg21398
I43
sg21399
VC0175683
p30065
sg21401
I4
sa(dp30066
g21395
I20
sg21396
g30054
sg21398
I34
sg21399
VC0268547
p30067
sg21401
I3
sasg21404
(lp30068
(dp30069
g21395
I58
sg21396
Vargininosuccinic acid synthetase
p30070
sg21398
I32
sg21408
g190
sg21401
I3
sa(dp30071
g21395
I20
sg21396
Vargininosuccinate lyase
p30072
sg21398
I23
sg21408
VP04424
p30073
sg21401
I2
sa(dp30074
g21395
I103
sg21396
g30053
sg21398
I51
sg21408
VP00480
p30075
sg21401
I6
sasa(dp30076
g21386
VThe 20 genes with at least a 3-fold change, annotated with known phenotypic associations in the current gene databank (phenotype association, fold change) were aspartoacylase (Canavan disease, 9.96), growth hormone receptor (Laron dwarfism, idiopathic short stature, 8.25), lipoprotein lipase (familial chylomicronemia syndrome, lipoprotein lipase deficiency, 8.00), vitamin D (1,25- dihydroxyvitamin D3) receptor (involutional osteoporosis, vitamin D resistant rickets, 7.94), intercellular adhesion molecule 1 human rhinovirus receptor (cerebral malaria susceptibility, 7.16), peroxisomal membrane protein 3 35-kDa (Refsum disease, infantile form, Zellweger syndrome-3, 6.00), Bardet-Biedl syndrome 2 (Bardet-Biedl syndrome, 5.87), ribosomal protein S19 (Diamond Blackfan anemia, 5.85), apolipoprotein C-III (hypertriglyceridemia, 5.44), argininosuccinate lyase (argininosuccinicaciduria, 5.22), myosin VA (Griscelli syndrome-type pigmentary dilution with mental retardation, 4.92), lysozyme (renal amyloidosis, 4.17), SAM domain, SH3 domain and nuclear localisation signals 1 (Cherubism, 4.12 ), von Hippel-Lindau syndrome (hemangioblastoma, cerebellar, somatic, von Hippel-Lindau syndrome, 3.94), early-onset breast cancer 1 (BRCA1, papillary serous carcinoma of the peritoneum, 3.73), UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (inclusion body myopathy, autosomal recessive, sialuria, 3.53), apolipoprotein A-I (amyloidosis, 3 or more types, hypoalphalipoproteinemia, 3.29), midline 1 Opitz/BBB syndrome (Opitz G syndrome, type I, 3.28), ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide (familial hemiplegic migraine, 3.05).
p30077
sg4
(dp30078
(Vaspartoacylase
p30079
VBBB syndrome
p30080
tp30081
I00
ssg21392
(lp30082
(dp30083
g21395
I492
sg21396
Vadhesion
p30084
sg21398
I8
sg21399
VC0001511
p30085
sg21401
I1
sa(dp30086
g21395
I225
sg21396
VLaron dwarfism
p30087
sg21398
I14
sg21399
VC0271568
p30088
sg21401
I2
sa(dp30089
g21395
I1237
sg21396
Vpapillary serous carcinoma
p30090
sg21398
I26
sg21399
VC0334359
p30091
sg21401
I3
sa(dp30092
g21395
I995
sg21396
Vrenal amyloidosis
p30093
sg21398
I17
sg21399
VC0268382
p30094
sg21401
I2
sa(dp30095
g21395
I865
sg21396
Vargininosuccinicaciduria
p30096
sg21398
I24
sg21399
VC0268547
p30097
sg21401
I1
sa(dp30098
g21395
I303
sg21396
Vchylomicronemia syndrome
p30099
sg21398
I24
sg21399
VC1274228
p30100
sg21401
I2
sa(dp30101
g21395
I757
sg21396
VDiamond Blackfan anemia
p30102
sg21398
I23
sg21399
VC1260899
p30103
sg21401
I3
sa(dp30104
g21395
I176
sg21396
VCanavan disease
p30105
sg21398
I15
sg21399
VC0206307
p30106
sg21401
I2
sa(dp30107
g21395
I442
sg21396
Vvitamin D resistant rickets
p30108
sg21398
I27
sg21399
VC2363065
p30109
sg21401
I4
sa(dp30110
g21395
I958
sg21396
Vmental retardation
p30111
sg21398
I18
sg21399
VC0025362
p30112
sg21401
I2
sa(dp30113
g21395
I329
sg21396
Vlipoprotein lipase deficiency
p30114
sg21398
I29
sg21399
VC0023817
p30115
sg21401
I3
sa(dp30116
g21395
I539
sg21396
Vcerebral malaria
p30117
sg21398
I16
sg21399
VC0024534
p30118
sg21401
I2
sa(dp30119
g21395
I679
sg21396
VBardet-Biedl syndrome 2
p30120
sg21398
I23
sg21399
VC2936863
p30121
sg21401
I3
sa(dp30122
g21395
I1099
sg21396
Vvon Hippel-Lindau syndrome
p30123
sg21398
I26
sg21399
VC0019562
p30124
sg21401
I3
sa(dp30125
g21395
I1080
sg21396
VCherubism
p30126
sg21398
I9
sg21399
VC0008029
p30127
sg21401
I1
sa(dp30128
g21395
I1400
sg21396
Vsialuria
p30129
sg21398
I8
sg21399
VC0342853
p30130
sg21401
I1
sa(dp30131
g21395
I241
sg21396
Vidiopathic short stature
p30132
sg21398
I24
sg21399
VC1740819
p30133
sg21401
I3
sa(dp30134
g21395
I1099
sg21396
Vvon Hippel-Lindau syndrome
p30135
sg21398
I26
sg21399
VC0019562
p30136
sg21401
I3
sa(dp30137
g21395
I1213
sg21396
Vbreast cancer
p30138
sg21398
I13
sg21399
VC0678222
p30139
sg21401
I2
sa(dp30140
g21395
I319
sg21396
Vsyndrome
p30141
sg21398
I8
sg21399
VC0039082
p30142
sg21401
I1
sa(dp30143
g21395
I618
sg21396
VRefsum disease, infantile form
p30144
sg21398
I30
sg21399
VC0282527
p30145
sg21401
I4
sa(dp30146
g21395
I1127
sg21396
Vhemangioblastoma
p30147
sg21398
I16
sg21399
VC0206734
p30148
sg21401
I1
sa(dp30149
g21395
I1536
sg21396
VG syndrome
p30150
sg21398
I10
sg21399
VC2936904
p30151
sg21401
I2
sa(dp30152
g21395
I650
sg21396
VZellweger syndrome
p30153
sg21398
I18
sg21399
VC0043459
p30154
sg21401
I2
sa(dp30155
g21395
I1021
sg21396
VSAM
p30156
sg21398
I3
sg21399
VC1563296
p30157
sg21401
I1
sa(dp30158
g21395
I415
sg21396
Vinvolutional osteoporosis
p30159
sg21398
I25
sg21399
VC0029459
p30160
sg21401
I2
sa(dp30161
g21395
I1354
sg21396
Vinclusion body myopathy, autosomal recessive
p30162
sg21398
I44
sg21399
VC1833373
p30163
sg21401
I5
sa(dp30164
g21395
I679
sg21396
VBardet-Biedl syndrome
p30165
sg21398
I21
sg21399
VC0752166
p30166
sg21401
I2
sa(dp30167
g21395
I1617
sg21396
Vfamilial hemiplegic migraine
p30168
sg21398
I28
sg21399
VC0338484
p30169
sg21401
I3
sa(dp30170
g21395
I1001
sg21396
Vamyloidosis
p30171
sg21398
I11
sg21399
VC0002726
p30172
sg21401
I1
sa(dp30173
g21395
I1516
sg21396
g30080
sg21398
I12
sg21399
VC2936904
p30174
sg21401
I2
sasg21404
(lp30175
(dp30176
g21395
I789
sg21396
Vapolipoprotein C-III
p30177
sg21398
I20
sg21408
VP02656
p30178
sg21401
I2
sa(dp30179
g21395
I274
sg21396
Vlipoprotein lipase
p30180
sg21398
I18
sg21408
VP06858
p30181
sg21401
I2
sa(dp30182
g21395
I898
sg21396
Vmyosin VA
p30183
sg21398
I9
sg21408
g190
sg21401
I2
sa(dp30184
g21395
I274
sg21396
Vlipoprotein lipase
p30185
sg21398
I18
sg21408
VP06858
p30186
sg21401
I2
sa(dp30187
g21395
I1201
sg21396
Vearly-onset breast cancer 1
p30188
sg21398
I27
sg21408
VP38398
p30189
sg21401
I4
sa(dp30190
g21395
I865
sg21396
Vargininosuccinicaciduria, 5.22
p30191
sg21398
I30
sg21408
VP04424
p30192
sg21401
I2
sa(dp30193
g21395
I985
sg21396
Vlysozyme
p30194
sg21398
I8
sg21408
VP61626
p30195
sg21401
I1
sa(dp30196
g21395
I1417
sg21396
Vapolipoprotein A-I
p30197
sg21398
I18
sg21408
VP02647
p30198
sg21401
I2
sa(dp30199
g21395
I840
sg21396
Vargininosuccinate lyase
p30200
sg21398
I23
sg21408
VP04424
p30201
sg21401
I2
sa(dp30202
g21395
I200
sg21396
Vgrowth hormone receptor
p30203
sg21398
I23
sg21408
VP10912
p30204
sg21401
I3
sa(dp30205
g21395
I478
sg21396
Vintercellular adhesion molecule 1 human rhinovirus receptor
p30206
sg21398
I59
sg21408
VP05362
p30207
sg21401
I7
sa(dp30208
g21395
I734
sg21396
Vribosomal protein S19
p30209
sg21398
I21
sg21408
VP39019
p30210
sg21401
I3
sa(dp30211
g21395
I1021
sg21396
VSAM domain
p30212
sg21398
I10
sg21408
g190
sg21401
I2
sa(dp30213
g21395
I1230
sg21396
VBRCA1
p30214
sg21398
I5
sg21408
VP38398
p30215
sg21401
I1
sa(dp30216
g21395
I1563
sg21396
VATPase
p30217
sg21398
I6
sg21408
VP38606
p30218
sg21401
I1
sa(dp30219
g21395
I160
sg21396
g30079
sg21398
I14
sg21408
VP45381
p30220
sg21401
I1
sasa(dp30221
g21386
VThirteen families were investigated, of which two were affected by N-acetylglutamate synthase deficiency, four by carbamoylphosphate synthetase 1 deficiency, one by ornithine transcarbamylase deficiency, three by argininosuccinate synthetase deficiency, two by argininosuccinate lyase deficiency, and one by arginase deficiency.
p30222
sg4
(dp30223
(Vornithine transcarbamylase
p30224
Vargininosuccinate lyase deficiency
p30225
tp30226
I00
ssg21392
(lp30227
(dp30228
g21395
I213
sg21396
Vargininosuccinate synthetase deficiency
p30229
sg21398
I39
sg21399
VC0175683
p30230
sg21401
I3
sa(dp30231
g21395
I308
sg21396
Varginase deficiency
p30232
sg21398
I19
sg21399
VC0268548
p30233
sg21401
I2
sa(dp30234
g21395
I165
sg21396
Vornithine transcarbamylase deficiency
p30235
sg21398
I37
sg21399
VC0268542
p30236
sg21401
I3
sa(dp30237
g21395
I67
sg21396
VN-acetylglutamate synthase deficiency
p30238
sg21398
I37
sg21399
VC0268543
p30239
sg21401
I3
sa(dp30240
g21395
I261
sg21396
g30225
sg21398
I34
sg21399
VC0268547
p30241
sg21401
I3
sasg21404
(lp30242
(dp30243
g21395
I67
sg21396
VN-acetylglutamate synthase
p30244
sg21398
I26
sg21408
g190
sg21401
I2
sa(dp30245
g21395
I261
sg21396
Vargininosuccinate lyase
p30246
sg21398
I23
sg21408
VP04424
p30247
sg21401
I2
sa(dp30248
g21395
I213
sg21396
Vargininosuccinate synthetase
p30249
sg21398
I28
sg21408
VP00966
p30250
sg21401
I2
sa(dp30251
g21395
I308
sg21396
Varginase
p30252
sg21398
I8
sg21408
VP05089
p30253
sg21401
I1
sa(dp30254
g21395
I114
sg21396
Vcarbamoylphosphate synthetase 1
p30255
sg21398
I31
sg21408
VP31327
p30256
sg21401
I3
sa(dp30257
g21395
I165
sg21396
g30224
sg21398
I26
sg21408
VP00480
p30258
sg21401
I2
sasa(dp30259
g21386
VIn this study, we examined the relationship between the lactic acid concentration and expression of LDHA and GLUT1, which are related to the Warburg effect, in human head and neck squamous cell carcinoma (HNSCC).
p30260
sg4
(dp30261
(VGLUT1
p30262
Vhead and neck squamous cell carcinoma
p30263
tp30264
I00
ssg21392
(lp30265
(dp30266
g21395
I141
sg21396
VWarburg effect
p30267
sg21398
I14
sg21399
VC1520120
p30268
sg21401
I2
sa(dp30269
g21395
I205
sg21396
VHNSCC
p30270
sg21398
I5
sg21399
VC1168401
p30271
sg21401
I1
sa(dp30272
g21395
I166
sg21396
g30263
sg21398
I37
sg21399
VC1168401
p30273
sg21401
I6
sasg21404
(lp30274
(dp30275
g21395
I100
sg21396
VLDHA
p30276
sg21398
I4
sg21408
VP00338
p30277
sg21401
I1
sa(dp30278
g21395
I109
sg21396
g30262
sg21398
I5
sg21408
VP11166
p30279
sg21401
I1
sasa(dp30280
g21386
VWe found that cetuximab downregulated lactate dehydrogenase A (LDH-A) and inhibited glycolysis in cetuximab-sensitive head and neck squamous cell carcinoma (HNSCC) cells in an HIF-1Alfa downregulation-dependent manner.
p30281
sg4
(dp30282
(VLDH-A
p30283
Vhead and neck squamous cell carcinoma
p30284
tp30285
I01
ssg21392
(lp30286
(dp30287
g21395
I157
sg21396
VHNSCC
p30288
sg21398
I5
sg21399
VC1168401
p30289
sg21401
I1
sa(dp30290
g21395
I118
sg21396
g30284
sg21398
I37
sg21399
VC1168401
p30291
sg21401
I6
sasg21404
(lp30292
(dp30293
g21395
I38
sg21396
Vlactate dehydrogenase A
p30294
sg21398
I23
sg21408
VP49366
p30295
sg21401
I3
sa(dp30296
g21395
I63
sg21396
g30283
sg21398
I5
sg21408
VP00338
p30297
sg21401
I1
sasa(dp30298
g21386
VAn Australian cohort of 252 unrelated familial hypertrophic cardiomyopathy patients were screened for mutations in the Ca(2+) regulatory genes, sorcin (SRI), calstabin (FKBP1B), calsequestrin (CASQ2), phospholamban (PLN), sarcolipin (SLN), calreticulin (CALR3) and calmodulin (CALM).
p30299
sg4
(dp30300
(VCa(2+) regulatory genes
p30301
Vfamilial hypertrophic cardiomyopathy
p30302
tp30303
I00
ssg21392
(lp30304
(dp30305
g21395
I38
sg21396
g30302
sg21398
I36
sg21399
VC0949658
p30306
sg21401
I3
sasg21404
(lp30307
(dp30308
g21395
I277
sg21396
VCALM
p30309
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp30310
g21395
I169
sg21396
VFKBP1B
p30311
sg21398
I6
sg21408
VP68106
p30312
sg21401
I1
sa(dp30313
g21395
I265
sg21396
Vcalmodulin
p30314
sg21398
I10
sg21408
g190
sg21401
I1
sa(dp30315
g21395
I240
sg21396
Vcalreticulin (CALR3)
p30316
sg21398
I20
sg21408
VP27797
p30317
sg21401
I2
sa(dp30318
g21395
I178
sg21396
Vcalsequestrin
p30319
sg21398
I13
sg21408
VP31415
p30320
sg21401
I1
sa(dp30321
g21395
I222
sg21396
Vsarcolipin
p30322
sg21398
I10
sg21408
g190
sg21401
I1
sa(dp30323
g21395
I193
sg21396
VCASQ2
p30324
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp30325
g21395
I234
sg21396
VSLN
p30326
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp30327
g21395
I144
sg21396
Vsorcin (SRI)
p30328
sg21398
I12
sg21408
VP30626
p30329
sg21401
I2
sa(dp30330
g21395
I119
sg21396
g30301
sg21398
I23
sg21408
VP01893
p30331
sg21401
I3
sasa(dp30332
g21386
VThe validated proteins contain the clinically used hepatocellular carcinoma (HCC) biomarker alpha-fetoprotein (AFP) and the reported biomarker candidates Heat shock protein HSP 90-beta (HSP90), fatty acid-binding protein, epidermal (FABP5) and alcohol dehydrogenase 4 (ADH4), which demonstrated the robustness of the strategy.
p30333
sg4
(dp30334
(VHSP90
p30335
VHSP
p30336
tp30337
I00
ssg21392
(lp30338
(dp30339
g21395
I77
sg21396
VHCC
p30340
sg21398
I3
sg21399
VC2239176
p30341
sg21401
I1
sa(dp30342
g21395
I51
sg21396
Vhepatocellular carcinoma
p30343
sg21398
I24
sg21399
VC2239176
p30344
sg21401
I2
sa(dp30345
g21395
I173
sg21396
g30336
sg21398
I3
sg21399
VC0034152
p30346
sg21401
I1
sasg21404
(lp30347
(dp30348
g21395
I269
sg21396
VADH4
p30349
sg21398
I4
sg21408
VP40394
p30350
sg21401
I1
sa(dp30351
g21395
I111
sg21396
VAFP
p30352
sg21398
I3
sg21408
VP02771
p30353
sg21401
I1
sa(dp30354
g21395
I194
sg21396
Vfatty acid-binding protein
p30355
sg21398
I26
sg21408
VP00505
p30356
sg21401
I3
sa(dp30357
g21395
I173
sg21396
VHSP 90-beta
p30358
sg21398
I11
sg21408
g190
sg21401
I2
sa(dp30359
g21395
I222
sg21396
Vepidermal (FABP5) and alcohol dehydrogenase 4
p30360
sg21398
I45
sg21408
VP08319
p30361
sg21401
I6
sa(dp30362
g21395
I92
sg21396
Valpha-fetoprotein
p30363
sg21398
I17
sg21408
VP02771
p30364
sg21401
I1
sa(dp30365
g21395
I186
sg21396
g30335
sg21398
I5
sg21408
VP07900
p30366
sg21401
I1
sasa(dp30367
g21386
VIn vivo, Hsp90Beta promoted VEGFRs and CD31 expression in human hepatocellular carcinoma tumor xenografts and was associated with increased tumor microvessel density.
p30368
sg4
(dp30369
(VHsp90Beta
p30370
Vhepatocellular carcinoma
p30371
tp30372
I00
ssg21392
(lp30373
(dp30374
g21395
I89
sg21396
Vtumor
p30375
sg21398
I5
sg21399
VC0027651
p30376
sg21401
I1
sa(dp30377
g21395
I64
sg21396
g30371
sg21398
I24
sg21399
VC1512411
p30378
sg21401
I2
sa(dp30379
g21395
I89
sg21396
Vtumor
p30380
sg21398
I5
sg21399
VC0027651
p30381
sg21401
I1
sasg21404
(lp30382
(dp30383
g21395
I28
sg21396
VVEGFRs
p30384
sg21398
I6
sg21408
VP35968
p30385
sg21401
I1
sa(dp30386
g21395
I39
sg21396
VCD31
p30387
sg21398
I4
sg21408
VP69905
p30388
sg21401
I1
sa(dp30389
g21395
I9
sg21396
g30370
sg21398
I9
sg21408
VP08238
p30390
sg21401
I1
sasa(dp30391
g21386
VIn this study we report an apparent synergy between TGF-Beta1 and Hsp90Beta in stimulating migratory behaviour of colon cancer cells when signalling occurs via AlfavBeta6 integrin as opposed to the canonical TGF-Beta1 pathway.
p30392
sg4
(dp30393
(VTGF-Beta1 and Hsp90Beta
p30394
Vcolon cancer
p30395
tp30396
I00
ssg21392
(lp30397
(dp30398
g21395
I114
sg21396
g30395
sg21398
I12
sg21399
VC0699790
p30399
sg21401
I2
sasg21404
(lp30400
(dp30401
g21395
I52
sg21396
VTGF-Beta1
p30402
sg21398
I9
sg21408
VP01137
p30403
sg21401
I1
sa(dp30404
g21395
I52
sg21396
g30394
sg21398
I23
sg21408
VP01137
p30405
sg21401
I3
sasa(dp30406
g21386
VOur findings indicate that the C allele of the novel colorectal cancer-associated variant rs2282151 is associated with increased expression levels of HSP90AB1, which is expressed higher in colorectal tumor tissues than in normal tissues.
p30407
sg4
(dp30408
(Vcolorectal cancer-associated variant rs2282151
p30409
Vcolorectal tumor
p30410
tp30411
I00
ssg21392
(lp30412
(dp30413
g21395
I53
sg21396
Vcolorectal cancer
p30414
sg21398
I17
sg21399
VC1527249
p30415
sg21401
I2
sa(dp30416
g21395
I189
sg21396
g30410
sg21398
I16
sg21399
VC0009404
p30417
sg21401
I2
sasg21404
(lp30418
(dp30419
g21395
I150
sg21396
VHSP90AB1
p30420
sg21398
I8
sg21408
VP08238
p30421
sg21401
I1
sa(dp30422
g21395
I53
sg21396
g30409
sg21398
I46
sg21408
VP31749
p30423
sg21401
I4
sasa(dp30424
g21386
VBortezomib induced internalization and degradation of c-KIT by binding c-KIT to Cbl, an E3 ubiquitin-protein ligase, and the subsequent release of Apaf-1, which was originally bound to the c-KIT-Hsp90Beta-Apaf-1 complex, induced primary apoptosis in GIST-T1 cells.
p30425
sg4
(dp30426
(Vc-KIT
p30427
VGIST
p30428
tp30429
I00
ssg21392
(lp30430
(dp30431
g21395
I250
sg21396
g30428
sg21398
I4
sg21399
VC1847319
p30432
sg21401
I1
sasg21404
(lp30433
(dp30434
g21395
I54
sg21396
Vc-KIT
p30435
sg21398
I5
sg21408
VP10721
p30436
sg21401
I1
sa(dp30437
g21395
I189
sg21396
Vc-KIT-Hsp90Beta
p30438
sg21398
I15
sg21408
VP10721
p30439
sg21401
I1
sa(dp30440
g21395
I91
sg21396
Vubiquitin-protein ligase
p30441
sg21398
I24
sg21408
VP49427
p30442
sg21401
I2
sa(dp30443
g21395
I80
sg21396
VCbl
p30444
sg21398
I3
sg21408
VP22681
p30445
sg21401
I1
sa(dp30446
g21395
I54
sg21396
g30427
sg21398
I5
sg21408
VP10721
p30447
sg21401
I1
sasa(dp30448
g21386
VBoth Annexin A1 and HSP90Beta were GlcNAcylated, and their protein expressions were elevated in colon cancer, compared to normal tissues.
p30449
sg4
(dp30450
(VHSP90Beta
p30451
Vcolon cancer
p30452
tp30453
I00
ssg21392
(lp30454
(dp30455
g21395
I96
sg21396
g30452
sg21398
I12
sg21399
VC0699790
p30456
sg21401
I2
sasg21404
(lp30457
(dp30458
g21395
I5
sg21396
VAnnexin A1
p30459
sg21398
I10
sg21408
VP04083
p30460
sg21401
I2
sa(dp30461
g21395
I20
sg21396
g30451
sg21398
I9
sg21408
VP08238
p30462
sg21401
I1
sasa(dp30463
g21386
VMoreover, specific changes of GlcNAc abundances in Annexin A1 and HSP90Beta suggested that tumor-specific glycan patterns could serve as candidate biomarkers of colon cancer for distinguishing cancer patients from healthy individuals.
p30464
sg4
(dp30465
(VAnnexin A1
p30466
Vcolon cancer
p30467
tp30468
I00
ssg21392
(lp30469
(dp30470
g21395
I91
sg21396
Vtumor
p30471
sg21398
I5
sg21399
VC0027651
p30472
sg21401
I1
sa(dp30473
g21395
I167
sg21396
Vcancer
p30474
sg21398
I6
sg21399
VC0006826
p30475
sg21401
I1
sa(dp30476
g21395
I161
sg21396
g30467
sg21398
I12
sg21399
VC0699790
p30477
sg21401
I2
sasg21404
(lp30478
(dp30479
g21395
I66
sg21396
VHSP90Beta
p30480
sg21398
I9
sg21408
VP08238
p30481
sg21401
I1
sa(dp30482
g21395
I51
sg21396
g30466
sg21398
I10
sg21408
VP04083
p30483
sg21401
I2
sasa(dp30484
g21386
VIn addition, the knockdown of PEPCK, which is the rate-limiting enzyme for gluconeogenesis, led to a reduction in glucose production in rat hepatoma H4IIEC3 cells.
p30485
sg4
(dp30486
(VPEPCK
p30487
Vhepatoma
p30488
tp30489
I00
ssg21392
(lp30490
(dp30491
g21395
I140
sg21396
g30488
sg21398
I8
sg21399
VC0023903
p30492
sg21401
I1
sasg21404
(lp30493
(dp30494
g21395
I30
sg21396
g30487
sg21398
I5
sg21408
VP35558
p30495
sg21401
I1
sasa(dp30496
g21386
VWe recently reported expression of the chemokine receptors CXC chemokine receptor 3 (CXCR3) and CC chemokine receptor 4 (CCR4) in adult T-cell leukemia/lymphoma and showed a preferential expression of CCR4 and its association with an unfavorable outcome.
p30497
sg4
(dp30498
(VCCR4
p30499
Vadult T-cell leukemia/lymphoma
p30500
tp30501
I00
ssg21392
(lp30502
(dp30503
g21395
I130
sg21396
g30500
sg21398
I30
sg21399
VC0023493
p30504
sg21401
I3
sasg21404
(lp30505
(dp30506
g21395
I39
sg21396
Vchemokine receptors CXC chemokine receptor 3
p30507
sg21398
I44
sg21408
VP55773
p30508
sg21401
I6
sa(dp30509
g21395
I96
sg21396
VCC chemokine receptor 4
p30510
sg21398
I23
sg21408
g190
sg21401
I4
sa(dp30511
g21395
I121
sg21396
VCCR4
p30512
sg21398
I4
sg21408
VP51679
p30513
sg21401
I1
sa(dp30514
g21395
I85
sg21396
VCXCR3
p30515
sg21398
I5
sg21408
VP49682
p30516
sg21401
I1
sa(dp30517
g21395
I121
sg21396
g30499
sg21398
I4
sg21408
VP51679
p30518
sg21401
I1
sasa(dp30519
g21386
VStaining patterns of MCT1 and TOMM20 in 35 human thyroid samples (15 ATC, 12 papillary thyroid cancer [PTC], and eight non-cancerous thyroid) and nine ATC mouse orthotopic xenografts were assessed by visual and Aperio digital scoring.
p30520
sg4
(dp30521
(VMCT1 and TOMM20
p30522
VPTC
p30523
tp30524
I00
ssg21392
(lp30525
(dp30526
g21395
I77
sg21396
Vpapillary thyroid cancer
p30527
sg21398
I24
sg21399
VC0238463
p30528
sg21401
I3
sa(dp30529
g21395
I103
sg21396
g30523
sg21398
I3
sg21399
VC0238463
p30530
sg21401
I1
sasg21404
(lp30531
(dp30532
g21395
I21
sg21396
g30522
sg21398
I15
sg21408
VP23946
p30533
sg21401
I3
sasa(dp30534
g21386
VATC has metabolic features that distinguish it from PTC and non-cancerous thyroid tissue, including high expression of MCT1 and TOMM20.
p30535
sg4
(dp30536
(VMCT1
p30537
VPTC
p30538
tp30539
I00
ssg21392
(lp30540
(dp30541
g21395
I52
sg21396
g30538
sg21398
I3
sg21399
VC0238463
p30542
sg21401
I1
sasg21404
(lp30543
(dp30544
g21395
I128
sg21396
VTOMM20
p30545
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp30546
g21395
I119
sg21396
g30537
sg21398
I4
sg21408
VP23946
p30547
sg21401
I1
sasa(dp30548
g21386
VPTC has low expression of MCT1 and non-cancerous thyroid tissue has low expression of both MCT1 and TOMM20.
p30549
sg4
(dp30550
(VMCT1
p30551
VPTC
p30552
tp30553
I00
ssg21392
(lp30554
(dp30555
g21395
I0
sg21396
g30552
sg21398
I3
sg21399
VC0238463
p30556
sg21401
I1
sasg21404
(lp30557
(dp30558
g21395
I100
sg21396
VTOMM20
p30559
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp30560
g21395
I26
sg21396
VMCT1
p30561
sg21398
I4
sg21408
VP23946
p30562
sg21401
I1
sa(dp30563
g21395
I26
sg21396
g30551
sg21398
I4
sg21408
VP23946
p30564
sg21401
I1
sa(dp30565
g21395
I0
sg21396
VPTC
p30566
sg21398
I3
sg21408
g190
sg21401
I1
sasa(dp30567
g21386
VFor example in prostate cancer cells, the TRPV2 activation following lysophospholipid or adrenomedullin stimulation enhances the invasiveness of cancer cells; furthermore, the increased malignancy of castration-resistant prostate cancer cells was associated with enhanced TRPV2 expression, mainly in metastatic prostate cancer cells.
p30568
sg4
(dp30569
(Vadrenomedullin
p30570
Vprostate cancer
p30571
tp30572
I00
ssg21392
(lp30573
(dp30574
g21395
I300
sg21396
Vmetastatic prostate cancer
p30575
sg21398
I26
sg21399
VC0936223
p30576
sg21401
I3
sa(dp30577
g21395
I186
sg21396
Vmalignancy
p30578
sg21398
I10
sg21399
VC0006826
p30579
sg21401
I1
sa(dp30580
g21395
I15
sg21396
Vprostate cancer
p30581
sg21398
I15
sg21399
VC0600139
p30582
sg21401
I2
sa(dp30583
g21395
I15
sg21396
g30571
sg21398
I15
sg21399
VC0600139
p30584
sg21401
I2
sa(dp30585
g21395
I24
sg21396
Vcancer
p30586
sg21398
I6
sg21399
VC0006826
p30587
sg21401
I1
sasg21404
(lp30588
(dp30589
g21395
I42
sg21396
VTRPV2
p30590
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp30591
g21395
I42
sg21396
VTRPV2
p30592
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp30593
g21395
I89
sg21396
g30570
sg21398
I14
sg21408
VP35318
p30594
sg21401
I1
sasa(dp30595
g21386
VFurthermore, knockdown of PFTK1 suppressed the expression of Shh as well as Smo, Ptc, and Gli-1 in colon cancer cells.
p30596
sg4
(dp30597
(VGli-1
p30598
VPtc
p30599
tp30600
I00
ssg21392
(lp30601
(dp30602
g21395
I99
sg21396
Vcolon cancer
p30603
sg21398
I12
sg21399
VC0699790
p30604
sg21401
I2
sa(dp30605
g21395
I81
sg21396
g30599
sg21398
I3
sg21399
VC0238463
p30606
sg21401
I1
sasg21404
(lp30607
(dp30608
g21395
I76
sg21396
VSmo
p30609
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp30610
g21395
I61
sg21396
VShh
p30611
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp30612
g21395
I81
sg21396
VPtc
p30613
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp30614
g21395
I90
sg21396
g30598
sg21398
I5
sg21408
VP08151
p30615
sg21401
I1
sasa(dp30616
g21386
VInhibition of MCM6 and MCM7 expression by nTZDpa and rosiglitazone paralleled their effect to inhibit phosphorylation of the retinoblastoma protein and cell proliferation.
p30617
sg4
(dp30618
(VMCM7
p30619
Vretinoblastoma
p30620
tp30621
I00
ssg21392
(lp30622
(dp30623
g21395
I125
sg21396
g30620
sg21398
I14
sg21399
VC0035335
p30624
sg21401
I1
sa(dp30625
g21395
I157
sg21396
Vproliferation
p30626
sg21398
I13
sg21399
VC0334094
p30627
sg21401
I1
sasg21404
(lp30628
(dp30629
g21395
I125
sg21396
Vretinoblastoma protein
p30630
sg21398
I22
sg21408
g190
sg21401
I2
sa(dp30631
g21395
I23
sg21396
g30619
sg21398
I4
sg21408
VP33993
p30632
sg21401
I1
sa(dp30633
g21395
I14
sg21396
VMCM6
p30634
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp30635
g21386
VHer son has type 1 diabetes, arthritis, reduced IgG levels and IgA deficiency, but has not inherited the TNFRSF13B/TACI mutation.
p30636
sg4
(dp30637
(VIgA
p30638
VIgA deficiency
p30639
tp30640
I00
ssg21392
(lp30641
(dp30642
g21395
I29
sg21396
Varthritis
p30643
sg21398
I9
sg21399
VC0003864
p30644
sg21401
I1
sa(dp30645
g21395
I12
sg21396
Vtype 1 diabetes
p30646
sg21398
I15
sg21399
VC0011854
p30647
sg21401
I3
sa(dp30648
g21395
I63
sg21396
g30639
sg21398
I14
sg21399
VC0162538
p30649
sg21401
I2
sasg21404
(lp30650
(dp30651
g21395
I63
sg21396
g30638
sg21398
I3
sg21408
VP11912
p30652
sg21401
I1
sa(dp30653
g21395
I105
sg21396
VTNFRSF13B
p30654
sg21398
I9
sg21408
g190
sg21401
I1
sa(dp30655
g21395
I115
sg21396
VTACI
p30656
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp30657
g21386
VOur results support the hypothesis that increased TACI expression on NOD B cells contributes to the pathogenesis of type 1 diabetes in the NOD mouse.
p30658
sg4
(dp30659
(VNOD B
p30660
VNOD
p30661
tp30662
I00
ssg21392
(lp30663
(dp30664
g21395
I116
sg21396
Vtype 1 diabetes
p30665
sg21398
I15
sg21399
VC0011854
p30666
sg21401
I3
sa(dp30667
g21395
I69
sg21396
VNOD
p30668
sg21398
I3
sg21399
VC0751781
p30669
sg21401
I1
sa(dp30670
g21395
I69
sg21396
g30661
sg21398
I3
sg21399
VC0751781
p30671
sg21401
I1
sa(dp30672
g21395
I100
sg21396
Vpathogenesis
p30673
sg21398
I12
sg21399
VC0699748
p30674
sg21401
I1
sasg21404
(lp30675
(dp30676
g21395
I69
sg21396
g30660
sg21398
I5
sg21408
VP54259
p30677
sg21401
I2
sa(dp30678
g21395
I50
sg21396
VTACI
p30679
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp30680
g21386
VA family member with a wild type TACI variant had CVID-related phenotype including IgA deficiency and type 1 diabetes.
p30681
sg4
(dp30682
(VIgA
p30683
VIgA deficiency
p30684
tp30685
I00
ssg21392
(lp30686
(dp30687
g21395
I102
sg21396
Vtype 1 diabetes
p30688
sg21398
I15
sg21399
VC0011854
p30689
sg21401
I3
sa(dp30690
g21395
I50
sg21396
VCVID
p30691
sg21398
I4
sg21399
VC0009447
p30692
sg21401
I1
sa(dp30693
g21395
I83
sg21396
g30684
sg21398
I14
sg21399
VC0162538
p30694
sg21401
I2
sasg21404
(lp30695
(dp30696
g21395
I50
sg21396
VCVID-related phenotype
p30697
sg21398
I22
sg21408
g190
sg21401
I2
sa(dp30698
g21395
I23
sg21396
Vwild type TACI variant
p30699
sg21398
I22
sg21408
g190
sg21401
I4
sa(dp30700
g21395
I83
sg21396
g30683
sg21398
I3
sg21408
VP11912
p30701
sg21401
I1
sasa(dp30702
g21386
VWe mapped the loci contributing to the increased proportion of TACI(high) expressing splenic B cells and found that the control of TACI expression was strongly linked to chromosome 1, in a region which includes the insulin-dependent diabetes (Idd) 5 loci.
p30703
sg4
(dp30704
(Vinsulin
p30705
VIdd
p30706
tp30707
I00
ssg21392
(lp30708
(dp30709
g21395
I215
sg21396
Vinsulin-dependent diabetes
p30710
sg21398
I26
sg21399
VC0011854
p30711
sg21401
I2
sa(dp30712
g21395
I243
sg21396
g30706
sg21398
I3
sg21399
VC0011854
p30713
sg21401
I1
sasg21404
(lp30714
(dp30715
g21395
I63
sg21396
VTACI
p30716
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp30717
g21395
I215
sg21396
g30705
sg21398
I7
sg21408
VP01308
p30718
sg21401
I1
sasa(dp30719
g21386
VOctamer-binding transcription factor 4 (OCT4) was closely related to pancreatic cancer progression, but its regulation in pancreatic cancer by microRNA (miRNA) is not fully clear.
p30720
sg4
(dp30721
(VOCT4
p30722
Vcancer progression
p30723
tp30724
I01
ssg21392
(lp30725
(dp30726
g21395
I69
sg21396
Vpancreatic cancer
p30727
sg21398
I17
sg21399
VC0235974
p30728
sg21401
I2
sa(dp30729
g21395
I80
sg21396
g30723
sg21398
I18
sg21399
VC0178874
p30730
sg21401
I2
sasg21404
(lp30731
(dp30732
g21395
I0
sg21396
VOctamer-binding transcription factor 4
p30733
sg21398
I38
sg21408
VP15884
p30734
sg21401
I4
sa(dp30735
g21395
I40
sg21396
g30722
sg21398
I4
sg21408
VP15884
p30736
sg21401
I1
sasa(dp30737
g21386
VThis study was designed to investigate the expression of the T-box transcription factor 4 (TBX4), a tumor biomarker that was previously identified by proteomics, in pancreatic ductal adenocarcinoma (PDAC) and evaluate its clinical utility as a potential prognostic biomarkers for PDAC.
p30738
sg4
(dp30739
(VT-box transcription factor 4
p30740
Vpancreatic ductal adenocarcinoma
p30741
tp30742
I00
ssg21392
(lp30743
(dp30744
g21395
I100
sg21396
Vtumor
p30745
sg21398
I5
sg21399
VC0027651
p30746
sg21401
I1
sa(dp30747
g21395
I199
sg21396
VPDAC
p30748
sg21398
I4
sg21399
VC1335302
p30749
sg21401
I1
sa(dp30750
g21395
I199
sg21396
VPDAC
p30751
sg21398
I4
sg21399
VC1335302
p30752
sg21401
I1
sa(dp30753
g21395
I165
sg21396
g30741
sg21398
I32
sg21399
VC1335302
p30754
sg21401
I3
sasg21404
(lp30755
(dp30756
g21395
I91
sg21396
VTBX4
p30757
sg21398
I4
sg21408
VP57082
p30758
sg21401
I1
sa(dp30759
g21395
I61
sg21396
g30740
sg21398
I28
sg21408
VP15884
p30760
sg21401
I4
sasa(dp30761
g21386
VThe major objective of this study is to address this gap in our understanding of how IDO1 expression contributes to the biology of GBM, and whether its level of expression is a determinant of GBM patient outcome.Experimental Design: Patient-resected GBM, The Cancer Genome Atlas, human T-cell:GBM cocultures, as well as nu/nu, NOD-scid, and humanized (NSG-SGM3-BLT) mice-engrafted human GBM form the basis of our investigation.Results:In situ hybridization for IDO1 revealed transcript expression throughout patient-resected GBM, whereas immunohistochemical IDO1 positivity was highly variable.
p30762
sg4
(dp30763
(VIDO1
p30764
VGBM
p30765
tp30766
I00
ssg21392
(lp30767
(dp30768
g21395
I331
sg21396
Vscid
p30769
sg21398
I4
sg21399
VC0085110
p30770
sg21401
I1
sa(dp30771
g21395
I131
sg21396
VGBM
p30772
sg21398
I3
sg21399
VC0017636
p30773
sg21401
I1
sa(dp30774
g21395
I259
sg21396
VCancer
p30775
sg21398
I6
sg21399
VC0006826
p30776
sg21401
I1
sa(dp30777
g21395
I327
sg21396
VNOD
p30778
sg21398
I3
sg21399
VC0751781
p30779
sg21401
I1
sa(dp30780
g21395
I131
sg21396
VGBM
p30781
sg21398
I3
sg21399
VC0017636
p30782
sg21401
I1
sa(dp30783
g21395
I131
sg21396
VGBM
p30784
sg21398
I3
sg21399
VC0017636
p30785
sg21401
I1
sa(dp30786
g21395
I131
sg21396
VGBM
p30787
sg21398
I3
sg21399
VC0017636
p30788
sg21401
I1
sa(dp30789
g21395
I131
sg21396
VGBM
p30790
sg21398
I3
sg21399
VC0017636
p30791
sg21401
I1
sa(dp30792
g21395
I131
sg21396
g30765
sg21398
I3
sg21399
VC0017636
p30793
sg21401
I1
sasg21404
(lp30794
(dp30795
g21395
I85
sg21396
VIDO1
p30796
sg21398
I4
sg21408
VP14902
p30797
sg21401
I1
sa(dp30798
g21395
I85
sg21396
g30764
sg21398
I4
sg21408
VP14902
p30799
sg21401
I1
sasa(dp30800
g21386
VTo test this idea, we infected migrating neural crest cells of chicken embryos with  replication-competent avian sarcoma virus expressing either FgfR2(C278F), a receptor mutation found in Crouzon syndrome or the ligand Fgf8.
p30801
sg4
(dp30802
(VFgf8
p30803
VCrouzon syndrome
p30804
tp30805
I00
ssg21392
(lp30806
(dp30807
g21395
I48
sg21396
Vcrest
p30808
sg21398
I5
sg21399
VC0206138
p30809
sg21401
I1
sa(dp30810
g21395
I188
sg21396
g30804
sg21398
I16
sg21399
VC0010273
p30811
sg21401
I2
sa(dp30812
g21395
I107
sg21396
Vavian sarcoma
p30813
sg21398
I13
sg21399
VC0004426
p30814
sg21401
I2
sasg21404
(lp30815
(dp30816
g21395
I219
sg21396
g30803
sg21398
I4
sg21408
VP55075
p30817
sg21401
I1
sasa(dp30818
g21386
VThese defects are similar in presentation to several human craniofacial disorders (e.g., craniosynostosis, hemifacial microsomia), and may be related to increased levels of bone metabolism observed in ace(ti282a)/fgf8 heterozygotes.
p30819
sg4
(dp30820
(Vfgf8
p30821
Vhemifacial microsomia
p30822
tp30823
I00
ssg21392
(lp30824
(dp30825
g21395
I89
sg21396
Vcraniosynostosis
p30826
sg21398
I16
sg21399
VC0010278
p30827
sg21401
I1
sa(dp30828
g21395
I107
sg21396
g30822
sg21398
I21
sg21399
VC1306710
p30829
sg21401
I2
sasg21404
(lp30830
(dp30831
g21395
I213
sg21396
g30821
sg21398
I4
sg21408
VP55075
p30832
sg21401
I1
sasa(dp30833
g21386
VSince FGF8 maps to the same chromosomal region as FGFR2, has indeed been shown to be a ligand for FGFR2, and has an expression pattern consistent with limb and craniofacial anomalies, we have screened two kindreds with Pfeiffer syndrome that were previously linked to markers from 10q24-25 and a large number of individuals with craniosynostosis and limb anomalies for mutations in the coding sequence of FGF8.
p30834
sg4
(dp30835
(VFGF8
p30836
Vcraniosynostosis
p30837
tp30838
I01
ssg21392
(lp30839
(dp30840
g21395
I329
sg21396
g30837
sg21398
I16
sg21399
VC0010278
p30841
sg21401
I1
sa(dp30842
g21395
I219
sg21396
VPfeiffer syndrome
p30843
sg21398
I17
sg21399
VC0265303
p30844
sg21401
I2
sasg21404
(lp30845
(dp30846
g21395
I6
sg21396
VFGF8
p30847
sg21398
I4
sg21408
VP55075
p30848
sg21401
I1
sa(dp30849
g21395
I6
sg21396
g30836
sg21398
I4
sg21408
VP55075
p30850
sg21401
I1
sasa(dp30851
g21386
VProenkephalin (pro-ENK), a stable and reliable surrogate marker for unstable enkephalins, was found to be associated with acute kidney injury and chronic renal failure in previous studies.
p30852
sg4
(dp30853
(Vpro-ENK
p30854
Vchronic renal failure
p30855
tp30856
I00
ssg21392
(lp30857
(dp30858
g21395
I146
sg21396
g30855
sg21398
I21
sg21399
VC0022661
p30859
sg21401
I3
sasg21404
(lp30860
(dp30861
g21395
I0
sg21396
VProenkephalin
p30862
sg21398
I13
sg21408
VP01210
p30863
sg21401
I1
sa(dp30864
g21395
I15
sg21396
g30854
sg21398
I7
sg21408
VP01210
p30865
sg21401
I1
sasa(dp30866
g21386
VPENK and NGAL concentrations were measured and GFR was estimated by using the isotope dilution mass spectrometry traceable-Modification of Diet in Renal Disease (MDRD) Study and three Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations: CKD-EPI(Cr), CDK-EPI(CysC), and CKD-EPI(Cr-CysC).
p30867
sg4
(dp30868
(VCKD-EPI
p30869
VEPI
p30870
tp30871
I00
ssg21392
(lp30872
(dp30873
g21395
I184
sg21396
VChronic Kidney Disease
p30874
sg21398
I22
sg21399
VC1561643
p30875
sg21401
I3
sa(dp30876
g21395
I239
sg21396
VEPI
p30877
sg21398
I3
sg21399
VC0267963
p30878
sg21401
I1
sa(dp30879
g21395
I147
sg21396
VRenal Disease
p30880
sg21398
I13
sg21399
VC0022658
p30881
sg21401
I2
sa(dp30882
g21395
I239
sg21396
VEPI
p30883
sg21398
I3
sg21399
VC0267963
p30884
sg21401
I1
sa(dp30885
g21395
I239
sg21396
VEPI
p30886
sg21398
I3
sg21399
VC0267963
p30887
sg21401
I1
sa(dp30888
g21395
I239
sg21396
g30870
sg21398
I3
sg21399
VC0267963
p30889
sg21401
I1
sasg21404
(lp30890
(dp30891
g21395
I268
sg21396
VCDK-EPI
p30892
sg21398
I7
sg21408
VP10646
p30893
sg21401
I1
sa(dp30894
g21395
I0
sg21396
VPENK
p30895
sg21398
I4
sg21408
VP01210
p30896
sg21401
I1
sa(dp30897
g21395
I184
sg21396
VChronic Kidney Disease Epidemiology Collaboration
p30898
sg21398
I49
sg21408
VP10646
p30899
sg21401
I5
sa(dp30900
g21395
I9
sg21396
VNGAL
p30901
sg21398
I4
sg21408
VP80188
p30902
sg21401
I1
sa(dp30903
g21395
I295
sg21396
VCr-CysC
p30904
sg21398
I7
sg21408
VP22676
p30905
sg21401
I1
sa(dp30906
g21395
I235
sg21396
g30869
sg21398
I7
sg21408
VP10646
p30907
sg21401
I1
sasa(dp30908
g21386
VProenkephalin cleavage products stored within cells, which included the 5.3-kDa peptide, could be released upon stimulation of cells with BaCl2 (2-fold above basal levels), 8-bromo-cAMP or CRF (7- and 8-fold above basal levels, respectively), and a mixture of BaCl2 and 8-bromo-cAMP (20-fold above basal levels).
p30909
sg4
(dp30910
(VProenkephalin
p30911
VCRF
p30912
tp30913
I00
ssg21392
(lp30914
(dp30915
g21395
I189
sg21396
g30912
sg21398
I3
sg21399
VC0022661
p30916
sg21401
I1
sasg21404
(lp30917
(dp30918
g21395
I0
sg21396
g30911
sg21398
I13
sg21408
VP01210
p30919
sg21401
I1
sasa(dp30920
g21386
VPart 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a summary and outlook.
p30921
sg4
(dp30922
(Vepidermal growth factor-related receptor
p30923
Vcerebellar degeneration
p30924
tp30925
I00
ssg21392
(lp30926
(dp30927
g21395
I227
sg21396
VACA
p30928
sg21398
I3
sg21399
VC0007758
p30929
sg21401
I1
sa(dp30930
g21395
I227
sg21396
VACA
p30931
sg21398
I3
sg21399
VC0007758
p30932
sg21401
I1
sa(dp30933
g21395
I227
sg21396
VACA
p30934
sg21398
I3
sg21399
VC0007758
p30935
sg21401
I1
sa(dp30936
g21395
I197
sg21396
Vautoimmune cerebellar ataxia
p30937
sg21398
I28
sg21399
VC0007758
p30938
sg21401
I3
sa(dp30939
g21395
I543
sg21396
g30924
sg21398
I23
sg21399
VC0262404
p30940
sg21401
I2
sasg21404
(lp30941
(dp30942
g21395
I59
sg21396
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p30943
sg21398
I126
sg21408
g190
sg21401
I12
sa(dp30944
g21395
I527
sg21396
VAP3B2
p30945
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp30946
g21395
I247
sg21396
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p30947
sg21398
I61
sg21408
VP05129
p30948
sg21401
I7
sa(dp30949
g21395
I18
sg21396
Vanti-metabotropic glutamate receptor 1
p30950
sg21398
I38
sg21408
VP42261
p30951
sg21401
I4
sa(dp30952
g21395
I356
sg21396
Vanti-voltage-gated calcium channel-associated ACA
p30953
sg21398
I49
sg21408
g190
sg21401
I4
sa(dp30954
g21395
I476
sg21396
g30923
sg21398
I40
sg21408
VP01133
p30955
sg21401
I4
sasa(dp30956
g21386
VPart 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects, and provides a summary and outlook.
p30957
sg4
(dp30958
(Vepidermal growth factor-related receptor
p30959
Vcerebellar degeneration
p30960
tp30961
I00
ssg21392
(lp30962
(dp30963
g21395
I227
sg21396
VACA
p30964
sg21398
I3
sg21399
VC0007758
p30965
sg21401
I1
sa(dp30966
g21395
I227
sg21396
VACA
p30967
sg21398
I3
sg21399
VC0007758
p30968
sg21401
I1
sa(dp30969
g21395
I227
sg21396
VACA
p30970
sg21398
I3
sg21399
VC0007758
p30971
sg21401
I1
sa(dp30972
g21395
I197
sg21396
Vautoimmune cerebellar ataxia
p30973
sg21398
I28
sg21399
VC0007758
p30974
sg21401
I3
sa(dp30975
g21395
I543
sg21396
g30960
sg21398
I23
sg21399
VC0262404
p30976
sg21401
I2
sasg21404
(lp30977
(dp30978
g21395
I59
sg21396
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p30979
sg21398
I126
sg21408
g190
sg21401
I12
sa(dp30980
g21395
I527
sg21396
VAP3B2
p30981
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp30982
g21395
I247
sg21396
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p30983
sg21398
I61
sg21408
VP05129
p30984
sg21401
I7
sa(dp30985
g21395
I18
sg21396
Vanti-metabotropic glutamate receptor 1
p30986
sg21398
I38
sg21408
VP42261
p30987
sg21401
I4
sa(dp30988
g21395
I356
sg21396
Vanti-voltage-gated calcium channel-associated ACA
p30989
sg21398
I49
sg21408
g190
sg21401
I4
sa(dp30990
g21395
I476
sg21396
g30959
sg21398
I40
sg21408
VP01133
p30991
sg21401
I4
sasa(dp30992
g21386
VPart 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a summary and outlook.
p30993
sg4
(dp30994
(Vepidermal growth factor-related receptor
p30995
Vcerebellar degeneration
p30996
tp30997
I00
ssg21392
(lp30998
(dp30999
g21395
I227
sg21396
VACA
p31000
sg21398
I3
sg21399
VC0007758
p31001
sg21401
I1
sa(dp31002
g21395
I227
sg21396
VACA
p31003
sg21398
I3
sg21399
VC0007758
p31004
sg21401
I1
sa(dp31005
g21395
I227
sg21396
VACA
p31006
sg21398
I3
sg21399
VC0007758
p31007
sg21401
I1
sa(dp31008
g21395
I197
sg21396
Vautoimmune cerebellar ataxia
p31009
sg21398
I28
sg21399
VC0007758
p31010
sg21401
I3
sa(dp31011
g21395
I543
sg21396
g30996
sg21398
I23
sg21399
VC0262404
p31012
sg21401
I2
sasg21404
(lp31013
(dp31014
g21395
I59
sg21396
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p31015
sg21398
I126
sg21408
g190
sg21401
I12
sa(dp31016
g21395
I527
sg21396
VAP3B2
p31017
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp31018
g21395
I247
sg21396
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p31019
sg21398
I61
sg21408
VP05129
p31020
sg21401
I7
sa(dp31021
g21395
I18
sg21396
Vanti-metabotropic glutamate receptor 1
p31022
sg21398
I38
sg21408
VP42261
p31023
sg21401
I4
sa(dp31024
g21395
I356
sg21396
Vanti-voltage-gated calcium channel-associated ACA
p31025
sg21398
I49
sg21408
g190
sg21401
I4
sa(dp31026
g21395
I476
sg21396
g30995
sg21398
I40
sg21408
VP01133
p31027
sg21401
I4
sasa(dp31028
g21386
VLastly, a recent study identified delta/notch-like epidermal growth factor-related receptor (DNER) as the target antigen of Tr antibodies, a marker of cerebellar ataxia and Hodgkin's lymphoma.
p31029
sg4
(dp31030
(Vepidermal growth factor-related receptor
p31031
Vcerebellar ataxia
p31032
tp31033
I00
ssg21392
(lp31034
(dp31035
g21395
I173
sg21396
VHodgkin's lymphoma
p31036
sg21398
I18
sg21399
VC0019829
p31037
sg21401
I2
sa(dp31038
g21395
I151
sg21396
g31032
sg21398
I17
sg21399
VC0007758
p31039
sg21401
I2
sasg21404
(lp31040
(dp31041
g21395
I51
sg21396
g31031
sg21398
I40
sg21408
VP01133
p31042
sg21401
I4
sasa(dp31043
g21386
VInsulin-dependent diabetes mellitus (IDDM) and Graves' disease (GD) are autoimmune endocrinopathies and associated with distinct HLA-DR and -DQ alleles as well as several tumor necrosis factor alpha (TNF-alpha) and beta (TNF-beta) alleles.
p31044
sg4
(dp31045
(VInsulin
p31046
VIDDM
p31047
tp31048
I00
ssg21392
(lp31049
(dp31050
g21395
I64
sg21396
VGD
p31051
sg21398
I2
sg21399
VC0018213
p31052
sg21401
I1
sa(dp31053
g21395
I72
sg21396
Vautoimmune
p31054
sg21398
I10
sg21399
VC0443146
p31055
sg21401
I1
sa(dp31056
g21395
I171
sg21396
Vtumor necrosis
p31057
sg21398
I14
sg21399
VC0333516
p31058
sg21401
I2
sa(dp31059
g21395
I0
sg21396
VInsulin-dependent diabetes mellitus
p31060
sg21398
I35
sg21399
VC0011854
p31061
sg21401
I3
sa(dp31062
g21395
I47
sg21396
VGraves' disease
p31063
sg21398
I15
sg21399
VC0018213
p31064
sg21401
I2
sa(dp31065
g21395
I83
sg21396
Vendocrinopathies
p31066
sg21398
I16
sg21399
VC0014130
p31067
sg21401
I1
sa(dp31068
g21395
I37
sg21396
g31047
sg21398
I4
sg21399
VC0011854
p31069
sg21401
I1
sasg21404
(lp31070
(dp31071
g21395
I129
sg21396
VHLA-DR
p31072
sg21398
I6
sg21408
VP30486
p31073
sg21401
I1
sa(dp31074
g21395
I171
sg21396
Vtumor necrosis factor alpha
p31075
sg21398
I27
sg21408
VP01375
p31076
sg21401
I4
sa(dp31077
g21395
I200
sg21396
VTNF-alpha
p31078
sg21398
I9
sg21408
VP01375
p31079
sg21401
I1
sa(dp31080
g21395
I221
sg21396
VTNF-beta
p31081
sg21398
I8
sg21408
VP01375
p31082
sg21401
I1
sa(dp31083
g21395
I0
sg21396
g31046
sg21398
I7
sg21408
VP01308
p31084
sg21401
I1
sasa(dp31085
g21386
VStudies in Caucasians have suggested that the TNFB gene might be a susceptibility gene for Graves' disease.
p31086
sg4
(dp31087
(VTNFB gene
p31088
VGraves' disease
p31089
tp31090
I00
ssg21392
(lp31091
(dp31092
g21395
I91
sg21396
g31089
sg21398
I15
sg21399
VC0018213
p31093
sg21401
I2
sasg21404
(lp31094
(dp31095
g21395
I46
sg21396
g31088
sg21398
I9
sg21408
VP10515
p31096
sg21401
I2
sasa(dp31097
g21386
VTo investigate further the role of TNFB in predisposition to Graves' disease, we determined whether the TNFB disease associations in the Chinese were similar to those in Caucasians.
p31098
sg4
(dp31099
(VTNFB
p31100
VGraves' disease
p31101
tp31102
I00
ssg21392
(lp31103
(dp31104
g21395
I61
sg21396
g31101
sg21398
I15
sg21399
VC0018213
p31105
sg21401
I2
sasg21404
(lp31106
(dp31107
g21395
I35
sg21396
g31100
sg21398
I4
sg21408
VP10515
p31108
sg21401
I1
sasa(dp31109
g21386
VThe TNFB gene is not a susceptibility gene for Graves' disease.
p31110
sg4
(dp31111
(VTNFB gene
p31112
VGraves' disease
p31113
tp31114
I00
ssg21392
(lp31115
(dp31116
g21395
I47
sg21396
g31113
sg21398
I15
sg21399
VC0018213
p31117
sg21401
I2
sasg21404
(lp31118
(dp31119
g21395
I4
sg21396
g31112
sg21398
I9
sg21408
VP10515
p31120
sg21401
I2
sasa(dp31121
g21386
VWe show here a significant association of TNF beta polymorphisms with Graves' disease.
p31122
sg4
(dp31123
(VTNF beta
p31124
VGraves' disease
p31125
tp31126
I00
ssg21392
(lp31127
(dp31128
g21395
I70
sg21396
g31125
sg21398
I15
sg21399
VC0018213
p31129
sg21401
I2
sasg21404
(lp31130
(dp31131
g21395
I42
sg21396
g31124
sg21398
I8
sg21408
VP01375
p31132
sg21401
I2
sasa(dp31133
g21386
VAlthough TNF beta polymorphisms are linked to A1B8DR3, these results suggest that they represent an additional susceptibility marker in Graves' disease.
p31134
sg4
(dp31135
(VTNF beta
p31136
VGraves' disease
p31137
tp31138
I00
ssg21392
(lp31139
(dp31140
g21395
I136
sg21396
g31137
sg21398
I15
sg21399
VC0018213
p31141
sg21401
I2
sasg21404
(lp31142
(dp31143
g21395
I9
sg21396
g31136
sg21398
I8
sg21408
VP01375
p31144
sg21401
I2
sasa(dp31145
g21386
VHere, we summarize our findings of targeted SOX9 destruction by SCFFBW7 (Skp1/Cul1/F-box) in medulloblastoma and its potential for therapeutic intervention.
p31146
sg4
(dp31147
(VSkp1
p31148
Vmedulloblastoma
p31149
tp31150
I00
ssg21392
(lp31151
(dp31152
g21395
I93
sg21396
g31149
sg21398
I15
sg21399
VC0025149
p31153
sg21401
I1
sasg21404
(lp31154
(dp31155
g21395
I78
sg21396
VCul1
p31156
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp31157
g21395
I44
sg21396
VSOX9 destruction
p31158
sg21398
I16
sg21408
VP48436
p31159
sg21401
I2
sa(dp31160
g21395
I73
sg21396
g31148
sg21398
I4
sg21408
VP63208
p31161
sg21401
I1
sasa(dp31162
g21386
VRather, we observed that, in ADAM23-heterotypic environments, ADAM23-negative cells promote tumor growth and metastasis by enhancing the proliferation and invasion of adjacent A23-positive cells through the production of LGI4 (Leucine-rich Glioma Inactivated 4) and nitric oxide (NO).
p31163
sg4
(dp31164
(VLeucine-rich Glioma Inactivated 4
p31165
Vmetastasis
p31166
tp31167
I00
ssg21392
(lp31168
(dp31169
g21395
I92
sg21396
Vtumor growth
p31170
sg21398
I12
sg21399
VC0598934
p31171
sg21401
I2
sa(dp31172
g21395
I137
sg21396
Vproliferation
p31173
sg21398
I13
sg21399
VC0334094
p31174
sg21401
I1
sa(dp31175
g21395
I155
sg21396
Vinvasion
p31176
sg21398
I8
sg21399
VC2699153
p31177
sg21401
I1
sa(dp31178
g21395
I240
sg21396
VGlioma
p31179
sg21398
I6
sg21399
VC0017638
p31180
sg21401
I1
sa(dp31181
g21395
I109
sg21396
g31166
sg21398
I10
sg21399
VC0027627
p31182
sg21401
I1
sasg21404
(lp31183
(dp31184
g21395
I227
sg21396
g31165
sg21398
I33
sg21408
VP30740
p31185
sg21401
I4
sa(dp31186
g21395
I221
sg21396
VLGI4
p31187
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp31188
g21386
VThe aim of the present study was to evaluate ADAM28 and Insulin Like Growth Factor Binding Protein-3 (IGFBP-3)) gene expression in colorectal carcinoma tissues with regard to the overweight or obese status of the patients using an oligonucleotide microarray technique.
p31189
sg4
(dp31190
(VInsulin Like Growth Factor Binding Protein-3
p31191
Voverweight
p31192
tp31193
I00
ssg21392
(lp31194
(dp31195
g21395
I193
sg21396
Vobese
p31196
sg21398
I5
sg21399
VC0028754
p31197
sg21401
I1
sa(dp31198
g21395
I131
sg21396
Vcolorectal carcinoma
p31199
sg21398
I20
sg21399
VC0009402
p31200
sg21401
I2
sa(dp31201
g21395
I179
sg21396
g31192
sg21398
I10
sg21399
VC0497406
p31202
sg21401
I1
sasg21404
(lp31203
(dp31204
g21395
I102
sg21396
VIGFBP-3
p31205
sg21398
I7
sg21408
VP17936
p31206
sg21401
I1
sa(dp31207
g21395
I45
sg21396
VADAM28
p31208
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp31209
g21395
I56
sg21396
g31191
sg21398
I44
sg21408
VP01308
p31210
sg21401
I6
sasa(dp31211
g21386
VTo describe 2 unrelated families with multiple members demonstrating a less commonly recognized vortex pattern of corneal deposits confirmed to be granular corneal dystrophy type 1 (GCD1) after identification of the p.(Arg555Trp) mutation in the transforming growth factor Beta-induced gene (TGFBI).
p31212
sg4
(dp31213
(Vtransforming growth factor Beta
p31214
Vgranular corneal dystrophy type 1
p31215
tp31216
I00
ssg21392
(lp31217
(dp31218
g21395
I182
sg21396
VGCD1
p31219
sg21398
I4
sg21399
VC1641846
p31220
sg21401
I1
sa(dp31221
g21395
I114
sg21396
Vcorneal deposits
p31222
sg21398
I16
sg21399
VC0162281
p31223
sg21401
I2
sa(dp31224
g21395
I147
sg21396
g31215
sg21398
I33
sg21399
VC1641846
p31225
sg21401
I5
sasg21404
(lp31226
(dp31227
g21395
I246
sg21396
g31214
sg21398
I31
sg21408
VP18075
p31228
sg21401
I4
sasa(dp31229
g21386
VTGFBeta1-induced expression of transforming growth factor Beta-induced protein (TGFBIp) and extracellular matrix (ECM) genes plays a major role in the development of granular corneal dystrophy type 2 (GCD2: also called Avellino corneal dystrophy).
p31230
sg4
(dp31231
(Vtransforming growth factor Beta
p31232
Vgranular corneal dystrophy type 2
p31233
tp31234
I00
ssg21392
(lp31235
(dp31236
g21395
I219
sg21396
VAvellino corneal dystrophy
p31237
sg21398
I26
sg21399
VC1275685
p31238
sg21401
I3
sa(dp31239
g21395
I166
sg21396
g31233
sg21398
I33
sg21399
VC1275685
p31240
sg21401
I5
sasg21404
(lp31241
(dp31242
g21395
I0
sg21396
VTGFBeta1
p31243
sg21398
I8
sg21408
VP01137
p31244
sg21401
I1
sa(dp31245
g21395
I31
sg21396
g31232
sg21398
I31
sg21408
VP18075
p31246
sg21401
I4
sa(dp31247
g21395
I92
sg21396
Vextracellular matrix (ECM) genes
p31248
sg21398
I32
sg21408
g190
sg21401
I4
sasa(dp31249
g21386
VWe show here that the Arg555Trp mutant of the fourth fasciclin 1 (FAS1-4) domain of the protein (TGFBIp/keratoepithelin/Betaig-h3), associated with granular corneal dystrophy type 1, is significantly less susceptible to proteolysis by thermolysin and trypsin than the WT domain.
p31250
sg4
(dp31251
(Vtrypsin
p31252
Vgranular corneal dystrophy
p31253
tp31254
I00
ssg21392
(lp31255
(dp31256
g21395
I32
sg21396
Vmutant
p31257
sg21398
I6
sg21399
VC0596988
p31258
sg21401
I1
sa(dp31259
g21395
I148
sg21396
g31253
sg21398
I26
sg21399
VC0018179
p31260
sg21401
I3
sasg21404
(lp31261
(dp31262
g21395
I66
sg21396
VFAS1-4
p31263
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp31264
g21395
I251
sg21396
g31252
sg21398
I7
sg21408
VP35030
p31265
sg21401
I1
sa(dp31266
g21395
I22
sg21396
VArg555Trp mutant
p31267
sg21398
I16
sg21408
g190
sg21401
I2
sasa(dp31268
g21386
VStem cell-related proteins such as c-MYC, NANOG, OCT4, and KLF4 and signaling pathways such as Wnt signaling were suppressed by restoration of miR-139-5p in bladder cancer cells.
p31269
sg4
(dp31270
(VStem cell-related proteins
p31271
Vbladder cancer
p31272
tp31273
I00
ssg21392
(lp31274
(dp31275
g21395
I157
sg21396
g31272
sg21398
I14
sg21399
VC0699885
p31276
sg21401
I2
sasg21404
(lp31277
(dp31278
g21395
I143
sg21396
VmiR-139-5p
p31279
sg21398
I10
sg21408
g190
sg21401
I1
sa(dp31280
g21395
I42
sg21396
VNANOG
p31281
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp31282
g21395
I35
sg21396
Vc-MYC
p31283
sg21398
I5
sg21408
VP12524
p31284
sg21401
I1
sa(dp31285
g21395
I59
sg21396
VKLF4
p31286
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp31287
g21395
I0
sg21396
g31271
sg21398
I26
sg21408
VP02649
p31288
sg21401
I3
sasa(dp31289
g21386
VGenetic association of rs678849 along with neuroimaging and biomarker phenotypes, parallel with the known involvements of the OPRD1 in drug abuse, provided additional support for targeting these receptors as potential therapeutic targets in both neurodegenerative diseases and neuropsychiactric disorders such as Alzheimer's disease.
p31290
sg4
(dp31291
(VOPRD1
p31292
Vdrug abuse
p31293
tp31294
I00
ssg21392
(lp31295
(dp31296
g21395
I313
sg21396
VAlzheimer's disease
p31297
sg21398
I19
sg21399
VC1521724
p31298
sg21401
I2
sa(dp31299
g21395
I246
sg21396
Vneurodegenerative diseases
p31300
sg21398
I26
sg21399
VC0524851
p31301
sg21401
I2
sa(dp31302
g21395
I135
sg21396
g31293
sg21398
I10
sg21399
VC0013146
p31303
sg21401
I2
sasg21404
(lp31304
(dp31305
g21395
I126
sg21396
g31292
sg21398
I5
sg21408
VP41143
p31306
sg21401
I1
sasa(dp31307
g21386
VTen genes of importance for HNK-1 biosynthesis (B3GAT1, B3GAT2, and CHST10) or for the formation of perineuronal nets (TNR, BCAN, NCAN, HAPLN1, HAPLN2, HAPLN3, and HAPLN4) were investigated for potential involvement in schizophrenia (SCZ) susceptibility, by genotyping 104 tagSNPs in the Scandinavian Collaboration on Psychiatric Etiology sample (849 cases; 1602 control subjects).
p31308
sg4
(dp31309
(VHAPLN1
p31310
Vschizophrenia
p31311
tp31312
I00
ssg21392
(lp31313
(dp31314
g21395
I234
sg21396
VSCZ
p31315
sg21398
I3
sg21399
VC0036341
p31316
sg21401
I1
sa(dp31317
g21395
I219
sg21396
g31311
sg21398
I13
sg21399
VC0036341
p31318
sg21401
I1
sasg21404
(lp31319
(dp31320
g21395
I144
sg21396
VHAPLN2
p31321
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp31322
g21395
I28
sg21396
VHNK-1
p31323
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp31324
g21395
I119
sg21396
VTNR
p31325
sg21398
I3
sg21408
g190
sg21401
I1
sa(dp31326
g21395
I83
sg21396
Vthe formation of perineuronal nets
p31327
sg21398
I34
sg21408
g190
sg21401
I5
sa(dp31328
g21395
I130
sg21396
VNCAN
p31329
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp31330
g21395
I136
sg21396
g31310
sg21398
I6
sg21408
VP10915
p31331
sg21401
I1
sa(dp31332
g21395
I124
sg21396
VBCAN
p31333
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp31334
g21395
I152
sg21396
VHAPLN3
p31335
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp31336
g21395
I48
sg21396
VB3GAT1
p31337
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp31338
g21395
I68
sg21396
VCHST10
p31339
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp31340
g21395
I56
sg21396
VB3GAT2
p31341
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp31342
g21395
I164
sg21396
VHAPLN4
p31343
sg21398
I6
sg21408
g190
sg21401
I1
sasa(dp31344
g21386
VWe show that CHST10 is also regulated by RARgamma in a significant subset of human melanoma cells, and three-dimensional cell culture migration assays suggest that CHST10 functions as a suppressor of invasiveness, but not proliferation, in these cells.
p31345
sg4
(dp31346
(VRARgamma
p31347
Vmelanoma
p31348
tp31349
I00
ssg21392
(lp31350
(dp31351
g21395
I83
sg21396
g31348
sg21398
I8
sg21399
VC0025202
p31352
sg21401
I1
sa(dp31353
g21395
I222
sg21396
Vproliferation
p31354
sg21398
I13
sg21399
VC0334094
p31355
sg21401
I1
sasg21404
(lp31356
(dp31357
g21395
I41
sg21396
g31347
sg21398
I8
sg21408
VP13631
p31358
sg21401
I1
sa(dp31359
g21395
I13
sg21396
VCHST10
p31360
sg21398
I6
sg21408
g190
sg21401
I1
sa(dp31361
g21395
I13
sg21396
VCHST10
p31362
sg21398
I6
sg21408
g190
sg21401
I1
sasa(dp31363
g21386
VInduction of CHST10 by RARgamma-activating retinoids may present a novel therapeutic strategy to inhibit invasiveness in a subset of melanoma patients.
p31364
sg4
(dp31365
(VRARgamma
p31366
Vmelanoma
p31367
tp31368
I00
ssg21392
(lp31369
(dp31370
g21395
I133
sg21396
g31367
sg21398
I8
sg21399
VC0025202
p31371
sg21401
I1
sasg21404
(lp31372
(dp31373
g21395
I23
sg21396
g31366
sg21398
I8
sg21408
VP13631
p31374
sg21401
I1
sa(dp31375
g21395
I13
sg21396
VCHST10
p31376
sg21398
I6
sg21408
g190
sg21401
I1
sasa(dp31377
g21386
VThrombospondin-1 (TSP1) is a ligand for CD47 and TSP1-/- mice are protected from pulmonary hypertension (PH).
p31378
sg4
(dp31379
(VThrombospondin-1
p31380
Vpulmonary hypertension
p31381
tp31382
I00
ssg21392
(lp31383
(dp31384
g21395
I105
sg21396
VPH
p31385
sg21398
I2
sg21399
VC0020542
p31386
sg21401
I1
sa(dp31387
g21395
I81
sg21396
g31381
sg21398
I22
sg21399
VC0020542
p31388
sg21401
I2
sasg21404
(lp31389
(dp31390
g21395
I18
sg21396
VTSP1
p31391
sg21398
I4
sg21408
VP07996
p31392
sg21401
I1
sa(dp31393
g21395
I18
sg21396
VTSP1
p31394
sg21398
I4
sg21408
VP07996
p31395
sg21401
I1
sa(dp31396
g21395
I0
sg21396
g31380
sg21398
I16
sg21408
VP07996
p31397
sg21401
I1
sa(dp31398
g21395
I40
sg21396
VCD47
p31399
sg21398
I4
sg21408
g190
sg21401
I1
sasa(dp31400
g21386
VIn addition, variations in JAG1 have been found to be associated with multiple types of cancer including breast cancer and adrenocortical carcinoma.
p31401
sg4
(dp31402
(VJAG1
p31403
Vadrenocortical carcinoma
p31404
tp31405
I01
ssg21392
(lp31406
(dp31407
g21395
I105
sg21396
Vbreast cancer
p31408
sg21398
I13
sg21399
VC0678222
p31409
sg21401
I2
sa(dp31410
g21395
I88
sg21396
Vcancer
p31411
sg21398
I6
sg21399
VC0006826
p31412
sg21401
I1
sa(dp31413
g21395
I123
sg21396
g31404
sg21398
I24
sg21399
VC0206686
p31414
sg21401
I2
sasg21404
(lp31415
(dp31416
g21395
I27
sg21396
g31403
sg21398
I4
sg21408
VP78504
p31417
sg21401
I1
sasa(dp31418
g21386
VOn day 25, pulmonary eosinophilia, airway hyperresponsiveness, mucus hypersecretion, inflammatory cytokines such as IL-4, -5 and -13 in BAL fluid, gene expression of inflammatory mediators such as 5-LOX, E-selectin, VCAM-1, CCL5, TNF-Alfa, AMCase, Ym2, YKL-40, Muc5ac, CCL2 and iNOS in animal lung tissues, and serum IgE were determined.
p31419
sg4
(dp31420
(VYKL-40
p31421
Vpulmonary eosinophilia
p31422
tp31423
I00
ssg21392
(lp31424
(dp31425
g21395
I317
sg21396
VIgE
p31426
sg21398
I3
sg21399
VC0270850
p31427
sg21401
I1
sa(dp31428
g21395
I11
sg21396
g31422
sg21398
I22
sg21399
VC0034068
p31429
sg21401
I2
sasg21404
(lp31430
(dp31431
g21395
I278
sg21396
ViNOS
p31432
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp31433
g21395
I269
sg21396
VCCL2
p31434
sg21398
I4
sg21408
VP13500
p31435
sg21401
I1
sa(dp31436
g21395
I224
sg21396
VCCL5
p31437
sg21398
I4
sg21408
VP13501
p31438
sg21401
I1
sa(dp31439
g21395
I311
sg21396
Vserum IgE
p31440
sg21398
I9
sg21408
VP01854
p31441
sg21401
I2
sa(dp31442
g21395
I204
sg21396
VE-selectin
p31443
sg21398
I10
sg21408
VP16581
p31444
sg21401
I1
sa(dp31445
g21395
I230
sg21396
VTNF-Alfa
p31446
sg21398
I8
sg21408
VP01375
p31447
sg21401
I1
sa(dp31448
g21395
I197
sg21396
V5-LOX
p31449
sg21398
I5
sg21408
VP09917
p31450
sg21401
I1
sa(dp31451
g21395
I116
sg21396
VIL-4
p31452
sg21398
I4
sg21408
VP05112
p31453
sg21401
I1
sa(dp31454
g21395
I216
sg21396
VVCAM-1
p31455
sg21398
I6
sg21408
VP19320
p31456
sg21401
I1
sa(dp31457
g21395
I253
sg21396
g31421
sg21398
I6
sg21408
VP36222
p31458
sg21401
I1
sasa(dp31459
g21386
VOur results show that tropical pulmonary eosinophilia mice exhibited increased levels of IL-4, IL-5, CCL5, and CCL11 in the bronchoalveolar lavage fluid and lung parenchyma along with elevated titers of IgE and IgG subtypes in the serum.
p31460
sg4
(dp31461
(VCCL5
p31462
Vtropical pulmonary eosinophilia
p31463
tp31464
I00
ssg21392
(lp31465
(dp31466
g21395
I203
sg21396
VIgE
p31467
sg21398
I3
sg21399
VC0270850
p31468
sg21401
I1
sa(dp31469
g21395
I22
sg21396
g31463
sg21398
I31
sg21399
VC0014458
p31470
sg21401
I3
sasg21404
(lp31471
(dp31472
g21395
I95
sg21396
VIL-5
p31473
sg21398
I4
sg21408
VP05113
p31474
sg21401
I1
sa(dp31475
g21395
I203
sg21396
VIgE
p31476
sg21398
I3
sg21408
VP01854
p31477
sg21401
I1
sa(dp31478
g21395
I111
sg21396
VCCL11
p31479
sg21398
I5
sg21408
VP51671
p31480
sg21401
I1
sa(dp31481
g21395
I89
sg21396
VIL-4
p31482
sg21398
I4
sg21408
VP05112
p31483
sg21401
I1
sa(dp31484
g21395
I101
sg21396
g31462
sg21398
I4
sg21408
VP13501
p31485
sg21401
I1
sasa(dp31486
g21386
VA(2B) R deficiency resulted in a dramatic reduction on Th2-type airways responses with decreased pulmonary eosinophilia without augmenting neutrophilia, and decreased lung IL-4, IL-5, and IL-13 production.
p31487
sg4
(dp31488
(VIL-5
p31489
Vpulmonary eosinophilia
p31490
tp31491
I00
ssg21392
(lp31492
(dp31493
g21395
I97
sg21396
g31490
sg21398
I22
sg21399
VC0034068
p31494
sg21401
I2
sasg21404
(lp31495
(dp31496
g21395
I188
sg21396
VIL-13
p31497
sg21398
I5
sg21408
VP35225
p31498
sg21401
I1
sa(dp31499
g21395
I167
sg21396
Vlung IL-4
p31500
sg21398
I9
sg21408
VP05112
p31501
sg21401
I2
sa(dp31502
g21395
I178
sg21396
g31489
sg21398
I4
sg21408
VP05113
p31503
sg21401
I1
sasa(dp31504
g21386
VBoth isoforms caused pulmonary infiltration of lymphocytes and neutrophils, whereas mm IL-33 also caused pulmonary eosinophilia and goblet cell hyperplasia and increased expression of IL-4, IL-5, IL-13, IL-17, MCP-1, and KC.
p31505
sg4
(dp31506
(VIL-13
p31507
Vpulmonary eosinophilia
p31508
tp31509
I00
ssg21392
(lp31510
(dp31511
g21395
I21
sg21396
Vpulmonary infiltration
p31512
sg21398
I22
sg21399
VC0235896
p31513
sg21401
I2
sa(dp31514
g21395
I144
sg21396
Vhyperplasia
p31515
sg21398
I11
sg21399
VC0020507
p31516
sg21401
I1
sa(dp31517
g21395
I105
sg21396
g31508
sg21398
I22
sg21399
VC0034068
p31518
sg21401
I2
sasg21404
(lp31519
(dp31520
g21395
I190
sg21396
VIL-5
p31521
sg21398
I4
sg21408
VP05113
p31522
sg21401
I1
sa(dp31523
g21395
I184
sg21396
VIL-4
p31524
sg21398
I4
sg21408
VP05112
p31525
sg21401
I1
sa(dp31526
g21395
I210
sg21396
VMCP-1
p31527
sg21398
I5
sg21408
VP41597
p31528
sg21401
I1
sa(dp31529
g21395
I196
sg21396
g31507
sg21398
I5
sg21408
VP35225
p31530
sg21401
I1
sasa(dp31531
g21386
VGermline deficiency of the cell surface receptor chain ST2 abrogated the mm IL-33-induced Th2-associated effects (pulmonary eosinophilia, goblet cell hyperplasia, and increased IL-4 and IL-5), yet the lymphocytic infiltration induced by full-length mouse IL-33 or mm IL-33 was not fully abrogated by the absence of ST2.
p31532
sg4
(dp31533
(VIL-5
p31534
Vhyperplasia
p31535
tp31536
I00
ssg21392
(lp31537
(dp31538
g21395
I114
sg21396
Vpulmonary eosinophilia
p31539
sg21398
I22
sg21399
VC0034068
p31540
sg21401
I2
sa(dp31541
g21395
I201
sg21396
Vlymphocytic infiltration
p31542
sg21398
I24
sg21399
VC1262091
p31543
sg21401
I2
sa(dp31544
g21395
I150
sg21396
g31535
sg21398
I11
sg21399
VC0020507
p31545
sg21401
I1
sasg21404
(lp31546
(dp31547
g21395
I177
sg21396
VIL-4
p31548
sg21398
I4
sg21408
VP05112
p31549
sg21401
I1
sa(dp31550
g21395
I237
sg21396
Vfull-length mouse IL-33
p31551
sg21398
I23
sg21408
g190
sg21401
I3
sa(dp31552
g21395
I186
sg21396
g31534
sg21398
I4
sg21408
VP05113
p31553
sg21401
I1
sasa(dp31554
g21386
VOVA-challenged STAT6-/- mice had neither AHR nor pulmonary eosinophilia, but had increased expression of mRNA for TNF-Alfa, IFN-Gamma and IL-4.
p31555
sg4
(dp31556
(VSTAT6
p31557
Vpulmonary eosinophilia
p31558
tp31559
I00
ssg21392
(lp31560
(dp31561
g21395
I49
sg21396
g31558
sg21398
I22
sg21399
VC0034068
p31562
sg21401
I2
sasg21404
(lp31563
(dp31564
g21395
I138
sg21396
VIL-4
p31565
sg21398
I4
sg21408
VP05112
p31566
sg21401
I1
sa(dp31567
g21395
I114
sg21396
VTNF
p31568
sg21398
I3
sg21408
VP01375
p31569
sg21401
I1
sa(dp31570
g21395
I124
sg21396
VIFN-Gamma
p31571
sg21398
I9
sg21408
VP01579
p31572
sg21401
I1
sa(dp31573
g21395
I41
sg21396
VAHR
p31574
sg21398
I3
sg21408
VP35869
p31575
sg21401
I1
sa(dp31576
g21395
I15
sg21396
g31557
sg21398
I5
sg21408
VP42226
p31577
sg21401
I1
sasa(dp31578
g21386
VIn a model of tubulointerstitial fibrosis induced by unilateral ureteral obstruction in mice, increased collagen I protein content and an almost complete disappearance of erythropoietin mRNA expression were observed in the ureteral ligated kidney with respect to the contralateral control.
p31579
sg4
(dp31580
(Vcollagen I protein
p31581
Vureteral obstruction
p31582
tp31583
I00
ssg21392
(lp31584
(dp31585
g21395
I33
sg21396
Vfibrosis
p31586
sg21398
I8
sg21399
VC0016059
p31587
sg21401
I1
sa(dp31588
g21395
I64
sg21396
g31582
sg21398
I20
sg21399
VC0041956
p31589
sg21401
I2
sasg21404
(lp31590
(dp31591
g21395
I171
sg21396
Verythropoietin mRNA
p31592
sg21398
I19
sg21408
VP01588
p31593
sg21401
I2
sa(dp31594
g21395
I104
sg21396
g31581
sg21398
I18
sg21408
VP42768
p31595
sg21401
I3
sasa(dp31596
g21386
VIn the present study, employing a mouse model of renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction (UUO), we demonstrated that EPO markedly reduced the disruption of the tubular basement membrane (TBM) through attenuating the activation of tissue plasminogen activator (tPA) and matrix metalloproteinase 9 (MMP9), the major matrix proteolytic network in the obstructed kidney.
p31597
sg4
(dp31598
(VMMP9
p31599
Vureteral obstruction
p31600
tp31601
I00
ssg21392
(lp31602
(dp31603
g21395
I127
sg21396
VUUO
p31604
sg21398
I3
sg21399
VC0041956
p31605
sg21401
I1
sa(dp31606
g21395
I74
sg21396
Vfibrosis
p31607
sg21398
I8
sg21399
VC0016059
p31608
sg21401
I1
sa(dp31609
g21395
I105
sg21396
g31600
sg21398
I20
sg21399
VC0041956
p31610
sg21401
I2
sasg21404
(lp31611
(dp31612
g21395
I297
sg21396
VtPA
p31613
sg21398
I3
sg21408
VP00747
p31614
sg21401
I1
sa(dp31615
g21395
I306
sg21396
Vmatrix metalloproteinase 9
p31616
sg21398
I26
sg21408
VP14780
p31617
sg21401
I3
sa(dp31618
g21395
I154
sg21396
VEPO
p31619
sg21398
I3
sg21408
VP01588
p31620
sg21401
I1
sa(dp31621
g21395
I267
sg21396
Vtissue plasminogen activator
p31622
sg21398
I28
sg21408
VP00747
p31623
sg21401
I3
sa(dp31624
g21395
I334
sg21396
g31599
sg21398
I4
sg21408
VP14780
p31625
sg21401
I1
sasa(dp31626
g21386
VThe MVs derived from untreated MSCs (MSC-MVs) or from MSCs incubated in different concentrations of EPO (1, 10, 100, and 500 IU/ml EPO-MVs) were used to treat renal injury of unilateral ureteral obstruction (UUO) in vivo, and transforming growth factor-Beta1 (TGF-Beta1)-induced fibrosis in a human renal proximal tubular epithelial (HK2) cell line in vitro.
p31627
sg4
(dp31628
(VTGF-Beta1
p31629
Vfibrosis
p31630
tp31631
I00
ssg21392
(lp31632
(dp31633
g21395
I208
sg21396
VUUO
p31634
sg21398
I3
sg21399
VC0041956
p31635
sg21401
I1
sa(dp31636
g21395
I186
sg21396
Vureteral obstruction
p31637
sg21398
I20
sg21399
VC0041956
p31638
sg21401
I2
sa(dp31639
g21395
I279
sg21396
g31630
sg21398
I8
sg21399
VC0016059
p31640
sg21401
I1
sasg21404
(lp31641
(dp31642
g21395
I100
sg21396
VEPO
p31643
sg21398
I3
sg21408
VP01588
p31644
sg21401
I1
sa(dp31645
g21395
I226
sg21396
Vtransforming growth factor-Beta1
p31646
sg21398
I32
sg21408
VP01137
p31647
sg21401
I3
sa(dp31648
g21395
I260
sg21396
g31629
sg21398
I9
sg21408
VP01137
p31649
sg21401
I1
sasa(dp31650
g21386
VTwenty-four male C57BL6 mice were randomly divided into four groups, each comprising six mice: (i) control group (Sh); (ii) unilateral ureteral obstruction (UUO) plus vehicle group (U+V); (#\u2172) UUO plus 300 U/kg body weight recombinant human (rh)EPO (U+E1) and (#\u2173) UUO plus 1,000 U/kg body weight rhEPO (U+E2).
p31651
sg4
(dp31652
(VEPO
p31653
VUUO
p31654
tp31655
I00
ssg21392
(lp31656
(dp31657
g21395
I157
sg21396
VUUO
p31658
sg21398
I3
sg21399
VC0041956
p31659
sg21401
I1
sa(dp31660
g21395
I157
sg21396
VUUO
p31661
sg21398
I3
sg21399
VC0041956
p31662
sg21401
I1
sa(dp31663
g21395
I135
sg21396
Vureteral obstruction
p31664
sg21398
I20
sg21399
VC0041956
p31665
sg21401
I2
sa(dp31666
g21395
I157
sg21396
g31654
sg21398
I3
sg21399
VC0041956
p31667
sg21401
I1
sasg21404
(lp31668
(dp31669
g21395
I245
sg21396
g31653
sg21398
I3
sg21408
VP01588
p31670
sg21401
I1
sasa(dp31671
g21386
VThe aim of this study is to show and compare the actions of Simvastatin (Simv) and Erythropoietin (Epo) in renal expression of nuclear factor kappa B (NFKB), transforming growth factor-Beta (TGF-Beta), basic fibroblast growth factor (bFGF), platelet-derived growth factor B (PDGF-B), fibronectin and development of interstitial fibrosis in rats with unilateral ureteral obstruction (UUO).
p31672
sg4
(dp31673
(Vbasic fibroblast growth factor
p31674
Vureteral obstruction
p31675
tp31676
I00
ssg21392
(lp31677
(dp31678
g21395
I383
sg21396
VUUO
p31679
sg21398
I3
sg21399
VC0041956
p31680
sg21401
I1
sa(dp31681
g21395
I315
sg21396
Vinterstitial fibrosis
p31682
sg21398
I21
sg21399
VC0240035
p31683
sg21401
I2
sa(dp31684
g21395
I361
sg21396
g31675
sg21398
I20
sg21399
VC0041956
p31685
sg21401
I2
sasg21404
(lp31686
(dp31687
g21395
I151
sg21396
VNFKB
p31688
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp31689
g21395
I99
sg21396
VEpo
p31690
sg21398
I3
sg21408
VP01588
p31691
sg21401
I1
sa(dp31692
g21395
I158
sg21396
Vtransforming growth factor-Beta
p31693
sg21398
I31
sg21408
VP18075
p31694
sg21401
I3
sa(dp31695
g21395
I191
sg21396
VTGF-Beta
p31696
sg21398
I8
sg21408
VP18075
p31697
sg21401
I1
sa(dp31698
g21395
I275
sg21396
VPDGF-B
p31699
sg21398
I6
sg21408
VP01127
p31700
sg21401
I1
sa(dp31701
g21395
I83
sg21396
VErythropoietin
p31702
sg21398
I14
sg21408
VP01588
p31703
sg21401
I1
sa(dp31704
g21395
I234
sg21396
VbFGF
p31705
sg21398
I4
sg21408
VP53370
p31706
sg21401
I1
sa(dp31707
g21395
I127
sg21396
Vnuclear factor kappa B
p31708
sg21398
I22
sg21408
VP01160
p31709
sg21401
I4
sa(dp31710
g21395
I241
sg21396
Vplatelet-derived growth factor B
p31711
sg21398
I32
sg21408
VP01127
p31712
sg21401
I4
sa(dp31713
g21395
I202
sg21396
g31674
sg21398
I30
sg21408
VP53370
p31714
sg21401
I4
sasa(dp31715
g21386
VIn a novel mouse model, unilateral ureteral obstruction-induced inflammatory milieu activated NFKB and Smad signaling pathways in REPs, rapidly repressed the Epo-producing potential of REPs, and led to myofibroblast transformation of these cells.
p31716
sg4
(dp31717
(VEpo
p31718
Vureteral obstruction
p31719
tp31720
I00
ssg21392
(lp31721
(dp31722
g21395
I35
sg21396
g31719
sg21398
I20
sg21399
VC0041956
p31723
sg21401
I2
sa(dp31724
g21395
I216
sg21396
Vtransformation
p31725
sg21398
I14
sg21399
VC1510411
p31726
sg21401
I1
sasg21404
(lp31727
(dp31728
g21395
I94
sg21396
VNFKB
p31729
sg21398
I4
sg21408
g190
sg21401
I1
sa(dp31730
g21395
I158
sg21396
g31718
sg21398
I3
sg21408
VP01588
p31731
sg21401
I1
sasa(dp31732
g21386
VReversing the unilateral ureteral obstruction-induced inflammatory microenvironment restored the Epo-producing potential and the physiologic phenotype of REPs.
p31733
sg4
(dp31734
(VEpo
p31735
Vureteral obstruction
p31736
tp31737
I00
ssg21392
(lp31738
(dp31739
g21395
I25
sg21396
g31736
sg21398
I20
sg21399
VC0041956
p31740
sg21401
I2
sasg21404
(lp31741
(dp31742
g21395
I97
sg21396
g31735
sg21398
I3
sg21408
VP01588
p31743
sg21401
I1
sasa(dp31744
g21386
VSecondary polycythemia with increased production of erythropoietin (EPO) is known to occur in kidney diseases such as hydronephrosis and cystic disease, but the mechanism remains unclear.
p31745
sg4
(dp31746
(VEPO
p31747
Vkidney diseases
p31748
tp31749
I00
ssg21392
(lp31750
(dp31751
g21395
I118
sg21396
Vhydronephrosis
p31752
sg21398
I14
sg21399
VC0020295
p31753
sg21401
I1
sa(dp31754
g21395
I0
sg21396
VSecondary polycythemia
p31755
sg21398
I22
sg21399
VC1318533
p31756
sg21401
I2
sa(dp31757
g21395
I137
sg21396
Vcystic disease
p31758
sg21398
I14
sg21399
VC0334054
p31759
sg21401
I2
sa(dp31760
g21395
I94
sg21396
g31748
sg21398
I15
sg21399
VC0022658
p31761
sg21401
I2
sasg21404
(lp31762
(dp31763
g21395
I52
sg21396
Verythropoietin
p31764
sg21398
I14
sg21408
VP01588
p31765
sg21401
I1
sa(dp31766
g21395
I68
sg21396
g31747
sg21398
I3
sg21408
VP01588
p31767
sg21401
I1
sasa(dp31768
g21386
VDecompartmentalized hemoglobin, arginase 1, asymmetric dimethylarginine, and adenine nucleotides are all products of hemolysis that promote vasomotor dysfunction, proliferative vasculopathy, and a multitude of clinical complications of pulmonary and systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic kidney disease, and large-artery ischemic stroke.
p31769
sg4
(dp31770
(Varginase 1
p31771
Vpriapism
p31772
tp31773
I00
ssg21392
(lp31774
(dp31775
g21395
I307
sg21396
Vleg ulcers
p31776
sg21398
I10
sg21399
VC0023223
p31777
sg21401
I2
sa(dp31778
g21395
I329
sg21396
Vchronic kidney disease
p31779
sg21398
I22
sg21399
VC1561643
p31780
sg21401
I3
sa(dp31781
g21395
I163
sg21396
Vproliferative
p31782
sg21398
I13
sg21399
VC0334094
p31783
sg21401
I1
sa(dp31784
g21395
I283
sg21396
Vpulmonary hypertension
p31785
sg21398
I22
sg21399
VC0020542
p31786
sg21401
I2
sa(dp31787
g21395
I370
sg21396
Vischemic stroke
p31788
sg21398
I15
sg21399
VC3272363
p31789
sg21401
I2
sa(dp31790
g21395
I117
sg21396
Vhemolysis
p31791
sg21398
I9
sg21399
VC0019054
p31792
sg21401
I1
sa(dp31793
g21395
I319
sg21396
g31772
sg21398
I8
sg21399
VC0033117
p31794
sg21401
I1
sasg21404
(lp31795
(dp31796
g21395
I20
sg21396
Vhemoglobin
p31797
sg21398
I10
sg21408
g190
sg21401
I1
sa(dp31798
g21395
I32
sg21396
g31771
sg21398
I10
sg21408
VP05089
p31799
sg21401
I2
sasa(dp31800
g21386
VFurthermore, pleiotrophin (PTN), an endogenous ligand of Ptprz, also induced gastritis specifically in Ptprz+/+ mice when administered orally.
p31801
sg4
(dp31802
(Vpleiotrophin
p31803
Vgastritis
p31804
tp31805
I00
ssg21392
(lp31806
(dp31807
g21395
I77
sg21396
g31804
sg21398
I9
sg21399
VC0017152
p31808
sg21401
I1
sasg21404
(lp31809
(dp31810
g21395
I27
sg21396
VPTN
p31811
sg21398
I3
sg21408
VP21246
p31812
sg21401
I1
sa(dp31813
g21395
I13
sg21396
g31803
sg21398
I12
sg21408
VP21246
p31814
sg21401
I1
sasa(dp31815
g21386
VWe aimed to determine whether serum levels of Krebs von den Lungen-6 (KL-6) and surfactant protein-D (SP-D) correlate with SSc/MCTD-associated ILD activity.
p31816
sg4
(dp31817
(Vsurfactant protein-D
p31818
VMCTD
p31819
tp31820
I00
ssg21392
(lp31821
(dp31822
g21395
I127
sg21396
g31819
sg21398
I4
sg21399
VC0026272
p31823
sg21401
I1
sasg21404
(lp31824
(dp31825
g21395
I102
sg21396
VSP-D
p31826
sg21398
I4
sg21408
VP35247
p31827
sg21401
I1
sa(dp31828
g21395
I80
sg21396
g31818
sg21398
I20
sg21408
VP35453
p31829
sg21401
I2
sasa(dp31830
g21386
VTo investigate the changes caused by the inhibition of IRS-1-mediated insulin signaling in neuroblastoma cells, we performed Western blot analysis, reverse transcription-PCR, and immunochemical analysis.
p31831
sg4
(dp31832
(Vinsulin
p31833
Vneuroblastoma
p31834
tp31835
I00
ssg21392
(lp31836
(dp31837
g21395
I91
sg21396
g31834
sg21398
I13
sg21399
VC0027819
p31838
sg21401
I1
sasg21404
(lp31839
(dp31840
g21395
I55
sg21396
VIRS-1
p31841
sg21398
I5
sg21408
VP35568
p31842
sg21401
I1
sa(dp31843
g21395
I70
sg21396
g31833
sg21398
I7
sg21408
VP01308
p31844
sg21401
I1
sasa(dp31845
g21386
VmiR-145 might act as a tumor suppressor in uveal melanoma, and downregulation of the target IRS-1 might be a potential mechanism.
p31846
sg4
(dp31847
(Vtarget IRS-1
p31848
Vuveal melanoma
p31849
tp31850
I00
ssg21392
(lp31851
(dp31852
g21395
I23
sg21396
Vtumor
p31853
sg21398
I5
sg21399
VC0027651
p31854
sg21401
I1
sa(dp31855
g21395
I43
sg21396
g31849
sg21398
I14
sg21399
VC0220633
p31856
sg21401
I2
sasg21404
(lp31857
(dp31858
g21395
I0
sg21396
VmiR-145
p31859
sg21398
I7
sg21408
g190
sg21401
I1
sa(dp31860
g21395
I85
sg21396
g31848
sg21398
I12
sg21408
VP35568
p31861
sg21401
I2
sasa(dp31862
g21386
VAlmost a decade ago, we reported the presence of nuclear IRS-1 in medulloblastoma clinical samples, which express viral oncoprotein, large T-antigen of human polyomavirus JC (JCV T-antigen).
p31863
sg4
(dp31864
(VJCV T-antigen
p31865
Vmedulloblastoma
p31866
tp31867
I00
ssg21392
(lp31868
(dp31869
g21395
I66
sg21396
g31866
sg21398
I15
sg21399
VC0025149
p31870
sg21401
I1
sasg21404
(lp31871
(dp31872
g21395
I133
sg21396
Vlarge T-antigen
p31873
sg21398
I15
sg21408
VP14209
p31874
sg21401
I2
sa(dp31875
g21395
I175
sg21396
g31865
sg21398
I13
sg21408
VP14209
p31876
sg21401
I2
sasa(dp31877
g21386
VMore recently, nuclear IRS-1 was detected in breast cancer cells in association with estrogen receptor alpha (ERAlfa), and in JC virus negative medulloblastoma cells expressing estrogen receptor beta (ERBeta), further implicating nuclear IRS-1 in cellular transformation.
p31878
sg4
(dp31879
(VERBeta
p31880
Vmedulloblastoma
p31881
tp31882
I00
ssg21392
(lp31883
(dp31884
g21395
I247
sg21396
Vcellular transformation
p31885
sg21398
I23
sg21399
VC1510411
p31886
sg21401
I2
sa(dp31887
g21395
I45
sg21396
Vbreast cancer
p31888
sg21398
I13
sg21399
VC0678222
p31889
sg21401
I2
sa(dp31890
g21395
I144
sg21396
g31881
sg21398
I15
sg21399
VC0025149
p31891
sg21401
I1
sasg21404
(lp31892
(dp31893
g21395
I85
sg21396
Vestrogen receptor alpha
p31894
sg21398
I23
sg21408
VP03372
p31895
sg21401
I3
sa(dp31896
g21395
I177
sg21396
Vestrogen receptor beta
p31897
sg21398
I22
sg21408
VP03372
p31898
sg21401
I3
sa(dp31899
g21395
I15
sg21396
Vnuclear IRS-1
p31900
sg21398
I13
sg21408
VP35568
p31901
sg21401
I2
sa(dp31902
g21395
I201
sg21396
g31880
sg21398
I6
sg21408
VP03372
p31903
sg21401
I1
sasa(dp31904
g21386
VWe have previously reported that ERBeta, which is highly expressed in medulloblastomas, translocates insulin receptor substrate 1 (IRS-1) to the nucleus, and that nuclear IRS-1 binds to Rad51 and attenuates homologous recombination directed DNA repair (HRR).
p31905
sg4
(dp31906
(VIRS-1
p31907
Vmedulloblastomas
p31908
tp31909
I00
ssg21392
(lp31910
(dp31911
g21395
I70
sg21396
g31908
sg21398
I16
sg21399
VC0025149
p31912
sg21401
I1
sasg21404
(lp31913
(dp31914
g21395
I186
sg21396
VRad51
p31915
sg21398
I5
sg21408
g190
sg21401
I1
sa(dp31916
g21395
I101
sg21396
Vinsulin receptor substrate 1
p31917
sg21398
I28
sg21408
VP35568
p31918
sg21401
I4
sa(dp31919
g21395
I163
sg21396
Vnuclear IRS-1
p31920
sg21398
I13
sg21408
VP35568
p31921
sg21401
I2
sa(dp31922
g21395
I131
sg21396
g31907
sg21398
I5
sg21408
VP35568
p31923
sg21401
I1
sasa(dp31924
S'line'
p31925
VZIC2 and OVOL1 may function in nasopharyngeal carcinoma through targeting significantly up-regulated genes (such as PTGS2, FN1, CXCL9 and CXCL10) in the Transcription factor-differentially expressed gene regulatory network (e.g., ZIC2-&gt;PTGS2 and OVOL1-&gt;CXCL10).
p31926
sg4
(dp31927
(VCXCL10
p31928
Vnasopharyngeal carcinoma
p31929
tp31930
I00
ssS'diseases'
p31931
(lp31932
(dp31933
S'index'
p31934
I31
sS'name'
p31935
g31929
sS'lengthInChars'
p31936
I24
sS'cui'
p31937
VC2931822
p31938
sS'lengthInWords'
p31939
I2
sasS'genes'
p31940
(lp31941
(dp31942
g31934
I116
sg31935
VPTGS2
p31943
sg31936
I5
sS'uniprot'
p31944
VP35354
p31945
sg31939
I1
sa(dp31946
g31934
I128
sg31935
VCXCL9
p31947
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp31948
g31934
I116
sg31935
VPTGS2
p31949
sg31936
I5
sg31944
VP35354
p31950
sg31939
I1
sa(dp31951
g31934
I0
sg31935
VZIC2
p31952
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp31953
g31934
I9
sg31935
VOVOL1
p31954
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp31955
g31934
I0
sg31935
VZIC2
p31956
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp31957
g31934
I-1
sg31935
VOVOL1->CXCL10
p31958
sg31936
I13
sg31944
g190
sg31939
I1
sa(dp31959
g31934
I138
sg31935
g31928
sg31936
I6
sg31944
VP02778
p31960
sg31939
I1
sasa(dp31961
g31925
VPTGS2, FN1, CXCL9, CXCL10, ZIC2 and OVOL1 might play roles in nasopharyngeal carcinoma.
p31962
sg4
(dp31963
(VPTGS2
p31964
Vnasopharyngeal carcinoma
p31965
tp31966
I00
ssg31931
(lp31967
(dp31968
g31934
I48
sg31935
Vplay roles
p31969
sg31936
I10
sg31937
VC0699820
p31970
sg31939
I2
sa(dp31971
g31934
I62
sg31935
g31965
sg31936
I24
sg31937
VC2931822
p31972
sg31939
I2
sasg31940
(lp31973
(dp31974
g31934
I12
sg31935
VCXCL9
p31975
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp31976
g31934
I36
sg31935
VOVOL1
p31977
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp31978
g31934
I27
sg31935
VZIC2
p31979
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp31980
g31934
I19
sg31935
VCXCL10
p31981
sg31936
I6
sg31944
VP02778
p31982
sg31939
I1
sa(dp31983
g31934
I0
sg31935
g31964
sg31936
I5
sg31944
VP35354
p31984
sg31939
I1
sasa(dp31985
g31925
VLiterature data indicate that hyperprolactinemia (HPRL) is one of the important factors in the pathogenesis and course of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis and Sjogren's syndrome.
p31986
sg4
(dp31987
(Vhyperprolactinemia
p31988
Vsystemic lupus erythematosus
p31989
tp31990
I00
ssg31931
(lp31991
(dp31992
g31934
I225
sg31935
VSjogren's syndrome
p31993
sg31936
I18
sg31937
VC1527336
p31994
sg31939
I2
sa(dp31995
g31934
I180
sg31935
Vrheumatoid arthritis
p31996
sg31936
I20
sg31937
VC0003873
p31997
sg31939
I2
sa(dp31998
g31934
I202
sg31935
Vsystemic sclerosis
p31999
sg31936
I18
sg31937
VC0036421
p32000
sg31939
I2
sa(dp32001
g31934
I30
sg31935
Vhyperprolactinemia
p32002
sg31936
I18
sg31937
VC0020514
p32003
sg31939
I1
sa(dp32004
g31934
I122
sg31935
Vautoimmune diseases
p32005
sg31936
I19
sg31937
VC0004364
p32006
sg31939
I2
sa(dp32007
g31934
I50
sg31935
VHPRL
p32008
sg31936
I4
sg31937
VC0020514
p32009
sg31939
I1
sa(dp32010
g31934
I95
sg31935
Vpathogenesis
p32011
sg31936
I12
sg31937
VC0699748
p32012
sg31939
I1
sa(dp32013
g31934
I150
sg31935
g31989
sg31936
I28
sg31937
VC0024141
p32014
sg31939
I3
sasg31940
(lp32015
(dp32016
g31934
I50
sg31935
VHPRL
p32017
sg31936
I4
sg31944
VP01236
p32018
sg31939
I1
sa(dp32019
g31934
I30
sg31935
g31988
sg31936
I18
sg31944
VP01236
p32020
sg31939
I1
sasa(dp32021
g31925
VFurthermore in the last 2 decades multi-organ and organ specific autoimmune diseases like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome (SS), Hashimoto's thyroiditis (HT), multiple sclerosis (MS), psoriasis, hepatitis C patients, Behcet's disease, peripartum cardiomyopathy (PPCM) and active celiac disease were discussed to be associated with HPRL.
p32022
sg4
(dp32023
(VHPRL
p32024
VHashimoto's thyroiditis
p32025
tp32026
I00
ssg31931
(lp32027
(dp32028
g31934
I148
sg31935
VRA
p32029
sg31936
I2
sg31937
VC0003873
p32030
sg31939
I1
sa(dp32031
g31934
I120
sg31935
VSLE
p32032
sg31936
I3
sg31937
VC0024141
p32033
sg31939
I1
sa(dp32034
g31934
I173
sg31935
VSS
p32035
sg31936
I2
sg31937
VC1527336
p32036
sg31939
I1
sa(dp32037
g31934
I244
sg31935
Vhepatitis C
p32038
sg31936
I11
sg31937
VC0019196
p32039
sg31939
I2
sa(dp32040
g31934
I90
sg31935
Vsystemic lupus erythematosus
p32041
sg31936
I28
sg31937
VC0024141
p32042
sg31939
I3
sa(dp32043
g31934
I233
sg31935
Vpsoriasis
p32044
sg31936
I9
sg31937
VC0033860
p32045
sg31939
I1
sa(dp32046
g31934
I208
sg31935
Vmultiple sclerosis
p32047
sg31936
I18
sg31937
VC0026769
p32048
sg31939
I2
sa(dp32049
g31934
I153
sg31935
VSjogren's syndrome
p32050
sg31936
I18
sg31937
VC1527336
p32051
sg31939
I2
sa(dp32052
g31934
I284
sg31935
Vperipartum cardiomyopathy
p32053
sg31936
I25
sg31937
VC0877208
p32054
sg31939
I2
sa(dp32055
g31934
I203
sg31935
VHT
p32056
sg31936
I2
sg31937
VC0920350
p32057
sg31939
I1
sa(dp32058
g31934
I65
sg31935
Vautoimmune diseases
p32059
sg31936
I19
sg31937
VC0004364
p32060
sg31939
I2
sa(dp32061
g31934
I266
sg31935
VBehcet's disease
p32062
sg31936
I16
sg31937
VC0004943
p32063
sg31939
I2
sa(dp32064
g31934
I228
sg31935
VMS
p32065
sg31936
I2
sg31937
VC0026769
p32066
sg31939
I1
sa(dp32067
g31934
I126
sg31935
Vrheumatoid arthritis
p32068
sg31936
I20
sg31937
VC0003873
p32069
sg31939
I2
sa(dp32070
g31934
I328
sg31935
Vceliac disease
p32071
sg31936
I14
sg31937
VC0007570
p32072
sg31939
I2
sa(dp32073
g31934
I311
sg31935
VPPCM
p32074
sg31936
I4
sg31937
VC0877208
p32075
sg31939
I1
sa(dp32076
g31934
I178
sg31935
g32025
sg31936
I23
sg31937
VC0920350
p32077
sg31939
I2
sasg31940
(lp32078
(dp32079
g31934
I380
sg31935
g32024
sg31936
I4
sg31944
VP01236
p32080
sg31939
I1
sasa(dp32081
g31925
VHyperprolactinemia (HPRL) is observed in multi-organ and organ specific autoimmune diseases like systemic lupus erythematosus (SLE) rheumatoid arthritis (RA), Sjogren's syndrome (SS), Hashimoto's thyroiditis (HT) and multiple sclerosis (MS).
p32082
sg4
(dp32083
(VHyperprolactinemia
p32084
VHT
p32085
tp32086
I00
ssg31931
(lp32087
(dp32088
g31934
I97
sg31935
Vsystemic lupus erythematosus
p32089
sg31936
I28
sg31937
VC0024141
p32090
sg31939
I3
sa(dp32091
g31934
I154
sg31935
VRA
p32092
sg31936
I2
sg31937
VC0003873
p32093
sg31939
I1
sa(dp32094
g31934
I127
sg31935
VSLE
p32095
sg31936
I3
sg31937
VC0024141
p32096
sg31939
I1
sa(dp32097
g31934
I159
sg31935
VSjogren's syndrome
p32098
sg31936
I18
sg31937
VC1527336
p32099
sg31939
I2
sa(dp32100
g31934
I179
sg31935
VSS
p32101
sg31936
I2
sg31937
VC1527336
p32102
sg31939
I1
sa(dp32103
g31934
I217
sg31935
Vmultiple sclerosis
p32104
sg31936
I18
sg31937
VC0026769
p32105
sg31939
I2
sa(dp32106
g31934
I132
sg31935
Vrheumatoid arthritis
p32107
sg31936
I20
sg31937
VC0003873
p32108
sg31939
I2
sa(dp32109
g31934
I20
sg31935
VHPRL
p32110
sg31936
I4
sg31937
VC0020514
p32111
sg31939
I1
sa(dp32112
g31934
I72
sg31935
Vautoimmune diseases
p32113
sg31936
I19
sg31937
VC0004364
p32114
sg31939
I2
sa(dp32115
g31934
I237
sg31935
VMS
p32116
sg31936
I2
sg31937
VC0026769
p32117
sg31939
I1
sa(dp32118
g31934
I0
sg31935
VHyperprolactinemia
p32119
sg31936
I18
sg31937
VC0020514
p32120
sg31939
I1
sa(dp32121
g31934
I184
sg31935
VHashimoto's thyroiditis
p32122
sg31936
I23
sg31937
VC0920350
p32123
sg31939
I2
sa(dp32124
g31934
I209
sg31935
g32085
sg31936
I2
sg31937
VC0920350
p32125
sg31939
I1
sasg31940
(lp32126
(dp32127
g31934
I20
sg31935
VHPRL
p32128
sg31936
I4
sg31944
VP01236
p32129
sg31939
I1
sa(dp32130
g31934
I0
sg31935
g32084
sg31936
I18
sg31944
VP01236
p32131
sg31939
I1
sasa(dp32132
g31925
VWe describe the role of PRL in the pathogenesis of rheumatic diseases, particularly connective tissue diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), primary Sjoegren's syndrome, systemic sclerosis, polymyalgia rheumatica, and seronegative arthritis.
p32133
sg4
(dp32134
(VPRL
p32135
Vrheumatic diseases
p32136
tp32137
I01
ssg31931
(lp32138
(dp32139
g31934
I214
sg31935
Vsystemic sclerosis
p32140
sg31936
I18
sg31937
VC0036421
p32141
sg31939
I2
sa(dp32142
g31934
I158
sg31935
Vrheumatoid arthritis
p32143
sg31936
I20
sg31937
VC0003873
p32144
sg31939
I2
sa(dp32145
g31934
I35
sg31935
Vpathogenesis
p32146
sg31936
I12
sg31937
VC0699748
p32147
sg31939
I1
sa(dp32148
g31934
I193
sg31935
VSjoegren's syndrome
p32149
sg31936
I19
sg31937
VC1527336
p32150
sg31939
I2
sa(dp32151
g31934
I122
sg31935
Vsystemic lupus erythematosus
p32152
sg31936
I28
sg31937
VC0024141
p32153
sg31939
I3
sa(dp32154
g31934
I152
sg31935
VSLE
p32155
sg31936
I3
sg31937
VC0024141
p32156
sg31939
I1
sa(dp32157
g31934
I262
sg31935
Vseronegative arthritis
p32158
sg31936
I22
sg31937
VC0409679
p32159
sg31939
I2
sa(dp32160
g31934
I180
sg31935
VRA
p32161
sg31936
I2
sg31937
VC0003873
p32162
sg31939
I1
sa(dp32163
g31934
I84
sg31935
Vconnective tissue diseases
p32164
sg31936
I26
sg31937
VC0009782
p32165
sg31939
I3
sa(dp32166
g31934
I234
sg31935
Vpolymyalgia rheumatica
p32167
sg31936
I22
sg31937
VC0032533
p32168
sg31939
I2
sa(dp32169
g31934
I51
sg31935
g32136
sg31936
I18
sg31937
VC0035435
p32170
sg31939
I2
sasg31940
(lp32171
(dp32172
g31934
I24
sg31935
g32135
sg31936
I3
sg31944
VP01236
p32173
sg31939
I1
sasa(dp32174
g31925
VMoreover, we show that the reduction of eosinophilia and the recruitment of inflammatory monocytes to the lungs required early triggering of TLR9, IFN-Gamma and CCR2 by immunotherapy components.
p32175
sg4
(dp32176
(VCCR2
p32177
Veosinophilia
p32178
tp32179
I00
ssg31931
(lp32180
(dp32181
g31934
I61
sg31935
Vrecruitment
p32182
sg31936
I11
sg31937
VC0271510
p32183
sg31939
I1
sa(dp32184
g31934
I40
sg31935
g32178
sg31936
I12
sg31937
VC0014457
p32185
sg31939
I1
sasg31940
(lp32186
(dp32187
g31934
I147
sg31935
VIFN-Gamma
p32188
sg31936
I9
sg31944
VP01579
p32189
sg31939
I1
sa(dp32190
g31934
I161
sg31935
g32177
sg31936
I4
sg31944
VP41597
p32191
sg31939
I1
sa(dp32192
g31934
I141
sg31935
VTLR9
p32193
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp32194
g31925
VHowever, genes like HSP90, PAK2, CD247 and others included in the first 1% of the prioritized list need to be further explored in preeclampsia pathogenesis through experimental approaches.
p32195
sg4
(dp32196
(VCD247
p32197
Vpreeclampsia
p32198
tp32199
I00
ssg31931
(lp32200
(dp32201
g31934
I143
sg31935
Vpathogenesis
p32202
sg31936
I12
sg31937
VC0699748
p32203
sg31939
I1
sa(dp32204
g31934
I130
sg31935
g32198
sg31936
I12
sg31937
VC0032914
p32205
sg31939
I1
sasg31940
(lp32206
(dp32207
g31934
I20
sg31935
VHSP90
p32208
sg31936
I5
sg31944
VP07900
p32209
sg31939
I1
sa(dp32210
g31934
I33
sg31935
g32197
sg31936
I5
sg31944
VP20963
p32211
sg31939
I1
sa(dp32212
g31934
I27
sg31935
VPAK2
p32213
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp32214
g31925
VWe report a case of acute pancreatitis with diabetic ketoacidosis associated with increased serum myoglobin concentration, acute renal failure, and disseminated intravascular coagulation.
p32215
sg4
(dp32216
(Vserum myoglobin
p32217
Vacute renal failure
p32218
tp32219
I01
ssg31931
(lp32220
(dp32221
g31934
I148
sg31935
Vdisseminated intravascular coagulation
p32222
sg31936
I38
sg31937
VC0012739
p32223
sg31939
I3
sa(dp32224
g31934
I44
sg31935
Vdiabetic ketoacidosis
p32225
sg31936
I21
sg31937
VC0011880
p32226
sg31939
I2
sa(dp32227
g31934
I20
sg31935
Vacute pancreatitis
p32228
sg31936
I18
sg31937
VC0001339
p32229
sg31939
I2
sa(dp32230
g31934
I123
sg31935
g32218
sg31936
I19
sg31937
VC0022660
p32231
sg31939
I3
sasg31940
(lp32232
(dp32233
g31934
I92
sg31935
g32217
sg31936
I15
sg31944
VP02144
p32234
sg31939
I2
sasa(dp32235
g31925
VThe frequency of nontraumatic rhabdomyolysis in diabetic ketoacidosis was investigated by serial measurements of the serum levels of myoglobin and the serum activity of creatine kinase isoenzyme MM in 12 consecutively admitted ketoacidotic patients.
p32236
sg4
(dp32237
(Vmyoglobin
p32238
Vdiabetic ketoacidosis
p32239
tp32240
I00
ssg31931
(lp32241
(dp32242
g31934
I30
sg31935
Vrhabdomyolysis
p32243
sg31936
I14
sg31937
VC0035410
p32244
sg31939
I1
sa(dp32245
g31934
I48
sg31935
g32239
sg31936
I21
sg31937
VC0011880
p32246
sg31939
I2
sasg31940
(lp32247
(dp32248
g31934
I133
sg31935
g32238
sg31936
I9
sg31944
VP02144
p32249
sg31939
I1
sa(dp32250
g31934
I169
sg31935
Vcreatine kinase
p32251
sg31936
I15
sg31944
VP12532
p32252
sg31939
I2
sasa(dp32253
g31925
VHigh-mobility group nucleosome-binding domain 5 (HMGN5), a well-known oncogene in gliomas, was identified as a functional target of miR-409-3p using bioinformatics, dual-luciferase reporter assay, real-time quantitative polymerase chain reaction, and Western blot analysis.
p32254
sg4
(dp32255
(VHigh-mobility group nucleosome-binding domain 5
p32256
Vgliomas
p32257
tp32258
I00
ssg31931
(lp32259
(dp32260
g31934
I82
sg31935
g32257
sg31936
I7
sg31937
VC0017638
p32261
sg31939
I1
sasg31940
(lp32262
(dp32263
g31934
I132
sg31935
VmiR-409-3p
p32264
sg31936
I10
sg31944
g190
sg31939
I1
sa(dp32265
g31934
I49
sg31935
VHMGN5
p32266
sg31936
I5
sg31944
VP82970
p32267
sg31939
I1
sa(dp32268
g31934
I0
sg31935
g32256
sg31936
I47
sg31944
VP00390
p32269
sg31939
I5
sasa(dp32270
g31925
VRestoration of HMGN5 expression significantly reversed the inhibitory effects of miR-409-3p overexpression on glioma cell invasion and proliferation.
p32271
sg4
(dp32272
(VHMGN5
p32273
Vglioma
p32274
tp32275
I01
ssg31931
(lp32276
(dp32277
g31934
I135
sg31935
Vproliferation
p32278
sg31936
I13
sg31937
VC0334094
p32279
sg31939
I1
sa(dp32280
g31934
I110
sg31935
g32274
sg31936
I6
sg31937
VC0017638
p32281
sg31939
I1
sa(dp32282
g31934
I117
sg31935
Vcell invasion
p32283
sg31936
I13
sg31937
VC2699153
p32284
sg31939
I2
sasg31940
(lp32285
(dp32286
g31934
I81
sg31935
VmiR-409-3p
p32287
sg31936
I10
sg31944
g190
sg31939
I1
sa(dp32288
g31934
I15
sg31935
g32273
sg31936
I5
sg31944
VP82970
p32289
sg31939
I1
sasa(dp32290
g31925
VTaken together, our results suggest that miR-409-3p inhibits glioma cell invasion and proliferation by targeting HMGN5, representing a potential therapeutic target for glioma.
p32291
sg4
(dp32292
(VHMGN5
p32293
Vglioma
p32294
tp32295
I01
ssg31931
(lp32296
(dp32297
g31934
I86
sg31935
Vproliferation
p32298
sg31936
I13
sg31937
VC0334094
p32299
sg31939
I1
sa(dp32300
g31934
I61
sg31935
Vglioma
p32301
sg31936
I6
sg31937
VC0017638
p32302
sg31939
I1
sa(dp32303
g31934
I68
sg31935
Vcell invasion
p32304
sg31936
I13
sg31937
VC2699153
p32305
sg31939
I2
sa(dp32306
g31934
I61
sg31935
g32294
sg31936
I6
sg31937
VC0017638
p32307
sg31939
I1
sasg31940
(lp32308
(dp32309
g31934
I41
sg31935
VmiR-409-3p
p32310
sg31936
I10
sg31944
g190
sg31939
I1
sa(dp32311
g31934
I113
sg31935
g32293
sg31936
I5
sg31944
VP82970
p32312
sg31939
I1
sasa(dp32313
g31925
VIt was first discovered in mouse, and recent studies found that the expressions of HMGN5 in many human cancers were also highly regulated, such as prostate, bladder, breast, and lung and clear cell renal cell carcinoma.
p32314
sg4
(dp32315
(VHMGN5
p32316
Vclear cell renal cell carcinoma
p32317
tp32318
I01
ssg31931
(lp32319
(dp32320
g31934
I103
sg31935
Vcancers
p32321
sg31936
I7
sg31937
VC0006826
p32322
sg31939
I1
sa(dp32323
g31934
I187
sg31935
g32317
sg31936
I31
sg31937
VC0279702
p32324
sg31939
I5
sasg31940
(lp32325
(dp32326
g31934
I83
sg31935
g32316
sg31936
I5
sg31944
VP82970
p32327
sg31939
I1
sasa(dp32328
g31925
VWe found that NSBP1 was highly expressed in non-small cell lung cancer (NSCLC) cells, and knockdown of NSBP1 by NSBP1 small interfering RNA (siRNA) significantly suppressed NSCLC cell proliferation and invasion.
p32329
sg4
(dp32330
(VNSBP1
p32331
VNSCLC
p32332
tp32333
I00
ssg31931
(lp32334
(dp32335
g31934
I72
sg31935
VNSCLC
p32336
sg31936
I5
sg31937
VC0007131
p32337
sg31939
I1
sa(dp32338
g31934
I44
sg31935
Vnon-small cell lung cancer
p32339
sg31936
I26
sg31937
VC0007131
p32340
sg31939
I4
sa(dp32341
g31934
I184
sg31935
Vproliferation
p32342
sg31936
I13
sg31937
VC0334094
p32343
sg31939
I1
sa(dp32344
g31934
I72
sg31935
g32332
sg31936
I5
sg31937
VC0007131
p32345
sg31939
I1
sa(dp32346
g31934
I202
sg31935
Vinvasion
p32347
sg31936
I8
sg31937
VC2699153
p32348
sg31939
I1
sasg31940
(lp32349
(dp32350
g31934
I112
sg31935
VNSBP1 small interfering RNA
p32351
sg31936
I27
sg31944
VP82970
p32352
sg31939
I4
sa(dp32353
g31934
I14
sg31935
VNSBP1
p32354
sg31936
I5
sg31944
VP82970
p32355
sg31939
I1
sa(dp32356
g31934
I14
sg31935
g32331
sg31936
I5
sg31944
VP82970
p32357
sg31939
I1
sasa(dp32358
g31925
VOverexpression of miR-326 significantly inhibited NSCLC cell proliferation and invasion, which mimicked the effect of NSBP1 siRNA.
p32359
sg4
(dp32360
(VNSBP1 siRNA
p32361
VNSCLC
p32362
tp32363
I00
ssg31931
(lp32364
(dp32365
g31934
I50
sg31935
g32362
sg31936
I5
sg31937
VC0007131
p32366
sg31939
I1
sa(dp32367
g31934
I79
sg31935
Vinvasion
p32368
sg31936
I8
sg31937
VC2699153
p32369
sg31939
I1
sa(dp32370
g31934
I61
sg31935
Vproliferation
p32371
sg31936
I13
sg31937
VC0334094
p32372
sg31939
I1
sasg31940
(lp32373
(dp32374
g31934
I118
sg31935
g32361
sg31936
I11
sg31944
VP82970
p32375
sg31939
I2
sa(dp32376
g31934
I18
sg31935
VmiR-326
p32377
sg31936
I7
sg31944
g190
sg31939
I1
sasa(dp32378
g31925
VIn addition, an inverse correlation between miR-326 and NSBP1 expression levels was found in NSCLC clinical specimens.
p32379
sg4
(dp32380
(VNSBP1
p32381
VNSCLC
p32382
tp32383
I00
ssg31931
(lp32384
(dp32385
g31934
I93
sg31935
g32382
sg31936
I5
sg31937
VC0007131
p32386
sg31939
I1
sasg31940
(lp32387
(dp32388
g31934
I56
sg31935
g32381
sg31936
I5
sg31944
VP82970
p32389
sg31939
I1
sasa(dp32390
g31925
VOur study demonstrated a direct target relationship between NSBP1 and miR-326 through which miR-326 inhibited cell proliferation and invasion of NSCLC cells.
p32391
sg4
(dp32392
(VNSBP1
p32393
VNSCLC
p32394
tp32395
I00
ssg31931
(lp32396
(dp32397
g31934
I133
sg31935
Vinvasion
p32398
sg31936
I8
sg31937
VC2699153
p32399
sg31939
I1
sa(dp32400
g31934
I115
sg31935
Vproliferation
p32401
sg31936
I13
sg31937
VC0334094
p32402
sg31939
I1
sa(dp32403
g31934
I145
sg31935
g32394
sg31936
I5
sg31937
VC0007131
p32404
sg31939
I1
sasg31940
(lp32405
(dp32406
g31934
I60
sg31935
g32393
sg31936
I5
sg31944
VP82970
p32407
sg31939
I1
sa(dp32408
g31934
I70
sg31935
VmiR-326
p32409
sg31936
I7
sg31944
g190
sg31939
I1
sasa(dp32410
g31925
VCorrelation analysis also showed that HMGN5 expression levels were significantly inversely correlated with the miR-340 expression in prostate cancer tissues.
p32411
sg4
(dp32412
(VHMGN5
p32413
Vprostate cancer
p32414
tp32415
I00
ssg31931
(lp32416
(dp32417
g31934
I133
sg31935
g32414
sg31936
I15
sg31937
VC0600139
p32418
sg31939
I2
sasg31940
(lp32419
(dp32420
g31934
I38
sg31935
g32413
sg31936
I5
sg31944
VP82970
p32421
sg31939
I1
sa(dp32422
g31934
I111
sg31935
VmiR-340
p32423
sg31936
I7
sg31944
g190
sg31939
I1
sasa(dp32424
g31925
VIn addition, overexpression of HMGN5 significantly reversed the inhibitory effect of miR-340 on prostate cancer cell proliferation and invasion.
p32425
sg4
(dp32426
(VHMGN5
p32427
Vprostate cancer
p32428
tp32429
I00
ssg31931
(lp32430
(dp32431
g31934
I135
sg31935
Vinvasion
p32432
sg31936
I8
sg31937
VC2699153
p32433
sg31939
I1
sa(dp32434
g31934
I117
sg31935
Vproliferation
p32435
sg31936
I13
sg31937
VC0334094
p32436
sg31939
I1
sa(dp32437
g31934
I96
sg31935
g32428
sg31936
I15
sg31937
VC0600139
p32438
sg31939
I2
sasg31940
(lp32439
(dp32440
g31934
I31
sg31935
g32427
sg31936
I5
sg31944
VP82970
p32441
sg31939
I1
sa(dp32442
g31934
I85
sg31935
VmiR-340
p32443
sg31936
I7
sg31944
g190
sg31939
I1
sasa(dp32444
g31925
VThus, miR340 and its target gene HMGN5 can serve as potentially useful therapeutic candidates for prostate cancer treatment.
p32445
sg4
(dp32446
(VHMGN5
p32447
Vprostate cancer
p32448
tp32449
I00
ssg31931
(lp32450
(dp32451
g31934
I98
sg31935
g32448
sg31936
I15
sg31937
VC0600139
p32452
sg31939
I2
sasg31940
(lp32453
(dp32454
g31934
I33
sg31935
g32447
sg31936
I5
sg31944
VP82970
p32455
sg31939
I1
sasa(dp32456
g31925
VHowever, the potential correlation between HMGN5 and prognosis in patients with meningiomas remains unknown.
p32457
sg4
(dp32458
(VHMGN5
p32459
Vmeningiomas
p32460
tp32461
I01
ssg31931
(lp32462
(dp32463
g31934
I80
sg31935
g32460
sg31936
I11
sg31937
VC0025286
p32464
sg31939
I1
sasg31940
(lp32465
(dp32466
g31934
I43
sg31935
g32459
sg31936
I5
sg31944
VP82970
p32467
sg31939
I1
sasa(dp32468
g31925
VIn the present study, we explored the expression of HMGN5 in meningiomas with immunohistochemistry and correlated the results to the patient outcome.
p32469
sg4
(dp32470
(VHMGN5
p32471
Vmeningiomas
p32472
tp32473
I01
ssg31931
(lp32474
(dp32475
g31934
I61
sg31935
g32472
sg31936
I11
sg31937
VC0025286
p32476
sg31939
I1
sasg31940
(lp32477
(dp32478
g31934
I52
sg31935
g32471
sg31936
I5
sg31944
VP82970
p32479
sg31939
I1
sasa(dp32480
g31925
VWe demonstrate that there is a positive association between HMGN5 expression and meningioma histological grade.
p32481
sg4
(dp32482
(VHMGN5
p32483
Vmeningioma
p32484
tp32485
I01
ssg31931
(lp32486
(dp32487
g31934
I81
sg31935
g32484
sg31936
I10
sg31937
VC0025286
p32488
sg31939
I1
sasg31940
(lp32489
(dp32490
g31934
I60
sg31935
g32483
sg31936
I5
sg31944
VP82970
p32491
sg31939
I1
sasa(dp32492
g31925
VStatistical analysis reveals that lower HMGN5 expression predict lower meningioma recurrence.
p32493
sg4
(dp32494
(VHMGN5
p32495
Vmeningioma
p32496
tp32497
I01
ssg31931
(lp32498
(dp32499
g31934
I82
sg31935
Vrecurrence
p32500
sg31936
I10
sg31937
VC1458156
p32501
sg31939
I1
sa(dp32502
g31934
I71
sg31935
g32496
sg31936
I10
sg31937
VC0025286
p32503
sg31939
I1
sasg31940
(lp32504
(dp32505
g31934
I40
sg31935
g32495
sg31936
I5
sg31944
VP82970
p32506
sg31939
I1
sasa(dp32507
g31925
VOur results further revealed that HMGN5 inhibition decreased P-glycoprotein (MDR-1) expression without affecting multidrug resistance associated proteins 1 (MRP-1) expression to increase chemosensitivity to temozolomide (TMZ) of meningioma cells.
p32508
sg4
(dp32509
(VMRP-1
p32510
Vmeningioma
p32511
tp32512
I00
ssg31931
(lp32513
(dp32514
g31934
I229
sg31935
g32511
sg31936
I10
sg31937
VC0025286
p32515
sg31939
I1
sasg31940
(lp32516
(dp32517
g31934
I113
sg31935
Vmultidrug resistance associated proteins 1
p32518
sg31936
I42
sg31944
g190
sg31939
I5
sa(dp32519
g31934
I61
sg31935
VP-glycoprotein
p32520
sg31936
I14
sg31944
VP08183
p32521
sg31939
I1
sa(dp32522
g31934
I34
sg31935
VHMGN5
p32523
sg31936
I5
sg31944
VP82970
p32524
sg31939
I1
sa(dp32525
g31934
I77
sg31935
VMDR-1
p32526
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp32527
g31934
I157
sg31935
g32510
sg31936
I5
sg31944
VP08183
p32528
sg31939
I1
sasa(dp32529
g31925
VCollectively, this study indicates that HMGN5 is a novel target for developing effective therapeutic strategies for malignant meningiomas.
p32530
sg4
(dp32531
(VHMGN5
p32532
Vmalignant meningiomas
p32533
tp32534
I01
ssg31931
(lp32535
(dp32536
g31934
I116
sg31935
g32533
sg31936
I21
sg31937
VC0259785
p32537
sg31939
I2
sasg31940
(lp32538
(dp32539
g31934
I40
sg31935
g32532
sg31936
I5
sg31944
VP82970
p32540
sg31939
I1
sasa(dp32541
g31925
VLuciferase reporter assay showed that miR-186 targets NSBP1 3'-untranslated region (UTR) directly and suppresses NSBP1 (HMGN5) expression in human bladder cancer cells.
p32542
sg4
(dp32543
(VHMGN5
p32544
Vbladder cancer
p32545
tp32546
I01
ssg31931
(lp32547
(dp32548
g31934
I147
sg31935
g32545
sg31936
I14
sg31937
VC0699885
p32549
sg31939
I2
sasg31940
(lp32550
(dp32551
g31934
I54
sg31935
VNSBP1 3
p32552
sg31936
I7
sg31944
VP82970
p32553
sg31939
I2
sa(dp32554
g31934
I54
sg31935
VNSBP1
p32555
sg31936
I5
sg31944
VP82970
p32556
sg31939
I1
sa(dp32557
g31934
I38
sg31935
VmiR-186 targets
p32558
sg31936
I15
sg31944
g190
sg31939
I2
sa(dp32559
g31934
I120
sg31935
g32544
sg31936
I5
sg31944
VP82970
p32560
sg31939
I1
sasa(dp32561
g31925
VOur data first time identified miR-186 as the upstream regulator of NSBP1 and also suggest miR-186-suppressed NSBP1 as a novel therapeutic approach for bladder cancer.
p32562
sg4
(dp32563
(VNSBP1
p32564
Vbladder cancer
p32565
tp32566
I01
ssg31931
(lp32567
(dp32568
g31934
I152
sg31935
g32565
sg31936
I14
sg31937
VC0699885
p32569
sg31939
I2
sasg31940
(lp32570
(dp32571
g31934
I91
sg31935
VmiR-186-suppressed NSBP1
p32572
sg31936
I24
sg31944
g190
sg31939
I2
sa(dp32573
g31934
I68
sg31935
g32564
sg31936
I5
sg31944
VP82970
p32574
sg31939
I1
sa(dp32575
g31934
I31
sg31935
VmiR-186
p32576
sg31936
I7
sg31944
g190
sg31939
I1
sasa(dp32577
g31925
VIn this study, we show that TK1 is upregulated and localizes on the plasma membrane of Burkitt's lymphoma, acute promyelocytic leukemia, T cell leukemia, and acute lymphoblastic leukemia (ALL).
p32578
sg4
(dp32579
(VTK1
p32580
VT cell leukemia
p32581
tp32582
I00
ssg31931
(lp32583
(dp32584
g31934
I107
sg31935
Vacute promyelocytic leukemia
p32585
sg31936
I28
sg31937
VC0023487
p32586
sg31939
I3
sa(dp32587
g31934
I87
sg31935
VBurkitt's lymphoma
p32588
sg31936
I18
sg31937
VC0006413
p32589
sg31939
I2
sa(dp32590
g31934
I188
sg31935
VALL
p32591
sg31936
I3
sg31937
VC1961102
p32592
sg31939
I1
sa(dp32593
g31934
I158
sg31935
Vacute lymphoblastic leukemia
p32594
sg31936
I28
sg31937
VC1961102
p32595
sg31939
I3
sa(dp32596
g31934
I137
sg31935
g32581
sg31936
I15
sg31937
VC0023492
p32597
sg31939
I3
sasg31940
(lp32598
(dp32599
g31934
I28
sg31935
g32580
sg31936
I3
sg31944
VP04183
p32600
sg31939
I1
sasa(dp32601
g31925
VTK1 has been reported as a reliable prognostic factor in solid tumors and chronic lymphocytic leukemia, but has not yet been tested in large populations of patients with non-Hodgkin lymphoma.
p32602
sg4
(dp32603
(VTK1
p32604
Vchronic lymphocytic leukemia
p32605
tp32606
I00
ssg31931
(lp32607
(dp32608
g31934
I57
sg31935
Vsolid tumors
p32609
sg31936
I12
sg31937
VC0280100
p32610
sg31939
I2
sa(dp32611
g31934
I170
sg31935
Vnon-Hodgkin lymphoma
p32612
sg31936
I20
sg31937
VC0024305
p32613
sg31939
I2
sa(dp32614
g31934
I74
sg31935
g32605
sg31936
I28
sg31937
VC0023434
p32615
sg31939
I3
sasg31940
(lp32616
(dp32617
g31934
I0
sg31935
g32604
sg31936
I3
sg31944
VP04183
p32618
sg31939
I1
sasa(dp32619
g31925
VIn this study, the prognostic significance of TK1 levels was assessed in 170 prospectively enrolled patients with previously untreated follicular lymphoma (FL).
p32620
sg4
(dp32621
(VTK1
p32622
VFL
p32623
tp32624
I00
ssg31931
(lp32625
(dp32626
g31934
I135
sg31935
Vfollicular lymphoma
p32627
sg31936
I19
sg31937
VC0024301
p32628
sg31939
I2
sa(dp32629
g31934
I156
sg31935
g32623
sg31936
I2
sg31937
VC0024301
p32630
sg31939
I1
sasg31940
(lp32631
(dp32632
g31934
I46
sg31935
g32622
sg31936
I3
sg31944
VP04183
p32633
sg31939
I1
sasa(dp32634
g31925
VThe TK1 level at the time of treatment initiation was shown to correlate with the clinical stage, Follicular Lymphoma International Prognostic Index (FLIPI) score, Beta(2)-microglobulin level, lactate dehydrogenase level and B symptoms.
p32635
sg4
(dp32636
(Vlactate dehydrogenase
p32637
VFollicular Lymphoma
p32638
tp32639
I00
ssg31931
(lp32640
(dp32641
g31934
I98
sg31935
g32638
sg31936
I19
sg31937
VC0024301
p32642
sg31939
I2
sasg31940
(lp32643
(dp32644
g31934
I164
sg31935
VBeta(2)-microglobulin
p32645
sg31936
I21
sg31944
VP61769
p32646
sg31939
I1
sa(dp32647
g31934
I4
sg31935
VTK1
p32648
sg31936
I3
sg31944
VP04183
p32649
sg31939
I1
sa(dp32650
g31934
I193
sg31935
g32637
sg31936
I21
sg31944
VP49366
p32651
sg31939
I2
sasa(dp32652
g31925
VWe show that high serum TK1 levels predict poorer overall survival and correlate with unmutated immunoglobulin variable region genes, CD38 and ZAP-70 expression, and subsequent risk of developing large B-cell lymphoma (Richter syndrome).
p32653
sg4
(dp32654
(VZAP-70
p32655
VB-cell lymphoma
p32656
tp32657
I00
ssg31931
(lp32658
(dp32659
g31934
I219
sg31935
VRichter syndrome
p32660
sg31936
I16
sg31937
VC0349631
p32661
sg31939
I2
sa(dp32662
g31934
I202
sg31935
g32656
sg31936
I15
sg31937
VC0079731
p32663
sg31939
I2
sasg31940
(lp32664
(dp32665
g31934
I134
sg31935
VCD38
p32666
sg31936
I4
sg31944
VP28907
p32667
sg31939
I1
sa(dp32668
g31934
I96
sg31935
Vimmunoglobulin variable region genes
p32669
sg31936
I36
sg31944
g190
sg31939
I4
sa(dp32670
g31934
I24
sg31935
VTK1
p32671
sg31936
I3
sg31944
VP04183
p32672
sg31939
I1
sa(dp32673
g31934
I143
sg31935
g32655
sg31936
I6
sg31944
VP43403
p32674
sg31939
I1
sasa(dp32675
g31925
VPodocalyxin (PODXL), which belongs to the CD34 family and regulates cell morphology, has been linked to EMT in lung cancer, and PODXL overexpression is associated with poor prognosis in several different classes of cancers.
p32676
sg4
(dp32677
(VCD34 family
p32678
Vlung cancer
p32679
tp32680
I01
ssg31931
(lp32681
(dp32682
g31934
I215
sg31935
Vcancers
p32683
sg31936
I7
sg31937
VC0006826
p32684
sg31939
I1
sa(dp32685
g31934
I111
sg31935
g32679
sg31936
I11
sg31937
VC0684249
p32686
sg31939
I2
sasg31940
(lp32687
(dp32688
g31934
I104
sg31935
VEMT
p32689
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp32690
g31934
I13
sg31935
VPODXL
p32691
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp32692
g31934
I42
sg31935
g32678
sg31936
I11
sg31944
VP28906
p32693
sg31939
I2
sa(dp32694
g31934
I13
sg31935
VPODXL
p32695
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp32696
g31934
I0
sg31935
VPodocalyxin
p32697
sg31936
I11
sg31944
g190
sg31939
I1
sasa(dp32698
g31925
VA highly selective inhibitor of phosphatidylinositol 3-kinase-Akt signaling attenuated EMT of PODXL-OE cells, while a transforming growth factor inhibitor did not, suggesting that PODXL induces EMT of lung adenocarcinoma cells via the phosphatidylinositol 3-kinase pathway.
p32699
sg4
(dp32700
(Vphosphatidylinositol 3-kinase
p32701
Vlung adenocarcinoma
p32702
tp32703
I00
ssg31931
(lp32704
(dp32705
g31934
I201
sg31935
g32702
sg31936
I19
sg31937
VC0152013
p32706
sg31939
I2
sasg31940
(lp32707
(dp32708
g31934
I87
sg31935
VEMT
p32709
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp32710
g31934
I118
sg31935
Vtransforming growth factor
p32711
sg31936
I26
sg31944
g190
sg31939
I3
sa(dp32712
g31934
I94
sg31935
VPODXL
p32713
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp32714
g31934
I32
sg31935
Vphosphatidylinositol 3-kinase
p32715
sg31936
I29
sg31944
VP42336
p32716
sg31939
I2
sa(dp32717
g31934
I32
sg31935
g32701
sg31936
I29
sg31944
VP42336
p32718
sg31939
I2
sa(dp32719
g31934
I94
sg31935
VPODXL-OE
p32720
sg31936
I8
sg31944
g190
sg31939
I1
sa(dp32721
g31934
I62
sg31935
VAkt
p32722
sg31936
I3
sg31944
g190
sg31939
I1
sasa(dp32723
g31925
VIn esophageal and gastric adenocarcinoma combined, the prognostic significance of PODXL expression on TTR was confirmed in unadjusted Cox regression analysis (HR = 5.36, 95 % CI 1.68-17.06, p = 0.005) and remained significant in the adjusted model (HR = 3.39, 95 % CI 1.01-11.35, p = 0.048).
p32724
sg4
(dp32725
(VTTR
p32726
Vgastric adenocarcinoma
p32727
tp32728
I00
ssg31931
(lp32729
(dp32730
g31934
I18
sg31935
g32727
sg31936
I22
sg31937
VC0278701
p32731
sg31939
I2
sasg31940
(lp32732
(dp32733
g31934
I82
sg31935
VPODXL
p32734
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp32735
g31934
I102
sg31935
g32726
sg31936
I3
sg31944
VP02766
p32736
sg31939
I1
sasa(dp32737
g31925
VFurthermore, transfection of a PODXL-rescue construct into pancreatic cancer cells in which both PODXL and gelsolin were suppressed failed to increase the formation of the protrusions.
p32738
sg4
(dp32739
(Vgelsolin
p32740
Vpancreatic cancer
p32741
tp32742
I00
ssg31931
(lp32743
(dp32744
g31934
I172
sg31935
Vprotrusions
p32745
sg31936
I11
sg31937
VC0333056
p32746
sg31939
I1
sa(dp32747
g31934
I59
sg31935
g32741
sg31936
I17
sg31937
VC0235974
p32748
sg31939
I2
sasg31940
(lp32749
(dp32750
g31934
I31
sg31935
VPODXL
p32751
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp32752
g31934
I107
sg31935
g32740
sg31936
I8
sg31944
VP06396
p32753
sg31939
I1
sa(dp32754
g31934
I31
sg31935
VPODXL-rescue construct
p32755
sg31936
I22
sg31944
g190
sg31939
I2
sasa(dp32756
g31925
VThe DEGs MAPT, DSTN, SPTBN1, ARHGEF2 and SKA1 are suggested to be candidate biomarkers for childhood obesity.
p32757
sg4
(dp32758
(VDSTN
p32759
Vchildhood obesity
p32760
tp32761
I00
ssg31931
(lp32762
(dp32763
g31934
I91
sg31935
g32760
sg31936
I17
sg31937
VC2362324
p32764
sg31939
I2
sasg31940
(lp32765
(dp32766
g31934
I4
sg31935
VDEGs MAPT
p32767
sg31936
I9
sg31944
g190
sg31939
I2
sa(dp32768
g31934
I15
sg31935
g32759
sg31936
I4
sg31944
VP60981
p32769
sg31939
I1
sa(dp32770
g31934
I29
sg31935
VARHGEF2
p32771
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp32772
g31934
I21
sg31935
VSPTBN1
p32773
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp32774
g31934
I41
sg31935
VSKA1
p32775
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp32776
g31925
VPb(II) increased the phosphorylated ERK1/2 and phosphorylated AKT but not the phosphorylated ERK5, phosphorylated p38 and JNK activity in human non-small cell lung adenocarcinoma CL3 cells.
p32777
sg4
(dp32778
(VJNK
p32779
Vlung adenocarcinoma
p32780
tp32781
I00
ssg31931
(lp32782
(dp32783
g31934
I159
sg31935
g32780
sg31936
I19
sg31937
VC0152013
p32784
sg31939
I2
sasg31940
(lp32785
(dp32786
g31934
I36
sg31935
VERK1/2
p32787
sg31936
I6
sg31944
VP27361
p32788
sg31939
I1
sa(dp32789
g31934
I93
sg31935
VERK5
p32790
sg31936
I4
sg31944
VP53778
p32791
sg31939
I1
sa(dp32792
g31934
I114
sg31935
Vp38
p32793
sg31936
I3
sg31944
VP46108
p32794
sg31939
I1
sa(dp32795
g31934
I122
sg31935
g32779
sg31936
I3
sg31944
VP53779
p32796
sg31939
I1
sa(dp32797
g31934
I62
sg31935
VAKT
p32798
sg31936
I3
sg31944
g190
sg31939
I1
sasa(dp32799
g31925
VIn this study we have explored the involvement of oxidative stress in Cr(VI)-induced JNK, p38 and ERK signaling pathways and their effects on Cr(VI) cytotoxicity in human non-small cell lung carcinoma CL3 cells.
p32800
sg4
(dp32801
(VJNK
p32802
Voxidative stress
p32803
tp32804
I00
ssg31931
(lp32805
(dp32806
g31934
I171
sg31935
Vnon-small cell lung carcinoma
p32807
sg31936
I29
sg31937
VC0007131
p32808
sg31939
I4
sa(dp32809
g31934
I149
sg31935
Vcytotoxicity
p32810
sg31936
I12
sg31937
VC0596402
p32811
sg31939
I1
sa(dp32812
g31934
I50
sg31935
g32803
sg31936
I16
sg31937
VC0242606
p32813
sg31939
I2
sasg31940
(lp32814
(dp32815
g31934
I90
sg31935
Vp38
p32816
sg31936
I3
sg31944
VP46108
p32817
sg31939
I1
sa(dp32818
g31934
I98
sg31935
VERK
p32819
sg31936
I3
sg31944
VP29323
p32820
sg31939
I1
sa(dp32821
g31934
I85
sg31935
g32802
sg31936
I3
sg31944
VP53779
p32822
sg31939
I1
sasa(dp32823
g31925
VcAMP response element-binding protein (CREB) is one downstream target of iPLA2 that is required for the transcriptional activation of iNOS in response to virus infection, and consistent with the effects of BEL enantiomers on iNOS expression, (S)-BEL more effectively inhibits EMCV-induced CREB phosphorylation than (R)-BEL in macrophages.
p32824
sg4
(dp32825
(VCREB
p32826
Vvirus infection
p32827
tp32828
I01
ssg31931
(lp32829
(dp32830
g31934
I154
sg31935
g32827
sg31936
I15
sg31937
VC0042769
p32831
sg31939
I2
sasg31940
(lp32832
(dp32833
g31934
I73
sg31935
ViPLA2
p32834
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp32835
g31934
I0
sg31935
VcAMP response element-binding protein
p32836
sg31936
I37
sg31944
g190
sg31939
I4
sa(dp32837
g31934
I39
sg31935
VCREB
p32838
sg31936
I4
sg31944
VP16220
p32839
sg31939
I1
sa(dp32840
g31934
I39
sg31935
g32826
sg31936
I4
sg31944
VP16220
p32841
sg31939
I1
sa(dp32842
g31934
I134
sg31935
ViNOS
p32843
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp32844
g31925
VSpecific attention will be placed on the ability of virus infection to activate multiple signaling cascades (such as PKR, MAPK, iPLA2, NF-kappaB) and how these pathways are integrated in the regulation of individual target gene expression.
p32845
sg4
(dp32846
(VMAPK
p32847
Vvirus infection
p32848
tp32849
I00
ssg31931
(lp32850
(dp32851
g31934
I52
sg31935
g32848
sg31936
I15
sg31937
VC0042769
p32852
sg31939
I2
sasg31940
(lp32853
(dp32854
g31934
I135
sg31935
VNF-kappaB
p32855
sg31936
I9
sg31944
VP19838
p32856
sg31939
I1
sa(dp32857
g31934
I117
sg31935
VPKR
p32858
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp32859
g31934
I122
sg31935
g32847
sg31936
I4
sg31944
VP53779
p32860
sg31939
I1
sa(dp32861
g31934
I128
sg31935
ViPLA2
p32862
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp32863
g31925
VHFD-fed mice lacking Cnot7 and Tob express elevated levels of Ucp1 mRNA in iWAT and are resistant to diet-induced obesity.
p32864
sg4
(dp32865
(VUcp1 mRNA
p32866
Vobesity
p32867
tp32868
I00
ssg31931
(lp32869
(dp32870
g31934
I114
sg31935
g32867
sg31936
I7
sg31937
VC0028754
p32871
sg31939
I1
sasg31940
(lp32872
(dp32873
g31934
I31
sg31935
VTob
p32874
sg31936
I3
sg31944
VP50616
p32875
sg31939
I1
sa(dp32876
g31934
I21
sg31935
VCnot7
p32877
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp32878
g31934
I62
sg31935
g32866
sg31936
I9
sg31944
VP25874
p32879
sg31939
I2
sasa(dp32880
g31925
VThus, the Cnot7-Tob-BRF1 axis inhibits Ucp1 expression and contributes to obesity.
p32881
sg4
(dp32882
(VTob
p32883
Vobesity
p32884
tp32885
I00
ssg31931
(lp32886
(dp32887
g31934
I74
sg31935
g32884
sg31936
I7
sg31937
VC0028754
p32888
sg31939
I1
sasg31940
(lp32889
(dp32890
g31934
I39
sg31935
VUcp1
p32891
sg31936
I4
sg31944
VP25874
p32892
sg31939
I1
sa(dp32893
g31934
I20
sg31935
VBRF1
p32894
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp32895
g31934
I16
sg31935
g32883
sg31936
I3
sg31944
VP50616
p32896
sg31939
I1
sa(dp32897
g31934
I10
sg31935
VCnot7
p32898
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp32899
g31925
VThe results showed that treatment with the MUC1-MBP/BCG anti-tumor vaccine did not cause any organ toxicity, except for arthritis or local nodules induced by BCG in several rats.
p32900
sg4
(dp32901
(VMBP
p32902
Vnodules
p32903
tp32904
I00
ssg31931
(lp32905
(dp32906
g31934
I120
sg31935
Varthritis
p32907
sg31936
I9
sg31937
VC0003864
p32908
sg31939
I1
sa(dp32909
g31934
I139
sg31935
g32903
sg31936
I7
sg31937
VC0028259
p32910
sg31939
I1
sa(dp32911
g31934
I61
sg31935
Vtumor
p32912
sg31936
I5
sg31937
VC0027651
p32913
sg31939
I1
sasg31940
(lp32914
(dp32915
g31934
I48
sg31935
g32902
sg31936
I3
sg31944
VP13727
p32916
sg31939
I1
sasa(dp32917
g31925
VTo investigate leptin, adiponectin, soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) levels and their relationship with each other and metabolic parameters in women with polycystic ovary syndrome (PCOS).
p32918
sg4
(dp32919
(Vleptin
p32920
Vpolycystic ovary syndrome
p32921
tp32922
I00
ssg31931
(lp32923
(dp32924
g31934
I253
sg31935
VPCOS
p32925
sg31936
I4
sg31937
VC0032460
p32926
sg31939
I1
sa(dp32927
g31934
I58
sg31935
Vadhesion
p32928
sg31936
I8
sg31937
VC0001511
p32929
sg31939
I1
sa(dp32930
g31934
I58
sg31935
Vadhesion
p32931
sg31936
I8
sg31937
VC0001511
p32932
sg31939
I1
sa(dp32933
g31934
I226
sg31935
g32921
sg31936
I25
sg31937
VC0032460
p32934
sg31939
I3
sasg31940
(lp32935
(dp32936
g31934
I23
sg31935
Vadiponectin
p32937
sg31936
I11
sg31944
g190
sg31939
I1
sa(dp32938
g31934
I97
sg31935
Vvascular cell adhesion molecule-1
p32939
sg31936
I33
sg31944
VP19320
p32940
sg31939
I4
sa(dp32941
g31934
I79
sg31935
VsICAM-1
p32942
sg31936
I7
sg31944
VP05362
p32943
sg31939
I1
sa(dp32944
g31934
I36
sg31935
Vsoluble intercellular adhesion molecule-1
p32945
sg31936
I41
sg31944
VP05362
p32946
sg31939
I4
sa(dp32947
g31934
I15
sg31935
g32920
sg31936
I6
sg31944
VP41159
p32948
sg31939
I1
sasa(dp32949
g31925
VNon-insulin resistant PCOS had significantly higher adiponectin and sVCAM-1 levels.
p32950
sg4
(dp32951
(Vinsulin
p32952
VPCOS
p32953
tp32954
I00
ssg31931
(lp32955
(dp32956
g31934
I22
sg31935
g32953
sg31936
I4
sg31937
VC0032460
p32957
sg31939
I1
sasg31940
(lp32958
(dp32959
g31934
I4
sg31935
g32952
sg31936
I7
sg31944
VP01308
p32960
sg31939
I1
sa(dp32961
g31934
I52
sg31935
Vadiponectin
p32962
sg31936
I11
sg31944
g190
sg31939
I1
sasa(dp32963
g31925
VIncreases in IL-6 and TNF-Alfa and adhesion molecules (E-selectin, ICAM-1 and VCAM-1) were also observed, particularly in the PCOS IR group, providing evidence that inflammation and oxidative stress are related in PCOS patients.
p32964
sg4
(dp32965
(VE-selectin
p32966
VPCOS
p32967
tp32968
I00
ssg31931
(lp32969
(dp32970
g31934
I182
sg31935
Voxidative stress
p32971
sg31936
I16
sg31937
VC0242606
p32972
sg31939
I2
sa(dp32973
g31934
I126
sg31935
VPCOS
p32974
sg31936
I4
sg31937
VC0032460
p32975
sg31939
I1
sa(dp32976
g31934
I165
sg31935
Vinflammation
p32977
sg31936
I12
sg31937
VC0021368
p32978
sg31939
I1
sa(dp32979
g31934
I35
sg31935
Vadhesion
p32980
sg31936
I8
sg31937
VC0001511
p32981
sg31939
I1
sa(dp32982
g31934
I126
sg31935
g32967
sg31936
I4
sg31937
VC0032460
p32983
sg31939
I1
sasg31940
(lp32984
(dp32985
g31934
I22
sg31935
VTNF-Alfa and adhesion molecules
p32986
sg31936
I31
sg31944
VP01375
p32987
sg31939
I4
sa(dp32988
g31934
I78
sg31935
VVCAM-1
p32989
sg31936
I6
sg31944
VP19320
p32990
sg31939
I1
sa(dp32991
g31934
I67
sg31935
VICAM-1
p32992
sg31936
I6
sg31944
VP05362
p32993
sg31939
I1
sa(dp32994
g31934
I13
sg31935
VIL-6
p32995
sg31936
I4
sg31944
VP05231
p32996
sg31939
I1
sa(dp32997
g31934
I55
sg31935
g32966
sg31936
I10
sg31944
VP16581
p32998
sg31939
I1
sasa(dp32999
g31925
VInflammation in PCOS induces leukocyte-endothelium interactions and a simultaneous increase in IL-6, TNF-Alfa, E-selectin, ICAM-1 and VCAM-1.
p33000
sg4
(dp33001
(VVCAM-1
p33002
VPCOS
p33003
tp33004
I01
ssg31931
(lp33005
(dp33006
g31934
I0
sg31935
VInflammation
p33007
sg31936
I12
sg31937
VC0021368
p33008
sg31939
I1
sa(dp33009
g31934
I16
sg31935
g33003
sg31936
I4
sg31937
VC0032460
p33010
sg31939
I1
sasg31940
(lp33011
(dp33012
g31934
I123
sg31935
VICAM-1
p33013
sg31936
I6
sg31944
VP05362
p33014
sg31939
I1
sa(dp33015
g31934
I95
sg31935
VIL-6
p33016
sg31936
I4
sg31944
VP05231
p33017
sg31939
I1
sa(dp33018
g31934
I101
sg31935
VTNF-Alfa
p33019
sg31936
I8
sg31944
VP01375
p33020
sg31939
I1
sa(dp33021
g31934
I111
sg31935
VE-selectin
p33022
sg31936
I10
sg31944
VP16581
p33023
sg31939
I1
sa(dp33024
g31934
I134
sg31935
g33002
sg31936
I6
sg31944
VP19320
p33025
sg31939
I1
sasa(dp33026
g31925
VIn conclusion, we disclosed a novel mechanism that JQ1 inhibits cell proliferation, induces cell senescence and apoptosis of chondrosarcoma cells through the regulation of the YAP/p21/c-Myc/Bcl-xL signaling axis.
p33027
sg4
(dp33028
(Vc-Myc
p33029
Vchondrosarcoma
p33030
tp33031
I00
ssg31931
(lp33032
(dp33033
g31934
I125
sg31935
g33030
sg31936
I14
sg31937
VC0008479
p33034
sg31939
I1
sa(dp33035
g31934
I69
sg31935
Vproliferation
p33036
sg31936
I13
sg31937
VC0334094
p33037
sg31939
I1
sasg31940
(lp33038
(dp33039
g31934
I190
sg31935
VBcl-xL
p33040
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp33041
g31934
I176
sg31935
VYAP
p33042
sg31936
I3
sg31944
VP46937
p33043
sg31939
I1
sa(dp33044
g31934
I180
sg31935
Vp21
p33045
sg31936
I3
sg31944
VP42857
p33046
sg31939
I1
sa(dp33047
g31934
I184
sg31935
g33029
sg31936
I5
sg31944
VP12524
p33048
sg31939
I1
sasa(dp33049
g31925
VBH-3 mimetics ABT-737 and ABT-263 are synthetic small-molecule inhibitors of anti-apoptotic proteins B-cell lymphoma-2 (Bcl2) and Bcl-xL, which play a critical role in survival of chondrosarcoma cells.
p33050
sg4
(dp33051
(VBcl2
p33052
VB-cell lymphoma
p33053
tp33054
I00
ssg31931
(lp33055
(dp33056
g31934
I180
sg31935
Vchondrosarcoma
p33057
sg31936
I14
sg31937
VC0008479
p33058
sg31939
I1
sa(dp33059
g31934
I101
sg31935
g33053
sg31936
I15
sg31937
VC0079731
p33060
sg31939
I2
sasg31940
(lp33061
(dp33062
g31934
I120
sg31935
g33052
sg31936
I4
sg31944
VP10415
p33063
sg31939
I1
sa(dp33064
g31934
I77
sg31935
Vanti-apoptotic proteins B-cell lymphoma-2
p33065
sg31936
I41
sg31944
g190
sg31939
I4
sa(dp33066
g31934
I130
sg31935
VBcl-xL
p33067
sg31936
I6
sg31944
g190
sg31939
I1
sasa(dp33068
g31925
VHere we show that the IHh signal pathway was activated in chondrosarcoma, and knocking down the expression of Gli1 attenuated the disturbed IHh signal pathway, which not only suppressed cell proliferation and promoted G2/M cell cycle arrest but also enhanced cell apoptosis by downregulating Bcl-2 and Bcl-xl expression.
p33069
sg4
(dp33070
(VGli1
p33071
VIHh
p33072
tp33073
I00
ssg31931
(lp33074
(dp33075
g31934
I191
sg31935
Vproliferation
p33076
sg31936
I13
sg31937
VC0334094
p33077
sg31939
I1
sa(dp33078
g31934
I22
sg31935
VIHh
p33079
sg31936
I3
sg31937
VC0342384
p33080
sg31939
I1
sa(dp33081
g31934
I58
sg31935
Vchondrosarcoma
p33082
sg31936
I14
sg31937
VC0008479
p33083
sg31939
I1
sa(dp33084
g31934
I22
sg31935
g33072
sg31936
I3
sg31937
VC0342384
p33085
sg31939
I1
sasg31940
(lp33086
(dp33087
g31934
I292
sg31935
VBcl-2
p33088
sg31936
I5
sg31944
VP10415
p33089
sg31939
I1
sa(dp33090
g31934
I22
sg31935
VIHh
p33091
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp33092
g31934
I110
sg31935
g33071
sg31936
I4
sg31944
VP08151
p33093
sg31939
I1
sa(dp33094
g31934
I302
sg31935
VBcl-xl
p33095
sg31936
I6
sg31944
g190
sg31939
I1
sasa(dp33096
g31925
VAs in conventional chondrosarcoma, antiapoptotic proteins (Bcl-2, and/or Bcl-xl) were highly expressed in all subtypes.
p33097
sg4
(dp33098
(VBcl-2
p33099
Vconventional chondrosarcoma
p33100
tp33101
I00
ssg31931
(lp33102
(dp33103
g31934
I6
sg31935
g33100
sg31936
I27
sg31937
VC1335473
p33104
sg31939
I2
sasg31940
(lp33105
(dp33106
g31934
I73
sg31935
VBcl-xl
p33107
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp33108
g31934
I59
sg31935
g33099
sg31936
I5
sg31944
VP10415
p33109
sg31939
I1
sasa(dp33110
g31925
VBPB induced upregulation of Bax, Bad and Bak, downregulation of Bcl-2, Bid and Bcl-XL and dysfunction of mitochondria in chondrosarcoma.
p33111
sg4
(dp33112
(VBid
p33113
Vchondrosarcoma
p33114
tp33115
I00
ssg31931
(lp33116
(dp33117
g31934
I121
sg31935
g33114
sg31936
I14
sg31937
VC0008479
p33118
sg31939
I1
sasg31940
(lp33119
(dp33120
g31934
I64
sg31935
VBcl-2
p33121
sg31936
I5
sg31944
VP10415
p33122
sg31939
I1
sa(dp33123
g31934
I71
sg31935
g33113
sg31936
I3
sg31944
VP55957
p33124
sg31939
I1
sa(dp33125
g31934
I79
sg31935
VBcl-XL
p33126
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp33127
g31934
I41
sg31935
VBak
p33128
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp33129
g31934
I33
sg31935
VBad
p33130
sg31936
I3
sg31944
g190
sg31939
I1
sasa(dp33131
g31925
VEGCG induced upregulation of Bax and Bak, downregulation of Bcl-2 and Bcl-XL, and dysfunction of mitochondria in chondrosarcoma.
p33132
sg4
(dp33133
(VBcl-2
p33134
Vchondrosarcoma
p33135
tp33136
I00
ssg31931
(lp33137
(dp33138
g31934
I113
sg31935
g33135
sg31936
I14
sg31937
VC0008479
p33139
sg31939
I1
sasg31940
(lp33140
(dp33141
g31934
I70
sg31935
VBcl-XL
p33142
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp33143
g31934
I37
sg31935
VBak
p33144
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp33145
g31934
I60
sg31935
g33134
sg31936
I5
sg31944
VP10415
p33146
sg31939
I1
sasa(dp33147
g31925
VFPTB induced up-regulation of Bax and Bak, down-regulation of Bcl-2 and Bcl-XL and dysfunction of mitochondria in chondrosarcoma.
p33148
sg4
(dp33149
(VFPTB
p33150
Vchondrosarcoma
p33151
tp33152
I00
ssg31931
(lp33153
(dp33154
g31934
I114
sg31935
g33151
sg31936
I14
sg31937
VC0008479
p33155
sg31939
I1
sasg31940
(lp33156
(dp33157
g31934
I72
sg31935
VBcl-XL
p33158
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp33159
g31934
I62
sg31935
VBcl-2
p33160
sg31936
I5
sg31944
VP10415
p33161
sg31939
I1
sa(dp33162
g31934
I38
sg31935
VBak
p33163
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp33164
g31934
I0
sg31935
g33150
sg31936
I4
sg31944
VP49356
p33165
sg31939
I1
sasa(dp33166
g31925
VThree-dimensional speckle tracking echocardiography (3D-STE) was used to evaluate the improvement of continuous subcutaneous insulin infusion on the left ventricular (LV) systolic function of patients with type 2 diabetes mellitu (T2DM).
p33167
sg4
(dp33168
(Vinsulin
p33169
Vtype 2 diabetes
p33170
tp33171
I00
ssg31931
(lp33172
(dp33173
g31934
I206
sg31935
g33170
sg31936
I15
sg31937
VC0011860
p33174
sg31939
I3
sasg31940
(lp33175
(dp33176
g31934
I125
sg31935
g33169
sg31936
I7
sg31944
VP01308
p33177
sg31939
I1
sasa(dp33178
g31925
VSince nerve functions are affected by inflammatory response during the course of leprosy, changes in the production of NGF and its receptor (NGF R) may be directly associated with disability and sensory loss.
p33179
sg4
(dp33180
(VNGF
p33181
Vleprosy
p33182
tp33183
I00
ssg31931
(lp33184
(dp33185
g31934
I38
sg31935
Vinflammatory response
p33186
sg31936
I21
sg31937
VC1155266
p33187
sg31939
I2
sa(dp33188
g31934
I195
sg31935
Vsensory loss
p33189
sg31936
I12
sg31937
VC0278134
p33190
sg31939
I2
sa(dp33191
g31934
I81
sg31935
g33182
sg31936
I7
sg31937
VC0023343
p33192
sg31939
I1
sasg31940
(lp33193
(dp33194
g31934
I119
sg31935
VNGF
p33195
sg31936
I3
sg31944
VP01138
p33196
sg31939
I1
sa(dp33197
g31934
I119
sg31935
g33181
sg31936
I3
sg31944
VP01138
p33198
sg31939
I1
sasa(dp33199
g31925
VSkin biopsies were collected and submitted to immunohistochemistry using specific antibodies to IL-17, NGF and NGF R. Quantitative analysis of NGF, NGFR and IL-17 immunostaining showed a significant difference between the clinical forms, with higher expression of NGF and NGFR in lepromatous leprosy and IL-17 in tuberculoid leprosy.
p33200
sg4
(dp33201
(VNGFR
p33202
Vtuberculoid leprosy
p33203
tp33204
I00
ssg31931
(lp33205
(dp33206
g31934
I280
sg31935
Vlepromatous leprosy
p33207
sg31936
I19
sg31937
VC0023348
p33208
sg31939
I2
sa(dp33209
g31934
I313
sg31935
g33203
sg31936
I19
sg31937
VC0023351
p33210
sg31939
I2
sasg31940
(lp33211
(dp33212
g31934
I111
sg31935
VNGF R
p33213
sg31936
I5
sg31944
VP01138
p33214
sg31939
I2
sa(dp33215
g31934
I103
sg31935
VNGF
p33216
sg31936
I3
sg31944
VP01138
p33217
sg31939
I1
sa(dp33218
g31934
I103
sg31935
VNGF
p33219
sg31936
I3
sg31944
VP01138
p33220
sg31939
I1
sa(dp33221
g31934
I103
sg31935
VNGF
p33222
sg31936
I3
sg31944
VP01138
p33223
sg31939
I1
sa(dp33224
g31934
I148
sg31935
VNGFR
p33225
sg31936
I4
sg31944
VP08138
p33226
sg31939
I1
sa(dp33227
g31934
I148
sg31935
g33202
sg31936
I4
sg31944
VP08138
p33228
sg31939
I1
sasa(dp33229
g31925
VNext, in human subjects, previously treated for pulmonary tuberculosis, the MTB-containing CD271(+) BM-MSCs exhibited high expression of hypoxia-inducible factor 1Alfa and low expression of CD146, a hypoxia down-regulated cell surface marker of human BM-MSCs.
p33230
sg4
(dp33231
(VCD146
p33232
Vhypoxia
p33233
tp33234
I00
ssg31931
(lp33235
(dp33236
g31934
I48
sg31935
Vpulmonary tuberculosis
p33237
sg31936
I22
sg31937
VC0041327
p33238
sg31939
I2
sa(dp33239
g31934
I137
sg31935
Vhypoxia
p33240
sg31936
I7
sg31937
VC0242184
p33241
sg31939
I1
sa(dp33242
g31934
I137
sg31935
g33233
sg31936
I7
sg31937
VC0242184
p33243
sg31939
I1
sasg31940
(lp33244
(dp33245
g31934
I137
sg31935
Vhypoxia-inducible factor 1Alfa
p33246
sg31936
I30
sg31944
g190
sg31939
I3
sa(dp33247
g31934
I190
sg31935
g33232
sg31936
I5
sg31944
VP43121
p33248
sg31939
I1
sasa(dp33249
g31925
VTherefore, the objective of this study was to correlate the immunoexpression patterns of NGF and NGF-R in the different clinical forms of leprosy, and to associate the findings with the in situ expression of TGF-Beta and clinical classification of the disease.
p33250
sg4
(dp33251
(VTGF-Beta
p33252
Vleprosy
p33253
tp33254
I00
ssg31931
(lp33255
(dp33256
g31934
I138
sg31935
g33253
sg31936
I7
sg31937
VC0023343
p33257
sg31939
I1
sasg31940
(lp33258
(dp33259
g31934
I89
sg31935
VNGF
p33260
sg31936
I3
sg31944
VP01138
p33261
sg31939
I1
sa(dp33262
g31934
I97
sg31935
VNGF-R
p33263
sg31936
I5
sg31944
VP01138
p33264
sg31939
I1
sa(dp33265
g31934
I208
sg31935
g33252
sg31936
I8
sg31944
VP18075
p33266
sg31939
I1
sasa(dp33267
g31925
VThere was a significant positive correlation between NGF and NGF-R in the different clinical forms of leprosy.
p33268
sg4
(dp33269
(VNGF-R
p33270
Vleprosy
p33271
tp33272
I00
ssg31931
(lp33273
(dp33274
g31934
I102
sg31935
g33271
sg31936
I7
sg31937
VC0023343
p33275
sg31939
I1
sasg31940
(lp33276
(dp33277
g31934
I53
sg31935
VNGF
p33278
sg31936
I3
sg31944
VP01138
p33279
sg31939
I1
sa(dp33280
g31934
I61
sg31935
g33270
sg31936
I5
sg31944
VP01138
p33281
sg31939
I1
sasa(dp33282
g31925
VMoreover, most viable M. tuberculosis was recovered from the bone marrow CD271(+)CD45(-)-enriched cell fraction, and only few viable bacteria could be isolated from the CD271(-)CD45(+) cell fraction.
p33283
sg4
(dp33284
(VCD271(-)CD45
p33285
Vtuberculosis
p33286
tp33287
I00
ssg31931
(lp33288
(dp33289
g31934
I25
sg31935
g33286
sg31936
I12
sg31937
VC0041296
p33290
sg31939
I1
sasg31940
(lp33291
(dp33292
g31934
I81
sg31935
VCD45
p33293
sg31936
I4
sg31944
VP08575
p33294
sg31939
I1
sa(dp33295
g31934
I169
sg31935
g33285
sg31936
I12
sg31944
VP08138
p33296
sg31939
I1
sasa(dp33297
g31925
VWe recently developed a systems biological approach to vaccine safety evaluation where identification of specific biomarkers in a rat pre-clinical study evaluated the safety of vaccines for pandemic H5N1 influenza including Irf7, Lgals9, Lgalsbp3, Cxcl11, Timp1, Tap2, Psmb9, Psme1, Tapbp, C2, Csf1, Mx2, Zbp1, Ifrd1, Trafd1, Cxcl9, Beta2m, Npc1, Ngfr and Ifi47.
p33298
sg4
(dp33299
(VCsf1
p33300
VNpc1
p33301
tp33302
I00
ssg31931
(lp33303
(dp33304
g31934
I341
sg31935
g33301
sg31936
I4
sg31937
VC3179455
p33305
sg31939
I1
sa(dp33306
g31934
I199
sg31935
VH5N1 influenza
p33307
sg31936
I14
sg31937
VC2748361
p33308
sg31939
I2
sasg31940
(lp33309
(dp33310
g31934
I318
sg31935
VTrafd1
p33311
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp33312
g31934
I326
sg31935
VCxcl9
p33313
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp33314
g31934
I311
sg31935
VIfrd1
p33315
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp33316
g31934
I300
sg31935
VMx2
p33317
sg31936
I3
sg31944
VP20592
p33318
sg31939
I1
sa(dp33319
g31934
I256
sg31935
VTimp1
p33320
sg31936
I5
sg31944
VP01033
p33321
sg31939
I1
sa(dp33322
g31934
I248
sg31935
VCxcl11
p33323
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp33324
g31934
I347
sg31935
VNgfr
p33325
sg31936
I4
sg31944
VP08138
p33326
sg31939
I1
sa(dp33327
g31934
I224
sg31935
VIrf7
p33328
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp33329
g31934
I341
sg31935
VNpc1
p33330
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp33331
g31934
I230
sg31935
VLgals9
p33332
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp33333
g31934
I333
sg31935
VBeta2m
p33334
sg31936
I6
sg31944
VP61769
p33335
sg31939
I1
sa(dp33336
g31934
I269
sg31935
VPsmb9
p33337
sg31936
I5
sg31944
VP28065
p33338
sg31939
I1
sa(dp33339
g31934
I294
sg31935
g33300
sg31936
I4
sg31944
VP09919
p33340
sg31939
I1
sa(dp33341
g31934
I263
sg31935
VTap2
p33342
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp33343
g31934
I276
sg31935
VPsme1
p33344
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp33345
g31934
I305
sg31935
VZbp1
p33346
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp33347
g31925
VWe speculate that E3 ubiquitin ligases MDM2 and MDM4 can be attractive therapeutic target for p53 and Notch signaling pathways in malignant melanoma by using small molecule inhibitors.
p33348
sg4
(dp33349
(VE3 ubiquitin
p33350
Vmalignant melanoma
p33351
tp33352
I00
ssg31931
(lp33353
(dp33354
g31934
I130
sg31935
g33351
sg31936
I18
sg31937
VC0025202
p33355
sg31939
I2
sasg31940
(lp33356
(dp33357
g31934
I94
sg31935
Vp53
p33358
sg31936
I3
sg31944
VP42771
p33359
sg31939
I1
sa(dp33360
g31934
I18
sg31935
g33350
sg31936
I12
sg31944
VP62979
p33361
sg31939
I2
sa(dp33362
g31934
I48
sg31935
VMDM4
p33363
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp33364
g31925
VThree proteins were uniquely altered in vaginal carcinoma (DDX48, erbB3-binding protein and biliverdin reductase) and five in cervical carcinoma (peroxiredoxin 2, annexin A2, sarcomeric tropomyosin kappa, human ribonuclease inhibitor and prolyl-4-hydrolase beta).
p33365
sg4
(dp33366
(Vhuman ribonuclease inhibitor
p33367
Vvaginal carcinoma
p33368
tp33369
I01
ssg31931
(lp33370
(dp33371
g31934
I126
sg31935
Vcervical carcinoma
p33372
sg31936
I18
sg31937
VC0302592
p33373
sg31939
I2
sa(dp33374
g31934
I40
sg31935
g33368
sg31936
I17
sg31937
VC0262659
p33375
sg31939
I2
sasg31940
(lp33376
(dp33377
g31934
I92
sg31935
Vbiliverdin reductase
p33378
sg31936
I20
sg31944
VP53004
p33379
sg31939
I2
sa(dp33380
g31934
I59
sg31935
VDDX48
p33381
sg31936
I5
sg31944
VP38919
p33382
sg31939
I1
sa(dp33383
g31934
I66
sg31935
VerbB3-binding protein
p33384
sg31936
I21
sg31944
VP21860
p33385
sg31939
I2
sa(dp33386
g31934
I163
sg31935
Vannexin A2, sarcomeric tropomyosin kappa
p33387
sg31936
I40
sg31944
VP07355
p33388
sg31939
I5
sa(dp33389
g31934
I146
sg31935
Vperoxiredoxin 2
p33390
sg31936
I15
sg31944
VP32119
p33391
sg31939
I2
sa(dp33392
g31934
I205
sg31935
g33367
sg31936
I28
sg31944
VP13489
p33393
sg31939
I3
sasa(dp33394
g31925
VMitochondrial (mt) DNA-associated NARP (neurogenic muscle weakness, ataxia, and retinitis pigmentosa) syndrome is due to mutation in the MT-ATP6 gene.
p33395
sg4
(dp33396
(VMT-ATP6 gene
p33397
Vataxia
p33398
tp33399
I00
ssg31931
(lp33400
(dp33401
g31934
I80
sg31935
Vretinitis pigmentosa
p33402
sg31936
I20
sg31937
VC0035334
p33403
sg31939
I2
sa(dp33404
g31934
I51
sg31935
Vmuscle weakness
p33405
sg31936
I15
sg31937
VC0030552
p33406
sg31939
I2
sa(dp33407
g31934
I68
sg31935
g33398
sg31936
I6
sg31937
VC0004134
p33408
sg31939
I1
sa(dp33409
g31934
I102
sg31935
Vsyndrome
p33410
sg31936
I8
sg31937
VC0039082
p33411
sg31939
I1
sasg31940
(lp33412
(dp33413
g31934
I34
sg31935
VNARP
p33414
sg31936
I4
sg31944
VP47972
p33415
sg31939
I1
sa(dp33416
g31934
I137
sg31935
g33397
sg31936
I12
sg31944
VP36543
p33417
sg31939
I2
sasa(dp33418
g31925
VPathogenic mutations in MT-ATP6 are associated with the Leigh syndrome, the syndrome of neuropathy, ataxia, and retinitis pigmentosa (NARP), as well as with non-classical phenotypes, while MT-ATP8 is less frequently mutated in patients with mitochondrial disease.
p33419
sg4
(dp33420
(VMT-ATP6
p33421
VLeigh syndrome
p33422
tp33423
I00
ssg31931
(lp33424
(dp33425
g31934
I241
sg31935
Vmitochondrial disease
p33426
sg31936
I21
sg31937
VC0751651
p33427
sg31939
I2
sa(dp33428
g31934
I88
sg31935
Vneuropathy, ataxia, and retinitis pigmentosa
p33429
sg31936
I44
sg31937
VC1328349
p33430
sg31939
I5
sa(dp33431
g31934
I56
sg31935
g33422
sg31936
I14
sg31937
VC0023264
p33432
sg31939
I2
sa(dp33433
g31934
I62
sg31935
Vsyndrome
p33434
sg31936
I8
sg31937
VC0039082
p33435
sg31939
I1
sasg31940
(lp33436
(dp33437
g31934
I189
sg31935
VMT-ATP8
p33438
sg31936
I7
sg31944
VP03928
p33439
sg31939
I1
sa(dp33440
g31934
I24
sg31935
g33421
sg31936
I7
sg31944
VP36543
p33441
sg31939
I1
sasa(dp33442
g31925
VNeurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP) is caused by m.8993T&gt;G/C mutations in the mitochondrial adenosine triphosphate synthase subunit 6 gene (MT-ATP6).
p33443
sg4
(dp33444
(VMT-ATP6
p33445
Vmuscle weakness
p33446
tp33447
I00
ssg31931
(lp33448
(dp33449
g31934
I28
sg31935
Vataxia
p33450
sg31936
I6
sg31937
VC0004134
p33451
sg31939
I1
sa(dp33452
g31934
I40
sg31935
Vretinitis pigmentosa
p33453
sg31936
I20
sg31937
VC0035334
p33454
sg31939
I2
sa(dp33455
g31934
I11
sg31935
g33446
sg31936
I15
sg31937
VC0030552
p33456
sg31939
I2
sasg31940
(lp33457
(dp33458
g31934
I113
sg31935
Vmitochondrial adenosine triphosphate synthase subunit 6 gene
p33459
sg31936
I60
sg31944
VP56381
p33460
sg31939
I7
sa(dp33461
g31934
I175
sg31935
g33445
sg31936
I7
sg31944
VP36543
p33462
sg31939
I1
sasa(dp33463
g31925
VNeuroblastoma cells treated with free myb-as or nontargeted CCL-myb-as showed the same level of c-myb protein expression as control cells.
p33464
sg4
(dp33465
(VCCL
p33466
VCCL
p33467
tp33468
I01
ssg31931
(lp33469
(dp33470
g31934
I0
sg31935
VNeuroblastoma
p33471
sg31936
I13
sg31937
VC0027819
p33472
sg31939
I1
sa(dp33473
g31934
I60
sg31935
g33467
sg31936
I3
sg31937
VC1852438
p33474
sg31939
I1
sasg31940
(lp33475
(dp33476
g31934
I96
sg31935
Vc-myb protein
p33477
sg31936
I13
sg31944
VP10243
p33478
sg31939
I2
sa(dp33479
g31934
I38
sg31935
Vmyb
p33480
sg31936
I3
sg31944
VP10243
p33481
sg31939
I1
sa(dp33482
g31934
I38
sg31935
Vmyb
p33483
sg31936
I3
sg31944
VP10243
p33484
sg31939
I1
sa(dp33485
g31934
I60
sg31935
g33466
sg31936
I3
sg31944
VP43320
p33486
sg31939
I1
sasa(dp33487
g31925
VWhile YY1 is known to exert both positive and negative regulatory influences on nuclear-encoded mitochondrial proteins, as well as on neurodegeneration-related genes, in all cell lines we studied (including neuroblastoma) the effect of YY1 on GDAP1 expression is activatory.
p33488
sg4
(dp33489
(Vnuclear-encoded mitochondrial proteins
p33490
Vneurodegeneration
p33491
tp33492
I00
ssg31931
(lp33493
(dp33494
g31934
I207
sg31935
Vneuroblastoma
p33495
sg31936
I13
sg31937
VC0027819
p33496
sg31939
I1
sa(dp33497
g31934
I134
sg31935
g33491
sg31936
I17
sg31937
VC0027746
p33498
sg31939
I1
sasg31940
(lp33499
(dp33500
g31934
I6
sg31935
VYY1
p33501
sg31936
I3
sg31944
VP25490
p33502
sg31939
I1
sa(dp33503
g31934
I6
sg31935
VYY1
p33504
sg31936
I3
sg31944
VP25490
p33505
sg31939
I1
sa(dp33506
g31934
I243
sg31935
VGDAP1
p33507
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp33508
g31934
I80
sg31935
g33490
sg31936
I38
sg31944
VP02649
p33509
sg31939
I3
sasa(dp33510
g31925
VUsing the DBH-expressing human neuroblastoma SK-N-BE(2)C and DBH-negative HeLa cell lines as model systems, we report here that this CRE/YY1/AP1 area interacts with multiple nuclear proteins, including CRE-binding protein (CREB) and transcription factor YY1 in a cell-specific manner.
p33511
sg4
(dp33512
(VAP1
p33513
Vneuroblastoma
p33514
tp33515
I00
ssg31931
(lp33516
(dp33517
g31934
I31
sg31935
g33514
sg31936
I13
sg31937
VC0027819
p33518
sg31939
I1
sasg31940
(lp33519
(dp33520
g31934
I202
sg31935
VCRE-binding protein
p33521
sg31936
I19
sg31944
g190
sg31939
I2
sa(dp33522
g31934
I233
sg31935
Vtranscription factor YY1
p33523
sg31936
I24
sg31944
VP25490
p33524
sg31939
I3
sa(dp33525
g31934
I10
sg31935
VDBH
p33526
sg31936
I3
sg31944
VP09172
p33527
sg31939
I1
sa(dp33528
g31934
I223
sg31935
VCREB
p33529
sg31936
I4
sg31944
VP16220
p33530
sg31939
I1
sa(dp33531
g31934
I137
sg31935
VYY1
p33532
sg31936
I3
sg31944
VP25490
p33533
sg31939
I1
sa(dp33534
g31934
I141
sg31935
g33513
sg31936
I3
sg31944
VP27695
p33535
sg31939
I1
sasa(dp33536
g31925
VThe expressions of 10 putative cell surface markers of CSCs, as well as aldehyde dehydrogenase (ALDH) activity, were studied, and the tumorigenic properties of cells were evaluated by in vitro tumorsphere assays and in vivo xenografts by limiting dilution assays.Results: We found that a subpopulation of gastric carcinoma cells expressing EPCAM, CD133, CD166, CD44, and a high ALDH activity presented the properties to generate new heterogeneous tumorspheres in vitro and tumors in vivo CD44 and CD166 were coexpressed, representing 6.1% to 37.5% of the cells; ALDH activity was detected in 1.6% to 15.4% of the cells; and the ALDH+ cells represented a core within the CD44+/CD166+ subpopulation that contained the highest frequency of tumorigenic CSCs in vivo The ALDH+ cells possessed drug efflux properties and were more resistant to standard chemotherapy than the ALDH- cells, a process that was partially reversed by verapamil treatment.Conclusions: CD44 and ALDH are the most specific biomarkers to detect and isolate tumorigenic and chemoresistant gastric CSCs in noncardia gastric carcinomas independently of the histologic classification of the tumor.
p33537
sg4
(dp33538
(Valdehyde dehydrogenase
p33539
Vgastric carcinoma
p33540
tp33541
I01
ssg31931
(lp33542
(dp33543
g31934
I193
sg31935
Vtumors
p33544
sg31936
I6
sg31937
VC0027651
p33545
sg31939
I1
sa(dp33546
g31934
I778
sg31935
Vpossessed
p33547
sg31936
I9
sg31937
VC0850310
p33548
sg31939
I1
sa(dp33549
g31934
I305
sg31935
g33540
sg31936
I17
sg31937
VC0699791
p33550
sg31939
I2
sa(dp33551
g31934
I134
sg31935
Vtumor
p33552
sg31936
I5
sg31937
VC0027651
p33553
sg31939
I1
sa(dp33554
g31934
I1090
sg31935
Vcarcinomas
p33555
sg31936
I10
sg31937
VC0007097
p33556
sg31939
I1
sasg31940
(lp33557
(dp33558
g31934
I96
sg31935
VALDH
p33559
sg31936
I4
sg31944
VP00352
p33560
sg31939
I1
sa(dp33561
g31934
I676
sg31935
VCD166+
p33562
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp33563
g31934
I354
sg31935
VCD166
p33564
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp33565
g31934
I340
sg31935
VEPCAM
p33566
sg31936
I5
sg31944
VP16422
p33567
sg31939
I1
sa(dp33568
g31934
I96
sg31935
VALDH
p33569
sg31936
I4
sg31944
VP49366
p33570
sg31939
I1
sa(dp33571
g31934
I96
sg31935
VALDH
p33572
sg31936
I4
sg31944
VP00352
p33573
sg31939
I1
sa(dp33574
g31934
I96
sg31935
VALDH
p33575
sg31936
I4
sg31944
VP00352
p33576
sg31939
I1
sa(dp33577
g31934
I354
sg31935
VCD166
p33578
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp33579
g31934
I96
sg31935
VALDH
p33580
sg31936
I4
sg31944
VP00352
p33581
sg31939
I1
sa(dp33582
g31934
I347
sg31935
VCD133
p33583
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp33584
g31934
I72
sg31935
g33539
sg31936
I22
sg31944
VP49366
p33585
sg31939
I2
sasa(dp33586
g31925
VClinically, low CD10 expression was consistent with a specific set of ovarian cancer patient samples.
p33587
sg4
(dp33588
(VCD10
p33589
Vovarian cancer
p33590
tp33591
I00
ssg31931
(lp33592
(dp33593
g31934
I70
sg31935
g33590
sg31936
I14
sg31937
VC1140680
p33594
sg31939
I2
sasg31940
(lp33595
(dp33596
g31934
I16
sg31935
g33589
sg31936
I4
sg31944
VP08473
p33597
sg31939
I1
sasa(dp33598
g31925
VFurthermore, our data indicate that primary stage targeting of CD10-/ALDH- CSCs in specific ovarian cancer patients in future may facilitate targeting of recurrent disease, before it ever develops.
p33599
sg4
(dp33600
(VCD10-/ALDH- CSCs
p33601
Vovarian cancer
p33602
tp33603
I00
ssg31931
(lp33604
(dp33605
g31934
I92
sg31935
g33602
sg31936
I14
sg31937
VC1140680
p33606
sg31939
I2
sa(dp33607
g31934
I154
sg31935
Vrecurrent disease
p33608
sg31936
I17
sg31937
VC0277556
p33609
sg31939
I2
sasg31940
(lp33610
(dp33611
g31934
I63
sg31935
g33601
sg31936
I16
sg31944
VP08473
p33612
sg31939
I2
sasa(dp33613
g31925
VAll cases were negative for CD10 and WT-1 ruling out endometrial stromal tumor and were negative for HMB-45 and melan-A ruling out perivascular epithelioid cell tumor (both endometrial stromal tumor and perivascular epithelioid cell tumor have prominent vessels but have different histomorphology).
p33614
sg4
(dp33615
(VCD10
p33616
Vendometrial stromal tumor
p33617
tp33618
I00
ssg31931
(lp33619
(dp33620
g31934
I53
sg31935
Vendometrial stromal tumor
p33621
sg31936
I25
sg31937
VC0334695
p33622
sg31939
I3
sa(dp33623
g31934
I73
sg31935
Vtumor
p33624
sg31936
I5
sg31937
VC0027651
p33625
sg31939
I1
sa(dp33626
g31934
I73
sg31935
Vtumor
p33627
sg31936
I5
sg31937
VC0027651
p33628
sg31939
I1
sa(dp33629
g31934
I53
sg31935
g33617
sg31936
I25
sg31937
VC0334695
p33630
sg31939
I3
sasg31940
(lp33631
(dp33632
g31934
I112
sg31935
Vmelan-A
p33633
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp33634
g31934
I28
sg31935
g33616
sg31936
I4
sg31944
VP08473
p33635
sg31939
I1
sa(dp33636
g31934
I101
sg31935
VHMB-45
p33637
sg31936
I6
sg31944
g190
sg31939
I1
sasa(dp33638
g31925
VImmunohistochemistry indicated a phenotypic transition from a uterine leiomyosarcoma to a vaginal epithelioid lesion; marker expression changed from the uterine tumor actin+/desmin+/caldesmon+/CD10- phenotype, through the tumor emboli, to an actin-/desmin-/caldesmon-/CD10+ phenotype in the vaginal lesion.
p33639
sg4
(dp33640
(VCD10
p33641
Vuterine tumor
p33642
tp33643
I00
ssg31931
(lp33644
(dp33645
g31934
I161
sg31935
Vtumor
p33646
sg31936
I5
sg31937
VC0027651
p33647
sg31939
I1
sa(dp33648
g31934
I44
sg31935
Vtransition
p33649
sg31936
I10
sg31937
VC0599156
p33650
sg31939
I1
sa(dp33651
g31934
I291
sg31935
Vvaginal lesion
p33652
sg31936
I14
sg31937
VC0566943
p33653
sg31939
I2
sa(dp33654
g31934
I62
sg31935
Vuterine leiomyosarcoma
p33655
sg31936
I22
sg31937
VC0280631
p33656
sg31939
I2
sa(dp33657
g31934
I153
sg31935
g33642
sg31936
I13
sg31937
VC0042138
p33658
sg31939
I2
sasg31940
(lp33659
(dp33660
g31934
I182
sg31935
Vcaldesmon+
p33661
sg31936
I10
sg31944
g190
sg31939
I1
sa(dp33662
g31934
I257
sg31935
Vcaldesmon-/CD10+ phenotype
p33663
sg31936
I26
sg31944
g190
sg31939
I2
sa(dp33664
g31934
I174
sg31935
Vdesmin+
p33665
sg31936
I7
sg31944
VP98155
p33666
sg31939
I1
sa(dp33667
g31934
I242
sg31935
Vactin-/desmin
p33668
sg31936
I13
sg31944
VP98155
p33669
sg31939
I1
sa(dp33670
g31934
I193
sg31935
g33641
sg31936
I4
sg31944
VP08473
p33671
sg31939
I1
sasa(dp33672
g31925
VImmunohistochemistry for IFITM1 and CD10 was performed in 20 cases of smooth muscle neoplasms (10 cases leiomyoma, 10 cases leiomyosarcoma), 14 cases of endometrial stromal sarcoma (ESS) (12 cases of low grade and 2 cases of high grade) and 12 cases of carcinosarcoma.
p33673
sg4
(dp33674
(VCD10
p33675
Vendometrial stromal sarcoma
p33676
tp33677
I00
ssg31931
(lp33678
(dp33679
g31934
I124
sg31935
Vleiomyosarcoma
p33680
sg31936
I14
sg31937
VC0023269
p33681
sg31939
I1
sa(dp33682
g31934
I182
sg31935
VESS
p33683
sg31936
I3
sg31937
VC0206630
p33684
sg31939
I1
sa(dp33685
g31934
I253
sg31935
Vcarcinosarcoma
p33686
sg31936
I14
sg31937
VC0007140
p33687
sg31939
I1
sa(dp33688
g31934
I77
sg31935
Vmuscle neoplasms
p33689
sg31936
I16
sg31937
VC0282606
p33690
sg31939
I2
sa(dp33691
g31934
I104
sg31935
Vleiomyoma
p33692
sg31936
I9
sg31937
VC0023267
p33693
sg31939
I1
sa(dp33694
g31934
I153
sg31935
g33676
sg31936
I27
sg31937
VC0206630
p33695
sg31939
I3
sasg31940
(lp33696
(dp33697
g31934
I25
sg31935
VIFITM1
p33698
sg31936
I6
sg31944
VP13164
p33699
sg31939
I1
sa(dp33700
g31934
I36
sg31935
g33675
sg31936
I4
sg31944
VP08473
p33701
sg31939
I1
sasa(dp33702
g31925
VWhile both IFITM1 (83%) and CD10 (91%) had high sensitivity in differentiating low-grade ESSs from smooth muscle neoplasms, IFITM1 (70%) had higher specificity compared with CD10 (45%).
p33703
sg4
(dp33704
(VIFITM1
p33705
Vmuscle neoplasms
p33706
tp33707
I00
ssg31931
(lp33708
(dp33709
g31934
I106
sg31935
g33706
sg31936
I16
sg31937
VC0282606
p33710
sg31939
I2
sasg31940
(lp33711
(dp33712
g31934
I28
sg31935
VCD10
p33713
sg31936
I4
sg31944
VP08473
p33714
sg31939
I1
sa(dp33715
g31934
I28
sg31935
VCD10
p33716
sg31936
I4
sg31944
VP08473
p33717
sg31939
I1
sa(dp33718
g31934
I11
sg31935
VIFITM1
p33719
sg31936
I6
sg31944
VP13164
p33720
sg31939
I1
sa(dp33721
g31934
I11
sg31935
g33705
sg31936
I6
sg31944
VP13164
p33722
sg31939
I1
sasa(dp33723
g31925
VIn this study IFITM1 appears to be a more specific marker of endometrial stromal differentiation compared with CD10 in differentiating low-grade ESSs from smooth muscle neoplasms.
p33724
sg4
(dp33725
(VCD10
p33726
Vmuscle neoplasms
p33727
tp33728
I00
ssg31931
(lp33729
(dp33730
g31934
I162
sg31935
g33727
sg31936
I16
sg31937
VC0282606
p33731
sg31939
I2
sasg31940
(lp33732
(dp33733
g31934
I111
sg31935
g33726
sg31936
I4
sg31944
VP08473
p33734
sg31939
I1
sasa(dp33735
g31925
VMeanwhile, gain or loss of function of miR-19a demonstrated that miR-19a can promote cell growth of bladder cancer cells and the further mechanism studies indicated that its oncogenic role was dependent on targeting PTEN.
p33736
sg4
(dp33737
(VPTEN
p33738
Vbladder cancer
p33739
tp33740
I00
ssg31931
(lp33741
(dp33742
g31934
I100
sg31935
g33739
sg31936
I14
sg31937
VC0699885
p33743
sg31939
I2
sasg31940
(lp33744
(dp33745
g31934
I39
sg31935
VmiR-19a
p33746
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp33747
g31934
I216
sg31935
g33738
sg31936
I4
sg31944
VP60484
p33748
sg31939
I1
sa(dp33749
g31934
I39
sg31935
VmiR-19a
p33750
sg31936
I7
sg31944
g190
sg31939
I1
sasa(dp33751
g31925
VThe oncogenic role of miR19a in bladder cancer was dependent on targeting PTEN.
p33752
sg4
(dp33753
(VPTEN
p33754
Vbladder cancer
p33755
tp33756
I00
ssg31931
(lp33757
(dp33758
g31934
I32
sg31935
g33755
sg31936
I14
sg31937
VC0699885
p33759
sg31939
I2
sasg31940
(lp33760
(dp33761
g31934
I74
sg31935
g33754
sg31936
I4
sg31944
VP60484
p33762
sg31939
I1
sasa(dp33763
g31925
VThere was significant decreases in serum albumin and haptoglobin and increases in alpha-1 globulin, ceruloplasmin and alpha-1 globulin, there were no significant differences between schistosomiasis patients and the controls in terms of changes in any laboratory test as a result of the treatment, thus suggesting that patients with active schistosomiasis do not incur a higher risk of hepatic dysfunction while using oral contraception.
p33764
sg4
(dp33765
(Vhaptoglobin
p33766
Vhepatic dysfunction
p33767
tp33768
I00
ssg31931
(lp33769
(dp33770
g31934
I182
sg31935
Vschistosomiasis
p33771
sg31936
I15
sg31937
VC0036323
p33772
sg31939
I1
sa(dp33773
g31934
I182
sg31935
Vschistosomiasis
p33774
sg31936
I15
sg31937
VC0036323
p33775
sg31939
I1
sa(dp33776
g31934
I385
sg31935
g33767
sg31936
I19
sg31937
VC0086565
p33777
sg31939
I2
sasg31940
(lp33778
(dp33779
g31934
I100
sg31935
Vceruloplasmin
p33780
sg31936
I13
sg31944
VP00450
p33781
sg31939
I1
sa(dp33782
g31934
I82
sg31935
Valpha-1 globulin
p33783
sg31936
I16
sg31944
VP25100
p33784
sg31939
I2
sa(dp33785
g31934
I82
sg31935
Valpha-1 globulin
p33786
sg31936
I16
sg31944
VP25100
p33787
sg31939
I2
sa(dp33788
g31934
I35
sg31935
Vserum albumin
p33789
sg31936
I13
sg31944
g190
sg31939
I2
sa(dp33790
g31934
I53
sg31935
g33766
sg31936
I11
sg31944
VP00738
p33791
sg31939
I1
sasa(dp33792
g31925
VAqueous flare values and the vitreous levels of VEGF, IL-6, MCP-1, sICAM-1, and sVEGFR-2 were compared between previously untreated patients with BRVO and patients with macular hole (MH).
p33793
sg4
(dp33794
(VIL-6
p33795
VMH
p33796
tp33797
I00
ssg31931
(lp33798
(dp33799
g31934
I169
sg31935
Vmacular hole
p33800
sg31936
I12
sg31937
VC0024441
p33801
sg31939
I2
sa(dp33802
g31934
I183
sg31935
g33796
sg31936
I2
sg31937
VC0024441
p33803
sg31939
I1
sa(dp33804
g31934
I8
sg31935
Vflare
p33805
sg31936
I5
sg31937
VC1517205
p33806
sg31939
I1
sasg31940
(lp33807
(dp33808
g31934
I60
sg31935
VMCP-1
p33809
sg31936
I5
sg31944
VP41597
p33810
sg31939
I1
sa(dp33811
g31934
I54
sg31935
g33795
sg31936
I4
sg31944
VP05231
p33812
sg31939
I1
sasa(dp33813
g31925
VWe investigated the relations between the aqueous flare value and vitreous levels of vascular endothelial growth factor (VEGF), soluble intercellular adhesion molecule-1 (sICAM-1), and interleukin-6 (IL-6) in patients with CRVO and macular edema or patients with idiopathic macular hole (MH).
p33814
sg4
(dp33815
(Vintercellular adhesion molecule-1
p33816
VMH
p33817
tp33818
I00
ssg31931
(lp33819
(dp33820
g31934
I274
sg31935
Vmacular hole
p33821
sg31936
I12
sg31937
VC0024441
p33822
sg31939
I2
sa(dp33823
g31934
I232
sg31935
Vmacular edema
p33824
sg31936
I13
sg31937
VC0271051
p33825
sg31939
I2
sa(dp33826
g31934
I150
sg31935
Vadhesion
p33827
sg31936
I8
sg31937
VC0001511
p33828
sg31939
I1
sa(dp33829
g31934
I288
sg31935
g33817
sg31936
I2
sg31937
VC0024441
p33830
sg31939
I1
sa(dp33831
g31934
I50
sg31935
Vflare
p33832
sg31936
I5
sg31937
VC1517205
p33833
sg31939
I1
sasg31940
(lp33834
(dp33835
g31934
I200
sg31935
VIL-6
p33836
sg31936
I4
sg31944
VP05231
p33837
sg31939
I1
sa(dp33838
g31934
I185
sg31935
Vinterleukin-6
p33839
sg31936
I13
sg31944
VP05231
p33840
sg31939
I1
sa(dp33841
g31934
I85
sg31935
Vvascular endothelial growth factor
p33842
sg31936
I34
sg31944
g190
sg31939
I4
sa(dp33843
g31934
I136
sg31935
g33816
sg31936
I33
sg31944
VP05362
p33844
sg31939
I3
sa(dp33845
g31934
I121
sg31935
VVEGF
p33846
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp33847
g31925
VVitreous fluid levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor 2 (sVEGFR-2), soluble intercellular adhesion molecule 1 (sICAM-1), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), and pentraxin 3 (PTX3) were significantly higher in CRVO patients than in macular hole patients.
p33848
sg4
(dp33849
(Vmonocyte chemotactic protein 1
p33850
Vmacular hole
p33851
tp33852
I00
ssg31931
(lp33853
(dp33854
g31934
I126
sg31935
Vadhesion
p33855
sg31936
I8
sg31937
VC0001511
p33856
sg31939
I1
sa(dp33857
g31934
I293
sg31935
g33851
sg31936
I12
sg31937
VC0024441
p33858
sg31939
I2
sasg31940
(lp33859
(dp33860
g31934
I61
sg31935
VVEGF
p33861
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp33862
g31934
I223
sg31935
Vpentraxin 3
p33863
sg31936
I11
sg31944
VP26022
p33864
sg31939
I2
sa(dp33865
g31934
I112
sg31935
Vintercellular adhesion molecule 1
p33866
sg31936
I33
sg31944
VP05362
p33867
sg31939
I4
sa(dp33868
g31934
I76
sg31935
VVEGF receptor 2
p33869
sg31936
I15
sg31944
g190
sg31939
I3
sa(dp33870
g31934
I236
sg31935
VPTX3
p33871
sg31936
I4
sg31944
VP26022
p33872
sg31939
I1
sa(dp33873
g31934
I211
sg31935
VMCP-1
p33874
sg31936
I5
sg31944
VP41597
p33875
sg31939
I1
sa(dp33876
g31934
I172
sg31935
VIL-6
p33877
sg31936
I4
sg31944
VP05231
p33878
sg31939
I1
sa(dp33879
g31934
I25
sg31935
Vvascular endothelial growth factor
p33880
sg31936
I34
sg31944
g190
sg31939
I4
sa(dp33881
g31934
I157
sg31935
Vinterleukin 6
p33882
sg31936
I13
sg31944
VP05231
p33883
sg31939
I2
sa(dp33884
g31934
I179
sg31935
g33850
sg31936
I30
sg31944
VP14222
p33885
sg31939
I4
sasa(dp33886
g31925
VIn 39 patients with BRVO and macular edema and 21 individuals with idiopathic macular hole (MH) serving as controls, vitreous fluid samples were obtained during vitreoretinal surgery, and the levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor 2 (sVEGFR-2), soluble intercellular adhesion molecule 1 (sICAM-1), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), pentraxin 3 (PTX3), and pigment epithelium-derived factor (PEDF) were measured by enzyme-linked immunosorbent assay.
p33887
sg4
(dp33888
(Vmonocyte chemotactic protein 1
p33889
Vadhesion
p33890
tp33891
I00
ssg31931
(lp33892
(dp33893
g31934
I92
sg31935
VMH
p33894
sg31936
I2
sg31937
VC0024441
p33895
sg31939
I1
sa(dp33896
g31934
I78
sg31935
Vmacular hole
p33897
sg31936
I12
sg31937
VC0024441
p33898
sg31939
I2
sa(dp33899
g31934
I29
sg31935
Vmacular edema
p33900
sg31936
I13
sg31937
VC0271051
p33901
sg31939
I2
sa(dp33902
g31934
I303
sg31935
g33890
sg31936
I8
sg31937
VC0001511
p33903
sg31939
I1
sasg31940
(lp33904
(dp33905
g31934
I202
sg31935
Vvascular endothelial growth factor
p33906
sg31936
I34
sg31944
g190
sg31939
I4
sa(dp33907
g31934
I238
sg31935
VVEGF
p33908
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp33909
g31934
I349
sg31935
VIL-6
p33910
sg31936
I4
sg31944
VP05231
p33911
sg31939
I1
sa(dp33912
g31934
I334
sg31935
Vinterleukin 6
p33913
sg31936
I13
sg31944
VP05231
p33914
sg31939
I2
sa(dp33915
g31934
I388
sg31935
VMCP-1
p33916
sg31936
I5
sg31944
VP41597
p33917
sg31939
I1
sa(dp33918
g31934
I409
sg31935
VPTX3
p33919
sg31936
I4
sg31944
VP26022
p33920
sg31939
I1
sa(dp33921
g31934
I396
sg31935
Vpentraxin 3
p33922
sg31936
I11
sg31944
VP26022
p33923
sg31939
I2
sa(dp33924
g31934
I289
sg31935
Vintercellular adhesion molecule 1
p33925
sg31936
I33
sg31944
VP05362
p33926
sg31939
I4
sa(dp33927
g31934
I356
sg31935
g33889
sg31936
I30
sg31944
VP14222
p33928
sg31939
I4
sa(dp33929
g31934
I253
sg31935
VVEGF receptor 2
p33930
sg31936
I15
sg31944
g190
sg31939
I3
sasa(dp33931
g31925
VTo investigate relationships among vitreous fluid levels of soluble vascular endothelial growth factor receptor-2 (sVEGFR-2), vascular endothelial growth factor (VEGF), and soluble intercellular adhesion molecule 1 (sICAM-1) in patients with branch retinal vein occlusion (BRVO) and macular edema or patients with idiopathic macular hole.
p33932
sg4
(dp33933
(Vintercellular adhesion molecule 1
p33934
VBRVO
p33935
tp33936
I00
ssg31931
(lp33937
(dp33938
g31934
I283
sg31935
Vmacular edema
p33939
sg31936
I13
sg31937
VC0271051
p33940
sg31939
I2
sa(dp33941
g31934
I325
sg31935
Vmacular hole
p33942
sg31936
I12
sg31937
VC0024441
p33943
sg31939
I2
sa(dp33944
g31934
I242
sg31935
Vbranch retinal vein occlusion
p33945
sg31936
I29
sg31937
VC0339505
p33946
sg31939
I4
sa(dp33947
g31934
I195
sg31935
Vadhesion
p33948
sg31936
I8
sg31937
VC0001511
p33949
sg31939
I1
sa(dp33950
g31934
I273
sg31935
g33935
sg31936
I4
sg31937
VC0339505
p33951
sg31939
I1
sasg31940
(lp33952
(dp33953
g31934
I116
sg31935
VVEGF
p33954
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp33955
g31934
I68
sg31935
Vvascular endothelial growth factor receptor-2
p33956
sg31936
I45
sg31944
VP35968
p33957
sg31939
I5
sa(dp33958
g31934
I181
sg31935
g33934
sg31936
I33
sg31944
VP05362
p33959
sg31939
I4
sa(dp33960
g31934
I68
sg31935
Vvascular endothelial growth factor
p33961
sg31936
I34
sg31944
g190
sg31939
I4
sasa(dp33962
g31925
VLevels of sICAM-1 in this group were compared with those in vitreous from 31 eyes with RRD without clinical risk factors for PVR, 32 eyes with established PVR and 10 eyes with macular holes.
p33963
sg4
(dp33964
(VPVR
p33965
Vmacular holes
p33966
tp33967
I01
ssg31931
(lp33968
(dp33969
g31934
I125
sg31935
VPVR
p33970
sg31936
I3
sg31937
VC1860404
p33971
sg31939
I1
sa(dp33972
g31934
I125
sg31935
VPVR
p33973
sg31936
I3
sg31937
VC1860404
p33974
sg31939
I1
sa(dp33975
g31934
I176
sg31935
g33966
sg31936
I13
sg31937
VC0024441
p33976
sg31939
I2
sasg31940
(lp33977
(dp33978
g31934
I125
sg31935
g33965
sg31936
I3
sg31944
VP15151
p33979
sg31939
I1
sasa(dp33980
g31925
VVitreous sICAM-1 levels in eyes with RRD at high risk of developing PVR were significantly lower than in eyes with established PVR (p=0.037), but higher than in eyes with macular holes (p &lt;0.0001).
p33981
sg4
(dp33982
(VPVR
p33983
Vmacular holes
p33984
tp33985
I01
ssg31931
(lp33986
(dp33987
g31934
I68
sg31935
VPVR
p33988
sg31936
I3
sg31937
VC1860404
p33989
sg31939
I1
sa(dp33990
g31934
I171
sg31935
g33984
sg31936
I13
sg31937
VC0024441
p33991
sg31939
I2
sa(dp33992
g31934
I68
sg31935
VPVR
p33993
sg31936
I3
sg31937
VC1860404
p33994
sg31939
I1
sasg31940
(lp33995
(dp33996
g31934
I68
sg31935
g33983
sg31936
I3
sg31944
VP15151
p33997
sg31939
I1
sasa(dp33998
g31925
VRare pathogenic alleles with high penetrance and associated haplotypes at 10 loci (CFTR, FAH, HBB, HEXA, LDLR, LPL, PAH, PABP2, PDDR, and SACS) are expressed in probands with cystic fibrosis, tyrosinemia, beta-thalassemia, Tay-Sachs, familial hypercholesterolemia, hyperchylomicronemia, PKU, oculopharyngeal muscular dystrophy, pseudo vitamin D deficiency rickets, and spastic ataxia of Charlevoix-Saguenay, respectively) reveal the interpopulation and intrapopulation genetic diversity of Quebec.
p33999
sg4
(dp34000
(VLPL
p34001
VPKU
p34002
tp34003
I00
ssg31931
(lp34004
(dp34005
g31934
I175
sg31935
Vcystic fibrosis
p34006
sg31936
I15
sg31937
VC0010674
p34007
sg31939
I2
sa(dp34008
g31934
I192
sg31935
Vtyrosinemia
p34009
sg31936
I11
sg31937
VC0268483
p34010
sg31939
I1
sa(dp34011
g31934
I292
sg31935
Voculopharyngeal muscular dystrophy
p34012
sg31936
I34
sg31937
VC0270952
p34013
sg31939
I3
sa(dp34014
g31934
I116
sg31935
VPAH
p34015
sg31936
I3
sg31937
VC0152171
p34016
sg31939
I1
sa(dp34017
g31934
I138
sg31935
VSACS
p34018
sg31936
I4
sg31937
VC1849140
p34019
sg31939
I1
sa(dp34020
g31934
I356
sg31935
Vrickets
p34021
sg31936
I7
sg31937
VC0035579
p34022
sg31939
I1
sa(dp34023
g31934
I369
sg31935
Vspastic ataxia of Charlevoix-Saguenay
p34024
sg31936
I37
sg31937
VC1849140
p34025
sg31939
I4
sa(dp34026
g31934
I205
sg31935
Vbeta-thalassemia
p34027
sg31936
I16
sg31937
VC0005283
p34028
sg31939
I1
sa(dp34029
g31934
I265
sg31935
Vhyperchylomicronemia
p34030
sg31936
I20
sg31937
VC0023817
p34031
sg31939
I1
sa(dp34032
g31934
I234
sg31935
Vfamilial hypercholesterolemia
p34033
sg31936
I29
sg31937
VC0020445
p34034
sg31939
I2
sa(dp34035
g31934
I335
sg31935
Vvitamin D deficiency
p34036
sg31936
I20
sg31937
VC0042870
p34037
sg31939
I3
sa(dp34038
g31934
I287
sg31935
g34002
sg31936
I3
sg31937
VC0031485
p34039
sg31939
I1
sasg31940
(lp34040
(dp34041
g31934
I89
sg31935
VFAH
p34042
sg31936
I3
sg31944
VP16930
p34043
sg31939
I1
sa(dp34044
g31934
I94
sg31935
VHBB
p34045
sg31936
I3
sg31944
VP02042
p34046
sg31939
I1
sa(dp34047
g31934
I83
sg31935
VCFTR
p34048
sg31936
I4
sg31944
VP13569
p34049
sg31939
I1
sa(dp34050
g31934
I128
sg31935
VPDDR
p34051
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp34052
g31934
I116
sg31935
VPAH
p34053
sg31936
I3
sg31944
VP00439
p34054
sg31939
I1
sa(dp34055
g31934
I99
sg31935
VHEXA
p34056
sg31936
I4
sg31944
VP06865
p34057
sg31939
I1
sa(dp34058
g31934
I105
sg31935
VLDLR
p34059
sg31936
I4
sg31944
VP01130
p34060
sg31939
I1
sa(dp34061
g31934
I121
sg31935
VPABP2
p34062
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp34063
g31934
I111
sg31935
g34001
sg31936
I3
sg31944
VP06858
p34064
sg31939
I1
sasa(dp34065
g31925
VBioinformatic analysis of human tumours revealed that several core autophagy genes, including GABARAP, correlate with oncogenic KRAS mutations and poor prognosis in human pancreatic cancer, supporting a potential tumour-suppressive effect of the pathway in Ras-driven human cancers.
p34066
sg4
(dp34067
(VRas
p34068
Vpancreatic cancer
p34069
tp34070
I00
ssg31931
(lp34071
(dp34072
g31934
I32
sg31935
Vtumours
p34073
sg31936
I7
sg31937
VC0027651
p34074
sg31939
I1
sa(dp34075
g31934
I32
sg31935
Vtumour
p34076
sg31936
I6
sg31937
VC0027651
p34077
sg31939
I1
sa(dp34078
g31934
I171
sg31935
g34069
sg31936
I17
sg31937
VC0235974
p34079
sg31939
I2
sa(dp34080
g31934
I274
sg31935
Vcancers
p34081
sg31936
I7
sg31937
VC0006826
p34082
sg31939
I1
sasg31940
(lp34083
(dp34084
g31934
I128
sg31935
VKRAS
p34085
sg31936
I4
sg31944
VP01116
p34086
sg31939
I1
sa(dp34087
g31934
I94
sg31935
VGABARAP
p34088
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp34089
g31934
I257
sg31935
g34068
sg31936
I3
sg31944
VP01116
p34090
sg31939
I1
sasa(dp34091
g31925
VUsing a yeast two-hybrid screening approach, based on a thyroid cancer patients library, we showed that CDH6 directly interacts with GABARAP, BNIP3 and BNIP3L, and that through these interactions CDH6 restrains autophagy and promotes re-organization of mitochondrial network through a DRP1-mediated mechanism.
p34092
sg4
(dp34093
(VCDH6
p34094
Vthyroid cancer
p34095
tp34096
I00
ssg31931
(lp34097
(dp34098
g31934
I56
sg31935
g34095
sg31936
I14
sg31937
VC0007115
p34099
sg31939
I2
sasg31940
(lp34100
(dp34101
g31934
I152
sg31935
VBNIP3L
p34102
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp34103
g31934
I104
sg31935
VCDH6
p34104
sg31936
I4
sg31944
VP55285
p34105
sg31939
I1
sa(dp34106
g31934
I285
sg31935
VDRP1
p34107
sg31936
I4
sg31944
VP46939
p34108
sg31939
I1
sa(dp34109
g31934
I104
sg31935
g34094
sg31936
I4
sg31944
VP55285
p34110
sg31939
I1
sa(dp34111
g31934
I133
sg31935
VGABARAP
p34112
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp34113
g31934
I142
sg31935
VBNIP3
p34114
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp34115
g31925
VOur data demonstrated that a specific decrease of GABARAPL1 expression in breast cancers was associated with both DNA methylation and histone deacetylation and that CREB-1 recruitment on GABARAPL1 promoter was required for GABARAPL1 expression.
p34116
sg4
(dp34117
(VCREB-1
p34118
Vbreast cancers
p34119
tp34120
I00
ssg31931
(lp34121
(dp34122
g31934
I172
sg31935
Vrecruitment
p34123
sg31936
I11
sg31937
VC0271510
p34124
sg31939
I1
sa(dp34125
g31934
I74
sg31935
g34119
sg31936
I14
sg31937
VC0006142
p34126
sg31939
I2
sasg31940
(lp34127
(dp34128
g31934
I50
sg31935
VGABARAPL1
p34129
sg31936
I9
sg31944
g190
sg31939
I1
sa(dp34130
g31934
I165
sg31935
g34118
sg31936
I6
sg31944
VP16220
p34131
sg31939
I1
sa(dp34132
g31934
I134
sg31935
Vhistone
p34133
sg31936
I7
sg31944
VP62805
p34134
sg31939
I1
sa(dp34135
g31934
I187
sg31935
VGABARAPL1 promoter
p34136
sg31936
I18
sg31944
g190
sg31939
I2
sa(dp34137
g31934
I50
sg31935
VGABARAPL1
p34138
sg31936
I9
sg31944
g190
sg31939
I1
sasa(dp34139
g31925
VHere we demonstrate that runx1 deletion in mice induces the persistence of MYH10 in platelets, and a similar persistence was observed in platelets of patients with constitutional (familial platelet disorder/acute myeloid leukemia) or acquired (chronic myelomonocytic leukemia) RUNX1 mutations.
p34140
sg4
(dp34141
(VMYH10
p34142
Vacute myeloid leukemia
p34143
tp34144
I01
ssg31931
(lp34145
(dp34146
g31934
I244
sg31935
Vchronic myelomonocytic leukemia
p34147
sg31936
I31
sg31937
VC0023480
p34148
sg31939
I3
sa(dp34149
g31934
I189
sg31935
Vplatelet disorder
p34150
sg31936
I17
sg31937
VC0005818
p34151
sg31939
I2
sa(dp34152
g31934
I207
sg31935
g34143
sg31936
I22
sg31937
VC0023467
p34153
sg31939
I3
sasg31940
(lp34154
(dp34155
g31934
I25
sg31935
Vrunx1 deletion
p34156
sg31936
I14
sg31944
VP01719
p34157
sg31939
I2
sa(dp34158
g31934
I75
sg31935
g34142
sg31936
I5
sg31944
VP35580
p34159
sg31939
I1
sasa(dp34160
g31925
VMYH10 was also detected in platelets of patients with the Paris-Trousseau syndrome, a thrombocytopenia related to the deletion of the transcription factor FLI1 that forms a complex with RUNX1 to regulate megakaryopoiesis, whereas MYH10 persistence was not observed in other inherited forms of thrombocytopenia.
p34161
sg4
(dp34162
(VMYH10
p34163
VParis-Trousseau syndrome
p34164
tp34165
I01
ssg31931
(lp34166
(dp34167
g31934
I58
sg31935
g34164
sg31936
I24
sg31937
VC0795841
p34168
sg31939
I2
sasg31940
(lp34169
(dp34170
g31934
I155
sg31935
VFLI1
p34171
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp34172
g31934
I0
sg31935
VMYH10
p34173
sg31936
I5
sg31944
VP35580
p34174
sg31939
I1
sa(dp34175
g31934
I0
sg31935
g34163
sg31936
I5
sg31944
VP35580
p34176
sg31939
I1
sasa(dp34177
g31925
VWe propose MYH10 detection as a new and simple tool to identify inherited platelet disorders and myeloid neoplasms with abnormalities in RUNX1 and its associated proteins.
p34178
sg4
(dp34179
(VMYH10
p34180
Vplatelet disorders
p34181
tp34182
I01
ssg31931
(lp34183
(dp34184
g31934
I74
sg31935
g34181
sg31936
I18
sg31937
VC0005818
p34185
sg31939
I2
sa(dp34186
g31934
I105
sg31935
Vneoplasms
p34187
sg31936
I9
sg31937
VC0027651
p34188
sg31939
I1
sasg31940
(lp34189
(dp34190
g31934
I11
sg31935
g34180
sg31936
I5
sg31944
VP35580
p34191
sg31939
I1
sasa(dp34192
g31925
VThe existence of gynecomastia, age, detection of heterogeneous nodules on ultrasound, and preoperative alpha-fetoprotein and beta HCG are relevant data in relation to histological type of tumor.
p34193
sg4
(dp34194
(Valpha-fetoprotein and beta HCG
p34195
Vgynecomastia
p34196
tp34197
I00
ssg31931
(lp34198
(dp34199
g31934
I130
sg31935
VHCG
p34200
sg31936
I3
sg31937
VC1855900
p34201
sg31939
I1
sa(dp34202
g31934
I63
sg31935
Vnodules
p34203
sg31936
I7
sg31937
VC0028259
p34204
sg31939
I1
sa(dp34205
g31934
I17
sg31935
g34196
sg31936
I12
sg31937
VC0018418
p34206
sg31939
I1
sa(dp34207
g31934
I188
sg31935
Vtumor
p34208
sg31936
I5
sg31937
VC0027651
p34209
sg31939
I1
sasg31940
(lp34210
(dp34211
g31934
I103
sg31935
g34195
sg31936
I30
sg31944
VP02771
p34212
sg31939
I4
sasa(dp34213
g31925
VList of Abbreviations: AO: Acridine orange, AIDS: Acquired immunodeficiency syndrome, ACT: Artemisinin-based combination therapy, CM:Cerebral malaria, BCP:Benzothiocarboxypurine, DDT:Dichloro-diphenyl-trichloroethane, DNA:DeoxyriboNucleic Acid, ELAM-1: Endothelial leukocyte adhesion molecule, G6PD: Glucose-6-Phosphate Dehydrogenase, HIV: Human immuno deficiency virus, HRP 2: Histidine Rich Protein 2, ICAM -1: Inter cellular adhesion molecule1, ICER: Incremental cost effectiveness ratio, IL-1: Interleukin -1, IFN-g: Interferon-gamma, IgG: Immunoglobulin G, MP: Malaria parasite, NADP: Oxidised Nicotinamide Adenine Dinucleotide Phosphate, NADPH: Reduced Nicotinamide Adenine Dinucleotide Phosphate, PCV: Packed Cell Volume (haematocrit), P. falciparum: Plasmodium falciparum, PLDH: Plasmodium lactate dehydrogenase, PCR: Polymerase Chain Reaction, PPV: Positive predictive value, QBC: Quantitative Buffy Coat examination, TNF: Tumour necrosis factor, NPV: Negative predictive value, RDT: Rapid diagnostic test, SP: Sulphadoxine -Pyrimethamine, SMA: Severe malarial anaemia, UM: Uncomplicated malaria, USA:United States of America, VCAM-1: Vascular cell adhesion molecule, WBC: White Blood Cell, WHO: World Health Organization.
p34214
sg4
(dp34215
(VPlasmodium lactate dehydrogenase
p34216
VTumour necrosis
p34217
tp34218
I00
ssg31931
(lp34219
(dp34220
g31934
I133
sg31935
VCerebral malaria
p34221
sg31936
I16
sg31937
VC0024534
p34222
sg31939
I2
sa(dp34223
g31934
I275
sg31935
Vadhesion
p34224
sg31936
I8
sg31937
VC0001511
p34225
sg31939
I1
sa(dp34226
g31934
I988
sg31935
VRDT
p34227
sg31936
I3
sg31937
VC0206743
p34228
sg31939
I1
sa(dp34229
g31934
I275
sg31935
Vadhesion
p34230
sg31936
I8
sg31937
VC0001511
p34231
sg31939
I1
sa(dp34232
g31934
I1049
sg31935
VSMA
p34233
sg31936
I3
sg31937
VC0026847
p34234
sg31939
I1
sa(dp34235
g31934
I275
sg31935
Vadhesion
p34236
sg31936
I8
sg31937
VC0001511
p34237
sg31939
I1
sa(dp34238
g31934
I50
sg31935
VAcquired immunodeficiency syndrome
p34239
sg31936
I34
sg31937
VC0001175
p34240
sg31939
I3
sa(dp34241
g31934
I142
sg31935
Vmalaria
p34242
sg31936
I7
sg31937
VC0024530
p34243
sg31939
I1
sa(dp34244
g31934
I335
sg31935
VHIV
p34245
sg31936
I3
sg31937
VC0019693
p34246
sg31939
I1
sa(dp34247
g31934
I566
sg31935
VMalaria
p34248
sg31936
I7
sg31937
VC0024530
p34249
sg31939
I1
sa(dp34250
g31934
I1070
sg31935
Vanaemia
p34251
sg31936
I7
sg31937
VC0002871
p34252
sg31939
I1
sa(dp34253
g31934
I932
sg31935
g34217
sg31936
I15
sg31937
VC0333516
p34254
sg31939
I2
sasg31940
(lp34255
(dp34256
g31934
I1144
sg31935
VVascular cell adhesion molecule
p34257
sg31936
I31
sg31944
g190
sg31939
I4
sa(dp34258
g31934
I521
sg31935
VInterferon-gamma
p34259
sg31936
I16
sg31944
VP01579
p34260
sg31939
I1
sa(dp34261
g31934
I413
sg31935
VInter cellular adhesion molecule1
p34262
sg31936
I33
sg31944
VP01185
p34263
sg31939
I4
sa(dp34264
g31934
I927
sg31935
VTNF
p34265
sg31936
I3
sg31944
VP01375
p34266
sg31939
I1
sa(dp34267
g31934
I514
sg31935
VIFN-g
p34268
sg31936
I5
sg31944
VP01579
p34269
sg31939
I1
sa(dp34270
g31934
I300
sg31935
VGlucose-6-Phosphate Dehydrogenase
p34271
sg31936
I33
sg31944
VP49366
p34272
sg31939
I2
sa(dp34273
g31934
I294
sg31935
VG6PD
p34274
sg31936
I4
sg31944
VP11441
p34275
sg31939
I1
sa(dp34276
g31934
I498
sg31935
VInterleukin -1
p34277
sg31936
I14
sg31944
VP60568
p34278
sg31939
I2
sa(dp34279
g31934
I245
sg31935
VELAM-1
p34280
sg31936
I6
sg31944
VP16581
p34281
sg31939
I1
sa(dp34282
g31934
I539
sg31935
VIgG: Immunoglobulin G
p34283
sg31936
I21
sg31944
g190
sg31939
I3
sa(dp34284
g31934
I492
sg31935
VIL-1
p34285
sg31936
I4
sg31944
VP01584
p34286
sg31939
I1
sa(dp34287
g31934
I1136
sg31935
VVCAM-1
p34288
sg31936
I6
sg31944
VP19320
p34289
sg31939
I1
sa(dp34290
g31934
I932
sg31935
VTumour necrosis factor
p34291
sg31936
I22
sg31944
VP01375
p34292
sg31939
I3
sa(dp34293
g31934
I340
sg31935
VHuman immuno deficiency virus, HRP 2: Histidine Rich Protein 2
p34294
sg31936
I62
sg31944
g190
sg31939
I10
sa(dp34295
g31934
I253
sg31935
VEndothelial leukocyte adhesion molecule
p34296
sg31936
I39
sg31944
g190
sg31939
I4
sa(dp34297
g31934
I787
sg31935
g34216
sg31936
I32
sg31944
VP49366
p34298
sg31939
I3
sasa(dp34299
g31925
VDecreased G6PD activity and, as a result, decreased NADPH level have been associated with diabetic kidney disease, altered nitric oxide production, aldosterone-mediated endothelial dysfunction, and dialysis-associated anemia.
p34300
sg4
(dp34301
(VG6PD
p34302
Vanemia
p34303
tp34304
I00
ssg31931
(lp34305
(dp34306
g31934
I169
sg31935
Vendothelial dysfunction
p34307
sg31936
I23
sg31937
VC0856169
p34308
sg31939
I2
sa(dp34309
g31934
I90
sg31935
Vdiabetic kidney disease
p34310
sg31936
I23
sg31937
VC0011881
p34311
sg31939
I3
sa(dp34312
g31934
I218
sg31935
g34303
sg31936
I6
sg31937
VC0002871
p34313
sg31939
I1
sasg31940
(lp34314
(dp34315
g31934
I10
sg31935
g34302
sg31936
I4
sg31944
VP11441
p34316
sg31939
I1
sasa(dp34317
g31925
VGlucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic disorder of red blood cells in human subjects, causing hemolytic anemia linked to impaired nicotinamide adenine dinucleotide phosphate (NADPH) production and imbalanced redox homeostasis in erythrocytes.
p34318
sg4
(dp34319
(VG6PD
p34320
Vhemolytic anemia
p34321
tp34322
I01
ssg31931
(lp34323
(dp34324
g31934
I163
sg31935
Vimpaired
p34325
sg31936
I8
sg31937
VC0684336
p34326
sg31939
I1
sa(dp34327
g31934
I136
sg31935
g34321
sg31936
I16
sg31937
VC0002878
p34328
sg31939
I2
sasg31940
(lp34329
(dp34330
g31934
I0
sg31935
VGlucose-6-phosphate dehydrogenase
p34331
sg31936
I33
sg31944
VP49366
p34332
sg31939
I2
sa(dp34333
g31934
I35
sg31935
g34320
sg31936
I4
sg31944
VP11441
p34334
sg31939
I1
sasa(dp34335
g31925
VHFD significantly enhanced the Asm activity, ceramide production, colocalization of Nlrp3 (Nod-like receptor protein 3) with ASC (apoptosis-associated speck-like protein) or Caspase-1, NADPH-dependent superoxide (O2(*-)) production in glomeruli of Asm(+/+) mice than in control diet-fed mice.
p34336
sg4
(dp34337
(VNlrp3
p34338
VNod
p34339
tp34340
I00
ssg31931
(lp34341
(dp34342
g31934
I91
sg31935
g34339
sg31936
I3
sg31937
VC0751781
p34343
sg31939
I1
sasg31940
(lp34344
(dp34345
g31934
I31
sg31935
VAsm
p34346
sg31936
I3
sg31944
VP17405
p34347
sg31939
I1
sa(dp34348
g31934
I91
sg31935
VNod-like receptor protein 3
p34349
sg31936
I27
sg31944
VP54259
p34350
sg31939
I4
sa(dp34351
g31934
I185
sg31935
VNADPH-dependent superoxide
p34352
sg31936
I26
sg31944
VP30043
p34353
sg31939
I2
sa(dp34354
g31934
I174
sg31935
VCaspase-1
p34355
sg31936
I9
sg31944
VP29466
p34356
sg31939
I1
sa(dp34357
g31934
I84
sg31935
g34338
sg31936
I5
sg31944
VP54259
p34358
sg31939
I1
sasa(dp34359
g31925
VLevel of several proteins including haptoglobin, transthyretin, osteopontin, vitronectin, complement factor H and different classes of immunoglobulins are found to be considerably increased in CSF of higher grades of gliomas.
p34360
sg4
(dp34361
(Vvitronectin
p34362
Vgliomas
p34363
tp34364
I00
ssg31931
(lp34365
(dp34366
g31934
I217
sg31935
g34363
sg31936
I7
sg31937
VC0017638
p34367
sg31939
I1
sasg31940
(lp34368
(dp34369
g31934
I36
sg31935
Vhaptoglobin
p34370
sg31936
I11
sg31944
VP00738
p34371
sg31939
I1
sa(dp34372
g31934
I49
sg31935
Vtransthyretin
p34373
sg31936
I13
sg31944
VP02766
p34374
sg31939
I1
sa(dp34375
g31934
I64
sg31935
Vosteopontin
p34376
sg31936
I11
sg31944
VP10451
p34377
sg31939
I1
sa(dp34378
g31934
I77
sg31935
g34362
sg31936
I11
sg31944
VP04004
p34379
sg31939
I1
sa(dp34380
g31934
I135
sg31935
Vimmunoglobulins
p34381
sg31936
I15
sg31944
g190
sg31939
I1
sa(dp34382
g31934
I90
sg31935
Vcomplement factor H
p34383
sg31936
I19
sg31944
g190
sg31939
I3
sasa(dp34384
g31925
VVitronectin is an extracellular matrix protein, the synthesis of which by glioma cells correlates with tumor grade.
p34385
sg4
(dp34386
(VVitronectin
p34387
Vglioma
p34388
tp34389
I00
ssg31931
(lp34390
(dp34391
g31934
I103
sg31935
Vtumor
p34392
sg31936
I5
sg31937
VC0027651
p34393
sg31939
I1
sa(dp34394
g31934
I74
sg31935
g34388
sg31936
I6
sg31937
VC0017638
p34395
sg31939
I1
sasg31940
(lp34396
(dp34397
g31934
I18
sg31935
Vextracellular matrix protein
p34398
sg31936
I28
sg31944
VP55082
p34399
sg31939
I3
sa(dp34400
g31934
I0
sg31935
g34387
sg31936
I11
sg31944
VP04004
p34401
sg31939
I1
sasa(dp34402
g31925
VThe current study was designed to investigate the relationship between serum vitronectin levels and clinicopathological characteristics, diagnosis and prognosis in glioma patients.
p34403
sg4
(dp34404
(Vserum vitronectin
p34405
Vglioma
p34406
tp34407
I00
ssg31931
(lp34408
(dp34409
g31934
I164
sg31935
g34406
sg31936
I6
sg31937
VC0017638
p34410
sg31939
I1
sasg31940
(lp34411
(dp34412
g31934
I71
sg31935
g34405
sg31936
I17
sg31944
VP04004
p34413
sg31939
I2
sasa(dp34414
g31925
VSerum vitronectin levels were significantly elevated in glioma patients as compared with other groups.
p34415
sg4
(dp34416
(VSerum vitronectin
p34417
Vglioma
p34418
tp34419
I00
ssg31931
(lp34420
(dp34421
g31934
I56
sg31935
g34418
sg31936
I6
sg31937
VC0017638
p34422
sg31939
I1
sasg31940
(lp34423
(dp34424
g31934
I0
sg31935
g34417
sg31936
I17
sg31944
VP04004
p34425
sg31939
I2
sasa(dp34426
g31925
VSerum vitronectin levels could significantly distinguish glioma patients from other groups and discriminate high-grade glioma from low-grade glioma.
p34427
sg4
(dp34428
(VSerum vitronectin
p34429
Vlow-grade glioma
p34430
tp34431
I00
ssg31931
(lp34432
(dp34433
g31934
I57
sg31935
Vglioma
p34434
sg31936
I6
sg31937
VC0017638
p34435
sg31939
I1
sa(dp34436
g31934
I57
sg31935
Vglioma
p34437
sg31936
I6
sg31937
VC0017638
p34438
sg31939
I1
sa(dp34439
g31934
I131
sg31935
g34430
sg31936
I16
sg31937
VC1997217
p34440
sg31939
I2
sasg31940
(lp34441
(dp34442
g31934
I0
sg31935
g34429
sg31936
I17
sg31944
VP04004
p34443
sg31939
I2
sasa(dp34444
g31925
VSerum vitronectin may be a promising diagnostic and prognostic biomarker that can be detected in the peripheral blood of patients with glioma.
p34445
sg4
(dp34446
(Vvitronectin
p34447
Vglioma
p34448
tp34449
I00
ssg31931
(lp34450
(dp34451
g31934
I135
sg31935
g34448
sg31936
I6
sg31937
VC0017638
p34452
sg31939
I1
sasg31940
(lp34453
(dp34454
g31934
I6
sg31935
g34447
sg31936
I11
sg31944
VP04004
p34455
sg31939
I1
sasa(dp34456
g31925
VBioinformatics analysis emphasized key roles of integrin Beta3, hypoxia and vitronectin and their strong correlations with EGFRvIII expression in malignant glioma patient samples in vivo.
p34457
sg4
(dp34458
(Vhypoxia and vitronectin
p34459
Vmalignant glioma
p34460
tp34461
I01
ssg31931
(lp34462
(dp34463
g31934
I64
sg31935
Vhypoxia
p34464
sg31936
I7
sg31937
VC0242184
p34465
sg31939
I1
sa(dp34466
g31934
I146
sg31935
g34460
sg31936
I16
sg31937
VC0555198
p34467
sg31939
I2
sasg31940
(lp34468
(dp34469
g31934
I64
sg31935
g34459
sg31936
I23
sg31944
VP04004
p34470
sg31939
I3
sasa(dp34471
g31925
VGlioma cells derived from the brain of the (12) V-Ha-Ras transgenic mice were used to study the effect of PI-3 kinase inhibitor SF1126 on activation of AKT and ERK signaling, proliferation, vitronectin mediated migration and changes in the distribution of cortical actin on vitronectin in the glioma cells in vitro.
p34472
sg4
(dp34473
(VRas
p34474
VGlioma
p34475
tp34476
I01
ssg31931
(lp34477
(dp34478
g31934
I293
sg31935
Vglioma
p34479
sg31936
I6
sg31937
VC0017638
p34480
sg31939
I1
sa(dp34481
g31934
I175
sg31935
Vproliferation
p34482
sg31936
I13
sg31937
VC0334094
p34483
sg31939
I1
sa(dp34484
g31934
I0
sg31935
g34475
sg31936
I6
sg31937
VC0017638
p34485
sg31939
I1
sasg31940
(lp34486
(dp34487
g31934
I106
sg31935
VPI-3 kinase
p34488
sg31936
I11
sg31944
g190
sg31939
I2
sa(dp34489
g31934
I190
sg31935
Vvitronectin
p34490
sg31936
I11
sg31944
VP04004
p34491
sg31939
I1
sa(dp34492
g31934
I190
sg31935
Vvitronectin
p34493
sg31936
I11
sg31944
VP04004
p34494
sg31939
I1
sa(dp34495
g31934
I152
sg31935
VAKT
p34496
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp34497
g31934
I160
sg31935
VERK
p34498
sg31936
I3
sg31944
VP29323
p34499
sg31939
I1
sa(dp34500
g31934
I53
sg31935
g34474
sg31936
I3
sg31944
VP01116
p34501
sg31939
I1
sasa(dp34502
g31925
VMost notably, treatment of SF1126 blocked integrin-dependent migration in transwell and scratch assays and caused a significant change in the organization and distribution of cortical actin on vitronectin in the glioma cells.
p34503
sg4
(dp34504
(Vvitronectin
p34505
Vglioma
p34506
tp34507
I00
ssg31931
(lp34508
(dp34509
g31934
I212
sg31935
g34506
sg31936
I6
sg31937
VC0017638
p34510
sg31939
I1
sasg31940
(lp34511
(dp34512
g31934
I193
sg31935
g34505
sg31936
I11
sg31944
VP04004
p34513
sg31939
I1
sasa(dp34514
g31925
VThe hit compound 5.3d inhibited invasion and migration of both GBM stem cells (Gli7 and Gli4) and GBM cancer cell lines (C6, SNB75) on fibronectin, vitronectin, and laminin.
p34515
sg4
(dp34516
(Vvitronectin
p34517
VGBM
p34518
tp34519
I00
ssg31931
(lp34520
(dp34521
g31934
I63
sg31935
VGBM
p34522
sg31936
I3
sg31937
VC0017636
p34523
sg31939
I1
sa(dp34524
g31934
I32
sg31935
Vinvasion
p34525
sg31936
I8
sg31937
VC2699153
p34526
sg31939
I1
sa(dp34527
g31934
I102
sg31935
Vcancer
p34528
sg31936
I6
sg31937
VC0006826
p34529
sg31939
I1
sa(dp34530
g31934
I63
sg31935
g34518
sg31936
I3
sg31937
VC0017636
p34531
sg31939
I1
sasg31940
(lp34532
(dp34533
g31934
I148
sg31935
g34517
sg31936
I11
sg31944
VP04004
p34534
sg31939
I1
sa(dp34535
g31934
I165
sg31935
Vlaminin
p34536
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp34537
g31934
I88
sg31935
VGli4
p34538
sg31936
I4
sg31944
VP10075
p34539
sg31939
I1
sasa(dp34540
g31925
VIn this study, efficient downregulation of cathepsin B and uPAR by siRNA treatments significantly reduced glioma cell adhesion to laminin as compared to vitronectin, fibronectin, or collagen I in U251 and 4910 glioma cell lines.
p34541
sg4
(dp34542
(Vvitronectin
p34543
Vadhesion
p34544
tp34545
I00
ssg31931
(lp34546
(dp34547
g31934
I106
sg31935
Vglioma
p34548
sg31936
I6
sg31937
VC0017638
p34549
sg31939
I1
sa(dp34550
g31934
I106
sg31935
Vglioma
p34551
sg31936
I6
sg31937
VC0017638
p34552
sg31939
I1
sa(dp34553
g31934
I118
sg31935
g34544
sg31936
I8
sg31937
VC0001511
p34554
sg31939
I1
sasg31940
(lp34555
(dp34556
g31934
I130
sg31935
Vlaminin
p34557
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp34558
g31934
I43
sg31935
Vcathepsin B
p34559
sg31936
I11
sg31944
VP07858
p34560
sg31939
I2
sa(dp34561
g31934
I153
sg31935
g34543
sg31936
I11
sg31944
VP04004
p34562
sg31939
I1
sasa(dp34563
g31925
VNecl-5, a cell surface receptor for vitronectin, is expressed in GBM but not normal brain.
p34564
sg4
(dp34565
(VNecl-5
p34566
VGBM
p34567
tp34568
I00
ssg31931
(lp34569
(dp34570
g31934
I65
sg31935
g34567
sg31936
I3
sg31937
VC0017636
p34571
sg31939
I1
sasg31940
(lp34572
(dp34573
g31934
I36
sg31935
Vvitronectin
p34574
sg31936
I11
sg31944
VP04004
p34575
sg31939
I1
sa(dp34576
g31934
I0
sg31935
g34566
sg31936
I6
sg31944
VP15151
p34577
sg31939
I1
sasa(dp34578
g31925
VTogether, these data suggest that IL11 could trigger an ER stress response in the placenta, which may contribute to obstetric complications such as preeclampsia.
p34579
sg4
(dp34580
(VIL11
p34581
Vpreeclampsia
p34582
tp34583
I00
ssg31931
(lp34584
(dp34585
g31934
I148
sg31935
g34582
sg31936
I12
sg31937
VC0032914
p34586
sg31939
I1
sasg31940
(lp34587
(dp34588
g31934
I34
sg31935
g34581
sg31936
I4
sg31944
VP20809
p34589
sg31939
I1
sasa(dp34590
g31925
VThe relationship between IL-11 and CLS has rarely been reported, especially in patients with colorectal cancer.
p34591
sg4
(dp34592
(VCLS
p34593
Vcolorectal cancer
p34594
tp34595
I01
ssg31931
(lp34596
(dp34597
g31934
I35
sg31935
VCLS
p34598
sg31936
I3
sg31937
VC0265252
p34599
sg31939
I1
sa(dp34600
g31934
I93
sg31935
g34594
sg31936
I17
sg31937
VC1527249
p34601
sg31939
I2
sasg31940
(lp34602
(dp34603
g31934
I25
sg31935
VIL-11
p34604
sg31936
I5
sg31944
VP20809
p34605
sg31939
I1
sa(dp34606
g31934
I35
sg31935
g34593
sg31936
I3
sg31944
VP51812
p34607
sg31939
I1
sasa(dp34608
g31925
VAlthough rare, CLS could be a severe side effect after the administration of IL-11.
p34609
sg4
(dp34610
(VIL-11
p34611
VCLS
p34612
tp34613
I00
ssg31931
(lp34614
(dp34615
g31934
I15
sg31935
g34612
sg31936
I3
sg31937
VC0265252
p34616
sg31939
I1
sa(dp34617
g31934
I37
sg31935
Vside effect
p34618
sg31936
I11
sg31937
VC0879626
p34619
sg31939
I2
sasg31940
(lp34620
(dp34621
g31934
I77
sg31935
g34611
sg31936
I5
sg31944
VP20809
p34622
sg31939
I1
sasa(dp34623
g31925
VWe describe four cases of the patients with ST-elevation myocardial infarction (STEMI) that were treated with interleukin-11 (IL-11), a cardioprotective cytokine.
p34624
sg4
(dp34625
(VIL-11
p34626
VST-elevation myocardial infarction
p34627
tp34628
I00
ssg31931
(lp34629
(dp34630
g31934
I80
sg31935
VSTEMI
p34631
sg31936
I5
sg31937
VC1536220
p34632
sg31939
I1
sa(dp34633
g31934
I44
sg31935
g34627
sg31936
I34
sg31937
VC1536220
p34634
sg31939
I3
sasg31940
(lp34635
(dp34636
g31934
I110
sg31935
Vinterleukin-11
p34637
sg31936
I14
sg31944
VP20809
p34638
sg31939
I1
sa(dp34639
g31934
I126
sg31935
g34626
sg31936
I5
sg31944
VP20809
p34640
sg31939
I1
sasa(dp34641
g31925
VThe protective role of IL-11, an IL-6 family cytokine, has been implicated in ischemia/reperfusion injury (IRI) in the heart and kidney, but its role has not been elucidated in liver IRI.
p34642
sg4
(dp34643
(VIL-11
p34644
Vischemia
p34645
tp34646
I00
ssg31931
(lp34647
(dp34648
g31934
I78
sg31935
g34645
sg31936
I8
sg31937
VC0022116
p34649
sg31939
I1
sasg31940
(lp34650
(dp34651
g31934
I33
sg31935
VIL-6 family cytokine
p34652
sg31936
I20
sg31944
VP05231
p34653
sg31939
I3
sa(dp34654
g31934
I23
sg31935
g34644
sg31936
I5
sg31944
VP20809
p34655
sg31939
I1
sasa(dp34656
g31925
VNext, IL-11 was injected intraperitoneally (ip) 1 hour before ischemia.
p34657
sg4
(dp34658
(VIL-11
p34659
Vischemia
p34660
tp34661
I00
ssg31931
(lp34662
(dp34663
g31934
I62
sg31935
g34660
sg31936
I8
sg31937
VC0022116
p34664
sg31939
I1
sasg31940
(lp34665
(dp34666
g31934
I6
sg31935
g34659
sg31936
I5
sg31944
VP20809
p34667
sg31939
I1
sasa(dp34668
g31925
VPCR assays targeting insertion sequence IS481 (IS), pertussis toxin ptxA promoter region (PT), and outer membrane porin (PO), or recA (RA) were evaluated in respiratory specimens collected from 4,442 patients with suspected pertussis.
p34669
sg4
(dp34670
(Vpertussis toxin ptxA promoter region (PT), and outer membrane porin
p34671
Vpertussis
p34672
tp34673
I00
ssg31931
(lp34674
(dp34675
g31934
I52
sg31935
Vpertussis
p34676
sg31936
I9
sg31937
VC0043167
p34677
sg31939
I1
sa(dp34678
g31934
I52
sg31935
g34672
sg31936
I9
sg31937
VC0043167
p34679
sg31939
I1
sasg31940
(lp34680
(dp34681
g31934
I52
sg31935
g34671
sg31936
I67
sg31944
VP0CE72
p34682
sg31939
I10
sa(dp34683
g31934
I135
sg31935
VRA
p34684
sg31936
I2
sg31944
g190
sg31939
I1
sa(dp34685
g31934
I129
sg31935
VrecA
p34686
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp34687
g31925
VExposure to bone morphogenetic protein (BMP)-4 was found to enhance a TrkAhigh/CD15-/CD184- neuroblastoma cellular subset, accompanied by a reduction in doublecortin-positive neuroblasts and of NMYC protein expression in SH-SY5Y cells.
p34688
sg4
(dp34689
(VCD184
p34690
Vneuroblastoma
p34691
tp34692
I00
ssg31931
(lp34693
(dp34694
g31934
I92
sg31935
g34691
sg31936
I13
sg31937
VC0027819
p34695
sg31939
I1
sasg31940
(lp34696
(dp34697
g31934
I79
sg31935
VCD15
p34698
sg31936
I4
sg31944
VP22083
p34699
sg31939
I1
sa(dp34700
g31934
I194
sg31935
VNMYC protein
p34701
sg31936
I12
sg31944
VP04198
p34702
sg31939
I2
sa(dp34703
g31934
I17
sg31935
Vmorphogenetic protein (BMP)-4
p34704
sg31936
I29
sg31944
VP18075
p34705
sg31939
I3
sa(dp34706
g31934
I85
sg31935
g34690
sg31936
I5
sg31944
VP61073
p34707
sg31939
I1
sasa(dp34708
g31925
VWe analyzed the coding sequences and exon-intron boundaries of GLIALCAM, encoding an IgG-like cell adhesion protein, in 81 individuals with Autism Spectrum Disorders, either with or without comorbid epilepsy, paroxysmal EEG and/or macrocephaly, and the PTEN gene in the subsample with macrocephaly.
p34709
sg4
(dp34710
(VIgG-like cell adhesion protein
p34711
VAutism Spectrum Disorders
p34712
tp34713
I00
ssg31931
(lp34714
(dp34715
g31934
I231
sg31935
Vmacrocephaly
p34716
sg31936
I12
sg31937
VC0221355
p34717
sg31939
I1
sa(dp34718
g31934
I199
sg31935
Vepilepsy
p34719
sg31936
I8
sg31937
VC0014544
p34720
sg31939
I1
sa(dp34721
g31934
I231
sg31935
Vmacrocephaly
p34722
sg31936
I12
sg31937
VC0221355
p34723
sg31939
I1
sa(dp34724
g31934
I99
sg31935
Vadhesion
p34725
sg31936
I8
sg31937
VC0001511
p34726
sg31939
I1
sa(dp34727
g31934
I140
sg31935
g34712
sg31936
I25
sg31937
VC1510586
p34728
sg31939
I3
sasg31940
(lp34729
(dp34730
g31934
I253
sg31935
VPTEN gene
p34731
sg31936
I9
sg31944
VP60484
p34732
sg31939
I2
sa(dp34733
g31934
I63
sg31935
VGLIALCAM
p34734
sg31936
I8
sg31944
g190
sg31939
I1
sa(dp34735
g31934
I85
sg31935
g34711
sg31936
I30
sg31944
VP01185
p34736
sg31939
I4
sasa(dp34737
g31925
VWhilst we detected in GLIALCAM several single nucleotide variants without clear pathogenic effects, we found a novel PTEN heterozygous frameshift mutation in one case with "extreme" macrocephaly, autism, intellectual disability and seizures.
p34738
sg4
(dp34739
(VPTEN
p34740
Vintellectual disability
p34741
tp34742
I00
ssg31931
(lp34743
(dp34744
g31934
I232
sg31935
Vseizures
p34745
sg31936
I8
sg31937
VC0036572
p34746
sg31939
I1
sa(dp34747
g31934
I182
sg31935
Vmacrocephaly
p34748
sg31936
I12
sg31937
VC0221355
p34749
sg31939
I1
sa(dp34750
g31934
I135
sg31935
Vframeshift mutation
p34751
sg31936
I19
sg31937
VC0079380
p34752
sg31939
I2
sa(dp34753
g31934
I196
sg31935
Vautism
p34754
sg31936
I6
sg31937
VC0004352
p34755
sg31939
I1
sa(dp34756
g31934
I204
sg31935
g34741
sg31936
I23
sg31937
VC0025362
p34757
sg31939
I2
sasg31940
(lp34758
(dp34759
g31934
I117
sg31935
g34740
sg31936
I4
sg31944
VP60484
p34760
sg31939
I1
sasa(dp34761
g31925
VThus, myocyte autonomous inhibition of PKCalpha protects the adult heart from decompensation and dilated cardiomyopathy after infarction injury in association with a primary enhancement in contractility.
p34762
sg4
(dp34763
(VPKCalpha
p34764
Vinfarction
p34765
tp34766
I00
ssg31931
(lp34767
(dp34768
g31934
I97
sg31935
Vdilated cardiomyopathy
p34769
sg31936
I22
sg31937
VC0007193
p34770
sg31939
I2
sa(dp34771
g31934
I126
sg31935
g34765
sg31936
I10
sg31937
VC0021308
p34772
sg31939
I1
sasg31940
(lp34773
(dp34774
g31934
I39
sg31935
g34764
sg31936
I8
sg31944
VP17252
p34775
sg31939
I1
sasa(dp34776
g31925
VHypercontractility caused by Prkca deletion protects against heart failure induced by pressure overload, and against dilated cardiomyopathy induced by deleting the gene encoding muscle LIM protein (Csrp3).
p34777
sg4
(dp34778
(Vgene encoding muscle LIM protein
p34779
Vdilated cardiomyopathy
p34780
tp34781
I00
ssg31931
(lp34782
(dp34783
g31934
I61
sg31935
Vheart failure
p34784
sg31936
I13
sg31937
VC0018802
p34785
sg31939
I2
sa(dp34786
g31934
I117
sg31935
g34780
sg31936
I22
sg31937
VC0007193
p34787
sg31939
I2
sasg31940
(lp34788
(dp34789
g31934
I198
sg31935
VCsrp3
p34790
sg31936
I5
sg31944
VP50461
p34791
sg31939
I1
sa(dp34792
g31934
I164
sg31935
g34779
sg31936
I32
sg31944
VP50461
p34793
sg31939
I5
sasa(dp34794
g31925
VIn conclusion, surface antigen expression profiling demonstrates that C/EBPBeta plays a critical role in the activation state of ALK+ ALCL cells and reveals CD147 and PD-L1 as important downstream targets.
p34795
sg4
(dp34796
(VCD147
p34797
VALCL
p34798
tp34799
I01
ssg31931
(lp34800
(dp34801
g31934
I134
sg31935
g34798
sg31936
I4
sg31937
VC0206180
p34802
sg31939
I1
sasg31940
(lp34803
(dp34804
g31934
I157
sg31935
g34797
sg31936
I5
sg31944
VP35613
p34805
sg31939
I1
sasa(dp34806
g31925
VThese unique features, which are strictly dependent on NPM-ALK activity and expression, include perpetual cell growth, proliferation, and survival; activation of the key signal transduction pathways STAT3 and mTORC1; and expression of CD30 (the hallmark of anaplastic large-cell lymphoma) and of immunosuppressive cytokine IL-10 and cell-surface protein PD-L1/CD274.
p34807
sg4
(dp34808
(VSTAT3
p34809
Vanaplastic large-cell lymphoma
p34810
tp34811
I00
ssg31931
(lp34812
(dp34813
g31934
I119
sg31935
Vproliferation
p34814
sg31936
I13
sg31937
VC0334094
p34815
sg31939
I1
sa(dp34816
g31934
I257
sg31935
g34810
sg31936
I30
sg31937
VC0206180
p34817
sg31939
I3
sasg31940
(lp34818
(dp34819
g31934
I59
sg31935
VALK
p34820
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp34821
g31934
I360
sg31935
VCD274
p34822
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp34823
g31934
I55
sg31935
VNPM
p34824
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp34825
g31934
I235
sg31935
VCD30
p34826
sg31936
I4
sg31944
VP28908
p34827
sg31939
I1
sa(dp34828
g31934
I199
sg31935
g34809
sg31936
I5
sg31944
VP40763
p34829
sg31939
I1
sasa(dp34830
g31925
VAnti-PD-L1 blocking antibody boosted proliferation and IFN-Gamma secretion by allogeneic T cells responding to ALCL and DLBCL cells.
p34831
sg4
(dp34832
(VIFN-Gamma
p34833
VALCL
p34834
tp34835
I01
ssg31931
(lp34836
(dp34837
g31934
I111
sg31935
g34834
sg31936
I4
sg31937
VC0206180
p34838
sg31939
I1
sa(dp34839
g31934
I11
sg31935
Vblocking
p34840
sg31936
I8
sg31937
VC0233660
p34841
sg31939
I1
sa(dp34842
g31934
I37
sg31935
Vproliferation
p34843
sg31936
I13
sg31937
VC0334094
p34844
sg31939
I1
sasg31940
(lp34845
(dp34846
g31934
I55
sg31935
g34833
sg31936
I9
sg31944
VP01579
p34847
sg31939
I1
sasa(dp34848
g31925
VIn autologous cultures of primary ALCL and DLBCL, PD-L1 blockade enhanced secretion of inflammatory cytokines IFN-Gamma, granulocyte macrophage colony-stimulating factor, interleukin (IL)-1, IL-6, IL-8, IL-13, TNF-Alfa, and macrophage inflammatory protein-1Alfa.
p34849
sg4
(dp34850
(VIL-6
p34851
VALCL
p34852
tp34853
I00
ssg31931
(lp34854
(dp34855
g31934
I34
sg31935
g34852
sg31936
I4
sg31937
VC0206180
p34856
sg31939
I1
sasg31940
(lp34857
(dp34858
g31934
I100
sg31935
Vcytokines IFN-Gamma
p34859
sg31936
I19
sg31944
VP01579
p34860
sg31939
I2
sa(dp34861
g31934
I203
sg31935
VIL-13
p34862
sg31936
I5
sg31944
VP35225
p34863
sg31939
I1
sa(dp34864
g31934
I210
sg31935
VTNF-Alfa
p34865
sg31936
I8
sg31944
VP01375
p34866
sg31939
I1
sa(dp34867
g31934
I121
sg31935
Vgranulocyte macrophage colony-stimulating factor
p34868
sg31936
I48
sg31944
VP04141
p34869
sg31939
I4
sa(dp34870
g31934
I171
sg31935
Vinterleukin (IL)-1
p34871
sg31936
I18
sg31944
VP60568
p34872
sg31939
I2
sa(dp34873
g31934
I191
sg31935
g34851
sg31936
I4
sg31944
VP05231
p34874
sg31939
I1
sasa(dp34875
g31925
VIn anaplastic lymphoma kinase-positive (ALK(+)) ALCL cells, B7-H1 expression was suppressed by the blocking of extracellular signal-regulated kinase (ERK) signaling and upregulated by the augmentation of ERK activity by phorbol 13-myristate 12-acetate stimulation, suggesting that B7-H1 expression is regulated by ERK signaling pathway in ALCL.
p34876
sg4
(dp34877
(VERK
p34878
Vanaplastic lymphoma
p34879
tp34880
I00
ssg31931
(lp34881
(dp34882
g31934
I48
sg31935
VALCL
p34883
sg31936
I4
sg31937
VC0206180
p34884
sg31939
I1
sa(dp34885
g31934
I99
sg31935
Vblocking
p34886
sg31936
I8
sg31937
VC0233660
p34887
sg31939
I1
sa(dp34888
g31934
I48
sg31935
VALCL
p34889
sg31936
I4
sg31937
VC0206180
p34890
sg31939
I1
sa(dp34891
g31934
I3
sg31935
g34879
sg31936
I19
sg31937
VC1321546
p34892
sg31939
I2
sasg31940
(lp34893
(dp34894
g31934
I150
sg31935
VERK
p34895
sg31936
I3
sg31944
VP29323
p34896
sg31939
I1
sa(dp34897
g31934
I60
sg31935
VB7-H1
p34898
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp34899
g31934
I111
sg31935
Vextracellular signal-regulated kinase
p34900
sg31936
I37
sg31944
VP53779
p34901
sg31939
I3
sa(dp34902
g31934
I150
sg31935
VERK
p34903
sg31936
I3
sg31944
VP29323
p34904
sg31939
I1
sa(dp34905
g31934
I150
sg31935
g34878
sg31936
I3
sg31944
VP29323
p34906
sg31939
I1
sa(dp34907
g31934
I60
sg31935
VB7-H1
p34908
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp34909
g31925
VERK is one of the downstream mediators of nucleophosmin (NPM)/ALK signaling in ALK(+)ALCL, and pharmacological inhibition of ALK was shown to dephosphorylate ERK and down-regulate B7-H1.
p34910
sg4
(dp34911
(VERK
p34912
VALCL
p34913
tp34914
I00
ssg31931
(lp34915
(dp34916
g31934
I85
sg31935
g34913
sg31936
I4
sg31937
VC0206180
p34917
sg31939
I1
sasg31940
(lp34918
(dp34919
g31934
I62
sg31935
VALK
p34920
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp34921
g31934
I62
sg31935
VALK
p34922
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp34923
g31934
I0
sg31935
VERK
p34924
sg31936
I3
sg31944
VP29323
p34925
sg31939
I1
sa(dp34926
g31934
I180
sg31935
VB7-H1
p34927
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp34928
g31934
I0
sg31935
g34912
sg31936
I3
sg31944
VP29323
p34929
sg31939
I1
sasa(dp34930
g31925
VThese results suggest that B7-H1 expression is controlled by common ERK signaling pathways in ALCL and HL cells.
p34931
sg4
(dp34932
(VERK
p34933
VALCL
p34934
tp34935
I00
ssg31931
(lp34936
(dp34937
g31934
I94
sg31935
g34934
sg31936
I4
sg31937
VC0206180
p34938
sg31939
I1
sasg31940
(lp34939
(dp34940
g31934
I68
sg31935
g34933
sg31936
I3
sg31944
VP29323
p34941
sg31939
I1
sa(dp34942
g31934
I27
sg31935
VB7-H1
p34943
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp34944
g31925
VThe applicability of clinical genetics in nephrology is due to the fact that many kidney diseases are characterized by genetic mutations (e.g., von-Hippel Lindau syndrome, MYH9 related disorders, Fabry's syndrome, Liddle's and Bartter's Syndrome, and others).
p34945
sg4
(dp34946
(VMYH9
p34947
VHippel Lindau syndrome
p34948
tp34949
I00
ssg31931
(lp34950
(dp34951
g31934
I204
sg31935
Vsyndrome, Liddle
p34952
sg31936
I16
sg31937
VC0221043
p34953
sg31939
I2
sa(dp34954
g31934
I227
sg31935
VBartter's Syndrome
p34955
sg31936
I18
sg31937
VC0004775
p34956
sg31939
I2
sa(dp34957
g31934
I82
sg31935
Vkidney diseases
p34958
sg31936
I15
sg31937
VC0022658
p34959
sg31939
I2
sa(dp34960
g31934
I148
sg31935
g34948
sg31936
I22
sg31937
VC0019562
p34961
sg31939
I3
sasg31940
(lp34962
(dp34963
g31934
I172
sg31935
g34947
sg31936
I4
sg31944
VP35579
p34964
sg31939
I1
sasa(dp34965
g31925
VIn this study, we tested the hypothesis that a common single nucleotide polymorphism rs16996677 in the MYH9 gene may contribute to the etiology of DN in type 2 diabetes (T2D) in a Taiwanese population with T2D.
p34966
sg4
(dp34967
(VMYH9 gene
p34968
Vtype 2 diabetes
p34969
tp34970
I00
ssg31931
(lp34971
(dp34972
g31934
I170
sg31935
VT2D
p34973
sg31936
I3
sg31937
VC0011860
p34974
sg31939
I1
sa(dp34975
g31934
I170
sg31935
VT2D
p34976
sg31936
I3
sg31937
VC0011860
p34977
sg31939
I1
sa(dp34978
g31934
I153
sg31935
g34969
sg31936
I15
sg31937
VC0011860
p34979
sg31939
I3
sasg31940
(lp34980
(dp34981
g31934
I103
sg31935
g34968
sg31936
I9
sg31944
VP35579
p34982
sg31939
I2
sasa(dp34983
g31925
VThe authors studied the methylation status of CDKN2A, CDKN2B, XAF1, CDH13, JUNB and a panel of soluble Wnt inhibitors including WIF1, DKK3, APC, SFRP1, SFRP2, SFRP4 and SFRP5 by methylation-specific PCR in 31 bone marrow and 21 peripheral blood samples of patients with essential thrombocythaemia.
p34984
sg4
(dp34985
(VJUNB
p34986
VAPC
p34987
tp34988
I00
ssg31931
(lp34989
(dp34990
g31934
I270
sg31935
Vessential thrombocythaemia
p34991
sg31936
I26
sg31937
VC0040028
p34992
sg31939
I2
sa(dp34993
g31934
I140
sg31935
g34987
sg31936
I3
sg31937
VC0033036
p34994
sg31939
I1
sasg31940
(lp34995
(dp34996
g31934
I54
sg31935
VCDKN2B
p34997
sg31936
I6
sg31944
VP42772
p34998
sg31939
I1
sa(dp34999
g31934
I62
sg31935
VXAF1
p35000
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp35001
g31934
I128
sg31935
VWIF1
p35002
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp35003
g31934
I134
sg31935
VDKK3
p35004
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp35005
g31934
I159
sg31935
VSFRP4
p35006
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp35007
g31934
I169
sg31935
VSFRP5
p35008
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp35009
g31934
I145
sg31935
VSFRP1
p35010
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp35011
g31934
I140
sg31935
VAPC
p35012
sg31936
I3
sg31944
VP25054
p35013
sg31939
I1
sa(dp35014
g31934
I68
sg31935
VCDH13
p35015
sg31936
I5
sg31944
VP55290
p35016
sg31939
I1
sa(dp35017
g31934
I46
sg31935
VCDKN2A
p35018
sg31936
I6
sg31944
VP42771
p35019
sg31939
I1
sa(dp35020
g31934
I152
sg31935
VSFRP2
p35021
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp35022
g31934
I75
sg31935
g34986
sg31936
I4
sg31944
VP17275
p35023
sg31939
I1
sasa(dp35024
g31925
VWe studied the activity of Wnt signaling and the methylation status of WIF1, DKK3, APC, SFRP1, SFRP2, SFRP4 and SFRP5 by methylation-specific PCR in myeloma cell lines and primary myeloma samples.
p35025
sg4
(dp35026
(VAPC
p35027
VAPC
p35028
tp35029
I00
ssg31931
(lp35030
(dp35031
g31934
I149
sg31935
Vmyeloma
p35032
sg31936
I7
sg31937
VC0026764
p35033
sg31939
I1
sa(dp35034
g31934
I149
sg31935
Vmyeloma
p35035
sg31936
I7
sg31937
VC0026764
p35036
sg31939
I1
sa(dp35037
g31934
I83
sg31935
g35028
sg31936
I3
sg31937
VC0033036
p35038
sg31939
I1
sasg31940
(lp35039
(dp35040
g31934
I71
sg31935
VWIF1
p35041
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp35042
g31934
I88
sg31935
VSFRP1
p35043
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp35044
g31934
I102
sg31935
VSFRP4
p35045
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp35046
g31934
I77
sg31935
VDKK3
p35047
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp35048
g31934
I112
sg31935
VSFRP5
p35049
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp35050
g31934
I95
sg31935
VSFRP2
p35051
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp35052
g31934
I83
sg31935
g35027
sg31936
I3
sg31944
VP25054
p35053
sg31939
I1
sasa(dp35054
g31925
VUsing a functional genomic approach, we identified a seven-gene panel (TNC, TFPI, TGFBI, SEL-1L, L1CAM, WWTR1, and CDC42BPA) that was differentially expressed across three different expression platforms, including pancreatic tumor/normal samples.
p35055
sg4
(dp35056
(VTNC
p35057
Vpancreatic tumor
p35058
tp35059
I00
ssg31931
(lp35060
(dp35061
g31934
I214
sg31935
g35058
sg31936
I16
sg31937
VC0030297
p35062
sg31939
I2
sasg31940
(lp35063
(dp35064
g31934
I76
sg31935
VTFPI
p35065
sg31936
I4
sg31944
VP10646
p35066
sg31939
I1
sa(dp35067
g31934
I97
sg31935
VL1CAM
p35068
sg31936
I5
sg31944
VP32004
p35069
sg31939
I1
sa(dp35070
g31934
I71
sg31935
g35057
sg31936
I3
sg31944
VP63316
p35071
sg31939
I1
sa(dp35072
g31934
I89
sg31935
VSEL-1L
p35073
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp35074
g31934
I104
sg31935
VWWTR1
p35075
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp35076
g31925
VOverexpression of SEL1L in stably transfected pancreatic cancer cells caused both a decrease in clonogenicity and anchorage-independent growth as well as a significant increase in the levels of activin A and SMAD4.
p35077
sg4
(dp35078
(Vactivin A
p35079
Vpancreatic cancer
p35080
tp35081
I00
ssg31931
(lp35082
(dp35083
g31934
I46
sg31935
g35080
sg31936
I17
sg31937
VC0235974
p35084
sg31939
I2
sasg31940
(lp35085
(dp35086
g31934
I208
sg31935
VSMAD4
p35087
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp35088
g31934
I194
sg31935
g35079
sg31936
I9
sg31944
VP08476
p35089
sg31939
I2
sa(dp35090
g31934
I18
sg31935
VSEL1L
p35091
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp35092
g31925
VLevels of angiogenic markers bFGF, angiogenin and VEGF in EBC significantly discriminated between 17 individuals with newly detected NSCLC versus stable and exacerbated chronic obstructive pulmonary disease (COPD) patients as well as healthy volunteers.
p35093
sg4
(dp35094
(Vangiogenin and VEGF
p35095
VNSCLC
p35096
tp35097
I00
ssg31931
(lp35098
(dp35099
g31934
I169
sg31935
Vchronic obstructive pulmonary disease
p35100
sg31936
I37
sg31937
VC0024117
p35101
sg31939
I4
sa(dp35102
g31934
I208
sg31935
VCOPD
p35103
sg31936
I4
sg31937
VC0024117
p35104
sg31939
I1
sa(dp35105
g31934
I133
sg31935
g35096
sg31936
I5
sg31937
VC0007131
p35106
sg31939
I1
sasg31940
(lp35107
(dp35108
g31934
I29
sg31935
VbFGF
p35109
sg31936
I4
sg31944
VP53370
p35110
sg31939
I1
sa(dp35111
g31934
I35
sg31935
g35095
sg31936
I19
sg31944
VP03950
p35112
sg31939
I3
sasa(dp35113
g31925
VPlasma fibrinogen, FII, FV, FVII, FVIII, FIX, FX, FXI and FXII activity levels and C4BP concentrations were determined in 73 patients with non-metastatic colorectal cancer (48 colon and 25 rectum) and in 67 matched control subjects.
p35114
sg4
(dp35115
(VC4BP
p35116
Vmetastatic colorectal cancer
p35117
tp35118
I00
ssg31931
(lp35119
(dp35120
g31934
I143
sg31935
g35117
sg31936
I28
sg31937
VC0948380
p35121
sg31939
I3
sasg31940
(lp35122
(dp35123
g31934
I34
sg31935
VFVIII
p35124
sg31936
I5
sg31944
VP00451
p35125
sg31939
I1
sa(dp35126
g31934
I7
sg31935
Vfibrinogen
p35127
sg31936
I10
sg31944
VP22087
p35128
sg31939
I1
sa(dp35129
g31934
I58
sg31935
VFXII
p35130
sg31936
I4
sg31944
VP00748
p35131
sg31939
I1
sa(dp35132
g31934
I50
sg31935
VFXI
p35133
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp35134
g31934
I41
sg31935
VFIX
p35135
sg31936
I3
sg31944
VP00740
p35136
sg31939
I1
sa(dp35137
g31934
I83
sg31935
g35116
sg31936
I4
sg31944
VP04003
p35138
sg31939
I1
sasa(dp35139
g31925
VMean plasma concentrations of fibrinogen (functional and antigen), FVIII, FIX, FV and C4BP were significantly higher in colorectal cancer patients than in control subjects, while FVII and FXII levels were significantly decreased.
p35140
sg4
(dp35141
(Vfibrinogen
p35142
Vcolorectal cancer
p35143
tp35144
I00
ssg31931
(lp35145
(dp35146
g31934
I120
sg31935
g35143
sg31936
I17
sg31937
VC1527249
p35147
sg31939
I2
sasg31940
(lp35148
(dp35149
g31934
I86
sg31935
VC4BP
p35150
sg31936
I4
sg31944
VP04003
p35151
sg31939
I1
sa(dp35152
g31934
I74
sg31935
VFIX
p35153
sg31936
I3
sg31944
VP00740
p35154
sg31939
I1
sa(dp35155
g31934
I67
sg31935
VFVIII
p35156
sg31936
I5
sg31944
VP00451
p35157
sg31939
I1
sa(dp35158
g31934
I188
sg31935
VFXII
p35159
sg31936
I4
sg31944
VP00748
p35160
sg31939
I1
sa(dp35161
g31934
I30
sg31935
g35142
sg31936
I10
sg31944
VP22087
p35162
sg31939
I1
sasa(dp35163
g31925
VIn colorectal cancer patients high plasma fibrinogen, FVIII and FIX levels might represent further risk factors for venous thrombotic complications in the immediate post-surgery period, while decreased FVII and FXII concentrations may be an index of intravascular coagulation activation, still in a subclinical phase.
p35164
sg4
(dp35165
(VFXII
p35166
Vcolorectal cancer
p35167
tp35168
I00
ssg31931
(lp35169
(dp35170
g31934
I3
sg31935
g35167
sg31936
I17
sg31937
VC1527249
p35171
sg31939
I2
sasg31940
(lp35172
(dp35173
g31934
I42
sg31935
Vfibrinogen, FVIII and FIX
p35174
sg31936
I25
sg31944
VP00451
p35175
sg31939
I4
sa(dp35176
g31934
I211
sg31935
g35166
sg31936
I4
sg31944
VP00748
p35177
sg31939
I1
sasa(dp35178
g31925
VWe measured the cerebrospinal fluid (CSF) and plasma concentrations of interleukin (IL)-1Alfa, IL-1Beta, IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-Alfa, TNF-Beta, interferon (IFN)-Gamma, the IL-1 receptor antagonist, and soluble IL-4 receptor (sIL-4r) by ELISA in 12 patients each with acute, monosymptomatic, idiopathic optic neuritis (ON), ON as part of MS, other attack forms of MS, and in neurological control subjects.
p35179
sg4
(dp35180
(Vtumor necrosis factor
p35181
Vtumor necrosis
p35182
tp35183
I00
ssg31931
(lp35184
(dp35185
g31934
I348
sg31935
VON
p35186
sg31936
I2
sg31937
VC0029134
p35187
sg31939
I1
sa(dp35188
g31934
I255
sg31935
VsIL
p35189
sg31936
I3
sg31937
VC0333873
p35190
sg31939
I1
sa(dp35191
g31934
I348
sg31935
VON
p35192
sg31936
I2
sg31937
VC0029134
p35193
sg31939
I1
sa(dp35194
g31934
I332
sg31935
Voptic neuritis
p35195
sg31936
I14
sg31937
VC0029134
p35196
sg31939
I2
sa(dp35197
g31934
I130
sg31935
g35182
sg31936
I14
sg31937
VC0333516
p35198
sg31939
I2
sasg31940
(lp35199
(dp35200
g31934
I105
sg31935
VIL-2
p35201
sg31936
I4
sg31944
VP60568
p35202
sg31939
I1
sa(dp35203
g31934
I95
sg31935
VIL-1Beta
p35204
sg31936
I8
sg31944
VP01584
p35205
sg31939
I1
sa(dp35206
g31934
I117
sg31935
VIL-6
p35207
sg31936
I4
sg31944
VP05231
p35208
sg31939
I1
sa(dp35209
g31934
I164
sg31935
VTNF-Beta
p35210
sg31936
I8
sg31944
VP01375
p35211
sg31939
I1
sa(dp35212
g31934
I153
sg31935
VTNF
p35213
sg31936
I3
sg31944
VP01375
p35214
sg31939
I1
sa(dp35215
g31934
I111
sg31935
VIL-4
p35216
sg31936
I4
sg31944
VP05112
p35217
sg31939
I1
sa(dp35218
g31934
I174
sg31935
Vinterferon
p35219
sg31936
I10
sg31944
VP01563
p35220
sg31939
I1
sa(dp35221
g31934
I255
sg31935
VsIL-4r
p35222
sg31936
I6
sg31944
VP40967
p35223
sg31939
I1
sa(dp35224
g31934
I232
sg31935
Vsoluble IL-4 receptor
p35225
sg31936
I21
sg31944
VP40967
p35226
sg31939
I3
sa(dp35227
g31934
I71
sg31935
Vinterleukin (IL)-1Alfa
p35228
sg31936
I22
sg31944
VP60568
p35229
sg31939
I2
sa(dp35230
g31934
I130
sg31935
g35181
sg31936
I21
sg31944
VP01375
p35231
sg31939
I3
sa(dp35232
g31934
I186
sg31935
VIFN
p35233
sg31936
I3
sg31944
VP01562
p35234
sg31939
I1
sa(dp35235
g31934
I202
sg31935
VIL-1 receptor
p35236
sg31936
I13
sg31944
g190
sg31939
I2
sasa(dp35237
g31925
VWe have reported previously that ocular infection of different strains of mice with recombinant herpes simplex virus 1 (HSV-1) constitutively expressing interleukin-2 (IL-2) provokes central nervous system (CNS) demyelination and optic neuropathy, as determined by changes in visual evoked cortical potentials and pathological changes in the optic nerve and CNS, whereas recombinant viruses expressing IL-4, gamma interferon, IL-12p35, IL-12p40, or IL-12p70 do not induce this neuropathy.
p35238
sg4
(dp35239
(VIL-4
p35240
Vdemyelination
p35241
tp35242
I00
ssg31931
(lp35243
(dp35244
g31934
I33
sg31935
Vocular infection
p35245
sg31936
I16
sg31937
VC0015403
p35246
sg31939
I2
sa(dp35247
g31934
I230
sg31935
Voptic neuropathy
p35248
sg31936
I16
sg31937
VC0029132
p35249
sg31939
I2
sa(dp35250
g31934
I236
sg31935
Vneuropathy
p35251
sg31936
I10
sg31937
VC0442874
p35252
sg31939
I1
sa(dp35253
g31934
I96
sg31935
Vherpes simplex
p35254
sg31936
I14
sg31937
VC0019348
p35255
sg31939
I2
sa(dp35256
g31934
I191
sg31935
Vnervous
p35257
sg31936
I7
sg31937
VC0027769
p35258
sg31939
I1
sa(dp35259
g31934
I212
sg31935
g35241
sg31936
I13
sg31937
VC0011304
p35260
sg31939
I1
sasg31940
(lp35261
(dp35262
g31934
I168
sg31935
VIL-2
p35263
sg31936
I4
sg31944
VP60568
p35264
sg31939
I1
sa(dp35265
g31934
I153
sg31935
Vinterleukin-2
p35266
sg31936
I13
sg31944
VP60568
p35267
sg31939
I1
sa(dp35268
g31934
I408
sg31935
Vgamma interferon
p35269
sg31936
I16
sg31944
VP01579
p35270
sg31939
I2
sa(dp35271
g31934
I402
sg31935
g35240
sg31936
I4
sg31944
VP05112
p35272
sg31939
I1
sasa(dp35273
g31925
VThe objective of this study was to detect interleukin-17 (IL-17), interferon-gamma (IFN-gamma), interleukin-4 (IL-4) and forkhead/winged helix transcription factor p3 (Foxp3) protein and gene expression of the optic nerve and to further explore the role of T helper cell subsets such as Th1, Th2, Th17 and Treg in the pathogenesis of optic neuritis in experimental autoimmune encephalomyelitis (EAE).
p35274
sg4
(dp35275
(VIL-4
p35276
Vencephalomyelitis
p35277
tp35278
I00
ssg31931
(lp35279
(dp35280
g31934
I334
sg31935
Voptic neuritis
p35281
sg31936
I14
sg31937
VC0029134
p35282
sg31939
I2
sa(dp35283
g31934
I395
sg31935
VEAE
p35284
sg31936
I3
sg31937
VC0014070
p35285
sg31939
I1
sa(dp35286
g31934
I318
sg31935
Vpathogenesis
p35287
sg31936
I12
sg31937
VC0699748
p35288
sg31939
I1
sa(dp35289
g31934
I365
sg31935
Vautoimmune
p35290
sg31936
I10
sg31937
VC0443146
p35291
sg31939
I1
sa(dp35292
g31934
I376
sg31935
g35277
sg31936
I17
sg31937
VC0014070
p35293
sg31939
I1
sasg31940
(lp35294
(dp35295
g31934
I42
sg31935
Vinterleukin-17
p35296
sg31936
I14
sg31944
VP60568
p35297
sg31939
I1
sa(dp35298
g31934
I121
sg31935
Vforkhead/winged helix transcription factor p3
p35299
sg31936
I45
sg31944
g190
sg31939
I5
sa(dp35300
g31934
I58
sg31935
VIL-17
p35301
sg31936
I5
sg31944
VP60568
p35302
sg31939
I1
sa(dp35303
g31934
I168
sg31935
VFoxp3
p35304
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp35305
g31934
I84
sg31935
VIFN-gamma
p35306
sg31936
I9
sg31944
VP01579
p35307
sg31939
I1
sa(dp35308
g31934
I96
sg31935
Vinterleukin-4
p35309
sg31936
I13
sg31944
VP05112
p35310
sg31939
I1
sa(dp35311
g31934
I66
sg31935
Vinterferon-gamma
p35312
sg31936
I16
sg31944
VP01579
p35313
sg31939
I1
sa(dp35314
g31934
I111
sg31935
g35276
sg31936
I4
sg31944
VP05112
p35315
sg31939
I1
sasa(dp35316
g31925
VIn MS and optic neuritis, IL-4 mRNA expressing cells predominated, followed by TGF-beta- and IFN-gamma-positive cells.
p35317
sg4
(dp35318
(VTGF-beta
p35319
Voptic neuritis
p35320
tp35321
I00
ssg31931
(lp35322
(dp35323
g31934
I10
sg31935
g35320
sg31936
I14
sg31937
VC0029134
p35324
sg31939
I2
sasg31940
(lp35325
(dp35326
g31934
I26
sg31935
VIL-4 mRNA
p35327
sg31936
I9
sg31944
VP05112
p35328
sg31939
I2
sa(dp35329
g31934
I93
sg31935
VIFN-gamma
p35330
sg31936
I9
sg31944
VP01579
p35331
sg31939
I1
sa(dp35332
g31934
I79
sg31935
g35319
sg31936
I8
sg31944
VP18075
p35333
sg31939
I1
sasa(dp35334
g31925
VGKN1, GKN2, and the trefoil factors TFF1 and TFF3 were examined in tissue microarrays from 155 distal gastric adenocarcinomas.
p35335
sg4
(dp35336
(Vtrefoil factors
p35337
Vadenocarcinomas
p35338
tp35339
I00
ssg31931
(lp35340
(dp35341
g31934
I110
sg31935
g35338
sg31936
I15
sg31937
VC0001418
p35342
sg31939
I1
sasg31940
(lp35343
(dp35344
g31934
I36
sg31935
VTFF1
p35345
sg31936
I4
sg31944
VP04155
p35346
sg31939
I1
sa(dp35347
g31934
I6
sg31935
VGKN2
p35348
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp35349
g31934
I20
sg31935
g35337
sg31936
I15
sg31944
VP19883
p35350
sg31939
I2
sa(dp35351
g31934
I45
sg31935
VTFF3
p35352
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp35353
g31934
I0
sg31935
VGKN1
p35354
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp35355
g31925
VThus, genetic ablation or pharmacologic inhibition of Shp2 suppresses the leukemogenic effect of Pten loss, yet simultaneously induces severe anemia in mice with Pten deficiency in blood cells.
p35356
sg4
(dp35357
(VPten loss
p35358
Vsevere anemia
p35359
tp35360
I00
ssg31931
(lp35361
(dp35362
g31934
I97
sg31935
VPten loss
p35363
sg31936
I9
sg31937
VC3272693
p35364
sg31939
I2
sa(dp35365
g31934
I135
sg31935
g35359
sg31936
I13
sg31937
VC0238644
p35366
sg31939
I2
sasg31940
(lp35367
(dp35368
g31934
I97
sg31935
VPten
p35369
sg31936
I4
sg31944
VP60484
p35370
sg31939
I1
sa(dp35371
g31934
I97
sg31935
g35358
sg31936
I9
sg31944
VP60484
p35372
sg31939
I2
sa(dp35373
g31934
I54
sg31935
VShp2
p35374
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp35375
g31925
VSurprisingly, the Shp2 and Pten double-knockout mice suffered lethal anemia, a phenotype that reveals previously unappreciated cooperative roles of Pten and Shp2 in erythropoiesis.
p35376
sg4
(dp35377
(VPten and Shp2
p35378
Vanemia
p35379
tp35380
I01
ssg31931
(lp35381
(dp35382
g31934
I53
sg31935
Vsuffered
p35383
sg31936
I8
sg31937
VC0683278
p35384
sg31939
I1
sa(dp35385
g31934
I69
sg31935
g35379
sg31936
I6
sg31937
VC0002871
p35386
sg31939
I1
sasg31940
(lp35387
(dp35388
g31934
I27
sg31935
VPten
p35389
sg31936
I4
sg31944
VP60484
p35390
sg31939
I1
sa(dp35391
g31934
I18
sg31935
VShp2
p35392
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp35393
g31934
I148
sg31935
g35378
sg31936
I13
sg31944
VP60484
p35394
sg31939
I3
sasa(dp35395
g31925
VThe human choroideremia-like (CHML) gene and a locus for Usher syndrome type 2 (USH2) were recently mapped to the 1q31-qter region employing physical mapping and genetic linkage studies, respectively.
p35396
sg4
(dp35397
(Vchoroideremia-like
p35398
Vchoroideremia
p35399
tp35400
I00
ssg31931
(lp35401
(dp35402
g31934
I57
sg31935
VUsher syndrome type 2
p35403
sg31936
I21
sg31937
VC0339534
p35404
sg31939
I4
sa(dp35405
g31934
I80
sg31935
VUSH2
p35406
sg31936
I4
sg31937
VC0339534
p35407
sg31939
I1
sa(dp35408
g31934
I10
sg31935
g35399
sg31936
I13
sg31937
VC0008525
p35409
sg31939
I1
sasg31940
(lp35410
(dp35411
g31934
I57
sg31935
VUsher syndrome type 2
p35412
sg31936
I21
sg31944
g190
sg31939
I4
sa(dp35413
g31934
I80
sg31935
VUSH2
p35414
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp35415
g31934
I30
sg31935
VCHML
p35416
sg31936
I4
sg31944
VP26374
p35417
sg31939
I1
sa(dp35418
g31934
I10
sg31935
g35398
sg31936
I18
sg31944
VP26374
p35419
sg31939
I1
sasa(dp35420
g31925
VIn induced apical periodontitis, osteoblastic expression of SIRT6 was significantly suppressed (P = 0.001) which was associated with significantly elevated levels of LDHA (P = 0.003) and 8-OHdG (P = 0.004) and significantly enhanced recruitment of macrophages (P = 0.004).
p35421
sg4
(dp35422
(VLDHA
p35423
Vapical periodontitis
p35424
tp35425
I00
ssg31931
(lp35426
(dp35427
g31934
I233
sg31935
Vrecruitment
p35428
sg31936
I11
sg31937
VC0271510
p35429
sg31939
I1
sa(dp35430
g31934
I11
sg31935
g35424
sg31936
I20
sg31937
VC0031030
p35431
sg31939
I2
sasg31940
(lp35432
(dp35433
g31934
I166
sg31935
g35423
sg31936
I4
sg31944
VP00338
p35434
sg31939
I1
sasa(dp35435
g31925
VThe main objective of this work was to evaluate a new therapeutic strategy against a colitis-related colorectal cancer in vivo and in vitro by targeting mTOR-signaling and lactate dehydrogenase A.
p35436
sg4
(dp35437
(Vlactate dehydrogenase A
p35438
Vcolorectal cancer
p35439
tp35440
I00
ssg31931
(lp35441
(dp35442
g31934
I85
sg31935
Vcolitis
p35443
sg31936
I7
sg31937
VC0009319
p35444
sg31939
I1
sa(dp35445
g31934
I101
sg31935
g35439
sg31936
I17
sg31937
VC1527249
p35446
sg31939
I2
sasg31940
(lp35447
(dp35448
g31934
I85
sg31935
Vcolitis-related colorectal cancer
p35449
sg31936
I33
sg31944
VP31749
p35450
sg31939
I3
sa(dp35451
g31934
I153
sg31935
VmTOR
p35452
sg31936
I4
sg31944
VP42345
p35453
sg31939
I1
sa(dp35454
g31934
I172
sg31935
g35438
sg31936
I23
sg31944
VP49366
p35455
sg31939
I3
sasa(dp35456
g31925
VTo determine Lactate Dehydrogenase Activity (LDHA) in whole saliva in individuals with periodontal disease and the effect of ultrasonic scaling on this enzyme activity.
p35457
sg4
(dp35458
(VLactate Dehydrogenase Activity
p35459
Vperiodontal disease
p35460
tp35461
I00
ssg31931
(lp35462
(dp35463
g31934
I87
sg31935
g35460
sg31936
I19
sg31937
VC0031090
p35464
sg31939
I2
sasg31940
(lp35465
(dp35466
g31934
I45
sg31935
VLDHA
p35467
sg31936
I4
sg31944
VP00338
p35468
sg31939
I1
sa(dp35469
g31934
I13
sg31935
g35459
sg31936
I30
sg31944
VP00338
p35470
sg31939
I3
sasa(dp35471
g31925
VHirudin variants (HV1 and HV2) were produced in infected insect cells as secreted proteins by joining their coding sequences to the leader peptide sequence of the vescicular stomatitis virus G protein.
p35472
sg4
(dp35473
(VHirudin variants
p35474
Vstomatitis
p35475
tp35476
I00
ssg31931
(lp35477
(dp35478
g31934
I174
sg31935
g35475
sg31936
I10
sg31937
VC0038362
p35479
sg31939
I1
sasg31940
(lp35480
(dp35481
g31934
I18
sg31935
VHV1
p35482
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp35483
g31934
I0
sg31935
g35474
sg31936
I16
sg31944
VP26640
p35484
sg31939
I2
sasa(dp35485
g31925
VTo systematically review evidence regarding the relationship between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis (RA), and the association between MIF gene polymorphisms and RA susceptibility.
p35486
sg4
(dp35487
(VMIF gene
p35488
Vrheumatoid arthritis
p35489
tp35490
I00
ssg31931
(lp35491
(dp35492
g31934
I159
sg31935
VRA
p35493
sg31936
I2
sg31937
VC0003873
p35494
sg31939
I1
sa(dp35495
g31934
I159
sg31935
VRA
p35496
sg31936
I2
sg31937
VC0003873
p35497
sg31939
I1
sa(dp35498
g31934
I137
sg31935
g35489
sg31936
I20
sg31937
VC0003873
p35499
sg31939
I2
sasg31940
(lp35500
(dp35501
g31934
I192
sg31935
g35488
sg31936
I8
sg31944
VP05109
p35502
sg31939
I2
sasa(dp35503
g31925
VRheumatoid SAAT secreted more adiponectin and macrophage migration inhibitory factor (MIF) than respective osteoarthritis tissue.
p35504
sg4
(dp35505
(VMIF
p35506
Vosteoarthritis
p35507
tp35508
I00
ssg31931
(lp35509
(dp35510
g31934
I107
sg31935
g35507
sg31936
I14
sg31937
VC0029408
p35511
sg31939
I1
sasg31940
(lp35512
(dp35513
g31934
I86
sg31935
g35506
sg31936
I3
sg31944
VP05109
p35514
sg31939
I1
sa(dp35515
g31934
I30
sg31935
Vadiponectin and macrophage migration inhibitory factor
p35516
sg31936
I54
sg31944
g190
sg31939
I6
sasa(dp35517
g31925
VMacrophage migration inhibitory factor (MIF) and vascular endothelial growth factor (VEGF), as crucial parameters of angiogenesis and inflammation, were evaluated to identify the role of cyclic citrullinated peptide antibodies (anti-CCP) during angiogenesis in rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
p35518
sg4
(dp35519
(Vanti-CCP
p35520
VCCP
p35521
tp35522
I01
ssg31931
(lp35523
(dp35524
g31934
I261
sg31935
Vrheumatoid arthritis
p35525
sg31936
I20
sg31937
VC0003873
p35526
sg31939
I2
sa(dp35527
g31934
I134
sg31935
Vinflammation
p35528
sg31936
I12
sg31937
VC0021368
p35529
sg31939
I1
sa(dp35530
g31934
I283
sg31935
VRA
p35531
sg31936
I2
sg31937
VC0003873
p35532
sg31939
I1
sa(dp35533
g31934
I312
sg31935
VPsA
p35534
sg31936
I3
sg31937
VC1519176
p35535
sg31939
I1
sa(dp35536
g31934
I291
sg31935
Vpsoriatic arthritis
p35537
sg31936
I19
sg31937
VC0003872
p35538
sg31939
I2
sa(dp35539
g31934
I233
sg31935
g35521
sg31936
I3
sg31937
VC1832526
p35540
sg31939
I1
sasg31940
(lp35541
(dp35542
g31934
I49
sg31935
Vvascular endothelial growth factor
p35543
sg31936
I34
sg31944
g190
sg31939
I4
sa(dp35544
g31934
I228
sg31935
g35520
sg31936
I8
sg31944
VP07320
p35545
sg31939
I1
sa(dp35546
g31934
I85
sg31935
VVEGF
p35547
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp35548
g31925
VThese include FGF3 in Michel aplasia; FGF8 in cleft lip/palate and in hypogonadotropic hypogonadism; FGF9 in carcinoma; FGF10 in the lacrimal/salivary glands aplasia, and lacrimo-auriculo-dento-digital syndrome; FGF14 in spinocerebellar ataxia; FGF20 in Parkinson disease; and FGF23 in tumoral calcinosis and hypophosphatemic rickets.
p35549
sg4
(dp35550
(VFGF3
p35551
Vspinocerebellar ataxia
p35552
tp35553
I00
ssg31931
(lp35554
(dp35555
g31934
I254
sg31935
VParkinson disease
p35556
sg31936
I17
sg31937
VC0030567
p35557
sg31939
I2
sa(dp35558
g31934
I29
sg31935
Vaplasia
p35559
sg31936
I7
sg31937
VC0243065
p35560
sg31939
I1
sa(dp35561
g31934
I171
sg31935
Vlacrimo-auriculo-dento-digital syndrome
p35562
sg31936
I39
sg31937
VC0265269
p35563
sg31939
I2
sa(dp35564
g31934
I46
sg31935
Vcleft lip/palate
p35565
sg31936
I16
sg31937
VC0158646
p35566
sg31939
I2
sa(dp35567
g31934
I309
sg31935
Vhypophosphatemic rickets
p35568
sg31936
I24
sg31937
VC1704375
p35569
sg31939
I2
sa(dp35570
g31934
I286
sg31935
Vtumoral calcinosis
p35571
sg31936
I18
sg31937
VC0263628
p35572
sg31939
I2
sa(dp35573
g31934
I109
sg31935
Vcarcinoma
p35574
sg31936
I9
sg31937
VC0007097
p35575
sg31939
I1
sa(dp35576
g31934
I29
sg31935
Vaplasia
p35577
sg31936
I7
sg31937
VC0243065
p35578
sg31939
I1
sa(dp35579
g31934
I70
sg31935
Vhypogonadotropic hypogonadism
p35580
sg31936
I29
sg31937
VC0022735
p35581
sg31939
I2
sa(dp35582
g31934
I221
sg31935
g35552
sg31936
I22
sg31937
VC0087012
p35583
sg31939
I2
sasg31940
(lp35584
(dp35585
g31934
I120
sg31935
VFGF10
p35586
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp35587
g31934
I277
sg31935
VFGF23
p35588
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp35589
g31934
I38
sg31935
VFGF8
p35590
sg31936
I4
sg31944
VP55075
p35591
sg31939
I1
sa(dp35592
g31934
I212
sg31935
VFGF14
p35593
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp35594
g31934
I101
sg31935
VFGF9
p35595
sg31936
I4
sg31944
VP31371
p35596
sg31939
I1
sa(dp35597
g31934
I14
sg31935
g35551
sg31936
I4
sg31944
VP11487
p35598
sg31939
I1
sasa(dp35599
g31925
VThe MLL-LCX fusion protein lacked a CXXC domain of LCX, but retained an alpha-helical coiled-coil region at the COOH terminus, similar to MLL-SEPTING, MLL-CDCREL1, MLL-AF1p/Eps15, and MLL-AF6, which suggests that these fusion proteins are involved in the pathogenesis of 11q23-associated leukemia through similar mechanisms.
p35600
sg4
(dp35601
(VAF1p
p35602
Vleukemia
p35603
tp35604
I00
ssg31931
(lp35605
(dp35606
g31934
I255
sg31935
Vpathogenesis
p35607
sg31936
I12
sg31937
VC0699748
p35608
sg31939
I1
sa(dp35609
g31934
I288
sg31935
g35603
sg31936
I8
sg31937
VC0023418
p35610
sg31939
I1
sasg31940
(lp35611
(dp35612
g31934
I4
sg31935
VMLL-LCX fusion protein
p35613
sg31936
I22
sg31944
g190
sg31939
I3
sa(dp35614
g31934
I173
sg31935
VEps15
p35615
sg31936
I5
sg31944
VP42566
p35616
sg31939
I1
sa(dp35617
g31934
I155
sg31935
VCDCREL1
p35618
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp35619
g31934
I4
sg31935
VMLL
p35620
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp35621
g31934
I4
sg31935
VMLL
p35622
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp35623
g31934
I188
sg31935
VAF6
p35624
sg31936
I3
sg31944
VP55196
p35625
sg31939
I1
sa(dp35626
g31934
I138
sg31935
VMLL-SEPTING
p35627
sg31936
I11
sg31944
g190
sg31939
I1
sa(dp35628
g31934
I168
sg31935
g35602
sg31936
I4
sg31944
VP42566
p35629
sg31939
I1
sa(dp35630
g31934
I4
sg31935
VMLL
p35631
sg31936
I3
sg31944
g190
sg31939
I1
sasa(dp35632
g31925
VThe incidence of human T cell lymphotropic virus type 1 (HLTV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is not well defined in the literature.
p35633
sg4
(dp35634
(VTSP
p35635
VHAM
p35636
tp35637
I00
ssg31931
(lp35638
(dp35639
g31934
I76
sg31935
Vmyelopathy
p35640
sg31936
I10
sg31937
VC0037928
p35641
sg31939
I1
sa(dp35642
g31934
I87
sg31935
Vtropical spastic paraparesis
p35643
sg31936
I28
sg31937
VC0030481
p35644
sg31939
I3
sa(dp35645
g31934
I117
sg31935
g35636
sg31936
I3
sg31937
VC0030481
p35646
sg31939
I1
sasg31940
(lp35647
(dp35648
g31934
I117
sg31935
VHAM
p35649
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp35650
g31934
I121
sg31935
g35635
sg31936
I3
sg31944
VP07996
p35651
sg31939
I1
sasa(dp35652
g31925
VPRG4 is one of the downstream molecules of the myxoid liposarcoma (MLS)-specific fusion oncoproteins TLS-CHOP and EWS-CHOP.
p35653
sg4
(dp35654
(VCHOP
p35655
Vmyxoid liposarcoma
p35656
tp35657
I00
ssg31931
(lp35658
(dp35659
g31934
I67
sg31935
VMLS
p35660
sg31936
I3
sg31937
VC0796070
p35661
sg31939
I1
sa(dp35662
g31934
I47
sg31935
g35656
sg31936
I18
sg31937
VC0206634
p35663
sg31939
I2
sasg31940
(lp35664
(dp35665
g31934
I101
sg31935
VTLS
p35666
sg31936
I3
sg31944
VP35637
p35667
sg31939
I1
sa(dp35668
g31934
I114
sg31935
VEWS
p35669
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp35670
g31934
I105
sg31935
VCHOP
p35671
sg31936
I4
sg31944
VP35638
p35672
sg31939
I1
sa(dp35673
g31934
I0
sg31935
VPRG4
p35674
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp35675
g31934
I105
sg31935
g35655
sg31936
I4
sg31944
VP35638
p35676
sg31939
I1
sasa(dp35677
g31925
VOf 24 patients with actionable mutations, five were given genotype-matched drugs corresponding to actionable mutations: everolimus to PIK3CA mutation in parotid carcinosarcoma (partial response) and tracheal squamous cell carcinoma (stable disease; 21% reduction), sorafenib to PDGFRA mutation in auditory canal adenocarcinoma (partial response), sorafenib to BRAF mutation in microcytic adnexal carcinoma (progressive disease), and afatinib to ERBB2 mutation in esophageal adenocarcinoma (progressive disease).
p35678
sg4
(dp35679
(VPDGFRA
p35680
Vcarcinosarcoma
p35681
tp35682
I01
ssg31931
(lp35683
(dp35684
g31934
I463
sg31935
Vesophageal adenocarcinoma
p35685
sg31936
I25
sg31937
VC0279628
p35686
sg31939
I2
sa(dp35687
g31934
I199
sg31935
Vtracheal squamous cell carcinoma
p35688
sg31936
I32
sg31937
VC0345946
p35689
sg31939
I4
sa(dp35690
g31934
I407
sg31935
Vprogressive disease
p35691
sg31936
I19
sg31937
VC0677932
p35692
sg31939
I2
sa(dp35693
g31934
I388
sg31935
Vadnexal carcinoma
p35694
sg31936
I17
sg31937
VC0206697
p35695
sg31939
I2
sa(dp35696
g31934
I407
sg31935
Vprogressive disease
p35697
sg31936
I19
sg31937
VC0677932
p35698
sg31939
I2
sa(dp35699
g31934
I312
sg31935
Vadenocarcinoma
p35700
sg31936
I14
sg31937
VC0001418
p35701
sg31939
I1
sa(dp35702
g31934
I161
sg31935
g35681
sg31936
I14
sg31937
VC0007140
p35703
sg31939
I1
sasg31940
(lp35704
(dp35705
g31934
I134
sg31935
VPIK3CA
p35706
sg31936
I6
sg31944
VP42336
p35707
sg31939
I1
sa(dp35708
g31934
I360
sg31935
VBRAF
p35709
sg31936
I4
sg31944
VP15056
p35710
sg31939
I1
sa(dp35711
g31934
I445
sg31935
VERBB2
p35712
sg31936
I5
sg31944
VP04626
p35713
sg31939
I1
sa(dp35714
g31934
I278
sg31935
g35680
sg31936
I6
sg31944
VP16234
p35715
sg31939
I1
sasa(dp35716
g31925
VThe objective of this study was to determine the efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma.
p35717
sg4
(dp35718
(VHER2
p35719
Vcarcinosarcoma
p35720
tp35721
I00
ssg31931
(lp35722
(dp35723
g31934
I106
sg31935
g35720
sg31936
I14
sg31937
VC0007140
p35724
sg31939
I1
sasg31940
(lp35725
(dp35726
g31934
I91
sg31935
g35719
sg31936
I4
sg31944
VP04626
p35727
sg31939
I1
sasa(dp35728
g31925
VThe efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma was determined in vitro using seven primary carcinosarcoma cell lines with differential expression of HER2/neu.
p35729
sg4
(dp35730
(VHER2
p35731
Vcarcinosarcoma
p35732
tp35733
I00
ssg31931
(lp35734
(dp35735
g31934
I61
sg31935
Vcarcinosarcoma
p35736
sg31936
I14
sg31937
VC0007140
p35737
sg31939
I1
sa(dp35738
g31934
I61
sg31935
g35732
sg31936
I14
sg31937
VC0007140
p35739
sg31939
I1
sasg31940
(lp35740
(dp35741
g31934
I183
sg31935
Vneu
p35742
sg31936
I3
sg31944
VP04626
p35743
sg31939
I1
sa(dp35744
g31934
I46
sg31935
VHER2
p35745
sg31936
I4
sg31944
VP04626
p35746
sg31939
I1
sa(dp35747
g31934
I46
sg31935
g35731
sg31936
I4
sg31944
VP04626
p35748
sg31939
I1
sasa(dp35749
g31925
VTwo of seven (28.5%) carcinosarcoma cell lines were HER2/neu amplified.
p35750
sg4
(dp35751
(Vneu
p35752
Vcarcinosarcoma
p35753
tp35754
I00
ssg31931
(lp35755
(dp35756
g31934
I21
sg31935
g35753
sg31936
I14
sg31937
VC0007140
p35757
sg31939
I1
sasg31940
(lp35758
(dp35759
g31934
I52
sg31935
VHER2
p35760
sg31936
I4
sg31944
VP04626
p35761
sg31939
I1
sa(dp35762
g31934
I57
sg31935
g35752
sg31936
I3
sg31944
VP04626
p35763
sg31939
I1
sasa(dp35764
g31925
VHER2/neu amplified cell lines SARARK6 and SARARK9 were significantly more sensitive to neratinib than the five non-HER2/neu amplified carcinosarcoma cell lines (mean+/-SEM IC50:0.014myM+/-0.004vs.0.164myM+/-0.019 p=0.0003).
p35765
sg4
(dp35766
(VHER2
p35767
VSEM
p35768
tp35769
I00
ssg31931
(lp35770
(dp35771
g31934
I134
sg31935
Vcarcinosarcoma
p35772
sg31936
I14
sg31937
VC0007140
p35773
sg31939
I1
sa(dp35774
g31934
I168
sg31935
g35768
sg31936
I3
sg31937
VC0432222
p35775
sg31939
I1
sasg31940
(lp35776
(dp35777
g31934
I5
sg31935
Vneu
p35778
sg31936
I3
sg31944
VP04626
p35779
sg31939
I1
sa(dp35780
g31934
I5
sg31935
Vneu
p35781
sg31936
I3
sg31944
VP04626
p35782
sg31939
I1
sa(dp35783
g31934
I0
sg31935
VHER2
p35784
sg31936
I4
sg31944
VP04626
p35785
sg31939
I1
sa(dp35786
g31934
I0
sg31935
g35767
sg31936
I4
sg31944
VP04626
p35787
sg31939
I1
sasa(dp35788
g31925
VNeratinib inhibits HER2 amplified carcinosarcoma proliferation, signaling, cell cycle progression and tumor growth in vitro.
p35789
sg4
(dp35790
(VHER2
p35791
Vcarcinosarcoma
p35792
tp35793
I00
ssg31931
(lp35794
(dp35795
g31934
I49
sg31935
Vproliferation
p35796
sg31936
I13
sg31937
VC0334094
p35797
sg31939
I1
sa(dp35798
g31934
I34
sg31935
g35792
sg31936
I14
sg31937
VC0007140
p35799
sg31939
I1
sa(dp35800
g31934
I102
sg31935
Vtumor growth
p35801
sg31936
I12
sg31937
VC0598934
p35802
sg31939
I2
sasg31940
(lp35803
(dp35804
g31934
I19
sg31935
g35791
sg31936
I4
sg31944
VP04626
p35805
sg31939
I1
sasa(dp35806
g31925
VNumerous correlative scientific investigations have demonstrated that the HER2 (ERBB2) gene is amplified in 17%-33% of carcinosarcoma, uterine serous carcinoma, and a subset of high-grade endometrioid endometrial tumors.
p35807
sg4
(dp35808
(VERBB2
p35809
Vcarcinosarcoma
p35810
tp35811
I00
ssg31931
(lp35812
(dp35813
g31934
I143
sg31935
Vserous carcinoma
p35814
sg31936
I16
sg31937
VC0206701
p35815
sg31939
I2
sa(dp35816
g31934
I213
sg31935
Vtumors
p35817
sg31936
I6
sg31937
VC0027651
p35818
sg31939
I1
sa(dp35819
g31934
I119
sg31935
g35810
sg31936
I14
sg31937
VC0007140
p35820
sg31939
I1
sasg31940
(lp35821
(dp35822
g31934
I74
sg31935
VHER2
p35823
sg31936
I4
sg31944
VP04626
p35824
sg31939
I1
sa(dp35825
g31934
I80
sg31935
g35809
sg31936
I5
sg31944
VP04626
p35826
sg31939
I1
sasa(dp35827
g31925
VThe analysis of human datasets and GBM tumors revealed higher expression of p65 in GBM-associated CD68+ macrophages compared to neighboring stroma.
p35828
sg4
(dp35829
(Vp65
p35830
VGBM
p35831
tp35832
I01
ssg31931
(lp35833
(dp35834
g31934
I39
sg31935
Vtumors
p35835
sg31936
I6
sg31937
VC0027651
p35836
sg31939
I1
sa(dp35837
g31934
I35
sg31935
VGBM
p35838
sg31936
I3
sg31937
VC0017636
p35839
sg31939
I1
sa(dp35840
g31934
I35
sg31935
g35831
sg31936
I3
sg31937
VC0017636
p35841
sg31939
I1
sasg31940
(lp35842
(dp35843
g31934
I76
sg31935
g35830
sg31936
I3
sg31944
VP21579
p35844
sg31939
I1
sa(dp35845
g31934
I83
sg31935
VGBM-associated CD68+
p35846
sg31936
I20
sg31944
g190
sg31939
I2
sasa(dp35847
g31925
VOf paramount importance in the recognition of oligodendroglial and astrocytic tumor cells were the double immunostainings for ATRX/GFAP, ATRX/IDH1R132H, ATRX/Iba-1 and ATRX/CD68.
p35848
sg4
(dp35849
(VCD68
p35850
VATRX
p35851
tp35852
I00
ssg31931
(lp35853
(dp35854
g31934
I126
sg31935
VATRX
p35855
sg31936
I4
sg31937
VC1845055
p35856
sg31939
I1
sa(dp35857
g31934
I126
sg31935
VATRX
p35858
sg31936
I4
sg31937
VC1845055
p35859
sg31939
I1
sa(dp35860
g31934
I126
sg31935
VATRX
p35861
sg31936
I4
sg31937
VC1845055
p35862
sg31939
I1
sa(dp35863
g31934
I67
sg31935
Vastrocytic tumor
p35864
sg31936
I16
sg31937
VC0004114
p35865
sg31939
I2
sa(dp35866
g31934
I126
sg31935
g35851
sg31936
I4
sg31937
VC1845055
p35867
sg31939
I1
sasg31940
(lp35868
(dp35869
g31934
I173
sg31935
g35850
sg31936
I4
sg31944
VP34810
p35870
sg31939
I1
sasa(dp35871
g31925
VIn addition to the well-known increase in glial fibrillary acidic protein and other proteins in reactive astrocytes, astrocytopathy is evidenced by deposition of abnormal proteins such as Beta-amyloid, hyper-phosphorylated tau, abnormal Alfa-synuclein, mutated huntingtin, phosphorylated TDP-43 and mutated SOD1, and PrPres , in Alzheimer's disease, tauopathies, Lewy body diseases, Huntington's disease, amyotrophic lateral sclerosis and Creutzfeldt-Jakob disease, respectively.
p35872
sg4
(dp35873
(Vglial fibrillary acidic protein
p35874
VCreutzfeldt-Jakob disease
p35875
tp35876
I00
ssg31931
(lp35877
(dp35878
g31934
I193
sg31935
Vamyloid
p35879
sg31936
I7
sg31937
VC0011560
p35880
sg31939
I1
sa(dp35881
g31934
I329
sg31935
VAlzheimer's disease
p35882
sg31936
I19
sg31937
VC1521724
p35883
sg31939
I2
sa(dp35884
g31934
I405
sg31935
Vamyotrophic lateral sclerosis
p35885
sg31936
I29
sg31937
VC0002736
p35886
sg31939
I3
sa(dp35887
g31934
I350
sg31935
Vtauopathies
p35888
sg31936
I11
sg31937
VC0949664
p35889
sg31939
I1
sa(dp35890
g31934
I383
sg31935
VHuntington's disease
p35891
sg31936
I20
sg31937
VC0020179
p35892
sg31939
I2
sa(dp35893
g31934
I439
sg31935
g35875
sg31936
I25
sg31937
VC0022336
p35894
sg31939
I2
sasg31940
(lp35895
(dp35896
g31934
I299
sg31935
Vmutated SOD1
p35897
sg31936
I12
sg31944
VP00441
p35898
sg31939
I2
sa(dp35899
g31934
I273
sg31935
Vphosphorylated TDP-43
p35900
sg31936
I21
sg31944
g190
sg31939
I2
sa(dp35901
g31934
I237
sg31935
VAlfa-synuclein
p35902
sg31936
I14
sg31944
VP37840
p35903
sg31939
I1
sa(dp35904
g31934
I253
sg31935
Vmutated huntingtin
p35905
sg31936
I18
sg31944
VP42858
p35906
sg31939
I2
sa(dp35907
g31934
I42
sg31935
g35874
sg31936
I31
sg31944
VP05230
p35908
sg31939
I4
sasa(dp35909
g31925
VInterestingly, BAG3-mediated selective macroautophagy is also involved in the clearance of aggregated proteins associated with age-related neurodegenerative disorders, like Alzheimer's disease (tau-protein), Huntington's disease (mutated huntingtin/polyQ proteins), and amyotrophic lateral sclerosis (mutated SOD1).
p35910
sg4
(dp35911
(VSOD1
p35912
Vneurodegenerative disorders
p35913
tp35914
I00
ssg31931
(lp35915
(dp35916
g31934
I173
sg31935
VAlzheimer's disease
p35917
sg31936
I19
sg31937
VC1521724
p35918
sg31939
I2
sa(dp35919
g31934
I270
sg31935
Vamyotrophic lateral sclerosis
p35920
sg31936
I29
sg31937
VC0002736
p35921
sg31939
I3
sa(dp35922
g31934
I208
sg31935
VHuntington's disease
p35923
sg31936
I20
sg31937
VC0020179
p35924
sg31939
I2
sa(dp35925
g31934
I139
sg31935
g35913
sg31936
I27
sg31937
VC0524851
p35926
sg31939
I2
sasg31940
(lp35927
(dp35928
g31934
I249
sg31935
VpolyQ proteins
p35929
sg31936
I14
sg31944
VP02649
p35930
sg31939
I2
sa(dp35931
g31934
I15
sg31935
VBAG3
p35932
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp35933
g31934
I238
sg31935
Vhuntingtin
p35934
sg31936
I10
sg31944
VP42858
p35935
sg31939
I1
sa(dp35936
g31934
I309
sg31935
g35912
sg31936
I4
sg31944
VP00441
p35937
sg31939
I1
sasa(dp35938
g31925
VAt present, variants of the 5-hydroxytryptamine receptor 2A (5-HTR2A) and interleukin-6 (IL-6) genes may be susceptible markers to develop for obstructive sleep apnea-hypopnea syndrome (OSAHS).
p35939
sg4
(dp35940
(Vinterleukin-6
p35941
Vobstructive sleep apnea-hypopnea syndrome
p35942
tp35943
I00
ssg31931
(lp35944
(dp35945
g31934
I186
sg31935
VOSAHS
p35946
sg31936
I5
sg31937
VC0520679
p35947
sg31939
I1
sa(dp35948
g31934
I143
sg31935
g35942
sg31936
I41
sg31937
VC0520679
p35949
sg31939
I4
sasg31940
(lp35950
(dp35951
g31934
I89
sg31935
VIL-6
p35952
sg31936
I4
sg31944
VP05231
p35953
sg31939
I1
sa(dp35954
g31934
I74
sg31935
g35941
sg31936
I13
sg31944
VP05231
p35955
sg31939
I1
sasa(dp35956
g31925
VThe results of our study showed that tumor necrosis factor-Alfa (TNF-Alfa) -308 G/A (OR = 3.70, 95 % CI = 1.39-9.83), gene-linked polymorphic region (LPR) (OR = 0.57, 95 % CI = 0.41-0.79), and variable number tandem repeat (VNTR) of the 5-hydroxytryptamine transporter gene (5-HTT) (OR = 3.44, 95 % CI = 1.49-7.95) polymorphisms were associated with OSAS risk in the Chinese population, while there was no significant association between 5-hydroxytryptamine 2A receptor (5-HTR2A) 102C/T, 5-HTR2A A1438G, angiotensin-converting enzyme (ACE) insertion (I)/deletion (D), or leptin receptor (LEPR)-Gln 223Arg polymorphism and risk of OSAS in the Chinese population.
p35957
sg4
(dp35958
(V5-HTR2A
p35959
VOSAS
p35960
tp35961
I00
ssg31931
(lp35962
(dp35963
g31934
I350
sg31935
VOSAS
p35964
sg31936
I4
sg31937
VC0520679
p35965
sg31939
I1
sa(dp35966
g31934
I37
sg31935
Vtumor necrosis
p35967
sg31936
I14
sg31937
VC0333516
p35968
sg31939
I2
sa(dp35969
g31934
I193
sg31935
Vvariable number tandem repeat
p35970
sg31936
I29
sg31937
VC1710347
p35971
sg31939
I4
sa(dp35972
g31934
I224
sg31935
VVNTR
p35973
sg31936
I4
sg31937
VC1710347
p35974
sg31939
I1
sa(dp35975
g31934
I350
sg31935
g35960
sg31936
I4
sg31937
VC0520679
p35976
sg31939
I1
sasg31940
(lp35977
(dp35978
g31934
I237
sg31935
V5-hydroxytryptamine transporter gene
p35979
sg31936
I36
sg31944
VP31645
p35980
sg31939
I3
sa(dp35981
g31934
I488
sg31935
V5-HTR2A A1438G
p35982
sg31936
I14
sg31944
VP28223
p35983
sg31939
I2
sa(dp35984
g31934
I588
sg31935
VLEPR
p35985
sg31936
I4
sg31944
VP48357
p35986
sg31939
I1
sa(dp35987
g31934
I535
sg31935
VACE
p35988
sg31936
I3
sg31944
VP12821
p35989
sg31939
I1
sa(dp35990
g31934
I37
sg31935
Vtumor necrosis factor-Alfa
p35991
sg31936
I26
sg31944
VP01375
p35992
sg31939
I3
sa(dp35993
g31934
I504
sg31935
Vangiotensin-converting enzyme
p35994
sg31936
I29
sg31944
VP12821
p35995
sg31939
I2
sa(dp35996
g31934
I65
sg31935
VTNF-Alfa
p35997
sg31936
I8
sg31944
VP01375
p35998
sg31939
I1
sa(dp35999
g31934
I571
sg31935
Vleptin receptor
p36000
sg31936
I15
sg31944
VP48357
p36001
sg31939
I2
sa(dp36002
g31934
I438
sg31935
V5-hydroxytryptamine 2A receptor
p36003
sg31936
I31
sg31944
VP34969
p36004
sg31939
I3
sa(dp36005
g31934
I275
sg31935
V5-HTT
p36006
sg31936
I5
sg31944
VP31645
p36007
sg31939
I1
sa(dp36008
g31934
I471
sg31935
g35959
sg31936
I7
sg31944
VP28223
p36009
sg31939
I1
sasa(dp36010
g31925
VOur study demonstrated that TNF-Alfa 308 G/A, 5-HTT LPR, and 5-HTT-VNTR polymorphisms were associated with OSAS risk, whereas little association was observed between 5-HTR2A 102C/T, 5-HTR2A A1438G, ACE I/D, or LEPR-Gln 223Arg polymorphism and risk of OSAS in the Chinese population.
p36011
sg4
(dp36012
(V5-HTR2A 102C
p36013
VOSAS
p36014
tp36015
I00
ssg31931
(lp36016
(dp36017
g31934
I107
sg31935
VOSAS
p36018
sg31936
I4
sg31937
VC0520679
p36019
sg31939
I1
sa(dp36020
g31934
I107
sg31935
g36014
sg31936
I4
sg31937
VC0520679
p36021
sg31939
I1
sasg31940
(lp36022
(dp36023
g31934
I198
sg31935
VACE I/D
p36024
sg31936
I7
sg31944
VP12821
p36025
sg31939
I2
sa(dp36026
g31934
I28
sg31935
VTNF
p36027
sg31936
I3
sg31944
VP01375
p36028
sg31939
I1
sa(dp36029
g31934
I182
sg31935
V5-HTR2A A1438G
p36030
sg31936
I14
sg31944
VP28223
p36031
sg31939
I2
sa(dp36032
g31934
I166
sg31935
g36013
sg31936
I12
sg31944
VP28223
p36033
sg31939
I2
sasa(dp36034
g31925
VWe performed a meta-analysis to better evaluate the associations between 5-HT2A, 5-HTT, and LEPR polymorphisms, and OSAS.
p36035
sg4
(dp36036
(V5-HTT
p36037
VOSAS
p36038
tp36039
I00
ssg31931
(lp36040
(dp36041
g31934
I116
sg31935
g36038
sg31936
I4
sg31937
VC0520679
p36042
sg31939
I1
sasg31940
(lp36043
(dp36044
g31934
I75
sg31935
VHT2A
p36045
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp36046
g31934
I81
sg31935
g36037
sg31936
I5
sg31944
VP31645
p36047
sg31939
I1
sasa(dp36048
g31925
V5-HT2A, 5-HTT, and LEPR polymorphisms and OSAS were identified in PubMed and EMBASE.
p36049
sg4
(dp36050
(V5-HTT
p36051
VOSAS
p36052
tp36053
I00
ssg31931
(lp36054
(dp36055
g31934
I42
sg31935
g36052
sg31936
I4
sg31937
VC0520679
p36056
sg31939
I1
sasg31940
(lp36057
(dp36058
g31934
I2
sg31935
VHT2A
p36059
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp36060
g31934
I8
sg31935
g36051
sg31936
I5
sg31944
VP31645
p36061
sg31939
I1
sasa(dp36062
g31925
VThere was no significant association between 5-HT2A 102C/T and OSAS risk, using any model.
p36063
sg4
(dp36064
(V5-HT2A 102C
p36065
VOSAS
p36066
tp36067
I00
ssg31931
(lp36068
(dp36069
g31934
I63
sg31935
g36066
sg31936
I4
sg31937
VC0520679
p36070
sg31939
I1
sasg31940
(lp36071
(dp36072
g31934
I45
sg31935
g36065
sg31936
I11
sg31944
VP28223
p36073
sg31939
I2
sasa(dp36074
g31925
VEight studies were finally included in the meta-analysis of the association between 5-HTR2A gene variants (including 102T/C and 1438G/A), 5-HTT gene polymorphisms (including 5-HTT gene-linked promoter region (5-HTTLRP), and serotonin transporter intron 2 variable number tandem repeat (STin2VNTR) and OSAS risk.
p36075
sg4
(dp36076
(V5-HTR2A gene
p36077
VOSAS
p36078
tp36079
I00
ssg31931
(lp36080
(dp36081
g31934
I301
sg31935
g36078
sg31936
I4
sg31937
VC0520679
p36082
sg31939
I1
sa(dp36083
g31934
I255
sg31935
Vvariable number tandem repeat
p36084
sg31936
I29
sg31937
VC1710347
p36085
sg31939
I4
sasg31940
(lp36086
(dp36087
g31934
I224
sg31935
Vserotonin transporter
p36088
sg31936
I21
sg31944
VP31645
p36089
sg31939
I2
sa(dp36090
g31934
I138
sg31935
V5-HTT gene
p36091
sg31936
I10
sg31944
VP31645
p36092
sg31939
I2
sa(dp36093
g31934
I84
sg31935
g36077
sg31936
I12
sg31944
VP28223
p36094
sg31939
I2
sasa(dp36095
g31925
VThe G allele of 5-HTR2A 1438G/A, long 5-HTTLPR, and 10-tandem-repeats STin2VNTR were shown to increase OSAS susceptibility, with ORs of 2.33 (A vs. G, 95% CI 1.48-3.66), 1.24 (L vs. S, 95% CI: 1.04-1.49), and 2.87 (10 vs. 12, 95% CI: 1.38-5.97), respectively.
p36096
sg4
(dp36097
(VOSAS susceptibility
p36098
VOSAS
p36099
tp36100
I00
ssg31931
(lp36101
(dp36102
g31934
I103
sg31935
g36099
sg31936
I4
sg31937
VC0520679
p36103
sg31939
I1
sasg31940
(lp36104
(dp36105
g31934
I4
sg31935
VG allele of 5-HTR2A 1438G/A, long 5-HTTLPR, and 10-tandem-repeats STin2VNTR
p36106
sg31936
I75
sg31944
VP28223
p36107
sg31939
I10
sa(dp36108
g31934
I103
sg31935
g36098
sg31936
I19
sg31944
VP27986
p36109
sg31939
I2
sasa(dp36110
g31925
VOf the 5-HTR2A 1438G/A gene polymorphism, the AA genotype increased the OSAS risk, with an OR of 4.21 (95% CI: 2.83-6.25) in a recessive model in male OSAS patients, but no significant association was found in females.
p36111
sg4
(dp36112
(V5-HTR2A 1438G
p36113
VOSAS
p36114
tp36115
I00
ssg31931
(lp36116
(dp36117
g31934
I72
sg31935
VOSAS
p36118
sg31936
I4
sg31937
VC0520679
p36119
sg31939
I1
sa(dp36120
g31934
I72
sg31935
g36114
sg31936
I4
sg31937
VC0520679
p36121
sg31939
I1
sasg31940
(lp36122
(dp36123
g31934
I7
sg31935
g36113
sg31936
I13
sg31944
VP28223
p36124
sg31939
I2
sasa(dp36125
g31925
VOur meta-analysis demonstrated that polymorphisms in the 5-HTR2A 1438G/A and 5-HTT genes contributed to susceptibility to OSAS.
p36126
sg4
(dp36127
(V5-HTR2A 1438G
p36128
VOSAS
p36129
tp36130
I00
ssg31931
(lp36131
(dp36132
g31934
I122
sg31935
g36129
sg31936
I4
sg31937
VC0520679
p36133
sg31939
I1
sasg31940
(lp36134
(dp36135
g31934
I77
sg31935
V5-HTT genes
p36136
sg31936
I11
sg31944
VP31645
p36137
sg31939
I2
sa(dp36138
g31934
I57
sg31935
g36128
sg31936
I13
sg31944
VP28223
p36139
sg31939
I2
sasa(dp36140
g31925
VOur findings suggest that upregulated functional TRPC5 gene may be one cause of EPO-induced hypertension in patients with chronic kidney disease.
p36141
sg4
(dp36142
(VEPO
p36143
Vchronic kidney disease
p36144
tp36145
I00
ssg31931
(lp36146
(dp36147
g31934
I92
sg31935
Vhypertension
p36148
sg31936
I12
sg31937
VC0020538
p36149
sg31939
I1
sa(dp36150
g31934
I122
sg31935
g36144
sg31936
I22
sg31937
VC1561643
p36151
sg31939
I3
sasg31940
(lp36152
(dp36153
g31934
I49
sg31935
VTRPC5 gene
p36154
sg31936
I10
sg31944
g190
sg31939
I2
sa(dp36155
g31934
I80
sg31935
g36143
sg31936
I3
sg31944
VP01588
p36156
sg31939
I1
sasa(dp36157
g31925
VTTR (transthyretin) gene could be a possible candidate for lumbosacral stenosis in Labrador retrievers based on previous human studies that have reported an association between human lumbar spinal stenosis and transthyretin protein amyloidosis.
p36158
sg4
(dp36159
(Vtransthyretin
p36160
Vamyloidosis
p36161
tp36162
I00
ssg31931
(lp36163
(dp36164
g31934
I59
sg31935
Vlumbosacral stenosis
p36165
sg31936
I20
sg31937
VC1299881
p36166
sg31939
I2
sa(dp36167
g31934
I183
sg31935
Vlumbar spinal stenosis
p36168
sg31936
I22
sg31937
VC0158288
p36169
sg31939
I3
sa(dp36170
g31934
I232
sg31935
g36161
sg31936
I11
sg31937
VC0002726
p36171
sg31939
I1
sasg31940
(lp36172
(dp36173
g31934
I0
sg31935
VTTR
p36174
sg31936
I3
sg31944
VP02766
p36175
sg31939
I1
sa(dp36176
g31934
I5
sg31935
Vtransthyretin
p36177
sg31936
I13
sg31944
VP02766
p36178
sg31939
I1
sa(dp36179
g31934
I5
sg31935
g36160
sg31936
I13
sg31944
VP02766
p36180
sg31939
I1
sasa(dp36181
g31925
VWild-type ATTR amyloidosis mainly involves the heart, although the reported occurrence of bilateral carpal tunnel syndrome, spinal stenosis and biceps tendon rupture in these patients speaks to more generalized protein deposition.
p36182
sg4
(dp36183
(VWild-type ATTR
p36184
Vamyloidosis
p36185
tp36186
I00
ssg31931
(lp36187
(dp36188
g31934
I100
sg31935
Vcarpal tunnel syndrome
p36189
sg31936
I22
sg31937
VC0007286
p36190
sg31939
I3
sa(dp36191
g31934
I124
sg31935
Vspinal stenosis
p36192
sg31936
I15
sg31937
VC0037944
p36193
sg31939
I2
sa(dp36194
g31934
I211
sg31935
Vprotein deposition
p36195
sg31936
I18
sg31937
VC0333584
p36196
sg31939
I2
sa(dp36197
g31934
I15
sg31935
g36185
sg31936
I11
sg31937
VC0002726
p36198
sg31939
I1
sasg31940
(lp36199
(dp36200
g31934
I0
sg31935
g36184
sg31936
I14
sg31944
VP02766
p36201
sg31939
I2
sasa(dp36202
g31925
VFurthermore, the involvement of functional GREM1 in the epithelial-mesenchymal transition (EMT) process of glioma was investigated by detecting the expression levels of glioma-associated oncogene homologue 3 (GLI3) and EMT-related molecules.
p36203
sg4
(dp36204
(VGLI3
p36205
Vglioma
p36206
tp36207
I00
ssg31931
(lp36208
(dp36209
g31934
I91
sg31935
VEMT
p36210
sg31936
I3
sg31937
VC0599156
p36211
sg31939
I1
sa(dp36212
g31934
I91
sg31935
VEMT
p36213
sg31936
I3
sg31937
VC0599156
p36214
sg31939
I1
sa(dp36215
g31934
I107
sg31935
Vglioma
p36216
sg31936
I6
sg31937
VC0017638
p36217
sg31939
I1
sa(dp36218
g31934
I56
sg31935
Vepithelial-mesenchymal transition
p36219
sg31936
I33
sg31937
VC0599156
p36220
sg31939
I2
sa(dp36221
g31934
I107
sg31935
g36206
sg31936
I6
sg31937
VC0017638
p36222
sg31939
I1
sasg31940
(lp36223
(dp36224
g31934
I219
sg31935
VEMT-related molecules
p36225
sg31936
I21
sg31944
g190
sg31939
I2
sa(dp36226
g31934
I43
sg31935
VGREM1
p36227
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp36228
g31934
I169
sg31935
Vglioma-associated oncogene homologue 3
p36229
sg31936
I38
sg31944
VP08151
p36230
sg31939
I4
sa(dp36231
g31934
I209
sg31935
g36205
sg31936
I4
sg31944
VP10071
p36232
sg31939
I1
sasa(dp36233
g31925
VSuppression of GLI1/GLI2 functions by a C-terminus truncated GLI3 repressor mutant (GLI3R), or by GANT61, a pharmacological inhibitor of GLI1/GLI2, reduced hTERT protein expression in human colon cancer, prostate cancer and Glioblastoma multiforme (GBM) cell lines.
p36234
sg4
(dp36235
(VGLI3 repressor mutant
p36236
VGBM
p36237
tp36238
I00
ssg31931
(lp36239
(dp36240
g31934
I196
sg31935
Vcancer, prostate
p36241
sg31936
I16
sg31937
VC0376358
p36242
sg31939
I2
sa(dp36243
g31934
I196
sg31935
Vcancer
p36244
sg31936
I6
sg31937
VC0006826
p36245
sg31939
I1
sa(dp36246
g31934
I224
sg31935
VGlioblastoma multiforme
p36247
sg31936
I23
sg31937
VC1621958
p36248
sg31939
I2
sa(dp36249
g31934
I249
sg31935
g36237
sg31936
I3
sg31937
VC1621958
p36250
sg31939
I1
sa(dp36251
g31934
I76
sg31935
Vmutant
p36252
sg31936
I6
sg31937
VC0596988
p36253
sg31939
I1
sa(dp36254
g31934
I0
sg31935
VSuppression
p36255
sg31936
I11
sg31937
VC0221103
p36256
sg31939
I1
sasg31940
(lp36257
(dp36258
g31934
I20
sg31935
VGLI2
p36259
sg31936
I4
sg31944
VP10070
p36260
sg31939
I1
sa(dp36261
g31934
I156
sg31935
VhTERT protein
p36262
sg31936
I13
sg31944
g190
sg31939
I2
sa(dp36263
g31934
I84
sg31935
VGLI3R
p36264
sg31936
I5
sg31944
VP10071
p36265
sg31939
I1
sa(dp36266
g31934
I15
sg31935
VGLI1
p36267
sg31936
I4
sg31944
VP08151
p36268
sg31939
I1
sa(dp36269
g31934
I20
sg31935
VGLI2
p36270
sg31936
I4
sg31944
VP10070
p36271
sg31939
I1
sa(dp36272
g31934
I15
sg31935
VGLI1
p36273
sg31936
I4
sg31944
VP08151
p36274
sg31939
I1
sa(dp36275
g31934
I61
sg31935
g36236
sg31936
I21
sg31944
VP10071
p36276
sg31939
I3
sasa(dp36277
g31925
VInhibitor of DNA binding protein-1 (ID1) has been shown to maintain the self-renewal capacity of neural stem cells and might be involved in the therapeutic resistance of GBM.
p36278
sg4
(dp36279
(VInhibitor of DNA binding protein-1
p36280
VGBM
p36281
tp36282
I00
ssg31931
(lp36283
(dp36284
g31934
I170
sg31935
g36281
sg31936
I3
sg31937
VC0017636
p36285
sg31939
I1
sasg31940
(lp36286
(dp36287
g31934
I36
sg31935
VID1
p36288
sg31936
I3
sg31944
VP29372
p36289
sg31939
I1
sa(dp36290
g31934
I0
sg31935
g36280
sg31936
I34
sg31944
VP29372
p36291
sg31939
I5
sasa(dp36292
g31925
VIn glioblastoma neurosphere cultures that contain cancer stem cells (GBM-CSCs), the bHLH family member inhibitors of DNA binding protein 2 and 4 (Id2 and Id4) were found to be upregulated during the differentiation of GBM-CSCs in response to histone deacetylase inhibitors.
p36293
sg4
(dp36294
(Vhistone deacetylase
p36295
VGBM
p36296
tp36297
I01
ssg31931
(lp36298
(dp36299
g31934
I69
sg31935
VGBM
p36300
sg31936
I3
sg31937
VC0017636
p36301
sg31939
I1
sa(dp36302
g31934
I50
sg31935
Vcancer
p36303
sg31936
I6
sg31937
VC0006826
p36304
sg31939
I1
sa(dp36305
g31934
I3
sg31935
Vglioblastoma
p36306
sg31936
I12
sg31937
VC0017636
p36307
sg31939
I1
sa(dp36308
g31934
I69
sg31935
g36296
sg31936
I3
sg31937
VC0017636
p36309
sg31939
I1
sasg31940
(lp36310
(dp36311
g31934
I84
sg31935
VbHLH family
p36312
sg31936
I11
sg31944
g190
sg31939
I2
sa(dp36313
g31934
I154
sg31935
VId4
p36314
sg31936
I3
sg31944
VP47928
p36315
sg31939
I1
sa(dp36316
g31934
I242
sg31935
g36295
sg31936
I19
sg31944
VP56524
p36317
sg31939
I2
sa(dp36318
g31934
I117
sg31935
VDNA binding protein 2 and 4
p36319
sg31936
I27
sg31944
VP51523
p36320
sg31939
I6
sa(dp36321
g31934
I146
sg31935
VId2
p36322
sg31936
I3
sg31944
g190
sg31939
I1
sasa(dp36323
g31925
VThis study was undertaken to examine changes in 1-cysPrx expression in human cataract samples, human lens epithelial (HLE B3) cell line, and rat organ-cultured lenses in response to oxidative insult induced by H2O2 or transforming growth factor-beta1 (TGF-beta1).
p36324
sg4
(dp36325
(Vtransforming growth factor-beta1
p36326
Vcataract
p36327
tp36328
I00
ssg31931
(lp36329
(dp36330
g31934
I77
sg31935
g36327
sg31936
I8
sg31937
VC0086543
p36331
sg31939
I1
sasg31940
(lp36332
(dp36333
g31934
I252
sg31935
VTGF-beta1
p36334
sg31936
I9
sg31944
VP01137
p36335
sg31939
I1
sa(dp36336
g31934
I218
sg31935
g36326
sg31936
I32
sg31944
VP01137
p36337
sg31939
I3
sasa(dp36338
g31925
VAR-12-stimulated the co-localization of Influenza, EBV and HIV virus proteins with LC3 in autophagosomes and reduced viral protein association with the chaperones HSP90, HSP70, and GRP78.
p36339
sg4
(dp36340
(VHSP90
p36341
VHIV
p36342
tp36343
I00
ssg31931
(lp36344
(dp36345
g31934
I40
sg31935
VInfluenza
p36346
sg31936
I9
sg31937
VC0021400
p36347
sg31939
I1
sa(dp36348
g31934
I59
sg31935
g36342
sg31936
I3
sg31937
VC0019693
p36349
sg31939
I1
sasg31940
(lp36350
(dp36351
g31934
I83
sg31935
VLC3
p36352
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp36353
g31934
I170
sg31935
VHSP70
p36354
sg31936
I5
sg31944
VP34932
p36355
sg31939
I1
sa(dp36356
g31934
I181
sg31935
VGRP78
p36357
sg31936
I5
sg31944
VP11021
p36358
sg31939
I1
sa(dp36359
g31934
I163
sg31935
g36341
sg31936
I5
sg31944
VP07900
p36360
sg31939
I1
sasa(dp36361
g31925
VHence, in agreement with heat shock protein 70 (HSP70) acting as Th1 cytokine-like adjuvant, an Escherichia coli-expressed r4M2e.HSP70c fusion protein comprising C-terminus of Mycobacterium tuberculosis HSP70 genetically fused to four tandem repeats of influenza A virus M2e was constructed.
p36362
sg4
(dp36363
(VHSP70c fusion protein
p36364
Vinfluenza
p36365
tp36366
I00
ssg31931
(lp36367
(dp36368
g31934
I190
sg31935
Vtuberculosis
p36369
sg31936
I12
sg31937
VC0041296
p36370
sg31939
I1
sa(dp36371
g31934
I253
sg31935
g36365
sg31936
I9
sg31937
VC0021400
p36372
sg31939
I1
sasg31940
(lp36373
(dp36374
g31934
I48
sg31935
VHSP70
p36375
sg31936
I5
sg31944
VP34932
p36376
sg31939
I1
sa(dp36377
g31934
I25
sg31935
Vheat shock protein 70
p36378
sg31936
I21
sg31944
VP34932
p36379
sg31939
I4
sa(dp36380
g31934
I48
sg31935
VHSP70
p36381
sg31936
I5
sg31944
VP34932
p36382
sg31939
I1
sa(dp36383
g31934
I253
sg31935
Vinfluenza A virus M2e
p36384
sg31936
I21
sg31944
g190
sg31939
I4
sa(dp36385
g31934
I129
sg31935
g36364
sg31936
I21
sg31944
VP35637
p36386
sg31939
I3
sasa(dp36387
g31925
VTo prepare an effective vaccine against influenza A viruses, a chimerical DNA plasmid encoding Influenza virus M2 protein and Leishmania major HSP70 was constructed.
p36388
sg4
(dp36389
(VLeishmania major HSP70
p36390
VInfluenza
p36391
tp36392
I00
ssg31931
(lp36393
(dp36394
g31934
I40
sg31935
Vinfluenza
p36395
sg31936
I9
sg31937
VC0021400
p36396
sg31939
I1
sa(dp36397
g31934
I95
sg31935
g36391
sg31936
I9
sg31937
VC0021400
p36398
sg31939
I1
sasg31940
(lp36399
(dp36400
g31934
I126
sg31935
g36390
sg31936
I22
sg31944
VP34932
p36401
sg31939
I3
sasa(dp36402
g31925
VThis protective immunity might be attributed to enhanced cell-mediated immunity, which is interpreted as increased lymphocytes proliferation, increased levels of Th1-type (IFN-Gamma) and Th2-type (IL-4) cytokines production and increased CD4(+) to CD8(+) ratios, resulting from the injection of four tandem repeats of the ectodomain of the conserved influenza matrix protein M2 (4xM2e) genetically fused to C-terminus of Mycobacterium tuberculosis HSP70 (mHSP70c).
p36403
sg4
(dp36404
(VIFN-Gamma
p36405
Vinfluenza
p36406
tp36407
I00
ssg31931
(lp36408
(dp36409
g31934
I435
sg31935
Vtuberculosis
p36410
sg31936
I12
sg31937
VC0041296
p36411
sg31939
I1
sa(dp36412
g31934
I350
sg31935
g36406
sg31936
I9
sg31937
VC0021400
p36413
sg31939
I1
sa(dp36414
g31934
I127
sg31935
Vproliferation
p36415
sg31936
I13
sg31937
VC0334094
p36416
sg31939
I1
sasg31940
(lp36417
(dp36418
g31934
I448
sg31935
VHSP70
p36419
sg31936
I5
sg31944
VP34932
p36420
sg31939
I1
sa(dp36421
g31934
I248
sg31935
VCD8
p36422
sg31936
I3
sg31944
VP01732
p36423
sg31939
I1
sa(dp36424
g31934
I238
sg31935
VCD4
p36425
sg31936
I3
sg31944
VP01730
p36426
sg31939
I1
sa(dp36427
g31934
I172
sg31935
g36405
sg31936
I9
sg31944
VP01579
p36428
sg31939
I1
sasa(dp36429
g31925
VHeat shock protein 70 (Hsp70) was identified as a cellular interaction partner of the influenza virus ribonucleoprotein (RNP) complex.
p36430
sg4
(dp36431
(VHsp70
p36432
Vinfluenza
p36433
tp36434
I00
ssg31931
(lp36435
(dp36436
g31934
I86
sg31935
g36433
sg31936
I9
sg31937
VC0021400
p36437
sg31939
I1
sasg31940
(lp36438
(dp36439
g31934
I0
sg31935
VHeat shock protein 70
p36440
sg31936
I21
sg31944
VP34932
p36441
sg31939
I4
sa(dp36442
g31934
I23
sg31935
g36432
sg31936
I5
sg31944
VP34932
p36443
sg31939
I1
sasa(dp36444
g31925
VHere we demonstrated that Hsp70 was involved in the regulation of influenza A viral transcription and replication.
p36445
sg4
(dp36446
(VHsp70
p36447
Vinfluenza
p36448
tp36449
I00
ssg31931
(lp36450
(dp36451
g31934
I66
sg31935
g36448
sg31936
I9
sg31937
VC0021400
p36452
sg31939
I1
sasg31940
(lp36453
(dp36454
g31934
I26
sg31935
g36447
sg31936
I5
sg31944
VP34932
p36455
sg31939
I1
sasa(dp36456
g31925
VFurthermore, delivered Hsp70 could inhibit the replication of influenza A virus in mice.
p36457
sg4
(dp36458
(VHsp70
p36459
Vinfluenza
p36460
tp36461
I00
ssg31931
(lp36462
(dp36463
g31934
I62
sg31935
g36460
sg31936
I9
sg31937
VC0021400
p36464
sg31939
I1
sasg31940
(lp36465
(dp36466
g31934
I23
sg31935
g36459
sg31936
I5
sg31944
VP34932
p36467
sg31939
I1
sasa(dp36468
g31925
VIn this study, antigenic peptides from tetanus toxin and influenza hemagglutinin complexed to human stress-inducible Hsp70 were found to enhance the proliferation and cytokine production of human antigen-specific CD4(+) T cells.
p36469
sg4
(dp36470
(Vhuman antigen-specific CD4
p36471
Vinfluenza
p36472
tp36473
I00
ssg31931
(lp36474
(dp36475
g31934
I57
sg31935
g36472
sg31936
I9
sg31937
VC0021400
p36476
sg31939
I1
sa(dp36477
g31934
I39
sg31935
Vtetanus
p36478
sg31936
I7
sg31937
VC0039614
p36479
sg31939
I1
sa(dp36480
g31934
I149
sg31935
Vproliferation
p36481
sg31936
I13
sg31937
VC0334094
p36482
sg31939
I1
sasg31940
(lp36483
(dp36484
g31934
I117
sg31935
VHsp70
p36485
sg31936
I5
sg31944
VP34932
p36486
sg31939
I1
sa(dp36487
g31934
I190
sg31935
g36471
sg31936
I26
sg31944
VP14209
p36488
sg31939
I3
sasa(dp36489
g31925
VHerein, to construct a recombinant M2e-based vaccine candidate with the appropriate structural conformation and immunogenicity the corresponding nucleotide sequence from an H9N2 influenza strain was fused to the N-terminus of the truncated Mycobacterium tuberculosis HSP70(359-610), as a potent adjuvant, and following its cloning into the pPICZ alpha A plasmid the fusion gene was expressed in Pichia pastoris KM71H yeast.
p36490
sg4
(dp36491
(VHSP70(359-610)
p36492
Vtuberculosis
p36493
tp36494
I00
ssg31931
(lp36495
(dp36496
g31934
I178
sg31935
Vinfluenza
p36497
sg31936
I9
sg31937
VC0021400
p36498
sg31939
I1
sa(dp36499
g31934
I254
sg31935
g36493
sg31936
I12
sg31937
VC0041296
p36500
sg31939
I1
sasg31940
(lp36501
(dp36502
g31934
I267
sg31935
g36492
sg31936
I14
sg31944
VP34932
p36503
sg31939
I1
sasa(dp36504
g31925
VAccording to previous reports, this study was designed to produce a novel influenza A virus recombinant fusion protein consisted of M2e, a potent immunogenic protein from influenza A virus, fused to C-terminal domain of mycobacterium tuberculosis HSP70, HSP70(359-610), as a carrier and adjuvant.
p36505
sg4
(dp36506
(VHSP70(359-610)
p36507
Vinfluenza
p36508
tp36509
I00
ssg31931
(lp36510
(dp36511
g31934
I234
sg31935
Vtuberculosis
p36512
sg31936
I12
sg31937
VC0041296
p36513
sg31939
I1
sa(dp36514
g31934
I74
sg31935
Vinfluenza
p36515
sg31936
I9
sg31937
VC0021400
p36516
sg31939
I1
sa(dp36517
g31934
I74
sg31935
g36508
sg31936
I9
sg31937
VC0021400
p36518
sg31939
I1
sasg31940
(lp36519
(dp36520
g31934
I247
sg31935
VHSP70
p36521
sg31936
I5
sg31944
VP34932
p36522
sg31939
I1
sa(dp36523
g31934
I254
sg31935
g36507
sg31936
I14
sg31944
VP34932
p36524
sg31939
I1
sasa(dp36525
g31925
VDe novo mutations in ATAD3A (ATPase family AAA-domain containing protein 3A) were recently found to cause a neurological syndrome with developmental delay, hypotonia, spasticity, optic atrophy, axonal neuropathy, and hypertrophic cardiomyopathy.
p36526
sg4
(dp36527
(VATPase family AAA-domain containing protein 3A
p36528
Vdevelopmental delay
p36529
tp36530
I00
ssg31931
(lp36531
(dp36532
g31934
I194
sg31935
Vaxonal neuropathy
p36533
sg31936
I17
sg31937
VC0270921
p36534
sg31939
I2
sa(dp36535
g31934
I156
sg31935
Vhypotonia
p36536
sg31936
I9
sg31937
VC0026827
p36537
sg31939
I1
sa(dp36538
g31934
I121
sg31935
Vsyndrome
p36539
sg31936
I8
sg31937
VC0039082
p36540
sg31939
I1
sa(dp36541
g31934
I179
sg31935
Voptic atrophy
p36542
sg31936
I13
sg31937
VC0029124
p36543
sg31939
I2
sa(dp36544
g31934
I167
sg31935
Vspasticity
p36545
sg31936
I10
sg31937
VC0026838
p36546
sg31939
I1
sa(dp36547
g31934
I43
sg31935
VAAA
p36548
sg31936
I3
sg31937
VC0162871
p36549
sg31939
I1
sa(dp36550
g31934
I217
sg31935
Vhypertrophic cardiomyopathy
p36551
sg31936
I27
sg31937
VC0007194
p36552
sg31939
I2
sa(dp36553
g31934
I135
sg31935
g36529
sg31936
I19
sg31937
VC0424605
p36554
sg31939
I2
sasg31940
(lp36555
(dp36556
g31934
I21
sg31935
VATAD3A
p36557
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp36558
g31934
I29
sg31935
g36528
sg31936
I46
sg31944
VP38606
p36559
sg31939
I6
sasa(dp36560
g31925
VImmunoblot and mass spectrometry analyses revealed that the 800-kDa complex contained the OMM translocator protein (18-kDa) and VDAC along with IMM CYP11A1, ATPase family AAA domain-containing protein 3A (ATAD3A), and optic atrophy type 1 proteins, but not ANT.
p36561
sg4
(dp36562
(VANT
p36563
VAAA
p36564
tp36565
I00
ssg31931
(lp36566
(dp36567
g31934
I218
sg31935
Voptic atrophy type 1
p36568
sg31936
I20
sg31937
VC0338508
p36569
sg31939
I4
sa(dp36570
g31934
I171
sg31935
g36564
sg31936
I3
sg31937
VC0162871
p36571
sg31939
I1
sasg31940
(lp36572
(dp36573
g31934
I144
sg31935
VIMM CYP11A1
p36574
sg31936
I11
sg31944
VP05108
p36575
sg31939
I2
sa(dp36576
g31934
I157
sg31935
VATPase family AAA domain-containing protein 3A
p36577
sg31936
I46
sg31944
g190
sg31939
I6
sa(dp36578
g31934
I257
sg31935
g36563
sg31936
I3
sg31944
VP12235
p36579
sg31939
I1
sa(dp36580
g31934
I90
sg31935
VOMM translocator protein
p36581
sg31936
I24
sg31944
VP30536
p36582
sg31939
I3
sa(dp36583
g31934
I205
sg31935
VATAD3A
p36584
sg31936
I6
sg31944
g190
sg31939
I1
sasa(dp36585
g31925
VKnockdown of ATAD3A, but not ANT or optic atrophy type 1, in Leydig cells resulted in a significant decrease in hormone-induced, but not 22R-hydroxycholesterol-supported, steroid production.
p36586
sg4
(dp36587
(VANT
p36588
Voptic atrophy type 1
p36589
tp36590
I00
ssg31931
(lp36591
(dp36592
g31934
I36
sg31935
g36589
sg31936
I20
sg31937
VC0338508
p36593
sg31939
I4
sasg31940
(lp36594
(dp36595
g31934
I29
sg31935
g36588
sg31936
I3
sg31944
VP12235
p36596
sg31939
I1
sa(dp36597
g31934
I13
sg31935
VATAD3A
p36598
sg31936
I6
sg31944
g190
sg31939
I1
sasa(dp36599
g31925
VSo, we attempted to evaluate the association between dopamine D2 (DRD2) receptor, serotonergic (5HT2A) receptor and CYP2D6 gene polymorphisms and response to treatment with risperidone in persons with schizophrenia from North India.
p36600
sg4
(dp36601
(Vserotonergic (5HT2A) receptor
p36602
Vschizophrenia
p36603
tp36604
I00
ssg31931
(lp36605
(dp36606
g31934
I201
sg31935
g36603
sg31936
I13
sg31937
VC0036341
p36607
sg31939
I1
sasg31940
(lp36608
(dp36609
g31934
I53
sg31935
Vdopamine D2 (DRD2) receptor
p36610
sg31936
I27
sg31944
VP14416
p36611
sg31939
I4
sa(dp36612
g31934
I116
sg31935
VCYP2D6 gene
p36613
sg31936
I11
sg31944
VP10635
p36614
sg31939
I2
sa(dp36615
g31934
I82
sg31935
g36602
sg31936
I29
sg31944
VP28223
p36616
sg31939
I3
sasa(dp36617
g31925
VPruritus was assessed by the number of scratching bouts, whilst skin inflammation was evaluated by the extravascular accumulation of intravenously injected 125I-albumin (plasma extravasation) and myeloperoxidase (MPO) activity (neutrophil recruitment).
p36618
sg4
(dp36619
(VMPO
p36620
VPruritus
p36621
tp36622
I00
ssg31931
(lp36623
(dp36624
g31934
I239
sg31935
Vrecruitment
p36625
sg31936
I11
sg31937
VC0271510
p36626
sg31939
I1
sa(dp36627
g31934
I64
sg31935
Vskin inflammation
p36628
sg31936
I17
sg31937
VC0011603
p36629
sg31939
I2
sa(dp36630
g31934
I0
sg31935
g36621
sg31936
I8
sg31937
VC0033774
p36631
sg31939
I1
sa(dp36632
g31934
I177
sg31935
Vextravasation
p36633
sg31936
I13
sg31937
VC0015376
p36634
sg31939
I1
sasg31940
(lp36635
(dp36636
g31934
I196
sg31935
Vmyeloperoxidase
p36637
sg31936
I15
sg31944
VP05164
p36638
sg31939
I1
sa(dp36639
g31934
I161
sg31935
Valbumin
p36640
sg31936
I7
sg31944
VP00441
p36641
sg31939
I1
sa(dp36642
g31934
I213
sg31935
g36620
sg31936
I3
sg31944
VP05164
p36643
sg31939
I1
sasa(dp36644
g31925
VThe neuropeptide PACAP and VPAC1 were previously found to negatively regulate megakaryopoiesis, and inhibition of their physiological pathway was found to have a thrombopoietic effect in conditions where megakaryopoiesis and thrombopoiesis were impaired, such as chemotherapy-induced thrombocytopenia and congenital thrombocytopenia.
p36645
sg4
(dp36646
(VVPAC1
p36647
Vcongenital thrombocytopenia
p36648
tp36649
I00
ssg31931
(lp36650
(dp36651
g31934
I305
sg31935
g36648
sg31936
I27
sg31937
VC0272278
p36652
sg31939
I2
sa(dp36653
g31934
I245
sg31935
Vimpaired
p36654
sg31936
I8
sg31937
VC0684336
p36655
sg31939
I1
sasg31940
(lp36656
(dp36657
g31934
I27
sg31935
g36647
sg31936
I5
sg31944
VP32241
p36658
sg31939
I1
sa(dp36659
g31934
I17
sg31935
VPACAP
p36660
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp36661
g31925
VThe present study explored the thrombopoietic effect of VPAC1 inhibition in a murine model of syngeneic bone marrow transplantation (BMT) and in passive immune thrombocytopenia.
p36662
sg4
(dp36663
(VVPAC1
p36664
Vimmune thrombocytopenia
p36665
tp36666
I00
ssg31931
(lp36667
(dp36668
g31934
I153
sg31935
g36665
sg31936
I23
sg31937
VC0272286
p36669
sg31939
I2
sasg31940
(lp36670
(dp36671
g31934
I56
sg31935
g36664
sg31936
I5
sg31944
VP32241
p36672
sg31939
I1
sasa(dp36673
g31925
VTo the differentiation-related markers, the BRAF/MAP2K1-mut LCH expressed CD14 but rarely expressed CD83 or CD86 (P &lt; .001).
p36674
sg4
(dp36675
(VBRAF
p36676
VLCH
p36677
tp36678
I00
ssg31931
(lp36679
(dp36680
g31934
I60
sg31935
g36677
sg31936
I3
sg31937
VC0019621
p36681
sg31939
I1
sasg31940
(lp36682
(dp36683
g31934
I56
sg31935
Vmut
p36684
sg31936
I3
sg31944
VP22033
p36685
sg31939
I1
sa(dp36686
g31934
I100
sg31935
VCD83
p36687
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp36688
g31934
I49
sg31935
VMAP2K1
p36689
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp36690
g31934
I74
sg31935
VCD14
p36691
sg31936
I4
sg31944
VP08571
p36692
sg31939
I1
sa(dp36693
g31934
I108
sg31935
VCD86
p36694
sg31936
I4
sg31944
VP42081
p36695
sg31939
I1
sa(dp36696
g31934
I44
sg31935
g36676
sg31936
I4
sg31944
VP15056
p36697
sg31939
I1
sasa(dp36698
g31925
VOn the contrary, BRAF/MAP2K1-wt LCH cells rarely expressed CD14 but expressed CD86, and some also expressed CD83 (P &lt; .001).
p36699
sg4
(dp36700
(VCD86
p36701
VLCH
p36702
tp36703
I00
ssg31931
(lp36704
(dp36705
g31934
I32
sg31935
g36702
sg31936
I3
sg31937
VC0019621
p36706
sg31939
I1
sasg31940
(lp36707
(dp36708
g31934
I108
sg31935
VCD83
p36709
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp36710
g31934
I59
sg31935
VCD14
p36711
sg31936
I4
sg31944
VP08571
p36712
sg31939
I1
sa(dp36713
g31934
I17
sg31935
VBRAF
p36714
sg31936
I4
sg31944
VP15056
p36715
sg31939
I1
sa(dp36716
g31934
I22
sg31935
VMAP2K1
p36717
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp36718
g31934
I78
sg31935
g36701
sg31936
I4
sg31944
VP42081
p36719
sg31939
I1
sasa(dp36720
g31925
VThree genes in this network, lipoprotein lipase (Lpl), lactamase beta (Lactb) and protein phosphatase 1-like (Ppm1l), are validated as previously unknown obesity genes, strengthening the association between this network and metabolic disease traits.
p36721
sg4
(dp36722
(Vlipoprotein lipase
p36723
Vmetabolic disease
p36724
tp36725
I00
ssg31931
(lp36726
(dp36727
g31934
I154
sg31935
Vobesity
p36728
sg31936
I7
sg31937
VC0028754
p36729
sg31939
I1
sa(dp36730
g31934
I224
sg31935
g36724
sg31936
I17
sg31937
VC0025517
p36731
sg31939
I2
sasg31940
(lp36732
(dp36733
g31934
I110
sg31935
VPpm1l
p36734
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp36735
g31934
I71
sg31935
VLactb
p36736
sg31936
I5
sg31944
VP83111
p36737
sg31939
I1
sa(dp36738
g31934
I49
sg31935
VLpl
p36739
sg31936
I3
sg31944
VP06858
p36740
sg31939
I1
sa(dp36741
g31934
I55
sg31935
Vlactamase beta
p36742
sg31936
I14
sg31944
VP83111
p36743
sg31939
I2
sa(dp36744
g31934
I29
sg31935
g36723
sg31936
I18
sg31944
VP06858
p36745
sg31939
I2
sa(dp36746
g31934
I82
sg31935
Vprotein phosphatase 1-like
p36747
sg31936
I26
sg31944
g190
sg31939
I3
sasa(dp36748
g31925
VBased on previous research, we hypothesized that RES regulates FoxO1 transcriptional activity through the phosphatidylinositol-3-kinase (PI3K)/AKT signaling pathway to achieve an antioxidative effect on osteoporosis and then we confirmed this hypothesis in the present study.
p36749
sg4
(dp36750
(Vphosphatidylinositol-3-kinase
p36751
Vosteoporosis
p36752
tp36753
I00
ssg31931
(lp36754
(dp36755
g31934
I203
sg31935
g36752
sg31936
I12
sg31937
VC0029456
p36756
sg31939
I1
sasg31940
(lp36757
(dp36758
g31934
I137
sg31935
VPI3K
p36759
sg31936
I4
sg31944
VP42336
p36760
sg31939
I1
sa(dp36761
g31934
I106
sg31935
g36751
sg31936
I29
sg31944
VP33981
p36762
sg31939
I1
sa(dp36763
g31934
I143
sg31935
VAKT
p36764
sg31936
I3
sg31944
g190
sg31939
I1
sasa(dp36765
g31925
VIn conclusion, our study revealed that the decline of FoxO1 is an important etiology factor of osteoporosis and unclosed a novel mechanism of FoxO1 regulation by TNF-Alfa.
p36766
sg4
(dp36767
(VTNF-Alfa
p36768
Vosteoporosis
p36769
tp36770
I00
ssg31931
(lp36771
(dp36772
g31934
I95
sg31935
g36769
sg31936
I12
sg31937
VC0029456
p36773
sg31939
I1
sasg31940
(lp36774
(dp36775
g31934
I162
sg31935
g36768
sg31936
I8
sg31944
VP01375
p36776
sg31939
I1
sa(dp36777
g31934
I54
sg31935
VFoxO1
p36778
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp36779
g31934
I54
sg31935
VFoxO1
p36780
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp36781
g31925
VIn addition, several new PheWAS findings were identified including a cluster of association near the NDFIP1 gene for mental retardation (best SNP rs10057309, p = 4.33 x 10(-7), OR = 1.70, 95%CI = 1.38 - 2.09); association near PLCL1 gene for developmental delays and speech disorder [best SNP rs1595825, p = 1.13 x 10(-8), OR = 0.65(0.57 - 0.76)]; a cluster of associations in the IL5-IL13 region with Eosinophilic Esophagitis (EoE) [best at rs12653750, p = 3.03 x 10(-9), OR = 1.73 95%CI = (1.44 - 2.07)], previously implicated in asthma, allergy, and eosinophilia; and association of variants in GCKR and JAZF1 with allergic rhinitis in our pediatric cohorts [best SNP rs780093, p = 2.18 x 10(-5), OR = 1.39, 95%CI = (1.19 - 1.61)], previously demonstrated in metabolic disease and diabetes in adults.
p36782
sg4
(dp36783
(VIL5-IL13 region
p36784
Vasthma
p36785
tp36786
I00
ssg31931
(lp36787
(dp36788
g31934
I428
sg31935
VEoE
p36789
sg31936
I3
sg31937
VC0341106
p36790
sg31939
I1
sa(dp36791
g31934
I762
sg31935
Vmetabolic disease
p36792
sg31936
I17
sg31937
VC0025517
p36793
sg31939
I2
sa(dp36794
g31934
I784
sg31935
Vdiabetes
p36795
sg31936
I8
sg31937
VC0011849
p36796
sg31939
I1
sa(dp36797
g31934
I553
sg31935
Veosinophilia
p36798
sg31936
I12
sg31937
VC0014457
p36799
sg31939
I1
sa(dp36800
g31934
I267
sg31935
Vspeech disorder
p36801
sg31936
I15
sg31937
VC0037822
p36802
sg31939
I2
sa(dp36803
g31934
I540
sg31935
Vallergy
p36804
sg31936
I7
sg31937
VC0020517
p36805
sg31939
I1
sa(dp36806
g31934
I117
sg31935
Vmental retardation
p36807
sg31936
I18
sg31937
VC0025362
p36808
sg31939
I2
sa(dp36809
g31934
I618
sg31935
Vallergic rhinitis
p36810
sg31936
I17
sg31937
VC2607914
p36811
sg31939
I2
sa(dp36812
g31934
I402
sg31935
VEosinophilic Esophagitis
p36813
sg31936
I24
sg31937
VC0341106
p36814
sg31939
I2
sa(dp36815
g31934
I532
sg31935
g36785
sg31936
I6
sg31937
VC0004096
p36816
sg31939
I1
sasg31940
(lp36817
(dp36818
g31934
I101
sg31935
VNDFIP1 gene
p36819
sg31936
I11
sg31944
g190
sg31939
I2
sa(dp36820
g31934
I227
sg31935
VPLCL1 gene
p36821
sg31936
I10
sg31944
g190
sg31939
I2
sa(dp36822
g31934
I598
sg31935
VGCKR
p36823
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp36824
g31934
I607
sg31935
VJAZF1
p36825
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp36826
g31934
I381
sg31935
g36784
sg31936
I15
sg31944
VP05113
p36827
sg31939
I2
sasa(dp36828
g31925
V177Lu-DOTATATE = lutetium octreotate; ACO = aconitase; Ad = adenine; AD = autosomal dominant; ATRX = ATRX chromatin remodeler; ccRCC = clear cell renal cell carcinoma; c-MYC = MYC proto oncognene; CoA = coenzyme A; COMT = catechol-O-methyl transferase; CPE = carboxypeptidase E; CS = citrate synthase; CT = computed tomography; DH = pyruvate dehydrogenase; DOTATATE = DOTA-octreotate; EGLN1/2 = egl-9 family hypoxia inducible factor 1/2; EGLN2/PHD1 = egl-9 family hypoxia inducible factor 2; elF-4E = eukaryotic initiation factor 4E; EMT = epithelial-to-mesenchymal transition; EPAS1/HIF2A = endothelial PAS domain protein 2/hypoxia-inducible factor 2Alfa; ERK = extracellular signal-regulated kinase; FH = fumarate hydroxylase; GSH = glutathione; H3F3A = histone 3.3 encoding gene; HIFs = Hypoxia-inducible factors; HIF-Alfa = hypoxia-inducible factor alpha; HNPGLs = head and neck paragangliomas; HRAS = HRas protooncogene; IDH = isocitrate dehydrogenase; IGF-1R = growth factor 1 receptor; KIF1B = kinesin family member 1B; MAX = myc-associated factor X; MDH2 = malate dehydrogenase; MN = metanephrine; MRI = magnetic resonance imaging; mTORC1 = mammalian target of rapamycin complex 1; MTY = methoxytyramine; NAd = nicotinamide adenine dinucleotide; NETs = neuroendocrine tumors; NF1 = neurofibromin 1; NMN = normetanephrine; OPLS-DA = orthogonal partial least square discriminant analysis; PFS = progression free survival; PHD = prolyl hydroxylase domain protein; PPGLs = Pheochromocytoma and Paragangliomas; PRRT = peptide receptor radionuclide therapy; Pvhl = von Hippel-Lindau protein; Raptor = regulatory associated protein of mTOR; RAS = rat sarcoma oncogene; RET = rearranged during transfection proto-oncogene; ROS = reactive oxygen species; S6K = S6 kinase; SDH = succinate dehydrogenase; SDHA, -B, -C, -D, = succinate dehydrogenase subunits A, B, C, D; SDHAF2 = succinate dehydrogenase complex assembly factor 2; SDHB, C, D = succinate dehydrogenase subunits B, C, D; SDHx = succinate dehydrogenase subunits; SSTRs = somatostatin receptors; SUCLG = succinyl-CoA synthase; TERRA = Telomeric Repeat-containing RNA; TET = ten-eleven-translocation methylcytosine dioxygenase; TMEM127 = transmembrane protein 127; VEGF = vascular endothelial growth factor; VHL = von Hippel-Lindau; Alfa-KGDH = alpha-ketoglutarate dehydrogenase.
p36829
sg4
(dp36830
(VMAX = myc-associated factor X
p36831
Vhypoxia
p36832
tp36833
I00
ssg31931
(lp36834
(dp36835
g31934
I1771
sg31935
VSDH
p36836
sg31936
I3
sg31937
VC0018946
p36837
sg31939
I1
sa(dp36838
g31934
I1261
sg31935
Vneuroendocrine tumors
p36839
sg31936
I21
sg31937
VC0206754
p36840
sg31939
I2
sa(dp36841
g31934
I1477
sg31935
VPheochromocytoma
p36842
sg31936
I16
sg31937
VC0031511
p36843
sg31939
I1
sa(dp36844
g31934
I1648
sg31935
Vrat sarcoma
p36845
sg31936
I11
sg31937
VC1882848
p36846
sg31939
I2
sa(dp36847
g31934
I408
sg31935
Vhypoxia
p36848
sg31936
I7
sg31937
VC0242184
p36849
sg31939
I1
sa(dp36850
g31934
I790
sg31935
VHypoxia
p36851
sg31936
I7
sg31937
VC0242184
p36852
sg31939
I1
sa(dp36853
g31934
I1213
sg31935
VNAd
p36854
sg31936
I3
sg31937
VC1850380
p36855
sg31939
I1
sa(dp36856
g31934
I94
sg31935
VATRX
p36857
sg31936
I4
sg31937
VC1845055
p36858
sg31939
I1
sa(dp36859
g31934
I197
sg31935
VCoA
p36860
sg31936
I3
sg31937
VC2678439
p36861
sg31939
I1
sa(dp36862
g31934
I1498
sg31935
VParagangliomas
p36863
sg31936
I14
sg31937
VC0030421
p36864
sg31939
I1
sa(dp36865
g31934
I883
sg31935
Vparagangliomas
p36866
sg31936
I14
sg31937
VC0030421
p36867
sg31939
I1
sa(dp36868
g31934
I408
sg31935
Vhypoxia
p36869
sg31936
I7
sg31937
VC0242184
p36870
sg31939
I1
sa(dp36871
g31934
I1284
sg31935
VNF1
p36872
sg31936
I3
sg31937
VC0027831
p36873
sg31939
I1
sa(dp36874
g31934
I408
sg31935
Vhypoxia
p36875
sg31936
I7
sg31937
VC0242184
p36876
sg31939
I1
sa(dp36877
g31934
I2266
sg31935
VVHL
p36878
sg31936
I3
sg31937
VC0019562
p36879
sg31939
I1
sa(dp36880
g31934
I729
sg31935
VGSH
p36881
sg31936
I3
sg31937
VC1260386
p36882
sg31939
I1
sa(dp36883
g31934
I135
sg31935
Vclear cell renal cell carcinoma
p36884
sg31936
I31
sg31937
VC0279702
p36885
sg31939
I5
sa(dp36886
g31934
I566
sg31935
Vtransition
p36887
sg31936
I10
sg31937
VC0599156
p36888
sg31939
I1
sa(dp36889
g31934
I94
sg31935
VATRX
p36890
sg31936
I4
sg31937
VC1845055
p36891
sg31939
I1
sa(dp36892
g31934
I2144
sg31935
Vtranslocation
p36893
sg31936
I13
sg31937
VC0040715
p36894
sg31939
I1
sa(dp36895
g31934
I197
sg31935
VCoA
p36896
sg31936
I3
sg31937
VC2678439
p36897
sg31939
I1
sa(dp36898
g31934
I408
sg31935
g36832
sg31936
I7
sg31937
VC0242184
p36899
sg31939
I1
sasg31940
(lp36900
(dp36901
g31934
I1876
sg31935
Vsuccinate dehydrogenase complex assembly factor 2
p36902
sg31936
I49
sg31944
VP49366
p36903
sg31939
I6
sa(dp36904
g31934
I1927
sg31935
VSDHB
p36905
sg31936
I4
sg31944
VP21912
p36906
sg31939
I1
sa(dp36907
g31934
I1771
sg31935
VSDH
p36908
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp36909
g31934
I2023
sg31935
VSSTRs = somatostatin receptors
p36910
sg31936
I30
sg31944
VP61278
p36911
sg31939
I4
sa(dp36912
g31934
I438
sg31935
VEGLN2
p36913
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp36914
g31934
I2266
sg31935
VVHL
p36915
sg31936
I3
sg31944
VP40337
p36916
sg31939
I1
sa(dp36917
g31934
I1802
sg31935
VSDHA
p36918
sg31936
I4
sg31944
VP31040
p36919
sg31939
I1
sa(dp36920
g31934
I1760
sg31935
VS6 kinase
p36921
sg31936
I9
sg31944
VP33981
p36922
sg31939
I2
sa(dp36923
g31934
I578
sg31935
VEPAS1
p36924
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp36925
g31934
I1434
sg31935
Vprolyl hydroxylase domain protein
p36926
sg31936
I33
sg31944
VP13674
p36927
sg31939
I4
sa(dp36928
g31934
I2303
sg31935
Valpha-ketoglutarate dehydrogenase
p36929
sg31936
I33
sg31944
VP49366
p36930
sg31939
I2
sa(dp36931
g31934
I464
sg31935
Vhypoxia inducible factor 2
p36932
sg31936
I26
sg31944
g190
sg31939
I4
sa(dp36933
g31934
I1140
sg31935
VmTOR
p36934
sg31936
I4
sg31944
VP42345
p36935
sg31939
I1
sa(dp36936
g31934
I1754
sg31935
VS6K
p36937
sg31936
I3
sg31944
VP62753
p36938
sg31939
I1
sa(dp36939
g31934
I592
sg31935
Vendothelial PAS domain protein 2
p36940
sg31936
I32
sg31944
g190
sg31939
I5
sa(dp36941
g31934
I492
sg31935
VelF
p36942
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp36943
g31934
I584
sg31935
VHIF2A
p36944
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp36945
g31934
I2063
sg31935
Vsuccinyl-CoA synthase
p36946
sg31936
I21
sg31944
g190
sg31939
I2
sa(dp36947
g31934
I231
sg31935
VO-methyl transferase
p36948
sg31936
I20
sg31944
VP31947
p36949
sg31939
I2
sa(dp36950
g31934
I958
sg31935
VIGF-1R = growth factor 1 receptor
p36951
sg31936
I33
sg31944
g190
sg31939
I6
sa(dp36952
g31934
I1777
sg31935
Vsuccinate dehydrogenase
p36953
sg31936
I23
sg31944
VP49366
p36954
sg31939
I2
sa(dp36955
g31934
I926
sg31935
VIDH = isocitrate dehydrogenase
p36956
sg31936
I30
sg31944
VP48735
p36957
sg31939
I4
sa(dp36958
g31934
I748
sg31935
VH3F3A
p36959
sg31936
I5
sg31944
VP84243
p36960
sg31939
I1
sa(dp36961
g31934
I900
sg31935
VRAS
p36962
sg31936
I3
sg31944
VP01116
p36963
sg31939
I1
sa(dp36964
g31934
I1058
sg31935
VMDH2 = malate dehydrogenase
p36965
sg31936
I27
sg31944
VP49366
p36966
sg31939
I4
sa(dp36967
g31934
I385
sg31935
VEGLN1/2
p36968
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp36969
g31934
I253
sg31935
VCPE = carboxypeptidase E
p36970
sg31936
I24
sg31944
VP16870
p36971
sg31939
I4
sa(dp36972
g31934
I1001
sg31935
Vkinesin
p36973
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp36974
g31934
I756
sg31935
Vhistone 3.3 encoding gene
p36975
sg31936
I25
sg31944
VP62805
p36976
sg31939
I4
sa(dp36977
g31934
I625
sg31935
Vhypoxia-inducible factor 2Alfa
p36978
sg31936
I30
sg31944
g190
sg31939
I3
sa(dp36979
g31934
I1648
sg31935
Vrat sarcoma oncogene
p36980
sg31936
I20
sg31944
VP35125
p36981
sg31939
I3
sa(dp36982
g31934
I1670
sg31935
VRET
p36983
sg31936
I3
sg31944
VP07949
p36984
sg31939
I1
sa(dp36985
g31934
I657
sg31935
VERK
p36986
sg31936
I3
sg31944
VP29323
p36987
sg31939
I1
sa(dp36988
g31934
I1027
sg31935
g36831
sg31936
I29
sg31944
VP61244
p36989
sg31939
I5
sa(dp36990
g31934
I408
sg31935
Vhypoxia inducible factor 1/2
p36991
sg31936
I28
sg31944
g190
sg31939
I4
sa(dp36992
g31934
I2230
sg31935
Vvascular endothelial growth factor
p36993
sg31936
I34
sg31944
g190
sg31939
I4
sa(dp36994
g31934
I444
sg31935
VPHD1
p36995
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp36996
g31925
VAlterations of von Hippel-Lindau (VHL), succinate dehydrogenase (SDHX), and TMEM127 have been associated with the development of pheochromocytomas (PCs) and paragangliomas (PGLs) and are also associated with the development of renal neoplasms.
p36997
sg4
(dp36998
(Vvon Hippel-Lindau
p36999
VPGLs
p37000
tp37001
I00
ssg31931
(lp37002
(dp37003
g31934
I129
sg31935
Vpheochromocytomas
p37004
sg31936
I17
sg31937
VC0031511
p37005
sg31939
I1
sa(dp37006
g31934
I15
sg31935
Vvon Hippel-Lindau
p37007
sg31936
I17
sg31937
VC0019562
p37008
sg31939
I2
sa(dp37009
g31934
I148
sg31935
VPCs
p37010
sg31936
I3
sg31937
VC1864389
p37011
sg31939
I1
sa(dp37012
g31934
I157
sg31935
Vparagangliomas
p37013
sg31936
I14
sg31937
VC0030421
p37014
sg31939
I1
sa(dp37015
g31934
I34
sg31935
VVHL
p37016
sg31936
I3
sg31937
VC0019562
p37017
sg31939
I1
sa(dp37018
g31934
I227
sg31935
Vrenal neoplasms
p37019
sg31936
I15
sg31937
VC0022665
p37020
sg31939
I2
sa(dp37021
g31934
I173
sg31935
g37000
sg31936
I4
sg31937
VC0030421
p37022
sg31939
I1
sasg31940
(lp37023
(dp37024
g31934
I40
sg31935
Vsuccinate dehydrogenase
p37025
sg31936
I23
sg31944
VP49366
p37026
sg31939
I2
sa(dp37027
g31934
I34
sg31935
VVHL
p37028
sg31936
I3
sg31944
VP40337
p37029
sg31939
I1
sa(dp37030
g31934
I76
sg31935
VTMEM127
p37031
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp37032
g31934
I15
sg31935
g36999
sg31936
I17
sg31944
VP40337
p37033
sg31939
I2
sasa(dp37034
g31925
VImmunohistochemistry for SDHB and mutation analysis for TMEM127 was performed, in addition to analysis of The Cancer Genome Atlas datasets for SDHX and TMEM127 mutated renal cell carcinomas (RCCs).
p37035
sg4
(dp37036
(VSDHB
p37037
VRCCs
p37038
tp37039
I00
ssg31931
(lp37040
(dp37041
g31934
I110
sg31935
VCancer
p37042
sg31936
I6
sg31937
VC0006826
p37043
sg31939
I1
sa(dp37044
g31934
I168
sg31935
Vrenal cell carcinomas
p37045
sg31936
I21
sg31937
VC0007134
p37046
sg31939
I3
sa(dp37047
g31934
I191
sg31935
g37038
sg31936
I4
sg31937
VC0007134
p37048
sg31939
I1
sasg31940
(lp37049
(dp37050
g31934
I25
sg31935
g37037
sg31936
I4
sg31944
VP21912
p37051
sg31939
I1
sa(dp37052
g31934
I56
sg31935
VTMEM127
p37053
sg31936
I7
sg31944
g190
sg31939
I1
sasa(dp37054
g31925
VThe expanding etiology for hereditary pheochromocytomas and paragangliomas has recently included SDHA, TMEM127, MAX, and SDHAF2 as susceptibility genes.
p37055
sg4
(dp37056
(VSDHA
p37057
Vparagangliomas
p37058
tp37059
I00
ssg31931
(lp37060
(dp37061
g31934
I38
sg31935
Vpheochromocytomas
p37062
sg31936
I17
sg31937
VC0031511
p37063
sg31939
I1
sa(dp37064
g31934
I60
sg31935
g37058
sg31936
I14
sg31937
VC0030421
p37065
sg31939
I1
sasg31940
(lp37066
(dp37067
g31934
I103
sg31935
VTMEM127
p37068
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp37069
g31934
I121
sg31935
VSDHAF2
p37070
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp37071
g31934
I97
sg31935
g37057
sg31936
I4
sg31944
VP31040
p37072
sg31939
I1
sasa(dp37073
g31925
VThis study analyzed the prospective, longitudinally followed up European-American-Asian Pheochromocytoma-Paraganglioma Registry for prevalence of SDHA, TMEM127, MAX, and SDHAF2 germline mutation carriers from 1993 to 2016.
p37074
sg4
(dp37075
(VSDHA
p37076
VPheochromocytoma
p37077
tp37078
I00
ssg31931
(lp37079
(dp37080
g31934
I177
sg31935
Vgermline mutation
p37081
sg31936
I17
sg31937
VC1705427
p37082
sg31939
I2
sa(dp37083
g31934
I105
sg31935
VParaganglioma
p37084
sg31936
I13
sg31937
VC0030421
p37085
sg31939
I1
sa(dp37086
g31934
I88
sg31935
g37077
sg31936
I16
sg31937
VC0031511
p37087
sg31939
I1
sasg31940
(lp37088
(dp37089
g31934
I146
sg31935
g37076
sg31936
I4
sg31944
VP31040
p37090
sg31939
I1
sa(dp37091
g31934
I170
sg31935
VSDHAF2
p37092
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp37093
g31934
I152
sg31935
VTMEM127
p37094
sg31936
I7
sg31944
g190
sg31939
I1
sasa(dp37095
g31925
VThe SDHA, TMEM127, MAX, and SDHAF2 genes may contribute to hereditary pheochromocytoma and paraganglioma.
p37096
sg4
(dp37097
(VSDHA
p37098
Vpheochromocytoma
p37099
tp37100
I00
ssg31931
(lp37101
(dp37102
g31934
I91
sg31935
Vparaganglioma
p37103
sg31936
I13
sg31937
VC0030421
p37104
sg31939
I1
sa(dp37105
g31934
I70
sg31935
g37099
sg31936
I16
sg31937
VC0031511
p37106
sg31939
I1
sasg31940
(lp37107
(dp37108
g31934
I4
sg31935
g37098
sg31936
I4
sg31944
VP31040
p37109
sg31939
I1
sa(dp37110
g31934
I28
sg31935
VSDHAF2 genes
p37111
sg31936
I12
sg31944
g190
sg31939
I2
sa(dp37112
g31934
I10
sg31935
VTMEM127
p37113
sg31936
I7
sg31944
g190
sg31939
I1
sasa(dp37114
g31925
V3-MT = 3-methoxytyramine; EPAS1 = endothelial pas domain protein 1; FH = fumarate hydratase; HIF2A = hypoxia inducible factor type 2A; MEN2 = multiple endocrine neoplasia type 2; NF1 = neurofibromatosis type 1; PNMT = phenylethanolamine N-methyltransferase; PPGL = pheochromocytoma and paraganglioma; RET = rearranged during transfection; SDH = succinate dehydrogenase; SDHAF2 = succinate dehydrogenase complex assembly factor 2; TCA = tricarboxylic acid; TH = tyrosine hydroxylase; TMEM127 = transmembrane protein 127; VHL = von Hippel-Lindau.
p37115
sg4
(dp37116
(Vsuccinate dehydrogenase
p37117
Vneurofibromatosis type 1
p37118
tp37119
I00
ssg31931
(lp37120
(dp37121
g31934
I265
sg31935
Vpheochromocytoma
p37122
sg31936
I16
sg31937
VC0031511
p37123
sg31939
I1
sa(dp37124
g31934
I286
sg31935
Vparaganglioma
p37125
sg31936
I13
sg31937
VC0030421
p37126
sg31939
I1
sa(dp37127
g31934
I179
sg31935
VNF1
p37128
sg31936
I3
sg31937
VC0027831
p37129
sg31939
I1
sa(dp37130
g31934
I520
sg31935
VVHL
p37131
sg31936
I3
sg31937
VC0019562
p37132
sg31939
I1
sa(dp37133
g31934
I142
sg31935
Vmultiple endocrine neoplasia type 2
p37134
sg31936
I35
sg31937
VC0025268
p37135
sg31939
I5
sa(dp37136
g31934
I101
sg31935
Vhypoxia
p37137
sg31936
I7
sg31937
VC0242184
p37138
sg31939
I1
sa(dp37139
g31934
I339
sg31935
VSDH
p37140
sg31936
I3
sg31937
VC0018946
p37141
sg31939
I1
sa(dp37142
g31934
I185
sg31935
g37118
sg31936
I24
sg31937
VC0027831
p37143
sg31939
I3
sasg31940
(lp37144
(dp37145
g31934
I370
sg31935
VSDHAF2
p37146
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp37147
g31934
I93
sg31935
VHIF2A
p37148
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp37149
g31934
I101
sg31935
Vhypoxia inducible factor type 2A
p37150
sg31936
I32
sg31944
g190
sg31939
I5
sa(dp37151
g31934
I483
sg31935
VTMEM127
p37152
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp37153
g31934
I456
sg31935
VTH = tyrosine hydroxylase
p37154
sg31936
I25
sg31944
VP07101
p37155
sg31939
I4
sa(dp37156
g31934
I339
sg31935
VSDH
p37157
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp37158
g31934
I345
sg31935
Vsuccinate dehydrogenase
p37159
sg31936
I23
sg31944
VP49366
p37160
sg31939
I2
sa(dp37161
g31934
I345
sg31935
g37117
sg31936
I23
sg31944
VP49366
p37162
sg31939
I2
sasa(dp37163
g31925
VWe determined the clusterin expression pattern in 72 triple negative breast cancers (TNBC) treated with NAC before surgery.
p37164
sg4
(dp37165
(Vclusterin
p37166
Vbreast cancers
p37167
tp37168
I00
ssg31931
(lp37169
(dp37170
g31934
I69
sg31935
g37167
sg31936
I14
sg31937
VC0006142
p37171
sg31939
I2
sasg31940
(lp37172
(dp37173
g31934
I18
sg31935
g37166
sg31936
I9
sg31944
VP10909
p37174
sg31939
I1
sasa(dp37175
g31925
VClusterin was present at higher levels in both fractions of patients with early and intermediate stages of breast cancer.
p37176
sg4
(dp37177
(VClusterin
p37178
Vbreast cancer
p37179
tp37180
I00
ssg31931
(lp37181
(dp37182
g31934
I107
sg31935
g37179
sg31936
I13
sg31937
VC0678222
p37183
sg31939
I2
sasg31940
(lp37184
(dp37185
g31934
I0
sg31935
g37178
sg31936
I9
sg31944
VP10909
p37186
sg31939
I1
sasa(dp37187
g31925
VDiscovery and development of a novel anticancer PEG-SMR-Clu peptide to prevent breast cancer metastasis.
p37188
sg4
(dp37189
(VPEG-SMR-Clu peptide
p37190
Vbreast cancer
p37191
tp37192
I00
ssg31931
(lp37193
(dp37194
g31934
I93
sg31935
Vmetastasis
p37195
sg31936
I10
sg31937
VC0027627
p37196
sg31939
I1
sa(dp37197
g31934
I79
sg31935
g37191
sg31936
I13
sg31937
VC0678222
p37198
sg31939
I2
sasg31940
(lp37199
(dp37200
g31934
I48
sg31935
g37190
sg31936
I19
sg31944
VP09466
p37201
sg31939
I2
sasa(dp37202
g31925
VPEG-SMRwt-Clu and PEG-SMRwt peptides inhibited the growth of both of MCF-7 (estrogen responsive, ER+) and MDA-MD-231 (estrogen non-responsive, ER-) human breast cancer cells in a dose and time-dependent manner, without inducing cytotoxic effects.
p37203
sg4
(dp37204
(VClu
p37205
Vbreast cancer
p37206
tp37207
I00
ssg31931
(lp37208
(dp37209
g31934
I154
sg31935
g37206
sg31936
I13
sg31937
VC0678222
p37210
sg31939
I2
sasg31940
(lp37211
(dp37212
g31934
I18
sg31935
VPEG-SMRwt peptides
p37213
sg31936
I18
sg31944
VP09466
p37214
sg31939
I2
sa(dp37215
g31934
I0
sg31935
VPEG
p37216
sg31936
I3
sg31944
VP09466
p37217
sg31939
I1
sa(dp37218
g31934
I10
sg31935
g37205
sg31936
I3
sg31944
VP10909
p37219
sg31939
I1
sasa(dp37220
g31925
VPEG-SMRwt-CLU peptides inhibited the growth of human breast cancer cells and blocked tumor exosome release in vitro.
p37221
sg4
(dp37222
(VPEG-SMRwt-CLU peptides
p37223
Vbreast cancer
p37224
tp37225
I00
ssg31931
(lp37226
(dp37227
g31934
I53
sg31935
g37224
sg31936
I13
sg31937
VC0678222
p37228
sg31939
I2
sa(dp37229
g31934
I85
sg31935
Vtumor
p37230
sg31936
I5
sg31937
VC0027651
p37231
sg31939
I1
sasg31940
(lp37232
(dp37233
g31934
I0
sg31935
g37223
sg31936
I22
sg31944
VP09466
p37234
sg31939
I2
sasa(dp37235
g31925
VClinically, breast cancer patients possess sCLU expression only in mature CD68(+) macrophages but not in immature CD33(+) immunosuppressive myeloid cells infiltrating the tumors.
p37236
sg4
(dp37237
(VCD68
p37238
Vbreast cancer
p37239
tp37240
I00
ssg31931
(lp37241
(dp37242
g31934
I35
sg31935
Vpossess
p37243
sg31936
I7
sg31937
VC0850310
p37244
sg31939
I1
sa(dp37245
g31934
I154
sg31935
Vinfiltrating
p37246
sg31936
I12
sg31937
VC0332448
p37247
sg31939
I1
sa(dp37248
g31934
I12
sg31935
g37239
sg31936
I13
sg31937
VC0678222
p37249
sg31939
I2
sa(dp37250
g31934
I171
sg31935
Vtumors
p37251
sg31936
I6
sg31937
VC0027651
p37252
sg31939
I1
sasg31940
(lp37253
(dp37254
g31934
I74
sg31935
g37238
sg31936
I4
sg31944
VP34810
p37255
sg31939
I1
sasa(dp37256
g31925
VImmunoblotting and MRM-based validation in a separate cohort testified a panel of 21 proteins such as zinc-alpha2-glycoprotein, A2GL, retinol-binding protein 4, annexin A1, SAP3, SRC8, gelsolin, kininogen 1, CO9, clusterin, ceruloplasmin, and Alfa1-antitrypsin could be a panel of candidate markers that could discriminate HE breast cancer from healthy controls.
p37257
sg4
(dp37258
(Vannexin A1
p37259
Vbreast cancer
p37260
tp37261
I00
ssg31931
(lp37262
(dp37263
g31934
I326
sg31935
g37260
sg31936
I13
sg31937
VC0678222
p37264
sg31939
I2
sasg31940
(lp37265
(dp37266
g31934
I224
sg31935
Vceruloplasmin
p37267
sg31936
I13
sg31944
VP00450
p37268
sg31939
I1
sa(dp37269
g31934
I208
sg31935
VCO9
p37270
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp37271
g31934
I173
sg31935
VSAP3
p37272
sg31936
I4
sg31944
VP17900
p37273
sg31939
I1
sa(dp37274
g31934
I134
sg31935
Vretinol-binding protein 4
p37275
sg31936
I25
sg31944
VP02753
p37276
sg31939
I3
sa(dp37277
g31934
I213
sg31935
Vclusterin
p37278
sg31936
I9
sg31944
VP10909
p37279
sg31939
I1
sa(dp37280
g31934
I243
sg31935
VAlfa1-antitrypsin
p37281
sg31936
I17
sg31944
g190
sg31939
I1
sa(dp37282
g31934
I185
sg31935
Vgelsolin
p37283
sg31936
I8
sg31944
VP06396
p37284
sg31939
I1
sa(dp37285
g31934
I195
sg31935
Vkininogen 1
p37286
sg31936
I11
sg31944
VP01042
p37287
sg31939
I2
sa(dp37288
g31934
I102
sg31935
Vzinc-alpha2-glycoprotein
p37289
sg31936
I24
sg31944
VP36222
p37290
sg31939
I1
sa(dp37291
g31934
I161
sg31935
g37259
sg31936
I10
sg31944
VP04083
p37292
sg31939
I2
sasa(dp37293
g31925
VTo evaluate potential biomarkers in HCC, we employed multiple methods in this study, including qPCR, immunostaining methods and tissue microarrays (TMAs), as well as histological and pathological analysis, to assess TGFBeta, XPO4, elF5A2 and ANGPTL4 in cancerous and paracancerous liver tissues from 280 patients suffering from liver cancer.
p37294
sg4
(dp37295
(VTGFBeta
p37296
VHCC
p37297
tp37298
I00
ssg31931
(lp37299
(dp37300
g31934
I313
sg31935
Vsuffering
p37301
sg31936
I9
sg31937
VC0683278
p37302
sg31939
I1
sa(dp37303
g31934
I328
sg31935
Vliver cancer
p37304
sg31936
I12
sg31937
VC0345904
p37305
sg31939
I2
sa(dp37306
g31934
I36
sg31935
g37297
sg31936
I3
sg31937
VC2239176
p37307
sg31939
I1
sasg31940
(lp37308
(dp37309
g31934
I225
sg31935
VXPO4
p37310
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp37311
g31934
I216
sg31935
g37296
sg31936
I7
sg31944
VP01137
p37312
sg31939
I1
sa(dp37313
g31934
I242
sg31935
VANGPTL4
p37314
sg31936
I7
sg31944
g190
sg31939
I1
sasa(dp37315
g31925
VAll the results above provide new insights into better understanding biological indicators, such as XPO4, TGFBeta1, ANGPTL4 and elF5A2, in the prediction and evaluation of liver cancer, as well as signaling pathways in the control of liver cancer.
p37316
sg4
(dp37317
(VTGFBeta1
p37318
Vliver cancer
p37319
tp37320
I00
ssg31931
(lp37321
(dp37322
g31934
I172
sg31935
Vliver cancer
p37323
sg31936
I12
sg31937
VC0345904
p37324
sg31939
I2
sa(dp37325
g31934
I172
sg31935
g37319
sg31936
I12
sg31937
VC0345904
p37326
sg31939
I2
sasg31940
(lp37327
(dp37328
g31934
I106
sg31935
g37318
sg31936
I8
sg31944
VP01137
p37329
sg31939
I1
sa(dp37330
g31934
I116
sg31935
VANGPTL4
p37331
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp37332
g31934
I100
sg31935
VXPO4
p37333
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp37334
g31925
VXPO4 and TGFBeta1 may serve as useful markers to evaluate the size and prognosis of liver cancer.
p37335
sg4
(dp37336
(VTGFBeta1
p37337
Vliver cancer
p37338
tp37339
I00
ssg31931
(lp37340
(dp37341
g31934
I84
sg31935
g37338
sg31936
I12
sg31937
VC0345904
p37342
sg31939
I2
sasg31940
(lp37343
(dp37344
g31934
I9
sg31935
g37337
sg31936
I8
sg31944
VP01137
p37345
sg31939
I1
sa(dp37346
g31934
I0
sg31935
VXPO4
p37347
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp37348
g31925
VNon-significantly increased SMRs were shown for lung cancer (Obs 45, Exp 40.7, SMR 111) and cancer of the prostate (Obs 9, Exp 7.5, SMR 116).
p37349
sg4
(dp37350
(VObs 9
p37351
Vlung cancer
p37352
tp37353
I00
ssg31931
(lp37354
(dp37355
g31934
I92
sg31935
Vcancer of the prostate
p37356
sg31936
I22
sg31937
VC0600139
p37357
sg31939
I4
sa(dp37358
g31934
I48
sg31935
g37352
sg31936
I11
sg31937
VC0684249
p37359
sg31939
I2
sasg31940
(lp37360
(dp37361
g31934
I79
sg31935
VSMR 111
p37362
sg31936
I7
sg31944
g190
sg31939
I2
sa(dp37363
g31934
I116
sg31935
g37351
sg31936
I5
sg31944
VP41159
p37364
sg31939
I2
sa(dp37365
g31934
I123
sg31935
VExp 7
p37366
sg31936
I5
sg31944
g190
sg31939
I2
sasa(dp37367
g31925
VIn this largest-ever GWAS meta-analysis for nicotine dependence and the largest-ever cross-ancestry GWAS meta-analysis for any smoking phenotype, we reconfirmed the well-known CHRNA5-CHRNA3-CHRNB4 genes and further yielded a novel association in the DNA methyltransferase gene DNMT3B.
p37368
sg4
(dp37369
(VCHRNA5-CHRNA3-CHRNB4 genes
p37370
Vnicotine dependence
p37371
tp37372
I00
ssg31931
(lp37373
(dp37374
g31934
I44
sg31935
g37371
sg31936
I19
sg31937
VC0028043
p37375
sg31939
I2
sasg31940
(lp37376
(dp37377
g31934
I250
sg31935
VDNA methyltransferase gene DNMT3B
p37378
sg31936
I33
sg31944
g190
sg31939
I4
sa(dp37379
g31934
I176
sg31935
g37370
sg31936
I26
sg31944
VP30532
p37380
sg31939
I2
sasa(dp37381
g31925
VThe relationship of HTR4 (rs3995090), HTR2A (rs6313), GRIK5 (rs8099939), GRIN2B (rs2268132), and CHRNB4 (rs1948) gene polymorphisms and COPD, as well as the contribution of these polymorphisms to the variations in quantitative characteristics that describe respiratory function, smoking behavior, and nicotine dependence was assessed in an ethnically homogeneous Tatar population.
p37382
sg4
(dp37383
(VCHRNB4
p37384
Vnicotine dependence
p37385
tp37386
I00
ssg31931
(lp37387
(dp37388
g31934
I136
sg31935
VCOPD
p37389
sg31936
I4
sg31937
VC0024117
p37390
sg31939
I1
sa(dp37391
g31934
I301
sg31935
g37385
sg31936
I19
sg31937
VC0028043
p37392
sg31939
I2
sasg31940
(lp37393
(dp37394
g31934
I38
sg31935
VHTR2A
p37395
sg31936
I5
sg31944
VP28223
p37396
sg31939
I1
sa(dp37397
g31934
I97
sg31935
g37384
sg31936
I6
sg31944
VP30926
p37398
sg31939
I1
sa(dp37399
g31934
I73
sg31935
VGRIN2B
p37400
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp37401
g31934
I54
sg31935
VGRIK5
p37402
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp37403
g31925
VGenome-wide association studies (GWASs) have identified associations between the CHRNA5-CHRNA3-CHRNB4 gene cluster and smoking heaviness and nicotine dependence.
p37404
sg4
(dp37405
(VCHRNA3
p37406
Vnicotine dependence
p37407
tp37408
I00
ssg31931
(lp37409
(dp37410
g31934
I141
sg31935
g37407
sg31936
I19
sg31937
VC0028043
p37411
sg31939
I2
sasg31940
(lp37412
(dp37413
g31934
I81
sg31935
VCHRNA5
p37414
sg31936
I6
sg31944
VP30532
p37415
sg31939
I1
sa(dp37416
g31934
I95
sg31935
VCHRNB4
p37417
sg31936
I6
sg31944
VP30926
p37418
sg31939
I1
sa(dp37419
g31934
I88
sg31935
g37406
sg31936
I6
sg31944
VP32297
p37420
sg31939
I1
sasa(dp37421
g31925
VPolymorphisms in the CHRNA5-CHRNA3-CHRNB4 gene cluster (Chr15q25) have been robustly associated with nicotine dependence, including genome-wide studies, as well as with cognitive and neuropsychological measures.
p37422
sg4
(dp37423
(VCHRNA5-CHRNA3-CHRNB4 gene cluster
p37424
Vnicotine dependence
p37425
tp37426
I00
ssg31931
(lp37427
(dp37428
g31934
I101
sg31935
g37425
sg31936
I19
sg31937
VC0028043
p37429
sg31939
I2
sasg31940
(lp37430
(dp37431
g31934
I21
sg31935
g37424
sg31936
I33
sg31944
VP30532
p37432
sg31939
I3
sasa(dp37433
g31925
VHere, we evaluated the effect of polymorphisms in CHRNA5-CHRNA3-CHRNB4 gene cluster and their interaction with tobacco smoking status on cognition in patients with Attention Deficit/Hyperactivity Disorder (ADHD).
p37434
sg4
(dp37435
(VCHRNA5-CHRNA3-CHRNB4 gene cluster
p37436
VADHD
p37437
tp37438
I00
ssg31931
(lp37439
(dp37440
g31934
I164
sg31935
VAttention Deficit/Hyperactivity Disorder
p37441
sg31936
I40
sg31937
VC1263846
p37442
sg31939
I3
sa(dp37443
g31934
I206
sg31935
g37437
sg31936
I4
sg31937
VC1263846
p37444
sg31939
I1
sasg31940
(lp37445
(dp37446
g31934
I50
sg31935
g37436
sg31936
I33
sg31944
VP30532
p37447
sg31939
I3
sasa(dp37448
g31925
VEight SNPs from the CHRNA5-CHRNA3-CHRNB4 gene cluster were evaluated on a clinical sample of 403 adults with ADHD.
p37449
sg4
(dp37450
(VCHRNA3
p37451
VADHD
p37452
tp37453
I00
ssg31931
(lp37454
(dp37455
g31934
I109
sg31935
g37452
sg31936
I4
sg31937
VC1263846
p37456
sg31939
I1
sasg31940
(lp37457
(dp37458
g31934
I34
sg31935
VCHRNB4
p37459
sg31936
I6
sg31944
VP30926
p37460
sg31939
I1
sa(dp37461
g31934
I20
sg31935
VCHRNA5
p37462
sg31936
I6
sg31944
VP30532
p37463
sg31939
I1
sa(dp37464
g31934
I27
sg31935
g37451
sg31936
I6
sg31944
VP32297
p37465
sg31939
I1
sasa(dp37466
g31925
VThe associations between CHRNA5-CHRNA3-CHRNB4 variants and cigarettes per day (CPD), the Fagerstroem Test for Nicotine Dependence (FTND), and craving were analyzed in data from 662 lifetime smokers from an Israeli adult Jewish household sample.
p37467
sg4
(dp37468
(VCHRNA5-CHRNA3-CHRNB4 variants
p37469
VNicotine Dependence
p37470
tp37471
I00
ssg31931
(lp37472
(dp37473
g31934
I110
sg31935
g37470
sg31936
I19
sg31937
VC0028043
p37474
sg31939
I2
sasg31940
(lp37475
(dp37476
g31934
I25
sg31935
g37469
sg31936
I29
sg31944
VP30532
p37477
sg31939
I2
sasa(dp37478
g31925
VWe found a significant increase in levels of adhesion molecules (VCAM-1) and selectins (E-selectin) in parallel with increased severity of diabetic retinopathy, with a significant difference of inflammatory markers between stages of retinopathy.
p37479
sg4
(dp37480
(VVCAM-1
p37481
Vadhesion
p37482
tp37483
I00
ssg31931
(lp37484
(dp37485
g31934
I148
sg31935
Vretinopathy
p37486
sg31936
I11
sg31937
VC0035309
p37487
sg31939
I1
sa(dp37488
g31934
I139
sg31935
Vdiabetic retinopathy
p37489
sg31936
I20
sg31937
VC0011884
p37490
sg31939
I2
sa(dp37491
g31934
I45
sg31935
g37482
sg31936
I8
sg31937
VC0001511
p37492
sg31939
I1
sasg31940
(lp37493
(dp37494
g31934
I88
sg31935
VE-selectin
p37495
sg31936
I10
sg31944
VP16581
p37496
sg31939
I1
sa(dp37497
g31934
I65
sg31935
g37481
sg31936
I6
sg31944
VP19320
p37498
sg31939
I1
sasa(dp37499
g31925
VOur aim was to investigate the role of soluble E-selectin in the formation of diabetic retinopathy.
p37500
sg4
(dp37501
(VE-selectin
p37502
Vdiabetic retinopathy
p37503
tp37504
I00
ssg31931
(lp37505
(dp37506
g31934
I78
sg31935
g37503
sg31936
I20
sg31937
VC0011884
p37507
sg31939
I2
sasg31940
(lp37508
(dp37509
g31934
I47
sg31935
g37502
sg31936
I10
sg31944
VP16581
p37510
sg31939
I1
sasa(dp37511
g31925
VAn elevated E-selectin level can play a role in the development of diabetic retinopathy, but it does not seem to alter disease severity.
p37512
sg4
(dp37513
(VE-selectin
p37514
Vdiabetic retinopathy
p37515
tp37516
I00
ssg31931
(lp37517
(dp37518
g31934
I67
sg31935
g37515
sg31936
I20
sg31937
VC0011884
p37519
sg31939
I2
sasg31940
(lp37520
(dp37521
g31934
I12
sg31935
g37514
sg31936
I10
sg31944
VP16581
p37522
sg31939
I1
sasa(dp37523
g31925
VHowever, glycemic control and the reduction of cardiovascular risk factors may also alter the level of E-selectin that might play a role in the prevention of diabetic retinopathy.
p37524
sg4
(dp37525
(VE-selectin
p37526
Vdiabetic retinopathy
p37527
tp37528
I00
ssg31931
(lp37529
(dp37530
g31934
I158
sg31935
g37527
sg31936
I20
sg31937
VC0011884
p37531
sg31939
I2
sasg31940
(lp37532
(dp37533
g31934
I103
sg31935
g37526
sg31936
I10
sg31944
VP16581
p37534
sg31939
I1
sasa(dp37535
g31925
VTo evaluate efficacy of the treatment, the progression of the disease (number of laser treatments, number of bevacizumab treatments, and incidence of retinal detachment) was evaluated by serial ophthalmologic examinations, and plasma soluble E-selectin levels were measured weekly.
p37536
sg4
(dp37537
(Vplasma soluble E-selectin
p37538
Vretinal detachment
p37539
tp37540
I00
ssg31931
(lp37541
(dp37542
g31934
I150
sg31935
g37539
sg31936
I18
sg31937
VC0035305
p37543
sg31939
I2
sasg31940
(lp37544
(dp37545
g31934
I227
sg31935
g37538
sg31936
I25
sg31944
VP16581
p37546
sg31939
I3
sasa(dp37547
g31925
VAfter adjusting for age, glycemic control, and other potential confounders, baseline plasma levels of E-selectin were associated significantly with progression of DR, E-selectin and tumor necrosis factor-Alfa (TNF-Alfa) levels with incidence of proliferative DR (PDR), and soluble intercellular adhesion molecule-1 (sICAM-1) and TNF-Alfa levels with incidence of macular edema (ME).
p37548
sg4
(dp37549
(Vtumor necrosis factor-Alfa
p37550
Vproliferative DR
p37551
tp37552
I01
ssg31931
(lp37553
(dp37554
g31934
I263
sg31935
VPDR
p37555
sg31936
I3
sg31937
VC1845050
p37556
sg31939
I1
sa(dp37557
g31934
I363
sg31935
Vmacular edema
p37558
sg31936
I13
sg31937
VC0271051
p37559
sg31939
I2
sa(dp37560
g31934
I182
sg31935
Vtumor necrosis
p37561
sg31936
I14
sg31937
VC0333516
p37562
sg31939
I2
sa(dp37563
g31934
I295
sg31935
Vadhesion
p37564
sg31936
I8
sg31937
VC0001511
p37565
sg31939
I1
sa(dp37566
g31934
I378
sg31935
VME
p37567
sg31936
I2
sg31937
VC0271051
p37568
sg31939
I1
sa(dp37569
g31934
I245
sg31935
g37551
sg31936
I16
sg31937
VC1845050
p37570
sg31939
I2
sasg31940
(lp37571
(dp37572
g31934
I210
sg31935
VTNF-Alfa
p37573
sg31936
I8
sg31944
VP01375
p37574
sg31939
I1
sa(dp37575
g31934
I210
sg31935
VTNF-Alfa
p37576
sg31936
I8
sg31944
VP01375
p37577
sg31939
I1
sa(dp37578
g31934
I102
sg31935
VE-selectin
p37579
sg31936
I10
sg31944
VP16581
p37580
sg31939
I1
sa(dp37581
g31934
I102
sg31935
VE-selectin
p37582
sg31936
I10
sg31944
VP16581
p37583
sg31939
I1
sa(dp37584
g31934
I281
sg31935
Vintercellular adhesion molecule-1
p37585
sg31936
I33
sg31944
VP05362
p37586
sg31939
I3
sa(dp37587
g31934
I182
sg31935
g37550
sg31936
I26
sg31944
VP01375
p37588
sg31939
I3
sasa(dp37589
g31925
VIn patients with systemic sclerosis (SSc), the relationship between innate immune activation, represented by increased expression of interferon (IFN)-regulated genes, and vascular injury/activation, manifest by increased endothelin-1 (ET-1), endothelin converting enzyme-1 (ECE1) and intercellular adhesion molecule-1, is uncertain.
p37590
sg4
(dp37591
(Vinterferon
p37592
VSSc
p37593
tp37594
I00
ssg31931
(lp37595
(dp37596
g31934
I298
sg31935
Vadhesion
p37597
sg31936
I8
sg31937
VC0001511
p37598
sg31939
I1
sa(dp37599
g31934
I17
sg31935
Vsystemic sclerosis
p37600
sg31936
I18
sg31937
VC0036421
p37601
sg31939
I2
sa(dp37602
g31934
I37
sg31935
g37593
sg31936
I3
sg31937
VC0036421
p37603
sg31939
I1
sasg31940
(lp37604
(dp37605
g31934
I274
sg31935
VECE1
p37606
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp37607
g31934
I145
sg31935
VIFN
p37608
sg31936
I3
sg31944
VP01562
p37609
sg31939
I1
sa(dp37610
g31934
I235
sg31935
VET-1
p37611
sg31936
I4
sg31944
VP05305
p37612
sg31939
I1
sa(dp37613
g31934
I221
sg31935
Vendothelin-1
p37614
sg31936
I12
sg31944
VP20800
p37615
sg31939
I1
sa(dp37616
g31934
I242
sg31935
Vendothelin converting enzyme-1
p37617
sg31936
I30
sg31944
g190
sg31939
I3
sa(dp37618
g31934
I284
sg31935
Vintercellular adhesion molecule-1
p37619
sg31936
I33
sg31944
VP05362
p37620
sg31939
I3
sa(dp37621
g31934
I133
sg31935
g37592
sg31936
I10
sg31944
VP01563
p37622
sg31939
I1
sasa(dp37623
g31925
VFurthermore, we performed immunohistochemistry analysis on human primary prostate cancer tissue sections derived from patients to investigate the correlation of SR-BI with clinicopathological parameters and the mTOR target pS6.
p37624
sg4
(dp37625
(VmTOR
p37626
Vprostate cancer
p37627
tp37628
I00
ssg31931
(lp37629
(dp37630
g31934
I73
sg31935
g37627
sg31936
I15
sg31937
VC0600139
p37631
sg31939
I2
sasg31940
(lp37632
(dp37633
g31934
I211
sg31935
g37626
sg31936
I4
sg31944
VP42345
p37634
sg31939
I1
sa(dp37635
g31934
I161
sg31935
VSR-BI
p37636
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp37637
g31925
VIn contrast to LDLR, we identified SR-BI mRNA and protein expression to be induced in high Gleason grade primary prostate cancers.
p37638
sg4
(dp37639
(VLDLR
p37640
Vprostate cancers
p37641
tp37642
I00
ssg31931
(lp37643
(dp37644
g31934
I113
sg31935
g37641
sg31936
I16
sg31937
VC0376358
p37645
sg31939
I2
sasg31940
(lp37646
(dp37647
g31934
I15
sg31935
g37640
sg31936
I4
sg31944
VP01130
p37648
sg31939
I1
sa(dp37649
g31934
I35
sg31935
VSR-BI mRNA
p37650
sg31936
I10
sg31944
g190
sg31939
I2
sasa(dp37651
g31925
VThe down-regulation of SR-BI significantly impacts PSA production of prostate cancer cells, as well as the viability of C4-2 cells in the presence and absence of HDL.
p37652
sg4
(dp37653
(VHDL
p37654
VPSA
p37655
tp37656
I00
ssg31931
(lp37657
(dp37658
g31934
I69
sg31935
Vprostate cancer
p37659
sg31936
I15
sg31937
VC0600139
p37660
sg31939
I2
sa(dp37661
g31934
I51
sg31935
g37655
sg31936
I3
sg31937
VC1519176
p37662
sg31939
I1
sasg31940
(lp37663
(dp37664
g31934
I51
sg31935
VPSA
p37665
sg31936
I3
sg31944
VP55786
p37666
sg31939
I1
sa(dp37667
g31934
I23
sg31935
VSR-BI
p37668
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp37669
g31934
I162
sg31935
g37654
sg31936
I3
sg31944
VP28845
p37670
sg31939
I1
sasa(dp37671
g31925
Vplay roles in preterm labor and preterm premature rupture of membranes (pPROM); 3) integrated aspects of maternal and fetal host responses (inflammation, altered immune adaptations, endocrine and paracrine mechanisms) play increasingly understood roles in premature activation of parturition; and 4) identification and systemic treatment of common genitourinary infections, most importantly bacterial vaginosis (BV), reduce the risks of preterm delivery and PROM.
p37672
sg4
(dp37673
(VpPROM
p37674
Vpreterm premature rupture of membranes
p37675
tp37676
I01
ssg31931
(lp37677
(dp37678
g31934
I391
sg31935
Vbacterial vaginosis
p37679
sg31936
I19
sg31937
VC0085166
p37680
sg31939
I2
sa(dp37681
g31934
I437
sg31935
Vpreterm delivery
p37682
sg31936
I16
sg31937
VC0151526
p37683
sg31939
I2
sa(dp37684
g31934
I14
sg31935
Vpreterm labor
p37685
sg31936
I13
sg31937
VC0022876
p37686
sg31939
I2
sa(dp37687
g31934
I362
sg31935
Vinfections
p37688
sg31936
I10
sg31937
VC0021311
p37689
sg31939
I1
sa(dp37690
g31934
I0
sg31935
Vplay roles
p37691
sg31936
I10
sg31937
VC0699820
p37692
sg31939
I2
sa(dp37693
g31934
I72
sg31935
VpPROM
p37694
sg31936
I5
sg31937
VC0729264
p37695
sg31939
I1
sa(dp37696
g31934
I140
sg31935
Vinflammation
p37697
sg31936
I12
sg31937
VC0021368
p37698
sg31939
I1
sa(dp37699
g31934
I32
sg31935
g37675
sg31936
I38
sg31937
VC0729264
p37700
sg31939
I5
sasg31940
(lp37701
(dp37702
g31934
I72
sg31935
g37674
sg31936
I5
sg31944
VP50454
p37703
sg31939
I1
sasa(dp37704
g31925
VHere, we showed that DUSP10 knockout (KO) mice had increased intestinal epithelial cell (IEC) proliferation and migration and developed less severe colitis than wild-type (WT) mice in response to dextran sodium sulphate (DSS) treatment, which is associated with increased ERK1/2 activation and Kruppel-like factor 5 (KLF5) expression in IEC.
p37705
sg4
(dp37706
(VERK1/2
p37707
Vdextran sodium sulphate
p37708
tp37709
I01
ssg31931
(lp37710
(dp37711
g31934
I221
sg31935
VDSS
p37712
sg31936
I3
sg31937
VC0011195
p37713
sg31939
I1
sa(dp37714
g31934
I148
sg31935
Vcolitis
p37715
sg31936
I7
sg31937
VC0009319
p37716
sg31939
I1
sa(dp37717
g31934
I196
sg31935
g37708
sg31936
I23
sg31937
VC0011195
p37718
sg31939
I3
sa(dp37719
g31934
I94
sg31935
Vproliferation
p37720
sg31936
I13
sg31937
VC0334094
p37721
sg31939
I1
sasg31940
(lp37722
(dp37723
g31934
I272
sg31935
g37707
sg31936
I6
sg31944
VP27361
p37724
sg31939
I1
sa(dp37725
g31934
I294
sg31935
VKruppel-like factor 5
p37726
sg31936
I21
sg31944
g190
sg31939
I3
sa(dp37727
g31934
I317
sg31935
VKLF5
p37728
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp37729
g31934
I21
sg31935
VDUSP10
p37730
sg31936
I6
sg31944
g190
sg31939
I1
sasa(dp37731
g31925
VIn addition, GWAS have suggested that DENND1A, epidermal growth factor signaling, and DNA repair pathways play a role in PCOS pathogenesis.
p37732
sg4
(dp37733
(Vepidermal growth factor
p37734
VPCOS
p37735
tp37736
I00
ssg31931
(lp37737
(dp37738
g31934
I126
sg31935
Vpathogenesis
p37739
sg31936
I12
sg31937
VC0699748
p37740
sg31939
I1
sa(dp37741
g31934
I121
sg31935
g37735
sg31936
I4
sg31937
VC0032460
p37742
sg31939
I1
sasg31940
(lp37743
(dp37744
g31934
I47
sg31935
g37734
sg31936
I23
sg31944
VP01133
p37745
sg31939
I3
sa(dp37746
g31934
I38
sg31935
VDENND1A
p37747
sg31936
I7
sg31944
g190
sg31939
I1
sasa(dp37748
g31925
VOur previous research had identified three susceptibility loci (rs2479106, DENND1A; rs13405728, LHCGR; rs13429458, THADA) for PCOS in Han Chinese women.
p37749
sg4
(dp37750
(VLHCGR
p37751
VPCOS
p37752
tp37753
I00
ssg31931
(lp37754
(dp37755
g31934
I126
sg31935
g37752
sg31936
I4
sg31937
VC0032460
p37756
sg31939
I1
sasg31940
(lp37757
(dp37758
g31934
I75
sg31935
VDENND1A
p37759
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp37760
g31934
I96
sg31935
g37751
sg31936
I5
sg31944
VP22888
p37761
sg31939
I1
sasa(dp37762
g31925
VThree of the eleven variants associated with PCOS in the Han Chinese genome-wide association studies were also associated with PCOS in at least one European population when corrected for multiple testing (DENND1A, THADA and YAP1).
p37763
sg4
(dp37764
(VYAP1
p37765
VPCOS
p37766
tp37767
I00
ssg31931
(lp37768
(dp37769
g31934
I45
sg31935
VPCOS
p37770
sg31936
I4
sg31937
VC0032460
p37771
sg31939
I1
sa(dp37772
g31934
I45
sg31935
g37766
sg31936
I4
sg31937
VC0032460
p37773
sg31939
I1
sasg31940
(lp37774
(dp37775
g31934
I224
sg31935
g37765
sg31936
I4
sg31944
VP46937
p37776
sg31939
I1
sa(dp37777
g31934
I205
sg31935
VDENND1A
p37778
sg31936
I7
sg31944
g190
sg31939
I1
sasa(dp37779
g31925
VMiR-106a as an oncogene could promote proliferation and metastasis of prostate cancer cells by directly targeting PTEN in vivo and in vitro.
p37780
sg4
(dp37781
(VPTEN
p37782
Vprostate cancer
p37783
tp37784
I00
ssg31931
(lp37785
(dp37786
g31934
I38
sg31935
Vproliferation
p37787
sg31936
I13
sg31937
VC0334094
p37788
sg31939
I1
sa(dp37789
g31934
I56
sg31935
Vmetastasis
p37790
sg31936
I10
sg31937
VC0027627
p37791
sg31939
I1
sa(dp37792
g31934
I70
sg31935
g37783
sg31936
I15
sg31937
VC0600139
p37793
sg31939
I2
sasg31940
(lp37794
(dp37795
g31934
I114
sg31935
g37782
sg31936
I4
sg31944
VP60484
p37796
sg31939
I1
sa(dp37797
g31934
I0
sg31935
VMiR-106a
p37798
sg31936
I8
sg31944
g190
sg31939
I1
sasa(dp37799
g31925
VCXCL1 secreted by hAdSCs downregulated miR-106a expression in triple negative breast cancer, and resulted in ABCG2 upregulation and doxorubicin resistance.
p37800
sg4
(dp37801
(VCXCL1
p37802
Vbreast cancer
p37803
tp37804
I00
ssg31931
(lp37805
(dp37806
g31934
I78
sg31935
g37803
sg31936
I13
sg31937
VC0678222
p37807
sg31939
I2
sasg31940
(lp37808
(dp37809
g31934
I39
sg31935
VmiR-106a
p37810
sg31936
I8
sg31944
g190
sg31939
I1
sa(dp37811
g31934
I0
sg31935
g37802
sg31936
I5
sg31944
VP09341
p37812
sg31939
I1
sasa(dp37813
g31925
VOur findings suggest that CXCL1 secreted by hAdSCs elicits doxorubicin resistance through miR-106a-mediated ABCG2 upregulation in triple negative breast cancer.
p37814
sg4
(dp37815
(VCXCL1
p37816
Vbreast cancer
p37817
tp37818
I00
ssg31931
(lp37819
(dp37820
g31934
I146
sg31935
g37817
sg31936
I13
sg31937
VC0678222
p37821
sg31939
I2
sasg31940
(lp37822
(dp37823
g31934
I90
sg31935
VmiR-106a
p37824
sg31936
I8
sg31944
g190
sg31939
I1
sa(dp37825
g31934
I26
sg31935
g37816
sg31936
I5
sg31944
VP09341
p37826
sg31939
I1
sasa(dp37827
g31925
VCopy number gains in SOX2 in the region of 3q26-28 occur in 94% of SQCCs, and appear to act both early and late in disease progression by stabilizing the initial squamous injury response in stem cells and promoting growth of invasive carcinoma.
p37828
sg4
(dp37829
(VSOX2
p37830
Vinvasive carcinoma
p37831
tp37832
I00
ssg31931
(lp37833
(dp37834
g31934
I225
sg31935
g37831
sg31936
I18
sg31937
VC1334274
p37835
sg31939
I2
sa(dp37836
g31934
I115
sg31935
Vdisease progression
p37837
sg31936
I19
sg31937
VC0242656
p37838
sg31939
I2
sasg31940
(lp37839
(dp37840
g31934
I21
sg31935
g37830
sg31936
I4
sg31944
VP48431
p37841
sg31939
I1
sasa(dp37842
g31925
VA key feature of high-grade serous ovarian carcinoma (HGSOC) is frequent amplification of the 3q26 locus harboring PRKC-l (PRKCI).
p37843
sg4
(dp37844
(VPRKCI
p37845
Vovarian carcinoma
p37846
tp37847
I01
ssg31931
(lp37848
(dp37849
g31934
I73
sg31935
Vamplification
p37850
sg31936
I13
sg31937
VC1705759
p37851
sg31939
I1
sa(dp37852
g31934
I35
sg31935
g37846
sg31936
I17
sg31937
VC0029925
p37853
sg31939
I2
sasg31940
(lp37854
(dp37855
g31934
I115
sg31935
VPRKC-l
p37856
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp37857
g31934
I123
sg31935
g37845
sg31936
I5
sg31944
VP41743
p37858
sg31939
I1
sasa(dp37859
g31925
VThe PIK3CA gene at chromosome 3q26.32 was found to be amplified in up to 45% of patients with squamous cell carcinoma of the lung.
p37860
sg4
(dp37861
(VPIK3CA gene
p37862
Vsquamous cell carcinoma of the lung
p37863
tp37864
I00
ssg31931
(lp37865
(dp37866
g31934
I94
sg31935
g37863
sg31936
I35
sg31937
VC0149782
p37867
sg31939
I6
sasg31940
(lp37868
(dp37869
g31934
I4
sg31935
g37862
sg31936
I11
sg31944
VP42336
p37870
sg31939
I2
sasa(dp37871
g31925
VAspirin/NSAID interacted with MAP3K7 (colon cancer) and with MAPK14, NFAT5, and TRAF2 (rectal cancer); smoking cigarettes interacted with NFAM1 and NFAT2 (colon cancer) and MAPK8, NFAT5, and TNFRSF1A (rectal cancer); BMI interacted with NFAM1 and NFAT5 (colon cancer) and with MAPK8 and TNFRSF1A (rectal cancer).
p37872
sg4
(dp37873
(VTNFRSF1A
p37874
Vcolon cancer
p37875
tp37876
I01
ssg31931
(lp37877
(dp37878
g31934
I87
sg31935
Vrectal cancer
p37879
sg31936
I13
sg31937
VC0007113
p37880
sg31939
I2
sa(dp37881
g31934
I87
sg31935
Vrectal cancer
p37882
sg31936
I13
sg31937
VC0007113
p37883
sg31939
I2
sa(dp37884
g31934
I38
sg31935
Vcolon cancer
p37885
sg31936
I12
sg31937
VC0699790
p37886
sg31939
I2
sa(dp37887
g31934
I38
sg31935
Vcolon cancer
p37888
sg31936
I12
sg31937
VC0699790
p37889
sg31939
I2
sa(dp37890
g31934
I87
sg31935
Vrectal cancer
p37891
sg31936
I13
sg31937
VC0007113
p37892
sg31939
I2
sa(dp37893
g31934
I38
sg31935
g37875
sg31936
I12
sg31937
VC0699790
p37894
sg31939
I2
sasg31940
(lp37895
(dp37896
g31934
I148
sg31935
VNFAT2 (colon cancer)
p37897
sg31936
I20
sg31944
g190
sg31939
I3
sa(dp37898
g31934
I191
sg31935
VTNFRSF1A
p37899
sg31936
I8
sg31944
VP19438
p37900
sg31939
I1
sa(dp37901
g31934
I69
sg31935
VNFAT5
p37902
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp37903
g31934
I138
sg31935
VNFAM1
p37904
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp37905
g31934
I69
sg31935
VNFAT5
p37906
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp37907
g31934
I30
sg31935
VMAP3K7 (colon cancer)
p37908
sg31936
I21
sg31944
g190
sg31939
I3
sa(dp37909
g31934
I80
sg31935
VTRAF2
p37910
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp37911
g31934
I173
sg31935
VMAPK8
p37912
sg31936
I5
sg31944
VP45983
p37913
sg31939
I1
sa(dp37914
g31934
I138
sg31935
VNFAM1
p37915
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp37916
g31934
I247
sg31935
VNFAT5 (colon cancer)
p37917
sg31936
I20
sg31944
g190
sg31939
I3
sa(dp37918
g31934
I173
sg31935
VMAPK8
p37919
sg31936
I5
sg31944
VP45983
p37920
sg31939
I1
sa(dp37921
g31934
I61
sg31935
VMAPK14
p37922
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp37923
g31934
I191
sg31935
g37874
sg31936
I8
sg31944
VP19438
p37924
sg31939
I1
sasa(dp37925
g31925
VWe found that TAPP2, syntrophin, and utrophin are coexpressed in normal human B cells and B-chronic lymphocytic leukemia (B-CLL) cells.
p37926
sg4
(dp37927
(Vutrophin
p37928
Vchronic lymphocytic leukemia
p37929
tp37930
I00
ssg31931
(lp37931
(dp37932
g31934
I124
sg31935
VCLL
p37933
sg31936
I3
sg31937
VC0023434
p37934
sg31939
I1
sa(dp37935
g31934
I92
sg31935
g37929
sg31936
I28
sg31937
VC0023434
p37936
sg31939
I3
sasg31940
(lp37937
(dp37938
g31934
I37
sg31935
g37928
sg31936
I8
sg31944
VP46939
p37939
sg31939
I1
sa(dp37940
g31934
I14
sg31935
VTAPP2
p37941
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp37942
g31925
VCREB1 expression, which was activated by E2F, was coupled with RFC3 expression during the G1/S progression in the KG-1 acute myeloid leukemia (AML) cell line.
p37943
sg4
(dp37944
(VRFC3
p37945
Vacute myeloid leukemia
p37946
tp37947
I01
ssg31931
(lp37948
(dp37949
g31934
I143
sg31935
VAML
p37950
sg31936
I3
sg31937
VC0023467
p37951
sg31939
I1
sa(dp37952
g31934
I119
sg31935
g37946
sg31936
I22
sg31937
VC0023467
p37953
sg31939
I3
sasg31940
(lp37954
(dp37955
g31934
I0
sg31935
VCREB1
p37956
sg31936
I5
sg31944
VP16220
p37957
sg31939
I1
sa(dp37958
g31934
I63
sg31935
g37945
sg31936
I4
sg31944
VP40938
p37959
sg31939
I1
sasa(dp37960
g31925
VThese results suggest that the interaction between sf-Stk and the envelope proteins of the polycythemia- and anemia-inducing variants of SFFV is architecturally different.
p37961
sg4
(dp37962
(Vsf-Stk
p37963
Vpolycythemia
p37964
tp37965
I00
ssg31931
(lp37966
(dp37967
g31934
I109
sg31935
Vanemia
p37968
sg31936
I6
sg31937
VC0002871
p37969
sg31939
I1
sa(dp37970
g31934
I91
sg31935
g37964
sg31936
I12
sg31937
VC0032461
p37971
sg31939
I1
sasg31940
(lp37972
(dp37973
g31934
I66
sg31935
Venvelope
p37974
sg31936
I8
sg31944
g190
sg31939
I1
sa(dp37975
g31934
I51
sg31935
g37963
sg31936
I6
sg31944
VP52823
p37976
sg31939
I1
sasa(dp37977
g31925
VColitis severity was assessed by body weight, colonoscopy, colon length, histological score, cytokine mRNA expression, and myeloperoxidase (MPO) activity.
p37978
sg4
(dp37979
(VMPO
p37980
VColitis
p37981
tp37982
I00
ssg31931
(lp37983
(dp37984
g31934
I0
sg31935
g37981
sg31936
I7
sg31937
VC0009319
p37985
sg31939
I1
sasg31940
(lp37986
(dp37987
g31934
I123
sg31935
Vmyeloperoxidase
p37988
sg31936
I15
sg31944
VP05164
p37989
sg31939
I1
sa(dp37990
g31934
I140
sg31935
g37980
sg31936
I3
sg31944
VP05164
p37991
sg31939
I1
sasa(dp37992
g31925
VPigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) is associated with recessive mutations in SLC29A3, encoding the equilibrative nucleoside transporter hENT3 expressed in mitochondria, causing PHID and H syndromes, familial Rosai-Dorfman disease, and histiocytosis-lymphadenopathy-plus syndrome.
p37993
sg4
(dp37994
(Vinsulin
p37995
Vinsulin-dependent diabetes mellitus
p37996
tp37997
I00
ssg31931
(lp37998
(dp37999
g31934
I82
sg31935
VPHID
p38000
sg31936
I4
sg31937
VC1864445
p38001
sg31939
I1
sa(dp38002
g31934
I241
sg31935
Vsyndrome
p38003
sg31936
I8
sg31937
VC0039082
p38004
sg31939
I1
sa(dp38005
g31934
I11
sg31935
Vhypertrichosis
p38006
sg31936
I14
sg31937
VC0020555
p38007
sg31939
I1
sa(dp38008
g31934
I288
sg31935
Vhistiocytosis
p38009
sg31936
I13
sg31937
VC0019618
p38010
sg31939
I1
sa(dp38011
g31934
I34
sg31935
Vautoimmune
p38012
sg31936
I10
sg31937
VC0443146
p38013
sg31939
I1
sa(dp38014
g31934
I241
sg31935
Vsyndromes
p38015
sg31936
I9
sg31937
VC0039082
p38016
sg31939
I1
sa(dp38017
g31934
I82
sg31935
VPHID
p38018
sg31936
I4
sg31937
VC1864445
p38019
sg31939
I1
sa(dp38020
g31934
I261
sg31935
VRosai-Dorfman disease
p38021
sg31936
I21
sg31937
VC0019625
p38022
sg31939
I2
sa(dp38023
g31934
I45
sg31935
g37996
sg31936
I35
sg31937
VC0011854
p38024
sg31939
I3
sasg31940
(lp38025
(dp38026
g31934
I45
sg31935
g37995
sg31936
I7
sg31944
VP01308
p38027
sg31939
I1
sa(dp38028
g31934
I166
sg31935
Vnucleoside transporter hENT3
p38029
sg31936
I28
sg31944
g190
sg31939
I3
sasa(dp38030
g31925
VThe patients share many of the characteristics previously reported with H syndrome, including hyperpigmentation, hypertrichosis, short stature, insulin-dependent diabetes, arthritis and systemic inflammation, as well as some novel features, including selective IgG subclass deficiency and autoimmune hepatitis.
p38031
sg4
(dp38032
(Vinsulin
p38033
Vhypertrichosis
p38034
tp38035
I00
ssg31931
(lp38036
(dp38037
g31934
I172
sg31935
Varthritis
p38038
sg31936
I9
sg31937
VC0003864
p38039
sg31939
I1
sa(dp38040
g31934
I251
sg31935
Vselective IgG subclass deficiency
p38041
sg31936
I33
sg31937
VC0162539
p38042
sg31939
I4
sa(dp38043
g31934
I129
sg31935
Vshort stature
p38044
sg31936
I13
sg31937
VC0013336
p38045
sg31939
I2
sa(dp38046
g31934
I195
sg31935
Vinflammation
p38047
sg31936
I12
sg31937
VC0021368
p38048
sg31939
I1
sa(dp38049
g31934
I94
sg31935
Vhyperpigmentation
p38050
sg31936
I17
sg31937
VC0162834
p38051
sg31939
I1
sa(dp38052
g31934
I72
sg31935
VH syndrome
p38053
sg31936
I10
sg31937
VC1864445
p38054
sg31939
I2
sa(dp38055
g31934
I289
sg31935
Vautoimmune hepatitis
p38056
sg31936
I20
sg31937
VC0241910
p38057
sg31939
I2
sa(dp38058
g31934
I144
sg31935
Vinsulin-dependent diabetes
p38059
sg31936
I26
sg31937
VC0011854
p38060
sg31939
I2
sa(dp38061
g31934
I113
sg31935
g38034
sg31936
I14
sg31937
VC0020555
p38062
sg31939
I1
sasg31940
(lp38063
(dp38064
g31934
I144
sg31935
g38033
sg31936
I7
sg31944
VP01308
p38065
sg31939
I1
sasa(dp38066
g31925
VLoss of function recessive mutations in the SLC29A3 gene that encodes human equilibrative nucleoside transporter 3 (ENT3) have been identified in patients with pigmented hypertrichotic dermatosis with insulin-dependent diabetes (PHID).
p38067
sg4
(dp38068
(Vinsulin
p38069
VPHID
p38070
tp38071
I00
ssg31931
(lp38072
(dp38073
g31934
I160
sg31935
Vpigmented hypertrichotic dermatosis with insulin-dependent diabetes
p38074
sg31936
I67
sg31937
VC1864445
p38075
sg31939
I6
sa(dp38076
g31934
I229
sg31935
g38070
sg31936
I4
sg31937
VC1864445
p38077
sg31939
I1
sasg31940
(lp38078
(dp38079
g31934
I70
sg31935
Vhuman equilibrative nucleoside transporter 3
p38080
sg31936
I44
sg31944
g190
sg31939
I5
sa(dp38081
g31934
I201
sg31935
g38069
sg31936
I7
sg31944
VP01308
p38082
sg31939
I1
sasa(dp38083
g31925
VThus, apoptotic loss of islet Beta-cells may contribute to the occurrence of autoantibody-negative insulin-dependent diabetes in individuals with non-functional ENT3 mutations.
p38084
sg4
(dp38085
(Vinsulin
p38086
Vinsulin-dependent diabetes
p38087
tp38088
I00
ssg31931
(lp38089
(dp38090
g31934
I99
sg31935
g38087
sg31936
I26
sg31937
VC0011854
p38091
sg31939
I2
sasg31940
(lp38092
(dp38093
g31934
I99
sg31935
g38086
sg31936
I7
sg31944
VP01308
p38094
sg31939
I1
sasa(dp38095
g31925
VH syndrome and pigmented hypertrichosis with insulin-dependent diabetes mellitus (PHID) had been described as two autosomal recessive disorders.
p38096
sg4
(dp38097
(Vinsulin
p38098
Vpigmented hypertrichosis with insulin-dependent diabetes mellitus
p38099
tp38100
I00
ssg31931
(lp38101
(dp38102
g31934
I82
sg31935
VPHID
p38103
sg31936
I4
sg31937
VC1864445
p38104
sg31939
I1
sa(dp38105
g31934
I0
sg31935
VH syndrome
p38106
sg31936
I10
sg31937
VC1864445
p38107
sg31939
I2
sa(dp38108
g31934
I15
sg31935
g38099
sg31936
I65
sg31937
VC1864445
p38109
sg31939
I6
sasg31940
(lp38110
(dp38111
g31934
I45
sg31935
g38098
sg31936
I7
sg31944
VP01308
p38112
sg31939
I1
sasa(dp38113
g31925
VMutations in SLC29A3 lead to pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) and H syndromes, familial Rosai-Dorfman disease, and histiocytosis-lymphadenopathy plus syndrome.
p38114
sg4
(dp38115
(Vinsulin
p38116
VRosai-Dorfman disease
p38117
tp38118
I00
ssg31931
(lp38119
(dp38120
g31934
I63
sg31935
Vautoimmune
p38121
sg31936
I10
sg31937
VC0443146
p38122
sg31939
I1
sa(dp38123
g31934
I74
sg31935
Vinsulin-dependent diabetes mellitus
p38124
sg31936
I35
sg31937
VC0011854
p38125
sg31939
I3
sa(dp38126
g31934
I170
sg31935
Vhistiocytosis-lymphadenopathy plus syndrome
p38127
sg31936
I43
sg31937
VC1864445
p38128
sg31939
I3
sa(dp38129
g31934
I123
sg31935
Vsyndromes
p38130
sg31936
I9
sg31937
VC0039082
p38131
sg31939
I1
sa(dp38132
g31934
I111
sg31935
VPHID
p38133
sg31936
I4
sg31937
VC1864445
p38134
sg31939
I1
sa(dp38135
g31934
I40
sg31935
Vhypertrichosis
p38136
sg31936
I14
sg31937
VC0020555
p38137
sg31939
I1
sa(dp38138
g31934
I143
sg31935
g38117
sg31936
I21
sg31937
VC0019625
p38139
sg31939
I2
sasg31940
(lp38140
(dp38141
g31934
I74
sg31935
g38116
sg31936
I7
sg31944
VP01308
p38142
sg31939
I1
sasa(dp38143
g31925
VThis report describes an insulin-dependent diabetes patient with a syndromic presentation in whom a homozygous SLC29A3 mutation was identified.
p38144
sg4
(dp38145
(Vinsulin
p38146
Vinsulin-dependent diabetes
p38147
tp38148
I00
ssg31931
(lp38149
(dp38150
g31934
I25
sg31935
g38147
sg31936
I26
sg31937
VC0011854
p38151
sg31939
I2
sasg31940
(lp38152
(dp38153
g31934
I25
sg31935
g38146
sg31936
I7
sg31944
VP01308
p38154
sg31939
I1
sasa(dp38155
g31925
VThese clinical features overlapped with pigmented hypertrichosis with insulin-dependent diabetes (PHID), H syndrome, Faisalabad histiocytosis and sinus histiocytosis with massive lymphadenopathy (SHML), all of which are also caused by SLC29A3 mutations.
p38156
sg4
(dp38157
(Vinsulin
p38158
VPHID
p38159
tp38160
I00
ssg31931
(lp38161
(dp38162
g31934
I146
sg31935
Vsinus histiocytosis with massive lymphadenopathy
p38163
sg31936
I48
sg31937
VC0019625
p38164
sg31939
I5
sa(dp38165
g31934
I105
sg31935
VH syndrome
p38166
sg31936
I10
sg31937
VC1864445
p38167
sg31939
I2
sa(dp38168
g31934
I40
sg31935
Vpigmented hypertrichosis with insulin-dependent diabetes
p38169
sg31936
I56
sg31937
VC1864445
p38170
sg31939
I5
sa(dp38171
g31934
I117
sg31935
VFaisalabad histiocytosis
p38172
sg31936
I24
sg31937
VC1864445
p38173
sg31939
I2
sa(dp38174
g31934
I196
sg31935
VSHML
p38175
sg31936
I4
sg31937
VC1864445
p38176
sg31939
I1
sa(dp38177
g31934
I98
sg31935
g38159
sg31936
I4
sg31937
VC1864445
p38178
sg31939
I1
sasg31940
(lp38179
(dp38180
g31934
I70
sg31935
g38158
sg31936
I7
sg31944
VP01308
p38181
sg31939
I1
sasa(dp38182
g31925
VGermline mutations in the SLC29A3 gene result in a range of recessive, clinically related syndromes: H syndrome, pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome, Faisalabad histiocytosis, and sinus histiocytosis with massive lymphadenopathy.
p38183
sg4
(dp38184
(Vinsulin
p38185
Vpigmented hypertrichosis with insulin-dependent diabetes mellitus
p38186
tp38187
I00
ssg31931
(lp38188
(dp38189
g31934
I101
sg31935
VH syndrome
p38190
sg31936
I10
sg31937
VC1864445
p38191
sg31939
I2
sa(dp38192
g31934
I219
sg31935
Vsinus histiocytosis with massive lymphadenopathy
p38193
sg31936
I48
sg31937
VC0019625
p38194
sg31939
I5
sa(dp38195
g31934
I189
sg31935
VFaisalabad histiocytosis
p38196
sg31936
I24
sg31937
VC1864445
p38197
sg31939
I2
sa(dp38198
g31934
I90
sg31935
Vsyndrome
p38199
sg31936
I8
sg31937
VC0039082
p38200
sg31939
I1
sa(dp38201
g31934
I113
sg31935
g38186
sg31936
I65
sg31937
VC1864445
p38202
sg31939
I6
sa(dp38203
g31934
I90
sg31935
Vsyndromes
p38204
sg31936
I9
sg31937
VC0039082
p38205
sg31939
I1
sasg31940
(lp38206
(dp38207
g31934
I143
sg31935
g38185
sg31936
I7
sg31944
VP01308
p38208
sg31939
I1
sasa(dp38209
g31925
VSome of the species are used in folk medicine, such as a group known as "pedra-hume-caa" or "pedra-ume-caa" or "insulina vegetal" (insulin plant) that it is used for the treatment of diabetes.
p38210
sg4
(dp38211
(Vinsulin
p38212
Vdiabetes
p38213
tp38214
I00
ssg31931
(lp38215
(dp38216
g31934
I84
sg31935
Vcaa
p38217
sg31936
I3
sg31937
VC1842937
p38218
sg31939
I1
sa(dp38219
g31934
I84
sg31935
Vcaa
p38220
sg31936
I3
sg31937
VC1842937
p38221
sg31939
I1
sa(dp38222
g31934
I183
sg31935
g38213
sg31936
I8
sg31937
VC0011849
p38223
sg31939
I1
sasg31940
(lp38224
(dp38225
g31934
I112
sg31935
g38212
sg31936
I7
sg31944
VP01308
p38226
sg31939
I1
sasa(dp38227
g31925
VSome of the species are used in folk medicine, such as a group known as "pedra-hume-caa" or "pedra-ume-caa" or "insulina vegetal" (insulin plant) that it is used for the treatment of diabetes.
p38228
sg4
(dp38229
(Vinsulin
p38230
Vdiabetes
p38231
tp38232
I00
ssg31931
(lp38233
(dp38234
g31934
I84
sg31935
Vcaa
p38235
sg31936
I3
sg31937
VC1842937
p38236
sg31939
I1
sa(dp38237
g31934
I84
sg31935
Vcaa
p38238
sg31936
I3
sg31937
VC1842937
p38239
sg31939
I1
sa(dp38240
g31934
I183
sg31935
g38231
sg31936
I8
sg31937
VC0011849
p38241
sg31939
I1
sasg31940
(lp38242
(dp38243
g31934
I112
sg31935
g38230
sg31936
I7
sg31944
VP01308
p38244
sg31939
I1
sasa(dp38245
g31925
VSome of the species are used in folk medicine, such as a group known as "pedra-hume-caa" or "pedra-ume-caa" or "insulina vegetal" (insulin plant) that it is used for the treatment of diabetes.
p38246
sg4
(dp38247
(Vinsulin
p38248
Vdiabetes
p38249
tp38250
I00
ssg31931
(lp38251
(dp38252
g31934
I84
sg31935
Vcaa
p38253
sg31936
I3
sg31937
VC1842937
p38254
sg31939
I1
sa(dp38255
g31934
I84
sg31935
Vcaa
p38256
sg31936
I3
sg31937
VC1842937
p38257
sg31939
I1
sa(dp38258
g31934
I183
sg31935
g38249
sg31936
I8
sg31937
VC0011849
p38259
sg31939
I1
sasg31940
(lp38260
(dp38261
g31934
I112
sg31935
g38248
sg31936
I7
sg31944
VP01308
p38262
sg31939
I1
sasa(dp38263
g31925
VAdult Tshz1(+/-) mice display glucose intolerance due to defects in glucose-stimulated insulin secretion associated with reduced Pdx1 and Clec16a expression in Tshz1(+/-) islets.
p38264
sg4
(dp38265
(Vinsulin
p38266
Vglucose intolerance
p38267
tp38268
I00
ssg31931
(lp38269
(dp38270
g31934
I30
sg31935
g38267
sg31936
I19
sg31937
VC0271650
p38271
sg31939
I2
sasg31940
(lp38272
(dp38273
g31934
I138
sg31935
VClec16a
p38274
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp38275
g31934
I129
sg31935
VPdx1
p38276
sg31936
I4
sg31944
VP52945
p38277
sg31939
I1
sa(dp38278
g31934
I6
sg31935
VTshz1
p38279
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38280
g31934
I87
sg31935
g38266
sg31936
I7
sg31944
VP01308
p38281
sg31939
I1
sasa(dp38282
g31925
VIn cultured rat hepatoma (H4IIE) cells, TNF-Alfa significantly increased hemopexin mRNA accumulation.
p38283
sg4
(dp38284
(VTNF-Alfa
p38285
Vhepatoma
p38286
tp38287
I00
ssg31931
(lp38288
(dp38289
g31934
I16
sg31935
g38286
sg31936
I8
sg31937
VC0023903
p38290
sg31939
I1
sasg31940
(lp38291
(dp38292
g31934
I73
sg31935
Vhemopexin mRNA
p38293
sg31936
I14
sg31944
VP02790
p38294
sg31939
I2
sa(dp38295
g31934
I40
sg31935
g38285
sg31936
I8
sg31944
VP01375
p38296
sg31939
I1
sasa(dp38297
g31925
VThis analytical method was applied to an in vitro diagnostic multivariate index assay where a panel of hepatocellular carcinoma (HCC) biomarkers comprising alpha-fetoprotein, hemopexin, and alpha-2-macroglobulin (A2M) was examined in terms of the serum level and their fuco-fractions.
p38298
sg4
(dp38299
(VA2M
p38300
Vhepatocellular carcinoma
p38301
tp38302
I00
ssg31931
(lp38303
(dp38304
g31934
I129
sg31935
VHCC
p38305
sg31936
I3
sg31937
VC2239176
p38306
sg31939
I1
sa(dp38307
g31934
I103
sg31935
g38301
sg31936
I24
sg31937
VC2239176
p38308
sg31939
I2
sasg31940
(lp38309
(dp38310
g31934
I175
sg31935
Vhemopexin
p38311
sg31936
I9
sg31944
VP02790
p38312
sg31939
I1
sa(dp38313
g31934
I156
sg31935
Valpha-fetoprotein
p38314
sg31936
I17
sg31944
VP02771
p38315
sg31939
I1
sa(dp38316
g31934
I190
sg31935
Valpha-2-macroglobulin
p38317
sg31936
I21
sg31944
VP01023
p38318
sg31939
I1
sa(dp38319
g31934
I213
sg31935
g38300
sg31936
I3
sg31944
VP01023
p38320
sg31939
I1
sasa(dp38321
g31925
VWe also analyze the ezrin-meditated regulation of critical pathways associated with asthma, such as the RhoA, Rho-associated protein kinase (ROCK), and protein kinase A (cAMP/PKA) pathways.
p38322
sg4
(dp38323
(VRhoA
p38324
Vasthma
p38325
tp38326
I01
ssg31931
(lp38327
(dp38328
g31934
I84
sg31935
g38325
sg31936
I6
sg31937
VC0004096
p38329
sg31939
I1
sasg31940
(lp38330
(dp38331
g31934
I141
sg31935
VROCK
p38332
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp38333
g31934
I170
sg31935
VcAMP/PKA
p38334
sg31936
I8
sg31944
VP49913
p38335
sg31939
I1
sa(dp38336
g31934
I110
sg31935
VRho-associated protein kinase
p38337
sg31936
I29
sg31944
VP08100
p38338
sg31939
I3
sa(dp38339
g31934
I152
sg31935
Vprotein kinase A
p38340
sg31936
I16
sg31944
VP17612
p38341
sg31939
I3
sa(dp38342
g31934
I104
sg31935
g38324
sg31936
I4
sg31944
VP61586
p38343
sg31939
I1
sasa(dp38344
g31925
VWe identify and replicate an association between the constituents of the apical plasma membrane and CF lung disease (p = 0.0099 and p = 0.0180, respectively) and highlight a role for the SLC9A3-SLC9A3R1/2-EZR complex in contributing to CF lung disease.
p38345
sg4
(dp38346
(VSLC9A3-SLC9A3R1/2-EZR complex
p38347
Vlung disease
p38348
tp38349
I00
ssg31931
(lp38350
(dp38351
g31934
I103
sg31935
Vlung disease
p38352
sg31936
I12
sg31937
VC0024115
p38353
sg31939
I2
sa(dp38354
g31934
I103
sg31935
g38348
sg31936
I12
sg31937
VC0024115
p38355
sg31939
I2
sasg31940
(lp38356
(dp38357
g31934
I187
sg31935
g38347
sg31936
I29
sg31944
VP48764
p38358
sg31939
I2
sasa(dp38359
g31925
VThe BrGR-expressing yeast strain induced the activation of metabolic enzymes (Hxt, G6PDH, GAPDH and Ald), antioxidant systems (Gpx, Trx2, Trx3, Trr1, Tsa1 and porin) and molecular chaperones (Hsp104, Hsp90, Hsp70, Hsp42, Hsp26, Grp, Sti1 and Zpr1), which led to lower oxidative protein damage after a reduction in the level of cellular ROS in the BrGR-expressing yeast strain exposed to H(2)O(2) than in the wild-type yeast strain.
p38360
sg4
(dp38361
(VSti1
p38362
VAld
p38363
tp38364
I00
ssg31931
(lp38365
(dp38366
g31934
I100
sg31935
g38363
sg31936
I3
sg31937
VC0162309
p38367
sg31939
I1
sasg31940
(lp38368
(dp38369
g31934
I100
sg31935
VAld
p38370
sg31936
I3
sg31944
VP33897
p38371
sg31939
I1
sa(dp38372
g31934
I127
sg31935
VGpx
p38373
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp38374
g31934
I228
sg31935
VGrp
p38375
sg31936
I3
sg31944
VP07492
p38376
sg31939
I1
sa(dp38377
g31934
I90
sg31935
VGAPDH
p38378
sg31936
I5
sg31944
VP04406
p38379
sg31939
I1
sa(dp38380
g31934
I159
sg31935
Vporin
p38381
sg31936
I5
sg31944
VP21796
p38382
sg31939
I1
sa(dp38383
g31934
I132
sg31935
VTrx2
p38384
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp38385
g31934
I150
sg31935
VTsa1
p38386
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp38387
g31934
I207
sg31935
VHsp70
p38388
sg31936
I5
sg31944
VP34932
p38389
sg31939
I1
sa(dp38390
g31934
I242
sg31935
VZpr1
p38391
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp38392
g31934
I83
sg31935
VG6PDH
p38393
sg31936
I5
sg31944
VP11413
p38394
sg31939
I1
sa(dp38395
g31934
I200
sg31935
VHsp90
p38396
sg31936
I5
sg31944
VP07900
p38397
sg31939
I1
sa(dp38398
g31934
I78
sg31935
VHxt
p38399
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp38400
g31934
I233
sg31935
g38362
sg31936
I4
sg31944
VP31948
p38401
sg31939
I1
sasa(dp38402
g31925
VBesides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).
p38403
sg4
(dp38404
(VCOX6A1
p38405
VCMT2K
p38406
tp38407
I00
ssg31931
(lp38408
(dp38409
g31934
I208
sg31935
VCMT2P
p38410
sg31936
I5
sg31937
VC3280797
p38411
sg31939
I1
sa(dp38412
g31934
I146
sg31935
VCMT2B2
p38413
sg31936
I6
sg31937
VC1854150
p38414
sg31939
I1
sa(dp38415
g31934
I294
sg31935
VGAN
p38416
sg31936
I3
sg31937
VC1850386
p38417
sg31939
I1
sa(dp38418
g31934
I449
sg31935
VSPG15
p38419
sg31936
I5
sg31937
VC1849128
p38420
sg31939
I1
sa(dp38421
g31934
I439
sg31935
VSPG7
p38422
sg31936
I4
sg31937
VC1846564
p38423
sg31939
I1
sa(dp38424
g31934
I133
sg31935
VCMT2B1
p38425
sg31936
I6
sg31937
VC1854154
p38426
sg31939
I1
sa(dp38427
g31934
I294
sg31935
VGAN
p38428
sg31936
I3
sg31937
VC1850386
p38429
sg31939
I1
sa(dp38430
g31934
I83
sg31935
VCharcot-Marie-Tooth disease
p38431
sg31936
I27
sg31937
VC0007959
p38432
sg31939
I2
sa(dp38433
g31934
I112
sg31935
VCMT2A2
p38434
sg31936
I6
sg31937
VC1836485
p38435
sg31939
I1
sa(dp38436
g31934
I119
sg31935
VHMSN2A2
p38437
sg31936
I7
sg31937
VC1836485
p38438
sg31939
I1
sa(dp38439
g31934
I409
sg31935
Vaxonal peripheral neuropathy
p38440
sg31936
I28
sg31937
VC1263857
p38441
sg31939
I3
sa(dp38442
g31934
I181
sg31935
VdHMN2B
p38443
sg31936
I6
sg31937
VC2608087
p38444
sg31939
I1
sa(dp38445
g31934
I610
sg31935
Vagenesis of the corpus callosum
p38446
sg31936
I31
sg31937
VC0175754
p38447
sg31939
I5
sa(dp38448
g31934
I464
sg31935
VSPG21
p38449
sg31936
I5
sg31937
VC1855346
p38450
sg31939
I1
sa(dp38451
g31934
I329
sg31935
Vautosomal recessive hereditary spastic paraplegia
p38452
sg31936
I49
sg31937
VC0751603
p38453
sg31939
I5
sa(dp38454
g31934
I416
sg31935
Vperipheral neuropathy
p38455
sg31936
I21
sg31937
VC0031117
p38456
sg31939
I2
sa(dp38457
g31934
I195
sg31935
g38406
sg31936
I5
sg31937
VC1842983
p38458
sg31939
I1
sasg31940
(lp38459
(dp38460
g31934
I133
sg31935
VCMT2B1
p38461
sg31936
I6
sg31944
VP02545
p38462
sg31939
I1
sa(dp38463
g31934
I112
sg31935
VCMT2A2
p38464
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp38465
g31934
I140
sg31935
VLMNA
p38466
sg31936
I4
sg31944
VP02545
p38467
sg31939
I1
sa(dp38468
g31934
I127
sg31935
VMFN2
p38469
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp38470
g31934
I214
sg31935
VLRSAM1
p38471
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp38472
g31934
I195
sg31935
VCMT2K
p38473
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38474
g31934
I235
sg31935
VCMT2S
p38475
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38476
g31934
I294
sg31935
VGAN
p38477
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp38478
g31934
I449
sg31935
VSPG15
p38479
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38480
g31934
I439
sg31935
VSPG7
p38481
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp38482
g31934
I294
sg31935
VGAN
p38483
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp38484
g31934
I483
sg31935
VFA2H
p38485
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp38486
g31934
I455
sg31935
VZFYVE26
p38487
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp38488
g31934
I241
sg31935
VIGHMBP2
p38489
sg31936
I7
sg31944
VP38935
p38490
sg31939
I1
sa(dp38491
g31934
I256
sg31935
VHSJ1
p38492
sg31936
I4
sg31944
VP25686
p38493
sg31939
I1
sa(dp38494
g31934
I444
sg31935
VPGN
p38495
sg31936
I3
sg31944
VP00747
p38496
sg31939
I1
sa(dp38497
g31934
I228
sg31935
VTRIM2
p38498
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38499
g31934
I153
sg31935
VMED25
p38500
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38501
g31934
I495
sg31935
VGBA2
p38502
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp38503
g31934
I167
sg31935
VNEFL
p38504
sg31936
I4
sg31944
VP07196
p38505
sg31939
I1
sa(dp38506
g31934
I285
sg31935
VHINT
p38507
sg31936
I4
sg31944
VP49773
p38508
sg31939
I1
sa(dp38509
g31934
I507
sg31935
VC12orf65
p38510
sg31936
I8
sg31944
g190
sg31939
I1
sa(dp38511
g31934
I470
sg31935
VACP33
p38512
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38513
g31934
I520
sg31935
VSPG56/CYP2U1
p38514
sg31936
I12
sg31944
g190
sg31939
I1
sa(dp38515
g31934
I201
sg31935
VGDAP1
p38516
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38517
g31934
I119
sg31935
VHMSN2A2
p38518
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp38519
g31934
I464
sg31935
VSPG21
p38520
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38521
g31934
I269
sg31935
g38405
sg31936
I6
sg31944
VP12074
p38522
sg31939
I1
sasa(dp38523
g31925
VPOEMS (acronym for polyneuropathy, organomegaly, endocrinopathy, M protein myeloma and skin changes), is a rare disease which occurs in the setting of plasma cell dyscrasias.
p38524
sg4
(dp38525
(VM protein
p38526
Vmyeloma
p38527
tp38528
I00
ssg31931
(lp38529
(dp38530
g31934
I107
sg31935
Vrare disease
p38531
sg31936
I12
sg31937
VC0678236
p38532
sg31939
I2
sa(dp38533
g31934
I49
sg31935
Vendocrinopathy
p38534
sg31936
I14
sg31937
VC0014130
p38535
sg31939
I1
sa(dp38536
g31934
I19
sg31935
Vpolyneuropathy
p38537
sg31936
I14
sg31937
VC0152025
p38538
sg31939
I1
sa(dp38539
g31934
I151
sg31935
Vplasma cell dyscrasias
p38540
sg31936
I22
sg31937
VC1136084
p38541
sg31939
I3
sa(dp38542
g31934
I75
sg31935
g38527
sg31936
I7
sg31937
VC0026764
p38543
sg31939
I1
sasg31940
(lp38544
(dp38545
g31934
I65
sg31935
g38526
sg31936
I9
sg31944
VP54296
p38546
sg31939
I2
sasa(dp38547
g31925
VPrevious case reports and studies have shown that anti-myelin-associated glycoprotein (MAG) antibody can be detected in patients with polyneuropathy without any detectable M-protein.
p38548
sg4
(dp38549
(Vanti-myelin-associated glycoprotein (MAG) antibody
p38550
Vpolyneuropathy
p38551
tp38552
I00
ssg31931
(lp38553
(dp38554
g31934
I134
sg31935
g38551
sg31936
I14
sg31937
VC0152025
p38555
sg31939
I1
sasg31940
(lp38556
(dp38557
g31934
I50
sg31935
g38550
sg31936
I50
sg31944
VP20916
p38558
sg31939
I4
sasa(dp38559
g31925
VThe re-initiation of leukemia was also significantly inhibited in absence of Inca1-/- in MLL-AF9- and c-myc/BCL2-positive leukemia mouse models.
p38560
sg4
(dp38561
(VBCL2
p38562
Vleukemia
p38563
tp38564
I00
ssg31931
(lp38565
(dp38566
g31934
I21
sg31935
Vleukemia
p38567
sg31936
I8
sg31937
VC0023418
p38568
sg31939
I1
sa(dp38569
g31934
I21
sg31935
g38563
sg31936
I8
sg31937
VC0023418
p38570
sg31939
I1
sasg31940
(lp38571
(dp38572
g31934
I102
sg31935
Vc-myc
p38573
sg31936
I5
sg31944
VP12524
p38574
sg31939
I1
sa(dp38575
g31934
I93
sg31935
VAF9
p38576
sg31936
I3
sg31944
VP42568
p38577
sg31939
I1
sa(dp38578
g31934
I108
sg31935
g38562
sg31936
I4
sg31944
VP10415
p38579
sg31939
I1
sa(dp38580
g31934
I77
sg31935
VInca1-/- in MLL
p38581
sg31936
I15
sg31944
g190
sg31939
I3
sasa(dp38582
g31925
VThis preliminary study indicated the tumor suppressing roles of miR-372 in cell cycle progression of TW01 cells, possibly via the down-regulation of CDK2 and CCNA1 as well as the up-regulation of CDKN1A and INCA1.Key Words: apoptosis, microRNA, nasopharyngeal carcinoma, miR-372, CDK2, CCNA1.
p38583
sg4
(dp38584
(VCCNA1
p38585
Vnasopharyngeal carcinoma
p38586
tp38587
I01
ssg31931
(lp38588
(dp38589
g31934
I245
sg31935
g38586
sg31936
I24
sg31937
VC2931822
p38590
sg31939
I2
sa(dp38591
g31934
I37
sg31935
Vtumor
p38592
sg31936
I5
sg31937
VC0027651
p38593
sg31939
I1
sasg31940
(lp38594
(dp38595
g31934
I158
sg31935
VCCNA1
p38596
sg31936
I5
sg31944
VP78396
p38597
sg31939
I1
sa(dp38598
g31934
I196
sg31935
VCDKN1A
p38599
sg31936
I6
sg31944
VP38936
p38600
sg31939
I1
sa(dp38601
g31934
I149
sg31935
VCDK2
p38602
sg31936
I4
sg31944
VP24941
p38603
sg31939
I1
sa(dp38604
g31934
I149
sg31935
VCDK2
p38605
sg31936
I4
sg31944
VP24941
p38606
sg31939
I1
sa(dp38607
g31934
I158
sg31935
g38585
sg31936
I5
sg31944
VP78396
p38608
sg31939
I1
sa(dp38609
g31934
I207
sg31935
VINCA1
p38610
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp38611
g31925
VBoth estradiol and global ischemia markedly increased ERalpha, but not ERbeta, protein in CA1.
p38612
sg4
(dp38613
(VERalpha
p38614
Vischemia
p38615
tp38616
I00
ssg31931
(lp38617
(dp38618
g31934
I26
sg31935
g38615
sg31936
I8
sg31937
VC0022116
p38619
sg31939
I1
sasg31940
(lp38620
(dp38621
g31934
I54
sg31935
g38614
sg31936
I7
sg31944
VP03372
p38622
sg31939
I1
sasa(dp38623
g31925
VBMPR2, phospho-SMAD1/5 (pSMAD1/5), and runt-related transcription factor 2 (RUNX2) expressions were found to be associated with the pathological grades of chondrosarcoma and could be a promising target of treatment outcome.
p38624
sg4
(dp38625
(VpSMAD1/5
p38626
Vchondrosarcoma
p38627
tp38628
I00
ssg31931
(lp38629
(dp38630
g31934
I39
sg31935
Vrunt
p38631
sg31936
I4
sg31937
VC0013336
p38632
sg31939
I1
sa(dp38633
g31934
I155
sg31935
g38627
sg31936
I14
sg31937
VC0008479
p38634
sg31939
I1
sasg31940
(lp38635
(dp38636
g31934
I76
sg31935
VRUNX2
p38637
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38638
g31934
I0
sg31935
VBMPR2
p38639
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38640
g31934
I7
sg31935
Vphospho-SMAD1/5
p38641
sg31936
I15
sg31944
VP41250
p38642
sg31939
I1
sa(dp38643
g31934
I24
sg31935
g38626
sg31936
I8
sg31944
VP41250
p38644
sg31939
I1
sasa(dp38645
g31925
VSilencing BMPR2 promoted G2/M cell cycle arrest, induced chondrosarcoma cell apoptosis through caspase-3-dependent pathway via repression of X-linked inhibitor of apoptosis protein (XIAP) and induced autophagy of chondrosarcoma cells via XIAP-Mdm2-p53 pathway.
p38646
sg4
(dp38647
(VX-linked inhibitor of apoptosis protein
p38648
Vchondrosarcoma
p38649
tp38650
I00
ssg31931
(lp38651
(dp38652
g31934
I57
sg31935
Vchondrosarcoma
p38653
sg31936
I14
sg31937
VC0008479
p38654
sg31939
I1
sa(dp38655
g31934
I57
sg31935
g38649
sg31936
I14
sg31937
VC0008479
p38656
sg31939
I1
sasg31940
(lp38657
(dp38658
g31934
I248
sg31935
Vp53
p38659
sg31936
I3
sg31944
VP42771
p38660
sg31939
I1
sa(dp38661
g31934
I95
sg31935
Vcaspase-3
p38662
sg31936
I9
sg31944
VP42574
p38663
sg31939
I1
sa(dp38664
g31934
I182
sg31935
VXIAP
p38665
sg31936
I4
sg31944
VP98170
p38666
sg31939
I1
sa(dp38667
g31934
I10
sg31935
VBMPR2
p38668
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38669
g31934
I182
sg31935
VXIAP
p38670
sg31936
I4
sg31944
VP98170
p38671
sg31939
I1
sa(dp38672
g31934
I141
sg31935
g38648
sg31936
I39
sg31944
VP98170
p38673
sg31939
I5
sasa(dp38674
g31925
VThe role of Beta-defensin-1 in asthma and chronic obstructive pulmonary disease (COPD) remains unclear.
p38675
sg4
(dp38676
(VBeta-defensin-1
p38677
Vasthma
p38678
tp38679
I00
ssg31931
(lp38680
(dp38681
g31934
I81
sg31935
VCOPD
p38682
sg31936
I4
sg31937
VC0024117
p38683
sg31939
I1
sa(dp38684
g31934
I42
sg31935
Vchronic obstructive pulmonary disease
p38685
sg31936
I37
sg31937
VC0024117
p38686
sg31939
I4
sa(dp38687
g31934
I31
sg31935
g38678
sg31936
I6
sg31937
VC0004096
p38688
sg31939
I1
sasg31940
(lp38689
(dp38690
g31934
I12
sg31935
g38677
sg31936
I15
sg31944
VP60022
p38691
sg31939
I1
sasa(dp38692
g31925
VIn Japanese and Chinese populations, two different beta-defensin-1 polymorphisms have been associated with chronic obstructive pulmonary disease phenotypes.
p38693
sg4
(dp38694
(Vbeta-defensin-1
p38695
Vchronic obstructive pulmonary disease
p38696
tp38697
I00
ssg31931
(lp38698
(dp38699
g31934
I107
sg31935
g38696
sg31936
I37
sg31937
VC0024117
p38700
sg31939
I4
sasg31940
(lp38701
(dp38702
g31934
I51
sg31935
g38695
sg31936
I15
sg31944
VP60022
p38703
sg31939
I1
sasa(dp38704
g31925
VThe autosomal recessive ataxias are separated into Friedreich ataxia, ataxia due to vitamin E deficiency, ataxia due to Abeta-lipoproteinemia, Refsum disease, late-onset Tay-Sachs disease, cerebrotendineous xanthomatosis, spinocerebellar ataxia with axonal neuropathy, ataxia telangiectasia, ataxia telangiectasia-like disorder, ataxia with oculomotor apraxia 1 and 2, spastic ataxia of Charlevoix-Saguenay, Cayman ataxia, Marinesco-Sjoegren syndrome, and autosomal recessive mitochondrial ataxias (AR-CPEO, SANDO, SCAE, AHS, IOSCA, MEMSA, LBSL CoQ-deficiency, PDC-deficiency).
p38705
sg4
(dp38706
(VSCAE
p38707
VPDC
p38708
tp38709
I00
ssg31931
(lp38710
(dp38711
g31934
I269
sg31935
Vataxia telangiectasia
p38712
sg31936
I21
sg31937
VC0004135
p38713
sg31939
I2
sa(dp38714
g31934
I508
sg31935
VSANDO
p38715
sg31936
I5
sg31937
VC1843851
p38716
sg31939
I1
sa(dp38717
g31934
I369
sg31935
Vspastic ataxia of Charlevoix-Saguenay
p38718
sg31936
I37
sg31937
VC1849140
p38719
sg31939
I4
sa(dp38720
g31934
I24
sg31935
Vataxias
p38721
sg31936
I7
sg31937
VC0004134
p38722
sg31939
I1
sa(dp38723
g31934
I515
sg31935
VSCAE
p38724
sg31936
I4
sg31937
VC1843852
p38725
sg31939
I1
sa(dp38726
g31934
I51
sg31935
VFriedreich ataxia
p38727
sg31936
I17
sg31937
VC0016719
p38728
sg31939
I2
sa(dp38729
g31934
I222
sg31935
Vspinocerebellar ataxia
p38730
sg31936
I22
sg31937
VC0087012
p38731
sg31939
I2
sa(dp38732
g31934
I207
sg31935
Vxanthomatosis
p38733
sg31936
I13
sg31937
VC0043325
p38734
sg31939
I1
sa(dp38735
g31934
I143
sg31935
VRefsum disease
p38736
sg31936
I14
sg31937
VC0034960
p38737
sg31939
I2
sa(dp38738
g31934
I526
sg31935
VIOSCA
p38739
sg31936
I5
sg31937
VC1849096
p38740
sg31939
I1
sa(dp38741
g31934
I250
sg31935
Vaxonal neuropathy
p38742
sg31936
I17
sg31937
VC0270921
p38743
sg31939
I2
sa(dp38744
g31934
I24
sg31935
Vataxia
p38745
sg31936
I6
sg31937
VC0004134
p38746
sg31939
I1
sa(dp38747
g31934
I341
sg31935
Voculomotor apraxia
p38748
sg31936
I18
sg31937
VC0271270
p38749
sg31939
I2
sa(dp38750
g31934
I84
sg31935
Vvitamin E deficiency
p38751
sg31936
I20
sg31937
VC0042875
p38752
sg31939
I3
sa(dp38753
g31934
I502
sg31935
VCPEO
p38754
sg31936
I4
sg31937
VC0162674
p38755
sg31939
I1
sa(dp38756
g31934
I170
sg31935
VTay-Sachs disease
p38757
sg31936
I17
sg31937
VC0039373
p38758
sg31939
I2
sa(dp38759
g31934
I442
sg31935
Vsyndrome
p38760
sg31936
I8
sg31937
VC0039082
p38761
sg31939
I1
sa(dp38762
g31934
I24
sg31935
Vataxia
p38763
sg31936
I6
sg31937
VC0004134
p38764
sg31939
I1
sa(dp38765
g31934
I24
sg31935
Vataxia
p38766
sg31936
I6
sg31937
VC0004134
p38767
sg31939
I1
sa(dp38768
g31934
I269
sg31935
Vataxia telangiectasia
p38769
sg31936
I21
sg31937
VC0004135
p38770
sg31939
I2
sa(dp38771
g31934
I24
sg31935
Vataxia
p38772
sg31936
I6
sg31937
VC0004134
p38773
sg31939
I1
sa(dp38774
g31934
I540
sg31935
VLBSL
p38775
sg31936
I4
sg31937
VC1970180
p38776
sg31939
I1
sa(dp38777
g31934
I24
sg31935
Vataxias
p38778
sg31936
I7
sg31937
VC0004134
p38779
sg31939
I1
sa(dp38780
g31934
I561
sg31935
g38708
sg31936
I3
sg31937
VC1869117
p38781
sg31939
I1
sasg31940
(lp38782
(dp38783
g31934
I120
sg31935
VAbeta
p38784
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38785
g31934
I526
sg31935
VIOSCA
p38786
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38787
g31934
I508
sg31935
VSANDO
p38788
sg31936
I5
sg31944
VP54098
p38789
sg31939
I1
sa(dp38790
g31934
I561
sg31935
VPDC
p38791
sg31936
I3
sg31944
VP20941
p38792
sg31939
I1
sa(dp38793
g31934
I521
sg31935
VAHS
p38794
sg31936
I3
sg31944
VP02765
p38795
sg31939
I1
sa(dp38796
g31934
I540
sg31935
VLBSL CoQ
p38797
sg31936
I8
sg31944
g190
sg31939
I2
sa(dp38798
g31934
I515
sg31935
g38707
sg31936
I4
sg31944
VP54098
p38799
sg31939
I1
sasa(dp38800
g31925
VOnly patients presenting PEO as part of their clinical phenotype had POLG mutations, in seven of them together with myopathic signs and in one with a sensori-motor peripheral neuropathy.
p38801
sg4
(dp38802
(VPOLG
p38803
Vmotor peripheral neuropathy
p38804
tp38805
I00
ssg31931
(lp38806
(dp38807
g31934
I158
sg31935
g38804
sg31936
I27
sg31937
VC0235025
p38808
sg31939
I3
sasg31940
(lp38809
(dp38810
g31934
I69
sg31935
g38803
sg31936
I4
sg31944
VP54098
p38811
sg31939
I1
sasa(dp38812
g31925
VHistological and clinical diagnoses of the 14 patients were as follows: IgA nephropathy 3, non-IgA GN 2, and asymptomatic significant microscopic hematuria [more than 100 red blood cells per high-power field (x400)] with or without proteinuria 9.
p38813
sg4
(dp38814
(VIgA nephropathy 3
p38815
VIgA nephropathy
p38816
tp38817
I01
ssg31931
(lp38818
(dp38819
g31934
I134
sg31935
Vmicroscopic hematuria
p38820
sg31936
I21
sg31937
VC0239937
p38821
sg31939
I2
sa(dp38822
g31934
I72
sg31935
g38816
sg31936
I15
sg31937
VC0017661
p38823
sg31939
I2
sasg31940
(lp38824
(dp38825
g31934
I91
sg31935
Vnon-IgA GN 2
p38826
sg31936
I12
sg31944
g190
sg31939
I3
sa(dp38827
g31934
I72
sg31935
g38815
sg31936
I17
sg31944
VP11912
p38828
sg31939
I3
sasa(dp38829
g31925
VThe aim of this study was to investigate the immunoreactivity to tryptase and to cathepsin-G of MC from human cutaneous mastocytosis and to compare their number in normal skin and cutaneous mastocytosis.
p38830
sg4
(dp38831
(Vcathepsin-G
p38832
Vcutaneous mastocytosis
p38833
tp38834
I00
ssg31931
(lp38835
(dp38836
g31934
I110
sg31935
Vcutaneous mastocytosis
p38837
sg31936
I22
sg31937
VC1136033
p38838
sg31939
I2
sa(dp38839
g31934
I110
sg31935
g38833
sg31936
I22
sg31937
VC1136033
p38840
sg31939
I2
sasg31940
(lp38841
(dp38842
g31934
I81
sg31935
g38832
sg31936
I11
sg31944
VP25774
p38843
sg31939
I1
sasa(dp38844
g31925
VMorphometric evaluation of MC number demostrated that the number of both tryptase- and cathepsin-G-positive MC was significantly higher in cutaneous mastocytosis as compared to normal skin and that in both conditions the number of tryptase-positive MC was significantly higher as compared to the number of cathepsin-G-positive MC.
p38845
sg4
(dp38846
(Vcathepsin-G
p38847
Vcutaneous mastocytosis
p38848
tp38849
I00
ssg31931
(lp38850
(dp38851
g31934
I139
sg31935
g38848
sg31936
I22
sg31937
VC1136033
p38852
sg31939
I2
sasg31940
(lp38853
(dp38854
g31934
I87
sg31935
Vcathepsin-G
p38855
sg31936
I11
sg31944
VP25774
p38856
sg31939
I1
sa(dp38857
g31934
I87
sg31935
g38847
sg31936
I11
sg31944
VP25774
p38858
sg31939
I1
sasa(dp38859
g31925
VIn conclusion, in this study, for the first time we have demonstrated the presence of MC with immunoreactivity to cathepsin-G in human cutaneous mastocytosis, as well as the co-localization of tryptase and cathepsin-G in MC secretory granules.
p38860
sg4
(dp38861
(Vcathepsin-G
p38862
Vcutaneous mastocytosis
p38863
tp38864
I00
ssg31931
(lp38865
(dp38866
g31934
I135
sg31935
g38863
sg31936
I22
sg31937
VC1136033
p38867
sg31939
I2
sasg31940
(lp38868
(dp38869
g31934
I114
sg31935
Vcathepsin-G
p38870
sg31936
I11
sg31944
VP25774
p38871
sg31939
I1
sa(dp38872
g31934
I114
sg31935
g38862
sg31936
I11
sg31944
VP25774
p38873
sg31939
I1
sasa(dp38874
g31925
VA similar change pattern was observed in the expression of apoptosis-regulated protein caspase 3 in cervical cancer cells transfected with miR-126-5p mimic or inhibitor.
p38875
sg4
(dp38876
(Vprotein caspase 3
p38877
Vcervical cancer
p38878
tp38879
I00
ssg31931
(lp38880
(dp38881
g31934
I100
sg31935
g38878
sg31936
I15
sg31937
VC0302592
p38882
sg31939
I2
sasg31940
(lp38883
(dp38884
g31934
I139
sg31935
VmiR-126-5p
p38885
sg31936
I10
sg31944
g190
sg31939
I1
sa(dp38886
g31934
I79
sg31935
g38877
sg31936
I17
sg31944
VP42574
p38887
sg31939
I3
sasa(dp38888
g31925
VThe presence of XBP-1s, the active form of XBP-1, after administration of anti-Ig to Akata Burkitt's lymphoma cells is consistent with a role for this factor in reactivation of the EBV lytic cycle, although signalling through MEF2D was quantitatively much more significant in activation of Zp.
p38889
sg4
(dp38890
(VXBP-1
p38891
VBurkitt's lymphoma
p38892
tp38893
I00
ssg31931
(lp38894
(dp38895
g31934
I185
sg31935
Vlytic
p38896
sg31936
I5
sg31937
VC0024348
p38897
sg31939
I1
sa(dp38898
g31934
I91
sg31935
g38892
sg31936
I18
sg31937
VC0006413
p38899
sg31939
I2
sasg31940
(lp38900
(dp38901
g31934
I16
sg31935
VXBP-1s
p38902
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp38903
g31934
I226
sg31935
VMEF2D
p38904
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38905
g31934
I16
sg31935
g38891
sg31936
I5
sg31944
VP17861
p38906
sg31939
I1
sasa(dp38907
g31925
VAs expected, markers of neuronal differentiation such as anti-apoptotic protein B-cell lymphoma 2 (BCL2), myocyte enhancer factor-2D (MEF2D) and zipper protein kinase (MAP3K12; aka ZPK/MUK/DLK) were each up-regulated in response to differentiation.
p38908
sg4
(dp38909
(VBCL2
p38910
VB-cell lymphoma
p38911
tp38912
I00
ssg31931
(lp38913
(dp38914
g31934
I80
sg31935
g38911
sg31936
I15
sg31937
VC0079731
p38915
sg31939
I2
sasg31940
(lp38916
(dp38917
g31934
I189
sg31935
VDLK
p38918
sg31936
I3
sg31944
VP80370
p38919
sg31939
I1
sa(dp38920
g31934
I99
sg31935
g38910
sg31936
I4
sg31944
VP10415
p38921
sg31939
I1
sa(dp38922
g31934
I134
sg31935
VMEF2D
p38923
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp38924
g31934
I168
sg31935
VMAP3K12
p38925
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp38926
g31934
I185
sg31935
VMUK
p38927
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp38928
g31934
I145
sg31935
Vzipper protein kinase
p38929
sg31936
I21
sg31944
g190
sg31939
I3
sa(dp38930
g31934
I106
sg31935
Vmyocyte enhancer factor-2D
p38931
sg31936
I26
sg31944
g190
sg31939
I3
sa(dp38932
g31934
I177
sg31935
Vaka ZPK
p38933
sg31936
I7
sg31944
g190
sg31939
I2
sa(dp38934
g31934
I57
sg31935
Vanti-apoptotic protein B-cell lymphoma 2
p38935
sg31936
I40
sg31944
g190
sg31939
I5
sasa(dp38936
g31925
VRai like protein (RaLP) is a newly identified Src homology 2 domain containing (Shc) family member selectively expressed during the transition to metastatic melanoma and thus is a potential melanoma-specific drugable target.
p38937
sg4
(dp38938
(VRai like protein
p38939
Vmetastatic melanoma
p38940
tp38941
I00
ssg31931
(lp38942
(dp38943
g31934
I132
sg31935
Vtransition
p38944
sg31936
I10
sg31937
VC0599156
p38945
sg31939
I1
sa(dp38946
g31934
I157
sg31935
Vmelanoma
p38947
sg31936
I8
sg31937
VC0025202
p38948
sg31939
I1
sa(dp38949
g31934
I146
sg31935
g38940
sg31936
I19
sg31937
VC0278883
p38950
sg31939
I2
sasg31940
(lp38951
(dp38952
g31934
I46
sg31935
VSrc homology 2 domain containing (Shc) family member
p38953
sg31936
I52
sg31944
VP12931
p38954
sg31939
I8
sa(dp38955
g31934
I18
sg31935
VRaLP
p38956
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp38957
g31934
I0
sg31935
g38939
sg31936
I16
sg31944
VP13489
p38958
sg31939
I3
sasa(dp38959
g31925
VThe objective of this study was to evaluate the nephroprotective potential of resveratrol and piperine at same dose on cationic bovine serum albumin (cBSA) induced immune complex glomerulonephritis (ICGN) in BALB/c mice.
p38960
sg4
(dp38961
(Vbovine serum albumin
p38962
Vimmune complex glomerulonephritis
p38963
tp38964
I00
ssg31931
(lp38965
(dp38966
g31934
I199
sg31935
VICGN
p38967
sg31936
I4
sg31937
VC0744421
p38968
sg31939
I1
sa(dp38969
g31934
I164
sg31935
g38963
sg31936
I33
sg31937
VC0744421
p38970
sg31939
I3
sasg31940
(lp38971
(dp38972
g31934
I128
sg31935
g38962
sg31936
I20
sg31944
VP49639
p38973
sg31939
I3
sasa(dp38974
g31925
VThe object of the present study was to investigate the effects of VA, alone and in combination with methylprednisolone (MP), on cationic bovine serum albumin (cBSA induced immune-complex glomerulonephritis in female BALB/c mice.
p38975
sg4
(dp38976
(Vcationic bovine serum albumin
p38977
Vimmune-complex glomerulonephritis
p38978
tp38979
I00
ssg31931
(lp38980
(dp38981
g31934
I172
sg31935
g38978
sg31936
I33
sg31937
VC0744421
p38982
sg31939
I2
sasg31940
(lp38983
(dp38984
g31934
I128
sg31935
g38977
sg31936
I29
sg31944
VP49639
p38985
sg31939
I4
sasa(dp38986
g31925
VBovine serum albumin (BSA) glomerulonephritis is a type of immune complex glomerulonephritis that is characterized by a large number of leukocytes infiltrating the kidney.
p38987
sg4
(dp38988
(VBovine serum albumin
p38989
Vimmune complex glomerulonephritis
p38990
tp38991
I00
ssg31931
(lp38992
(dp38993
g31934
I27
sg31935
Vglomerulonephritis
p38994
sg31936
I18
sg31937
VC0017658
p38995
sg31939
I1
sa(dp38996
g31934
I147
sg31935
Vinfiltrating
p38997
sg31936
I12
sg31937
VC0332448
p38998
sg31939
I1
sa(dp38999
g31934
I59
sg31935
g38990
sg31936
I33
sg31937
VC0744421
p39000
sg31939
I3
sasg31940
(lp39001
(dp39002
g31934
I22
sg31935
VBSA
p39003
sg31936
I3
sg31944
VP49639
p39004
sg31939
I1
sa(dp39005
g31934
I0
sg31935
g38989
sg31936
I20
sg31944
VP49639
p39006
sg31939
I3
sasa(dp39007
g31925
VGATA binding protein 3 (GATA3) and suppressors of cytokine signalling3 mRNA were differentially regulated in HDM and influenza-stimulated cultures+/-IFN-Beta.
p39008
sg4
(dp39009
(VGATA3
p39010
Vinfluenza
p39011
tp39012
I01
ssg31931
(lp39013
(dp39014
g31934
I117
sg31935
g39011
sg31936
I9
sg31937
VC0021400
p39015
sg31939
I1
sasg31940
(lp39016
(dp39017
g31934
I149
sg31935
VIFN-Beta
p39018
sg31936
I8
sg31944
VP01574
p39019
sg31939
I1
sa(dp39020
g31934
I0
sg31935
VGATA binding protein 3
p39021
sg31936
I22
sg31944
VP23771
p39022
sg31939
I4
sa(dp39023
g31934
I24
sg31935
g39010
sg31936
I5
sg31944
VP23771
p39024
sg31939
I1
sasa(dp39025
g31925
VMany epidemiological studies have evaluated associations of platelet glycoprotein receptor alpha2beta1 integrin (ITGA2) and glycoprotein IIIa (ITGB3) gene polymorphisms with diabetic retinopathy (DR), but the published data are inconclusive.
p39026
sg4
(dp39027
(VITGA2
p39028
VDR
p39029
tp39030
I00
ssg31931
(lp39031
(dp39032
g31934
I174
sg31935
Vdiabetic retinopathy
p39033
sg31936
I20
sg31937
VC0011884
p39034
sg31939
I2
sa(dp39035
g31934
I196
sg31935
g39029
sg31936
I2
sg31937
VC0011884
p39036
sg31939
I1
sasg31940
(lp39037
(dp39038
g31934
I124
sg31935
Vglycoprotein IIIa
p39039
sg31936
I17
sg31944
VP05106
p39040
sg31939
I2
sa(dp39041
g31934
I60
sg31935
Vplatelet glycoprotein receptor alpha2beta1 integrin
p39042
sg31936
I51
sg31944
VP14770
p39043
sg31939
I5
sa(dp39044
g31934
I143
sg31935
VITGB3
p39045
sg31936
I5
sg31944
VP05106
p39046
sg31939
I1
sa(dp39047
g31934
I113
sg31935
g39028
sg31936
I5
sg31944
VP17301
p39048
sg31939
I1
sasa(dp39049
g31925
VGenetic polymorphisms of the alpha2beta1 integrin and glycoprotein IIIa (GPIIIa) have been associated with myocardial infarction, stroke, and diabetic retinopathy.
p39050
sg4
(dp39051
(VGPIIIa
p39052
Vmyocardial infarction
p39053
tp39054
I00
ssg31931
(lp39055
(dp39056
g31934
I130
sg31935
Vstroke
p39057
sg31936
I6
sg31937
VC0038454
p39058
sg31939
I1
sa(dp39059
g31934
I142
sg31935
Vdiabetic retinopathy
p39060
sg31936
I20
sg31937
VC0011884
p39061
sg31939
I2
sa(dp39062
g31934
I107
sg31935
g39053
sg31936
I21
sg31937
VC0027051
p39063
sg31939
I2
sasg31940
(lp39064
(dp39065
g31934
I29
sg31935
Valpha2beta1 integrin and glycoprotein IIIa
p39066
sg31936
I42
sg31944
VP05106
p39067
sg31939
I5
sa(dp39068
g31934
I73
sg31935
g39052
sg31936
I6
sg31944
VP05106
p39069
sg31939
I1
sasa(dp39070
g31925
VImmunostaining procedures were used to seek for the expression of the following 30 membrane antigens related to the immune system, using dendriform cells obtained in conjunctival specimens from 80 normal subjects and 105 with chronic conjunctivitis: class II antigens HLADR and DQ, CD1a (T6) and CD5, which usually mark Langerhans cells, macrophage markers CD14, CD36 and CD63, various lymphocyte antigens (CD2, CD4 and CD8), receptor to interleukin 2 (CD25), adhesion molecules and integrins (CD11a, CD11b, CD11c, CD18, CD29, CD41, CD61), the selectin CD62, ICAM-1 (CD54), ICAM-3 (CD50) and ELAM-1, CD45RO, related to activation of immune cells, and its ligand CD22, receptors to immunoglobulins (CD23 and CD32) and complement (CD21), transferrin receptor CD71, tryptase and vimentin, were thus investigated.
p39071
sg4
(dp39072
(VCD14
p39073
Vadhesion
p39074
tp39075
I00
ssg31931
(lp39076
(dp39077
g31934
I226
sg31935
Vchronic conjunctivitis
p39078
sg31936
I22
sg31937
VC0155145
p39079
sg31939
I2
sa(dp39080
g31934
I460
sg31935
g39074
sg31936
I8
sg31937
VC0001511
p39081
sg31939
I1
sasg31940
(lp39082
(dp39083
g31934
I592
sg31935
VELAM-1
p39084
sg31936
I6
sg31944
VP16581
p39085
sg31939
I1
sa(dp39086
g31934
I296
sg31935
VCD5
p39087
sg31936
I3
sg31944
VP06127
p39088
sg31939
I1
sa(dp39089
g31934
I420
sg31935
VCD8
p39090
sg31936
I3
sg31944
VP01732
p39091
sg31939
I1
sa(dp39092
g31934
I527
sg31935
VCD41
p39093
sg31936
I4
sg31944
VP08514
p39094
sg31939
I1
sa(dp39095
g31934
I508
sg31935
VCD11c
p39096
sg31936
I5
sg31944
VP20702
p39097
sg31939
I1
sa(dp39098
g31934
I372
sg31935
VCD63
p39099
sg31936
I4
sg31944
VP08962
p39100
sg31939
I1
sa(dp39101
g31934
I494
sg31935
VCD11a
p39102
sg31936
I5
sg31944
VP20701
p39103
sg31939
I1
sa(dp39104
g31934
I438
sg31935
Vinterleukin 2
p39105
sg31936
I13
sg31944
VP60568
p39106
sg31939
I2
sa(dp39107
g31934
I501
sg31935
VCD11b
p39108
sg31936
I5
sg31944
VP11215
p39109
sg31939
I1
sa(dp39110
g31934
I707
sg31935
VCD32
p39111
sg31936
I4
sg31944
VP12318
p39112
sg31939
I1
sa(dp39113
g31934
I453
sg31935
VCD25
p39114
sg31936
I4
sg31944
VP01589
p39115
sg31939
I1
sa(dp39116
g31934
I412
sg31935
VCD4
p39117
sg31936
I3
sg31944
VP01730
p39118
sg31939
I1
sa(dp39119
g31934
I574
sg31935
VICAM-3
p39120
sg31936
I6
sg31944
VP32942
p39121
sg31939
I1
sa(dp39122
g31934
I698
sg31935
VCD23
p39123
sg31936
I4
sg31944
VP06734
p39124
sg31939
I1
sa(dp39125
g31934
I736
sg31935
Vtransferrin receptor CD71
p39126
sg31936
I25
sg31944
VP02787
p39127
sg31939
I3
sa(dp39128
g31934
I567
sg31935
VCD54
p39129
sg31936
I4
sg31944
VP05362
p39130
sg31939
I1
sa(dp39131
g31934
I515
sg31935
VCD18
p39132
sg31936
I4
sg31944
VP05107
p39133
sg31939
I1
sa(dp39134
g31934
I533
sg31935
VCD61
p39135
sg31936
I4
sg31944
VP05106
p39136
sg31939
I1
sa(dp39137
g31934
I559
sg31935
VICAM-1
p39138
sg31936
I6
sg31944
VP05362
p39139
sg31939
I1
sa(dp39140
g31934
I407
sg31935
VCD2
p39141
sg31936
I3
sg31944
VP06729
p39142
sg31939
I1
sa(dp39143
g31934
I282
sg31935
VCD1a
p39144
sg31936
I4
sg31944
VP15813
p39145
sg31939
I1
sa(dp39146
g31934
I681
sg31935
Vimmunoglobulins
p39147
sg31936
I15
sg31944
g190
sg31939
I1
sa(dp39148
g31934
I386
sg31935
Vlymphocyte antigens
p39149
sg31936
I19
sg31944
VP30486
p39150
sg31939
I2
sa(dp39151
g31934
I582
sg31935
VCD50
p39152
sg31936
I4
sg31944
VP32942
p39153
sg31939
I1
sa(dp39154
g31934
I729
sg31935
VCD21
p39155
sg31936
I4
sg31944
VP20023
p39156
sg31939
I1
sa(dp39157
g31934
I250
sg31935
Vclass II
p39158
sg31936
I8
sg31944
g190
sg31939
I2
sa(dp39159
g31934
I553
sg31935
VCD62
p39160
sg31936
I4
sg31944
VP16109
p39161
sg31939
I1
sa(dp39162
g31934
I357
sg31935
g39073
sg31936
I4
sg31944
VP08571
p39163
sg31939
I1
sasa(dp39164
g31925
VIn order to elucidate the involvement of adhesion mechanisms in the process of megakaryocyte-dependent fibroblast growth, we applied BSA-coupled polymers of glucose, galactose, fucose, mannose, and several lectins (AAA, LCA, LTA, UEA-I) to cocultures of CD61 -positive (CD61+)/MACS-enriched megakaryocytes and human bone marrow fibroblasts.
p39165
sg4
(dp39166
(VLTA
p39167
VAAA
p39168
tp39169
I00
ssg31931
(lp39170
(dp39171
g31934
I41
sg31935
Vadhesion
p39172
sg31936
I8
sg31937
VC0001511
p39173
sg31939
I1
sa(dp39174
g31934
I220
sg31935
VLCA
p39175
sg31936
I3
sg31937
VC0339527
p39176
sg31939
I1
sa(dp39177
g31934
I215
sg31935
g39168
sg31936
I3
sg31937
VC0162871
p39178
sg31939
I1
sasg31940
(lp39179
(dp39180
g31934
I254
sg31935
VCD61 -positive
p39181
sg31936
I14
sg31944
VP05106
p39182
sg31939
I2
sa(dp39183
g31934
I270
sg31935
VCD61+
p39184
sg31936
I5
sg31944
VP05106
p39185
sg31939
I1
sa(dp39186
g31934
I215
sg31935
VAAA
p39187
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp39188
g31934
I133
sg31935
VBSA
p39189
sg31936
I3
sg31944
VP49639
p39190
sg31939
I1
sa(dp39191
g31934
I220
sg31935
VLCA
p39192
sg31936
I3
sg31944
VP09496
p39193
sg31939
I1
sa(dp39194
g31934
I225
sg31935
g39167
sg31936
I3
sg31944
VP10515
p39195
sg31939
I1
sasa(dp39196
g31925
VSeveral signaling systems downstream of G-CSFR have been identified that are defective or hyperactivated in myeloid cells of patients with congenital neutropenia: severely reduced expression of myeloid-specific transcription factors LEF-1 and C/EBPAlfa, severely reduced expression and functions of HCLS1 protein, severely reduced expression of neutrophil elastase protein, dramatic compensatory up-regulation of the NAMPT/NAD(+)/SIRT pathway leading to continuous activation of emergency granulopoiesis via the transcription factor C/EBPBeta, and hyperactivation of STAT5 protein by tyrosine phosphorylation.
p39197
sg4
(dp39198
(VSTAT5 protein
p39199
VNAD
p39200
tp39201
I00
ssg31931
(lp39202
(dp39203
g31934
I139
sg31935
Vcongenital neutropenia
p39204
sg31936
I22
sg31937
VC0340970
p39205
sg31939
I2
sa(dp39206
g31934
I479
sg31935
Vemergency
p39207
sg31936
I9
sg31937
VC2745965
p39208
sg31939
I1
sa(dp39209
g31934
I423
sg31935
g39200
sg31936
I3
sg31937
VC1850380
p39210
sg31939
I1
sasg31940
(lp39211
(dp39212
g31934
I40
sg31935
VG-CSFR
p39213
sg31936
I6
sg31944
VP07333
p39214
sg31939
I1
sa(dp39215
g31934
I345
sg31935
Vneutrophil elastase
p39216
sg31936
I19
sg31944
VP08246
p39217
sg31939
I2
sa(dp39218
g31934
I299
sg31935
VHCLS1 protein
p39219
sg31936
I13
sg31944
VP14317
p39220
sg31939
I2
sa(dp39221
g31934
I512
sg31935
Vtranscription factor C/EBPBeta
p39222
sg31936
I30
sg31944
VP35398
p39223
sg31939
I3
sa(dp39224
g31934
I194
sg31935
Vmyeloid-specific transcription factors LEF-1
p39225
sg31936
I44
sg31944
g190
sg31939
I4
sa(dp39226
g31934
I567
sg31935
g39199
sg31936
I13
sg31944
VP42229
p39227
sg31939
I2
sasa(dp39228
g31925
VIn vivo studies in Adult Dark Agouti (DA) rats with unilateral surgically-induced ocular hypertension (OHT) treated with either CoQ10/TPGS micelles or TPGS vehicle twice daily for three weeks were performed, following which retinal cell health was assessed in vivo using DARC (Detection of Apoptotic Retinal Cells) and post-mortem with Brn3a histological assessment on whole retinal mounts.
p39229
sg4
(dp39230
(VDetection of Apoptotic Retinal Cells
p39231
Vocular hypertension
p39232
tp39233
I00
ssg31931
(lp39234
(dp39235
g31934
I103
sg31935
VOHT
p39236
sg31936
I3
sg31937
VC0028840
p39237
sg31939
I1
sa(dp39238
g31934
I82
sg31935
g39232
sg31936
I19
sg31937
VC0028840
p39239
sg31939
I2
sasg31940
(lp39240
(dp39241
g31934
I271
sg31935
VDARC
p39242
sg31936
I4
sg31944
VP55283
p39243
sg31939
I1
sa(dp39244
g31934
I277
sg31935
g39231
sg31936
I36
sg31944
VP55283
p39245
sg31939
I5
sa(dp39246
g31934
I336
sg31935
VBrn3a
p39247
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp39248
g31925
VThree lncRNAs, sex determining region Y-box 2 overlapping transcript (SOX2-OT), NCBP2 antisense RNA 2 (NCBP2-AS2) and ubiquitin like with PHD and ring finger domains 1 (UHRF1), were predicted to be associated with lung cancer; RT-qPCR confirmed that SOX2-OT and NCBP2-AS2 were associated with lung cancer.
p39249
sg4
(dp39250
(VSOX2-OT
p39251
Vlung cancer
p39252
tp39253
I00
ssg31931
(lp39254
(dp39255
g31934
I214
sg31935
Vlung cancer
p39256
sg31936
I11
sg31937
VC0684249
p39257
sg31939
I2
sa(dp39258
g31934
I214
sg31935
g39252
sg31936
I11
sg31937
VC0684249
p39259
sg31939
I2
sasg31940
(lp39260
(dp39261
g31934
I118
sg31935
Vubiquitin like with PHD and ring finger domains 1
p39262
sg31936
I49
sg31944
g190
sg31939
I9
sa(dp39263
g31934
I169
sg31935
VUHRF1
p39264
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp39265
g31934
I103
sg31935
VNCBP2-AS2
p39266
sg31936
I9
sg31944
VP52298
p39267
sg31939
I1
sa(dp39268
g31934
I70
sg31935
VSOX2-OT
p39269
sg31936
I7
sg31944
VP48431
p39270
sg31939
I1
sa(dp39271
g31934
I103
sg31935
VNCBP2-AS2
p39272
sg31936
I9
sg31944
VP52298
p39273
sg31939
I1
sa(dp39274
g31934
I80
sg31935
VNCBP2 antisense RNA 2
p39275
sg31936
I21
sg31944
VP52298
p39276
sg31939
I4
sa(dp39277
g31934
I15
sg31935
Vsex determining region Y-box 2 overlapping transcript
p39278
sg31936
I53
sg31944
VP48431
p39279
sg31939
I7
sa(dp39280
g31934
I70
sg31935
g39251
sg31936
I7
sg31944
VP48431
p39281
sg31939
I1
sasa(dp39282
g31925
VSignificantly higher concentrations of HMGB1 were found in nasal secretions from patients with chronic rhinosinusitis with nasal polyp or allergic rhinitis compared with the control subjects.
p39283
sg4
(dp39284
(VHMGB1
p39285
Vallergic rhinitis
p39286
tp39287
I00
ssg31931
(lp39288
(dp39289
g31934
I123
sg31935
Vnasal polyp
p39290
sg31936
I11
sg31937
VC0027430
p39291
sg31939
I2
sa(dp39292
g31934
I95
sg31935
Vchronic rhinosinusitis
p39293
sg31936
I22
sg31937
VC0149516
p39294
sg31939
I2
sa(dp39295
g31934
I138
sg31935
g39286
sg31936
I17
sg31937
VC2607914
p39296
sg31939
I2
sasg31940
(lp39297
(dp39298
g31934
I39
sg31935
g39285
sg31936
I5
sg31944
VP09429
p39299
sg31939
I1
sasa(dp39300
g31925
VPrevious studies have shown that HMGB1 is elevated in the nasal lavage fluids (NLF) of children suffering from allergic rhinitis (AR) and is associated with the severity of this disease.
p39301
sg4
(dp39302
(VHMGB1
p39303
Vallergic rhinitis
p39304
tp39305
I00
ssg31931
(lp39306
(dp39307
g31934
I96
sg31935
Vsuffering
p39308
sg31936
I9
sg31937
VC0683278
p39309
sg31939
I1
sa(dp39310
g31934
I130
sg31935
VAR
p39311
sg31936
I2
sg31937
VC2607914
p39312
sg31939
I1
sa(dp39313
g31934
I111
sg31935
g39304
sg31936
I17
sg31937
VC2607914
p39314
sg31939
I2
sasg31940
(lp39315
(dp39316
g31934
I33
sg31935
g39303
sg31936
I5
sg31944
VP09429
p39317
sg31939
I1
sasa(dp39318
g31925
VThis review briefly touches on CF genetics as it applies to lung disease and will focus on the current hypotheses of CFTR (dys)function and its impact on pulmonary fluid homeostasis.
p39319
sg4
(dp39320
(Vdys
p39321
Vlung disease
p39322
tp39323
I00
ssg31931
(lp39324
(dp39325
g31934
I123
sg31935
Vdys
p39326
sg31936
I3
sg31937
VC0013364
p39327
sg31939
I1
sa(dp39328
g31934
I60
sg31935
g39322
sg31936
I12
sg31937
VC0024115
p39329
sg31939
I2
sasg31940
(lp39330
(dp39331
g31934
I117
sg31935
VCFTR
p39332
sg31936
I4
sg31944
VP13569
p39333
sg31939
I1
sa(dp39334
g31934
I123
sg31935
g39321
sg31936
I3
sg31944
VP11532
p39335
sg31939
I1
sasa(dp39336
g31925
VTo investigate the expression of the CDH13 gene and BCR/ABL fusion gene in chronic myeloid leukemia(CML) patients at different stages and explore their relationship.
p39337
sg4
(dp39338
(VABL
p39339
Vchronic myeloid leukemia
p39340
tp39341
I00
ssg31931
(lp39342
(dp39343
g31934
I100
sg31935
VCML
p39344
sg31936
I3
sg31937
VC0023473
p39345
sg31939
I1
sa(dp39346
g31934
I56
sg31935
VABL
p39347
sg31936
I3
sg31937
VC0000744
p39348
sg31939
I1
sa(dp39349
g31934
I75
sg31935
g39340
sg31936
I24
sg31937
VC0023473
p39350
sg31939
I3
sasg31940
(lp39351
(dp39352
g31934
I52
sg31935
VBCR
p39353
sg31936
I3
sg31944
VP11274
p39354
sg31939
I1
sa(dp39355
g31934
I37
sg31935
VCDH13 gene
p39356
sg31936
I10
sg31944
VP55290
p39357
sg31939
I2
sa(dp39358
g31934
I56
sg31935
g39339
sg31936
I3
sg31944
VP55157
p39359
sg31939
I1
sasa(dp39360
g31925
VWe performed genomewide screening for methylated CpG islands and identified 8 genes frequently methylated in leukemia cell lines and in patients with acute myeloid leukemia (AML): NOR1, CDH13, p15, NPM2, OLIG2, PGR, HIN1, and SLC26A4.
p39361
sg4
(dp39362
(Vp15
p39363
Vleukemia
p39364
tp39365
I00
ssg31931
(lp39366
(dp39367
g31934
I150
sg31935
Vacute myeloid leukemia
p39368
sg31936
I22
sg31937
VC0023467
p39369
sg31939
I3
sa(dp39370
g31934
I174
sg31935
VAML
p39371
sg31936
I3
sg31937
VC0023467
p39372
sg31939
I1
sa(dp39373
g31934
I109
sg31935
g39364
sg31936
I8
sg31937
VC0023418
p39374
sg31939
I1
sasg31940
(lp39375
(dp39376
g31934
I198
sg31935
VNPM2
p39377
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp39378
g31934
I204
sg31935
VOLIG2
p39379
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp39380
g31934
I180
sg31935
VNOR1
p39381
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp39382
g31934
I186
sg31935
VCDH13
p39383
sg31936
I5
sg31944
VP55290
p39384
sg31939
I1
sa(dp39385
g31934
I226
sg31935
VSLC26A4
p39386
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp39387
g31934
I216
sg31935
VHIN1
p39388
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp39389
g31934
I211
sg31935
VPGR
p39390
sg31936
I3
sg31944
VP06401
p39391
sg31939
I1
sa(dp39392
g31934
I193
sg31935
g39363
sg31936
I3
sg31944
VP53999
p39393
sg31939
I1
sasa(dp39394
g31925
VAlthough defective progenitor-stromal adhesion is a well-recognized feature of chronic myeloid leukemia (CML), the role of CDH13 abnormalities has not been evaluated in this disease.
p39395
sg4
(dp39396
(VCDH13
p39397
Vchronic myeloid leukemia
p39398
tp39399
I01
ssg31931
(lp39400
(dp39401
g31934
I38
sg31935
Vadhesion
p39402
sg31936
I8
sg31937
VC0001511
p39403
sg31939
I1
sa(dp39404
g31934
I105
sg31935
VCML
p39405
sg31936
I3
sg31937
VC0023473
p39406
sg31939
I1
sa(dp39407
g31934
I79
sg31935
g39398
sg31936
I24
sg31937
VC0023473
p39408
sg31939
I3
sasg31940
(lp39409
(dp39410
g31934
I123
sg31935
g39397
sg31936
I5
sg31944
VP55290
p39411
sg31939
I1
sasa(dp39412
g31925
VRecent work from our laboratory suggested pIgR may be upregulated in pancreatic ductal adenocarcinoma (PDAC).
p39413
sg4
(dp39414
(VpIgR
p39415
Vpancreatic ductal adenocarcinoma
p39416
tp39417
I00
ssg31931
(lp39418
(dp39419
g31934
I103
sg31935
VPDAC
p39420
sg31936
I4
sg31937
VC1335302
p39421
sg31939
I1
sa(dp39422
g31934
I69
sg31935
g39416
sg31936
I32
sg31937
VC1335302
p39423
sg31939
I3
sasg31940
(lp39424
(dp39425
g31934
I42
sg31935
g39415
sg31936
I4
sg31944
VP01833
p39426
sg31939
I1
sasa(dp39427
g31925
VDue to the inverse interaction of Rac1 and Ras homolog family member A (RhoA) signaling in the transition between mesenchymal and amoeboid morphology, simultaneous treatment of NSC23766 and Y27632 (selective Rho associated coiled-coil containing protein kinase 1 inhibitor), abolished U87 GBM cell migration through inhibiting MAT and amoeboid-mesenchymal transition.
p39428
sg4
(dp39429
(VRho
p39430
VGBM
p39431
tp39432
I00
ssg31931
(lp39433
(dp39434
g31934
I289
sg31935
g39431
sg31936
I3
sg31937
VC0017636
p39435
sg31939
I1
sa(dp39436
g31934
I95
sg31935
Vtransition
p39437
sg31936
I10
sg31937
VC0599156
p39438
sg31939
I1
sa(dp39439
g31934
I95
sg31935
Vtransition
p39440
sg31936
I10
sg31937
VC0599156
p39441
sg31939
I1
sasg31940
(lp39442
(dp39443
g31934
I285
sg31935
VU87 GBM
p39444
sg31936
I7
sg31944
g190
sg31939
I2
sa(dp39445
g31934
I327
sg31935
VMAT
p39446
sg31936
I3
sg31944
VP24752
p39447
sg31939
I1
sa(dp39448
g31934
I43
sg31935
VRas homolog family member A
p39449
sg31936
I27
sg31944
VP01116
p39450
sg31939
I5
sa(dp39451
g31934
I34
sg31935
VRac1
p39452
sg31936
I4
sg31944
VP63000
p39453
sg31939
I1
sa(dp39454
g31934
I72
sg31935
VRhoA
p39455
sg31936
I4
sg31944
VP61586
p39456
sg31939
I1
sa(dp39457
g31934
I223
sg31935
Vcoiled-coil containing protein kinase 1
p39458
sg31936
I39
sg31944
VP38432
p39459
sg31939
I5
sa(dp39460
g31934
I72
sg31935
g39430
sg31936
I3
sg31944
VP08100
p39461
sg31939
I1
sasa(dp39462
g31925
VThe combined inhibition of Rac1 and RhoA signaling would be a promising strategy to suppress GBM invasion.
p39463
sg4
(dp39464
(VRac1
p39465
VGBM
p39466
tp39467
I00
ssg31931
(lp39468
(dp39469
g31934
I97
sg31935
Vinvasion
p39470
sg31936
I8
sg31937
VC2699153
p39471
sg31939
I1
sa(dp39472
g31934
I93
sg31935
g39466
sg31936
I3
sg31937
VC0017636
p39473
sg31939
I1
sasg31940
(lp39474
(dp39475
g31934
I36
sg31935
VRhoA
p39476
sg31936
I4
sg31944
VP61586
p39477
sg31939
I1
sa(dp39478
g31934
I27
sg31935
g39465
sg31936
I4
sg31944
VP63000
p39479
sg31939
I1
sasa(dp39480
g31925
VSpecifically, combination therapy inhibited TLR7 expression in the kidneys of mice with lupus nephritis; combination of tacrolimus and mycophenolate mofetil led to better stabilization of the podocyte actin cytoskeleton through the reciprocal regulation of RhoA and Rac1 activities.
p39481
sg4
(dp39482
(VRac1
p39483
Vlupus nephritis
p39484
tp39485
I00
ssg31931
(lp39486
(dp39487
g31934
I88
sg31935
g39484
sg31936
I15
sg31937
VC0024143
p39488
sg31939
I2
sasg31940
(lp39489
(dp39490
g31934
I44
sg31935
VTLR7
p39491
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp39492
g31934
I257
sg31935
VRhoA
p39493
sg31936
I4
sg31944
VP61586
p39494
sg31939
I1
sa(dp39495
g31934
I266
sg31935
g39483
sg31936
I4
sg31944
VP63000
p39496
sg31939
I1
sasa(dp39497
g31925
VWe hypothesized that mutations in AP2S1 and GNA11 are causative in Danish patients with suspected FHH and that these mutations are not found in patients with primary hyperparathyroidism (PHPT), which is the main differential diagnostic disorder.
p39498
sg4
(dp39499
(VAP2S1
p39500
Vprimary hyperparathyroidism
p39501
tp39502
I00
ssg31931
(lp39503
(dp39504
g31934
I187
sg31935
VPHPT
p39505
sg31936
I4
sg31937
VC0221002
p39506
sg31939
I1
sa(dp39507
g31934
I158
sg31935
g39501
sg31936
I27
sg31937
VC0221002
p39508
sg31939
I2
sasg31940
(lp39509
(dp39510
g31934
I44
sg31935
VGNA11
p39511
sg31936
I5
sg31944
VP29992
p39512
sg31939
I1
sa(dp39513
g31934
I34
sg31935
g39500
sg31936
I5
sg31944
VP53680
p39514
sg31939
I1
sasa(dp39515
g31925
VFamilial hypocalciuric hypercalcemia (FHH) is a genetically heterogeneous condition resembling primary hyperparathyroidism (PHPT) but not curable by surgery; FHH types 1, 2, and 3 are due to loss-of-function mutations of the CASR, GNA11, or AP2S1 genes, respectively.
p39516
sg4
(dp39517
(VAP2S1 genes
p39518
VFamilial hypocalciuric hypercalcemia
p39519
tp39520
I00
ssg31931
(lp39521
(dp39522
g31934
I124
sg31935
VPHPT
p39523
sg31936
I4
sg31937
VC0221002
p39524
sg31939
I1
sa(dp39525
g31934
I74
sg31935
Vcondition
p39526
sg31936
I9
sg31937
VC0012634
p39527
sg31939
I1
sa(dp39528
g31934
I38
sg31935
VFHH
p39529
sg31936
I3
sg31937
VC0342637
p39530
sg31939
I1
sa(dp39531
g31934
I38
sg31935
VFHH
p39532
sg31936
I3
sg31937
VC0342637
p39533
sg31939
I1
sa(dp39534
g31934
I95
sg31935
Vprimary hyperparathyroidism
p39535
sg31936
I27
sg31937
VC0221002
p39536
sg31939
I2
sa(dp39537
g31934
I0
sg31935
g39519
sg31936
I36
sg31937
VC0342637
p39538
sg31939
I3
sasg31940
(lp39539
(dp39540
g31934
I225
sg31935
VCASR
p39541
sg31936
I4
sg31944
VP41180
p39542
sg31939
I1
sa(dp39543
g31934
I231
sg31935
VGNA11
p39544
sg31936
I5
sg31944
VP29992
p39545
sg31939
I1
sa(dp39546
g31934
I241
sg31935
g39518
sg31936
I11
sg31944
VP53680
p39547
sg31939
I2
sasa(dp39548
g31925
VThe aim of this study was to analyse prevalence and pathogenicity of CaSR, GNA11 and AP2S1 mutations in patients with an FHH phenotype and to compare them with a sample of patients with primary hyperparathyroidism (PHPT) in order to identify the most useful laboratory parameter for a differential diagnosis.
p39549
sg4
(dp39550
(VFHH
p39551
Vprimary hyperparathyroidism
p39552
tp39553
I00
ssg31931
(lp39554
(dp39555
g31934
I215
sg31935
VPHPT
p39556
sg31936
I4
sg31937
VC0221002
p39557
sg31939
I1
sa(dp39558
g31934
I186
sg31935
g39552
sg31936
I27
sg31937
VC0221002
p39559
sg31939
I2
sasg31940
(lp39560
(dp39561
g31934
I85
sg31935
VAP2S1
p39562
sg31936
I5
sg31944
VP53680
p39563
sg31939
I1
sa(dp39564
g31934
I69
sg31935
VCaSR
p39565
sg31936
I4
sg31944
VP41180
p39566
sg31939
I1
sa(dp39567
g31934
I75
sg31935
VGNA11
p39568
sg31936
I5
sg31944
VP29992
p39569
sg31939
I1
sa(dp39570
g31934
I121
sg31935
g39551
sg31936
I3
sg31944
VP41180
p39571
sg31939
I1
sasa(dp39572
g31925
VIn the present work, we clearly demonstrate that HMGB1 secreted by cancer cells is N-glycosylated at Asn37, which facilitates monocytic (M)-MDSC differentiation from bone marrow via the p38/NFKB/Erk1/2 pathway and also contributes to conversion of monocytes into MDSC-like cells; HMGB1 blockade by a monoclonal antibody against the HMGB1 B box obviously reduced the accumulation of M-MDSC in tumor-bearing mice, delaying tumor growth and development; additionally, MDSC expansion and HMGB1 up-regulation were also found in breast cancer patients.
p39573
sg4
(dp39574
(VHMGB1 B
p39575
Vbreast cancer
p39576
tp39577
I00
ssg31931
(lp39578
(dp39579
g31934
I67
sg31935
Vcancer
p39580
sg31936
I6
sg31937
VC0006826
p39581
sg31939
I1
sa(dp39582
g31934
I523
sg31935
g39576
sg31936
I13
sg31937
VC0678222
p39583
sg31939
I2
sa(dp39584
g31934
I421
sg31935
Vtumor growth
p39585
sg31936
I12
sg31937
VC0598934
p39586
sg31939
I2
sa(dp39587
g31934
I392
sg31935
Vtumor
p39588
sg31936
I5
sg31937
VC0027651
p39589
sg31939
I1
sasg31940
(lp39590
(dp39591
g31934
I195
sg31935
VErk1/2
p39592
sg31936
I6
sg31944
VP27361
p39593
sg31939
I1
sa(dp39594
g31934
I49
sg31935
VHMGB1
p39595
sg31936
I5
sg31944
VP09429
p39596
sg31939
I1
sa(dp39597
g31934
I190
sg31935
VNFKB
p39598
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp39599
g31934
I49
sg31935
VHMGB1
p39600
sg31936
I5
sg31944
VP09429
p39601
sg31939
I1
sa(dp39602
g31934
I186
sg31935
Vp38
p39603
sg31936
I3
sg31944
VP46108
p39604
sg31939
I1
sa(dp39605
g31934
I49
sg31935
VHMGB1
p39606
sg31936
I5
sg31944
VP09429
p39607
sg31939
I1
sa(dp39608
g31934
I332
sg31935
g39575
sg31936
I7
sg31944
VP09429
p39609
sg31939
I2
sasa(dp39610
g31925
VWe examined a possible association between the COMT Val158Met polymorphism and conversion disorder in a study of 48 patients with conversion disorder and 48 control patients.
p39611
sg4
(dp39612
(VCOMT Val158Met
p39613
Vconversion disorder
p39614
tp39615
I00
ssg31931
(lp39616
(dp39617
g31934
I79
sg31935
Vconversion disorder
p39618
sg31936
I19
sg31937
VC0009946
p39619
sg31939
I2
sa(dp39620
g31934
I79
sg31935
g39614
sg31936
I19
sg31937
VC0009946
p39621
sg31939
I2
sasg31940
(lp39622
(dp39623
g31934
I47
sg31935
g39613
sg31936
I14
sg31944
VP21964
p39624
sg31939
I2
sasa(dp39625
g31925
VWe conclude that the COMT Val158Met genotype is quite common in Turkey and that it is not a risk factor for conversion disorder in the Turkish population.
p39626
sg4
(dp39627
(VCOMT Val158Met genotype
p39628
Vconversion disorder
p39629
tp39630
I00
ssg31931
(lp39631
(dp39632
g31934
I108
sg31935
g39629
sg31936
I19
sg31937
VC0009946
p39633
sg31939
I2
sasg31940
(lp39634
(dp39635
g31934
I21
sg31935
g39628
sg31936
I23
sg31944
VP21964
p39636
sg31939
I3
sasa(dp39637
g31925
VFactor VII (FVII) activating protease (FSAP) is a circulating serine protease that is likely to be involved in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer.
p39638
sg4
(dp39639
(Vserine protease
p39640
Vthrombosis
p39641
tp39642
I00
ssg31931
(lp39643
(dp39644
g31934
I150
sg31935
Vstroke
p39645
sg31936
I6
sg31937
VC0038454
p39646
sg31939
I1
sa(dp39647
g31934
I158
sg31935
Vatherosclerosis
p39648
sg31936
I15
sg31937
VC0004153
p39649
sg31939
I1
sa(dp39650
g31934
I175
sg31935
Vliver fibrosis
p39651
sg31936
I14
sg31937
VC0239946
p39652
sg31939
I2
sa(dp39653
g31934
I206
sg31935
Vcancer
p39654
sg31936
I6
sg31937
VC0006826
p39655
sg31939
I1
sa(dp39656
g31934
I191
sg31935
g39641
sg31936
I10
sg31937
VC0040053
p39657
sg31939
I1
sasg31940
(lp39658
(dp39659
g31934
I0
sg31935
VFactor VII (FVII) activating protease
p39660
sg31936
I37
sg31944
VP08709
p39661
sg31939
I5
sa(dp39662
g31934
I39
sg31935
VFSAP
p39663
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp39664
g31934
I62
sg31935
g39640
sg31936
I15
sg31944
VP57727
p39665
sg31939
I2
sasa(dp39666
g31925
VWith purpose to study content of alpha-defensins (1-3) and synthesis and liberation of other proteins and peptides by neutrophils the concentrations of alpha-defensins, lipoprotein (alpha), C-reactive protein, precursor of cerebral natriuretic peptide, coagulation factor VII and von Willebrand factor were determined in supernatants of leukocytal cultures in patients with exertional angina pectoris and atherosclerosis of lower extremities.
p39667
sg4
(dp39668
(Vlipoprotein (alpha)
p39669
Vatherosclerosis
p39670
tp39671
I00
ssg31931
(lp39672
(dp39673
g31934
I374
sg31935
Vexertional angina
p39674
sg31936
I17
sg31937
VC0577698
p39675
sg31939
I2
sa(dp39676
g31934
I405
sg31935
g39670
sg31936
I15
sg31937
VC0004153
p39677
sg31939
I1
sasg31940
(lp39678
(dp39679
g31934
I280
sg31935
Vvon Willebrand factor
p39680
sg31936
I21
sg31944
VP04275
p39681
sg31939
I3
sa(dp39682
g31934
I190
sg31935
VC-reactive protein
p39683
sg31936
I18
sg31944
VP02741
p39684
sg31939
I2
sa(dp39685
g31934
I223
sg31935
Vcerebral natriuretic peptide
p39686
sg31936
I28
sg31944
VP16860
p39687
sg31939
I3
sa(dp39688
g31934
I33
sg31935
Valpha-defensins
p39689
sg31936
I15
sg31944
VP59665
p39690
sg31939
I1
sa(dp39691
g31934
I253
sg31935
Vcoagulation factor VII
p39692
sg31936
I22
sg31944
VP08709
p39693
sg31939
I3
sa(dp39694
g31934
I169
sg31935
g39669
sg31936
I19
sg31944
VP02652
p39695
sg31939
I2
sasa(dp39696
g31925
VDetection rates were as follows: IL-7: NVG higher than POAG; IL-10: POAG lower than cataract or NVG; and GM-CSF: cataract higher than POAG or NVG.
p39697
sg4
(dp39698
(VIL-7
p39699
VPOAG
p39700
tp39701
I00
ssg31931
(lp39702
(dp39703
g31934
I55
sg31935
VPOAG
p39704
sg31936
I4
sg31937
VC0339573
p39705
sg31939
I1
sa(dp39706
g31934
I84
sg31935
Vcataract
p39707
sg31936
I8
sg31937
VC0086543
p39708
sg31939
I1
sa(dp39709
g31934
I55
sg31935
VPOAG
p39710
sg31936
I4
sg31937
VC0339573
p39711
sg31939
I1
sa(dp39712
g31934
I84
sg31935
Vcataract
p39713
sg31936
I8
sg31937
VC0086543
p39714
sg31939
I1
sa(dp39715
g31934
I55
sg31935
g39700
sg31936
I4
sg31937
VC0339573
p39716
sg31939
I1
sasg31940
(lp39717
(dp39718
g31934
I105
sg31935
VGM-CSF
p39719
sg31936
I6
sg31944
VP04141
p39720
sg31939
I1
sa(dp39721
g31934
I33
sg31935
g39699
sg31936
I4
sg31944
VP13232
p39722
sg31939
I1
sasa(dp39723
g31925
VPoly I:C induces IL-7 production, early inflammatory responses, and characteristic pathologies of SS-like dacryoadenitis in non-autoimmune-prone C57BL/6 mice.
p39724
sg4
(dp39725
(VIL-7
p39726
Vdacryoadenitis
p39727
tp39728
I00
ssg31931
(lp39729
(dp39730
g31934
I40
sg31935
Vinflammatory responses
p39731
sg31936
I22
sg31937
VC1155266
p39732
sg31939
I2
sa(dp39733
g31934
I106
sg31935
g39727
sg31936
I14
sg31937
VC0155223
p39734
sg31939
I1
sa(dp39735
g31934
I128
sg31935
Vautoimmune
p39736
sg31936
I10
sg31937
VC0443146
p39737
sg31939
I1
sasg31940
(lp39738
(dp39739
g31934
I17
sg31935
g39726
sg31936
I4
sg31944
VP13232
p39740
sg31939
I1
sasa(dp39741
g31925
VThe regulatory role of AVP on the hypothalamic-pituitary-adrenal (HPA) axis suggests potential uses for AVP receptor modulators in various CNS indications, including depression, anxiety and post-traumatic stress disorder.
p39742
sg4
(dp39743
(VAVP
p39744
Vdepression
p39745
tp39746
I00
ssg31931
(lp39747
(dp39748
g31934
I190
sg31935
Vpost-traumatic stress disorder
p39749
sg31936
I30
sg31937
VC0038436
p39750
sg31939
I3
sa(dp39751
g31934
I166
sg31935
g39745
sg31936
I10
sg31937
VC0011581
p39752
sg31939
I1
sasg31940
(lp39753
(dp39754
g31934
I104
sg31935
VAVP receptor
p39755
sg31936
I12
sg31944
VP01185
p39756
sg31939
I2
sa(dp39757
g31934
I23
sg31935
g39744
sg31936
I3
sg31944
VP01185
p39758
sg31939
I1
sasa(dp39759
g31925
VWhen POLN was ectopically overexpressed in human cells, it specifically coimmunoprecipitated with the homologous recombination factors BRCA1 and FANCJ, but not with previously suggested interaction partners (HELQ and members of the Fanconi anemia core complex).
p39760
sg4
(dp39761
(Vhomologous recombination factors BRCA1
p39762
VFANCJ
p39763
tp39764
I00
ssg31931
(lp39765
(dp39766
g31934
I232
sg31935
VFanconi anemia
p39767
sg31936
I14
sg31937
VC3469521
p39768
sg31939
I2
sa(dp39769
g31934
I145
sg31935
g39763
sg31936
I5
sg31937
VC1836860
p39770
sg31939
I1
sasg31940
(lp39771
(dp39772
g31934
I208
sg31935
VHELQ
p39773
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp39774
g31934
I232
sg31935
VFanconi anemia core complex
p39775
sg31936
I27
sg31944
VP51587
p39776
sg31939
I4
sa(dp39777
g31934
I145
sg31935
VFANCJ
p39778
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp39779
g31934
I102
sg31935
g39762
sg31936
I38
sg31944
VP19883
p39780
sg31939
I4
sasa(dp39781
g31925
VHerein we describe a new phenotype associated with a mutation in exon 11 of the LMNA gene: hypertrophic cardiomyopathy, atrioventricular block, severe dyslipidemia and diabetes.
p39782
sg4
(dp39783
(VLMNA gene
p39784
Vdyslipidemia
p39785
tp39786
I00
ssg31931
(lp39787
(dp39788
g31934
I168
sg31935
Vdiabetes
p39789
sg31936
I8
sg31937
VC0011849
p39790
sg31939
I1
sa(dp39791
g31934
I91
sg31935
Vhypertrophic cardiomyopathy
p39792
sg31936
I27
sg31937
VC0007194
p39793
sg31939
I2
sa(dp39794
g31934
I120
sg31935
Vatrioventricular block
p39795
sg31936
I22
sg31937
VC0004245
p39796
sg31939
I2
sa(dp39797
g31934
I151
sg31935
g39785
sg31936
I12
sg31937
VC0242339
p39798
sg31939
I1
sasg31940
(lp39799
(dp39800
g31934
I80
sg31935
g39784
sg31936
I9
sg31944
VP02545
p39801
sg31939
I2
sasa(dp39802
g31925
VIndependent analysis of LMNA variants via the type 2 diabetes (T2D) Knowledge Portal showed that variant p.G602S associated significantly with type 2 diabetes (p = 0.02; odds ratio = 4.58), and was more frequent in African Americans (allele frequency 0.297%).
p39803
sg4
(dp39804
(VLMNA variants
p39805
Vtype 2 diabetes
p39806
tp39807
I00
ssg31931
(lp39808
(dp39809
g31934
I63
sg31935
VT2D
p39810
sg31936
I3
sg31937
VC0011860
p39811
sg31939
I1
sa(dp39812
g31934
I46
sg31935
Vtype 2 diabetes
p39813
sg31936
I15
sg31937
VC0011860
p39814
sg31939
I3
sa(dp39815
g31934
I46
sg31935
g39806
sg31936
I15
sg31937
VC0011860
p39816
sg31939
I3
sasg31940
(lp39817
(dp39818
g31934
I24
sg31935
g39805
sg31936
I13
sg31944
VP02545
p39819
sg31939
I2
sasa(dp39820
g31925
VLipodystrophy is a rare disorder characterized by the complete or partial loss of subcutaneous adipose tissue, insulin resistance, diabetes mellitus and hyperlipidemia.Proteinuric renal disease is a prevalent feature of generalized lipodystrophy but rare in familial partial lipodystrophy.Patients carrying the c.1045C &gt; T missense LMNA mutation (p.R349W) may present with familial partial lipodystrophy, proteinuric nephropathy, cardiomyopathy and atypical myopathy.
p39821
sg4
(dp39822
(Vinsulin
p39823
VLipodystrophy
p39824
tp39825
I01
ssg31931
(lp39826
(dp39827
g31934
I220
sg31935
Vgeneralized lipodystrophy
p39828
sg31936
I25
sg31937
VC0221032
p39829
sg31939
I2
sa(dp39830
g31934
I131
sg31935
Vdiabetes mellitus
p39831
sg31936
I17
sg31937
VC0011849
p39832
sg31939
I2
sa(dp39833
g31934
I258
sg31935
Vfamilial partial lipodystrophy
p39834
sg31936
I30
sg31937
VC0271694
p39835
sg31939
I3
sa(dp39836
g31934
I439
sg31935
Vmyopathy
p39837
sg31936
I8
sg31937
VC0026848
p39838
sg31939
I1
sa(dp39839
g31934
I420
sg31935
Vnephropathy
p39840
sg31936
I11
sg31937
VC0022658
p39841
sg31939
I1
sa(dp39842
g31934
I433
sg31935
Vcardiomyopathy
p39843
sg31936
I14
sg31937
VC0878544
p39844
sg31939
I1
sa(dp39845
g31934
I153
sg31935
Vhyperlipidemia
p39846
sg31936
I14
sg31937
VC0020473
p39847
sg31939
I1
sa(dp39848
g31934
I180
sg31935
Vrenal disease
p39849
sg31936
I13
sg31937
VC0022658
p39850
sg31939
I2
sa(dp39851
g31934
I111
sg31935
Vinsulin resistance
p39852
sg31936
I18
sg31937
VC0021655
p39853
sg31939
I2
sa(dp39854
g31934
I19
sg31935
Vrare disorder
p39855
sg31936
I13
sg31937
VC0678236
p39856
sg31939
I2
sa(dp39857
g31934
I258
sg31935
Vfamilial partial lipodystrophy
p39858
sg31936
I30
sg31937
VC0271694
p39859
sg31939
I3
sa(dp39860
g31934
I0
sg31935
g39824
sg31936
I13
sg31937
VC0023787
p39861
sg31939
I1
sasg31940
(lp39862
(dp39863
g31934
I111
sg31935
g39823
sg31936
I7
sg31944
VP01308
p39864
sg31939
I1
sasa(dp39865
g31925
VBAT 5'-deiodinase activity was unaffected by propylthiouracil (PTU) and was elevated in hypothyroid rats, whereas EPI 5'-deiodinase was totally inhibited by PTU and was depressed in hypothyroidism.
p39866
sg4
(dp39867
(VEPI 5'-deiodinase
p39868
Vhypothyroidism
p39869
tp39870
I00
ssg31931
(lp39871
(dp39872
g31934
I88
sg31935
Vhypothyroid
p39873
sg31936
I11
sg31937
VC0020676
p39874
sg31939
I1
sa(dp39875
g31934
I114
sg31935
VEPI
p39876
sg31936
I3
sg31937
VC0267963
p39877
sg31939
I1
sa(dp39878
g31934
I182
sg31935
g39869
sg31936
I14
sg31937
VC0020676
p39879
sg31939
I1
sasg31940
(lp39880
(dp39881
g31934
I114
sg31935
g39868
sg31936
I17
sg31944
VP10646
p39882
sg31939
I2
sa(dp39883
g31934
I0
sg31935
VBAT 5'-deiodinase
p39884
sg31936
I17
sg31944
g190
sg31939
I2
sasa(dp39885
g31925
VCockayne syndrome is caused by biallelic ERCC8 (CSA) or ERCC6 (CSB) mutations and is characterized by growth restriction, microcephaly, developmental delay, and premature pathological aging.
p39886
sg4
(dp39887
(VCSB
p39888
Vdevelopmental delay
p39889
tp39890
I00
ssg31931
(lp39891
(dp39892
g31934
I122
sg31935
Vmicrocephaly
p39893
sg31936
I12
sg31937
VC0025958
p39894
sg31939
I1
sa(dp39895
g31934
I0
sg31935
VCockayne syndrome
p39896
sg31936
I17
sg31937
VC0009207
p39897
sg31939
I2
sa(dp39898
g31934
I48
sg31935
VCSA
p39899
sg31936
I3
sg31937
VC0751039
p39900
sg31939
I1
sa(dp39901
g31934
I63
sg31935
VCSB
p39902
sg31936
I3
sg31937
VC1858160
p39903
sg31939
I1
sa(dp39904
g31934
I21
sg31935
Vcaused by biallelic ERCC8
p39905
sg31936
I25
sg31937
VC0751039
p39906
sg31939
I4
sa(dp39907
g31934
I136
sg31935
g39889
sg31936
I19
sg31937
VC0424605
p39908
sg31939
I2
sasg31940
(lp39909
(dp39910
g31934
I41
sg31935
VERCC8 (CSA)
p39911
sg31936
I11
sg31944
VP01243
p39912
sg31939
I2
sa(dp39913
g31934
I56
sg31935
VERCC6
p39914
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp39915
g31934
I63
sg31935
g39888
sg31936
I3
sg31944
VP35548
p39916
sg31939
I1
sasa(dp39917
g31925
VA microarray analysis of the B-1 lymphocytes revealed that IL-10 deficiency is associated with down-regulation of the genes that code for claudin-10, a protein that is involved in cell-to-cell contact and that has been linked to lung adenocarcinoma.
p39918
sg4
(dp39919
(Vclaudin-10
p39920
Vlung adenocarcinoma
p39921
tp39922
I00
ssg31931
(lp39923
(dp39924
g31934
I229
sg31935
g39921
sg31936
I19
sg31937
VC0152013
p39925
sg31939
I2
sasg31940
(lp39926
(dp39927
g31934
I138
sg31935
g39920
sg31936
I10
sg31944
VP78369
p39928
sg31939
I1
sasa(dp39929
g31925
VThus, our findings suggest that the axis IL-10/claudin-10 is a promising target for the development of therapeutic agents against aggressive melanoma.
p39930
sg4
(dp39931
(Vclaudin-10
p39932
Vaggressive
p39933
tp39934
I00
ssg31931
(lp39935
(dp39936
g31934
I141
sg31935
Vmelanoma
p39937
sg31936
I8
sg31937
VC0025202
p39938
sg31939
I1
sa(dp39939
g31934
I130
sg31935
g39933
sg31936
I10
sg31937
VC0001807
p39940
sg31939
I1
sasg31940
(lp39941
(dp39942
g31934
I47
sg31935
g39932
sg31936
I10
sg31944
VP78369
p39943
sg31939
I1
sasa(dp39944
g31925
VTo explore the expression distinction of the cell adhesion proteins claudin-10,-14,-17 and E-cadherin in the adjacent non-neoplastic tissues and gastric cancer tissues, 50 gastric cancer tissues and 50 samples of adjacent non-neoplastic tissues adjacent to the tumors were examined for expression of claudin-10,-14,-17 and E-cadherin by streptavidin-perosidase immunohistochemical staining method.
p39945
sg4
(dp39946
(VE-cadherin
p39947
Vgastric cancer
p39948
tp39949
I00
ssg31931
(lp39950
(dp39951
g31934
I145
sg31935
Vgastric cancer
p39952
sg31936
I14
sg31937
VC0024623
p39953
sg31939
I2
sa(dp39954
g31934
I261
sg31935
Vtumors
p39955
sg31936
I6
sg31937
VC0027651
p39956
sg31939
I1
sa(dp39957
g31934
I50
sg31935
Vadhesion
p39958
sg31936
I8
sg31937
VC0001511
p39959
sg31939
I1
sa(dp39960
g31934
I145
sg31935
g39948
sg31936
I14
sg31937
VC0024623
p39961
sg31939
I2
sasg31940
(lp39962
(dp39963
g31934
I68
sg31935
Vclaudin-10,-14,-17
p39964
sg31936
I18
sg31944
VP78369
p39965
sg31939
I1
sa(dp39966
g31934
I337
sg31935
Vstreptavidin-perosidase
p39967
sg31936
I23
sg31944
g190
sg31939
I1
sa(dp39968
g31934
I68
sg31935
Vclaudin-10,-14,-17
p39969
sg31936
I18
sg31944
VP78369
p39970
sg31939
I1
sa(dp39971
g31934
I91
sg31935
VE-cadherin
p39972
sg31936
I10
sg31944
VP12830
p39973
sg31939
I1
sa(dp39974
g31934
I91
sg31935
g39947
sg31936
I10
sg31944
VP12830
p39975
sg31939
I1
sasa(dp39976
g31925
VThe positive expression rates of claudin-10 in gastric cancer tissues and adjacent non-neoplastic tissues were 24% and 72% respectively (P &lt; 0.01).
p39977
sg4
(dp39978
(Vclaudin-10
p39979
Vgastric cancer
p39980
tp39981
I00
ssg31931
(lp39982
(dp39983
g31934
I47
sg31935
g39980
sg31936
I14
sg31937
VC0024623
p39984
sg31939
I2
sasg31940
(lp39985
(dp39986
g31934
I33
sg31935
g39979
sg31936
I10
sg31944
VP78369
p39987
sg31939
I1
sasa(dp39988
g31925
VIn contrast, the positive expression rates of claudin-14 in gastric cancer tissues and adjacent non-neoplastic tissues were 58% and 24% respectively (P = 0.015 &lt; 0.05) Thus in our study, the expression of E-cadherin, claudin-10, and claudin-17 was down-regulated in gastric cancer tissue while the expression of claudin-14 was up-regulated.
p39989
sg4
(dp39990
(Vclaudin-10
p39991
Vgastric cancer
p39992
tp39993
I00
ssg31931
(lp39994
(dp39995
g31934
I60
sg31935
Vgastric cancer
p39996
sg31936
I14
sg31937
VC0024623
p39997
sg31939
I2
sa(dp39998
g31934
I60
sg31935
g39992
sg31936
I14
sg31937
VC0024623
p39999
sg31939
I2
sasg31940
(lp40000
(dp40001
g31934
I46
sg31935
Vclaudin-14
p40002
sg31936
I10
sg31944
g190
sg31939
I1
sa(dp40003
g31934
I208
sg31935
VE-cadherin
p40004
sg31936
I10
sg31944
VP12830
p40005
sg31939
I1
sa(dp40006
g31934
I236
sg31935
Vclaudin-17
p40007
sg31936
I10
sg31944
VP56750
p40008
sg31939
I1
sa(dp40009
g31934
I220
sg31935
g39991
sg31936
I10
sg31944
VP78369
p40010
sg31939
I1
sasa(dp40011
g31925
VOur study reveals that the expression of E-cadherin, claudin-10, and claudin-17 were down-regulated in gastric cancer tissue while the expression of claudin-14 was up-regulated and correlation between claudins and E-cadherin expression with lymphatic metastasis were observed.
p40012
sg4
(dp40013
(Vclaudin-10
p40014
Vlymphatic metastasis
p40015
tp40016
I00
ssg31931
(lp40017
(dp40018
g31934
I103
sg31935
Vgastric cancer
p40019
sg31936
I14
sg31937
VC0024623
p40020
sg31939
I2
sa(dp40021
g31934
I241
sg31935
g40015
sg31936
I20
sg31937
VC0024232
p40022
sg31939
I2
sasg31940
(lp40023
(dp40024
g31934
I69
sg31935
Vclaudin-17
p40025
sg31936
I10
sg31944
VP56750
p40026
sg31939
I1
sa(dp40027
g31934
I41
sg31935
VE-cadherin
p40028
sg31936
I10
sg31944
VP12830
p40029
sg31939
I1
sa(dp40030
g31934
I41
sg31935
VE-cadherin
p40031
sg31936
I10
sg31944
VP12830
p40032
sg31939
I1
sa(dp40033
g31934
I53
sg31935
g40014
sg31936
I10
sg31944
VP78369
p40034
sg31939
I1
sasa(dp40035
g31925
VFour genes (MMP-2, c-fos, claudin 1 (CLDN1) and claudin 10(CLDN10)) were correlated with the results of microarray and real time RT-PCR analyses for the gene-expression data in samples from 41 patients with lung adenocarcinoma.
p40036
sg4
(dp40037
(VCLDN10
p40038
Vlung adenocarcinoma
p40039
tp40040
I00
ssg31931
(lp40041
(dp40042
g31934
I207
sg31935
g40039
sg31936
I19
sg31937
VC0152013
p40043
sg31939
I2
sasg31940
(lp40044
(dp40045
g31934
I12
sg31935
VMMP-2
p40046
sg31936
I5
sg31944
VP08253
p40047
sg31939
I1
sa(dp40048
g31934
I48
sg31935
Vclaudin 10
p40049
sg31936
I10
sg31944
VP78369
p40050
sg31939
I2
sa(dp40051
g31934
I19
sg31935
Vc-fos
p40052
sg31936
I5
sg31944
VP01100
p40053
sg31939
I1
sa(dp40054
g31934
I26
sg31935
Vclaudin 1
p40055
sg31936
I9
sg31944
g190
sg31939
I2
sa(dp40056
g31934
I37
sg31935
VCLDN1
p40057
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp40058
g31934
I59
sg31935
g40038
sg31936
I6
sg31944
VP78369
p40059
sg31939
I1
sasa(dp40060
g31925
VImmunohistochemical staining for these genes in samples from 81 cases of lung adenocarcinoma demonstrated the expressions of CLDN1 and CLDN10 were correlated with overall survival of patients with lung adenocarcinoma.
p40061
sg4
(dp40062
(VCLDN10
p40063
Vlung adenocarcinoma
p40064
tp40065
I00
ssg31931
(lp40066
(dp40067
g31934
I73
sg31935
Vlung adenocarcinoma
p40068
sg31936
I19
sg31937
VC0152013
p40069
sg31939
I2
sa(dp40070
g31934
I73
sg31935
g40064
sg31936
I19
sg31937
VC0152013
p40071
sg31939
I2
sasg31940
(lp40072
(dp40073
g31934
I135
sg31935
g40063
sg31936
I6
sg31944
VP78369
p40074
sg31939
I1
sa(dp40075
g31934
I125
sg31935
VCLDN1
p40076
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp40077
g31925
VOverexpression of CLDN1 and CLDN10 indicates a favorable prognosis for overall survival in some patients with lung adenocarcinoma.
p40078
sg4
(dp40079
(VCLDN10
p40080
Vlung adenocarcinoma
p40081
tp40082
I00
ssg31931
(lp40083
(dp40084
g31934
I110
sg31935
g40081
sg31936
I19
sg31937
VC0152013
p40085
sg31939
I2
sasg31940
(lp40086
(dp40087
g31934
I18
sg31935
VCLDN1
p40088
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp40089
g31934
I28
sg31935
g40080
sg31936
I6
sg31944
VP78369
p40090
sg31939
I1
sasa(dp40091
g31925
VThe highest rates of somatic, non-synonymous mutations were found in GNG10 and GNAZ, neither of which has been previously reported to be mutated in melanoma.
p40092
sg4
(dp40093
(VGNAZ
p40094
Vmelanoma
p40095
tp40096
I01
ssg31931
(lp40097
(dp40098
g31934
I148
sg31935
g40095
sg31936
I8
sg31937
VC0025202
p40099
sg31939
I1
sasg31940
(lp40100
(dp40101
g31934
I69
sg31935
VGNG10
p40102
sg31936
I5
sg31944
VP50151
p40103
sg31939
I1
sa(dp40104
g31934
I79
sg31935
g40094
sg31936
I4
sg31944
VP19086
p40105
sg31939
I1
sasa(dp40106
g31925
VVarious other protein products of genes associated with bipolar disorder either bind to or are affected by phosphatidyl-inositol phosphate products of this pathway (ADBRK2, HIP1R, KCNQ2, RGS4, WFS1), are associated with its constituent elements (BCR, DUSP6, FAT, GNAZ) or are downstream targets of this signalling cascade (DPYSL2, DRD3, GAD1, G6PD, GCH1, KCNQ2, NOS3, SLC6A3, SLC6A4, SST, TH, TIMELESS).
p40107
sg4
(dp40108
(VRGS4
p40109
VWFS1
p40110
tp40111
I00
ssg31931
(lp40112
(dp40113
g31934
I56
sg31935
Vbipolar disorder
p40114
sg31936
I16
sg31937
VC0005586
p40115
sg31939
I2
sa(dp40116
g31934
I193
sg31935
g40110
sg31936
I4
sg31937
VC0043207
p40117
sg31939
I1
sasg31940
(lp40118
(dp40119
g31934
I343
sg31935
VG6PD
p40120
sg31936
I4
sg31944
VP11441
p40121
sg31939
I1
sa(dp40122
g31934
I193
sg31935
VWFS1
p40123
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp40124
g31934
I384
sg31935
VSST
p40125
sg31936
I3
sg31944
VP61278
p40126
sg31939
I1
sa(dp40127
g31934
I251
sg31935
VDUSP6
p40128
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp40129
g31934
I263
sg31935
VGNAZ
p40130
sg31936
I4
sg31944
VP19086
p40131
sg31939
I1
sa(dp40132
g31934
I337
sg31935
VGAD1
p40133
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp40134
g31934
I258
sg31935
VFAT
p40135
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp40136
g31934
I323
sg31935
VDPYSL2
p40137
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp40138
g31934
I349
sg31935
VGCH1
p40139
sg31936
I4
sg31944
VP30793
p40140
sg31939
I1
sa(dp40141
g31934
I393
sg31935
VTIMELESS
p40142
sg31936
I8
sg31944
VP60174
p40143
sg31939
I1
sa(dp40144
g31934
I362
sg31935
VNOS3
p40145
sg31936
I4
sg31944
VP60323
p40146
sg31939
I1
sa(dp40147
g31934
I376
sg31935
VSLC6A4
p40148
sg31936
I6
sg31944
VP31645
p40149
sg31939
I1
sa(dp40150
g31934
I368
sg31935
VSLC6A3
p40151
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp40152
g31934
I246
sg31935
VBCR
p40153
sg31936
I3
sg31944
VP11274
p40154
sg31939
I1
sa(dp40155
g31934
I180
sg31935
VKCNQ2
p40156
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp40157
g31934
I331
sg31935
VDRD3
p40158
sg31936
I4
sg31944
VP35462
p40159
sg31939
I1
sa(dp40160
g31934
I173
sg31935
VHIP1R
p40161
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp40162
g31934
I187
sg31935
g40109
sg31936
I4
sg31944
VP49798
p40163
sg31939
I1
sa(dp40164
g31934
I180
sg31935
VKCNQ2
p40165
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp40166
g31925
VIn a recent study we found that the risk for unilateral retinoblastoma in offspring is 4 fold higher in women that are homozygotes for the 19 bp deletion in the DHFR gene and took folic acid supplement during pregnancy.
p40167
sg4
(dp40168
(VDHFR gene
p40169
Vunilateral retinoblastoma
p40170
tp40171
I00
ssg31931
(lp40172
(dp40173
g31934
I45
sg31935
g40170
sg31936
I25
sg31937
VC0854915
p40174
sg31939
I2
sasg31940
(lp40175
(dp40176
g31934
I161
sg31935
g40169
sg31936
I9
sg31944
VP00374
p40177
sg31939
I2
sasa(dp40178
g31925
VRetinoblastoma protein (pRb) was highly phosphorylated but p107 was upregulated, and the expression of E2f target genes was dysregulated as shown by upregulation of Cdc6 but downregulation of cyclin E, dihydrofolate reductase (dhfr), Cdc25a and B-Myb in chondrocytes of K6(H)/D1(H) mice.
p40179
sg4
(dp40180
(Vdihydrofolate reductase
p40181
VRetinoblastoma
p40182
tp40183
I00
ssg31931
(lp40184
(dp40185
g31934
I0
sg31935
g40182
sg31936
I14
sg31937
VC0035335
p40186
sg31939
I1
sasg31940
(lp40187
(dp40188
g31934
I103
sg31935
VE2f target genes
p40189
sg31936
I16
sg31944
VP01893
p40190
sg31939
I3
sa(dp40191
g31934
I192
sg31935
Vcyclin E
p40192
sg31936
I8
sg31944
VP24864
p40193
sg31939
I2
sa(dp40194
g31934
I234
sg31935
VCdc25a
p40195
sg31936
I6
sg31944
VP30304
p40196
sg31939
I1
sa(dp40197
g31934
I227
sg31935
Vdhfr
p40198
sg31936
I4
sg31944
VP00374
p40199
sg31939
I1
sa(dp40200
g31934
I0
sg31935
VRetinoblastoma protein
p40201
sg31936
I22
sg31944
g190
sg31939
I2
sa(dp40202
g31934
I245
sg31935
VB-Myb
p40203
sg31936
I5
sg31944
VP10244
p40204
sg31939
I1
sa(dp40205
g31934
I24
sg31935
VpRb
p40206
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp40207
g31934
I165
sg31935
VCdc6
p40208
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp40209
g31934
I59
sg31935
Vp107
p40210
sg31936
I4
sg31944
VP28749
p40211
sg31939
I1
sa(dp40212
g31934
I202
sg31935
g40181
sg31936
I23
sg31944
VP00374
p40213
sg31939
I2
sasa(dp40214
g31925
VThe authors used a case-control study design to examine the association between retinoblastoma risk and maternal variations in the folate-metabolizing genes methylenetetrahydrofolate reductase (MTHFR) (a cytosine-to-thymine substitution at nucleotide 677 [MTHFR677C-&gt;T]; reference single nucleotide polymorphism rs1801133) and dihydrofolate reductase (DHFR) (a 19-base-pair deletion of intron 1a [DHFR19bpdel]; rs70991108).
p40215
sg4
(dp40216
(Vfolate-metabolizing genes methylenetetrahydrofolate reductase
p40217
Vretinoblastoma
p40218
tp40219
I00
ssg31931
(lp40220
(dp40221
g31934
I80
sg31935
g40218
sg31936
I14
sg31937
VC0035335
p40222
sg31939
I1
sasg31940
(lp40223
(dp40224
g31934
I330
sg31935
Vdihydrofolate reductase
p40225
sg31936
I23
sg31944
VP00374
p40226
sg31939
I2
sa(dp40227
g31934
I355
sg31935
VDHFR
p40228
sg31936
I4
sg31944
VP00374
p40229
sg31939
I1
sa(dp40230
g31934
I194
sg31935
VMTHFR
p40231
sg31936
I5
sg31944
VP42898
p40232
sg31939
I1
sa(dp40233
g31934
I131
sg31935
g40217
sg31936
I61
sg31944
VP42898
p40234
sg31939
I4
sasa(dp40235
g31925
VMaternal homozygosity for a polymorphism in the DHFR gene necessary for converting synthetic folic acid into biologic folate was associated with an increased risk for retinoblastoma.
p40236
sg4
(dp40237
(VDHFR gene
p40238
Vretinoblastoma
p40239
tp40240
I00
ssg31931
(lp40241
(dp40242
g31934
I167
sg31935
g40239
sg31936
I14
sg31937
VC0035335
p40243
sg31939
I1
sasg31940
(lp40244
(dp40245
g31934
I48
sg31935
g40238
sg31936
I9
sg31944
VP00374
p40246
sg31939
I2
sasa(dp40247
g31925
VMolecular analysis of the GYS2 gene was not feasible, but this particular gene was included in the panel of hypoglycemia of whole exome sequencing (WES) which was at our disposal.
p40248
sg4
(dp40249
(VGYS2 gene
p40250
Vhypoglycemia
p40251
tp40252
I00
ssg31931
(lp40253
(dp40254
g31934
I108
sg31935
g40251
sg31936
I12
sg31937
VC0020615
p40255
sg31939
I1
sasg31940
(lp40256
(dp40257
g31934
I26
sg31935
g40250
sg31936
I9
sg31944
VP54840
p40258
sg31939
I2
sasa(dp40259
g31925
VTo understand the frequency of GSD0 in patients presenting with ketotic hypoglycaemia and to report a novel mutation in the GYS2 gene.
p40260
sg4
(dp40261
(VGYS2 gene
p40262
Vketotic hypoglycaemia
p40263
tp40264
I00
ssg31931
(lp40265
(dp40266
g31934
I64
sg31935
g40263
sg31936
I21
sg31937
VC0271713
p40267
sg31939
I2
sa(dp40268
g31934
I102
sg31935
Vnovel mutation
p40269
sg31936
I14
sg31937
VC2985438
p40270
sg31939
I2
sasg31940
(lp40271
(dp40272
g31934
I124
sg31935
g40262
sg31936
I9
sg31944
VP54840
p40273
sg31939
I2
sasa(dp40274
g31925
VThe GYS2 gene was sequenced in 50 patients diagnosed with ketotic hypoglycaemia.
p40275
sg4
(dp40276
(VGYS2 gene
p40277
Vketotic hypoglycaemia
p40278
tp40279
I00
ssg31931
(lp40280
(dp40281
g31934
I58
sg31935
g40278
sg31936
I21
sg31937
VC0271713
p40282
sg31939
I2
sasg31940
(lp40283
(dp40284
g31934
I4
sg31935
g40277
sg31936
I9
sg31944
VP54840
p40285
sg31939
I2
sasa(dp40286
g31925
VSequencing of the GYS2 gene is more likely to be positive in patients with fasting ketotic hypoglycaemia and concomitant postprandial hyperglycaemia with hyperlactataemia.
p40287
sg4
(dp40288
(VGYS2 gene
p40289
Vhyperglycaemia
p40290
tp40291
I00
ssg31931
(lp40292
(dp40293
g31934
I83
sg31935
Vketotic hypoglycaemia
p40294
sg31936
I21
sg31937
VC0271713
p40295
sg31939
I2
sa(dp40296
g31934
I134
sg31935
g40290
sg31936
I14
sg31937
VC0020456
p40297
sg31939
I1
sasg31940
(lp40298
(dp40299
g31934
I18
sg31935
g40289
sg31936
I9
sg31944
VP54840
p40300
sg31939
I2
sasa(dp40301
g31925
VBiochemical evaluation as well as direct sequencing of exons and exon-intron boundary regions of the GYS2 gene were performed in a patient presenting fasting hypoglycemia and postprandial hyperglycemia and her parents.
p40302
sg4
(dp40303
(VGYS2 gene
p40304
Vfasting hypoglycemia
p40305
tp40306
I00
ssg31931
(lp40307
(dp40308
g31934
I188
sg31935
Vhyperglycemia
p40309
sg31936
I13
sg31937
VC0020456
p40310
sg31939
I1
sa(dp40311
g31934
I150
sg31935
g40305
sg31936
I20
sg31937
VC0271708
p40312
sg31939
I2
sasg31940
(lp40313
(dp40314
g31934
I101
sg31935
g40304
sg31936
I9
sg31944
VP54840
p40315
sg31939
I2
sasa(dp40316
g31925
VA 7 year-old boy presenting with growth retardation, fasting hypoglycemia and ketoacidosis was diagnosed as having both idiopathic growth hormone (GH) deficiency and hepatic glycogen synthase (GS) deficiency caused by a homozygous mutation in exon 5 of the liver glycogen synthase gene (GYS-2).
p40317
sg4
(dp40318
(VGS
p40319
Vgrowth retardation
p40320
tp40321
I00
ssg31931
(lp40322
(dp40323
g31934
I53
sg31935
Vfasting hypoglycemia
p40324
sg31936
I20
sg31937
VC0271708
p40325
sg31939
I2
sa(dp40326
g31934
I78
sg31935
Vketoacidosis
p40327
sg31936
I12
sg31937
VC0220982
p40328
sg31939
I1
sa(dp40329
g31934
I33
sg31935
g40320
sg31936
I18
sg31937
VC0151686
p40330
sg31939
I2
sasg31940
(lp40331
(dp40332
g31934
I120
sg31935
Vidiopathic growth hormone
p40333
sg31936
I25
sg31944
VP01242
p40334
sg31939
I3
sa(dp40335
g31934
I287
sg31935
VGYS-2
p40336
sg31936
I5
sg31944
VP13807
p40337
sg31939
I1
sa(dp40338
g31934
I263
sg31935
Vglycogen synthase gene
p40339
sg31936
I22
sg31944
VP13807
p40340
sg31939
I3
sa(dp40341
g31934
I193
sg31935
g40319
sg31936
I2
sg31944
VP15104
p40342
sg31939
I1
sa(dp40343
g31934
I166
sg31935
Vhepatic glycogen synthase
p40344
sg31936
I25
sg31944
g190
sg31939
I3
sasa(dp40345
g31925
VGPB exhibits delayed release characteristics, presumably reflecting gradual PBA release by pancreatic lipases, and is well tolerated in adults with cirrhosis, suggesting that further clinical testing for HE is warranted.
p40346
sg4
(dp40347
(Vlipases
p40348
Vcirrhosis
p40349
tp40350
I00
ssg31931
(lp40351
(dp40352
g31934
I148
sg31935
g40349
sg31936
I9
sg31937
VC0023890
p40353
sg31939
I1
sasg31940
(lp40354
(dp40355
g31934
I0
sg31935
VGPB
p40356
sg31936
I3
sg31944
VP06028
p40357
sg31939
I1
sa(dp40358
g31934
I102
sg31935
g40348
sg31936
I7
sg31944
VP04118
p40359
sg31939
I1
sasa(dp40360
g31925
VHowever, the role of S1PR1 in the progression of human acute myeloid leukemia (AML) remains to be fully elucidated.
p40361
sg4
(dp40362
(VS1PR1
p40363
Vacute myeloid leukemia
p40364
tp40365
I00
ssg31931
(lp40366
(dp40367
g31934
I79
sg31935
VAML
p40368
sg31936
I3
sg31937
VC0023467
p40369
sg31939
I1
sa(dp40370
g31934
I55
sg31935
g40364
sg31936
I22
sg31937
VC0023467
p40371
sg31939
I3
sasg31940
(lp40372
(dp40373
g31934
I21
sg31935
g40363
sg31936
I5
sg31944
VP21453
p40374
sg31939
I1
sasa(dp40375
g31925
VUsing overexpression and RNA interference knockdown assays, it was shown that the expression of S1PR1 in several human myeloid leukemia cell lines contributed to the suppression of cell apoptosis and promotion of cell proliferation.
p40376
sg4
(dp40377
(VS1PR1
p40378
Vmyeloid leukemia
p40379
tp40380
I00
ssg31931
(lp40381
(dp40382
g31934
I218
sg31935
Vproliferation
p40383
sg31936
I13
sg31937
VC0334094
p40384
sg31939
I1
sa(dp40385
g31934
I166
sg31935
Vsuppression
p40386
sg31936
I11
sg31937
VC0221103
p40387
sg31939
I1
sa(dp40388
g31934
I119
sg31935
g40379
sg31936
I16
sg31937
VC0023470
p40389
sg31939
I2
sasg31940
(lp40390
(dp40391
g31934
I96
sg31935
g40378
sg31936
I5
sg31944
VP21453
p40392
sg31939
I1
sasa(dp40393
g31925
VCirculating chronic lymphocytic leukemia (CLL) cells display an abnormal increase in the surface levels of the homing receptors CCR7 and CXCR4 concomitant with low S1P receptor 1 (S1P1) expression.
p40394
sg4
(dp40395
(VCXCR4
p40396
VCLL
p40397
tp40398
I00
ssg31931
(lp40399
(dp40400
g31934
I12
sg31935
Vchronic lymphocytic leukemia
p40401
sg31936
I28
sg31937
VC0023434
p40402
sg31939
I3
sa(dp40403
g31934
I42
sg31935
g40397
sg31936
I3
sg31937
VC0023434
p40404
sg31939
I1
sasg31940
(lp40405
(dp40406
g31934
I128
sg31935
VCCR7
p40407
sg31936
I4
sg31944
VP32248
p40408
sg31939
I1
sa(dp40409
g31934
I164
sg31935
VS1P receptor 1
p40410
sg31936
I14
sg31944
g190
sg31939
I3
sa(dp40411
g31934
I137
sg31935
g40396
sg31936
I5
sg31944
VP61073
p40412
sg31939
I1
sa(dp40413
g31934
I180
sg31935
VS1P1
p40414
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp40415
g31925
VPrevious work in our laboratory identified keratin 17 (K17) as a specific and sensitive biomarker for high-grade squamous intraepithelial lesions and cervical squamous cell carcinoma (SCC).
p40416
sg4
(dp40417
(Vkeratin 17
p40418
Vcervical squamous cell carcinoma
p40419
tp40420
I01
ssg31931
(lp40421
(dp40422
g31934
I150
sg31935
g40419
sg31936
I32
sg31937
VC0279671
p40423
sg31939
I4
sasg31940
(lp40424
(dp40425
g31934
I55
sg31935
VK17
p40426
sg31936
I3
sg31944
VP02533
p40427
sg31939
I1
sa(dp40428
g31934
I43
sg31935
g40418
sg31936
I10
sg31944
VP02533
p40429
sg31939
I2
sasa(dp40430
g31925
VIn this study, we show that high expression of keratin-17 (K17) predicts poor outcome in patients with cervical cancer, at early or late stages of disease, surpassing in accuracy either tumor staging or loss of p27(KIP1) as a negative prognostic marker in this setting.
p40431
sg4
(dp40432
(VKIP1
p40433
Vcervical cancer
p40434
tp40435
I00
ssg31931
(lp40436
(dp40437
g31934
I103
sg31935
g40434
sg31936
I15
sg31937
VC0302592
p40438
sg31939
I2
sa(dp40439
g31934
I186
sg31935
Vtumor
p40440
sg31936
I5
sg31937
VC0027651
p40441
sg31939
I1
sasg31940
(lp40442
(dp40443
g31934
I47
sg31935
Vkeratin-17
p40444
sg31936
I10
sg31944
VP02533
p40445
sg31939
I1
sa(dp40446
g31934
I211
sg31935
Vp27
p40447
sg31936
I3
sg31944
VP40305
p40448
sg31939
I1
sa(dp40449
g31934
I59
sg31935
VK17
p40450
sg31936
I3
sg31944
VP02533
p40451
sg31939
I1
sa(dp40452
g31934
I215
sg31935
g40433
sg31936
I4
sg31944
VP46527
p40453
sg31939
I1
sasa(dp40454
g31925
VIn summary, both KRT4 and KRT17 expressions are related to the histopathology of the cervical squamous mucosa; KRT17 is highly overexpressed in immature squamous metaplasia, in HSIL, and in squamous cell carcinoma and the level of KRT17 in squamous cell carcinoma may help to identify patients who are at greatest risk for cervical cancer mortality.
p40455
sg4
(dp40456
(VKRT4
p40457
Vsquamous cell carcinoma
p40458
tp40459
I00
ssg31931
(lp40460
(dp40461
g31934
I323
sg31935
Vcervical cancer
p40462
sg31936
I15
sg31937
VC0302592
p40463
sg31939
I2
sa(dp40464
g31934
I153
sg31935
Vsquamous metaplasia
p40465
sg31936
I19
sg31937
VC0025570
p40466
sg31939
I2
sa(dp40467
g31934
I177
sg31935
VHSIL
p40468
sg31936
I4
sg31937
VC0333875
p40469
sg31939
I1
sa(dp40470
g31934
I190
sg31935
Vsquamous cell carcinoma
p40471
sg31936
I23
sg31937
VC0007137
p40472
sg31939
I3
sa(dp40473
g31934
I190
sg31935
g40458
sg31936
I23
sg31937
VC0007137
p40474
sg31939
I3
sasg31940
(lp40475
(dp40476
g31934
I17
sg31935
g40457
sg31936
I4
sg31944
VP19013
p40477
sg31939
I1
sasa(dp40478
g31925
VStromal tissue was isolated from epithelial cells with laser capture microdissection (LCMD) and analyzed by cDNA array for the expression of TGFalpha, TGF-beta1, HGF, PDGF-alpha, IGFII, bFGF, aFGF, VEGFC, and VEGF.
p40479
sg4
(dp40480
(VIGFII
p40481
VHGF
p40482
tp40483
I00
ssg31931
(lp40484
(dp40485
g31934
I162
sg31935
g40482
sg31936
I3
sg31937
VC0399440
p40486
sg31939
I1
sasg31940
(lp40487
(dp40488
g31934
I151
sg31935
VTGF-beta1
p40489
sg31936
I9
sg31944
VP01137
p40490
sg31939
I1
sa(dp40491
g31934
I192
sg31935
VaFGF
p40492
sg31936
I4
sg31944
VP05230
p40493
sg31939
I1
sa(dp40494
g31934
I198
sg31935
VVEGFC
p40495
sg31936
I5
sg31944
VP49767
p40496
sg31939
I1
sa(dp40497
g31934
I141
sg31935
VTGFalpha
p40498
sg31936
I8
sg31944
VP01135
p40499
sg31939
I1
sa(dp40500
g31934
I167
sg31935
VPDGF-alpha
p40501
sg31936
I10
sg31944
VP04085
p40502
sg31939
I1
sa(dp40503
g31934
I162
sg31935
VHGF
p40504
sg31936
I3
sg31944
VP05231
p40505
sg31939
I1
sa(dp40506
g31934
I186
sg31935
VbFGF
p40507
sg31936
I4
sg31944
VP53370
p40508
sg31939
I1
sa(dp40509
g31934
I179
sg31935
g40481
sg31936
I5
sg31944
VP01344
p40510
sg31939
I1
sasa(dp40511
g31925
VHere, we demonstrate that Inositol Polyphosphate-5-Phosphatase F (INPP5F), one of the polyphosphoinositide phosphatases, is differentially expressed in GSCs from glioma patients, and is identified as an inhibitor of STAT3 signaling via interaction with STAT3 and inhibition of its phosphorylation.
p40512
sg4
(dp40513
(VSTAT3
p40514
Vglioma
p40515
tp40516
I00
ssg31931
(lp40517
(dp40518
g31934
I162
sg31935
g40515
sg31936
I6
sg31937
VC0017638
p40519
sg31939
I1
sasg31940
(lp40520
(dp40521
g31934
I66
sg31935
VINPP5F
p40522
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp40523
g31934
I216
sg31935
VSTAT3
p40524
sg31936
I5
sg31944
VP40763
p40525
sg31939
I1
sa(dp40526
g31934
I216
sg31935
g40514
sg31936
I5
sg31944
VP40763
p40527
sg31939
I1
sa(dp40528
g31934
I26
sg31935
VInositol Polyphosphate-5-Phosphatase F
p40529
sg31936
I38
sg31944
g190
sg31939
I3
sasa(dp40530
g31925
VThese findings suggest that INPP5F is a potential tumor suppressor in gliomas via inhibition of STAT3 pathway, and that deregulation of INPP5F may lead to contribution to gliomagenesis.
p40531
sg4
(dp40532
(VSTAT3
p40533
Vgliomas
p40534
tp40535
I00
ssg31931
(lp40536
(dp40537
g31934
I70
sg31935
g40534
sg31936
I7
sg31937
VC0017638
p40538
sg31939
I1
sa(dp40539
g31934
I50
sg31935
Vtumor
p40540
sg31936
I5
sg31937
VC0027651
p40541
sg31939
I1
sasg31940
(lp40542
(dp40543
g31934
I28
sg31935
VINPP5F
p40544
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp40545
g31934
I96
sg31935
g40533
sg31936
I5
sg31944
VP40763
p40546
sg31939
I1
sa(dp40547
g31934
I28
sg31935
VINPP5F
p40548
sg31936
I6
sg31944
g190
sg31939
I1
sasa(dp40549
g31925
VSignificant associations with SAFS compared with atopic asthma included Toll-like receptor 3 (TLR3) (p = .009), TLR9 (p = .025), C-type lectin domain family seven member A (dectin-1) (p = .043), interleukin-10 (IL-10) (p = .0010), mannose-binding lectin (MBL2) (p = .007), CC-chemokine ligand 2 (CCL2) (2 SNPs, p = .025 and .041), CCL17 (p = .002), plasminogen (p = .049) and adenosine A2a receptor (p = .024).
p40550
sg4
(dp40551
(VCC-chemokine ligand 2
p40552
Vatopic asthma
p40553
tp40554
I01
ssg31931
(lp40555
(dp40556
g31934
I49
sg31935
g40553
sg31936
I13
sg31937
VC0155877
p40557
sg31939
I2
sasg31940
(lp40558
(dp40559
g31934
I211
sg31935
VIL-10
p40560
sg31936
I5
sg31944
VP22301
p40561
sg31939
I1
sa(dp40562
g31934
I94
sg31935
VTLR3
p40563
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp40564
g31934
I129
sg31935
VC-type lectin domain family seven member A
p40565
sg31936
I42
sg31944
g190
sg31939
I7
sa(dp40566
g31934
I195
sg31935
Vinterleukin-10
p40567
sg31936
I14
sg31944
VP22301
p40568
sg31939
I1
sa(dp40569
g31934
I376
sg31935
Vadenosine A2a receptor
p40570
sg31936
I22
sg31944
VP29274
p40571
sg31939
I3
sa(dp40572
g31934
I349
sg31935
Vplasminogen
p40573
sg31936
I11
sg31944
VP00747
p40574
sg31939
I1
sa(dp40575
g31934
I112
sg31935
VTLR9
p40576
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp40577
g31934
I72
sg31935
VToll-like receptor 3
p40578
sg31936
I20
sg31944
g190
sg31939
I3
sa(dp40579
g31934
I255
sg31935
VMBL2
p40580
sg31936
I4
sg31944
VP11226
p40581
sg31939
I1
sa(dp40582
g31934
I331
sg31935
VCCL17
p40583
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp40584
g31934
I296
sg31935
VCCL2
p40585
sg31936
I4
sg31944
VP13500
p40586
sg31939
I1
sa(dp40587
g31934
I231
sg31935
Vmannose-binding lectin
p40588
sg31936
I22
sg31944
VP11226
p40589
sg31939
I2
sa(dp40590
g31934
I273
sg31935
g40552
sg31936
I21
sg31944
VP51671
p40591
sg31939
I3
sasa(dp40592
g31925
VSoluble tumor necrosis factor receptor 1 (sTNF-R1), interleukin-1 receptor antagonist (IL-1Ra), von Willebrand factor (VWF), and osteoprotegerin (OPG) were measured in schizophrenia (n = 69) and affective (n = 55) spectrum patients at baseline and at one-year follow-up, and compared to healthy controls (HC) (n = 92) with analysis of covariance.
p40593
sg4
(dp40594
(VVWF
p40595
Vtumor necrosis
p40596
tp40597
I00
ssg31931
(lp40598
(dp40599
g31934
I168
sg31935
Vschizophrenia
p40600
sg31936
I13
sg31937
VC0036341
p40601
sg31939
I1
sa(dp40602
g31934
I8
sg31935
g40596
sg31936
I14
sg31937
VC0333516
p40603
sg31939
I2
sasg31940
(lp40604
(dp40605
g31934
I96
sg31935
Vvon Willebrand factor
p40606
sg31936
I21
sg31944
VP04275
p40607
sg31939
I3
sa(dp40608
g31934
I129
sg31935
Vosteoprotegerin
p40609
sg31936
I15
sg31944
g190
sg31939
I1
sa(dp40610
g31934
I52
sg31935
Vinterleukin-1 receptor antagonist
p40611
sg31936
I33
sg31944
VP18510
p40612
sg31939
I3
sa(dp40613
g31934
I0
sg31935
VSoluble tumor necrosis factor receptor 1
p40614
sg31936
I40
sg31944
g190
sg31939
I6
sa(dp40615
g31934
I146
sg31935
VOPG
p40616
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp40617
g31934
I87
sg31935
VIL-1Ra
p40618
sg31936
I6
sg31944
VP18510
p40619
sg31939
I1
sa(dp40620
g31934
I119
sg31935
g40595
sg31936
I3
sg31944
VP04275
p40621
sg31939
I1
sa(dp40622
g31934
I42
sg31935
VsTNF-R1
p40623
sg31936
I7
sg31944
g190
sg31939
I1
sasa(dp40624
g31925
VPlasma levels of soluble tumor necrosis factor receptor 1 (sTNF-R1), interleukin 1 receptor antagonist (IL-1Ra), osteoprotegerin (OPG), and von Willebrand factor (vWf) were measured in patients (n=992) with schizophrenia spectrum (SCZ, n=584), schizoaffective disorder (SA, n=93), affective spectrum disorders (AFF, n=315), and healthy controls (HC, n=638).
p40625
sg4
(dp40626
(Vvon Willebrand factor
p40627
Vschizophrenia
p40628
tp40629
I01
ssg31931
(lp40630
(dp40631
g31934
I244
sg31935
Vschizoaffective disorder
p40632
sg31936
I24
sg31937
VC0036337
p40633
sg31939
I2
sa(dp40634
g31934
I25
sg31935
Vtumor necrosis
p40635
sg31936
I14
sg31937
VC0333516
p40636
sg31939
I2
sa(dp40637
g31934
I270
sg31935
VSA
p40638
sg31936
I2
sg31937
VC0036337
p40639
sg31939
I1
sa(dp40640
g31934
I207
sg31935
g40628
sg31936
I13
sg31937
VC0036341
p40641
sg31939
I1
sasg31940
(lp40642
(dp40643
g31934
I163
sg31935
VvWf
p40644
sg31936
I3
sg31944
VP04275
p40645
sg31939
I1
sa(dp40646
g31934
I17
sg31935
Vsoluble tumor necrosis factor receptor 1
p40647
sg31936
I40
sg31944
g190
sg31939
I6
sa(dp40648
g31934
I104
sg31935
VIL-1Ra
p40649
sg31936
I6
sg31944
VP18510
p40650
sg31939
I1
sa(dp40651
g31934
I130
sg31935
VOPG
p40652
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp40653
g31934
I59
sg31935
VsTNF-R1
p40654
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp40655
g31934
I69
sg31935
Vinterleukin 1 receptor antagonist
p40656
sg31936
I33
sg31944
VP18510
p40657
sg31939
I4
sa(dp40658
g31934
I140
sg31935
g40627
sg31936
I21
sg31944
VP04275
p40659
sg31939
I3
sa(dp40660
g31934
I113
sg31935
Vosteoprotegerin
p40661
sg31936
I15
sg31944
g190
sg31939
I1
sasa(dp40662
g31925
VThis study suggests that consecutive PNC contributed to the improvement of the protein intake, serum levels of albumin, cholesterol and to the delay of muscle wasting, which could also have a positive impact on the nutritional status, particularly in malnourished patients receiving HD treatment.
p40663
sg4
(dp40664
(Valbumin
p40665
Vmalnourished
p40666
tp40667
I01
ssg31931
(lp40668
(dp40669
g31934
I152
sg31935
Vmuscle wasting
p40670
sg31936
I14
sg31937
VC0026846
p40671
sg31939
I2
sa(dp40672
g31934
I251
sg31935
g40666
sg31936
I12
sg31937
VC0162429
p40673
sg31939
I1
sasg31940
(lp40674
(dp40675
g31934
I111
sg31935
g40665
sg31936
I7
sg31944
VP00441
p40676
sg31939
I1
sasa(dp40677
g31925
VGCs = glucocorticoids; HDG = high-dose glucocorticoids; A1C = Hemoglobin A1C; GA = Glycated Albumin; FBG = fasting blood glucose; IG = interstitial glucose; BG = blood glucose; GIH = Glucocorticoids-induced hyperglycemia; HOMA-IR = Homeostasis Model Assessment-Insulin Resistance; CGMS = continuous glucose monitoring system; AUC = the area under the curve; MODD = absolute means of daily differences; LAGE = the largest amplitude of glycemic excursions; BMI = body mass index; DM = diabetes mellitus; SLE = systemic lupus erythematosus; IQR = interquartile range; HR = hazard ratio; PUMCH = Peking Union Medical College Hospital.
p40678
sg4
(dp40679
(VInsulin
p40680
Vhyperglycemia
p40681
tp40682
I00
ssg31931
(lp40683
(dp40684
g31934
I502
sg31935
VSLE
p40685
sg31936
I3
sg31937
VC0024141
p40686
sg31939
I1
sa(dp40687
g31934
I508
sg31935
Vsystemic lupus erythematosus
p40688
sg31936
I28
sg31937
VC0024141
p40689
sg31939
I3
sa(dp40690
g31934
I483
sg31935
Vdiabetes mellitus
p40691
sg31936
I17
sg31937
VC0011849
p40692
sg31939
I2
sa(dp40693
g31934
I261
sg31935
VInsulin Resistance
p40694
sg31936
I18
sg31937
VC0021655
p40695
sg31939
I2
sa(dp40696
g31934
I207
sg31935
g40681
sg31936
I13
sg31937
VC0020456
p40697
sg31939
I1
sasg31940
(lp40698
(dp40699
g31934
I261
sg31935
g40680
sg31936
I7
sg31944
VP01308
p40700
sg31939
I1
sa(dp40701
g31934
I62
sg31935
VHemoglobin
p40702
sg31936
I10
sg31944
g190
sg31939
I1
sasa(dp40703
g31925
VObjective To evaluate the presence and localization of folate receptor expressing macrophages in the rat groove model of osteoarthritis and determine the suitability of a new folate conjugate with albumin-binding entity (cm09) for in vivo SPECT (single-photon emission computed tomography) analysis.
p40704
sg4
(dp40705
(Valbumin
p40706
Vosteoarthritis
p40707
tp40708
I01
ssg31931
(lp40709
(dp40710
g31934
I121
sg31935
g40707
sg31936
I14
sg31937
VC0029408
p40711
sg31939
I1
sasg31940
(lp40712
(dp40713
g31934
I55
sg31935
Vfolate receptor
p40714
sg31936
I15
sg31944
VP15328
p40715
sg31939
I2
sa(dp40716
g31934
I197
sg31935
g40706
sg31936
I7
sg31944
VP00441
p40717
sg31939
I1
sasa(dp40718
g31925
VResults In vivo SPECT/CT imaging of the new folate conjugate (cm09) was as useful as a folate conjugate without albumin-binding entity in the groove model of osteoarthritis with less renal accumulation.
p40719
sg4
(dp40720
(Valbumin
p40721
Vosteoarthritis
p40722
tp40723
I01
ssg31931
(lp40724
(dp40725
g31934
I158
sg31935
g40722
sg31936
I14
sg31937
VC0029408
p40726
sg31939
I1
sasg31940
(lp40727
(dp40728
g31934
I112
sg31935
g40721
sg31936
I7
sg31944
VP00441
p40729
sg31939
I1
sasa(dp40730
g31925
VAmong identified psoriasis risk variants, three were more strongly associated with PsC than PsA (rs12189871 near HLA-C, p = 5.0 x 10(-19); rs4908742 near TNFRSF9, p = 0.00020; rs10888503 near LCE3A, p = 0.0014), and two were more strongly associated with PsA than PsC (rs12044149 near IL23R, p = 0.00018; rs9321623 near TNFAIP3, p = 0.00022).
p40731
sg4
(dp40732
(VTNFAIP3
p40733
Vpsoriasis
p40734
tp40735
I00
ssg31931
(lp40736
(dp40737
g31934
I83
sg31935
VPsC
p40738
sg31936
I3
sg31937
VC0566602
p40739
sg31939
I1
sa(dp40740
g31934
I92
sg31935
VPsA
p40741
sg31936
I3
sg31937
VC1519176
p40742
sg31939
I1
sa(dp40743
g31934
I83
sg31935
VPsC
p40744
sg31936
I3
sg31937
VC0566602
p40745
sg31939
I1
sa(dp40746
g31934
I92
sg31935
VPsA
p40747
sg31936
I3
sg31937
VC1519176
p40748
sg31939
I1
sa(dp40749
g31934
I17
sg31935
g40734
sg31936
I9
sg31937
VC0033860
p40750
sg31939
I1
sasg31940
(lp40751
(dp40752
g31934
I192
sg31935
VLCE3A
p40753
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp40754
g31934
I154
sg31935
VTNFRSF9
p40755
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp40756
g31934
I320
sg31935
g40733
sg31936
I7
sg31944
VP21580
p40757
sg31939
I1
sa(dp40758
g31934
I113
sg31935
VHLA
p40759
sg31936
I3
sg31944
VP30486
p40760
sg31939
I1
sasa(dp40761
g31925
VTo investigate the expression of the peripheral blood retinoid-related orphan receptor gamma t (RORgamma t) and 4-1BB/4-1BBL mRNA in oral lichen planus (OLP) patients.
p40762
sg4
(dp40763
(Vorphan receptor gamma t (RORgamma t) and 4-1BB/4-1BBL mRNA
p40764
Voral lichen planus
p40765
tp40766
I00
ssg31931
(lp40767
(dp40768
g31934
I153
sg31935
VOLP
p40769
sg31936
I3
sg31937
VC0206139
p40770
sg31939
I1
sa(dp40771
g31934
I133
sg31935
g40765
sg31936
I18
sg31937
VC0206139
p40772
sg31939
I3
sasg31940
(lp40773
(dp40774
g31934
I71
sg31935
g40764
sg31936
I58
sg31944
VP25106
p40775
sg31939
I9
sasa(dp40776
g31925
VBlood and tissue eosinophils from patients with IgE-mediated allergic responses (atopic dermatitis, extrinsic asthma) express CD137.
p40777
sg4
(dp40778
(VIgE
p40779
VIgE
p40780
tp40781
I01
ssg31931
(lp40782
(dp40783
g31934
I81
sg31935
Vatopic dermatitis
p40784
sg31936
I17
sg31937
VC0011615
p40785
sg31939
I2
sa(dp40786
g31934
I100
sg31935
Vextrinsic asthma
p40787
sg31936
I16
sg31937
VC0155877
p40788
sg31939
I2
sa(dp40789
g31934
I48
sg31935
g40780
sg31936
I3
sg31937
VC0270850
p40790
sg31939
I1
sasg31940
(lp40791
(dp40792
g31934
I126
sg31935
VCD137
p40793
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp40794
g31934
I48
sg31935
g40779
sg31936
I3
sg31944
VP01854
p40795
sg31939
I1
sasa(dp40796
g31925
VProteomic analysis revealed 14 statistically significant differentially expressed proteins, with nine showing increased expression (PDIA3, VIM/HEXA, SELENBP1, ENO1, CAPZA1, ERP29, TPI1, PARK7, and FABP3) and five showing decreased expression (EIF2S, PSMA3, RPSA, TUBB, and TUBA1B) in uveal melanomas that subsequently metastasized compared with those that did not.
p40797
sg4
(dp40798
(VTPI1
p40799
VPARK7
p40800
tp40801
I00
ssg31931
(lp40802
(dp40803
g31934
I318
sg31935
Vmetastasized
p40804
sg31936
I12
sg31937
VC0027627
p40805
sg31939
I1
sa(dp40806
g31934
I290
sg31935
Vmelanomas
p40807
sg31936
I9
sg31937
VC0025202
p40808
sg31939
I1
sa(dp40809
g31934
I186
sg31935
g40800
sg31936
I5
sg31937
VC1853445
p40810
sg31939
I1
sasg31940
(lp40811
(dp40812
g31934
I165
sg31935
VCAPZA1
p40813
sg31936
I6
sg31944
VP52907
p40814
sg31939
I1
sa(dp40815
g31934
I149
sg31935
VSELENBP1
p40816
sg31936
I8
sg31944
g190
sg31939
I1
sa(dp40817
g31934
I132
sg31935
VPDIA3
p40818
sg31936
I5
sg31944
VP30101
p40819
sg31939
I1
sa(dp40820
g31934
I143
sg31935
VHEXA
p40821
sg31936
I4
sg31944
VP06865
p40822
sg31939
I1
sa(dp40823
g31934
I273
sg31935
VTUBA1B
p40824
sg31936
I6
sg31944
VP68363
p40825
sg31939
I1
sa(dp40826
g31934
I197
sg31935
VFABP3
p40827
sg31936
I5
sg31944
VP05413
p40828
sg31939
I1
sa(dp40829
g31934
I173
sg31935
VERP29
p40830
sg31936
I5
sg31944
VP30040
p40831
sg31939
I1
sa(dp40832
g31934
I250
sg31935
VPSMA3
p40833
sg31936
I5
sg31944
VP25788
p40834
sg31939
I1
sa(dp40835
g31934
I263
sg31935
VTUBB
p40836
sg31936
I4
sg31944
VP04350
p40837
sg31939
I1
sa(dp40838
g31934
I180
sg31935
g40799
sg31936
I4
sg31944
VP60174
p40839
sg31939
I1
sa(dp40840
g31934
I186
sg31935
VPARK7
p40841
sg31936
I5
sg31944
g190
sg31939
I1
sasa(dp40842
g31925
VAmong these, 14 genes (FTL, K-ALPHA1, LDHA, RPL4, ENO1, ANXA2, RPL9, RPL10, RPL13A, GNB2L1, AMBP, GC, A1BG, and SERPINC1), in addition to previously well-known liver cancer related genes, were confirmed to be differentially expressed in seven liver cancer cell lines and 17 HCC tissues by semi-quantitative RT-PCR.
p40843
sg4
(dp40844
(VLDHA
p40845
Vliver cancer
p40846
tp40847
I01
ssg31931
(lp40848
(dp40849
g31934
I160
sg31935
Vliver cancer
p40850
sg31936
I12
sg31937
VC0345904
p40851
sg31939
I2
sa(dp40852
g31934
I274
sg31935
VHCC
p40853
sg31936
I3
sg31937
VC2239176
p40854
sg31939
I1
sa(dp40855
g31934
I160
sg31935
g40846
sg31936
I12
sg31937
VC0345904
p40856
sg31939
I2
sasg31940
(lp40857
(dp40858
g31934
I69
sg31935
VRPL10
p40859
sg31936
I5
sg31944
VP61313
p40860
sg31939
I1
sa(dp40861
g31934
I56
sg31935
VANXA2
p40862
sg31936
I5
sg31944
VP07355
p40863
sg31939
I1
sa(dp40864
g31934
I28
sg31935
VK-ALPHA1
p40865
sg31936
I8
sg31944
VP25100
p40866
sg31939
I1
sa(dp40867
g31934
I92
sg31935
VAMBP
p40868
sg31936
I4
sg31944
VP02760
p40869
sg31939
I1
sa(dp40870
g31934
I76
sg31935
VRPL13A
p40871
sg31936
I6
sg31944
VP40429
p40872
sg31939
I1
sa(dp40873
g31934
I102
sg31935
VA1BG
p40874
sg31936
I4
sg31944
VP04217
p40875
sg31939
I1
sa(dp40876
g31934
I63
sg31935
VRPL9
p40877
sg31936
I4
sg31944
VP32969
p40878
sg31939
I1
sa(dp40879
g31934
I44
sg31935
VRPL4
p40880
sg31936
I4
sg31944
VP36578
p40881
sg31939
I1
sa(dp40882
g31934
I23
sg31935
VFTL
p40883
sg31936
I3
sg31944
VP02792
p40884
sg31939
I1
sa(dp40885
g31934
I84
sg31935
VGNB2L1
p40886
sg31936
I6
sg31944
VP63244
p40887
sg31939
I1
sa(dp40888
g31934
I38
sg31935
g40845
sg31936
I4
sg31944
VP00338
p40889
sg31939
I1
sasa(dp40890
g31925
VExpression profiles of the 9 genes ACTB, ALAS1, G6PD, GAPD, HMBS, HPRT1, K-ALPHA-1, SDHA and TBP were established in matched malignant and nonmalignant tissue specimens from 14 patients with bladder cancer.
p40891
sg4
(dp40892
(VHMBS
p40893
Vbladder cancer
p40894
tp40895
I00
ssg31931
(lp40896
(dp40897
g31934
I191
sg31935
g40894
sg31936
I14
sg31937
VC0699885
p40898
sg31939
I2
sasg31940
(lp40899
(dp40900
g31934
I73
sg31935
VK-ALPHA-1
p40901
sg31936
I9
sg31944
VP68363
p40902
sg31939
I1
sa(dp40903
g31934
I41
sg31935
VALAS1
p40904
sg31936
I5
sg31944
VP13196
p40905
sg31939
I1
sa(dp40906
g31934
I66
sg31935
VHPRT1
p40907
sg31936
I5
sg31944
VP55884
p40908
sg31939
I1
sa(dp40909
g31934
I93
sg31935
VTBP
p40910
sg31936
I3
sg31944
VP20226
p40911
sg31939
I1
sa(dp40912
g31934
I48
sg31935
VG6PD
p40913
sg31936
I4
sg31944
VP11441
p40914
sg31939
I1
sa(dp40915
g31934
I54
sg31935
VGAPD
p40916
sg31936
I4
sg31944
VP04406
p40917
sg31939
I1
sa(dp40918
g31934
I35
sg31935
VACTB
p40919
sg31936
I4
sg31944
VP63261
p40920
sg31939
I1
sa(dp40921
g31934
I84
sg31935
VSDHA
p40922
sg31936
I4
sg31944
VP31040
p40923
sg31939
I1
sa(dp40924
g31934
I60
sg31935
g40893
sg31936
I4
sg31944
VP08397
p40925
sg31939
I1
sasa(dp40926
g31925
VThe use of HPRT1 alone as a reference gene shown in our study was sufficient, but the normalization factors generated from two (HRPT1, ALAS1) or all three genes (HRPT1, ALAS1, K-ALPHA-1) should be considered for an improved reliability of normalization in gene profiling studies of prostate cancer.
p40927
sg4
(dp40928
(VALAS1
p40929
VHRPT1
p40930
tp40931
I00
ssg31931
(lp40932
(dp40933
g31934
I128
sg31935
VHRPT1
p40934
sg31936
I5
sg31937
VC1840402
p40935
sg31939
I1
sa(dp40936
g31934
I282
sg31935
Vprostate cancer
p40937
sg31936
I15
sg31937
VC0600139
p40938
sg31939
I2
sa(dp40939
g31934
I128
sg31935
g40930
sg31936
I5
sg31937
VC1840402
p40940
sg31939
I1
sasg31940
(lp40941
(dp40942
g31934
I128
sg31935
VHRPT1
p40943
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp40944
g31934
I176
sg31935
VK-ALPHA-1
p40945
sg31936
I9
sg31944
VP68363
p40946
sg31939
I1
sa(dp40947
g31934
I128
sg31935
VHRPT1
p40948
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp40949
g31934
I11
sg31935
VHPRT1
p40950
sg31936
I5
sg31944
VP55884
p40951
sg31939
I1
sa(dp40952
g31934
I135
sg31935
VALAS1
p40953
sg31936
I5
sg31944
VP13196
p40954
sg31939
I1
sa(dp40955
g31934
I135
sg31935
g40929
sg31936
I5
sg31944
VP13196
p40956
sg31939
I1
sasa(dp40957
g31925
VWe show that glucose clearance rates are affected in both children with marasmus as well as kwashiorkor, which correlate with plasma albumin concentrations.
p40958
sg4
(dp40959
(Vplasma albumin
p40960
Vmarasmus
p40961
tp40962
I00
ssg31931
(lp40963
(dp40964
g31934
I92
sg31935
Vkwashiorkor
p40965
sg31936
I11
sg31937
VC0022806
p40966
sg31939
I1
sa(dp40967
g31934
I72
sg31935
g40961
sg31936
I8
sg31937
VC0086588
p40968
sg31939
I1
sasg31940
(lp40969
(dp40970
g31934
I126
sg31935
g40960
sg31936
I14
sg31944
VP00441
p40971
sg31939
I2
sasa(dp40972
g31925
VTotal proteins, albumin and transferrin were all significantly lower in children with edema than in those with marasmus.
p40973
sg4
(dp40974
(Valbumin
p40975
Vmarasmus
p40976
tp40977
I00
ssg31931
(lp40978
(dp40979
g31934
I86
sg31935
Vedema
p40980
sg31936
I5
sg31937
VC0013604
p40981
sg31939
I1
sa(dp40982
g31934
I111
sg31935
g40976
sg31936
I8
sg31937
VC0086588
p40983
sg31939
I1
sasg31940
(lp40984
(dp40985
g31934
I28
sg31935
Vtransferrin
p40986
sg31936
I11
sg31944
VP02787
p40987
sg31939
I1
sa(dp40988
g31934
I16
sg31935
g40975
sg31936
I7
sg31944
VP00441
p40989
sg31939
I1
sasa(dp40990
g31925
VIn this condition, 8CR inhibited edema and myonecrosis induced by the sPLA2 activity of Crotalus durissus terrificus in a dose-dependent manner by decreasing interleukin-1Beta (IL-1Beta), tumor necrosis factor Alfa (TNF-Alfa), prostaglandin E2 (PGE2), and lipid peroxidation.
p40991
sg4
(dp40992
(VsPLA2
p40993
Vtumor necrosis
p40994
tp40995
I00
ssg31931
(lp40996
(dp40997
g31934
I8
sg31935
Vcondition
p40998
sg31936
I9
sg31937
VC0012634
p40999
sg31939
I1
sa(dp41000
g31934
I43
sg31935
Vmyonecrosis
p41001
sg31936
I11
sg31937
VC0235957
p41002
sg31939
I1
sa(dp41003
g31934
I33
sg31935
Vedema
p41004
sg31936
I5
sg31937
VC0013604
p41005
sg31939
I1
sa(dp41006
g31934
I188
sg31935
g40994
sg31936
I14
sg31937
VC0333516
p41007
sg31939
I2
sasg31940
(lp41008
(dp41009
g31934
I216
sg31935
VTNF-Alfa
p41010
sg31936
I8
sg31944
VP01375
p41011
sg31939
I1
sa(dp41012
g31934
I177
sg31935
VIL-1Beta
p41013
sg31936
I8
sg31944
VP01584
p41014
sg31939
I1
sa(dp41015
g31934
I158
sg31935
Vinterleukin-1Beta
p41016
sg31936
I17
sg31944
VP01584
p41017
sg31939
I1
sa(dp41018
g31934
I188
sg31935
Vtumor necrosis factor Alfa
p41019
sg31936
I26
sg31944
VP01375
p41020
sg31939
I4
sa(dp41021
g31934
I70
sg31935
g40993
sg31936
I5
sg31944
VP14555
p41022
sg31939
I1
sasa(dp41023
g31925
VIn addition, it was shown that Crotalus durissus terrificus sPLA2 increases cell oxidative stress during edema and myonecrosis, and the antioxidant properties of the polyphenolic compound may be significant in mitigating the pharmacological effect induced by sPLA2 and other snake venom toxins.
p41024
sg4
(dp41025
(VsPLA2
p41026
Voxidative stress
p41027
tp41028
I00
ssg31931
(lp41029
(dp41030
g31934
I115
sg31935
Vmyonecrosis
p41031
sg31936
I11
sg31937
VC0235957
p41032
sg31939
I1
sa(dp41033
g31934
I105
sg31935
Vedema
p41034
sg31936
I5
sg31937
VC0013604
p41035
sg31939
I1
sa(dp41036
g31934
I81
sg31935
g41027
sg31936
I16
sg31937
VC0242606
p41037
sg31939
I2
sasg31940
(lp41038
(dp41039
g31934
I60
sg31935
g41026
sg31936
I5
sg31944
VP14555
p41040
sg31939
I1
sasa(dp41041
g31925
VIncubation with pertussis toxin prior to the addition of either sPLA2 or LPA only showed abrogation of the response to LPA, thus suggesting the involvement of pertussis-sensitive Gi-proteins in the case of LPA.
p41042
sg4
(dp41043
(VGi-proteins
p41044
Vpertussis
p41045
tp41046
I00
ssg31931
(lp41047
(dp41048
g31934
I16
sg31935
Vpertussis
p41049
sg31936
I9
sg31937
VC0043167
p41050
sg31939
I1
sa(dp41051
g31934
I16
sg31935
g41045
sg31936
I9
sg31937
VC0043167
p41052
sg31939
I1
sasg31940
(lp41053
(dp41054
g31934
I64
sg31935
VsPLA2
p41055
sg31936
I5
sg31944
VP14555
p41056
sg31939
I1
sa(dp41057
g31934
I16
sg31935
Vpertussis toxin
p41058
sg31936
I15
sg31944
g190
sg31939
I2
sa(dp41059
g31934
I179
sg31935
g41044
sg31936
I11
sg31944
VP63096
p41060
sg31939
I1
sasa(dp41061
g31925
VArchival tissue from 38 patients with superficial smooth muscle cell and so-called fibrohistiocytic tumors (8 benign fibrous histiocytomas (BFHs), 6 dermatofibrosarcoma protuberans (DFPT), 9 malignant fibrous histiocytomas (MFHs), 9 leiomyomas (LMs) and 6 leiomyosarcomas (LMSs)) were immunostained with antibodies against SMA, HCD, CALP, PLAP and HPL.
p41062
sg4
(dp41063
(VHPL
p41064
VMFHs
p41065
tp41066
I00
ssg31931
(lp41067
(dp41068
g31934
I110
sg31935
Vbenign fibrous histiocytomas
p41069
sg31936
I28
sg31937
VC0206644
p41070
sg31939
I3
sa(dp41071
g31934
I233
sg31935
Vleiomyomas
p41072
sg31936
I10
sg31937
VC0023267
p41073
sg31939
I1
sa(dp41074
g31934
I100
sg31935
Vtumors
p41075
sg31936
I6
sg31937
VC0027651
p41076
sg31939
I1
sa(dp41077
g31934
I191
sg31935
Vmalignant fibrous histiocytomas
p41078
sg31936
I31
sg31937
VC0334463
p41079
sg31939
I3
sa(dp41080
g31934
I256
sg31935
Vleiomyosarcomas
p41081
sg31936
I15
sg31937
VC0023269
p41082
sg31939
I1
sa(dp41083
g31934
I323
sg31935
VSMA
p41084
sg31936
I3
sg31937
VC0026847
p41085
sg31939
I1
sa(dp41086
g31934
I328
sg31935
VHCD
p41087
sg31936
I3
sg31937
VC0235833
p41088
sg31939
I1
sa(dp41089
g31934
I245
sg31935
VLMs
p41090
sg31936
I3
sg31937
VC1851710
p41091
sg31939
I1
sa(dp41092
g31934
I149
sg31935
Vdermatofibrosarcoma protuberans
p41093
sg31936
I31
sg31937
VC0392784
p41094
sg31939
I2
sa(dp41095
g31934
I273
sg31935
VLMSs
p41096
sg31936
I4
sg31937
VC0023269
p41097
sg31939
I1
sa(dp41098
g31934
I224
sg31935
g41065
sg31936
I4
sg31937
VC0334463
p41099
sg31939
I1
sasg31940
(lp41100
(dp41101
g31934
I323
sg31935
VSMA
p41102
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp41103
g31934
I339
sg31935
VPLAP
p41104
sg31936
I4
sg31944
VP51003
p41105
sg31939
I1
sa(dp41106
g31934
I348
sg31935
g41064
sg31936
I3
sg31944
VP09382
p41107
sg31939
I1
sa(dp41108
g31934
I328
sg31935
VHCD
p41109
sg31936
I3
sg31944
VP0C7U2
p41110
sg31939
I1
sa(dp41111
g31934
I333
sg31935
VCALP
p41112
sg31936
I4
sg31944
g190
sg31939
I1
sasa(dp41113
g31925
VIn cell culture, d12.CALP at low multiplicity of infection (0.001 plaque-forming unit/cell) selectively killed calponin-positive human synovial sarcoma, leiomyosarcoma, and osteosarcoma cells.
p41114
sg4
(dp41115
(Vcalponin
p41116
Vleiomyosarcoma
p41117
tp41118
I00
ssg31931
(lp41119
(dp41120
g31934
I49
sg31935
Vinfection
p41121
sg31936
I9
sg31937
VC0009450
p41122
sg31939
I1
sa(dp41123
g31934
I66
sg31935
Vplaque
p41124
sg31936
I6
sg31937
VC0011389
p41125
sg31939
I1
sa(dp41126
g31934
I173
sg31935
Vosteosarcoma
p41127
sg31936
I12
sg31937
VC0029463
p41128
sg31939
I1
sa(dp41129
g31934
I135
sg31935
Vsynovial sarcoma
p41130
sg31936
I16
sg31937
VC0039101
p41131
sg31939
I2
sa(dp41132
g31934
I153
sg31935
g41117
sg31936
I14
sg31937
VC0023269
p41133
sg31939
I1
sasg31940
(lp41134
(dp41135
g31934
I111
sg31935
g41116
sg31936
I8
sg31944
VP51911
p41136
sg31939
I1
sasa(dp41137
g31925
VTo investigate the possible role of beta-defensins in gingival health and periodontal disease, we examined the effect of several stimuli on the expression of interleukin-8 (IL-8), human beta-defensin-1, -2, -3, and -4 (hBD) in primary human diseased gingival epithelial (HGE) cell cultures from periodontitis patients by quantitative TaqMan reverse transcription polymerase chain reaction (RT-PCR).
p41138
sg4
(dp41139
(Vinterleukin-8
p41140
Vperiodontal disease
p41141
tp41142
I01
ssg31931
(lp41143
(dp41144
g31934
I219
sg31935
VhBD
p41145
sg31936
I3
sg31937
VC1840321
p41146
sg31939
I1
sa(dp41147
g31934
I295
sg31935
Vperiodontitis
p41148
sg31936
I13
sg31937
VC0031099
p41149
sg31939
I1
sa(dp41150
g31934
I74
sg31935
g41141
sg31936
I19
sg31937
VC0031090
p41151
sg31939
I2
sasg31940
(lp41152
(dp41153
g31934
I219
sg31935
VhBD
p41154
sg31936
I3
sg31944
VP02042
p41155
sg31939
I1
sa(dp41156
g31934
I36
sg31935
Vbeta-defensins
p41157
sg31936
I14
sg31944
g190
sg31939
I1
sa(dp41158
g31934
I173
sg31935
VIL-8
p41159
sg31936
I4
sg31944
VP60568
p41160
sg31939
I1
sa(dp41161
g31934
I158
sg31935
g41140
sg31936
I13
sg31944
VP60568
p41162
sg31939
I1
sasa(dp41163
g31925
VIn this study, CYP2E1*5B, CYP2E1*6, CYP2E1*7B, GSTO1 (A140D), and TP53 (Arg72Pro) polymorphisms and response to platinum-based chemotherapy and survival in 137 advanced stage NSCLC patients were investigated.
p41164
sg4
(dp41165
(VCYP2E1*6
p41166
VNSCLC
p41167
tp41168
I00
ssg31931
(lp41169
(dp41170
g31934
I175
sg31935
g41167
sg31936
I5
sg31937
VC0007131
p41171
sg31939
I1
sasg31940
(lp41172
(dp41173
g31934
I36
sg31935
VCYP2E1*7B
p41174
sg31936
I9
sg31944
VP05181
p41175
sg31939
I1
sa(dp41176
g31934
I15
sg31935
VCYP2E1*5B
p41177
sg31936
I9
sg31944
VP05181
p41178
sg31939
I1
sa(dp41179
g31934
I47
sg31935
VGSTO1 (A140D), and TP53
p41180
sg31936
I23
sg31944
VP78417
p41181
sg31939
I4
sa(dp41182
g31934
I26
sg31935
g41166
sg31936
I8
sg31944
VP05181
p41183
sg31939
I1
sasa(dp41184
g31925
VGSTO1-1 expression pattern has not been studied in transitional cell carcinoma (TCC), as yet.
p41185
sg4
(dp41186
(VGSTO1-1
p41187
Vtransitional cell carcinoma
p41188
tp41189
I00
ssg31931
(lp41190
(dp41191
g31934
I80
sg31935
VTCC
p41192
sg31936
I3
sg31937
VC1861305
p41193
sg31939
I1
sa(dp41194
g31934
I51
sg31935
g41188
sg31936
I27
sg31937
VC0007138
p41195
sg31939
I3
sasg31940
(lp41196
(dp41197
g31934
I0
sg31935
g41187
sg31936
I7
sg31944
VP78417
p41198
sg31939
I1
sasa(dp41199
g31925
VIncreased GSTO1-1 expression might contribute to TCC development and/or progression supporting the notion that GSTO1-1 may be a promising novel cancer target.
p41200
sg4
(dp41201
(VGSTO1-1
p41202
VTCC
p41203
tp41204
I00
ssg31931
(lp41205
(dp41206
g31934
I49
sg31935
g41203
sg31936
I3
sg31937
VC1861305
p41207
sg31939
I1
sa(dp41208
g31934
I144
sg31935
Vcancer
p41209
sg31936
I6
sg31937
VC0006826
p41210
sg31939
I1
sasg31940
(lp41211
(dp41212
g31934
I10
sg31935
VGSTO1-1
p41213
sg31936
I7
sg31944
VP78417
p41214
sg31939
I1
sa(dp41215
g31934
I10
sg31935
g41202
sg31936
I7
sg31944
VP78417
p41216
sg31939
I1
sasa(dp41217
g31925
VThese potent GSTO1 inhibitors suppress cancer cell growth, enhance the cytotoxic effects of cisplatin and inhibit tumour growth in colon cancer models as single agent.
p41218
sg4
(dp41219
(VGSTO1
p41220
Vcolon cancer
p41221
tp41222
I00
ssg31931
(lp41223
(dp41224
g31934
I114
sg31935
Vtumour
p41225
sg31936
I6
sg31937
VC0027651
p41226
sg31939
I1
sa(dp41227
g31934
I131
sg31935
g41221
sg31936
I12
sg31937
VC0699790
p41228
sg31939
I2
sa(dp41229
g31934
I39
sg31935
Vcancer cell growth
p41230
sg31936
I18
sg31937
VC1516170
p41231
sg31939
I3
sasg31940
(lp41232
(dp41233
g31934
I13
sg31935
g41220
sg31936
I5
sg31944
VP78417
p41234
sg31939
I1
sasa(dp41235
g31925
VOur findings demonstrate the therapeutic utility of GSTO1 inhibitors as anticancer agents and identify the novel cellular pathways under GSTO1 regulation in colorectal cancer.
p41236
sg4
(dp41237
(VGSTO1
p41238
Vcolorectal cancer
p41239
tp41240
I00
ssg31931
(lp41241
(dp41242
g31934
I157
sg31935
g41239
sg31936
I17
sg31937
VC1527249
p41243
sg31939
I2
sasg31940
(lp41244
(dp41245
g31934
I52
sg31935
g41238
sg31936
I5
sg31944
VP78417
p41246
sg31939
I1
sasa(dp41247
g31925
VMany genes previously known to be affected by BPA and involved in obesity, hypertension, or heart disease were altered following these treatments, and AP-1, EGR1, and EGFR were key hubs affected by BPA and/or overfeeding.
p41248
sg4
(dp41249
(VAP-1
p41250
Vheart disease
p41251
tp41252
I00
ssg31931
(lp41253
(dp41254
g31934
I66
sg31935
Vobesity
p41255
sg31936
I7
sg31937
VC0028754
p41256
sg31939
I1
sa(dp41257
g31934
I75
sg31935
Vhypertension
p41258
sg31936
I12
sg31937
VC0020538
p41259
sg31939
I1
sa(dp41260
g31934
I92
sg31935
g41251
sg31936
I13
sg31937
VC0018799
p41261
sg31939
I2
sasg31940
(lp41262
(dp41263
g31934
I157
sg31935
VEGR1
p41264
sg31936
I4
sg31944
VP18146
p41265
sg31939
I1
sa(dp41266
g31934
I151
sg31935
g41250
sg31936
I4
sg31944
VP01100
p41267
sg31939
I1
sasa(dp41268
g31925
VUsing immunohistochemistry, we studied Egr-1 expression specifically in a wide morphologic spectrum of pulmonary arteries in the lung tissue of 72 patients with different forms and stages of PAH, specifically idiopathic PAH (n = 18), advanced-stage congenital heart disease-associated PAH (PAH-CHD) (n = 21), early-stage PAH-CHD (n = 19) and non-neointimal hypoxic pulmonary hypertension (PH) (n = 4), and controls (n = 10).
p41269
sg4
(dp41270
(VPAH
p41271
VPAH
p41272
tp41273
I00
ssg31931
(lp41274
(dp41275
g31934
I389
sg31935
VPH
p41276
sg31936
I2
sg31937
VC0020542
p41277
sg31939
I1
sa(dp41278
g31934
I365
sg31935
Vpulmonary hypertension
p41279
sg31936
I22
sg31937
VC0020542
p41280
sg31939
I2
sa(dp41281
g31934
I191
sg31935
VPAH
p41282
sg31936
I3
sg31937
VC0152171
p41283
sg31939
I1
sa(dp41284
g31934
I191
sg31935
VPAH
p41285
sg31936
I3
sg31937
VC0152171
p41286
sg31939
I1
sa(dp41287
g31934
I191
sg31935
VPAH
p41288
sg31936
I3
sg31937
VC0152171
p41289
sg31939
I1
sa(dp41290
g31934
I191
sg31935
VPAH
p41291
sg31936
I3
sg31937
VC0152171
p41292
sg31939
I1
sa(dp41293
g31934
I357
sg31935
Vhypoxic
p41294
sg31936
I7
sg31937
VC0242184
p41295
sg31939
I1
sa(dp41296
g31934
I249
sg31935
Vcongenital heart disease
p41297
sg31936
I24
sg31937
VC0152021
p41298
sg31939
I3
sa(dp41299
g31934
I191
sg31935
g41272
sg31936
I3
sg31937
VC0152171
p41300
sg31939
I1
sasg31940
(lp41301
(dp41302
g31934
I290
sg31935
VPAH-CHD
p41303
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp41304
g31934
I191
sg31935
VPAH
p41305
sg31936
I3
sg31944
VP00439
p41306
sg31939
I1
sa(dp41307
g31934
I39
sg31935
VEgr-1
p41308
sg31936
I5
sg31944
VP18146
p41309
sg31939
I1
sa(dp41310
g31934
I191
sg31935
g41271
sg31936
I3
sg31944
VP00439
p41311
sg31939
I1
sasa(dp41312
g31925
VParkin substrates include two septins; SEPT4/CDCrel-2 which coaggregates with Alfa-synuclein as Lewy bodies in Parkinson's disease, and its closest homolog SEPT5/CDCrel-1/PNUTL1 whose overload with viral vector can rapidly eliminate dopamine neurons in rats.
p41313
sg4
(dp41314
(VAlfa-synuclein
p41315
VParkinson's disease
p41316
tp41317
I00
ssg31931
(lp41318
(dp41319
g31934
I111
sg31935
g41316
sg31936
I19
sg31937
VC0030567
p41320
sg31939
I2
sasg31940
(lp41321
(dp41322
g31934
I156
sg31935
VSEPT5
p41323
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp41324
g31934
I30
sg31935
Vseptins
p41325
sg31936
I7
sg31944
g190
sg31939
I1
sa(dp41326
g31934
I171
sg31935
VPNUTL1
p41327
sg31936
I6
sg31944
g190
sg31939
I1
sa(dp41328
g31934
I78
sg31935
g41315
sg31936
I14
sg31944
VP37840
p41329
sg31939
I1
sa(dp41330
g31934
I39
sg31935
VSEPT4
p41331
sg31936
I5
sg31944
g190
sg31939
I1
sa(dp41332
g31934
I162
sg31935
VCDCrel-1
p41333
sg31936
I8
sg31944
g190
sg31939
I1
sa(dp41334
g31934
I45
sg31935
VCDCrel-2
p41335
sg31936
I8
sg31944
g190
sg31939
I1
sasa(dp41336
g31925
VAfter validation by Western blot and quantitative real-time PCR, the expressions of three proteins related to neurodegenerative disease, septin 5, Alfa-internexin, and Alfa-synuclein, were identified to be altered by MCLR exposure.
p41337
sg4
(dp41338
(VAlfa-synuclein
p41339
Vneurodegenerative disease
p41340
tp41341
I00
ssg31931
(lp41342
(dp41343
g31934
I110
sg31935
g41340
sg31936
I25
sg31937
VC0524851
p41344
sg31939
I2
sasg31940
(lp41345
(dp41346
g31934
I168
sg31935
g41339
sg31936
I14
sg31944
VP37840
p41347
sg31939
I1
sa(dp41348
g31934
I137
sg31935
Vseptin 5
p41349
sg31936
I8
sg31944
g190
sg31939
I2
sasa(dp41350
g31925
VThis study was to investigate HSP70 expression in the peripheral lung tissues of chronic obstructive pulmonary disease (COPD) patients and in human bronchial epithelial cells (16-HBE) exposed to cigarette smoke extract (CSE).
p41351
sg4
(dp41352
(VHSP70
p41353
VCOPD
p41354
tp41355
I01
ssg31931
(lp41356
(dp41357
g31934
I220
sg31935
VCSE
p41358
sg31936
I3
sg31937
VC1832855
p41359
sg31939
I1
sa(dp41360
g31934
I81
sg31935
Vchronic obstructive pulmonary disease
p41361
sg31936
I37
sg31937
VC0024117
p41362
sg31939
I4
sa(dp41363
g31934
I195
sg31935
Vcigarette smoke extract
p41364
sg31936
I23
sg31937
VC1832855
p41365
sg31939
I3
sa(dp41366
g31934
I120
sg31935
g41354
sg31936
I4
sg31937
VC0024117
p41367
sg31939
I1
sasg31940
(lp41368
(dp41369
g31934
I30
sg31935
g41353
sg31936
I5
sg31944
VP34932
p41370
sg31939
I1
sasa(dp41371
g31925
VMicrovascular dysfunction under septic shock is related to: increased capillary permeability that manifests as a breakdown of the microvascular endothelial barrier (factors which may contribute to capillary leak syndrome include endogenous proinflammatory cytokines, angiopoietin 2, vascular endothelial growth factor); arteriolar hyporesponsiveness to vasoconstrictors and vasodilators, the loss of adrenergic sensitivity and tone of smooth muscle cells lining the arterioles; loss of the anti-adhesive function of endothelial surfaces; decreased density of perfused capillaries (due to several contributing factors: decreased deformability of erythrocytes and neutrophils; activation of the clotting cascade with fibrin deposition and the formation of microthrombi; dysfunction of vascular autoregulatory mechanisms by nitric oxide; enhanced functional arteriovenous shunting of the microcirculation).
p41372
sg4
(dp41373
(Vfibrin
p41374
Vseptic shock
p41375
tp41376
I00
ssg31931
(lp41377
(dp41378
g31934
I113
sg31935
Vbreakdown
p41379
sg31936
I9
sg31937
VC1265875
p41380
sg31939
I1
sa(dp41381
g31934
I715
sg31935
Vfibrin deposition
p41382
sg31936
I17
sg31937
VC0333565
p41383
sg31939
I2
sa(dp41384
g31934
I197
sg31935
Vcapillary leak syndrome
p41385
sg31936
I23
sg31937
VC0343084
p41386
sg31939
I3
sa(dp41387
g31934
I32
sg31935
g41375
sg31936
I12
sg31937
VC0036983
p41388
sg31939
I2
sasg31940
(lp41389
(dp41390
g31934
I283
sg31935
Vvascular endothelial growth factor
p41391
sg31936
I34
sg31944
g190
sg31939
I4
sa(dp41392
g31934
I267
sg31935
Vangiopoietin 2
p41393
sg31936
I14
sg31944
g190
sg31939
I2
sa(dp41394
g31934
I715
sg31935
g41374
sg31936
I6
sg31944
VP22087
p41395
sg31939
I1
sasa(dp41396
g31925
VIn this study, we examined whether recurrent hypoglycemia alters the capacity of the ephrinA5 ligand to activate VMH EphA5 receptors, and if so, whether these changes could contribute to pathogenesis of defective glucose counterregulation in response to a standard hypoglycemic stimulus.
p41397
sg4
(dp41398
(VVMH EphA5 receptors
p41399
Vhypoglycemia
p41400
tp41401
I00
ssg31931
(lp41402
(dp41403
g31934
I187
sg31935
Vpathogenesis
p41404
sg31936
I12
sg31937
VC0699748
p41405
sg31939
I1
sa(dp41406
g31934
I45
sg31935
g41400
sg31936
I12
sg31937
VC0020615
p41407
sg31939
I1
sasg31940
(lp41408
(dp41409
g31934
I85
sg31935
VephrinA5 ligand
p41410
sg31936
I15
sg31944
g190
sg31939
I2
sa(dp41411
g31934
I113
sg31935
g41399
sg31936
I19
sg31944
VP54756
p41412
sg31939
I3
sasa(dp41413
g31925
VThe expression of ephrinA5, but not EphA5 receptors within the VMH, was reduced by antecedent recurrent hypoglycemia.
p41414
sg4
(dp41415
(VEphA5 receptors
p41416
Vhypoglycemia
p41417
tp41418
I00
ssg31931
(lp41419
(dp41420
g31934
I104
sg31935
g41417
sg31936
I12
sg31937
VC0020615
p41421
sg31939
I1
sasg31940
(lp41422
(dp41423
g31934
I36
sg31935
g41416
sg31936
I15
sg31944
VP54756
p41424
sg31939
I2
sasa(dp41425
g31925
VActivation of VMH EphA5 receptors via targeted microinjection of ephrinA5-Fc before a hyperinsulinemic hypoglycemic clamp study caused a reduction in the glucose infusion rate in nondiabetic rats exposed to recurrent hypoglycemia.
p41426
sg4
(dp41427
(VVMH EphA5 receptors
p41428
Vhypoglycemia
p41429
tp41430
I00
ssg31931
(lp41431
(dp41432
g31934
I217
sg31935
g41429
sg31936
I12
sg31937
VC0020615
p41433
sg31939
I1
sasg31940
(lp41434
(dp41435
g31934
I14
sg31935
g41428
sg31936
I19
sg31944
VP54756
p41436
sg31939
I3
sasa(dp41437
g31925
VThese data suggest that changes in ephrinA5/EphA5 interactions and synaptic plasticity within the VMH, a key glucose-sensing region in the brain, may contribute to the impairment in glucagon secretion and counterregulatory responses caused by recurrent hypoglycemia.
p41438
sg4
(dp41439
(Vglucagon
p41440
Vhypoglycemia
p41441
tp41442
I00
ssg31931
(lp41443
(dp41444
g31934
I253
sg31935
g41441
sg31936
I12
sg31937
VC0020615
p41445
sg31939
I1
sa(dp41446
g31934
I168
sg31935
Vimpairment
p41447
sg31936
I10
sg31937
VC0684336
p41448
sg31939
I1
sasg31940
(lp41449
(dp41450
g31934
I44
sg31935
VEphA5
p41451
sg31936
I5
sg31944
VP54756
p41452
sg31939
I1
sa(dp41453
g31934
I182
sg31935
g41440
sg31936
I8
sg31944
VP01275
p41454
sg31939
I1
sasa(dp41455
g31925
VActivation of Beta-cell EphA5 receptors by its ligand ephrinA5 from adjacent Beta-cells has been reported to decrease insulin secretion during hypoglycemia.
p41456
sg4
(dp41457
(Vinsulin
p41458
Vhypoglycemia
p41459
tp41460
I00
ssg31931
(lp41461
(dp41462
g31934
I143
sg31935
g41459
sg31936
I12
sg31937
VC0020615
p41463
sg31939
I1
sasg31940
(lp41464
(dp41465
g31934
I14
sg31935
VBeta-cell EphA5 receptors
p41466
sg31936
I25
sg31944
VP54756
p41467
sg31939
I3
sa(dp41468
g31934
I118
sg31935
g41458
sg31936
I7
sg31944
VP01308
p41469
sg31939
I1
sasa(dp41470
g31925
VGiven the similarities between islet and ventromedial hypothalamus (VMH) glucose sensing, we tested the hypothesis that the EphA5/ephrinA5 system might function within the VMH during hypoglycemia to stimulate counterregulatory hormone release as well.
p41471
sg4
(dp41472
(VEphA5
p41473
Vhypoglycemia
p41474
tp41475
I00
ssg31931
(lp41476
(dp41477
g31934
I183
sg31935
g41474
sg31936
I12
sg31937
VC0020615
p41478
sg31939
I1
sasg31940
(lp41479
(dp41480
g31934
I124
sg31935
g41473
sg31936
I5
sg31944
VP54756
p41481
sg31939
I1
sasa(dp41482
g31925
VLocal stimulation of VMH EphA5 receptors by ephrinA5-Fc or ephrinA5 overexpression increased, whereas knockdown of VMH ephrinA5 reduced counterregulatory responses during hypoglycemia.
p41483
sg4
(dp41484
(VVMH EphA5 receptors
p41485
Vhypoglycemia
p41486
tp41487
I00
ssg31931
(lp41488
(dp41489
g31934
I171
sg31935
g41486
sg31936
I12
sg31937
VC0020615
p41490
sg31939
I1
sasg31940
(lp41491
(dp41492
g31934
I21
sg31935
g41485
sg31936
I19
sg31944
VP54756
p41493
sg31939
I3
sasa(dp41494
g31925
VFractionation of dichloromethane (DCM) molecules with different chlorine isotopes by aerobic methylobacteria Methylobacterium dichloromethanicum DM4 and Albibacter nethylovorans DM10; cell-free extract of strain DM4; and transconjugant Methylobacterium evtorquens Al1/pME 8220, expressing the dcmA gene for DCM dehalogenase but unable to grow on DCM, was studied.
p41495
sg4
(dp41496
(VpME
p41497
VdcmA
p41498
tp41499
I00
ssg31931
(lp41500
(dp41501
g31934
I268
sg31935
VpME
p41502
sg31936
I3
sg31937
VC0751785
p41503
sg31939
I1
sa(dp41504
g31934
I293
sg31935
g41498
sg31936
I4
sg31937
VC1857776
p41505
sg31939
I1
sasg31940
(lp41506
(dp41507
g31934
I268
sg31935
g41497
sg31936
I3
sg31944
VP04080
p41508
sg31939
I1
sa(dp41509
g31934
I293
sg31935
VdcmA gene
p41510
sg31936
I9
sg31944
g190
sg31939
I2
sasa(dp41511
g31925
VWe also describe the first RCC with a DVL2-TFE3 gene fusion, in addition to an extrarenal pigmented PEComa with a NONO-TFE3 gene fusion.
p41512
sg4
(dp41513
(VTFE3
p41514
VRCC
p41515
tp41516
I00
ssg31931
(lp41517
(dp41518
g31934
I48
sg31935
Vgene fusion
p41519
sg31936
I11
sg31937
VC1705736
p41520
sg31939
I2
sa(dp41521
g31934
I100
sg31935
VPEComa
p41522
sg31936
I6
sg31937
VC1300127
p41523
sg31939
I1
sa(dp41524
g31934
I48
sg31935
Vgene fusion
p41525
sg31936
I11
sg31937
VC1705736
p41526
sg31939
I2
sa(dp41527
g31934
I27
sg31935
g41515
sg31936
I3
sg31937
VC0007134
p41528
sg31939
I1
sasg31940
(lp41529
(dp41530
g31934
I43
sg31935
VTFE3
p41531
sg31936
I4
sg31944
VP19532
p41532
sg31939
I1
sa(dp41533
g31934
I114
sg31935
VNONO
p41534
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp41535
g31934
I38
sg31935
VDVL2
p41536
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp41537
g31934
I43
sg31935
g41514
sg31936
I4
sg31944
VP19532
p41538
sg31939
I1
sasa(dp41539
g31925
VFurthermore, among neoplasms with the SFPQ-TFE3, NONO-TFE3, DVL2-TFE3, and ASPL-TFE3 gene fusions, the RCCs are almost always PAX8 positive, cathepsin K negative by immunohistochemistry, whereas the mesenchymal counterparts (Xp11 translocation PEComas, melanotic Xp11 translocation renal cancers, and alveolar soft part sarcoma) are PAX8 negative, cathepsin K positive.
p41540
sg4
(dp41541
(VTFE3
p41542
VRCCs
p41543
tp41544
I00
ssg31931
(lp41545
(dp41546
g31934
I244
sg31935
VPEComas
p41547
sg31936
I7
sg31937
VC1300127
p41548
sg31939
I1
sa(dp41549
g31934
I19
sg31935
Vneoplasms
p41550
sg31936
I9
sg31937
VC0027651
p41551
sg31939
I1
sa(dp41552
g31934
I230
sg31935
Vtranslocation
p41553
sg31936
I13
sg31937
VC0040715
p41554
sg31939
I1
sa(dp41555
g31934
I230
sg31935
Vtranslocation
p41556
sg31936
I13
sg31937
VC0040715
p41557
sg31939
I1
sa(dp41558
g31934
I282
sg31935
Vrenal cancers
p41559
sg31936
I13
sg31937
VC0740457
p41560
sg31939
I2
sa(dp41561
g31934
I301
sg31935
Valveolar soft part sarcoma
p41562
sg31936
I26
sg31937
VC0206657
p41563
sg31939
I4
sa(dp41564
g31934
I103
sg31935
g41543
sg31936
I4
sg31937
VC0007134
p41565
sg31939
I1
sasg31940
(lp41566
(dp41567
g31934
I225
sg31935
VXp11 translocation PEComas
p41568
sg31936
I26
sg31944
g190
sg31939
I3
sa(dp41569
g31934
I49
sg31935
VNONO
p41570
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp41571
g31934
I38
sg31935
VSFPQ
p41572
sg31936
I4
sg31944
VP23246
p41573
sg31939
I1
sa(dp41574
g31934
I43
sg31935
VTFE3
p41575
sg31936
I4
sg31944
VP19532
p41576
sg31939
I1
sa(dp41577
g31934
I126
sg31935
VPAX8
p41578
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp41579
g31934
I43
sg31935
VTFE3
p41580
sg31936
I4
sg31944
VP19532
p41581
sg31939
I1
sa(dp41582
g31934
I141
sg31935
Vcathepsin K
p41583
sg31936
I11
sg31944
VP43235
p41584
sg31939
I2
sa(dp41585
g31934
I75
sg31935
VASPL
p41586
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp41587
g31934
I253
sg31935
Vmelanotic Xp11 translocation renal cancers
p41588
sg31936
I42
sg31944
g190
sg31939
I5
sa(dp41589
g31934
I43
sg31935
VTFE3
p41590
sg31936
I4
sg31944
VP19532
p41591
sg31939
I1
sa(dp41592
g31934
I126
sg31935
VPAX8
p41593
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp41594
g31934
I60
sg31935
VDVL2
p41595
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp41596
g31934
I141
sg31935
Vcathepsin K
p41597
sg31936
I11
sg31944
VP43235
p41598
sg31939
I2
sa(dp41599
g31934
I43
sg31935
g41542
sg31936
I4
sg31944
VP19532
p41600
sg31939
I1
sasa(dp41601
g31925
VAs a proof-of-principle, we have identified cytochrome C and Histone H4 as two of the predominant protein species in the 3D colon carcinoma cultures.
p41602
sg4
(dp41603
(Vcytochrome C
p41604
Vcolon carcinoma
p41605
tp41606
I00
ssg31931
(lp41607
(dp41608
g31934
I124
sg31935
g41605
sg31936
I15
sg31937
VC0699790
p41609
sg31939
I2
sasg31940
(lp41610
(dp41611
g31934
I44
sg31935
g41604
sg31936
I12
sg31944
VP99999
p41612
sg31939
I2
sa(dp41613
g31934
I61
sg31935
VHistone H4
p41614
sg31936
I10
sg31944
VP62805
p41615
sg31939
I2
sasa(dp41616
g31925
VThe nitroreductase oxidored-nitro domain containing protein 1 (NOR1) gene may be involved in the chemical carcinogenesis of hepatic cancer and nasopharyngeal carcinoma (NPC).
p41617
sg4
(dp41618
(Vnitroreductase oxidored-nitro domain containing protein 1
p41619
Vnasopharyngeal carcinoma
p41620
tp41621
I00
ssg31931
(lp41622
(dp41623
g31934
I124
sg31935
Vhepatic cancer
p41624
sg31936
I14
sg31937
VC0345904
p41625
sg31939
I2
sa(dp41626
g31934
I97
sg31935
Vchemical carcinogenesis
p41627
sg31936
I23
sg31937
VC0596321
p41628
sg31939
I2
sa(dp41629
g31934
I169
sg31935
VNPC
p41630
sg31936
I3
sg31937
VC2931822
p41631
sg31939
I1
sa(dp41632
g31934
I143
sg31935
g41620
sg31936
I24
sg31937
VC2931822
p41633
sg31939
I2
sasg31940
(lp41634
(dp41635
g31934
I63
sg31935
VNOR1
p41636
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp41637
g31934
I4
sg31935
g41619
sg31936
I57
sg31944
VP14222
p41638
sg31939
I6
sasa(dp41639
g31925
VUsing cDNA microarrays and quantitative real-time PCR, we previously discovered that NOR1 increases the expression of growth factor receptor-bound protein 2 (Grb2) mRNA by 4.8-fold in the human hepatocellular carcinoma cell line HepG2.
p41640
sg4
(dp41641
(Vgrowth factor receptor-bound protein 2
p41642
Vhepatocellular carcinoma
p41643
tp41644
I00
ssg31931
(lp41645
(dp41646
g31934
I194
sg31935
g41643
sg31936
I24
sg31937
VC1512411
p41647
sg31939
I2
sasg31940
(lp41648
(dp41649
g31934
I158
sg31935
VGrb2
p41650
sg31936
I4
sg31944
VP62993
p41651
sg31939
I1
sa(dp41652
g31934
I85
sg31935
VNOR1
p41653
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp41654
g31934
I118
sg31935
g41642
sg31936
I38
sg31944
VP62993
p41655
sg31939
I5
sasa(dp41656
g31925
VThe angiogenic proteins vascular endothelial growth factor (VEGF) and prokineticin1 (PROK1) proteins are considered important in colorectal cancer, the relationship between their simultaneous expression and prognosis was investigated in the present study.
p41657
sg4
(dp41658
(Vprokineticin1 (PROK1) proteins
p41659
Vcolorectal cancer
p41660
tp41661
I00
ssg31931
(lp41662
(dp41663
g31934
I129
sg31935
g41660
sg31936
I17
sg31937
VC1527249
p41664
sg31939
I2
sasg31940
(lp41665
(dp41666
g31934
I60
sg31935
VVEGF
p41667
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp41668
g31934
I24
sg31935
Vvascular endothelial growth factor
p41669
sg31936
I34
sg31944
g190
sg31939
I4
sa(dp41670
g31934
I70
sg31935
g41659
sg31936
I30
sg31944
VP58294
p41671
sg31939
I3
sasa(dp41672
g31925
VVEGF and PROK1 expression in 620 primary human colorectal cancer lesions was confirmed via immunohistochemical staining with anti-VEGF and anti-PROK1 antibodies, and the correlation between the expression of these 2 proteins and recurrence/prognosis were investigated.
p41673
sg4
(dp41674
(VPROK1
p41675
Vcolorectal cancer
p41676
tp41677
I00
ssg31931
(lp41678
(dp41679
g31934
I229
sg31935
Vrecurrence
p41680
sg31936
I10
sg31937
VC1458156
p41681
sg31939
I1
sa(dp41682
g31934
I47
sg31935
g41676
sg31936
I17
sg31937
VC1527249
p41683
sg31939
I2
sasg31940
(lp41684
(dp41685
g31934
I139
sg31935
Vanti-PROK1 antibodies
p41686
sg31936
I21
sg31944
VP58294
p41687
sg31939
I2
sa(dp41688
g31934
I9
sg31935
g41675
sg31936
I5
sg31944
VP58294
p41689
sg31939
I1
sasa(dp41690
g31925
VThe prognosis was poorer in colorectal cancers that expressed both PROK1 and VEGF relative to the cases that expressed only 1 protein, and the expression of both proteins was found to be an independent prognostic factor.
p41691
sg4
(dp41692
(VPROK1
p41693
Vcolorectal cancers
p41694
tp41695
I00
ssg31931
(lp41696
(dp41697
g31934
I28
sg31935
g41694
sg31936
I18
sg31937
VC1527249
p41698
sg31939
I2
sasg31940
(lp41699
(dp41700
g31934
I67
sg31935
g41693
sg31936
I5
sg31944
VP58294
p41701
sg31939
I1
sasa(dp41702
g31925
VTwo angiogenic growth factors, in particular, Vascular endothelial growth factor (VEGF) and Prokineticin1(PROK1), are considered to have an important role in hematogenous metastasis of colorectal cancer.
p41703
sg4
(dp41704
(VPROK1
p41705
Vmetastasis
p41706
tp41707
I01
ssg31931
(lp41708
(dp41709
g31934
I185
sg31935
Vcolorectal cancer
p41710
sg31936
I17
sg31937
VC1527249
p41711
sg31939
I2
sa(dp41712
g31934
I171
sg31935
g41706
sg31936
I10
sg31937
VC0027627
p41713
sg31939
I1
sasg31940
(lp41714
(dp41715
g31934
I4
sg31935
Vangiogenic growth factors
p41716
sg31936
I25
sg31944
VP19883
p41717
sg31939
I3
sa(dp41718
g31934
I82
sg31935
VVEGF
p41719
sg31936
I4
sg31944
g190
sg31939
I1
sa(dp41720
g31934
I46
sg31935
VVascular endothelial growth factor
p41721
sg31936
I34
sg31944
g190
sg31939
I4
sa(dp41722
g31934
I106
sg31935
g41705
sg31936
I5
sg31944
VP58294
p41723
sg31939
I1
sasa(dp41724
g31925
VAccordingly, we report our findings on the importance of the anti-tumor efffect by inhibiting these two factors in human colorectal cancer.When the culture fluid of Colorectal cancer cell lines(DLD-1, HCT116, and LoVo) with high levels of VEGF/PROK1 expression was injected subcutaneously into mice, the culture fluid increased subcutaneous angiogenesis.
p41725
sg4
(dp41726
(VPROK1
p41727
Vcolorectal cancer
p41728
tp41729
I00
ssg31931
(lp41730
(dp41731
g31934
I66
sg31935
Vtumor
p41732
sg31936
I5
sg31937
VC0027651
p41733
sg31939
I1
sa(dp41734
g31934
I165
sg31935
VColorectal cancer
p41735
sg31936
I17
sg31937
VC1527249
p41736
sg31939
I2
sa(dp41737
g31934
I121
sg31935
g41728
sg31936
I17
sg31937
VC1527249
p41738
sg31939
I2
sasg31940
(lp41739
(dp41740
g31934
I194
sg31935
VDLD-1
p41741
sg31936
I5
sg31944
VP98173
p41742
sg31939
I1
sa(dp41743
g31934
I244
sg31935
g41727
sg31936
I5
sg31944
VP58294
p41744
sg31939
I1
sasa(dp41745
g31925
VAlso, tumor masses were produced in mice by subcutaneously embedding colorectal cancer cells with high levels VEGF/PROK1 expression.
p41746
sg4
(dp41747
(VPROK1
p41748
Vcolorectal cancer
p41749
tp41750
I00
ssg31931
(lp41751
(dp41752
g31934
I6
sg31935
Vtumor
p41753
sg31936
I5
sg31937
VC0027651
p41754
sg31939
I1
sa(dp41755
g31934
I69
sg31935
g41749
sg31936
I17
sg31937
VC1527249
p41756
sg31939
I2
sasg31940
(lp41757
(dp41758
g31934
I115
sg31935
g41748
sg31936
I5
sg31944
VP58294
p41759
sg31939
I1
sasa(dp41760
g31925
VWhen both anti-PROK1 and anti-VEGF antibodies were simultaneously applied, tumor formation and peritumoral angiogenesis were strongly suppressed, compared with when either anti-PROK1 antibody or anti-VEGF antibody was applied alone.Simultaneous targeting of both angiogenic growth factors (VEGF/PROK1) may prove more useful in colorectal cancer.
p41761
sg4
(dp41762
(Vangiogenic growth factors
p41763
Vcolorectal cancer
p41764
tp41765
I00
ssg31931
(lp41766
(dp41767
g31934
I327
sg31935
g41764
sg31936
I17
sg31937
VC1527249
p41768
sg31939
I2
sa(dp41769
g31934
I75
sg31935
Vtumor
p41770
sg31936
I5
sg31937
VC0027651
p41771
sg31939
I1
sasg31940
(lp41772
(dp41773
g31934
I15
sg31935
VPROK1
p41774
sg31936
I5
sg31944
VP58294
p41775
sg31939
I1
sa(dp41776
g31934
I172
sg31935
Vanti-PROK1 antibody
p41777
sg31936
I19
sg31944
VP58294
p41778
sg31939
I2
sa(dp41779
g31934
I10
sg31935
Vanti-PROK1
p41780
sg31936
I10
sg31944
VP58294
p41781
sg31939
I1
sa(dp41782
g31934
I263
sg31935
g41763
sg31936
I25
sg31944
VP19883
p41783
sg31939
I3
sasa(dp41784
g31925
VThe current study established the anti-PROK1 monoclonal antibody (mAb) and examined the relationship between the expression of PROK1 protein and human colorectal cancer.
p41785
sg4
(dp41786
(VPROK1 protein
p41787
Vcolorectal cancer
p41788
tp41789
I00
ssg31931
(lp41790
(dp41791
g31934
I151
sg31935
g41788
sg31936
I17
sg31937
VC1527249
p41792
sg31939
I2
sasg31940
(lp41793
(dp41794
g31934
I34
sg31935
Vanti-PROK1 monoclonal antibody
p41795
sg31936
I30
sg31944
VP58294
p41796
sg31939
I3
sa(dp41797
g31934
I127
sg31935
g41787
sg31936
I13
sg31944
VP58294
p41798
sg31939
I2
sasa(dp41799
g31925
VThe expression of PROK1 protein was assessed in 620 resected sporadic colorectal cancer tissue samples by immunohistochemical staining with in-house-developed human PROK1 mAb to investigate the relationship of PROK1 expression to clinicopathologic factors, recurrence, and survival rate and to evaluate its prognostic significance.
p41800
sg4
(dp41801
(Vhuman PROK1 mAb
p41802
Vcolorectal cancer
p41803
tp41804
I00
ssg31931
(lp41805
(dp41806
g31934
I70
sg31935
g41803
sg31936
I17
sg31937
VC1527249
p41807
sg31939
I2
sa(dp41808
g31934
I257
sg31935
Vrecurrence
p41809
sg31936
I10
sg31937
VC1458156
p41810
sg31939
I1
sasg31940
(lp41811
(dp41812
g31934
I18
sg31935
VPROK1 protein
p41813
sg31936
I13
sg31944
VP58294
p41814
sg31939
I2
sa(dp41815
g31934
I18
sg31935
VPROK1
p41816
sg31936
I5
sg31944
VP58294
p41817
sg31939
I1
sa(dp41818
g31934
I159
sg31935
g41802
sg31936
I15
sg31944
VP58294
p41819
sg31939
I3
sasa(dp41820
g31925
VThe expression of PROK1 protein was detected in 36 % (223/620) of human primary colorectal cancer lesions but no in the healthy mucosa adjacent to the colorectal cancer lesions.
p41821
sg4
(dp41822
(VPROK1 protein
p41823
Vcolorectal cancer
p41824
tp41825
I00
ssg31931
(lp41826
(dp41827
g31934
I80
sg31935
Vcolorectal cancer
p41828
sg31936
I17
sg31937
VC1527249
p41829
sg31939
I2
sa(dp41830
g31934
I80
sg31935
g41824
sg31936
I17
sg31937
VC1527249
p41831
sg31939
I2
sasg31940
(lp41832
(dp41833
g31934
I18
sg31935
g41823
sg31936
I13
sg31944
VP58294
p41834
sg31939
I2
sasa(dp41835
g31925
VThe expression of PROK1 protein was identified for the first time as a new prognostic factor in colorectal cancer.
p41836
sg4
(dp41837
(VPROK1 protein
p41838
Vcolorectal cancer
p41839
tp41840
I00
ssg31931
(lp41841
(dp41842
g31934
I96
sg31935
g41839
sg31936
I17
sg31937
VC1527249
p41843
sg31939
I2
sasg31940
(lp41844
(dp41845
g31934
I18
sg31935
g41838
sg31936
I13
sg31944
VP58294
p41846
sg31939
I2
sasa(dp41847
g31925
VHere we investigated how the anti-PROK1 monoclonal antibody (mAb; established by our department) would affect the high-PROK1-expressing colorectal cancer (CRC) cells in vitro and vivo.
p41848
sg4
(dp41849
(VPROK1
p41850
Vcolorectal cancer
p41851
tp41852
I00
ssg31931
(lp41853
(dp41854
g31934
I155
sg31935
VCRC
p41855
sg31936
I3
sg31937
VC1527249
p41856
sg31939
I1
sa(dp41857
g31934
I136
sg31935
g41851
sg31936
I17
sg31937
VC1527249
p41858
sg31939
I2
sasg31940
(lp41859
(dp41860
g31934
I29
sg31935
Vanti-PROK1 monoclonal antibody
p41861
sg31936
I30
sg31944
VP58294
p41862
sg31939
I3
sa(dp41863
g31934
I34
sg31935
g41850
sg31936
I5
sg31944
VP58294
p41864
sg31939
I1
sasa(dp41865
g31925
VPROK1 expression was not observed in healthy gastrointestinal mucosa, but was observed in the primary lesions in 23 out of 98 (31.6%) patients with colorectal cancer, 19 out of 55 (34.5%) patients with gastric cancer, and 5 of 10 (50%) patients with cancer of the small intestine.
p41866
sg4
(dp41867
(VPROK1
p41868
Vgastric cancer
p41869
tp41870
I00
ssg31931
(lp41871
(dp41872
g31934
I148
sg31935
Vcolorectal cancer
p41873
sg31936
I17
sg31937
VC1527249
p41874
sg31939
I2
sa(dp41875
g31934
I202
sg31935
g41869
sg31936
I14
sg31937
VC0024623
p41876
sg31939
I2
sa(dp41877
g31934
I159
sg31935
Vcancer
p41878
sg31936
I6
sg31937
VC0006826
p41879
sg31939
I1
sasg31940
(lp41880
(dp41881
g31934
I0
sg31935
g41868
sg31936
I5
sg31944
VP58294
p41882
sg31939
I1
sasa(dp41883
g31925
VEndocrine gland-derived vascular endothelial growth factor (EG-VEGF) has             recently been identified as one of the vascular endothelial growth factors, and             it is considered that the overexpression of EG-VEGF in colon cancer is related             to hepatic metastasis.
p41884
sg4
(dp41885
(VEG-VEGF
p41886
Vcolon cancer
p41887
tp41888
I00
ssg31931
(lp41889
(dp41890
g31934
I271
sg31935
Vhepatic metastasis
p41891
sg31936
I18
sg31937
VC0494165
p41892
sg31939
I2
sa(dp41893
g31934
I232
sg31935
g41887
sg31936
I12
sg31937
VC0699790
p41894
sg31939
I2
sasg31940
(lp41895
(dp41896
g31934
I60
sg31935
VEG-VEGF
p41897
sg31936
I7
sg31944
VP58294
p41898
sg31939
I1
sa(dp41899
g31934
I124
sg31935
Vvascular endothelial growth factors
p41900
sg31936
I35
sg31944
VP19883
p41901
sg31939
I4
sa(dp41902
g31934
I0
sg31935
VEndocrine gland-derived vascular endothelial growth factor
p41903
sg31936
I58
sg31944
VP58294
p41904
sg31939
I6
sa(dp41905
g31934
I60
sg31935
g41886
sg31936
I7
sg31944
VP58294
p41906
sg31939
I1
sasa(dp41907
g31925
VIn this study, we report our recent novel findings of the             involvement of EG-VEGF in cell invasion of colon cancer cells.
p41908
sg4
(dp41909
(VEG-VEGF
p41910
Vcolon cancer
p41911
tp41912
I00
ssg31931
(lp41913
(dp41914
g31934
I113
sg31935
g41911
sg31936
I12
sg31937
VC0699790
p41915
sg31939
I2
sa(dp41916
g31934
I96
sg31935
Vcell invasion
p41917
sg31936
I13
sg31937
VC2699153
p41918
sg31939
I2
sasg31940
(lp41919
(dp41920
g31934
I85
sg31935
g41910
sg31936
I7
sg31944
VP58294
p41921
sg31939
I1
sasa(dp41922
g31925
VFinally, the EG-VEGF receptor on the colon cancer cell membrane             was blocked by anti-PK-R1 and -PK-R2 antibodies to study whether cell invasion             ability would be altered.
p41923
sg4
(dp41924
(VEG-VEGF receptor
p41925
Vcolon cancer
p41926
tp41927
I00
ssg31931
(lp41928
(dp41929
g31934
I141
sg31935
Vcell invasion
p41930
sg31936
I13
sg31937
VC2699153
p41931
sg31939
I2
sa(dp41932
g31934
I37
sg31935
g41926
sg31936
I12
sg31937
VC0699790
p41933
sg31939
I2
sasg31940
(lp41934
(dp41935
g31934
I13
sg31935
g41925
sg31936
I16
sg31944
VP58294
p41936
sg31939
I2
sa(dp41937
g31934
I91
sg31935
Vanti-PK-R1 and -PK-R2 antibodies
p41938
sg31936
I32
sg31944
g190
sg31939
I4
sasa(dp41939
g31925
VIn colon cancer cell lines where the expression of PK-R1             and 2 was confirmed, stimulation with EG-VEGF increased cell invasion a maximum             of ~3-5 times.
p41940
sg4
(dp41941
(VEG-VEGF
p41942
Vcolon cancer
p41943
tp41944
I00
ssg31931
(lp41945
(dp41946
g31934
I3
sg31935
g41943
sg31936
I12
sg31937
VC0699790
p41947
sg31939
I2
sa(dp41948
g31934
I125
sg31935
Vcell invasion
p41949
sg31936
I13
sg31937
VC2699153
p41950
sg31939
I2
sasg31940
(lp41951
(dp41952
g31934
I107
sg31935
g41942
sg31936
I7
sg31944
VP58294
p41953
sg31939
I1
sasa(dp41954
g31925
VThe study showed that the EG-VEGF             protein may act on MMP-2, -7 and -9 via PK-R2 to strengthen cell invasion ability             in colon cancer cell lines.
p41955
sg4
(dp41956
(VMMP-2, -7
p41957
Vcolon cancer
p41958
tp41959
I00
ssg31931
(lp41960
(dp41961
g31934
I143
sg31935
g41958
sg31936
I12
sg31937
VC0699790
p41962
sg31939
I2
sa(dp41963
g31934
I106
sg31935
Vcell invasion
p41964
sg31936
I13
sg31937
VC2699153
p41965
sg31939
I2
sasg31940
(lp41966
(dp41967
g31934
I26
sg31935
VEG-VEGF
p41968
sg31936
I7
sg31944
VP58294
p41969
sg31939
I1
sa(dp41970
g31934
I65
sg31935
g41957
sg31936
I9
sg31944
VP08253
p41971
sg31939
I2
sasa(dp41972
g31925
VTo study the implication of prokineticin 1 (PK1/EG-VEGF) and prokineticin 2 (PK2/Bv8) in hepatocellular carcinoma angiogenesis.
p41973
sg4
(dp41974
(VEG-VEGF
p41975
Vhepatocellular carcinoma
p41976
tp41977
I00
ssg31931
(lp41978
(dp41979
g31934
I89
sg31935
g41976
sg31936
I24
sg31937
VC1512411
p41980
sg31939
I2
sasg31940
(lp41981
(dp41982
g31934
I28
sg31935
Vprokineticin 1
p41983
sg31936
I14
sg31944
VP58294
p41984
sg31939
I2
sa(dp41985
g31934
I77
sg31935
VPK2
p41986
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp41987
g31934
I81
sg31935
VBv8
p41988
sg31936
I3
sg31944
g190
sg31939
I1
sa(dp41989
g31934
I61
sg31935
Vprokineticin 2
p41990
sg31936
I14
sg31944
g190
sg31939
I2
sa(dp41991
g31934
I44
sg31935
VPK1
p41992
sg31936
I3
sg31944
VP58294
p41993
sg31939
I1
sa(dp41994
g31934
I48
sg31935
g41975
sg31936
I7
sg31944
VP58294
p41995
sg31939
I1
sasa(dp41996
S'line'
p41997
VIn this study, we investigated the expression of EG-VEGF in colorectal cancer, the relationship between its expression and clinicopathological factors, and the in vitro activity of EG-VEGF transfectants.
p41998
sg4
(dp41999
(VEG-VEGF
p42000
Vcolorectal cancer
p42001
tp42002
I00
ssS'diseases'
p42003
(lp42004
(dp42005
S'index'
p42006
I60
sS'name'
p42007
g42001
sS'lengthInChars'
p42008
I17
sS'cui'
p42009
VC1527249
p42010
sS'lengthInWords'
p42011
I2
sasS'genes'
p42012
(lp42013
(dp42014
g42006
I49
sg42007
VEG-VEGF
p42015
sg42008
I7
sS'uniprot'
p42016
VP58294
p42017
sg42011
I1
sa(dp42018
g42006
I49
sg42007
g42000
sg42008
I7
sg42016
VP58294
p42019
sg42011
I1
sasa(dp42020
g41997
VWe determined expression levels of EG-VEGF in 113 advanced colorectal cancers resected in our hospital by quantitative PCR, and compared the expression levels and clinicopathological findings by multivariate analyses.
p42021
sg4
(dp42022
(VEG-VEGF
p42023
Vcolorectal cancers
p42024
tp42025
I00
ssg42003
(lp42026
(dp42027
g42006
I59
sg42007
g42024
sg42008
I18
sg42009
VC1527249
p42028
sg42011
I2
sasg42012
(lp42029
(dp42030
g42006
I35
sg42007
g42023
sg42008
I7
sg42016
VP58294
p42031
sg42011
I1
sasa(dp42032
g41997
VWe speculate that, in colorectal cancers, the EG-VEGF gene functions as an important factor in angiogenesis in primary and metastatic lesions, and consider that it is useful as a novel prognostic factor.
p42033
sg4
(dp42034
(VEG-VEGF gene
p42035
Vcolorectal cancers
p42036
tp42037
I00
ssg42003
(lp42038
(dp42039
g42006
I22
sg42007
g42036
sg42008
I18
sg42009
VC1527249
p42040
sg42011
I2
sasg42012
(lp42041
(dp42042
g42006
I46
sg42007
g42035
sg42008
I12
sg42016
VP58294
p42043
sg42011
I2
sasa(dp42044
g41997
VThe aim of the present study was to detect the correlation between the expression of vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2), ephrinB2 and endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and carcinogenesis or portal vein tumor thrombus (PVTT) formation in human hepatocellular carcinoma (HCC).
p42045
sg4
(dp42046
(Vendocrine gland-derived vascular endothelial growth factor
p42047
Vhepatocellular carcinoma
p42048
tp42049
I00
ssg42003
(lp42050
(dp42051
g42006
I334
sg42007
VHCC
p42052
sg42008
I3
sg42009
VC2239176
p42053
sg42011
I1
sa(dp42054
g42006
I237
sg42007
Vcarcinogenesis
p42055
sg42008
I14
sg42009
VC0596263
p42056
sg42011
I1
sa(dp42057
g42006
I267
sg42007
Vtumor thrombus
p42058
sg42008
I14
sg42009
VC3163918
p42059
sg42011
I2
sa(dp42060
g42006
I308
sg42007
g42048
sg42008
I24
sg42009
VC2239176
p42061
sg42011
I2
sasg42012
(lp42062
(dp42063
g42006
I128
sg42007
Vangiopoietin 2
p42064
sg42008
I14
sg42016
g190
sg42011
I2
sa(dp42065
g42006
I85
sg42007
Vvascular endothelial growth factor
p42066
sg42008
I34
sg42016
g190
sg42011
I4
sa(dp42067
g42006
I151
sg42007
VephrinB2
p42068
sg42008
I8
sg42016
VP52799
p42069
sg42011
I1
sa(dp42070
g42006
I224
sg42007
VEG-VEGF
p42071
sg42008
I7
sg42016
VP58294
p42072
sg42011
I1
sa(dp42073
g42006
I164
sg42007
g42047
sg42008
I58
sg42016
VP58294
p42074
sg42011
I6
sa(dp42075
g42006
I144
sg42007
VAng2
p42076
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp42077
g42006
I121
sg42007
VVEGF
p42078
sg42008
I4
sg42016
g190
sg42011
I1
sasa(dp42079
g41997
VMechanistically, HCMV upregulated two specific cellular antiapoptotic proteins, myeloid leukemia sequence 1 (Mcl-1) and heat shock protein 27 (HSP27), to block the two proteolytic cleavages necessary for the formation of fully active caspase 3 and the subsequent initiation of apoptosis.
p42080
sg4
(dp42081
(Vcaspase 3
p42082
Vmyeloid leukemia
p42083
tp42084
I01
ssg42003
(lp42085
(dp42086
g42006
I109
sg42007
VMcl
p42087
sg42008
I3
sg42009
VC1708350
p42088
sg42011
I1
sa(dp42089
g42006
I80
sg42007
g42083
sg42008
I16
sg42009
VC0023470
p42090
sg42011
I2
sasg42012
(lp42091
(dp42092
g42006
I120
sg42007
Vheat shock protein 27
p42093
sg42008
I21
sg42016
VP34931
p42094
sg42011
I4
sa(dp42095
g42006
I109
sg42007
VMcl-1
p42096
sg42008
I5
sg42016
VP07954
p42097
sg42011
I1
sa(dp42098
g42006
I234
sg42007
g42082
sg42008
I9
sg42016
VP42574
p42099
sg42011
I2
sa(dp42100
g42006
I143
sg42007
VHSP27
p42101
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp42102
g41997
VHeat shock protein 27 (HSP27) has been reported to promote the development of leukemia by protecting tumor cells from apoptosis through various mechanisms.
p42103
sg4
(dp42104
(VHeat shock protein 27
p42105
Vleukemia
p42106
tp42107
I01
ssg42003
(lp42108
(dp42109
g42006
I101
sg42007
Vtumor
p42110
sg42008
I5
sg42009
VC0027651
p42111
sg42011
I1
sa(dp42112
g42006
I78
sg42007
g42106
sg42008
I8
sg42009
VC0023418
p42113
sg42011
I1
sasg42012
(lp42114
(dp42115
g42006
I0
sg42007
g42105
sg42008
I21
sg42016
VP34931
p42116
sg42011
I4
sa(dp42117
g42006
I23
sg42007
VHSP27
p42118
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp42119
g41997
VAmong these proteins, enolase, aldolase, HSP70 and sorcin were up-regulated in doxorubicin-resistant myelogenous leukemia cell line, whereas HSP27 was down-regulated.
p42120
sg4
(dp42121
(Vsorcin
p42122
Vmyelogenous leukemia
p42123
tp42124
I00
ssg42003
(lp42125
(dp42126
g42006
I101
sg42007
g42123
sg42008
I20
sg42009
VC0023470
p42127
sg42011
I2
sasg42012
(lp42128
(dp42129
g42006
I22
sg42007
Venolase
p42130
sg42008
I7
sg42016
VP13929
p42131
sg42011
I1
sa(dp42132
g42006
I31
sg42007
Valdolase
p42133
sg42008
I8
sg42016
VP05062
p42134
sg42011
I1
sa(dp42135
g42006
I41
sg42007
VHSP70
p42136
sg42008
I5
sg42016
VP34932
p42137
sg42011
I1
sa(dp42138
g42006
I141
sg42007
VHSP27
p42139
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp42140
g42006
I51
sg42007
g42122
sg42008
I6
sg42016
VP30626
p42141
sg42011
I1
sasa(dp42142
g41997
VHsp27 was abundantly expressed in newly diagnosed AML-M4/M5 bone marrow             mononuclear cells (BMMCs) and THP-1, OCI/AML-3 leukemia cell lines.
p42143
sg4
(dp42144
(VAML
p42145
VAML
p42146
tp42147
I00
ssg42003
(lp42148
(dp42149
g42006
I131
sg42007
Vleukemia
p42150
sg42008
I8
sg42009
VC0023418
p42151
sg42011
I1
sa(dp42152
g42006
I50
sg42007
VAML
p42153
sg42008
I3
sg42009
VC0023467
p42154
sg42011
I1
sa(dp42155
g42006
I50
sg42007
g42146
sg42008
I3
sg42009
VC0023467
p42156
sg42011
I1
sasg42012
(lp42157
(dp42158
g42006
I50
sg42007
g42145
sg42008
I3
sg42016
VP41212
p42159
sg42011
I1
sa(dp42160
g42006
I0
sg42007
VHsp27
p42161
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp42162
g41997
VIntegrin alpha 8 (ITGA8) encodes the alpha 8 subunit of the integrin alpha8beta1 protein and has recently been suggested as a new candidate gene for Parkinson's disease, an age related neurodegenerative disease with unknown etiology.
p42163
sg4
(dp42164
(VIntegrin alpha 8
p42165
Vneurodegenerative disease
p42166
tp42167
I00
ssg42003
(lp42168
(dp42169
g42006
I149
sg42007
VParkinson's disease
p42170
sg42008
I19
sg42009
VC0030567
p42171
sg42011
I2
sa(dp42172
g42006
I185
sg42007
g42166
sg42008
I25
sg42009
VC0524851
p42173
sg42011
I2
sasg42012
(lp42174
(dp42175
g42006
I18
sg42007
VITGA8
p42176
sg42008
I5
sg42016
VP53708
p42177
sg42011
I1
sa(dp42178
g42006
I0
sg42007
g42165
sg42008
I16
sg42016
VP53708
p42179
sg42011
I3
sasa(dp42180
g41997
VScreen a Swedish case control material for rs7077361, a genetic variant in ITGA8, in order to investigate its possible implication in Parkinson's disease in Sweden.
p42181
sg4
(dp42182
(VITGA8
p42183
VParkinson's disease
p42184
tp42185
I00
ssg42003
(lp42186
(dp42187
g42006
I134
sg42007
g42184
sg42008
I19
sg42009
VC0030567
p42188
sg42011
I2
sasg42012
(lp42189
(dp42190
g42006
I75
sg42007
g42183
sg42008
I5
sg42016
VP53708
p42191
sg42011
I1
sasa(dp42192
g41997
VOur results do not support the hypothesis of ITGA8 as a candidate gene for Parkinson's disease in Sweden.
p42193
sg4
(dp42194
(VITGA8
p42195
VParkinson's disease
p42196
tp42197
I00
ssg42003
(lp42198
(dp42199
g42006
I75
sg42007
g42196
sg42008
I19
sg42009
VC0030567
p42200
sg42011
I2
sasg42012
(lp42201
(dp42202
g42006
I45
sg42007
g42195
sg42008
I5
sg42016
VP53708
p42203
sg42011
I1
sasa(dp42204
g41997
VCYFIP1 maps to the interval between proximal breakpoint 1 (BP1) and breakpoint 2 (BP2) of chromosomal 15q11-q13 deletions that are implicated in the Angelman (AS) and Prader-Willi syndrome (PWS).
p42205
sg4
(dp42206
(VBP2
p42207
VPWS
p42208
tp42209
I00
ssg42003
(lp42210
(dp42211
g42006
I167
sg42007
VPrader-Willi syndrome
p42212
sg42008
I21
sg42009
VC0032897
p42213
sg42011
I2
sa(dp42214
g42006
I190
sg42007
g42208
sg42008
I3
sg42009
VC0032897
p42215
sg42011
I1
sasg42012
(lp42216
(dp42217
g42006
I82
sg42007
g42207
sg42008
I3
sg42016
VP18065
p42218
sg42011
I1
sa(dp42219
g42006
I45
sg42007
Vbreakpoint 1 (BP1) and breakpoint 2
p42220
sg42008
I35
sg42016
g190
sg42011
I6
sa(dp42221
g42006
I0
sg42007
VCYFIP1
p42222
sg42008
I6
sg42016
g190
sg42011
I1
sasa(dp42223
g41997
VWe found copy number variants in PDE10A (phosphodiesterase 10A), CYFIP1 [cytoplasmic FMR1 (Fragile X mental retardation 1)-interacting protein 1], K(+) channel genes KCNE1 and KCNE2, the Down's syndrome critical region 1 gene RCAN1 (regulator of calcineurin 1), cell-recognition protein CHL1 (cell adhesion molecule with homology with L1CAM), the transcription factor SP4 (specificity protein 4) and histone deacetylase HDAC9, among others (see http://www.genes2cognition.org/SCZ-CNV).
p42224
sg4
(dp42225
(VKCNE1
p42226
Vmental retardation
p42227
tp42228
I00
ssg42003
(lp42229
(dp42230
g42006
I298
sg42007
Vadhesion
p42231
sg42008
I8
sg42009
VC0001511
p42232
sg42011
I1
sa(dp42233
g42006
I187
sg42007
VDown's syndrome
p42234
sg42008
I15
sg42009
VC0013080
p42235
sg42011
I2
sa(dp42236
g42006
I101
sg42007
g42227
sg42008
I18
sg42009
VC0025362
p42237
sg42011
I2
sasg42012
(lp42238
(dp42239
g42006
I335
sg42007
VL1CAM
p42240
sg42008
I5
sg42016
VP32004
p42241
sg42011
I1
sa(dp42242
g42006
I33
sg42007
VPDE10A
p42243
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp42244
g42006
I166
sg42007
g42226
sg42008
I5
sg42016
VP15382
p42245
sg42011
I1
sa(dp42246
g42006
I176
sg42007
VKCNE2
p42247
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp42248
g42006
I41
sg42007
Vphosphodiesterase 10A
p42249
sg42008
I21
sg42016
g190
sg42011
I2
sa(dp42250
g42006
I400
sg42007
Vhistone deacetylase HDAC9
p42251
sg42008
I25
sg42016
g190
sg42011
I3
sa(dp42252
g42006
I287
sg42007
VCHL1 (cell adhesion molecule
p42253
sg42008
I28
sg42016
g190
sg42011
I4
sasa(dp42254
g41997
VTherefore, we recruited 50 untreated house dust mite-sensitive allergic rhinitis patients and 29 non-atopic healthy individuals and performed comprehensive simultaneous flow cytometric analysis of mutual correlations between levels of CD14, CD16, CD163, CD206, CD124 (IL-4R), CD210 (IL-10R) and CD25, CD124, CD127 (IL-7R), CD210, ICOS expression on monocytes and CD4+ T cells, respectively.
p42255
sg4
(dp42256
(VCD16
p42257
Vatopic
p42258
tp42259
I00
ssg42003
(lp42260
(dp42261
g42006
I63
sg42007
Vallergic rhinitis
p42262
sg42008
I17
sg42009
VC2607914
p42263
sg42011
I2
sa(dp42264
g42006
I101
sg42007
g42258
sg42008
I6
sg42009
VC0392707
p42265
sg42011
I1
sasg42012
(lp42266
(dp42267
g42006
I254
sg42007
VCD206
p42268
sg42008
I5
sg42016
VP22897
p42269
sg42011
I1
sa(dp42270
g42006
I363
sg42007
VCD4+
p42271
sg42008
I4
sg42016
VP01730
p42272
sg42011
I1
sa(dp42273
g42006
I295
sg42007
VCD25
p42274
sg42008
I4
sg42016
VP01589
p42275
sg42011
I1
sa(dp42276
g42006
I283
sg42007
VIL-10R
p42277
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp42278
g42006
I247
sg42007
VCD163
p42279
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp42280
g42006
I235
sg42007
VCD14
p42281
sg42008
I4
sg42016
VP08571
p42282
sg42011
I1
sa(dp42283
g42006
I241
sg42007
g42257
sg42008
I4
sg42016
VP08637
p42284
sg42011
I1
sasa(dp42285
g41997
VExpression of the Growth Hormone (GH)-stimulated gene Socs2 (Suppressor of Cytokine Signaling 2) is mediated by the transcription activator STAT5 (Signal Transducer and Activator of Transcription 5) and the transcription repressor BCL6 (B-Cell Lymphoma 6).
p42286
sg4
(dp42287
(VB-Cell Lymphoma 6
p42288
VB-Cell Lymphoma
p42289
tp42290
I00
ssg42003
(lp42291
(dp42292
g42006
I237
sg42007
g42289
sg42008
I15
sg42009
VC0079731
p42293
sg42011
I2
sasg42012
(lp42294
(dp42295
g42006
I18
sg42007
VGrowth Hormone
p42296
sg42008
I14
sg42016
VP01242
p42297
sg42011
I2
sa(dp42298
g42006
I140
sg42007
VSTAT5
p42299
sg42008
I5
sg42016
VP42229
p42300
sg42011
I1
sa(dp42301
g42006
I34
sg42007
VGH
p42302
sg42008
I2
sg42016
VP01242
p42303
sg42011
I1
sa(dp42304
g42006
I54
sg42007
VSocs2
p42305
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp42306
g42006
I61
sg42007
VSuppressor of Cytokine Signaling 2
p42307
sg42008
I34
sg42016
g190
sg42011
I5
sa(dp42308
g42006
I231
sg42007
VBCL6
p42309
sg42008
I4
sg42016
VP41182
p42310
sg42011
I1
sa(dp42311
g42006
I147
sg42007
VSignal Transducer and Activator of Transcription 5
p42312
sg42008
I50
sg42016
VP42229
p42313
sg42011
I7
sa(dp42314
g42006
I237
sg42007
g42288
sg42008
I17
sg42016
VP41182
p42315
sg42011
I3
sasa(dp42316
g41997
VGene expression analysis revealed increased expression of MAPK1, AKT1, PRKCE, IL4R and DROSHA and decreased expression of CDKN1A/p21, SOCS2, CHEK1, RAD51, KLF4, BLIMP1 and IRF4 in follicular lymphoma.
p42317
sg4
(dp42318
(VMAPK1
p42319
Vfollicular lymphoma
p42320
tp42321
I01
ssg42003
(lp42322
(dp42323
g42006
I180
sg42007
g42320
sg42008
I19
sg42009
VC0024301
p42324
sg42011
I2
sasg42012
(lp42325
(dp42326
g42006
I141
sg42007
VCHEK1
p42327
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp42328
g42006
I129
sg42007
Vp21
p42329
sg42008
I3
sg42016
VP42857
p42330
sg42011
I1
sa(dp42331
g42006
I161
sg42007
VBLIMP1
p42332
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp42333
g42006
I155
sg42007
VKLF4
p42334
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp42335
g42006
I172
sg42007
VIRF4
p42336
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp42337
g42006
I87
sg42007
VDROSHA
p42338
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp42339
g42006
I122
sg42007
VCDKN1A
p42340
sg42008
I6
sg42016
VP38936
p42341
sg42011
I1
sa(dp42342
g42006
I148
sg42007
VRAD51
p42343
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp42344
g42006
I134
sg42007
VSOCS2
p42345
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp42346
g42006
I65
sg42007
VAKT1
p42347
sg42008
I4
sg42016
VP31749
p42348
sg42011
I1
sa(dp42349
g42006
I58
sg42007
g42319
sg42008
I5
sg42016
VP28482
p42350
sg42011
I1
sa(dp42351
g42006
I71
sg42007
VPRKCE
p42352
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp42353
g41997
VmiR-20a/b and miR-194 target CDKN1A and SOCS2 in follicular lymphoma, potentially contributing to tumor cell proliferation and survival.
p42354
sg4
(dp42355
(VCDKN1A
p42356
Vfollicular lymphoma
p42357
tp42358
I01
ssg42003
(lp42359
(dp42360
g42006
I98
sg42007
Vtumor
p42361
sg42008
I5
sg42009
VC0027651
p42362
sg42011
I1
sa(dp42363
g42006
I49
sg42007
g42357
sg42008
I19
sg42009
VC0024301
p42364
sg42011
I2
sa(dp42365
g42006
I109
sg42007
Vproliferation
p42366
sg42008
I13
sg42009
VC0334094
p42367
sg42011
I1
sasg42012
(lp42368
(dp42369
g42006
I40
sg42007
VSOCS2
p42370
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp42371
g42006
I0
sg42007
VmiR-20a/b
p42372
sg42008
I9
sg42016
g190
sg42011
I1
sa(dp42373
g42006
I29
sg42007
g42356
sg42008
I6
sg42016
VP38936
p42374
sg42011
I1
sa(dp42375
g42006
I14
sg42007
VmiR-194
p42376
sg42008
I7
sg42016
g190
sg42011
I1
sasa(dp42377
g41997
VThese results support the conclusion that dental caries is highly affected by the activity of CA VI in saliva as well as by the salivary flow rate.
p42378
sg4
(dp42379
(VCA VI
p42380
Vdental caries
p42381
tp42382
I01
ssg42003
(lp42383
(dp42384
g42006
I42
sg42007
g42381
sg42008
I13
sg42009
VC0333519
p42385
sg42011
I2
sasg42012
(lp42386
(dp42387
g42006
I94
sg42007
g42380
sg42008
I5
sg42016
VP23280
p42388
sg42011
I2
sasa(dp42389
g41997
VEleven articles found a consistent association between salivary protein polymorphisms and risk of dental caries, for proteins related to antimicrobial activity (beta defensin 1 and lysozyme-like protein), pH control (carbonic anhydrase VI), and bacterial colonization/adhesion (lactotransferrin, mucin, and proline-rich protein Db).
p42390
sg4
(dp42391
(Vbeta defensin 1 and lysozyme-like protein
p42392
Vdental caries
p42393
tp42394
I00
ssg42003
(lp42395
(dp42396
g42006
I268
sg42007
Vadhesion
p42397
sg42008
I8
sg42009
VC0001511
p42398
sg42011
I1
sa(dp42399
g42006
I98
sg42007
g42393
sg42008
I13
sg42009
VC0333519
p42400
sg42011
I2
sasg42012
(lp42401
(dp42402
g42006
I217
sg42007
Vcarbonic anhydrase VI
p42403
sg42008
I21
sg42016
VP23280
p42404
sg42011
I3
sa(dp42405
g42006
I161
sg42007
g42392
sg42008
I41
sg42016
VP60022
p42406
sg42011
I6
sa(dp42407
g42006
I296
sg42007
Vmucin
p42408
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp42409
g41997
VThe rs17032907 genetic variant and the haplotype (ACA) of CA VI may be associated with dental caries susceptibility.
p42410
sg4
(dp42411
(VCA VI
p42412
Vdental caries
p42413
tp42414
I01
ssg42003
(lp42415
(dp42416
g42006
I87
sg42007
g42413
sg42008
I13
sg42009
VC0333519
p42417
sg42011
I2
sasg42012
(lp42418
(dp42419
g42006
I58
sg42007
g42412
sg42008
I5
sg42016
VP23280
p42420
sg42011
I2
sasa(dp42421
g41997
VThe oral pathogenic bacterium involved in human dental caries formation Streptococcus mutans, encodes for two carbonic anhydrase (CA, EC 4.2.1.1) one belonging to the Alfa- and the other one to the Beta-class.
p42422
sg4
(dp42423
(VCA
p42424
Vdental caries
p42425
tp42426
I00
ssg42003
(lp42427
(dp42428
g42006
I48
sg42007
g42425
sg42008
I13
sg42009
VC0333519
p42429
sg42011
I2
sasg42012
(lp42430
(dp42431
g42006
I110
sg42007
Vcarbonic anhydrase
p42432
sg42008
I18
sg42016
VP35218
p42433
sg42011
I2
sa(dp42434
g42006
I130
sg42007
g42424
sg42008
I2
sg42016
VP35218
p42435
sg42011
I1
sasa(dp42436
g41997
VStreptococcus mutans, the oral pathogenic bacterium provoking dental caries formation, encodes for a Beta-class carbonic anhydrase (CA, EC 4.2.1.1), SmuCA.
p42437
sg4
(dp42438
(VBeta-class carbonic anhydrase
p42439
Vdental caries
p42440
tp42441
I00
ssg42003
(lp42442
(dp42443
g42006
I62
sg42007
g42440
sg42008
I13
sg42009
VC0333519
p42444
sg42011
I2
sasg42012
(lp42445
(dp42446
g42006
I101
sg42007
g42439
sg42008
I29
sg42016
VP35218
p42447
sg42011
I3
sasa(dp42448
g41997
VWe used mice lacking the CNTNAP2 gene, which has been implicated in autism, and achieved a temporally precise reduction in E:I balance in the medial prefrontal cortex (mPFC) either by optogenetically increasing the excitability of inhibitory parvalbumin (PV) neurons or decreasing the excitability of excitatory pyramidal neurons.
p42449
sg4
(dp42450
(Vparvalbumin
p42451
Vautism
p42452
tp42453
I01
ssg42003
(lp42454
(dp42455
g42006
I215
sg42007
Vexcitability
p42456
sg42008
I12
sg42009
VC0235169
p42457
sg42011
I1
sa(dp42458
g42006
I68
sg42007
g42452
sg42008
I6
sg42009
VC0004352
p42459
sg42011
I1
sa(dp42460
g42006
I215
sg42007
Vexcitability
p42461
sg42008
I12
sg42009
VC0235169
p42462
sg42011
I1
sasg42012
(lp42463
(dp42464
g42006
I255
sg42007
VPV
p42465
sg42008
I2
sg42016
VP20472
p42466
sg42011
I1
sa(dp42467
g42006
I242
sg42007
g42451
sg42008
I11
sg42016
VP20472
p42468
sg42011
I1
sa(dp42469
g42006
I25
sg42007
VCNTNAP2 gene
p42470
sg42008
I12
sg42016
g190
sg42011
I2
sasa(dp42471
g41997
VPost-mortem analyses have demonstrated a selective reduction in the expression of parvalbumin (PV) in GABAergic interneurons in the frontal rather than the sensory cortex of patients with neuropsychiatric disorders such as schizophrenia, autism spectrum disorders, and bipolar disorders.
p42472
sg4
(dp42473
(VPV
p42474
Vautism spectrum disorders
p42475
tp42476
I00
ssg42003
(lp42477
(dp42478
g42006
I223
sg42007
Vschizophrenia
p42479
sg42008
I13
sg42009
VC0036341
p42480
sg42011
I1
sa(dp42481
g42006
I269
sg42007
Vbipolar disorders
p42482
sg42008
I17
sg42009
VC0005586
p42483
sg42011
I2
sa(dp42484
g42006
I238
sg42007
g42475
sg42008
I25
sg42009
VC1510586
p42485
sg42011
I3
sasg42012
(lp42486
(dp42487
g42006
I82
sg42007
Vparvalbumin
p42488
sg42008
I11
sg42016
VP20472
p42489
sg42011
I1
sa(dp42490
g42006
I95
sg42007
g42474
sg42008
I2
sg42016
VP20472
p42491
sg42011
I1
sasa(dp42492
g41997
VRecent neuropathology studies in human brains indicate that several areas of the prefrontal cortex have decreased numbers of parvalbumin interneurons or decreased parvalbumin expression in Autism Spectrum disorders (ASD) [Hashemi, Ariza, Rogers, Noctor, &amp; Martinez-Cerdeno, 2017; Zikopoulos &amp; Barbas, ].
p42493
sg4
(dp42494
(Vparvalbumin
p42495
VASD
p42496
tp42497
I00
ssg42003
(lp42498
(dp42499
g42006
I189
sg42007
VAutism Spectrum disorders
p42500
sg42008
I25
sg42009
VC1510586
p42501
sg42011
I3
sa(dp42502
g42006
I216
sg42007
g42496
sg42008
I3
sg42009
VC1510586
p42503
sg42011
I1
sa(dp42504
g42006
I7
sg42007
Vneuropathology
p42505
sg42008
I14
sg42009
VC1540677
p42506
sg42011
I1
sasg42012
(lp42507
(dp42508
g42006
I125
sg42007
Vparvalbumin
p42509
sg42008
I11
sg42016
VP20472
p42510
sg42011
I1
sa(dp42511
g42006
I125
sg42007
g42495
sg42008
I11
sg42016
VP20472
p42512
sg42011
I1
sasa(dp42513
g41997
VIn view of the documented association between parvalbumin-expressing neurons and autism, the objective of the present study was to determine if parvalbumin gene expression is also altered in Purkinje neurons of the cerebellum.
p42514
sg4
(dp42515
(Vparvalbumin gene
p42516
Vautism
p42517
tp42518
I01
ssg42003
(lp42519
(dp42520
g42006
I81
sg42007
g42517
sg42008
I6
sg42009
VC0004352
p42521
sg42011
I1
sasg42012
(lp42522
(dp42523
g42006
I46
sg42007
Vparvalbumin
p42524
sg42008
I11
sg42016
VP20472
p42525
sg42011
I1
sa(dp42526
g42006
I144
sg42007
g42516
sg42008
I16
sg42016
VP20472
p42527
sg42011
I2
sasa(dp42528
g41997
VOur hypothesis is that parvalbumin, a molecule that controls and coordinate many cellular brain functions, contributes to the excitatory/inhibitory imbalance in Autism.
p42529
sg4
(dp42530
(Vparvalbumin
p42531
VAutism
p42532
tp42533
I01
ssg42003
(lp42534
(dp42535
g42006
I148
sg42007
Vimbalance
p42536
sg42008
I9
sg42009
VC1397014
p42537
sg42011
I1
sa(dp42538
g42006
I161
sg42007
g42532
sg42008
I6
sg42009
VC0004352
p42539
sg42011
I1
sasg42012
(lp42540
(dp42541
g42006
I23
sg42007
g42531
sg42008
I11
sg42016
VP20472
p42542
sg42011
I1
sasa(dp42543
g41997
VWe report that parvalbumin expression is depressed in Purkinje cells of the cerebellum in autism.
p42544
sg4
(dp42545
(Vparvalbumin
p42546
Vautism
p42547
tp42548
I01
ssg42003
(lp42549
(dp42550
g42006
I90
sg42007
g42547
sg42008
I6
sg42009
VC0004352
p42551
sg42011
I1
sasg42012
(lp42552
(dp42553
g42006
I15
sg42007
g42546
sg42008
I11
sg42016
VP20472
p42554
sg42011
I1
sasa(dp42555
g41997
VThe expression pattern of WNT3A is consistent with BRG1 in colon cancer tissues and WNT3A expression was inhibited in BRG1 knockdown cells.
p42556
sg4
(dp42557
(VWNT3A
p42558
Vcolon cancer
p42559
tp42560
I00
ssg42003
(lp42561
(dp42562
g42006
I59
sg42007
g42559
sg42008
I12
sg42009
VC0699790
p42563
sg42011
I2
sasg42012
(lp42564
(dp42565
g42006
I51
sg42007
VBRG1
p42566
sg42008
I4
sg42016
VP51532
p42567
sg42011
I1
sa(dp42568
g42006
I26
sg42007
VWNT3A
p42569
sg42008
I5
sg42016
VP56704
p42570
sg42011
I1
sa(dp42571
g42006
I51
sg42007
VBRG1 in colon cancer tissues
p42572
sg42008
I28
sg42016
VP51532
p42573
sg42011
I5
sa(dp42574
g42006
I26
sg42007
g42558
sg42008
I5
sg42016
VP56704
p42575
sg42011
I1
sasa(dp42576
g41997
VIn this study, we demonstrate that BRG1 may contribute to colon cancer progression through upregulating WNT3A expression.
p42577
sg4
(dp42578
(VBRG1
p42579
Vcancer progression
p42580
tp42581
I00
ssg42003
(lp42582
(dp42583
g42006
I64
sg42007
g42580
sg42008
I18
sg42009
VC0178874
p42584
sg42011
I2
sasg42012
(lp42585
(dp42586
g42006
I104
sg42007
VWNT3A
p42587
sg42008
I5
sg42016
VP56704
p42588
sg42011
I1
sa(dp42589
g42006
I35
sg42007
g42579
sg42008
I4
sg42016
VP51532
p42590
sg42011
I1
sasa(dp42591
g41997
VVM-positive colon cancer samples showed increased Wnt3a expression (p &lt; 0.001) and Beta-catenin nuclear expression (p &lt; 0.001) compared with the VM-negative samples.
p42592
sg4
(dp42593
(VBeta-catenin
p42594
Vcolon cancer
p42595
tp42596
I00
ssg42003
(lp42597
(dp42598
g42006
I12
sg42007
g42595
sg42008
I12
sg42009
VC0699790
p42599
sg42011
I2
sasg42012
(lp42600
(dp42601
g42006
I50
sg42007
VWnt3a
p42602
sg42008
I5
sg42016
VP56704
p42603
sg42011
I1
sa(dp42604
g42006
I86
sg42007
g42594
sg42008
I12
sg42016
VP35222
p42605
sg42011
I1
sasa(dp42606
g41997
VIn vitro, over-regulated Wnt3a expression in HT29 colon cancer cells promoted the capacity to form tube-like structures in the three-dimensional (3-D) culture together with increased expression of endothelial phenotype-associated proteins such as VEGFR2 and VE-cadherin.
p42607
sg4
(dp42608
(VWnt3a
p42609
Vcolon cancer
p42610
tp42611
I00
ssg42003
(lp42612
(dp42613
g42006
I50
sg42007
g42610
sg42008
I12
sg42009
VC0699790
p42614
sg42011
I2
sasg42012
(lp42615
(dp42616
g42006
I258
sg42007
VVE-cadherin
p42617
sg42008
I11
sg42016
VP33151
p42618
sg42011
I1
sa(dp42619
g42006
I247
sg42007
VVEGFR2
p42620
sg42008
I6
sg42016
VP35968
p42621
sg42011
I1
sa(dp42622
g42006
I25
sg42007
g42609
sg42008
I5
sg42016
VP56704
p42623
sg42011
I1
sasa(dp42624
g41997
VHowever, the roles of Wnt3a, the representative canonical Wnt ligand, in EMT and colon cancer progression have not yet been fully explored.
p42625
sg4
(dp42626
(VWnt3a
p42627
Vcancer progression
p42628
tp42629
I00
ssg42003
(lp42630
(dp42631
g42006
I87
sg42007
g42628
sg42008
I18
sg42009
VC0178874
p42632
sg42011
I2
sasg42012
(lp42633
(dp42634
g42006
I58
sg42007
VWnt ligand
p42635
sg42008
I10
sg42016
g190
sg42011
I2
sa(dp42636
g42006
I22
sg42007
g42627
sg42008
I5
sg42016
VP56704
p42637
sg42011
I1
sa(dp42638
g42006
I73
sg42007
VEMT
p42639
sg42008
I3
sg42016
g190
sg42011
I1
sasa(dp42640
g41997
VThe expression levels of Wnt3a and EMT-associated proteins (E-cadherin, vimentin, and Beta-catenin) were assessed by immunohistochemistry in human colon cancer tissues to evaluate the clinicopathological significance of Wnt3a, as well as the correlation between Wnt3a and EMT.
p42641
sg4
(dp42642
(VWnt3a
p42643
Vcolon cancer
p42644
tp42645
I00
ssg42003
(lp42646
(dp42647
g42006
I147
sg42007
g42644
sg42008
I12
sg42009
VC0699790
p42648
sg42011
I2
sasg42012
(lp42649
(dp42650
g42006
I25
sg42007
VWnt3a
p42651
sg42008
I5
sg42016
VP56704
p42652
sg42011
I1
sa(dp42653
g42006
I35
sg42007
VEMT-associated proteins
p42654
sg42008
I23
sg42016
g190
sg42011
I2
sa(dp42655
g42006
I60
sg42007
VE-cadherin
p42656
sg42008
I10
sg42016
VP12830
p42657
sg42011
I1
sa(dp42658
g42006
I86
sg42007
VBeta-catenin
p42659
sg42008
I12
sg42016
VP35222
p42660
sg42011
I1
sa(dp42661
g42006
I35
sg42007
VEMT
p42662
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp42663
g42006
I25
sg42007
VWnt3a
p42664
sg42008
I5
sg42016
VP56704
p42665
sg42011
I1
sa(dp42666
g42006
I25
sg42007
g42643
sg42008
I5
sg42016
VP56704
p42667
sg42011
I1
sasa(dp42668
g41997
VWe then upregulated Wnt3a expression in HCT116 colon cancer cells, established a nude mouse xenograft model, detected the expression of EMT and Wnt/Beta-catenin signaling-associated proteins, and observed invasion and clone-initiating abilities.
p42669
sg4
(dp42670
(VBeta-catenin
p42671
Vcolon cancer
p42672
tp42673
I00
ssg42003
(lp42674
(dp42675
g42006
I47
sg42007
g42672
sg42008
I12
sg42009
VC0699790
p42676
sg42011
I2
sa(dp42677
g42006
I205
sg42007
Vinvasion
p42678
sg42008
I8
sg42009
VC2699153
p42679
sg42011
I1
sasg42012
(lp42680
(dp42681
g42006
I20
sg42007
VWnt3a
p42682
sg42008
I5
sg42016
VP56704
p42683
sg42011
I1
sa(dp42684
g42006
I136
sg42007
VEMT
p42685
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp42686
g42006
I148
sg42007
g42671
sg42008
I12
sg42016
VP35222
p42687
sg42011
I1
sasa(dp42688
g41997
VIn 203 human colon cancer tissue samples, Wnt3a protein overexpression was related to colon cancer histological differentiation (P = 0.004), clinical stage (P = 0.008), presence of metastasis and recurrence (P = 0.036), and survival time (P = 0.007) of colon cancer patients.
p42689
sg4
(dp42690
(VWnt3a
p42691
Vcolon cancer
p42692
tp42693
I00
ssg42003
(lp42694
(dp42695
g42006
I181
sg42007
Vmetastasis
p42696
sg42008
I10
sg42009
VC0027627
p42697
sg42011
I1
sa(dp42698
g42006
I13
sg42007
Vcolon cancer
p42699
sg42008
I12
sg42009
VC0699790
p42700
sg42011
I2
sa(dp42701
g42006
I13
sg42007
Vcolon cancer
p42702
sg42008
I12
sg42009
VC0699790
p42703
sg42011
I2
sa(dp42704
g42006
I13
sg42007
g42692
sg42008
I12
sg42009
VC0699790
p42705
sg42011
I2
sa(dp42706
g42006
I196
sg42007
Vrecurrence
p42707
sg42008
I10
sg42009
VC1458156
p42708
sg42011
I1
sasg42012
(lp42709
(dp42710
g42006
I42
sg42007
g42691
sg42008
I5
sg42016
VP56704
p42711
sg42011
I1
sasa(dp42712
g41997
VWnt3a expression was associated with EMT and promoted colon cancer progression.
p42713
sg4
(dp42714
(VWnt3a
p42715
Vcancer progression
p42716
tp42717
I00
ssg42003
(lp42718
(dp42719
g42006
I60
sg42007
g42716
sg42008
I18
sg42009
VC0178874
p42720
sg42011
I2
sasg42012
(lp42721
(dp42722
g42006
I37
sg42007
VEMT
p42723
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp42724
g42006
I0
sg42007
g42715
sg42008
I5
sg42016
VP56704
p42725
sg42011
I1
sasa(dp42726
g41997
VTo evaluate the GH-releasing hormone (GH-RH)-induced response of GH in patients affected by hypothalamic amenorrhea.
p42727
sg4
(dp42728
(VGH-releasing hormone
p42729
Vhypothalamic amenorrhea
p42730
tp42731
I00
ssg42003
(lp42732
(dp42733
g42006
I92
sg42007
g42730
sg42008
I23
sg42009
VC0341862
p42734
sg42011
I2
sasg42012
(lp42735
(dp42736
g42006
I38
sg42007
VGH-RH
p42737
sg42008
I5
sg42016
VP01286
p42738
sg42011
I1
sa(dp42739
g42006
I16
sg42007
g42729
sg42008
I20
sg42016
VP01286
p42740
sg42011
I2
sasa(dp42741
g41997
VWe report the case of a 17-year-old girl presenting short stature (height 149 cm, below the 3rd percentile), obesity (weight 83.5 kg, body mass index 37 kg/m2) and secondary amenorrhea, in whom endocrinological evaluation disclosed an absolute lack of GH responsiveness to both suprapituitary challenges and repetitive growth hormone releasing hormone administration together with failure of plasma gonadotropins and PRL, low under basal conditions, to rise in response to GnRH and insulin-hypoglycemia, respectively.
p42742
sg4
(dp42743
(VGnRH
p42744
Vshort stature
p42745
tp42746
I00
ssg42003
(lp42747
(dp42748
g42006
I164
sg42007
Vsecondary amenorrhea
p42749
sg42008
I20
sg42009
VC0232940
p42750
sg42011
I2
sa(dp42751
g42006
I109
sg42007
Vobesity
p42752
sg42008
I7
sg42009
VC0028754
p42753
sg42011
I1
sa(dp42754
g42006
I490
sg42007
Vhypoglycemia
p42755
sg42008
I12
sg42009
VC0020615
p42756
sg42011
I1
sa(dp42757
g42006
I52
sg42007
g42745
sg42008
I13
sg42009
VC0013336
p42758
sg42011
I2
sasg42012
(lp42759
(dp42760
g42006
I319
sg42007
Vgrowth hormone
p42761
sg42008
I14
sg42016
VP01242
p42762
sg42011
I2
sa(dp42763
g42006
I482
sg42007
Vinsulin
p42764
sg42008
I7
sg42016
VP01308
p42765
sg42011
I1
sa(dp42766
g42006
I417
sg42007
VPRL
p42767
sg42008
I3
sg42016
VP01236
p42768
sg42011
I1
sa(dp42769
g42006
I473
sg42007
g42744
sg42008
I4
sg42016
VP01148
p42770
sg42011
I1
sasa(dp42771
g41997
VCommon genes include Jagged 1 (Jag1), Tetraspanin 2 (Tspan2), neuroblastoma, suppression of tumourigenicity 1 (Nbl1) and N-myc downstream regulated gene 2 (Ndrg2).
p42772
sg4
(dp42773
(VJag1
p42774
Vneuroblastoma
p42775
tp42776
I00
ssg42003
(lp42777
(dp42778
g42006
I62
sg42007
g42775
sg42008
I13
sg42009
VC0027819
p42779
sg42011
I1
sa(dp42780
g42006
I77
sg42007
Vsuppression
p42781
sg42008
I11
sg42009
VC0221103
p42782
sg42011
I1
sasg42012
(lp42783
(dp42784
g42006
I21
sg42007
VJagged 1
p42785
sg42008
I8
sg42016
VP78504
p42786
sg42011
I2
sa(dp42787
g42006
I121
sg42007
VN-myc
p42788
sg42008
I5
sg42016
VP04198
p42789
sg42011
I1
sa(dp42790
g42006
I38
sg42007
VTetraspanin 2
p42791
sg42008
I13
sg42016
g190
sg42011
I2
sa(dp42792
g42006
I31
sg42007
g42774
sg42008
I4
sg42016
VP78504
p42793
sg42011
I1
sa(dp42794
g42006
I53
sg42007
VTspan2
p42795
sg42008
I6
sg42016
g190
sg42011
I1
sasa(dp42796
g41997
VThe purpose of this study was to evaluate the correlation of somatostatin receptor-2 (SSTR2) expression with 68Ga-DOTA-TATE uptake and 177Lu-DOTA-TATE therapy in neuroblastoma (NB) xenograft models.
p42797
sg4
(dp42798
(Vsomatostatin receptor-2
p42799
Vneuroblastoma
p42800
tp42801
I00
ssg42003
(lp42802
(dp42803
g42006
I177
sg42007
VNB
p42804
sg42008
I2
sg42009
VC0027819
p42805
sg42011
I1
sa(dp42806
g42006
I162
sg42007
g42800
sg42008
I13
sg42009
VC0027819
p42807
sg42011
I1
sasg42012
(lp42808
(dp42809
g42006
I86
sg42007
VSSTR2
p42810
sg42008
I5
sg42016
VP30874
p42811
sg42011
I1
sa(dp42812
g42006
I61
sg42007
g42799
sg42008
I23
sg42016
VP61278
p42813
sg42011
I2
sasa(dp42814
g41997
VNeuroblastoma may be treated with molecular radiotherapy, 131I meta-Iodobenzylguanidine and 177Lu Lutetium DOTATATE, directed at distinct molecular targets: Noradrenaline Transporter Molecule (NAT) and Somatostatin Receptor (SSTR2), respectively.
p42815
sg4
(dp42816
(VSomatostatin Receptor
p42817
VNeuroblastoma
p42818
tp42819
I00
ssg42003
(lp42820
(dp42821
g42006
I0
sg42007
g42818
sg42008
I13
sg42009
VC0027819
p42822
sg42011
I1
sasg42012
(lp42823
(dp42824
g42006
I225
sg42007
VSSTR2
p42825
sg42008
I5
sg42016
VP30874
p42826
sg42011
I1
sa(dp42827
g42006
I202
sg42007
g42817
sg42008
I21
sg42016
VP61278
p42828
sg42011
I2
sasa(dp42829
g41997
VTissue bank samples of formalin fixed paraffin embedded neuroblastoma tissue from patients for whom clinical outcome data were available were sectioned and stained with haematoxylin and eosin, and monoclonal antibodies directed against NAT and SSTR2.
p42830
sg4
(dp42831
(VNAT
p42832
Vneuroblastoma
p42833
tp42834
I00
ssg42003
(lp42835
(dp42836
g42006
I56
sg42007
g42833
sg42008
I13
sg42009
VC0027819
p42837
sg42011
I1
sasg42012
(lp42838
(dp42839
g42006
I244
sg42007
VSSTR2
p42840
sg42008
I5
sg42016
VP30874
p42841
sg42011
I1
sa(dp42842
g42006
I236
sg42007
g42832
sg42008
I3
sg42016
VP18440
p42843
sg42011
I1
sasa(dp42844
g41997
V68Ga-DOTATATE PET/CT enables detection of meningioma tissue based on somatostatin receptor 2 expression.
p42845
sg4
(dp42846
(Vsomatostatin receptor 2
p42847
Vmeningioma
p42848
tp42849
I01
ssg42003
(lp42850
(dp42851
g42006
I42
sg42007
g42848
sg42008
I10
sg42009
VC0025286
p42852
sg42011
I1
sasg42012
(lp42853
(dp42854
g42006
I69
sg42007
g42847
sg42008
I23
sg42016
VP61278
p42855
sg42011
I3
sasa(dp42856
g41997
VImmunohistochemistry for the meningioma markers EMA and SSTR2A raised the possibility of intraosseous meningioma, as all 3 lesions were convincingly positive for epithelial membrane antigen (EMA) and 1 lesion was convincingly positive for the somatostatin receptor subtype 2A (SSTR2A); weak, questionable positivity for SSTR2 was present in the remaining 2 cases.
p42857
sg4
(dp42858
(VEMA
p42859
Vepithelial membrane antigen
p42860
tp42861
I00
ssg42003
(lp42862
(dp42863
g42006
I29
sg42007
Vmeningioma
p42864
sg42008
I10
sg42009
VC0025286
p42865
sg42011
I1
sa(dp42866
g42006
I48
sg42007
VEMA
p42867
sg42008
I3
sg42009
VC0268596
p42868
sg42011
I1
sa(dp42869
g42006
I29
sg42007
Vmeningioma
p42870
sg42008
I10
sg42009
VC0025286
p42871
sg42011
I1
sa(dp42872
g42006
I48
sg42007
VEMA
p42873
sg42008
I3
sg42009
VC0268596
p42874
sg42011
I1
sa(dp42875
g42006
I162
sg42007
g42860
sg42008
I27
sg42009
VC0268596
p42876
sg42011
I3
sasg42012
(lp42877
(dp42878
g42006
I56
sg42007
VSSTR2A
p42879
sg42008
I6
sg42016
VP61278
p42880
sg42011
I1
sa(dp42881
g42006
I162
sg42007
Vepithelial membrane antigen
p42882
sg42008
I27
sg42016
VP12830
p42883
sg42011
I3
sa(dp42884
g42006
I48
sg42007
VEMA
p42885
sg42008
I3
sg42016
VP13804
p42886
sg42011
I1
sa(dp42887
g42006
I56
sg42007
VSSTR2
p42888
sg42008
I5
sg42016
VP30874
p42889
sg42011
I1
sa(dp42890
g42006
I56
sg42007
VSSTR2A
p42891
sg42008
I6
sg42016
VP61278
p42892
sg42011
I1
sa(dp42893
g42006
I243
sg42007
Vsomatostatin receptor subtype 2A
p42894
sg42008
I32
sg42016
VP61278
p42895
sg42011
I4
sa(dp42896
g42006
I48
sg42007
g42859
sg42008
I3
sg42016
VP12830
p42897
sg42011
I1
sasa(dp42898
g41997
VSomatostatine receptors subtype 2 (SSTR2) are regarded as a potential target in neuroblastoma (NB) for imaging and promising therapeutic approaches.
p42899
sg4
(dp42900
(VSSTR2
p42901
VNB
p42902
tp42903
I00
ssg42003
(lp42904
(dp42905
g42006
I80
sg42007
Vneuroblastoma
p42906
sg42008
I13
sg42009
VC0027819
p42907
sg42011
I1
sa(dp42908
g42006
I95
sg42007
g42902
sg42008
I2
sg42009
VC0027819
p42909
sg42011
I1
sasg42012
(lp42910
(dp42911
g42006
I0
sg42007
VSomatostatine receptors subtype 2
p42912
sg42008
I33
sg42016
g190
sg42011
I4
sa(dp42913
g42006
I35
sg42007
g42901
sg42008
I5
sg42016
VP30874
p42914
sg42011
I1
sasa(dp42915
g41997
VGaTATE PET was positive in a high proportion of patients with refractory neuroblastoma, correlating with SSTR 2 on IHC, with additional disease identified compared with MIBG imaging.
p42916
sg4
(dp42917
(VSSTR 2
p42918
Vneuroblastoma
p42919
tp42920
I00
ssg42003
(lp42921
(dp42922
g42006
I73
sg42007
g42919
sg42008
I13
sg42009
VC0027819
p42923
sg42011
I1
sasg42012
(lp42924
(dp42925
g42006
I105
sg42007
g42918
sg42008
I6
sg42016
VP31391
p42926
sg42011
I2
sasa(dp42927
g41997
VPET using the SSTR2 analog (68)Ga-DOTATATE has recently been introduced for imaging of meningiomas.
p42928
sg4
(dp42929
(VSSTR2
p42930
Vmeningiomas
p42931
tp42932
I00
ssg42003
(lp42933
(dp42934
g42006
I87
sg42007
g42931
sg42008
I11
sg42009
VC0025286
p42935
sg42011
I1
sasg42012
(lp42936
(dp42937
g42006
I14
sg42007
g42930
sg42008
I5
sg42016
VP30874
p42938
sg42011
I1
sasa(dp42939
g41997
V(68)Ga-DOTATATE uptake correlates with SSTR2 expression and offers high diagnostic accuracy to delineate meningioma from tumor-free tissue even in recurrent tumors after previous therapy.
p42940
sg4
(dp42941
(VSSTR2
p42942
Vmeningioma
p42943
tp42944
I00
ssg42003
(lp42945
(dp42946
g42006
I105
sg42007
g42943
sg42008
I10
sg42009
VC0025286
p42947
sg42011
I1
sa(dp42948
g42006
I121
sg42007
Vtumor
p42949
sg42008
I5
sg42009
VC0027651
p42950
sg42011
I1
sa(dp42951
g42006
I157
sg42007
Vtumors
p42952
sg42008
I6
sg42009
VC0027651
p42953
sg42011
I1
sasg42012
(lp42954
(dp42955
g42006
I39
sg42007
g42942
sg42008
I5
sg42016
VP30874
p42956
sg42011
I1
sasa(dp42957
g41997
VWe aimed to compare the frequency of perineurial marker expression in these two entities, and to determine whether somatostatin receptor 2 (SSTR2) and progesterone receptor (PR), both expressed frequently in meningiomas, are also expressed in perineuriomas.
p42958
sg4
(dp42959
(VSSTR2
p42960
Vperineuriomas
p42961
tp42962
I00
ssg42003
(lp42963
(dp42964
g42006
I208
sg42007
Vmeningiomas
p42965
sg42008
I11
sg42009
VC0025286
p42966
sg42011
I1
sa(dp42967
g42006
I243
sg42007
g42961
sg42008
I13
sg42009
VC0751691
p42968
sg42011
I1
sasg42012
(lp42969
(dp42970
g42006
I115
sg42007
Vsomatostatin receptor 2
p42971
sg42008
I23
sg42016
VP61278
p42972
sg42011
I3
sa(dp42973
g42006
I151
sg42007
Vprogesterone receptor
p42974
sg42008
I21
sg42016
VP06401
p42975
sg42011
I2
sa(dp42976
g42006
I174
sg42007
VPR
p42977
sg42008
I2
sg42016
VP06401
p42978
sg42011
I1
sa(dp42979
g42006
I140
sg42007
g42960
sg42008
I5
sg42016
VP30874
p42980
sg42011
I1
sasa(dp42981
g41997
VAll tumours were stained using five antibodies against antigens that are known to be expressed in perineuriomas or meningiomas: epithelial membrane antigen (EMA), claudin-1, GLUT-1 (glucose transporter-1), SSTR2, and PR.
p42982
sg4
(dp42983
(VEMA
p42984
VEMA
p42985
tp42986
I00
ssg42003
(lp42987
(dp42988
g42006
I98
sg42007
Vperineuriomas
p42989
sg42008
I13
sg42009
VC0751691
p42990
sg42011
I1
sa(dp42991
g42006
I115
sg42007
Vmeningiomas
p42992
sg42008
I11
sg42009
VC0025286
p42993
sg42011
I1
sa(dp42994
g42006
I128
sg42007
Vepithelial membrane antigen
p42995
sg42008
I27
sg42009
VC0268596
p42996
sg42011
I3
sa(dp42997
g42006
I4
sg42007
Vtumours
p42998
sg42008
I7
sg42009
VC0027651
p42999
sg42011
I1
sa(dp43000
g42006
I157
sg42007
g42985
sg42008
I3
sg42009
VC0268596
p43001
sg42011
I1
sasg42012
(lp43002
(dp43003
g42006
I174
sg42007
VGLUT-1
p43004
sg42008
I6
sg42016
VP11166
p43005
sg42011
I1
sa(dp43006
g42006
I128
sg42007
Vepithelial membrane antigen
p43007
sg42008
I27
sg42016
VP12830
p43008
sg42011
I3
sa(dp43009
g42006
I182
sg42007
Vglucose transporter-1
p43010
sg42008
I21
sg42016
VP11166
p43011
sg42011
I2
sa(dp43012
g42006
I206
sg42007
VSSTR2
p43013
sg42008
I5
sg42016
VP30874
p43014
sg42011
I1
sa(dp43015
g42006
I157
sg42007
g42984
sg42008
I3
sg42016
VP13804
p43016
sg42011
I1
sa(dp43017
g42006
I163
sg42007
Vclaudin-1
p43018
sg42008
I9
sg42016
g190
sg42011
I1
sasa(dp43019
g41997
VThe SSTR2-positive/PR-positive phenotype was detected in 42 of 60 meningiomas, but in none of 20 perineuriomas.
p43020
sg4
(dp43021
(VSSTR2
p43022
Vperineuriomas
p43023
tp43024
I00
ssg42003
(lp43025
(dp43026
g42006
I66
sg42007
Vmeningiomas
p43027
sg42008
I11
sg42009
VC0025286
p43028
sg42011
I1
sa(dp43029
g42006
I97
sg42007
g43023
sg42008
I13
sg42009
VC0751691
p43030
sg42011
I1
sasg42012
(lp43031
(dp43032
g42006
I4
sg42007
g43022
sg42008
I5
sg42016
VP30874
p43033
sg42011
I1
sasa(dp43034
g41997
VSSTR2 and PR are highly sensitive and, in this context, specific meningioma markers.
p43035
sg4
(dp43036
(VSSTR2
p43037
Vmeningioma
p43038
tp43039
I00
ssg42003
(lp43040
(dp43041
g42006
I65
sg42007
g43038
sg42008
I10
sg42009
VC0025286
p43042
sg42011
I1
sasg42012
(lp43043
(dp43044
g42006
I0
sg42007
g43037
sg42008
I5
sg42016
VP30874
p43045
sg42011
I1
sasa(dp43046
g41997
VWe utilized inhibitors of cPLA2 alpha, COX-1/2 and 5-LO to determine the potential roles of these enzymes in development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).
p43047
sg4
(dp43048
(VcPLA2 alpha
p43049
Vmultiple sclerosis
p43050
tp43051
I01
ssg42003
(lp43052
(dp43053
g42006
I167
sg42007
VEAE
p43054
sg42008
I3
sg42009
VC0014070
p43055
sg42011
I1
sa(dp43056
g42006
I212
sg42007
VMS
p43057
sg42008
I2
sg42009
VC0026769
p43058
sg42011
I1
sa(dp43059
g42006
I148
sg42007
Vencephalomyelitis
p43060
sg42008
I17
sg42009
VC0014070
p43061
sg42011
I1
sa(dp43062
g42006
I192
sg42007
g43050
sg42008
I18
sg42009
VC0026769
p43063
sg42011
I2
sa(dp43064
g42006
I137
sg42007
Vautoimmune
p43065
sg42008
I10
sg42009
VC0443146
p43066
sg42011
I1
sasg42012
(lp43067
(dp43068
g42006
I39
sg42007
VCOX-1/2
p43069
sg42008
I7
sg42016
VP00395
p43070
sg42011
I1
sa(dp43071
g42006
I26
sg42007
g43049
sg42008
I11
sg42016
VP47712
p43072
sg42011
I2
sasa(dp43073
g41997
VThis study aimed to better understand the role of miR-200a-3p and its correlation with HBx in HBV-induced hepatocellular carcinoma (HCC).
p43074
sg4
(dp43075
(VHBx
p43076
VHCC
p43077
tp43078
I00
ssg42003
(lp43079
(dp43080
g42006
I106
sg42007
Vhepatocellular carcinoma
p43081
sg42008
I24
sg42009
VC2239176
p43082
sg42011
I2
sa(dp43083
g42006
I94
sg42007
VHBV
p43084
sg42008
I3
sg42009
VC0019163
p43085
sg42011
I1
sa(dp43086
g42006
I132
sg42007
g43077
sg42008
I3
sg42009
VC2239176
p43087
sg42011
I1
sasg42012
(lp43088
(dp43089
g42006
I87
sg42007
g43076
sg42008
I3
sg42016
VP24821
p43090
sg42011
I1
sa(dp43091
g42006
I50
sg42007
VmiR-200a-3p
p43092
sg42008
I11
sg42016
g190
sg42011
I1
sasa(dp43093
g41997
VFurther study suggested that lncRNA-PE downregulated miR-200a/b by repressing the primary transcript expression, enhanced ZEB1 expression, and promoted epithelial-mesenchymal transition of hepatocellular carcinoma cells.
p43094
sg4
(dp43095
(VZEB1
p43096
Vhepatocellular carcinoma
p43097
tp43098
I00
ssg42003
(lp43099
(dp43100
g42006
I175
sg42007
Vtransition
p43101
sg42008
I10
sg42009
VC0599156
p43102
sg42011
I1
sa(dp43103
g42006
I189
sg42007
g43097
sg42008
I24
sg42009
VC1512411
p43104
sg42011
I2
sasg42012
(lp43105
(dp43106
g42006
I53
sg42007
VmiR-200a/b
p43107
sg42008
I10
sg42016
g190
sg42011
I1
sa(dp43108
g42006
I29
sg42007
VlncRNA-PE
p43109
sg42008
I9
sg42016
VP48147
p43110
sg42011
I1
sa(dp43111
g42006
I122
sg42007
g43096
sg42008
I4
sg42016
VP37275
p43112
sg42011
I1
sasa(dp43113
g41997
VAll these data imply that lncRNA-PE might play an important role in hepatocellular carcinoma development via the miR-200a/b-ZEB1 pathway.
p43114
sg4
(dp43115
(VZEB1
p43116
Vhepatocellular carcinoma
p43117
tp43118
I00
ssg42003
(lp43119
(dp43120
g42006
I68
sg42007
g43117
sg42008
I24
sg42009
VC1512411
p43121
sg42011
I2
sasg42012
(lp43122
(dp43123
g42006
I26
sg42007
VlncRNA-PE
p43124
sg42008
I9
sg42016
VP48147
p43125
sg42011
I1
sa(dp43126
g42006
I124
sg42007
g43116
sg42008
I4
sg42016
VP37275
p43127
sg42011
I1
sa(dp43128
g42006
I113
sg42007
VmiR-200a
p43129
sg42008
I8
sg42016
g190
sg42011
I1
sasa(dp43130
g41997
VLong noncoding RNAs (lncRNAs)-activated by transforming growth factor beta (lncRNA-ATB) is known to be involved in the invasion of hepatocellular carcinoma by regulating target genes of miR-200a.
p43131
sg4
(dp43132
(Vtransforming growth factor beta
p43133
Vhepatocellular carcinoma
p43134
tp43135
I00
ssg42003
(lp43136
(dp43137
g42006
I119
sg42007
Vinvasion
p43138
sg42008
I8
sg42009
VC2699153
p43139
sg42011
I1
sa(dp43140
g42006
I131
sg42007
g43134
sg42008
I24
sg42009
VC1512411
p43141
sg42011
I2
sasg42012
(lp43142
(dp43143
g42006
I186
sg42007
VmiR-200a
p43144
sg42008
I8
sg42016
g190
sg42011
I1
sa(dp43145
g42006
I76
sg42007
VlncRNA-ATB
p43146
sg42008
I10
sg42016
VP00325
p43147
sg42011
I1
sa(dp43148
g42006
I43
sg42007
g43133
sg42008
I31
sg42016
VP18075
p43149
sg42011
I4
sasa(dp43150
g41997
VOur data indicate that nine distinct genes associated with multiple sclerosis risk, Bach2, Il2ra, Irf8, Mertk, Odf3b, Plek, Rgs1, Slc30a7 and Thada, can be confirmed to be differentially regulated in pathogenic CD4(+) T cells.
p43151
sg4
(dp43152
(VPlek
p43153
Vmultiple sclerosis
p43154
tp43155
I00
ssg42003
(lp43156
(dp43157
g42006
I59
sg42007
g43154
sg42008
I18
sg42009
VC0026769
p43158
sg42011
I2
sasg42012
(lp43159
(dp43160
g42006
I111
sg42007
VOdf3b
p43161
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp43162
g42006
I98
sg42007
VIrf8
p43163
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43164
g42006
I91
sg42007
VIl2ra
p43165
sg42008
I5
sg42016
VP01589
p43166
sg42011
I1
sa(dp43167
g42006
I104
sg42007
VMertk
p43168
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp43169
g42006
I211
sg42007
VCD4
p43170
sg42008
I3
sg42016
VP01730
p43171
sg42011
I1
sa(dp43172
g42006
I84
sg42007
VBach2
p43173
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp43174
g42006
I130
sg42007
VSlc30a7
p43175
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp43176
g42006
I124
sg42007
VRgs1
p43177
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43178
g42006
I118
sg42007
g43153
sg42008
I4
sg42016
VP08567
p43179
sg42011
I1
sasa(dp43180
g41997
VGenetic polymorphisms within a single locus encoding the transcription factor BACH2 are associated with numerous autoimmune and allergic diseases including asthma, Crohn's disease, coeliac disease, vitiligo, multiple sclerosis and type 1 diabetes.
p43181
sg4
(dp43182
(Vtranscription factor BACH2
p43183
Vasthma
p43184
tp43185
I00
ssg42003
(lp43186
(dp43187
g42006
I208
sg42007
Vmultiple sclerosis
p43188
sg42008
I18
sg42009
VC0026769
p43189
sg42011
I2
sa(dp43190
g42006
I164
sg42007
VCrohn's disease
p43191
sg42008
I15
sg42009
VC0010346
p43192
sg42011
I2
sa(dp43193
g42006
I113
sg42007
Vautoimmune
p43194
sg42008
I10
sg42009
VC0443146
p43195
sg42011
I1
sa(dp43196
g42006
I181
sg42007
Vcoeliac disease
p43197
sg42008
I15
sg42009
VC0007570
p43198
sg42011
I2
sa(dp43199
g42006
I231
sg42007
Vtype 1 diabetes
p43200
sg42008
I15
sg42009
VC0011854
p43201
sg42011
I3
sa(dp43202
g42006
I198
sg42007
Vvitiligo
p43203
sg42008
I8
sg42009
VC0042900
p43204
sg42011
I1
sa(dp43205
g42006
I156
sg42007
g43184
sg42008
I6
sg42009
VC0004096
p43206
sg42011
I1
sasg42012
(lp43207
(dp43208
g42006
I57
sg42007
g43183
sg42008
I26
sg42016
VP35398
p43209
sg42011
I3
sasa(dp43210
g41997
VHowever, array-based copy number analysis and qPCR were used to detect a hemizygous deletion in the PACD linkage interval containing 4 genes encoding small leucine-rich proteoglycans (SLRPs): KERA, LUM, DCN, and EPYC.
p43211
sg4
(dp43212
(Vsmall leucine-rich proteoglycans
p43213
VPACD
p43214
tp43215
I00
ssg42003
(lp43216
(dp43217
g42006
I100
sg42007
g43214
sg42008
I4
sg42009
VC2748502
p43218
sg42011
I1
sasg42012
(lp43219
(dp43220
g42006
I192
sg42007
VKERA
p43221
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43222
g42006
I212
sg42007
VEPYC
p43223
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43224
g42006
I198
sg42007
VLUM
p43225
sg42008
I3
sg42016
VP51884
p43226
sg42011
I1
sa(dp43227
g42006
I203
sg42007
VDCN
p43228
sg42008
I3
sg42016
VP07585
p43229
sg42011
I1
sa(dp43230
g42006
I184
sg42007
VSLRPs
p43231
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp43232
g42006
I150
sg42007
g43213
sg42008
I32
sg42016
VP30740
p43233
sg42011
I3
sasa(dp43234
g41997
VThe authors performed clinical evaluation of a previously unreported pedigree with PACD, light and electron microscopic examination of an excised corneal button, genomewide linkage analysis, fine mapping linkage and haplotype analysis, and screening of four candidate genes (KERA, LUM, DCN, and EPYC).
p43235
sg4
(dp43236
(VLUM
p43237
VPACD
p43238
tp43239
I00
ssg42003
(lp43240
(dp43241
g42006
I83
sg42007
g43238
sg42008
I4
sg42009
VC2748502
p43242
sg42011
I1
sasg42012
(lp43243
(dp43244
g42006
I295
sg42007
VEPYC
p43245
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43246
g42006
I286
sg42007
VDCN
p43247
sg42008
I3
sg42016
VP07585
p43248
sg42011
I1
sa(dp43249
g42006
I275
sg42007
VKERA
p43250
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43251
g42006
I281
sg42007
g43237
sg42008
I3
sg42016
VP51884
p43252
sg42011
I1
sasa(dp43253
g41997
VThe results suggest that CD164 expression may have affected the proliferation and apoptosis of human glioma cells via the PTEN/phosphoinositide 3-kinase/AKT pathway, and may therefore present a potential target for the diagnosis and treatment of glioma.
p43254
sg4
(dp43255
(VPTEN
p43256
Vglioma
p43257
tp43258
I00
ssg42003
(lp43259
(dp43260
g42006
I64
sg42007
Vproliferation
p43261
sg42008
I13
sg42009
VC0334094
p43262
sg42011
I1
sa(dp43263
g42006
I101
sg42007
Vglioma
p43264
sg42008
I6
sg42009
VC0017638
p43265
sg42011
I1
sa(dp43266
g42006
I101
sg42007
g43257
sg42008
I6
sg42009
VC0017638
p43267
sg42011
I1
sasg42012
(lp43268
(dp43269
g42006
I127
sg42007
Vphosphoinositide 3-kinase
p43270
sg42008
I25
sg42016
g190
sg42011
I2
sa(dp43271
g42006
I122
sg42007
g43256
sg42008
I4
sg42016
VP60484
p43272
sg42011
I1
sa(dp43273
g42006
I153
sg42007
VAKT
p43274
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp43275
g42006
I25
sg42007
VCD164
p43276
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp43277
g41997
VWe recently demonstrated the high expression of CD164 on CD4+ T cells from Sezary syndrome patients with a wide range of circulating tumor burdens.
p43278
sg4
(dp43279
(VCD4+
p43280
VSezary syndrome
p43281
tp43282
I01
ssg42003
(lp43283
(dp43284
g42006
I133
sg42007
Vtumor
p43285
sg42008
I5
sg42009
VC0027651
p43286
sg42011
I1
sa(dp43287
g42006
I75
sg42007
g43281
sg42008
I15
sg42009
VC0036920
p43288
sg42011
I2
sasg42012
(lp43289
(dp43290
g42006
I48
sg42007
VCD164
p43291
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp43292
g42006
I57
sg42007
g43280
sg42008
I4
sg42016
VP01730
p43293
sg42011
I1
sasa(dp43294
g41997
VIn a cohort of patients with Sezary syndrome, CD164 expression on total CD4+ lymphocytes was significantly upregulated compared with healthy controls.
p43295
sg4
(dp43296
(VCD4+
p43297
VSezary syndrome
p43298
tp43299
I01
ssg42003
(lp43300
(dp43301
g42006
I29
sg42007
g43298
sg42008
I15
sg42009
VC0036920
p43302
sg42011
I2
sasg42012
(lp43303
(dp43304
g42006
I72
sg42007
g43297
sg42008
I4
sg42016
VP01730
p43305
sg42011
I1
sa(dp43306
g42006
I46
sg42007
VCD164
p43307
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp43308
g41997
VDespite the known engagement of the AFAP1-AS in several human diseases, its biological function in Hirschsprung disease (HSCR) remains elusive.
p43309
sg4
(dp43310
(VHirschsprung disease
p43311
VHirschsprung disease
p43312
tp43313
I00
ssg42003
(lp43314
(dp43315
g42006
I121
sg42007
VHSCR
p43316
sg42008
I4
sg42009
VC2931876
p43317
sg42011
I1
sa(dp43318
g42006
I99
sg42007
g43312
sg42008
I20
sg42009
VC0019569
p43319
sg42011
I2
sasg42012
(lp43320
(dp43321
g42006
I36
sg42007
VAFAP1-AS
p43322
sg42008
I8
sg42016
g190
sg42011
I1
sa(dp43323
g42006
I121
sg42007
VHSCR
p43324
sg42008
I4
sg42016
VP14138
p43325
sg42011
I1
sa(dp43326
g42006
I99
sg42007
g43311
sg42008
I20
sg42016
VP14138
p43327
sg42011
I2
sasa(dp43328
g41997
VConquerFear participants had clinically and statistically greater improvements than control participants from T0 to T1 on FCRI total ( P &lt; .001) and severity subscale scores ( P = .001), which were maintained at T2 ( P = .017 and P = .023, respectively) and, for FCRI total only, at T3 ( P = .018), and from T0 to T1 on three FCRI subscales (coping, psychological distress, and triggers) as well as in general anxiety, cancer-specific distress (total), and mental quality of life and metacognitions (total).
p43329
sg4
(dp43330
(VFCRI
p43331
Vpsychological distress
p43332
tp43333
I00
ssg42003
(lp43334
(dp43335
g42006
I353
sg42007
g43332
sg42008
I22
sg42009
VC0815107
p43336
sg42011
I2
sa(dp43337
g42006
I422
sg42007
Vcancer
p43338
sg42008
I6
sg42009
VC0006826
p43339
sg42011
I1
sasg42012
(lp43340
(dp43341
g42006
I122
sg42007
VFCRI
p43342
sg42008
I4
sg42016
VP12314
p43343
sg42011
I1
sa(dp43344
g42006
I122
sg42007
g43331
sg42008
I4
sg42016
VP12314
p43345
sg42011
I1
sasa(dp43346
g41997
VSixty-four patients with hematological tumors were selected and divided into the group complicated with bacterial infection (infection group, 33 cases) and the non-infection group (31 cases), the flow cytometry was be used to detect the related peripheral blood markers CD64 and CD14, the nCD64 IND and CD14 IND were calculated, and the peripheral blood WBC count, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were determined at the same time.
p43347
sg4
(dp43348
(VCD14 IND
p43349
Vbacterial infection
p43350
tp43351
I00
ssg42003
(lp43352
(dp43353
g42006
I25
sg42007
Vhematological tumors
p43354
sg42008
I20
sg42009
VC0376545
p43355
sg42011
I2
sa(dp43356
g42006
I104
sg42007
g43350
sg42008
I19
sg42009
VC0004623
p43357
sg42011
I2
sa(dp43358
g42006
I114
sg42007
Vinfection
p43359
sg42008
I9
sg42009
VC0009450
p43360
sg42011
I1
sa(dp43361
g42006
I114
sg42007
Vinfection
p43362
sg42008
I9
sg42009
VC0009450
p43363
sg42011
I1
sasg42012
(lp43364
(dp43365
g42006
I406
sg42007
VC-reactive protein
p43366
sg42008
I18
sg42016
VP02741
p43367
sg42011
I2
sa(dp43368
g42006
I279
sg42007
VCD14
p43369
sg42008
I4
sg42016
VP08571
p43370
sg42011
I1
sa(dp43371
g42006
I426
sg42007
VCRP
p43372
sg42008
I3
sg42016
VP02741
p43373
sg42011
I1
sa(dp43374
g42006
I270
sg42007
VCD64
p43375
sg42008
I4
sg42016
VP12314
p43376
sg42011
I1
sa(dp43377
g42006
I303
sg42007
g43349
sg42008
I8
sg42016
VP08571
p43378
sg42011
I2
sasa(dp43379
g41997
VFCI features, with single-tube 8-color combination using CD45, CD34, HAL-DR, CD11b, CD13, CD33, and CD117 and CD64, were compared for the 30 consecutive APL and 30 non-APL acute myeloid leukemia (AML) cases which morphologically mimicked an APL.
p43380
sg4
(dp43381
(VCD34
p43382
VAPL
p43383
tp43384
I00
ssg42003
(lp43385
(dp43386
g42006
I196
sg42007
VAML
p43387
sg42008
I3
sg42009
VC0023467
p43388
sg42011
I1
sa(dp43389
g42006
I153
sg42007
VAPL
p43390
sg42008
I3
sg42009
VC0023487
p43391
sg42011
I1
sa(dp43392
g42006
I172
sg42007
Vacute myeloid leukemia
p43393
sg42008
I22
sg42009
VC0023467
p43394
sg42011
I3
sa(dp43395
g42006
I153
sg42007
VAPL
p43396
sg42008
I3
sg42009
VC0023487
p43397
sg42011
I1
sa(dp43398
g42006
I153
sg42007
g43383
sg42008
I3
sg42009
VC0023487
p43399
sg42011
I1
sasg42012
(lp43400
(dp43401
g42006
I100
sg42007
VCD117
p43402
sg42008
I5
sg42016
VP10721
p43403
sg42011
I1
sa(dp43404
g42006
I57
sg42007
VCD45
p43405
sg42008
I4
sg42016
VP08575
p43406
sg42011
I1
sa(dp43407
g42006
I90
sg42007
VCD33
p43408
sg42008
I4
sg42016
VP20138
p43409
sg42011
I1
sa(dp43410
g42006
I84
sg42007
VCD13
p43411
sg42008
I4
sg42016
VP15144
p43412
sg42011
I1
sa(dp43413
g42006
I77
sg42007
VCD11b
p43414
sg42008
I5
sg42016
VP11215
p43415
sg42011
I1
sa(dp43416
g42006
I69
sg42007
VHAL-DR
p43417
sg42008
I6
sg42016
VP42357
p43418
sg42011
I1
sa(dp43419
g42006
I110
sg42007
VCD64
p43420
sg42008
I4
sg42016
VP12314
p43421
sg42011
I1
sa(dp43422
g42006
I63
sg42007
g43382
sg42008
I4
sg42016
VP28906
p43423
sg42011
I1
sasa(dp43424
g41997
VOne patient with nesidioblastosis had no response to secretin, indicating that the pathophysiology of this entity is distinct from that of other forms of islet hyperplasia.
p43425
sg4
(dp43426
(Vsecretin
p43427
Vnesidioblastosis
p43428
tp43429
I00
ssg42003
(lp43430
(dp43431
g42006
I160
sg42007
Vhyperplasia
p43432
sg42008
I11
sg42009
VC0020507
p43433
sg42011
I1
sa(dp43434
g42006
I17
sg42007
g43428
sg42008
I16
sg42009
VC0027773
p43435
sg42011
I1
sasg42012
(lp43436
(dp43437
g42006
I53
sg42007
g43427
sg42008
I8
sg42016
VP09683
p43438
sg42011
I1
sasa(dp43439
g41997
VIn addition, the ability to respond to secretin appears to be lost in patients with single insulinomas and nesidioblastosis, but not in those with multiple B-cell adenomas and hyperplasia.
p43440
sg4
(dp43441
(Vsecretin
p43442
Vadenomas
p43443
tp43444
I00
ssg42003
(lp43445
(dp43446
g42006
I176
sg42007
Vhyperplasia
p43447
sg42008
I11
sg42009
VC0020507
p43448
sg42011
I1
sa(dp43449
g42006
I91
sg42007
Vinsulinomas
p43450
sg42008
I11
sg42009
VC0021670
p43451
sg42011
I1
sa(dp43452
g42006
I107
sg42007
Vnesidioblastosis
p43453
sg42008
I16
sg42009
VC0027773
p43454
sg42011
I1
sa(dp43455
g42006
I163
sg42007
g43443
sg42008
I8
sg42009
VC0001430
p43456
sg42011
I1
sasg42012
(lp43457
(dp43458
g42006
I39
sg42007
g43442
sg42008
I8
sg42016
VP09683
p43459
sg42011
I1
sasa(dp43460
g41997
VIn addition, HLXB9 is recurrently rearranged in young children with acute myeloid leukemia characterized by a chromosomal translocation t(7;12)-HLXB9/TEL and concomitant high expression of the unrearranged, wild-type HLXB9 allele.
p43461
sg4
(dp43462
(VHLXB9
p43463
Vacute myeloid leukemia
p43464
tp43465
I00
ssg42003
(lp43466
(dp43467
g42006
I110
sg42007
Vchromosomal translocation
p43468
sg42008
I25
sg42009
VC0040715
p43469
sg42011
I2
sa(dp43470
g42006
I68
sg42007
g43464
sg42008
I22
sg42009
VC0023467
p43471
sg42011
I3
sasg42012
(lp43472
(dp43473
g42006
I13
sg42007
VHLXB9
p43474
sg42008
I5
sg42016
VP50219
p43475
sg42011
I1
sa(dp43476
g42006
I207
sg42007
Vwild-type HLXB9 allele
p43477
sg42008
I22
sg42016
VP50219
p43478
sg42011
I3
sa(dp43479
g42006
I150
sg42007
VTEL
p43480
sg42008
I3
sg42016
VP41212
p43481
sg42011
I1
sa(dp43482
g42006
I13
sg42007
g43463
sg42008
I5
sg42016
VP50219
p43483
sg42011
I1
sasa(dp43484
g41997
VHerein, we report the clinical course of an 8-month-old patient with acute myeloid leukemia, M2 subtype and with a HLXB9/TEL rearrangement.
p43485
sg4
(dp43486
(VHLXB9
p43487
Vacute myeloid leukemia
p43488
tp43489
I00
ssg42003
(lp43490
(dp43491
g42006
I69
sg42007
g43488
sg42008
I22
sg42009
VC0023467
p43492
sg42011
I3
sasg42012
(lp43493
(dp43494
g42006
I121
sg42007
VTEL
p43495
sg42008
I3
sg42016
VP41212
p43496
sg42011
I1
sa(dp43497
g42006
I115
sg42007
g43487
sg42008
I5
sg42016
VP50219
p43498
sg42011
I1
sasa(dp43499
g41997
VUsing RT-PCR, we screened members of the EHG family of homeobox genes, comprising EN1 (at 2q14), GBX2 (at 2q36), and EN2, GBX1, and HLXB9 (at 7q36), for dysregulation in acute myeloid leukemia (AML) cell lines indicated by chromosomal breakpoints at these sites.
p43500
sg4
(dp43501
(VEN2
p43502
Vacute myeloid leukemia
p43503
tp43504
I00
ssg42003
(lp43505
(dp43506
g42006
I194
sg42007
VAML
p43507
sg42008
I3
sg42009
VC0023467
p43508
sg42011
I1
sa(dp43509
g42006
I170
sg42007
g43503
sg42008
I22
sg42009
VC0023467
p43510
sg42011
I3
sasg42012
(lp43511
(dp43512
g42006
I55
sg42007
Vhomeobox genes
p43513
sg42008
I14
sg42016
VP52954
p43514
sg42011
I2
sa(dp43515
g42006
I97
sg42007
VGBX2
p43516
sg42008
I4
sg42016
VP52951
p43517
sg42011
I1
sa(dp43518
g42006
I122
sg42007
VGBX1
p43519
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43520
g42006
I132
sg42007
VHLXB9
p43521
sg42008
I5
sg42016
VP50219
p43522
sg42011
I1
sa(dp43523
g42006
I117
sg42007
g43502
sg42008
I3
sg42016
VP41208
p43524
sg42011
I1
sasa(dp43525
g41997
VPreviously, we showed that KLF5 is a mediator of RAS/MAPK and WNT signaling pathways under homeostatic conditions and that it promotes their tumorigenic functions during the development and progression of intestinal adenomas.
p43526
sg4
(dp43527
(VRAS
p43528
Vadenomas
p43529
tp43530
I00
ssg42003
(lp43531
(dp43532
g42006
I216
sg42007
g43529
sg42008
I8
sg42009
VC0001430
p43533
sg42011
I1
sasg42012
(lp43534
(dp43535
g42006
I27
sg42007
VKLF5
p43536
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43537
g42006
I53
sg42007
VMAPK
p43538
sg42008
I4
sg42016
VP53779
p43539
sg42011
I1
sa(dp43540
g42006
I49
sg42007
g43528
sg42008
I3
sg42016
VP01116
p43541
sg42011
I1
sasa(dp43542
g41997
VMoreover, production of lethal adenomas and carcinomas by specific expression of an oncogenic mutant of Beta-catenin in Lgr5(+) stem cells was suppressed completely by Klf5 deletion in the same cells.
p43543
sg4
(dp43544
(VBeta-catenin
p43545
Vadenomas
p43546
tp43547
I00
ssg42003
(lp43548
(dp43549
g42006
I31
sg42007
g43546
sg42008
I8
sg42009
VC0001430
p43550
sg42011
I1
sa(dp43551
g42006
I44
sg42007
Vcarcinomas
p43552
sg42008
I10
sg42009
VC0007097
p43553
sg42011
I1
sa(dp43554
g42006
I94
sg42007
Vmutant
p43555
sg42008
I6
sg42009
VC0596988
p43556
sg42011
I1
sasg42012
(lp43557
(dp43558
g42006
I168
sg42007
VKlf5 deletion
p43559
sg42008
I13
sg42016
g190
sg42011
I2
sa(dp43560
g42006
I120
sg42007
VLgr5
p43561
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43562
g42006
I104
sg42007
g43545
sg42008
I12
sg42016
VP35222
p43563
sg42011
I1
sasa(dp43564
g41997
VTo determine whether KLF5 contributes to intestinal adenoma formation, we examined tumor burdens in Apc(Min/+) mice and Apc(Min/+)/Klf5(+/-) mice.
p43565
sg4
(dp43566
(VApc
p43567
VApc
p43568
tp43569
I00
ssg42003
(lp43570
(dp43571
g42006
I41
sg42007
Vintestinal adenoma
p43572
sg42008
I18
sg42009
VC1142339
p43573
sg42011
I2
sa(dp43574
g42006
I83
sg42007
Vtumor
p43575
sg42008
I5
sg42009
VC0027651
p43576
sg42011
I1
sa(dp43577
g42006
I100
sg42007
VApc
p43578
sg42008
I3
sg42009
VC0033036
p43579
sg42011
I1
sa(dp43580
g42006
I100
sg42007
g43568
sg42008
I3
sg42009
VC0033036
p43581
sg42011
I1
sasg42012
(lp43582
(dp43583
g42006
I100
sg42007
VApc
p43584
sg42008
I3
sg42016
VP25054
p43585
sg42011
I1
sa(dp43586
g42006
I100
sg42007
g43567
sg42008
I3
sg42016
VP25054
p43587
sg42011
I1
sa(dp43588
g42006
I21
sg42007
VKLF5
p43589
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43590
g42006
I131
sg42007
VKlf5
p43591
sg42008
I4
sg42016
g190
sg42011
I1
sasa(dp43592
g41997
VCompared with Apc(Min/+) mice, Apc(Min/+)/Klf5(+/-) mice had a 96% reduction in the number of intestinal adenomas.
p43593
sg4
(dp43594
(VApc
p43595
VApc
p43596
tp43597
I00
ssg42003
(lp43598
(dp43599
g42006
I14
sg42007
VApc
p43600
sg42008
I3
sg42009
VC0033036
p43601
sg42011
I1
sa(dp43602
g42006
I105
sg42007
Vadenomas
p43603
sg42008
I8
sg42009
VC0001430
p43604
sg42011
I1
sa(dp43605
g42006
I14
sg42007
g43596
sg42008
I3
sg42009
VC0033036
p43606
sg42011
I1
sasg42012
(lp43607
(dp43608
g42006
I14
sg42007
VApc
p43609
sg42008
I3
sg42016
VP25054
p43610
sg42011
I1
sa(dp43611
g42006
I42
sg42007
VKlf5
p43612
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43613
g42006
I14
sg42007
g43595
sg42008
I3
sg42016
VP25054
p43614
sg42011
I1
sasa(dp43615
g41997
VThus, KLF5 is necessary for the tumor-initiating activity of beta-catenin during intestinal adenoma formation in Apc(Min/+) mice, and reduced expression of KLF5 offsets the tumor-initiating activity of the Apc(Min) mutation by reducing the nuclear localization and activity of beta-catenin.
p43616
sg4
(dp43617
(VApc
p43618
VApc
p43619
tp43620
I00
ssg42003
(lp43621
(dp43622
g42006
I113
sg42007
VApc
p43623
sg42008
I3
sg42009
VC0033036
p43624
sg42011
I1
sa(dp43625
g42006
I81
sg42007
Vintestinal adenoma
p43626
sg42008
I18
sg42009
VC1142339
p43627
sg42011
I2
sa(dp43628
g42006
I32
sg42007
Vtumor
p43629
sg42008
I5
sg42009
VC0027651
p43630
sg42011
I1
sa(dp43631
g42006
I113
sg42007
g43619
sg42008
I3
sg42009
VC0033036
p43632
sg42011
I1
sa(dp43633
g42006
I32
sg42007
Vtumor
p43634
sg42008
I5
sg42009
VC0027651
p43635
sg42011
I1
sasg42012
(lp43636
(dp43637
g42006
I6
sg42007
VKLF5
p43638
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43639
g42006
I61
sg42007
Vbeta-catenin
p43640
sg42008
I12
sg42016
VP35222
p43641
sg42011
I1
sa(dp43642
g42006
I113
sg42007
VApc
p43643
sg42008
I3
sg42016
VP25054
p43644
sg42011
I1
sa(dp43645
g42006
I6
sg42007
VKLF5
p43646
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43647
g42006
I61
sg42007
Vbeta-catenin
p43648
sg42008
I12
sg42016
VP35222
p43649
sg42011
I1
sa(dp43650
g42006
I113
sg42007
g43618
sg42008
I3
sg42016
VP25054
p43651
sg42011
I1
sasa(dp43652
g41997
VKLF5 expression was examined in intestinal tumors derived from transgenic mice expressing KRAS(V12G) under villin promoter and in human colorectal cancers with mutated KRAS.
p43653
sg4
(dp43654
(VKRAS
p43655
Vcolorectal cancers
p43656
tp43657
I00
ssg42003
(lp43658
(dp43659
g42006
I32
sg42007
Vintestinal tumors
p43660
sg42008
I17
sg42009
VC0021841
p43661
sg42011
I2
sa(dp43662
g42006
I136
sg42007
g43656
sg42008
I18
sg42009
VC1527249
p43663
sg42011
I2
sasg42012
(lp43664
(dp43665
g42006
I90
sg42007
VKRAS
p43666
sg42008
I4
sg42016
VP01116
p43667
sg42011
I1
sa(dp43668
g42006
I107
sg42007
Vvillin promoter
p43669
sg42008
I15
sg42016
VP09327
p43670
sg42011
I2
sa(dp43671
g42006
I0
sg42007
VKLF5
p43672
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43673
g42006
I90
sg42007
g43655
sg42008
I4
sg42016
VP01116
p43674
sg42011
I1
sasa(dp43675
g41997
VIn vivo, both intestinal tumors derived from mice transgenic for villin-KRAS(V12G) and human primary colorectal cancers with mutated KRAS contained high levels of KLF5 and increased staining of the proliferative marker Ki67.
p43676
sg4
(dp43677
(VKRAS
p43678
Vcolorectal cancers
p43679
tp43680
I00
ssg42003
(lp43681
(dp43682
g42006
I198
sg42007
Vproliferative
p43683
sg42008
I13
sg42009
VC0334094
p43684
sg42011
I1
sa(dp43685
g42006
I14
sg42007
Vintestinal tumors
p43686
sg42008
I17
sg42009
VC0021841
p43687
sg42011
I2
sa(dp43688
g42006
I101
sg42007
g43679
sg42008
I18
sg42009
VC1527249
p43689
sg42011
I2
sasg42012
(lp43690
(dp43691
g42006
I65
sg42007
Vvillin
p43692
sg42008
I6
sg42016
VP09327
p43693
sg42011
I1
sa(dp43694
g42006
I72
sg42007
VKRAS
p43695
sg42008
I4
sg42016
VP01116
p43696
sg42011
I1
sa(dp43697
g42006
I72
sg42007
g43678
sg42008
I4
sg42016
VP01116
p43698
sg42011
I1
sa(dp43699
g42006
I163
sg42007
VKLF5
p43700
sg42008
I4
sg42016
g190
sg42011
I1
sasa(dp43701
g41997
VElevated levels of KLF5 protein are strongly correlated with activating KRAS mutations in intestinal tumors in vitro and in vivo.
p43702
sg4
(dp43703
(VKRAS
p43704
Vintestinal tumors
p43705
tp43706
I00
ssg42003
(lp43707
(dp43708
g42006
I90
sg42007
g43705
sg42008
I17
sg42009
VC0021841
p43709
sg42011
I2
sasg42012
(lp43710
(dp43711
g42006
I19
sg42007
VKLF5 protein
p43712
sg42008
I12
sg42016
g190
sg42011
I2
sa(dp43713
g42006
I72
sg42007
g43704
sg42008
I4
sg42016
VP01116
p43714
sg42011
I1
sasa(dp43715
g41997
VRas-transformation also markedly down-regulated KLF5; further analysis indicated that reduced expression of KLF5 mRNA and destabilization of KLF5 protein occur in intestinal tumors.
p43716
sg4
(dp43717
(VRas
p43718
Vintestinal tumors
p43719
tp43720
I00
ssg42003
(lp43721
(dp43722
g42006
I163
sg42007
g43719
sg42008
I17
sg42009
VC0021841
p43723
sg42011
I2
sa(dp43724
g42006
I4
sg42007
Vtransformation
p43725
sg42008
I14
sg42009
VC1510411
p43726
sg42011
I1
sasg42012
(lp43727
(dp43728
g42006
I141
sg42007
VKLF5 protein
p43729
sg42008
I12
sg42016
g190
sg42011
I2
sa(dp43730
g42006
I108
sg42007
VKLF5 mRNA
p43731
sg42008
I9
sg42016
g190
sg42011
I2
sa(dp43732
g42006
I48
sg42007
VKLF5
p43733
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43734
g42006
I0
sg42007
g43718
sg42008
I3
sg42016
VP01116
p43735
sg42011
I1
sasa(dp43736
g41997
VVariable major lipoprotein (Vmp) is a major tumor necrosis factor (TNF)-inducing component of Borrelia recurrentis, the agent of louse-borne relapsing fever.
p43737
sg4
(dp43738
(VTNF
p43739
Vtumor necrosis
p43740
tp43741
I00
ssg42003
(lp43742
(dp43743
g42006
I94
sg42007
VBorrelia
p43744
sg42008
I8
sg42009
VC0024198
p43745
sg42011
I1
sa(dp43746
g42006
I129
sg42007
Vlouse-borne relapsing fever
p43747
sg42008
I27
sg42009
VC0152061
p43748
sg42011
I3
sa(dp43749
g42006
I44
sg42007
g43740
sg42008
I14
sg42009
VC0333516
p43750
sg42011
I2
sasg42012
(lp43751
(dp43752
g42006
I44
sg42007
Vtumor necrosis factor
p43753
sg42008
I21
sg42016
VP01375
p43754
sg42011
I3
sa(dp43755
g42006
I67
sg42007
g43739
sg42008
I3
sg42016
VP01375
p43756
sg42011
I1
sasa(dp43757
g41997
VLouse-borne relapsing fever, caused by Borrelia recurrentis, provides one of the best documented examples of the causative role of tumor necrosis factor (TNF) in the pathology of severe infection in humans.
p43758
sg4
(dp43759
(Vtumor necrosis factor
p43760
VBorrelia
p43761
tp43762
I01
ssg42003
(lp43763
(dp43764
g42006
I186
sg42007
Vinfection
p43765
sg42008
I9
sg42009
VC0009450
p43766
sg42011
I1
sa(dp43767
g42006
I166
sg42007
Vpathology
p43768
sg42008
I9
sg42009
VC0677042
p43769
sg42011
I1
sa(dp43770
g42006
I0
sg42007
VLouse-borne relapsing fever
p43771
sg42008
I27
sg42009
VC0152061
p43772
sg42011
I3
sa(dp43773
g42006
I131
sg42007
Vtumor necrosis
p43774
sg42008
I14
sg42009
VC0333516
p43775
sg42011
I2
sa(dp43776
g42006
I39
sg42007
g43761
sg42008
I8
sg42009
VC0024198
p43777
sg42011
I1
sasg42012
(lp43778
(dp43779
g42006
I154
sg42007
VTNF
p43780
sg42008
I3
sg42016
VP01375
p43781
sg42011
I1
sa(dp43782
g42006
I131
sg42007
g43760
sg42008
I21
sg42016
VP01375
p43783
sg42011
I3
sasa(dp43784
g41997
VSevere Jarisch Herxheimer reaction (J-HR) precipitated by antibiotic treatment of louse-borne relapsing fever (LBRF) is associated with a transient, marked rise in circulating tumour necrosis factor alpha (TNF alpha), interleukin 6 (IL-6) and interleukin 8 (IL-8).
p43785
sg4
(dp43786
(Vinterleukin 8
p43787
Vtumour necrosis
p43788
tp43789
I00
ssg42003
(lp43790
(dp43791
g42006
I111
sg42007
VLBRF
p43792
sg42008
I4
sg42009
VC0152061
p43793
sg42011
I1
sa(dp43794
g42006
I82
sg42007
Vlouse-borne relapsing fever
p43795
sg42008
I27
sg42009
VC0152061
p43796
sg42011
I3
sa(dp43797
g42006
I176
sg42007
g43788
sg42008
I15
sg42009
VC0333516
p43798
sg42011
I2
sasg42012
(lp43799
(dp43800
g42006
I206
sg42007
VTNF alpha
p43801
sg42008
I9
sg42016
VP01375
p43802
sg42011
I2
sa(dp43803
g42006
I258
sg42007
VIL-8
p43804
sg42008
I4
sg42016
VP60568
p43805
sg42011
I1
sa(dp43806
g42006
I218
sg42007
Vinterleukin 6
p43807
sg42008
I13
sg42016
VP05231
p43808
sg42011
I2
sa(dp43809
g42006
I233
sg42007
VIL-6
p43810
sg42008
I4
sg42016
VP05231
p43811
sg42011
I1
sa(dp43812
g42006
I176
sg42007
Vtumour necrosis factor alpha
p43813
sg42008
I28
sg42016
VP01375
p43814
sg42011
I4
sa(dp43815
g42006
I243
sg42007
g43787
sg42008
I13
sg42016
VP60568
p43816
sg42011
I2
sasa(dp43817
g41997
VIn patients with louse-borne relapsing fever (Borrelia recurrentis infection), antimicrobial treatment is often followed by sudden fever, rigors, and persistent hypotension (Jarisch-Herxheimer reactions) that are associated with increases in plasma concentrations of tumor necrosis factor alpha (TNF-alpha), interleukin-6, and interleukin-8.
p43818
sg4
(dp43819
(Vtumor necrosis factor alpha
p43820
Vrigors
p43821
tp43822
I00
ssg42003
(lp43823
(dp43824
g42006
I267
sg42007
Vtumor necrosis
p43825
sg42008
I14
sg42009
VC0333516
p43826
sg42011
I2
sa(dp43827
g42006
I17
sg42007
Vlouse-borne relapsing fever
p43828
sg42008
I27
sg42009
VC0152061
p43829
sg42011
I3
sa(dp43830
g42006
I46
sg42007
VBorrelia recurrentis infection
p43831
sg42008
I30
sg42009
VC0857817
p43832
sg42011
I3
sa(dp43833
g42006
I138
sg42007
g43821
sg42008
I6
sg42009
VC0424790
p43834
sg42011
I1
sasg42012
(lp43835
(dp43836
g42006
I296
sg42007
VTNF-alpha
p43837
sg42008
I9
sg42016
VP01375
p43838
sg42011
I1
sa(dp43839
g42006
I327
sg42007
Vinterleukin-8
p43840
sg42008
I13
sg42016
VP60568
p43841
sg42011
I1
sa(dp43842
g42006
I308
sg42007
Vinterleukin-6
p43843
sg42008
I13
sg42016
VP05231
p43844
sg42011
I1
sa(dp43845
g42006
I267
sg42007
g43820
sg42008
I27
sg42016
VP01375
p43846
sg42011
I4
sasa(dp43847
g41997
VPretreatment with sheep anti-TNF-alpha Fab suppresses Jarisch-Herxheimer reactions that occur after penicillin treatment for louse-borne relapsing fever, reduces the associated increases in plasma concentrations of interleukin-6 and interleukin-8, and may be useful in other forms of sepsis.
p43848
sg4
(dp43849
(Vanti-TNF-alpha Fab
p43850
Vsepsis
p43851
tp43852
I00
ssg42003
(lp43853
(dp43854
g42006
I125
sg42007
Vlouse-borne relapsing fever
p43855
sg42008
I27
sg42009
VC0152061
p43856
sg42011
I3
sa(dp43857
g42006
I284
sg42007
g43851
sg42008
I6
sg42009
VC0243026
p43858
sg42011
I1
sasg42012
(lp43859
(dp43860
g42006
I233
sg42007
Vinterleukin-8
p43861
sg42008
I13
sg42016
VP60568
p43862
sg42011
I1
sa(dp43863
g42006
I215
sg42007
Vinterleukin-6
p43864
sg42008
I13
sg42016
VP05231
p43865
sg42011
I1
sa(dp43866
g42006
I24
sg42007
g43850
sg42008
I18
sg42016
VP01375
p43867
sg42011
I2
sasa(dp43868
g41997
VThe FGF9 subfamily, including FGF9, FGF16, and FGF20, in addition to rhFGF16, rhFGF9, and rhFGF20, were shown to stimulate the proliferation and migration of HuH7 human hepatocellular carcinoma (HCC) cells.
p43869
sg4
(dp43870
(VFGF9
p43871
VHCC
p43872
tp43873
I00
ssg42003
(lp43874
(dp43875
g42006
I169
sg42007
Vhepatocellular carcinoma
p43876
sg42008
I24
sg42009
VC2239176
p43877
sg42011
I2
sa(dp43878
g42006
I195
sg42007
g43872
sg42008
I3
sg42009
VC2239176
p43879
sg42011
I1
sa(dp43880
g42006
I127
sg42007
Vproliferation
p43881
sg42008
I13
sg42009
VC0334094
p43882
sg42011
I1
sasg42012
(lp43883
(dp43884
g42006
I4
sg42007
VFGF9 subfamily
p43885
sg42008
I14
sg42016
VP31371
p43886
sg42011
I2
sa(dp43887
g42006
I4
sg42007
g43871
sg42008
I4
sg42016
VP31371
p43888
sg42011
I1
sa(dp43889
g42006
I36
sg42007
VFGF16
p43890
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp43891
g42006
I47
sg42007
VFGF20
p43892
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp43893
g41997
VOur previous work has shown that JBS is caused by mutations in human UBR1, which encodes one of the E3 ubiquitin ligases of the N-end rule pathway.
p43894
sg4
(dp43895
(VE3 ubiquitin ligases
p43896
VJBS
p43897
tp43898
I00
ssg42003
(lp43899
(dp43900
g42006
I33
sg42007
g43897
sg42008
I3
sg42009
VC0795841
p43901
sg42011
I1
sasg42012
(lp43902
(dp43903
g42006
I63
sg42007
Vhuman UBR1
p43904
sg42008
I10
sg42016
g190
sg42011
I2
sa(dp43905
g42006
I33
sg42007
VJBS
p43906
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp43907
g42006
I100
sg42007
g43896
sg42008
I20
sg42016
VP62979
p43908
sg42011
I3
sasa(dp43909
g41997
V* Sixteen distinct haplotypes were detected from 258 individuals in the C. conica complex inferred from the cpDNA sequences of intergenic spacer (IGS) between atpB and rbcL, IGS between trnT and trnL, trnL intron, and IGS between trnL and trnF.
p43910
sg4
(dp43911
(VatpB
p43912
VIGS
p43913
tp43914
I00
ssg42003
(lp43915
(dp43916
g42006
I146
sg42007
VIGS
p43917
sg42008
I3
sg42009
VC1306856
p43918
sg42011
I1
sa(dp43919
g42006
I146
sg42007
VIGS
p43920
sg42008
I3
sg42009
VC1306856
p43921
sg42011
I1
sa(dp43922
g42006
I146
sg42007
g43913
sg42008
I3
sg42009
VC1306856
p43923
sg42011
I1
sasg42012
(lp43924
(dp43925
g42006
I146
sg42007
VIGS
p43926
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp43927
g42006
I186
sg42007
VtrnT
p43928
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp43929
g42006
I201
sg42007
VtrnL intron
p43930
sg42008
I11
sg42016
VP49184
p43931
sg42011
I2
sa(dp43932
g42006
I146
sg42007
VIGS
p43933
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp43934
g42006
I195
sg42007
VtrnL
p43935
sg42008
I4
sg42016
VP49184
p43936
sg42011
I1
sa(dp43937
g42006
I159
sg42007
g43912
sg42008
I4
sg42016
VP05026
p43938
sg42011
I1
sa(dp43939
g42006
I195
sg42007
VtrnL
p43940
sg42008
I4
sg42016
VP49184
p43941
sg42011
I1
sasa(dp43942
g41997
VMaximum parsimony and Bayesian inference analyses of DNA sequence data of the plastid (the trnT-L igs, the trnL intron, two parts of the trnK intron, and the psbA-trnH igs) and nuclear genome (ITS1, 5.8S, and ITS2) showed these markers to be suitable to assess the species composition of sect.
p43943
sg4
(dp43944
(VpsbA-trnH igs
p43945
Vigs
p43946
tp43947
I00
ssg42003
(lp43948
(dp43949
g42006
I98
sg42007
Vigs
p43950
sg42008
I3
sg42009
VC1306856
p43951
sg42011
I1
sa(dp43952
g42006
I98
sg42007
g43946
sg42008
I3
sg42009
VC1306856
p43953
sg42011
I1
sasg42012
(lp43954
(dp43955
g42006
I158
sg42007
g43945
sg42008
I13
sg42016
VP40306
p43956
sg42011
I2
sa(dp43957
g42006
I107
sg42007
VtrnL intron
p43958
sg42008
I11
sg42016
VP49184
p43959
sg42011
I2
sa(dp43960
g42006
I91
sg42007
VtrnT-L igs
p43961
sg42008
I10
sg42016
g190
sg42011
I2
sa(dp43962
g42006
I137
sg42007
VtrnK intron
p43963
sg42008
I11
sg42016
g190
sg42011
I2
sasa(dp43964
g41997
VHowever, the primers for amplification of chloroplast trnD-trnT intron and rRNA IGS failed to amplify the respective region in Elymus species.
p43965
sg4
(dp43966
(Vchloroplast trnD-trnT intron
p43967
VIGS
p43968
tp43969
I00
ssg42003
(lp43970
(dp43971
g42006
I25
sg42007
Vamplification
p43972
sg42008
I13
sg42009
VC1705759
p43973
sg42011
I1
sa(dp43974
g42006
I80
sg42007
g43968
sg42008
I3
sg42009
VC1306856
p43975
sg42011
I1
sasg42012
(lp43976
(dp43977
g42006
I42
sg42007
g43967
sg42008
I28
sg42016
VP27708
p43978
sg42011
I3
sasa(dp43979
g41997
VIn the present study, we investigated the effect of taspine derivative 12k on human colorectal cancer targeted at EphrinB2 and its PDZ.
p43980
sg4
(dp43981
(VEphrinB2
p43982
Vcolorectal cancer
p43983
tp43984
I01
ssg42003
(lp43985
(dp43986
g42006
I84
sg42007
g43983
sg42008
I17
sg42009
VC1527249
p43987
sg42011
I2
sasg42012
(lp43988
(dp43989
g42006
I114
sg42007
g43982
sg42008
I8
sg42016
VP52799
p43990
sg42011
I1
sasa(dp43991
g41997
VTwenty proteins from different signaling pathways (epidermal growth factor receptor [EGFR], phosphorylated extracellular signal regulated kinase [pERK], receptor for hyalouronic acid mediated motility [RHAMM], Raf-1 kinase inhibitor protein [RKIP], Beta-catenin, E-cadherin, phosphorylated AK transforming [pAKT], p16, p21, Ki-67, B-cell Lymphoma-2 [BCL2], vascular endothelial growth factor, apoptosis protease activating factor 1 [APAF-1], mucin1 [MUC1], ephrin B2 receptor [EphB2], matrix metalloproteinase 7 [MMP7], phosphorylated mothers against decapentaplegic 2 [pSMAD2], caudal type homeobox transcription factor 2 [CDX2], Laminin5Gamma2, and mammalian sterile 20-like kinase 1 [MST1]) involved in colorectal cancer progression were studied immunohistochemically on 220 well-characterized patients using a multiple-punch tissue microarray including 437 and 430 samples from the tumor center and the invasive front, respectively.
p43992
sg4
(dp43993
(Vextracellular signal regulated kinase [pERK], receptor for hyalouronic acid mediated motility
p43994
VB-cell Lymphoma
p43995
tp43996
I00
ssg42003
(lp43997
(dp43998
g42006
I717
sg42007
Vcancer progression
p43999
sg42008
I18
sg42009
VC0178874
p44000
sg42011
I2
sa(dp44001
g42006
I886
sg42007
Vtumor
p44002
sg42008
I5
sg42009
VC0027651
p44003
sg42011
I1
sa(dp44004
g42006
I661
sg42007
Vsterile
p44005
sg42008
I7
sg42009
VC0678108
p44006
sg42011
I1
sa(dp44007
g42006
I331
sg42007
g43995
sg42008
I15
sg42009
VC0079731
p44008
sg42011
I2
sasg42012
(lp44009
(dp44010
g42006
I223
sg42007
Vinhibitor protein [RKIP]
p44011
sg42008
I24
sg42016
VP30086
p44012
sg42011
I3
sa(dp44013
g42006
I210
sg42007
VRaf-1 kinase
p44014
sg42008
I12
sg42016
VP04049
p44015
sg42011
I2
sa(dp44016
g42006
I51
sg42007
Vepidermal growth factor receptor
p44017
sg42008
I32
sg42016
VP01133
p44018
sg42011
I4
sa(dp44019
g42006
I201
sg42007
V[RHAMM]
p44020
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp44021
g42006
I249
sg42007
VBeta-catenin
p44022
sg42008
I12
sg42016
VP35222
p44023
sg42011
I1
sa(dp44024
g42006
I263
sg42007
VE-cadherin
p44025
sg42008
I10
sg42016
VP12830
p44026
sg42011
I1
sa(dp44027
g42006
I579
sg42007
Vcaudal type homeobox transcription factor 2 [CDX2]
p44028
sg42008
I50
sg42016
g190
sg42011
I7
sa(dp44029
g42006
I357
sg42007
Vvascular endothelial growth factor
p44030
sg42008
I34
sg42016
g190
sg42011
I4
sa(dp44031
g42006
I314
sg42007
Vp16
p44032
sg42008
I3
sg42016
VP42771
p44033
sg42011
I1
sa(dp44034
g42006
I393
sg42007
Vapoptosis protease activating factor 1
p44035
sg42008
I38
sg42016
VP63123
p44036
sg42011
I5
sa(dp44037
g42006
I324
sg42007
VKi-67
p44038
sg42008
I5
sg42016
VP46013
p44039
sg42011
I1
sa(dp44040
g42006
I319
sg42007
Vp21
p44041
sg42008
I3
sg42016
VP42857
p44042
sg42011
I1
sa(dp44043
g42006
I669
sg42007
V20-like kinase 1
p44044
sg42008
I16
sg42016
VP27361
p44045
sg42011
I3
sa(dp44046
g42006
I275
sg42007
Vphosphorylated AK
p44047
sg42008
I17
sg42016
VP55263
p44048
sg42011
I2
sa(dp44049
g42006
I457
sg42007
Vephrin B2 receptor [EphB2], matrix metalloproteinase 7 [MMP7]
p44050
sg42008
I61
sg42016
VP52799
p44051
sg42011
I8
sa(dp44052
g42006
I331
sg42007
VB-cell Lymphoma-2 [BCL2]
p44053
sg42008
I24
sg42016
VP10415
p44054
sg42011
I3
sa(dp44055
g42006
I687
sg42007
VMST1
p44056
sg42008
I4
sg42016
VP26927
p44057
sg42011
I1
sa(dp44058
g42006
I107
sg42007
g43994
sg42008
I93
sg42016
VP53778
p44059
sg42011
I11
sasa(dp44060
g41997
VAbundant expression of IFN-Gamma-inducible protein 10 (IP-10) was observed on macrophages and in T cells in perimysial infiltrates of dermatomyositis (DM), and strong chemokine (C-X-C motif) receptor (CXCR)3 expression was observed on the majority of T cells in DM.
p44061
sg4
(dp44062
(VIFN-Gamma
p44063
VDM
p44064
tp44065
I00
ssg42003
(lp44066
(dp44067
g42006
I151
sg42007
VDM
p44068
sg42008
I2
sg42009
VC0221056
p44069
sg42011
I1
sa(dp44070
g42006
I119
sg42007
Vinfiltrates
p44071
sg42008
I11
sg42009
VC0332448
p44072
sg42011
I1
sa(dp44073
g42006
I134
sg42007
Vdermatomyositis
p44074
sg42008
I15
sg42009
VC0221056
p44075
sg42011
I1
sa(dp44076
g42006
I151
sg42007
g44064
sg42008
I2
sg42009
VC0221056
p44077
sg42011
I1
sasg42012
(lp44078
(dp44079
g42006
I23
sg42007
g44063
sg42008
I9
sg42016
VP01579
p44080
sg42011
I1
sasa(dp44081
g41997
VFurthermore, the lack of interdigital programmed cell death and associated syndactyly was related to down-regulated gene expression of Bmp2, Bmp7, Msx1, and Msx2, which are known to promote apoptosis in the interdigital mesenchyme.
p44082
sg4
(dp44083
(VMsx2
p44084
Vsyndactyly
p44085
tp44086
I00
ssg42003
(lp44087
(dp44088
g42006
I75
sg42007
g44085
sg42008
I10
sg42009
VC0039075
p44089
sg42011
I1
sasg42012
(lp44090
(dp44091
g42006
I135
sg42007
VBmp2
p44092
sg42008
I4
sg42016
VP12643
p44093
sg42011
I1
sa(dp44094
g42006
I147
sg42007
VMsx1
p44095
sg42008
I4
sg42016
VP28360
p44096
sg42011
I1
sa(dp44097
g42006
I141
sg42007
VBmp7
p44098
sg42008
I4
sg42016
VP18075
p44099
sg42011
I1
sa(dp44100
g42006
I157
sg42007
g44084
sg42008
I4
sg42016
VP35548
p44101
sg42011
I1
sasa(dp44102
g41997
VThe CPK, aldolase, GOT, GPT, and LDH concentrations in the serum and lumbar CSF of 80 patients with neuromuscular diseases and 20 controls were measured.
p44103
sg4
(dp44104
(VGPT
p44105
Vneuromuscular diseases
p44106
tp44107
I00
ssg42003
(lp44108
(dp44109
g42006
I100
sg42007
g44106
sg42008
I22
sg42009
VC0027868
p44110
sg42011
I2
sasg42012
(lp44111
(dp44112
g42006
I33
sg42007
VLDH
p44113
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp44114
g42006
I9
sg42007
Valdolase
p44115
sg42008
I8
sg42016
VP05062
p44116
sg42011
I1
sa(dp44117
g42006
I69
sg42007
Vlumbar CSF
p44118
sg42008
I10
sg42016
VP04141
p44119
sg42011
I2
sa(dp44120
g42006
I4
sg42007
VCPK
p44121
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp44122
g42006
I24
sg42007
g44105
sg42008
I3
sg42016
VP24298
p44123
sg42011
I1
sasa(dp44124
g41997
VIn 60 cases of various neuromuscular diseases, serum CA-III, CPK and aldolase were measured.
p44125
sg4
(dp44126
(Valdolase
p44127
Vneuromuscular diseases
p44128
tp44129
I00
ssg42003
(lp44130
(dp44131
g42006
I23
sg42007
g44128
sg42008
I22
sg42009
VC0027868
p44132
sg42011
I2
sasg42012
(lp44133
(dp44134
g42006
I53
sg42007
VCA-III
p44135
sg42008
I6
sg42016
VP07451
p44136
sg42011
I1
sa(dp44137
g42006
I69
sg42007
g44127
sg42008
I8
sg42016
VP05062
p44138
sg42011
I1
sa(dp44139
g42006
I61
sg42007
VCPK
p44140
sg42008
I3
sg42016
g190
sg42011
I1
sasa(dp44141
g41997
VTissue sections ranging from normal mucosa to moderately-differentiated oral squamous cell carcinoma were studied using monoclonal antibodies against N-ras and ets-1 proteins.
p44142
sg4
(dp44143
(Vets-1 proteins
p44144
Vsquamous cell carcinoma
p44145
tp44146
I01
ssg42003
(lp44147
(dp44148
g42006
I77
sg42007
g44145
sg42008
I23
sg42009
VC0007137
p44149
sg42011
I3
sasg42012
(lp44150
(dp44151
g42006
I152
sg42007
Vras
p44152
sg42008
I3
sg42016
VP01116
p44153
sg42011
I1
sa(dp44154
g42006
I160
sg42007
g44144
sg42008
I14
sg42016
VP14921
p44155
sg42011
I2
sasa(dp44156
g41997
VThe use of nicotinic acid to treat dyslipidemia is limited by induction of a "flushing" response, mediated in part by the interaction of prostaglandin D(2) (PGD(2)) with its G-protein coupled receptor, DP1 (Ptgdr).
p44157
sg4
(dp44158
(VG-protein coupled receptor
p44159
Vdyslipidemia
p44160
tp44161
I00
ssg42003
(lp44162
(dp44163
g42006
I78
sg42007
Vflushing
p44164
sg42008
I8
sg42009
VC0016382
p44165
sg42011
I1
sa(dp44166
g42006
I35
sg42007
g44160
sg42008
I12
sg42009
VC0242339
p44167
sg42011
I1
sasg42012
(lp44168
(dp44169
g42006
I174
sg42007
g44159
sg42008
I26
sg42016
VP32247
p44170
sg42011
I3
sa(dp44171
g42006
I202
sg42007
VDP1
p44172
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp44173
g42006
I207
sg42007
VPtgdr
p44174
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp44175
g41997
VApart from primary aldosteronism, mineralocorticoid excess can be caused by congenital adrenal hyperplasia (CAH) due to mutations of the 11beta-hydroxylase and 17alpha-hydroxylase genes, by inactivating mutations of the glucocorticoid receptor gene (Chrousos syndrome), endogenous hypercortisolism (Cushing's syndrome), by mutations of the 11beta-hydroxysteroid dehydrogenase type 2 gene (apparent mineralocorticoid excess/AME) or licorice/carbenoxolone intake, mutations of the epithelial sodium channel genes (Liddle syndrome), mutations of the mineralocorticoid receptor gene (Geller syndrome), and by mutations in the WNK1, WNK4, KLHL3, CUL3 genes (pseudohypoaldosteronism type 2 or Gordon syndrome).
p44176
sg4
(dp44177
(Vepithelial sodium channel genes
p44178
Vpseudohypoaldosteronism type 2
p44179
tp44180
I00
ssg42003
(lp44181
(dp44182
g42006
I11
sg42007
Vprimary aldosteronism
p44183
sg42008
I21
sg42009
VC1384514
p44184
sg42011
I2
sa(dp44185
g42006
I259
sg42007
Vsyndrome
p44186
sg42008
I8
sg42009
VC0039082
p44187
sg42011
I1
sa(dp44188
g42006
I281
sg42007
Vhypercortisolism
p44189
sg42008
I16
sg42009
VC0010481
p44190
sg42011
I1
sa(dp44191
g42006
I259
sg42007
Vsyndrome
p44192
sg42008
I8
sg42009
VC0039082
p44193
sg42011
I1
sa(dp44194
g42006
I76
sg42007
Vcongenital adrenal hyperplasia
p44195
sg42008
I30
sg42009
VC0001627
p44196
sg42011
I3
sa(dp44197
g42006
I687
sg42007
VGordon syndrome
p44198
sg42008
I15
sg42009
VC0220666
p44199
sg42011
I2
sa(dp44200
g42006
I299
sg42007
VCushing's syndrome
p44201
sg42008
I18
sg42009
VC0010481
p44202
sg42011
I2
sa(dp44203
g42006
I108
sg42007
VCAH
p44204
sg42008
I3
sg42009
VC0520463
p44205
sg42011
I1
sa(dp44206
g42006
I389
sg42007
Vapparent mineralocorticoid excess
p44207
sg42008
I33
sg42009
VC2936861
p44208
sg42011
I3
sa(dp44209
g42006
I512
sg42007
VLiddle syndrome
p44210
sg42008
I15
sg42009
VC0221043
p44211
sg42011
I2
sa(dp44212
g42006
I653
sg42007
g44179
sg42008
I30
sg42009
VC1449844
p44213
sg42011
I3
sasg42012
(lp44214
(dp44215
g42006
I340
sg42007
V11beta-hydroxysteroid dehydrogenase type 2 gene
p44216
sg42008
I47
sg42016
VP49366
p44217
sg42011
I5
sa(dp44218
g42006
I220
sg42007
Vglucocorticoid receptor gene
p44219
sg42008
I28
sg42016
VP04150
p44220
sg42011
I3
sa(dp44221
g42006
I641
sg42007
VCUL3 genes
p44222
sg42008
I10
sg42016
g190
sg42011
I2
sa(dp44223
g42006
I622
sg42007
VWNK1
p44224
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp44225
g42006
I160
sg42007
V17alpha-hydroxylase genes
p44226
sg42008
I25
sg42016
VP01893
p44227
sg42011
I2
sa(dp44228
g42006
I547
sg42007
Vmineralocorticoid receptor gene
p44229
sg42008
I31
sg42016
VP08235
p44230
sg42011
I3
sa(dp44231
g42006
I634
sg42007
VKLHL3
p44232
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp44233
g42006
I628
sg42007
VWNK4
p44234
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp44235
g42006
I479
sg42007
g44178
sg42008
I31
sg42016
VP12830
p44236
sg42011
I4
sasa(dp44237
g41997
VNeuro-immunoreactivity for fractalkine and CX3CR1 was strongest in patients suffering from severe pain and pancreatic neuritis.
p44238
sg4
(dp44239
(VCX3CR1
p44240
Vneuritis
p44241
tp44242
I00
ssg42003
(lp44243
(dp44244
g42006
I76
sg42007
Vsuffering
p44245
sg42008
I9
sg42009
VC0683278
p44246
sg42011
I1
sa(dp44247
g42006
I91
sg42007
Vsevere pain
p44248
sg42008
I11
sg42009
VC0278140
p44249
sg42011
I2
sa(dp44250
g42006
I118
sg42007
g44241
sg42008
I8
sg42009
VC0027813
p44251
sg42011
I1
sasg42012
(lp44252
(dp44253
g42006
I43
sg42007
g44240
sg42008
I6
sg42016
VP78423
p44254
sg42011
I1
sasa(dp44255
g41997
VThe index patients were homozygotes for both a dominant mutation of the PABPN1 gene, (GCN)13, and a recessive mutation of the NRL gene, p.R31X, on chromosome 14q11.1, leading to early-onset OPMD accompanied by night blindness and reduced visual acuity.
p44256
sg4
(dp44257
(VNRL gene
p44258
VOPMD
p44259
tp44260
I00
ssg42003
(lp44261
(dp44262
g42006
I210
sg42007
Vnight blindness
p44263
sg42008
I15
sg42009
VC0028077
p44264
sg42011
I2
sa(dp44265
g42006
I190
sg42007
g44259
sg42008
I4
sg42009
VC0270952
p44266
sg42011
I1
sasg42012
(lp44267
(dp44268
g42006
I126
sg42007
g44258
sg42008
I8
sg42016
VP54845
p44269
sg42011
I2
sa(dp44270
g42006
I72
sg42007
VPABPN1 gene
p44271
sg42008
I11
sg42016
g190
sg42011
I2
sasa(dp44272
g41997
VHomozygosity for the recessive NRL mutation described here appears to be associated with a distinct retinal phenotype, demonstrating ERG characteristics similar to those of ESCS patients.
p44273
sg4
(dp44274
(VNRL mutation
p44275
VESCS
p44276
tp44277
I00
ssg42003
(lp44278
(dp44279
g42006
I173
sg42007
g44276
sg42008
I4
sg42009
VC1849394
p44280
sg42011
I1
sasg42012
(lp44281
(dp44282
g42006
I31
sg42007
g44275
sg42008
I12
sg42016
VP54845
p44283
sg42011
I2
sasa(dp44284
g41997
VThis report expands the spectrum of NRL recessive mutations, as well as the genetic spectrum of ESCS, and indicates a new syndrome of OPMD with an ESCS-like phenotype.
p44285
sg4
(dp44286
(VNRL
p44287
VOPMD
p44288
tp44289
I00
ssg42003
(lp44290
(dp44291
g42006
I96
sg42007
VESCS
p44292
sg42008
I4
sg42009
VC1849394
p44293
sg42011
I1
sa(dp44294
g42006
I122
sg42007
Vsyndrome
p44295
sg42008
I8
sg42009
VC0039082
p44296
sg42011
I1
sa(dp44297
g42006
I96
sg42007
VESCS
p44298
sg42008
I4
sg42009
VC1849394
p44299
sg42011
I1
sa(dp44300
g42006
I134
sg42007
g44288
sg42008
I4
sg42009
VC0270952
p44301
sg42011
I1
sasg42012
(lp44302
(dp44303
g42006
I96
sg42007
VESCS
p44304
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp44305
g42006
I36
sg42007
g44287
sg42008
I3
sg42016
VP54845
p44306
sg42011
I1
sa(dp44307
g42006
I147
sg42007
VESCS-like
p44308
sg42008
I9
sg42016
g190
sg42011
I1
sasa(dp44309
g41997
VBlue light exposure of the R91W;Nrl(-/-) mouse could therefore be used to study molecular events preceding edema formation in a cone-rich environment, and thus potentially help to develop treatment strategies for edema-based complications in macular degenerations.
p44310
sg4
(dp44311
(VNrl(-/-)
p44312
Vedema
p44313
tp44314
I00
ssg42003
(lp44315
(dp44316
g42006
I107
sg42007
Vedema
p44317
sg42008
I5
sg42009
VC0013604
p44318
sg42011
I1
sa(dp44319
g42006
I242
sg42007
Vmacular degenerations
p44320
sg42008
I21
sg42009
VC0242383
p44321
sg42011
I2
sa(dp44322
g42006
I107
sg42007
g44313
sg42008
I5
sg42009
VC0013604
p44323
sg42011
I1
sasg42012
(lp44324
(dp44325
g42006
I32
sg42007
g44312
sg42008
I8
sg42016
VP54845
p44326
sg42011
I1
sasa(dp44327
g41997
VCXCL6 and CXCL2 enhanced angiogenesis by HUVECs when cultured with fibroblast cells and colon cancer cells (P &lt; 0.01).
p44328
sg4
(dp44329
(VCXCL2
p44330
Vcolon cancer
p44331
tp44332
I01
ssg42003
(lp44333
(dp44334
g42006
I88
sg42007
g44331
sg42008
I12
sg42009
VC0699790
p44335
sg42011
I2
sasg42012
(lp44336
(dp44337
g42006
I0
sg42007
VCXCL6
p44338
sg42008
I5
sg42016
VP80162
p44339
sg42011
I1
sa(dp44340
g42006
I10
sg42007
g44330
sg42008
I5
sg42016
VP19875
p44341
sg42011
I1
sasa(dp44342
g41997
VAfter quality and quantity measurements, gene expression analysis of a colorectal cancer-specific marker set with 11 genes (CA7, COL12A1, CXCL1, CXCL2, CHI3L1, GREM1, IL1B, IL1RN, IL8, MMP3, SLC5A7) was performed with array real-time PCR using Transcriptor First Strand cDNA Synthesis Kit (Roche) and RealTime ready assays on LightCycler480 System (Roche).
p44343
sg4
(dp44344
(VCXCL2
p44345
Vcolorectal cancer
p44346
tp44347
I00
ssg42003
(lp44348
(dp44349
g42006
I71
sg42007
g44346
sg42008
I17
sg42009
VC1527249
p44350
sg42011
I2
sasg42012
(lp44351
(dp44352
g42006
I167
sg42007
VIL1B
p44353
sg42008
I4
sg42016
VP01584
p44354
sg42011
I1
sa(dp44355
g42006
I173
sg42007
VIL1RN
p44356
sg42008
I5
sg42016
VP18510
p44357
sg42011
I1
sa(dp44358
g42006
I152
sg42007
VCHI3L1
p44359
sg42008
I6
sg42016
VP36222
p44360
sg42011
I1
sa(dp44361
g42006
I160
sg42007
VGREM1
p44362
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp44363
g42006
I124
sg42007
VCA7
p44364
sg42008
I3
sg42016
VP43166
p44365
sg42011
I1
sa(dp44366
g42006
I138
sg42007
VCXCL1
p44367
sg42008
I5
sg42016
VP09341
p44368
sg42011
I1
sa(dp44369
g42006
I185
sg42007
VMMP3
p44370
sg42008
I4
sg42016
VP08254
p44371
sg42011
I1
sa(dp44372
g42006
I145
sg42007
g44345
sg42008
I5
sg42016
VP19875
p44373
sg42011
I1
sa(dp44374
g42006
I129
sg42007
VCOL12A1
p44375
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp44376
g42006
I191
sg42007
VSLC5A7
p44377
sg42008
I6
sg42016
g190
sg42011
I1
sasa(dp44378
g41997
VThese observations indicate a crucial role for TANs in the initiation and progression of CAC and suggest that the CXCL2-CXCR2 axis might be useful in reducing the risk of UC-associated colon cancer.
p44379
sg4
(dp44380
(VCXCL2
p44381
Vcolon cancer
p44382
tp44383
I01
ssg42003
(lp44384
(dp44385
g42006
I185
sg42007
g44382
sg42008
I12
sg42009
VC0699790
p44386
sg42011
I2
sasg42012
(lp44387
(dp44388
g42006
I120
sg42007
VCXCR2
p44389
sg42008
I5
sg42016
VP25025
p44390
sg42011
I1
sa(dp44391
g42006
I114
sg42007
g44381
sg42008
I5
sg42016
VP19875
p44392
sg42011
I1
sasa(dp44393
g41997
VGene expression analysis of a colorectal cancer-specific marker set (with 7 genes: COL12A1, CXCL1, CXCL2, GREM1, IL1B, IL8, SLC7A5) was performed with array real-time PCR using Transcriptor First Strand cDNA Synthesis Kit (Roche) and RealTime ready assays on LightCycler(R) 480 System (Roche).
p44394
sg4
(dp44395
(VCXCL1
p44396
Vcolorectal cancer
p44397
tp44398
I00
ssg42003
(lp44399
(dp44400
g42006
I30
sg42007
g44397
sg42008
I17
sg42009
VC1527249
p44401
sg42011
I2
sasg42012
(lp44402
(dp44403
g42006
I99
sg42007
VCXCL2
p44404
sg42008
I5
sg42016
VP19875
p44405
sg42011
I1
sa(dp44406
g42006
I83
sg42007
VCOL12A1
p44407
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp44408
g42006
I124
sg42007
VSLC7A5
p44409
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp44410
g42006
I113
sg42007
VIL1B
p44411
sg42008
I4
sg42016
VP01584
p44412
sg42011
I1
sa(dp44413
g42006
I92
sg42007
g44396
sg42008
I5
sg42016
VP09341
p44414
sg42011
I1
sa(dp44415
g42006
I106
sg42007
VGREM1
p44416
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp44417
g41997
VWe previously showed that Decorin--a leucine-rich proteoglycan inhibiting the progression of glomerulonephritis and glomerular sclerosis--can be degraded by the ubiquitin-proteasome pathway and deubiquitinated and stabilized by ubiquitin-specific processing protease 2-69(Usp2-69).
p44418
sg4
(dp44419
(Vubiquitin
p44420
Vglomerulonephritis
p44421
tp44422
I00
ssg42003
(lp44423
(dp44424
g42006
I116
sg42007
Vglomerular sclerosis
p44425
sg42008
I20
sg42009
VC0178664
p44426
sg42011
I2
sa(dp44427
g42006
I93
sg42007
g44421
sg42008
I18
sg42009
VC0017658
p44428
sg42011
I1
sasg42012
(lp44429
(dp44430
g42006
I26
sg42007
VDecorin
p44431
sg42008
I7
sg42016
VP07585
p44432
sg42011
I1
sa(dp44433
g42006
I161
sg42007
g44420
sg42008
I9
sg42016
VP62979
p44434
sg42011
I1
sa(dp44435
g42006
I228
sg42007
Vubiquitin-specific processing protease 2-69
p44436
sg42008
I43
sg42016
g190
sg42011
I4
sa(dp44437
g42006
I272
sg42007
VUsp2-69
p44438
sg42008
I7
sg42016
g190
sg42011
I1
sasa(dp44439
g41997
VHere, we explored the effect of Usp2-69 on MC proliferation and ECM deposition by transfecting Usp2-69 plasmid into rat anti-Thy1.1 nephritis model and into cultured MCs, as well as detected Usp2-69 and Decorin in rat anti-Thy1.1 nephritis model by western blot.
p44440
sg4
(dp44441
(VDecorin
p44442
Vnephritis
p44443
tp44444
I00
ssg42003
(lp44445
(dp44446
g42006
I166
sg42007
VMCs
p44447
sg42008
I3
sg42009
VC0036221
p44448
sg42011
I1
sa(dp44449
g42006
I132
sg42007
Vnephritis
p44450
sg42008
I9
sg42009
VC0027697
p44451
sg42011
I1
sa(dp44452
g42006
I46
sg42007
Vproliferation
p44453
sg42008
I13
sg42009
VC0334094
p44454
sg42011
I1
sa(dp44455
g42006
I132
sg42007
g44443
sg42008
I9
sg42009
VC0027697
p44456
sg42011
I1
sasg42012
(lp44457
(dp44458
g42006
I32
sg42007
VUsp2-69
p44459
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp44460
g42006
I32
sg42007
VUsp2-69
p44461
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp44462
g42006
I116
sg42007
Vrat anti-Thy1
p44463
sg42008
I13
sg42016
VP04216
p44464
sg42011
I2
sa(dp44465
g42006
I203
sg42007
g44442
sg42008
I7
sg42016
VP07585
p44466
sg42011
I1
sa(dp44467
g42006
I32
sg42007
VUsp2-69
p44468
sg42008
I7
sg42016
g190
sg42011
I1
sasa(dp44469
g41997
VOverexpressing Usp2-69 at the early stage, but not advanced stage, of anti-Thy1.1 nephritis alleviated cell proliferation and ECM deposition, which was shown by decreased Ki-67, Collagen IV and Fibronectin detected by immunohistochemistry.
p44470
sg4
(dp44471
(Vanti-Thy1.1
p44472
Vnephritis
p44473
tp44474
I00
ssg42003
(lp44475
(dp44476
g42006
I82
sg42007
g44473
sg42008
I9
sg42009
VC0027697
p44477
sg42011
I1
sa(dp44478
g42006
I108
sg42007
Vproliferation
p44479
sg42008
I13
sg42009
VC0334094
p44480
sg42011
I1
sasg42012
(lp44481
(dp44482
g42006
I15
sg42007
VUsp2-69
p44483
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp44484
g42006
I171
sg42007
VKi-67
p44485
sg42008
I5
sg42016
VP46013
p44486
sg42011
I1
sa(dp44487
g42006
I70
sg42007
g44472
sg42008
I11
sg42016
VP04216
p44488
sg42011
I1
sasa(dp44489
g41997
VIn conclusion, our findings suggest that Usp2-69 overexpression alleviates the progression of rat anti-Thy1.1 nephritis and, therefore, that exogenous plasmid injection via the renal artery enhanced by electrotransfer technology could be a promising avenue for glomerular disease research.
p44490
sg4
(dp44491
(Vrat anti-Thy1.1
p44492
Vnephritis
p44493
tp44494
I00
ssg42003
(lp44495
(dp44496
g42006
I261
sg42007
Vglomerular disease
p44497
sg42008
I18
sg42009
VC0268731
p44498
sg42011
I2
sa(dp44499
g42006
I110
sg42007
g44493
sg42008
I9
sg42009
VC0027697
p44500
sg42011
I1
sasg42012
(lp44501
(dp44502
g42006
I94
sg42007
g44492
sg42008
I15
sg42016
VP04216
p44503
sg42011
I2
sa(dp44504
g42006
I41
sg42007
VUsp2-69
p44505
sg42008
I7
sg42016
g190
sg42011
I1
sasa(dp44506
g41997
VThe proportion of USP2-69 positive area in the glomeruli was 3.90% in normal kidney, 4.96% in minimal change disease, and 4.39% in membranous glomerulonephritides, while it was 14.84% in IgA nephropathy (IgAN) (mesangial proliferative type), 16.18% in lupus nephritis (LN; diffuse proliferative type) and 15.54% in acute proliferative glomerulonephritides (APGN); the difference of the percentages between IgAN, LN (IV subtype) and APGN and normal kidney were statistically significant (P &lt; 0.05).
p44507
sg4
(dp44508
(VIgAN
p44509
Vminimal change disease
p44510
tp44511
I00
ssg42003
(lp44512
(dp44513
g42006
I187
sg42007
VIgA nephropathy
p44514
sg42008
I15
sg42009
VC0017661
p44515
sg42011
I2
sa(dp44516
g42006
I269
sg42007
VLN
p44517
sg42008
I2
sg42009
VC0024143
p44518
sg42011
I1
sa(dp44519
g42006
I357
sg42007
VAPGN
p44520
sg42008
I4
sg42009
VC0017658
p44521
sg42011
I1
sa(dp44522
g42006
I221
sg42007
Vproliferative
p44523
sg42008
I13
sg42009
VC0334094
p44524
sg42011
I1
sa(dp44525
g42006
I269
sg42007
VLN
p44526
sg42008
I2
sg42009
VC0024143
p44527
sg42011
I1
sa(dp44528
g42006
I131
sg42007
Vmembranous glomerulonephritides
p44529
sg42008
I31
sg42009
VC0017665
p44530
sg42011
I2
sa(dp44531
g42006
I252
sg42007
Vlupus nephritis
p44532
sg42008
I15
sg42009
VC0024143
p44533
sg42011
I2
sa(dp44534
g42006
I204
sg42007
VIgAN
p44535
sg42008
I4
sg42009
VC0017661
p44536
sg42011
I1
sa(dp44537
g42006
I315
sg42007
Vacute proliferative glomerulonephritides
p44538
sg42008
I40
sg42009
VC0017658
p44539
sg42011
I3
sa(dp44540
g42006
I357
sg42007
VAPGN
p44541
sg42008
I4
sg42009
VC0017658
p44542
sg42011
I1
sa(dp44543
g42006
I221
sg42007
Vproliferative
p44544
sg42008
I13
sg42009
VC0334094
p44545
sg42011
I1
sa(dp44546
g42006
I204
sg42007
VIgAN
p44547
sg42008
I4
sg42009
VC0017661
p44548
sg42011
I1
sa(dp44549
g42006
I94
sg42007
g44510
sg42008
I22
sg42009
VC1704320
p44550
sg42011
I3
sasg42012
(lp44551
(dp44552
g42006
I187
sg42007
VIgA nephropathy
p44553
sg42008
I15
sg42016
VP11912
p44554
sg42011
I2
sa(dp44555
g42006
I204
sg42007
VIgAN
p44556
sg42008
I4
sg42016
VP11912
p44557
sg42011
I1
sa(dp44558
g42006
I18
sg42007
VUSP2-69
p44559
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp44560
g42006
I204
sg42007
g44509
sg42008
I4
sg42016
VP11912
p44561
sg42011
I1
sasa(dp44562
g41997
VWe analysed surviving human SN DA neurons from patients with Parkinson's disease and from controls, and detected elevated messenger RNA levels of D2-autoreceptors and GIRK2 in Parkinson's disease.
p44563
sg4
(dp44564
(VGIRK2
p44565
VParkinson's disease
p44566
tp44567
I00
ssg42003
(lp44568
(dp44569
g42006
I61
sg42007
VParkinson's disease
p44570
sg42008
I19
sg42009
VC0030567
p44571
sg42011
I2
sa(dp44572
g42006
I61
sg42007
g44566
sg42008
I19
sg42009
VC0030567
p44573
sg42011
I2
sasg42012
(lp44574
(dp44575
g42006
I167
sg42007
g44565
sg42008
I5
sg42016
VP48051
p44576
sg42011
I1
sasa(dp44577
g41997
VThus, our findings provide a novel homeostatic functional link in SN DA neurons between Cav1.3- L-type-Ca(2+) channels and D2-autoreceptor activity, controlled by NCS-1, and indicate that this adaptive signalling network (Cav1.3/NCS-1/D2/GIRK2) is also active in human SN DA neurons, and contributes to Parkinson's disease pathology.
p44578
sg4
(dp44579
(VGIRK2
p44580
VParkinson's disease
p44581
tp44582
I00
ssg42003
(lp44583
(dp44584
g42006
I323
sg42007
Vpathology
p44585
sg42008
I9
sg42009
VC0677042
p44586
sg42011
I1
sa(dp44587
g42006
I303
sg42007
g44581
sg42008
I19
sg42009
VC0030567
p44588
sg42011
I2
sasg42012
(lp44589
(dp44590
g42006
I88
sg42007
VCav1.3- L
p44591
sg42008
I9
sg42016
g190
sg42011
I2
sa(dp44592
g42006
I222
sg42007
VCav1.3/NCS-1
p44593
sg42008
I12
sg42016
VP62166
p44594
sg42011
I1
sa(dp44595
g42006
I238
sg42007
g44580
sg42008
I5
sg42016
VP48051
p44596
sg42011
I1
sasa(dp44597
g41997
VSeveral proapoptotic genes (AKT1 and AKT2) were down-regulated and antiapoptotic genes (APAF1 and BCL2L1) were up-regulated in multiple myeloma, both symptomatic and asymptomatic, compared to monoclonal gammopathy of undetermined significance.
p44598
sg4
(dp44599
(VAKT1
p44600
Vmultiple myeloma
p44601
tp44602
I00
ssg42003
(lp44603
(dp44604
g42006
I192
sg42007
Vmonoclonal gammopathy of undetermined significance
p44605
sg42008
I50
sg42009
VC0026470
p44606
sg42011
I5
sa(dp44607
g42006
I127
sg42007
g44601
sg42008
I16
sg42009
VC0026764
p44608
sg42011
I2
sasg42012
(lp44609
(dp44610
g42006
I98
sg42007
VBCL2L1
p44611
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp44612
g42006
I37
sg42007
VAKT2
p44613
sg42008
I4
sg42016
VP31751
p44614
sg42011
I1
sa(dp44615
g42006
I28
sg42007
g44600
sg42008
I4
sg42016
VP31749
p44616
sg42011
I1
sasa(dp44617
g41997
VTo study the role of gene promoter hypermethylation of the putative tumour suppressor genes involved in the death-associated protein (DAP) kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma (MM).
p44618
sg4
(dp44619
(Vp14
p44620
Vmultiple myeloma
p44621
tp44622
I00
ssg42003
(lp44623
(dp44624
g42006
I187
sg42007
g44621
sg42008
I16
sg42009
VC0026764
p44625
sg42011
I2
sa(dp44626
g42006
I68
sg42007
Vtumour
p44627
sg42008
I6
sg42009
VC0027651
p44628
sg42011
I1
sasg42012
(lp44629
(dp44630
g42006
I155
sg42007
Vp53
p44631
sg42008
I3
sg42016
VP42771
p44632
sg42011
I1
sa(dp44633
g42006
I134
sg42007
VDAP
p44634
sg42008
I3
sg42016
VP51397
p44635
sg42011
I1
sa(dp44636
g42006
I108
sg42007
Vdeath-associated protein
p44637
sg42008
I24
sg42016
VP51397
p44638
sg42011
I2
sa(dp44639
g42006
I146
sg42007
g44620
sg42008
I3
sg42016
VP03971
p44640
sg42011
I1
sasa(dp44641
g41997
VThe other was a spermatocytic seminoma with focal primitive neuroectodermal differentiation: formation of Homer-Wright rosettes and perivascular pseudorosettes, with immunoreactivity for S-100 protein, neuron-specific enolase, synaptophysin, neurofilament-68 kDa, microtubule-associated protein 2, and vimentin.
p44642
sg4
(dp44643
(Vsynaptophysin
p44644
Vspermatocytic seminoma
p44645
tp44646
I00
ssg42003
(lp44647
(dp44648
g42006
I16
sg42007
g44645
sg42008
I22
sg42009
VC0334517
p44649
sg42011
I2
sasg42012
(lp44650
(dp44651
g42006
I264
sg42007
Vmicrotubule-associated protein 2
p44652
sg42008
I32
sg42016
VP11137
p44653
sg42011
I3
sa(dp44654
g42006
I187
sg42007
VS-100 protein
p44655
sg42008
I13
sg42016
VP04271
p44656
sg42011
I2
sa(dp44657
g42006
I202
sg42007
Vneuron-specific enolase
p44658
sg42008
I23
sg42016
VP09104
p44659
sg42011
I2
sa(dp44660
g42006
I227
sg42007
g44644
sg42008
I13
sg42016
VP08247
p44661
sg42011
I1
sasa(dp44662
g41997
VIn addition to Rett syndrome and breast/ovarian cancer observed in other studies, we report evidence for the first time, to our knowledge, that overexpression of ubiquinol-cytochrome c reductase core protein I might affect mitochondrial morphology and/or physiology and lead to development of obesity and related conditions.
p44663
sg4
(dp44664
(Vubiquinol-cytochrome c reductase core protein I
p44665
Vovarian cancer
p44666
tp44667
I01
ssg42003
(lp44668
(dp44669
g42006
I293
sg42007
Vobesity
p44670
sg42008
I7
sg42009
VC0028754
p44671
sg42011
I1
sa(dp44672
g42006
I15
sg42007
VRett syndrome
p44673
sg42008
I13
sg42009
VC0035372
p44674
sg42011
I2
sa(dp44675
g42006
I40
sg42007
g44666
sg42008
I14
sg42009
VC1140680
p44676
sg42011
I2
sasg42012
(lp44677
(dp44678
g42006
I162
sg42007
g44665
sg42008
I47
sg42016
VP99999
p44679
sg42011
I6
sasa(dp44680
g41997
VFrom the therapeutic standpoint, colitis-associated cancers are associated with a lower prevalence of KRAS mutations than the sporadic variant.
p44681
sg4
(dp44682
(VKRAS
p44683
Vcolitis
p44684
tp44685
I00
ssg42003
(lp44686
(dp44687
g42006
I33
sg42007
g44684
sg42008
I7
sg42009
VC0009319
p44688
sg42011
I1
sa(dp44689
g42006
I52
sg42007
Vcancers
p44690
sg42008
I7
sg42009
VC0006826
p44691
sg42011
I1
sasg42012
(lp44692
(dp44693
g42006
I102
sg42007
g44683
sg42008
I4
sg42016
VP01116
p44694
sg42011
I1
sasa(dp44695
g41997
VIn a murine acute systemic candidiasis model, C albicans strongly stimulated hepcidin, accompanied by a major reduction in transferrin saturation.
p44696
sg4
(dp44697
(Vtransferrin
p44698
Vsystemic candidiasis
p44699
tp44700
I00
ssg42003
(lp44701
(dp44702
g42006
I18
sg42007
g44699
sg42008
I20
sg42009
VC0153252
p44703
sg42011
I2
sasg42012
(lp44704
(dp44705
g42006
I123
sg42007
g44698
sg42008
I11
sg42016
VP02787
p44706
sg42011
I1
sasa(dp44707
g41997
VOn the other hand, iron overload (iron saturated transferrin) is a serious risk factor for candidiasis in newborn and in leukemic patients.
p44708
sg4
(dp44709
(Vtransferrin
p44710
Vcandidiasis
p44711
tp44712
I00
ssg42003
(lp44713
(dp44714
g42006
I19
sg42007
Viron overload
p44715
sg42008
I13
sg42009
VC0282193
p44716
sg42011
I2
sa(dp44717
g42006
I91
sg42007
g44711
sg42008
I11
sg42009
VC0006840
p44718
sg42011
I1
sasg42012
(lp44719
(dp44720
g42006
I49
sg42007
g44710
sg42008
I11
sg42016
VP02787
p44721
sg42011
I1
sasa(dp44722
g41997
VIt has been suggested that blockade of the Na+/H+ exchanger (NHE1) can prevent atrial fibrillation (AF)-induced electrical remodeling and the development of AF.
p44723
sg4
(dp44724
(VNHE1
p44725
VAF
p44726
tp44727
I00
ssg42003
(lp44728
(dp44729
g42006
I79
sg42007
Vatrial fibrillation
p44730
sg42008
I19
sg42009
VC0004238
p44731
sg42011
I2
sa(dp44732
g42006
I100
sg42007
VAF
p44733
sg42008
I2
sg42009
VC0232197
p44734
sg42011
I1
sa(dp44735
g42006
I100
sg42007
g44726
sg42008
I2
sg42009
VC0232197
p44736
sg42011
I1
sasg42012
(lp44737
(dp44738
g42006
I61
sg42007
g44725
sg42008
I4
sg42016
VP19634
p44739
sg42011
I1
sasa(dp44740
g41997
VThe phenotype is usually T-B+NK+ SCID with lymphopenia where the clinical findings may be mild (CD3Gamma) or severe (CD3Delta, Epsilon, Zeta) owing to the underlying molecular defect.
p44741
sg4
(dp44742
(VT-B+NK+ SCID
p44743
VSCID
p44744
tp44745
I00
ssg42003
(lp44746
(dp44747
g42006
I43
sg42007
Vlymphopenia
p44748
sg42008
I11
sg42009
VC0024312
p44749
sg42011
I1
sa(dp44750
g42006
I65
sg42007
Vclinical findings
p44751
sg42008
I17
sg42009
VC0037088
p44752
sg42011
I2
sa(dp44753
g42006
I33
sg42007
g44744
sg42008
I4
sg42009
VC0085110
p44754
sg42011
I1
sasg42012
(lp44755
(dp44756
g42006
I25
sg42007
g44743
sg42008
I12
sg42016
VP31785
p44757
sg42011
I2
sasa(dp44758
g41997
VHigher DARs were associated with lower rates of moderate or severe paravalvular aortic regurgitation: DAR &lt;=10%, 17.6%; DAR 10% to 15%, 9.9%; DAR 15% to 20%, 6.3%; and DAR &gt;20%, 4.9%; P&lt;0.001.
p44759
sg4
(dp44760
(VDARs
p44761
VDAR
p44762
tp44763
I00
ssg42003
(lp44764
(dp44765
g42006
I7
sg42007
VDAR
p44766
sg42008
I3
sg42009
VC0022595
p44767
sg42011
I1
sa(dp44768
g42006
I7
sg42007
VDAR
p44769
sg42008
I3
sg42009
VC0022595
p44770
sg42011
I1
sa(dp44771
g42006
I80
sg42007
Vaortic regurgitation
p44772
sg42008
I20
sg42009
VC0003504
p44773
sg42011
I2
sa(dp44774
g42006
I7
sg42007
VDAR
p44775
sg42008
I3
sg42009
VC0022595
p44776
sg42011
I1
sa(dp44777
g42006
I7
sg42007
g44762
sg42008
I3
sg42009
VC0022595
p44778
sg42011
I1
sasg42012
(lp44779
(dp44780
g42006
I7
sg42007
g44761
sg42008
I4
sg42016
VP14868
p44781
sg42011
I1
sasa(dp44782
g41997
VIn this study, we showed that a high percentage of lung cancer lines expressed Jagged1, Notch receptors, and their transcriptional target genes (HES1, Hey1), suggesting that the Notch pathway plays an important role in lung cancer biology.
p44783
sg4
(dp44784
(VJagged1
p44785
Vlung cancer
p44786
tp44787
I00
ssg42003
(lp44788
(dp44789
g42006
I51
sg42007
Vlung cancer
p44790
sg42008
I11
sg42009
VC0684249
p44791
sg42011
I2
sa(dp44792
g42006
I51
sg42007
g44786
sg42008
I11
sg42009
VC0684249
p44793
sg42011
I2
sasg42012
(lp44794
(dp44795
g42006
I145
sg42007
VHES1
p44796
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp44797
g42006
I79
sg42007
g44785
sg42008
I7
sg42016
VP78504
p44798
sg42011
I1
sa(dp44799
g42006
I151
sg42007
VHey1
p44800
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp44801
g42006
I88
sg42007
VNotch receptors
p44802
sg42008
I15
sg42016
g190
sg42011
I2
sasa(dp44803
g41997
VALPs easily insert in the outer leaflet of the plasma membrane and cross the membrane via an ATP-dependent CDC50a-containing 'flippase' complex (in carcinoma cells), or are internalized by lipid raft-dependent endocytosis (in lymphoma/leukemic cells).
p44804
sg4
(dp44805
(VALPs
p44806
VALPs
p44807
tp44808
I00
ssg42003
(lp44809
(dp44810
g42006
I148
sg42007
Vcarcinoma
p44811
sg42008
I9
sg42009
VC0007097
p44812
sg42011
I1
sa(dp44813
g42006
I226
sg42007
Vlymphoma
p44814
sg42008
I8
sg42009
VC0024299
p44815
sg42011
I1
sa(dp44816
g42006
I0
sg42007
g44807
sg42008
I4
sg42009
VC1328840
p44817
sg42011
I1
sasg42012
(lp44818
(dp44819
g42006
I107
sg42007
VCDC50a
p44820
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp44821
g42006
I125
sg42007
V'flippase
p44822
sg42008
I9
sg42016
VP98196
p44823
sg42011
I1
sa(dp44824
g42006
I0
sg42007
g44806
sg42008
I4
sg42016
VP03973
p44825
sg42011
I1
sasa(dp44826
g41997
VLevels of 27 transcripts were investigated as potential novel markers for prostate cancer, including genes encoding plasma membrane proteins (ADAM2, ELOVL5, MARCKSL1, RAMP1, TMEM30A, and TMEM66); secreted proteins (SPON2, TMEM30A, TMEM66, and truncated TMEFF2 (called POP4)); intracellular proteins (CAMK2N1, DHCR24, GLO1, NGFRAP1, PGK1, PSMA7, SBDS, and YWHAQ); and noncoding transcripts (POP1 (100 kb) from mRNA AK000023), POP2 (4 kb from mRNA AL832227), POP3 (50 kb from EST CFI40309), POP5 (intron of NCAM2, accession DO668384), POP6 (intron of FHIT), POP7 (intron of TNFAIP8), POP8 (intron of EFNA5), POP9 (intron of DSTN), POP10 (intron of ADAM2, accession DO668396), POP11 (87kb from EST BG194644), and POP12 (intron of EST BQ226050)).
p44827
sg4
(dp44828
(Vplasma membrane proteins
p44829
Vprostate cancer
p44830
tp44831
I00
ssg42003
(lp44832
(dp44833
g42006
I74
sg42007
g44830
sg42008
I15
sg42009
VC0600139
p44834
sg42011
I2
sasg42012
(lp44835
(dp44836
g42006
I489
sg42007
VPOP5
p44837
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp44838
g42006
I149
sg42007
VELOVL5
p44839
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp44840
g42006
I332
sg42007
VPGK1
p44841
sg42008
I4
sg42016
VP00558
p44842
sg42011
I1
sa(dp44843
g42006
I174
sg42007
VTMEM30A
p44844
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp44845
g42006
I582
sg42007
VPOP8 (intron of EFNA5)
p44846
sg42008
I22
sg42016
VP52803
p44847
sg42011
I4
sa(dp44848
g42006
I157
sg42007
VMARCKSL1
p44849
sg42008
I8
sg42016
VP49006
p44850
sg42011
I1
sa(dp44851
g42006
I142
sg42007
VADAM2
p44852
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp44853
g42006
I309
sg42007
VDHCR24
p44854
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp44855
g42006
I300
sg42007
VCAMK2N1
p44856
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp44857
g42006
I317
sg42007
VGLO1
p44858
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp44859
g42006
I142
sg42007
VADAM2
p44860
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp44861
g42006
I187
sg42007
VTMEM66
p44862
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp44863
g42006
I323
sg42007
VNGFRAP1
p44864
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp44865
g42006
I556
sg42007
VPOP7 (intron of TNFAIP8)
p44866
sg42008
I24
sg42016
g190
sg42011
I4
sa(dp44867
g42006
I533
sg42007
VPOP6 (intron of FHIT)
p44868
sg42008
I21
sg42016
VP49789
p44869
sg42011
I4
sa(dp44870
g42006
I505
sg42007
VNCAM2
p44871
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp44872
g42006
I167
sg42007
VRAMP1
p44873
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp44874
g42006
I268
sg42007
VPOP4
p44875
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp44876
g42006
I457
sg42007
VPOP3 (50 kb from EST CFI40309
p44877
sg42008
I29
sg42016
VP49888
p44878
sg42011
I6
sa(dp44879
g42006
I174
sg42007
VTMEM30A
p44880
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp44881
g42006
I187
sg42007
VTMEM66
p44882
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp44883
g42006
I116
sg42007
g44829
sg42008
I24
sg42016
VP35968
p44884
sg42011
I3
sa(dp44885
g42006
I338
sg42007
VPSMA7
p44886
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp44887
g42006
I215
sg42007
VSPON2
p44888
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp44889
g42006
I390
sg42007
VPOP1 (100 kb) from mRNA AK000023
p44890
sg42008
I32
sg42016
g190
sg42011
I6
sasa(dp44891
g41997
VFinally, ephrin-B2/Fc promoted angiogenesis in vivo in corneal neovascularization and Matrigel plug assays in adult mice, whereas LY294002 reduced angiogenesis in Matrigel that was induced by ephrin-B2/Fc.
p44892
sg4
(dp44893
(Vephrin-B2
p44894
Vcorneal neovascularization
p44895
tp44896
I00
ssg42003
(lp44897
(dp44898
g42006
I55
sg42007
g44895
sg42008
I26
sg42009
VC0085109
p44899
sg42011
I2
sasg42012
(lp44900
(dp44901
g42006
I9
sg42007
g44894
sg42008
I9
sg42016
VP52799
p44902
sg42011
I1
sasa(dp44903
g41997
VFurthermore, the LTP-regulated phosphoproteins, which included the scaffold proteins Shank3, Syngap1, Dlgap1, and Dlg4, represented the "PSD risk" for schizophrenia and autism spectrum disorder, such that without these proteins in the analysis, the association with the PSD and these two psychiatric diseases was not present.
p44904
sg4
(dp44905
(VDlg4
p44906
Vautism spectrum disorder
p44907
tp44908
I00
ssg42003
(lp44909
(dp44910
g42006
I151
sg42007
Vschizophrenia
p44911
sg42008
I13
sg42009
VC0036341
p44912
sg42011
I1
sa(dp44913
g42006
I169
sg42007
g44907
sg42008
I24
sg42009
VC1510586
p44914
sg42011
I3
sasg42012
(lp44915
(dp44916
g42006
I102
sg42007
VDlgap1
p44917
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp44918
g42006
I114
sg42007
g44906
sg42008
I4
sg42016
VP78352
p44919
sg42011
I1
sa(dp44920
g42006
I137
sg42007
VPSD
p44921
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp44922
g42006
I85
sg42007
VShank3
p44923
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp44924
g42006
I93
sg42007
VSyngap1
p44925
sg42008
I7
sg42016
g190
sg42011
I1
sasa(dp44926
g41997
VThe only two genes upregulated across all transcriptome-wide PE analyses to date (microarray, RNA-Seq and PAS-Seq) are NRIP1 (RIP140), a transcriptional co-regulator linked to metabolic syndromes associated with obesity, and Flt1.
p44927
sg4
(dp44928
(VFlt1
p44929
Vmetabolic syndromes
p44930
tp44931
I00
ssg42003
(lp44932
(dp44933
g42006
I212
sg42007
Vobesity
p44934
sg42008
I7
sg42009
VC0028754
p44935
sg42011
I1
sa(dp44936
g42006
I176
sg42007
g44930
sg42008
I19
sg42009
VC0524620
p44937
sg42011
I2
sasg42012
(lp44938
(dp44939
g42006
I126
sg42007
VRIP140
p44940
sg42008
I6
sg42016
VP48552
p44941
sg42011
I1
sa(dp44942
g42006
I106
sg42007
VPAS-Seq
p44943
sg42008
I7
sg42016
VP05165
p44944
sg42011
I1
sa(dp44945
g42006
I119
sg42007
VNRIP1
p44946
sg42008
I5
sg42016
VP48552
p44947
sg42011
I1
sa(dp44948
g42006
I225
sg42007
g44929
sg42008
I4
sg42016
VP17948
p44949
sg42011
I1
sasa(dp44950
g41997
VFurthermore, endothelial Flt1 gene deletion enhanced the effect of VEGFB, activating the thermogenic program in subcutaneous adipose tissue, which increased the basal metabolic rate, thus preventing diet-induced obesity and related metabolic complications.
p44951
sg4
(dp44952
(VVEGFB
p44953
Vobesity
p44954
tp44955
I00
ssg42003
(lp44956
(dp44957
g42006
I212
sg42007
g44954
sg42008
I7
sg42009
VC0028754
p44958
sg42011
I1
sa(dp44959
g42006
I30
sg42007
Vgene deletion
p44960
sg42008
I13
sg42009
VC1442161
p44961
sg42011
I2
sasg42012
(lp44962
(dp44963
g42006
I25
sg42007
VFlt1
p44964
sg42008
I4
sg42016
VP17948
p44965
sg42011
I1
sa(dp44966
g42006
I67
sg42007
g44953
sg42008
I5
sg42016
VP49765
p44967
sg42011
I1
sasa(dp44968
g41997
V(2016) demonstrate that VEGF-B, by displacing VEGF-A from VEGFR1 and activating VEGFR2, increases adipose tissue vascularity, improves insulin sensitivity, diminishes obesity, and alleviates metabolic syndrome.
p44969
sg4
(dp44970
(Vactivating VEGFR2
p44971
Vobesity
p44972
tp44973
I00
ssg42003
(lp44974
(dp44975
g42006
I135
sg42007
Vinsulin sensitivity
p44976
sg42008
I19
sg42009
VC0920563
p44977
sg42011
I2
sa(dp44978
g42006
I191
sg42007
Vmetabolic syndrome
p44979
sg42008
I18
sg42009
VC0524620
p44980
sg42011
I2
sa(dp44981
g42006
I167
sg42007
g44972
sg42008
I7
sg42009
VC0028754
p44982
sg42011
I1
sasg42012
(lp44983
(dp44984
g42006
I135
sg42007
Vinsulin
p44985
sg42008
I7
sg42016
VP01308
p44986
sg42011
I1
sa(dp44987
g42006
I58
sg42007
VVEGFR1
p44988
sg42008
I6
sg42016
VP17948
p44989
sg42011
I1
sa(dp44990
g42006
I24
sg42007
VVEGF-B
p44991
sg42008
I6
sg42016
VP49765
p44992
sg42011
I1
sa(dp44993
g42006
I69
sg42007
g44971
sg42008
I17
sg42016
VP35968
p44994
sg42011
I2
sasa(dp44995
g41997
VHere, we hypothesized that increased activity of PlGF/VEGFR-1 signaling mediates obesity-induced tumor progression by augmenting tumor angiogenesis and TAM recruitment/activity.
p44996
sg4
(dp44997
(VVEGFR-1
p44998
VTAM
p44999
tp45000
I00
ssg42003
(lp45001
(dp45002
g42006
I81
sg42007
Vobesity
p45003
sg42008
I7
sg42009
VC0028754
p45004
sg42011
I1
sa(dp45005
g42006
I156
sg42007
Vrecruitment
p45006
sg42008
I11
sg42009
VC0271510
p45007
sg42011
I1
sa(dp45008
g42006
I97
sg42007
Vtumor progression
p45009
sg42008
I17
sg42009
VC0178874
p45010
sg42011
I2
sa(dp45011
g42006
I129
sg42007
Vtumor angiogenesis
p45012
sg42008
I18
sg42009
VC1519670
p45013
sg42011
I2
sa(dp45014
g42006
I152
sg42007
g44999
sg42008
I3
sg42009
VC1834582
p45015
sg42011
I1
sasg42012
(lp45016
(dp45017
g42006
I49
sg42007
VPlGF
p45018
sg42008
I4
sg42016
VP49763
p45019
sg42011
I1
sa(dp45020
g42006
I54
sg42007
g44998
sg42008
I7
sg42016
VP17948
p45021
sg42011
I1
sasa(dp45022
g41997
VAblation of VEGFR-1 signaling prevented obesity-induced tumor progression and shifted the tumor immune environment toward an antitumor phenotype.
p45023
sg4
(dp45024
(VVEGFR-1
p45025
Vobesity
p45026
tp45027
I01
ssg42003
(lp45028
(dp45029
g42006
I56
sg42007
Vtumor
p45030
sg42008
I5
sg42009
VC0027651
p45031
sg42011
I1
sa(dp45032
g42006
I56
sg42007
Vtumor progression
p45033
sg42008
I17
sg42009
VC0178874
p45034
sg42011
I2
sa(dp45035
g42006
I40
sg42007
g45026
sg42008
I7
sg42009
VC0028754
p45036
sg42011
I1
sasg42012
(lp45037
(dp45038
g42006
I12
sg42007
g45025
sg42008
I7
sg42016
VP17948
p45039
sg42011
I1
sasa(dp45040
g41997
VTargeting PlGF/VEGFR-1 signaling reprograms the tumor immune microenvironment and inhibits obesity-induced acceleration of tumor progression.
p45041
sg4
(dp45042
(VPlGF
p45043
Vobesity
p45044
tp45045
I00
ssg42003
(lp45046
(dp45047
g42006
I123
sg42007
Vtumor progression
p45048
sg42008
I17
sg42009
VC0178874
p45049
sg42011
I2
sa(dp45050
g42006
I91
sg42007
g45044
sg42008
I7
sg42009
VC0028754
p45051
sg42011
I1
sa(dp45052
g42006
I48
sg42007
Vtumor
p45053
sg42008
I5
sg42009
VC0027651
p45054
sg42011
I1
sasg42012
(lp45055
(dp45056
g42006
I15
sg42007
VVEGFR-1
p45057
sg42008
I7
sg42016
VP17948
p45058
sg42011
I1
sa(dp45059
g42006
I10
sg42007
g45043
sg42008
I4
sg42016
VP49763
p45060
sg42011
I1
sasa(dp45061
g41997
VIt is hoped that the same will happen in other MPN with specific genetic alterations: polycythemia vera (JAK2 V617F and other JAK2 mutations), essential thrombocythemia (JAK2V617F and MPL515 mutations), primary myelofibrosis (JAK2 V617F and MPL515 mutations), systemic mastocytosis (KITD816V and other KIT mutations) and stem cell leukaemia/lymphoma (ZNF198-FGFR1 and other FGFR1 fusion genes).
p45062
sg4
(dp45063
(VFGFR1
p45064
Vlymphoma
p45065
tp45066
I00
ssg42003
(lp45067
(dp45068
g42006
I321
sg42007
Vstem cell leukaemia
p45069
sg42008
I19
sg42009
VC1378511
p45070
sg42011
I3
sa(dp45071
g42006
I203
sg42007
Vprimary myelofibrosis
p45072
sg42008
I21
sg42009
VC0001815
p45073
sg42011
I2
sa(dp45074
g42006
I143
sg42007
Vessential thrombocythemia
p45075
sg42008
I25
sg42009
VC0040028
p45076
sg42011
I2
sa(dp45077
g42006
I260
sg42007
Vsystemic mastocytosis
p45078
sg42008
I21
sg42009
VC0221013
p45079
sg42011
I2
sa(dp45080
g42006
I86
sg42007
Vpolycythemia vera
p45081
sg42008
I17
sg42009
VC0032463
p45082
sg42011
I2
sa(dp45083
g42006
I341
sg42007
g45065
sg42008
I8
sg42009
VC0024299
p45084
sg42011
I1
sasg42012
(lp45085
(dp45086
g42006
I126
sg42007
VJAK2 mutations
p45087
sg42008
I14
sg42016
g190
sg42011
I2
sa(dp45088
g42006
I302
sg42007
VKIT mutations
p45089
sg42008
I13
sg42016
VP10721
p45090
sg42011
I2
sa(dp45091
g42006
I374
sg42007
VFGFR1 fusion genes
p45092
sg42008
I18
sg42016
VP35637
p45093
sg42011
I3
sa(dp45094
g42006
I105
sg42007
VJAK2 V617F
p45095
sg42008
I10
sg42016
g190
sg42011
I2
sa(dp45096
g42006
I105
sg42007
VJAK2 V617F
p45097
sg42008
I10
sg42016
g190
sg42011
I2
sa(dp45098
g42006
I358
sg42007
g45064
sg42008
I5
sg42016
VP20930
p45099
sg42011
I1
sasa(dp45100
g41997
VWe activated purified CVID B-cells with surrogate T-dependent (anti-CD40), T-independent (TLR-9 ligand) stimuli or through B-cell receptor engagement (anti-IgM) with or without IL-21.
p45101
sg4
(dp45102
(Vanti-IgM
p45103
VCVID
p45104
tp45105
I00
ssg42003
(lp45106
(dp45107
g42006
I22
sg42007
g45104
sg42008
I4
sg42009
VC0009447
p45108
sg42011
I1
sasg42012
(lp45109
(dp45110
g42006
I123
sg42007
VB-cell receptor engagement
p45111
sg42008
I26
sg42016
g190
sg42011
I3
sa(dp45112
g42006
I151
sg42007
g45103
sg42008
I8
sg42016
VP29965
p45113
sg42011
I1
sasa(dp45114
g41997
VMoreover, studies at the single cell level showed that DCs from CVID patients and healthy controls produced similar amounts of interferon-Alfa or interleukin-12 and expressed similar levels of activation markers in response to human cytomegalovirus and ligands for TLR-7 and TLR-9.
p45115
sg4
(dp45116
(Vinterleukin-12
p45117
VDCs
p45118
tp45119
I00
ssg42003
(lp45120
(dp45121
g42006
I64
sg42007
VCVID
p45122
sg42008
I4
sg42009
VC0009447
p45123
sg42011
I1
sa(dp45124
g42006
I55
sg42007
g45118
sg42008
I3
sg42009
VC0268238
p45125
sg42011
I1
sasg42012
(lp45126
(dp45127
g42006
I127
sg42007
Vinterferon-Alfa
p45128
sg42008
I15
sg42016
VP01563
p45129
sg42011
I1
sa(dp45130
g42006
I146
sg42007
g45117
sg42008
I14
sg42016
VP60568
p45131
sg42011
I1
sa(dp45132
g42006
I265
sg42007
VTLR-7
p45133
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp45134
g42006
I275
sg42007
VTLR-9
p45135
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp45136
g41997
VThe CD21(low) V(H)1-69(+) B cells of MC patients, like those of CVID and HIV patients, are anergic to BCR and TLR9 stimulation and display deregulation of several anergy-related genes; proliferative anergy is also observed in CD21(high) MZ-like V(H)1-69(+) B cells, that over-express the antiproliferative transcriptional repressor Stra13.
p45137
sg4
(dp45138
(VBCR
p45139
VHIV
p45140
tp45141
I00
ssg42003
(lp45142
(dp45143
g42006
I185
sg42007
Vproliferative
p45144
sg42008
I13
sg42009
VC0334094
p45145
sg42011
I1
sa(dp45146
g42006
I64
sg42007
VCVID
p45147
sg42008
I4
sg42009
VC0009447
p45148
sg42011
I1
sa(dp45149
g42006
I73
sg42007
g45140
sg42008
I3
sg42009
VC0019693
p45150
sg42011
I1
sasg42012
(lp45151
(dp45152
g42006
I4
sg42007
VCD21(low) V(H)1-69
p45153
sg42008
I18
sg42016
VP20023
p45154
sg42011
I2
sa(dp45155
g42006
I226
sg42007
VCD21(high) MZ-like V(H)1-69
p45156
sg42008
I27
sg42016
VP20023
p45157
sg42011
I3
sa(dp45158
g42006
I332
sg42007
VStra13
p45159
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp45160
g42006
I102
sg42007
g45139
sg42008
I3
sg42016
VP11274
p45161
sg42011
I1
sa(dp45162
g42006
I110
sg42007
VTLR9
p45163
sg42008
I4
sg42016
g190
sg42011
I1
sasa(dp45164
g41997
VThe secretion of glucagon by islet Alfa cells is normally suppressed by high blood glucose, but this suppressibility is impaired in patients with diabetes or cystic fibrosis (CF), a disease caused by mutations in the gene encoding CF transmembrane conductance regulator (CFTR), a cyclic adenosine monophosphate-activated Cl- channel.
p45165
sg4
(dp45166
(VCFTR
p45167
VCF
p45168
tp45169
I01
ssg42003
(lp45170
(dp45171
g42006
I175
sg42007
VCF
p45172
sg42008
I2
sg42009
VC0016059
p45173
sg42011
I1
sa(dp45174
g42006
I158
sg42007
Vcystic fibrosis
p45175
sg42008
I15
sg42009
VC0010674
p45176
sg42011
I2
sa(dp45177
g42006
I146
sg42007
Vdiabetes
p45178
sg42008
I8
sg42009
VC0011849
p45179
sg42011
I1
sa(dp45180
g42006
I120
sg42007
Vimpaired
p45181
sg42008
I8
sg42009
VC0684336
p45182
sg42011
I1
sa(dp45183
g42006
I175
sg42007
g45168
sg42008
I2
sg42009
VC0016059
p45184
sg42011
I1
sasg42012
(lp45185
(dp45186
g42006
I17
sg42007
Vglucagon
p45187
sg42008
I8
sg42016
VP01275
p45188
sg42011
I1
sa(dp45189
g42006
I231
sg42007
VCF transmembrane conductance regulator
p45190
sg42008
I38
sg42016
g190
sg42011
I4
sa(dp45191
g42006
I271
sg42007
g45167
sg42008
I4
sg42016
VP13569
p45192
sg42011
I1
sasa(dp45193
g41997
VThe results reveal that by potentiating KATP channels, CFTR acts as a glucose-sensing negative regulator of glucagon secretion in Alfa cells, a defect of which may contribute to glucose intolerance in CF and other types of diabetes.
p45194
sg4
(dp45195
(Vglucagon
p45196
Vdiabetes
p45197
tp45198
I00
ssg42003
(lp45199
(dp45200
g42006
I178
sg42007
Vglucose intolerance
p45201
sg42008
I19
sg42009
VC0271650
p45202
sg42011
I2
sa(dp45203
g42006
I223
sg42007
g45197
sg42008
I8
sg42009
VC0011849
p45204
sg42011
I1
sasg42012
(lp45205
(dp45206
g42006
I55
sg42007
VCFTR
p45207
sg42008
I4
sg42016
VP13569
p45208
sg42011
I1
sa(dp45209
g42006
I108
sg42007
g45196
sg42008
I8
sg42016
VP01275
p45210
sg42011
I1
sasa(dp45211
g41997
VAlthough Beta-cell dysfunction in cystic fibrosis (CF) leads to diabetes, the mechanism by which the cystic fibrosis transmembrane conductance regulator (CFTR) channel influences islet insulin secretion remains debated.
p45212
sg4
(dp45213
(VCFTR
p45214
VCF
p45215
tp45216
I00
ssg42003
(lp45217
(dp45218
g42006
I64
sg42007
Vdiabetes
p45219
sg42008
I8
sg42009
VC0011849
p45220
sg42011
I1
sa(dp45221
g42006
I34
sg42007
Vcystic fibrosis
p45222
sg42008
I15
sg42009
VC0010674
p45223
sg42011
I2
sa(dp45224
g42006
I34
sg42007
Vcystic fibrosis
p45225
sg42008
I15
sg42009
VC0010674
p45226
sg42011
I2
sa(dp45227
g42006
I51
sg42007
g45215
sg42008
I2
sg42009
VC0010674
p45228
sg42011
I1
sasg42012
(lp45229
(dp45230
g42006
I101
sg42007
Vcystic fibrosis transmembrane conductance regulator
p45231
sg42008
I51
sg42016
VP13569
p45232
sg42011
I5
sa(dp45233
g42006
I9
sg42007
VBeta-cell dysfunction in cystic fibrosis (CF)
p45234
sg42008
I45
sg42016
VP13569
p45235
sg42011
I6
sa(dp45236
g42006
I185
sg42007
Vinsulin
p45237
sg42008
I7
sg42016
VP01308
p45238
sg42011
I1
sa(dp45239
g42006
I154
sg42007
g45214
sg42008
I4
sg42016
VP13569
p45240
sg42011
I1
sasa(dp45241
g41997
VBaseline estimated cost in 2008 for a hypothetical underweight, homozygous F508del-CFTR 6-year-old female without chronic Pseudomonas aeruginosa/Staphylococcus aureus, CF-related diabetes (CFRD) or methicillin-resistant S. aureus (MRSA), and with a poor percent predicted forced expiratory volume in 1 s (ppFEV1) was Euro10,113, and was Euro21,082 in a 25-year-old with the same hypothetical profile.
p45242
sg4
(dp45243
(VF508del-CFTR 6
p45244
VMRSA
p45245
tp45246
I00
ssg42003
(lp45247
(dp45248
g42006
I179
sg42007
Vdiabetes
p45249
sg42008
I8
sg42009
VC0011849
p45250
sg42011
I1
sa(dp45251
g42006
I231
sg42007
g45245
sg42008
I4
sg42009
VC0343401
p45252
sg42011
I1
sasg42012
(lp45253
(dp45254
g42006
I75
sg42007
g45244
sg42008
I14
sg42016
VP13569
p45255
sg42011
I2
sasa(dp45256
g41997
VThe goal of this work was to evaluate renal function and the expression of megalin, cubilin, CFTR (cystic fibrosis transmembrane conductance regulator), and ClC-5 in the proximal tubule and renal cortex of rats with type 1 diabetes.
p45257
sg4
(dp45258
(Vmegalin
p45259
Vcystic fibrosis
p45260
tp45261
I00
ssg42003
(lp45262
(dp45263
g42006
I216
sg42007
Vtype 1 diabetes
p45264
sg42008
I15
sg42009
VC0011854
p45265
sg42011
I3
sa(dp45266
g42006
I99
sg42007
g45260
sg42008
I15
sg42009
VC0010674
p45267
sg42011
I2
sasg42012
(lp45268
(dp45269
g42006
I157
sg42007
VClC-5
p45270
sg42008
I5
sg42016
VP51795
p45271
sg42011
I1
sa(dp45272
g42006
I84
sg42007
Vcubilin
p45273
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp45274
g42006
I75
sg42007
g45259
sg42008
I7
sg42016
VP54317
p45275
sg42011
I1
sasa(dp45276
g41997
VThese observations indicate that HYA and PIIINP mainly reflect expansive synovitis proliferation while galectin-3 is more closely linked to autoimmunity, smoking and joint destructive processes.
p45277
sg4
(dp45278
(Vgalectin-3
p45279
Vautoimmunity
p45280
tp45281
I00
ssg42003
(lp45282
(dp45283
g42006
I73
sg42007
Vsynovitis
p45284
sg42008
I9
sg42009
VC0039103
p45285
sg42011
I1
sa(dp45286
g42006
I83
sg42007
Vproliferation
p45287
sg42008
I13
sg42009
VC0334094
p45288
sg42011
I1
sa(dp45289
g42006
I140
sg42007
g45280
sg42008
I12
sg42009
VC0004368
p45290
sg42011
I1
sasg42012
(lp45291
(dp45292
g42006
I103
sg42007
g45279
sg42008
I10
sg42016
VP17931
p45293
sg42011
I1
sasa(dp45294
g41997
VIn the entire UA cohort, galectin-3 correlated with the MRI bone marrow edema score, while PIIANP correlated with the MRI erosion score, and HYA with the synovitis and erosion scores.
p45295
sg4
(dp45296
(Vgalectin-3
p45297
Vbone marrow edema
p45298
tp45299
I00
ssg42003
(lp45300
(dp45301
g42006
I122
sg42007
Verosion
p45302
sg42008
I7
sg42009
VC1959609
p45303
sg42011
I1
sa(dp45304
g42006
I154
sg42007
Vsynovitis
p45305
sg42008
I9
sg42009
VC0039103
p45306
sg42011
I1
sa(dp45307
g42006
I60
sg42007
g45298
sg42008
I17
sg42009
VC0948162
p45308
sg42011
I3
sa(dp45309
g42006
I122
sg42007
Verosion
p45310
sg42008
I7
sg42009
VC1959609
p45311
sg42011
I1
sasg42012
(lp45312
(dp45313
g42006
I25
sg42007
g45297
sg42008
I10
sg42016
VP17931
p45314
sg42011
I1
sasa(dp45315
g41997
VPrevious studies have reported overexpression of Galectin-3 in RA synovitis and increased levels in synovial fluid and serum in long-standing RA compared with osteoarthritis and healthy controls.
p45316
sg4
(dp45317
(VGalectin-3
p45318
Vsynovitis
p45319
tp45320
I00
ssg42003
(lp45321
(dp45322
g42006
I159
sg42007
Vosteoarthritis
p45323
sg42008
I14
sg42009
VC0029408
p45324
sg42011
I1
sa(dp45325
g42006
I66
sg42007
g45319
sg42008
I9
sg42009
VC0039103
p45326
sg42011
I1
sasg42012
(lp45327
(dp45328
g42006
I49
sg42007
g45318
sg42008
I10
sg42016
VP17931
p45329
sg42011
I1
sasa(dp45330
g41997
VWe defined by immunohistology the infiltrating cells and examined the in situ expression of plausible protagonists in synovitis of FMF: myeloperoxidase, lysozyme, galectin 1, galectin 3, p65 (RelA)/nuclear factor KB, inducible nitric-oxide synthase, cyclooxygenase 2, and cleaved caspase 3.
p45331
sg4
(dp45332
(Vmyeloperoxidase
p45333
Vsynovitis
p45334
tp45335
I00
ssg42003
(lp45336
(dp45337
g42006
I131
sg42007
VFMF
p45338
sg42008
I3
sg42009
VC0031069
p45339
sg42011
I1
sa(dp45340
g42006
I34
sg42007
Vinfiltrating
p45341
sg42008
I12
sg42009
VC0332448
p45342
sg42011
I1
sa(dp45343
g42006
I118
sg42007
g45334
sg42008
I9
sg42009
VC0039103
p45344
sg42011
I1
sasg42012
(lp45345
(dp45346
g42006
I192
sg42007
VRelA
p45347
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp45348
g42006
I187
sg42007
Vp65
p45349
sg42008
I3
sg42016
VP21579
p45350
sg42011
I1
sa(dp45351
g42006
I131
sg42007
VFMF
p45352
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp45353
g42006
I153
sg42007
Vlysozyme
p45354
sg42008
I8
sg42016
VP61626
p45355
sg42011
I1
sa(dp45356
g42006
I280
sg42007
Vcaspase 3
p45357
sg42008
I9
sg42016
VP42574
p45358
sg42011
I2
sa(dp45359
g42006
I163
sg42007
Vgalectin 1
p45360
sg42008
I10
sg42016
VP09382
p45361
sg42011
I2
sa(dp45362
g42006
I198
sg42007
Vnuclear factor KB
p45363
sg42008
I17
sg42016
VP01160
p45364
sg42011
I3
sa(dp45365
g42006
I175
sg42007
Vgalectin 3
p45366
sg42008
I10
sg42016
VP17931
p45367
sg42011
I2
sa(dp45368
g42006
I250
sg42007
Vcyclooxygenase 2
p45369
sg42008
I16
sg42016
VP35354
p45370
sg42011
I2
sa(dp45371
g42006
I227
sg42007
Vnitric-oxide synthase
p45372
sg42008
I21
sg42016
VP29475
p45373
sg42011
I2
sa(dp45374
g42006
I136
sg42007
g45333
sg42008
I15
sg42016
VP05164
p45375
sg42011
I1
sasa(dp45376
g41997
VChanges in the frequencies of genotypes and mutant alleles of ACE, AGTR1, AGT, and ITGB3 genes were analyzed in patients with arterial hypertension coupled with metabolic syndrome (N=15) and compared with population data and corresponding parameters in patients with isolated hypertension (N=15).
p45377
sg4
(dp45378
(VAGT
p45379
Vmetabolic syndrome
p45380
tp45381
I00
ssg42003
(lp45382
(dp45383
g42006
I126
sg42007
Varterial hypertension
p45384
sg42008
I21
sg42009
VC0020538
p45385
sg42011
I2
sa(dp45386
g42006
I135
sg42007
Vhypertension
p45387
sg42008
I12
sg42009
VC0020538
p45388
sg42011
I1
sa(dp45389
g42006
I44
sg42007
Vmutant
p45390
sg42008
I6
sg42009
VC0596988
p45391
sg42011
I1
sa(dp45392
g42006
I161
sg42007
g45380
sg42008
I18
sg42009
VC0524620
p45393
sg42011
I2
sasg42012
(lp45394
(dp45395
g42006
I67
sg42007
VAGTR1
p45396
sg42008
I5
sg42016
VP30556
p45397
sg42011
I1
sa(dp45398
g42006
I62
sg42007
VACE
p45399
sg42008
I3
sg42016
VP12821
p45400
sg42011
I1
sa(dp45401
g42006
I83
sg42007
VITGB3 genes
p45402
sg42008
I11
sg42016
VP05106
p45403
sg42011
I2
sa(dp45404
g42006
I67
sg42007
g45379
sg42008
I3
sg42016
VP21549
p45405
sg42011
I1
sasa(dp45406
g41997
VWe examined associations between 15 single nucleotide polymorphisms (SNPs) across ITGB3 and five CVD-related traits in the Hutterites: plasma levels of high density lipoprotein-cholesterol (HDL-c), triglycerides (TG), low density lipoprotein-cholesterol (LDL-c), and lipoprotein(a) [Lp(a)] and blood pressure or hypertension.
p45407
sg4
(dp45408
(VHDL-c
p45409
Vhypertension
p45410
tp45411
I00
ssg42003
(lp45412
(dp45413
g42006
I97
sg42007
VCVD
p45414
sg42008
I3
sg42009
VC0007222
p45415
sg42011
I1
sa(dp45416
g42006
I312
sg42007
g45410
sg42008
I12
sg42009
VC0020538
p45417
sg42011
I1
sasg42012
(lp45418
(dp45419
g42006
I218
sg42007
Vlow density lipoprotein-cholesterol
p45420
sg42008
I35
sg42016
VP02652
p45421
sg42011
I3
sa(dp45422
g42006
I255
sg42007
VLDL-c
p45423
sg42008
I5
sg42016
VP02652
p45424
sg42011
I1
sa(dp45425
g42006
I152
sg42007
Vhigh density lipoprotein-cholesterol
p45426
sg42008
I36
sg42016
VP28845
p45427
sg42011
I3
sa(dp45428
g42006
I267
sg42007
Vlipoprotein(a)
p45429
sg42008
I14
sg42016
VP02652
p45430
sg42011
I1
sa(dp45431
g42006
I190
sg42007
g45409
sg42008
I5
sg42016
VP28845
p45432
sg42011
I1
sasa(dp45433
g41997
VThe present study was performed to investigate the expressions of transforming growth factor Beta1 (TGF-Beta1) and matrix metalloproteinase-9 (MMP-9) in an experimental model of tympanosclerosis and their possible roles in the formation of this disorder.
p45434
sg4
(dp45435
(VMMP-9
p45436
Vtympanosclerosis
p45437
tp45438
I00
ssg42003
(lp45439
(dp45440
g42006
I178
sg42007
g45437
sg42008
I16
sg42009
VC0395887
p45441
sg42011
I1
sasg42012
(lp45442
(dp45443
g42006
I66
sg42007
Vtransforming growth factor Beta1
p45444
sg42008
I32
sg42016
VP01137
p45445
sg42011
I4
sa(dp45446
g42006
I100
sg42007
VTGF-Beta1
p45447
sg42008
I9
sg42016
VP01137
p45448
sg42011
I1
sa(dp45449
g42006
I115
sg42007
Vmatrix metalloproteinase-9
p45450
sg42008
I26
sg42016
VP14780
p45451
sg42011
I2
sa(dp45452
g42006
I143
sg42007
g45436
sg42008
I5
sg42016
VP14780
p45453
sg42011
I1
sasa(dp45454
g41997
VRT-PCR analysis showed that the overall transcriptional activity of the main HS biosynthesis-involved genes (EXT1, EXT2, NDST1, NDST2, GLCE, HS2ST1, HS3ST1, HS3ST2, HS6ST1, HS6ST2, SULF1, SULF2, HPSE) was decreased by 1.5-2-fold in Grade II-III glioma (p &lt; 0.01) and by 3-fold in Grade IV glioma (glioblastoma multiforme, GBM) (p &lt; 0.05), as compared with the para-tumourous tissue.
p45455
sg4
(dp45456
(VNDST1
p45457
VGBM
p45458
tp45459
I00
ssg42003
(lp45460
(dp45461
g42006
I115
sg42007
VEXT2
p45462
sg42008
I4
sg42009
VC1851413
p45463
sg42011
I1
sa(dp45464
g42006
I245
sg42007
Vglioma
p45465
sg42008
I6
sg42009
VC0017638
p45466
sg42011
I1
sa(dp45467
g42006
I245
sg42007
Vglioma
p45468
sg42008
I6
sg42009
VC0017638
p45469
sg42011
I1
sa(dp45470
g42006
I300
sg42007
Vglioblastoma multiforme
p45471
sg42008
I23
sg42009
VC1621958
p45472
sg42011
I2
sa(dp45473
g42006
I109
sg42007
VEXT1
p45474
sg42008
I4
sg42009
VC0015306
p45475
sg42011
I1
sa(dp45476
g42006
I325
sg42007
g45458
sg42008
I3
sg42009
VC1621958
p45477
sg42011
I1
sasg42012
(lp45478
(dp45479
g42006
I157
sg42007
VHS3ST2
p45480
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp45481
g42006
I115
sg42007
VEXT2
p45482
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp45483
g42006
I195
sg42007
VHPSE
p45484
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp45485
g42006
I181
sg42007
VSULF1
p45486
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp45487
g42006
I128
sg42007
VNDST2
p45488
sg42008
I5
sg42016
VP52849
p45489
sg42011
I1
sa(dp45490
g42006
I141
sg42007
VHS2ST1
p45491
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp45492
g42006
I121
sg42007
g45457
sg42008
I5
sg42016
VP52848
p45493
sg42011
I1
sa(dp45494
g42006
I135
sg42007
VGLCE
p45495
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp45496
g42006
I109
sg42007
VEXT1
p45497
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp45498
g42006
I149
sg42007
VHS3ST1
p45499
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp45500
g42006
I165
sg42007
VHS6ST1
p45501
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp45502
g42006
I188
sg42007
VSULF2
p45503
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp45504
g41997
VGene microarray analysis revealed that silencing HS6ST3 significantly changed the expression of IGF1R and XAF1 in breast cancer cells.
p45505
sg4
(dp45506
(VIGF1R
p45507
Vbreast cancer
p45508
tp45509
I00
ssg42003
(lp45510
(dp45511
g42006
I114
sg42007
g45508
sg42008
I13
sg42009
VC0678222
p45512
sg42011
I2
sasg42012
(lp45513
(dp45514
g42006
I96
sg42007
g45507
sg42008
I5
sg42016
VP08069
p45515
sg42011
I1
sa(dp45516
g42006
I49
sg42007
VHS6ST3
p45517
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp45518
g42006
I106
sg42007
VXAF1
p45519
sg42008
I4
sg42016
g190
sg42011
I1
sasa(dp45520
g41997
VFurther functional studies showed that the cellular processes were mediated by IGF1R and XAF1 after silencing HS6ST3 in breast cancer cells.
p45521
sg4
(dp45522
(VIGF1R
p45523
Vbreast cancer
p45524
tp45525
I00
ssg42003
(lp45526
(dp45527
g42006
I120
sg42007
g45524
sg42008
I13
sg42009
VC0678222
p45528
sg42011
I2
sasg42012
(lp45529
(dp45530
g42006
I89
sg42007
VXAF1
p45531
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp45532
g42006
I79
sg42007
g45523
sg42008
I5
sg42016
VP08069
p45533
sg42011
I1
sa(dp45534
g42006
I110
sg42007
VHS6ST3
p45535
sg42008
I6
sg42016
g190
sg42011
I1
sasa(dp45536
g41997
VHere we demonstrate that HS 6-O-sulfotransferases 1 and 2 (HS6ST-1 and HS6ST-2), which perform sulfation at 6-O position in glucosamine in HS, impact ovarian cancer angiogenesis through the HS-dependent HB-EGF/EGFR axis that subsequently modulates the expression of multiple angiogenic cytokines.
p45537
sg4
(dp45538
(VHS-dependent HB-EGF
p45539
Vcancer angiogenesis
p45540
tp45541
I00
ssg42003
(lp45542
(dp45543
g42006
I158
sg42007
g45540
sg42008
I19
sg42009
VC1536999
p45544
sg42011
I2
sasg42012
(lp45545
(dp45546
g42006
I190
sg42007
g45539
sg42008
I19
sg42016
VP19525
p45547
sg42011
I2
sa(dp45548
g42006
I59
sg42007
VHS6ST-1
p45549
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp45550
g42006
I25
sg42007
VHS 6-O-sulfotransferases 1 and 2
p45551
sg42008
I32
sg42016
g190
sg42011
I5
sa(dp45552
g42006
I71
sg42007
VHS6ST-2
p45553
sg42008
I7
sg42016
g190
sg42011
I1
sasa(dp45554
g41997
VDown-regulation of HS6ST-1 or HS6ST-2 in human ovarian cancer cell lines results in 30-50% reduction in glucosamine 6-O-sulfate levels in HS, impairing HB-EGF-dependent EGFR signaling and diminishing FGF2, IL-6, and IL-8 mRNA and protein levels in cancer cells.
p45555
sg4
(dp45556
(VIL-6
p45557
Vovarian cancer
p45558
tp45559
I00
ssg42003
(lp45560
(dp45561
g42006
I55
sg42007
Vcancer
p45562
sg42008
I6
sg42009
VC0006826
p45563
sg42011
I1
sa(dp45564
g42006
I47
sg42007
g45558
sg42008
I14
sg42009
VC1140680
p45565
sg42011
I2
sasg42012
(lp45566
(dp45567
g42006
I19
sg42007
VHS6ST-1
p45568
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp45569
g42006
I30
sg42007
VHS6ST-2
p45570
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp45571
g42006
I152
sg42007
VHB-EGF-dependent EGFR
p45572
sg42008
I21
sg42016
g190
sg42011
I2
sa(dp45573
g42006
I206
sg42007
g45557
sg42008
I4
sg42016
VP05231
p45574
sg42011
I1
sa(dp45575
g42006
I200
sg42007
VFGF2
p45576
sg42008
I4
sg42016
g190
sg42011
I1
sasa(dp45577
g41997
VOur results show that in addition to the critical role that 6-O-sulfate moieties play in angiogenic cytokine activation, HS 6-O-sulfation level, determined by the expression of HS6ST isoforms in ovarian cancer cells, is a major regulator of angiogenic program in ovarian cancer cells impacting HB-EGF signaling and subsequent expression of angiogenic cytokines by cancer cells.
p45578
sg4
(dp45579
(VEGF
p45580
Vovarian cancer
p45581
tp45582
I00
ssg42003
(lp45583
(dp45584
g42006
I195
sg42007
Vovarian cancer
p45585
sg42008
I14
sg42009
VC1140680
p45586
sg42011
I2
sa(dp45587
g42006
I203
sg42007
Vcancer
p45588
sg42008
I6
sg42009
VC0006826
p45589
sg42011
I1
sa(dp45590
g42006
I195
sg42007
g45581
sg42008
I14
sg42009
VC1140680
p45591
sg42011
I2
sasg42012
(lp45592
(dp45593
g42006
I340
sg42007
Vangiogenic cytokines
p45594
sg42008
I20
sg42016
VP01374
p45595
sg42011
I2
sa(dp45596
g42006
I297
sg42007
g45580
sg42008
I3
sg42016
VP01133
p45597
sg42011
I1
sa(dp45598
g42006
I177
sg42007
VHS6ST isoforms
p45599
sg42008
I14
sg42016
g190
sg42011
I2
sasa(dp45600
g41997
VThus, neutrophils and NK cells act as important disease-promoting immune cells in experimental osteoarthritis and their functional interaction is promoted by the CXCL10/CXCR3 axis.
p45601
sg4
(dp45602
(VCXCR3
p45603
Vosteoarthritis
p45604
tp45605
I01
ssg42003
(lp45606
(dp45607
g42006
I95
sg42007
g45604
sg42008
I14
sg42009
VC0029408
p45608
sg42011
I1
sasg42012
(lp45609
(dp45610
g42006
I162
sg42007
VCXCL10
p45611
sg42008
I6
sg42016
VP02778
p45612
sg42011
I1
sa(dp45613
g42006
I169
sg42007
g45603
sg42008
I5
sg42016
VP49682
p45614
sg42011
I1
sasa(dp45615
g41997
VIt was indicated that SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily D, member 1, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily D, member 1, dihydropyrimidinase-like 2, RMND5A and ANGPTL1 were potential prognostic markers in breast cancer, and the cell cycle may be involved in the regulation of breast cancer.
p45616
sg4
(dp45617
(VSWI
p45618
Vbreast cancer
p45619
tp45620
I00
ssg42003
(lp45621
(dp45622
g42006
I304
sg42007
Vbreast cancer
p45623
sg42008
I13
sg42009
VC0678222
p45624
sg42011
I2
sa(dp45625
g42006
I304
sg42007
g45619
sg42008
I13
sg42009
VC0678222
p45626
sg42011
I2
sasg42012
(lp45627
(dp45628
g42006
I186
sg42007
Vchromatin, subfamily D, member 1, dihydropyrimidinase-like 2
p45629
sg42008
I60
sg42016
g190
sg42011
I7
sa(dp45630
g42006
I259
sg42007
VANGPTL1
p45631
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp45632
g42006
I248
sg42007
VRMND5A
p45633
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp45634
g42006
I22
sg42007
VSWI
p45635
sg42008
I3
sg42016
VP28370
p45636
sg42011
I1
sa(dp45637
g42006
I26
sg42007
VSNF
p45638
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp45639
g42006
I26
sg42007
VSNF
p45640
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp45641
g42006
I87
sg42007
Vchromatin, subfamily D, member 1
p45642
sg42008
I32
sg42016
g190
sg42011
I5
sa(dp45643
g42006
I22
sg42007
g45618
sg42008
I3
sg42016
VP28370
p45644
sg42011
I1
sasa(dp45645
g41997
VMiR-490-3p plays a tumour suppressor role in epithelial ovarian cancer by targeting CDK1 regulation and influencing SMARCD1 and cyclin D1 (CCND1) expressions.
p45646
sg4
(dp45647
(Vcyclin D1
p45648
Vepithelial ovarian cancer
p45649
tp45650
I00
ssg42003
(lp45651
(dp45652
g42006
I19
sg42007
Vtumour
p45653
sg42008
I6
sg42009
VC0027651
p45654
sg42011
I1
sa(dp45655
g42006
I45
sg42007
g45649
sg42008
I25
sg42009
VC0677886
p45656
sg42011
I3
sasg42012
(lp45657
(dp45658
g42006
I84
sg42007
VCDK1
p45659
sg42008
I4
sg42016
VP06493
p45660
sg42011
I1
sa(dp45661
g42006
I139
sg42007
VCCND1
p45662
sg42008
I5
sg42016
VP24385
p45663
sg42011
I1
sa(dp45664
g42006
I116
sg42007
VSMARCD1
p45665
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp45666
g42006
I0
sg42007
VMiR-490-3p
p45667
sg42008
I10
sg42016
g190
sg42011
I1
sa(dp45668
g42006
I128
sg42007
g45648
sg42008
I9
sg42016
VP24385
p45669
sg42011
I2
sasa(dp45670
g41997
VOur investigation into the involvement of the EGFR-regulated microRNA pathway in the SWI/SNF chromatin remodeling complex suggests that EGFR-mediated miR-7 suppresses the coupling of the chromatin remodeling factor SMARCD1 with p53, resulting in increased chemo-resistance of lung cancer cells.
p45671
sg4
(dp45672
(VSWI
p45673
Vlung cancer
p45674
tp45675
I00
ssg42003
(lp45676
(dp45677
g42006
I276
sg42007
g45674
sg42008
I11
sg42009
VC0684249
p45678
sg42011
I2
sasg42012
(lp45679
(dp45680
g42006
I187
sg42007
Vchromatin remodeling factor
p45681
sg42008
I27
sg42016
g190
sg42011
I3
sa(dp45682
g42006
I85
sg42007
g45673
sg42008
I3
sg42016
VP28370
p45683
sg42011
I1
sa(dp45684
g42006
I89
sg42007
VSNF
p45685
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp45686
g42006
I150
sg42007
VmiR-7
p45687
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp45688
g42006
I215
sg42007
VSMARCD1
p45689
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp45690
g42006
I228
sg42007
Vp53
p45691
sg42008
I3
sg42016
VP42771
p45692
sg42011
I1
sasa(dp45693
g41997
VmiR-490-3p exerted growth- and metastasis-suppressive effects on gastric cancer cells through directly targeting SMARCD1, a SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling complex subunit.
p45694
sg4
(dp45695
(VSWI
p45696
Vmetastasis
p45697
tp45698
I01
ssg42003
(lp45699
(dp45700
g42006
I65
sg42007
Vgastric cancer
p45701
sg42008
I14
sg42009
VC0024623
p45702
sg42011
I2
sa(dp45703
g42006
I31
sg42007
g45697
sg42008
I10
sg42009
VC0027627
p45704
sg42011
I1
sasg42012
(lp45705
(dp45706
g42006
I159
sg42007
VSNF
p45707
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp45708
g42006
I124
sg42007
g45696
sg42008
I3
sg42016
VP28370
p45709
sg42011
I1
sa(dp45710
g42006
I0
sg42007
VmiR-490-3p
p45711
sg42008
I10
sg42016
g190
sg42011
I1
sa(dp45712
g42006
I113
sg42007
VSMARCD1
p45713
sg42008
I7
sg42016
g190
sg42011
I1
sasa(dp45714
g41997
VSilencing CCM3 by siRNA stimulated endothelial proliferation, migration and sprouting accompanied by significant downregulation of the core components of Notch signalling including DLL4, Notch4, HEY2 and HES1 and by activation of VEGF and Erk pathways.
p45715
sg4
(dp45716
(VErk
p45717
VCCM3
p45718
tp45719
I00
ssg42003
(lp45720
(dp45721
g42006
I10
sg42007
g45718
sg42008
I4
sg42009
VC1864040
p45722
sg42011
I1
sa(dp45723
g42006
I47
sg42007
Vproliferation
p45724
sg42008
I13
sg42009
VC0334094
p45725
sg42011
I1
sasg42012
(lp45726
(dp45727
g42006
I204
sg42007
VHES1
p45728
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp45729
g42006
I195
sg42007
VHEY2
p45730
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp45731
g42006
I181
sg42007
VDLL4
p45732
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp45733
g42006
I10
sg42007
VCCM3
p45734
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp45735
g42006
I239
sg42007
g45717
sg42008
I3
sg42016
VP29323
p45736
sg42011
I1
sa(dp45737
g42006
I187
sg42007
VNotch4
p45738
sg42008
I6
sg42016
g190
sg42011
I1
sasa(dp45739
g41997
VOur goal was to assess the patterns of familial aggregation of three melanoma risk factors: great number of naevi (GNN), light phototype (LP) and high degree of sun exposure (HDSE).
p45740
sg4
(dp45741
(Vmelanoma risk factors
p45742
Vmelanoma
p45743
tp45744
I00
ssg42003
(lp45745
(dp45746
g42006
I69
sg42007
g45743
sg42008
I8
sg42009
VC0025202
p45747
sg42011
I1
sasg42012
(lp45748
(dp45749
g42006
I69
sg42007
g45742
sg42008
I21
sg42016
VP19883
p45750
sg42011
I3
sasa(dp45751
g41997
VThe levels of PTH/PTHrP receptor mRNA (corrected by beta-actin mRNA) in the kidney of GNN, GNI, CRF and ARF patients was markedly decreased by up to 35.7%, 68.5%, 77.9% and 92.2%, respectively.
p45752
sg4
(dp45753
(Vbeta-actin mRNA
p45754
VCRF
p45755
tp45756
I00
ssg42003
(lp45757
(dp45758
g42006
I104
sg42007
VARF
p45759
sg42008
I3
sg42009
VC0264490
p45760
sg42011
I1
sa(dp45761
g42006
I96
sg42007
g45755
sg42008
I3
sg42009
VC0022661
p45762
sg42011
I1
sasg42012
(lp45763
(dp45764
g42006
I86
sg42007
VGNN
p45765
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp45766
g42006
I96
sg42007
VCRF
p45767
sg42008
I3
sg42016
VP06850
p45768
sg42011
I1
sa(dp45769
g42006
I14
sg42007
VPTH
p45770
sg42008
I3
sg42016
VP01270
p45771
sg42011
I1
sa(dp45772
g42006
I18
sg42007
VPTHrP receptor mRNA
p45773
sg42008
I19
sg42016
VP12272
p45774
sg42011
I3
sa(dp45775
g42006
I52
sg42007
g45754
sg42008
I15
sg42016
VP63261
p45776
sg42011
I2
sa(dp45777
g42006
I104
sg42007
VARF
p45778
sg42008
I3
sg42016
VP42771
p45779
sg42011
I1
sasa(dp45780
g41997
VThree interacting partners of dysferlin are also implicated in membrane resealing: caveolin-3 (in limb girdle muscular dystrophy type 1C), annexin A1, and the newly identified protein mitsugumin 53 (MG53).
p45781
sg4
(dp45782
(Vcaveolin-3
p45783
Vlimb girdle muscular dystrophy
p45784
tp45785
I00
ssg42003
(lp45786
(dp45787
g42006
I98
sg42007
g45784
sg42008
I30
sg42009
VC0686353
p45788
sg42011
I4
sasg42012
(lp45789
(dp45790
g42006
I139
sg42007
Vannexin A1
p45791
sg42008
I10
sg42016
VP04083
p45792
sg42011
I2
sa(dp45793
g42006
I83
sg42007
g45783
sg42008
I10
sg42016
VP56539
p45794
sg42011
I1
sasa(dp45795
g41997
VThe patients carrying either one or both of GCT and AGG alleles of SP-A2 and patients with A allele at position 1011 of MBL had markedly higher eosinophilia, total IgE antibodies and lower FEV1 (the clinical markers of ABPA).
p45796
sg4
(dp45797
(VIgE
p45798
VIgE
p45799
tp45800
I01
ssg42003
(lp45801
(dp45802
g42006
I219
sg42007
VABPA
p45803
sg42008
I4
sg42009
VC0004031
p45804
sg42011
I1
sa(dp45805
g42006
I144
sg42007
Veosinophilia
p45806
sg42008
I12
sg42009
VC0014457
p45807
sg42011
I1
sa(dp45808
g42006
I164
sg42007
g45799
sg42008
I3
sg42009
VC0270850
p45809
sg42011
I1
sasg42012
(lp45810
(dp45811
g42006
I164
sg42007
g45798
sg42008
I3
sg42016
VP01854
p45812
sg42011
I1
sasa(dp45813
g41997
VThe patients carrying either one or both of GCT and AGG alleles of SP-A2 and patients with A allele at position 1011 of MBL had markedly higher eosinophilia, total IgE antibodies and lower FEV1 (the clinical markers of ABPA).
p45814
sg4
(dp45815
(VIgE
p45816
VIgE
p45817
tp45818
I01
ssg42003
(lp45819
(dp45820
g42006
I219
sg42007
VABPA
p45821
sg42008
I4
sg42009
VC0004031
p45822
sg42011
I1
sa(dp45823
g42006
I144
sg42007
Veosinophilia
p45824
sg42008
I12
sg42009
VC0014457
p45825
sg42011
I1
sa(dp45826
g42006
I164
sg42007
g45817
sg42008
I3
sg42009
VC0270850
p45827
sg42011
I1
sasg42012
(lp45828
(dp45829
g42006
I164
sg42007
g45816
sg42008
I3
sg42016
VP01854
p45830
sg42011
I1
sasa(dp45831
g41997
Vsph1- and spa2-deleted cells possess defects in mating projection morphology and pseudohyphal growth.
p45832
sg4
(dp45833
(Vsph1
p45834
Vsph1
p45835
tp45836
I00
ssg42003
(lp45837
(dp45838
g42006
I29
sg42007
Vpossess
p45839
sg42008
I7
sg42009
VC0850310
p45840
sg42011
I1
sa(dp45841
g42006
I0
sg42007
g45835
sg42008
I4
sg42009
VC2674218
p45842
sg42011
I1
sasg42012
(lp45843
(dp45844
g42006
I0
sg42007
g45834
sg42008
I4
sg42016
VP16157
p45845
sg42011
I1
sa(dp45846
g42006
I10
sg42007
Vspa2
p45847
sg42008
I4
sg42016
g190
sg42011
I1
sasa(dp45848
g41997
Vsph1(Delta) spa2(Delta) double mutants also exhibit a strong haploid invasive growth defect and an exacerbated mating projection defect relative to either sph1(Delta) or spa2(Delta) single mutants.
p45849
sg4
(dp45850
(Vsph1(Delta) spa2(Delta) double mutants
p45851
Vsph1
p45852
tp45853
I00
ssg42003
(lp45854
(dp45855
g42006
I0
sg42007
Vsph1
p45856
sg42008
I4
sg42009
VC2674218
p45857
sg42011
I1
sa(dp45858
g42006
I0
sg42007
g45852
sg42008
I4
sg42009
VC2674218
p45859
sg42011
I1
sa(dp45860
g42006
I69
sg42007
Vinvasive growth
p45861
sg42008
I15
sg42009
VC1156244
p45862
sg42011
I2
sasg42012
(lp45863
(dp45864
g42006
I170
sg42007
Vspa2(Delta) single mutants
p45865
sg42008
I26
sg42016
g190
sg42011
I3
sa(dp45866
g42006
I0
sg42007
Vsph1(Delta)
p45867
sg42008
I11
sg42016
VP16157
p45868
sg42011
I1
sa(dp45869
g42006
I0
sg42007
g45851
sg42008
I38
sg42016
VP16157
p45870
sg42011
I4
sasa(dp45871
g41997
VSPH1, which is similar to SPA2, is required for bipolar budding and plays a role in shmoo formation.
p45872
sg4
(dp45873
(VSPH1
p45874
VSPH1
p45875
tp45876
I00
ssg42003
(lp45877
(dp45878
g42006
I0
sg42007
g45875
sg42008
I4
sg42009
VC2674218
p45879
sg42011
I1
sasg42012
(lp45880
(dp45881
g42006
I0
sg42007
g45874
sg42008
I4
sg42016
VP16157
p45882
sg42011
I1
sa(dp45883
g42006
I26
sg42007
VSPA2
p45884
sg42008
I4
sg42016
g190
sg42011
I1
sasa(dp45885
g41997
VThis study was undertaken to evaluate the effect of ADAM8 on the proliferation and apoptosis of hepatocytes and hepatoma carcinoma cells during hepatocellular carcinoma (HCC) progression.
p45886
sg4
(dp45887
(VADAM8
p45888
Vhepatoma
p45889
tp45890
I00
ssg42003
(lp45891
(dp45892
g42006
I170
sg42007
VHCC
p45893
sg42008
I3
sg42009
VC2239176
p45894
sg42011
I1
sa(dp45895
g42006
I65
sg42007
Vproliferation
p45896
sg42008
I13
sg42009
VC0334094
p45897
sg42011
I1
sa(dp45898
g42006
I121
sg42007
Vcarcinoma
p45899
sg42008
I9
sg42009
VC0007097
p45900
sg42011
I1
sa(dp45901
g42006
I144
sg42007
Vhepatocellular carcinoma
p45902
sg42008
I24
sg42009
VC2239176
p45903
sg42011
I2
sa(dp45904
g42006
I112
sg42007
g45889
sg42008
I8
sg42009
VC2239176
p45905
sg42011
I1
sasg42012
(lp45906
(dp45907
g42006
I52
sg42007
g45888
sg42008
I5
sg42016
VP78325
p45908
sg42011
I1
sasa(dp45909
g41997
VIn conclusion, our study suggested that ADAM8 could promote the proliferation of normal hepatocytes and render hepatoma carcinoma cells more resistant to apoptosis to play important roles during the progression of HCC.
p45910
sg4
(dp45911
(VADAM8
p45912
VHCC
p45913
tp45914
I00
ssg42003
(lp45915
(dp45916
g42006
I64
sg42007
Vproliferation
p45917
sg42008
I13
sg42009
VC0334094
p45918
sg42011
I1
sa(dp45919
g42006
I111
sg42007
Vhepatoma
p45920
sg42008
I8
sg42009
VC2239176
p45921
sg42011
I1
sa(dp45922
g42006
I120
sg42007
Vcarcinoma
p45923
sg42008
I9
sg42009
VC0007097
p45924
sg42011
I1
sa(dp45925
g42006
I214
sg42007
g45913
sg42008
I3
sg42009
VC2239176
p45926
sg42011
I1
sasg42012
(lp45927
(dp45928
g42006
I40
sg42007
g45912
sg42008
I5
sg42016
VP78325
p45929
sg42011
I1
sasa(dp45930
g41997
VThus, our data integrate ADAM8 in pancreatic cancer signalling and validate ADAM8 as a target for PDAC therapy.
p45931
sg4
(dp45932
(VADAM8
p45933
Vpancreatic cancer
p45934
tp45935
I01
ssg42003
(lp45936
(dp45937
g42006
I34
sg42007
g45934
sg42008
I17
sg42009
VC0235974
p45938
sg42011
I2
sasg42012
(lp45939
(dp45940
g42006
I25
sg42007
VADAM8
p45941
sg42008
I5
sg42016
VP78325
p45942
sg42011
I1
sa(dp45943
g42006
I25
sg42007
g45933
sg42008
I5
sg42016
VP78325
p45944
sg42011
I1
sasa(dp45945
g41997
VThis study focuses on investigating the concrete role of a disintegrin and metalloproteinase 8 (ADAM8) in the progression of hepatocellular carcinoma (HCC).
p45946
sg4
(dp45947
(Vdisintegrin and metalloproteinase 8 (ADAM8)
p45948
VHCC
p45949
tp45950
I00
ssg42003
(lp45951
(dp45952
g42006
I125
sg42007
Vhepatocellular carcinoma
p45953
sg42008
I24
sg42009
VC2239176
p45954
sg42011
I2
sa(dp45955
g42006
I151
sg42007
g45949
sg42008
I3
sg42009
VC2239176
p45956
sg42011
I1
sasg42012
(lp45957
(dp45958
g42006
I59
sg42007
g45948
sg42008
I43
sg42016
VP78325
p45959
sg42011
I5
sasa(dp45960
g41997
VHowever, no studies have examined ADAM8 association in colorectal cancer (CRC).
p45961
sg4
(dp45962
(VADAM8 association in colorectal cancer (CRC)
p45963
Vcolorectal cancer
p45964
tp45965
I01
ssg42003
(lp45966
(dp45967
g42006
I74
sg42007
VCRC
p45968
sg42008
I3
sg42009
VC1527249
p45969
sg42011
I1
sa(dp45970
g42006
I55
sg42007
g45964
sg42008
I17
sg42009
VC1527249
p45971
sg42011
I2
sasg42012
(lp45972
(dp45973
g42006
I34
sg42007
g45963
sg42008
I44
sg42016
VP78325
p45974
sg42011
I6
sasa(dp45975
g41997
VSubgroup analysis showed that 5-year OS of colon cancer, T3-T4 stage and N0 stage was worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p &lt; 0.05).
p45976
sg4
(dp45977
(VADAM8
p45978
Vcolon cancer
p45979
tp45980
I00
ssg42003
(lp45981
(dp45982
g42006
I125
sg42007
Vtumors
p45983
sg42008
I6
sg42009
VC0027651
p45984
sg42011
I1
sa(dp45985
g42006
I43
sg42007
g45979
sg42008
I12
sg42009
VC0699790
p45986
sg42011
I2
sa(dp45987
g42006
I125
sg42007
Vtumors
p45988
sg42008
I6
sg42009
VC0027651
p45989
sg42011
I1
sasg42012
(lp45990
(dp45991
g42006
I110
sg42007
g45978
sg42008
I5
sg42016
VP78325
p45992
sg42011
I1
sasa(dp45993
g41997
VThe 5-year DFS in colon cancer, T3-T4 stage, N0 stage, TNM stage II, adenocarcinoma, moderate differentiation and male patient subgroups was also worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p &lt; 0.05).
p45994
sg4
(dp45995
(VADAM8
p45996
Vcolon cancer
p45997
tp45998
I00
ssg42003
(lp45999
(dp46000
g42006
I69
sg42007
Vadenocarcinoma
p46001
sg42008
I14
sg42009
VC0001418
p46002
sg42011
I1
sa(dp46003
g42006
I18
sg42007
g45997
sg42008
I12
sg42009
VC0699790
p46004
sg42011
I2
sa(dp46005
g42006
I185
sg42007
Vtumors
p46006
sg42008
I6
sg42009
VC0027651
p46007
sg42011
I1
sa(dp46008
g42006
I185
sg42007
Vtumors
p46009
sg42008
I6
sg42009
VC0027651
p46010
sg42011
I1
sasg42012
(lp46011
(dp46012
g42006
I170
sg42007
g45996
sg42008
I5
sg42016
VP78325
p46013
sg42011
I1
sa(dp46014
g42006
I55
sg42007
VTNM stage II
p46015
sg42008
I12
sg42016
g190
sg42011
I3
sasa(dp46016
g41997
VThe aim of this study was to examine the role of the inflammatory cells in the invasion of pancreatic cancer cells, focusing on the involvement of a disintegrin and metalloproteinase 8 (ADAM8) and matrix metalloproteinase 9 (MMP9) proteins.
p46017
sg4
(dp46018
(Vdisintegrin and metalloproteinase 8 (ADAM8)
p46019
Vpancreatic cancer
p46020
tp46021
I01
ssg42003
(lp46022
(dp46023
g42006
I91
sg42007
g46020
sg42008
I17
sg42009
VC0235974
p46024
sg42011
I2
sa(dp46025
g42006
I79
sg42007
Vinvasion
p46026
sg42008
I8
sg42009
VC2699153
p46027
sg42011
I1
sasg42012
(lp46028
(dp46029
g42006
I197
sg42007
Vmatrix metalloproteinase 9 (MMP9) proteins
p46030
sg42008
I42
sg42016
VP14780
p46031
sg42011
I5
sa(dp46032
g42006
I149
sg42007
g46019
sg42008
I43
sg42016
VP78325
p46033
sg42011
I5
sasa(dp46034
g41997
VADAM8 expression is associated with worse survival of pancreatic cancer patients.
p46035
sg4
(dp46036
(VADAM8
p46037
Vpancreatic cancer
p46038
tp46039
I01
ssg42003
(lp46040
(dp46041
g42006
I54
sg42007
g46038
sg42008
I17
sg42009
VC0235974
p46042
sg42011
I2
sasg42012
(lp46043
(dp46044
g42006
I0
sg42007
g46037
sg42008
I5
sg42016
VP78325
p46045
sg42011
I1
sasa(dp46046
g41997
VAnti-inflammatory macrophages increase pancreatic cancer cell migration rate in basement membrane matrix by inducing ADAM8 and MMP9 expression in cancer cells, thereby possibly enhancing the invasiveness of cancer.
p46047
sg4
(dp46048
(VADAM8
p46049
Vpancreatic cancer
p46050
tp46051
I01
ssg42003
(lp46052
(dp46053
g42006
I39
sg42007
g46050
sg42008
I17
sg42009
VC0235974
p46054
sg42011
I2
sa(dp46055
g42006
I50
sg42007
Vcancer
p46056
sg42008
I6
sg42009
VC0006826
p46057
sg42011
I1
sa(dp46058
g42006
I50
sg42007
Vcancer
p46059
sg42008
I6
sg42009
VC0006826
p46060
sg42011
I1
sasg42012
(lp46061
(dp46062
g42006
I127
sg42007
VMMP9
p46063
sg42008
I4
sg42016
VP14780
p46064
sg42011
I1
sa(dp46065
g42006
I117
sg42007
g46049
sg42008
I5
sg42016
VP78325
p46066
sg42011
I1
sasa(dp46067
g41997
VIn this study,we investigated the ADAM8 expression in hepatocellular carcinoma (HCC) and its correlation with clinicopathologic features,including the survival of patients with HCC.
p46068
sg4
(dp46069
(VADAM8
p46070
VHCC
p46071
tp46072
I00
ssg42003
(lp46073
(dp46074
g42006
I54
sg42007
Vhepatocellular carcinoma
p46075
sg42008
I24
sg42009
VC2239176
p46076
sg42011
I2
sa(dp46077
g42006
I80
sg42007
VHCC
p46078
sg42008
I3
sg42009
VC2239176
p46079
sg42011
I1
sa(dp46080
g42006
I80
sg42007
g46071
sg42008
I3
sg42009
VC2239176
p46081
sg42011
I1
sasg42012
(lp46082
(dp46083
g42006
I34
sg42007
g46070
sg42008
I5
sg42016
VP78325
p46084
sg42011
I1
sasa(dp46085
g41997
VOther studies have demonstrated overexpression of some ADAM family proteins in a variety of human tumors, but no report is available on the actual expression of ADAM8 and the correlation between clinicopathologic features and prognosis of hepatocellular carcinoma (HCC) patients.
p46086
sg4
(dp46087
(VADAM8
p46088
Vhepatocellular carcinoma
p46089
tp46090
I00
ssg42003
(lp46091
(dp46092
g42006
I98
sg42007
Vtumors
p46093
sg42008
I6
sg42009
VC0027651
p46094
sg42011
I1
sa(dp46095
g42006
I265
sg42007
VHCC
p46096
sg42008
I3
sg42009
VC2239176
p46097
sg42011
I1
sa(dp46098
g42006
I239
sg42007
g46089
sg42008
I24
sg42009
VC2239176
p46099
sg42011
I2
sasg42012
(lp46100
(dp46101
g42006
I55
sg42007
VADAM family proteins
p46102
sg42008
I20
sg42016
VP02649
p46103
sg42011
I3
sa(dp46104
g42006
I161
sg42007
g46088
sg42008
I5
sg42016
VP78325
p46105
sg42011
I1
sasa(dp46106
g41997
VTo evaluate the association between ADAM8 tissue expression and patient prognosis in hepatocellular carcinoma (HCC).
p46107
sg4
(dp46108
(VADAM8
p46109
Vhepatocellular carcinoma
p46110
tp46111
I00
ssg42003
(lp46112
(dp46113
g42006
I111
sg42007
VHCC
p46114
sg42008
I3
sg42009
VC2239176
p46115
sg42011
I1
sa(dp46116
g42006
I85
sg42007
g46110
sg42008
I24
sg42009
VC2239176
p46117
sg42011
I2
sasg42012
(lp46118
(dp46119
g42006
I36
sg42007
g46109
sg42008
I5
sg42016
VP78325
p46120
sg42011
I1
sasa(dp46121
g41997
VSome of the previously reported gout associated loci (except ALDH16A1), including ABCG2, SLC2A9, GCKR, ALDH2 and CNIH2, were replicated.
p46122
sg4
(dp46123
(VALDH2
p46124
Vgout
p46125
tp46126
I00
ssg42003
(lp46127
(dp46128
g42006
I32
sg42007
g46125
sg42008
I4
sg42009
VC0018099
p46129
sg42011
I1
sasg42012
(lp46130
(dp46131
g42006
I113
sg42007
VCNIH2
p46132
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46133
g42006
I89
sg42007
VSLC2A9
p46134
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46135
g42006
I103
sg42007
g46124
sg42008
I5
sg42016
VP05091
p46136
sg42011
I1
sa(dp46137
g42006
I61
sg42007
VALDH16A1
p46138
sg42008
I8
sg42016
g190
sg42011
I1
sa(dp46139
g42006
I97
sg42007
VGCKR
p46140
sg42008
I4
sg42016
g190
sg42011
I1
sasa(dp46141
g41997
VThe aim of this study was to examine the role of SLC2A9 and ABCG2 variants in tophaceous disease in people with gout.
p46142
sg4
(dp46143
(VABCG2 variants
p46144
Vgout
p46145
tp46146
I00
ssg42003
(lp46147
(dp46148
g42006
I112
sg42007
g46145
sg42008
I4
sg42009
VC0018099
p46149
sg42011
I1
sasg42012
(lp46150
(dp46151
g42006
I49
sg42007
VSLC2A9
p46152
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46153
g42006
I60
sg42007
g46144
sg42008
I14
sg42016
VP26640
p46154
sg42011
I2
sasa(dp46155
g41997
VTo investigate the nature of mutations in exons 4 and 5 of the uromodulin (UM) gene, including in the area encoding the domain of 8 cysteines (D8C), in patients with multiple myeloma (MM) with the secretion of monoclonal light chains (LC) in cast nephropathy (CN) and without kidney injury.
p46156
sg4
(dp46157
(Vuromodulin (UM) gene
p46158
Vmultiple myeloma
p46159
tp46160
I00
ssg42003
(lp46161
(dp46162
g42006
I247
sg42007
Vnephropathy
p46163
sg42008
I11
sg42009
VC0022658
p46164
sg42011
I1
sa(dp46165
g42006
I166
sg42007
g46159
sg42008
I16
sg42009
VC0026764
p46166
sg42011
I2
sasg42012
(lp46167
(dp46168
g42006
I63
sg42007
g46158
sg42008
I20
sg42016
VP07911
p46169
sg42011
I3
sasa(dp46170
g41997
VThe aim of the study was to investigate the association of the uromodulin (UMOD) genotype with patient health status and with renal cell carcinoma (RCC) aggressiveness.
p46171
sg4
(dp46172
(Vuromodulin
p46173
Vaggressiveness
p46174
tp46175
I00
ssg42003
(lp46176
(dp46177
g42006
I148
sg42007
VRCC
p46178
sg42008
I3
sg42009
VC0007134
p46179
sg42011
I1
sa(dp46180
g42006
I126
sg42007
Vrenal cell carcinoma
p46181
sg42008
I20
sg42009
VC0007134
p46182
sg42011
I3
sa(dp46183
g42006
I153
sg42007
g46174
sg42008
I14
sg42009
VC0001807
p46184
sg42011
I1
sasg42012
(lp46185
(dp46186
g42006
I75
sg42007
VUMOD
p46187
sg42008
I4
sg42016
VP07911
p46188
sg42011
I1
sa(dp46189
g42006
I63
sg42007
g46173
sg42008
I10
sg42016
VP07911
p46190
sg42011
I1
sasa(dp46191
g41997
VIn patients diagnosed with renal cell carcinoma and treated with surgery, uromodulin homozygous genotype is associated with more aggressive renal cell carcinoma clinical and pathological characteristics.
p46192
sg4
(dp46193
(Vuromodulin
p46194
Vrenal cell carcinoma
p46195
tp46196
I00
ssg42003
(lp46197
(dp46198
g42006
I129
sg42007
Vaggressive
p46199
sg42008
I10
sg42009
VC0001807
p46200
sg42011
I1
sa(dp46201
g42006
I27
sg42007
Vrenal cell carcinoma
p46202
sg42008
I20
sg42009
VC0007134
p46203
sg42011
I3
sa(dp46204
g42006
I27
sg42007
g46195
sg42008
I20
sg42009
VC0007134
p46205
sg42011
I3
sasg42012
(lp46206
(dp46207
g42006
I74
sg42007
g46194
sg42008
I10
sg42016
VP07911
p46208
sg42011
I1
sasa(dp46209
g41997
VCYP11B2 was sequenced if the aldosterone level was high (primary aldosteronism phenotype); SCNN1B, NEDD4L, GRK4, UMOD, and NPPA genes were sequenced if the aldosterone level was low (Liddle phenotype).
p46210
sg4
(dp46211
(VUMOD
p46212
Vprimary aldosteronism
p46213
tp46214
I00
ssg42003
(lp46215
(dp46216
g42006
I57
sg42007
g46213
sg42008
I21
sg42009
VC1384514
p46217
sg42011
I2
sasg42012
(lp46218
(dp46219
g42006
I91
sg42007
VSCNN1B
p46220
sg42008
I6
sg42016
VP51168
p46221
sg42011
I1
sa(dp46222
g42006
I0
sg42007
VCYP11B2
p46223
sg42008
I7
sg42016
VP19099
p46224
sg42011
I1
sa(dp46225
g42006
I123
sg42007
VNPPA genes
p46226
sg42008
I10
sg42016
VP01160
p46227
sg42011
I2
sa(dp46228
g42006
I113
sg42007
g46212
sg42008
I4
sg42016
VP07911
p46229
sg42011
I1
sasa(dp46230
g41997
VMT1F, MT1G, MT1X, and MT2A gene expression was significantly downregulated in colon cancer tissue (p&lt;0.05).
p46231
sg4
(dp46232
(VMT2A gene
p46233
Vcolon cancer
p46234
tp46235
I01
ssg42003
(lp46236
(dp46237
g42006
I78
sg42007
g46234
sg42008
I12
sg42009
VC0699790
p46238
sg42011
I2
sasg42012
(lp46239
(dp46240
g42006
I12
sg42007
VMT1X
p46241
sg42008
I4
sg42016
VP80297
p46242
sg42011
I1
sa(dp46243
g42006
I6
sg42007
VMT1G
p46244
sg42008
I4
sg42016
VP04733
p46245
sg42011
I1
sa(dp46246
g42006
I0
sg42007
VMT1F
p46247
sg42008
I4
sg42016
VP04733
p46248
sg42011
I1
sa(dp46249
g42006
I22
sg42007
g46233
sg42008
I9
sg42016
VP02795
p46250
sg42011
I2
sasa(dp46251
g41997
VHere, we describe the discovery of a new MSI marker for colorectal cancer located in the 3'-untranslated region (3'UTR, T20 mononucleotide repeat) of the metallothionein 1X gene (MT1XT20).
p46252
sg4
(dp46253
(Vmetallothionein 1X gene
p46254
Vcolorectal cancer
p46255
tp46256
I00
ssg42003
(lp46257
(dp46258
g42006
I41
sg42007
VMSI
p46259
sg42008
I3
sg42009
VC0920269
p46260
sg42011
I1
sa(dp46261
g42006
I56
sg42007
g46255
sg42008
I17
sg42009
VC1527249
p46262
sg42011
I2
sasg42012
(lp46263
(dp46264
g42006
I154
sg42007
g46254
sg42008
I23
sg42016
VP80297
p46265
sg42011
I3
sasa(dp46266
g41997
VHNF-1Beta regulates tissue-specific gene expression in endometriosis, as well as the expression of several genes, including CD44v9, which binds several molecules, including hyaluronan, epidermal growth factor receptor (EGFR), leukemia-associated Rho-guanine nucleotide exchange factor (LARG), IQ motif containing GTPase activating protein 1 (IQGAP1), macrophage migration inhibitory factor (MIF), major histocompatibility complex, class II invariant chain (CD74), cystine transporter subunit (xCT), Fas and extracellular matrix (ECM) proteins.
p46267
sg4
(dp46268
(Vepidermal growth factor receptor
p46269
VFas
p46270
tp46271
I00
ssg42003
(lp46272
(dp46273
g42006
I226
sg42007
Vleukemia
p46274
sg42008
I8
sg42009
VC0023418
p46275
sg42011
I1
sa(dp46276
g42006
I55
sg42007
Vendometriosis
p46277
sg42008
I13
sg42009
VC0014175
p46278
sg42011
I1
sa(dp46279
g42006
I499
sg42007
g46270
sg42008
I3
sg42009
VC0015923
p46280
sg42011
I1
sasg42012
(lp46281
(dp46282
g42006
I342
sg42007
VIQGAP1
p46283
sg42008
I6
sg42016
VP46940
p46284
sg42011
I1
sa(dp46285
g42006
I286
sg42007
VLARG
p46286
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp46287
g42006
I0
sg42007
VHNF-1Beta
p46288
sg42008
I9
sg42016
g190
sg42011
I1
sa(dp46289
g42006
I507
sg42007
Vextracellular matrix (ECM) proteins
p46290
sg42008
I35
sg42016
g190
sg42011
I4
sa(dp46291
g42006
I293
sg42007
VIQ motif containing GTPase activating protein 1
p46292
sg42008
I47
sg42016
VP46940
p46293
sg42011
I7
sa(dp46294
g42006
I226
sg42007
Vleukemia-associated Rho-guanine nucleotide exchange factor
p46295
sg42008
I58
sg42016
g190
sg42011
I5
sa(dp46296
g42006
I219
sg42007
VEGFR
p46297
sg42008
I4
sg42016
VP01133
p46298
sg42011
I1
sa(dp46299
g42006
I499
sg42007
VFas
p46300
sg42008
I3
sg42016
VP48023
p46301
sg42011
I1
sa(dp46302
g42006
I457
sg42007
VCD74
p46303
sg42008
I4
sg42016
VP04233
p46304
sg42011
I1
sa(dp46305
g42006
I397
sg42007
Vmajor histocompatibility complex, class II invariant chain
p46306
sg42008
I58
sg42016
VP18464
p46307
sg42011
I7
sa(dp46308
g42006
I464
sg42007
Vcystine transporter subunit
p46309
sg42008
I27
sg42016
g190
sg42011
I3
sa(dp46310
g42006
I185
sg42007
g46269
sg42008
I32
sg42016
VP01133
p46311
sg42011
I4
sa(dp46312
g42006
I493
sg42007
VxCT
p46313
sg42008
I3
sg42016
g190
sg42011
I1
sasa(dp46314
g41997
VIf true, plasma L-arg should be severely reduced in chronic renal failure (CRF); however, plasma L-arg is frequently unchanged in CRF.
p46315
sg4
(dp46316
(Vchronic renal failure
p46317
VCRF
p46318
tp46319
I00
ssg42003
(lp46320
(dp46321
g42006
I75
sg42007
VCRF
p46322
sg42008
I3
sg42009
VC0022661
p46323
sg42011
I1
sa(dp46324
g42006
I52
sg42007
Vchronic renal failure
p46325
sg42008
I21
sg42009
VC0022661
p46326
sg42011
I3
sa(dp46327
g42006
I75
sg42007
g46318
sg42008
I3
sg42009
VC0022661
p46328
sg42011
I1
sasg42012
(lp46329
(dp46330
g42006
I75
sg42007
VCRF
p46331
sg42008
I3
sg42016
VP06850
p46332
sg42011
I1
sa(dp46333
g42006
I52
sg42007
g46317
sg42008
I21
sg42016
VP06850
p46334
sg42011
I3
sasa(dp46335
g41997
VAs expected, a physiological analgesia is produced by administration of inhibitors, especially kelatorphan and analogues, demonstrating unambiguously the implication of enkephalinase and aminopeptidase M in enkephalin metabolism.
p46336
sg4
(dp46337
(Venkephalinase
p46338
Vanalgesia
p46339
tp46340
I00
ssg42003
(lp46341
(dp46342
g42006
I29
sg42007
g46339
sg42008
I9
sg42009
VC0344307
p46343
sg42011
I1
sasg42012
(lp46344
(dp46345
g42006
I187
sg42007
Vaminopeptidase M
p46346
sg42008
I16
sg42016
VP15144
p46347
sg42011
I2
sa(dp46348
g42006
I169
sg42007
g46338
sg42008
I13
sg42016
VP08473
p46349
sg42011
I1
sasa(dp46350
g41997
VAssociated with antigliadin and anti-HSP antibodies, children with autism and patients with autoimmune disease developed anti-dipeptidylpeptidase I (DPP I), anti-dipeptidylpeptidase IV (DPP IV [or CD26]) and anti-aminopeptidase N (CD13) autoantibodies.
p46351
sg4
(dp46352
(Vanti-dipeptidylpeptidase IV
p46353
Vautism
p46354
tp46355
I01
ssg42003
(lp46356
(dp46357
g42006
I92
sg42007
Vautoimmune disease
p46358
sg42008
I18
sg42009
VC0004364
p46359
sg42011
I2
sa(dp46360
g42006
I37
sg42007
VHSP
p46361
sg42008
I3
sg42009
VC0034152
p46362
sg42011
I1
sa(dp46363
g42006
I67
sg42007
g46354
sg42008
I6
sg42009
VC0004352
p46364
sg42011
I1
sasg42012
(lp46365
(dp46366
g42006
I32
sg42007
Vanti-HSP antibodies
p46367
sg42008
I19
sg42016
g190
sg42011
I2
sa(dp46368
g42006
I149
sg42007
VDPP I
p46369
sg42008
I5
sg42016
g190
sg42011
I2
sa(dp46370
g42006
I121
sg42007
Vanti-dipeptidylpeptidase I
p46371
sg42008
I26
sg42016
g190
sg42011
I2
sa(dp46372
g42006
I208
sg42007
Vanti-aminopeptidase N
p46373
sg42008
I21
sg42016
VP15144
p46374
sg42011
I2
sa(dp46375
g42006
I231
sg42007
VCD13
p46376
sg42008
I4
sg42016
VP15144
p46377
sg42011
I1
sa(dp46378
g42006
I186
sg42007
VDPP IV
p46379
sg42008
I6
sg42016
VP27487
p46380
sg42011
I2
sa(dp46381
g42006
I157
sg42007
g46353
sg42008
I27
sg42016
VP27487
p46382
sg42011
I2
sasa(dp46383
g41997
VIn both cultured melanoma cell lines and in vivo in melanoma cell-derived tumor xenografts, 1-benzyl-I3C disrupted canonical Wnt/Beta-catenin signaling that resulted in the down regulation of Beta-catenin protein levels with a concomitant increase in levels of the Beta-catenin destruction complex components GSK3Beta and Axin.
p46384
sg4
(dp46385
(VBeta-catenin
p46386
Vmelanoma
p46387
tp46388
I00
ssg42003
(lp46389
(dp46390
g42006
I74
sg42007
Vtumor
p46391
sg42008
I5
sg42009
VC0027651
p46392
sg42011
I1
sa(dp46393
g42006
I17
sg42007
Vmelanoma
p46394
sg42008
I8
sg42009
VC0025202
p46395
sg42011
I1
sa(dp46396
g42006
I17
sg42007
g46387
sg42008
I8
sg42009
VC0025202
p46397
sg42011
I1
sasg42012
(lp46398
(dp46399
g42006
I192
sg42007
VBeta-catenin protein
p46400
sg42008
I20
sg42016
VP35222
p46401
sg42011
I2
sa(dp46402
g42006
I129
sg42007
g46386
sg42008
I12
sg42016
VP35222
p46403
sg42011
I1
sa(dp46404
g42006
I322
sg42007
VAxin
p46405
sg42008
I4
sg42016
g190
sg42011
I1
sasa(dp46406
g41997
VInter-individual variation in CCAAT/enhancer binding protein gamma (CEBPG) transcript expression in normal human bronchial epithelial cells (NBEC) is associated with predisposition to lung cancer.
p46407
sg4
(dp46408
(VCEBPG
p46409
Vlung cancer
p46410
tp46411
I00
ssg42003
(lp46412
(dp46413
g42006
I184
sg42007
g46410
sg42008
I11
sg42009
VC0684249
p46414
sg42011
I2
sasg42012
(lp46415
(dp46416
g42006
I30
sg42007
VCCAAT/enhancer binding protein gamma
p46417
sg42008
I36
sg42016
g190
sg42011
I4
sa(dp46418
g42006
I68
sg42007
g46409
sg42008
I5
sg42016
VP53567
p46419
sg42011
I1
sasa(dp46420
g41997
VThese data support the hypothesis that genetic variation in linkage disequilibrium with rs2772 influences regulation of CEBPG transcript expression through a trans-effect downstream of RNA polymerase II transcription and confirm that cis-acting genetic variation contributes to inter-individual variation in CEBPG transcript expression in NBEC, which is associated with variation in lung cancer risk.
p46421
sg4
(dp46422
(VRNA polymerase II
p46423
Vdisequilibrium
p46424
tp46425
I00
ssg42003
(lp46426
(dp46427
g42006
I383
sg42007
Vlung cancer
p46428
sg42008
I11
sg42009
VC0684249
p46429
sg42011
I2
sa(dp46430
g42006
I234
sg42007
Vcis
p46431
sg42008
I3
sg42009
VC0007099
p46432
sg42011
I1
sa(dp46433
g42006
I68
sg42007
g46424
sg42008
I14
sg42009
VC0394006
p46434
sg42011
I1
sasg42012
(lp46435
(dp46436
g42006
I120
sg42007
VCEBPG transcript
p46437
sg42008
I16
sg42016
VP53567
p46438
sg42011
I2
sa(dp46439
g42006
I120
sg42007
VCEBPG transcript
p46440
sg42008
I16
sg42016
VP53567
p46441
sg42011
I2
sa(dp46442
g42006
I185
sg42007
g46423
sg42008
I17
sg42016
VP19388
p46443
sg42011
I3
sasa(dp46444
g41997
VIn an effort to develop a biomarker for lung cancer risk, we evaluated the transcript expressions of 14 antioxidant, DNA repair, and transcription factor genes in normal bronchial epithelial cells (HUGO names CAT, CEBPG, E2F1, ERCC4, ERCC5, GPX1, GPX3, GSTM3, GSTP1, GSTT1, GSTZ1, MGST1, SOD1, and XRCC1).
p46445
sg4
(dp46446
(VGPX1
p46447
Vlung cancer
p46448
tp46449
I00
ssg42003
(lp46450
(dp46451
g42006
I40
sg42007
g46448
sg42008
I11
sg42009
VC0684249
p46452
sg42011
I2
sasg42012
(lp46453
(dp46454
g42006
I227
sg42007
VERCC4
p46455
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46456
g42006
I209
sg42007
VCAT
p46457
sg42008
I3
sg42016
VP04040
p46458
sg42011
I1
sa(dp46459
g42006
I234
sg42007
VERCC5
p46460
sg42008
I5
sg42016
VP28715
p46461
sg42011
I1
sa(dp46462
g42006
I274
sg42007
VGSTZ1
p46463
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46464
g42006
I214
sg42007
VCEBPG
p46465
sg42008
I5
sg42016
VP53567
p46466
sg42011
I1
sa(dp46467
g42006
I221
sg42007
VE2F1
p46468
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp46469
g42006
I267
sg42007
VGSTT1
p46470
sg42008
I5
sg42016
VP30711
p46471
sg42011
I1
sa(dp46472
g42006
I260
sg42007
VGSTP1
p46473
sg42008
I5
sg42016
VP09211
p46474
sg42011
I1
sa(dp46475
g42006
I288
sg42007
VSOD1
p46476
sg42008
I4
sg42016
VP00441
p46477
sg42011
I1
sa(dp46478
g42006
I298
sg42007
VXRCC1
p46479
sg42008
I5
sg42016
VP18887
p46480
sg42011
I1
sa(dp46481
g42006
I253
sg42007
VGSTM3
p46482
sg42008
I5
sg42016
VP21266
p46483
sg42011
I1
sa(dp46484
g42006
I281
sg42007
VMGST1
p46485
sg42008
I5
sg42016
VP10620
p46486
sg42011
I1
sa(dp46487
g42006
I247
sg42007
VGPX3
p46488
sg42008
I4
sg42016
VP22352
p46489
sg42011
I1
sa(dp46490
g42006
I241
sg42007
g46447
sg42008
I4
sg42016
VP07203
p46491
sg42011
I1
sasa(dp46492
g41997
VFifteen rearrangements detected in Sezary syndrome patients and SeAx resulted in an expression of new fusion transcripts, nine of them were in frame (EHD1-CAPN12, TMEM66-BAIAP2, MBD4-PTPRC, PTPRC-CPN2, MYB-MBNL1, TFG-GPR128, MAP4K3-FIGLA, DCP1A-CCL27, MBNL1-KIAA2018) and five resulted in ectopic expression of fragments of genes not expressed in normal T-cells (BAIAP2, CPN2, GPR128, CAPN12, FIGLA).
p46493
sg4
(dp46494
(VPTPRC
p46495
VSezary syndrome
p46496
tp46497
I00
ssg42003
(lp46498
(dp46499
g42006
I35
sg42007
g46496
sg42008
I15
sg42009
VC0036920
p46500
sg42011
I2
sasg42012
(lp46501
(dp46502
g42006
I150
sg42007
VEHD1
p46503
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp46504
g42006
I163
sg42007
VTMEM66
p46505
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46506
g42006
I190
sg42007
VPTPRC-CPN2
p46507
sg42008
I10
sg42016
VP08575
p46508
sg42011
I1
sa(dp46509
g42006
I232
sg42007
VFIGLA
p46510
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46511
g42006
I217
sg42007
VGPR128
p46512
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46513
g42006
I155
sg42007
VCAPN12
p46514
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46515
g42006
I252
sg42007
VMBNL1-KIAA2018
p46516
sg42008
I14
sg42016
g190
sg42011
I1
sa(dp46517
g42006
I217
sg42007
VGPR128
p46518
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46519
g42006
I178
sg42007
VMBD4
p46520
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp46521
g42006
I232
sg42007
VFIGLA
p46522
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46523
g42006
I155
sg42007
VCAPN12
p46524
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46525
g42006
I225
sg42007
VMAP4K3
p46526
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46527
g42006
I206
sg42007
VMBNL1
p46528
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46529
g42006
I170
sg42007
VBAIAP2
p46530
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46531
g42006
I213
sg42007
VTFG
p46532
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp46533
g42006
I170
sg42007
VBAIAP2
p46534
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46535
g42006
I196
sg42007
VCPN2
p46536
sg42008
I4
sg42016
VP15538
p46537
sg42011
I1
sa(dp46538
g42006
I202
sg42007
VMYB
p46539
sg42008
I3
sg42016
VP10243
p46540
sg42011
I1
sa(dp46541
g42006
I239
sg42007
VDCP1A
p46542
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46543
g42006
I245
sg42007
VCCL27
p46544
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46545
g42006
I183
sg42007
g46495
sg42008
I5
sg42016
VP08575
p46546
sg42011
I1
sasa(dp46547
g41997
VIn addition, we found eleven potential cancer-related genes with mutations (EZH1, SPOP, NF1, TCF12, IGF2BP3, KMT2C, CNOT1, BRIP1, KDM5C, STAG2 and MAP4K3) that have not been reported in thyroid follicular tumors.
p46548
sg4
(dp46549
(VNF1
p46550
VNF1
p46551
tp46552
I00
ssg42003
(lp46553
(dp46554
g42006
I194
sg42007
Vfollicular tumors
p46555
sg42008
I17
sg42009
VC0474808
p46556
sg42011
I2
sa(dp46557
g42006
I39
sg42007
Vcancer
p46558
sg42008
I6
sg42009
VC0006826
p46559
sg42011
I1
sa(dp46560
g42006
I88
sg42007
g46551
sg42008
I3
sg42009
VC0027831
p46561
sg42011
I1
sasg42012
(lp46562
(dp46563
g42006
I123
sg42007
VBRIP1
p46564
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46565
g42006
I82
sg42007
VSPOP
p46566
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp46567
g42006
I137
sg42007
VSTAG2
p46568
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46569
g42006
I109
sg42007
VKMT2C
p46570
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46571
g42006
I130
sg42007
VKDM5C
p46572
sg42008
I5
sg42016
VP41229
p46573
sg42011
I1
sa(dp46574
g42006
I88
sg42007
g46550
sg42008
I3
sg42016
VP21359
p46575
sg42011
I1
sa(dp46576
g42006
I93
sg42007
VTCF12
p46577
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46578
g42006
I76
sg42007
VEZH1
p46579
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp46580
g42006
I147
sg42007
VMAP4K3
p46581
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46582
g42006
I100
sg42007
VIGF2BP3
p46583
sg42008
I7
sg42016
g190
sg42011
I1
sasa(dp46584
g41997
VSince GLK (also named MAP4K3) induces activation of NF-KB, which contributes to tumor progression, we investigated the role of GLK in NSCLC.
p46585
sg4
(dp46586
(VGLK
p46587
VNSCLC
p46588
tp46589
I00
ssg42003
(lp46590
(dp46591
g42006
I80
sg42007
Vtumor progression
p46592
sg42008
I17
sg42009
VC0178874
p46593
sg42011
I2
sa(dp46594
g42006
I134
sg42007
g46588
sg42008
I5
sg42009
VC0007131
p46595
sg42011
I1
sasg42012
(lp46596
(dp46597
g42006
I6
sg42007
VGLK
p46598
sg42008
I3
sg42016
VP35557
p46599
sg42011
I1
sa(dp46600
g42006
I22
sg42007
VMAP4K3
p46601
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46602
g42006
I6
sg42007
g46587
sg42008
I3
sg42016
VP35557
p46603
sg42011
I1
sasa(dp46604
g41997
VGLK protein levels of 190 samples from pulmonary tissue arrays and 58 pulmonary resection samples from stage I to stage III NSCLC patients were studied using immunohistochemistry or immunoblotting.
p46605
sg4
(dp46606
(VGLK
p46607
Vstage III NSCLC
p46608
tp46609
I00
ssg42003
(lp46610
(dp46611
g42006
I114
sg42007
g46608
sg42008
I15
sg42009
VC0278506
p46612
sg42011
I3
sasg42012
(lp46613
(dp46614
g42006
I0
sg42007
g46607
sg42008
I3
sg42016
VP35557
p46615
sg42011
I1
sasa(dp46616
g41997
VHigh levels of GLK proteins were detected in pulmonary tissues from NSCLC patients.
p46617
sg4
(dp46618
(VGLK proteins
p46619
VNSCLC
p46620
tp46621
I00
ssg42003
(lp46622
(dp46623
g42006
I68
sg42007
g46620
sg42008
I5
sg42009
VC0007131
p46624
sg42011
I1
sasg42012
(lp46625
(dp46626
g42006
I15
sg42007
g46619
sg42008
I12
sg42016
VP35557
p46627
sg42011
I2
sasa(dp46628
g41997
VElevated GLK protein levels were correlated with increased recurrence risks and poor recurrence-free survival rates in NSCLC patients after adjusting for pathologic stage, smoking status, alcohol status, and EGFR levels.
p46629
sg4
(dp46630
(VGLK protein
p46631
VNSCLC
p46632
tp46633
I00
ssg42003
(lp46634
(dp46635
g42006
I59
sg42007
Vrecurrence
p46636
sg42008
I10
sg42009
VC1458156
p46637
sg42011
I1
sa(dp46638
g42006
I59
sg42007
Vrecurrence
p46639
sg42008
I10
sg42009
VC1458156
p46640
sg42011
I1
sa(dp46641
g42006
I119
sg42007
g46632
sg42008
I5
sg42009
VC0007131
p46642
sg42011
I1
sasg42012
(lp46643
(dp46644
g42006
I9
sg42007
g46631
sg42008
I11
sg42016
VP35557
p46645
sg42011
I2
sasa(dp46646
g41997
VThus, GLK is a novel prognostic biomarker for NSCLC recurrence.
p46647
sg4
(dp46648
(VGLK
p46649
VNSCLC
p46650
tp46651
I00
ssg42003
(lp46652
(dp46653
g42006
I46
sg42007
g46650
sg42008
I5
sg42009
VC0007131
p46654
sg42011
I1
sa(dp46655
g42006
I52
sg42007
Vrecurrence
p46656
sg42008
I10
sg42009
VC1458156
p46657
sg42011
I1
sasg42012
(lp46658
(dp46659
g42006
I6
sg42007
g46649
sg42008
I3
sg42016
VP35557
p46660
sg42011
I1
sasa(dp46661
g41997
VRNA fusion-based CISs were identified corresponding to both DNA-based CISs (Cdkn2a, Mycl1, Nf2, Pten, Sema6d, and Rere) and additional regions strongly associated with cancer that were not observed by LM-PCR (Myc, Akt1, Pth, Csf1r, Fgfr2, Wisp1, Map3k5, and Map4k3).
p46662
sg4
(dp46663
(VAkt1
p46664
VNf2
p46665
tp46666
I00
ssg42003
(lp46667
(dp46668
g42006
I168
sg42007
Vcancer
p46669
sg42008
I6
sg42009
VC0006826
p46670
sg42011
I1
sa(dp46671
g42006
I91
sg42007
g46665
sg42008
I3
sg42009
VC0027832
p46672
sg42011
I1
sasg42012
(lp46673
(dp46674
g42006
I84
sg42007
VMyc
p46675
sg42008
I3
sg42016
VP12524
p46676
sg42011
I1
sa(dp46677
g42006
I258
sg42007
VMap4k3
p46678
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46679
g42006
I84
sg42007
VMycl1
p46680
sg42008
I5
sg42016
VP12524
p46681
sg42011
I1
sa(dp46682
g42006
I96
sg42007
VPten
p46683
sg42008
I4
sg42016
VP60484
p46684
sg42011
I1
sa(dp46685
g42006
I225
sg42007
VCsf1r
p46686
sg42008
I5
sg42016
VP09619
p46687
sg42011
I1
sa(dp46688
g42006
I220
sg42007
VPth
p46689
sg42008
I3
sg42016
VP01270
p46690
sg42011
I1
sa(dp46691
g42006
I76
sg42007
VCdkn2a
p46692
sg42008
I6
sg42016
VP42771
p46693
sg42011
I1
sa(dp46694
g42006
I239
sg42007
VWisp1
p46695
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46696
g42006
I17
sg42007
VCISs
p46697
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp46698
g42006
I214
sg42007
g46664
sg42008
I4
sg42016
VP31749
p46699
sg42011
I1
sa(dp46700
g42006
I246
sg42007
VMap3k5
p46701
sg42008
I6
sg42016
g190
sg42011
I1
sasa(dp46702
g41997
VComputationally, PTPRF, PRKAR2B, MAP4K3, and RICTOR were calculated as highly drug-targetable genes for breast cancer.
p46703
sg4
(dp46704
(VPTPRF
p46705
Vbreast cancer
p46706
tp46707
I00
ssg42003
(lp46708
(dp46709
g42006
I104
sg42007
g46706
sg42008
I13
sg42009
VC0678222
p46710
sg42011
I2
sasg42012
(lp46711
(dp46712
g42006
I24
sg42007
VPRKAR2B
p46713
sg42008
I7
sg42016
VP31323
p46714
sg42011
I1
sa(dp46715
g42006
I33
sg42007
VMAP4K3
p46716
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46717
g42006
I17
sg42007
g46705
sg42008
I5
sg42016
VP10586
p46718
sg42011
I1
sa(dp46719
g42006
I45
sg42007
VRICTOR
p46720
sg42008
I6
sg42016
g190
sg42011
I1
sasa(dp46721
g41997
VTreatment of MCF-7 breast cancer cells with transforming growth factor beta 1 repressed TMSB15A expression but had no effect on TMSB15B.
p46722
sg4
(dp46723
(Vtransforming growth factor beta 1
p46724
Vbreast cancer
p46725
tp46726
I00
ssg42003
(lp46727
(dp46728
g42006
I19
sg42007
g46725
sg42008
I13
sg42009
VC0678222
p46729
sg42011
I2
sasg42012
(lp46730
(dp46731
g42006
I88
sg42007
VTMSB15A
p46732
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp46733
g42006
I128
sg42007
VTMSB15B
p46734
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp46735
g42006
I44
sg42007
g46724
sg42008
I33
sg42016
VP01137
p46736
sg42011
I5
sasa(dp46737
g41997
VsiRNA specific to the TMSB15B isoform suppressed cell migration of prostate cancer cells to epidermal growth factor, suggesting a functional role for this second isoform.
p46738
sg4
(dp46739
(Vepidermal growth factor
p46740
Vprostate cancer
p46741
tp46742
I00
ssg42003
(lp46743
(dp46744
g42006
I67
sg42007
g46741
sg42008
I15
sg42009
VC0600139
p46745
sg42011
I2
sasg42012
(lp46746
(dp46747
g42006
I92
sg42007
g46740
sg42008
I23
sg42016
VP01133
p46748
sg42011
I3
sasa(dp46749
g41997
VHuman NB thymosin beta is a beta-thymosin originally found in neuroblastoma.
p46750
sg4
(dp46751
(Vbeta-thymosin
p46752
Vneuroblastoma
p46753
tp46754
I00
ssg42003
(lp46755
(dp46756
g42006
I62
sg42007
g46753
sg42008
I13
sg42009
VC0027819
p46757
sg42011
I1
sasg42012
(lp46758
(dp46759
g42006
I0
sg42007
VHuman NB thymosin beta
p46760
sg42008
I22
sg42016
VP20962
p46761
sg42011
I4
sa(dp46762
g42006
I28
sg42007
g46752
sg42008
I13
sg42016
VP20962
p46763
sg42011
I1
sasa(dp46764
g41997
VUpk1b(RFP/RFP) mice developed age-dependent progressive hydronephrosis.
p46765
sg4
(dp46766
(VRFP
p46767
Vhydronephrosis
p46768
tp46769
I00
ssg42003
(lp46770
(dp46771
g42006
I56
sg42007
g46768
sg42008
I14
sg42009
VC0020295
p46772
sg42011
I1
sasg42012
(lp46773
(dp46774
g42006
I0
sg42007
VUpk1b
p46775
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46776
g42006
I6
sg42007
VRFP
p46777
sg42008
I3
sg42016
VP25090
p46778
sg42011
I1
sa(dp46779
g42006
I6
sg42007
g46767
sg42008
I3
sg42016
VP25090
p46780
sg42011
I1
sasa(dp46781
g41997
VThe role of serotonin7 (5-HT7) receptors in the regulation of depression is poorly understood, particularly in Parkinson's disease-associated depression.
p46782
sg4
(dp46783
(Vserotonin7 (5-HT7) receptors
p46784
Vdepression
p46785
tp46786
I00
ssg42003
(lp46787
(dp46788
g42006
I62
sg42007
Vdepression
p46789
sg42008
I10
sg42009
VC0011581
p46790
sg42011
I1
sa(dp46791
g42006
I111
sg42007
VParkinson's disease
p46792
sg42008
I19
sg42009
VC0030567
p46793
sg42011
I2
sa(dp46794
g42006
I62
sg42007
g46785
sg42008
I10
sg42009
VC0011581
p46795
sg42011
I1
sasg42012
(lp46796
(dp46797
g42006
I12
sg42007
g46784
sg42008
I28
sg42016
VP34969
p46798
sg42011
I3
sasa(dp46799
g41997
VConsistently, Bhlhb2 expression was significantly higher in PFC of ADHD model SHR than control.
p46800
sg4
(dp46801
(VPFC
p46802
VADHD
p46803
tp46804
I00
ssg42003
(lp46805
(dp46806
g42006
I67
sg42007
g46803
sg42008
I4
sg42009
VC1263846
p46807
sg42011
I1
sasg42012
(lp46808
(dp46809
g42006
I67
sg42007
VADHD model SHR
p46810
sg42008
I14
sg42016
g190
sg42011
I3
sa(dp46811
g42006
I14
sg42007
VBhlhb2
p46812
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46813
g42006
I60
sg42007
g46802
sg42008
I3
sg42016
VP27918
p46814
sg42011
I1
sasa(dp46815
g41997
VWe examined ANG expression in WTs, human fetal kidney (FK) and childhood kidney (NK) samples and studied its relationship with microvascular density (MVD) and with three other hypoxia-induced angiogenic factors: lactate dehydrogenase A (LDHA), vascular endothelial growth factor (VEGFA) and BHLHE40 (basic helix-loop-helix transcription factor E40).
p46816
sg4
(dp46817
(VLDHA
p46818
VWTs
p46819
tp46820
I00
ssg42003
(lp46821
(dp46822
g42006
I176
sg42007
Vhypoxia
p46823
sg42008
I7
sg42009
VC0242184
p46824
sg42011
I1
sa(dp46825
g42006
I30
sg42007
g46819
sg42008
I3
sg42009
VC1839736
p46826
sg42011
I1
sasg42012
(lp46827
(dp46828
g42006
I244
sg42007
Vvascular endothelial growth factor
p46829
sg42008
I34
sg42016
g190
sg42011
I4
sa(dp46830
g42006
I291
sg42007
VBHLHE40
p46831
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp46832
g42006
I280
sg42007
VVEGFA
p46833
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46834
g42006
I212
sg42007
Vlactate dehydrogenase A
p46835
sg42008
I23
sg42016
VP49366
p46836
sg42011
I3
sa(dp46837
g42006
I237
sg42007
g46818
sg42008
I4
sg42016
VP00338
p46838
sg42011
I1
sa(dp46839
g42006
I300
sg42007
Vbasic helix-loop-helix transcription factor E40
p46840
sg42008
I47
sg42016
g190
sg42011
I5
sasa(dp46841
g41997
VANG, CD31, VEGFA and BHLHE40 mRNA levels were significantly lower in 15 WTs compared with matched-paired NKs.
p46842
sg4
(dp46843
(VANG
p46844
VWTs
p46845
tp46846
I00
ssg42003
(lp46847
(dp46848
g42006
I72
sg42007
g46845
sg42008
I3
sg42009
VC1839736
p46849
sg42011
I1
sasg42012
(lp46850
(dp46851
g42006
I0
sg42007
g46844
sg42008
I3
sg42016
VP03950
p46852
sg42011
I1
sa(dp46853
g42006
I5
sg42007
VCD31
p46854
sg42008
I4
sg42016
VP69905
p46855
sg42011
I1
sa(dp46856
g42006
I21
sg42007
VBHLHE40 mRNA
p46857
sg42008
I12
sg42016
g190
sg42011
I2
sasa(dp46858
g41997
VThe same technique was used for the assays of the hepatic levels of FGF-21, silent information regulator (SIRT1), malondialdehyde (MDA),IL-10, tumor necrosis factor-Alfa (TNF-Alfa) as well as the apoptotic markers; caspase-3 and B-cell lymphoma (Bcl-2).
p46859
sg4
(dp46860
(Vtumor necrosis factor-Alfa
p46861
Vtumor necrosis
p46862
tp46863
I00
ssg42003
(lp46864
(dp46865
g42006
I229
sg42007
VB-cell lymphoma
p46866
sg42008
I15
sg42009
VC0079731
p46867
sg42011
I2
sa(dp46868
g42006
I143
sg42007
g46862
sg42008
I14
sg42009
VC0333516
p46869
sg42011
I2
sasg42012
(lp46870
(dp46871
g42006
I68
sg42007
VFGF-21
p46872
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp46873
g42006
I171
sg42007
VTNF-Alfa
p46874
sg42008
I8
sg42016
VP01375
p46875
sg42011
I1
sa(dp46876
g42006
I215
sg42007
Vcaspase-3
p46877
sg42008
I9
sg42016
VP42574
p46878
sg42011
I1
sa(dp46879
g42006
I106
sg42007
VSIRT1
p46880
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp46881
g42006
I143
sg42007
g46861
sg42008
I26
sg42016
VP01375
p46882
sg42011
I3
sasa(dp46883
g41997
VWe report here the case of a 25-year-old woman with a bulbar onset ALS that progressed in less than 12 months to invasive ventilation due to respiratory failure; Genetic screening identified a new mutation in the FUS gene that lies within the last codon.
p46884
sg4
(dp46885
(VFUS gene
p46886
VALS
p46887
tp46888
I00
ssg42003
(lp46889
(dp46890
g42006
I141
sg42007
Vrespiratory failure
p46891
sg42008
I19
sg42009
VC1145670
p46892
sg42011
I2
sa(dp46893
g42006
I193
sg42007
Vnew mutation
p46894
sg42008
I12
sg42009
VC2985439
p46895
sg42011
I2
sa(dp46896
g42006
I67
sg42007
g46887
sg42008
I3
sg42009
VC0002736
p46897
sg42011
I1
sasg42012
(lp46898
(dp46899
g42006
I213
sg42007
g46886
sg42008
I8
sg42016
VP35637
p46900
sg42011
I2
sasa(dp46901
g41997
VThe expression and biological function of Grb2-associated binding 2 (Gab2) in renal cell carcinoma (RCC) cells was tested here.
p46902
sg4
(dp46903
(VGrb2-associated binding 2
p46904
VRCC
p46905
tp46906
I00
ssg42003
(lp46907
(dp46908
g42006
I78
sg42007
Vrenal cell carcinoma
p46909
sg42008
I20
sg42009
VC0007134
p46910
sg42011
I3
sa(dp46911
g42006
I100
sg42007
g46905
sg42008
I3
sg42009
VC0007134
p46912
sg42011
I1
sasg42012
(lp46913
(dp46914
g42006
I69
sg42007
VGab2
p46915
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp46916
g42006
I42
sg42007
g46904
sg42008
I25
sg42016
VP62993
p46917
sg42011
I3
sasa(dp46918
g41997
VHowever, the significance of Grb2 and Sos proteins, which is related to EGF-triggered Ras activation, has not been elucidated in human bladder cancer.
p46919
sg4
(dp46920
(VRas
p46921
Vbladder cancer
p46922
tp46923
I00
ssg42003
(lp46924
(dp46925
g42006
I135
sg42007
g46922
sg42008
I14
sg42009
VC0699885
p46926
sg42011
I2
sasg42012
(lp46927
(dp46928
g42006
I72
sg42007
VEGF
p46929
sg42008
I3
sg42016
VP01133
p46930
sg42011
I1
sa(dp46931
g42006
I29
sg42007
VGrb2
p46932
sg42008
I4
sg42016
VP62993
p46933
sg42011
I1
sa(dp46934
g42006
I86
sg42007
g46921
sg42008
I3
sg42016
VP01116
p46935
sg42011
I1
sa(dp46936
g42006
I38
sg42007
VSos proteins
p46937
sg42008
I12
sg42016
g190
sg42011
I2
sasa(dp46938
g41997
VOn the other hand, expression of Grb2 and Sos proteins was substantially increased in all human bladder cancer cell lines examined in comparison with cultured normal urothelial cells, whether codon 12 of H-ras was mutated or not.
p46939
sg4
(dp46940
(VGrb2
p46941
Vbladder cancer
p46942
tp46943
I01
ssg42003
(lp46944
(dp46945
g42006
I96
sg42007
g46942
sg42008
I14
sg42009
VC0699885
p46946
sg42011
I2
sasg42012
(lp46947
(dp46948
g42006
I42
sg42007
VSos proteins
p46949
sg42008
I12
sg42016
g190
sg42011
I2
sa(dp46950
g42006
I204
sg42007
VH-ras
p46951
sg42008
I5
sg42016
VP01112
p46952
sg42011
I1
sa(dp46953
g42006
I33
sg42007
g46941
sg42008
I4
sg42016
VP62993
p46954
sg42011
I1
sasa(dp46955
g41997
VThese results suggest that the amplification of both Grb2 and SOS proteins plays an important role in the carcinogenesis of human bladder cancer.
p46956
sg4
(dp46957
(VGrb2
p46958
Vcarcinogenesis
p46959
tp46960
I00
ssg42003
(lp46961
(dp46962
g42006
I31
sg42007
Vamplification
p46963
sg42008
I13
sg42009
VC1705759
p46964
sg42011
I1
sa(dp46965
g42006
I130
sg42007
Vbladder cancer
p46966
sg42008
I14
sg42009
VC0699885
p46967
sg42011
I2
sa(dp46968
g42006
I106
sg42007
g46959
sg42008
I14
sg42009
VC0596263
p46969
sg42011
I1
sasg42012
(lp46970
(dp46971
g42006
I62
sg42007
VSOS proteins
p46972
sg42008
I12
sg42016
g190
sg42011
I2
sa(dp46973
g42006
I53
sg42007
g46958
sg42008
I4
sg42016
VP62993
p46974
sg42011
I1
sasa(dp46975
g41997
VBased on our finding of a phosphatase-null de novo mutation in PTPRG associated with a case of sporadic schizophrenia, we used PTPRG knockout (KO) mice to model the effect of a loss-of-function mutation.
p46976
sg4
(dp46977
(VPTPRG
p46978
Vschizophrenia
p46979
tp46980
I00
ssg42003
(lp46981
(dp46982
g42006
I43
sg42007
Vde novo mutation
p46983
sg42008
I16
sg42009
VC2985439
p46984
sg42011
I3
sa(dp46985
g42006
I104
sg42007
g46979
sg42008
I13
sg42009
VC0036341
p46986
sg42011
I1
sasg42012
(lp46987
(dp46988
g42006
I63
sg42007
g46978
sg42008
I5
sg42016
VP23470
p46989
sg42011
I1
sasa(dp46990
g41997
VThe most notable behavioral consequences of PTPRG gene inactivation were reduced immobilization in the forced swim test, suggestive of some negative symptoms of schizophrenia.
p46991
sg4
(dp46992
(VPTPRG gene
p46993
Vschizophrenia
p46994
tp46995
I00
ssg42003
(lp46996
(dp46997
g42006
I161
sg42007
g46994
sg42008
I13
sg42009
VC0036341
p46998
sg42011
I1
sa(dp46999
g42006
I55
sg42007
Vinactivation
p47000
sg42008
I12
sg42009
VC0544461
p47001
sg42011
I1
sasg42012
(lp47002
(dp47003
g42006
I44
sg42007
g46993
sg42008
I10
sg42016
VP23470
p47004
sg42011
I2
sasa(dp47005
g41997
VThe subgroups significantly differed in important features, including specific working memory deficits for PTPRG (n=5); severe negative symptoms, global cognitive deficits and poor educational attainment, suggesting a developmental disorder, for SLC39A13 (n=4); slow processing speed, childhood attention deficit disorder and milder symptoms for TGM5 (n=4); and global cognitive deficits with good educational attainment suggesting neurodegeneration for ARMS/KIDINS220 (n=5).
p47006
sg4
(dp47007
(VPTPRG
p47008
VARMS
p47009
tp47010
I00
ssg42003
(lp47011
(dp47012
g42006
I432
sg42007
Vneurodegeneration
p47013
sg42008
I17
sg42009
VC0027746
p47014
sg42011
I1
sa(dp47015
g42006
I153
sg42007
Vcognitive deficits
p47016
sg42008
I18
sg42009
VC0679466
p47017
sg42011
I2
sa(dp47018
g42006
I87
sg42007
Vmemory deficits
p47019
sg42008
I15
sg42009
VC0233794
p47020
sg42011
I2
sa(dp47021
g42006
I295
sg42007
Vattention deficit disorder
p47022
sg42008
I26
sg42009
VC0339002
p47023
sg42011
I3
sa(dp47024
g42006
I153
sg42007
Vcognitive deficits
p47025
sg42008
I18
sg42009
VC0679466
p47026
sg42011
I2
sa(dp47027
g42006
I218
sg42007
Vdevelopmental disorder
p47028
sg42008
I22
sg42009
VC0008073
p47029
sg42011
I2
sa(dp47030
g42006
I454
sg42007
g47009
sg42008
I4
sg42009
VC0206655
p47031
sg42011
I1
sasg42012
(lp47032
(dp47033
g42006
I246
sg42007
VSLC39A13
p47034
sg42008
I8
sg42016
g190
sg42011
I1
sa(dp47035
g42006
I346
sg42007
VTGM5
p47036
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp47037
g42006
I107
sg42007
g47008
sg42008
I5
sg42016
VP23470
p47038
sg42011
I1
sa(dp47039
g42006
I459
sg42007
VKIDINS220
p47040
sg42008
I9
sg42016
g190
sg42011
I1
sasa(dp47041
g41997
VFirst, whole exome sequencing was conducted to identify disruptive de novo mutations in 14 complete parent-offspring trios with sporadic schizophrenia from Jerusalem, which identified 5 sporadic cases with de novo gene mutations in 5 different genes (PTPRG, TGM5, SLC39A13, BTK, CDKN3).
p47042
sg4
(dp47043
(VPTPRG
p47044
Vschizophrenia
p47045
tp47046
I00
ssg42003
(lp47047
(dp47048
g42006
I137
sg42007
g47045
sg42008
I13
sg42009
VC0036341
p47049
sg42011
I1
sasg42012
(lp47050
(dp47051
g42006
I258
sg42007
VTGM5
p47052
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp47053
g42006
I264
sg42007
VSLC39A13
p47054
sg42008
I8
sg42016
g190
sg42011
I1
sa(dp47055
g42006
I251
sg42007
g47044
sg42008
I5
sg42016
VP23470
p47056
sg42011
I1
sa(dp47057
g42006
I274
sg42007
VBTK
p47058
sg42008
I3
sg42016
g190
sg42011
I1
sasa(dp47059
g41997
VAqueous humor (AH) samples from 14 patients with presumed tuberculous uveitis (PTU), and 30 control patients were assayed for the proinflammatory cytokines interleukin IL-4, IL-12, IL-15, IL-17, interferon (IFN)-Gamma, and tumor necrosis factor (TNF)-Alfa, the immunosuppressive cytokine IL-10, and the chemokines GRO-Alfa/CXCL1, IL-8/CXCL8, MIG/CXCL9, IP-10/CXCL10 and SDF-1/CXCL12 with the use of a multiplex assay.
p47060
sg4
(dp47061
(VCXCL12
p47062
Vtumor necrosis
p47063
tp47064
I00
ssg42003
(lp47065
(dp47066
g42006
I0
sg42007
VAqueous humor
p47067
sg42008
I13
sg42009
VC0595936
p47068
sg42011
I2
sa(dp47069
g42006
I15
sg42007
VAH
p47070
sg42008
I2
sg42009
VC0595936
p47071
sg42011
I1
sa(dp47072
g42006
I58
sg42007
Vtuberculous uveitis
p47073
sg42008
I19
sg42009
VC1281935
p47074
sg42011
I2
sa(dp47075
g42006
I223
sg42007
g47063
sg42008
I14
sg42009
VC0333516
p47076
sg42011
I2
sasg42012
(lp47077
(dp47078
g42006
I342
sg42007
VMIG
p47079
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp47080
g42006
I353
sg42007
VIP-10
p47081
sg42008
I5
sg42016
VP02778
p47082
sg42011
I1
sa(dp47083
g42006
I370
sg42007
VSDF-1
p47084
sg42008
I5
sg42016
VP48061
p47085
sg42011
I1
sa(dp47086
g42006
I314
sg42007
VGRO
p47087
sg42008
I3
sg42016
VP09341
p47088
sg42011
I1
sa(dp47089
g42006
I207
sg42007
VIFN
p47090
sg42008
I3
sg42016
VP01562
p47091
sg42011
I1
sa(dp47092
g42006
I195
sg42007
Vinterferon
p47093
sg42008
I10
sg42016
VP01563
p47094
sg42011
I1
sa(dp47095
g42006
I346
sg42007
VCXCL9
p47096
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp47097
g42006
I156
sg42007
Vinterleukin IL-4
p47098
sg42008
I16
sg42016
VP05112
p47099
sg42011
I2
sa(dp47100
g42006
I223
sg42007
Vtumor necrosis factor (TNF)-Alfa
p47101
sg42008
I32
sg42016
VP01375
p47102
sg42011
I4
sa(dp47103
g42006
I181
sg42007
VIL-15
p47104
sg42008
I5
sg42016
VP40933
p47105
sg42011
I1
sa(dp47106
g42006
I359
sg42007
VCXCL10
p47107
sg42008
I6
sg42016
VP02778
p47108
sg42011
I1
sa(dp47109
g42006
I323
sg42007
VCXCL1
p47110
sg42008
I5
sg42016
VP09341
p47111
sg42011
I1
sa(dp47112
g42006
I376
sg42007
g47062
sg42008
I6
sg42016
VP48061
p47113
sg42011
I1
sasa(dp47114
g41997
VAqueous humor (AH) samples from patients with Behcet's disease (BD) (n=29), Vogt-Koyanagi-Harada (VKH) disease (n=21), and HLA-B27-associated uveitis (n=8), and 42 control patients were assayed for the neutrophil chemoattractants CXCL1/GRO-Alfa and CXCL8/IL-8 and the lymphocyte chemoattractants CXCL9/MIG, CXCL10/IP-10 and CXCL12/SDF-1 with the use of a multiplex chemokine assay.
p47115
sg4
(dp47116
(VCXCL10
p47117
VBD
p47118
tp47119
I00
ssg42003
(lp47120
(dp47121
g42006
I0
sg42007
VAqueous humor
p47122
sg42008
I13
sg42009
VC0595936
p47123
sg42011
I2
sa(dp47124
g42006
I15
sg42007
VAH
p47125
sg42008
I2
sg42009
VC0595936
p47126
sg42011
I1
sa(dp47127
g42006
I46
sg42007
VBehcet's disease
p47128
sg42008
I16
sg42009
VC0004943
p47129
sg42011
I2
sa(dp47130
g42006
I142
sg42007
Vuveitis
p47131
sg42008
I7
sg42009
VC0042164
p47132
sg42011
I1
sa(dp47133
g42006
I64
sg42007
g47118
sg42008
I2
sg42009
VC0004943
p47134
sg42011
I1
sasg42012
(lp47135
(dp47136
g42006
I331
sg42007
VSDF-1
p47137
sg42008
I5
sg42016
VP48061
p47138
sg42011
I1
sa(dp47139
g42006
I236
sg42007
VGRO
p47140
sg42008
I3
sg42016
VP09341
p47141
sg42011
I1
sa(dp47142
g42006
I314
sg42007
VIP-10
p47143
sg42008
I5
sg42016
VP02778
p47144
sg42011
I1
sa(dp47145
g42006
I296
sg42007
VCXCL9
p47146
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp47147
g42006
I324
sg42007
VCXCL12
p47148
sg42008
I6
sg42016
VP48061
p47149
sg42011
I1
sa(dp47150
g42006
I123
sg42007
VHLA-B27
p47151
sg42008
I7
sg42016
VP30486
p47152
sg42011
I1
sa(dp47153
g42006
I302
sg42007
VMIG
p47154
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp47155
g42006
I230
sg42007
VCXCL1
p47156
sg42008
I5
sg42016
VP09341
p47157
sg42011
I1
sa(dp47158
g42006
I307
sg42007
g47117
sg42008
I6
sg42016
VP02778
p47159
sg42011
I1
sasa(dp47160
g41997
VIn patients with the same disease activity, AH levels of GRO-Alfa and IP-10 were significantly higher in patients with BD than in patients with VKH disease and HLA-B27-associated uveitis (p=0.0474; p&lt;0.001, respectively).
p47161
sg4
(dp47162
(VGRO-Alfa
p47163
Vuveitis
p47164
tp47165
I00
ssg42003
(lp47166
(dp47167
g42006
I179
sg42007
g47164
sg42008
I7
sg42009
VC0042164
p47168
sg42011
I1
sasg42012
(lp47169
(dp47170
g42006
I160
sg42007
VHLA-B27
p47171
sg42008
I7
sg42016
VP30486
p47172
sg42011
I1
sa(dp47173
g42006
I70
sg42007
VIP-10
p47174
sg42008
I5
sg42016
VP02778
p47175
sg42011
I1
sa(dp47176
g42006
I57
sg42007
g47163
sg42008
I8
sg42016
VP09341
p47177
sg42011
I1
sasa(dp47178
g41997
VThese data suggest that GRO-Alfa and IP-10 are the predominant CXC chemokines involved in neutrophil and activated T lymphocyte chemoattraction in endogenous uveitis, particularly in BD.
p47179
sg4
(dp47180
(VIP-10
p47181
Vuveitis
p47182
tp47183
I00
ssg42003
(lp47184
(dp47185
g42006
I158
sg42007
g47182
sg42008
I7
sg42009
VC0042164
p47186
sg42011
I1
sasg42012
(lp47187
(dp47188
g42006
I24
sg42007
VGRO
p47189
sg42008
I3
sg42016
VP09341
p47190
sg42011
I1
sa(dp47191
g42006
I37
sg42007
g47181
sg42008
I5
sg42016
VP02778
p47192
sg42011
I1
sasa(dp47193
g41997
VThe purpose of this study was to investigate the role and regulation of the CXC chemokine GRO and the interaction between GRO and IL-8 in LPS-induced uveitis in rabbits.
p47194
sg4
(dp47195
(VGRO
p47196
Vuveitis
p47197
tp47198
I00
ssg42003
(lp47199
(dp47200
g42006
I138
sg42007
VLPS
p47201
sg42008
I3
sg42009
VC0175697
p47202
sg42011
I1
sa(dp47203
g42006
I150
sg42007
g47197
sg42008
I7
sg42009
VC0042164
p47204
sg42011
I1
sasg42012
(lp47205
(dp47206
g42006
I90
sg42007
g47196
sg42008
I3
sg42016
VP09341
p47207
sg42011
I1
sasa(dp47208
g41997
VTaken together, our results suggest that GRO is an essential mediator for neutrophil infiltration in LPS-induced uveitis in rabbits.
p47209
sg4
(dp47210
(VGRO
p47211
VLPS
p47212
tp47213
I00
ssg42003
(lp47214
(dp47215
g42006
I113
sg42007
Vuveitis
p47216
sg42008
I7
sg42009
VC0042164
p47217
sg42011
I1
sa(dp47218
g42006
I101
sg42007
g47212
sg42008
I3
sg42009
VC0175697
p47219
sg42011
I1
sa(dp47220
g42006
I85
sg42007
Vinfiltration
p47221
sg42008
I12
sg42009
VC0332448
p47222
sg42011
I1
sasg42012
(lp47223
(dp47224
g42006
I41
sg42007
g47211
sg42008
I3
sg42016
VP09341
p47225
sg42011
I1
sasa(dp47226
g41997
VNa(+)K(+)ATPase, NKCC1, and alpha-syntrophin were expressed within sensory epithelia and were unaltered in Meniere's disease specimens.
p47227
sg4
(dp47228
(VNa(+)K(+)ATPase
p47229
VMeniere's disease
p47230
tp47231
I00
ssg42003
(lp47232
(dp47233
g42006
I107
sg42007
g47230
sg42008
I17
sg42009
VC0025281
p47234
sg42011
I2
sasg42012
(lp47235
(dp47236
g42006
I17
sg42007
VNKCC1
p47237
sg42008
I5
sg42016
VP55011
p47238
sg42011
I1
sa(dp47239
g42006
I28
sg42007
Valpha-syntrophin
p47240
sg42008
I16
sg42016
g190
sg42011
I1
sa(dp47241
g42006
I0
sg42007
g47229
sg42008
I15
sg42016
VP38606
p47242
sg42011
I1
sasa(dp47243
g41997
VAlthough an elevated hemoglobin A1c (HbAc1) level is an independent predictor of worse survival in patients with both digestive cancer and diabetes mellitus, its relationship to short-term prognosis in these patients has not been addressed.
p47244
sg4
(dp47245
(VHbAc1
p47246
Vdigestive cancer
p47247
tp47248
I00
ssg42003
(lp47249
(dp47250
g42006
I139
sg42007
Vdiabetes mellitus
p47251
sg42008
I17
sg42009
VC0011849
p47252
sg42011
I2
sa(dp47253
g42006
I118
sg42007
g47247
sg42008
I16
sg42009
VC0685938
p47254
sg42011
I2
sasg42012
(lp47255
(dp47256
g42006
I37
sg42007
g47246
sg42008
I5
sg42016
VP40145
p47257
sg42011
I1
sa(dp47258
g42006
I21
sg42007
Vhemoglobin A1c
p47259
sg42008
I14
sg42016
g190
sg42011
I2
sasa(dp47260
g41997
VWe identified novel driver mutations that developed during adenoma and cancer evolution, particularly in OR1B1 (GPCR signaling pathway) for adenoma evolution, and LAMA1 (PI3K-Akt signaling pathway) and ADCY3 (FGFR signaling pathway) for CRC evolution.
p47261
sg4
(dp47262
(VADCY3
p47263
Vadenoma
p47264
tp47265
I00
ssg42003
(lp47266
(dp47267
g42006
I59
sg42007
Vadenoma
p47268
sg42008
I7
sg42009
VC0001430
p47269
sg42011
I1
sa(dp47270
g42006
I237
sg42007
VCRC
p47271
sg42008
I3
sg42009
VC1527249
p47272
sg42011
I1
sa(dp47273
g42006
I59
sg42007
g47264
sg42008
I7
sg42009
VC0001430
p47274
sg42011
I1
sa(dp47275
g42006
I71
sg42007
Vcancer
p47276
sg42008
I6
sg42009
VC0006826
p47277
sg42011
I1
sasg42012
(lp47278
(dp47279
g42006
I163
sg42007
VLAMA1
p47280
sg42008
I5
sg42016
VP25391
p47281
sg42011
I1
sa(dp47282
g42006
I175
sg42007
VAkt
p47283
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp47284
g42006
I112
sg42007
VGPCR
p47285
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp47286
g42006
I170
sg42007
VPI3K
p47287
sg42008
I4
sg42016
VP42336
p47288
sg42011
I1
sa(dp47289
g42006
I105
sg42007
VOR1B1
p47290
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp47291
g42006
I237
sg42007
VCRC
p47292
sg42008
I3
sg42016
VP31749
p47293
sg42011
I1
sa(dp47294
g42006
I202
sg42007
g47263
sg42008
I5
sg42016
VP40145
p47295
sg42011
I1
sasa(dp47296
g41997
VRecently, we provided human validation for a cooperating oncogenic role for cAMP in brain tumorigenesis when we found that SNPs in ADCY8 were correlated with glioma (brain tumor) risk in individuals with Neurofibromatosis type 1 (NF1).
p47297
sg4
(dp47298
(VNeurofibromatosis type 1
p47299
Vbrain tumorigenesis when we found that SNPs in ADCY8 were correlated with glioma
p47300
tp47301
I00
ssg42003
(lp47302
(dp47303
g42006
I230
sg42007
VNF1
p47304
sg42008
I3
sg42009
VC0027831
p47305
sg42011
I1
sa(dp47306
g42006
I84
sg42007
Vbrain tumor
p47307
sg42008
I11
sg42009
VC0006118
p47308
sg42011
I2
sa(dp47309
g42006
I204
sg42007
VNeurofibromatosis type 1
p47310
sg42008
I24
sg42009
VC0027831
p47311
sg42011
I3
sa(dp47312
g42006
I84
sg42007
g47300
sg42008
I80
sg42009
VC0006118
p47313
sg42011
I13
sasg42012
(lp47314
(dp47315
g42006
I230
sg42007
VNF1
p47316
sg42008
I3
sg42016
VP21359
p47317
sg42011
I1
sa(dp47318
g42006
I131
sg42007
VADCY8
p47319
sg42008
I5
sg42016
VP40145
p47320
sg42011
I1
sa(dp47321
g42006
I204
sg42007
g47299
sg42008
I24
sg42016
VP21359
p47322
sg42011
I3
sasa(dp47323
g41997
VHowever, the cAMP pathway is well-known to be sexually dimorphic, and SNPs in ADCY8 affected glioma risk in a sex-specific fashion, elevating the risk for females while protecting males.
p47324
sg4
(dp47325
(VADCY8
p47326
Vglioma
p47327
tp47328
I01
ssg42003
(lp47329
(dp47330
g42006
I93
sg42007
g47327
sg42008
I6
sg42009
VC0017638
p47331
sg42011
I1
sasg42012
(lp47332
(dp47333
g42006
I78
sg42007
g47326
sg42008
I5
sg42016
VP40145
p47334
sg42011
I1
sasa(dp47335
g41997
VHere, we report genetic polymorphisms in the human adenylate cyclase gene adenylate cyclase 8 (ADCY8) that correlate with glioma risk in NF1 in a sex-specific manner, elevating risk in females while reducing risk in males.
p47336
sg4
(dp47337
(VNF1
p47338
VNF1
p47339
tp47340
I00
ssg42003
(lp47341
(dp47342
g42006
I122
sg42007
Vglioma
p47343
sg42008
I6
sg42009
VC0017638
p47344
sg42011
I1
sa(dp47345
g42006
I137
sg42007
g47339
sg42008
I3
sg42009
VC0027831
p47346
sg42011
I1
sasg42012
(lp47347
(dp47348
g42006
I95
sg42007
VADCY8
p47349
sg42008
I5
sg42016
VP40145
p47350
sg42011
I1
sa(dp47351
g42006
I45
sg42007
Vhuman adenylate cyclase gene adenylate cyclase 8
p47352
sg42008
I48
sg42016
g190
sg42011
I7
sa(dp47353
g42006
I137
sg42007
g47338
sg42008
I3
sg42016
VP21359
p47354
sg42011
I1
sasa(dp47355
g41997
VOverall, our results establish a sex-specific role for cAMP regulation in human gliomagenesis, specifically identifying ADCY8 as a modifier of glioma risk in NF1.
p47356
sg4
(dp47357
(VADCY8
p47358
Vglioma
p47359
tp47360
I01
ssg42003
(lp47361
(dp47362
g42006
I158
sg42007
VNF1
p47363
sg42008
I3
sg42009
VC0027831
p47364
sg42011
I1
sa(dp47365
g42006
I80
sg42007
g47359
sg42008
I6
sg42009
VC0017638
p47366
sg42011
I1
sasg42012
(lp47367
(dp47368
g42006
I158
sg42007
VNF1
p47369
sg42008
I3
sg42016
VP21359
p47370
sg42011
I1
sa(dp47371
g42006
I120
sg42007
g47358
sg42008
I5
sg42016
VP40145
p47372
sg42011
I1
sasa(dp47373
g41997
VThe effect of insulin on the oxidative desaturation of 1-14C palmitic acid to palmitoleic acid (delta 9 desaturase) 1-14C linoleic acid to alpha-linolenic acid (delta 6 desaturase) on rat liver microsomes and 1-14C eicosa-8,11,14-trienoic acid to arachidonic acid (delta 5 desaturase) on rat liver microsomes and hepatoma tissue culture (HTC) cells was studied.
p47374
sg4
(dp47375
(Vinsulin
p47376
Vhepatoma
p47377
tp47378
I00
ssg42003
(lp47379
(dp47380
g42006
I313
sg42007
g47377
sg42008
I8
sg42009
VC0023903
p47381
sg42011
I1
sasg42012
(lp47382
(dp47383
g42006
I265
sg42007
Vdelta 5 desaturase
p47384
sg42008
I18
sg42016
VP28072
p47385
sg42011
I3
sa(dp47386
g42006
I161
sg42007
Vdelta 6 desaturase
p47387
sg42008
I18
sg42016
VP28072
p47388
sg42011
I3
sa(dp47389
g42006
I14
sg42007
g47376
sg42008
I7
sg42016
VP01308
p47390
sg42011
I1
sasa(dp47391
g41997
VMethylation of CALCA, CDH1, DAPK1, and EVX2 was more common in squamous cell carcinomas (SCC) compared to adenocarcinomas (ADC).
p47392
sg4
(dp47393
(VDAPK1
p47394
VADC
p47395
tp47396
I00
ssg42003
(lp47397
(dp47398
g42006
I89
sg42007
VSCC
p47399
sg42008
I3
sg42009
VC0007137
p47400
sg42011
I1
sa(dp47401
g42006
I63
sg42007
Vsquamous cell carcinomas
p47402
sg42008
I24
sg42009
VC0007137
p47403
sg42011
I3
sa(dp47404
g42006
I106
sg42007
Vadenocarcinomas
p47405
sg42008
I15
sg42009
VC0001418
p47406
sg42011
I1
sa(dp47407
g42006
I123
sg42007
g47395
sg42008
I3
sg42009
VC0001418
p47408
sg42011
I1
sasg42012
(lp47409
(dp47410
g42006
I39
sg42007
VEVX2
p47411
sg42008
I4
sg42016
VP55085
p47412
sg42011
I1
sa(dp47413
g42006
I22
sg42007
VCDH1
p47414
sg42008
I4
sg42016
VP12830
p47415
sg42011
I1
sa(dp47416
g42006
I28
sg42007
g47394
sg42008
I5
sg42016
VP53355
p47417
sg42011
I1
sasa(dp47418
g41997
VOverall, CALCA, DAPK, ESR1, TIMP3, APC and RAR-beta2 promoters were significantly more often hypermethylated in cancers than in controls, while adenocarcinomas were more often hypermethylated above the highest control ratio for APC, TIMP3 and RASSF1A promoters.
p47419
sg4
(dp47420
(VTIMP3
p47421
VAPC
p47422
tp47423
I00
ssg42003
(lp47424
(dp47425
g42006
I112
sg42007
Vcancers
p47426
sg42008
I7
sg42009
VC0006826
p47427
sg42011
I1
sa(dp47428
g42006
I144
sg42007
Vadenocarcinomas
p47429
sg42008
I15
sg42009
VC0001418
p47430
sg42011
I1
sa(dp47431
g42006
I35
sg42007
VAPC
p47432
sg42008
I3
sg42009
VC0033036
p47433
sg42011
I1
sa(dp47434
g42006
I35
sg42007
g47422
sg42008
I3
sg42009
VC0033036
p47435
sg42011
I1
sasg42012
(lp47436
(dp47437
g42006
I28
sg42007
VTIMP3
p47438
sg42008
I5
sg42016
VP35625
p47439
sg42011
I1
sa(dp47440
g42006
I35
sg42007
VAPC
p47441
sg42008
I3
sg42016
VP25054
p47442
sg42011
I1
sa(dp47443
g42006
I9
sg42007
VCALCA
p47444
sg42008
I5
sg42016
VP06881
p47445
sg42011
I1
sa(dp47446
g42006
I16
sg42007
VDAPK
p47447
sg42008
I4
sg42016
VP53355
p47448
sg42011
I1
sa(dp47449
g42006
I22
sg42007
VESR1
p47450
sg42008
I4
sg42016
VP03372
p47451
sg42011
I1
sa(dp47452
g42006
I43
sg42007
VRAR-beta2 promoters
p47453
sg42008
I19
sg42016
VP10276
p47454
sg42011
I2
sa(dp47455
g42006
I35
sg42007
VAPC
p47456
sg42008
I3
sg42016
VP25054
p47457
sg42011
I1
sa(dp47458
g42006
I28
sg42007
g47421
sg42008
I5
sg42016
VP35625
p47459
sg42011
I1
sasa(dp47460
g41997
VCombining 4 genes (CALCA, DAPK, ESR1 and APC) yielded a sensitivity of 89% (with all adenocarcinomas identified), equal to cytomorphology (89%) and high-risk human papilloma virus (Hr-HPV; 90%).
p47461
sg4
(dp47462
(VESR1
p47463
Vpapilloma
p47464
tp47465
I01
ssg42003
(lp47466
(dp47467
g42006
I41
sg42007
VAPC
p47468
sg42008
I3
sg42009
VC0033036
p47469
sg42011
I1
sa(dp47470
g42006
I85
sg42007
Vadenocarcinomas
p47471
sg42008
I15
sg42009
VC0001418
p47472
sg42011
I1
sa(dp47473
g42006
I164
sg42007
g47464
sg42008
I9
sg42009
VC0030354
p47474
sg42011
I1
sasg42012
(lp47475
(dp47476
g42006
I26
sg42007
VDAPK
p47477
sg42008
I4
sg42016
VP53355
p47478
sg42011
I1
sa(dp47479
g42006
I19
sg42007
VCALCA
p47480
sg42008
I5
sg42016
VP06881
p47481
sg42011
I1
sa(dp47482
g42006
I0
sg42007
VCombining 4 genes
p47483
sg42008
I17
sg42016
VP01893
p47484
sg42011
I3
sa(dp47485
g42006
I41
sg42007
VAPC
p47486
sg42008
I3
sg42016
VP25054
p47487
sg42011
I1
sa(dp47488
g42006
I32
sg42007
g47463
sg42008
I4
sg42016
VP03372
p47489
sg42011
I1
sasa(dp47490
g41997
VThe thyroid tumor was diagnosed as metastasis to the thyroid from lung adenocarcinoma, because it showed mucin production, positive immunoreactivity for carcinoembryonic antigen and negative immunoreactivities for thyroglobulin and calcitonin.
p47491
sg4
(dp47492
(Vcarcinoembryonic antigen
p47493
Vthyroid tumor
p47494
tp47495
I00
ssg42003
(lp47496
(dp47497
g42006
I66
sg42007
Vlung adenocarcinoma
p47498
sg42008
I19
sg42009
VC0152013
p47499
sg42011
I2
sa(dp47500
g42006
I4
sg42007
g47494
sg42008
I13
sg42009
VC0040136
p47501
sg42011
I2
sa(dp47502
g42006
I35
sg42007
Vmetastasis to the thyroid
p47503
sg42008
I25
sg42009
VC0347023
p47504
sg42011
I4
sasg42012
(lp47505
(dp47506
g42006
I153
sg42007
g47493
sg42008
I24
sg42016
VP40198
p47507
sg42011
I2
sa(dp47508
g42006
I214
sg42007
Vthyroglobulin
p47509
sg42008
I13
sg42016
g190
sg42011
I1
sa(dp47510
g42006
I105
sg42007
Vmucin
p47511
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp47512
g42006
I232
sg42007
Vcalcitonin
p47513
sg42008
I10
sg42016
VP06881
p47514
sg42011
I1
sasa(dp47515
g41997
VWe searched Medline for clinical trials that assessed disease-modifying drugs for relapsing-remitting multiple sclerosis published from Sept 1, 2008, to Oct 31, 2012.
p47516
sg4
(dp47517
(VOct 31
p47518
Vrelapsing-remitting multiple sclerosis
p47519
tp47520
I00
ssg42003
(lp47521
(dp47522
g42006
I82
sg42007
g47519
sg42008
I38
sg42009
VC0751967
p47523
sg42011
I3
sasg42012
(lp47524
(dp47525
g42006
I153
sg42007
g47518
sg42008
I6
sg42016
VP00480
p47526
sg42011
I2
sasa(dp47527
g41997
VFinally, we evaluated the effect of the pro-arousal neuropeptides CRF and Hcrt-1/Ox-A in NPSR-deficient mice.
p47528
sg4
(dp47529
(VHcrt-1
p47530
VCRF
p47531
tp47532
I00
ssg42003
(lp47533
(dp47534
g42006
I66
sg42007
g47531
sg42008
I3
sg42009
VC0022661
p47535
sg42011
I1
sasg42012
(lp47536
(dp47537
g42006
I74
sg42007
g47530
sg42008
I6
sg42016
VP50336
p47538
sg42011
I1
sasa(dp47539
g41997
VThe administration of CRF and Hcrt-1/Ox-A, two classic pro-arousal peptides, elicited the same effects in both NPSR(-/-) and wild type mice, ruling out the possibility that adaptive mechanisms occurring at the level of these two systems could have occurred during NPSR(-/-) development to compensate for the lack of NPSR receptors.
p47540
sg4
(dp47541
(VCRF
p47542
VCRF
p47543
tp47544
I00
ssg42003
(lp47545
(dp47546
g42006
I22
sg42007
g47543
sg42008
I3
sg42009
VC0022661
p47547
sg42011
I1
sasg42012
(lp47548
(dp47549
g42006
I30
sg42007
VHcrt-1
p47550
sg42008
I6
sg42016
VP50336
p47551
sg42011
I1
sa(dp47552
g42006
I316
sg42007
VNPSR receptors
p47553
sg42008
I14
sg42016
g190
sg42011
I2
sa(dp47554
g42006
I22
sg42007
g47542
sg42008
I3
sg42016
VP06850
p47555
sg42011
I1
sasa(dp47556
g41997
VMoreover, we demonstrated that the deletion of NPSR did not lead to compensatory changes in the vigilance-promoting effects of the CRF and Hcrt-1/Ox-A systems.
p47557
sg4
(dp47558
(VHcrt-1
p47559
VCRF
p47560
tp47561
I00
ssg42003
(lp47562
(dp47563
g42006
I131
sg42007
g47560
sg42008
I3
sg42009
VC0022661
p47564
sg42011
I1
sasg42012
(lp47565
(dp47566
g42006
I131
sg42007
VCRF
p47567
sg42008
I3
sg42016
VP06850
p47568
sg42011
I1
sa(dp47569
g42006
I139
sg42007
g47559
sg42008
I6
sg42016
VP50336
p47570
sg42011
I1
sasa(dp47571
g41997
VPrevious studies identified a variety of putative target genes from several pathways associated with DNA damage repair, chromatin remodeling complex, PI3K-AKT-mTOR signaling, Notch signaling, cell cycle checkpoint signaling, BRCA-associated complex and Fanconi's anemia susceptibility genes that could be used as biomarkers or therapeutic targets for PARP inhibition.
p47572
sg4
(dp47573
(VmTOR
p47574
VFanconi's anemia
p47575
tp47576
I01
ssg42003
(lp47577
(dp47578
g42006
I101
sg42007
VDNA damage
p47579
sg42008
I10
sg42009
VC0012860
p47580
sg42011
I2
sa(dp47581
g42006
I253
sg42007
g47575
sg42008
I16
sg42009
VC0015625
p47582
sg42011
I2
sasg42012
(lp47583
(dp47584
g42006
I155
sg42007
VAKT
p47585
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp47586
g42006
I351
sg42007
VPARP
p47587
sg42008
I4
sg42016
VP09874
p47588
sg42011
I1
sa(dp47589
g42006
I150
sg42007
VPI3K
p47590
sg42008
I4
sg42016
VP42336
p47591
sg42011
I1
sa(dp47592
g42006
I159
sg42007
g47574
sg42008
I4
sg42016
VP42345
p47593
sg42011
I1
sasa(dp47594
g41997
VHematologic toxicities, including neutropenia, thrombocytopenia, and anemia, are major adverse effects of PARP inhibitors (PARPis), but the incidence rate and overall risk has not been systematically studied.
p47595
sg4
(dp47596
(VPARP
p47597
Vanemia
p47598
tp47599
I00
ssg42003
(lp47600
(dp47601
g42006
I69
sg42007
g47598
sg42008
I6
sg42009
VC0002871
p47602
sg42011
I1
sa(dp47603
g42006
I87
sg42007
Vadverse effects
p47604
sg42008
I15
sg42009
VC0879626
p47605
sg42011
I2
sasg42012
(lp47606
(dp47607
g42006
I106
sg42007
g47597
sg42008
I4
sg42016
VP09874
p47608
sg42011
I1
sasa(dp47609
g41997
VExamples of endocrine syndromes are classical carcinoid syndrome caused by serotonin (measured in the urine as its metabolite 5-HIAA), insulinoma syndrome caused by insulin or proinsulin, Zollinger-Ellison syndrome resulting from gastrin secretion, glucagonoma syndrome caused by glucagon, WDHA syndrome caused by vasoactive intestinal peptide, or Cushing's syndrome resulting from ectopic production of adrenocorticotropic hormone or corticotropin-releasing hormone.
p47610
sg4
(dp47611
(Vadrenocorticotropic hormone
p47612
VCushing's syndrome
p47613
tp47614
I00
ssg42003
(lp47615
(dp47616
g42006
I135
sg42007
Vinsulinoma
p47617
sg42008
I10
sg42009
VC0021670
p47618
sg42011
I1
sa(dp47619
g42006
I22
sg42007
Vsyndrome
p47620
sg42008
I8
sg42009
VC0039082
p47621
sg42011
I1
sa(dp47622
g42006
I188
sg42007
VZollinger-Ellison syndrome
p47623
sg42008
I26
sg42009
VC0043515
p47624
sg42011
I2
sa(dp47625
g42006
I22
sg42007
Vsyndromes
p47626
sg42008
I9
sg42009
VC0039082
p47627
sg42011
I1
sa(dp47628
g42006
I46
sg42007
Vcarcinoid syndrome
p47629
sg42008
I18
sg42009
VC0024586
p47630
sg42011
I2
sa(dp47631
g42006
I249
sg42007
Vglucagonoma syndrome
p47632
sg42008
I20
sg42009
VC0017689
p47633
sg42011
I2
sa(dp47634
g42006
I290
sg42007
VWDHA syndrome
p47635
sg42008
I13
sg42009
VC0086768
p47636
sg42011
I2
sa(dp47637
g42006
I348
sg42007
g47613
sg42008
I18
sg42009
VC0010481
p47638
sg42011
I2
sasg42012
(lp47639
(dp47640
g42006
I230
sg42007
Vgastrin
p47641
sg42008
I7
sg42016
VP01350
p47642
sg42011
I1
sa(dp47643
g42006
I176
sg42007
Vproinsulin
p47644
sg42008
I10
sg42016
VP01308
p47645
sg42011
I1
sa(dp47646
g42006
I435
sg42007
Vcorticotropin-releasing hormone
p47647
sg42008
I31
sg42016
VP06850
p47648
sg42011
I2
sa(dp47649
g42006
I135
sg42007
Vinsulin
p47650
sg42008
I7
sg42016
VP01308
p47651
sg42011
I1
sa(dp47652
g42006
I249
sg42007
Vglucagon
p47653
sg42008
I8
sg42016
VP01275
p47654
sg42011
I1
sa(dp47655
g42006
I404
sg42007
g47612
sg42008
I27
sg42016
VP01189
p47656
sg42011
I2
sasa(dp47657
g41997
VWe have previously reported and confirmed that vasoactive intestinal peptide (VIP) is a significant stimulator of ACTH and cortisol secretion in at least some patients with Cushing's disease.
p47658
sg4
(dp47659
(Vvasoactive intestinal peptide
p47660
VCushing's disease
p47661
tp47662
I00
ssg42003
(lp47663
(dp47664
g42006
I173
sg42007
g47661
sg42008
I17
sg42009
VC0221406
p47665
sg42011
I2
sasg42012
(lp47666
(dp47667
g42006
I78
sg42007
VVIP
p47668
sg42008
I3
sg42016
VP01282
p47669
sg42011
I1
sa(dp47670
g42006
I114
sg42007
VACTH
p47671
sg42008
I4
sg42016
VP01189
p47672
sg42011
I1
sa(dp47673
g42006
I47
sg42007
g47660
sg42008
I29
sg42016
VP01282
p47674
sg42011
I3
sasa(dp47675
g41997
VWe have also found that the hormonal responses to corticotropin-releasing hormone (CRH) in VIP-responsive patients with Cushing's disease were higher than those in VIP non-responders, which suggested a linkage between the actions of CRH and VIP in this disorder.
p47676
sg4
(dp47677
(VVIP
p47678
VCushing's disease
p47679
tp47680
I00
ssg42003
(lp47681
(dp47682
g42006
I120
sg42007
g47679
sg42008
I17
sg42009
VC0221406
p47683
sg42011
I2
sasg42012
(lp47684
(dp47685
g42006
I83
sg42007
VCRH
p47686
sg42008
I3
sg42016
VP06850
p47687
sg42011
I1
sa(dp47688
g42006
I50
sg42007
Vcorticotropin-releasing hormone
p47689
sg42008
I31
sg42016
VP06850
p47690
sg42011
I2
sa(dp47691
g42006
I83
sg42007
VCRH
p47692
sg42008
I3
sg42016
VP06850
p47693
sg42011
I1
sa(dp47694
g42006
I91
sg42007
g47678
sg42008
I3
sg42016
VP01282
p47695
sg42011
I1
sasa(dp47696
g41997
VThis study is the first to demonstrate the parallel inhibition by DEX of ACTH and cortisol responses to CRH and VIP in Cushing's disease.
p47697
sg4
(dp47698
(VCRH
p47699
VCushing's disease
p47700
tp47701
I00
ssg42003
(lp47702
(dp47703
g42006
I119
sg42007
g47700
sg42008
I17
sg42009
VC0221406
p47704
sg42011
I2
sasg42012
(lp47705
(dp47706
g42006
I73
sg42007
VACTH
p47707
sg42008
I4
sg42016
VP01189
p47708
sg42011
I1
sa(dp47709
g42006
I112
sg42007
VVIP
p47710
sg42008
I3
sg42016
VP01282
p47711
sg42011
I1
sa(dp47712
g42006
I104
sg42007
g47699
sg42008
I3
sg42016
VP06850
p47713
sg42011
I1
sasa(dp47714
g41997
VOf the patients with Cushing's disease, 9 (75%) were responsive to hCRH, 5 (42%) were to VIP, and 3 (25%) were to PHM, showing significant increases in both ACTH and cortisol.
p47715
sg4
(dp47716
(VACTH
p47717
VCushing's disease
p47718
tp47719
I00
ssg42003
(lp47720
(dp47721
g42006
I21
sg42007
g47718
sg42008
I17
sg42009
VC0221406
p47722
sg42011
I2
sasg42012
(lp47723
(dp47724
g42006
I89
sg42007
VVIP
p47725
sg42008
I3
sg42016
VP01282
p47726
sg42011
I1
sa(dp47727
g42006
I157
sg42007
g47717
sg42008
I4
sg42016
VP01189
p47728
sg42011
I1
sasa(dp47729
g41997
VIn addition, in the patients with Cushing's disease the coadministration of hCRH with PHM or VIP produced additive increases in both ACTH and cortisol.
p47730
sg4
(dp47731
(VACTH
p47732
VCushing's disease
p47733
tp47734
I00
ssg42003
(lp47735
(dp47736
g42006
I34
sg42007
g47733
sg42008
I17
sg42009
VC0221406
p47737
sg42011
I2
sasg42012
(lp47738
(dp47739
g42006
I93
sg42007
VVIP
p47740
sg42008
I3
sg42016
VP01282
p47741
sg42011
I1
sa(dp47742
g42006
I133
sg42007
g47732
sg42008
I4
sg42016
VP01189
p47743
sg42011
I1
sasa(dp47744
g41997
VAbnormalities in hypothalamic-pituitary adrenal axis function were demonstrated by measuring plasma adrenocorticotropin abnormal concentrations following Vasoactive Intestinal Peptide (VIP) and Corticotropin Releasing Hormone (CRH) administration during a phase of remission of Cushing's disease in a 45-year-old female patient.
p47745
sg4
(dp47746
(VCRH
p47747
VCushing's disease
p47748
tp47749
I00
ssg42003
(lp47750
(dp47751
g42006
I278
sg42007
g47748
sg42008
I17
sg42009
VC0221406
p47752
sg42011
I2
sa(dp47753
g42006
I265
sg42007
Vremission
p47754
sg42008
I9
sg42009
VC0687702
p47755
sg42011
I1
sasg42012
(lp47756
(dp47757
g42006
I194
sg42007
VCorticotropin Releasing Hormone
p47758
sg42008
I31
sg42016
VP06850
p47759
sg42011
I3
sa(dp47760
g42006
I100
sg42007
Vadrenocorticotropin
p47761
sg42008
I19
sg42016
VP01189
p47762
sg42011
I1
sa(dp47763
g42006
I185
sg42007
VVIP
p47764
sg42008
I3
sg42016
VP01282
p47765
sg42011
I1
sa(dp47766
g42006
I154
sg42007
VVasoactive Intestinal Peptide
p47767
sg42008
I29
sg42016
VP01282
p47768
sg42011
I3
sa(dp47769
g42006
I227
sg42007
g47747
sg42008
I3
sg42016
VP06850
p47770
sg42011
I1
sasa(dp47771
g41997
VWe conclude that the study of ACTH and cortisol response to VIP and CRH may be useful in revealing Cushing's disease even during a remission phase of the disorder.
p47772
sg4
(dp47773
(VVIP
p47774
VCushing's disease
p47775
tp47776
I00
ssg42003
(lp47777
(dp47778
g42006
I131
sg42007
Vremission
p47779
sg42008
I9
sg42009
VC0687702
p47780
sg42011
I1
sa(dp47781
g42006
I99
sg42007
g47775
sg42008
I17
sg42009
VC0221406
p47782
sg42011
I2
sasg42012
(lp47783
(dp47784
g42006
I68
sg42007
VCRH
p47785
sg42008
I3
sg42016
VP06850
p47786
sg42011
I1
sa(dp47787
g42006
I30
sg42007
VACTH
p47788
sg42008
I4
sg42016
VP01189
p47789
sg42011
I1
sa(dp47790
g42006
I60
sg42007
g47774
sg42008
I3
sg42016
VP01282
p47791
sg42011
I1
sasa(dp47792
g41997
VTU alternans was investigated by MAP recordings in six normal dogs, following the administration of anthopleurin-A (AP-A), a drug shown to delay sodium inactivation and to induce bradycardia dependent long QTU, EADs, and TdP.
p47793
sg4
(dp47794
(Vbradycardia dependent long QTU, EADs
p47795
Vbradycardia
p47796
tp47797
I00
ssg42003
(lp47798
(dp47799
g42006
I179
sg42007
g47796
sg42008
I11
sg42009
VC0428977
p47800
sg42011
I1
sa(dp47801
g42006
I152
sg42007
Vinactivation
p47802
sg42008
I12
sg42009
VC0544461
p47803
sg42011
I1
sasg42012
(lp47804
(dp47805
g42006
I179
sg42007
g47795
sg42008
I36
sg42016
VP19525
p47806
sg42011
I5
sa(dp47807
g42006
I100
sg42007
Vanthopleurin-A
p47808
sg42008
I14
sg42016
g190
sg42011
I1
sa(dp47809
g42006
I116
sg42007
VAP-A
p47810
sg42008
I4
sg42016
g190
sg42011
I1
sasa(dp47811
g41997
VHere, we report that inhibition of the cell cycle-dependent kinase 9 (Cdk9) by RNA interference, or the compound flavopiridol, blocked infections with HAdV-C2/5, EKC-causing HAdV-D8/37, and progeny formation in human corneal epithelial and cancer cells.
p47812
sg4
(dp47813
(VCdk9
p47814
VEKC
p47815
tp47816
I00
ssg42003
(lp47817
(dp47818
g42006
I240
sg42007
Vcancer
p47819
sg42008
I6
sg42009
VC0006826
p47820
sg42011
I1
sa(dp47821
g42006
I135
sg42007
Vinfections
p47822
sg42008
I10
sg42009
VC0021311
p47823
sg42011
I1
sa(dp47824
g42006
I162
sg42007
g47815
sg42008
I3
sg42009
VC0014493
p47825
sg42011
I1
sasg42012
(lp47826
(dp47827
g42006
I44
sg42007
Vcycle-dependent kinase 9
p47828
sg42008
I24
sg42016
VP19525
p47829
sg42011
I3
sa(dp47830
g42006
I70
sg42007
g47814
sg42008
I4
sg42016
VP50750
p47831
sg42011
I1
sasa(dp47832
g41997
VThe study identifies Cdk9 as a postexposure drug target against adenovirus infections in vitro and suggests that the clinically tested anticancer drug flavopiridol is a candidate for treating adenoviral EKC or adenovirus emergence upon immune suppression.
p47833
sg4
(dp47834
(VCdk9
p47835
Vadenovirus
p47836
tp47837
I00
ssg42003
(lp47838
(dp47839
g42006
I64
sg42007
Vadenovirus infections
p47840
sg42008
I21
sg42009
VC0001486
p47841
sg42011
I2
sa(dp47842
g42006
I236
sg42007
Vimmune suppression
p47843
sg42008
I18
sg42009
VC1840264
p47844
sg42011
I2
sa(dp47845
g42006
I203
sg42007
VEKC
p47846
sg42008
I3
sg42009
VC0014493
p47847
sg42011
I1
sa(dp47848
g42006
I64
sg42007
g47836
sg42008
I10
sg42009
VC0001486
p47849
sg42011
I1
sasg42012
(lp47850
(dp47851
g42006
I21
sg42007
g47835
sg42008
I4
sg42016
VP50750
p47852
sg42011
I1
sasa(dp47853
g41997
VPresence of antibodies to carbamylated fetal calf serum (CarP-FCS) and fibrinogen (CarP-Fib) was determined by inhouse ELISAs among RA cases in the Leiden Early Arthritis Clinic (n=846) and in the Swedish Epidemiological Investigation of Rheumatoid Arthritis (n=1985) cohorts.
p47854
sg4
(dp47855
(VCarP-Fib
p47856
VArthritis
p47857
tp47858
I00
ssg42003
(lp47859
(dp47860
g42006
I57
sg42007
VCarP
p47861
sg42008
I4
sg42009
VC0263385
p47862
sg42011
I1
sa(dp47863
g42006
I238
sg42007
VRheumatoid Arthritis
p47864
sg42008
I20
sg42009
VC0003873
p47865
sg42011
I2
sa(dp47866
g42006
I57
sg42007
VCarP
p47867
sg42008
I4
sg42009
VC0263385
p47868
sg42011
I1
sa(dp47869
g42006
I161
sg42007
g47857
sg42008
I9
sg42009
VC0003864
p47870
sg42011
I1
sasg42012
(lp47871
(dp47872
g42006
I57
sg42007
VCarP-FCS
p47873
sg42008
I8
sg42016
VP35219
p47874
sg42011
I1
sa(dp47875
g42006
I71
sg42007
Vfibrinogen
p47876
sg42008
I10
sg42016
VP22087
p47877
sg42011
I1
sa(dp47878
g42006
I83
sg42007
g47856
sg42008
I8
sg42016
VP35219
p47879
sg42011
I1
sasa(dp47880
g41997
VTo detect the antibodies against human fibrinogen (FIB) Beta67-77 peptide and citrullinated human FIB Beta67-77 peptide in rheumatoid arthritis (RA) and examine their diagnostic values in RA.
p47881
sg4
(dp47882
(Vhuman fibrinogen
p47883
VRA
p47884
tp47885
I00
ssg42003
(lp47886
(dp47887
g42006
I123
sg42007
Vrheumatoid arthritis
p47888
sg42008
I20
sg42009
VC0003873
p47889
sg42011
I2
sa(dp47890
g42006
I145
sg42007
VRA
p47891
sg42008
I2
sg42009
VC0003873
p47892
sg42011
I1
sa(dp47893
g42006
I145
sg42007
g47884
sg42008
I2
sg42009
VC0003873
p47894
sg42011
I1
sasg42012
(lp47895
(dp47896
g42006
I92
sg42007
Vhuman FIB Beta67-77 peptide
p47897
sg42008
I27
sg42016
VP22087
p47898
sg42011
I4
sa(dp47899
g42006
I51
sg42007
VFIB
p47900
sg42008
I3
sg42016
VP22087
p47901
sg42011
I1
sa(dp47902
g42006
I56
sg42007
VBeta67-77 peptide
p47903
sg42008
I17
sg42016
g190
sg42011
I2
sa(dp47904
g42006
I33
sg42007
g47883
sg42008
I16
sg42016
VP22087
p47905
sg42011
I2
sasa(dp47906
g41997
VCBR1, DYRK1A, HMGN1, ITSN1, RCAN1, SON, TMEM50B, and TTC3 were each up-regulated two-fold in Down syndrome samples compared to normal samples; of these, SON and TTC3 were newly reported.
p47907
sg4
(dp47908
(VHMGN1
p47909
VDown syndrome
p47910
tp47911
I00
ssg42003
(lp47912
(dp47913
g42006
I93
sg42007
g47910
sg42008
I13
sg42009
VC0013080
p47914
sg42011
I2
sasg42012
(lp47915
(dp47916
g42006
I21
sg42007
VITSN1
p47917
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp47918
g42006
I40
sg42007
VTMEM50B
p47919
sg42008
I7
sg42016
VP56557
p47920
sg42011
I1
sa(dp47921
g42006
I0
sg42007
VCBR1
p47922
sg42008
I4
sg42016
VP16152
p47923
sg42011
I1
sa(dp47924
g42006
I6
sg42007
VDYRK1A
p47925
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp47926
g42006
I14
sg42007
g47909
sg42008
I5
sg42016
VP05114
p47927
sg42011
I1
sasa(dp47928
g41997
VNonchimeric polytransgenic 152F7 mice encompassing four human chromosome 21 genes (DSCR3, DSCR5, TTC3, and DYRK1A) within the Down syndrome critical region present with learning and memory impairment.
p47929
sg4
(dp47930
(VDSCR5
p47931
Vmemory impairment
p47932
tp47933
I00
ssg42003
(lp47934
(dp47935
g42006
I126
sg42007
VDown syndrome critical region
p47936
sg42008
I29
sg42009
VC1860787
p47937
sg42011
I4
sa(dp47938
g42006
I182
sg42007
g47932
sg42008
I17
sg42009
VC0233794
p47939
sg42011
I2
sasg42012
(lp47940
(dp47941
g42006
I90
sg42007
g47931
sg42008
I5
sg42016
VP57054
p47942
sg42011
I1
sa(dp47943
g42006
I107
sg42007
VDYRK1A
p47944
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp47945
g42006
I83
sg42007
VDSCR3
p47946
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp47947
g41997
VMultivariate regression analysis revealed that plasma VWF Ag level is an independent predictor of mortality in ARDS pediatric patients.
p47948
sg4
(dp47949
(Vplasma VWF Ag
p47950
VARDS
p47951
tp47952
I00
ssg42003
(lp47953
(dp47954
g42006
I111
sg42007
g47951
sg42008
I4
sg42009
VC0035222
p47955
sg42011
I1
sasg42012
(lp47956
(dp47957
g42006
I47
sg42007
g47950
sg42008
I13
sg42016
VP04275
p47958
sg42011
I3
sasa(dp47959
g41997
VPlasma VWF Ag level is an excellent predictive marker for outcome in children with ALI/ARDS.
p47960
sg4
(dp47961
(VPlasma VWF Ag
p47962
VARDS
p47963
tp47964
I00
ssg42003
(lp47965
(dp47966
g42006
I87
sg42007
g47963
sg42008
I4
sg42009
VC0035222
p47967
sg42011
I1
sasg42012
(lp47968
(dp47969
g42006
I0
sg42007
g47962
sg42008
I13
sg42016
VP04275
p47970
sg42011
I3
sasa(dp47971
g41997
VIn the multicenter study, patients with direct ARDS also had lower levels of von Willebrand factor antigen and IL-6 and IL-8, markers of endothelial injury and inflammation, respectively.
p47972
sg4
(dp47973
(Vvon Willebrand factor antigen
p47974
Vinflammation
p47975
tp47976
I00
ssg42003
(lp47977
(dp47978
g42006
I47
sg42007
VARDS
p47979
sg42008
I4
sg42009
VC0035222
p47980
sg42011
I1
sa(dp47981
g42006
I160
sg42007
g47975
sg42008
I12
sg42009
VC0021368
p47982
sg42011
I1
sasg42012
(lp47983
(dp47984
g42006
I111
sg42007
VIL-6
p47985
sg42008
I4
sg42016
VP05231
p47986
sg42011
I1
sa(dp47987
g42006
I77
sg42007
g47974
sg42008
I29
sg42016
VP04275
p47988
sg42011
I4
sasa(dp47989
g41997
VTo investigate the role of endothelial cell mediators, E-selectin (ES), intercellular adhesion molecule-1 (ICAM-1), tissue factor (TF), and von Willebrand factor (vWF), in the early phase of severe acute pancreatitis (SAP) complicated with respiratory failure [pancreatitis-associated lung injury (PALI)].
p47990
sg4
(dp47991
(Vendothelial cell mediators, E-selectin
p47992
Vacute pancreatitis
p47993
tp47994
I00
ssg42003
(lp47995
(dp47996
g42006
I86
sg42007
Vadhesion
p47997
sg42008
I8
sg42009
VC0001511
p47998
sg42011
I1
sa(dp47999
g42006
I240
sg42007
Vrespiratory failure
p48000
sg42008
I19
sg42009
VC1145670
p48001
sg42011
I2
sa(dp48002
g42006
I204
sg42007
Vpancreatitis
p48003
sg42008
I12
sg42009
VC0030305
p48004
sg42011
I1
sa(dp48005
g42006
I198
sg42007
g47993
sg42008
I18
sg42009
VC0001339
p48006
sg42011
I2
sasg42012
(lp48007
(dp48008
g42006
I72
sg42007
Vintercellular adhesion molecule-1
p48009
sg42008
I33
sg42016
VP05362
p48010
sg42011
I3
sa(dp48011
g42006
I140
sg42007
Vvon Willebrand factor
p48012
sg42008
I21
sg42016
VP04275
p48013
sg42011
I3
sa(dp48014
g42006
I163
sg42007
VvWF
p48015
sg42008
I3
sg42016
VP04275
p48016
sg42011
I1
sa(dp48017
g42006
I107
sg42007
VICAM-1
p48018
sg42008
I6
sg42016
VP05362
p48019
sg42011
I1
sa(dp48020
g42006
I27
sg42007
g47992
sg42008
I38
sg42016
VP16581
p48021
sg42011
I4
sasa(dp48022
g41997
VThus, CLC-2 may be a promising and potential novel therapeutic strategy for combating primary open-angle glaucoma.
p48023
sg4
(dp48024
(VCLC-2
p48025
Vprimary open-angle glaucoma
p48026
tp48027
I00
ssg42003
(lp48028
(dp48029
g42006
I86
sg42007
g48026
sg42008
I27
sg42009
VC0339573
p48030
sg42011
I3
sasg42012
(lp48031
(dp48032
g42006
I6
sg42007
g48025
sg42008
I5
sg42016
VP51788
p48033
sg42011
I1
sasa(dp48034
g41997
VIn type 2 diabetes mellitus (T2DM) patients, chronic kidney disease (CKD) progression may occur without detectable changes in urinary albumin excretion (UAE) rate.
p48035
sg4
(dp48036
(Valbumin
p48037
VCKD
p48038
tp48039
I01
ssg42003
(lp48040
(dp48041
g42006
I45
sg42007
Vchronic kidney disease
p48042
sg42008
I22
sg42009
VC1561643
p48043
sg42011
I3
sa(dp48044
g42006
I3
sg42007
Vtype 2 diabetes mellitus
p48045
sg42008
I24
sg42009
VC0011860
p48046
sg42011
I4
sa(dp48047
g42006
I29
sg42007
VT2DM
p48048
sg42008
I4
sg42009
VC0011860
p48049
sg42011
I1
sa(dp48050
g42006
I69
sg42007
g48038
sg42008
I3
sg42009
VC1561643
p48051
sg42011
I1
sasg42012
(lp48052
(dp48053
g42006
I134
sg42007
g48037
sg42008
I7
sg42016
VP00441
p48054
sg42011
I1
sasa(dp48055
g41997
VAssays of carboxypeptidase B-like activity and C3 in serum from patients with cystic fibrosis and appropriate control subjects failed to demonstrate a deficiency of carboxypeptidase B-like activity or a consistent increase in C3, as was suggested by Conover and associates.
p48056
sg4
(dp48057
(Vcarboxypeptidase B-like
p48058
Vdeficiency of carboxypeptidase B
p48059
tp48060
I00
ssg42003
(lp48061
(dp48062
g42006
I78
sg42007
Vcystic fibrosis
p48063
sg42008
I15
sg42009
VC0010674
p48064
sg42011
I2
sa(dp48065
g42006
I151
sg42007
g48059
sg42008
I32
sg42009
VC0398782
p48066
sg42011
I4
sasg42012
(lp48067
(dp48068
g42006
I10
sg42007
Vcarboxypeptidase B-like
p48069
sg42008
I23
sg42016
VP15086
p48070
sg42011
I2
sa(dp48071
g42006
I10
sg42007
g48058
sg42008
I23
sg42016
VP15086
p48072
sg42011
I2
sasa(dp48073
g41997
VDifferences between men and women with cystic fibrosis were apparent, in that women with cystic fibrosis had higher concentrations of both serum carboxypeptidase B-like activity and C3 than either men with cystic fibrosis or control subjects.
p48074
sg4
(dp48075
(Vserum carboxypeptidase B
p48076
Vcystic fibrosis
p48077
tp48078
I00
ssg42003
(lp48079
(dp48080
g42006
I39
sg42007
Vcystic fibrosis
p48081
sg42008
I15
sg42009
VC0010674
p48082
sg42011
I2
sa(dp48083
g42006
I39
sg42007
Vcystic fibrosis
p48084
sg42008
I15
sg42009
VC0010674
p48085
sg42011
I2
sa(dp48086
g42006
I39
sg42007
g48077
sg42008
I15
sg42009
VC0010674
p48087
sg42011
I2
sasg42012
(lp48088
(dp48089
g42006
I139
sg42007
g48076
sg42008
I24
sg42016
VP15086
p48090
sg42011
I3
sasa(dp48091
g41997
VThe properties and lysosomal distribution of the enzyme indicated that it was a carboxypeptidase B. Substrate affinity, thermolability, pH stability, the fall and rise in activity with subculture, the cyclical pattern of activity through serial passage and the level of activity were similar for the control and cystic fibrosis enzyme.
p48092
sg4
(dp48093
(Vcystic fibrosis enzyme
p48094
Vcystic fibrosis
p48095
tp48096
I00
ssg42003
(lp48097
(dp48098
g42006
I312
sg42007
g48095
sg42008
I15
sg42009
VC0010674
p48099
sg42011
I2
sasg42012
(lp48100
(dp48101
g42006
I80
sg42007
Vcarboxypeptidase B
p48102
sg42008
I18
sg42016
VP15086
p48103
sg42011
I2
sa(dp48104
g42006
I312
sg42007
g48094
sg42008
I22
sg42016
VP13569
p48105
sg42011
I3
sasa(dp48106
g41997
VIndeed, many selenoproteins have antioxidant activity which can attenuate cancer development by minimizing oxidative insult and resultant DNA damage.
p48107
sg4
(dp48108
(Vselenoproteins
p48109
VDNA damage
p48110
tp48111
I00
ssg42003
(lp48112
(dp48113
g42006
I138
sg42007
g48110
sg42008
I10
sg42009
VC0012860
p48114
sg42011
I2
sa(dp48115
g42006
I74
sg42007
Vcancer
p48116
sg42008
I6
sg42009
VC0006826
p48117
sg42011
I1
sasg42012
(lp48118
(dp48119
g42006
I13
sg42007
g48109
sg42008
I14
sg42016
VP55073
p48120
sg42011
I1
sasa(dp48121
g41997
VIn this review, we discuss what is currently known about selenoproteins in tumorigenesis with a focus on their contextual roles in cancer development, growth, and progression.
p48122
sg4
(dp48123
(Vselenoproteins
p48124
Vtumorigenesis
p48125
tp48126
I00
ssg42003
(lp48127
(dp48128
g42006
I75
sg42007
g48125
sg42008
I13
sg42009
VC0007621
p48129
sg42011
I1
sa(dp48130
g42006
I131
sg42007
Vcancer
p48131
sg42008
I6
sg42009
VC0006826
p48132
sg42011
I1
sasg42012
(lp48133
(dp48134
g42006
I57
sg42007
g48124
sg42008
I14
sg42016
VP55073
p48135
sg42011
I1
sasa(dp48136
g41997
VNew aspects of Se actions in breast cancer have emerged such as the impact of genetic polymorphisms on Se metabolism and response, new functions of selenoproteins, epigenetic modulation of gene expression, and long-term influence of early-life exposure on disease risk.
p48137
sg4
(dp48138
(Vselenoproteins
p48139
Vbreast cancer
p48140
tp48141
I00
ssg42003
(lp48142
(dp48143
g42006
I29
sg42007
g48140
sg42008
I13
sg42009
VC0678222
p48144
sg42011
I2
sasg42012
(lp48145
(dp48146
g42006
I148
sg42007
g48139
sg42008
I14
sg42016
VP55073
p48147
sg42011
I1
sasa(dp48148
g41997
VThe results suggest that decreased NPY expression in the extended amygdala might be causally linked with the depression induced following type 2 diabetes and that the antidepressant action of imipramine in diabetic mice might be mediated by NPY-NPY Y1 receptor system.
p48149
sg4
(dp48150
(VNPY-NPY Y1 receptor
p48151
Vdepression
p48152
tp48153
I00
ssg42003
(lp48154
(dp48155
g42006
I138
sg42007
Vtype 2 diabetes
p48156
sg42008
I15
sg42009
VC0011860
p48157
sg42011
I3
sa(dp48158
g42006
I109
sg42007
g48152
sg42008
I10
sg42009
VC0011581
p48159
sg42011
I1
sasg42012
(lp48160
(dp48161
g42006
I35
sg42007
VNPY
p48162
sg42008
I3
sg42016
VP25929
p48163
sg42011
I1
sa(dp48164
g42006
I241
sg42007
g48151
sg42008
I19
sg42016
VP25929
p48165
sg42011
I3
sasa(dp48166
g41997
VNumerous models of obesity and diabetes are characterized by increased central nervous system (CNS) neuropeptide Y (NPY); in fact, a single intracerebroventricular (icv) administration of NPY in lean fasted rats elevates hepatic VLDL-TG secretion and does so, in large part, via signaling through the CNS NPY Y1 receptor.
p48167
sg4
(dp48168
(Vneuropeptide Y
p48169
Vobesity
p48170
tp48171
I00
ssg42003
(lp48172
(dp48173
g42006
I31
sg42007
Vdiabetes
p48174
sg42008
I8
sg42009
VC0011849
p48175
sg42011
I1
sa(dp48176
g42006
I19
sg42007
g48170
sg42008
I7
sg42009
VC0028754
p48177
sg42011
I1
sa(dp48178
g42006
I79
sg42007
Vnervous
p48179
sg42008
I7
sg42009
VC0027769
p48180
sg42011
I1
sasg42012
(lp48181
(dp48182
g42006
I301
sg42007
VCNS NPY Y1 receptor
p48183
sg42008
I19
sg42016
VP25929
p48184
sg42011
I4
sa(dp48185
g42006
I116
sg42007
VNPY
p48186
sg42008
I3
sg42016
VP25929
p48187
sg42011
I1
sa(dp48188
g42006
I116
sg42007
VNPY
p48189
sg42008
I3
sg42016
VP25929
p48190
sg42011
I1
sa(dp48191
g42006
I100
sg42007
g48169
sg42008
I14
sg42016
VP01303
p48192
sg42011
I2
sasa(dp48193
g41997
VTo investigate the utility of 26 immunohistochemical markers (CAM 5.2, CK [cytokeratin] 7, CK20, CK17, CK19, MUC1, MUC2, MUC4, MUC5AC, MUC6, p53, DPC4/SMAD4, CDX2, pVHL [von Hippel-Lindau tumor suppressor gene protein], S100P, IMP-3 [insulin-like growth factor 2 messenger RNA binding protein 3], maspin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, PSCA [prostate stem cell antigen], MOC31, CEA [carcinoembryonic antigen], and CA19-9 [cancer antigen 19-9]) in the diagnosis of ductal adenocarcinoma of the pancreas.
p48194
sg4
(dp48195
(Vinsulin-like growth factor 2 messenger RNA binding protein 3
p48196
Vductal adenocarcinoma of the pancreas
p48197
tp48198
I00
ssg42003
(lp48199
(dp48200
g42006
I446
sg42007
Vcancer
p48201
sg42008
I6
sg42009
VC0006826
p48202
sg42011
I1
sa(dp48203
g42006
I62
sg42007
VCAM
p48204
sg42008
I3
sg42009
VC1861821
p48205
sg42011
I1
sa(dp48206
g42006
I488
sg42007
g48197
sg42008
I37
sg42009
VC1335302
p48207
sg42011
I5
sa(dp48208
g42006
I188
sg42007
Vtumor
p48209
sg42008
I5
sg42009
VC0027651
p48210
sg42011
I1
sasg42012
(lp48211
(dp48212
g42006
I135
sg42007
VMUC6
p48213
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp48214
g42006
I220
sg42007
VS100P
p48215
sg42008
I5
sg42016
VP25815
p48216
sg42011
I1
sa(dp48217
g42006
I328
sg42007
Vclaudin 18
p48218
sg42008
I10
sg42016
VP56856
p48219
sg42011
I2
sa(dp48220
g42006
I91
sg42007
VCK20
p48221
sg42008
I4
sg42016
VP35900
p48222
sg42011
I1
sa(dp48223
g42006
I151
sg42007
VSMAD4
p48224
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp48225
g42006
I158
sg42007
VCDX2
p48226
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp48227
g42006
I317
sg42007
Vclaudin 4
p48228
sg42008
I9
sg42016
g190
sg42011
I2
sa(dp48229
g42006
I227
sg42007
VIMP-3
p48230
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp48231
g42006
I115
sg42007
VMUC2
p48232
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp48233
g42006
I164
sg42007
VpVHL
p48234
sg42008
I4
sg42016
VP40337
p48235
sg42011
I1
sa(dp48236
g42006
I402
sg42007
VCEA
p48237
sg42008
I3
sg42016
VP40198
p48238
sg42011
I1
sa(dp48239
g42006
I352
sg42007
Vfascin
p48240
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp48241
g42006
I395
sg42007
VMOC31
p48242
sg42008
I5
sg42016
VP16422
p48243
sg42011
I1
sa(dp48244
g42006
I340
sg42007
Vannexin A8
p48245
sg42008
I10
sg42016
VP13928
p48246
sg42011
I2
sa(dp48247
g42006
I360
sg42007
VPSCA
p48248
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp48249
g42006
I62
sg42007
VCAM 5.2
p48250
sg42008
I7
sg42016
VP01768
p48251
sg42011
I2
sa(dp48252
g42006
I297
sg42007
Vmaspin
p48253
sg42008
I6
sg42016
VP36952
p48254
sg42011
I1
sa(dp48255
g42006
I141
sg42007
Vp53
p48256
sg42008
I3
sg42016
VP42771
p48257
sg42011
I1
sa(dp48258
g42006
I234
sg42007
g48196
sg42008
I60
sg42016
VP01308
p48259
sg42011
I9
sa(dp48260
g42006
I71
sg42007
VCK [cytokeratin] 7
p48261
sg42008
I18
sg42016
g190
sg42011
I3
sa(dp48262
g42006
I146
sg42007
VDPC4
p48263
sg42008
I4
sg42016
g190
sg42011
I1
sasa(dp48264
g41997
VClaudin 18 and annexin A8 are frequently highly overexpressed in infiltrating ductal adenocarcinomas when compared with normal reactive ducts, suggesting a role for these molecules in pancreatic ductal adenocarcinomas.
p48265
sg4
(dp48266
(VClaudin 18
p48267
Vadenocarcinomas
p48268
tp48269
I00
ssg42003
(lp48270
(dp48271
g42006
I85
sg42007
Vadenocarcinomas
p48272
sg42008
I15
sg42009
VC0001418
p48273
sg42011
I1
sa(dp48274
g42006
I85
sg42007
g48268
sg42008
I15
sg42009
VC0001418
p48275
sg42011
I1
sa(dp48276
g42006
I65
sg42007
Vinfiltrating
p48277
sg42008
I12
sg42009
VC0332448
p48278
sg42011
I1
sasg42012
(lp48279
(dp48280
g42006
I15
sg42007
Vannexin A8
p48281
sg42008
I10
sg42016
VP13928
p48282
sg42011
I2
sa(dp48283
g42006
I0
sg42007
g48267
sg42008
I10
sg42016
VP56856
p48284
sg42011
I2
sasa(dp48285
g41997
VVenous stasis (e.g., immobilization, congestive heart failure, acute myocardial infarction, obesity), hypercoagulability (e.g., malignancy, inflammatory bowel disease, hyperhomocysteinemia, protein C resistance, antithrombin III, protein C or S deficiency) and endothelial trauma (e.g., surgical trauma, venous trauma, in-dwelling venous instrumentation) are risk factors.
p48286
sg4
(dp48287
(Vantithrombin III
p48288
Vhypercoagulability
p48289
tp48290
I00
ssg42003
(lp48291
(dp48292
g42006
I0
sg42007
VVenous stasis
p48293
sg42008
I13
sg42009
VC0277919
p48294
sg42011
I2
sa(dp48295
g42006
I140
sg42007
Vinflammatory bowel disease
p48296
sg42008
I26
sg42009
VC0021390
p48297
sg42011
I3
sa(dp48298
g42006
I168
sg42007
Vhyperhomocysteinemia
p48299
sg42008
I20
sg42009
VC0598608
p48300
sg42011
I1
sa(dp48301
g42006
I37
sg42007
Vcongestive heart failure
p48302
sg42008
I24
sg42009
VC0018802
p48303
sg42011
I3
sa(dp48304
g42006
I92
sg42007
Vobesity
p48305
sg42008
I7
sg42009
VC0028754
p48306
sg42011
I1
sa(dp48307
g42006
I63
sg42007
Vacute myocardial infarction
p48308
sg42008
I27
sg42009
VC0155626
p48309
sg42011
I3
sa(dp48310
g42006
I128
sg42007
Vmalignancy
p48311
sg42008
I10
sg42009
VC0006826
p48312
sg42011
I1
sa(dp48313
g42006
I102
sg42007
g48289
sg42008
I18
sg42009
VC0398623
p48314
sg42011
I1
sasg42012
(lp48315
(dp48316
g42006
I212
sg42007
g48288
sg42008
I16
sg42016
VP05546
p48317
sg42011
I2
sa(dp48318
g42006
I190
sg42007
Vprotein C
p48319
sg42008
I9
sg42016
VP02810
p48320
sg42011
I2
sasa(dp48321
g41997
VHere we show that KIAA0793, containing substantial sequence homology with the catalytic Dbl homology domain of the faciogenital dysplasia gene product (FGD1), is a specific GEF for Cdc42.
p48322
sg4
(dp48323
(VGEF
p48324
Vfaciogenital dysplasia
p48325
tp48326
I00
ssg42003
(lp48327
(dp48328
g42006
I152
sg42007
VFGD1
p48329
sg42008
I4
sg42009
VC1859974
p48330
sg42011
I1
sa(dp48331
g42006
I115
sg42007
g48325
sg42008
I22
sg42009
VC0175701
p48332
sg42011
I2
sasg42012
(lp48333
(dp48334
g42006
I181
sg42007
VCdc42
p48335
sg42008
I5
sg42016
VP60953
p48336
sg42011
I1
sa(dp48337
g42006
I152
sg42007
VFGD1
p48338
sg42008
I4
sg42016
VP98174
p48339
sg42011
I1
sa(dp48340
g42006
I173
sg42007
g48324
sg42008
I3
sg42016
VP10911
p48341
sg42011
I1
sa(dp48342
g42006
I78
sg42007
Vcatalytic Dbl homology domain
p48343
sg42008
I29
sg42016
g190
sg42011
I4
sasa(dp48344
g41997
VThe faciogenital dysplasia gene product, FGD1, is a Dbl family member that has recently been shown to function as a CDC42-specific GEF.
p48345
sg4
(dp48346
(VCDC42-specific GEF
p48347
Vfaciogenital dysplasia
p48348
tp48349
I01
ssg42003
(lp48350
(dp48351
g42006
I41
sg42007
VFGD1
p48352
sg42008
I4
sg42009
VC1859974
p48353
sg42011
I1
sa(dp48354
g42006
I4
sg42007
g48348
sg42008
I22
sg42009
VC0175701
p48355
sg42011
I2
sasg42012
(lp48356
(dp48357
g42006
I52
sg42007
VDbl family member
p48358
sg42008
I17
sg42016
VP10911
p48359
sg42011
I3
sa(dp48360
g42006
I41
sg42007
VFGD1
p48361
sg42008
I4
sg42016
VP98174
p48362
sg42011
I1
sa(dp48363
g42006
I116
sg42007
g48347
sg42008
I18
sg42016
VP60953
p48364
sg42011
I2
sasa(dp48365
g41997
VThe majority of proteins that contain a DH (Dbl homology) domain were isolated as oncogenes in transfection assays, but two members of the DH family, FGD1 (the product of the faciogenital dysplasia or Aarskog-Scott syndrome locus) and Vav, have been shown to be essential for normal embryonic development.
p48366
sg4
(dp48367
(VFGD1
p48368
VFGD1
p48369
tp48370
I00
ssg42003
(lp48371
(dp48372
g42006
I201
sg42007
VAarskog-Scott syndrome
p48373
sg42008
I22
sg42009
VC0175701
p48374
sg42011
I2
sa(dp48375
g42006
I175
sg42007
Vfaciogenital dysplasia
p48376
sg42008
I22
sg42009
VC0175701
p48377
sg42011
I2
sa(dp48378
g42006
I150
sg42007
g48369
sg42008
I4
sg42009
VC1859974
p48379
sg42011
I1
sasg42012
(lp48380
(dp48381
g42006
I44
sg42007
VDbl
p48382
sg42008
I3
sg42016
VP10911
p48383
sg42011
I1
sa(dp48384
g42006
I235
sg42007
VVav
p48385
sg42008
I3
sg42016
VP15498
p48386
sg42011
I1
sa(dp48387
g42006
I150
sg42007
g48368
sg42008
I4
sg42016
VP98174
p48388
sg42011
I1
sasa(dp48389
g41997
VHere we have examined the role of a Dbl-like molecule, the faciogenital dysplasia gene product (FGD1), which when mutated in its Dbl homology domain, cosegregates with the developmental disease Aarskog-Scott syndrome.
p48390
sg4
(dp48391
(VFGD1
p48392
VAarskog-Scott syndrome
p48393
tp48394
I00
ssg42003
(lp48395
(dp48396
g42006
I59
sg42007
Vfaciogenital dysplasia
p48397
sg42008
I22
sg42009
VC0175701
p48398
sg42011
I2
sa(dp48399
g42006
I96
sg42007
VFGD1
p48400
sg42008
I4
sg42009
VC1859974
p48401
sg42011
I1
sa(dp48402
g42006
I194
sg42007
g48393
sg42008
I22
sg42009
VC0175701
p48403
sg42011
I2
sasg42012
(lp48404
(dp48405
g42006
I129
sg42007
VDbl homology domain
p48406
sg42008
I19
sg42016
VP10911
p48407
sg42011
I3
sa(dp48408
g42006
I36
sg42007
VDbl-like molecule
p48409
sg42008
I17
sg42016
VP10911
p48410
sg42011
I2
sa(dp48411
g42006
I96
sg42007
g48392
sg42008
I4
sg42016
VP98174
p48412
sg42011
I1
sasa(dp48413
g41997
VThe objective of this study was to determine the prognostic significance of CD163(+) cells, interleukin-10 (IL-10), and interferon-gamma (IFN-Gamma) in oral lesions associated with oral squamous cell carcinoma (OSCC).
p48414
sg4
(dp48415
(VIL-10
p48416
Vsquamous cell carcinoma
p48417
tp48418
I00
ssg42003
(lp48419
(dp48420
g42006
I186
sg42007
g48417
sg42008
I23
sg42009
VC0007137
p48421
sg42011
I3
sasg42012
(lp48422
(dp48423
g42006
I92
sg42007
Vinterleukin-10
p48424
sg42008
I14
sg42016
VP22301
p48425
sg42011
I1
sa(dp48426
g42006
I120
sg42007
Vinterferon-gamma
p48427
sg42008
I16
sg42016
VP01579
p48428
sg42011
I1
sa(dp48429
g42006
I76
sg42007
VCD163
p48430
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp48431
g42006
I138
sg42007
VIFN-Gamma
p48432
sg42008
I9
sg42016
VP01579
p48433
sg42011
I1
sa(dp48434
g42006
I108
sg42007
g48416
sg42008
I5
sg42016
VP22301
p48435
sg42011
I1
sasa(dp48436
g41997
Vbeta-defensin expression was quantitatively assessed using real-time polymerase chain reactions in OSCC and control cell lines after exposure to interleukin-1beta, tumor necrosis factor-alpha, and interferon-gamma.
p48437
sg4
(dp48438
(Vinterferon-gamma
p48439
Vtumor necrosis
p48440
tp48441
I01
ssg42003
(lp48442
(dp48443
g42006
I164
sg42007
g48440
sg42008
I14
sg42009
VC0333516
p48444
sg42011
I2
sasg42012
(lp48445
(dp48446
g42006
I0
sg42007
Vbeta-defensin
p48447
sg42008
I13
sg42016
VP59861
p48448
sg42011
I1
sa(dp48449
g42006
I145
sg42007
Vinterleukin-1beta
p48450
sg42008
I17
sg42016
VP01584
p48451
sg42011
I1
sa(dp48452
g42006
I164
sg42007
Vtumor necrosis factor-alpha
p48453
sg42008
I27
sg42016
VP01375
p48454
sg42011
I3
sa(dp48455
g42006
I197
sg42007
g48439
sg42008
I16
sg42016
VP01579
p48456
sg42011
I1
sasa(dp48457
g41997
VWe investigated the utility of J chain and MEF2B in the diagnosis of CHL, NLPHL, PMBL, T-cell/histiocyte-rich large B-cell lymphoma (TCRLBL), and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and CHL (BCLU, DLBCL/CHL) compared to OCT-2 and BOB.1.
p48458
sg4
(dp48459
(VOCT-2
p48460
Vdiffuse large B-cell lymphoma
p48461
tp48462
I01
ssg42003
(lp48463
(dp48464
g42006
I87
sg42007
VT-cell/histiocyte-rich large B-cell lymphoma
p48465
sg42008
I44
sg42009
VC1321547
p48466
sg42011
I4
sa(dp48467
g42006
I74
sg42007
VNLPHL
p48468
sg42008
I5
sg42009
VC1334968
p48469
sg42011
I1
sa(dp48470
g42006
I116
sg42007
VB-cell lymphoma
p48471
sg42008
I15
sg42009
VC0079731
p48472
sg42011
I2
sa(dp48473
g42006
I133
sg42007
VTCRLBL
p48474
sg42008
I6
sg42009
VC1321547
p48475
sg42011
I1
sa(dp48476
g42006
I214
sg42007
g48461
sg42008
I29
sg42009
VC0079744
p48477
sg42011
I4
sasg42012
(lp48478
(dp48479
g42006
I292
sg42007
VBOB.1
p48480
sg42008
I5
sg42016
VP49685
p48481
sg42011
I1
sa(dp48482
g42006
I282
sg42007
g48460
sg42008
I5
sg42016
VP09086
p48483
sg42011
I1
sasa(dp48484
g41997
VJ chain and MEF2B are highly sensitive and specific markers of NLPHL versus CHL, are particularly useful in highlighting LP cells, and, with rare exception, are of greater utility than OCT-2 and BOB.1 in differentiating CHL from NLPHL and other large B-cell lymphomas.
p48485
sg4
(dp48486
(VOCT-2
p48487
VNLPHL
p48488
tp48489
I01
ssg42003
(lp48490
(dp48491
g42006
I251
sg42007
VB-cell lymphomas
p48492
sg42008
I16
sg42009
VC0079731
p48493
sg42011
I2
sa(dp48494
g42006
I63
sg42007
VNLPHL
p48495
sg42008
I5
sg42009
VC1334968
p48496
sg42011
I1
sa(dp48497
g42006
I63
sg42007
g48488
sg42008
I5
sg42009
VC1334968
p48498
sg42011
I1
sasg42012
(lp48499
(dp48500
g42006
I12
sg42007
VMEF2B
p48501
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp48502
g42006
I195
sg42007
VBOB.1
p48503
sg42008
I5
sg42016
VP49685
p48504
sg42011
I1
sa(dp48505
g42006
I185
sg42007
g48487
sg42008
I5
sg42016
VP09086
p48506
sg42011
I1
sasa(dp48507
g41997
VWe identified several consensus differentially expressed genes and these genes were further confirmed with literature mining; at last, two genes, that is, immunoglobulin J chain and C-X-C motif chemokine ligand 17, were screened as novel gastric cancer associated genes.
p48508
sg4
(dp48509
(VC-X-C motif chemokine ligand 17
p48510
Vgastric cancer
p48511
tp48512
I00
ssg42003
(lp48513
(dp48514
g42006
I238
sg42007
g48511
sg42008
I14
sg42009
VC0024623
p48515
sg42011
I2
sasg42012
(lp48516
(dp48517
g42006
I155
sg42007
Vimmunoglobulin J chain
p48518
sg42008
I22
sg42016
VP01591
p48519
sg42011
I3
sa(dp48520
g42006
I182
sg42007
g48510
sg42008
I31
sg42016
VP55773
p48521
sg42011
I5
sasa(dp48522
g41997
VFor the transcriptome analysis, we found some genes related to Alzheimer's disease (LRP1), an insulin-like growth factor receptor (IGF2R), immunity genes (IGL family and IGJ), two genes related to inflammatory reaction (CXCL5 and CCL3), one gene related to maintenance of cellular morphology (NHS), one gene considered to be a strong apoptosis inductor (LGALS14), and several transcripts of the neuroblastoma breakpoint family (NBPF).
p48523
sg4
(dp48524
(VIGL family
p48525
Vneuroblastoma
p48526
tp48527
I00
ssg42003
(lp48528
(dp48529
g42006
I63
sg42007
VAlzheimer's disease
p48530
sg42008
I19
sg42009
VC1521724
p48531
sg42011
I2
sa(dp48532
g42006
I197
sg42007
Vinflammatory reaction
p48533
sg42008
I21
sg42009
VC0021368
p48534
sg42011
I2
sa(dp48535
g42006
I293
sg42007
VNHS
p48536
sg42008
I3
sg42009
VC0796085
p48537
sg42011
I1
sa(dp48538
g42006
I395
sg42007
g48526
sg42008
I13
sg42009
VC0027819
p48539
sg42011
I1
sasg42012
(lp48540
(dp48541
g42006
I220
sg42007
VCXCL5
p48542
sg42008
I5
sg42016
VP42830
p48543
sg42011
I1
sa(dp48544
g42006
I170
sg42007
VIGJ
p48545
sg42008
I3
sg42016
VP01591
p48546
sg42011
I1
sa(dp48547
g42006
I230
sg42007
VCCL3
p48548
sg42008
I4
sg42016
VP10147
p48549
sg42011
I1
sa(dp48550
g42006
I428
sg42007
VNBPF
p48551
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp48552
g42006
I395
sg42007
Vneuroblastoma breakpoint family
p48553
sg42008
I31
sg42016
g190
sg42011
I3
sa(dp48554
g42006
I131
sg42007
VIGF2R
p48555
sg42008
I5
sg42016
VP11717
p48556
sg42011
I1
sa(dp48557
g42006
I94
sg42007
Vinsulin-like growth factor receptor
p48558
sg42008
I35
sg42016
VP01308
p48559
sg42011
I4
sa(dp48560
g42006
I84
sg42007
VLRP1
p48561
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp48562
g42006
I155
sg42007
g48525
sg42008
I10
sg42016
VP15814
p48563
sg42011
I2
sasa(dp48564
g41997
VUsing principal components analysis, spots containing immunoglobulin J chain, apolipoprotein A-I, procollagen C-endopeptidase enhancer-1 and complement C4-A were associated with lymphoma development (P &lt; 0.0001).
p48565
sg4
(dp48566
(Vapolipoprotein A-I
p48567
Vlymphoma
p48568
tp48569
I00
ssg42003
(lp48570
(dp48571
g42006
I37
sg42007
Vspots
p48572
sg42008
I5
sg42009
VC0015230
p48573
sg42011
I1
sa(dp48574
g42006
I178
sg42007
g48568
sg42008
I8
sg42009
VC0024299
p48575
sg42011
I1
sasg42012
(lp48576
(dp48577
g42006
I54
sg42007
Vimmunoglobulin J chain
p48578
sg42008
I22
sg42016
VP01591
p48579
sg42011
I3
sa(dp48580
g42006
I98
sg42007
Vprocollagen C-endopeptidase enhancer-1
p48581
sg42008
I38
sg42016
g190
sg42011
I3
sa(dp48582
g42006
I141
sg42007
Vcomplement C4-A
p48583
sg42008
I15
sg42016
g190
sg42011
I2
sa(dp48584
g42006
I78
sg42007
g48567
sg42008
I18
sg42016
VP02647
p48585
sg42011
I2
sasa(dp48586
g41997
VExperimental models of malaria have shown that the regulatory molecules, cytotoxic T-lymphocyte attenuator-4 (CTLA-4), lymphocyte activation gene-3 (LAG-3), and programmed death-1 (PD-1) are involved in the functional impairment of T cells during infection.
p48587
sg4
(dp48588
(VPD-1
p48589
Vmalaria
p48590
tp48591
I00
ssg42003
(lp48592
(dp48593
g42006
I23
sg42007
g48590
sg42008
I7
sg42009
VC0024530
p48594
sg42011
I1
sa(dp48595
g42006
I218
sg42007
Vimpairment
p48596
sg42008
I10
sg42009
VC0684336
p48597
sg42011
I1
sa(dp48598
g42006
I247
sg42007
Vinfection
p48599
sg42008
I9
sg42009
VC0009450
p48600
sg42011
I1
sasg42012
(lp48601
(dp48602
g42006
I119
sg42007
Vlymphocyte activation gene-3
p48603
sg42008
I28
sg42016
VP05154
p48604
sg42011
I3
sa(dp48605
g42006
I110
sg42007
VCTLA-4
p48606
sg42008
I6
sg42016
VP16410
p48607
sg42011
I1
sa(dp48608
g42006
I149
sg42007
VLAG-3
p48609
sg42008
I5
sg42016
VP16949
p48610
sg42011
I1
sa(dp48611
g42006
I161
sg42007
Vprogrammed death-1
p48612
sg42008
I18
sg42016
VP18621
p48613
sg42011
I2
sa(dp48614
g42006
I73
sg42007
Vcytotoxic T-lymphocyte attenuator-4
p48615
sg42008
I35
sg42016
VP16410
p48616
sg42011
I3
sa(dp48617
g42006
I181
sg42007
g48589
sg42008
I4
sg42016
VP18621
p48618
sg42011
I1
sasa(dp48619
g41997
VWe evaluated the HLA-G 3' untranslated region (3'UTR) polymorphic sites (associated with mRNA stability and target for microRNA binding) and HLA-G tissue expression (heart, colon, and esophagus) in patients presenting Chagas disease, stratified according to the major clinical variants.
p48620
sg4
(dp48621
(VHLA-G
p48622
VChagas disease
p48623
tp48624
I00
ssg42003
(lp48625
(dp48626
g42006
I218
sg42007
g48623
sg42008
I14
sg42009
VC0041234
p48627
sg42011
I2
sasg42012
(lp48628
(dp48629
g42006
I17
sg42007
g48622
sg42008
I5
sg42016
VP17693
p48630
sg42011
I1
sasa(dp48631
g41997
VChagas disease patients exhibited differential HLA-G 3'UTR susceptibility allele/genotype/haplotype patterns, according to the major clinical variant (digestive/cardiac/mixed/indeterminate).
p48632
sg4
(dp48633
(VHLA-G 3'UTR susceptibility
p48634
VChagas disease
p48635
tp48636
I00
ssg42003
(lp48637
(dp48638
g42006
I0
sg42007
g48635
sg42008
I14
sg42009
VC0041234
p48639
sg42011
I2
sasg42012
(lp48640
(dp48641
g42006
I47
sg42007
g48634
sg42008
I26
sg42016
VP17693
p48642
sg42011
I3
sasa(dp48643
g41997
VThe C825T polymorphism (rs5443) of the Guanine Nucleotide-Binding protein subunit Beta3 (GNB3) gene has been associated with obesity, essential hypertension, atherosclerosis, coronary diseases, and cerebrovascular events, but with some sex-specific effects.
p48644
sg4
(dp48645
(VGNB3
p48646
Vessential hypertension
p48647
tp48648
I00
ssg42003
(lp48649
(dp48650
g42006
I125
sg42007
Vobesity
p48651
sg42008
I7
sg42009
VC0028754
p48652
sg42011
I1
sa(dp48653
g42006
I158
sg42007
Vatherosclerosis, coronary
p48654
sg42008
I25
sg42009
VC0010054
p48655
sg42011
I2
sa(dp48656
g42006
I134
sg42007
g48647
sg42008
I22
sg42009
VC0085580
p48657
sg42011
I2
sasg42012
(lp48658
(dp48659
g42006
I39
sg42007
VGuanine Nucleotide-Binding protein subunit Beta3
p48660
sg42008
I48
sg42016
VP09471
p48661
sg42011
I5
sa(dp48662
g42006
I89
sg42007
g48646
sg42008
I4
sg42016
VP16520
p48663
sg42011
I1
sasa(dp48664
g41997
VThe guanine nucleotide-binding protein beta polypeptide 3 (GNB3) 825T allele encodes a product that enhances the activation of heterotrimeric G proteins, which is associated with the occurrence of the splice variant GBeta3 s that could play a role in vascular reactivity and hyperproliferation of smooth muscle cells, that makes such proteins attractive candidate gene products for susceptibility to essential hypertension (EH).
p48665
sg4
(dp48666
(VGNB3
p48667
VEH
p48668
tp48669
I00
ssg42003
(lp48670
(dp48671
g42006
I400
sg42007
Vessential hypertension
p48672
sg42008
I22
sg42009
VC0085580
p48673
sg42011
I2
sa(dp48674
g42006
I424
sg42007
g48668
sg42008
I2
sg42009
VC0085580
p48675
sg42011
I1
sasg42012
(lp48676
(dp48677
g42006
I201
sg42007
Vsplice variant GBeta3 s
p48678
sg42008
I23
sg42016
VP26640
p48679
sg42011
I4
sa(dp48680
g42006
I4
sg42007
Vguanine nucleotide-binding protein beta polypeptide 3
p48681
sg42008
I53
sg42016
VP09471
p48682
sg42011
I6
sa(dp48683
g42006
I127
sg42007
Vheterotrimeric G proteins
p48684
sg42008
I25
sg42016
g190
sg42011
I3
sa(dp48685
g42006
I59
sg42007
g48667
sg42008
I4
sg42016
VP16520
p48686
sg42011
I1
sasa(dp48687
g41997
VIn our investigation of how Ang II signals are converted by the AT1R from physiological to pathological outputs, we found that the purinergic P2Y6 receptor (P2Y6R), an inflammation-inducible G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptor (GPCR), promoted Ang II-induced hypertension in mice.
p48688
sg4
(dp48689
(VAng II
p48690
Vinflammation
p48691
tp48692
I00
ssg42003
(lp48693
(dp48694
g42006
I302
sg42007
Vhypertension
p48695
sg42008
I12
sg42009
VC0020538
p48696
sg42011
I1
sa(dp48697
g42006
I168
sg42007
g48691
sg42008
I12
sg42009
VC0021368
p48698
sg42011
I1
sasg42012
(lp48699
(dp48700
g42006
I28
sg42007
VAng II
p48701
sg42008
I6
sg42016
VP01019
p48702
sg42011
I2
sa(dp48703
g42006
I64
sg42007
VAT1R
p48704
sg42008
I4
sg42016
VP30556
p48705
sg42011
I1
sa(dp48706
g42006
I271
sg42007
VGPCR
p48707
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp48708
g42006
I28
sg42007
g48690
sg42008
I6
sg42016
VP01019
p48709
sg42011
I2
sa(dp48710
g42006
I131
sg42007
Vpurinergic P2Y6 receptor
p48711
sg42008
I24
sg42016
g190
sg42011
I3
sa(dp48712
g42006
I191
sg42007
VG protein
p48713
sg42008
I9
sg42016
g190
sg42011
I2
sasa(dp48714
g41997
VWe identified the role of regulator of G protein (heterotrimeric guanine nucleotide-binding protein) signaling 5 (RGS5) in blood pressure regulation during pregnancy and preeclampsia.
p48715
sg4
(dp48716
(Vheterotrimeric guanine nucleotide-binding protein
p48717
Vpreeclampsia
p48718
tp48719
I00
ssg42003
(lp48720
(dp48721
g42006
I170
sg42007
g48718
sg42008
I12
sg42009
VC0032914
p48722
sg42011
I1
sasg42012
(lp48723
(dp48724
g42006
I114
sg42007
VRGS5
p48725
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp48726
g42006
I39
sg42007
VG protein
p48727
sg42008
I9
sg42016
g190
sg42011
I2
sa(dp48728
g42006
I50
sg42007
g48717
sg42008
I49
sg42016
VP09471
p48729
sg42011
I4
sasa(dp48730
g41997
VTo evaluate the prognostic significance of PSA nadir (nPSA) and the time to nadir in disease free of recurrence (DFR) in localized carcinoma of prostate treated with radical radiotherapy (RTR).
p48731
sg4
(dp48732
(VPSA nadir
p48733
VPSA
p48734
tp48735
I00
ssg42003
(lp48736
(dp48737
g42006
I101
sg42007
Vrecurrence
p48738
sg42008
I10
sg42009
VC1458156
p48739
sg42011
I1
sa(dp48740
g42006
I131
sg42007
Vcarcinoma of prostate
p48741
sg42008
I21
sg42009
VC0600139
p48742
sg42011
I3
sa(dp48743
g42006
I43
sg42007
g48734
sg42008
I3
sg42009
VC1519176
p48744
sg42011
I1
sasg42012
(lp48745
(dp48746
g42006
I43
sg42007
g48733
sg42008
I9
sg42016
VP55786
p48747
sg42011
I2
sasa(dp48748
g41997
VThe present study was aimed to determine the effect of steviol on PC1, CFTR, and Beta-catenin levels in renal epithelial cells with defective PC1 biogenesis and expression (Prkcsh-/- cell) and postnatal Pkd1 homozygous cell (Pkd1-/- cells).
p48749
sg4
(dp48750
(VPC1
p48751
VPC1
p48752
tp48753
I00
ssg42003
(lp48754
(dp48755
g42006
I203
sg42007
VPkd1
p48756
sg42008
I4
sg42009
VC3149841
p48757
sg42011
I1
sa(dp48758
g42006
I203
sg42007
VPkd1
p48759
sg42008
I4
sg42009
VC3149841
p48760
sg42011
I1
sa(dp48761
g42006
I66
sg42007
VPC1
p48762
sg42008
I3
sg42009
VC1706595
p48763
sg42011
I1
sa(dp48764
g42006
I66
sg42007
g48752
sg42008
I3
sg42009
VC1706595
p48765
sg42011
I1
sasg42012
(lp48766
(dp48767
g42006
I71
sg42007
VCFTR
p48768
sg42008
I4
sg42016
VP13569
p48769
sg42011
I1
sa(dp48770
g42006
I203
sg42007
VPkd1 homozygous cell
p48771
sg42008
I20
sg42016
VP98161
p48772
sg42011
I3
sa(dp48773
g42006
I203
sg42007
VPkd1
p48774
sg42008
I4
sg42016
VP98161
p48775
sg42011
I1
sa(dp48776
g42006
I81
sg42007
VBeta-catenin
p48777
sg42008
I12
sg42016
VP35222
p48778
sg42011
I1
sa(dp48779
g42006
I66
sg42007
g48751
sg42008
I3
sg42016
VP98161
p48780
sg42011
I1
sasa(dp48781
g41997
VUsing western blot analysis, it was found that steviol treatment at 100myM for 24-48h substantially enhanced and stabilized PC1 C-terminal expression, while decreasing CFTR and Beta-catenin protein expression in both Prkcsh-/- and Pkd1-/- cells.
p48782
sg4
(dp48783
(VBeta-catenin protein
p48784
VPC1
p48785
tp48786
I00
ssg42003
(lp48787
(dp48788
g42006
I231
sg42007
VPkd1
p48789
sg42008
I4
sg42009
VC3149841
p48790
sg42011
I1
sa(dp48791
g42006
I124
sg42007
g48785
sg42008
I3
sg42009
VC1706595
p48792
sg42011
I1
sasg42012
(lp48793
(dp48794
g42006
I231
sg42007
VPkd1
p48795
sg42008
I4
sg42016
VP98161
p48796
sg42011
I1
sa(dp48797
g42006
I124
sg42007
VPC1 C
p48798
sg42008
I5
sg42016
VP98161
p48799
sg42011
I2
sa(dp48800
g42006
I168
sg42007
VCFTR
p48801
sg42008
I4
sg42016
VP13569
p48802
sg42011
I1
sa(dp48803
g42006
I177
sg42007
g48784
sg42008
I20
sg42016
VP35222
p48804
sg42011
I2
sasa(dp48805
g41997
VKPT-9274 can attenuate cellular proliferation and induce apoptosis associated with a decrease in active (phosphorylated) PAK4 and Beta-catenin in several Pkd1-null murine cell lines, with a less pronounced effect on the corresponding phenotypically normal cells.
p48806
sg4
(dp48807
(VPkd1-null
p48808
Vcellular proliferation
p48809
tp48810
I00
ssg42003
(lp48811
(dp48812
g42006
I154
sg42007
VPkd1
p48813
sg42008
I4
sg42009
VC3149841
p48814
sg42011
I1
sa(dp48815
g42006
I23
sg42007
g48809
sg42008
I22
sg42009
VC0020507
p48816
sg42011
I2
sasg42012
(lp48817
(dp48818
g42006
I130
sg42007
VBeta-catenin
p48819
sg42008
I12
sg42016
VP35222
p48820
sg42011
I1
sa(dp48821
g42006
I121
sg42007
VPAK4
p48822
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp48823
g42006
I154
sg42007
g48808
sg42008
I9
sg42016
VP98161
p48824
sg42011
I1
sasa(dp48825
g41997
VGiven the fundamental role of Beta-catenin signaling in intestinal epithelial cell proliferation and the growth-promoting function of protein kinase D1 (PKD1) in these cells, we hypothesized that PKDs mediate cross talk with Beta-catenin signaling.
p48826
sg4
(dp48827
(VPKD1
p48828
VPKD1
p48829
tp48830
I00
ssg42003
(lp48831
(dp48832
g42006
I134
sg42007
Vprotein kinase D1
p48833
sg42008
I17
sg42009
VC3149841
p48834
sg42011
I3
sa(dp48835
g42006
I83
sg42007
Vproliferation
p48836
sg42008
I13
sg42009
VC0334094
p48837
sg42011
I1
sa(dp48838
g42006
I153
sg42007
g48829
sg42008
I4
sg42009
VC3149841
p48839
sg42011
I1
sasg42012
(lp48840
(dp48841
g42006
I134
sg42007
Vprotein kinase D1
p48842
sg42008
I17
sg42016
g190
sg42011
I3
sa(dp48843
g42006
I30
sg42007
VBeta-catenin
p48844
sg42008
I12
sg42016
VP35222
p48845
sg42011
I1
sa(dp48846
g42006
I196
sg42007
VPKDs
p48847
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp48848
g42006
I30
sg42007
VBeta-catenin
p48849
sg42008
I12
sg42016
VP35222
p48850
sg42011
I1
sa(dp48851
g42006
I153
sg42007
g48828
sg42008
I4
sg42016
VP98161
p48852
sg42011
I1
sasa(dp48853
g41997
VGPCR stimulation also induced the formation of a complex between PKD1 and Beta-catenin, as shown by coimmunoprecipitation that depended on PKD1 catalytic activation, as it was abrogated by cell treatment with PKD family inhibitors.
p48854
sg4
(dp48855
(VPKD1
p48856
VPKD1
p48857
tp48858
I00
ssg42003
(lp48859
(dp48860
g42006
I65
sg42007
VPKD
p48861
sg42008
I3
sg42009
VC1868682
p48862
sg42011
I1
sa(dp48863
g42006
I65
sg42007
VPKD1
p48864
sg42008
I4
sg42009
VC3149841
p48865
sg42011
I1
sa(dp48866
g42006
I65
sg42007
g48857
sg42008
I4
sg42009
VC3149841
p48867
sg42011
I1
sasg42012
(lp48868
(dp48869
g42006
I74
sg42007
VBeta-catenin
p48870
sg42008
I12
sg42016
VP35222
p48871
sg42011
I1
sa(dp48872
g42006
I209
sg42007
VPKD family
p48873
sg42008
I10
sg42016
VP98161
p48874
sg42011
I2
sa(dp48875
g42006
I0
sg42007
VGPCR
p48876
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp48877
g42006
I65
sg42007
VPKD1
p48878
sg42008
I4
sg42016
VP98161
p48879
sg42011
I1
sa(dp48880
g42006
I65
sg42007
g48856
sg42008
I4
sg42016
VP98161
p48881
sg42011
I1
sasa(dp48882
g41997
VUsing transgenic mice that express elevated PKD1 protein in the intestinal epithelium, we detected a marked increase in the localization of Beta-catenin in the nucleus of crypt epithelial cells in the ileum of PKD1 transgenic mice, compared with nontransgenic littermates.
p48883
sg4
(dp48884
(VPKD1 protein
p48885
VPKD1
p48886
tp48887
I00
ssg42003
(lp48888
(dp48889
g42006
I44
sg42007
VPKD1
p48890
sg42008
I4
sg42009
VC3149841
p48891
sg42011
I1
sa(dp48892
g42006
I44
sg42007
g48886
sg42008
I4
sg42009
VC3149841
p48893
sg42011
I1
sasg42012
(lp48894
(dp48895
g42006
I44
sg42007
VPKD1
p48896
sg42008
I4
sg42016
VP98161
p48897
sg42011
I1
sa(dp48898
g42006
I140
sg42007
VBeta-catenin
p48899
sg42008
I12
sg42016
VP35222
p48900
sg42011
I1
sa(dp48901
g42006
I44
sg42007
g48885
sg42008
I12
sg42016
VP98161
p48902
sg42011
I2
sasa(dp48903
g41997
VPachyonychia congenita subjects were sampled who exhibited a mutation in KRT6A, KRT6B, KRT6C, KRT16 or KRT17, and the proteins were digested and analyzed by tandem mass spectrometry.
p48904
sg4
(dp48905
(VKRT6B
p48906
VPachyonychia congenita
p48907
tp48908
I00
ssg42003
(lp48909
(dp48910
g42006
I0
sg42007
g48907
sg42008
I22
sg42009
VC0265334
p48911
sg42011
I2
sasg42012
(lp48912
(dp48913
g42006
I73
sg42007
VKRT6A
p48914
sg42008
I5
sg42016
VP02538
p48915
sg42011
I1
sa(dp48916
g42006
I94
sg42007
VKRT16
p48917
sg42008
I5
sg42016
VP08779
p48918
sg42011
I1
sa(dp48919
g42006
I87
sg42007
VKRT6C
p48920
sg42008
I5
sg42016
VP48668
p48921
sg42011
I1
sa(dp48922
g42006
I80
sg42007
g48906
sg42008
I5
sg42016
VP08779
p48923
sg42011
I1
sasa(dp48924
g41997
VWe thus performed extensive biomarker measures in these compartments using univariate and multivariate approaches to correlate disease biomarkers with SCORAD and with a combined hyperplasia score [thickness and keratin 16 (K16) mRNA] at baseline and after cyclosporine A treatment in 25 moderate to severe AD patients.
p48925
sg4
(dp48926
(Vkeratin 16
p48927
Vhyperplasia
p48928
tp48929
I00
ssg42003
(lp48930
(dp48931
g42006
I178
sg42007
g48928
sg42008
I11
sg42009
VC0020507
p48932
sg42011
I1
sasg42012
(lp48933
(dp48934
g42006
I223
sg42007
VK16
p48935
sg42008
I3
sg42016
VP04264
p48936
sg42011
I1
sa(dp48937
g42006
I211
sg42007
g48927
sg42008
I10
sg42016
VP04264
p48938
sg42011
I2
sasa(dp48939
g41997
VIn addition to increased abundance, KRT16 demonstrated autoantigenicity, since sera from both fracture mice and CRPS patients showed increased autoantibody binding to recombinant kRT16 protein.
p48940
sg4
(dp48941
(VKRT16
p48942
VCRPS
p48943
tp48944
I00
ssg42003
(lp48945
(dp48946
g42006
I112
sg42007
g48943
sg42008
I4
sg42009
VC0458219
p48947
sg42011
I1
sasg42012
(lp48948
(dp48949
g42006
I167
sg42007
Vrecombinant kRT16 protein
p48950
sg42008
I25
sg42016
VP08779
p48951
sg42011
I3
sa(dp48952
g42006
I36
sg42007
g48942
sg42008
I5
sg42016
VP08779
p48953
sg42011
I1
sasa(dp48954
g41997
VThe identification of autoantibodies against KRT16 as a biomarker in mice and in humans is a critical step towards these goals, and towards redefining CRPS as having an autoimmune etiology.
p48955
sg4
(dp48956
(VKRT16
p48957
VCRPS
p48958
tp48959
I00
ssg42003
(lp48960
(dp48961
g42006
I169
sg42007
Vautoimmune
p48962
sg42008
I10
sg42009
VC0443146
p48963
sg42011
I1
sa(dp48964
g42006
I151
sg42007
g48958
sg42008
I4
sg42009
VC0458219
p48965
sg42011
I1
sasg42012
(lp48966
(dp48967
g42006
I45
sg42007
g48957
sg42008
I5
sg42016
VP08779
p48968
sg42011
I1
sasa(dp48969
g41997
VThese findings were associated with upregulation of mitochondrial Bak and Bcl-2/Bcl-xL, proapoptotic and prosurvival members in the Bcl-2 family, respectively, as well as increased mitochondrial cytochrome c release, caspase activation, and apoptosis in pancreatitis in PKCEpsilon knockout mice.
p48970
sg4
(dp48971
(VBcl-2 family
p48972
Vpancreatitis
p48973
tp48974
I00
ssg42003
(lp48975
(dp48976
g42006
I254
sg42007
g48973
sg42008
I12
sg42009
VC0030305
p48977
sg42011
I1
sasg42012
(lp48978
(dp48979
g42006
I181
sg42007
Vmitochondrial cytochrome c release
p48980
sg42008
I34
sg42016
VP99999
p48981
sg42011
I4
sa(dp48982
g42006
I66
sg42007
VBak
p48983
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp48984
g42006
I80
sg42007
VBcl-xL
p48985
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp48986
g42006
I74
sg42007
VBcl-2
p48987
sg42008
I5
sg42016
VP10415
p48988
sg42011
I1
sa(dp48989
g42006
I217
sg42007
Vcaspase
p48990
sg42008
I7
sg42016
VP39880
p48991
sg42011
I1
sa(dp48992
g42006
I132
sg42007
g48972
sg42008
I12
sg42016
VP10415
p48993
sg42011
I2
sasa(dp48994
g41997
VWe then microinjected a GABAA receptor antagonist, an inhibitor of lactate transport (4CIN), or an inhibitor of lactate dehydrogenase, oxamate (OX), into the VMH prior to inducing hypoglycemia.
p48995
sg4
(dp48996
(Vlactate dehydrogenase
p48997
Vhypoglycemia
p48998
tp48999
I00
ssg42003
(lp49000
(dp49001
g42006
I180
sg42007
g48998
sg42008
I12
sg42009
VC0020615
p49002
sg42011
I1
sasg42012
(lp49003
(dp49004
g42006
I24
sg42007
VGABAA receptor
p49005
sg42008
I14
sg42016
g190
sg42011
I2
sa(dp49006
g42006
I112
sg42007
g48997
sg42008
I21
sg42016
VP49366
p49007
sg42011
I2
sasa(dp49008
g41997
VMechanistically, we show that the protective effect of IL-22 on pancreatitis was mediated via the induction of Bcl-2 and Bcl-X(L), which bind to Beclin-1 and subsequently inhibit autophagosome formation to ameliorate pancreatitis.
p49009
sg4
(dp49010
(VBcl-2
p49011
Vpancreatitis
p49012
tp49013
I00
ssg42003
(lp49014
(dp49015
g42006
I64
sg42007
Vpancreatitis
p49016
sg42008
I12
sg42009
VC0030305
p49017
sg42011
I1
sa(dp49018
g42006
I64
sg42007
g49012
sg42008
I12
sg42009
VC0030305
p49019
sg42011
I1
sasg42012
(lp49020
(dp49021
g42006
I111
sg42007
g49011
sg42008
I5
sg42016
VP10415
p49022
sg42011
I1
sa(dp49023
g42006
I55
sg42007
VIL-22
p49024
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp49025
g42006
I145
sg42007
VBeclin-1
p49026
sg42008
I8
sg42016
g190
sg42011
I1
sa(dp49027
g42006
I121
sg42007
VBcl-X(L)
p49028
sg42008
I8
sg42016
g190
sg42011
I1
sasa(dp49029
g41997
VWe used genetically modified rat models to investigate the role of MYL4 in atrial cardiomyopathy.
p49030
sg4
(dp49031
(VMYL4
p49032
Vcardiomyopathy
p49033
tp49034
I00
ssg42003
(lp49035
(dp49036
g42006
I82
sg42007
g49033
sg42008
I14
sg42009
VC0878544
p49037
sg42011
I1
sasg42012
(lp49038
(dp49039
g42006
I67
sg42007
g49032
sg42008
I4
sg42016
VP12829
p49040
sg42011
I1
sasa(dp49041
g41997
VExome sequencing and systematic bioinformatic analyses identified a rare missense variant of MYL4 (c.31G&gt;A [p.E11K]) in a large multiplex atrial cardiomyopathy family pedigree.
p49042
sg4
(dp49043
(VMYL4
p49044
Vcardiomyopathy
p49045
tp49046
I00
ssg42003
(lp49047
(dp49048
g42006
I148
sg42007
g49045
sg42008
I14
sg42009
VC0878544
p49049
sg42011
I1
sasg42012
(lp49050
(dp49051
g42006
I93
sg42007
g49044
sg42008
I4
sg42016
VP12829
p49052
sg42011
I1
sasa(dp49053
g41997
VMYL4 knockout rats showed a similar atrial cardiomyopathy phenotype, whereas rats with an adjacent 4-amino-acid deletion showed no phenotype.
p49054
sg4
(dp49055
(VMYL4
p49056
Vcardiomyopathy
p49057
tp49058
I00
ssg42003
(lp49059
(dp49060
g42006
I43
sg42007
g49057
sg42008
I14
sg42009
VC0878544
p49061
sg42011
I1
sasg42012
(lp49062
(dp49063
g42006
I0
sg42007
g49056
sg42008
I4
sg42016
VP12829
p49064
sg42011
I1
sasa(dp49065
g41997
VLoss-of-function MYL4 gene variants cause progressive atrial cardiomyopathy in humans and rats.
p49066
sg4
(dp49067
(VMYL4 gene variants
p49068
Vcardiomyopathy
p49069
tp49070
I00
ssg42003
(lp49071
(dp49072
g42006
I61
sg42007
g49069
sg42008
I14
sg42009
VC0878544
p49073
sg42011
I1
sasg42012
(lp49074
(dp49075
g42006
I17
sg42007
g49068
sg42008
I18
sg42016
VP12829
p49076
sg42011
I3
sasa(dp49077
g41997
VGenome-wide association studies (GWAS) have yielded variants at &gt;30 loci that associate with atrial fibrillation (AF), including rare coding mutations in the sarcomere genes MYH6 and MYL4.
p49078
sg4
(dp49079
(VMYH6
p49080
VAF
p49081
tp49082
I00
ssg42003
(lp49083
(dp49084
g42006
I96
sg42007
Vatrial fibrillation
p49085
sg42008
I19
sg42009
VC0004238
p49086
sg42011
I2
sa(dp49087
g42006
I117
sg42007
g49081
sg42008
I2
sg42009
VC0004238
p49088
sg42011
I1
sasg42012
(lp49089
(dp49090
g42006
I186
sg42007
VMYL4
p49091
sg42008
I4
sg42016
VP12829
p49092
sg42011
I1
sa(dp49093
g42006
I177
sg42007
g49080
sg42008
I4
sg42016
VP13533
p49094
sg42011
I1
sasa(dp49095
g41997
VWe imputed these variants into 104,220 individuals down to a minor allele frequency of 0.1% and found a recessive frameshift mutation in MYL4 that causes early-onset atrial fibrillation, several mutations in ABCB4 that increase risk of liver diseases and an intronic variant in GNAS associating with increased thyroid-stimulating hormone levels when maternally inherited.
p49096
sg4
(dp49097
(Vthyroid-stimulating hormone
p49098
Vliver diseases
p49099
tp49100
I00
ssg42003
(lp49101
(dp49102
g42006
I166
sg42007
Vatrial fibrillation
p49103
sg42008
I19
sg42009
VC0004238
p49104
sg42011
I2
sa(dp49105
g42006
I236
sg42007
g49099
sg42008
I14
sg42009
VC0023895
p49106
sg42011
I2
sa(dp49107
g42006
I114
sg42007
Vframeshift mutation
p49108
sg42008
I19
sg42009
VC0079380
p49109
sg42011
I2
sasg42012
(lp49110
(dp49111
g42006
I137
sg42007
VMYL4
p49112
sg42008
I4
sg42016
VP12829
p49113
sg42011
I1
sa(dp49114
g42006
I208
sg42007
VABCB4
p49115
sg42008
I5
sg42016
VP21439
p49116
sg42011
I1
sa(dp49117
g42006
I310
sg42007
g49098
sg42008
I27
sg42016
VP01222
p49118
sg42011
I2
sasa(dp49119
g41997
VThe aim of this study is to examine the mitochondrial targeting of NDUFV2 and dissect the pathogenetic mechanism of one human deletion mutation present in patients with early-onset hypertrophic cardiomyopathy and encephalopathy.
p49120
sg4
(dp49121
(VNDUFV2
p49122
Vencephalopathy
p49123
tp49124
I00
ssg42003
(lp49125
(dp49126
g42006
I181
sg42007
Vhypertrophic cardiomyopathy
p49127
sg42008
I27
sg42009
VC0007194
p49128
sg42011
I2
sa(dp49129
g42006
I213
sg42007
g49123
sg42008
I14
sg42009
VC0085584
p49130
sg42011
I1
sasg42012
(lp49131
(dp49132
g42006
I67
sg42007
g49122
sg42008
I6
sg42016
VP19404
p49133
sg42011
I1
sasa(dp49134
g41997
VThe deletion mutant mimicking the human early-onset hypertrophic cardiomyopathy and encephalopathy lacked 19-40 residues in NDUFV2 and exhibited a significant reduction in its mitochondrial targeting ability.
p49135
sg4
(dp49136
(VNDUFV2
p49137
Vencephalopathy
p49138
tp49139
I00
ssg42003
(lp49140
(dp49141
g42006
I13
sg42007
Vmutant
p49142
sg42008
I6
sg42009
VC0596988
p49143
sg42011
I1
sa(dp49144
g42006
I52
sg42007
Vhypertrophic cardiomyopathy
p49145
sg42008
I27
sg42009
VC0007194
p49146
sg42011
I2
sa(dp49147
g42006
I84
sg42007
g49138
sg42008
I14
sg42009
VC0085584
p49148
sg42011
I1
sasg42012
(lp49149
(dp49150
g42006
I124
sg42007
g49137
sg42008
I6
sg42016
VP19404
p49151
sg42011
I1
sasa(dp49152
g41997
VThe results of human disease cell model established that the impairment of mitochondrial localization of NDUFV2 as a mechanistic basis for early-onset hypertrophic cardiomyopathy and encephalopathy.
p49153
sg4
(dp49154
(VNDUFV2
p49155
Vhypertrophic cardiomyopathy
p49156
tp49157
I00
ssg42003
(lp49158
(dp49159
g42006
I61
sg42007
Vimpairment
p49160
sg42008
I10
sg42009
VC0684336
p49161
sg42011
I1
sa(dp49162
g42006
I183
sg42007
Vencephalopathy
p49163
sg42008
I14
sg42009
VC0085584
p49164
sg42011
I1
sa(dp49165
g42006
I151
sg42007
g49156
sg42008
I27
sg42009
VC0007194
p49166
sg42011
I2
sasg42012
(lp49167
(dp49168
g42006
I105
sg42007
g49155
sg42008
I6
sg42016
VP19404
p49169
sg42011
I1
sasa(dp49170
g41997
VA small deletion in the second intron of human NDUFV2 (IVS2+5_+8delGTAA) has been shown to cause hypertrophic cardiomyopathy and encephalomyopathy [Benit, P., Beugnot, R., Chretien, D., Giurgea, I., de Lonlay-Debeney, P., Issartel, J.P., Kerscher, S., Rustin, P., Roetig, A.
p49171
sg4
(dp49172
(Vhuman NDUFV2 (IVS2+5_+8delGTAA)
p49173
Vhypertrophic cardiomyopathy
p49174
tp49175
I00
ssg42003
(lp49176
(dp49177
g42006
I97
sg42007
g49174
sg42008
I27
sg42009
VC0007194
p49178
sg42011
I2
sasg42012
(lp49179
(dp49180
g42006
I41
sg42007
g49173
sg42008
I31
sg42016
VP19404
p49181
sg42011
I3
sasa(dp49182
g41997
VWhile mutations in the NDUFS3 gene thus result in Leigh syndrome, a dissimilar clinical phenotype is observed in mutations in the NDUFV2 and NDUFS2 genes, resulting in encephalomyopathy and cardiomyopathy.
p49183
sg4
(dp49184
(VNDUFV2
p49185
Vcardiomyopathy
p49186
tp49187
I00
ssg42003
(lp49188
(dp49189
g42006
I50
sg42007
VLeigh syndrome
p49190
sg42008
I14
sg42009
VC0023264
p49191
sg42011
I2
sa(dp49192
g42006
I190
sg42007
g49186
sg42008
I14
sg42009
VC0878544
p49193
sg42011
I1
sasg42012
(lp49194
(dp49195
g42006
I141
sg42007
VNDUFS2 genes
p49196
sg42008
I12
sg42016
g190
sg42011
I2
sa(dp49197
g42006
I130
sg42007
g49185
sg42008
I6
sg42016
VP19404
p49198
sg42011
I1
sa(dp49199
g42006
I23
sg42007
VNDUFS3 gene
p49200
sg42008
I11
sg42016
g190
sg42011
I2
sasa(dp49201
g41997
VCombination of denaturing high performance liquid chromatography and sequence analysis allowed us to show that a 4-bp deletion in intron 2 (IVS2+5_+8delGTAA) of the NDUFV2 gene (encoding NADH dehydrogenase ubiquinone flavoprotein 2) causes complex I deficiency and early onset hypertrophic cardiomyopathy with trunk hypotonia in three affected sibs of a consanguineous family.
p49202
sg4
(dp49203
(VNDUFV2 gene
p49204
Vcomplex I deficiency
p49205
tp49206
I01
ssg42003
(lp49207
(dp49208
g42006
I316
sg42007
Vhypotonia
p49209
sg42008
I9
sg42009
VC0026827
p49210
sg42011
I1
sa(dp49211
g42006
I277
sg42007
Vhypertrophic cardiomyopathy
p49212
sg42008
I27
sg42009
VC0007194
p49213
sg42011
I2
sa(dp49214
g42006
I240
sg42007
g49205
sg42008
I20
sg42009
VC0342776
p49215
sg42011
I3
sasg42012
(lp49216
(dp49217
g42006
I187
sg42007
VNADH dehydrogenase ubiquinone flavoprotein 2
p49218
sg42008
I44
sg42016
VP49366
p49219
sg42011
I5
sa(dp49220
g42006
I165
sg42007
g49204
sg42008
I11
sg42016
VP19404
p49221
sg42011
I2
sasa(dp49222
g41997
VWhile mutation in a number of genes encoding complex I subunits essentially result in neurological symptoms, this first mutation in NDUFV2 is strikingly associated with cardiomyopathy, as previously observed in the unique case of NDFUS2 mutations.
p49223
sg4
(dp49224
(VNDUFV2
p49225
Vcardiomyopathy
p49226
tp49227
I00
ssg42003
(lp49228
(dp49229
g42006
I86
sg42007
Vneurological symptoms
p49230
sg42008
I21
sg42009
VC0235031
p49231
sg42011
I2
sa(dp49232
g42006
I169
sg42007
g49226
sg42008
I14
sg42009
VC0878544
p49233
sg42011
I1
sasg42012
(lp49234
(dp49235
g42006
I132
sg42007
g49225
sg42008
I6
sg42016
VP19404
p49236
sg42011
I1
sasa(dp49237
g41997
VGAL and GALP concentrations may be taken as potential biomarkers to predict development of obesity.
p49238
sg4
(dp49239
(VGAL
p49240
Vobesity
p49241
tp49242
I01
ssg42003
(lp49243
(dp49244
g42006
I91
sg42007
g49241
sg42008
I7
sg42009
VC0028754
p49245
sg42011
I1
sasg42012
(lp49246
(dp49247
g42006
I0
sg42007
g49240
sg42008
I3
sg42016
VP16278
p49248
sg42011
I1
sa(dp49249
g42006
I8
sg42007
VGALP
p49250
sg42008
I4
sg42016
g190
sg42011
I1
sasa(dp49251
g41997
VWhen we considered the host genetic effects alone, gene-gene interactions consistently decreased the risks of gastric cancer and/or atrophic gastritis, including three two-way interactions: PGC rs6912200-PTPN11 rs12229892, PGC rs4711690-IL1B rs1143623 and PTPN11 rs12229892-IL1B rs1143623 and a three-way interaction: PGC rs4711690-PGC rs6912200-PTPN11 rs12229892.
p49252
sg4
(dp49253
(VPGC rs4711690-PGC rs6912200-PTPN11 rs12229892
p49254
Vgastric cancer
p49255
tp49256
I00
ssg42003
(lp49257
(dp49258
g42006
I132
sg42007
Vatrophic gastritis
p49259
sg42008
I18
sg42009
VC0017154
p49260
sg42011
I2
sa(dp49261
g42006
I110
sg42007
g49255
sg42008
I14
sg42009
VC0024623
p49262
sg42011
I2
sasg42012
(lp49263
(dp49264
g42006
I190
sg42007
VPGC rs6912200-PTPN11 rs12229892
p49265
sg42008
I31
sg42016
VP20142
p49266
sg42011
I3
sa(dp49267
g42006
I223
sg42007
VPGC rs4711690-IL1B rs1143623
p49268
sg42008
I28
sg42016
VP20142
p49269
sg42011
I3
sa(dp49270
g42006
I318
sg42007
g49254
sg42008
I45
sg42016
VP20142
p49271
sg42011
I4
sa(dp49272
g42006
I256
sg42007
VPTPN11 rs12229892-IL1B rs1143623
p49273
sg42008
I32
sg42016
g190
sg42011
I3
sasa(dp49274
g41997
VThe interaction between Src homology 2 domain-containing protein tyrosine phosphatase (SHP-2) of gastric epithelial cells and cagA from H. pylori plays a crucial role in developments of gastric atrophy and gastric cancer.
p49275
sg4
(dp49276
(VcagA
p49277
Vgastric cancer
p49278
tp49279
I00
ssg42003
(lp49280
(dp49281
g42006
I186
sg42007
Vgastric atrophy
p49282
sg42008
I15
sg42009
VC0017154
p49283
sg42011
I2
sa(dp49284
g42006
I206
sg42007
g49278
sg42008
I14
sg42009
VC0024623
p49285
sg42011
I2
sasg42012
(lp49286
(dp49287
g42006
I24
sg42007
VSrc homology 2 domain-containing protein tyrosine phosphatase
p49288
sg42008
I61
sg42016
VP12931
p49289
sg42011
I7
sa(dp49290
g42006
I126
sg42007
g49277
sg42008
I4
sg42016
VP05109
p49291
sg42011
I1
sa(dp49292
g42006
I87
sg42007
VSHP-2
p49293
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp49294
g41997
VThe present study indicated that overexpression of GRP78 in colon cancer cells could promote cell-matrix adhesion through the upregulation of fibronectin, integrin-Beta1 and phosphorylated FAK.
p49295
sg4
(dp49296
(VGRP78
p49297
Vadhesion
p49298
tp49299
I00
ssg42003
(lp49300
(dp49301
g42006
I60
sg42007
Vcolon cancer
p49302
sg42008
I12
sg42009
VC0699790
p49303
sg42011
I2
sa(dp49304
g42006
I105
sg42007
g49298
sg42008
I8
sg42009
VC0001511
p49305
sg42011
I1
sasg42012
(lp49306
(dp49307
g42006
I189
sg42007
VFAK
p49308
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp49309
g42006
I51
sg42007
g49297
sg42008
I5
sg42016
VP11021
p49310
sg42011
I1
sasa(dp49311
g41997
VCollectively, our results suggest that berberine-induced AMPK activation inhibits the metastatic potential of colon cancer cells by decreasing integrin Beta1 protein levels and downstream signaling.
p49312
sg4
(dp49313
(VAMPK
p49314
Vcolon cancer
p49315
tp49316
I00
ssg42003
(lp49317
(dp49318
g42006
I110
sg42007
g49315
sg42008
I12
sg42009
VC0699790
p49319
sg42011
I2
sasg42012
(lp49320
(dp49321
g42006
I57
sg42007
g49314
sg42008
I4
sg42016
VP54646
p49322
sg42011
I1
sasa(dp49323
g41997
VOn multivariate analysis, the independent predictors of gene expression were hepatitis C (Mx1, OAS2, PKR and IFI16), donor age (IFI16) and recipient gender (IRF7A) (P &lt; .05 for all).
p49324
sg4
(dp49325
(VMx1
p49326
Vhepatitis C
p49327
tp49328
I00
ssg42003
(lp49329
(dp49330
g42006
I77
sg42007
g49327
sg42008
I11
sg42009
VC0019196
p49331
sg42011
I2
sasg42012
(lp49332
(dp49333
g42006
I101
sg42007
VPKR
p49334
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp49335
g42006
I95
sg42007
VOAS2
p49336
sg42008
I4
sg42016
VP29728
p49337
sg42011
I1
sa(dp49338
g42006
I90
sg42007
g49326
sg42008
I3
sg42016
VP20591
p49339
sg42011
I1
sa(dp49340
g42006
I157
sg42007
VIRF7A
p49341
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp49342
g41997
VThe present study by examining the mRNA and/or protein levels of TrkA and TrkB in the distal colon and in colonic primary afferent neurons in the dorsal root ganglia (DRG) during colitis demonstrated that colitis elicited location-specific changes in the mRNA and protein levels of TrkA and TrkB in colonic primary sensory pathways.
p49343
sg4
(dp49344
(VTrkA
p49345
Vcolitis
p49346
tp49347
I00
ssg42003
(lp49348
(dp49349
g42006
I179
sg42007
Vcolitis
p49350
sg42008
I7
sg42009
VC0009319
p49351
sg42011
I1
sa(dp49352
g42006
I179
sg42007
g49346
sg42008
I7
sg42009
VC0009319
p49353
sg42011
I1
sasg42012
(lp49354
(dp49355
g42006
I65
sg42007
VTrkA
p49356
sg42008
I4
sg42016
VP06753
p49357
sg42011
I1
sa(dp49358
g42006
I74
sg42007
VTrkB
p49359
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp49360
g42006
I65
sg42007
g49345
sg42008
I4
sg42016
VP06753
p49361
sg42011
I1
sa(dp49362
g42006
I74
sg42007
VTrkB
p49363
sg42008
I4
sg42016
g190
sg42011
I1
sasa(dp49364
g41997
VIn colitis both the TrkA and TrkB protein levels were increased in the L1 and S1 DRGs in a time-dependent manner; however, the level of TrkB mRNA but not TrkA mRNA was increased in these DRGs.
p49365
sg4
(dp49366
(VTrkA
p49367
Vcolitis
p49368
tp49369
I00
ssg42003
(lp49370
(dp49371
g42006
I3
sg42007
g49368
sg42008
I7
sg42009
VC0009319
p49372
sg42011
I1
sasg42012
(lp49373
(dp49374
g42006
I29
sg42007
VTrkB protein
p49375
sg42008
I12
sg42016
g190
sg42011
I2
sa(dp49376
g42006
I154
sg42007
VTrkA mRNA
p49377
sg42008
I9
sg42016
VP06753
p49378
sg42011
I2
sa(dp49379
g42006
I136
sg42007
VTrkB mRNA
p49380
sg42008
I9
sg42016
g190
sg42011
I2
sa(dp49381
g42006
I20
sg42007
g49367
sg42008
I4
sg42016
VP06753
p49382
sg42011
I1
sa(dp49383
g42006
I78
sg42007
VS1 DRGs
p49384
sg42008
I7
sg42016
g190
sg42011
I2
sasa(dp49385
g41997
VFurther experiments showed that colitis facilitated a retrograde transport of TrkA protein toward and an anterograde transport of TrkA mRNA away from the DRG, which may contribute to the increased TrkA mRNA level in the distal colon during colitis.
p49386
sg4
(dp49387
(VTrkA protein
p49388
Vcolitis
p49389
tp49390
I00
ssg42003
(lp49391
(dp49392
g42006
I32
sg42007
Vcolitis
p49393
sg42008
I7
sg42009
VC0009319
p49394
sg42011
I1
sa(dp49395
g42006
I32
sg42007
g49389
sg42008
I7
sg42009
VC0009319
p49396
sg42011
I1
sasg42012
(lp49397
(dp49398
g42006
I130
sg42007
VTrkA mRNA
p49399
sg42008
I9
sg42016
VP06753
p49400
sg42011
I2
sa(dp49401
g42006
I130
sg42007
VTrkA mRNA
p49402
sg42008
I9
sg42016
VP06753
p49403
sg42011
I2
sa(dp49404
g42006
I78
sg42007
g49388
sg42008
I12
sg42016
VP06753
p49405
sg42011
I2
sasa(dp49406
g41997
VDouble staining showed that the expression of TrkA but not TrkB was increased in the specifically labeled colonic afferent neurons in the L1 and S1 DRGs during colitis; this increase in TrkA level was attenuated by pretreatment with resiniferatoxin.
p49407
sg4
(dp49408
(VTrkA
p49409
Vcolitis
p49410
tp49411
I00
ssg42003
(lp49412
(dp49413
g42006
I160
sg42007
g49410
sg42008
I7
sg42009
VC0009319
p49414
sg42011
I1
sasg42012
(lp49415
(dp49416
g42006
I46
sg42007
VTrkA
p49417
sg42008
I4
sg42016
VP06753
p49418
sg42011
I1
sa(dp49419
g42006
I145
sg42007
VS1 DRGs
p49420
sg42008
I7
sg42016
g190
sg42011
I2
sa(dp49421
g42006
I59
sg42007
VTrkB
p49422
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp49423
g42006
I46
sg42007
g49409
sg42008
I4
sg42016
VP06753
p49424
sg42011
I1
sasa(dp49425
g41997
VThese results suggested that colitis-induced primary afferent activation involved retrograde transport of TrkA but not TrkB from the distal colon to primary afferent neurons in DRG.
p49426
sg4
(dp49427
(VTrkA
p49428
Vcolitis
p49429
tp49430
I00
ssg42003
(lp49431
(dp49432
g42006
I29
sg42007
g49429
sg42008
I7
sg42009
VC0009319
p49433
sg42011
I1
sasg42012
(lp49434
(dp49435
g42006
I106
sg42007
g49428
sg42008
I4
sg42016
VP06753
p49436
sg42011
I1
sa(dp49437
g42006
I119
sg42007
VTrkB
p49438
sg42008
I4
sg42016
g190
sg42011
I1
sasa(dp49439
g41997
VIn fact, receptor rearrangements or point mutations convert RET and NTRK1 in dominantly acting transforming genes leading to thyroid tumors, whereas inactivating mutations, associated with Hirschsprung's disease (HSCR) and congenital insensitivity to pain with anhidrosis (CIPA), impair RET and NTRK1 functions, respectively.
p49440
sg4
(dp49441
(VHSCR
p49442
VCIPA
p49443
tp49444
I00
ssg42003
(lp49445
(dp49446
g42006
I223
sg42007
Vcongenital insensitivity to pain with anhidrosis
p49447
sg42008
I48
sg42009
VC0020074
p49448
sg42011
I6
sa(dp49449
g42006
I189
sg42007
VHirschsprung's disease
p49450
sg42008
I22
sg42009
VC0019569
p49451
sg42011
I2
sa(dp49452
g42006
I125
sg42007
Vthyroid tumors
p49453
sg42008
I14
sg42009
VC0040136
p49454
sg42011
I2
sa(dp49455
g42006
I213
sg42007
VHSCR
p49456
sg42008
I4
sg42009
VC2931876
p49457
sg42011
I1
sa(dp49458
g42006
I273
sg42007
g49443
sg42008
I4
sg42009
VC0020074
p49459
sg42011
I1
sasg42012
(lp49460
(dp49461
g42006
I60
sg42007
VRET
p49462
sg42008
I3
sg42016
VP07949
p49463
sg42011
I1
sa(dp49464
g42006
I60
sg42007
VRET
p49465
sg42008
I3
sg42016
VP07949
p49466
sg42011
I1
sa(dp49467
g42006
I189
sg42007
VHirschsprung's disease
p49468
sg42008
I22
sg42016
VP14138
p49469
sg42011
I2
sa(dp49470
g42006
I213
sg42007
g49442
sg42008
I4
sg42016
VP14138
p49471
sg42011
I1
sasa(dp49472
g41997
VThus, our results corroborate that therapeutic strategies based on the modulation of CCR1/CCR5-mediated cell migration and/or effector function may contribute to cardiac tissue damage limitation during chronic Chagas disease.
p49473
sg4
(dp49474
(VCCR5
p49475
VChagas disease
p49476
tp49477
I00
ssg42003
(lp49478
(dp49479
g42006
I210
sg42007
g49476
sg42008
I14
sg42009
VC0041234
p49480
sg42011
I2
sasg42012
(lp49481
(dp49482
g42006
I85
sg42007
VCCR1
p49483
sg42008
I4
sg42016
VP32246
p49484
sg42011
I1
sa(dp49485
g42006
I90
sg42007
g49475
sg42008
I4
sg42016
VP32302
p49486
sg42011
I1
sasa(dp49487
g41997
VThe results of integrated analysis explored 3 OA-related pathways (rheumatoid arthritis, osteoclast differentiation and ECM-receptor interaction) and 4 candidate genes of OA (BST2, HDAC4, ITGB2 and VCAM1) that may be therapeutic targets.
p49488
sg4
(dp49489
(VHDAC4
p49490
Vrheumatoid arthritis
p49491
tp49492
I00
ssg42003
(lp49493
(dp49494
g42006
I67
sg42007
g49491
sg42008
I20
sg42009
VC0003873
p49495
sg42011
I2
sasg42012
(lp49496
(dp49497
g42006
I188
sg42007
VITGB2
p49498
sg42008
I5
sg42016
VP05107
p49499
sg42011
I1
sa(dp49500
g42006
I175
sg42007
VBST2
p49501
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp49502
g42006
I198
sg42007
VVCAM1
p49503
sg42008
I5
sg42016
VP19320
p49504
sg42011
I1
sa(dp49505
g42006
I120
sg42007
VECM-receptor
p49506
sg42008
I12
sg42016
g190
sg42011
I1
sa(dp49507
g42006
I181
sg42007
g49490
sg42008
I5
sg42016
VP56524
p49508
sg42011
I1
sasa(dp49509
g41997
VThe patient showed moderate expression of CD18 in neutrophils with a homozygous splice mutation with c.41_c.58+2dup20 of ITGB2 and experienced recurrent severe infections complicated with systemic lupus erythematosus.
p49510
sg4
(dp49511
(VCD18
p49512
Vsystemic lupus erythematosus
p49513
tp49514
I00
ssg42003
(lp49515
(dp49516
g42006
I188
sg42007
g49513
sg42008
I28
sg42009
VC0024141
p49517
sg42011
I3
sa(dp49518
g42006
I160
sg42007
Vinfections
p49519
sg42008
I10
sg42009
VC0021311
p49520
sg42011
I1
sasg42012
(lp49521
(dp49522
g42006
I101
sg42007
Vc.41_c.58+2dup20 of ITGB2
p49523
sg42008
I25
sg42016
VP05107
p49524
sg42011
I3
sa(dp49525
g42006
I42
sg42007
g49512
sg42008
I4
sg42016
VP05107
p49526
sg42011
I1
sasa(dp49527
g41997
VShe received hematopoietic stem cell transplantation from a matched elder brother with heterozygous mutation of ITGB2, and has since remained free of infection and systemic lupus erythematosus symptoms without immunosuppression therapy.
p49528
sg4
(dp49529
(Vmutation of ITGB2
p49530
Vsystemic lupus erythematosus
p49531
tp49532
I00
ssg42003
(lp49533
(dp49534
g42006
I150
sg42007
Vinfection
p49535
sg42008
I9
sg42009
VC0009450
p49536
sg42011
I1
sa(dp49537
g42006
I164
sg42007
g49531
sg42008
I28
sg42009
VC0024141
p49538
sg42011
I3
sasg42012
(lp49539
(dp49540
g42006
I100
sg42007
g49530
sg42008
I17
sg42016
VP05107
p49541
sg42011
I3
sasa(dp49542
g41997
VUsing mice deficient in all beta2 integrins (CD18 null mice), we demonstrate that expression of these heterodimeric adhesion molecules is critical for arthritis induction in the K/B x N serum transfer model.
p49543
sg4
(dp49544
(Vheterodimeric adhesion molecules
p49545
Vadhesion
p49546
tp49547
I00
ssg42003
(lp49548
(dp49549
g42006
I151
sg42007
Varthritis
p49550
sg42008
I9
sg42009
VC0003864
p49551
sg42011
I1
sa(dp49552
g42006
I116
sg42007
g49546
sg42008
I8
sg42009
VC0001511
p49553
sg42011
I1
sasg42012
(lp49554
(dp49555
g42006
I45
sg42007
VCD18 null
p49556
sg42008
I9
sg42016
VP05107
p49557
sg42011
I2
sa(dp49558
g42006
I102
sg42007
g49545
sg42008
I32
sg42016
VP01185
p49559
sg42011
I3
sasa(dp49560
g41997
VUsing null-allele mice and blocking mAbs, we demonstrate specifically that CD11a/CD18 (LFA-1) is absolutely required for the development of arthritis in this model.
p49561
sg4
(dp49562
(VCD11a
p49563
Varthritis
p49564
tp49565
I01
ssg42003
(lp49566
(dp49567
g42006
I27
sg42007
Vblocking
p49568
sg42008
I8
sg42009
VC0233660
p49569
sg42011
I1
sa(dp49570
g42006
I140
sg42007
g49564
sg42008
I9
sg42009
VC0003864
p49571
sg42011
I1
sasg42012
(lp49572
(dp49573
g42006
I87
sg42007
VLFA-1
p49574
sg42008
I5
sg42016
VP20701
p49575
sg42011
I1
sa(dp49576
g42006
I81
sg42007
VCD18
p49577
sg42008
I4
sg42016
VP05107
p49578
sg42011
I1
sa(dp49579
g42006
I75
sg42007
g49563
sg42008
I5
sg42016
VP20701
p49580
sg42011
I1
sasa(dp49581
g41997
VThus, key proteins in Alzheimer Disease and Amyotrophic lateral sclerosis (ALS), including amyloid-Beta precursor protein, Tau and superoxide dismutase 1 (SOD1), spread to adjacent cells in their misfolded aggregated forms and exhibit template-directed misfolding to induce further misfolding, disruptions to proteostasis and toxicity.
p49582
sg4
(dp49583
(VTau
p49584
VAlzheimer Disease
p49585
tp49586
I00
ssg42003
(lp49587
(dp49588
g42006
I44
sg42007
VAmyotrophic lateral sclerosis
p49589
sg42008
I29
sg42009
VC0002736
p49590
sg42011
I3
sa(dp49591
g42006
I75
sg42007
VALS
p49592
sg42008
I3
sg42009
VC0002736
p49593
sg42011
I1
sa(dp49594
g42006
I22
sg42007
g49585
sg42008
I17
sg42009
VC0002395
p49595
sg42011
I2
sa(dp49596
g42006
I91
sg42007
Vamyloid
p49597
sg42008
I7
sg42009
VC0011560
p49598
sg42011
I1
sasg42012
(lp49599
(dp49600
g42006
I155
sg42007
VSOD1
p49601
sg42008
I4
sg42016
VP00441
p49602
sg42011
I1
sa(dp49603
g42006
I91
sg42007
Vamyloid-Beta precursor protein
p49604
sg42008
I30
sg42016
VP17342
p49605
sg42011
I3
sa(dp49606
g42006
I131
sg42007
Vsuperoxide dismutase 1
p49607
sg42008
I22
sg42016
VP00441
p49608
sg42011
I3
sa(dp49609
g42006
I123
sg42007
g49584
sg42008
I3
sg42016
VP49768
p49610
sg42011
I1
sasa(dp49611
g41997
VSeveral findings suggest that the amyloid precursor protein (APP) and the amyloid cascade may play a role in motor neuron disease (MND).
p49612
sg4
(dp49613
(Vamyloid precursor protein
p49614
Vmotor neuron disease
p49615
tp49616
I00
ssg42003
(lp49617
(dp49618
g42006
I131
sg42007
VMND
p49619
sg42008
I3
sg42009
VC0085084
p49620
sg42011
I1
sa(dp49621
g42006
I34
sg42007
Vamyloid
p49622
sg42008
I7
sg42009
VC0011560
p49623
sg42011
I1
sa(dp49624
g42006
I109
sg42007
g49615
sg42008
I20
sg42009
VC0085084
p49625
sg42011
I3
sa(dp49626
g42006
I34
sg42007
Vamyloid
p49627
sg42008
I7
sg42009
VC0011560
p49628
sg42011
I1
sasg42012
(lp49629
(dp49630
g42006
I34
sg42007
g49614
sg42008
I25
sg42016
VP17342
p49631
sg42011
I3
sa(dp49632
g42006
I61
sg42007
VAPP
p49633
sg42008
I3
sg42016
g190
sg42011
I1
sasa(dp49634
g41997
VImmunohistochemical studies and confocal microscopy were used to analyze the expression of APP, TDP-43, pho-TDP-43, ABeta, APP intracellular cytoplasmatic domain (AICD) peptide, Fe65 protein, and pho-TAU in the hippocampus of seven patients with ALS, two patients with ALS-FTD, and four controls.
p49635
sg4
(dp49636
(Vpho-TAU
p49637
VALS
p49638
tp49639
I00
ssg42003
(lp49640
(dp49641
g42006
I273
sg42007
VFTD
p49642
sg42008
I3
sg42009
VC0338451
p49643
sg42011
I1
sa(dp49644
g42006
I246
sg42007
VALS
p49645
sg42008
I3
sg42009
VC0002736
p49646
sg42011
I1
sa(dp49647
g42006
I246
sg42007
g49638
sg42008
I3
sg42009
VC0002736
p49648
sg42011
I1
sasg42012
(lp49649
(dp49650
g42006
I104
sg42007
Vpho-TDP-43
p49651
sg42008
I10
sg42016
g190
sg42011
I1
sa(dp49652
g42006
I196
sg42007
g49637
sg42008
I7
sg42016
VP49768
p49653
sg42011
I1
sa(dp49654
g42006
I91
sg42007
VAPP
p49655
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp49656
g42006
I141
sg42007
Vcytoplasmatic domain (AICD) peptide
p49657
sg42008
I35
sg42016
g190
sg42011
I4
sa(dp49658
g42006
I91
sg42007
VAPP
p49659
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp49660
g42006
I178
sg42007
VFe65 protein
p49661
sg42008
I12
sg42016
g190
sg42011
I2
sa(dp49662
g42006
I96
sg42007
VTDP-43
p49663
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp49664
g42006
I116
sg42007
VABeta
p49665
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp49666
g41997
VIntraperitoneal and oral glucose tolerance tests in Sidt2 knockout mice indicated glucose intolerance and decreased serum insulin level.
p49667
sg4
(dp49668
(Vserum insulin
p49669
Vglucose intolerance
p49670
tp49671
I00
ssg42003
(lp49672
(dp49673
g42006
I33
sg42007
Vtolerance
p49674
sg42008
I9
sg42009
VC0020963
p49675
sg42011
I1
sa(dp49676
g42006
I82
sg42007
g49670
sg42008
I19
sg42009
VC0271650
p49677
sg42011
I2
sasg42012
(lp49678
(dp49679
g42006
I116
sg42007
g49669
sg42008
I13
sg42016
VP01308
p49680
sg42011
I2
sasa(dp49681
g41997
VFor example, CDH15 and PCDH19 are associated with cognitive impairment; CDH5, CDH8, CDH9, CDH10, CDH13, CDH15, PCDH10, PCDH19 and PCDHb4 with autism; CDH7, CDH12, CDH18, PCDH12 and FAT with bipolar disease and schizophrenia; and CDH11, CDH12 and CDH13 with methamphetamine and alcohol dependency.
p49682
sg4
(dp49683
(VCDH15
p49684
Vschizophrenia
p49685
tp49686
I00
ssg42003
(lp49687
(dp49688
g42006
I142
sg42007
Vautism
p49689
sg42008
I6
sg42009
VC0004352
p49690
sg42011
I1
sa(dp49691
g42006
I277
sg42007
Valcohol dependency
p49692
sg42008
I18
sg42009
VC0001973
p49693
sg42011
I2
sa(dp49694
g42006
I50
sg42007
Vcognitive impairment
p49695
sg42008
I20
sg42009
VC0338656
p49696
sg42011
I2
sa(dp49697
g42006
I210
sg42007
g49685
sg42008
I13
sg42009
VC0036341
p49698
sg42011
I1
sasg42012
(lp49699
(dp49700
g42006
I13
sg42007
VCDH15
p49701
sg42008
I5
sg42016
VP55291
p49702
sg42011
I1
sa(dp49703
g42006
I90
sg42007
VCDH10
p49704
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp49705
g42006
I78
sg42007
VCDH8
p49706
sg42008
I4
sg42016
VP55286
p49707
sg42011
I1
sa(dp49708
g42006
I130
sg42007
VPCDHb4
p49709
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp49710
g42006
I229
sg42007
VCDH11
p49711
sg42008
I5
sg42016
VP55287
p49712
sg42011
I1
sa(dp49713
g42006
I156
sg42007
VCDH12
p49714
sg42008
I5
sg42016
VP55289
p49715
sg42011
I1
sa(dp49716
g42006
I156
sg42007
VCDH12
p49717
sg42008
I5
sg42016
VP55289
p49718
sg42011
I1
sa(dp49719
g42006
I163
sg42007
VCDH18
p49720
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp49721
g42006
I23
sg42007
VPCDH19
p49722
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp49723
g42006
I170
sg42007
VPCDH12
p49724
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp49725
g42006
I97
sg42007
VCDH13
p49726
sg42008
I5
sg42016
VP55290
p49727
sg42011
I1
sa(dp49728
g42006
I23
sg42007
VPCDH19
p49729
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp49730
g42006
I72
sg42007
VCDH5
p49731
sg42008
I4
sg42016
VP33151
p49732
sg42011
I1
sa(dp49733
g42006
I150
sg42007
VCDH7
p49734
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp49735
g42006
I97
sg42007
VCDH13
p49736
sg42008
I5
sg42016
VP55290
p49737
sg42011
I1
sa(dp49738
g42006
I84
sg42007
VCDH9
p49739
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp49740
g42006
I111
sg42007
VPCDH10
p49741
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp49742
g42006
I13
sg42007
g49684
sg42008
I5
sg42016
VP55291
p49743
sg42011
I1
sasa(dp49744
g41997
VThe ability of HMGA1 to regulate the plasminogen activator system may constitute an important mechanism by which HMGA1 promotes cancer progression.
p49745
sg4
(dp49746
(Vplasminogen activator system
p49747
Vcancer progression
p49748
tp49749
I00
ssg42003
(lp49750
(dp49751
g42006
I128
sg42007
g49748
sg42008
I18
sg42009
VC0178874
p49752
sg42011
I2
sasg42012
(lp49753
(dp49754
g42006
I15
sg42007
VHMGA1
p49755
sg42008
I5
sg42016
VP17096
p49756
sg42011
I1
sa(dp49757
g42006
I15
sg42007
VHMGA1
p49758
sg42008
I5
sg42016
VP17096
p49759
sg42011
I1
sa(dp49760
g42006
I37
sg42007
g49747
sg42008
I28
sg42016
VP00747
p49761
sg42011
I3
sasa(dp49762
g41997
VKCNJ1 variation is associated with multiple diseases, such as antenatal Bartter syndrome and diabetes.
p49763
sg4
(dp49764
(VKCNJ1
p49765
Vdiabetes
p49766
tp49767
I00
ssg42003
(lp49768
(dp49769
g42006
I72
sg42007
VBartter syndrome
p49770
sg42008
I16
sg42009
VC0004775
p49771
sg42011
I2
sa(dp49772
g42006
I93
sg42007
g49766
sg42008
I8
sg42009
VC0011849
p49773
sg42011
I1
sasg42012
(lp49774
(dp49775
g42006
I0
sg42007
g49765
sg42008
I5
sg42016
VP48048
p49776
sg42011
I1
sasa(dp49777
g41997
VNeither diabetes mellitus nor Tempol altered Kir1.1, Kir2.1, Kir6.1, or SUR2B protein levels in renal cortical microvessels.
p49778
sg4
(dp49779
(VKir1.1
p49780
Vdiabetes mellitus
p49781
tp49782
I00
ssg42003
(lp49783
(dp49784
g42006
I8
sg42007
g49781
sg42008
I17
sg42009
VC0011849
p49785
sg42011
I2
sasg42012
(lp49786
(dp49787
g42006
I53
sg42007
VKir2.1
p49788
sg42008
I6
sg42016
VP63252
p49789
sg42011
I1
sa(dp49790
g42006
I72
sg42007
VSUR2B protein
p49791
sg42008
I13
sg42016
g190
sg42011
I2
sa(dp49792
g42006
I61
sg42007
VKir6.1
p49793
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp49794
g42006
I45
sg42007
g49780
sg42008
I6
sg42016
VP48048
p49795
sg42011
I1
sasa(dp49796
g41997
VTo the extent that the effects of Tempol reflect its antioxidant actions, our observations indicate that oxidative stress contributes to the exaggerated impact of Kir1.1, Kir2.1, and K(ATP) channels on afferent arteriolar tone during diabetes mellitus and that this phenomenon involves posttranslational modulation of channel function.
p49797
sg4
(dp49798
(VKir1.1
p49799
Voxidative stress
p49800
tp49801
I00
ssg42003
(lp49802
(dp49803
g42006
I234
sg42007
Vdiabetes mellitus
p49804
sg42008
I17
sg42009
VC0011849
p49805
sg42011
I2
sa(dp49806
g42006
I105
sg42007
g49800
sg42008
I16
sg42009
VC0242606
p49807
sg42011
I2
sasg42012
(lp49808
(dp49809
g42006
I171
sg42007
VKir2.1
p49810
sg42008
I6
sg42016
VP63252
p49811
sg42011
I1
sa(dp49812
g42006
I163
sg42007
g49799
sg42008
I6
sg42016
VP48048
p49813
sg42011
I1
sasa(dp49814
g41997
VIn this review we will summarize recent evidence for an involvement of TRP channels (TRPA1, TRPC4, TRPC6, TRPV1, TRPV4, TRPM2 and TRPM8) expressed in the lung in pathways of toxin sensing and as mediators of lung inflammation and associated diseases like asthma, COPD, lung fibrosis and edema formation.
p49815
sg4
(dp49816
(VTRPM2
p49817
Vlung fibrosis
p49818
tp49819
I00
ssg42003
(lp49820
(dp49821
g42006
I208
sg42007
Vlung inflammation
p49822
sg42008
I17
sg42009
VC0032285
p49823
sg42011
I2
sa(dp49824
g42006
I255
sg42007
Vasthma
p49825
sg42008
I6
sg42009
VC0004096
p49826
sg42011
I1
sa(dp49827
g42006
I263
sg42007
VCOPD
p49828
sg42008
I4
sg42009
VC0024117
p49829
sg42011
I1
sa(dp49830
g42006
I287
sg42007
Vedema
p49831
sg42008
I5
sg42009
VC0013604
p49832
sg42011
I1
sa(dp49833
g42006
I269
sg42007
g49818
sg42008
I13
sg42009
VC0034069
p49834
sg42011
I2
sasg42012
(lp49835
(dp49836
g42006
I71
sg42007
VTRP channels
p49837
sg42008
I12
sg42016
VP13686
p49838
sg42011
I2
sa(dp49839
g42006
I120
sg42007
g49817
sg42008
I5
sg42016
VP10909
p49840
sg42011
I1
sa(dp49841
g42006
I130
sg42007
VTRPM8
p49842
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp49843
g42006
I99
sg42007
VTRPC6
p49844
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp49845
g42006
I92
sg42007
VTRPC4
p49846
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp49847
g42006
I106
sg42007
VTRPV1
p49848
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp49849
g42006
I85
sg42007
VTRPA1
p49850
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp49851
g41997
VLogistic regression analysis further demonstrated that TRPV1 mRNA level, EOS, IL-4 and IL-5 may be risk factors for children bronchial asthma.
p49852
sg4
(dp49853
(VIL-5
p49854
VEOS
p49855
tp49856
I00
ssg42003
(lp49857
(dp49858
g42006
I125
sg42007
Vbronchial asthma
p49859
sg42008
I16
sg42009
VC0004096
p49860
sg42011
I2
sa(dp49861
g42006
I73
sg42007
g49855
sg42008
I3
sg42009
VC1836122
p49862
sg42011
I1
sasg42012
(lp49863
(dp49864
g42006
I78
sg42007
VIL-4
p49865
sg42008
I4
sg42016
VP05112
p49866
sg42011
I1
sa(dp49867
g42006
I87
sg42007
g49854
sg42008
I4
sg42016
VP05113
p49868
sg42011
I1
sa(dp49869
g42006
I55
sg42007
VTRPV1 mRNA
p49870
sg42008
I10
sg42016
g190
sg42011
I2
sa(dp49871
g42006
I73
sg42007
VEOS
p49872
sg42008
I3
sg42016
g190
sg42011
I1
sasa(dp49873
g41997
VThe levels of two miRNAs, hsa-miR-132-5p and hsa-miR-221-5p, were inversely correlated with the expression of CYP1A2 mRNA transcripts in normal human liver tissue samples represented in The Cancer Genome Atlas (TCGA) dataset.
p49874
sg4
(dp49875
(VCYP1A2 mRNA transcripts
p49876
Vhsa
p49877
tp49878
I00
ssg42003
(lp49879
(dp49880
g42006
I190
sg42007
VCancer
p49881
sg42008
I6
sg42009
VC0006826
p49882
sg42011
I1
sa(dp49883
g42006
I26
sg42007
Vhsa
p49884
sg42008
I3
sg42009
VC0393754
p49885
sg42011
I1
sa(dp49886
g42006
I26
sg42007
g49877
sg42008
I3
sg42009
VC0393754
p49887
sg42011
I1
sasg42012
(lp49888
(dp49889
g42006
I26
sg42007
Vhsa-miR-132-5p
p49890
sg42008
I14
sg42016
g190
sg42011
I1
sa(dp49891
g42006
I110
sg42007
g49876
sg42008
I23
sg42016
VP05177
p49892
sg42011
I3
sa(dp49893
g42006
I45
sg42007
Vhsa-miR-221-5p
p49894
sg42008
I14
sg42016
g190
sg42011
I1
sasa(dp49895
g41997
VParticularly, CLN1, CLN2 and CLN3 were obtained by adding derivatives C1, C2 or C3 during nanoparticles preparation, while CLN2-Pt were obtained by treating preformed CLN2 with Pt(II).
p49896
sg4
(dp49897
(VCLN1
p49898
VCLN2
p49899
tp49900
I00
ssg42003
(lp49901
(dp49902
g42006
I20
sg42007
VCLN2
p49903
sg42008
I4
sg42009
VC1876161
p49904
sg42011
I1
sa(dp49905
g42006
I20
sg42007
VCLN2
p49906
sg42008
I4
sg42009
VC1876161
p49907
sg42011
I1
sa(dp49908
g42006
I29
sg42007
VCLN3
p49909
sg42008
I4
sg42009
VC2931674
p49910
sg42011
I1
sa(dp49911
g42006
I14
sg42007
VCLN1
p49912
sg42008
I4
sg42009
VC1850451
p49913
sg42011
I1
sa(dp49914
g42006
I20
sg42007
g49899
sg42008
I4
sg42009
VC1876161
p49915
sg42011
I1
sasg42012
(lp49916
(dp49917
g42006
I20
sg42007
VCLN2
p49918
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp49919
g42006
I20
sg42007
VCLN2
p49920
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp49921
g42006
I29
sg42007
VCLN3
p49922
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp49923
g42006
I123
sg42007
VCLN2-Pt
p49924
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp49925
g42006
I14
sg42007
g49898
sg42008
I4
sg42016
VP50897
p49926
sg42011
I1
sasa(dp49927
g41997
VNo association with vitiligo was found for the MECL1 gene, which encodes a third immunoproteasome subunit and is unlinked to the MHC class II region.
p49928
sg4
(dp49929
(VMECL1 gene
p49930
Vvitiligo
p49931
tp49932
I00
ssg42003
(lp49933
(dp49934
g42006
I20
sg42007
g49931
sg42008
I8
sg42009
VC0042900
p49935
sg42011
I1
sasg42012
(lp49936
(dp49937
g42006
I129
sg42007
VMHC class II region
p49938
sg42008
I19
sg42016
VP13747
p49939
sg42011
I4
sa(dp49940
g42006
I47
sg42007
g49930
sg42008
I10
sg42016
VP40313
p49941
sg42011
I2
sasa(dp49942
g41997
VWe report a novel LHX3 mutation, which is associated with combined pituitary hormone deficiency including ACTH deficiency, short neck, and sensorineural hearing loss.
p49943
sg4
(dp49944
(VACTH
p49945
VACTH deficiency
p49946
tp49947
I00
ssg42003
(lp49948
(dp49949
g42006
I139
sg42007
Vsensorineural hearing loss
p49950
sg42008
I26
sg42009
VC0018784
p49951
sg42011
I3
sa(dp49952
g42006
I77
sg42007
Vhormone deficiency
p49953
sg42008
I18
sg42009
VC0599750
p49954
sg42011
I2
sa(dp49955
g42006
I106
sg42007
g49946
sg42008
I15
sg42009
VC0342388
p49956
sg42011
I2
sasg42012
(lp49957
(dp49958
g42006
I58
sg42007
Vcombined pituitary hormone
p49959
sg42008
I26
sg42016
VP18509
p49960
sg42011
I3
sa(dp49961
g42006
I18
sg42007
VLHX3
p49962
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp49963
g42006
I106
sg42007
g49945
sg42008
I4
sg42016
VP01189
p49964
sg42011
I1
sasa(dp49965
g41997
VSo-called stress hormones, like adrenocorticotropic hormone, cortisol, and antidiuretic hormone, are released concomitant with nausea and vomiting in motion sickness, but do not seem to be involved in the aetiology of motion sickness.
p49966
sg4
(dp49967
(Vadrenocorticotropic hormone
p49968
Vmotion sickness
p49969
tp49970
I00
ssg42003
(lp49971
(dp49972
g42006
I150
sg42007
Vmotion sickness
p49973
sg42008
I15
sg42009
VC0026603
p49974
sg42011
I2
sa(dp49975
g42006
I127
sg42007
Vnausea and vomiting
p49976
sg42008
I19
sg42009
VC0027498
p49977
sg42011
I3
sa(dp49978
g42006
I150
sg42007
g49969
sg42008
I15
sg42009
VC0026603
p49979
sg42011
I2
sasg42012
(lp49980
(dp49981
g42006
I32
sg42007
g49968
sg42008
I27
sg42016
VP01189
p49982
sg42011
I2
sasa(dp49983
g41997
VMMP-1/7 serum levels were measured using Luminex xMAP technology in 139 patients- 47 IPF, 36 non-IPF Usual Interstitial Pneumonia (UIP), 14 idiopathic Nonspecific Interstitial Pneumonia (iNSIP), 29 secondary NSIP (secNSIP), 13 stage IV sarcoidosis- and 20 healthy controls, and compared using the Mann-Whitney U test.
p49984
sg4
(dp49985
(VMMP-1
p49986
VUIP
p49987
tp49988
I01
ssg42003
(lp49989
(dp49990
g42006
I101
sg42007
VUsual Interstitial Pneumonia
p49991
sg42008
I28
sg42009
VC0085786
p49992
sg42011
I3
sa(dp49993
g42006
I151
sg42007
VNonspecific Interstitial Pneumonia
p49994
sg42008
I34
sg42009
VC1290344
p49995
sg42011
I3
sa(dp49996
g42006
I236
sg42007
Vsarcoidosis
p49997
sg42008
I11
sg42009
VC0036202
p49998
sg42011
I1
sa(dp49999
g42006
I131
sg42007
g49987
sg42008
I3
sg42009
VC0085786
p50000
sg42011
I1
sasg42012
(lp50001
(dp50002
g42006
I0
sg42007
g49986
sg42008
I5
sg42016
VP03956
p50003
sg42011
I1
sasa(dp50004
g41997
VThis activity is regulated by such inhibitors as metalloprvteinase 1 tissue inhibitor and cystatin C. The comparative analysis was applied concerning matrix metalloproteinase 1 precursor; metalloproteinase I tissue inhibitor and cystatin C--indicators of conditions of the "proteolysis-antiproteolysis" system in the bronchoalveolar secretion of patients with chronic obstructive lung disease, bronchial asthma and pneumonia.
p50005
sg4
(dp50006
(Vcystatin C
p50007
Vchronic obstructive lung disease
p50008
tp50009
I01
ssg42003
(lp50010
(dp50011
g42006
I394
sg42007
Vbronchial asthma
p50012
sg42008
I16
sg42009
VC0004096
p50013
sg42011
I2
sa(dp50014
g42006
I415
sg42007
Vpneumonia
p50015
sg42008
I9
sg42009
VC0032285
p50016
sg42011
I1
sa(dp50017
g42006
I360
sg42007
g50008
sg42008
I32
sg42009
VC0024117
p50018
sg42011
I4
sasg42012
(lp50019
(dp50020
g42006
I90
sg42007
Vcystatin C
p50021
sg42008
I10
sg42016
VP01034
p50022
sg42011
I2
sa(dp50023
g42006
I150
sg42007
Vmatrix metalloproteinase 1 precursor; metalloproteinase I tissue inhibitor
p50024
sg42008
I74
sg42016
VP03956
p50025
sg42011
I8
sa(dp50026
g42006
I90
sg42007
g50007
sg42008
I10
sg42016
VP01034
p50027
sg42011
I2
sasa(dp50028
g41997
VTo observe the effects of Dureping Injection on the contents of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in the lung tissue of mice with pneumonia of influenza virus infection.
p50029
sg4
(dp50030
(VTIMP-1
p50031
Vvirus infection
p50032
tp50033
I00
ssg42003
(lp50034
(dp50035
g42006
I204
sg42007
Vinfluenza
p50036
sg42008
I9
sg42009
VC0021400
p50037
sg42011
I1
sa(dp50038
g42006
I191
sg42007
Vpneumonia
p50039
sg42008
I9
sg42009
VC0032285
p50040
sg42011
I1
sa(dp50041
g42006
I214
sg42007
g50032
sg42008
I15
sg42009
VC0042769
p50042
sg42011
I2
sasg42012
(lp50043
(dp50044
g42006
I64
sg42007
Vmatrix metalloproteinase-9
p50045
sg42008
I26
sg42016
VP14780
p50046
sg42011
I2
sa(dp50047
g42006
I92
sg42007
VMMP-9
p50048
sg42008
I5
sg42016
VP14780
p50049
sg42011
I1
sa(dp50050
g42006
I103
sg42007
Vtissue inhibitor of matrix metalloproteinase-1
p50051
sg42008
I46
sg42016
VP01033
p50052
sg42011
I5
sa(dp50053
g42006
I151
sg42007
g50031
sg42008
I6
sg42016
VP01033
p50054
sg42011
I1
sasa(dp50055
g41997
VThe cognitive function of each sub-domain, functional impairments, depressive symptoms, and caregiver burden were assessed using the dementia version of Seoul Neuropsychological Screening Battery (SNSB-D), Barthel Index for Daily Living Activities (ADL), Seoul-Instrumental Activities of Daily Living (S-IADL), the Clinical Dementia Rating Sum of Box (CDR-SB), the Global Deterioration Scale (GDS), the Korean version of the Neuropsychiatric Inventory (K-NPI), and the 15-item Geriatric Depression Scale.
p50056
sg4
(dp50057
(VClinical Dementia Rating Sum of Box
p50058
Vdepressive symptoms
p50059
tp50060
I00
ssg42003
(lp50061
(dp50062
g42006
I324
sg42007
VDementia
p50063
sg42008
I8
sg42009
VC0497327
p50064
sg42011
I1
sa(dp50065
g42006
I133
sg42007
Vdementia
p50066
sg42008
I8
sg42009
VC0497327
p50067
sg42011
I1
sa(dp50068
g42006
I487
sg42007
VDepression
p50069
sg42008
I10
sg42009
VC0011581
p50070
sg42011
I1
sa(dp50071
g42006
I67
sg42007
g50059
sg42008
I19
sg42009
VC0086132
p50072
sg42011
I2
sasg42012
(lp50073
(dp50074
g42006
I352
sg42007
VCDR-SB
p50075
sg42008
I6
sg42016
VP51861
p50076
sg42011
I1
sa(dp50077
g42006
I315
sg42007
g50058
sg42008
I35
sg42016
VP51861
p50078
sg42011
I6
sasa(dp50079
g41997
VBone and cartilage and their disorders are addressed under the following headings: functions of bone; normal and abnormal bone remodeling; osteopetrosis and osteoporosis; epithelial-mesenchymal interaction, condensation and differentiation; osteoblasts, markers of bone formation, osteoclasts, components of bone, and pathology of bone; chondroblasts, markers of cartilage formation, secondary cartilage, components of cartilage, and pathology of cartilage; intramembranous and endochondral bone formation; RUNX genes and cleidocranial dysplasia (CCD); osterix; histone deacetylase 4 and Runx2; Ligand to receptor activator of NFkappaB (RANKL), RANK, osteoprotegerin, and osteoimmunology; WNT signaling, LRP5 mutations, and beta-catenin; the role of leptin in bone remodeling; collagens, collagenopathies, and osteogenesis imperfecta; FGFs/FGFRs, FGFR3 skeletal dysplasias, craniosynostosis, and other disorders; short limb chondrodysplasias; molecular control of the growth plate in endochondral bone formation and genetic disorders of IHH and PTHR1; ANKH, craniometaphyseal dysplasia, and chondrocalcinosis; transforming growth factor beta, Camurati-Engelmann disease (CED), and Marfan syndrome, types I and II; an ACVR1 mutation and fibrodysplasia ossificans progressiva; MSX1 and MSX2: biology, mutations, and associated disorders; G protein, activation of adenylyl cyclase, GNAS1 mutations, McCune-Albright syndrome, fibrous dysplasia, and Albright hereditary osteodystrophy; FLNA and associated disorders; and morphological development of teeth and their genetic mutations.
p50080
sg4
(dp50081
(Vadenylyl cyclase
p50082
VCED
p50083
tp50084
I00
ssg42003
(lp50085
(dp50086
g42006
I1016
sg42007
Vgenetic disorders
p50087
sg42008
I17
sg42009
VC0019247
p50088
sg42011
I2
sa(dp50089
g42006
I157
sg42007
Vosteoporosis
p50090
sg42008
I12
sg42009
VC0029456
p50091
sg42011
I1
sa(dp50092
g42006
I862
sg42007
Vdysplasias
p50093
sg42008
I10
sg42009
VC0334044
p50094
sg42011
I1
sa(dp50095
g42006
I522
sg42007
Vcleidocranial dysplasia
p50096
sg42008
I23
sg42009
VC0008928
p50097
sg42011
I2
sa(dp50098
g42006
I1422
sg42007
Vfibrous dysplasia
p50099
sg42008
I17
sg42009
VC0259779
p50100
sg42011
I2
sa(dp50101
g42006
I810
sg42007
Vosteogenesis imperfecta
p50102
sg42008
I23
sg42009
VC0029434
p50103
sg42011
I2
sa(dp50104
g42006
I547
sg42007
VCCD
p50105
sg42008
I3
sg42009
VC0008928
p50106
sg42011
I1
sa(dp50107
g42006
I1058
sg42007
Vcraniometaphyseal dysplasia
p50108
sg42008
I27
sg42009
VC0265292
p50109
sg42011
I2
sa(dp50110
g42006
I1091
sg42007
Vchondrocalcinosis
p50111
sg42008
I17
sg42009
VC0553730
p50112
sg42011
I1
sa(dp50113
g42006
I318
sg42007
Vpathology
p50114
sg42008
I9
sg42009
VC0677042
p50115
sg42011
I1
sa(dp50116
g42006
I1445
sg42007
VAlbright hereditary osteodystrophy
p50117
sg42008
I34
sg42009
VC2931404
p50118
sg42011
I3
sa(dp50119
g42006
I1037
sg42007
VIHH
p50120
sg42008
I3
sg42009
VC0342384
p50121
sg42011
I1
sa(dp50122
g42006
I1143
sg42007
VCamurati-Engelmann disease
p50123
sg42008
I26
sg42009
VC0011989
p50124
sg42011
I2
sa(dp50125
g42006
I139
sg42007
Vosteopetrosis
p50126
sg42008
I13
sg42009
VC0029454
p50127
sg42011
I1
sa(dp50128
g42006
I1396
sg42007
VMcCune-Albright syndrome
p50129
sg42008
I24
sg42009
VC0242292
p50130
sg42011
I2
sa(dp50131
g42006
I318
sg42007
Vpathology
p50132
sg42008
I9
sg42009
VC0677042
p50133
sg42011
I1
sa(dp50134
g42006
I207
sg42007
Vcondensation
p50135
sg42008
I12
sg42009
VC0233656
p50136
sg42011
I1
sa(dp50137
g42006
I924
sg42007
Vchondrodysplasias
p50138
sg42008
I17
sg42009
VC0343284
p50139
sg42011
I1
sa(dp50140
g42006
I1236
sg42007
Vfibrodysplasia ossificans progressiva
p50141
sg42008
I37
sg42009
VC0016037
p50142
sg42011
I3
sa(dp50143
g42006
I1181
sg42007
VMarfan syndrome
p50144
sg42008
I15
sg42009
VC0024796
p50145
sg42011
I2
sa(dp50146
g42006
I874
sg42007
Vcraniosynostosis
p50147
sg42008
I16
sg42009
VC0010278
p50148
sg42011
I1
sa(dp50149
g42006
I1171
sg42007
g50083
sg42008
I3
sg42009
VC0011989
p50150
sg42011
I1
sasg42012
(lp50151
(dp50152
g42006
I562
sg42007
Vhistone deacetylase 4
p50153
sg42008
I21
sg42016
VP56524
p50154
sg42011
I3
sa(dp50155
g42006
I704
sg42007
VLRP5
p50156
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp50157
g42006
I1217
sg42007
VACVR1
p50158
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50159
g42006
I1284
sg42007
VMSX2
p50160
sg42008
I4
sg42016
VP35548
p50161
sg42011
I1
sa(dp50162
g42006
I1045
sg42007
VPTHR1
p50163
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50164
g42006
I1037
sg42007
VIHH
p50165
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp50166
g42006
I627
sg42007
VNFkappaB
p50167
sg42008
I8
sg42016
VP19838
p50168
sg42011
I1
sa(dp50169
g42006
I1275
sg42007
VMSX1
p50170
sg42008
I4
sg42016
VP28360
p50171
sg42011
I1
sa(dp50172
g42006
I1379
sg42007
VGNAS1
p50173
sg42008
I5
sg42016
VP84996
p50174
sg42011
I1
sa(dp50175
g42006
I1171
sg42007
VCED
p50176
sg42008
I3
sg42016
VP01137
p50177
sg42011
I1
sa(dp50178
g42006
I588
sg42007
VRunx2
p50179
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50180
g42006
I847
sg42007
VFGFR3
p50181
sg42008
I5
sg42016
VP22607
p50182
sg42011
I1
sa(dp50183
g42006
I1052
sg42007
VANKH
p50184
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp50185
g42006
I1143
sg42007
VCamurati-Engelmann disease
p50186
sg42008
I26
sg42016
VP01137
p50187
sg42011
I2
sa(dp50188
g42006
I1110
sg42007
Vtransforming growth factor beta
p50189
sg42008
I31
sg42016
VP18075
p50190
sg42011
I4
sa(dp50191
g42006
I750
sg42007
Vleptin
p50192
sg42008
I6
sg42016
VP41159
p50193
sg42011
I1
sa(dp50194
g42006
I724
sg42007
Vbeta-catenin
p50195
sg42008
I12
sg42016
VP35222
p50196
sg42011
I1
sa(dp50197
g42006
I1361
sg42007
g50082
sg42008
I16
sg42016
VP51828
p50198
sg42011
I2
sa(dp50199
g42006
I651
sg42007
Vosteoprotegerin
p50200
sg42008
I15
sg42016
g190
sg42011
I1
sa(dp50201
g42006
I637
sg42007
VRANKL
p50202
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp50203
g41997
VTo detect the mucin gene (MUC2, MUC5AC, MUC5B, MUC18 and MUC19) expression in the nasal polyps, allergic rhinitis (AR) and the normal nasal mucosa in human.
p50204
sg4
(dp50205
(VMUC18
p50206
Vnasal polyps
p50207
tp50208
I00
ssg42003
(lp50209
(dp50210
g42006
I96
sg42007
Vallergic rhinitis
p50211
sg42008
I17
sg42009
VC2607914
p50212
sg42011
I2
sa(dp50213
g42006
I115
sg42007
VAR
p50214
sg42008
I2
sg42009
VC2607914
p50215
sg42011
I1
sa(dp50216
g42006
I82
sg42007
g50207
sg42008
I12
sg42009
VC0027430
p50217
sg42011
I2
sasg42012
(lp50218
(dp50219
g42006
I26
sg42007
VMUC2
p50220
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp50221
g42006
I47
sg42007
g50206
sg42008
I5
sg42016
VP43121
p50222
sg42011
I1
sa(dp50223
g42006
I14
sg42007
Vmucin gene
p50224
sg42008
I10
sg42016
g190
sg42011
I2
sa(dp50225
g42006
I57
sg42007
VMUC19
p50226
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp50227
g41997
VWe aimed to assess the impact of hypocretin deficiency on attentional functioning by comparing performances on the attention network test (ANT) of narcoleptic patients with hypocretin deficiency (narcolepsy type 1-NT1) versus patients without hypocretin deficiency (narcolepsy type 2-NT2) and healthy controls.
p50228
sg4
(dp50229
(Vhypocretin
p50230
Vnarcolepsy
p50231
tp50232
I00
ssg42003
(lp50233
(dp50234
g42006
I196
sg42007
Vnarcolepsy
p50235
sg42008
I10
sg42009
VC0027404
p50236
sg42011
I1
sa(dp50237
g42006
I196
sg42007
g50231
sg42008
I10
sg42009
VC0027404
p50238
sg42011
I1
sasg42012
(lp50239
(dp50240
g42006
I33
sg42007
Vhypocretin
p50241
sg42008
I10
sg42016
VP50336
p50242
sg42011
I1
sa(dp50243
g42006
I33
sg42007
Vhypocretin
p50244
sg42008
I10
sg42016
VP50336
p50245
sg42011
I1
sa(dp50246
g42006
I33
sg42007
g50230
sg42008
I10
sg42016
VP50336
p50247
sg42011
I1
sasa(dp50248
g41997
VA randomized, double-blind prospective trial among recent onset type 1 diabetes patients has been designed using Cyclosporine A and a proton-pump inhibitor, which increases gastrin levels and has been shown to work through the Reg receptor to transform pancreatic duct cells into islets.
p50249
sg4
(dp50250
(Vgastrin
p50251
Vtype 1 diabetes
p50252
tp50253
I01
ssg42003
(lp50254
(dp50255
g42006
I21
sg42007
Vblind
p50256
sg42008
I5
sg42009
VC0456909
p50257
sg42011
I1
sa(dp50258
g42006
I64
sg42007
g50252
sg42008
I15
sg42009
VC0011854
p50259
sg42011
I3
sasg42012
(lp50260
(dp50261
g42006
I173
sg42007
g50251
sg42008
I7
sg42016
VP01350
p50262
sg42011
I1
sa(dp50263
g42006
I227
sg42007
VReg receptor
p50264
sg42008
I12
sg42016
g190
sg42011
I2
sasa(dp50265
g41997
VIn the A(1)AR agonist area, clinical candidates have been discovered for the following conditions: atrial arrhythmias (tecadenoson, selodenoson and PJ-875); Type II diabetes and insulin sensitizing agents (GR79236, ARA, RPR-749, and CVT-3619); and angina (BAY 68-4986).
p50266
sg4
(dp50267
(Vinsulin
p50268
VCVT
p50269
tp50270
I00
ssg42003
(lp50271
(dp50272
g42006
I99
sg42007
Vatrial arrhythmias
p50273
sg42008
I18
sg42009
VC0085611
p50274
sg42011
I2
sa(dp50275
g42006
I157
sg42007
VType II diabetes
p50276
sg42008
I16
sg42009
VC0011860
p50277
sg42011
I3
sa(dp50278
g42006
I248
sg42007
Vangina
p50279
sg42008
I6
sg42009
VC0002962
p50280
sg42011
I1
sa(dp50281
g42006
I233
sg42007
g50269
sg42008
I3
sg42009
VC0240912
p50282
sg42011
I1
sasg42012
(lp50283
(dp50284
g42006
I178
sg42007
g50268
sg42008
I7
sg42016
VP01308
p50285
sg42011
I1
sasa(dp50286
g41997
VReg protein acts as an autocrine/paracrine growth factor to induce beta-cell replication via the Reg receptor and ameliorates experimental diabetes.
p50287
sg4
(dp50288
(VReg protein
p50289
Vdiabetes
p50290
tp50291
I00
ssg42003
(lp50292
(dp50293
g42006
I139
sg42007
g50290
sg42008
I8
sg42009
VC0011849
p50294
sg42011
I1
sasg42012
(lp50295
(dp50296
g42006
I97
sg42007
VReg receptor
p50297
sg42008
I12
sg42016
g190
sg42011
I2
sa(dp50298
g42006
I0
sg42007
g50289
sg42008
I11
sg42016
VP05451
p50299
sg42011
I2
sasa(dp50300
g41997
VWe have demonstrated in vitro and in vivo that the exogenous addition of rat and human Reg gene products, Reg/REG proteins, induced beta-cell replication via the Reg receptor and thereby ameliorated experimental diabetes.
p50301
sg4
(dp50302
(VREG
p50303
Vdiabetes
p50304
tp50305
I00
ssg42003
(lp50306
(dp50307
g42006
I212
sg42007
g50304
sg42008
I8
sg42009
VC0011849
p50308
sg42011
I1
sasg42012
(lp50309
(dp50310
g42006
I87
sg42007
VReg
p50311
sg42008
I3
sg42016
VP05451
p50312
sg42011
I1
sa(dp50313
g42006
I81
sg42007
Vhuman Reg gene products
p50314
sg42008
I23
sg42016
VP05451
p50315
sg42011
I4
sa(dp50316
g42006
I162
sg42007
VReg receptor
p50317
sg42008
I12
sg42016
g190
sg42011
I2
sa(dp50318
g42006
I110
sg42007
g50303
sg42008
I3
sg42016
VP05451
p50319
sg42011
I1
sasa(dp50320
g41997
VFrom the regenerating islet-derived cDNA library we isolated Reg (Regenerating Gene) and demonstrated that Reg protein induces beta-cell replication via the Reg receptor and ameliorates experimental diabetes.
p50321
sg4
(dp50322
(VReg
p50323
Vdiabetes
p50324
tp50325
I00
ssg42003
(lp50326
(dp50327
g42006
I199
sg42007
g50324
sg42008
I8
sg42009
VC0011849
p50328
sg42011
I1
sasg42012
(lp50329
(dp50330
g42006
I107
sg42007
VReg protein
p50331
sg42008
I11
sg42016
VP05451
p50332
sg42011
I2
sa(dp50333
g42006
I61
sg42007
g50323
sg42008
I3
sg42016
VP05451
p50334
sg42011
I1
sa(dp50335
g42006
I157
sg42007
VReg receptor
p50336
sg42008
I12
sg42016
g190
sg42011
I2
sasa(dp50337
g41997
VGenomic DNA was isolated from patients with hypopituitarism to amplify and sequence eight pituitary specific transcription factors (HESX1, LHX3, LHX4, OTX2, PITX2, POU1F1, PROP1, and SIX6).
p50338
sg4
(dp50339
(Vpituitary specific transcription factors
p50340
Vhypopituitarism
p50341
tp50342
I00
ssg42003
(lp50343
(dp50344
g42006
I44
sg42007
g50341
sg42008
I15
sg42009
VC0020635
p50345
sg42011
I1
sasg42012
(lp50346
(dp50347
g42006
I132
sg42007
VHESX1
p50348
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50349
g42006
I172
sg42007
VPROP1
p50350
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50351
g42006
I145
sg42007
VLHX4
p50352
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp50353
g42006
I164
sg42007
VPOU1F1
p50354
sg42008
I6
sg42016
VP28069
p50355
sg42011
I1
sa(dp50356
g42006
I151
sg42007
VOTX2
p50357
sg42008
I4
sg42016
VP32243
p50358
sg42011
I1
sa(dp50359
g42006
I157
sg42007
VPITX2
p50360
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50361
g42006
I139
sg42007
VLHX3
p50362
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp50363
g42006
I183
sg42007
VSIX6
p50364
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp50365
g42006
I90
sg42007
g50340
sg42008
I40
sg42016
VP19883
p50366
sg42011
I4
sasa(dp50367
g41997
VRat insulinoma INS-1E cells and mouse beta-TC3 cells stably expressing Gadd45b were generated.
p50368
sg4
(dp50369
(VRat insulinoma INS-1E
p50370
Vinsulinoma
p50371
tp50372
I00
ssg42003
(lp50373
(dp50374
g42006
I15
sg42007
VINS
p50375
sg42008
I3
sg42009
VC1533172
p50376
sg42011
I1
sa(dp50377
g42006
I4
sg42007
g50371
sg42008
I10
sg42009
VC0021670
p50378
sg42011
I1
sasg42012
(lp50379
(dp50380
g42006
I0
sg42007
g50370
sg42008
I21
sg42016
VP01308
p50381
sg42011
I3
sa(dp50382
g42006
I71
sg42007
VGadd45b
p50383
sg42008
I7
sg42016
g190
sg42011
I1
sasa(dp50384
g41997
VHigh nuclear ATF2 expression was mainly observed in translocation-associated and/or spindle cell sarcomas including synovial sarcoma, desmoplastic small round cell tumor, endometrial stromal sarcoma, gastrointestinal stromal tumor, malignant peripheral nerve sheath tumor, and solitary fibrous tumor.
p50385
sg4
(dp50386
(VHigh nuclear ATF2
p50387
Vperipheral nerve sheath tumor
p50388
tp50389
I00
ssg42003
(lp50390
(dp50391
g42006
I134
sg42007
Vdesmoplastic small round cell tumor
p50392
sg42008
I35
sg42009
VC0281508
p50393
sg42011
I5
sa(dp50394
g42006
I171
sg42007
Vendometrial stromal sarcoma
p50395
sg42008
I27
sg42009
VC0206630
p50396
sg42011
I3
sa(dp50397
g42006
I84
sg42007
Vspindle cell sarcomas
p50398
sg42008
I21
sg42009
VC0205945
p50399
sg42011
I3
sa(dp50400
g42006
I116
sg42007
Vsynovial sarcoma
p50401
sg42008
I16
sg42009
VC0039101
p50402
sg42011
I2
sa(dp50403
g42006
I277
sg42007
Vsolitary fibrous tumor
p50404
sg42008
I22
sg42009
VC1266119
p50405
sg42011
I3
sa(dp50406
g42006
I52
sg42007
Vtranslocation
p50407
sg42008
I13
sg42009
VC0040715
p50408
sg42011
I1
sa(dp50409
g42006
I200
sg42007
Vgastrointestinal stromal tumor, malignant
p50410
sg42008
I41
sg42009
VC3179349
p50411
sg42011
I4
sa(dp50412
g42006
I242
sg42007
g50388
sg42008
I29
sg42009
VC0751689
p50413
sg42011
I4
sasg42012
(lp50414
(dp50415
g42006
I0
sg42007
g50387
sg42008
I17
sg42016
VP15336
p50416
sg42011
I3
sasa(dp50417
g41997
VPathologic diagnosis of CD117-negative GISTs can be facilitated with the application of a panel of immunohistochemical markers, including DOG-1 and WT-1.
p50418
sg4
(dp50419
(VCD117-negative GISTs
p50420
VGISTs
p50421
tp50422
I00
ssg42003
(lp50423
(dp50424
g42006
I39
sg42007
g50421
sg42008
I5
sg42009
VC0238198
p50425
sg42011
I1
sasg42012
(lp50426
(dp50427
g42006
I138
sg42007
VDOG-1
p50428
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50429
g42006
I24
sg42007
g50420
sg42008
I20
sg42016
VP10721
p50430
sg42011
I2
sasa(dp50431
g41997
VThe expression of WT-1 was compared with other immunohistochemical markers of GIST and the association with clinicopathological features was also evaluated.
p50432
sg4
(dp50433
(VGIST
p50434
VGIST
p50435
tp50436
I00
ssg42003
(lp50437
(dp50438
g42006
I78
sg42007
g50435
sg42008
I4
sg42009
VC1847319
p50439
sg42011
I1
sasg42012
(lp50440
(dp50441
g42006
I78
sg42007
g50434
sg42008
I4
sg42016
VP10721
p50442
sg42011
I1
sasa(dp50443
g41997
VWe found that all 28 cases (100%) of GIST are positive for WT-1, diffusely (&gt;75%, 3+) in 13 (46.4%) cases, moderately (26% to 75%, 2+) in 13 (46.4%) cases, and focally (5% to 25%, 1+) in 2 (7.2%) cases.
p50444
sg4
(dp50445
(VGIST
p50446
VGIST
p50447
tp50448
I00
ssg42003
(lp50449
(dp50450
g42006
I37
sg42007
g50447
sg42008
I4
sg42009
VC1847319
p50451
sg42011
I1
sasg42012
(lp50452
(dp50453
g42006
I37
sg42007
g50446
sg42008
I4
sg42016
VP10721
p50454
sg42011
I1
sasa(dp50455
g41997
VThis review will discuss five types of sarcoma that display aberrant tyrosine kinase pathway signaling: gastrointestinal stromal tumor, inflammatory myofibroblastic tumor, congenital fibrosarcoma and mesoblastic nephroma, dermatofibrosarcoma protuberans, and desmoplastic small round cell tumor; one sarcoma predisposition syndrome with specific dysregulation of the ras pathway--neurofibromatosis--will also be discussed.
p50456
sg4
(dp50457
(Vras
p50458
Vdermatofibrosarcoma protuberans
p50459
tp50460
I00
ssg42003
(lp50461
(dp50462
g42006
I39
sg42007
Vsarcoma
p50463
sg42008
I7
sg42009
VC1261473
p50464
sg42011
I1
sa(dp50465
g42006
I172
sg42007
Vcongenital fibrosarcoma
p50466
sg42008
I23
sg42009
VC0334459
p50467
sg42011
I2
sa(dp50468
g42006
I200
sg42007
Vmesoblastic nephroma
p50469
sg42008
I20
sg42009
VC0206628
p50470
sg42011
I2
sa(dp50471
g42006
I380
sg42007
Vneurofibromatosis
p50472
sg42008
I17
sg42009
VC0162678
p50473
sg42011
I1
sa(dp50474
g42006
I104
sg42007
Vgastrointestinal stromal tumor
p50475
sg42008
I30
sg42009
VC0238198
p50476
sg42011
I3
sa(dp50477
g42006
I39
sg42007
Vsarcoma
p50478
sg42008
I7
sg42009
VC1261473
p50479
sg42011
I1
sa(dp50480
g42006
I323
sg42007
Vsyndrome
p50481
sg42008
I8
sg42009
VC0039082
p50482
sg42011
I1
sa(dp50483
g42006
I259
sg42007
Vdesmoplastic small round cell tumor
p50484
sg42008
I35
sg42009
VC0281508
p50485
sg42011
I5
sa(dp50486
g42006
I136
sg42007
Vinflammatory myofibroblastic tumor
p50487
sg42008
I34
sg42009
VC0334121
p50488
sg42011
I3
sa(dp50489
g42006
I222
sg42007
g50459
sg42008
I31
sg42009
VC0392784
p50490
sg42011
I2
sasg42012
(lp50491
(dp50492
g42006
I69
sg42007
Vtyrosine kinase
p50493
sg42008
I15
sg42016
VP29401
p50494
sg42011
I2
sa(dp50495
g42006
I367
sg42007
g50458
sg42008
I3
sg42016
VP01116
p50496
sg42011
I1
sasa(dp50497
g41997
VWe conclude that although RAB32 methylation is rare in endometrial cancers, it is strongly associated with hMLH1 hypermethylation and MSI in gastric adenocarcinomas.
p50498
sg4
(dp50499
(VhMLH1
p50500
Vadenocarcinomas
p50501
tp50502
I00
ssg42003
(lp50503
(dp50504
g42006
I134
sg42007
VMSI
p50505
sg42008
I3
sg42009
VC0920269
p50506
sg42011
I1
sa(dp50507
g42006
I55
sg42007
Vendometrial cancers
p50508
sg42008
I19
sg42009
VC0476089
p50509
sg42011
I2
sa(dp50510
g42006
I149
sg42007
g50501
sg42008
I15
sg42009
VC0001418
p50511
sg42011
I1
sasg42012
(lp50512
(dp50513
g42006
I107
sg42007
g50500
sg42008
I5
sg42016
VP40692
p50514
sg42011
I1
sa(dp50515
g42006
I26
sg42007
VRAB32
p50516
sg42008
I5
sg42016
g190
sg42011
I1
sasa(dp50517
g41997
VPanel, consisting of 16 new potential markers for early and differentiated diagnosis of prostatic gland cancer, was identified: BHLHE40, FOXP1, LOC285205, ITGA9, CTDSPL, FGF12, LOC440944/SETD5, VHL, CLCN2, OSBPL10/ZNF860, LMCD1, FAM19A4, CAND2, MAP4, KY and LRRC58.
p50518
sg4
(dp50519
(VFGF12
p50520
VVHL
p50521
tp50522
I00
ssg42003
(lp50523
(dp50524
g42006
I104
sg42007
Vcancer
p50525
sg42008
I6
sg42009
VC0006826
p50526
sg42011
I1
sa(dp50527
g42006
I194
sg42007
g50521
sg42008
I3
sg42009
VC0019562
p50528
sg42011
I1
sasg42012
(lp50529
(dp50530
g42006
I177
sg42007
VLOC440944
p50531
sg42008
I9
sg42016
g190
sg42011
I1
sa(dp50532
g42006
I199
sg42007
VCLCN2
p50533
sg42008
I5
sg42016
VP51788
p50534
sg42011
I1
sa(dp50535
g42006
I245
sg42007
VMAP4
p50536
sg42008
I4
sg42016
VP27816
p50537
sg42011
I1
sa(dp50538
g42006
I238
sg42007
VCAND2
p50539
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50540
g42006
I222
sg42007
VLMCD1
p50541
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50542
g42006
I229
sg42007
VFAM19A4
p50543
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp50544
g42006
I162
sg42007
VCTDSPL
p50545
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp50546
g42006
I128
sg42007
VBHLHE40
p50547
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp50548
g42006
I187
sg42007
VSETD5
p50549
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50550
g42006
I258
sg42007
VLRRC58
p50551
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp50552
g42006
I137
sg42007
VFOXP1
p50553
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50554
g42006
I194
sg42007
VVHL
p50555
sg42008
I3
sg42016
VP40337
p50556
sg42011
I1
sa(dp50557
g42006
I206
sg42007
VOSBPL10
p50558
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp50559
g42006
I170
sg42007
g50520
sg42008
I5
sg42016
VP61328
p50560
sg42011
I1
sa(dp50561
g42006
I155
sg42007
VITGA9
p50562
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50563
g42006
I214
sg42007
VZNF860
p50564
sg42008
I6
sg42016
g190
sg42011
I1
sasa(dp50565
g41997
V#\u80cc#\u666f#\u4e0e#\u76ee#\u7684 #\u68d8#\u76ae#\u52a8#\u7269#\u5fae#\u7ba1#\u76f8#\u5173#\u86cb#\u767d4 (echinoderm microtubule-associated protein 4, EML4) #\u4e0e#\u95f4#\u53d8#\u6027#\u6dcb#\u5df4#\u7624#\u6fc0#\u9176 (anaplastic lymphatic tumor kinase, ALK) #\u91cd#\u6392#\u5f62#\u6210#\u7684#\u878d#\u5408#\u57fa#\u56e0#\u5b58#\u5728#\u4e8e#\u5927#\u7ea65%#\u7684#\u975e#\u5c0f#\u7ec6#\u80de#\u80ba#\u764c (non-small cell lung cancer, NSCLC) #\u60a3#\u8005#\u4e2d, #\u662f#\u7ee7#\u8868#\u76ae#\u751f#\u957f#\u56e0#\u5b50#\u53d7#\u4f53 (epidermal growth factor receptor, EGFR) #\u3001K-ras#\u4e4b#\u540e#\u53c8#\u4e00#\u65b0#\u578b#\u9776#\u70b9#\u57fa#\u56e0#\u3002#\u6709#\u6570#\u636e#\u663e#\u793a#\u643a#\u5e26EML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u7684NSCLC#\u60a3#\u8005#\u63a5#\u53d7ALK#\u6291#\u5236#\u5242#\u6cbb#\u7597#\u540e, #\u5176#\u75be#\u75c5#\u63a7#\u5236#\u7684#\u6709#\u6548#\u7387#\u53ef#\u8fbe80%, #\u63a2#\u7d22#\u548c#\u5efa#\u7acb#\u80fd#\u591f#\u51c6#\u786e#\u5feb#\u901f#\u68c0#\u6d4b#\u51faNSCLC#\u60a3#\u8005EML4-ALK#\u878d#\u5408#\u7a81#\u53d8#\u7684#\u65b9#\u6cd5, #\u662f#\u7b5b#\u9009#\u51fa#\u9002#\u5408#\u6cbb#\u7597#\u7684#\u4f18#\u52bf#\u4eba#\u7fa4#\u7684#\u5173#\u952e#\u3002#\u672c#\u7814#\u7a76#\u5206#\u6790#\u514d#\u75ab#\u7ec4#\u5316#\u6cd5 (immunohistochemistry, IHC) #\u68c0#\u6d4bEML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u7a81#\u53d8#\u7684#\u654f#\u611f#\u5ea6#\u4e0e#\u7279#\u5f02#\u5ea6, #\u8bc4#\u4ef7#\u8be5#\u65b9#\u6cd5#\u51c6#\u786e#\u6027#\u53ca#\u4e34#\u5e8a#\u5e94#\u7528#\u4ef7#\u503c, #\u4ece#\u800c#\u4e3a#\u80ba#\u764c#\u60a3#\u8005"#\u4e2a#\u4f53#\u5316#\u5206#\u5b50#\u6cbb#\u7597"#\u63d0#\u4f9b#\u4f9d#\u636e#\u3002#\u65b9#\u6cd5 #\u901a#\u8fc7Pubmed#\u6570#\u636e#\u5e93#\u68c0#\u7d22#\u6240#\u6709#\u7b26#\u5408#\u68c0#\u7d22#\u6761#\u4ef6#\u7684#\u6587#\u732e, #\u672b#\u6b21#\u68c0#\u7d22#\u65e5#\u671f#\u4e3a2015#\u5e742#\u670825#\u65e5, #\u6839#\u636e#\u7eb3#\u5165#\u548c#\u6392#\u9664#\u6807#\u51c6#\u8fdb#\u884c#\u8fdb#\u4e00#\u6b65#\u7b5b#\u9009, #\u91c7#\u7528#\u8bca#\u65ad#\u8bd5#\u9a8cmeta#\u5206#\u6790#\u65b9#\u6cd5, #\u6bd4#\u8f83#\u7279#\u5f02#\u6027#\u6297#\u4f53#\u514d#\u75ab#\u7ec4#\u5316#\u6cd5#\u4e0e"#\u91d1#\u6807#\u51c6"#\u8367#\u5149#\u539f#\u4f4d#\u6742#\u4ea4 (fluorescence in situ hybridization, FISH) #\u6cd5#\u7684#\u654f#\u611f#\u5ea6#\u3001#\u7279#\u5f02#\u5ea6, #\u4ee5#\u660e#\u786e#\u7279#\u5f02#\u6027#\u6297#\u4f53IHC#\u4f5c#\u4e3a#\u7b5b#\u67e5#\u65b9#\u6cd5#\u7684#\u53ef#\u884c#\u6027#\u3002#\u7ed3#\u679c #\u672c#\u658711#\u7bc7#\u6587#\u732e#\u7eb3#\u5165meta#\u5206#\u6790, EML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u514d#\u75ab#\u7ec4#\u5316#\u7d2f#\u8ba1#\u75c5#\u4f8b3,234#\u4f8b, #\u8bca#\u65ad#\u6bd4#\u503c#\u6bd4 (diagnositic odds ratio, DOR) #\u4e3a1,135.00 (95%CI: 337.10-3,821.46) #\uff1b#\u7efc#\u5408#\u53d7#\u8bd5#\u8005#\u5de5#\u4f5c#\u7279#\u5f81#\u66f2#\u7ebf  (summary receiver operating characteristic curve, SROC) #\u4e0b#\u9762#\u79ef#\u4e3a0.992,3 (SEAUC=0.003,2) , Q*#\u7edf#\u8ba1#\u91cf#\u4e3a0.964,4 (SEQ*=0.008,7) #\u3002#\u7ed3#\u8bba #\u7279#\u5f02#\u6027#\u6297#\u4f53IHC#\u6cd5#\u68c0#\u6d4bEML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u7684#\u65b9#\u6cd5#\u53ef#\u884c, #\u5177#\u6709#\u9ad8#\u7279#\u5f02#\u5ea6#\u548c#\u654f#\u611f#\u5ea6, #\u53ef#\u4f5c#\u4e3a#\u4e00#\u79cd#\u7b80#\u5355#\u5feb#\u901f#\u7684#\u7b5b#\u67e5#\u65b9#\u6cd5, #\u5177#\u6709#\u4e34#\u5e8a#\u5e94#\u7528#\u4ef7#\u503c#\u3002.
p50566
sg4
(dp50567
(Vras
p50568
VNSCLC
p50569
tp50570
I00
ssg42003
(lp50571
(dp50572
g42006
I191
sg42007
Vnon-small cell lung cancer
p50573
sg42008
I26
sg42009
VC0007131
p50574
sg42011
I4
sa(dp50575
g42006
I126
sg42007
Vtumor
p50576
sg42008
I5
sg42009
VC0027651
p50577
sg42011
I1
sa(dp50578
g42006
I219
sg42007
g50569
sg42008
I5
sg42009
VC0007131
p50579
sg42011
I1
sasg42012
(lp50580
(dp50581
g42006
I256
sg42007
Vepidermal growth factor receptor
p50582
sg42008
I32
sg42016
VP01133
p50583
sg42011
I4
sa(dp50584
g42006
I45
sg42007
Vmicrotubule-associated protein 4
p50585
sg42008
I32
sg42016
VP27816
p50586
sg42011
I3
sa(dp50587
g42006
I79
sg42007
VEML4
p50588
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp50589
g42006
I140
sg42007
VALK
p50590
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp50591
g42006
I79
sg42007
VEML4
p50592
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp50593
g42006
I140
sg42007
VALK
p50594
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp50595
g42006
I140
sg42007
VALK
p50596
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp50597
g42006
I140
sg42007
VALK
p50598
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp50599
g42006
I300
sg42007
g50568
sg42008
I3
sg42016
VP01116
p50600
sg42011
I1
sa(dp50601
g42006
I140
sg42007
VALK
p50602
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp50603
g42006
I140
sg42007
VALK
p50604
sg42008
I3
sg42016
g190
sg42011
I1
sasa(dp50605
g41997
VBased on these data, we proposed the set of potential biomarkers for detection of prostate cancer and discrimination between prostate tumors with different malignancy and aggressiveness: BHLHE40, FOXP1, LOC285205, ITGA9, CTDSPL, FGF12, LOC440944/SETD5, VHL, CLCN2, OSBPL10/ZNF860, LMCD1, FAM19A4, CAND2, MAP4, KY, and LRRC58.
p50606
sg4
(dp50607
(VMAP4
p50608
VVHL
p50609
tp50610
I00
ssg42003
(lp50611
(dp50612
g42006
I82
sg42007
Vprostate cancer
p50613
sg42008
I15
sg42009
VC0600139
p50614
sg42011
I2
sa(dp50615
g42006
I125
sg42007
Vprostate tumors
p50616
sg42008
I15
sg42009
VC0033578
p50617
sg42011
I2
sa(dp50618
g42006
I171
sg42007
Vaggressiveness
p50619
sg42008
I14
sg42009
VC0001807
p50620
sg42011
I1
sa(dp50621
g42006
I156
sg42007
Vmalignancy
p50622
sg42008
I10
sg42009
VC0006826
p50623
sg42011
I1
sa(dp50624
g42006
I253
sg42007
g50609
sg42008
I3
sg42009
VC0019562
p50625
sg42011
I1
sasg42012
(lp50626
(dp50627
g42006
I258
sg42007
VCLCN2
p50628
sg42008
I5
sg42016
VP51788
p50629
sg42011
I1
sa(dp50630
g42006
I318
sg42007
VLRRC58
p50631
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp50632
g42006
I281
sg42007
VLMCD1
p50633
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50634
g42006
I187
sg42007
VBHLHE40
p50635
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp50636
g42006
I196
sg42007
VFOXP1
p50637
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50638
g42006
I253
sg42007
VVHL
p50639
sg42008
I3
sg42016
VP40337
p50640
sg42011
I1
sa(dp50641
g42006
I246
sg42007
VSETD5
p50642
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50643
g42006
I288
sg42007
VFAM19A4
p50644
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp50645
g42006
I229
sg42007
VFGF12
p50646
sg42008
I5
sg42016
VP61328
p50647
sg42011
I1
sa(dp50648
g42006
I221
sg42007
VCTDSPL
p50649
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp50650
g42006
I304
sg42007
g50608
sg42008
I4
sg42016
VP27816
p50651
sg42011
I1
sa(dp50652
g42006
I214
sg42007
VITGA9
p50653
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50654
g42006
I265
sg42007
VOSBPL10
p50655
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp50656
g42006
I297
sg42007
VCAND2
p50657
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp50658
g42006
I273
sg42007
VZNF860
p50659
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp50660
g42006
I236
sg42007
VLOC440944
p50661
sg42008
I9
sg42016
g190
sg42011
I1
sasa(dp50662
g41997
VWe also analyzed gene expression of MAP4 in 34 patients with bladder cancer using immunohistochemical staining assay.
p50663
sg4
(dp50664
(VMAP4
p50665
Vbladder cancer
p50666
tp50667
I01
ssg42003
(lp50668
(dp50669
g42006
I61
sg42007
g50666
sg42008
I14
sg42009
VC0699885
p50670
sg42011
I2
sasg42012
(lp50671
(dp50672
g42006
I36
sg42007
g50665
sg42008
I4
sg42016
VP27816
p50673
sg42011
I1
sasa(dp50674
g41997
VWe used cAMP elevators and small interfering RNA of MAP4 here, found that both of them can potently inhibit the invasion and the migration of bladder cancer cells by disrupting microtubule (MT) cytoskeleton.
p50675
sg4
(dp50676
(VMAP4
p50677
Vbladder cancer
p50678
tp50679
I01
ssg42003
(lp50680
(dp50681
g42006
I112
sg42007
Vinvasion
p50682
sg42008
I8
sg42009
VC2699153
p50683
sg42011
I1
sa(dp50684
g42006
I142
sg42007
g50678
sg42008
I14
sg42009
VC0699885
p50685
sg42011
I2
sasg42012
(lp50686
(dp50687
g42006
I52
sg42007
g50677
sg42008
I4
sg42016
VP27816
p50688
sg42011
I1
sasa(dp50689
g41997
VConsistently, the bladder cancer grade is positively correlated with the protein level of MAP4.
p50690
sg4
(dp50691
(VMAP4
p50692
Vbladder cancer
p50693
tp50694
I01
ssg42003
(lp50695
(dp50696
g42006
I18
sg42007
g50693
sg42008
I14
sg42009
VC0699885
p50697
sg42011
I2
sasg42012
(lp50698
(dp50699
g42006
I90
sg42007
g50692
sg42008
I4
sg42016
VP27816
p50700
sg42011
I1
sasa(dp50701
g41997
VOur results indicated that the cAMP/PKA signaling pathway might inhibit bladder cancer cell invasion by targeting MAP4-dependent microtubule dynamics, which could be exploited for the therapy of invasive bladder cancer.
p50702
sg4
(dp50703
(VPKA
p50704
Vbladder cancer
p50705
tp50706
I00
ssg42003
(lp50707
(dp50708
g42006
I87
sg42007
Vcell invasion
p50709
sg42008
I13
sg42009
VC2699153
p50710
sg42011
I2
sa(dp50711
g42006
I72
sg42007
g50705
sg42008
I14
sg42009
VC0699885
p50712
sg42011
I2
sa(dp50713
g42006
I195
sg42007
Vinvasive bladder cancer
p50714
sg42008
I23
sg42009
VC0859917
p50715
sg42011
I3
sasg42012
(lp50716
(dp50717
g42006
I114
sg42007
VMAP4
p50718
sg42008
I4
sg42016
VP27816
p50719
sg42011
I1
sa(dp50720
g42006
I36
sg42007
g50704
sg42008
I3
sg42016
VP17612
p50721
sg42011
I1
sasa(dp50722
g41997
VThese findings suggest that a relatively small increase in plasma TNF-Alfa, and decreases in urine TNF-Alfa, GM-CSF, and IL-15 from just before to just after the diagnosis of pneumonia could be markers for an increased risk of PUs in individuals with pneumonia after traumatic SCI.
p50723
sg4
(dp50724
(VTNF
p50725
Vpneumonia
p50726
tp50727
I00
ssg42003
(lp50728
(dp50729
g42006
I175
sg42007
Vpneumonia
p50730
sg42008
I9
sg42009
VC0032285
p50731
sg42011
I1
sa(dp50732
g42006
I175
sg42007
g50726
sg42008
I9
sg42009
VC0032285
p50733
sg42011
I1
sasg42012
(lp50734
(dp50735
g42006
I121
sg42007
VIL-15
p50736
sg42008
I5
sg42016
VP40933
p50737
sg42011
I1
sa(dp50738
g42006
I93
sg42007
Vurine TNF-Alfa
p50739
sg42008
I14
sg42016
VP01375
p50740
sg42011
I2
sa(dp50741
g42006
I109
sg42007
VGM-CSF
p50742
sg42008
I6
sg42016
VP04141
p50743
sg42011
I1
sa(dp50744
g42006
I66
sg42007
g50725
sg42008
I3
sg42016
VP01375
p50745
sg42011
I1
sasa(dp50746
g41997
VThe study aimed to investigate the innate cytokine interleukin-15 (IL-15) as a marker of disease severity.A prospective single-centre observational study was conducted in a university-affiliated paediatric teaching hospital, comparing children (0-18 months) hospitalised for viral bronchiolitis, those admitted to the paediatric intensive care unit with severe disease and healthy age-matched controls.
p50747
sg4
(dp50748
(VIL-15
p50749
Vviral bronchiolitis
p50750
tp50751
I00
ssg42003
(lp50752
(dp50753
g42006
I275
sg42007
g50750
sg42008
I19
sg42009
VC0006274
p50754
sg42011
I2
sasg42012
(lp50755
(dp50756
g42006
I67
sg42007
g50749
sg42008
I5
sg42016
VP40933
p50757
sg42011
I1
sa(dp50758
g42006
I42
sg42007
Vcytokine interleukin-15
p50759
sg42008
I23
sg42016
VP13236
p50760
sg42011
I2
sasa(dp50761
g41997
VPeripheral blood mononuclear cell (PBMC) IL-15 mRNA expression was significantly higher in those with moderate severity bronchiolitis compared with controls and those with severe disease.
p50762
sg4
(dp50763
(Vblood mononuclear cell (PBMC) IL-15 mRNA
p50764
Vbronchiolitis
p50765
tp50766
I01
ssg42003
(lp50767
(dp50768
g42006
I120
sg42007
g50765
sg42008
I13
sg42009
VC0006271
p50769
sg42011
I1
sasg42012
(lp50770
(dp50771
g42006
I11
sg42007
g50764
sg42008
I40
sg42016
VP40933
p50772
sg42011
I6
sasa(dp50773
g41997
VTargets of de-regulated miRNA were differentially expressed in bronchiolitis, including JAK3, STAT5A and NFKB1 on the IL-15 signalling pathway.IL-15 is associated with disease severity in children hospitalised with viral bronchiolitis.
p50774
sg4
(dp50775
(VSTAT5A
p50776
Vbronchiolitis
p50777
tp50778
I00
ssg42003
(lp50779
(dp50780
g42006
I215
sg42007
Vviral bronchiolitis
p50781
sg42008
I19
sg42009
VC0006274
p50782
sg42011
I2
sa(dp50783
g42006
I63
sg42007
g50777
sg42008
I13
sg42009
VC0006271
p50784
sg42011
I1
sasg42012
(lp50785
(dp50786
g42006
I88
sg42007
VJAK3
p50787
sg42008
I4
sg42016
VP52333
p50788
sg42011
I1
sa(dp50789
g42006
I118
sg42007
VIL-15 signalling pathway.IL-15
p50790
sg42008
I30
sg42016
VP40933
p50791
sg42011
I3
sa(dp50792
g42006
I105
sg42007
VNFKB1
p50793
sg42008
I5
sg42016
VP19838
p50794
sg42011
I1
sa(dp50795
g42006
I94
sg42007
g50776
sg42008
I6
sg42016
VP42229
p50796
sg42011
I1
sasa(dp50797
g41997
VThe present study aimed to investigate the role of Interleukin 15 (IL-15) in protein degradation in skeletal muscle mediated by the ubiquitin-proteasome pathway (UPP) in a rat model of chronic obstructive pulmonary disease (COPD).
p50798
sg4
(dp50799
(VIL-15
p50800
VCOPD
p50801
tp50802
I01
ssg42003
(lp50803
(dp50804
g42006
I185
sg42007
Vchronic obstructive pulmonary disease
p50805
sg42008
I37
sg42009
VC0024117
p50806
sg42011
I4
sa(dp50807
g42006
I224
sg42007
g50801
sg42008
I4
sg42009
VC0024117
p50808
sg42011
I1
sasg42012
(lp50809
(dp50810
g42006
I132
sg42007
Vubiquitin
p50811
sg42008
I9
sg42016
VP62979
p50812
sg42011
I1
sa(dp50813
g42006
I51
sg42007
VInterleukin 15
p50814
sg42008
I14
sg42016
VP40933
p50815
sg42011
I2
sa(dp50816
g42006
I67
sg42007
g50800
sg42008
I5
sg42016
VP40933
p50817
sg42011
I1
sasa(dp50818
g41997
VPreviously, we reported an increase of V1aR mRNA and a decrease of V2R mRNA in the collecting ducts under chronic metabolic acidosis.
p50819
sg4
(dp50820
(VV2R mRNA
p50821
Vmetabolic acidosis
p50822
tp50823
I00
ssg42003
(lp50824
(dp50825
g42006
I114
sg42007
g50822
sg42008
I18
sg42009
VC0220981
p50826
sg42011
I2
sasg42012
(lp50827
(dp50828
g42006
I39
sg42007
VV1aR mRNA
p50829
sg42008
I9
sg42016
VP37288
p50830
sg42011
I2
sa(dp50831
g42006
I67
sg42007
g50821
sg42008
I8
sg42016
VP30518
p50832
sg42011
I2
sasa(dp50833
g41997
VThis multiplex immunoassay (MIA) can simultaneously determine levels of specific mouse serum IgG antibodies to P antigens P.69 pertactin (P.69 Prn), filamentous hemagglutinin (FHA), pertussis toxin (Ptx), and combined fimbria type 2 and 3 antigens (Fim2/3) and to diphtheria toxin (Dtx) and tetanus toxin (TT) in a single well.
p50834
sg4
(dp50835
(Vcombined fimbria type 2 and 3 antigens
p50836
Vfilamentous hemagglutinin
p50837
tp50838
I00
ssg42003
(lp50839
(dp50840
g42006
I182
sg42007
Vpertussis
p50841
sg42008
I9
sg42009
VC0043167
p50842
sg42011
I1
sa(dp50843
g42006
I264
sg42007
Vdiphtheria
p50844
sg42008
I10
sg42009
VC0012546
p50845
sg42011
I1
sa(dp50846
g42006
I176
sg42007
VFHA
p50847
sg42008
I3
sg42009
VC1704429
p50848
sg42011
I1
sa(dp50849
g42006
I149
sg42007
g50837
sg42008
I25
sg42009
VC1704429
p50850
sg42011
I2
sa(dp50851
g42006
I291
sg42007
Vtetanus
p50852
sg42008
I7
sg42009
VC0039614
p50853
sg42011
I1
sasg42012
(lp50854
(dp50855
g42006
I199
sg42007
VPtx
p50856
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp50857
g42006
I249
sg42007
VFim2/3
p50858
sg42008
I6
sg42016
VP07333
p50859
sg42011
I1
sa(dp50860
g42006
I138
sg42007
VP.69 Prn
p50861
sg42008
I8
sg42016
g190
sg42011
I2
sa(dp50862
g42006
I81
sg42007
Vmouse serum IgG antibodies
p50863
sg42008
I26
sg42016
g190
sg42011
I4
sa(dp50864
g42006
I111
sg42007
VP antigens P.69 pertactin
p50865
sg42008
I25
sg42016
VP01893
p50866
sg42011
I4
sa(dp50867
g42006
I264
sg42007
Vdiphtheria toxin
p50868
sg42008
I16
sg42016
g190
sg42011
I2
sa(dp50869
g42006
I209
sg42007
g50836
sg42008
I38
sg42016
VP01893
p50870
sg42011
I7
sa(dp50871
g42006
I282
sg42007
VDtx
p50872
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp50873
g42006
I182
sg42007
Vpertussis toxin
p50874
sg42008
I15
sg42016
g190
sg42011
I2
sasa(dp50875
g41997
VOur recent study showed reduced G protein Gamma2 subunit (Gng2/GNG2) expression levels in malignant melanoma cells compared with those in benign melanocytic cells in both mice and humans.
p50876
sg4
(dp50877
(VG protein Gamma2 subunit
p50878
Vmalignant melanoma
p50879
tp50880
I01
ssg42003
(lp50881
(dp50882
g42006
I90
sg42007
g50879
sg42008
I18
sg42009
VC0025202
p50883
sg42011
I2
sasg42012
(lp50884
(dp50885
g42006
I63
sg42007
VGNG2
p50886
sg42008
I4
sg42016
VP59768
p50887
sg42011
I1
sa(dp50888
g42006
I58
sg42007
VGng2
p50889
sg42008
I4
sg42016
VP59768
p50890
sg42011
I1
sa(dp50891
g42006
I32
sg42007
g50878
sg42008
I24
sg42016
VP59768
p50892
sg42011
I4
sasa(dp50893
g41997
VOur recent study also showed that reduced GNG2 alone augmented proliferation of malignant melanoma cells.
p50894
sg4
(dp50895
(VGNG2
p50896
Vmalignant melanoma
p50897
tp50898
I01
ssg42003
(lp50899
(dp50900
g42006
I80
sg42007
g50897
sg42008
I18
sg42009
VC0025202
p50901
sg42011
I2
sa(dp50902
g42006
I63
sg42007
Vproliferation
p50903
sg42008
I13
sg42009
VC0334094
p50904
sg42011
I1
sasg42012
(lp50905
(dp50906
g42006
I42
sg42007
g50896
sg42008
I4
sg42016
VP59768
p50907
sg42011
I1
sasa(dp50908
g41997
VTo our knowledge, however, there is no evidence showing an effect of Gng2/GNG2 alone on metastasis of any cancers including malignant melanoma.
p50909
sg4
(dp50910
(VGNG2
p50911
Vmalignant melanoma
p50912
tp50913
I01
ssg42003
(lp50914
(dp50915
g42006
I106
sg42007
Vcancers
p50916
sg42008
I7
sg42009
VC0006826
p50917
sg42011
I1
sa(dp50918
g42006
I88
sg42007
Vmetastasis
p50919
sg42008
I10
sg42009
VC0027627
p50920
sg42011
I1
sa(dp50921
g42006
I124
sg42007
g50912
sg42008
I18
sg42009
VC0025202
p50922
sg42011
I2
sasg42012
(lp50923
(dp50924
g42006
I69
sg42007
VGng2
p50925
sg42008
I4
sg42016
VP59768
p50926
sg42011
I1
sa(dp50927
g42006
I74
sg42007
g50911
sg42008
I4
sg42016
VP59768
p50928
sg42011
I1
sasa(dp50929
g41997
VIn his study, we first prepared GNG2-overexpressed SK-Mel28 human malignant melanoma cells, in which GNG2 protein expression level was undetectably low.
p50930
sg4
(dp50931
(VGNG2 protein
p50932
Vmalignant melanoma
p50933
tp50934
I01
ssg42003
(lp50935
(dp50936
g42006
I66
sg42007
g50933
sg42008
I18
sg42009
VC0025202
p50937
sg42011
I2
sasg42012
(lp50938
(dp50939
g42006
I32
sg42007
VGNG2
p50940
sg42008
I4
sg42016
VP59768
p50941
sg42011
I1
sa(dp50942
g42006
I101
sg42007
g50932
sg42008
I12
sg42016
VP59768
p50943
sg42011
I2
sasa(dp50944
g41997
VMigration and invasion activities of the GNG2-overexpressed malignant melanoma cells were suppressed up to 1/10th, with decreased activity of focal adhesion kinase (FAK).
p50945
sg4
(dp50946
(VGNG2
p50947
Vadhesion
p50948
tp50949
I00
ssg42003
(lp50950
(dp50951
g42006
I60
sg42007
Vmalignant melanoma
p50952
sg42008
I18
sg42009
VC0025202
p50953
sg42011
I2
sa(dp50954
g42006
I120
sg42007
Vdecreased activity
p50955
sg42008
I18
sg42009
VC0086439
p50956
sg42011
I2
sa(dp50957
g42006
I14
sg42007
Vinvasion
p50958
sg42008
I8
sg42009
VC2699153
p50959
sg42011
I1
sa(dp50960
g42006
I148
sg42007
g50948
sg42008
I8
sg42009
VC0001511
p50961
sg42011
I1
sasg42012
(lp50962
(dp50963
g42006
I165
sg42007
VFAK
p50964
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp50965
g42006
I142
sg42007
Vfocal adhesion kinase
p50966
sg42008
I21
sg42016
g190
sg42011
I3
sa(dp50967
g42006
I41
sg42007
g50947
sg42008
I4
sg42016
VP59768
p50968
sg42011
I1
sasa(dp50969
g41997
VTaken together, our results suggest that overexpression of GNG2 alone inhibits metastasis in human malignant melanoma cells with decreased FAK activity.
p50970
sg4
(dp50971
(VGNG2
p50972
Vmalignant melanoma
p50973
tp50974
I01
ssg42003
(lp50975
(dp50976
g42006
I79
sg42007
Vmetastasis
p50977
sg42008
I10
sg42009
VC0027627
p50978
sg42011
I1
sa(dp50979
g42006
I99
sg42007
g50973
sg42008
I18
sg42009
VC0025202
p50980
sg42011
I2
sasg42012
(lp50981
(dp50982
g42006
I139
sg42007
VFAK
p50983
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp50984
g42006
I59
sg42007
g50972
sg42008
I4
sg42016
VP59768
p50985
sg42011
I1
sasa(dp50986
g41997
VThus, GNG2 might be a candidate of molecular targets of prevention and therapy for metastasis of malignant melanoma.
p50987
sg4
(dp50988
(VGNG2
p50989
Vmalignant melanoma
p50990
tp50991
I01
ssg42003
(lp50992
(dp50993
g42006
I83
sg42007
Vmetastasis
p50994
sg42008
I10
sg42009
VC0027627
p50995
sg42011
I1
sa(dp50996
g42006
I97
sg42007
g50990
sg42008
I18
sg42009
VC0025202
p50997
sg42011
I2
sasg42012
(lp50998
(dp50999
g42006
I6
sg42007
g50989
sg42008
I4
sg42016
VP59768
p51000
sg42011
I1
sasa(dp51001
g41997
VOur recent study showed reduced G protein Gamma2 subunit (Gng2/GNG2) expression levels in malignant melanoma cells compared with those in benign melanocytic cells in both mice and humans.
p51002
sg4
(dp51003
(VG protein Gamma2 subunit
p51004
Vmalignant melanoma
p51005
tp51006
I01
ssg42003
(lp51007
(dp51008
g42006
I90
sg42007
g51005
sg42008
I18
sg42009
VC0025202
p51009
sg42011
I2
sasg42012
(lp51010
(dp51011
g42006
I63
sg42007
VGNG2
p51012
sg42008
I4
sg42016
VP59768
p51013
sg42011
I1
sa(dp51014
g42006
I58
sg42007
VGng2
p51015
sg42008
I4
sg42016
VP59768
p51016
sg42011
I1
sa(dp51017
g42006
I32
sg42007
g51004
sg42008
I24
sg42016
VP59768
p51018
sg42011
I4
sasa(dp51019
g41997
VThe purpose of this study was to examine the biological significance of GNG2 in human malignant melanoma cells.
p51020
sg4
(dp51021
(VGNG2
p51022
Vmalignant melanoma
p51023
tp51024
I01
ssg42003
(lp51025
(dp51026
g42006
I86
sg42007
g51023
sg42008
I18
sg42009
VC0025202
p51027
sg42011
I2
sasg42012
(lp51028
(dp51029
g42006
I72
sg42007
g51022
sg42008
I4
sg42016
VP59768
p51030
sg42011
I1
sasa(dp51031
g41997
VLevels of proliferation and activities of signal transduction molecules were examined in both GNG2-overexpressed and -depleted human malignant melanoma cells.
p51032
sg4
(dp51033
(VGNG2
p51034
Vmalignant melanoma
p51035
tp51036
I01
ssg42003
(lp51037
(dp51038
g42006
I10
sg42007
Vproliferation
p51039
sg42008
I13
sg42009
VC0334094
p51040
sg42011
I1
sa(dp51041
g42006
I133
sg42007
g51035
sg42008
I18
sg42009
VC0025202
p51042
sg42011
I2
sasg42012
(lp51043
(dp51044
g42006
I94
sg42007
g51034
sg42008
I4
sg42016
VP59768
p51045
sg42011
I1
sasa(dp51046
g41997
VProliferation of GNG2-overexpressed SK-Mel28 human malignant melanoma cells was suppressed with decreased c-SRC and AKT activities and increased p21(Cip/WAF1) expression level in vitro.
p51047
sg4
(dp51048
(Vp21
p51049
Vmalignant melanoma
p51050
tp51051
I00
ssg42003
(lp51052
(dp51053
g42006
I51
sg42007
g51050
sg42008
I18
sg42009
VC0025202
p51054
sg42011
I2
sa(dp51055
g42006
I0
sg42007
VProliferation
p51056
sg42008
I13
sg42009
VC0334094
p51057
sg42011
I1
sasg42012
(lp51058
(dp51059
g42006
I153
sg42007
VWAF1
p51060
sg42008
I4
sg42016
VP38936
p51061
sg42011
I1
sa(dp51062
g42006
I106
sg42007
Vc-SRC
p51063
sg42008
I5
sg42016
VP12931
p51064
sg42011
I1
sa(dp51065
g42006
I17
sg42007
VGNG2
p51066
sg42008
I4
sg42016
VP59768
p51067
sg42011
I1
sa(dp51068
g42006
I116
sg42007
VAKT
p51069
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp51070
g42006
I145
sg42007
g51049
sg42008
I3
sg42016
VP42857
p51071
sg42011
I1
sa(dp51072
g42006
I149
sg42007
VCip
p51073
sg42008
I3
sg42016
g190
sg42011
I1
sasa(dp51074
g41997
VIn contrast, proliferation of GNG2-depleted A375P human malignant melanoma cells was enhanced with increased c-SRC and AKT activities and decreased p21(Cip/WAF1) expression level in vitro.
p51075
sg4
(dp51076
(VGNG2
p51077
Vmalignant melanoma
p51078
tp51079
I01
ssg42003
(lp51080
(dp51081
g42006
I13
sg42007
Vproliferation
p51082
sg42008
I13
sg42009
VC0334094
p51083
sg42011
I1
sa(dp51084
g42006
I56
sg42007
g51078
sg42008
I18
sg42009
VC0025202
p51085
sg42011
I2
sasg42012
(lp51086
(dp51087
g42006
I152
sg42007
VCip
p51088
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp51089
g42006
I156
sg42007
VWAF1
p51090
sg42008
I4
sg42016
VP38936
p51091
sg42011
I1
sa(dp51092
g42006
I109
sg42007
Vc-SRC
p51093
sg42008
I5
sg42016
VP12931
p51094
sg42011
I1
sa(dp51095
g42006
I119
sg42007
VAKT
p51096
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp51097
g42006
I148
sg42007
Vp21
p51098
sg42008
I3
sg42016
VP42857
p51099
sg42011
I1
sa(dp51100
g42006
I30
sg42007
g51077
sg42008
I4
sg42016
VP59768
p51101
sg42011
I1
sasa(dp51102
g41997
VWe demonstrated for the first time that increased protein expression level of GNG2 alone inhibits proliferation of malignant melanoma cells in vitro and in vivo, suggesting that GNG2 could be a novel molecular target for malignant melanoma therapy.
p51103
sg4
(dp51104
(VGNG2
p51105
Vmalignant melanoma
p51106
tp51107
I01
ssg42003
(lp51108
(dp51109
g42006
I115
sg42007
Vmalignant melanoma
p51110
sg42008
I18
sg42009
VC0025202
p51111
sg42011
I2
sa(dp51112
g42006
I98
sg42007
Vproliferation
p51113
sg42008
I13
sg42009
VC0334094
p51114
sg42011
I1
sa(dp51115
g42006
I115
sg42007
g51106
sg42008
I18
sg42009
VC0025202
p51116
sg42011
I2
sasg42012
(lp51117
(dp51118
g42006
I78
sg42007
VGNG2
p51119
sg42008
I4
sg42016
VP59768
p51120
sg42011
I1
sa(dp51121
g42006
I78
sg42007
g51105
sg42008
I4
sg42016
VP59768
p51122
sg42011
I1
sasa(dp51123
g41997
VGng2 transcript expression levels in a malignant melanoma were less than 1/10 of the level in a benign tumor.
p51124
sg4
(dp51125
(VGng2 transcript
p51126
Vmalignant melanoma
p51127
tp51128
I01
ssg42003
(lp51129
(dp51130
g42006
I96
sg42007
Vbenign tumor
p51131
sg42008
I12
sg42009
VC0086692
p51132
sg42011
I2
sa(dp51133
g42006
I39
sg42007
g51127
sg42008
I18
sg42009
VC0025202
p51134
sg42011
I2
sasg42012
(lp51135
(dp51136
g42006
I0
sg42007
g51126
sg42008
I15
sg42016
VP59768
p51137
sg42011
I2
sasa(dp51138
g41997
VThe difference in Gng2 transcript expression levels between benign tumors and malignant melanomas was greatest among all of the G protein Gamma subunits examined in this study.
p51139
sg4
(dp51140
(VGng2 transcript
p51141
Vmalignant melanomas
p51142
tp51143
I01
ssg42003
(lp51144
(dp51145
g42006
I60
sg42007
Vbenign tumors
p51146
sg42008
I13
sg42009
VC0086692
p51147
sg42011
I2
sa(dp51148
g42006
I78
sg42007
g51142
sg42008
I19
sg42009
VC0025202
p51149
sg42011
I2
sasg42012
(lp51150
(dp51151
g42006
I18
sg42007
g51141
sg42008
I15
sg42016
VP59768
p51152
sg42011
I2
sa(dp51153
g42006
I128
sg42007
VG protein Gamma subunits
p51154
sg42008
I24
sg42016
g190
sg42011
I4
sasa(dp51155
g41997
VMoreover, protein expression levels of Gng2 were decreased in malignant melanomas compared with those in benign melanocytic tumors in RET-mice.
p51156
sg4
(dp51157
(VGng2
p51158
Vmalignant melanomas
p51159
tp51160
I01
ssg42003
(lp51161
(dp51162
g42006
I124
sg42007
Vtumors
p51163
sg42008
I6
sg42009
VC0027651
p51164
sg42011
I1
sa(dp51165
g42006
I62
sg42007
g51159
sg42008
I19
sg42009
VC0025202
p51166
sg42011
I2
sasg42012
(lp51167
(dp51168
g42006
I39
sg42007
g51158
sg42008
I4
sg42016
VP59768
p51169
sg42011
I1
sasa(dp51170
g41997
VAnalysis of human malignant melanomas also showed reduced GNG2 protein expression levels in five human malignant melanoma cell lines compared with the expression levels in normal human epithelial melanocytes (NHEM).
p51171
sg4
(dp51172
(VGNG2 protein
p51173
Vmalignant melanoma
p51174
tp51175
I01
ssg42003
(lp51176
(dp51177
g42006
I18
sg42007
Vmalignant melanomas
p51178
sg42008
I19
sg42009
VC0025202
p51179
sg42011
I2
sa(dp51180
g42006
I18
sg42007
g51174
sg42008
I18
sg42009
VC0025202
p51181
sg42011
I2
sasg42012
(lp51182
(dp51183
g42006
I58
sg42007
g51173
sg42008
I12
sg42016
VP59768
p51184
sg42011
I2
sasa(dp51185
g41997
VThus, we demonstrated for the first time that Gng2/GNG2 expression levels are reduced in malignant melanoma, suggesting that GNG2 could be a novel biomarker for malignant melanoma.
p51186
sg4
(dp51187
(VGNG2
p51188
Vmalignant melanoma
p51189
tp51190
I01
ssg42003
(lp51191
(dp51192
g42006
I89
sg42007
Vmalignant melanoma
p51193
sg42008
I18
sg42009
VC0025202
p51194
sg42011
I2
sa(dp51195
g42006
I89
sg42007
g51189
sg42008
I18
sg42009
VC0025202
p51196
sg42011
I2
sasg42012
(lp51197
(dp51198
g42006
I46
sg42007
VGng2
p51199
sg42008
I4
sg42016
VP59768
p51200
sg42011
I1
sa(dp51201
g42006
I51
sg42007
VGNG2
p51202
sg42008
I4
sg42016
VP59768
p51203
sg42011
I1
sa(dp51204
g42006
I51
sg42007
g51188
sg42008
I4
sg42016
VP59768
p51205
sg42011
I1
sasa(dp51206
g41997
VSeveral DNA repair enzymes are essential for comprehensive neural repair mechanisms after stroke, including PolBeta and NEIL3 for neurogenesis, APE1 for white matter repair, Gadd45b for axonal regeneration, and DNA-PKs for neurovascular remodeling.
p51207
sg4
(dp51208
(VAPE1
p51209
VPKs
p51210
tp51211
I00
ssg42003
(lp51212
(dp51213
g42006
I90
sg42007
Vstroke
p51214
sg42008
I6
sg42009
VC0038454
p51215
sg42011
I1
sa(dp51216
g42006
I215
sg42007
g51210
sg42008
I3
sg42009
VC0265449
p51217
sg42011
I1
sasg42012
(lp51218
(dp51219
g42006
I144
sg42007
g51209
sg42008
I4
sg42016
VP27695
p51220
sg42011
I1
sa(dp51221
g42006
I120
sg42007
VNEIL3
p51222
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp51223
g42006
I174
sg42007
VGadd45b
p51224
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp51225
g42006
I8
sg42007
VDNA repair enzymes
p51226
sg42008
I18
sg42016
g190
sg42011
I3
sa(dp51227
g42006
I211
sg42007
VDNA-PKs
p51228
sg42008
I7
sg42016
g190
sg42011
I1
sasa(dp51229
g41997
VWe evaluated 401 endometrial carcinomas cases by using four immunomarkers - oestrogen receptor (ER), progesterone receptor (PR), insulin-like growth factor II mRNA - binding protein 3 (IMP3), and intestinal trefoil factor 3 (TFF3)-on a tissue microarray.
p51230
sg4
(dp51231
(VPR
p51232
Vendometrial carcinomas
p51233
tp51234
I00
ssg42003
(lp51235
(dp51236
g42006
I17
sg42007
g51233
sg42008
I22
sg42009
VC0476089
p51237
sg42011
I2
sasg42012
(lp51238
(dp51239
g42006
I101
sg42007
Vprogesterone receptor
p51240
sg42008
I21
sg42016
VP06401
p51241
sg42011
I2
sa(dp51242
g42006
I129
sg42007
Vinsulin-like growth factor II mRNA - binding protein 3
p51243
sg42008
I54
sg42016
VP01344
p51244
sg42011
I9
sa(dp51245
g42006
I225
sg42007
VTFF3
p51246
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp51247
g42006
I76
sg42007
Voestrogen receptor
p51248
sg42008
I18
sg42016
VP03372
p51249
sg42011
I2
sa(dp51250
g42006
I196
sg42007
Vintestinal trefoil factor 3
p51251
sg42008
I27
sg42016
g190
sg42011
I4
sa(dp51252
g42006
I185
sg42007
VIMP3
p51253
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp51254
g42006
I124
sg42007
g51232
sg42008
I2
sg42016
VP06401
p51255
sg42011
I1
sasa(dp51256
g41997
VIn addition, DRR1 and COMMD1 suppressed the cyclin D1 expression, G1/S transition and cell proliferation of neuroblastoma cells.
p51257
sg4
(dp51258
(Vcyclin D1
p51259
Vneuroblastoma
p51260
tp51261
I00
ssg42003
(lp51262
(dp51263
g42006
I91
sg42007
Vproliferation
p51264
sg42008
I13
sg42009
VC0334094
p51265
sg42011
I1
sa(dp51266
g42006
I71
sg42007
Vtransition
p51267
sg42008
I10
sg42009
VC0599156
p51268
sg42011
I1
sa(dp51269
g42006
I108
sg42007
g51260
sg42008
I13
sg42009
VC0027819
p51270
sg42011
I1
sasg42012
(lp51271
(dp51272
g42006
I13
sg42007
VDRR1
p51273
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp51274
g42006
I22
sg42007
VCOMMD1
p51275
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp51276
g42006
I44
sg42007
g51259
sg42008
I9
sg42016
VP24385
p51277
sg42011
I2
sasa(dp51278
g41997
VWe recently characterized a stress and glucocorticoid-regulated gene, down-regulated in renal cell carcinoma - DRR1 (Fam107A).
p51279
sg4
(dp51280
(Vglucocorticoid-regulated gene
p51281
Vrenal cell carcinoma
p51282
tp51283
I00
ssg42003
(lp51284
(dp51285
g42006
I88
sg42007
g51282
sg42008
I20
sg42009
VC0007134
p51286
sg42011
I3
sasg42012
(lp51287
(dp51288
g42006
I117
sg42007
VFam107A
p51289
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp51290
g42006
I111
sg42007
VDRR1
p51291
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp51292
g42006
I39
sg42007
g51281
sg42008
I29
sg42016
VP48506
p51293
sg42011
I2
sasa(dp51294
g41997
VA neuroblastoma model, MYCN transgenic mice, revealed that DRR1 protein was expressed in the celiac ganglion 2 weeks after birth when neuroblast hyperplasia was also observed; however, there was no longer any expression of DRR1 protein in tumors originating from the ganglion 8 weeks after birth.
p51295
sg4
(dp51296
(VMYCN
p51297
Vhyperplasia
p51298
tp51299
I01
ssg42003
(lp51300
(dp51301
g42006
I100
sg42007
Vganglion
p51302
sg42008
I8
sg42009
VC1258666
p51303
sg42011
I1
sa(dp51304
g42006
I2
sg42007
Vneuroblastoma
p51305
sg42008
I13
sg42009
VC0027819
p51306
sg42011
I1
sa(dp51307
g42006
I239
sg42007
Vtumors
p51308
sg42008
I6
sg42009
VC0027651
p51309
sg42011
I1
sa(dp51310
g42006
I100
sg42007
Vganglion
p51311
sg42008
I8
sg42009
VC1258666
p51312
sg42011
I1
sa(dp51313
g42006
I145
sg42007
g51298
sg42008
I11
sg42009
VC0020507
p51314
sg42011
I1
sasg42012
(lp51315
(dp51316
g42006
I59
sg42007
VDRR1 protein
p51317
sg42008
I12
sg42016
g190
sg42011
I2
sa(dp51318
g42006
I23
sg42007
g51297
sg42008
I4
sg42016
VP04198
p51319
sg42011
I1
sa(dp51320
g42006
I59
sg42007
VDRR1 protein
p51321
sg42008
I12
sg42016
g190
sg42011
I2
sasa(dp51322
g41997
VThe aim of this study was to examine the association between GCK, GCKR, FADS1, DGKB/TMEM195 and CDKAL1 gene polymorphisms and the development of gestational diabetes.
p51323
sg4
(dp51324
(VGCK
p51325
Vgestational diabetes
p51326
tp51327
I00
ssg42003
(lp51328
(dp51329
g42006
I145
sg42007
g51326
sg42008
I20
sg42009
VC0085207
p51330
sg42011
I2
sasg42012
(lp51331
(dp51332
g42006
I66
sg42007
VGCKR
p51333
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp51334
g42006
I84
sg42007
VTMEM195
p51335
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp51336
g42006
I96
sg42007
VCDKAL1 gene
p51337
sg42008
I11
sg42016
g190
sg42011
I2
sa(dp51338
g42006
I61
sg42007
g51325
sg42008
I3
sg42016
VP35557
p51339
sg42011
I1
sasa(dp51340
g41997
VBackground Familial hemiplegic migraine type 3 is a monogenic subtype of migraine caused by missense mutations in the neuronal voltage-gated sodium channel gene SCN1A, with 10 different mutations reported so far.
p51341
sg4
(dp51342
(Vneuronal voltage-gated sodium channel gene SCN1A
p51343
VFamilial hemiplegic migraine
p51344
tp51345
I00
ssg42003
(lp51346
(dp51347
g42006
I31
sg42007
Vmigraine
p51348
sg42008
I8
sg42009
VC0149931
p51349
sg42011
I1
sa(dp51350
g42006
I11
sg42007
g51344
sg42008
I28
sg42009
VC0338484
p51351
sg42011
I3
sasg42012
(lp51352
(dp51353
g42006
I118
sg42007
g51343
sg42008
I48
sg42016
VP29475
p51354
sg42011
I6
sasa(dp51355
g41997
VResults In both pedigrees, we identified SCN1A mutation p.F1499L, which has been previously associated with familial hemiplegic migraine type 3 and elicited repetitive daily blindness.
p51356
sg4
(dp51357
(VSCN1A mutation p.F1499L
p51358
Vfamilial hemiplegic migraine
p51359
tp51360
I00
ssg42003
(lp51361
(dp51362
g42006
I174
sg42007
Vblindness
p51363
sg42008
I9
sg42009
VC0456909
p51364
sg42011
I1
sa(dp51365
g42006
I108
sg42007
g51359
sg42008
I28
sg42009
VC0338484
p51366
sg42011
I3
sasg42012
(lp51367
(dp51368
g42006
I41
sg42007
g51358
sg42008
I23
sg42016
VP35498
p51369
sg42011
I3
sasa(dp51370
g41997
VConclusion Like a substantial proportion of other familial hemiplegic migraine type 3 mutations, p.F1499L affects the intracellular linker between domains III and IV of SCN1A, which seems to be a mutational hot-spot.
p51371
sg4
(dp51372
(VSCN1A
p51373
Vfamilial hemiplegic migraine
p51374
tp51375
I00
ssg42003
(lp51376
(dp51377
g42006
I50
sg42007
g51374
sg42008
I28
sg42009
VC0338484
p51378
sg42011
I3
sasg42012
(lp51379
(dp51380
g42006
I169
sg42007
g51373
sg42008
I5
sg42016
VP35498
p51381
sg42011
I1
sasa(dp51382
g41997
VA genetic link between these two diseases is particularly evident in familial hemiplegic migraine: mutations of ATP1A2, SCN1A and CACNA1A genes, identified in this disease, have also been involved in different types of epilepsy and febrile seizures.
p51383
sg4
(dp51384
(VCACNA1A genes
p51385
Vepilepsy
p51386
tp51387
I00
ssg42003
(lp51388
(dp51389
g42006
I232
sg42007
Vfebrile seizures
p51390
sg42008
I16
sg42009
VC0009952
p51391
sg42011
I2
sa(dp51392
g42006
I69
sg42007
Vfamilial hemiplegic migraine
p51393
sg42008
I28
sg42009
VC0338484
p51394
sg42011
I3
sa(dp51395
g42006
I219
sg42007
g51386
sg42008
I8
sg42009
VC0014544
p51396
sg42011
I1
sasg42012
(lp51397
(dp51398
g42006
I112
sg42007
VATP1A2
p51399
sg42008
I6
sg42016
VP50993
p51400
sg42011
I1
sa(dp51401
g42006
I120
sg42007
VSCN1A
p51402
sg42008
I5
sg42016
VP35498
p51403
sg42011
I1
sa(dp51404
g42006
I130
sg42007
g51385
sg42008
I13
sg42016
VP01893
p51405
sg42011
I2
sasa(dp51406
g41997
VAmong these, nine SCN1A gene mutations were reported to cause familial hemiplegic migraine type 3 (FHM3).
p51407
sg4
(dp51408
(VSCN1A gene
p51409
VFHM3
p51410
tp51411
I00
ssg42003
(lp51412
(dp51413
g42006
I62
sg42007
Vfamilial hemiplegic migraine type 3
p51414
sg42008
I35
sg42009
VC1864987
p51415
sg42011
I5
sa(dp51416
g42006
I99
sg42007
g51410
sg42008
I4
sg42009
VC1864987
p51417
sg42011
I1
sasg42012
(lp51418
(dp51419
g42006
I62
sg42007
Vfamilial hemiplegic migraine type 3
p51420
sg42008
I35
sg42016
VP35498
p51421
sg42011
I5
sa(dp51422
g42006
I99
sg42007
VFHM3
p51423
sg42008
I4
sg42016
VP35498
p51424
sg42011
I1
sa(dp51425
g42006
I18
sg42007
g51409
sg42008
I10
sg42016
VP35498
p51426
sg42011
I2
sasa(dp51427
g41997
VMutations in four genes have been identified in familial hemiplegic migraine (FHM), from which CACNA1A (FHM type 1) and SCN1A (FHM type 3) code for neuronal voltage-gated calcium or sodium channels, respectively, while ATP1A2 (FHM type 2) encodes the Alfa2 isoform of the Na(+),K(+)-ATPase's catalytic subunit, thus classifying FHM primarily as an ion channel/ion transporter pathology.
p51428
sg4
(dp51429
(VATPase
p51430
Vfamilial hemiplegic migraine
p51431
tp51432
I00
ssg42003
(lp51433
(dp51434
g42006
I78
sg42007
VFHM
p51435
sg42008
I3
sg42009
VC1832894
p51436
sg42011
I1
sa(dp51437
g42006
I78
sg42007
VFHM
p51438
sg42008
I3
sg42009
VC1832894
p51439
sg42011
I1
sa(dp51440
g42006
I376
sg42007
Vpathology
p51441
sg42008
I9
sg42009
VC0677042
p51442
sg42011
I1
sa(dp51443
g42006
I78
sg42007
VFHM
p51444
sg42008
I3
sg42009
VC1832894
p51445
sg42011
I1
sa(dp51446
g42006
I48
sg42007
g51431
sg42008
I28
sg42009
VC0338484
p51447
sg42011
I3
sa(dp51448
g42006
I78
sg42007
VFHM
p51449
sg42008
I3
sg42009
VC1832894
p51450
sg42011
I1
sa(dp51451
g42006
I78
sg42007
VFHM
p51452
sg42008
I3
sg42009
VC1832894
p51453
sg42011
I1
sasg42012
(lp51454
(dp51455
g42006
I219
sg42007
VATP1A2
p51456
sg42008
I6
sg42016
VP50993
p51457
sg42011
I1
sa(dp51458
g42006
I120
sg42007
VSCN1A
p51459
sg42008
I5
sg42016
VP35498
p51460
sg42011
I1
sa(dp51461
g42006
I283
sg42007
g51430
sg42008
I6
sg42016
VP38606
p51462
sg42011
I1
sasa(dp51463
g41997
VMoreover, three genes (CACNA1A, ATP1A2, and SCN1A) have come from studies performed in individuals with familial hemiplegic migraine (FHM), a monogenic form of migraine with aura.
p51464
sg4
(dp51465
(VATP1A2
p51466
Vfamilial hemiplegic migraine
p51467
tp51468
I00
ssg42003
(lp51469
(dp51470
g42006
I134
sg42007
VFHM
p51471
sg42008
I3
sg42009
VC1832894
p51472
sg42011
I1
sa(dp51473
g42006
I160
sg42007
Vmigraine with aura
p51474
sg42008
I18
sg42009
VC0154723
p51475
sg42011
I3
sa(dp51476
g42006
I104
sg42007
g51467
sg42008
I28
sg42009
VC0338484
p51477
sg42011
I3
sasg42012
(lp51478
(dp51479
g42006
I44
sg42007
VSCN1A
p51480
sg42008
I5
sg42016
VP35498
p51481
sg42011
I1
sa(dp51482
g42006
I32
sg42007
g51466
sg42008
I6
sg42016
VP50993
p51483
sg42011
I1
sasa(dp51484
g41997
VThe FHM3 subtype is caused by mutations in SCN1A, which is also the most frequent epilepsy gene encoding the voltage-gated Na+ channel NaV1.1.
p51485
sg4
(dp51486
(VFHM3 subtype
p51487
VFHM3
p51488
tp51489
I00
ssg42003
(lp51490
(dp51491
g42006
I82
sg42007
Vepilepsy
p51492
sg42008
I8
sg42009
VC0014544
p51493
sg42011
I1
sa(dp51494
g42006
I4
sg42007
g51488
sg42008
I4
sg42009
VC1864987
p51495
sg42011
I1
sasg42012
(lp51496
(dp51497
g42006
I123
sg42007
VNa+ channel NaV1.1
p51498
sg42008
I18
sg42016
VP37088
p51499
sg42011
I3
sa(dp51500
g42006
I43
sg42007
VSCN1A
p51501
sg42008
I5
sg42016
VP35498
p51502
sg42011
I1
sa(dp51503
g42006
I4
sg42007
g51487
sg42008
I12
sg42016
VP35498
p51504
sg42011
I2
sasa(dp51505
g41997
VThe aim of this study was to explore the clinical, genetic and pathogenetic features of a pure FHM3 family.
p51506
sg4
(dp51507
(VFHM3 family
p51508
VFHM3
p51509
tp51510
I00
ssg42003
(lp51511
(dp51512
g42006
I95
sg42007
g51509
sg42008
I4
sg42009
VC1864987
p51513
sg42011
I1
sasg42012
(lp51514
(dp51515
g42006
I95
sg42007
g51508
sg42008
I11
sg42016
VP35498
p51516
sg42011
I2
sasa(dp51517
g41997
VL1624P locates in S3 of domain IV, the same domain as two of four known pure FHM3 mutations.
p51518
sg4
(dp51519
(VFHM3
p51520
VFHM3
p51521
tp51522
I00
ssg42003
(lp51523
(dp51524
g42006
I77
sg42007
g51521
sg42008
I4
sg42009
VC1864987
p51525
sg42011
I1
sasg42012
(lp51526
(dp51527
g42006
I77
sg42007
g51520
sg42008
I4
sg42016
VP35498
p51528
sg42011
I1
sasa(dp51529
g41997
VSimilar to the known FHM3 mutations, this novel mutation predicts hyperexcitability of GABAergic inhibitory neurons.
p51530
sg4
(dp51531
(VFHM3 mutations
p51532
VFHM3
p51533
tp51534
I00
ssg42003
(lp51535
(dp51536
g42006
I21
sg42007
g51533
sg42008
I4
sg42009
VC1864987
p51537
sg42011
I1
sa(dp51538
g42006
I42
sg42007
Vnovel mutation
p51539
sg42008
I14
sg42009
VC2985438
p51540
sg42011
I2
sasg42012
(lp51541
(dp51542
g42006
I21
sg42007
g51532
sg42008
I14
sg42016
VP35498
p51543
sg42011
I2
sasa(dp51544
g41997
VSixty patients with migraine without aura (MO) or with different types of migraine with aura (MA), including sporadic hemiplegic, familial hemiplegic, and probable familial hemiplegic, were screened for mutations in the four genes previously linked with different types of migraine (ATP1A2, CACNA1A, SCN1A, and KCNK18).
p51545
sg4
(dp51546
(VATP1A2
p51547
Vmigraine with aura
p51548
tp51549
I00
ssg42003
(lp51550
(dp51551
g42006
I94
sg42007
VMA
p51552
sg42008
I2
sg42009
VC0154723
p51553
sg42011
I1
sa(dp51554
g42006
I20
sg42007
Vmigraine without aura
p51555
sg42008
I21
sg42009
VC0338480
p51556
sg42011
I3
sa(dp51557
g42006
I20
sg42007
Vmigraine
p51558
sg42008
I8
sg42009
VC0149931
p51559
sg42011
I1
sa(dp51560
g42006
I43
sg42007
VMO
p51561
sg42008
I2
sg42009
VC0338480
p51562
sg42011
I1
sa(dp51563
g42006
I74
sg42007
g51548
sg42008
I18
sg42009
VC0154723
p51564
sg42011
I3
sasg42012
(lp51565
(dp51566
g42006
I300
sg42007
VSCN1A
p51567
sg42008
I5
sg42016
VP35498
p51568
sg42011
I1
sa(dp51569
g42006
I283
sg42007
g51547
sg42008
I6
sg42016
VP50993
p51570
sg42011
I1
sa(dp51571
g42006
I311
sg42007
VKCNK18
p51572
sg42008
I6
sg42016
g190
sg42011
I1
sasa(dp51573
g41997
VMutations of the voltage gated Na(+) channel Na(V)1.1 (SCN1A) are important causes of different genetic epilepsies and can also cause familial hemiplegic migraine (FHM-III).
p51574
sg4
(dp51575
(VSCN1A
p51576
Vfamilial hemiplegic migraine
p51577
tp51578
I00
ssg42003
(lp51579
(dp51580
g42006
I104
sg42007
Vepilepsies
p51581
sg42008
I10
sg42009
VC0014544
p51582
sg42011
I1
sa(dp51583
g42006
I164
sg42007
VFHM-III
p51584
sg42008
I7
sg42009
VC0338484
p51585
sg42011
I1
sa(dp51586
g42006
I134
sg42007
g51577
sg42008
I28
sg42009
VC0338484
p51587
sg42011
I3
sasg42012
(lp51588
(dp51589
g42006
I55
sg42007
g51576
sg42008
I5
sg42016
VP35498
p51590
sg42011
I1
sasa(dp51591
g41997
VA mutation causing FHM type 3 (FHM3) has been identified in SCN1A encoding the Nav1.1 Na(+) channel.
p51592
sg4
(dp51593
(VFHM3
p51594
VFHM3
p51595
tp51596
I00
ssg42003
(lp51597
(dp51598
g42006
I19
sg42007
VFHM type 3
p51599
sg42008
I10
sg42009
VC1864987
p51600
sg42011
I3
sa(dp51601
g42006
I31
sg42007
g51595
sg42008
I4
sg42009
VC1864987
p51602
sg42011
I1
sasg42012
(lp51603
(dp51604
g42006
I60
sg42007
VSCN1A
p51605
sg42008
I5
sg42016
VP35498
p51606
sg42011
I1
sa(dp51607
g42006
I19
sg42007
VFHM type 3
p51608
sg42008
I10
sg42016
VP35498
p51609
sg42011
I3
sa(dp51610
g42006
I79
sg42007
VNav1.1 Na(+)
p51611
sg42008
I12
sg42016
VP35498
p51612
sg42011
I2
sa(dp51613
g42006
I31
sg42007
g51594
sg42008
I4
sg42016
VP35498
p51614
sg42011
I1
sasa(dp51615
g41997
VIn particular, we investigate the dynamical repertoire from normal spiking (milliseconds) to spreading depression and anoxic depolarization (tens of seconds) and show that FHM3 mutations render gray matter tissue more vulnerable to spreading depression despite opposing effects associated with action potential generation.
p51616
sg4
(dp51617
(VFHM3
p51618
Vdepression
p51619
tp51620
I00
ssg42003
(lp51621
(dp51622
g42006
I172
sg42007
VFHM3
p51623
sg42008
I4
sg42009
VC1864987
p51624
sg42011
I1
sa(dp51625
g42006
I103
sg42007
Vdepression
p51626
sg42008
I10
sg42009
VC0011581
p51627
sg42011
I1
sa(dp51628
g42006
I103
sg42007
g51619
sg42008
I10
sg42009
VC0011581
p51629
sg42011
I1
sasg42012
(lp51630
(dp51631
g42006
I172
sg42007
g51618
sg42008
I4
sg42016
VP35498
p51632
sg42011
I1
sasa(dp51633
g41997
VPAR2 gene expression correlated positively with transcript levels of IL-8, IL-1Beta as well mucosal SLPI levels in H. pylori-infected patients (r: 0.47-0.84; p &lt; .0001), whereas no correlation was found with the degree of gastritis.
p51634
sg4
(dp51635
(VIL-1Beta
p51636
Vgastritis
p51637
tp51638
I00
ssg42003
(lp51639
(dp51640
g42006
I225
sg42007
g51637
sg42008
I9
sg42009
VC0017152
p51641
sg42011
I1
sasg42012
(lp51642
(dp51643
g42006
I0
sg42007
VPAR2
p51644
sg42008
I4
sg42016
VP55085
p51645
sg42011
I1
sa(dp51646
g42006
I75
sg42007
g51636
sg42008
I8
sg42016
VP01584
p51647
sg42011
I1
sasa(dp51648
g41997
VSLPI expression is generally induced during inflammation; however, Helicobacter pylori-mediated gastritis is associated with significantly decreased antral SLPI levels.
p51649
sg4
(dp51650
(VSLPI
p51651
Vgastritis
p51652
tp51653
I01
ssg42003
(lp51654
(dp51655
g42006
I44
sg42007
Vinflammation
p51656
sg42008
I12
sg42009
VC0021368
p51657
sg42011
I1
sa(dp51658
g42006
I96
sg42007
g51652
sg42008
I9
sg42009
VC0017152
p51659
sg42011
I1
sasg42012
(lp51660
(dp51661
g42006
I0
sg42007
g51651
sg42008
I4
sg42016
VP03973
p51662
sg42011
I1
sasa(dp51663
g41997
VIn comparison with the control group, the SLPI expression of antral mucosa in H. pylori-mediated and lymphocytic gastritis was significantly lower (P&lt;0.001), whereas epithelial SLPI expression was not affected in NSAID-enhanced and autoimmune gastritis either in the antrum or corpus, respectively.
p51664
sg4
(dp51665
(Vepithelial SLPI
p51666
Vautoimmune gastritis
p51667
tp51668
I01
ssg42003
(lp51669
(dp51670
g42006
I101
sg42007
Vlymphocytic gastritis
p51671
sg42008
I21
sg42009
VC1283271
p51672
sg42011
I2
sa(dp51673
g42006
I235
sg42007
g51667
sg42008
I20
sg42009
VC0017154
p51674
sg42011
I2
sasg42012
(lp51675
(dp51676
g42006
I42
sg42007
VSLPI
p51677
sg42008
I4
sg42016
VP03973
p51678
sg42011
I1
sa(dp51679
g42006
I169
sg42007
g51666
sg42008
I15
sg42016
VP12830
p51680
sg42011
I2
sasa(dp51681
g41997
VBoth the H. pylori-mediated and lymphocytic gastritis revealed a significantly lower expression of SLPI in infiltrating immune cells (P&lt;0.01), whereas immune cells infiltrating the corpus in autoimmune gastritis showed higher SLPI levels than the immune cells of other groups (P&lt;0.03).
p51682
sg4
(dp51683
(VSLPI
p51684
Vautoimmune gastritis
p51685
tp51686
I00
ssg42003
(lp51687
(dp51688
g42006
I32
sg42007
Vlymphocytic gastritis
p51689
sg42008
I21
sg42009
VC1283271
p51690
sg42011
I2
sa(dp51691
g42006
I194
sg42007
g51685
sg42008
I20
sg42009
VC0017154
p51692
sg42011
I2
sa(dp51693
g42006
I107
sg42007
Vinfiltrating
p51694
sg42008
I12
sg42009
VC0332448
p51695
sg42011
I1
sa(dp51696
g42006
I107
sg42007
Vinfiltrating
p51697
sg42008
I12
sg42009
VC0332448
p51698
sg42011
I1
sasg42012
(lp51699
(dp51700
g42006
I99
sg42007
g51684
sg42008
I4
sg42016
VP03973
p51701
sg42011
I1
sasa(dp51702
g41997
VPharmacological inhibition of different signaling pathways and genetic knockdown of Notch-2 further revealed JNK as an upstream effector of Notch-2 in TGF-Beta1-mediated renal fibrosis.
p51703
sg4
(dp51704
(VTGF-Beta1
p51705
Vrenal fibrosis
p51706
tp51707
I00
ssg42003
(lp51708
(dp51709
g42006
I170
sg42007
g51706
sg42008
I14
sg42009
VC0151650
p51710
sg42011
I2
sasg42012
(lp51711
(dp51712
g42006
I109
sg42007
VJNK
p51713
sg42008
I3
sg42016
VP53779
p51714
sg42011
I1
sa(dp51715
g42006
I151
sg42007
g51705
sg42008
I9
sg42016
VP01137
p51716
sg42011
I1
sa(dp51717
g42006
I84
sg42007
VNotch-2
p51718
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp51719
g42006
I84
sg42007
VNotch-2
p51720
sg42008
I7
sg42016
g190
sg42011
I1
sasa(dp51721
g41997
VConsistently, we also demonstrated that administration of TSA or a Gamma-secretase inhibitor RO4929097 in the mouse model of unilateral ureteral obstruction significantly ameliorated renal fibrosis through suppression of the JNK/Notch-2 signaling activation.
p51722
sg4
(dp51723
(VJNK
p51724
Vrenal fibrosis
p51725
tp51726
I00
ssg42003
(lp51727
(dp51728
g42006
I136
sg42007
Vureteral obstruction
p51729
sg42008
I20
sg42009
VC0041956
p51730
sg42011
I2
sa(dp51731
g42006
I183
sg42007
g51725
sg42008
I14
sg42009
VC0151650
p51732
sg42011
I2
sa(dp51733
g42006
I206
sg42007
Vsuppression
p51734
sg42008
I11
sg42009
VC0221103
p51735
sg42011
I1
sasg42012
(lp51736
(dp51737
g42006
I229
sg42007
VNotch-2
p51738
sg42008
I7
sg42016
g190
sg42011
I1
sa(dp51739
g42006
I225
sg42007
g51724
sg42008
I3
sg42016
VP53779
p51740
sg42011
I1
sasa(dp51741
g41997
VThe role of NOTCH2 and JAG1 in formation of proximal nephron structures and podocytes might explain the observed phenotypes of renal dysplasia and proteinuria in patients with Alagille syndrome, and renal tubular acidosis may be the result of JAG1 expression in the collecting ducts.
p51742
sg4
(dp51743
(VJAG1
p51744
VAlagille syndrome
p51745
tp51746
I00
ssg42003
(lp51747
(dp51748
g42006
I127
sg42007
Vrenal dysplasia
p51749
sg42008
I15
sg42009
VC0266313
p51750
sg42011
I2
sa(dp51751
g42006
I199
sg42007
Vrenal tubular acidosis
p51752
sg42008
I22
sg42009
VC0001126
p51753
sg42011
I3
sa(dp51754
g42006
I176
sg42007
g51745
sg42008
I17
sg42009
VC0085280
p51755
sg42011
I2
sasg42012
(lp51756
(dp51757
g42006
I12
sg42007
VNOTCH2
p51758
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp51759
g42006
I23
sg42007
VJAG1
p51760
sg42008
I4
sg42016
VP78504
p51761
sg42011
I1
sa(dp51762
g42006
I23
sg42007
g51744
sg42008
I4
sg42016
VP78504
p51763
sg42011
I1
sasa(dp51764
g41997
VThe oral pathogenic bacterium involved in human dental caries formation Streptococcus mutans, encodes for two carbonic anhydrase (CA, EC 4.2.1.1) one belonging to the Alfa- and the other one to the Beta-class.
p51765
sg4
(dp51766
(VCA
p51767
Vdental caries
p51768
tp51769
I00
ssg42003
(lp51770
(dp51771
g42006
I48
sg42007
g51768
sg42008
I13
sg42009
VC0333519
p51772
sg42011
I2
sasg42012
(lp51773
(dp51774
g42006
I110
sg42007
Vcarbonic anhydrase
p51775
sg42008
I18
sg42016
VP35218
p51776
sg42011
I2
sa(dp51777
g42006
I130
sg42007
g51767
sg42008
I2
sg42016
VP35218
p51778
sg42011
I1
sasa(dp51779
g41997
VStreptococcus mutans, the oral pathogenic bacterium provoking dental caries formation, encodes for a Beta-class carbonic anhydrase (CA, EC 4.2.1.1), SmuCA.
p51780
sg4
(dp51781
(VBeta-class carbonic anhydrase
p51782
Vdental caries
p51783
tp51784
I00
ssg42003
(lp51785
(dp51786
g42006
I62
sg42007
g51783
sg42008
I13
sg42009
VC0333519
p51787
sg42011
I2
sasg42012
(lp51788
(dp51789
g42006
I101
sg42007
g51782
sg42008
I29
sg42016
VP35218
p51790
sg42011
I3
sasa(dp51791
g41997
VA carbonic anhydrase (CA, EC 4.2.1.1) denominated PgiCA, belonging to the Gamma-class, from the oral pathogenic bacteria Porphyromonas gingivalis, the main causative agent of periodontitis, was investigated for its inhibition profile with sulfonamides and one sulfamate.
p51792
sg4
(dp51793
(Vcarbonic anhydrase
p51794
Vperiodontitis
p51795
tp51796
I00
ssg42003
(lp51797
(dp51798
g42006
I175
sg42007
g51795
sg42008
I13
sg42009
VC0031099
p51799
sg42011
I1
sasg42012
(lp51800
(dp51801
g42006
I22
sg42007
VCA
p51802
sg42008
I2
sg42016
VP35218
p51803
sg42011
I1
sa(dp51804
g42006
I2
sg42007
g51794
sg42008
I18
sg42016
VP35218
p51805
sg42011
I2
sasa(dp51806
g41997
VRecently, an interaction between FIR (FUSE-Binding Protein-Interacting Repressor) and TFIIH/p89/XPB helicase was found to repress c-myc transcription and so might be important for suppressing tumor formation.
p51807
sg4
(dp51808
(VTFIIH
p51809
VXPB
p51810
tp51811
I01
ssg42003
(lp51812
(dp51813
g42006
I192
sg42007
Vtumor
p51814
sg42008
I5
sg42009
VC0027651
p51815
sg42011
I1
sa(dp51816
g42006
I96
sg42007
g51810
sg42008
I3
sg42009
VC0268136
p51817
sg42011
I1
sasg42012
(lp51818
(dp51819
g42006
I130
sg42007
Vc-myc
p51820
sg42008
I5
sg42016
VP12524
p51821
sg42011
I1
sa(dp51822
g42006
I96
sg42007
VXPB helicase
p51823
sg42008
I12
sg42016
VP19447
p51824
sg42011
I2
sa(dp51825
g42006
I86
sg42007
g51809
sg42008
I5
sg42016
VP32780
p51826
sg42011
I1
sasa(dp51827
g41997
VIn XPB cells carrying mutant TFIIH, loop formation failed and the serum response was abnormal; RNAi depletion of FIR similarly disabled c-myc regulation.
p51828
sg4
(dp51829
(VTFIIH
p51830
VXPB
p51831
tp51832
I01
ssg42003
(lp51833
(dp51834
g42006
I3
sg42007
g51831
sg42008
I3
sg42009
VC0268136
p51835
sg42011
I1
sa(dp51836
g42006
I22
sg42007
Vmutant
p51837
sg42008
I6
sg42009
VC0596988
p51838
sg42011
I1
sasg42012
(lp51839
(dp51840
g42006
I113
sg42007
VFIR
p51841
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp51842
g42006
I136
sg42007
Vc-myc
p51843
sg42008
I5
sg42016
VP12524
p51844
sg42011
I1
sa(dp51845
g42006
I29
sg42007
g51830
sg42008
I5
sg42016
VP32780
p51846
sg42011
I1
sasa(dp51847
g41997
VRecently, an interaction between FUSE-binding protein-interacting repressor (FIR) and TFIIH/p89/XPB helicase was found to repress c-myc transcription and might be important for suppressing tumor formation.
p51848
sg4
(dp51849
(VTFIIH
p51850
VXPB
p51851
tp51852
I01
ssg42003
(lp51853
(dp51854
g42006
I189
sg42007
Vtumor
p51855
sg42008
I5
sg42009
VC0027651
p51856
sg42011
I1
sa(dp51857
g42006
I96
sg42007
g51851
sg42008
I3
sg42009
VC0268136
p51858
sg42011
I1
sasg42012
(lp51859
(dp51860
g42006
I130
sg42007
Vc-myc
p51861
sg42008
I5
sg42016
VP12524
p51862
sg42011
I1
sa(dp51863
g42006
I77
sg42007
VFIR
p51864
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp51865
g42006
I96
sg42007
VXPB helicase
p51866
sg42008
I12
sg42016
VP19447
p51867
sg42011
I2
sa(dp51868
g42006
I86
sg42007
g51850
sg42008
I5
sg42016
VP32780
p51869
sg42011
I1
sa(dp51870
g42006
I33
sg42007
VFUSE-binding protein-interacting repressor
p51871
sg42008
I42
sg42016
g190
sg42011
I3
sasa(dp51872
g41997
VHere, XPB and XPD mutations are shown to block transcription activation by the FUSE Binding Protein (FBP), a regulator of c-myc expression, and repression by the FBP Interacting Repressor (FIR).
p51873
sg4
(dp51874
(VXPD
p51875
VXPB
p51876
tp51877
I01
ssg42003
(lp51878
(dp51879
g42006
I14
sg42007
VXPD
p51880
sg42008
I3
sg42009
VC0268138
p51881
sg42011
I1
sa(dp51882
g42006
I6
sg42007
g51876
sg42008
I3
sg42009
VC0268136
p51883
sg42011
I1
sasg42012
(lp51884
(dp51885
g42006
I189
sg42007
VFIR
p51886
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp51887
g42006
I101
sg42007
VFBP
p51888
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp51889
g42006
I122
sg42007
Vc-myc
p51890
sg42008
I5
sg42016
VP12524
p51891
sg42011
I1
sa(dp51892
g42006
I6
sg42007
VXPB
p51893
sg42008
I3
sg42016
VP19447
p51894
sg42011
I1
sa(dp51895
g42006
I14
sg42007
g51875
sg42008
I3
sg42016
VP18074
p51896
sg42011
I1
sa(dp51897
g42006
I79
sg42007
VFUSE Binding Protein
p51898
sg42008
I20
sg42016
g190
sg42011
I3
sa(dp51899
g42006
I162
sg42007
VFBP Interacting Repressor
p51900
sg42008
I25
sg42016
g190
sg42011
I3
sasa(dp51901
g41997
VThe repression domain of FIR targeted only TFIIH's p89/XPB helicase, required at several stages in transcription, but not factors required for promoter selection.
p51902
sg4
(dp51903
(VTFIIH
p51904
VXPB
p51905
tp51906
I01
ssg42003
(lp51907
(dp51908
g42006
I55
sg42007
g51905
sg42008
I3
sg42009
VC0268136
p51909
sg42011
I1
sasg42012
(lp51910
(dp51911
g42006
I55
sg42007
VXPB helicase
p51912
sg42008
I12
sg42016
VP19447
p51913
sg42011
I2
sa(dp51914
g42006
I25
sg42007
VFIR
p51915
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp51916
g42006
I43
sg42007
g51904
sg42008
I5
sg42016
VP32780
p51917
sg42011
I1
sasa(dp51918
g41997
VUsing skin samples from patients with mycosis fungoides (n = 21), healthy volunteers (n = 17), and individuals with atopic dermatitis (n = 17) and psoriasis (n = 9), we found IL32 mRNA expression significantly higher in mycosis fungoides samples than in samples from benign inflammatory skin diseases, and its expression increases with disease progression.
p51919
sg4
(dp51920
(VIL32 mRNA
p51921
Vskin diseases
p51922
tp51923
I01
ssg42003
(lp51924
(dp51925
g42006
I116
sg42007
Vatopic dermatitis
p51926
sg42008
I17
sg42009
VC0011615
p51927
sg42011
I2
sa(dp51928
g42006
I38
sg42007
Vmycosis fungoides
p51929
sg42008
I17
sg42009
VC0026948
p51930
sg42011
I2
sa(dp51931
g42006
I336
sg42007
Vdisease progression
p51932
sg42008
I19
sg42009
VC0242656
p51933
sg42011
I2
sa(dp51934
g42006
I147
sg42007
Vpsoriasis
p51935
sg42008
I9
sg42009
VC0033860
p51936
sg42011
I1
sa(dp51937
g42006
I38
sg42007
Vmycosis fungoides
p51938
sg42008
I17
sg42009
VC0026948
p51939
sg42011
I2
sa(dp51940
g42006
I287
sg42007
g51922
sg42008
I13
sg42009
VC0037274
p51941
sg42011
I2
sasg42012
(lp51942
(dp51943
g42006
I175
sg42007
g51921
sg42008
I9
sg42016
VP24001
p51944
sg42011
I2
sasa(dp51945
g41997
VASPP2-transfected choriocarcinoma cells (JEG-3 and JAR) showed an increase in apoptosis and a decrease in cell migration as detected by TdT-mediated dUTP nick end labeling and wound healing assays, respectively, illustrating the complex action of ASPP2 on cell functions other than programmed cell death.
p51946
sg4
(dp51947
(VTdT
p51948
Vchoriocarcinoma
p51949
tp51950
I00
ssg42003
(lp51951
(dp51952
g42006
I18
sg42007
g51949
sg42008
I15
sg42009
VC0008497
p51953
sg42011
I1
sasg42012
(lp51954
(dp51955
g42006
I0
sg42007
VASPP2
p51956
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp51957
g42006
I0
sg42007
VASPP2
p51958
sg42008
I5
sg42016
g190
sg42011
I1
sa(dp51959
g42006
I136
sg42007
g51948
sg42008
I3
sg42016
VP04053
p51960
sg42011
I1
sasa(dp51961
g41997
VNo correlation between erythrocyte TDP concentration and transketolase activity and/or alpha-ETK was observed in ESRD patients, either before or 10 h after administration.
p51962
sg4
(dp51963
(Valpha-ETK
p51964
VESRD
p51965
tp51966
I00
ssg42003
(lp51967
(dp51968
g42006
I113
sg42007
g51965
sg42008
I4
sg42009
VC0022661
p51969
sg42011
I1
sasg42012
(lp51970
(dp51971
g42006
I57
sg42007
Vtransketolase
p51972
sg42008
I13
sg42016
VP29401
p51973
sg42011
I1
sa(dp51974
g42006
I87
sg42007
g51964
sg42008
I9
sg42016
VP51813
p51975
sg42011
I1
sasa(dp51976
g41997
VScores for VEGF, TIMP-1, TIMP-3, SLPI and PAI-1 were all increased in OA compared with PM, and higher scores were associated with greater chondropathy.
p51977
sg4
(dp51978
(VSLPI
p51979
Vchondropathy
p51980
tp51981
I00
ssg42003
(lp51982
(dp51983
g42006
I138
sg42007
g51980
sg42008
I12
sg42009
VC0007302
p51984
sg42011
I1
sasg42012
(lp51985
(dp51986
g42006
I42
sg42007
VPAI-1
p51987
sg42008
I5
sg42016
VP05121
p51988
sg42011
I1
sa(dp51989
g42006
I25
sg42007
VTIMP-3
p51990
sg42008
I6
sg42016
VP35625
p51991
sg42011
I1
sa(dp51992
g42006
I17
sg42007
VTIMP-1
p51993
sg42008
I6
sg42016
VP01033
p51994
sg42011
I1
sa(dp51995
g42006
I33
sg42007
g51979
sg42008
I4
sg42016
VP03973
p51996
sg42011
I1
sasa(dp51997
g41997
VConcentrations of the plasminogen activators pro-urokinase, tissue plasminogen activator, plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2), plasminogen, and fibrin split product D-dimer in synovial fluid (SF) and blood plasma of 29 patients with rheumatoid arthritis (RA) were compared with the concentrations of 18 patients with spondyloarthropathy (SpA).
p51998
sg4
(dp51999
(VPAI-2
p52000
Vrheumatoid arthritis
p52001
tp52002
I00
ssg42003
(lp52003
(dp52004
g42006
I278
sg42007
VRA
p52005
sg42008
I2
sg42009
VC0003873
p52006
sg42011
I1
sa(dp52007
g42006
I361
sg42007
VSpA
p52008
sg42008
I3
sg42009
VC0949691
p52009
sg42011
I1
sa(dp52010
g42006
I340
sg42007
Vspondyloarthropathy
p52011
sg42008
I19
sg42009
VC0949691
p52012
sg42011
I1
sa(dp52013
g42006
I256
sg42007
g52001
sg42008
I20
sg42009
VC0003873
p52014
sg42011
I2
sasg42012
(lp52015
(dp52016
g42006
I132
sg42007
VPAI-1
p52017
sg42008
I5
sg42016
VP05121
p52018
sg42011
I1
sa(dp52019
g42006
I60
sg42007
Vtissue plasminogen activator
p52020
sg42008
I28
sg42016
VP00747
p52021
sg42011
I3
sa(dp52022
g42006
I22
sg42007
Vplasminogen
p52023
sg42008
I11
sg42016
VP00747
p52024
sg42011
I1
sa(dp52025
g42006
I22
sg42007
Vplasminogen activators pro-urokinase
p52026
sg42008
I36
sg42016
VP00747
p52027
sg42011
I3
sa(dp52028
g42006
I90
sg42007
Vplasminogen activator inhibitors 1 and 2
p52029
sg42008
I40
sg42016
VP00747
p52030
sg42011
I6
sa(dp52031
g42006
I167
sg42007
Vfibrin
p52032
sg42008
I6
sg42016
VP22087
p52033
sg42011
I1
sa(dp52034
g42006
I142
sg42007
g52000
sg42008
I5
sg42016
VP05120
p52035
sg42011
I1
sasa(dp52036
g41997
VBesides myeloperoxidase (MPO), which was used as the gold standard in differentiating AML from other type of ALs, the most specific markers for AML in our study were CD14 and CD64 (99.5 and 95.6%).
p52037
sg4
(dp52038
(VMPO
p52039
VAML
p52040
tp52041
I00
ssg42003
(lp52042
(dp52043
g42006
I86
sg42007
VAML
p52044
sg42008
I3
sg42009
VC0023467
p52045
sg42011
I1
sa(dp52046
g42006
I109
sg42007
VALs
p52047
sg42008
I3
sg42009
VC0002736
p52048
sg42011
I1
sa(dp52049
g42006
I86
sg42007
g52040
sg42008
I3
sg42009
VC0023467
p52050
sg42011
I1
sasg42012
(lp52051
(dp52052
g42006
I8
sg42007
Vmyeloperoxidase
p52053
sg42008
I15
sg42016
VP05164
p52054
sg42011
I1
sa(dp52055
g42006
I166
sg42007
VCD14
p52056
sg42008
I4
sg42016
VP08571
p52057
sg42011
I1
sa(dp52058
g42006
I25
sg42007
g52039
sg42008
I3
sg42016
VP05164
p52059
sg42011
I1
sasa(dp52060
g41997
VThey were characterized as follows: (1) disease onset with initial signs/symptoms due to intractable otitis media with effusion or granulation, which did not respond to ordinary treatments such as antibiotics and insertion of tympanic ventilation tubes, followed by progressive hearing loss; (2) predominantly female (73%) and older (median age: 68 years); (3) predominantly myeloperoxidase (MPO)-ANCA-positive (60%), followed by proteinase 3 (PR3)-ANCA-positive (19%) and both ANCAs-negative (16%); (4) frequently observed accompanying facial palsy (36%) and hypertrophic pachymeningitis (28%); and (5) disease often involving lung (35%) and kidney (26%) lesions.
p52061
sg4
(dp52062
(VMPO
p52063
Vhearing loss
p52064
tp52065
I00
ssg42003
(lp52066
(dp52067
g42006
I537
sg42007
Vfacial palsy
p52068
sg42008
I12
sg42009
VC0015469
p52069
sg42011
I2
sa(dp52070
g42006
I101
sg42007
Votitis media with effusion
p52071
sg42008
I26
sg42009
VC0029883
p52072
sg42011
I4
sa(dp52073
g42006
I278
sg42007
g52064
sg42008
I12
sg42009
VC0011053
p52074
sg42011
I2
sa(dp52075
g42006
I560
sg42007
Vhypertrophic pachymeningitis
p52076
sg42008
I28
sg42009
VC0948402
p52077
sg42011
I2
sasg42012
(lp52078
(dp52079
g42006
I430
sg42007
Vproteinase 3
p52080
sg42008
I12
sg42016
VP63123
p52081
sg42011
I2
sa(dp52082
g42006
I444
sg42007
VPR3
p52083
sg42008
I3
sg42016
VP63123
p52084
sg42011
I1
sa(dp52085
g42006
I375
sg42007
Vmyeloperoxidase
p52086
sg42008
I15
sg42016
VP05164
p52087
sg42011
I1
sa(dp52088
g42006
I392
sg42007
g52063
sg42008
I3
sg42016
VP05164
p52089
sg42011
I1
sasa(dp52090
g41997
VThe altered tissue steroid concentrations in endometriosis were in line with the expression of various steroidogenic enzymes in the lesions, of which HSD3B2 showed constantly high expression, whereas CYP11A1 expression was low.
p52091
sg4
(dp52092
(VHSD3B2
p52093
Vendometriosis
p52094
tp52095
I01
ssg42003
(lp52096
(dp52097
g42006
I45
sg42007
g52094
sg42008
I13
sg42009
VC0014175
p52098
sg42011
I1
sasg42012
(lp52099
(dp52100
g42006
I200
sg42007
VCYP11A1
p52101
sg42008
I7
sg42016
VP05108
p52102
sg42011
I1
sa(dp52103
g42006
I150
sg42007
g52093
sg42008
I6
sg42016
VP26439
p52104
sg42011
I1
sasa(dp52105
g41997
VType III groups together 10 autoimmune diseases (autoimmune thyroid disease, myasthenia and/or thymoma, Sjoegren's syndrome, pernicious anaemia, idiopathic thrombocytopaenic purpura, Addison's disease, insulin-dependent diabetes, vitiligo, autoimmune haemolytic anaemia, systemic lupus erythematosus) for which a genetic predisposition (phenotype HLA B8 and/or DR3 or DR5) seems to be an important factor.
p52106
sg4
(dp52107
(Vinsulin
p52108
Vautoimmune haemolytic anaemia
p52109
tp52110
I00
ssg42003
(lp52111
(dp52112
g42006
I49
sg42007
Vautoimmune thyroid disease
p52113
sg42008
I26
sg42009
VC0178468
p52114
sg42011
I3
sa(dp52115
g42006
I271
sg42007
Vsystemic lupus erythematosus
p52116
sg42008
I28
sg42009
VC0024141
p52117
sg42011
I3
sa(dp52118
g42006
I183
sg42007
VAddison's disease
p52119
sg42008
I17
sg42009
VC0001403
p52120
sg42011
I2
sa(dp52121
g42006
I202
sg42007
Vinsulin-dependent diabetes
p52122
sg42008
I26
sg42009
VC0011854
p52123
sg42011
I2
sa(dp52124
g42006
I230
sg42007
Vvitiligo
p52125
sg42008
I8
sg42009
VC0042900
p52126
sg42011
I1
sa(dp52127
g42006
I95
sg42007
Vthymoma
p52128
sg42008
I7
sg42009
VC0040100
p52129
sg42011
I1
sa(dp52130
g42006
I28
sg42007
Vautoimmune diseases
p52131
sg42008
I19
sg42009
VC0004364
p52132
sg42011
I2
sa(dp52133
g42006
I77
sg42007
Vmyasthenia
p52134
sg42008
I10
sg42009
VC0947912
p52135
sg42011
I1
sa(dp52136
g42006
I104
sg42007
VSjoegren's syndrome
p52137
sg42008
I19
sg42009
VC1527336
p52138
sg42011
I2
sa(dp52139
g42006
I156
sg42007
Vthrombocytopaenic purpura
p52140
sg42008
I25
sg42009
VC0857305
p52141
sg42011
I2
sa(dp52142
g42006
I125
sg42007
Vpernicious anaemia
p52143
sg42008
I18
sg42009
VC0002892
p52144
sg42011
I2
sa(dp52145
g42006
I240
sg42007
g52109
sg42008
I29
sg42009
VC0002880
p52146
sg42011
I3
sasg42012
(lp52147
(dp52148
g42006
I202
sg42007
g52108
sg42008
I7
sg42016
VP01308
p52149
sg42011
I1
sasa(dp52150
g41997
VUC treatment obviously reduced the expression levels of IL-2, IFN-Gamma, NF-KBp65, ICAM-1 and VEGF and increased inhibitory kappa B alpha (IKB-Alfa) expression in the grafts, where no obvious inflammatory cell infiltration or corneal neovascularization was found.
p52151
sg4
(dp52152
(VIFN-Gamma
p52153
Vcorneal neovascularization
p52154
tp52155
I00
ssg42003
(lp52156
(dp52157
g42006
I192
sg42007
Vinflammatory cell infiltration
p52158
sg42008
I30
sg42009
VC0302158
p52159
sg42011
I3
sa(dp52160
g42006
I226
sg42007
g52154
sg42008
I26
sg42009
VC0085109
p52161
sg42011
I2
sasg42012
(lp52162
(dp52163
g42006
I56
sg42007
VIL-2
p52164
sg42008
I4
sg42016
VP60568
p52165
sg42011
I1
sa(dp52166
g42006
I83
sg42007
VICAM-1
p52167
sg42008
I6
sg42016
VP05362
p52168
sg42011
I1
sa(dp52169
g42006
I139
sg42007
VIKB-Alfa
p52170
sg42008
I8
sg42016
VP25963
p52171
sg42011
I1
sa(dp52172
g42006
I62
sg42007
g52153
sg42008
I9
sg42016
VP01579
p52173
sg42011
I1
sasa(dp52174
g41997
VCDC6 and GDF-9 expressions in 108 gallbladder adenocarcinomas, 15 gallbladder polyps, 35 chronic cholecystitis tissues, and 46 peritumoral tissues were detected using immunohistochemistry (IHC).
p52175
sg4
(dp52176
(VGDF-9
p52177
Vchronic cholecystitis
p52178
tp52179
I00
ssg42003
(lp52180
(dp52181
g42006
I66
sg42007
Vgallbladder polyps
p52182
sg42008
I18
sg42009
VC0262493
p52183
sg42011
I2
sa(dp52184
g42006
I46
sg42007
Vadenocarcinomas
p52185
sg42008
I15
sg42009
VC0001418
p52186
sg42011
I1
sa(dp52187
g42006
I89
sg42007
g52178
sg42008
I21
sg42009
VC0085694
p52188
sg42011
I2
sasg42012
(lp52189
(dp52190
g42006
I0
sg42007
VCDC6
p52191
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp52192
g42006
I9
sg42007
g52177
sg42008
I5
sg42016
VP09466
p52193
sg42011
I1
sasa(dp52194
g41997
VWe demonstrated that positive CDC6 and GDF-9 expressions were significantly higher in adenocarcinomas than that in peritumoral tissues, polyps, and chronic cholecystitis (p &lt; 0.01).
p52195
sg4
(dp52196
(VGDF-9
p52197
Vadenocarcinomas
p52198
tp52199
I01
ssg42003
(lp52200
(dp52201
g42006
I148
sg42007
Vchronic cholecystitis
p52202
sg42008
I21
sg42009
VC0085694
p52203
sg42011
I2
sa(dp52204
g42006
I136
sg42007
Vpolyps
p52205
sg42008
I6
sg42009
VC0032584
p52206
sg42011
I1
sa(dp52207
g42006
I86
sg42007
g52198
sg42008
I15
sg42009
VC0001418
p52208
sg42011
I1
sasg42012
(lp52209
(dp52210
g42006
I30
sg42007
VCDC6
p52211
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp52212
g42006
I39
sg42007
g52197
sg42008
I5
sg42016
VP09466
p52213
sg42011
I1
sasa(dp52214
g41997
VPreviously, we identified MFAP4 as a serum biomarker candidate for hepatic fibrosis and cirrhosis in hepatitis C patients.
p52215
sg4
(dp52216
(VMFAP4
p52217
Vhepatitis C
p52218
tp52219
I00
ssg42003
(lp52220
(dp52221
g42006
I67
sg42007
Vhepatic fibrosis
p52222
sg42008
I16
sg42009
VC0239946
p52223
sg42011
I2
sa(dp52224
g42006
I88
sg42007
Vcirrhosis
p52225
sg42008
I9
sg42009
VC0023890
p52226
sg42011
I1
sa(dp52227
g42006
I101
sg42007
g52218
sg42008
I11
sg42009
VC0019196
p52228
sg42011
I2
sasg42012
(lp52229
(dp52230
g42006
I26
sg42007
g52217
sg42008
I5
sg42016
VP55083
p52231
sg42011
I1
sasa(dp52232
g41997
VThe aim of the present study was to elucidate the potential of MFAP4 as biomarker for hepatic fibrosis with a focus on the differentiation of no to moderate (F0-F2) and severe fibrosis stages and cirrhosis (F3 and F4, Desmet-Scheuer scoring system).
p52233
sg4
(dp52234
(VMFAP4
p52235
Vfibrosis
p52236
tp52237
I00
ssg42003
(lp52238
(dp52239
g42006
I196
sg42007
Vcirrhosis
p52240
sg42008
I9
sg42009
VC0023890
p52241
sg42011
I1
sa(dp52242
g42006
I86
sg42007
Vhepatic fibrosis
p52243
sg42008
I16
sg42009
VC0239946
p52244
sg42011
I2
sa(dp52245
g42006
I94
sg42007
g52236
sg42008
I8
sg42009
VC0016059
p52246
sg42011
I1
sasg42012
(lp52247
(dp52248
g42006
I63
sg42007
g52235
sg42008
I5
sg42016
VP55083
p52249
sg42011
I1
sasa(dp52250
g41997
VMicrofibrillar-associated protein 4 (MFAP4) is a systemic biomarker that is significantly elevated in samples from patients suffering from hepatic cirrhosis.
p52251
sg4
(dp52252
(VMFAP4
p52253
Vhepatic cirrhosis
p52254
tp52255
I00
ssg42003
(lp52256
(dp52257
g42006
I124
sg42007
Vsuffering
p52258
sg42008
I9
sg42009
VC0683278
p52259
sg42011
I1
sa(dp52260
g42006
I139
sg42007
g52254
sg42008
I17
sg42009
VC0023890
p52261
sg42011
I2
sasg42012
(lp52262
(dp52263
g42006
I0
sg42007
VMicrofibrillar-associated protein 4
p52264
sg42008
I35
sg42016
VP55083
p52265
sg42011
I3
sa(dp52266
g42006
I37
sg42007
g52253
sg42008
I5
sg42016
VP55083
p52267
sg42011
I1
sasa(dp52268
g41997
VTropomyosin and MFAP-4 demonstrated high serum levels in patients with hepatic cirrhosis of different causes.
p52269
sg4
(dp52270
(VTropomyosin
p52271
Vhepatic cirrhosis
p52272
tp52273
I00
ssg42003
(lp52274
(dp52275
g42006
I71
sg42007
g52272
sg42008
I17
sg42009
VC0023890
p52276
sg42011
I2
sasg42012
(lp52277
(dp52278
g42006
I0
sg42007
g52271
sg42008
I11
sg42016
VP07951
p52279
sg42011
I1
sasa(dp52280
g41997
VLow CRF had PARs of 9.3% and 10.5% for cancer mortality in subjects who had overweight and obesity, respectively.
p52281
sg4
(dp52282
(VCRF
p52283
Voverweight and obesity
p52284
tp52285
I00
ssg42003
(lp52286
(dp52287
g42006
I4
sg42007
VCRF
p52288
sg42008
I3
sg42009
VC0022661
p52289
sg42011
I1
sa(dp52290
g42006
I39
sg42007
Vcancer
p52291
sg42008
I6
sg42009
VC0006826
p52292
sg42011
I1
sa(dp52293
g42006
I76
sg42007
g52284
sg42008
I22
sg42009
VC1561826
p52294
sg42011
I3
sasg42012
(lp52295
(dp52296
g42006
I4
sg42007
g52283
sg42008
I3
sg42016
VP06850
p52297
sg42011
I1
sasa(dp52298
g41997
VThrombin-induced activation of protease-activated receptors (PARs) represents a link between inflammation and cancer.
p52299
sg4
(dp52300
(VThrombin
p52301
Vinflammation
p52302
tp52303
I00
ssg42003
(lp52304
(dp52305
g42006
I93
sg42007
g52302
sg42008
I12
sg42009
VC0021368
p52306
sg42011
I1
sa(dp52307
g42006
I110
sg42007
Vcancer
p52308
sg42008
I6
sg42009
VC0006826
p52309
sg42011
I1
sasg42012
(lp52310
(dp52311
g42006
I61
sg42007
VPARs
p52312
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp52313
g42006
I31
sg42007
Vprotease-activated receptors
p52314
sg42008
I28
sg42016
VP63123
p52315
sg42011
I2
sa(dp52316
g42006
I0
sg42007
g52301
sg42008
I8
sg42016
VP00734
p52317
sg42011
I1
sasa(dp52318
g41997
VFrozen tunica vaginalis specimens from patients with adult-onset primary hydrocele testis and control male nonhydrocele patients were subjected to Western blot analysis for the detection of AQP1 and AQP3 proteins.
p52319
sg4
(dp52320
(VAQP1
p52321
Vvaginalis
p52322
tp52323
I00
ssg42003
(lp52324
(dp52325
g42006
I73
sg42007
Vhydrocele testis
p52326
sg42008
I16
sg42009
VC1720771
p52327
sg42011
I2
sa(dp52328
g42006
I14
sg42007
g52322
sg42008
I9
sg42009
VC0750103
p52329
sg42011
I1
sasg42012
(lp52330
(dp52331
g42006
I190
sg42007
g52321
sg42008
I4
sg42016
VP29972
p52332
sg42011
I1
sa(dp52333
g42006
I199
sg42007
VAQP3 proteins
p52334
sg42008
I13
sg42016
g190
sg42011
I2
sasa(dp52335
g41997
VAQP1 protein expression in the tunica vaginalis was significantly higher in patients with adult-onset hydrocele testis than in the controls.
p52336
sg4
(dp52337
(VAQP1
p52338
Vhydrocele testis
p52339
tp52340
I00
ssg42003
(lp52341
(dp52342
g42006
I38
sg42007
Vvaginalis
p52343
sg42008
I9
sg42009
VC0750103
p52344
sg42011
I1
sa(dp52345
g42006
I102
sg42007
g52339
sg42008
I16
sg42009
VC1720771
p52346
sg42011
I2
sasg42012
(lp52347
(dp52348
g42006
I0
sg42007
g52338
sg42008
I4
sg42016
VP29972
p52349
sg42011
I1
sasa(dp52350
g41997
VThe densities of AQP1-expressing capillaries and lymphatic vessels were similar between the tunica vaginalis of the controls and those of hydrocele patients.
p52351
sg4
(dp52352
(VAQP1
p52353
Vhydrocele
p52354
tp52355
I00
ssg42003
(lp52356
(dp52357
g42006
I99
sg42007
Vvaginalis
p52358
sg42008
I9
sg42009
VC0750103
p52359
sg42011
I1
sa(dp52360
g42006
I138
sg42007
g52354
sg42008
I9
sg42009
VC1720771
p52361
sg42011
I1
sasg42012
(lp52362
(dp52363
g42006
I17
sg42007
g52353
sg42008
I4
sg42016
VP29972
p52364
sg42011
I1
sasa(dp52365
g41997
VIn conclusion, overexpression of the AQP1 protein in individual capillary endothelial cells of the tunica vaginalis may contribute to the development of adult-onset primary noncommunicating hydrocele testis as another aquaporin-related disease.
p52366
sg4
(dp52367
(VAQP1 protein
p52368
Vvaginalis
p52369
tp52370
I00
ssg42003
(lp52371
(dp52372
g42006
I190
sg42007
Vhydrocele testis
p52373
sg42008
I16
sg42009
VC1720771
p52374
sg42011
I2
sa(dp52375
g42006
I106
sg42007
g52369
sg42008
I9
sg42009
VC0750103
p52376
sg42011
I1
sasg42012
(lp52377
(dp52378
g42006
I218
sg42007
Vaquaporin
p52379
sg42008
I9
sg42016
VP30301
p52380
sg42011
I1
sa(dp52381
g42006
I37
sg42007
g52368
sg42008
I12
sg42016
VP29972
p52382
sg42011
I2
sasa(dp52383
g41997
VCollectively, the MLN CD11b- CD103+ PD-L1High DC subset probably takes up luminal antigens in the intestine, migrates to MLNs, and highly induces regulatory T cells through TGF-Beta activation.
p52384
sg4
(dp52385
(VTGF-Beta
p52386
VMLNs
p52387
tp52388
I00
ssg42003
(lp52389
(dp52390
g42006
I121
sg42007
g52387
sg42008
I4
sg42009
VC0026691
p52391
sg42011
I1
sasg42012
(lp52392
(dp52393
g42006
I121
sg42007
VMLNs
p52394
sg42008
I4
sg42016
VP12872
p52395
sg42011
I1
sa(dp52396
g42006
I18
sg42007
VMLN CD11b- CD103+ PD-L1High
p52397
sg42008
I27
sg42016
VP12872
p52398
sg42011
I4
sa(dp52399
g42006
I173
sg42007
g52386
sg42008
I8
sg42016
VP18075
p52400
sg42011
I1
sasa(dp52401
g41997
VFurthermore, Ye were found exclusively associated with CD103(+) DCs in the MLNs from wild-type mice, but not from CCR7(-/-) mice, demonstrating a CCR7 dependent transport of Ye by CD103(+) DCs from LP to the MLNs.
p52402
sg4
(dp52403
(VCCR7
p52404
VDCs
p52405
tp52406
I00
ssg42003
(lp52407
(dp52408
g42006
I75
sg42007
VMLNs
p52409
sg42008
I4
sg42009
VC0026691
p52410
sg42011
I1
sa(dp52411
g42006
I75
sg42007
VMLNs
p52412
sg42008
I4
sg42009
VC0026691
p52413
sg42011
I1
sa(dp52414
g42006
I64
sg42007
VDCs
p52415
sg42008
I3
sg42009
VC0268238
p52416
sg42011
I1
sa(dp52417
g42006
I64
sg42007
g52405
sg42008
I3
sg42009
VC0268238
p52418
sg42011
I1
sasg42012
(lp52419
(dp52420
g42006
I55
sg42007
VCD103(+) DCs
p52421
sg42008
I12
sg42016
VP38570
p52422
sg42011
I2
sa(dp52423
g42006
I55
sg42007
VCD103(+) DCs
p52424
sg42008
I12
sg42016
VP38570
p52425
sg42011
I2
sa(dp52426
g42006
I114
sg42007
VCCR7
p52427
sg42008
I4
sg42016
VP32248
p52428
sg42011
I1
sa(dp52429
g42006
I114
sg42007
g52404
sg42008
I4
sg42016
VP32248
p52430
sg42011
I1
sasa(dp52431
g41997
VDespite tolerance development, CD103(+)CD11b(+) DCs, which are the major migratory DC population in the MLNs, and the tolerance-related retinoic acid-generating enzyme RALDH2 were virtually absent from the ILNs.
p52432
sg4
(dp52433
(VCD103(+)CD11b(+) DCs
p52434
VMLNs
p52435
tp52436
I00
ssg42003
(lp52437
(dp52438
g42006
I8
sg42007
Vtolerance
p52439
sg42008
I9
sg42009
VC0020963
p52440
sg42011
I1
sa(dp52441
g42006
I48
sg42007
VDCs
p52442
sg42008
I3
sg42009
VC0268238
p52443
sg42011
I1
sa(dp52444
g42006
I8
sg42007
Vtolerance
p52445
sg42008
I9
sg42009
VC0020963
p52446
sg42011
I1
sa(dp52447
g42006
I104
sg42007
g52435
sg42008
I4
sg42009
VC0026691
p52448
sg42011
I1
sasg42012
(lp52449
(dp52450
g42006
I168
sg42007
VRALDH2
p52451
sg42008
I6
sg42016
g190
sg42011
I1
sa(dp52452
g42006
I31
sg42007
g52434
sg42008
I20
sg42016
VP38570
p52453
sg42011
I2
sasa(dp52454
g41997
VHere, we demonstrate that GVHD markedly enhances alloantigen presentation within the mesenteric lymph nodes (mLNs), mediated by donor CD103(+)CD11b(-) dendritic cells (DCs) that migrate from the colon under the influence of CCR7.
p52455
sg4
(dp52456
(VCD103(+)CD11b(-)
p52457
Vdendritic cells
p52458
tp52459
I00
ssg42003
(lp52460
(dp52461
g42006
I85
sg42007
Vmesenteric lymph nodes
p52462
sg42008
I22
sg42009
VC0026691
p52463
sg42011
I3
sa(dp52464
g42006
I168
sg42007
VDCs
p52465
sg42008
I3
sg42009
VC0268238
p52466
sg42011
I1
sa(dp52467
g42006
I26
sg42007
VGVHD
p52468
sg42008
I4
sg42009
VC0018133
p52469
sg42011
I1
sa(dp52470
g42006
I109
sg42007
VmLNs
p52471
sg42008
I4
sg42009
VC0026691
p52472
sg42011
I1
sa(dp52473
g42006
I151
sg42007
g52458
sg42008
I15
sg42009
VC0268238
p52474
sg42011
I2
sasg42012
(lp52475
(dp52476
g42006
I224
sg42007
VCCR7
p52477
sg42008
I4
sg42016
VP32248
p52478
sg42011
I1
sa(dp52479
g42006
I134
sg42007
g52457
sg42008
I16
sg42016
VP38570
p52480
sg42011
I1
sasa(dp52481
g41997
VCD103(+) dendritic cells (DCs) continuously migrate from the intestine to the mesenteric lymph nodes (MLNs) and maintain tolerance by driving the development of regulatory T cells (Treg) in the gut.
p52482
sg4
(dp52483
(VCD103
p52484
Vdendritic cells
p52485
tp52486
I00
ssg42003
(lp52487
(dp52488
g42006
I26
sg42007
VDCs
p52489
sg42008
I3
sg42009
VC0268238
p52490
sg42011
I1
sa(dp52491
g42006
I78
sg42007
Vmesenteric lymph nodes
p52492
sg42008
I22
sg42009
VC0026691
p52493
sg42011
I3
sa(dp52494
g42006
I121
sg42007
Vtolerance
p52495
sg42008
I9
sg42009
VC0020963
p52496
sg42011
I1
sa(dp52497
g42006
I102
sg42007
VMLNs
p52498
sg42008
I4
sg42009
VC0026691
p52499
sg42011
I1
sa(dp52500
g42006
I9
sg42007
g52485
sg42008
I15
sg42009
VC0268238
p52501
sg42011
I2
sasg42012
(lp52502
(dp52503
g42006
I0
sg42007
g52484
sg42008
I5
sg42016
VP38570
p52504
sg42011
I1
sasa(dp52505
g41997
VTreatment with PBS followed by 1 single dose of VSL#3, 18 h before killing, was associated with a 2-fold increase in CD103(+)CD11c(+) dendritic cells in MLNs and PPs.
p52506
sg4
(dp52507
(VCD103(+)CD11c
p52508
VMLNs
p52509
tp52510
I00
ssg42003
(lp52511
(dp52512
g42006
I162
sg42007
VPPs
p52513
sg42008
I3
sg42009
VC0265259
p52514
sg42011
I1
sa(dp52515
g42006
I15
sg42007
VPBS
p52516
sg42008
I3
sg42009
VC1720830
p52517
sg42011
I1
sa(dp52518
g42006
I153
sg42007
g52509
sg42008
I4
sg42009
VC0026691
p52519
sg42011
I1
sasg42012
(lp52520
(dp52521
g42006
I117
sg42007
g52508
sg42008
I13
sg42016
VP38570
p52522
sg42011
I1
sasa(dp52523
g41997
VReduced numbers of Th17 cells, suppressed interleukin (IL)-6 production by intestinal explants, and increased Tregs and CD103-positive regulatory dendritic cells in mesenteric lymph nodes (MLNs) were observed.
p52524
sg4
(dp52525
(VCD103
p52526
Vmesenteric lymph nodes
p52527
tp52528
I00
ssg42003
(lp52529
(dp52530
g42006
I189
sg42007
VMLNs
p52531
sg42008
I4
sg42009
VC0026691
p52532
sg42011
I1
sa(dp52533
g42006
I165
sg42007
g52527
sg42008
I22
sg42009
VC0026691
p52534
sg42011
I3
sasg42012
(lp52535
(dp52536
g42006
I42
sg42007
Vinterleukin (IL)-6
p52537
sg42008
I18
sg42016
VP60568
p52538
sg42011
I2
sa(dp52539
g42006
I120
sg42007
g52526
sg42008
I5
sg42016
VP38570
p52540
sg42011
I1
sasa(dp52541
g41997
VThus, oral administration of C. kefyr ameliorated EAE by altering the microflora, accompanied by increased Tregs and CD103-positive regulatory dendritic cells in MLNs and decreased Th17 cells in the intestinal lamina propria.
p52542
sg4
(dp52543
(VCD103
p52544
VMLNs
p52545
tp52546
I00
ssg42003
(lp52547
(dp52548
g42006
I162
sg42007
g52545
sg42008
I4
sg42009
VC0026691
p52549
sg42011
I1
sasg42012
(lp52550
(dp52551
g42006
I117
sg42007
g52544
sg42008
I5
sg42016
VP38570
p52552
sg42011
I1
sasa(dp52553
g41997
VThe proportion of CD103 DCs in PPs and MLNs and IL-10-expressing CD4 T cells of PPs and the LP increased after indomethacin treatment.
p52554
sg4
(dp52555
(VCD103 DCs
p52556
VMLNs
p52557
tp52558
I00
ssg42003
(lp52559
(dp52560
g42006
I31
sg42007
VPPs
p52561
sg42008
I3
sg42009
VC0265259
p52562
sg42011
I1
sa(dp52563
g42006
I24
sg42007
VDCs
p52564
sg42008
I3
sg42009
VC0268238
p52565
sg42011
I1
sa(dp52566
g42006
I31
sg42007
VPPs
p52567
sg42008
I3
sg42009
VC0265259
p52568
sg42011
I1
sa(dp52569
g42006
I39
sg42007
g52557
sg42008
I4
sg42009
VC0026691
p52570
sg42011
I1
sasg42012
(lp52571
(dp52572
g42006
I31
sg42007
VPPs
p52573
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp52574
g42006
I31
sg42007
VPPs
p52575
sg42008
I3
sg42016
g190
sg42011
I1
sa(dp52576
g42006
I48
sg42007
VIL-10-expressing CD4 T
p52577
sg42008
I22
sg42016
VP01730
p52578
sg42011
I3
sa(dp52579
g42006
I39
sg42007
VMLNs
p52580
sg42008
I4
sg42016
VP12872
p52581
sg42011
I1
sa(dp52582
g42006
I18
sg42007
g52556
sg42008
I9
sg42016
VP38570
p52583
sg42011
I2
sasa(dp52584
g41997
VThe PP-null mice showed greater indomethacin-induced enteropathy, fewer CD103 DCs in their MLNs, and lower proportion of IL-10-expressing CD4 T cells of their LP than WT mice, regardless of commensal bacteria.
p52585
sg4
(dp52586
(VIL-10-expressing CD4 T
p52587
VDCs
p52588
tp52589
I00
ssg42003
(lp52590
(dp52591
g42006
I53
sg42007
Venteropathy
p52592
sg42008
I11
sg42009
VC0021831
p52593
sg42011
I1
sa(dp52594
g42006
I91
sg42007
VMLNs
p52595
sg42008
I4
sg42009
VC0026691
p52596
sg42011
I1
sa(dp52597
g42006
I78
sg42007
g52588
sg42008
I3
sg42009
VC0268238
p52598
sg42011
I1
sasg42012
(lp52599
(dp52600
g42006
I72
sg42007
VCD103 DCs
p52601
sg42008
I9
sg42016
VP38570
p52602
sg42011
I2
sa(dp52603
g42006
I121
sg42007
g52587
sg42008
I22
sg42016
VP01730
p52604
sg42011
I3
sasa(dp52605
g41997
VNaive splenic CD4 T cells co-cultured with CD103 DCs isolated from the MLNs of indomethacin-injected WT mice produced a higher amount of IL-10 compared with those co-cultured with CD103 DCs.
p52606
sg4
(dp52607
(VCD103 DCs
p52608
VDCs
p52609
tp52610
I00
ssg42003
(lp52611
(dp52612
g42006
I71
sg42007
VMLNs
p52613
sg42008
I4
sg42009
VC0026691
p52614
sg42011
I1
sa(dp52615
g42006
I49
sg42007
VDCs
p52616
sg42008
I3
sg42009
VC0268238
p52617
sg42011
I1
sa(dp52618
g42006
I49
sg42007
g52609
sg42008
I3
sg42009
VC0268238
p52619
sg42011
I1
sasg42012
(lp52620
(dp52621
g42006
I14
sg42007
VCD4
p52622
sg42008
I3
sg42016
VP01730
p52623
sg42011
I1
sa(dp52624
g42006
I43
sg42007
VCD103 DCs
p52625
sg42008
I9
sg42016
VP38570
p52626
sg42011
I2
sa(dp52627
g42006
I43
sg42007
g52608
sg42008
I9
sg42016
VP38570
p52628
sg42011
I2
sasa(dp52629
g41997
VIn rickets, on the other hand, no PTH/PTHrP receptor gene expression was observed in the growth plate from day 8 of a vitamin D-deficient diet.
p52630
sg4
(dp52631
(VPTH
p52632
Vrickets
p52633
tp52634
I00
ssg42003
(lp52635
(dp52636
g42006
I3
sg42007
g52633
sg42008
I7
sg42009
VC0035579
p52637
sg42011
I1
sasg42012
(lp52638
(dp52639
g42006
I38
sg42007
VPTHrP receptor gene
p52640
sg42008
I19
sg42016
VP12272
p52641
sg42011
I3
sa(dp52642
g42006
I34
sg42007
g52632
sg42008
I3
sg42016
VP01270
p52643
sg42011
I1
sasa(dp52644
g41997
VThese results suggest that alterations in the PTH/PTHrP receptor gene expression are associated with rickets but not with TD.
p52645
sg4
(dp52646
(VPTH
p52647
Vrickets
p52648
tp52649
I00
ssg42003
(lp52650
(dp52651
g42006
I101
sg42007
g52648
sg42008
I7
sg42009
VC0035579
p52652
sg42011
I1
sasg42012
(lp52653
(dp52654
g42006
I50
sg42007
VPTHrP receptor gene
p52655
sg42008
I19
sg42016
VP12272
p52656
sg42011
I3
sa(dp52657
g42006
I46
sg42007
g52647
sg42008
I3
sg42016
VP01270
p52658
sg42011
I1
sasa(dp52659
g41997
VThe reduction in the PTH/PTHrP receptor gene expression in rickets may be due to the high plasma levels of PTH.
p52660
sg4
(dp52661
(VPTH
p52662
Vrickets
p52663
tp52664
I00
ssg42003
(lp52665
(dp52666
g42006
I59
sg42007
g52663
sg42008
I7
sg42009
VC0035579
p52667
sg42011
I1
sasg42012
(lp52668
(dp52669
g42006
I21
sg42007
VPTH
p52670
sg42008
I3
sg42016
VP01270
p52671
sg42011
I1
sa(dp52672
g42006
I25
sg42007
VPTHrP receptor gene
p52673
sg42008
I19
sg42016
VP12272
p52674
sg42011
I3
sa(dp52675
g42006
I21
sg42007
g52662
sg42008
I3
sg42016
VP01270
p52676
sg42011
I1
sasa(dp52677
g41997
VAs a first step towards understanding the role of OPN in retinal degeneration (RD), we examined changes in OPN expression in a mouse model of RD induced by exposure to a blue light-emitting diode (LED).
p52678
sg4
(dp52679
(VOPN
p52680
VRD
p52681
tp52682
I00
ssg42003
(lp52683
(dp52684
g42006
I57
sg42007
Vretinal degeneration
p52685
sg42008
I20
sg42009
VC0035304
p52686
sg42011
I2
sa(dp52687
g42006
I79
sg42007
VRD
p52688
sg42008
I2
sg42009
VC0035304
p52689
sg42011
I1
sa(dp52690
g42006
I79
sg42007
g52681
sg42008
I2
sg42009
VC0035304
p52691
sg42011
I1
sasg42012
(lp52692
(dp52693
g42006
I50
sg42007
g52680
sg42008
I3
sg42016
VP10451
p52694
sg42011
I1
sasa(dp52695
g41997
VSimilarly, those who had retinal disease had higher osteopontin concentrations than those without (16.8+/-2 vs. 12.4+/-3 mg/L; p=0.005).
p52696
sg4
(dp52697
(Vosteopontin
p52698
Vretinal disease
p52699
tp52700
I00
ssg42003
(lp52701
(dp52702
g42006
I25
sg42007
g52699
sg42008
I15
sg42009
VC0035309
p52703
sg42011
I2
sasg42012
(lp52704
(dp52705
g42006
I52
sg42007
g52698
sg42008
I11
sg42016
VP10451
p52706
sg42011
I1
sasa(dp52707
g41997
VWe investigated the expression of S100A4 and correlated it with clinical disease activity as well as with the levels of osteopontin (OPN), soluble syndecan-1, and vascular endothelial growth factor (VEGF) in proliferative diabetic retinopathy (PDR).
p52708
sg4
(dp52709
(VOPN
p52710
VPDR
p52711
tp52712
I00
ssg42003
(lp52713
(dp52714
g42006
I208
sg42007
Vproliferative diabetic retinopathy
p52715
sg42008
I34
sg42009
VC0154830
p52716
sg42011
I3
sa(dp52717
g42006
I244
sg42007
g52711
sg42008
I3
sg42009
VC0154830
p52718
sg42011
I1
sasg42012
(lp52719
(dp52720
g42006
I199
sg42007
VVEGF
p52721
sg42008
I4
sg42016
g190
sg42011
I1
sa(dp52722
g42006
I34
sg42007
VS100A4
p52723
sg42008
I6
sg42016
VP26447
p52724
sg42011
I1
sa(dp52725
g42006
I163
sg42007
Vvascular endothelial growth factor
p52726
sg42008
I34
sg42016
g190
sg42011
I4
sa(dp52727
g42006
I120
sg42007
Vosteopontin
p52728
sg42008
I11
sg42016
VP10451
p52729
sg42011
I1
sa(dp52730
g42006
I147
sg42007
Vsyndecan-1
p52731
sg42008
I10
sg42016
VP18827
p52732
sg42011
I1
sa(dp52733
g42006
I133
sg42007
g52710
sg42008
I3
sg42016
VP10451
p52734
sg42011
I1
sasa.